company_name,openfda_substance_name,openfda_pharm_class_pe,initial_posting_date,update_type,openfda_route,generic_name,openfda_rxcui,related_info_link,openfda_spl_set_id,update_date,openfda_product_type,discontinued_date,therapeutic_category,openfda_brand_name,openfda_product_ndc,openfda_manufacturer_name,openfda_spl_id,openfda_package_ndc,presentation,dosage_form,availability,openfda_nui,openfda_application_number,openfda_pharm_class_cs,openfda_generic_name,openfda_pharm_class_epc,resolved_note,status,shortage_reason,related_info,change_date,openfda_unii,package_ndc,contact_info,openfda_pharm_class_moa
"Hikma Pharmaceuticals USA, Inc.",LIDOCAINE HYDROCHLORIDE,,06/13/2018,Revised,"EPIDURAL, INFILTRATION, INTRACAUDAL",Lidocaine Hydrochloride Injection,"1737566, 1737761",,1631e5ca-03d0-4d3b-91e3-2dc14f4eb0e1,07/23/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,LIDOCAINE HYDROCHLORIDE,"0143-9594, 0143-9595",Hikma Pharmaceuticals USA Inc.,94a2c3cf-9d57-4185-884d-e52af6c139c8,"0143-9595-01, 0143-9595-25, 0143-9594-01, 0143-9594-25","Lidocaine Hydrochloride, Preservative Free, Injection, 20 mg/1 mL (NDC 0143-9594-25)",Injection,Available,,ANDA084625,,LIDOCAINE HYDROCHLORIDE,,,Current,,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,V13007Z41A,0143-9594-25,800-631-2174,
Takeda Pharmaceuticals USA Inc.,PARATHYROID HORMONE,,09/11/2019,Reverified,SUBCUTANEOUS,Parathyroid Hormone Injection,"1602023, 1602028, 1602032, 1602034, 1602038, 1602040, 1602044, 1602046",,d11fba31-0a6c-11e3-8ffd-0800200c9a66,08/15/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,NATPARA (PARATHYROID HORMONE),"68875-0205, 68875-0202, 68875-0203, 68875-0204","Takeda Pharmaceuticals America, Inc.",17d2bb82-605c-43be-9918-63aeb7102d8c,"68875-0202-1, 68875-0202-2, 68875-0203-1, 68875-0203-2, 68875-0204-1, 68875-0204-2, 68875-0205-1, 68875-0205-2","Natpara, Injection, 100 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0205-2)",Powder,Unavailable,"M0015931, N0000180851",BLA125511,Parathyroid Hormone [CS],PARATHYROID HORMONE,Parathyroid Hormone [EPC],,Current,Discontinuation of the manufacture of the drug,The 100 Mcg Cartridge Is No Longer Available And Takeda Is Unable To Resupply Prior To Ceasing Of Manufacturing Of Natpara At The End Of 2024.,,N19A0T0E5J,68875-0205-2,866-888-0660,
"Hospira, Inc., a Pfizer Company","BUPIVACAINE HYDROCHLORIDE, EPINEPHRINE BITARTRATE",,02/20/2018,Revised,"EPIDURAL, INTRACAUDAL, PERINEURAL","Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","1012377, 1012384, 1012396, 1012404, 1672917, 1672919, 1724786, 1724787, 1724880, 1724884, 1725078, 1725082, 1867594, 1867596",,02a845c3-4521-4926-e397-25ab536e7cf6,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE,"0409-9045, 0409-1159, 0409-1160, 0409-1162, 0409-1163, 0409-1165, 0409-9043, 0409-9046, 0409-9042","Hospira, Inc.",3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7,"0409-1159-18, 0409-1159-01, 0409-1159-19, 0409-1159-02, 0409-1160-18, 0409-1160-01, 0409-1162-18, 0409-1162-01, 0409-1162-19, 0409-1162-02, 0409-1163-18, 0409-1163-01, 0409-1165-18, 0409-1165-01, 0409-1165-19, 0409-1165-02, 0409-9043-11, 0409-9043-01, 0409-9046-11, 0409-9046-01, 0409-9045-11, 0409-9045-01, 0409-9045-16, 0409-9045-17, 0409-9042-11, 0409-9042-01, 0409-9042-16, 0409-9042-17","Bupivacaine Hydrochloride and Epinephrine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-9045-17)",Injection,Unavailable,,ANDA071168,,BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE,,,Current,Other,Shortage per Manufacturer: Manufacturing Delay,,"30Q7KI53AK, 7TQO7W3VT8",0409-9045-17,844-646-4398,
"Teva Pharmaceuticals USA, Inc.",CLONAZEPAM,,03/10/2023,Revised,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,8069b1a0-7c06-4252-b44e-e2eef065d9b8,09/15/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"0093-3213, 0093-0832, 0093-3212","Teva Pharmaceuticals USA, Inc.",d6abe4e3-7699-4ead-95f4-739a961b23ad,"0093-0832-01, 0093-0832-05, 0093-3212-01, 0093-3212-05, 0093-3213-01, 0093-3213-05","Clonazepam, Tablet, 2 mg (NDC 0093-3213-01)",Tablet,Available,"N0000175694, M0002356",ANDA074569,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,Other,,,5PE9FDE8GB,0093-3213-01,800-545-8800,
Aurobindo Pharma USA,"AMLODIPINE BESYLATE, BENAZEPRIL HYDROCHLORIDE",,03/04/2025,New,ORAL,Amlodipine Besylate; Benazepril Hydrochloride Capsule,"898342, 898346, 898350, 898353, 898356, 898359",,99ed4927-9a34-4e8d-8eea-60b63c867d46,03/04/2025,HUMAN PRESCRIPTION DRUG,03/04/2025,Cardiovascular,AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE,"65862-585, 65862-582, 65862-583, 65862-584, 65862-586, 65862-587",Aurobindo Pharma Limited,a45ec3e8-1d14-4c27-9685-976323df8cad,"65862-582-01, 65862-582-05, 65862-583-01, 65862-583-05, 65862-584-01, 65862-584-05, 65862-585-01, 65862-585-05, 65862-586-01, 65862-586-05, 65862-587-01, 65862-587-05","Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 40 mg (NDC 65862-585-01)",Capsule,,,ANDA202239,,AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE,,,To Be Discontinued,,,,"864V2Q084H, N1SN99T69T",65862-585-01,866-850-2876,
"Teva Pharmaceuticals USA, Inc.",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Revised,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release","1091155, 1091170, 1091185, 1091210",,85ef422d-af27-4126-9841-6892af1871d6,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE HYDROCHLORIDE,"62037-734, 62037-725, 62037-726, 62037-727","Actavis Pharma, Inc.",794291a5-d481-4cfe-9dbb-2d1391bb68d5,"62037-725-01, 62037-734-01, 62037-726-01, 62037-727-01","Methylphenidate Hydrochloride Extended-Release Tablets, USP   CII, Tablet, Extended Release, 27 mg (NDC 62037-734-01)",Tablet,Available,,ANDA076772,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,,,,4B3SC438HI,62037-734-01,800-545-8800,
Watson Pharma Private Limited,POTASSIUM CITRATE,,07/17/2025,New,ORAL,"Potassium Citrate Tablet, Extended Release","199376, 199381, 898490",,ac173781-486b-461c-97ae-8b5c69e20792,07/17/2025,HUMAN PRESCRIPTION DRUG,07/17/2025,Renal,POTASSIUM CITRATE,"0591-2729, 0591-2682, 0591-2742","Actavis Pharma, Inc.",b81078a3-490a-4a03-a9a5-9c64acde67bf,"0591-2682-01, 0591-2729-01, 0591-2742-01","Potassium Citrate, Tablet, Extended Release, 10 meq (NDC 0591-2729-01)",Tablet,,,ANDA209758,,POTASSIUM CITRATE,,,To Be Discontinued,,A business decision was made to discontinue.,,EE90ONI6FF,0591-2729-01,800-545-8800,
"Fresenius Kabi USA, LLC","BUPIVACAINE HYDROCHLORIDE, EPINEPHRINE BITARTRATE",,02/20/2018,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL","Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","1672917, 1672919, 1673296, 1673298, 1724880, 1724881, 1724884, 1724885, 1725078, 1725082, 1725175, 1725177, 1012391, 1012396, 1012404, 1012421, 1012455, 1012457",,"dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175, eb6d8fee-def4-4c96-9972-695e8cea8ea8",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,SENSORCAINE MPF,"63323-462, 63323-464, 63323-466, 63323-465, 63323-467, 63323-460","Fresenius Kabi USA, LLC","13a48007-3784-46f2-bd4d-da1004186b81, 2b1a1f80-cb29-4ac1-9e72-20225ed45715","63323-462-03, 63323-462-38, 63323-464-09, 63323-464-39, 63323-466-09, 63323-466-39, 63323-465-01, 63323-465-57, 63323-467-01, 63323-467-57, 63323-460-01, 63323-460-37, 63323-464-02, 63323-464-37, 63323-464-03, 63323-464-31, 63323-466-01, 63323-466-37, 63323-466-02, 63323-466-31, 63323-462-04, 63323-462-17, 63323-462-01, 63323-462-37, 63323-462-02, 63323-462-31","Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)",Injection,Available,,NDA018304,,BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE,,,Current,,Check wholesalers for inventory,,"30Q7KI53AK, 7TQO7W3VT8",63323-462-17,888-386-1300,
Baxter Healthcare,CLINDAMYCIN PHOSPHATE,,03/21/2023,Revised,INTRAVENOUS,Clindamycin Phosphate Injection,"309335, 309336, 309339",,78832ac6-04c5-45e0-ae4d-f56d7920dda9,09/23/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,CLINDAMYCIN PHOSPHATE,"0338-3410, 0338-3612, 0338-3814",Baxter Healthcare Company,9373fc85-1d70-4907-842a-ae9e2a3958b3,"0338-3410-50, 0338-3410-24, 0338-3612-50, 0338-3612-24, 0338-3814-50, 0338-3814-24","Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-3410-50)",Injection,Available,,ANDA208084,,CLINDAMYCIN PHOSPHATE,,,Current,,,,EH6D7113I8,0338-3410-50,888-229-0001,
Eugia US LLC,DEXAMETHASONE SODIUM PHOSPHATE,,02/08/2019,Revised,"INTRA-ARTICULAR, INTRALESIONAL, INTRAMUSCULAR, INTRAVENOUS, SOFT TISSUE",Dexamethasone Sodium Phosphate Injection,"1116927, 1812194",,ce7ad5a4-a9c5-42d6-87cc-ca16556208d2,09/05/2025,HUMAN PRESCRIPTION DRUG,,"Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Other, Pulmonary/Allergy, Rheumatology",DEXAMETHASONE SODIUM PHOSPHATE,"55150-238, 55150-237, 55150-239",Eugia US LLC,34b1362a-f970-485f-bdac-3a02217157c9,"55150-237-01, 55150-238-05, 55150-239-30","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 55150-238-05)",Injection,Unavailable,,ANDA206781,,DEXAMETHASONE SODIUM PHOSPHATE,,,Current,Demand increase for the drug,On backorder. Recovery: TBD. Check wholesalers for inventory,,AI9376Y64P,55150-238-05,888-238-7880,
"Teva Pharmaceuticals USA, Inc.","FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE",,06/13/2025,New,RESPIRATORY (INHALATION),Fluticasone Propionate; Salmeterol Xinafoate Powder,"1918194, 1918199, 1918203, 1918205, 1918209, 1918211",,9c122b91-a11f-49ca-80bb-3eec5112db87,06/13/2025,HUMAN PRESCRIPTION DRUG,06/13/2025,Pulmonary/Allergy,AIRDUO RESPICLICK,"59310-805, 59310-812, 59310-822","Teva Respiratory, LLC",b597bc2d-bf1e-4f9b-826a-b3e39ed56545,"59310-805-06, 59310-805-08, 59310-812-06, 59310-812-08, 59310-822-06, 59310-822-08","AirDuo RespiClick, Powder, 55 ug; 14 ug (NDC 59310-805-06)",Powder,,,NDA208799,,FLUTICASONE PROPIONATE AND SALMETEROL,,,To Be Discontinued,,,,"O2GMZ0LF5W, 6EW8Q962A5",59310-805-06,800-545-8800,
Sintetica US,LIDOCAINE HYDROCHLORIDE ANHYDROUS,,02/22/2012,Reverified,INFILTRATION,Lidocaine Hydrochloride Injection,"1737566, 1737568, 1737570, 1737757, 1737761, 1737763",,aa3e688a-308c-4a82-a268-28ccf1677c55,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",NA,"83090-002, 83090-001, 83090-003, 83090-004, 83090-005, 83090-006",Sintetica US LLC,0d18f291-3a92-421e-8841-6be743b1f154,"83090-001-01, 83090-001-10, 83090-002-01, 83090-002-10, 83090-003-01, 83090-003-10, 83090-004-01, 83090-004-10, 83090-005-01, 83090-005-10, 83090-006-01, 83090-006-10","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 83090-002-10)",Injection,Available,,ANDA214267,,LIDOCAINE HYDROCHLORIDE,,,Current,,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 1% 10X5ML)  is Preservative free.",,EC2CNF7XFP,83090-002-10,"844-425-3131, SinteticaCS@eversana.com",
Alvogen,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,7f2dd6ee-3363-c87c-9693-ed838942556c,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"47781-566, 47781-562, 47781-563, 47781-564, 47781-565, 47781-567, 47781-568",Alvogen Inc.,9114d946-92cb-c19d-c6f2-aef77294461f,"47781-562-01, 47781-563-01, 47781-564-01, 47781-565-01, 47781-566-01, 47781-567-01, 47781-568-01","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 47781-566-01)",Capsule,Available,,ANDA214547,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,47781-566-01,844-842-8672 and email: CustomerService-US@alvogen.com,
Pfizer Inc.,,,07/17/2025,New,,Pemetrexed Ditromethamine Injection,,,,07/17/2025,,07/17/2025,Oncology,,,,,,"Pemetrexed Ditromethamine, Injection, 100 mg Single Dose Vial (NDC 0409-1060-01)",Injection,,,,,,,,To Be Discontinued,,Discontinuation of the manufacture of the drug.,,,0409-1060-01,844-646-4398,
"Leadiant Biosciences, Inc.",,,08/08/2025,New,,Amphotericin B Injection,,,,08/08/2025,,08/08/2025,Anti-Infective,,,,,,"Abelcet, Injection, 5 mg/1 mL; 3.4 mg/1 mL; 1.5 mg/1 mL (NDC 57665-101-41)",Injection,,,,,,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,,57665-101-41,800-447-0169,
"Hikma Pharmaceuticals USA, Inc.",BUMETANIDE,Increased Diuresis at Loop of Henle [PE],01/31/2018,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Bumetanide Injection,"282486, 1727569",,681b5e9d-e2c7-4f29-aaad-e06d4a528c11,07/23/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,BUMETANIDE,"0641-6008, 0641-6007",Hikma Pharmaceuticals USA Inc.,99d2fc38-7e1e-4209-aa57-089794eda8a6,"0641-6007-01, 0641-6007-10, 0641-6008-01, 0641-6008-10","Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6008-10)",Injection,Available,"N0000175366, N0000175590",ANDA079196,,BUMETANIDE,Loop Diuretic [EPC],,Current,,,,0Y2S3XUQ5H,0641-6008-10,800-631-2174,
Amneal Pharmaceuticals,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718906, 1718909",,eb1ba463-ab42-4f49-9ebe-3ad5af108326,09/17/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE HYDROCHLORIDE,"70121-1388, 70121-1389",Amneal Pharmaceuticals LLC,795f643f-855c-4ba4-9bad-a96334c1a2fb,"70121-1388-1, 70121-1388-8, 70121-1389-1, 70121-1389-7","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1388-8)",Injection,Available,,ANDA207551,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,,,,1018WH7F9I,70121-1388-8,866-525-7270,
Torrent Pharma Inc.,"AMLODIPINE, HYDROCHLOROTHIAZIDE, OLMESARTAN MEDOXOMIL",Increased Diuresis [PE],06/13/2025,New,ORAL,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,"999967, 999986, 999991, 999996, 1000001",,85b8f9c6-aa53-4aa1-85d6-19f823d0d252,06/13/2025,HUMAN PRESCRIPTION DRUG,06/13/2025,Cardiovascular,"OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE 40/5/25 MG","13668-385, 13668-397, 13668-386, 13668-383, 13668-382",Torrent Pharmaceuticals Limited,5bedf6c6-6b23-40e7-8c96-2cedcc682973,"13668-397-30, 13668-397-90, 13668-397-05, 13668-386-30, 13668-386-90, 13668-386-05, 13668-385-30, 13668-385-90, 13668-385-05, 13668-383-30, 13668-383-90, 13668-383-05, 13668-382-30, 13668-382-90, 13668-382-05","Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 25 mg; 40 mg (NDC 13668-385-30)",Tablet,,"N0000175359, N0000175419, M0471776, N0000000069, N0000175421, N0000175566, M0006414, N0000190114",ANDA203580,"Thiazides [CS], Dihydropyridines [CS]","OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE TABLET 40/5/25 MG","Thiazide Diuretic [EPC], Dihydropyridine Calcium Channel Blocker [EPC], Calcium Channel Blocker [EPC]",,To Be Discontinued,,A business decision was made to discontinue manufacture of the product.,,"0J48LPH2TH, 1J444QC288, 6M97XTV3HD",13668-385-30,908-280-3333,"Calcium Channel Antagonists [MoA], Cytochrome P450 3A Inhibitors [MoA]"
"Upsher-Smith Laboratories, LLC",MIDODRINE HYDROCHLORIDE,,04/28/2025,New,ORAL,Midodrine Hydrochloride Tablet,"993462, 993466, 993470",,4c3517f3-1c68-4ade-b5f1-c488a3a335c1,04/28/2025,HUMAN PRESCRIPTION DRUG,04/28/2025,Cardiovascular,MIDODRINE HYDROCHLORIDE,"0245-0212, 0245-0211, 0245-0213","Upsher-Smith laboratories, LLC",18b0b9f5-6026-479e-af12-92b0e71a9d6b,"0245-0211-11, 0245-0211-89, 0245-0211-01, 0245-0212-11, 0245-0212-89, 0245-0212-01, 0245-0213-11, 0245-0213-89, 0245-0213-01","Orvaten, Tablet, 5 mg (NDC 0245-0212-11)",Tablet,,,ANDA076725,,MIDODRINE HYDROCHLORIDE,,,To Be Discontinued,,,,59JV96YTXV,0245-0212-11,800-654-2299,
"Hikma Pharmaceuticals USA, Inc.",LORAZEPAM,,09/05/2018,Revised,"INTRAMUSCULAR, INTRAVENOUS",Lorazepam Injection,"238100, 238101, 1665188, 1665326",,e9b54e42-04cf-4c62-90e1-36f7b31a4e81,07/23/2025,HUMAN PRESCRIPTION DRUG,,Neurology,LORAZEPAM,"0641-6045, 0641-6044, 0641-6046, 0641-6047",Hikma Pharmaceuticals USA Inc.,7c73dbc6-2623-4443-9b05-97dec7a0be2e,"0641-6044-01, 0641-6044-25, 0641-6046-01, 0641-6046-10, 0641-6045-01, 0641-6045-25, 0641-6047-01, 0641-6047-10","Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25)",Injection,Unavailable,"N0000175694, M0002356",NDA018140,Benzodiazepines [CS],LORAZEPAM,Benzodiazepine [EPC],,Current,Regulatory delay,Shortage duration unknown,,O26FZP769L,0641-6045-25,800-631-2174,
Janssen Pharmaceuticals,METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Reverified,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release","1091155, 1091157, 1091170, 1091172, 1091185, 1091187, 1091210, 1091212",,1a88218c-5b18-4220-8f56-526de1a276cd,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,CONCERTA,"50458-588, 50458-585, 50458-586, 50458-587","Janssen Pharmaceuticals, Inc.",23987e85-013d-3aaa-e063-6394a90a1f2d,"50458-585-01, 50458-588-01, 50458-586-01, 50458-587-01","Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01)",Tablet,Available,,NDA021121,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,,,,4B3SC438HI,50458-588-01,800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET,
"Fresenius Kabi USA, LLC","BUPIVACAINE HYDROCHLORIDE, EPINEPHRINE BITARTRATE",,02/20/2018,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL","Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","1672917, 1672919, 1673296, 1673298, 1724880, 1724881, 1724884, 1724885, 1725078, 1725082, 1725175, 1725177, 1012391, 1012396, 1012404, 1012421, 1012455, 1012457",,"dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175, eb6d8fee-def4-4c96-9972-695e8cea8ea8",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,SENSORCAINE MPF,"63323-462, 63323-464, 63323-466, 63323-465, 63323-467, 63323-460","Fresenius Kabi USA, LLC","13a48007-3784-46f2-bd4d-da1004186b81, 2b1a1f80-cb29-4ac1-9e72-20225ed45715","63323-462-03, 63323-462-38, 63323-464-09, 63323-464-39, 63323-466-09, 63323-466-39, 63323-465-01, 63323-465-57, 63323-467-01, 63323-467-57, 63323-460-01, 63323-460-37, 63323-464-02, 63323-464-37, 63323-464-03, 63323-464-31, 63323-466-01, 63323-466-37, 63323-466-02, 63323-466-31, 63323-462-04, 63323-462-17, 63323-462-01, 63323-462-37, 63323-462-02, 63323-462-31","Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-37)",Injection,Available,,NDA018304,,BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE,,,Current,,Check wholesalers for inventory,,"30Q7KI53AK, 7TQO7W3VT8",63323-462-37,888-386-1300,
Baxter Healthcare,KETOROLAC TROMETHAMINE,,06/06/2018,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Ketorolac Tromethamine Injection,"860092, 1665459, 1665461",,4b58836d-9d58-4539-9691-9e11c505ef2a,09/23/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,KETOROLAC TROMETHAMINE,"0338-0072, 0338-0069, 0338-0076",Baxter Healthcare Corporation,2da4dd8a-1b18-481d-b733-9c031d9ea7e3,"0338-0069-10, 0338-0072-25, 0338-0076-10","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)",Injection,Available,,ANDA209900,,KETOROLAC TROMETHAMINE,,,Current,,,,4EVE5946BQ,0338-0072-25,888-229-0001,
Accord Healthcare Inc.,ATROPINE SULFATE,,01/01/2020,Revised,INTRAVENOUS,Atropine Sulfate Injection,"1190546, 1190551, 1190552",,c82cb295-ffce-47d6-97ad-a8aa723f4e4f,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology, Pediatric",ATROPINE SULFATE,"16729-484, 16729-483","Accord Healthcare, Inc.,",275da8b0-80b1-6c78-e063-6394a90a97a3,"16729-483-03, 16729-483-31, 16729-484-90, 16729-484-31, 16729-484-45, 16729-484-03","Atropine Sulfate, Injection, 0.1 mg/1 mL (NDC 16729-484-45)",Injection,"Unavailable, 75 days",,ANDA212868,,ATROPINE SULFATE,,,Current,Requirements related to complying with good manufacturing practices,Manufacturing in process,,03J5ZE7KA5,16729-484-45,"866-941-7875, option 2",
"Fresenius Kabi USA, LLC",DEXTROSE MONOHYDRATE,,03/01/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 10% Injection,"1795477, 1795480, 1795481",,3b8f2692-4371-4f1a-95af-b41842131fdd,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,63323-824,"Fresenius Kabi USA, LLC",d4eda8d8-e374-469e-8ac0-9c9fb7a58aaf,"63323-824-24, 63323-824-74, 63323-824-25, 63323-824-75, 63323-824-26, 63323-824-76","Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-75)",Injection,Unavailable,,ANDA209448,,DEXTROSE MONOHYDRATE,,,Current,Demand increase for the drug,Backordered. Next release not available at this time. Check wholesalers for inventory.,,LX22YL083G,63323-824-75,888-386-1300,
"Boehringer Ingelheim Pharmaceuticals, Inc.",,,01/06/2025,New,,Adalimumab-adbm Injection,"797544, 2640883, 2640891, 2640893, 2640895, 2640900, 2640902, 2680743, 2680748, 2680756, 2680759",,62f39a7c-00df-4519-a8d4-39bbd0a649ed,01/06/2025,HUMAN PRESCRIPTION DRUG,01/06/2025,Rheumatology,ADALIMUMAB-ADBM,"0597-0575, 0597-0595, 0597-0555, 0597-0585, 0597-0545, 0597-0565","Boehringer Ingelheim Pharmaceuticals, Inc.",79fdef1e-7f86-429d-bc7d-2e99f286204b,"0597-0595-20, 0597-0590-26, 0597-0555-80, 0597-0550-06, 0597-0585-89, 0597-0580-37, 0597-0545-22, 0597-0545-44, 0597-0545-66, 0597-0540-10, 0597-0575-50, 0597-0575-40, 0597-0575-60, 0597-0570-32, 0597-0565-20, 0597-0560-12","Cyltezo, Injection, Kit (NDC 0597-0575-40)",Injection,,,BLA761058,,ADALIMUMAB-ADBM,,,To Be Discontinued,,,,,0597-0575-40,800-243-0127,
"Fresenius Kabi USA, LLC",ROCURONIUM BROMIDE,,02/15/2023,Reverified,INTRAVENOUS,Rocuronium Bromide Injection,1234995,,"f1933332-1ae0-4dc1-be4c-694849e6c9f9, fb9524b2-c353-4747-8954-7ca2529eabb2",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROCURONIUM,63323-426,"Fresenius Kabi USA, LLC","d6e2ff8d-838d-4c27-8e73-230548b09d63, 3f4d5e11-2c14-4406-8954-04dba2fc65ff","63323-426-02, 63323-426-05, 63323-426-01, 63323-426-10, 63323-426-12, 63323-426-15","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)",Injection,Unavailable,,ANDA078651,,ROCURONIUM BROMIDE,,,Current,Delay in shipping of the drug,Backordered. Next release October 2025. Check wholesaers for inventory.,,I65MW4OFHZ,63323-426-10,888-386-1300,
"Somerset Therapeutics, LLC",ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Reverified,"EPIDURAL, INFILTRATION, PERINEURAL",Ropivacaine Hydrochloride Injection,"905189, 1734084, 1734090, 1734203, 1734207, 1734475, 1734483",,ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64,08/19/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROPIVACAINE HYDROCHLORIDE,"70069-062, 70069-061, 70069-063, 70069-064, 70069-065, 70069-066, 70069-067","Somerset Therapeutics, LLC",5d7b0e44-19ce-4127-b3e8-d7e6e65f1818,"70069-061-01, 70069-061-25, 70069-061-10, 70069-062-01, 70069-062-25, 70069-062-10, 70069-063-01, 70069-063-25, 70069-064-01, 70069-064-10, 70069-064-25, 70069-065-01, 70069-065-25, 70069-066-01, 70069-066-25, 70069-066-10, 70069-067-01, 70069-067-25, 70069-067-10","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-25)",Injection,Available,,ANDA207636,,ROPIVACAINE HYDROCHLORIDE,,,Current,,,,V910P86109,70069-062-25,732-554-1019,
"Fresenius Kabi USA, LLC",ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Reverified,"EPIDURAL, INFILTRATION",Ropivacaine Hydrochloride Injection,"1734203, 1734204, 1734207, 1734208, 1734347, 1734348, 1734355, 1734356, 1734475, 1734476, 1734479, 1734480, 1734481, 1734482, 1734483, 1734484, 905189, 905191, 1734084, 1734086, 1734090, 1734091",,"dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7, 23d2d448-a744-4877-9f2d-7e57c198da89, c6613708-c1f7-4f5c-91a3-ebbc1d7905c6",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,NAROPIN,"63323-285, 63323-286, 63323-287, 63323-288","Fresenius Kabi USA, LLC","324532ac-4e54-4659-a1a2-9ade22a1ed3f, cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9, 73218c89-8925-468c-84bf-9960b4b3dc3c","63323-286-41, 63323-286-27, 63323-286-43, 63323-286-38, 63323-285-41, 63323-285-28, 63323-285-53, 63323-285-68, 63323-285-59, 63323-285-73, 63323-286-01, 63323-286-20, 63323-286-05, 63323-286-23, 63323-286-09, 63323-286-31, 63323-286-11, 63323-286-35, 63323-286-03, 63323-286-00, 63323-286-33, 63323-286-63, 63323-286-30, 63323-287-01, 63323-287-20, 63323-287-03, 63323-287-21, 63323-288-01, 63323-288-10, 63323-288-06, 63323-288-20, 63323-288-03, 63323-288-11, 63323-288-07, 63323-288-21, 63323-285-01, 63323-285-10, 63323-285-06, 63323-285-20, 63323-285-03, 63323-285-13, 63323-285-07, 63323-285-23, 63323-285-57, 63323-285-64, 63323-285-51, 63323-285-65, 63323-285-02, 63323-285-61, 63323-285-04, 63323-285-63, 63323-285-55, 63323-285-67, 63323-288-23, 63323-288-29, 63323-286-93, 63323-286-95","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-63)",Injection,Unavailable,,NDA020533,,ROPIVACAINE HYDROCHLORIDE,,,Current,Delay in shipping of the drug,Next release not available at this time.,,V910P86109,63323-285-63,888-386-1300,
Baxter Healthcare,WATER,,04/28/2023,Reverified,IRRIGATION,Sterile Water Irrigant,150985,,ef3e79c5-3f58-4b36-a296-64b7d9a651c1,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",STERILE WATER,"0338-0004, 0338-0003",Baxter Healthcare Corporation,43dc7530-ed0a-4976-af2a-0d39a2532fb7,"0338-0003-44, 0338-0003-46, 0338-0003-47, 0338-0004-02, 0338-0004-03, 0338-0004-04, 0338-0004-05","Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)",Irrigant,Available,,NDA017428,,WATER,,,Current,,,,059QF0KO0R,0338-0004-03,888-229-0001,
"Hospira, Inc., a Pfizer Company",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,"EPIDURAL, INTRACAUDAL, PERINEURAL",Bupivacaine Hydrochloride Injection,"1012377, 1012384, 1012396, 1012404, 1672917, 1672919, 1724786, 1724787, 1724880, 1724884, 1725078, 1725082, 1867594, 1867596",,02a845c3-4521-4926-e397-25ab536e7cf6,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE,"0409-1162, 0409-1159, 0409-1160, 0409-1163, 0409-1165, 0409-9043, 0409-9046, 0409-9045, 0409-9042","Hospira, Inc.",3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7,"0409-1159-18, 0409-1159-01, 0409-1159-19, 0409-1159-02, 0409-1160-18, 0409-1160-01, 0409-1162-18, 0409-1162-01, 0409-1162-19, 0409-1162-02, 0409-1163-18, 0409-1163-01, 0409-1165-18, 0409-1165-01, 0409-1165-19, 0409-1165-02, 0409-9043-11, 0409-9043-01, 0409-9046-11, 0409-9046-01, 0409-9045-11, 0409-9045-01, 0409-9045-16, 0409-9045-17, 0409-9042-11, 0409-9042-01, 0409-9042-16, 0409-9042-17","Bupivacaine Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-1162-01)",Injection,Available,,ANDA070584,,BUPIVACAINE HYDROCHLORIDE,,,Current,,,,"30Q7KI53AK, 7TQO7W3VT8",0409-1162-01,844-646-4398,
"Fresenius Kabi USA, LLC",ROCURONIUM BROMIDE,,02/15/2023,Reverified,INTRAVENOUS,Rocuronium Bromide Injection,1234995,,209a654d-f92d-4242-bfef-2dcc90a30d3f,09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROCURONIUM,65219-065,"Fresenius Kabi USA, LLC",68f8f5e7-46a8-47f9-a622-6339df1a3d1b,"65219-065-02, 65219-065-05","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-065-05)",Injection,Unavailable,,ANDA078651,,ROCURONIUM BROMIDE,,,Current,Delay in shipping of the drug,Backordered. Next release not available at this time. Check wholesaler for inventory.,,I65MW4OFHZ,65219-065-05,888-386-1300,
Otsuka ICU Medical LLC,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807548, 1807549, 1807550, 1807551, 1807552, 1807627, 1807630, 1807631, 1807632, 1807633, 1807634, 1807639",,5f372b75-d7a4-471e-8ac6-290040fc84b0,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0990-7984, 0990-7730, 0990-7983, 0990-7985",ICU Medical Inc.,87c57bfa-0bf7-41fd-b954-eb753d5d9d7f,"0990-7730-36, 0990-7730-37, 0990-7983-61, 0990-7983-02, 0990-7983-03, 0990-7983-09, 0990-7983-55, 0990-7983-53, 0990-7984-37, 0990-7984-20, 0990-7984-13, 0990-7984-23, 0990-7984-36, 0990-7985-02, 0990-7985-03, 0990-7985-09","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-37)",Injection,,,NDA016366,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0990-7984-37,1-866-829-9025 or ProductAvailability@icumed.com,
"Teva Pharmaceuticals USA, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Revised,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,cffbbb15-d776-41ae-a8a6-687f2c07bfa4,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","0555-0775, 0555-0971, 0555-0972, 0555-0776, 0555-0777, 0555-0973, 0555-0974","Teva Pharmaceuticals USA, Inc.",88468f3d-7d03-4cee-aabf-3abc8c9b5e38,"0555-0971-02, 0555-0775-02, 0555-0972-02, 0555-0776-02, 0555-0777-02, 0555-0973-02, 0555-0974-02","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0555-0775-02)",Tablet,Available,,ANDA040422,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",0555-0775-02,800-545-8800,
Aurobindo Pharma USA,AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","239191, 313797",,234d0dfc-cb24-413f-b798-129c73eb848e,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"65862-706, 65862-707",Aurobindo Pharma Limited,f4a410c9-3a78-48f9-8195-915896a974ff,"65862-706-80, 65862-706-01, 65862-706-55, 65862-707-80, 65862-707-01, 65862-707-55","Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 65862-706-80)","Powder, For Suspension",,,ANDA204030,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,65862-706-80,866-850-2876,
SpecGx LLC,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,806a1c15-0842-4787-b2ad-09a21fd96b37,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0406-5112, 0406-5111, 0406-5113, 0406-5114, 0406-5115, 0406-5116, 0406-5117",SpecGx LLC,3ffc0695-83f7-4898-9fd7-451c0989cfe0,"0406-5111-01, 0406-5112-01, 0406-5113-01, 0406-5114-01, 0406-5115-01, 0406-5116-01, 0406-5117-01","Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0406-5112-01)",Capsule,Limited Availability,,ANDA211840,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,Allocation to all customers.,,SJT761GEGS,0406-5112-01,800-325-8888,
"Amphastar Pharmaceuticals, Inc.",LORAZEPAM,,05/03/2018,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Lorazepam Injection,238100,,7dda070d-7809-46c4-8592-eb4e4c509707,09/16/2025,HUMAN PRESCRIPTION DRUG,,Neurology,LORAZEPAM,76329-8261,"International Medication Systems, Limited",b85a6695-55b9-4780-a803-33f8f2464138,76329-8261-1,"Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1)",Injection,Limited Availability,"N0000175694, M0002356",ANDA076150,Benzodiazepines [CS],LORAZEPAM,Benzodiazepine [EPC],,Current,Demand increase for the drug,,,O26FZP769L,76329-8261-1,800-423-4136,
"Upsher-Smith Laboratories, LLC",POTASSIUM CHLORIDE,,07/23/2025,New,ORAL,"Potassium Chloride Tablet, Extended Release","312529, 628953, 628958, 832718",,1ff53330-065c-4213-9c0c-ac498621d09d,07/23/2025,HUMAN PRESCRIPTION DRUG,07/23/2025,"Endocrinology/Metabolism, Gastroenterology",KLOR-CON,"0245-5315, 0245-5316","Upsher-Smith Laboratories, LLC",39e77e07-bdc8-28e9-e063-6394a90a120c,"0245-5315-11, 0245-5315-15, 0245-5315-89, 0245-5315-01, 0245-5316-11, 0245-5316-15, 0245-5316-89, 0245-5316-01","Klor-Con, Tablet, Extended Release, 600 mg (NDC 0245-5315-11)",Tablet,,,NDA019123,,POTASSIUM CHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug product,,660YQ98I10,0245-5315-11,763-315-2000,
"Hikma Pharmaceuticals USA, Inc.",DEXAMETHASONE SODIUM PHOSPHATE,,02/08/2019,Revised,"INTRA-ARTICULAR, INTRALESIONAL, INTRAMUSCULAR, INTRAVENOUS, SOFT TISSUE",Dexamethasone Sodium Phosphate Injection,"309696, 1116927, 1812194",,0277cc0a-2fd4-4605-a310-b613be84ee26,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Other, Pulmonary/Allergy, Rheumatology",DEXAMETHASONE SODIUM PHOSPHATE,"0641-6145, 0641-0367, 0641-6146",Hikma Pharmaceuticals USA Inc.,84665497-7e82-4733-bcfd-3177817ac0b3,"0641-0367-21, 0641-0367-25, 0641-6145-01, 0641-6145-25, 0641-6146-01, 0641-6146-10, 0641-6146-25","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6145-25)",Injection,Available,,ANDA084282,,DEXAMETHASONE SODIUM PHOSPHATE,,,Current,,Currently available.  Additional product will be made available as it is released.,,AI9376Y64P,0641-6145-25,800-631-2174,
"Caplin Steriles, Ltd.",ETOMIDATE,General Anesthesia [PE],10/05/2022,Reverified,INTRAVENOUS,Etomidate Injection,"1654006, 1654008",,"f38fad46-f2dd-4692-a2a9-a13d0a717bf8, d07efb9e-5264-461d-96d8-e11fa71c5751",09/16/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ETOMIDATE,"65219-445, 65219-447","Fresenius Kabi USA, LLC","446487f1-002e-41d3-846a-67570e797171, 30488a7e-ea9e-4a27-95a9-a07149c50282","65219-445-12, 65219-445-22, 65219-445-01, 65219-445-10, 65219-447-02, 65219-447-20","Etomidate, Injection, 2 mg/1 mL (NDC 65219-445-10)",Injection,Available,"N0000175975, N0000175681",ANDA215028,,ETOMIDATE,General Anesthetic [EPC],,Current,,Check wholesalers for inventory; Marketed by Fresenius Kabi,,Z22628B598,65219-445-10,800-551-7176,
Alembic Pharmaceuticals,KETOROLAC TROMETHAMINE,,03/23/2018,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Ketorolac Tromethamine Injection,"860092, 1665459, 1665461",,419cf756-3c96-4bb8-ae96-6aea5a5f3afd,09/17/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,KETOROLAC TROMETHAMINE,"62332-601, 62332-599, 62332-600",Alembic Pharmaceuticals Inc.,9030f496-5021-4454-ac16-dbb376315608,"62332-599-01, 62332-599-25, 62332-600-01, 62332-600-25, 62332-601-02, 62332-601-25","Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 62332-601-25)",Injection,Available,,ANDA214456,,KETOROLAC TROMETHAMINE,,,Current,,,,4EVE5946BQ,62332-601-25,908-393-9604,
"Hikma Pharmaceuticals USA, Inc.",LEUCOVORIN CALCIUM,,01/01/2012,Revised,"INTRAMUSCULAR, INTRAVENOUS",Leucovorin Calcium Injection,"237788, 1803930, 1803932, 1803937",,cc52077f-5663-4f79-a273-0aecf655e038,07/08/2025,HUMAN PRESCRIPTION DRUG,,"Oncology, Pediatric",LEUCOVORIN CALCIUM,"0143-9552, 0143-9555, 0143-9554, 0143-9553",Hikma Pharmaceuticals USA Inc.,e2d1484b-2920-45ab-9207-4caa5285fef4,"0143-9555-01, 0143-9554-01, 0143-9553-01, 0143-9552-01","Leucovorin Calcium, Injection, 350 mg/17.5 mL (NDC 0143-9552-01)",Injection,,,ANDA040335,,LEUCOVORIN CALCIUM,,Available,Resolved,,,07/08/2025,RPR1R4C0P4,0143-9552-01,800-631-2174,
"Teva Pharmaceuticals USA, Inc.",AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension",,,4c0f348a-a65d-409c-8668-207c82a5e3cb,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0093-4155, 0093-2263, 0093-2264, 0093-4160, 0093-4161, 0093-2267, 0093-2268, 0093-3107, 0093-3109","Teva Pharmaceuticals USA, Inc.",8988589b-0893-4233-ac9c-9884ceb0c2c4,"0093-2263-01, 0093-2264-01, 0093-4160-76, 0093-4160-78, 0093-4160-73, 0093-4155-79, 0093-4155-73, 0093-4155-80, 0093-4161-76, 0093-4161-78, 0093-4161-73, 0093-2267-01, 0093-2268-01, 0093-3107-01, 0093-3107-05, 0093-3109-53, 0093-3109-06, 0093-3109-01, 0093-3109-05","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0093-4155-80)","Powder, For Suspension",,,ANDA061931,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0093-4155-80,800-545-8800,
Piramal Critical Care Inc.,MORPHINE SULFATE,,10/31/2017,Revised,"EPIDURAL, INTRATHECAL",Morphine Sulfate Injection,,,728f3d83-9a63-0c1f-e053-2a91aa0ac7db,09/18/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,MITIGO,"66794-160, 66794-162","Piramal Critical Care, Inc.",3f72fcc3-7855-bdf8-e063-6294a90a20b2,"66794-160-02, 66794-162-02","Mitigo (Morphine Sulfate Injection, USP), Injection, 200 mg/20 mL (NDC 66794-160-02)",Injection,Unavailable,,ANDA204393,,MORPHINE SULFATE,,,Current,Other,Estimated recovery: October 2025; Manufacturing Delay,,X3P646A2J0,66794-160-02,800-414-1901,
Sanofi-Aventis U.S. LLC,RIFAPENTINE,,03/25/2020,Reverified,ORAL,"Rifapentine Tablet, Film Coated","242671, 261101",,3a64fb70-b85e-43d9-8bcd-7e893f568ae1,09/17/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,PRIFTIN,0088-2102,sanofi-aventis U.S. LLC,ec69d365-607b-45bd-9cc8-5fea540f8b23,"0088-2102-01, 0088-2102-24","Priftin, Tablet, Film Coated, 150 mg (NDC 0088-2102-24)",Tablet,Available,"N0000175501, M0019113",NDA021024,Rifamycins [CS],RIFAPENTINE,Rifamycin Antimycobacterial [EPC],,Current,,,,XJM390A33U,0088-2102-24,800-633-1610 Option 7,
"Fresenius Kabi USA, LLC",ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Reverified,"EPIDURAL, INFILTRATION, PERINEURAL",Ropivacaine Hydrochloride Injection,"1734203, 1734204, 1734207, 1734208, 1734347, 1734348, 1734355, 1734356, 1734475, 1734476, 1734479, 1734480, 1734481, 1734482, 1734483, 1734484, 905189, 905191, 1734084, 1734086, 1734090, 1734091",,"dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7, 23d2d448-a744-4877-9f2d-7e57c198da89, c6613708-c1f7-4f5c-91a3-ebbc1d7905c6",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,NAROPIN,"63323-286, 63323-285, 63323-287, 63323-288","Fresenius Kabi USA, LLC","324532ac-4e54-4659-a1a2-9ade22a1ed3f, cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9, 73218c89-8925-468c-84bf-9960b4b3dc3c","63323-286-41, 63323-286-27, 63323-286-43, 63323-286-38, 63323-285-41, 63323-285-28, 63323-285-53, 63323-285-68, 63323-285-59, 63323-285-73, 63323-286-01, 63323-286-20, 63323-286-05, 63323-286-23, 63323-286-09, 63323-286-31, 63323-286-11, 63323-286-35, 63323-286-03, 63323-286-00, 63323-286-33, 63323-286-63, 63323-286-30, 63323-287-01, 63323-287-20, 63323-287-03, 63323-287-21, 63323-288-01, 63323-288-10, 63323-288-06, 63323-288-20, 63323-288-03, 63323-288-11, 63323-288-07, 63323-288-21, 63323-285-01, 63323-285-10, 63323-285-06, 63323-285-20, 63323-285-03, 63323-285-13, 63323-285-07, 63323-285-23, 63323-285-57, 63323-285-64, 63323-285-51, 63323-285-65, 63323-285-02, 63323-285-61, 63323-285-04, 63323-285-63, 63323-285-55, 63323-285-67, 63323-288-23, 63323-288-29, 63323-286-93, 63323-286-95","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-35)",Injection,Available,,NDA020533,,ROPIVACAINE HYDROCHLORIDE,,,Current,,,,V910P86109,63323-286-35,888-386-1300,
Baxter Healthcare,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807631, 1807632",,fbc01464-8885-4075-af41-911ffec5ae92,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,0338-0553,Baxter Healthcare Corporation,aca96e4a-a57b-47ac-bd60-e65c29e19743,"0338-0553-11, 0338-0553-18","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0338-0553-11)",Injection,,,NDA020178,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0338-0553-11,888-229-0001,
"Novo Nordisk, Inc.",INSULIN ASPART,,07/21/2025,New,SUBCUTANEOUS,Insulin Aspart Protamine and Insulin Aspart Mix 70/30 Injectable Suspension,"351297, 847191",,fc94baa4-3606-48bc-a781-9617ab6960ef,07/21/2025,HUMAN PRESCRIPTION DRUG,07/21/2025,Endocrinology/Metabolism,INSULIN ASPART PROTAMINE AND INSULIN ASPART MIX 70/30,"73070-200, 73070-203","Novo Nordisk Pharma, Inc.",ec67820c-4008-4894-b933-34b28704221d,"73070-200-11, 73070-203-10, 73070-203-15","Insulin Aspart Protamine and Insulin Aspart Mix 70/30, Injectable Suspension, 10 mL Insulin aspart protamine and insulin aspart Mix 70/30 vial (NDC 73070-200-11)",Injectable Suspension,,"M0011417, N0000175453",BLA021172,Insulin [CS],INSULIN ASPART,Insulin Analog [EPC],,To Be Discontinued,,"Unbranded Insulin Aspart Protamine and Insulin Aspart Mix 70/30 10 mL vial will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,D933668QVX,73070-200-11,609-987-5800,
"Vertical Pharmaceuticals, LLC",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Reverified,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release",,,22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d,09/16/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,RELEXXII,"68025-095, 68025-088, 68025-089, 68025-096, 68025-097, 68025-084, 68025-098","Vertical Pharmaceuticals, LLC",86f477e9-07fc-466b-913e-1a4434c91df4,"68025-088-30, 68025-089-30, 68025-095-10, 68025-095-30, 68025-096-10, 68025-096-30, 68025-097-10, 68025-097-30, 68025-084-30, 68025-098-10, 68025-098-30","Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10)",Tablet,Unavailable,,NDA216117,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,Other,Estimated recovery: TBD,,4B3SC438HI,68025-095-10,800-541-4802,
"Meitheal Pharmaceuticals, Inc.",ROCURONIUM BROMIDE,,02/15/2023,Reverified,INTRAVENOUS,Rocuronium Bromide Injection,1234995,,b9abaf64-760d-43e0-8669-a9ca70feab11,08/19/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROCURONIUM BROMIDE,"71288-718, 71288-700",Meitheal Pharmaceuticals Inc.,37295b13-65a4-40fa-8d6c-53aeb45e2939,"71288-700-05, 71288-700-06, 71288-718-10, 71288-718-11","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-718-11)",Injection,Available,,ANDA213453,,ROCURONIUM BROMIDE,,,Current,,,,I65MW4OFHZ,71288-718-11,844-824-8426,
Aurobindo Pharma USA,AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","239191, 313797",,234d0dfc-cb24-413f-b798-129c73eb848e,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"65862-706, 65862-707",Aurobindo Pharma Limited,f4a410c9-3a78-48f9-8195-915896a974ff,"65862-706-80, 65862-706-01, 65862-706-55, 65862-707-80, 65862-707-01, 65862-707-55","Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 65862-706-55)","Powder, For Suspension",,,ANDA204030,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,65862-706-55,866-850-2876,
"Teva Pharmaceuticals USA, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Revised,ORAL,Lisdexamfetamine Dimesylate Capsule,,,c32b5dce-2de4-4db0-a4ba-d2ce3b0a32fc,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0480-3570, 0480-3565, 0480-3566, 0480-3567, 0480-3568, 0480-3569, 0480-3564","Teva Pharmaceuticals, Inc.",6cfe6c98-51b1-45a4-831c-33624ab129cb,"0480-3565-01, 0480-3566-01, 0480-3567-01, 0480-3568-01, 0480-3569-01, 0480-3570-01, 0480-3564-01","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0480-3570-01)",Capsule,Limited Availability,,ANDA202802,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Other,Limited Availability,,SJT761GEGS,0480-3570-01,800-545-8800,
"Hospira, Inc., a Pfizer Company",METHOTREXATE SODIUM,,03/13/2023,Reverified,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Methotrexate Sodium Injection,"1655956, 1946772",,"0d63ba29-b692-41b4-87e8-351265c8273f, 0e30eaef-5a09-4104-8a11-c32933eadeab",08/15/2025,HUMAN PRESCRIPTION DRUG,,"Rheumatology, Oncology",METHOTREXATE,"61703-350, 61703-408","Hospira, Inc.","95b8b8da-da4e-4bba-9038-3cf65f3d5c1a, 37b3e76b-ac3d-4f93-adf1-91f52f676b8a","61703-350-37, 61703-350-38, 61703-408-41, 61703-350-09, 61703-350-10, 61703-408-25","Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38)",Injection,Available,,NDA011719,,METHOTREXATE,,,Current,,,,3IG1E710ZN,61703-350-38,844-646-4398,
"Fresenius Kabi USA, LLC","BUPIVACAINE HYDROCHLORIDE, EPINEPHRINE BITARTRATE",,02/20/2018,Reverified,PERINEURAL,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","1012377, 1012384, 1012413, 1012417, 1724786, 1724787, 1724809, 1724810, 1867594, 1867596, 1867618, 1867620",,bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb,09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,SENSORCAINE,"63323-463, 63323-472, 63323-461, 63323-468","Fresenius Kabi USA, LLC",cc1f6507-eb3e-4398-a1d3-0c56a2099e6b,"63323-472-03, 63323-472-17, 63323-472-01, 63323-472-37, 63323-463-01, 63323-463-57, 63323-461-01, 63323-461-57, 63323-468-02, 63323-468-37, 63323-468-01, 63323-468-17","Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-463-57)",Injection,Available,,ANDA070968,,BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE,,,Current,,Check wholesaler for inventory,,"30Q7KI53AK, 7TQO7W3VT8",63323-463-57,888-386-1300,
Pfizer Inc.,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718906, 1718907, 1718909, 1718910",,92b7ddaa-e45a-4b64-a802-bb5df8771dd6,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,PRECEDEX,"0409-4596, 0409-0155","Hospira, Inc.",1fdb4815-2990-4926-ba76-25241810489e,"0409-4596-01, 0409-4596-20, 0409-0155-01, 0409-0155-02","Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-4596-20)",Injection,Available,,NDA021038,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,,,,1018WH7F9I,0409-4596-20,844-646-4398,
"Hikma Pharmaceuticals USA, Inc.",HYDROMORPHONE HYDROCHLORIDE,,11/03/2017,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Hydromorphone Hydrochloride Injection,"897745, 1724276",,b325028e-0722-4c8c-9fdb-ab6fb0dc460c,07/23/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,HYDROMORPHONE HYDROCHLORIDE,"0641-0121, 0641-2341",Hikma Pharmaceuticals USA Inc.,65cfa15d-13f8-4848-826a-6eeb4b082932,"0641-0121-21, 0641-0121-25, 0641-2341-39, 0641-2341-41","Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-0121-25)",Injection,Available,,,,HYDROMORPHONE HYDROCHLORIDE,,,Current,,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,01/03/2025,L960UP2KRW,0641-0121-25,800-631-2174,
Eugia US LLC,METHYLPREDNISOLONE ACETATE,,12/15/2021,Revised,"INTRA-ARTICULAR, INTRALESIONAL, INTRAMUSCULAR, SOFT TISSUE",Methylprednisolone Acetate Injection,"1358610, 1358617",,a0cbcdb5-f657-49f7-8f86-cc5959d69db0,09/05/2025,HUMAN PRESCRIPTION DRUG,,Rheumatology,METHYLPREDNISOLONE ACETATE,"55150-314, 55150-313",Eugia US LLC,a0cbcdb5-f657-49f7-8f86-cc5959d69db0,"55150-313-25, 55150-313-01, 55150-314-25, 55150-314-01","Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 55150-314-01)",Injection,Unavailable,,ANDA211930,,METHYLPREDNISOLONE ACETATE,,,Current,Demand increase for the drug,On backorder. Recovery: TBD. Check wholesalers for inventory,,43502P7F0P,55150-314-01,888-238-7880,
Nephron Pharmaceuticals Corporation,ALBUTEROL SULFATE,,10/25/2022,Reverified,RESPIRATORY (INHALATION),Albuterol Sulfate Solution,245314,,ecc00500-58b8-491f-80df-dc6c89a08cae,09/15/2025,HUMAN PRESCRIPTION DRUG,,"Pulmonary/Allergy, Pediatric",ALBUTEROL SULFATE,0487-9901,Nephron Pharmaceuticals Corporation,30dbae21-c906-0624-e063-6394a90a299c,"0487-9901-30, 0487-9901-02","Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 0487-9901-30)",Solution,Available,,ANDA075664,,ALBUTEROL SULFATE,,,Current,Other,"Albuterol 0.5% is in stock, though demand remains high; additional supply can be produced as needed.",,021SEF3731,0487-9901-30,800-443-4313,
"Hikma Pharmaceuticals USA, Inc.",ETOMIDATE,General Anesthesia [PE],10/05/2022,Revised,INTRAVENOUS,Etomidate Injection,"1654006, 1654008",,75bf0494-7cb9-4e8a-8edd-af62f035d236,07/23/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ETOMIDATE,"0143-9507, 0143-9506",Hikma Pharmaceuticals USA Inc.,98560882-bfdf-404e-ab8b-3ee2a6875830,"0143-9506-01, 0143-9506-10, 0143-9507-01, 0143-9507-10","Etomidate, Injection, 2 mg/1 mL (NDC 0143-9507-10)",Injection,Available,"N0000175975, N0000175681",ANDA202354,,ETOMIDATE,General Anesthetic [EPC],,Current,,Currently available.  Additional product will be made available as it is released.,,Z22628B598,0143-9507-10,800-631-2174,
"Teva Pharmaceuticals USA, Inc.","EZETIMIBE, SIMVASTATIN",Decreased Cholesterol Absorption [PE],01/06/2025,New,ORAL,Ezetimibe; Simvastatin Tablet,"476345, 476349, 476350, 476351",,00680bea-d2fb-4362-ba67-e866b732e9ed,01/06/2025,HUMAN PRESCRIPTION DRUG,01/06/2025,Cardiovascular,EZETIMIBE AND SIMVASTATIN,"45963-565, 45963-566, 45963-567, 45963-568","Actavis Pharma, Inc.",bd64aee1-c95f-4767-8d31-af93dd0ab692,"45963-565-30, 45963-565-08, 45963-566-30, 45963-566-08, 45963-567-30, 45963-567-08, 45963-568-30, 45963-568-08","EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 10 mg (NDC 45963-565-30)",Tablet,,"N0000175589, N0000000121, N0000008553, N0000175911",ANDA202968,,EZETIMIBE AND SIMVASTATIN,"HMG-CoA Reductase Inhibitor [EPC], Dietary Cholesterol Absorption Inhibitor [EPC]",,To Be Discontinued,,,,"AGG2FN16EV, EOR26LQQ24",45963-565-30,800-545-8800,Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]
Baxter Healthcare,"CALCIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, SODIUM LACTATE",,10/11/2024,Reverified,INTRAVENOUS,Lactated Ringers Injection,847630,,dad7735c-709b-40ea-ab7a-15577e24a966,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other",LACTATED RINGERS,0338-0117,Baxter Healthcare Company,a3c6770a-d279-4ea9-b8ed-5484be18121e,"0338-0117-02, 0338-0117-03, 0338-0117-04","Lactated Ringers, Injection, 20 mg/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0338-0117-04)",Injection,Available,,NDA016682,,"SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM LACTATE AND CALCIUM CHLORIDE",,,Current,,,,"M4I0D6VV5M, 660YQ98I10, 451W47IQ8X, TU7HW0W0QT",0338-0117-04,888-229-0001,
"Sun Pharmaceutical Industries, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Revised,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856, 1871456, 1871460, 1871462, 1871464, 1871466, 1871468",,da3148af-f9b6-4725-adae-3595b4c7dc4b,09/22/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"57664-048, 57664-047, 57664-046, 57664-049, 57664-050, 57664-051, 57664-052, 57664-083, 57664-084, 57664-085, 57664-086, 57664-087, 57664-088","Sun Pharmaceutical Industries, Inc.",0b77417a-5789-8818-e063-6294a90ad2e3,"57664-047-88, 57664-046-88, 57664-048-88, 57664-049-88, 57664-050-88, 57664-051-88, 57664-052-88, 57664-083-88, 57664-084-88, 57664-085-88, 57664-086-88, 57664-087-88, 57664-088-88","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 57664-048-88)",Capsule,Limited Availability,,ANDA214484,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,Additional supply anticipated early 2026,,SJT761GEGS,57664-048-88,800-818-4555,
"Hikma Pharmaceuticals USA, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,6740a621-9bec-4178-a4fc-a3fc89f34e0a,07/23/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0054-0371, 0054-0660, 0054-0370, 0054-0372, 0054-0373, 0054-0374, 0054-0375",Hikma Pharmaceuticals USA Inc.,5d119550-4386-4bfa-a5d0-bb18e66191b7,"0054-0660-25, 0054-0370-25, 0054-0371-25, 0054-0372-25, 0054-0373-25, 0054-0374-25, 0054-0375-25","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0054-0371-25)",Capsule,Limited Availability,,ANDA202827,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,Available on allocation,,SJT761GEGS,0054-0371-25,800-631-2174,
Baxter Healthcare,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807631, 1807632, 1807633, 1807634, 1807639",,958d35f0-6834-43be-a700-fa58f38b4c19,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0338-9543, 0338-9657, 0338-9659, 0338-9661, 0338-9663",Baxter Healthcare Corporation,6680afa2-1474-4bc3-afee-a333a042fd3f,"0338-9543-01, 0338-9543-02, 0338-9543-03, 0338-9543-04, 0338-9543-05, 0338-9543-06, 0338-9543-12, 0338-9657-75, 0338-9659-75, 0338-9661-60, 0338-9663-60","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-02)",Injection,,,NDA016677,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0338-9543-02,888-229-0001,
Otsuka ICU Medical LLC,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807548, 1807549, 1807550, 1807551, 1807552, 1807627, 1807630, 1807631, 1807632, 1807633, 1807634, 1807639",,5f372b75-d7a4-471e-8ac6-290040fc84b0,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0990-7984, 0990-7730, 0990-7983, 0990-7985",ICU Medical Inc.,87c57bfa-0bf7-41fd-b954-eb753d5d9d7f,"0990-7730-36, 0990-7730-37, 0990-7983-61, 0990-7983-02, 0990-7983-03, 0990-7983-09, 0990-7983-55, 0990-7983-53, 0990-7984-37, 0990-7984-20, 0990-7984-13, 0990-7984-23, 0990-7984-36, 0990-7985-02, 0990-7985-03, 0990-7985-09","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-20)",Injection,,,NDA016366,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0990-7984-20,1-866-829-9025 or ProductAvailability@icumed.com,
"Teva Pharmaceuticals USA, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Revised,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,cffbbb15-d776-41ae-a8a6-687f2c07bfa4,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","0555-0973, 0555-0971, 0555-0775, 0555-0972, 0555-0776, 0555-0777, 0555-0974","Teva Pharmaceuticals USA, Inc.",88468f3d-7d03-4cee-aabf-3abc8c9b5e38,"0555-0971-02, 0555-0775-02, 0555-0972-02, 0555-0776-02, 0555-0777-02, 0555-0973-02, 0555-0974-02","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)",Tablet,Limited Availability,,ANDA040422,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,Other,Estimated recovery: September 2025,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",0555-0973-02,800-545-8800,
Otsuka ICU Medical LLC,DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795477, 1795480, 1795481, 1795607, 1795609, 1795610, 1795612, 1795616, 1795618, 1795621",,8b25b7e0-703e-4b43-a4eb-52863511602d,09/17/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0990-7922, 0990-7923, 0990-7930","ICU Medical, Inc.",09b10612-c937-4d10-becb-9768e10caa2c,"0990-7923-20, 0990-7923-23, 0990-7923-36, 0990-7923-37, 0990-7923-13, 0990-7922-02, 0990-7922-03, 0990-7922-09, 0990-7922-53, 0990-7922-55, 0990-7922-61, 0990-7930-02, 0990-7930-03, 0990-7930-09","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-61)",Injection,Available,,NDA016367,,DEXTROSE MONOHYDRATE,,,Current,,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,LX22YL083G,0990-7922-61,1-866-829-9025 or ProductAvailability@icumed.com,
Baxter Healthcare,DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795609, 1795616",,0bfb32b2-d034-4219-a055-3448f0c424f7,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0338-9143, 0338-9147",Baxter Healthcare Company,539f43d0-ac05-4261-a87d-8b34b07e0dd7,"0338-9147-30, 0338-9143-30","Dextrose 5% In Plastic Container, Injection, 2.5 g/50 mL (NDC 0338-9143-30)",Injection,Available,,NDA020179,,DEXTROSE MONOHYDRATE,,,Current,,,,LX22YL083G,0338-9143-30,888-229-0001,
"Hikma Pharmaceuticals USA, Inc.",DOPAMINE HYDROCHLORIDE,,11/06/2017,Revised,INTRAVENOUS,Dopamine Hydrochloride Injection,"1743938, 1743941, 1743950, 1743953",,0e499952-46c7-4172-8c70-186312e240a3,07/23/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,DOPAMINE HYDROCHLORIDE,"0143-9254, 0143-9252, 0143-9253, 0143-9255",Hikma Pharmaceuticals USA Inc.,67349236-e8e3-45ec-a76d-2a0a150d8d59,"0143-9252-01, 0143-9252-25, 0143-9253-01, 0143-9253-25, 0143-9254-01, 0143-9254-25, 0143-9255-01, 0143-9255-25","Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)",Injection,Unavailable,,ANDA207707,,DOPAMINE HYDROCHLORIDE,,,Current,Demand increase for the drug,Additional lots will be available in the October 2025 timeframe.  Product will be made available as it is released.,,7L3E358N9L,0143-9254-25,800-631-2174,
Aurobindo Pharma USA,AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","308189, 313850",,3cacd754-73f4-496e-a529-9ca39fa6692d,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"65862-070, 65862-071",Aurobindo Pharma Limited,3e3ca279-1838-4348-a01c-df10a8bcb8b9,"65862-070-50, 65862-070-75, 65862-070-01, 65862-071-50, 65862-071-75, 65862-071-01","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 65862-070-75)","Powder, For Suspension",,,ANDA065334,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,65862-070-75,866-850-2876,
Sandoz Inc.,AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","239191, 308182, 308189, 308191, 308192, 308194, 313797, 313850",,13bd4214-9b7f-425b-af5f-fc1ddc678230,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0781-6157, 0781-2020, 0781-2613, 0781-5060, 0781-5061, 0781-6039, 0781-6156, 0781-6041",Sandoz Inc,6aa02079-d11c-4d2f-acaf-9548dd9a7ed6,"0781-2020-31, 0781-2020-76, 0781-2020-01, 0781-2020-05, 0781-2613-31, 0781-2613-76, 0781-2613-01, 0781-2613-05, 0781-5060-20, 0781-5060-01, 0781-5061-20, 0781-5061-01, 0781-6039-58, 0781-6039-46, 0781-6039-55, 0781-6156-52, 0781-6156-57, 0781-6156-46, 0781-6041-58, 0781-6041-46, 0781-6041-55, 0781-6157-52, 0781-6157-57, 0781-6157-46","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0781-6157-52)","Powder, For Suspension",,,ANDA065378,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0781-6157-52,800-525-8747,
"Teva Pharmaceuticals USA, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Revised,ORAL,Lisdexamfetamine Dimesylate Capsule,,,c32b5dce-2de4-4db0-a4ba-d2ce3b0a32fc,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0480-3564, 0480-3565, 0480-3566, 0480-3567, 0480-3568, 0480-3569, 0480-3570","Teva Pharmaceuticals, Inc.",6cfe6c98-51b1-45a4-831c-33624ab129cb,"0480-3565-01, 0480-3566-01, 0480-3567-01, 0480-3568-01, 0480-3569-01, 0480-3570-01, 0480-3564-01","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0480-3564-01)",Capsule,Available,,ANDA202802,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,0480-3564-01,800-545-8800,
Pfizer Inc.,METHYLPREDNISOLONE ACETATE,,12/15/2021,Revised,"INTRALESIONAL, INTRAMUSCULAR, INTRASYNOVIAL, SOFT TISSUE, INTRA-ARTICULAR",Methylprednisolone Acetate Injection,"1743779, 1743781, 1743855, 1743856",,"bf1b104d-85cb-414d-a366-78068c82c883, 9a7b3837-e038-48bf-97e9-78ad463760dc",08/15/2025,HUMAN PRESCRIPTION DRUG,,Rheumatology,DEPO-MEDROL,"0009-3073, 0009-3475",Pharmacia & Upjohn Company LLC,"d7ccf8b4-deb4-43c1-b67b-1f610d6d8425, befd723e-d1e2-41b9-83f1-17bca0c2a941","0009-3073-22, 0009-3073-23, 0009-3475-22, 0009-3475-23, 0009-3073-01, 0009-3073-03, 0009-3475-01, 0009-3475-03","Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03)",Injection,Unavailable,,NDA011757,,METHYLPREDNISOLONE ACETATE,,,Current,Demand increase for the drug,Next Delivery and Estimated Recovery: September 2025,,43502P7F0P,0009-3073-03,844-646-4398,
"Upsher-Smith Laboratories, LLC",POTASSIUM CHLORIDE,,07/23/2025,New,ORAL,"Potassium Chloride Tablet, Extended Release","312529, 628953, 628958, 832718",,1ff53330-065c-4213-9c0c-ac498621d09d,07/23/2025,HUMAN PRESCRIPTION DRUG,07/23/2025,"Endocrinology/Metabolism, Gastroenterology",KLOR-CON,"0245-5316, 0245-5315","Upsher-Smith Laboratories, LLC",39e77e07-bdc8-28e9-e063-6394a90a120c,"0245-5315-11, 0245-5315-15, 0245-5315-89, 0245-5315-01, 0245-5316-11, 0245-5316-15, 0245-5316-89, 0245-5316-01","Klor-Con, Tablet, Extended Release, 750 mg (NDC 0245-5316-11)",Tablet,,,NDA019123,,POTASSIUM CHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug product,,660YQ98I10,0245-5316-11,763-315-2000,
"Upsher-Smith Laboratories, LLC",BACLOFEN,,04/23/2025,New,ORAL,Baclofen Tablet,"197391, 197392",,b2747a9d-5fca-4657-9e4b-4112607f30d8,04/23/2025,HUMAN PRESCRIPTION DRUG,04/23/2025,Neurology,BACLOFEN,"0832-1055, 0832-1054","Upsher-Smith Laboratories, LLC",395d77da-1674-a9a4-e063-6394a90aa3d7,"0832-1054-90, 0832-1054-11, 0832-1054-15, 0832-1054-10, 0832-1055-90, 0832-1055-11, 0832-1055-15, 0832-1055-10","Baclofen, Tablet, 20 mg (NDC 0832-1055-11)",Tablet,,"N0000000196, N0000000116, N0000175759",ANDA074584,,BACLOFEN,gamma-Aminobutyric Acid-ergic Agonist [EPC],,To Be Discontinued,,,,H789N3FKE8,0832-1055-11,716-315-2000,"GABA A Agonists [MoA], GABA B Agonists [MoA]"
"Teva Pharmaceuticals USA, Inc.",CELECOXIB,,08/15/2025,New,ORAL,Celecoxib Capsule,"205322, 205323, 349514, 686379",,05224473-27dc-4f6d-a52a-c40a7af2f2f4,08/15/2025,HUMAN PRESCRIPTION DRUG,08/15/2025,Analgesia/Addiction,CELECOXIB,"0591-3984, 0591-3982, 0591-3983, 0591-3985","Actavis Pharma, Inc.",64c601bc-9b67-400f-9e30-e26de56f2f8b,"0591-3982-60, 0591-3983-01, 0591-3983-05, 0591-3984-01, 0591-3984-05, 0591-3985-60","Celecoxib, Capsule, 200 mg (NDC 0591-3984-01)",Capsule,,"N0000000160, M0001335, N0000175722",ANDA200562,"Anti-Inflammatory Agents, Non-Steroidal [CS]",CELECOXIB,Nonsteroidal Anti-inflammatory Drug [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,JCX84Q7J1L,0591-3984-01,800-545-8800,Cyclooxygenase Inhibitors [MoA]
Eli Lilly and Co.,FLUOXETINE HYDROCHLORIDE,,10/03/2024,New,ORAL,Fluoxetine Hydrochloride Capsule,"104849, 205535, 261287, 310384, 310385, 313989",,c88f33ed-6dfb-4c5e-bc01-d8e36dd97299,10/03/2024,HUMAN PRESCRIPTION DRUG,10/03/2024,Psychiatry,PROZAC,"0777-3104, 0777-3105, 0777-3107",Dista Products Company,d7b3b74e-319e-4360-aa57-af39ccbfb19a,"0777-3104-02, 0777-3105-02, 0777-3105-30, 0777-3107-30","Prozac, Capsule, 10 mg (NDC 0777-3104-02)",Capsule,,,NDA018936,,FLUOXETINE HYDROCHLORIDE,,,To Be Discontinued,,,,I9W7N6B1KJ,0777-3104-02,800-545-5979,
"Noven Pharmaceuticals, Inc.",METHYLPHENIDATE,Central Nervous System Stimulation [PE],02/28/2025,Reverified,TRANSDERMAL,"Methylphenidate Film, Extended Release",,,2c312c31-3198-4775-91ab-294e0b4b9e7f,08/19/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,DAYTRANA,"68968-5553, 68968-5552, 68968-5554, 68968-5555","Noven Therapeutics, LLC",55f4b5f4-6d3c-4677-a94c-d47ffb59a91a,"68968-5552-3, 68968-5553-3, 68968-5554-3, 68968-5555-3","Daytrana, Film, Extended Release, 15 mg (NDC 68968-5553-3)","Film, Extended Release",Unavailable,"N0000175739, N0000175729",NDA021514,,METHYLPHENIDATE,Central Nervous System Stimulant [EPC],,Current,Shortage of an active ingredient,Estimated availability TBD,,207ZZ9QZ49,68968-5553-3,800-455-8070,
"Prinston Pharmaceutical, Inc.",CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,4acbb7a9-4db5-4497-b8db-9f358b3f6fb4,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"43547-407, 43547-406, 43547-408",Solco Healthcare LLC,dc17b9d4-2890-4f6c-8476-daa39d0cbc9c,"43547-406-10, 43547-406-50, 43547-406-11, 43547-407-10, 43547-407-50, 43547-407-11, 43547-408-10, 43547-408-50","Clonazepam, Tablet, 1 mg (NDC 43547-407-10)",Tablet,Available,"N0000175694, M0002356",ANDA077856,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,Marketed by Solco Healthcare,,5PE9FDE8GB,43547-407-10,"For orders, Solco Healthcare 866-931-9829",
Chartwell Molecular Holdings LLC,FLURAZEPAM HYDROCHLORIDE,,08/03/2022,Reverified,ORAL,Flurazepam Hydrochloride Capsule,"1298088, 1298091",,8f476891-1346-4e8c-ac1b-f8cbdc64f5a1,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Other",FLURAZEPAM HYDROCHLORIDE,"62135-737, 62135-736","Chartwell RX, LLC",25893c92-c8f1-567a-e063-6294a90a00d4,"62135-736-30, 62135-736-90, 62135-737-30, 62135-737-90","Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-30)",Capsule,Available,,ANDA072369,,FLURAZEPAM HYDROCHLORIDE,,,Current,,,,756RDM536M,62135-737-30,845-268-5000 Ext. 510,
Kindos Pharmaceuticals Co. Ltd.,LEUCOVORIN CALCIUM,,01/01/2012,Revised,"INTRAMUSCULAR, INTRAVENOUS",Leucovorin Calcium Injection,"237788, 1803930, 1803932, 1803937, 2055036",,9df20901-6980-4d4e-89ec-40f3c1f91852,07/08/2025,HUMAN PRESCRIPTION DRUG,,"Oncology, Pediatric",LEUCOVORIN CALCIUM,"71288-160, 71288-161, 71288-162, 71288-163, 71288-164",Meitheal Pharmaceuticals Inc.,077a459b-e884-4452-aed3-0857a38ce26f,"71288-160-10, 71288-161-20, 71288-162-30, 71288-163-30, 71288-164-50","Leucovorin Calcium, Injection, 50 mg/5 mL (NDC 71288-160-10)",Injection,,,ANDA216590,,LEUCOVORIN CALCIUM,,Available,Resolved,,,07/08/2025,RPR1R4C0P4,71288-160-10,"Meitheal Pharmaceuticals, Inc.: 844-824-8426",
"Upsher-Smith Laboratories, LLC",POTASSIUM CHLORIDE,,07/23/2025,New,ORAL,"Potassium Chloride Tablet, Extended Release","312529, 628953, 628958, 832718",,1ff53330-065c-4213-9c0c-ac498621d09d,07/23/2025,HUMAN PRESCRIPTION DRUG,07/23/2025,"Endocrinology/Metabolism, Gastroenterology",KLOR-CON,"0245-5315, 0245-5316","Upsher-Smith Laboratories, LLC",39e77e07-bdc8-28e9-e063-6394a90a120c,"0245-5315-11, 0245-5315-15, 0245-5315-89, 0245-5315-01, 0245-5316-11, 0245-5316-15, 0245-5316-89, 0245-5316-01","Klor-Con, Tablet, Extended Release, 600 mg (NDC 0245-5315-15)",Tablet,,,NDA019123,,POTASSIUM CHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug product,,660YQ98I10,0245-5315-15,763-315-2000,
Pfizer Inc.,,,01/30/2025,New,,Ramipril Capsule,,,,01/30/2025,,01/30/2025,Cardiovascular,,,,,,"Altace, Capsule, 2.5 mg (NDC 61570-111-01)",Capsule,,,,,,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,,61570-111-01,844-646-4398,
InfoRLife SA,ROPIVACAINE HYDROCHLORIDE,,03/27/2018,Reverified,"EPIDURAL, INFILTRATION",Ropivacaine Hydrochloride Injection,"1734347, 1734355, 1734479, 1734481",,"8c5c762f-d266-4b1a-809e-f11bfc89bc2d, 9572b3de-684c-4028-a577-5aa69ba6b02d",08/26/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROPIVACAINE HYDROCHLORIDE,"25021-671, 25021-652",Sagent Pharmaceuticals,"04d1b1c6-1963-4b42-8479-dbf787b6de17, 2eb59cb8-dab8-43f4-ad73-672446e104ca","25021-671-82, 25021-671-87, 25021-652-82, 25021-652-87, 25021-671-66, 25021-671-67","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-82)",Injection,Available,,ANDA206166,,ROPIVACAINE HYDROCHLORIDE,,,Current,,Marketed by Sagent Pharmaceuticals,,V910P86109,25021-671-82,Sagent: 866-625-1618,
"Medefil, Inc.",SODIUM CHLORIDE,,08/02/2018,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Sodium Chloride 0.9% Injection,727820,,d1468c0f-dd4f-4d38-a84c-c1d110303965,08/08/2025,HUMAN PRESCRIPTION DRUG,,Other,SODIUM CHLORIDE,64253-202,"Medefil, Inc.",12dde6de-967e-cb5e-e063-6294a90acede,64253-202-30,"Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 64253-202-30)",Injection,,,NDA202832,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,64253-202-30,630-682-4600,
Pfizer Inc.,TAFAMIDIS MEGLUMINE,,09/29/2025,New,ORAL,Tafamidis Meglumine Capsule,"2168534, 2168540, 2168542, 2168548",,1b4121ee-a733-4456-a917-be2603477839,09/29/2025,HUMAN PRESCRIPTION DRUG,09/29/2025,Cardiovascular,VYNDAQEL,"0069-1975, 0069-8730",Pfizer Laboratories Div Pfizer Inc,9485b5fb-0676-4783-9668-4c076b01c497,"0069-1975-12, 0069-1975-40, 0069-8730-01, 0069-8730-30","Vyndaqel, Capsule, 20 mg soft gelatin capsules; blister card (120 total capsules) (NDC 0069-1975-40)",Capsule,,,NDA211996,,TAFAMIDIS MEGLUMINE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug.,,"8FG9H9D31J, ZU7CF08A1A",0069-1975-40,800-879-3477,
"Fresenius Kabi USA, LLC",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,"EPIDURAL, INTRACAUDAL, PERINEURAL, INFILTRATION",Bupivacaine Hydrochloride Injection,"1724880, 1724881, 1725078, 1725175, 1724884, 1724885, 1725082, 1725177, 1672917, 1672919, 1673296, 1673298, 1012391, 1012396, 1012404, 1012421, 1012455, 1012457",,"e700eb7b-8b14-49c9-96b2-331f18776e45, b6bfc04a-1868-4630-9ca1-8c027af97ce3, dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175, eb6d8fee-def4-4c96-9972-695e8cea8ea8",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,SENSORCAINE MPF,"63323-466, 63323-464, 63323-462, 63323-465, 63323-467, 63323-460","Fresenius Kabi USA, LLC","b41b5dbd-7aff-4d97-ac97-f4355393ee4e, d3ba9fb9-63c8-4597-bb0a-cd01d31a24b6, 13a48007-3784-46f2-bd4d-da1004186b81, 2b1a1f80-cb29-4ac1-9e72-20225ed45715","63323-464-01, 63323-464-17, 63323-466-03, 63323-466-17, 63323-464-08, 63323-464-38, 63323-466-08, 63323-466-38, 63323-462-03, 63323-462-38, 63323-464-09, 63323-464-39, 63323-466-09, 63323-466-39, 63323-465-01, 63323-465-57, 63323-467-01, 63323-467-57, 63323-460-01, 63323-460-37, 63323-464-02, 63323-464-37, 63323-464-03, 63323-464-31, 63323-466-01, 63323-466-37, 63323-466-02, 63323-466-31, 63323-462-04, 63323-462-17, 63323-462-01, 63323-462-37, 63323-462-02, 63323-462-31","Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-17)",Injection,Available,,"ANDA070553, NDA018304",,BUPIVACAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,"7TQO7W3VT8, 30Q7KI53AK",63323-466-17,888-386-1300,
Baxter Healthcare,"ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, PROLINE, SERINE, THREONINE, TRYPTOPHAN, TYROSINE, VALINE",,12/08/2020,Reverified,INTRAVENOUS,Amino Acid Injection,"800584, 800588",,65ffc962-7538-41ea-9afb-4af5fbce4c5b,09/23/2025,HUMAN PRESCRIPTION DRUG,,Gastroenterology,CLINISOL,0338-0502,Baxter Healthcare Corporation,7eab93b5-5590-4381-8674-113a05edeff0,"0338-0502-03, 0338-0502-06","Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)",Injection,Available,"N0000175780, M0000922",ANDA020512,Amino Acids [CS],"LYSINE, LEUCINE, PHENYLALANINE, VALINE, HISTIDINE, ISOLEUCINE, METHIONINE, THREONINE, TRYPTOPHAN, ALANINE, ARGININE, GLYCINE, PROLINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID, TYROSINE",Amino Acid [EPC],,Current,,,,"OF5P57N2ZX, 94ZLA3W45F, 30KYC7MIAI, 3KX376GY7L, TE7660XO1C, 4QD397987E, 04Y7590D77, GMW67QNF9C, TTL6G7LIWZ, AE28F7PNPL, 47E5O17Y3R, 9DLQ4CIU6V, 452VLY9402, 2ZD004190S, 8DUH1N11BX, 42HK56048U, HG18B9YRS7",0338-0502-06,888-229-0001,
"Upsher-Smith Laboratories, LLC",DIVALPROEX SODIUM,,04/28/2025,New,ORAL,"Divalproex Sodium Tablet, Delayed Release","1099625, 1099678, 1099870",,02304a23-4a5f-47bc-9687-4044b43f7a20,04/28/2025,HUMAN PRESCRIPTION DRUG,04/28/2025,Neurology,DIVALPROEX SODIUM,"0832-7124, 0832-7122, 0832-7123","Upsher-Smith Laboratories, LLC",38e51a59-5802-77a6-e063-6394a90af6c6,"0832-7122-11, 0832-7122-15, 0832-7123-11, 0832-7123-15, 0832-7123-89, 0832-7123-01, 0832-7124-11, 0832-7124-15, 0832-7124-89, 0832-7124-01","Divalproex Sodium, Tablet, Delayed Release, 500 mg (NDC 0832-7124-01)",Tablet,,,ANDA078182,,DIVALPROEX SODIUM,,,To Be Discontinued,,Discontinuation of manufacture of drug based on business decision.,,644VL95AO6,0832-7124-01,800-654-2299,
Chartwell Molecular Holdings LLC,FLURAZEPAM HYDROCHLORIDE,,08/03/2022,Reverified,ORAL,Flurazepam Hydrochloride Capsule,"1298088, 1298091",,8f476891-1346-4e8c-ac1b-f8cbdc64f5a1,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Other",FLURAZEPAM HYDROCHLORIDE,"62135-737, 62135-736","Chartwell RX, LLC",25893c92-c8f1-567a-e063-6294a90a00d4,"62135-736-30, 62135-736-90, 62135-737-30, 62135-737-90","Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-90)",Capsule,Available,,ANDA072369,,FLURAZEPAM HYDROCHLORIDE,,,Current,,,,756RDM536M,62135-737-90,845-268-5000 Ext. 510,
B. Braun Medical Inc.,HEPARIN SODIUM,,11/14/2017,Reverified,INTRAVENOUS,Heparin Sodium Injection,"1658690, 1658692",,a3041c04-0ea8-4d36-81ce-c5091c906316,09/16/2025,HUMAN PRESCRIPTION DRUG,,Hematology,HEPARIN SODIUM IN SODIUM CHLORIDE,0264-9872,B. Braun Medical Inc.,48e17807-e73d-4ea2-81bc-901355903aa7,"0264-9872-10, 0264-9872-00","Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)",Injection,Available,,NDA019953,,HEPARIN SODIUM IN SODIUM CHLORIDE,,,Current,,,,ZZ45AB24CA,0264-9872-00,800-227-2862,
"Novo Nordisk, Inc.",LIRAGLUTIDE,,07/18/2023,Reverified,SUBCUTANEOUS,Liraglutide Injection,"897122, 897126",,5a9ef4ea-c76a-4d34-a604-27c5b505f5a4,09/16/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,VICTOZA,0169-4060,Novo Nordisk,e11a497a-578e-4b29-b546-3d65d451966d,"0169-4060-13, 0169-4060-12, 0169-4060-90, 0169-4060-97, 0169-4060-98, 0169-4060-99","Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)",Injection,Limited Availability,"N0000178480, M0160181, N0000020058",NDA022341,Glucagon-Like Peptide 1 [CS],LIRAGLUTIDE,GLP-1 Receptor Agonist [EPC],,Current,Delay in shipping of the drug,Estimated shortage duration TBD,,839I73S42A,0169-4060-13,833-493-4689,Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
Fresenius Medical Care North America,SODIUM CHLORIDE,,06/10/2025,New,INTRAVENOUS,Sodium Chloride 0.9% Injection,1807639,,af5cdf1a-19f4-11e2-892e-0800200c9a66,06/10/2025,HUMAN PRESCRIPTION DRUG,06/10/2025,"Gastroenterology, Renal",SODIUM CHLORIDE,49230-300,Fresenius Medical Care North America,26587576-d68d-4c98-e063-6394a90ac53d,49230-300-10,"Sodium Chloride 0.9% in Plastic Container, Injection, 900 mg/100 mL (NDC 49230-300-10)",Injection,,,ANDA078177,,SODIUM CHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,451W47IQ8X,49230-300-10,800-323-5188,
"Rising Pharma Holdings, Inc.",CROMOLYN SODIUM,,11/03/2023,Revised,ORAL,Cromolyn Sodium Concentrate,831261,,61c9cb85-129e-4490-b5f7-357307fcecbf,08/15/2025,HUMAN PRESCRIPTION DRUG,,Pulmonary/Allergy,CROMOLYN SODIUM,16571-600,"Rising Pharma Holdings, Inc.",ca2c72ae-db00-4694-9fd0-d4b6b45f8108,16571-600-96,"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 16571-600-96)",Concentrate,Available,,ANDA202583,,CROMOLYN SODIUM,,,Current,,,,Q2WXR1I0PK,16571-600-96,(201) 961-9000 or contact@risingpharma.com,
Sun Pharmaceutical Industries Limited,DIGOXIN,,12/05/2024,New,ORAL,Digoxin Tablet,"197604, 197606",,62795623-a2bc-4dd2-8989-3b9782bfd80e,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Cardiovascular,DIGOXIN,"57664-437, 57664-441","Sun Pharmaceutical Industries, Inc.",1a3e469c-1452-3d1e-e063-6394a90ae73a,"57664-437-88, 57664-437-18, 57664-441-88, 57664-441-18","Digoxin, Tablet, 125 ug (NDC 57664-437-88)",Tablet,,"N0000175568, M0003451",ANDA076363,Cardiac Glycosides [CS],DIGOXIN,Cardiac Glycoside [EPC],,To Be Discontinued,,Discontinuing for business reasons,,73K4184T59,57664-437-88,800-818-4555,
Guerbet LLC,SODIUM CHLORIDE,,06/21/2018,Revised,INTRAVASCULAR,Sodium Chloride 0.9% Injection,,,e4540d03-06b4-4b4d-b859-75c13e5c20dd,08/08/2025,HUMAN PRESCRIPTION DRUG,,Other,SODIUM CHLORIDE,0019-1188,Liebel-Flarsheim Company LLC,cdff7813-7b00-4f61-a017-18ab8910d49d,"0019-1188-81, 0019-1188-27","Sodium Chloride 0.9% In Plastic Container, Injection, .9 mg/1 mL (NDC 0019-1188-81)",Injection,,,NDA021569,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0019-1188-81,877-729-6679,
Pfizer Inc.,DOCETAXEL ANHYDROUS,Microtubule Inhibition [PE],01/15/2025,New,INTRAVENOUS,Docetaxel Injection,1093280,,644c5035-20d2-4686-beaa-bef08e99051c,01/15/2025,HUMAN PRESCRIPTION DRUG,01/15/2025,Oncology,DOCETAXEL,"0409-1732, 0409-7870","Hospira, Inc.",5b12d54f-e7fd-4369-afb3-431f6f08ec76,"0409-7870-01, 0409-1732-01","Docetaxel, Injection, 10 mg/1 mL (NDC 0409-1732-01)",Injection,,"N0000175085, N0000175592",NDA022234,,DOCETAXEL ANHYDROUS,Microtubule Inhibitor [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,699121PHCA,0409-1732-01,844-646-4398,
Torrent Pharma Inc.,"AMLODIPINE, HYDROCHLOROTHIAZIDE, OLMESARTAN MEDOXOMIL",Increased Diuresis [PE],06/13/2025,New,ORAL,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,"999967, 999986, 999991, 999996, 1000001",,85b8f9c6-aa53-4aa1-85d6-19f823d0d252,06/13/2025,HUMAN PRESCRIPTION DRUG,06/13/2025,Cardiovascular,"OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE 20/5/12.5 MG","13668-397, 13668-386, 13668-385, 13668-383, 13668-382",Torrent Pharmaceuticals Limited,5bedf6c6-6b23-40e7-8c96-2cedcc682973,"13668-397-30, 13668-397-90, 13668-397-05, 13668-386-30, 13668-386-90, 13668-386-05, 13668-385-30, 13668-385-90, 13668-385-05, 13668-383-30, 13668-383-90, 13668-383-05, 13668-382-30, 13668-382-90, 13668-382-05","Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 20 mg (NDC 13668-397-90)",Tablet,,"N0000175359, N0000175419, M0471776, N0000000069, N0000175421, N0000175566, M0006414, N0000190114",ANDA203580,"Thiazides [CS], Dihydropyridines [CS]","OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE TABLET 20/5/12.5 MG","Thiazide Diuretic [EPC], Dihydropyridine Calcium Channel Blocker [EPC], Calcium Channel Blocker [EPC]",,To Be Discontinued,,A business decision was made to discontinue manufacture of the product.,,"0J48LPH2TH, 1J444QC288, 6M97XTV3HD",13668-397-90,908-280-3333,"Calcium Channel Antagonists [MoA], Cytochrome P450 3A Inhibitors [MoA]"
"Hospira, Inc., a Pfizer Company",ETOMIDATE,General Anesthesia [PE],10/05/2022,Reverified,INTRAVENOUS,Etomidate Injection,"1654006, 1654008, 1654009, 1654011",,b7ed5bf8-ba75-44dc-8f81-96b4ad5766be,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,AMIDATE,0409-6695,"Hospira, Inc.",b59f4852-2843-4a8f-a597-306ebddb259a,"0409-6695-11, 0409-6695-01, 0409-6695-12, 0409-6695-02","Amidate, Injection, 2 mg/1 mL (NDC 0409-6695-01)",Injection,Available,"N0000175975, N0000175681",NDA018227,,ETOMIDATE,General Anesthetic [EPC],,Current,,,,Z22628B598,0409-6695-01,844-646-4398,
"Fresenius Kabi USA, LLC",FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Furosemide Injection,"1719286, 1719290, 1719291",,"3747bbcd-783d-4baa-bb5b-b6827bf390e3, c794c95a-654e-48fe-9596-201fc122ff75",09/18/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,63323-280,"Fresenius Kabi USA, LLC","9804efac-5457-417a-8de7-a688467759c0, 64b3fb5f-3516-4e39-b74e-e0e402ed9c4d","63323-280-41, 63323-280-16, 63323-280-43, 63323-280-26, 63323-280-45, 63323-280-36, 63323-280-01, 63323-280-02, 63323-280-03, 63323-280-04, 63323-280-05, 63323-280-10","Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-10)",Injection,Available,"N0000175366, N0000175590",NDA018902,,FUROSEMIDE,Loop Diuretic [EPC],,Current,,Check wholesalers for inventory,,7LXU5N7ZO5,63323-280-10,888-386-1300,
Gland Pharma Limited,,,03/23/2018,Reverified,,Ketorolac Tromethamine Injection,,,,09/29/2025,,,Analgesia/Addiction,,,,,,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 70860-701-04)",Injection,Available,,,,,,,Current,Other,"Athenex is not active, supplying through Sagent NDC 25021-701-02",,,70860-701-04,833-291-9645,
"Fresenius Kabi USA, LLC",LIDOCAINE HYDROCHLORIDE ANHYDROUS,,02/22/2012,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010035, 1010671, 1010673, 1010688, 1010692, 1010745, 1010749, 1010751, 1010755, 1010759, 1010763, 1010900, 1010902, 1737343, 1737345, 1737562, 1737563, 1737566, 1737567, 1737568, 1737569, 1737570, 1737571, 1737757, 1737758, 1737761, 1737762, 1867938, 1867940, 1867943, 1867944, 1867992, 1867993, 1867996, 1867997, 1868028, 1868029, 1737636, 1737637, 1737640, 1737641, 1737763, 1737764",,"ba082c2f-64f4-419d-9c88-74f203316e17, 4dd52202-8eef-4136-92dd-ada573b7cf74, d5e0d06f-ba1e-44d4-aa89-39d6c146dc23",09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",XYLOCAINE MPF,"63323-492, 63323-491, 63323-495, 63323-485, 63323-486, 63323-484, 63323-489, 63323-488, 63323-481, 63323-483, 63323-482, 63323-487, 63323-493, 63323-496","Fresenius Kabi USA, LLC","ea480a68-5927-4278-9deb-2956961da428, 0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33, fa12a8e8-09fd-496f-8cc6-ffe0eb02e2df","63323-492-04, 63323-492-27, 63323-492-09, 63323-492-57, 63323-492-07, 63323-492-37, 63323-492-03, 63323-492-31, 63323-491-01, 63323-491-57, 63323-495-09, 63323-495-27, 63323-495-04, 63323-495-07, 63323-485-01, 63323-485-27, 63323-485-03, 63323-485-57, 63323-486-01, 63323-486-17, 63323-486-02, 63323-486-27, 63323-486-05, 63323-486-57, 63323-484-57, 63323-489-02, 63323-489-27, 63323-489-03, 63323-489-21, 63323-489-01, 63323-489-17, 63323-488-07, 63323-488-37, 63323-488-03, 63323-488-31, 63323-488-01, 63323-488-17, 63323-481-01, 63323-481-57, 63323-483-03, 63323-483-27, 63323-483-01, 63323-483-57, 63323-482-01, 63323-482-17, 63323-482-03, 63323-482-27, 63323-482-05, 63323-482-57, 63323-487-01, 63323-487-17, 63323-487-07, 63323-487-37, 63323-487-03, 63323-487-31, 63323-492-41, 63323-492-16, 63323-492-43, 63323-492-36, 63323-492-45, 63323-492-26, 63323-485-41, 63323-485-26, 63323-486-41, 63323-486-26, 63323-482-41, 63323-482-26, 63323-495-41, 63323-495-26, 63323-492-08, 63323-492-97, 63323-493-03, 63323-493-97, 63323-493-01, 63323-493-91, 63323-496-03, 63323-496-97","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-31)",Injection,Unavailable,,NDA006488,,LIDOCAINE HYDROCHLORIDE,,,Current,Demand increase for the drug,Next release not available at this time.,,"EC2CNF7XFP, 30Q7KI53AK",63323-492-31,888-386-1300,
Organon,MONTELUKAST SODIUM,,03/24/2025,New,ORAL,Montelukast Sodium Granule,"153892, 153893, 200224, 242438, 261367, 311759, 351246, 404406",,482dcc92-b47f-4ea6-854a-f5ac2aea7842,03/24/2025,HUMAN PRESCRIPTION DRUG,03/24/2025,Pulmonary/Allergy,SINGULAIR,"78206-171, 78206-170, 78206-173, 78206-172",Organon LLC,57a12189-3bb3-4a5d-b5fe-fc57db87c134,"78206-171-01, 78206-170-01, 78206-173-01, 78206-172-01, 78206-172-02","Singulair, Granule, 4 mg (NDC 78206-171-01)",Granule,,,NDA021409,,MONTELUKAST SODIUM,,,To Be Discontinued,,,,U1O3J18SFL,78206-171-01,844-674-3200,
"Hikma Pharmaceuticals USA, Inc.",MORPHINE SULFATE,,11/03/2017,Reverified,"EPIDURAL, INTRATHECAL",Morphine Sulfate Injection,"892652, 1731522, 1731998, 1731999",,db9ac9e3-d761-4a99-9f34-4946ebe8f255,07/23/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,INFUMORPH 500,"0641-6040, 0641-6039",Hikma Pharmaceuticals USA Inc.,cd3674c8-d894-4dcf-8044-7a1198ed8ed9,"0641-6039-01, 0641-6040-01","Infumorph 500 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 25 mg/1 mL (NDC 0641-6040-01)",Injection,Available,,NDA018565,,MORPHINE SULFATE,,,Current,,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,X3P646A2J0,0641-6040-01,800-631-2174,
"Prinston Pharmaceutical, Inc.",CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,4acbb7a9-4db5-4497-b8db-9f358b3f6fb4,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"43547-406, 43547-407, 43547-408",Solco Healthcare LLC,dc17b9d4-2890-4f6c-8476-daa39d0cbc9c,"43547-406-10, 43547-406-50, 43547-406-11, 43547-407-10, 43547-407-50, 43547-407-11, 43547-408-10, 43547-408-50","Clonazepam, Tablet, .5 mg (NDC 43547-406-50)",Tablet,Available,"N0000175694, M0002356",ANDA077856,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,Marketed by Solco Healthcare,,5PE9FDE8GB,43547-406-50,"For orders, Solco Healthcare 866-931-9829",
Aurobindo Pharma USA,AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","308189, 313850",,3cacd754-73f4-496e-a529-9ca39fa6692d,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"65862-071, 65862-070",Aurobindo Pharma Limited,3e3ca279-1838-4348-a01c-df10a8bcb8b9,"65862-070-50, 65862-070-75, 65862-070-01, 65862-071-50, 65862-071-75, 65862-071-01","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 65862-071-01)","Powder, For Suspension",,,ANDA065334,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,65862-071-01,866-850-2876,
"Teva Pharmaceuticals USA, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Revised,ORAL,Lisdexamfetamine Dimesylate Capsule,,,c32b5dce-2de4-4db0-a4ba-d2ce3b0a32fc,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0480-3567, 0480-3565, 0480-3566, 0480-3568, 0480-3569, 0480-3570, 0480-3564","Teva Pharmaceuticals, Inc.",6cfe6c98-51b1-45a4-831c-33624ab129cb,"0480-3565-01, 0480-3566-01, 0480-3567-01, 0480-3568-01, 0480-3569-01, 0480-3570-01, 0480-3564-01","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0480-3567-01)",Capsule,Available,,ANDA202802,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,0480-3567-01,800-545-8800,
Pfizer Inc.,METHYLPREDNISOLONE ACETATE,,12/15/2021,Reverified,"INTRALESIONAL, INTRAMUSCULAR, INTRASYNOVIAL, SOFT TISSUE",Methylprednisolone Acetate Injection,"1358510, 1358512, 1358610, 1358612, 1358617, 1358619",,823b0010-2b57-4e76-b5ac-4a8c2963438f,08/15/2025,HUMAN PRESCRIPTION DRUG,,Rheumatology,DEPO-MEDROL,"0009-0280, 0009-0274, 0009-0306",Pharmacia & Upjohn Company LLC,4cf5a255-1360-4511-9b58-b92e3492ef12,"0009-0274-01, 0009-0280-02, 0009-0280-51, 0009-0280-03, 0009-0280-52, 0009-0306-02, 0009-0306-12","Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-52)",Injection,Available,,NDA011757,,METHYLPREDNISOLONE ACETATE,,,Current,,,,43502P7F0P,0009-0280-52,844-646-4398,
"Epic Pharma, LLC",RIFAMPIN,,12/22/2021,Reverified,ORAL,Rifampin Capsule,"198201, 198202",,0391f1e1-70d4-4b15-8b58-055bb6a385b8,09/18/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,RIFAMPIN,"42806-799, 42806-801","EPIC PHARMA, LLC",a4ac02e8-68ac-4e79-8ca5-0939dd002c87,"42806-801-30, 42806-801-01, 42806-799-30, 42806-799-60, 42806-799-01, 42806-799-05","Rifampin, Capsule, 300 mg (NDC 42806-799-30)",Capsule,Unavailable,"N0000175500, M0019113",ANDA064150,Rifamycins [CS],RIFAMPIN,Rifamycin Antibacterial [EPC],,Current,Discontinuation of the manufacture of the drug,Discontinuation of the manufacture of the drug.,,VJT6J7R4TR,42806-799-30,(718) 276-8600 ext. 3,
"Hikma Pharmaceuticals USA, Inc.",AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","308189, 313850",,d46f1091-33dc-4f8f-9c34-75dcfedb4b4c,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0143-9886, 0143-9887",Hikma Pharmaceuticals USA Inc.,606474e1-adba-4ffa-83d5-6565fc12c892,"0143-9886-01, 0143-9886-50, 0143-9886-75, 0143-9887-01, 0143-9887-50, 0143-9887-75","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0143-9886-01)","Powder, For Suspension",,,ANDA065325,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0143-9886-01,800-631-2174,
"Hospira, Inc., a Pfizer Company",SODIUM CHLORIDE,,12/08/2021,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Sodium Chloride 0.9% Injection,313002,,376093e7-e09e-4a57-3199-195e45251866,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",BACTERIOSTATIC SODIUM CHLORIDE,0409-1966,"Hospira, Inc.",2d3125e0-c89b-46d5-a350-07d1e7936ebd,"0409-1966-02, 0409-1966-07, 0409-1966-06, 0409-1966-12, 0409-1966-01, 0409-1966-05","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-1966-07)",Injection,,,NDA018800,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0409-1966-07,844-646-4398,
"Teva Pharmaceuticals USA, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Revised,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,cffbbb15-d776-41ae-a8a6-687f2c07bfa4,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","0555-0971, 0555-0775, 0555-0972, 0555-0776, 0555-0777, 0555-0973, 0555-0974","Teva Pharmaceuticals USA, Inc.",88468f3d-7d03-4cee-aabf-3abc8c9b5e38,"0555-0971-02, 0555-0775-02, 0555-0972-02, 0555-0776-02, 0555-0777-02, 0555-0973-02, 0555-0974-02","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0555-0971-02)",Tablet,Available,,ANDA040422,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",0555-0971-02,800-545-8800,
Sagent Pharmaceuticals,BUMETANIDE,Increased Diuresis at Loop of Henle [PE],01/31/2018,New,"INTRAMUSCULAR, INTRAVENOUS",Bumetanide Injection,"282486, 1727569",,c38a404d-a919-4a2c-9fbb-d0655dee9516,08/25/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,BUMETANIDE,25021-321,Sagent Pharmaceuticals,befc1cf3-b71c-4228-bc42-3495b1d4b00d,"25021-321-04, 25021-321-10","Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-10)",Injection,Available,"N0000175366, N0000175590",ANDA074441,,BUMETANIDE,Loop Diuretic [EPC],,Current,,,,0Y2S3XUQ5H,25021-321-10,866-625-1618,
"Fresenius Kabi USA, LLC",DEXAMETHASONE SODIUM PHOSPHATE,,02/08/2019,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Dexamethasone Sodium Phosphate Injection,"1116927, 1812194",,"2b626a48-c7aa-4443-9164-a08ff069ccd1, 4fedef4f-ec96-4f36-b2f0-01e243e3b89e",09/18/2025,HUMAN PRESCRIPTION DRUG,,"Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Other, Pulmonary/Allergy, Rheumatology",DEXAMETHASONE SODIUM PHOSPHATE,63323-165,"Fresenius Kabi USA, LLC","a832bff9-0bb3-4350-abb5-d57b9417070c, 9dd90418-e564-4bc5-9077-506a1c2c1bce","63323-165-11, 63323-165-51, 63323-165-13, 63323-165-53, 63323-165-02, 63323-165-01, 63323-165-03, 63323-165-05, 63323-165-30, 63323-165-16, 63323-165-26","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-05)",Injection,Available,,ANDA084916,,DEXAMETHASONE SODIUM PHOSPHATE,,,Current,,Check wholesalers for inventory.,,AI9376Y64P,63323-165-05,888-386-1300,
Strides Pharma Inc.,DONEPEZIL HYDROCHLORIDE,,01/28/2025,New,ORAL,Donepezil Hydrochloride Tablet,"997223, 997229",,297e86e8-d248-4cc9-9d9c-2ef9efb4414d,01/28/2025,HUMAN PRESCRIPTION DRUG,01/28/2025,Neurology,DONEPEZIL HYDROCHLORIDE,"71093-128, 71093-127","ACI Healthcare USA, Inc.",a4736add-da84-411f-8e6f-9de67bf467f8,"71093-127-01, 71093-127-03, 71093-127-05, 71093-127-06, 71093-128-01, 71093-128-03, 71093-128-05, 71093-128-06","Donepezil Hydrochloride, Tablet, 10 mg (NDC 71093-128-01)",Tablet,,,ANDA078662,,DONEPEZIL HYDROCHLORIDE,,,To Be Discontinued,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,3O2T2PJ89D,71093-128-01,877-244-9825,
"Upsher-Smith Laboratories, LLC",FLUPHENAZINE HYDROCHLORIDE,,09/18/2025,New,ORAL,Fluphenazine Hydrochloride Tablet,"859841, 860918, 865117, 865123",,f07bb3f1-c68c-441b-9de4-99a219f2500a,09/18/2025,HUMAN PRESCRIPTION DRUG,09/18/2025,"Neurology, Psychiatry",FLUPHENAZINE HYDROCHLORIDE,"0832-6004, 0832-6003, 0832-6005, 0832-6006","Upsher-Smith Laboratories,LLC",3bb74f82-8872-9829-e063-6294a90aeace,"0832-6004-11, 0832-6003-11, 0832-6005-11, 0832-6006-11","Fluphenazine Hydrochloride, Tablet, 2.5 mg (NDC 0832-6004-11)",Tablet,,,ANDA213784,,FLUPHENAZINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug.,,ZOU145W1XL,0832-6004-11,763-315-2000,
"Fresenius Kabi USA, LLC",LIDOCAINE HYDROCHLORIDE,,02/22/2012,Reverified,"INFILTRATION, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1737757",,cddb2b22-fce3-8967-6e54-dca3df5ac4b3,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE,"63323-201, 63323-202","Fresenius Kabi USA, LLC",d19c26f4-1214-40f7-9680-43c885613306,"63323-201-01, 63323-201-02, 63323-201-03, 63323-201-10, 63323-202-01, 63323-202-02","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-201-10)",Injection,Available,,ANDA088586,,LIDOCAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,V13007Z41A,63323-201-10,888-386-1300,
Oryza Pharmaceuticals Inc.,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Revised,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 1009145",,acd27181-a3f3-4c38-85d8-029a4a82e7c2,09/16/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","72516-011, 72516-016, 72516-015, 72516-014, 72516-013, 72516-012",Oryza Pharmaceuticals Inc.,39fb17a2-617d-37dc-e063-6394a90a1be3,"72516-016-01, 72516-015-01, 72516-014-01, 72516-013-01, 72516-012-01, 72516-011-01","Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 72516-011-01)",Tablet,Unavailable,,ANDA210293,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,Shortage of an active ingredient,Estimated availability October 2025,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",72516-011-01,855-257-0292,
Accord Healthcare Inc.,FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Revised,"INTRAMUSCULAR, INTRAVENOUS",Furosemide Injection,"1719286, 1719290, 1719291",,f6f64972-714c-4ee9-8a5e-9ffcab41a73b,09/16/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,"16729-502, 16729-500, 16729-501","Accord Healthcare, Inc.",1cfab300-d796-6a68-e063-6394a90a73f9,"16729-500-30, 16729-500-08, 16729-501-64, 16729-501-43, 16729-502-03, 16729-502-43","Furosemide, Injection, 10 mg/1 mL (NDC 16729-502-43)",Injection,Unavailable,"N0000175366, N0000175590",ANDA070017,,FUROSEMIDE,Loop Diuretic [EPC],,Current,Requirements related to complying with good manufacturing practices,Unavailable,,7LXU5N7ZO5,16729-502-43,866-941-7875,
Gland Pharma Limited,,,03/23/2018,Reverified,,Ketorolac Tromethamine Injection,,,,09/29/2025,,,Analgesia/Addiction,,,,,,"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 70860-701-03)",Injection,Available,,,,,,,Current,Other,"Athenex is not active, supplying through Sagent NDC 25021-701-01",,,70860-701-03,833-291-9645,
Milla Pharmaceuticals,,,02/03/2016,Revised,,Sodium Acetate Injection,,,,09/16/2025,,,"Endocrinology/Metabolism, Gastroenterology, Pediatric, Total Parenteral Nutrition",,,,,,"Sodium Acetate, Injection, 400 mEq/100mL (4 mEq/mL) (NDC 69784-232-01)",Injection,Limited Availability,,,,,,,Current,Other,Limited Availability,,,69784-232-01,833-251-8463,
"Hikma Pharmaceuticals USA, Inc.",ETOMIDATE,General Anesthesia [PE],10/05/2022,Revised,INTRAVENOUS,Etomidate Injection,"1654006, 1654008",,75bf0494-7cb9-4e8a-8edd-af62f035d236,07/23/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ETOMIDATE,"0143-9506, 0143-9507",Hikma Pharmaceuticals USA Inc.,98560882-bfdf-404e-ab8b-3ee2a6875830,"0143-9506-01, 0143-9506-10, 0143-9507-01, 0143-9507-10","Etomidate, Injection, 2 mg/1 mL (NDC 0143-9506-10)",Injection,Unavailable,"N0000175975, N0000175681",ANDA202354,,ETOMIDATE,General Anesthetic [EPC],,Current,Demand increase for the drug,Additional lots will be available in the October 2025 timeframe.  Product will be made available as it is released.,,Z22628B598,0143-9506-10,800-631-2174,
"Mylan Pharmaceuticals Inc., a Viatris Company",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,efbde0f6-b848-4664-b741-c6c630e66108,09/17/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0378-6856, 0378-6854, 0378-6855, 0378-6857, 0378-6858, 0378-6859, 0378-6860",Mylan Pharmaceuticals Inc.,2dfa8600-1b2a-47e8-b58d-c9681b8795cb,"0378-6854-77, 0378-6855-77, 0378-6856-77, 0378-6857-77, 0378-6858-77, 0378-6859-77, 0378-6860-77","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0378-6856-77)",Capsule,Available,,ANDA202835,,LISDEXAMFETAMINE,,,Current,,,,SJT761GEGS,0378-6856-77,800-796-9526,
"Upsher-Smith Laboratories, LLC",PROPAFENONE HYDROCHLORIDE,,05/14/2025,New,ORAL,"Propafenone Hydrochloride Capsule, Extended Release","861156, 861164, 861171",,8aa6f58a-2980-4caa-9c54-d55d69d5d132,05/14/2025,HUMAN PRESCRIPTION DRUG,05/14/2025,Cardiovascular,PROPAFENONE HYDROCHLORIDE,"0832-0740, 0832-0741, 0832-0742","Upsher-Smith Laboratories, LLC",398513af-dd95-49eb-e063-6394a90a73f4,"0832-0740-60, 0832-0741-60, 0832-0742-60","Propafenone Hydrochloride, Capsule, Extended Release, 225 mg (NDC 0832-0740-60)","Capsule, Extended Release",,,ANDA212744,,PROPAFENONE HYDROCHLORIDE,,,To Be Discontinued,,A business decision was made to discontinue the product.,,33XCH0HOCD,0832-0740-60,800-654-2299,
"Mylan Institutional, a Viatris Company",REMIFENTANIL HYDROCHLORIDE,,06/28/2022,Reverified,INTRAVENOUS,Remifentanil Hydrochloride Injection,"1729578, 1729581, 1729584, 1729586, 1729710, 1729712",,8b4c8696-e23e-4c51-a4d2-babab5bd945a,09/17/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,ULTIVA,"72078-036, 72078-034, 72078-035",Mylan Institutional LLC,c10cf43f-066a-43ff-9166-242cbb7754af,"72078-034-00, 72078-034-01, 72078-035-00, 72078-035-02, 72078-036-00, 72078-036-05","Ultiva, Injection, 5 mg (NDC 72078-036-05)",Injection,Available,,NDA020630,,REMIFENTANIL HYDROCHLORIDE,,,Current,,,,5V444H5WIC,72078-036-05,800-796-9526,
B. Braun Medical Inc.,SODIUM CHLORIDE,,04/28/2023,Revised,IRRIGATION,Sodium Chloride 0.9% Irrigation,486515,,0d59a04a-32e6-485b-b638-a1e6c09e9642,07/02/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,0264-2201,B. Braun Medical Inc.,35e26a6d-60d6-4388-84e9-c481a3b69ee7,"0264-2201-00, 0264-2201-10, 0264-2201-50, 0264-2201-70","Sodium Chloride 0.9%, Irrigation, .9 g/100mL (NDC 0264-2201-10)",Irrigation,,,NDA016733,,SODIUM CHLORIDE,,Available,Resolved,,,07/02/2025,451W47IQ8X,0264-2201-10,800-227-2862,
Apotex Corp.,,,01/28/2025,New,,Teriflunomide Tablet,,,,01/28/2025,,01/28/2025,Neurology,,,,,,"Teriflunomide, Tablet, 7 mg (NDC 60505-4477-3)",Tablet,,,,,,,,To Be Discontinued,,,,,60505-4477-3,800-706-5575,
Baxter Healthcare,DEXTROSE MONOHYDRATE,,10/11/2024,Reverified,INTRAVENOUS,Dextrose Monohydrate 70% Injection,237656,,0332f34a-7038-47cc-ba59-d55cad6b73ca,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,0338-0719,Baxter Healthcare Corporation,aa64f648-e931-4a99-9b81-791a3827272c,0338-0719-06,"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0338-0719-06)",Injection,Available,,NDA020047,,DEXTROSE MONOHYDRATE,,,Current,,,,LX22YL083G,0338-0719-06,888-229-0001,
"Novo Nordisk, Inc.",LIRAGLUTIDE,,07/18/2023,Reverified,SUBCUTANEOUS,Liraglutide Injection,"897122, 897126",,5a9ef4ea-c76a-4d34-a604-27c5b505f5a4,09/16/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,VICTOZA,0169-4060,Novo Nordisk,e11a497a-578e-4b29-b546-3d65d451966d,"0169-4060-13, 0169-4060-12, 0169-4060-90, 0169-4060-97, 0169-4060-98, 0169-4060-99","Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)",Injection,Limited Availability,"N0000178480, M0160181, N0000020058",NDA022341,Glucagon-Like Peptide 1 [CS],LIRAGLUTIDE,GLP-1 Receptor Agonist [EPC],,Current,Delay in shipping of the drug,Estimated shortage duration TBD,,839I73S42A,0169-4060-12,833-493-4689,Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
"Mylan Pharmaceuticals Inc., a Viatris Company",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,efbde0f6-b848-4664-b741-c6c630e66108,09/17/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0378-6857, 0378-6854, 0378-6855, 0378-6856, 0378-6858, 0378-6859, 0378-6860",Mylan Pharmaceuticals Inc.,2dfa8600-1b2a-47e8-b58d-c9681b8795cb,"0378-6854-77, 0378-6855-77, 0378-6856-77, 0378-6857-77, 0378-6858-77, 0378-6859-77, 0378-6860-77","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0378-6857-77)",Capsule,Available,,ANDA202835,,LISDEXAMFETAMINE,,,Current,,,,SJT761GEGS,0378-6857-77,800-796-9526,
Aurobindo Pharma USA,"HYDROCHLOROTHIAZIDE, QUINAPRIL HYDROCHLORIDE",Increased Diuresis [PE],01/19/2023,Reverified,ORAL,Quinapril/Hydrochlorothiazide Tablet,"310796, 310797, 310809",,50a58159-9572-4445-9859-b392632597da,09/17/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE,"65862-162, 65862-161, 65862-163",Aurobindo Pharma Limited,5842ecc2-874a-481b-8997-afa9d862dc5d,"65862-161-90, 65862-162-30, 65862-162-90, 65862-163-90","Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 65862-162-90)",Tablet,Discontinued,"N0000175359, N0000175419, M0471776",ANDA078450,Thiazides [CS],QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE,Thiazide Diuretic [EPC],,Current,Discontinuation of the manufacture of the drug,,,"0J48LPH2TH, 33067B3N2M",65862-162-90,866-850-2876,
"Somerset Therapeutics, LLC",ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Reverified,"EPIDURAL, INFILTRATION, PERINEURAL",Ropivacaine Hydrochloride Injection,"905189, 1734084, 1734090, 1734203, 1734207, 1734475, 1734483",,ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64,08/19/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROPIVACAINE HYDROCHLORIDE,"70069-064, 70069-061, 70069-062, 70069-063, 70069-065, 70069-066, 70069-067","Somerset Therapeutics, LLC",5d7b0e44-19ce-4127-b3e8-d7e6e65f1818,"70069-061-01, 70069-061-25, 70069-061-10, 70069-062-01, 70069-062-25, 70069-062-10, 70069-063-01, 70069-063-25, 70069-064-01, 70069-064-10, 70069-064-25, 70069-065-01, 70069-065-25, 70069-066-01, 70069-066-25, 70069-066-10, 70069-067-01, 70069-067-25, 70069-067-10","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-10)",Injection,Available,,ANDA207636,,ROPIVACAINE HYDROCHLORIDE,,,Current,,,,V910P86109,70069-064-10,732-554-1019,
"Upsher-Smith Laboratories, LLC",BACLOFEN,,04/23/2025,New,ORAL,Baclofen Tablet,"197391, 197392",,b2747a9d-5fca-4657-9e4b-4112607f30d8,04/23/2025,HUMAN PRESCRIPTION DRUG,04/23/2025,Neurology,BACLOFEN,"0832-1055, 0832-1054","Upsher-Smith Laboratories, LLC",395d77da-1674-a9a4-e063-6394a90aa3d7,"0832-1054-90, 0832-1054-11, 0832-1054-15, 0832-1054-10, 0832-1055-90, 0832-1055-11, 0832-1055-15, 0832-1055-10","Baclofen, Tablet, 20 mg (NDC 0832-1055-15)",Tablet,,"N0000000196, N0000000116, N0000175759",ANDA074584,,BACLOFEN,gamma-Aminobutyric Acid-ergic Agonist [EPC],,To Be Discontinued,,,,H789N3FKE8,0832-1055-15,716-315-2000,"GABA A Agonists [MoA], GABA B Agonists [MoA]"
"Somerset Therapeutics, LLC",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,"INFILTRATION, PERINEURAL",Bupivacaine Hydrochloride Injection,"1012396, 1012404",,bcaab86f-20f0-4482-8d73-e29b36dced58,08/19/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE,"70069-752, 70069-753","Somerset Therapeutics, LLC",2b24af95-6f20-4945-bf8c-742f1d6f2721,"70069-752-25, 70069-752-10, 70069-752-01, 70069-753-25, 70069-753-01, 70069-753-10","Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-25)",Injection,Available,,ANDA217792,,BUPIVACAINE HYDROCHLORIDE,,,Current,,,,7TQO7W3VT8,70069-752-25,732-554-1037,
Sun Pharmaceutical Industries Limited,IMATINIB MESYLATE,,12/05/2024,New,ORAL,Imatinib Mesylate Tablet,"403878, 403879",,07764bf9-21b4-4e32-9d7e-e348f8e4291f,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Hematology,IMATINIB MESYLATE,"47335-475, 47335-472","Sun Pharmaceutical Industries, Inc.",ad13dbca-474d-4492-9c25-e0e175143d8c,"47335-472-83, 47335-472-88, 47335-472-13, 47335-472-81, 47335-475-83, 47335-475-88, 47335-475-13, 47335-475-64","Imatinib Mesylate, Tablet, 400 mg (NDC 47335-475-13)",Tablet,,,ANDA078340,,IMATINIB MESYLATE,,,To Be Discontinued,,Discontinuing for business reasons,,8A1O1M485B,47335-475-13,800-818-4555,
Novadaq Technologies,,,08/23/2024,Revised,,Indocyanine Green Injection,,,,08/26/2025,,,"Medical Imaging, Ophthalmology, Other",,,,,,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-937-16)",Injection,,,,,,,Available,Resolved,,,08/26/2025,,66259-937-16,800-624-4422,
Accord Healthcare Inc.,MITOMYCIN,,01/17/2025,New,INTRAVENOUS,Mitomycin Injection,"1740894, 1740898, 1740900",,ff676355-313d-4575-8f2f-e4a1e9527477,01/17/2025,HUMAN PRESCRIPTION DRUG,01/17/2025,Anti-Infective,MITOMYCIN,"16729-108, 16729-116, 16729-115","Accord Healthcare, Inc.",3363b2a9-5d4f-d921-e063-6294a90a7fbb,"16729-116-38, 16729-108-11, 16729-115-05","Mitomycin, Injection, 20 mg/40 mL (NDC 16729-108-11)",Injection,,"N0000000236, N0000175558",ANDA064144,,MITOMYCIN,Alkylating Drug [EPC],,To Be Discontinued,,Permanent discontinuation in the manufacturing of the drug.,,50SG953SK6,16729-108-11,866-941-7875,Alkylating Activity [MoA]
"Hospira, Inc., a Pfizer Company",SODIUM CHLORIDE,,06/21/2018,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Sodium Chloride 0.9% Injection,"1807628, 1807631, 1807637, 1807638",,8eb172da-dcd4-4660-4a8f-ad44a14b4af7,08/08/2025,HUMAN PRESCRIPTION DRUG,,Other,SODIUM CHLORIDE,"0409-4888, 0409-1918","Hospira, Inc.",9ee88abb-024a-4a3b-9776-1777eaf2f760,"0409-4888-02, 0409-4888-10, 0409-4888-03, 0409-4888-20, 0409-4888-06, 0409-4888-50, 0409-4888-01, 0409-4888-12, 0409-4888-90, 0409-1918-42, 0409-1918-32, 0409-1918-43, 0409-1918-33, 0409-1918-45, 0409-1918-35","Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-4888-10)",Injection,,,NDA018803,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0409-4888-10,844-646-4398,
"ICU Medical, Inc.",SODIUM CHLORIDE,,04/28/2023,Revised,IRRIGATION,Sodium Chloride 0.9% Irrigation,486515,,3cfdeee0-ff14-4341-8396-b11c2a037c60,07/02/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0990-7138, 0990-6138, 0990-7972",ICU Medical Inc.,9ceb78f6-0be4-4dbb-9fd0-9728b5ad5c7b,"0990-7138-09, 0990-7138-36, 0990-6138-22, 0990-6138-03, 0990-7972-05, 0990-7972-07","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0990-7138-09)",Irrigation,,,NDA017514,,SODIUM CHLORIDE,,Available,Resolved,,,07/02/2025,451W47IQ8X,0990-7138-09,1-866-829-9025 or ProductAvailability@icumed.com,
"American Regent, Inc.",ATROPINE SULFATE,,01/01/2012,Reverified,INTRAVENOUS,Atropine Sulfate Injection,"1190795, 1666781",,6fee1727-52b7-4f73-ab45-ef47d6a1c5bb,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology, Pediatric",ATROPINE SULFATE,"0517-1004, 0517-1001","American Regent, Inc.",1c500ed9-94a9-472c-bfb7-50e1fcfc31fb,"0517-1004-01, 0517-1004-25, 0517-1001-01, 0517-1001-25","Atropine Sulfate, Injection, .4 mg/1 mL (NDC 0517-1004-25)",Injection,Available,,ANDA216120,,ATROPINE SULFATE,,,Current,,old NDC 0517-0401-25,,03J5ZE7KA5,0517-1004-25,800-645-1706,
"Upsher-Smith Laboratories, LLC",AMANTADINE HYDROCHLORIDE,,07/23/2025,New,ORAL,Amantadine Hydrochloride Tablet,849395,,63d9d4aa-5f92-45b0-98d0-d6ec38b727cb,07/23/2025,HUMAN PRESCRIPTION DRUG,07/23/2025,"Antiviral, Neurology",AMANTADINE HYDROCHLORIDE,0832-0111,"Upsher-Smith Laboratories, LLC",395d9ef2-7ea2-c602-e063-6394a90a6ef0,"0832-0111-00, 0832-0111-50, 0832-0111-89, 0832-0111-03","Amantadine Hydrochloride, Tablet, 100 mg (NDC 0832-0111-50)",Tablet,,,ANDA076186,,AMANTADINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug product,,M6Q1EO9TD0,0832-0111-50,763-315-2000,
"Prinston Pharmaceutical, Inc.",CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,4acbb7a9-4db5-4497-b8db-9f358b3f6fb4,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"43547-406, 43547-407, 43547-408",Solco Healthcare LLC,dc17b9d4-2890-4f6c-8476-daa39d0cbc9c,"43547-406-10, 43547-406-50, 43547-406-11, 43547-407-10, 43547-407-50, 43547-407-11, 43547-408-10, 43547-408-50","Clonazepam, Tablet, .5 mg (NDC 43547-406-11)",Tablet,Available,"N0000175694, M0002356",ANDA077856,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,Marketed by Solco Healthcare,,5PE9FDE8GB,43547-406-11,"For orders, Solco Healthcare 866-931-9829",
"Fresenius Kabi USA, LLC",LIDOCAINE HYDROCHLORIDE ANHYDROUS,,02/22/2012,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Lidocaine Hydrochloride Injection,"1737562, 1737563, 1737566, 1737567, 1737568, 1737569, 1737570, 1737571, 1737636, 1737637, 1737640, 1737641, 1737763, 1737764",,d5e0d06f-ba1e-44d4-aa89-39d6c146dc23,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",XYLOCAINE MPF,"63323-493, 63323-492, 63323-496","Fresenius Kabi USA, LLC",fa12a8e8-09fd-496f-8cc6-ffe0eb02e2df,"63323-492-08, 63323-492-97, 63323-493-03, 63323-493-97, 63323-493-01, 63323-493-91, 63323-496-03, 63323-496-97","Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-91)",Injection,Unavailable,,NDA006488,,LIDOCAINE HYDROCHLORIDE,,,Current,Demand increase for the drug,Next release not available at this time.,,EC2CNF7XFP,63323-493-91,888-386-1300,
Amneal Pharmaceuticals,METHYLPREDNISOLONE ACETATE,,12/15/2021,Reverified,"INTRA-ARTICULAR, INTRALESIONAL, INTRAMUSCULAR, SOFT TISSUE",Methylprednisolone Acetate Injection,"1743779, 1743855",,d944240d-2c19-46ba-ad4f-3fbee7b8629c,09/17/2025,HUMAN PRESCRIPTION DRUG,,Rheumatology,METHYLPREDNISOLONE ACETATE,"70121-1574, 70121-1573",Amneal Pharmaceuticals LLC,0bdaa3cf-cf32-4959-b87a-65215ac4648d,"70121-1573-1, 70121-1573-5, 70121-1574-1, 70121-1574-5","Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-5)",Injection,Available,,ANDA210043,,METHYLPREDNISOLONE ACETATE,,,Current,,,,43502P7F0P,70121-1574-5,866-525-7270,
Pfizer Inc.,METHYLPREDNISOLONE SODIUM SUCCINATE,,10/10/2024,New,"INTRAMUSCULAR, INTRAVENOUS",Methylprednisolone Sodium Succinate Injection,"207191, 207193, 311659, 314099, 1357886, 1357888, 1743704, 1743707, 1743720, 1743722, 1743726, 1743729",,"cd99be87-c8d9-48d6-a8e5-e081052e3f19, 7271310c-7764-4812-aa30-a5e90987c7a9",10/10/2024,HUMAN PRESCRIPTION DRUG,10/10/2024,Rheumatology,SOLU-MEDROL,"0009-0698, 0009-0758, 0009-0039, 0009-0047, 0009-0003, 0009-0018, 0009-0850",Pharmacia & Upjohn Company LLC,"7b47ae23-e487-4679-95c9-561052ecc1a1, 7ab2f4a2-6651-49e8-bc69-0c9c65e38cef","0009-0758-01, 0009-0698-01, 0009-0039-30, 0009-0039-28, 0009-0039-33, 0009-0039-32, 0009-0047-25, 0009-0047-22, 0009-0047-27, 0009-0047-26, 0009-0003-02, 0009-0018-20, 0009-0850-01, 0009-0698-02, 0009-0039-06, 0009-0047-04","Solu-Medrol, Injection, 1 g/1 mL (NDC 0009-0698-02)",Injection,,,NDA011856,,METHYLPREDNISOLONE SODIUM SUCCINATE,,,To Be Discontinued,,,,LEC9GKY20K,0009-0698-02,844-646-4398,
Baxter Healthcare,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807631, 1807632, 1807633, 1807634, 1807639",,958d35f0-6834-43be-a700-fa58f38b4c19,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0338-9543, 0338-9657, 0338-9659, 0338-9661, 0338-9663",Baxter Healthcare Corporation,6680afa2-1474-4bc3-afee-a333a042fd3f,"0338-9543-01, 0338-9543-02, 0338-9543-03, 0338-9543-04, 0338-9543-05, 0338-9543-06, 0338-9543-12, 0338-9657-75, 0338-9659-75, 0338-9661-60, 0338-9663-60","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-04)",Injection,,,NDA016677,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0338-9543-04,888-229-0001,
Aurobindo Pharma USA,"AMLODIPINE BESYLATE, BENAZEPRIL HYDROCHLORIDE",,03/04/2025,New,ORAL,Amlodipine Besylate; Benazepril Hydrochloride Capsule,"898342, 898346, 898350, 898353, 898356, 898359",,99ed4927-9a34-4e8d-8eea-60b63c867d46,03/04/2025,HUMAN PRESCRIPTION DRUG,03/04/2025,Cardiovascular,AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE,"65862-585, 65862-582, 65862-583, 65862-584, 65862-586, 65862-587",Aurobindo Pharma Limited,a45ec3e8-1d14-4c27-9685-976323df8cad,"65862-582-01, 65862-582-05, 65862-583-01, 65862-583-05, 65862-584-01, 65862-584-05, 65862-585-01, 65862-585-05, 65862-586-01, 65862-586-05, 65862-587-01, 65862-587-05","Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 40 mg (NDC 65862-585-05)",Capsule,,,ANDA202239,,AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE,,,To Be Discontinued,,,,"864V2Q084H, N1SN99T69T",65862-585-05,866-850-2876,
"Hospira, Inc., a Pfizer Company",METHOTREXATE SODIUM,,01/08/2025,New,"INTRAMUSCULAR, INTRATHECAL, INTRAVENOUS, SUBCUTANEOUS",Methotrexate Sodium Injection,"1655956, 1946772",,bd287e89-32f9-4396-95fa-4b562869f476,01/08/2025,HUMAN PRESCRIPTION DRUG,01/08/2025,"Oncology, Rheumatology",METHOTREXATE,"61703-161, 61703-124","Hospira, Inc.",6bb8643f-6ab4-4e1c-bcf9-b82e8cf18910,"61703-124-40, 61703-161-02, 61703-161-05","Injection, 25 mg/1 mL (NDC 61703-161-05)",Injection,,,NDA011719,,METHOTREXATE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,3IG1E710ZN,61703-161-05,844-646-4398,
"Hikma Pharmaceuticals USA, Inc.",MIDAZOLAM HYDROCHLORIDE,,04/02/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Midazolam Hydrochloride Injection,"311700, 311702",,575d8bf0-7af7-427c-a231-966e2a5e070d,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology",MIDAZOLAM,"0641-6060, 0641-6057, 0641-6059, 0641-6056, 0641-6061, 0641-6063",Hikma Pharmaceuticals USA Inc.,559c03fb-24ea-4b7b-8afd-e33cb3a2340a,"0641-6057-01, 0641-6057-10, 0641-6057-25, 0641-6059-01, 0641-6059-10, 0641-6056-01, 0641-6056-10, 0641-6061-01, 0641-6061-10, 0641-6061-25, 0641-6063-01, 0641-6063-10, 0641-6063-25, 0641-6060-01, 0641-6060-10","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6060-10)",Injection,Available,,ANDA075243,,MIDAZOLAM,,,Current,,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,W7TTW573JJ,0641-6060-10,800-631-2174,
"Teva Pharmaceuticals USA, Inc.",,,01/06/2025,New,,Cisatracurium Besylate Injection,,,,01/06/2025,,01/06/2025,Anesthesia,,,,,,"CISATRACURIUM BESYLATE PRESERVATIVE FREE, Injection, 200 mg/20 mL (NDC 0703-2045-03)",Injection,,,,,,,,To Be Discontinued,,,,,0703-2045-03,800-545-8800,
Pfizer Inc.,CLINDAMYCIN PHOSPHATE,,03/21/2023,Revised,"INTRAMUSCULAR, INTRAVENOUS",Clindamycin Phosphate Injection,"205964, 309335, 309336, 309339, 685574, 685576, 685578, 706461, 1737244, 1737245, 1737578, 1737579, 1737581, 1737582",,05a75685-0af5-407c-ac57-e380c882b49d,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,CLEOCIN PHOSPHATE,"0009-0775, 0009-0870, 0009-0902, 0009-0728, 0009-3124, 0009-3447, 0009-3381, 0009-3375, 0009-3382, 0009-6582",Pharmacia & Upjohn Company LLC,ac3ba828-3240-4b06-8741-5d1b58e313da,"0009-0870-21, 0009-0870-26, 0009-0775-20, 0009-0775-26, 0009-0902-11, 0009-0902-18, 0009-0728-05, 0009-0728-09, 0009-3124-01, 0009-3124-03, 0009-3447-01, 0009-3447-03, 0009-3381-01, 0009-3381-02, 0009-3375-01, 0009-3375-02, 0009-3382-01, 0009-3382-02, 0009-6582-02, 0009-6582-01","Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26)",Injection,Unavailable,,NDA050441,,CLINDAMYCIN PHOSPHATE,,,Current,Other,Next Delivery and Estimated Recovery: December 2025,,EH6D7113I8,0009-0775-26,800-533-4535,
"Hospira, Inc., a Pfizer Company",DOBUTAMINE HYDROCHLORIDE,,11/06/2017,Revised,INTRAVENOUS,Dobutamine Hydrochloride Injection,"309985, 309986, 309987",,9943a961-3b50-4847-8a84-d8414ce38daa,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Cardiovascular, Pediatric, Renal",DOBUTAMINE IN DEXTROSE,"0409-2347, 0409-2346, 0409-3724","Hospira, Inc.",2cd41f69-c1ea-44a0-9b56-b6f9d963f6a5,"0409-2347-31, 0409-2347-32, 0409-2346-31, 0409-2346-32, 0409-3724-11, 0409-3724-32","Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-2347-32)",Injection,Unavailable,,NDA020201,,DOBUTAMINE IN DEXTROSE,,,Current,Demand increase for the drug,Next Delivery: November 2025; Estimated Recovery: December 2025,12/19/2024,0WR771DJXV,0409-2347-32,844-646-4398,
"Teva Pharmaceuticals USA, Inc.","ETHINYL ESTRADIOL, ETONOGESTREL",,06/16/2025,New,VAGINAL,Ethinyl Estradiol; Etonogestrel Ring,1367436,,a8cc104a-d522-49ad-af54-2f312b829b61,06/16/2025,HUMAN PRESCRIPTION DRUG,06/16/2025,Reproductive,ETONOGESTREL AND ETHINYL ESTRADIOL,0093-7679,"Teva Pharmaceuticals USA, Inc.",d0827dbf-9df5-4438-a0c2-92d7d593e71c,"0093-7679-01, 0093-7679-02","Ethinyl Estradiol; Etonogestrel, Ring, .015 mg/1 d; .12 mg/1 d (NDC 0093-7679-02)",Ring,,"N0000175825, N0000000100, M0447349, N0000175602",ANDA204305,Progesterone Congeners [CS],ETONOGESTREL AND ETHINYL ESTRADIOL,"Estrogen [EPC], Progestin [EPC]",,To Be Discontinued,,Discontinuation of the manufacture of the drug,,"423D2T571U, 304GTH6RNH",0093-7679-02,800-545-8800,Estrogen Receptor Agonists [MoA]
"Fresenius Kabi USA, LLC",LEUCOVORIN CALCIUM,,03/23/2018,Revised,"INTRAMUSCULAR, INTRAVENOUS",Leucovorin Calcium Injection,"2099993, 2104714",,"d5d4f0fd-7520-43a9-9acc-f7e117e1f6ee, 4b72d1fd-f389-45d9-b43b-510b45c92263",07/08/2025,HUMAN PRESCRIPTION DRUG,,"Oncology, Pediatric",LEUCOVORIN CALCIUM,63323-631,"Fresenius Kabi USA, LLC","d1c72e5d-c25e-4b9c-b3dc-a8d0b746db3f, a0d41f71-6197-4c9a-8cd2-217945cb722b","63323-631-10, 63323-631-50","Leucovorin Calcium, Injection, 10 mg/1 mL (NDC 63323-631-50)",Injection,,,"ANDA207241, ANDA207226",,LEUCOVORIN CALCIUM,,Available,Resolved,,,07/08/2025,RPR1R4C0P4,63323-631-50,888-386-1300,
Baxter Healthcare,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807631, 1807632",,aeaed9cb-b629-4019-88d2-a916179427de,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0338-9159, 0338-9151",Baxter Healthcare Corporation,39f15dfb-4e73-4959-ad9b-4ee502278b4b,"0338-9159-30, 0338-9151-30","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0338-9159-30)",Injection,,,NDA020178,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0338-9159-30,888-229-0001,
"Teva Pharmaceuticals USA, Inc.",,,01/06/2025,New,,Cisatracurium Besylate Injection,,,,01/06/2025,,01/06/2025,Anesthesia,,,,,,"Injection, 20 mg/10 mL (NDC 0703-2056-03)",Injection,,,,,,,,To Be Discontinued,,,,,0703-2056-03,800-545-8800,
Aurobindo Pharma USA,"AMLODIPINE BESYLATE, BENAZEPRIL HYDROCHLORIDE",,03/04/2025,New,ORAL,Amlodipine Besylate; Benazepril Hydrochloride Capsule,"898342, 898346, 898350, 898353, 898356, 898359",,99ed4927-9a34-4e8d-8eea-60b63c867d46,03/04/2025,HUMAN PRESCRIPTION DRUG,03/04/2025,Cardiovascular,AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE,"65862-587, 65862-582, 65862-583, 65862-584, 65862-585, 65862-586",Aurobindo Pharma Limited,a45ec3e8-1d14-4c27-9685-976323df8cad,"65862-582-01, 65862-582-05, 65862-583-01, 65862-583-05, 65862-584-01, 65862-584-05, 65862-585-01, 65862-585-05, 65862-586-01, 65862-586-05, 65862-587-01, 65862-587-05","Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 10 mg; 40 mg (NDC 65862-587-01)",Capsule,,,ANDA202239,,AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE,,,To Be Discontinued,,,,"864V2Q084H, N1SN99T69T",65862-587-01,866-850-2876,
"Hospira, Inc., a Pfizer Company",DOBUTAMINE HYDROCHLORIDE,,11/06/2017,Revised,INTRAVENOUS,Dobutamine Hydrochloride Injection,"309985, 309986, 309987",,9943a961-3b50-4847-8a84-d8414ce38daa,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Cardiovascular, Pediatric, Renal",DOBUTAMINE IN DEXTROSE,"0409-3724, 0409-2347, 0409-2346","Hospira, Inc.",2cd41f69-c1ea-44a0-9b56-b6f9d963f6a5,"0409-2347-31, 0409-2347-32, 0409-2346-31, 0409-2346-32, 0409-3724-11, 0409-3724-32","Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-3724-32)",Injection,Unavailable,,NDA020201,,DOBUTAMINE IN DEXTROSE,,,Current,Demand increase for the drug,Next Delivery: November 2025; Estimated Recovery: December 2025,12/19/2024,0WR771DJXV,0409-3724-32,844-646-4398,
"Hospira, Inc., a Pfizer Company",LIDOCAINE HYDROCHLORIDE,,02/22/2012,Reverified,"INFILTRATION, INTRAVENOUS",Lidocaine Hydrochloride Injection,"1010033, 1010671, 1010900, 1737343, 1737562, 1737566, 1737568, 1737636, 1737757, 1737763",,3b2dd84e-cee8-4e58-d494-395a65a353a0,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE HYDROCHLORIDE,"0409-4278, 0409-4713, 0409-4279, 0409-4776, 0409-4282, 0409-4277, 0409-4276, 0409-4275","Hospira, Inc.",c0b4635b-1473-4c48-89c6-620762cd687f,"0409-4713-12, 0409-4713-26, 0409-4713-02, 0409-4713-72, 0409-4713-62, 0409-4713-75, 0409-4713-65, 0409-4713-42, 0409-4713-25, 0409-4713-32, 0409-4278-16, 0409-4278-01, 0409-4279-16, 0409-4279-02, 0409-4776-10, 0409-4776-01, 0409-4282-11, 0409-4282-25, 0409-4282-01, 0409-4282-12, 0409-4282-02, 0409-4277-16, 0409-4277-01, 0409-4277-17, 0409-4277-02, 0409-4276-16, 0409-4276-01, 0409-4276-17, 0409-4276-02, 0409-4275-16, 0409-4275-01","Lidocaine Hydrochloride, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4278-01)",Injection,Available,,ANDA088328,,LIDOCAINE HYDROCHLORIDE,,,Current,,,,V13007Z41A,0409-4278-01,844-646-4398,
Granules Pharmaceuticals Inc.,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,b0b4eccc-34c7-483d-966f-82d588358e1b,09/08/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","70010-112, 70010-111, 70010-113, 70010-114, 70010-115, 70010-116, 70010-117",Granules Pharmaceuticals Inc.,2fab399e-2a43-5134-e063-6294a90ae09a,"70010-111-01, 70010-111-03, 70010-112-01, 70010-112-03, 70010-113-01, 70010-113-03, 70010-114-01, 70010-114-03, 70010-115-01, 70010-115-03, 70010-116-01, 70010-116-03, 70010-117-01, 70010-117-03","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 70010-112-01)",Tablet,Available,,ANDA215771,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",70010-112-01,877-770-3183,
"Sun Pharmaceutical Industries, Inc.",NALTREXONE HYDROCHLORIDE,,02/29/2024,Revised,ORAL,Naltrexone Hydrochloride Tablet,1483744,,0f30f885-d0cd-4fa6-a8e0-142f08a56792,09/22/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,NALTREXONE HYDROCHLORIDE,47335-326,"Sun Pharmaceutical Industries, Inc.",b0c2b60a-dc96-483b-933e-2fed58b64372,"47335-326-83, 47335-326-88, 47335-326-08, 47335-326-18","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 47335-326-83)",Tablet,Limited Availability,,ANDA090356,,NALTREXONE HYDROCHLORIDE,,,Current,Other,Additional supply anticipated early 2026,,Z6375YW9SF,47335-326-83,800-818-4555,
"Spectra Medical Devices, LLC",SODIUM CHLORIDE,,06/21/2018,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Sodium Chloride 0.9% Injection,"1807637, 1807646",,7e316d21-d6ad-4976-bd90-268fd7e51361,08/08/2025,HUMAN PRESCRIPTION DRUG,,Other,SODIUM CHLORIDE,"65282-1505, 65282-1510","Spectra Medical Deviecs, LLC",0e649488-3951-382e-e063-6294a90a55c1,"65282-1510-1, 65282-1505-1","Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 65282-1505-1)",Injection,,,ANDA206171,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,65282-1505-1,978-657-0889,
GlaxoSmithKline,DAPRODUSTAT,,11/21/2024,New,ORAL,Daprodustat Tablet,"2628215, 2628221, 2628223, 2628225, 2628227, 2628229, 2628231, 2628233, 2628235, 2628237",,d82aa06e-5a33-4844-99b7-4701313455a4,11/21/2024,HUMAN PRESCRIPTION DRUG,11/21/2024,Hematology,JESDUVROQ,"0173-0906, 0173-0897, 0173-0903, 0173-0911, 0173-0914",GlaxoSmithKline LLC,d52a823a-35bd-4c6a-a016-4b4f21a43d7d,"0173-0897-13, 0173-0897-56, 0173-0903-13, 0173-0903-56, 0173-0906-13, 0173-0906-56, 0173-0911-13, 0173-0911-56, 0173-0914-13, 0173-0914-56","Jesduvroq, Tablet, 4 mg (NDC 0173-0906-56)",Tablet,,"N0000194080, N0000194079",NDA216951,,DAPRODUSTAT,Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC],,To Be Discontinued,,Discontinuing for Business Reasons.,,JVR38ZM64B,0173-0906-56,888-825-5249,Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors [MoA]
"Meitheal Pharmaceuticals, Inc.",FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Furosemide Injection,"1719286, 1719290, 1719291",,a2e3c748-28ce-4c50-a182-721912919840,08/19/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,71288-203,Meitheal Pharmaceuticals Inc.,78b32838-f75b-4aba-9b4b-9978f755fced,"71288-203-02, 71288-203-03, 71288-203-04, 71288-203-05, 71288-203-10, 71288-203-11","Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-11)",Injection,Available,"N0000175366, N0000175590",ANDA212803,,FUROSEMIDE,Loop Diuretic [EPC],,Current,,,,7LXU5N7ZO5,71288-203-11,844-824-8426,
"EMD Serono, Inc.",LEVOTHYROXINE SODIUM,,07/10/2025,New,ORAL,Levothyroxine Sodium Tablet,"892246, 892251, 966153, 966160, 966166, 966173, 966177, 966182, 966187, 966196, 966202, 966207, 966220, 966221, 966222, 966224, 966225, 966248, 966249, 966253, 966270, 2104866",,bc3c6830-ba68-4ba3-9896-a12d0ad0b275,07/10/2025,HUMAN PRESCRIPTION DRUG,07/10/2025,Endocrinology/Metabolism,EUTHYROX,"72305-125, 72305-025, 72305-050, 72305-075, 72305-088, 72305-100, 72305-112, 72305-137, 72305-150, 72305-175, 72305-200","Provell Pharmaceuticals, LLC",45657074-8874-49f4-a8ef-3ca7e210c16e,"72305-025-30, 72305-025-90, 72305-050-30, 72305-050-90, 72305-075-30, 72305-075-90, 72305-088-30, 72305-088-90, 72305-100-30, 72305-100-90, 72305-112-30, 72305-112-90, 72305-125-30, 72305-125-90, 72305-137-30, 72305-137-90, 72305-150-30, 72305-150-90, 72305-175-30, 72305-175-90, 72305-200-30, 72305-200-90","Euthyrox, Tablet, 125 ug (NDC 72305-125-30)",Tablet,,,NDA021292,,LEVOTHYROXINE SODIUM,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,9J765S329G,72305-125-30,888-899-7041,
"Trigen Laboratories, LLC",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Reverified,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release",,,dd8d7b6e-c23d-4e16-bb53-959e9127ebc6,09/04/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE HYDROCHLORIDE,"13811-711, 13811-700","Trigen Laboratories, LLC",ba649db4-df0d-4587-8370-3f866e66e54b,"13811-711-30, 13811-700-30","Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30)",Tablet,Limited Availability,,NDA216117,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,Demand increase for the drug,Allocation to current contracted customers,,4B3SC438HI,13811-711-30,800-541-4802,
Aurobindo Pharma USA,METOPROLOL TARTRATE,,06/03/2025,New,ORAL,Metoprolol Tartrate Tablet,"866511, 866514, 866924",,2b705cb6-cb75-4c2a-907a-4bd45d18bc2c,06/03/2025,HUMAN PRESCRIPTION DRUG,06/03/2025,Cardiovascular,METOPROLOL TARTRATE,"65862-064, 65862-062, 65862-063",Aurobindo Pharma Limited,d265c99d-8e77-4a78-b542-15e957d9d335,"65862-062-01, 65862-062-99, 65862-063-60, 65862-063-01, 65862-063-99, 65862-064-60, 65862-064-01, 65862-064-99","Metoprolol Tartrate, Tablet, 100 mg (NDC 65862-064-39)",Tablet,,,ANDA077739,,METOPROLOL TARTRATE,,,To Be Discontinued,,Permanent discontinuation in the manufacturing of the drug,,W5S57Y3A5L,65862-064-39,866-850-2876,
Piramal Critical Care Inc.,ROCURONIUM BROMIDE,,02/15/2023,Reverified,INTRAVENOUS,Rocuronium Bromide Injection,,,98255b70-51f9-8d16-e053-2995a90a8f97,09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROCURONIUM,"66794-229, 66794-228",Piramal Critical Care Inc,3f9e12e4-d3c5-fba6-e063-6294a90a7fd6,"66794-229-02, 66794-229-41, 66794-228-02, 66794-228-41","Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 66794-229-41)",Injection,Available,,ANDA210437,,ROCURONIUM,,,Current,,,,I65MW4OFHZ,66794-229-41,800-414-1901,
Pfizer Inc.,DOCETAXEL ANHYDROUS,Microtubule Inhibition [PE],06/24/2025,New,INTRAVENOUS,Docetaxel Injection,"1093280, 1860619",,00c61d11-d6b7-4618-b6f6-2592dbcc8af7,06/24/2025,HUMAN PRESCRIPTION DRUG,06/24/2025,Oncology,DOCETAXEL,"0409-2026, 0409-0016","Hospira, Inc.",8156a5f8-7002-479d-a08d-3c68f92c1396,"0409-2026-01, 0409-0016-01","Docetaxel, Injection, 20 mg/2 mL (10 mg/mL) Single Dose ONCO-TAIN™ Glass Fliptop Vial Novaplus®  (NDC 0409-2026-01)",Injection,,"N0000175085, N0000175592",NDA022234,,DOCETAXEL ANHYDROUS,Microtubule Inhibitor [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,699121PHCA,0409-2026-01,844-646-4398,
Intercept Pharmaceuticals,OBETICHOLIC ACID,,09/19/2025,New,ORAL,Obeticholic Acid Tablet,"1798364, 1798370, 1798373, 1798375",,cdfbe0cd-eb15-45a1-ac17-531bcda21aec,09/19/2025,HUMAN PRESCRIPTION DRUG,09/19/2025,Gastroenterology,OCALIVA,"69516-010, 69516-005",Intercept Pharmaceuticals Inc,44a7331c-fc85-4906-948e-01bbba5e7e61,"69516-005-30, 69516-010-30","Ocaliva, Tablet, 10 mg (NDC 69516-010-30)",Tablet,,"N0000192561, N0000192560",NDA207999,,OBETICHOLIC ACID,Farnesoid X Receptor Agonist [EPC],,To Be Discontinued,,"Business decision. Products will not be available after November 14, 2025.",,0462Z4S4OZ,69516-010-30,1-844-782-4278,Farnesoid X Receptor Agonists [MoA]
Eli Lilly and Co.,,,10/29/2024,New,"INTRAMUSCULAR, SUBCUTANEOUS",Somatropin Injection,"582969, 582971, 582974, 582976, 729232, 729234",,a774e1ae-3997-49ee-8b0e-99a2b315d409,10/29/2024,HUMAN PRESCRIPTION DRUG,10/29/2024,Endocrinology/Metabolism,HUMATROPE,"0002-8147, 0002-8148, 0002-8149",Eli Lilly and Company,aa99e905-657f-4561-8c02-d7c0409c44e3,"0002-8147-01, 0002-7554-01, 0002-7618-01, 0002-8148-01, 0002-7555-01, 0002-7619-01, 0002-8149-01, 0002-7556-01","Humatrope, Injection, Humatrope Kit 6 mg (0002-8147-01): 1 TRAY in 1 CARTON (0002-8147-01) / 1 KIT in 1 TRAY * 2.88 mL in 1 CARTRIDGE (0002-7554-01) * 2.88 mL in 1 SYRINGE (0002-7618-01) (NDC 0002-8147-01)",Injection,,,BLA019640,,SOMATROPIN,,,To Be Discontinued,,Business decision to discontinue. Discontinuation includes the associated HumatroPen injection device.,,,0002-8147-01,800-545-5979,
"Teva Pharmaceuticals USA, Inc.",URSODIOL,,03/28/2025,New,ORAL,Ursodiol Tablet,"858733, 858751",,0a7c1ae6-4878-43e7-9026-073f74af64c0,03/28/2025,HUMAN PRESCRIPTION DRUG,03/28/2025,Other,URSODIOL,"0591-2998, 0591-3005","Actavis Pharma, Inc.",3ca902a9-d8c3-4c4b-a49f-efc62cf2028a,"0591-2998-01, 0591-3005-01","Ursodiol, Tablet, 250 mg (NDC 0591-2998-01)",Tablet,,"N0000175802, M0002475",NDA020675,Bile Acids and Salts [CS],URSODIOL,Bile Acid [EPC],,To Be Discontinued,,A business decision was made to discontinue manufacture of the drug.,,724L30Y2QR,0591-2998-01,800-545-8800,
Sagent Pharmaceuticals,BUMETANIDE,Increased Diuresis at Loop of Henle [PE],01/31/2018,New,"INTRAMUSCULAR, INTRAVENOUS",Bumetanide Injection,"282486, 1727569",,c38a404d-a919-4a2c-9fbb-d0655dee9516,08/25/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,BUMETANIDE,25021-321,Sagent Pharmaceuticals,befc1cf3-b71c-4228-bc42-3495b1d4b00d,"25021-321-04, 25021-321-10","Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-04)",Injection,Available,"N0000175366, N0000175590",ANDA074441,,BUMETANIDE,Loop Diuretic [EPC],,Current,,,,0Y2S3XUQ5H,25021-321-04,866-625-1618,
Strides Pharma Inc.,DONEPEZIL HYDROCHLORIDE,,01/28/2025,New,ORAL,Donepezil Hydrochloride Tablet,"997223, 997229",,297e86e8-d248-4cc9-9d9c-2ef9efb4414d,01/28/2025,HUMAN PRESCRIPTION DRUG,01/28/2025,Neurology,DONEPEZIL HYDROCHLORIDE,"71093-127, 71093-128","ACI Healthcare USA, Inc.",a4736add-da84-411f-8e6f-9de67bf467f8,"71093-127-01, 71093-127-03, 71093-127-05, 71093-127-06, 71093-128-01, 71093-128-03, 71093-128-05, 71093-128-06","Donepezil Hydrochloride, Tablet, 5 mg (NDC 71093-127-06)",Tablet,,,ANDA078662,,DONEPEZIL HYDROCHLORIDE,,,To Be Discontinued,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,3O2T2PJ89D,71093-127-06,877-244-9825,
"Avet Pharmaceuticals, Inc.",FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Furosemide Injection,"1719286, 1719290, 1719291",,7d0db0f7-bf4f-4b0b-9359-2a838626e04b,09/15/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,83634-302,Avenacy Inc.,1b3f2803-b618-4447-b5ac-cd2bdc7de3e8,"83634-302-42, 83634-302-02, 83634-302-43, 83634-302-04, 83634-302-41, 83634-302-10","Furosemide, Injection, 10 mg/1 mL; 4mL vial (NDC 83634-302-04)",Injection,Available,"N0000175366, N0000175590",ANDA203428,,FUROSEMIDE,Loop Diuretic [EPC],,Current,,Distributed by Avenacy; Contact information: 877-283-6229,,7LXU5N7ZO5,83634-302-04,855-228-9470,
B. Braun Medical Inc.,"DEXTROSE MONOHYDRATE, LIDOCAINE HYDROCHLORIDE ANHYDROUS",,10/25/2017,Reverified,INTRAVENOUS,Lidocaine Hydrochloride Injection,"1737723, 1737742, 1737744",,7dff29d9-522d-40eb-a9d9-42377912d640,09/16/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,LIDOCAINE HYDROCHLORIDE AND DEXTROSE,"0264-9594, 0264-9598",B. Braun Medical Inc.,26f23356-9e1f-4c5f-9959-06d53037a715,"0264-9598-20, 0264-9594-20, 0264-9594-10","Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-20)",Injection,Available,,NDA019830,,LIDOCAINE HYDROCHLORIDE ANHYDROUS AND DEXTROSE MONOHYDRATE,,,Current,,,,"LX22YL083G, EC2CNF7XFP",0264-9594-20,800-227-2862,
Pfizer Inc.,RAMIPRIL,,01/30/2025,New,ORAL,Ramipril Capsule,"104384, 104385, 198188, 198189, 260333, 261962, 845488, 845489",,0fc34cd8-86e6-4034-73bd-4263a68ba046,01/30/2025,HUMAN PRESCRIPTION DRUG,01/30/2025,Cardiovascular,ALTACE,"61570-120, 61570-110, 61570-111, 61570-112",Pfizer Laboratories Div Pfizer Inc,73b079d2-930b-4f37-990f-acfcde1ceddd,"61570-110-01, 61570-111-01, 61570-112-01, 61570-120-01","Altace, Capsule, 10 mg (NDC 61570-120-01)",Capsule,,"N0000175562, N0000000181",NDA019901,,RAMIPRIL,Angiotensin Converting Enzyme Inhibitor [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,L35JN3I7SJ,61570-120-01,844-646-4398,Angiotensin-converting Enzyme Inhibitors [MoA]
Merck Sharp & Dohme LLC,BEZLOTOXUMAB,,12/23/2024,New,INTRAVENOUS,Bezlotoxumab Injection,"1855052, 1855057",,8f479bfe-2bfa-4cc5-9aee-1357364480b0,12/23/2024,HUMAN PRESCRIPTION DRUG,12/23/2024,Anti-Infective,ZINPLAVA,0006-3025,Merck Sharp & Dohme LLC,11479917-fedd-4f25-bfdd-bc8c97c93773,"0006-3025-01, 0006-3025-00","Zinplava, Injection, 25 mg/1 mL (NDC 0006-3025-00)",Injection,,,BLA761046,,BEZLOTOXUMAB,,,To Be Discontinued,,"To be discontinued on January 31, 2025",,4H5YMK1H2E,0006-3025-00,800-672-6372,
"Teva Pharmaceuticals USA, Inc.",CELECOXIB,,08/15/2025,New,ORAL,Celecoxib Capsule,"205322, 205323, 349514, 686379",,05224473-27dc-4f6d-a52a-c40a7af2f2f4,08/15/2025,HUMAN PRESCRIPTION DRUG,08/15/2025,Analgesia/Addiction,CELECOXIB,"0591-3983, 0591-3982, 0591-3984, 0591-3985","Actavis Pharma, Inc.",64c601bc-9b67-400f-9e30-e26de56f2f8b,"0591-3982-60, 0591-3983-01, 0591-3983-05, 0591-3984-01, 0591-3984-05, 0591-3985-60","Celecoxib, Capsule, 100 mg (NDC 0591-3983-01)",Capsule,,"N0000000160, M0001335, N0000175722",ANDA200562,"Anti-Inflammatory Agents, Non-Steroidal [CS]",CELECOXIB,Nonsteroidal Anti-inflammatory Drug [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,JCX84Q7J1L,0591-3983-01,800-545-8800,Cyclooxygenase Inhibitors [MoA]
"EMD Serono, Inc.",LEVOTHYROXINE SODIUM,,07/10/2025,New,ORAL,Levothyroxine Sodium Tablet,"892246, 892251, 966153, 966160, 966166, 966173, 966177, 966182, 966187, 966196, 966202, 966207, 966220, 966221, 966222, 966224, 966225, 966248, 966249, 966253, 966270, 2104866",,bc3c6830-ba68-4ba3-9896-a12d0ad0b275,07/10/2025,HUMAN PRESCRIPTION DRUG,07/10/2025,Endocrinology/Metabolism,EUTHYROX,"72305-100, 72305-025, 72305-050, 72305-075, 72305-088, 72305-112, 72305-125, 72305-137, 72305-150, 72305-175, 72305-200","Provell Pharmaceuticals, LLC",45657074-8874-49f4-a8ef-3ca7e210c16e,"72305-025-30, 72305-025-90, 72305-050-30, 72305-050-90, 72305-075-30, 72305-075-90, 72305-088-30, 72305-088-90, 72305-100-30, 72305-100-90, 72305-112-30, 72305-112-90, 72305-125-30, 72305-125-90, 72305-137-30, 72305-137-90, 72305-150-30, 72305-150-90, 72305-175-30, 72305-175-90, 72305-200-30, 72305-200-90","Euthyrox, Tablet, 100 ug (NDC 72305-100-90)",Tablet,,,NDA021292,,LEVOTHYROXINE SODIUM,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,9J765S329G,72305-100-90,888-899-7041,
"Somerset Therapeutics, LLC",ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Reverified,"EPIDURAL, INFILTRATION, PERINEURAL",Ropivacaine Hydrochloride Injection,"905189, 1734084, 1734090, 1734203, 1734207, 1734475, 1734483",,ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64,08/19/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROPIVACAINE HYDROCHLORIDE,"70069-062, 70069-061, 70069-063, 70069-064, 70069-065, 70069-066, 70069-067","Somerset Therapeutics, LLC",5d7b0e44-19ce-4127-b3e8-d7e6e65f1818,"70069-061-01, 70069-061-25, 70069-061-10, 70069-062-01, 70069-062-25, 70069-062-10, 70069-063-01, 70069-063-25, 70069-064-01, 70069-064-10, 70069-064-25, 70069-065-01, 70069-065-25, 70069-066-01, 70069-066-25, 70069-066-10, 70069-067-01, 70069-067-25, 70069-067-10","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-10)",Injection,Available,,ANDA207636,,ROPIVACAINE HYDROCHLORIDE,,,Current,,,,V910P86109,70069-062-10,732-554-1019,
Baxter Healthcare,WATER,,04/28/2023,Revised,IRRIGATION,Sterile Water Irrigant,150985,,ef3e79c5-3f58-4b36-a296-64b7d9a651c1,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",STERILE WATER,"0338-0004, 0338-0003",Baxter Healthcare Corporation,43dc7530-ed0a-4976-af2a-0d39a2532fb7,"0338-0003-44, 0338-0003-46, 0338-0003-47, 0338-0004-02, 0338-0004-03, 0338-0004-04, 0338-0004-05","Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-02)",Irrigant,Limited Availability,,NDA017428,,WATER,,,Current,Other,Estimated recovery: October 2025,,059QF0KO0R,0338-0004-02,888-229-0001,
Kindos Pharmaceuticals Co. Ltd.,BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Bupivacaine Hydrochloride Injection,"1724786, 1724787, 1724880, 1724884, 1725078, 1725082",,daec9ee4-b666-485e-a153-4b5e5acc48a1,08/19/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE,"71288-722, 71288-721, 71288-724, 71288-725, 71288-727, 71288-728",Meitheal Pharmaceuticals Inc,b085b86e-d32f-494e-8a4a-3080ff240109,"71288-721-11, 71288-722-32, 71288-724-11, 71288-725-32, 71288-727-11, 71288-728-32","Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32)",Injection,Available,,ANDA216040,,BUPIVACAINE HYDROCHLORIDE,,,Current,,Meitheal Pharmaceuticals is distributor/labeler; product is available,,7TQO7W3VT8,71288-722-32,844-824-8426,
"Fresenius Kabi USA, LLC",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,"EPIDURAL, INTRACAUDAL, PERINEURAL, INFILTRATION",Bupivacaine Hydrochloride Injection,"1724880, 1724881, 1725078, 1725175, 1724884, 1724885, 1725082, 1725177, 1672917, 1672919, 1673296, 1673298, 1012391, 1012396, 1012404, 1012421, 1012455, 1012457",,"e700eb7b-8b14-49c9-96b2-331f18776e45, b6bfc04a-1868-4630-9ca1-8c027af97ce3, dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175, eb6d8fee-def4-4c96-9972-695e8cea8ea8",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,SENSORCAINE MPF,"63323-466, 63323-464, 63323-462, 63323-465, 63323-467, 63323-460","Fresenius Kabi USA, LLC","b41b5dbd-7aff-4d97-ac97-f4355393ee4e, d3ba9fb9-63c8-4597-bb0a-cd01d31a24b6, 13a48007-3784-46f2-bd4d-da1004186b81, 2b1a1f80-cb29-4ac1-9e72-20225ed45715","63323-464-01, 63323-464-17, 63323-466-03, 63323-466-17, 63323-464-08, 63323-464-38, 63323-466-08, 63323-466-38, 63323-462-03, 63323-462-38, 63323-464-09, 63323-464-39, 63323-466-09, 63323-466-39, 63323-465-01, 63323-465-57, 63323-467-01, 63323-467-57, 63323-460-01, 63323-460-37, 63323-464-02, 63323-464-37, 63323-464-03, 63323-464-31, 63323-466-01, 63323-466-37, 63323-466-02, 63323-466-31, 63323-462-04, 63323-462-17, 63323-462-01, 63323-462-37, 63323-462-02, 63323-462-31","Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-37)",Injection,Available,,"ANDA070553, NDA018304",,BUPIVACAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,"7TQO7W3VT8, 30Q7KI53AK",63323-466-37,888-386-1300,
Torrent Pharma Inc.,,,06/13/2025,New,,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,,,,06/13/2025,,06/13/2025,Cardiovascular,,,,,,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 40 mg (NDC 13668-386-30)",Tablet,,,,,,,,To Be Discontinued,,A business decision was made to discontinue manufacture of the product.,,,13668-386-30,908-280-3333,
"Hikma Pharmaceuticals USA, Inc.",KETOROLAC TROMETHAMINE,,06/06/2018,Revised,INTRAMUSCULAR,Ketorolac Tromethamine Injection,"860092, 1665459, 1665461",,0c2c75c9-ed7b-46a8-9543-429bf2d8f090,07/23/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,KETOROLAC TROMETHAMINE,"0641-6043, 0641-6042, 0641-6041",Hikma Pharmaceuticals USA Inc.,25d6c438-45d2-4162-91c2-b5caa0f86bf3,"0641-6043-01, 0641-6043-25, 0641-6042-01, 0641-6042-25, 0641-6041-01, 0641-6041-25","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6043-25)",Injection,Unavailable,,ANDA075772,,KETOROLAC TROMETHAMINE,,,Current,Other,Shortage recovery: TBD,,4EVE5946BQ,0641-6043-25,800-631-2174,
Baxter Healthcare,"CALCIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, SODIUM LACTATE",,10/11/2024,Reverified,INTRAVENOUS,Lactated Ringers Injection,847630,,dad7735c-709b-40ea-ab7a-15577e24a966,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other",LACTATED RINGERS,0338-0117,Baxter Healthcare Company,a3c6770a-d279-4ea9-b8ed-5484be18121e,"0338-0117-02, 0338-0117-03, 0338-0117-04","Lactated Ringers, Injection, 250 mL bag, 36 count (NDC 0338-0117-02)",Injection,Available,,NDA016682,,"SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM LACTATE AND CALCIUM CHLORIDE",,,Current,,,,"M4I0D6VV5M, 660YQ98I10, 451W47IQ8X, TU7HW0W0QT",0338-0117-02,888-229-0001,
"Trigen Laboratories, LLC",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Reverified,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release","1091155, 1091170, 1091185, 1091210, 1995461",,c45dc1de-adfa-4b3c-a7dc-cffbc8eac74f,09/04/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE HYDROCHLORIDE,"13811-706, 13811-709, 13811-707, 13811-708, 13811-710","Trigen Laboratories, LLC",354443b1-a623-43b0-b984-f8de2f6c60b2,"13811-709-10, 13811-706-10, 13811-707-10, 13811-708-10, 13811-710-10, 13811-710-30","Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10)",Tablet,Limited Availability,,ANDA205327,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,Demand increase for the drug,Allocation to current contracted customers,,4B3SC438HI,13811-706-10,800-541-4802,
"Lannett Company, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,f92497b5-baea-4760-b615-45a0b6184402,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","0527-0760, 0527-0761, 0527-0762, 0527-0763, 0527-0764, 0527-0765, 0527-0766","Lannett Company, Inc.",e0804f43-4685-4017-b839-3212d1167362,"0527-0760-37, 0527-0761-37, 0527-0762-37, 0527-0763-37, 0527-0764-37, 0527-0765-37, 0527-0766-37","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0527-0760-37)",Tablet,Available,,ANDA215565,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",0527-0760-37,844-834-0530,
"Hospira, Inc., a Pfizer Company",SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807547, 1807631, 1807632, 1807633",,a2a964f7-c3ec-4dfb-e3a0-6d8136a80397,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0409-7101, 0409-7132","Hospira, Inc.",9d75502b-257f-4a37-9a85-b98c4278c474,"0409-7101-68, 0409-7101-66, 0409-7101-69, 0409-7101-67, 0409-7101-04, 0409-7101-02, 0409-7132-68, 0409-7132-66, 0409-7132-69, 0409-7132-67, 0409-7132-04, 0409-7132-02","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (9%, 9mg/mL) (NDC 0409-7101-66)",Injection,,,NDA019465,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0409-7101-66,844-646-4398,
"Upsher-Smith Laboratories, LLC",TOPIRAMATE,Decreased Central Nervous System Disorganized Electrical Activity [PE],04/24/2025,New,ORAL,"Topiramate Capsule, Extended Release","1494766, 1494769, 1494771, 1494775, 1494778, 1494781, 1812419, 1812421, 1812425, 1812427",,46f54677-3a22-4c38-9b92-923020164e15,04/24/2025,HUMAN PRESCRIPTION DRUG,04/24/2025,Neurology,QUDEXY XR,"0245-1074, 0245-1071, 0245-1072, 0245-1075, 0245-1073","Upsher-Smith Laboratories, LLC",374eeb55-b017-48fd-e063-6294a90a6ad7,"0245-1071-30, 0245-1071-90, 0245-1072-30, 0245-1072-90, 0245-1074-30, 0245-1074-90, 0245-1075-30, 0245-1075-90, 0245-1073-30, 0245-1073-90","Qudexy XR, Capsule, Extended Release, 100 mg (NDC 0245-1074-30)","Capsule, Extended Release",,"N0000008486, N0000185506, N0000182140",NDA205122,,TOPIRAMATE,,,To Be Discontinued,,Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.,,0H73WJJ391,0245-1074-30,716-315-2000,"Cytochrome P450 3A4 Inducers [MoA], Cytochrome P450 2C19 Inhibitors [MoA]"
Sandoz Inc.,CLINDAMYCIN,"Decreased Sebaceous Gland Activity [PE], Neuromuscular Blockade [PE]",03/21/2023,Reverified,INTRAVENOUS,Clindamycin Phosphate Injection,"309335, 309336",,80217bd6-2bc4-401c-9345-22532b36a24f,09/24/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,CLINDAMYCIN IN 5 PERCENT DEXTROSE,"72572-076, 72572-074","Civica, Inc.",e40b6e7f-1d37-4d0a-ace3-e5accc461e02,"72572-074-01, 72572-074-24, 72572-076-01, 72572-076-24","Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 72572-076-24)",Injection,Available,"N0000009982, N0000175443, M0515779, N0000175731",ANDA201692,Lincosamides [CS],CLINDAMYCIN IN 5 PERCENT DEXTROSE,Lincosamide Antibacterial [EPC],,Current,,Civica Label,,3U02EL437C,72572-076-24,800-525-8747,
Baxter Healthcare,DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795477, 1795480, 1795481, 1795607, 1795609, 1795610, 1795612, 1795616, 1795618",,3bb406a9-f5cb-403a-b1bb-5c4facbea3d5,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0338-0017, 0338-0023",Baxter Healthcare Corporation,31bb4a5f-733e-4354-9fbf-138dede4db0f,"0338-0017-10, 0338-0017-41, 0338-0017-11, 0338-0017-31, 0338-0017-48, 0338-0017-18, 0338-0017-38, 0338-0017-02, 0338-0017-03, 0338-0017-04, 0338-0023-02, 0338-0023-03, 0338-0023-04","Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-10)",Injection,Available,,NDA016673,,DEXTROSE MONOHYDRATE,,,Current,,,,LX22YL083G,0338-0017-10,888-229-0001,
Janssen Pharmaceuticals,HALOPERIDOL DECANOATE,,04/07/2025,New,INTRAMUSCULAR,Haloperidol Decanoate Injection,"1719803, 1719847, 1719862, 1720026",,af0159a8-dff5-449a-aa2b-a0c430081e21,04/07/2025,HUMAN PRESCRIPTION DRUG,04/07/2025,Psychiatry,HALDOL DECANOATE,"50458-253, 50458-254","Janssen Pharmaceuticals, Inc.",2cf0430f-e455-8d17-e063-6394a90a5cd3,"50458-253-01, 50458-253-03, 50458-254-14","Haldol, Injection, 50 mg/1 mL (NDC 50458-253-03)",Injection,,,NDA018701,,HALOPERIDOL DECANOATE,,,To Be Discontinued,,Last batch expiration date 5/31/2025,,AC20PJ4101,50458-253-03,800-526-7736,
Alembic Pharmaceuticals,KETOROLAC TROMETHAMINE,,03/23/2018,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Ketorolac Tromethamine Injection,"860092, 1665459, 1665461",,419cf756-3c96-4bb8-ae96-6aea5a5f3afd,09/17/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,KETOROLAC TROMETHAMINE,"62332-600, 62332-599, 62332-601",Alembic Pharmaceuticals Inc.,9030f496-5021-4454-ac16-dbb376315608,"62332-599-01, 62332-599-25, 62332-600-01, 62332-600-25, 62332-601-02, 62332-601-25","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 62332-600-25)",Injection,Available,,ANDA214456,,KETOROLAC TROMETHAMINE,,,Current,,,,4EVE5946BQ,62332-600-25,908-393-9604,
"Assertio Specialty Pharmaceuticals, LLC",METHOTREXATE,,08/29/2025,New,SUBCUTANEOUS,Methotrexate Injection,"1441402, 1441407, 1441411, 1441413, 1441416, 1441418, 1441422, 1441424, 1747179, 1747181, 1747185, 1747187, 1747192, 1747194",,7dcd02d7-1ce0-43fc-8f25-2f0bb0caba2f,08/29/2025,HUMAN PRESCRIPTION DRUG,08/29/2025,Rheumatology,OTREXUP,"82497-020, 82497-010, 82497-012, 82497-015, 82497-017, 82497-022, 82497-025","Otter Pharmaceuticals, LLC",9aaba145-f343-4498-b754-fb7c78181bd7,"82497-010-02, 82497-010-04, 82497-012-02, 82497-012-04, 82497-015-02, 82497-015-04, 82497-017-02, 82497-017-04, 82497-020-02, 82497-020-04, 82497-022-02, 82497-022-04, 82497-025-02, 82497-025-04","Otrexup, Injection, 20 mg/.4 mL (NDC 82497-020-04)",Injection,,"N0000175584, N0000000111",NDA204824,,METHOTREXATE,Folate Analog Metabolic Inhibitor [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,YL5FZ2Y5U1,82497-020-04,224-441-6390,Folic Acid Metabolism Inhibitors [MoA]
Eugia US LLC,ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Revised,"EPIDURAL, PERINEURAL",Ropivacaine Hydrochloride Injection,"905189, 1734084, 1734090, 1734207, 1734347, 1734475, 1734483",,3763b7b6-da49-4658-b93d-28f5da24d09e,09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROPIVACAINE HYDROCHLORIDE,"55150-199, 55150-195, 55150-196, 55150-197, 55150-198, 55150-200, 55150-201",Eugia US LLC,34725b26-d6e9-4d1b-95a0-da03764cc102,"55150-195-20, 55150-196-99, 55150-197-20, 55150-198-30, 55150-199-20, 55150-200-10, 55150-201-20","Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)",Injection,Unavailable,,ANDA205612,,ROPIVACAINE HYDROCHLORIDE,,,Current,Demand increase for the drug,On backorder. Recovery: TBD. Check wholesalers for inventory,,V910P86109,55150-199-20,888-238-7880,
"Sun Pharmaceutical Industries, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Revised,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856, 1871456, 1871460, 1871462, 1871464, 1871466, 1871468",,da3148af-f9b6-4725-adae-3595b4c7dc4b,09/22/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"57664-046, 57664-047, 57664-048, 57664-049, 57664-050, 57664-051, 57664-052, 57664-083, 57664-084, 57664-085, 57664-086, 57664-087, 57664-088","Sun Pharmaceutical Industries, Inc.",0b77417a-5789-8818-e063-6294a90ad2e3,"57664-047-88, 57664-046-88, 57664-048-88, 57664-049-88, 57664-050-88, 57664-051-88, 57664-052-88, 57664-083-88, 57664-084-88, 57664-085-88, 57664-086-88, 57664-087-88, 57664-088-88","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 57664-046-88)",Capsule,Limited Availability,,ANDA214484,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,Additional supply anticipated early 2026,,SJT761GEGS,57664-046-88,800-818-4555,
"Teva Pharmaceuticals USA, Inc.",POTASSIUM CHLORIDE,,05/19/2025,New,ORAL,"Potassium Chloride Capsule, Extended Release","312504, 315183",,ed5baaf6-270b-4dd3-b100-36030c0098fc,05/19/2025,HUMAN PRESCRIPTION DRUG,05/19/2025,"Endocrinology/Metabolism, Gastroenterology",POTASSIUM CHLORIDE,"62037-560, 62037-559","Actavis Pharma, Inc.",b97da107-c56e-48ea-ba34-d3d64a5b9f46,"62037-559-01, 62037-559-05, 62037-560-01, 62037-560-05, 62037-560-10, 62037-560-90","Potassium Chloride, Capsule, Extended Release, 750 mg (NDC 62037-560-90)","Capsule, Extended Release",,,ANDA077419,,POTASSIUM CHLORIDE,,,To Be Discontinued,,,,660YQ98I10,62037-560-90,800-545-8800,
Gland Pharma Limited,FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Furosemide Injection,"1719286, 1719290, 1719291",,d63c1277-dd7e-4d21-9e80-68143f55e2dc,09/29/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,25021-311,Sagent Pharmaceuticals,222ce48f-2856-4be2-b16f-6fca38c0dceb,"25021-311-02, 25021-311-04, 25021-311-10","Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)",Injection,Available,"N0000175366, N0000175590",ANDA213902,,FUROSEMIDE,Loop Diuretic [EPC],,Current,Other,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,7LXU5N7ZO5,25021-311-02,866-625-1618,
Amneal Pharmaceuticals,METHYLPREDNISOLONE ACETATE,,12/15/2021,Reverified,"INTRA-ARTICULAR, INTRALESIONAL, INTRAMUSCULAR, SOFT TISSUE",Methylprednisolone Acetate Injection,"1743779, 1743855",,d944240d-2c19-46ba-ad4f-3fbee7b8629c,09/17/2025,HUMAN PRESCRIPTION DRUG,,Rheumatology,METHYLPREDNISOLONE ACETATE,"70121-1574, 70121-1573",Amneal Pharmaceuticals LLC,0bdaa3cf-cf32-4959-b87a-65215ac4648d,"70121-1573-1, 70121-1573-5, 70121-1574-1, 70121-1574-5","Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-1)",Injection,Available,,ANDA210043,,METHYLPREDNISOLONE ACETATE,,,Current,,,,43502P7F0P,70121-1574-1,866-525-7270,
"Hospira, Inc., a Pfizer Company","BUPIVACAINE HYDROCHLORIDE, EPINEPHRINE BITARTRATE",,02/20/2018,Revised,"EPIDURAL, INTRACAUDAL, PERINEURAL","Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","1012377, 1012384, 1012396, 1012404, 1672917, 1672919, 1724786, 1724787, 1724880, 1724884, 1725078, 1725082, 1867594, 1867596",,02a845c3-4521-4926-e397-25ab536e7cf6,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE,"0409-9045, 0409-1159, 0409-1160, 0409-1162, 0409-1163, 0409-1165, 0409-9043, 0409-9046, 0409-9042","Hospira, Inc.",3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7,"0409-1159-18, 0409-1159-01, 0409-1159-19, 0409-1159-02, 0409-1160-18, 0409-1160-01, 0409-1162-18, 0409-1162-01, 0409-1162-19, 0409-1162-02, 0409-1163-18, 0409-1163-01, 0409-1165-18, 0409-1165-01, 0409-1165-19, 0409-1165-02, 0409-9043-11, 0409-9043-01, 0409-9046-11, 0409-9046-01, 0409-9045-11, 0409-9045-01, 0409-9045-16, 0409-9045-17, 0409-9042-11, 0409-9042-01, 0409-9042-16, 0409-9042-17","Bupivacaine Hydrochloride And Epinephrine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-9045-01)",Injection,Unavailable,,ANDA071168,,BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE,,,Current,Other,Shortage per Manufacturer: Manufacturing Delay,,"30Q7KI53AK, 7TQO7W3VT8",0409-9045-01,844-646-4398,
Sagent Pharmaceuticals,LEUCOVORIN CALCIUM,,01/01/2012,Revised,"INTRAMUSCULAR, INTRAVENOUS",Leucovorin Calcium Injection,2055036,,c0cbcbf6-6fd2-4cf3-877a-bb0fe3df4e59,07/08/2025,HUMAN PRESCRIPTION DRUG,,"Oncology, Pediatric",LEUCOVORIN CALCIUM,25021-828,Sagent Pharmaceuticals,4619074b-a86b-41a6-bd98-76d15166764c,25021-828-50,"Leucovorin Calcium Preservative Free, Injection, 500 mg/50 mL (NDC 25021-828-50)",Injection,,,ANDA209110,,LEUCOVORIN CALCIUM,,Available,Resolved,,,07/08/2025,RPR1R4C0P4,25021-828-50,866-625-1618,
Janssen Pharmaceuticals,METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Reverified,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release","1091155, 1091157, 1091170, 1091172, 1091185, 1091187, 1091210, 1091212",,1a88218c-5b18-4220-8f56-526de1a276cd,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,CONCERTA,"50458-585, 50458-588, 50458-586, 50458-587","Janssen Pharmaceuticals, Inc.",23987e85-013d-3aaa-e063-6394a90a1f2d,"50458-585-01, 50458-588-01, 50458-586-01, 50458-587-01","Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01)",Tablet,Available,,NDA021121,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,,,,4B3SC438HI,50458-585-01,800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET,
"Fresenius Kabi USA, LLC",MIDAZOLAM HYDROCHLORIDE,,04/02/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Midazolam Hydrochloride Injection,"311700, 311702",,"a91ce254-14a3-4cbf-8ab8-5da252aa3fdc, 09daf48f-1d44-4b7b-bb53-bd5635b93ca6",09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology",MIDAZOLAM,"63323-412, 63323-411","Fresenius Kabi USA, LLC","9814447b-a93e-42ad-b57e-5db0a5b7f552, c2aaa2df-aa73-4ea7-96be-528010260e25","63323-411-22, 63323-411-27, 63323-411-15, 63323-411-12, 63323-411-18, 63323-411-25, 63323-411-13, 63323-411-10, 63323-412-18, 63323-412-25, 63323-412-03, 63323-412-02, 63323-412-06, 63323-412-05, 63323-412-13, 63323-412-10, 63323-412-00","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-02)",Injection,Available,,"ANDA075154, ANDA208878",,MIDAZOLAM HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,W7TTW573JJ,63323-412-02,888-386-1300,
Strides Pharma Inc.,SERTRALINE HYDROCHLORIDE,,01/22/2025,New,ORAL,Sertraline Hydrochloride Tablet,"312938, 312940, 312941",,1f99e897-1b70-40b0-8c19-71d0bba19422,01/22/2025,HUMAN PRESCRIPTION DRUG,01/22/2025,Psychiatry,SERTRALINE HYDROCHLORIDE,"71093-129, 71093-130, 71093-131","ACI Healthcare USA, Inc.",3f41fc19-b54a-46fd-acbf-b411816bccd5,"71093-129-01, 71093-129-03, 71093-129-05, 71093-130-01, 71093-130-03, 71093-130-05, 71093-131-01, 71093-131-03, 71093-131-05","Sertraline Hydrochloride, Tablet, 25 mg (NDC 71093-129-05)",Tablet,,,ANDA076881,,SERTRALINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,UTI8907Y6X,71093-129-05,877-244-9825,
Sandoz Inc.,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577961",,288dafc4-fe6e-4891-832f-511022c87445,09/24/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","0185-2099, 0185-0831, 0185-0842, 0185-0853, 0185-0864, 0185-2098",Sandoz Inc,d68cd1d1-3bb4-4afa-9786-687cf1766ae1,"0185-0831-01, 0185-0842-01, 0185-0853-01, 0185-0864-01, 0185-2099-01, 0185-2098-01","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0185-2099-01)",Tablet,Available,,ANDA040439,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",0185-2099-01,800-525-8747,
Medexus,TRIAMCINOLONE HEXACETONIDE,,05/04/2021,Reverified,INTRA-ARTICULAR,Triamcinolone Hexacetonide Injection,"2539176, 2539181",https://www.fda.gov/media/154709/download,bc07ae9f-8a74-6bc8-e053-2995a90afc0d,09/17/2025,HUMAN PRESCRIPTION DRUG,,Rheumatology,HEXATRIONE 2%,59137-570,"Medexus Pharma, Inc.",f1eb64e8-05c0-931b-e053-2995a90a2fe8,59137-570-01,"Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)",Injection,Unavailable,,,,TRIAMCINOLONE HEXACETONIDE,,,Current,Delay in shipping of the drug,,,I7GT1U99Y9,59137-570-01,1-855-336-3322 Option 9,
Pfizer Inc.,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Revised,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"284397, 309710, 1718900, 1718902, 1718906, 1718907, 1718909, 1718910, 2396891, 2396892",,548a88c0-afda-427e-75ac-5af0cfa2224c,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,PRECEDEX,"0409-1434, 0409-1660, 0409-1638, 0409-1596, 0409-7838, 0409-7853, 0409-7875","Hospira, Inc.",231f50fe-2c91-44b9-946e-33b836c07b94,"0409-1660-55, 0409-1660-50, 0409-1660-35, 0409-1660-10, 0409-1660-22, 0409-1660-20, 0409-1638-32, 0409-1638-02, 0409-1434-01, 0409-1596-01, 0409-1596-10, 0409-7838-01, 0409-7838-24, 0409-7853-01, 0409-7853-24, 0409-7875-01, 0409-7875-12","Precedex, Injection, 1000 mcg/250 mL Single Dose Glass Bottle (NDC 0409-1434-01)",Injection,Unavailable,,NDA021038,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,Other,Unavailable. Next Delivery: October 2025; Estimated Recovery: December 2025,,1018WH7F9I,0409-1434-01,844-646-4398,
"Caplin Steriles, Ltd.",ETOMIDATE,General Anesthesia [PE],10/05/2022,Reverified,INTRAVENOUS,Etomidate Injection,"1654006, 1654008",,75467058-da52-48fa-8d4e-e1025ec7d461,09/16/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ETOMIDATE,"72485-509, 72485-508",Armas Pharmaceuticals Inc.,7444860b-36c1-459d-94ba-d7301d9dc2ca,"72485-508-01, 72485-508-10, 72485-509-01, 72485-509-10","Etomidate, Injection, 2 mg/mL (NDC 72485-509-10)",Injection,Available,"N0000175975, N0000175681",ANDA215028,,ETOMIDATE,General Anesthetic [EPC],,Current,,"Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586",,Z22628B598,72485-509-10,908-803-2586,
"Actavis Pharma, Inc.",ONDANSETRON HYDROCHLORIDE,,11/04/2024,New,ORAL,Ondansetron Hydrochloride Tablet,"198052, 312086",,90d19fd2-6de4-4e55-9469-53b8957c8326,11/04/2024,HUMAN PRESCRIPTION DRUG,11/04/2024,Gastroenterology,ONDANSETRON,"45963-539, 45963-538","ACTAVIS PHARMA, INC.",362baa9c-5ad9-402b-b4cb-7c4f2e051686,"45963-538-30, 45963-539-30","Tablet, 8 mg (NDC 45963-539-30)",Tablet,,,ANDA077851,,ONDANSETRON,,,To Be Discontinued,,,,NMH84OZK2B,45963-539-30,800-545-8800,
Baxter Healthcare,ROCURONIUM BROMIDE,,02/15/2023,Reverified,INTRAVENOUS,Rocuronium Bromide Injection,1234995,,31e15c3f-aefa-4379-b684-7707744fe40d,09/23/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROCURONIUM BROMIDE,"43066-013, 43066-007",Baxter Healthcare Corporation,9e0317de-2d78-4fd8-8926-4c7b476f3ed4,"43066-007-10, 43066-013-10","Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 43066-013-10)",Injection,Available,,ANDA091115,,ROCURONIUM BROMIDE,,,Current,,,,I65MW4OFHZ,43066-013-10,888-229-0001,
"Hospira, Inc., a Pfizer Company",BUPIVACAINE HYDROCHLORIDE,,01/10/2025,New,PERINEURAL,Bupivacaine Hydrochloride Injection,"1012377, 1012381, 1012384, 1012388, 1012396, 1012400, 1012404, 1012406, 1672917, 1672919, 1673242, 1673243, 1724786, 1724787, 1724794, 1724796, 1724880, 1724884, 1725044, 1725046, 1725078, 1725079, 1725082, 1725083, 1867594, 1867596, 1867612, 1867614",,67578b56-7540-487e-1fba-481255620e78,01/10/2025,HUMAN PRESCRIPTION DRUG,01/10/2025,Anesthesia,MARCAINE,"0409-1610, 0409-1559, 0409-1560, 0409-1582, 0409-1587, 0409-1746, 0409-1749, 0409-1752, 0409-1755, 0409-2510, 0409-7535, 0409-1250, 0409-5010, 0409-1530, 0409-0525, 0409-7510, 0409-2253","Hospira, Inc.",b083f440-bfb7-449a-b601-c2f59a6f9dcf,"0409-1559-18, 0409-1559-10, 0409-1559-19, 0409-1559-30, 0409-1560-18, 0409-1560-10, 0409-1560-19, 0409-1560-29, 0409-1582-18, 0409-1582-10, 0409-1582-19, 0409-1582-29, 0409-1587-50, 0409-1610-50, 0409-1746-70, 0409-1746-10, 0409-1746-71, 0409-1746-30, 0409-1749-70, 0409-1749-10, 0409-1749-71, 0409-1749-29, 0409-1752-50, 0409-1755-50, 0409-2510-01, 0409-2510-25, 0409-7535-01, 0409-7535-25, 0409-1250-01, 0409-1250-25, 0409-5010-01, 0409-5010-25, 0409-1530-01, 0409-1530-25, 0409-0525-01, 0409-0525-25, 0409-7510-01, 0409-7510-25, 0409-2253-01, 0409-2253-25","Marcaine, Injection, 250 mg/50 mL (5 mg/mL); Multiple Dose Glass Fliptop Vial (NDC 0409-1610-50)",Injection,,,NDA016964,,BUPIVACAINE HYDROCHLORIDE,,,To Be Discontinued,,"Discontinuation of the manufacture of the drug.
Replaced with NDC 0409-0525-01",,"30Q7KI53AK, 7TQO7W3VT8",0409-1610-50,844-646-4398,
Otsuka ICU Medical LLC,DEXTROSE MONOHYDRATE,,03/01/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 10% Injection,"1795477, 1795480, 1795481, 1795607, 1795609, 1795610, 1795612, 1795616, 1795618, 1795621",,8b25b7e0-703e-4b43-a4eb-52863511602d,09/17/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0990-7930, 0990-7923, 0990-7922","ICU Medical, Inc.",09b10612-c937-4d10-becb-9768e10caa2c,"0990-7923-20, 0990-7923-23, 0990-7923-36, 0990-7923-37, 0990-7923-13, 0990-7922-02, 0990-7922-03, 0990-7922-09, 0990-7922-53, 0990-7922-55, 0990-7922-61, 0990-7930-02, 0990-7930-03, 0990-7930-09","Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-09)",Injection,Available,,NDA018080,,DEXTROSE MONOHYDRATE,,,Current,,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,LX22YL083G,0990-7930-09,1-866-829-9025 or ProductAvailability@icumed.com,
Sagent Pharmaceuticals,,,04/07/2020,Reverified,,Furosemide Injection,,,,08/26/2025,,,Cardiovascular,,,,,,"Furosemide, Injection, 10 mg/1 mL (NDC 70860-302-04)",Injection,Unavailable,,,,,,,Current,Other,Use Sagent NDC 25021-311-04,,,70860-302-04,866-625-1618,
"Avet Pharmaceuticals, Inc.",FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Reverified,INTRAVENOUS,Furosemide Injection,"1719286, 1719290, 1719291",,1b9117d5-0dd9-4577-a1fd-bb0aaf7e68ec,09/15/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,23155-473,Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.,936eaafa-5088-4ebc-85bc-685ffb85c81f,"23155-473-31, 23155-473-41, 23155-473-32, 23155-473-42, 23155-473-43, 23155-473-33, 23155-473-44, 23155-473-45","Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-41)",Injection,Available,"N0000175366, N0000175590",ANDA203428,,FUROSEMIDE,Loop Diuretic [EPC],,Current,,,,7LXU5N7ZO5,23155-473-41,855-228-9470,
B. Braun Medical Inc.,HEPARIN SODIUM,,11/14/2017,Reverified,INTRAVENOUS,Heparin Sodium Injection,"1658690, 1658692",,a3041c04-0ea8-4d36-81ce-c5091c906316,09/16/2025,HUMAN PRESCRIPTION DRUG,,Hematology,HEPARIN SODIUM IN SODIUM CHLORIDE,0264-9872,B. Braun Medical Inc.,48e17807-e73d-4ea2-81bc-901355903aa7,"0264-9872-10, 0264-9872-00","Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)",Injection,Available,,NDA019953,,HEPARIN SODIUM IN SODIUM CHLORIDE,,,Current,,,,ZZ45AB24CA,0264-9872-10,800-227-2862,
"Hospira, Inc., a Pfizer Company",HYDROMORPHONE HYDROCHLORIDE,,10/31/2017,Reverified,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Hydromorphone Hydrochloride Injection,"897653, 897753, 897756, 897757, 897758, 1433251, 1724276, 1724383, 1724644",,e9c9ef18-7dfc-4322-b2fc-29b934c30f8b,08/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,HYDROMORPHONE HYDROCHLORIDE,"0409-3365, 0409-2552, 0409-3356, 0409-2540, 0409-1283, 0409-1312, 0409-1304","Hospira, Inc.",58ff0e68-b78f-4ebd-a91b-b53bbdefc544,"0409-2552-11, 0409-2552-01, 0409-3356-11, 0409-3356-01, 0409-2540-11, 0409-2540-01, 0409-3365-11, 0409-3365-01, 0409-3365-10, 0409-1283-03, 0409-1283-31, 0409-1283-09, 0409-1283-10, 0409-1283-04, 0409-1283-05, 0409-1312-03, 0409-1312-30, 0409-1312-09, 0409-1312-10, 0409-1304-03, 0409-1304-31","Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-3365-10)",Injection,Available,,NDA200403,,HYDROMORPHONE HYDROCHLORIDE,,,Current,,,,L960UP2KRW,0409-3365-10,844-646-4398,
Apotex Corp.,LISDEXAMFETAMINE DIMESYLATE,,11/01/2023,Revised,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,ecad4442-a644-18e3-6ff2-fdbac45eec47,09/29/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"60505-4739, 60505-4740, 60505-4741, 60505-4742, 60505-4743, 60505-4744, 60505-4745",Apotex Corp.,c8e0c70d-2f5b-8d85-fa45-572e8f5f7b4c,"60505-4739-1, 60505-4740-1, 60505-4741-1, 60505-4742-1, 60505-4743-1, 60505-4744-1, 60505-4745-1","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 60505-4739-1)",Capsule,Limited Availability,,ANDA216944,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Delay in shipping of the drug,Next resupply date is Late September 2025,,SJT761GEGS,60505-4739-1,800-706-5575,
"Epic Pharma, LLC","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961",,1757e132-061d-4773-89ed-fdc77f69008f,09/18/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","42806-339, 42806-341, 42806-343, 42806-344, 42806-345","Epic Pharma, LLC",f11301e2-3b5d-468d-b44c-45839e7e5dfb,"42806-339-01, 42806-341-01, 42806-343-01, 42806-344-01, 42806-345-01","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)",Tablet,Limited Availability,,ANDA040444,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,Shortage of an active ingredient,Limited availability until end of September 2025,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",42806-339-01,(718) 276-8600 ext. 3,
Baxter Healthcare,"CALCIUM CHLORIDE, ICODEXTRIN, MAGNESIUM CHLORIDE, SODIUM CHLORIDE, SODIUM LACTATE",,10/11/2024,Revised,INTRAPERITONEAL,Peritoneal Dialysis Solution,"1100742, 1100746",,d5b85158-b0d6-4855-9d07-8d1b3ad9ab71,07/07/2025,HUMAN PRESCRIPTION DRUG,,Renal,EXTRANEAL,0941-0679,Vantive US Healthcare LLC,3005f010-638d-670e-e063-6294a90af468,"0941-0679-52, 0941-0679-53, 0941-0679-06, 0941-0679-05","Peritoneal Dialysis, Solution, Various NDCs (NDC 0941-0679-05)",Solution,,,NDA021321,,"ICODEXTRIN, SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE",,Available,Resolved,,,07/07/2025,"M4I0D6VV5M, 2NX48Z0A9G, 02F3473H9O, 451W47IQ8X, TU7HW0W0QT",0941-0679-05,888-229-0001,
"Teva Pharmaceuticals USA, Inc.",PHENTERMINE HYDROCHLORIDE,,06/13/2025,New,ORAL,Phentermine Hydrochloride Tablet,"803353, 803354",,f5b2f9d8-2226-476e-9caf-9d41e6891c46,06/13/2025,HUMAN PRESCRIPTION DRUG,06/13/2025,Other,ADIPEX-P,57844-140,"Teva Pharmaceuticals USA, Inc.",0b8644f4-40ad-4c0b-bacb-97dcd2fc2dcd,"57844-140-56, 57844-140-01","Adipex-P, Tablet, 37.5 mg (NDC 57844-140-01)",Tablet,,,ANDA085128,,PHENTERMINE HYDROCHLORIDE,,,To Be Discontinued,,,,0K2I505OTV,57844-140-01,800-545-8800,
Eugia US LLC,LIDOCAINE HYDROCHLORIDE,,06/13/2018,Revised,"INFILTRATION, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010671",,"ccc38d8a-43fd-44c0-985e-32af9ed956ab, ef782e5e-e2d7-465a-99c6-b12611f3158c",09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,LIDOCAINE HYDROCHLORIDE,"55150-252, 55150-251, 55150-254, 55150-255, 55150-253, 55150-256",Eugia US LLC,"ccc38d8a-43fd-44c0-985e-32af9ed956ab, 0b1f03c2-db2f-4f90-acc0-d73abd731bf6","55150-251-24, 55150-252-24, 55150-254-24, 55150-255-24, 55150-251-10, 55150-252-20, 55150-253-50, 55150-254-10, 55150-255-20, 55150-256-50","Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)",Injection,Available,,ANDA207182,,LIDOCAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,V13007Z41A,55150-252-20,888-238-7880,
B. Braun Medical Inc.,SODIUM CHLORIDE,,06/21/2018,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807552, 1807634, 1807639",,e44c41ae-c9c8-4dd8-ba6c-cebb585378aa,08/08/2025,HUMAN PRESCRIPTION DRUG,,Other,SODIUM CHLORIDE,"0264-5802, 0264-5804",B. Braun Medical Inc.,d34ea9bc-a1f9-402a-97cf-894505cee75d,"0264-5802-00, 0264-5802-10, 0264-5804-00","Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-5802-00)",Injection,,,NDA019635,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0264-5802-00,800-227-2862,
"Hospira, Inc., a Pfizer Company",CARBOPLATIN,,04/28/2023,Reverified,INTRAVENOUS,Carboplatin Injection,597195,,47677091-fd20-49af-933c-c9dd2be21de9,08/15/2025,HUMAN PRESCRIPTION DRUG,,Oncology,CARBOPLATIN,"61703-262, 61703-360, 61703-150, 61703-600","Hospira, Inc.",5aa72c15-8033-4559-b257-373371b18958,"61703-360-18, 61703-150-05, 61703-262-05, 61703-600-05","Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05)",Injection,Available,"N0000175413, N0000175073",ANDA076517,,CARBOPLATIN,Platinum-based Drug [EPC],,Current,,,,BG3F62OND5,61703-262-05,844-646-4398,
"Hospira, Inc., a Pfizer Company",FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Revised,"INTRAMUSCULAR, INTRAVENOUS",Furosemide Injection,"1719286, 1719290, 1719291",,"aaced7a8-c3d7-4d66-8c07-aa407b8b3f35, 39fd32f2-6bb7-4a65-d298-e48d26bc80c7",08/15/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,0409-6102,"Hospira, Inc.","c529b0df-a5cb-46ce-8131-38674ee756af, 0d4a39f2-904e-434a-9af1-83bb4febf124","0409-6102-35, 0409-6102-25, 0409-6102-36, 0409-6102-26, 0409-6102-37, 0409-6102-27, 0409-6102-19, 0409-6102-02, 0409-6102-18, 0409-6102-04, 0409-6102-20, 0409-6102-10","Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-04)",Injection,Limited Availability,"N0000175366, N0000175590",NDA018667,,FUROSEMIDE,Loop Diuretic [EPC],,Current,Other,Limited Supply Available. Next Delivery and Estimated Recovery: December 2025,,7LXU5N7ZO5,0409-6102-04,844-646-4398,
"Upsher-Smith Laboratories, LLC",NYSTATIN,,04/28/2025,New,TOPICAL,Nystatin Topical Powder,"584414, 646456",,01b44f91-9b68-464a-9693-b5d3e793bf3c,04/28/2025,HUMAN PRESCRIPTION DRUG,04/28/2025,"Anti-Infective, Dermatology",NYAMYC,0832-0465,"Upsher-Smith Laboratories, LLC",3984f88f-d61f-1fa9-e063-6394a90acb11,"0832-0465-15, 0832-0465-30, 0832-0465-60","Nystatin, Topical Powder, 100000 [USP'U]/1 g (NDC 0832-0465-30)",Topical Powder,,"N0000175498, M0017172",ANDA065183,Polyenes [CS],NYSTATIN,Polyene Antifungal [EPC],,To Be Discontinued,,,,BDF1O1C72E,0832-0465-30,800-654-2299,
AstraZeneca AB,EXENATIDE,,10/28/2024,New,SUBCUTANEOUS,"Exenatide Synthetic Injectable Suspension, Extended Release","1990866, 1990869",,2d18cfc4-e0de-4814-a712-c1b7c504bff5,10/28/2024,HUMAN PRESCRIPTION DRUG,10/28/2024,Endocrinology/Metabolism,BYDUREON BCISE,0310-6540,AstraZeneca Pharmaceuticals LP,8017da29-f155-4835-a278-3f21c00fb118,"0310-6540-01, 0310-6540-04, 0310-6540-85","Bydureon BCise, Injectable Suspension, Extended Release, 2 mg/.85 mL (NDC 0310-6540-04)",Injectable Suspension,,"N0000178480, M0160181, N0000020058",NDA209210,Glucagon-Like Peptide 1 [CS],EXENATIDE,GLP-1 Receptor Agonist [EPC],,To Be Discontinued,,,,9P1872D4OL,0310-6540-04,800-236-9933,Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
Eugia US LLC,FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Furosemide Injection,"1719286, 1719290, 1719291",,421aa6d5-623b-4dc2-abd5-bb9e7765bf37,09/25/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,"55150-323, 55150-322, 55150-324",Eugia US LLC,26acfb26-d058-453e-8c05-61ec44b25118,"55150-322-01, 55150-322-25, 55150-323-01, 55150-323-25, 55150-324-01, 55150-324-25","Furosemide, Injection, 40 mg/4 mL (NDC 55150-323-25)",Injection,Available,"N0000175366, N0000175590",ANDA212174,,FUROSEMIDE,Loop Diuretic [EPC],,Current,,Check wholesalers for inventory,,7LXU5N7ZO5,55150-323-25,888-238-7880,
"Hospira, Inc., a Pfizer Company",LIDOCAINE HYDROCHLORIDE,,02/22/2012,Revised,INTRAVENOUS,Lidocaine Hydrochloride Injection,"1012066, 1012068",,ad1ef0a8-88db-4648-c098-d009eaeb4e5b,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE HYDROCHLORIDE,"0409-4904, 0409-4903, 0409-1323, 0409-9137","Hospira, Inc.",477abea3-c873-4265-82e8-5508ef54399f,"0409-4903-11, 0409-4903-34, 0409-4904-11, 0409-4904-34, 0409-1323-15, 0409-1323-05, 0409-9137-11, 0409-9137-05","Lidocaine Hydrochloride, Injection, 50 mg/5mL (1%,10 mg/1 mL) Syringes (NDC 0409-4904-34)",Injection,Unavailable,,ANDA083158,,LIDOCAINE HYDROCHLORIDE,,,Current,Other,Next Delivery: January 2026; Estimated Recovery: March 2026,12/19/2024,V13007Z41A,0409-4904-34,844-646-4398,
Takeda Pharmaceuticals USA Inc.,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,"Lisdexamfetamine Dimesylate Tablet, Chewable","854830, 854832, 854834, 854836, 854838, 854840, 854842, 854844, 854846, 854848, 854850, 854852, 1593856, 1593858, 1871456, 1871459, 1871460, 1871461, 1871462, 1871463, 1871464, 1871465, 1871466, 1871467, 1871468, 1871469",,704e4378-ca83-445c-8b45-3cfa51c1ecad,08/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,VYVANSE,"59417-116, 59417-101, 59417-102, 59417-103, 59417-104, 59417-105, 59417-106, 59417-107, 59417-115, 59417-117, 59417-118, 59417-119, 59417-120","Takeda Pharmaceuticals America, Inc.",756b98a0-fada-44b2-a606-f2e71ef8cc84,"59417-101-10, 59417-102-10, 59417-103-10, 59417-104-10, 59417-105-10, 59417-106-10, 59417-107-10, 59417-115-01, 59417-116-01, 59417-117-01, 59417-118-01, 59417-119-01, 59417-120-01","Vyvanse, Tablet, Chewable, 20 mg (NDC 59417-116-01)","Tablet, Chewable",Available,,NDA208510,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,59417-116-01,877-TAKEDA-7 (1-877-825-3327),
"Fresenius Kabi USA, LLC",ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Reverified,EPIDURAL,Ropivacaine Hydrochloride Injection,"905189, 905191, 1734084, 1734086, 1734090, 1734091, 1734203, 1734204, 1734207, 1734208, 1734347, 1734348, 1734355, 1734356, 1734475, 1734476, 1734479, 1734480, 1734481, 1734482, 1734483, 1734484",,"23d2d448-a744-4877-9f2d-7e57c198da89, c6613708-c1f7-4f5c-91a3-ebbc1d7905c6, 56dfabf7-f7a8-4601-b17a-cb16fb995b0f",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,NAROPIN,"63323-288, 63323-286, 63323-287, 63323-285","Fresenius Kabi USA, LLC","cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9, 73218c89-8925-468c-84bf-9960b4b3dc3c, 75465ceb-e894-487d-aa80-671fa0841fce","63323-286-01, 63323-286-20, 63323-286-05, 63323-286-23, 63323-286-09, 63323-286-31, 63323-286-11, 63323-286-35, 63323-286-03, 63323-286-00, 63323-286-33, 63323-286-63, 63323-286-30, 63323-287-01, 63323-287-20, 63323-287-03, 63323-287-21, 63323-288-01, 63323-288-10, 63323-288-06, 63323-288-20, 63323-288-03, 63323-288-11, 63323-288-07, 63323-288-21, 63323-285-01, 63323-285-10, 63323-285-06, 63323-285-20, 63323-285-03, 63323-285-13, 63323-285-07, 63323-285-23, 63323-285-57, 63323-285-64, 63323-285-51, 63323-285-65, 63323-285-02, 63323-285-61, 63323-285-04, 63323-285-63, 63323-285-55, 63323-285-67, 63323-288-23, 63323-288-29, 63323-286-93, 63323-286-95, 63323-288-25, 63323-288-27","Naropin, Injection, 10 mg/1 mL (NDC 63323-288-10)",Injection,Unavailable,,NDA020533,,ROPIVACAINE HYDROCHLORIDE,,,Current,Delay in shipping of the drug,Next release not available at this time.,,V910P86109,63323-288-10,888-386-1300,
Baxter Healthcare,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807551, 1807552, 1807627, 1807630, 1807631, 1807632, 1807633, 1807634, 1807639",,f55bd888-5e01-474d-871b-24654c070178,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0338-0049, 0338-0043",Baxter Healthcare Corporation,6ab23768-efd2-4ff1-b336-0dda08dc56e1,"0338-0049-01, 0338-0049-02, 0338-0049-03, 0338-0049-04, 0338-0049-10, 0338-0049-41, 0338-0049-11, 0338-0049-31, 0338-0049-48, 0338-0049-18, 0338-0049-38, 0338-0043-03, 0338-0043-04","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-31)",Injection,,,NDA016677,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0338-0049-31,888-229-0001,
"Teva Pharmaceuticals USA, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Revised,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541365, 541878, 541879, 541892, 541894, 577957, 577960, 577961, 577962, 687043, 687045, 1009145, 1009147",,f22635fe-821d-4cde-aa12-419f8b53db81,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,ADDERALL,"57844-130, 57844-105, 57844-117, 57844-110, 57844-112, 57844-115, 57844-120","Teva Pharmaceuticals USA, Inc.",79af1dc6-c7cf-41b1-a750-e9b47c2187ff,"57844-105-01, 57844-117-01, 57844-110-01, 57844-112-01, 57844-115-01, 57844-120-01, 57844-130-01","Adderall, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 57844-130-01)",Tablet,Available,,ANDA040422,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",57844-130-01,800-545-8800,
Pfizer Inc.,,,01/06/2023,Revised,,Somatropin Injection,"241975, 762830, 762833, 762834, 762836, 762837, 762839, 762841, 762843, 762846, 762849, 762850, 762852, 762857, 762859, 762866, 762868, 762873, 762875, 762895, 762897, 763488, 763489, 996558, 996559",,ffebf88b-d257-4542-9808-74d9b7167765,08/28/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,GENOTROPIN,"0013-2651, 0013-2626, 0013-2646, 0013-2649, 0013-2650, 0013-2652, 0013-2653, 0013-2654, 0013-2655, 0013-2656, 0013-2657, 0013-2658",Pfizer Laboratories Div Pfizer Inc,f09acf87-6e30-47ad-9891-8a49bf6dffbc,"0013-2626-81, 0013-2646-81, 0013-2649-02, 0013-2650-02, 0013-2651-02, 0013-2652-02, 0013-2653-02, 0013-2654-02, 0013-2655-02, 0013-2656-02, 0013-2657-02, 0013-2658-02","Genotropin, Injection, 0.6 mg preservative free (NDC 0013-2651-02)",Injection,,,BLA020280,,SOMATROPIN,,Available,Resolved,,,08/28/2025,,0013-2651-02,800-533-4535,
"Mylan Pharmaceuticals Inc., a Viatris Company",VARENICLINE TARTRATE,,02/06/2025,New,ORAL,Varenicline Tartrate Tablet,"636671, 636676, 749289",,4233fb78-ac6c-49f3-aad8-7e4bee18cac6,02/06/2025,HUMAN PRESCRIPTION DRUG,02/06/2025,Analgesia/Addiction,VARENICLINE,"0378-5089, 0378-5090, 0378-5091",Mylan Pharmaceuticals Inc.,5b7b6e3b-f427-4000-b252-968f3adbaa3b,"0378-5089-73, 0378-5090-73, 0378-5091-85, 0378-5089-46, 0378-5090-23","Varenicline Tartrate, Tablet, .5 mg (NDC 0378-5089-73)",Tablet,,,ANDA202019,,VARENICLINE,,,To Be Discontinued,,Permanent discontinuation in the manufacturing of the drug,,82269ASB48,0378-5089-73,800-796-9526,
"American Regent, Inc.",ATROPINE SULFATE,,01/01/2012,Reverified,INTRAVENOUS,Atropine Sulfate Injection,"1190795, 1666781",,6fee1727-52b7-4f73-ab45-ef47d6a1c5bb,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology, Pediatric",ATROPINE SULFATE,"0517-1001, 0517-1004","American Regent, Inc.",1c500ed9-94a9-472c-bfb7-50e1fcfc31fb,"0517-1004-01, 0517-1004-25, 0517-1001-01, 0517-1001-25","Atropine Sulfate, Injection, 1 mg/1 mL (NDC 0517-1001-25)",Injection,Available,,ANDA216120,,ATROPINE SULFATE,,,Current,,old NDC 0517-1010-25,,03J5ZE7KA5,0517-1001-25,800-645-1706,
Pfizer Inc.,,,01/06/2023,Revised,,Somatropin Injection,"241975, 762830, 762833, 762834, 762836, 762837, 762839, 762841, 762843, 762846, 762849, 762850, 762852, 762857, 762859, 762866, 762868, 762873, 762875, 762895, 762897, 763488, 763489, 996558, 996559",,ffebf88b-d257-4542-9808-74d9b7167765,08/28/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,GENOTROPIN,"0013-2626, 0013-2646, 0013-2649, 0013-2650, 0013-2651, 0013-2652, 0013-2653, 0013-2654, 0013-2655, 0013-2656, 0013-2657, 0013-2658",Pfizer Laboratories Div Pfizer Inc,f09acf87-6e30-47ad-9891-8a49bf6dffbc,"0013-2626-81, 0013-2646-81, 0013-2649-02, 0013-2650-02, 0013-2651-02, 0013-2652-02, 0013-2653-02, 0013-2654-02, 0013-2655-02, 0013-2656-02, 0013-2657-02, 0013-2658-02","Genotropin, Injection, 5 mg/mL, w/ preservative (NDC 0013-2626-81)",Injection,,,BLA020280,,SOMATROPIN,,Available,Resolved,,,08/28/2025,,0013-2626-81,800-533-4535,
"Upsher-Smith Laboratories, LLC",TOPIRAMATE,Decreased Central Nervous System Disorganized Electrical Activity [PE],04/24/2025,New,ORAL,"Topiramate Capsule, Extended Release","1494766, 1494769, 1494771, 1494775, 1494778, 1494781, 1812419, 1812421, 1812425, 1812427",,46f54677-3a22-4c38-9b92-923020164e15,04/24/2025,HUMAN PRESCRIPTION DRUG,04/24/2025,Neurology,QUDEXY XR,"0245-1071, 0245-1072, 0245-1074, 0245-1075, 0245-1073","Upsher-Smith Laboratories, LLC",374eeb55-b017-48fd-e063-6294a90a6ad7,"0245-1071-30, 0245-1071-90, 0245-1072-30, 0245-1072-90, 0245-1074-30, 0245-1074-90, 0245-1075-30, 0245-1075-90, 0245-1073-30, 0245-1073-90","Qudexy XR, Capsule, Extended Release, 25 mg (NDC 0245-1071-30)","Capsule, Extended Release",,"N0000008486, N0000185506, N0000182140",NDA205122,,TOPIRAMATE,,,To Be Discontinued,,Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.,,0H73WJJ391,0245-1071-30,716-315-2000,"Cytochrome P450 3A4 Inducers [MoA], Cytochrome P450 2C19 Inhibitors [MoA]"
"Hospira, Inc., a Pfizer Company",DOBUTAMINE HYDROCHLORIDE,,11/06/2017,Revised,INTRAVENOUS,Dobutamine Hydrochloride Injection,"309985, 309986, 309987",,9943a961-3b50-4847-8a84-d8414ce38daa,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Cardiovascular, Pediatric, Renal",DOBUTAMINE IN DEXTROSE,"0409-2346, 0409-2347, 0409-3724","Hospira, Inc.",2cd41f69-c1ea-44a0-9b56-b6f9d963f6a5,"0409-2347-31, 0409-2347-32, 0409-2346-31, 0409-2346-32, 0409-3724-11, 0409-3724-32","Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-2346-32)",Injection,Unavailable,,NDA020201,,DOBUTAMINE IN DEXTROSE,,,Current,Demand increase for the drug,Next Delivery: November 2025; Estimated Recovery: December 2025,,0WR771DJXV,0409-2346-32,844-646-4398,
"Teva Pharmaceuticals USA, Inc.",ISOSORBIDE MONONITRATE,Vasodilation [PE],11/13/2024,New,ORAL,Isosorbide Mononitrate Tablet,"311192, 311197",,ae8f74f0-e600-4452-8557-958b603e2709,11/13/2024,HUMAN PRESCRIPTION DRUG,11/13/2024,Cardiovascular,ISOSORBIDE MONONITRATE,"0228-2620, 0228-2631","Actavis Pharma, Inc.",1cb05f66-1c19-4300-8745-8c74c1dccb2b,"0228-2631-11, 0228-2620-11","Tablet, 20 mg (NDC 0228-2620-11)",Tablet,,"N0000175415, M0014874, N0000009909",ANDA075037,Nitrates [CS],ISOSORBIDE MONONITRATE,Nitrate Vasodilator [EPC],,To Be Discontinued,,A business decision was made to discontinue manufacture of this product.,,LX1OH63030,0228-2620-11,800-545-8800,
B. Braun Medical Inc.,"CALCIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, SODIUM LACTATE",,10/11/2024,Reverified,INTRAVENOUS,Lactated Ringers Injection,847627,,190da07e-a616-46e6-b4e5-1c0ba39306e5,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other",DEXTROSE IN LACTATED RINGERS,0264-7751,B. Braun Medical Inc.,63aa1cd2-fda4-4386-8d11-5d1617634ef7,"0264-7751-00, 0264-7751-10","Lactated Ringers, Injection, .02 g/100 mL; 5 g/100 mL; .03 g/100 mL; .6 g/100 mL; .31 g/100 mL (NDC 0264-7751-00)",Injection,Available,,NDA019634,,"DEXTROSE, SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, AND CALCIUM CHLORIDE",,,Current,,,,"M4I0D6VV5M, LX22YL083G, 660YQ98I10, 451W47IQ8X, TU7HW0W0QT",0264-7751-00,800-227-2862,
"Hospira, Inc., a Pfizer Company",MIDAZOLAM HYDROCHLORIDE,,04/02/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Midazolam Hydrochloride Injection,"311700, 311702",,affecd4d-1f78-4bbe-5a8d-86849bbdc520,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology",MIDAZOLAM,"0409-2587, 0409-2596","Hospira, Inc.",923cfac2-557d-40b4-9ee0-3e933685a5fc,"0409-2587-04, 0409-2587-05, 0409-2596-13, 0409-2596-03, 0409-2596-15, 0409-2596-05","Midazolam Hydrochloride, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-2587-05)",Injection,Available,,ANDA075293,,MIDAZOLAM HYDROCHLORIDE,,,Current,,,,W7TTW573JJ,0409-2587-05,844-646-4398,
"Mylan Institutional, a Viatris Company",ROCURONIUM BROMIDE,,02/15/2023,Reverified,INTRAVENOUS,Rocuronium Bromide Injection,,,f58803b0-f173-4997-b2f8-0f415b94dacf,09/17/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROCURONIUM BROMIDE,67457-228,Mylan Institutional LLC,3316cfdc-67e7-437d-9c90-1c383b53b272,"67457-228-00, 67457-228-05, 67457-228-99, 67457-228-10","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-05)",Injection,Available,,ANDA079199,,ROCURONIUM BROMIDE,,,Current,,,,I65MW4OFHZ,67457-228-05,800-796-9526,
"Hospira, Inc., a Pfizer Company",SODIUM ACETATE ANHYDROUS,,02/03/2016,Reverified,INTRAVENOUS,Sodium Acetate Injection,237371,,"abc41ed1-9512-4bea-9295-1a9ca134b6c2, c3be2468-45e8-4ecc-a30b-e966743a563f",08/15/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Pediatric, Total Parenteral Nutrition",SODIUM ACETATE,0409-3299,"Hospira, Inc.","eadea22b-c475-4596-8c15-e738af5a711d, 99255488-8958-49ab-965c-083119f5ba3c","0409-3299-15, 0409-3299-05, 0409-3299-16, 0409-3299-06, 0409-3299-45, 0409-3299-25, 0409-3299-46, 0409-3299-26","Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-06)",Injection,Available,,NDA018893,,SODIUM ACETATE,,,Current,,,,NVG71ZZ7P0,0409-3299-06,844-646-4398,
"Hospira, Inc., a Pfizer Company",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Bupivacaine Hydrochloride Injection,"1725078, 1725082, 1012377, 1012384, 1012396, 1012404, 1672917, 1672919, 1724786, 1724787, 1724880, 1724884, 1867594, 1867596",,"bb44c7e1-d911-4788-908f-09b7b271969b, 02a845c3-4521-4926-e397-25ab536e7cf6",08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE,"0409-1159, 0409-1160, 0409-1162, 0409-1163, 0409-1165, 0409-9043, 0409-9046, 0409-9045, 0409-9042","Hospira, Inc.","40bfa804-5f31-4bd2-b1e3-dcf428710dc1, 3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7","0409-1159-09, 0409-1159-10, 0409-1159-18, 0409-1159-01, 0409-1159-19, 0409-1159-02, 0409-1160-18, 0409-1160-01, 0409-1162-18, 0409-1162-01, 0409-1162-19, 0409-1162-02, 0409-1163-18, 0409-1163-01, 0409-1165-18, 0409-1165-01, 0409-1165-19, 0409-1165-02, 0409-9043-11, 0409-9043-01, 0409-9046-11, 0409-9046-01, 0409-9045-11, 0409-9045-01, 0409-9045-16, 0409-9045-17, 0409-9042-11, 0409-9042-01, 0409-9042-16, 0409-9042-17","Bupivacaine Hydrochloride, Injection, 0.25%; 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-10)",Injection,Unavailable,,ANDA070583,,BUPIVACAINE HYDROCHLORIDE,,,Current,Other,Next Delivery and Estimated Recovery: December 2028,,"7TQO7W3VT8, 30Q7KI53AK",0409-1159-10,844-646-4398,
Ferring,,,03/12/2021,Reverified,,Desmopressin Acetate Spray,,,,09/17/2025,,,Hematology,,,,,,"Ddavp, Spray, .1 ug/1 mL (NDC 55566-2500-0)",Spray,Unavailable,,,,,,,Current,Requirements related to complying with good manufacturing practices,,,,55566-2500-0,888-337-7464,
B. Braun Medical Inc.,"DEXTROSE, UNSPECIFIED FORM",,03/01/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 10% Injection,"1795477, 1795480, 1795481, 1795607, 1795610, 1795612",,085614c7-ada4-4e2c-87c0-c9bc2f18365a,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0264-7520, 0264-7510",B. Braun Medical Inc.,c9f87749-8dd5-41fd-b393-f63d45fd00ef,"0264-7510-00, 0264-7510-10, 0264-7510-20, 0264-7520-00, 0264-7520-10, 0264-7520-20","Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-20)",Injection,Available,,NDA019626,,DEXTROSE,,,Current,,,,IY9XDZ35W2,0264-7520-20,800-227-2862,
Pfizer Inc.,DOCETAXEL ANHYDROUS,Microtubule Inhibition [PE],01/15/2025,New,INTRAVENOUS,Docetaxel Injection,1093280,,644c5035-20d2-4686-beaa-bef08e99051c,01/15/2025,HUMAN PRESCRIPTION DRUG,01/15/2025,Oncology,DOCETAXEL,"0409-7870, 0409-1732","Hospira, Inc.",5b12d54f-e7fd-4369-afb3-431f6f08ec76,"0409-7870-01, 0409-1732-01","Docetaxel, Injection, 10 mg/1 mL (NDC 0409-7870-01)",Injection,,"N0000175085, N0000175592",NDA022234,,DOCETAXEL ANHYDROUS,Microtubule Inhibitor [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,699121PHCA,0409-7870-01,844-646-4398,
"Hospira, Inc., a Pfizer Company",HYDROCORTISONE SODIUM SUCCINATE,,03/24/2023,Revised,"INTRAMUSCULAR, INTRAVENOUS",Hydrocortisone Sodium Succinate Injection,"105398, 238755, 1738586, 1738589, 1738590, 1738592, 1738594, 1738596",https://cdernexus.fda.gov/suite/sites/dsm/page/home,65eefd58-b166-4d71-ade6-45c8fdf86922,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Pulmonary/Allergy, Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Pediatric, Renal, Rheumatology",SOLU-CORTEF,"0009-0011, 0009-0825, 0009-0013, 0009-0016, 0009-0005",Pharmacia & Upjohn Company LLC,8512044a-4a54-4634-bb97-9e20126adc61,"0009-0825-01, 0009-0011-03, 0009-0011-04, 0009-0013-05, 0009-0013-06, 0009-0016-12, 0009-0005-01","Solu-Cortef, Injection, 100 mg/vial (NDC 0009-0011-03)",Injection,Limited Availability,,NDA009866,,HYDROCORTISONE SODIUM SUCCINATE,,,Current,Demand increase for the drug,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,12/19/2024,50LQB69S1Z,0009-0011-03,844-646-4398,
"Fresenius Kabi USA, LLC",HYDROMORPHONE HYDROCHLORIDE,,10/31/2017,Reverified,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Hydromorphone Hydrochloride Injection,"897756, 897757, 1433251, 1872265, 1872269, 1872752, 2277368, 2277370",,9eebd88a-5632-460f-b7b6-26c8a180540d,09/18/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,DILAUDID,"76045-009, 76045-010, 76045-121","Fresenius Kabi USA, LLC",97bfcafb-2037-47dc-a0ae-f7b8007c47df,"76045-009-96, 76045-009-06, 76045-009-01, 76045-009-11, 76045-010-01, 76045-010-11, 76045-121-01, 76045-121-11","Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-11)",Injection,Available,,NDA019034,,HYDROMORPHONE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,L960UP2KRW,76045-009-11,888-386-1300,
"Fresenius Kabi USA, LLC",LIDOCAINE HYDROCHLORIDE ANHYDROUS,,02/22/2012,Reverified,"INFILTRATION, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010035, 1010671, 1010673, 1010688, 1010692, 1010745, 1010749, 1010751, 1010755, 1010759, 1010763, 1010900, 1010902, 1737343, 1737345, 1737562, 1737563, 1737566, 1737567, 1737568, 1737569, 1737570, 1737571, 1737757, 1737758, 1737761, 1737762, 1867938, 1867940, 1867943, 1867944, 1867992, 1867993, 1867996, 1867997, 1868028, 1868029",,"ba082c2f-64f4-419d-9c88-74f203316e17, 4dd52202-8eef-4136-92dd-ada573b7cf74",09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",XYLOCAINE,"63323-485, 63323-492, 63323-491, 63323-495, 63323-486, 63323-484, 63323-489, 63323-488, 63323-481, 63323-483, 63323-482, 63323-487","Fresenius Kabi USA, LLC","ea480a68-5927-4278-9deb-2956961da428, 0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33","63323-492-04, 63323-492-27, 63323-492-09, 63323-492-57, 63323-492-07, 63323-492-37, 63323-492-03, 63323-492-31, 63323-491-01, 63323-491-57, 63323-495-09, 63323-495-27, 63323-495-04, 63323-495-07, 63323-485-01, 63323-485-27, 63323-485-03, 63323-485-57, 63323-486-01, 63323-486-17, 63323-486-02, 63323-486-27, 63323-486-05, 63323-486-57, 63323-484-57, 63323-489-02, 63323-489-27, 63323-489-03, 63323-489-21, 63323-489-01, 63323-489-17, 63323-488-07, 63323-488-37, 63323-488-03, 63323-488-31, 63323-488-01, 63323-488-17, 63323-481-01, 63323-481-57, 63323-483-03, 63323-483-27, 63323-483-01, 63323-483-57, 63323-482-01, 63323-482-17, 63323-482-03, 63323-482-27, 63323-482-05, 63323-482-57, 63323-487-01, 63323-487-17, 63323-487-07, 63323-487-37, 63323-487-03, 63323-487-31, 63323-492-41, 63323-492-16, 63323-492-43, 63323-492-36, 63323-492-45, 63323-492-26, 63323-485-41, 63323-485-26, 63323-486-41, 63323-486-26, 63323-482-41, 63323-482-26, 63323-495-41, 63323-495-26","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-57)",Injection,Available,,NDA006488,,LIDOCAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,"EC2CNF7XFP, 30Q7KI53AK",63323-485-57,888-386-1300,
Pfizer Inc.,METHYLPREDNISOLONE ACETATE,,12/15/2021,Reverified,"INTRALESIONAL, INTRAMUSCULAR, INTRASYNOVIAL, SOFT TISSUE, INTRA-ARTICULAR",Methylprednisolone Acetate Injection,"1743779, 1743781, 1743855, 1743856",,"bf1b104d-85cb-414d-a366-78068c82c883, 9a7b3837-e038-48bf-97e9-78ad463760dc",08/15/2025,HUMAN PRESCRIPTION DRUG,,Rheumatology,DEPO-MEDROL,"0009-3073, 0009-3475",Pharmacia & Upjohn Company LLC,"d7ccf8b4-deb4-43c1-b67b-1f610d6d8425, befd723e-d1e2-41b9-83f1-17bca0c2a941","0009-3073-22, 0009-3073-23, 0009-3475-22, 0009-3475-23, 0009-3073-01, 0009-3073-03, 0009-3475-01, 0009-3475-03","Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)",Injection,Available,,NDA011757,,METHYLPREDNISOLONE ACETATE,,,Current,,,,43502P7F0P,0009-3073-01,844-646-4398,
Aurobindo Pharma USA,METOPROLOL TARTRATE,,06/03/2025,New,ORAL,Metoprolol Tartrate Tablet,"866511, 866514, 866924",,2b705cb6-cb75-4c2a-907a-4bd45d18bc2c,06/03/2025,HUMAN PRESCRIPTION DRUG,06/03/2025,Cardiovascular,METOPROLOL TARTRATE,"65862-064, 65862-062, 65862-063",Aurobindo Pharma Limited,d265c99d-8e77-4a78-b542-15e957d9d335,"65862-062-01, 65862-062-99, 65862-063-60, 65862-063-01, 65862-063-99, 65862-064-60, 65862-064-01, 65862-064-99","Metoprolol Tartrate, Tablet, 100 mg (NDC 65862-064-99)",Tablet,,,ANDA077739,,METOPROLOL TARTRATE,,,To Be Discontinued,,Permanent discontinuation in the manufacturing of the drug,,W5S57Y3A5L,65862-064-99,866-850-2876,
"Elite Laboratories, Inc.",NALTREXONE HYDROCHLORIDE,,02/29/2024,Revised,ORAL,Naltrexone Hydrochloride Tablet,1483744,,b09b4b5e-795a-48e7-b7cc-2e29f41c5660,09/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,NALTREXONE HYDROCHLORIDE,68094-909,Precision Dose Inc.,48b82306-b0ba-4cb8-817d-896ccde0367b,"68094-909-30, 68094-909-50","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 68094-909-30)",Tablet,Available,,ANDA075274,,NALTREXONE HYDROCHLORIDE,,,Current,,Marketed by Precision Dose; Customer service: 800-397-9228,,Z6375YW9SF,68094-909-30,888-852-6657,
"Upsher-Smith Laboratories, LLC",POTASSIUM CHLORIDE,,07/23/2025,New,ORAL,"Potassium Chloride Tablet, Extended Release","312529, 628953, 628958, 832718",,1ff53330-065c-4213-9c0c-ac498621d09d,07/23/2025,HUMAN PRESCRIPTION DRUG,07/23/2025,"Endocrinology/Metabolism, Gastroenterology",KLOR-CON,"0245-5316, 0245-5315","Upsher-Smith Laboratories, LLC",39e77e07-bdc8-28e9-e063-6394a90a120c,"0245-5315-11, 0245-5315-15, 0245-5315-89, 0245-5315-01, 0245-5316-11, 0245-5316-15, 0245-5316-89, 0245-5316-01","Klor-Con, Tablet, Extended Release, 750 mg (NDC 0245-5316-15)",Tablet,,,NDA019123,,POTASSIUM CHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug product,,660YQ98I10,0245-5316-15,763-315-2000,
"Mylan Institutional, a Viatris Company",REMIFENTANIL HYDROCHLORIDE,,06/28/2022,Reverified,INTRAVENOUS,Remifentanil Hydrochloride Injection,"1729578, 1729581, 1729584, 1729586, 1729710, 1729712",,8b4c8696-e23e-4c51-a4d2-babab5bd945a,09/17/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,ULTIVA,"72078-035, 72078-034, 72078-036",Mylan Institutional LLC,c10cf43f-066a-43ff-9166-242cbb7754af,"72078-034-00, 72078-034-01, 72078-035-00, 72078-035-02, 72078-036-00, 72078-036-05","Ultiva, Injection, 2 mg (NDC 72078-035-02)",Injection,Available,,NDA020630,,REMIFENTANIL HYDROCHLORIDE,,,Current,,,,5V444H5WIC,72078-035-02,800-796-9526,
"Fresenius Kabi USA, LLC",,,03/23/2018,Reverified,,Ropivacaine Hydrochloride Injection,,,,09/18/2025,,,Anesthesia,,,,,,"Naropin, Injection, 2 mg/1 mL (NDC 65219-632-20)",Injection,Available,,,,,,,Current,,,,,65219-632-20,888-386-1300,
"Laboratorios Grifols, S.A.",SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807631, 1807632, 1807633, 1807634, 1807639",,eb811d79-fdb8-1f1a-c2ad-1cc4bfc7eadf,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,76297-001,LABORATORIOS GRIFOLS SA,ff5ef1ef-2a0d-476d-8483-ffd7cd47c635,"76297-001-12, 76297-001-11, 76297-001-22, 76297-001-21, 76297-001-32, 76297-001-31, 76297-001-02, 76297-001-01, 76297-001-42, 76297-001-41, 76297-001-52, 76297-001-51, 76297-001-62, 76297-001-61, 76297-001-72, 76297-001-71, 76297-001-82, 76297-001-81, 76297-001-92, 76297-001-91","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-31)",Injection,,,ANDA207956,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,76297-001-31,800-848-0462,
"Novo Nordisk, Inc.",SOMATROPIN,,01/06/2023,Revised,SUBCUTANEOUS,Somatropin Injection,"847243, 847245, 847247, 847348, 849850, 849851, 1736262, 1736329",,1058e17c-9261-459c-a3e6-fae38d196c14,08/28/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,NORDITROPIN,"0169-7705, 0169-7704, 0169-7708, 0169-7703",Novo Nordisk,b67c2419-4feb-4ce1-b97e-88760a8e1aee,"0169-7704-21, 0169-7704-92, 0169-7705-21, 0169-7705-92, 0169-7708-21, 0169-7708-92, 0169-7703-11, 0169-7703-91, 0169-7703-21, 0169-7703-92","Norditropin, Injection, 10 mg/1.5 mL (NDC 0169-7705-21)",Injection,,"N0000175606, M0028842",BLA021148,Human Growth Hormone [CS],SOMATROPIN,Recombinant Human Growth Hormone [EPC],Available,Resolved,,,08/28/2025,NQX9KB6PCL,0169-7705-21,609-987-5800,
"Teva Pharmaceuticals USA, Inc.",FINASTERIDE,,08/19/2025,New,ORAL,Finasteride Tablet,310346,,77589cc3-c440-4695-800c-82a0e5128a6c,08/19/2025,HUMAN PRESCRIPTION DRUG,08/19/2025,Urology,FINASTERIDE,0093-7355,"Teva Pharmaceuticals USA, Inc.",ea83e229-c434-4097-81dd-e3b48814d5dc,"0093-7355-56, 0093-7355-98, 0093-7355-05","Finasteride, Tablet, 5 mg (NDC 0093-7355-98)",Tablet,,"N0000175836, N0000000126",ANDA076511,,FINASTERIDE,5-alpha Reductase Inhibitor [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug product,,57GNO57U7G,0093-7355-98,800-545-8800,5-alpha Reductase Inhibitors [MoA]
"EMD Serono, Inc.",LEVOTHYROXINE SODIUM,,07/10/2025,New,ORAL,Levothyroxine Sodium Tablet,"892246, 892251, 966153, 966160, 966166, 966173, 966177, 966182, 966187, 966196, 966202, 966207, 966220, 966221, 966222, 966224, 966225, 966248, 966249, 966253, 966270, 2104866",,bc3c6830-ba68-4ba3-9896-a12d0ad0b275,07/10/2025,HUMAN PRESCRIPTION DRUG,07/10/2025,Endocrinology/Metabolism,EUTHYROX,"72305-100, 72305-025, 72305-050, 72305-075, 72305-088, 72305-112, 72305-125, 72305-137, 72305-150, 72305-175, 72305-200","Provell Pharmaceuticals, LLC",45657074-8874-49f4-a8ef-3ca7e210c16e,"72305-025-30, 72305-025-90, 72305-050-30, 72305-050-90, 72305-075-30, 72305-075-90, 72305-088-30, 72305-088-90, 72305-100-30, 72305-100-90, 72305-112-30, 72305-112-90, 72305-125-30, 72305-125-90, 72305-137-30, 72305-137-90, 72305-150-30, 72305-150-90, 72305-175-30, 72305-175-90, 72305-200-30, 72305-200-90","Euthyrox, Tablet, 100 ug (NDC 72305-100-30)",Tablet,,,NDA021292,,LEVOTHYROXINE SODIUM,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,9J765S329G,72305-100-30,888-899-7041,
SpecGx LLC,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 1009145",,72ddd1c9-ddbd-4c95-acd9-003189a353a3,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE,"0406-8893, 0406-8891, 0406-8884, 0406-8892, 0406-8885, 0406-8894",SpecGx LLC,b25a2f3f-ee3a-44c0-a475-f371025c767b,"0406-8891-01, 0406-8884-01, 0406-8892-01, 0406-8885-01, 0406-8893-01, 0406-8894-01","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0406-8893-01)",Tablet,Available,,ANDA040440,,DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE,,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",0406-8893-01,800-325-8888,
"Hikma Pharmaceuticals USA, Inc.",OXYCODONE HYDROCHLORIDE,,09/11/2025,New,ORAL,Oxycodone Hydrochloride Oral Solution,1049604,,d8e87c66-f872-4e1d-9ade-ef11490af63b,09/11/2025,HUMAN PRESCRIPTION DRUG,09/11/2025,Analgesia/Addiction,OXYCODONE HYDROCHLORIDE,0054-0390,Hikma Pharmceuticals USA Inc.,57a6f3e9-0330-41dd-adfb-0b554536d78f,"0054-0390-41, 0054-0390-63","Oxycodone Hydrochloride, Oral Solution, 5 mg/5 mL (NDC 0054-0390-41)",Oral Solution,,,ANDA204037,,OXYCODONE HYDROCHLORIDE,,,To Be Discontinued,,Hikma has permanently discontinued (NDC 0054-0390-41) for the 15 mL bottle configuration. Hikma will continue to distribute Oxycodone Hydrochloride Oral Solution 5 mg/5 mL in the 500 mL bottle (NDC 0054-0390-63).,,C1ENJ2TE6C,0054-0390-41,800-631-2174,
Laboratorios Atral,PENICILLIN G BENZATHINE,,04/26/2023,Reverified,INTRAMUSCULAR,Penicillin G Benzathine Injection,"2671687, 2684991",https://www.fda.gov/media/182165/download?attachment,1a4e5124-618b-ce44-e063-6394a90a43e3,09/17/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,LENTOCILIN,84383-110,"LABORATRIOS ATRAL, S.A.",1a4e5124-618c-ce44-e063-6394a90a43e3,84383-110-01,"Lentocilin, Injection, 1200000 U/4 mL (NDC 84383-110-01)",Injection,Available,,,,PENICILLIN G BENZATHIN,,,Current,,,,RIT82F58GK,84383-110-01,Mark Cuban Cost Plus Drug Company: 682-428-8081,
"Exela Pharma Sciences, LLC",SODIUM BICARBONATE,,07/24/2017,Revised,INTRAVENOUS,Sodium Bicarbonate Injection,"807284, 1868486, 1923484, 2198792",,e9698a4f-1a95-4f28-a945-e8009d1d6dd4,09/15/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Pediatric",SODIUM BICARBONATE,"51754-5001, 51754-5011, 51754-5002, 51754-5012","Exela Pharma Sciences, LLC",4da0ba66-756d-4b4d-8018-81ca16578ef1,"51754-5001-5, 51754-5001-4, 51754-5011-4, 51754-5002-5, 51754-5012-4","Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5001-5)",Injection,Available,,ANDA211091,,SODIUM BICARBONATE,,,Current,,Clearing all backorders today.,,8MDF5V39QO,51754-5001-5,828-758-5474 ext. 154,
B. Braun Medical Inc.,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807551, 1807552, 1807633, 1807634, 1807639",,7f22c06b-6b4d-4b49-a4b2-d2169f2bd653,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0264-7802, 0264-7800",B. Braun Medical Inc.,9fa9f6b4-63b5-4632-8104-37c3dd1ee8fa,"0264-7800-00, 0264-7800-10, 0264-7800-20, 0264-7802-00, 0264-7802-10","Sodium Chloride 0.9%, Injection, .45 g/100 mL (NDC 0264-7802-10)",Injection,,,NDA019635,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0264-7802-10,800-227-2862,
Otsuka ICU Medical LLC,WATER,,04/28/2023,Reverified,IRRIGATION,Sterile Water Irrigant,150985,https://www.fda.gov/media/182619/download?attachment,e3484bc6-ed7f-43ef-9d49-c131a8dff2dd,09/17/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",STERILE WATER,"0990-7139, 0990-6139, 0990-7973",ICU Medical Inc.,22b6a1e5-20c1-481b-96d5-329e3fc999f5,"0990-6139-22, 0990-6139-03, 0990-7139-09, 0990-7139-36, 0990-7973-05, 0990-7973-07, 0990-7973-08","Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-36)",Irrigant,Limited Availability,,NDA017513,,WATER,,,Current,Other,"Allocated to Contracted Customers Only. Estimated Recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,059QF0KO0R,0990-7139-36,1-866-829-9025 or ProductAvailability@icumed.com,
"Hikma Pharmaceuticals USA, Inc.",AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","239191, 313797",,077f4a65-3cfb-4cb1-99f2-e27ffc5939c0,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0143-9888, 0143-9889",Hikma Pharmaceuticals USA Inc.,c2fa2c99-c735-4834-a8a5-04a30da8a002,"0143-9888-80, 0143-9888-01, 0143-9888-15, 0143-9889-80, 0143-9889-01, 0143-9889-15","Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0143-9888-15)","Powder, For Suspension",,,ANDA065322,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0143-9888-15,800-631-2174,
Sagent Pharmaceuticals,FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Furosemide Injection,"1719286, 1719290, 1719291",,d63c1277-dd7e-4d21-9e80-68143f55e2dc,08/26/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,25021-311,Sagent Pharmaceuticals,222ce48f-2856-4be2-b16f-6fca38c0dceb,"25021-311-02, 25021-311-04, 25021-311-10","Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)",Injection,Available,"N0000175366, N0000175590",ANDA213902,,FUROSEMIDE,Loop Diuretic [EPC],,Current,,,,7LXU5N7ZO5,25021-311-02,866-625-1618,
"Meitheal Pharmaceuticals, Inc.",LIRAGLUTIDE,,07/18/2023,Reverified,SUBCUTANEOUS,Liraglutide Injection,897122,,0efc3a89-211a-4496-baab-e8265e07de2b,08/19/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,LIRAGLUTIDE,71288-563,Meitheal Pharmaceuticals Inc.,31f901b4-0477-38aa-e063-6294a90ac708,"71288-563-84, 71288-563-85","Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)",Injection,Available,"N0000178480, M0160181, N0000020058",ANDA218115,Glucagon-Like Peptide 1 [CS],LIRAGLUTIDE,GLP-1 Receptor Agonist [EPC],,Current,,,,839I73S42A,71288-563-85,844-824-8426,Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
Strides Pharma Inc.,MINOCYCLINE HYDROCHLORIDE,,01/22/2025,New,ORAL,Minocycline Hydrochloride Tablet,"207362, 207364, 403840",,d6e136ba-c9b1-4846-ae2a-98a29cb4504d,01/22/2025,HUMAN PRESCRIPTION DRUG,01/22/2025,Antiviral,MINOCYCLINE HYDROCHLORIDE,"64380-156, 64380-154, 64380-155",Strides Pharma Science Limited,73a30dc4-352b-4307-b902-07ffefc99a99,"64380-154-01, 64380-155-01, 64380-156-01","Minocycline Hydrochloride, Tablet, 100 mg (NDC 64380-156-01)",Tablet,,,ANDA065131,,MINOCYCLINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,0020414E5U,64380-156-01,877-244-9825,
"Fresenius Kabi USA, LLC",SODIUM CHLORIDE,,06/21/2018,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Sodium Chloride 0.9% Injection,"1807632, 1807636, 1807637, 1807638",,"f2a98378-9678-4738-9670-fc7a215c0606, f62481fd-fcdb-4be6-ac13-29c590e925c3",08/08/2025,HUMAN PRESCRIPTION DRUG,,Other,SODIUM CHLORIDE,63323-186,"Fresenius Kabi USA, LLC","debc17b5-4d24-473c-8396-e409433ce57c, 75c567e3-582b-4fff-9a72-f326f1d13c8f","63323-186-00, 63323-186-04, 63323-186-02, 63323-186-01, 63323-186-10, 63323-186-03, 63323-186-20","Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 63323-186-00)",Injection,,,ANDA088912,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,63323-186-00,888-386-1300,
Otsuka ICU Medical LLC,DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795477, 1795480, 1795481, 1795607, 1795609, 1795610, 1795612, 1795616, 1795618, 1795621",,8b25b7e0-703e-4b43-a4eb-52863511602d,09/17/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0990-7922, 0990-7923, 0990-7930","ICU Medical, Inc.",09b10612-c937-4d10-becb-9768e10caa2c,"0990-7923-20, 0990-7923-23, 0990-7923-36, 0990-7923-37, 0990-7923-13, 0990-7922-02, 0990-7922-03, 0990-7922-09, 0990-7922-53, 0990-7922-55, 0990-7922-61, 0990-7930-02, 0990-7930-03, 0990-7930-09","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-55)",Injection,Available,,NDA016367,,DEXTROSE MONOHYDRATE,,,Current,,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,LX22YL083G,0990-7922-55,1-866-829-9025 or ProductAvailability@icumed.com,
BTG International Inc.,HYDROXOCOBALAMIN,,11/04/2024,Revised,INTRAVENOUS,Hydroxocobalamin Injection,"700496, 700499",https://www.fda.gov/media/185400/download,d56fcc8d-bd64-46ab-b0c0-2124bd745a6b,08/05/2025,HUMAN PRESCRIPTION DRUG,,Other,CYANOKIT,50633-310,BTG INTERNATIONAL INC.,9955075c-c059-4b63-b387-e98ef13e60dc,50633-310-11,"Cyanokit, Injection, 5 g/250mL (NDC 50633-310-11)",Injection,Limited Availability,N0000175429,NDA022041,,HYDROXOCOBALAMIN,Antidote [EPC],,Current,Requirements related to complying with good manufacturing practices,"Cyanokit is available to order. To address the drug shortage, BTG International Inc (a SERB Pharmaceuticals company) coordinated with the U.S. Food and Drug Administration (FDA) to make the following impacted batches available to U.S. patients during this period of shortage.",,Q40X8H422O,50633-310-11,844-293-0007,
Kindos Pharmaceuticals Co. Ltd.,LEUCOVORIN CALCIUM,,01/01/2012,Revised,"INTRAMUSCULAR, INTRAVENOUS",Leucovorin Calcium Injection,"237788, 1803930, 1803932, 1803937, 2055036",,9df20901-6980-4d4e-89ec-40f3c1f91852,07/08/2025,HUMAN PRESCRIPTION DRUG,,"Oncology, Pediatric",LEUCOVORIN CALCIUM,"71288-163, 71288-160, 71288-161, 71288-162, 71288-164",Meitheal Pharmaceuticals Inc.,077a459b-e884-4452-aed3-0857a38ce26f,"71288-160-10, 71288-161-20, 71288-162-30, 71288-163-30, 71288-164-50","Leucovorin Calcium, Injection, 350 mg/17.5 mL (NDC 71288-163-30)",Injection,,,ANDA216590,,LEUCOVORIN CALCIUM,,Available,Resolved,,,07/08/2025,RPR1R4C0P4,71288-163-30,"Meitheal Pharmaceuticals, Inc.: 844-824-8426",
Eugia US LLC,LIDOCAINE HYDROCHLORIDE,,02/20/2018,Revised,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Lidocaine Hydrochloride Injection,"1737566, 1737568, 1737757",,5524cbfd-d6e6-42eb-aaa5-22495e0a86b6,09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,LIDOCAINE HYDROCHLORIDE,"55150-158, 55150-159, 55150-160",Eugia US LLC,e2600451-756c-4986-9e8e-26ce1d865afd,"55150-158-72, 55150-159-74, 55150-160-72","Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-158-72)",Injection,Unavailable,,ANDA203040,,LIDOCAINE HYDROCHLORIDE,,,Current,Demand increase for the drug,On backorder. Recovery: TBD. Check wholesalers for inventory,,V13007Z41A,55150-158-72,888-238-7880,
"Solco Healthcare US, LLC",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,68b10d9f-ca3e-493d-a309-45f1d7e08061,08/05/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"43547-606, 43547-602, 43547-603, 43547-604, 43547-605, 43547-607, 43547-608","Solco Healthcare US,LLC",7bb11568-67a4-4221-bb9b-23af37a1791c,"43547-602-10, 43547-603-10, 43547-604-10, 43547-605-10, 43547-606-10, 43547-607-10, 43547-608-10","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 43547-606-10)",Capsule,Limited Availability,,ANDA216266,,LISDEXAMFETAMINE DIMESYLATE CAPSULES,,,Current,Shortage of an active ingredient,On allocation,,SJT761GEGS,43547-606-10,866-931-9829,
"Hospira, Inc., a Pfizer Company",METHOTREXATE SODIUM,,03/13/2023,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Methotrexate Sodium Injection,"1655956, 1946772",,"0d63ba29-b692-41b4-87e8-351265c8273f, 0e30eaef-5a09-4104-8a11-c32933eadeab",08/15/2025,HUMAN PRESCRIPTION DRUG,,"Rheumatology, Oncology",METHOTREXATE,"61703-350, 61703-408","Hospira, Inc.","95b8b8da-da4e-4bba-9038-3cf65f3d5c1a, 37b3e76b-ac3d-4f93-adf1-91f52f676b8a","61703-350-37, 61703-350-38, 61703-408-41, 61703-350-09, 61703-350-10, 61703-408-25","Methotrexate Sodium, Injection, 50 mg/2 mL  (25 mg/mL) (NDC 61703-350-10)",Injection,Limited Availability,,NDA011719,,METHOTREXATE,,,Current,Other,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: December 2025,,3IG1E710ZN,61703-350-10,844-646-4398,
Strides Pharma Inc.,SERTRALINE HYDROCHLORIDE,,01/22/2025,New,ORAL,Sertraline Hydrochloride Tablet,"312938, 312940, 312941",,1f99e897-1b70-40b0-8c19-71d0bba19422,01/22/2025,HUMAN PRESCRIPTION DRUG,01/22/2025,Psychiatry,SERTRALINE HYDROCHLORIDE,"71093-129, 71093-130, 71093-131","ACI Healthcare USA, Inc.",3f41fc19-b54a-46fd-acbf-b411816bccd5,"71093-129-01, 71093-129-03, 71093-129-05, 71093-130-01, 71093-130-03, 71093-130-05, 71093-131-01, 71093-131-03, 71093-131-05","Sertraline Hydrochloride, Tablet, 25 mg (NDC 71093-129-01)",Tablet,,,ANDA076881,,SERTRALINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,UTI8907Y6X,71093-129-01,877-244-9825,
"Novo Nordisk, Inc.",SOMATROPIN,,01/06/2023,Revised,SUBCUTANEOUS,Somatropin Injection,"847243, 847245, 847247, 847348, 849850, 849851, 1736262, 1736329",,1058e17c-9261-459c-a3e6-fae38d196c14,08/28/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,NORDITROPIN,"0169-7708, 0169-7704, 0169-7705, 0169-7703",Novo Nordisk,b67c2419-4feb-4ce1-b97e-88760a8e1aee,"0169-7704-21, 0169-7704-92, 0169-7705-21, 0169-7705-92, 0169-7708-21, 0169-7708-92, 0169-7703-11, 0169-7703-91, 0169-7703-21, 0169-7703-92","Norditropin, Injection, 15 mg/1.5 mL (NDC 0169-7708-21)",Injection,,"N0000175606, M0028842",BLA021148,Human Growth Hormone [CS],SOMATROPIN,Recombinant Human Growth Hormone [EPC],Available,Resolved,,,08/28/2025,NQX9KB6PCL,0169-7708-21,609-987-5800,
"Fresenius Kabi USA, LLC","BUPIVACAINE HYDROCHLORIDE, EPINEPHRINE BITARTRATE",,02/20/2018,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL","Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","1867594, 1867596, 1867618, 1867620, 1012377, 1012384, 1012413, 1012417, 1724786, 1724787, 1724809, 1724810",,"b671015d-f620-4930-a890-5e27a40ae42f, bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,SENSORCAINE MPF,"63323-468, 63323-472, 63323-463, 63323-461","Fresenius Kabi USA, LLC","b671015d-f620-4930-a890-5e27a40ae42f, cc1f6507-eb3e-4398-a1d3-0c56a2099e6b","63323-468-08, 63323-468-38, 63323-472-03, 63323-472-17, 63323-472-01, 63323-472-37, 63323-463-01, 63323-463-57, 63323-461-01, 63323-461-57, 63323-468-02, 63323-468-37, 63323-468-01, 63323-468-17","Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-17)",Injection,Available,,ANDA070966,,BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE,,,Current,,Check wholesalers for inventory,,"7TQO7W3VT8, 30Q7KI53AK",63323-468-17,888-386-1300,
Pfizer Inc.,DOBUTAMINE HYDROCHLORIDE,,08/27/2025,New,INTRAVENOUS,Dobutamine Hydrochloride Injection,1812168,,"dc537761-d5f4-488d-24ab-b2bcd2b17b7a, 89becb0c-da60-4f43-0a98-29ff7a9eca58",08/27/2025,HUMAN PRESCRIPTION DRUG,08/27/2025,"Cardiovascular, Pediatric, Renal",DOBUTAMINE,0409-2344,"Hospira, Inc.","e71e9520-871b-479d-9652-1857fceca863, 5d6b1dfe-d679-4aea-97a6-3d074a202afe","0409-2344-01, 0409-2344-62, 0409-2344-02, 0409-2344-68, 0409-2344-88","Dobutamine Hydrochloride, Injection, 12.5 mg/1 mL (NDC 0409-2344-88)",Injection,,,ANDA074086,,DOBUTAMINE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,0WR771DJXV,0409-2344-88,844-646-4398,
Sandoz Inc.,AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","239191, 308182, 308189, 308191, 308192, 308194, 313797, 313850",,13bd4214-9b7f-425b-af5f-fc1ddc678230,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0781-6039, 0781-2020, 0781-2613, 0781-5060, 0781-5061, 0781-6156, 0781-6041, 0781-6157",Sandoz Inc,6aa02079-d11c-4d2f-acaf-9548dd9a7ed6,"0781-2020-31, 0781-2020-76, 0781-2020-01, 0781-2020-05, 0781-2613-31, 0781-2613-76, 0781-2613-01, 0781-2613-05, 0781-5060-20, 0781-5060-01, 0781-5061-20, 0781-5061-01, 0781-6039-58, 0781-6039-46, 0781-6039-55, 0781-6156-52, 0781-6156-57, 0781-6156-46, 0781-6041-58, 0781-6041-46, 0781-6041-55, 0781-6157-52, 0781-6157-57, 0781-6157-46","Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0781-6039-55)","Powder, For Suspension",,,ANDA065387,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0781-6039-55,800-525-8747,
"Hospira, Inc., a Pfizer Company",MORPHINE SULFATE,,07/08/2025,New,INTRAVENOUS,Morphine Sulfate Injection,,,be420e8b-bcb0-49b5-bb4d-1df8b9959809,07/08/2025,HUMAN PRESCRIPTION DRUG,07/08/2025,Analgesia/Addiction,MORPHINE SULFATE,"0409-1891, 0409-1890, 0409-1892, 0409-1893, 0409-1894","Hospira, Inc.",cced2ec0-6c94-4cf0-87fb-041667ee3214,"0409-1890-03, 0409-1890-01, 0409-1890-13, 0409-1890-23, 0409-1891-03, 0409-1891-01, 0409-1891-13, 0409-1891-23, 0409-1892-03, 0409-1892-01, 0409-1892-13, 0409-1892-23, 0409-1893-03, 0409-1893-01, 0409-1893-13, 0409-1893-23, 0409-1894-03, 0409-1894-01","Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0409-1891-23)",Injection,,,NDA202515,,MORPHINE SULFATE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,X3P646A2J0,0409-1891-23,844-646-4398,
"Fresenius Kabi USA, LLC",ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Reverified,EPIDURAL,Ropivacaine Hydrochloride Injection,"905189, 905191, 1734084, 1734086, 1734090, 1734091, 1734203, 1734204, 1734207, 1734208, 1734347, 1734348, 1734355, 1734356, 1734475, 1734476, 1734479, 1734480, 1734481, 1734482, 1734483, 1734484",,"23d2d448-a744-4877-9f2d-7e57c198da89, c6613708-c1f7-4f5c-91a3-ebbc1d7905c6, 56dfabf7-f7a8-4601-b17a-cb16fb995b0f",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,NAROPIN,"63323-288, 63323-286, 63323-287, 63323-285","Fresenius Kabi USA, LLC","cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9, 73218c89-8925-468c-84bf-9960b4b3dc3c, 75465ceb-e894-487d-aa80-671fa0841fce","63323-286-01, 63323-286-20, 63323-286-05, 63323-286-23, 63323-286-09, 63323-286-31, 63323-286-11, 63323-286-35, 63323-286-03, 63323-286-00, 63323-286-33, 63323-286-63, 63323-286-30, 63323-287-01, 63323-287-20, 63323-287-03, 63323-287-21, 63323-288-01, 63323-288-10, 63323-288-06, 63323-288-20, 63323-288-03, 63323-288-11, 63323-288-07, 63323-288-21, 63323-285-01, 63323-285-10, 63323-285-06, 63323-285-20, 63323-285-03, 63323-285-13, 63323-285-07, 63323-285-23, 63323-285-57, 63323-285-64, 63323-285-51, 63323-285-65, 63323-285-02, 63323-285-61, 63323-285-04, 63323-285-63, 63323-285-55, 63323-285-67, 63323-288-23, 63323-288-29, 63323-286-93, 63323-286-95, 63323-288-25, 63323-288-27","Naropin, Injection, 10 mg/1 mL (NDC 63323-288-11)",Injection,Available,,NDA020533,,ROPIVACAINE HYDROCHLORIDE,,,Current,,,,V910P86109,63323-288-11,888-386-1300,
Prasco Laboratories,SUMATRIPTAN,,09/08/2025,New,NASAL,Sumatriptan Nasal Spray,"313159, 314227",,f63e616b-ae0c-432b-badc-8c45023aa725,09/08/2025,HUMAN PRESCRIPTION DRUG,09/08/2025,Neurology,SUMATRIPTAN,"66993-081, 66993-082",Prasco Laboratories,b15509b9-4a5b-46ed-be80-b5f6e6e79444,"66993-081-69, 66993-082-69","Imitrex, Nasal Spray, 5 mg/100 uL (NDC 66993-081-69)",Nasal Spray,,"N0000175763, N0000175764, N0000175765",NDA020626,,SUMATRIPTAN,Serotonin-1b and Serotonin-1d Receptor Agonist [EPC],,To Be Discontinued,,"This product discontinuation is a business-related decision. The anticipated date that Prasco will cease distribution of the product is approximately February 28, 2026.",,8R78F6L9VO,66993-081-69,866-525-0688,"Serotonin 1b Receptor Agonists [MoA], Serotonin 1d Receptor Agonists [MoA]"
"Hospira, Inc., a Pfizer Company",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Revised,"EPIDURAL, INTRACAUDAL, PERINEURAL",Bupivacaine Hydrochloride Injection,"1012377, 1012381, 1012384, 1012388, 1012396, 1012400, 1012404, 1012406, 1672917, 1672919, 1673242, 1673243, 1724786, 1724787, 1724794, 1724796, 1724880, 1724884, 1725044, 1725046, 1725078, 1725079, 1725082, 1725083, 1867594, 1867596, 1867612, 1867614",,67578b56-7540-487e-1fba-481255620e78,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,MARCAINE,"0409-1560, 0409-1559, 0409-1582, 0409-1587, 0409-1610, 0409-1746, 0409-1749, 0409-1752, 0409-1755, 0409-2510, 0409-7535, 0409-1250, 0409-5010, 0409-1530, 0409-0525, 0409-7510, 0409-2253","Hospira, Inc.",b083f440-bfb7-449a-b601-c2f59a6f9dcf,"0409-1559-18, 0409-1559-10, 0409-1559-19, 0409-1559-30, 0409-1560-18, 0409-1560-10, 0409-1560-19, 0409-1560-29, 0409-1582-18, 0409-1582-10, 0409-1582-19, 0409-1582-29, 0409-1587-50, 0409-1610-50, 0409-1746-70, 0409-1746-10, 0409-1746-71, 0409-1746-30, 0409-1749-70, 0409-1749-10, 0409-1749-71, 0409-1749-29, 0409-1752-50, 0409-1755-50, 0409-2510-01, 0409-2510-25, 0409-7535-01, 0409-7535-25, 0409-1250-01, 0409-1250-25, 0409-5010-01, 0409-5010-25, 0409-1530-01, 0409-1530-25, 0409-0525-01, 0409-0525-25, 0409-7510-01, 0409-7510-25, 0409-2253-01, 0409-2253-25","Marcaine, Injection, Marcaine 150 mg/30 mL (5 mg/mL) (NDC 0409-1560-29)",Injection,Limited Availability,,NDA016964,,BUPIVACAINE HYDROCHLORIDE,,,Current,Other,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: December 2025,,"30Q7KI53AK, 7TQO7W3VT8",0409-1560-29,844-646-4398,
"Hospira, Inc., a Pfizer Company",,,10/31/2017,Revised,,Morphine Sulfate Injection,,,,08/15/2025,,,Analgesia/Addiction,,,,,,"Morphine Sulfate, Injection, 8 mg/1 mL Syringes (NDC 0409-1892-01)",Injection,Unavailable,,,,,,,Current,Discontinuation of the manufacture of the drug,,01/03/2025,,0409-1892-01,844-646-4398,
HQ Specialty Pharma,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718906, 1718909, 1788947",,0d2710f2-ee47-4114-ab5c-8dca74cdcb8d,09/17/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE,"44567-601, 44567-600, 44567-602, 44567-603","WG Critical Care, LLC",e6fa3e27-b374-49b6-a678-a5954f5beae8,"44567-600-04, 44567-601-04, 44567-602-24, 44567-603-24","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-601-04)",Injection,Available,,NDA206628,,DEXMEDETOMIDINE,,,Current,,Marketed by WG Critical Care,,1018WH7F9I,44567-601-04,WG Critical Care 888-493-0861,
Novadaq Technologies,,,08/23/2024,Revised,,Indocyanine Green Injection,,,,08/26/2025,,,"Medical Imaging, Ophthalmology, Other",,,,,,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-306-13)",Injection,,,,,,,Available,Resolved,,,08/26/2025,,66259-306-13,800-624-4422,
"Teva Pharmaceuticals USA, Inc.",IRINOTECAN HYDROCHLORIDE,,08/04/2025,New,INTRAVENOUS,Irinotecan Hydrochloride Injection,"1726319, 1726324",,5e1fdcaa-918f-4cd8-9c7a-4c538d866198,08/04/2025,HUMAN PRESCRIPTION DRUG,08/04/2025,Oncology,IRINOTECAN HYDROCHLORIDE,45963-614,"Actavis Pharma, Inc.",8f2da07f-1d3e-4d8b-8083-805da8a780db,"45963-614-51, 45963-614-55","Irinotecan Hydrochloride, Injection, 20 mg/1 mL (NDC 45963-614-51)",Injection,,,ANDA078589,,IRINOTECAN HYDROCHLORIDE,,,To Be Discontinued,,Product not anticipated to be available beyond mid-late October 2025,,042LAQ1IIS,45963-614-51,800-545-8800,
"Hospira, Inc., a Pfizer Company",MORPHINE SULFATE,,10/31/2017,Reverified,INTRAVENOUS,Morphine Sulfate Injection,"1731517, 1731537, 1731545",,cadc3fdb-8edc-44cd-aaea-89e68aaf9a04,08/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,MORPHINE SULFATE,"0409-1134, 0409-1135","Hospira, Inc.",a641ae70-f6ba-4f49-b5fc-b2895ef3408f,"0409-1134-03, 0409-1134-05, 0409-1135-02","Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1134-05)",Injection,Available,,,,MORPHINE SULFATE,,,Current,,,01/03/2025,X3P646A2J0,0409-1134-05,844-646-4398,
"Somerset Therapeutics, LLC",ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Reverified,"EPIDURAL, INFILTRATION, PERINEURAL",Ropivacaine Hydrochloride Injection,"905189, 1734084, 1734090, 1734203, 1734207, 1734475, 1734483",,ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64,08/19/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROPIVACAINE HYDROCHLORIDE,"70069-064, 70069-061, 70069-062, 70069-063, 70069-065, 70069-066, 70069-067","Somerset Therapeutics, LLC",5d7b0e44-19ce-4127-b3e8-d7e6e65f1818,"70069-061-01, 70069-061-25, 70069-061-10, 70069-062-01, 70069-062-25, 70069-062-10, 70069-063-01, 70069-063-25, 70069-064-01, 70069-064-10, 70069-064-25, 70069-065-01, 70069-065-25, 70069-066-01, 70069-066-25, 70069-066-10, 70069-067-01, 70069-067-25, 70069-067-10","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-25)",Injection,Available,,ANDA207636,,ROPIVACAINE HYDROCHLORIDE,,,Current,,,,V910P86109,70069-064-25,732-554-1019,
"Fresenius Kabi USA, LLC",ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Reverified,"EPIDURAL, INFILTRATION, PERINEURAL",Ropivacaine Hydrochloride Injection,"1734203, 1734204, 1734207, 1734208, 1734347, 1734348, 1734355, 1734356, 1734475, 1734476, 1734479, 1734480, 1734481, 1734482, 1734483, 1734484, 905189, 905191, 1734084, 1734086, 1734090, 1734091",,"dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7, 23d2d448-a744-4877-9f2d-7e57c198da89, c6613708-c1f7-4f5c-91a3-ebbc1d7905c6",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,NAROPIN,"63323-286, 63323-285, 63323-287, 63323-288","Fresenius Kabi USA, LLC","324532ac-4e54-4659-a1a2-9ade22a1ed3f, cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9, 73218c89-8925-468c-84bf-9960b4b3dc3c","63323-286-41, 63323-286-27, 63323-286-43, 63323-286-38, 63323-285-41, 63323-285-28, 63323-285-53, 63323-285-68, 63323-285-59, 63323-285-73, 63323-286-01, 63323-286-20, 63323-286-05, 63323-286-23, 63323-286-09, 63323-286-31, 63323-286-11, 63323-286-35, 63323-286-03, 63323-286-00, 63323-286-33, 63323-286-63, 63323-286-30, 63323-287-01, 63323-287-20, 63323-287-03, 63323-287-21, 63323-288-01, 63323-288-10, 63323-288-06, 63323-288-20, 63323-288-03, 63323-288-11, 63323-288-07, 63323-288-21, 63323-285-01, 63323-285-10, 63323-285-06, 63323-285-20, 63323-285-03, 63323-285-13, 63323-285-07, 63323-285-23, 63323-285-57, 63323-285-64, 63323-285-51, 63323-285-65, 63323-285-02, 63323-285-61, 63323-285-04, 63323-285-63, 63323-285-55, 63323-285-67, 63323-288-23, 63323-288-29, 63323-286-93, 63323-286-95","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-00)",Injection,Available,,NDA020533,,ROPIVACAINE HYDROCHLORIDE,,,Current,,,,V910P86109,63323-286-00,888-386-1300,
Baxter Healthcare,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718906, 1718909",,8ccb45a7-8290-469c-9644-a4dca967d88f,09/23/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE HYDROCHLORIDE,"0338-9555, 0338-9557",Baxter Healthcare Company,34598b0d-5824-4586-b19c-5189a626c27a,"0338-9555-24, 0338-9557-12","Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 0338-9555-24)",Injection,Available,,ANDA208532,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,,,,1018WH7F9I,0338-9555-24,888-229-0001,
Pfizer Inc.,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"284397, 309710, 1718900, 1718902, 1718906, 1718907, 1718909, 1718910, 2396891, 2396892",,548a88c0-afda-427e-75ac-5af0cfa2224c,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,PRECEDEX,"0409-1660, 0409-1638, 0409-1434, 0409-1596, 0409-7838, 0409-7853, 0409-7875","Hospira, Inc.",231f50fe-2c91-44b9-946e-33b836c07b94,"0409-1660-55, 0409-1660-50, 0409-1660-35, 0409-1660-10, 0409-1660-22, 0409-1660-20, 0409-1638-32, 0409-1638-02, 0409-1434-01, 0409-1596-01, 0409-1596-10, 0409-7838-01, 0409-7838-24, 0409-7853-01, 0409-7853-24, 0409-7875-01, 0409-7875-12","Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-1660-20)",Injection,Available,,NDA021038,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,,,,1018WH7F9I,0409-1660-20,844-646-4398,
"Trigen Laboratories, LLC",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Reverified,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release","1091155, 1091170, 1091185, 1091210, 1995461",,c45dc1de-adfa-4b3c-a7dc-cffbc8eac74f,09/04/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE HYDROCHLORIDE,"13811-709, 13811-706, 13811-707, 13811-708, 13811-710","Trigen Laboratories, LLC",354443b1-a623-43b0-b984-f8de2f6c60b2,"13811-709-10, 13811-706-10, 13811-707-10, 13811-708-10, 13811-710-10, 13811-710-30","Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10)",Tablet,Limited Availability,,ANDA205327,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,Demand increase for the drug,Allocation to current contracted customers,,4B3SC438HI,13811-709-10,800-541-4802,
Sagent Pharmaceuticals,ROCURONIUM BROMIDE,,02/15/2023,Reverified,INTRAVENOUS,Rocuronium Bromide Injection,1234995,,01825411-be08-4402-b101-cb546291c972,08/26/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROCURONIUM BROMIDE,25021-687,Sagent Pharmaceuticals,1d066c67-eac2-494a-ad10-ba7e9c60b0e9,"25021-687-05, 25021-687-10","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 25021-687-05)",Injection,Available,,ANDA205656,,ROCURONIUM BROMIDE,,,Current,,,,I65MW4OFHZ,25021-687-05,866-625-1618,
"Somerset Therapeutics, LLC",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,"INFILTRATION, PERINEURAL",Bupivacaine Hydrochloride Injection,"1012396, 1012404",,bcaab86f-20f0-4482-8d73-e29b36dced58,08/19/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE,"70069-753, 70069-752","Somerset Therapeutics, LLC",2b24af95-6f20-4945-bf8c-742f1d6f2721,"70069-752-25, 70069-752-10, 70069-752-01, 70069-753-25, 70069-753-01, 70069-753-10","Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-25)",Injection,Available,,ANDA217792,,BUPIVACAINE HYDROCHLORIDE,,,Current,,,,7TQO7W3VT8,70069-753-25,732-554-1037,
"Fresenius Kabi USA, LLC",DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795607, 1795609, 1795610, 1795612, 1795616",,576a22d8-5f2f-497e-80ad-1842ca74bb53,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"65219-460, 65219-456, 65219-464, 65219-458, 65219-462","FRESENIUS KABI USA, LLC",efc3b0c9-518a-47db-bb3e-ebdfd4646e9b,"65219-456-05, 65219-456-60, 65219-464-05, 65219-464-50, 65219-458-05, 65219-458-30, 65219-460-05, 65219-460-20, 65219-462-05, 65219-462-10","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-460-20)",Injection,Available,,ANDA207449,,DEXTROSE MONOHYDRATE,,,Current,,Check wholesalers for inventory,,LX22YL083G,65219-460-20,888-386-1300,
"Meitheal Pharmaceuticals, Inc.",HYDRALAZINE HYDROCHLORIDE,,04/07/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Furosemide Injection,966571,,f3c806a4-b971-421c-bcb9-9979c6d7aaec,08/19/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,HYDRALAZINE HYDROCHLORIDE,71288-205,Meitheal Pharmaceuticals Inc.,9c7f84bf-c884-49fd-8f1f-d368f64d63ff,"71288-205-01, 71288-205-02","Furosemide, Injection, 10 mg/mL, 2 mL (NDC 71288-205-03)",Injection,Available,,ANDA217501,,HYDRALAZINE HYDROCHLORIDE,,,Current,,,,FD171B778Y,71288-205-03,844-824-8426,
"Hospira, Inc., a Pfizer Company",MEPERIDINE HYDROCHLORIDE,,05/30/2025,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Meperidine Hydrochloride Injection,"860792, 861463, 861473, 861493, 861494, 861522, 861529, 861617, 1242106, 1242503, 2539186, 2539188, 2539191, 2539192",,b31d1308-28c3-43f4-e0a6-2f3ed76b8975,08/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,DEMEROL,"0409-1179, 0409-1181, 0409-1176, 0409-1178, 0409-1180, 0409-1362, 0409-1418","Hospira, Inc.",1271f15f-ccda-4892-8fb0-9bb2d38ded4a,"0409-1181-30, 0409-1176-03, 0409-1176-30, 0409-1178-03, 0409-1178-30, 0409-1179-03, 0409-1179-30, 0409-1180-59, 0409-1180-69, 0409-1362-11, 0409-1362-01, 0409-1418-11, 0409-1418-01","Demerol, Injection, 75 mg/1 mL (NDC 0409-1179-30)",Injection,Unavailable,,NDA021171,,MEPERIDINE HYDROCHLORIDE,,,Current,Discontinuation of the manufacture of the drug,,,N8E7F7Q170,0409-1179-30,844-646-4398,
"Noven Pharmaceuticals, Inc.",METHYLPHENIDATE,Central Nervous System Stimulation [PE],02/28/2025,Reverified,TRANSDERMAL,"Methylphenidate Film, Extended Release",,,2c312c31-3198-4775-91ab-294e0b4b9e7f,08/19/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,DAYTRANA,"68968-5552, 68968-5553, 68968-5554, 68968-5555","Noven Therapeutics, LLC",55f4b5f4-6d3c-4677-a94c-d47ffb59a91a,"68968-5552-3, 68968-5553-3, 68968-5554-3, 68968-5555-3","Daytrana, Film, Extended Release, 10 mg (NDC 68968-5552-3)","Film, Extended Release",Unavailable,"N0000175739, N0000175729",NDA021514,,METHYLPHENIDATE,Central Nervous System Stimulant [EPC],,Current,Shortage of an active ingredient,Estimated availability TBD,,207ZZ9QZ49,68968-5552-3,800-455-8070,
"Vertical Pharmaceuticals, LLC",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Reverified,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release",,,22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d,09/16/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,RELEXXII,"68025-089, 68025-088, 68025-095, 68025-096, 68025-097, 68025-084, 68025-098","Vertical Pharmaceuticals, LLC",86f477e9-07fc-466b-913e-1a4434c91df4,"68025-088-30, 68025-089-30, 68025-095-10, 68025-095-30, 68025-096-10, 68025-096-30, 68025-097-10, 68025-097-30, 68025-084-30, 68025-098-10, 68025-098-30","Relexxii, Tablet, Extended Release, 63 mg (NDC 68025-089-30)",Tablet,Available,,NDA216117,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,,,,4B3SC438HI,68025-089-30,800-541-4802,
"Hikma Pharmaceuticals USA, Inc.",,,05/03/2022,Revised,,Sufentanil Citrate Injection,,,,07/23/2025,,,"Analgesia/Addiction, Pediatric",,,,,,"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-05)",Injection,Unavailable,,,,,,,Current,Other,Not currently manufactured,,,17478-050-05,800-631-2174,
"Hospira, Inc., a Pfizer Company",CARBOPLATIN,,04/28/2023,Reverified,INTRAVENOUS,Carboplatin Injection,597195,,c3ae9880-44bb-4f4e-93d8-8a5e21708a30,08/15/2025,HUMAN PRESCRIPTION DRUG,,Oncology,CARBOPLATIN,61703-339,"Hospira, Inc.",0ddf4411-7138-412a-908a-fadf22bdfb79,"61703-339-18, 61703-339-22, 61703-339-50, 61703-339-56","Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18)",Injection,Available,"N0000175413, N0000175073",ANDA076517,,CARBOPLATIN,Platinum-based Drug [EPC],,Current,,,,BG3F62OND5,61703-339-18,844-646-4398,
Otsuka ICU Medical LLC,"ACETYL L-TYROSINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, PROLINE, SERINE, THREONINE, TRYPTOPHAN, VALINE",,12/08/2020,Reverified,INTRAVENOUS,Amino Acid Injection,"800188, 800192, 800237, 800241",,5b426208-f090-4650-86c3-89040ba45c2d,09/17/2025,HUMAN PRESCRIPTION DRUG,,Gastroenterology,AMINOSYN II,"0990-7172, 0990-7171",ICU Medical Inc.,8e4121e2-89a0-4f4e-98b9-1530dec5972b,"0990-7172-17, 0990-7171-17","Aminosyn II 10% In Plastic Container, Injection, 0.1 (NDC 0990-7172-17)",Injection,Available,"N0000175780, M0000922",NDA020015,Amino Acids [CS],"ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, HISTIDINE, PROLINE, SERINE, N-ACETYLTYROSINE, AND GLYCINE",Amino Acid [EPC],,Current,,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,"9DLQ4CIU6V, 452VLY9402, 3KX376GY7L, 2ZD004190S, DA8G610ZO5, 30KYC7MIAI, AE28F7PNPL, GMW67QNF9C, 94ZLA3W45F, OF5P57N2ZX, TE7660XO1C, 4QD397987E, TTL6G7LIWZ, 47E5O17Y3R, 8DUH1N11BX, 04Y7590D77, HG18B9YRS7",0990-7172-17,1-866-829-9025 or ProductAvailability@icumed.com,
"Upsher-Smith Laboratories, LLC",BACLOFEN,,04/23/2025,New,ORAL,Baclofen Tablet,"197391, 197392",,b2747a9d-5fca-4657-9e4b-4112607f30d8,04/23/2025,HUMAN PRESCRIPTION DRUG,04/23/2025,Neurology,BACLOFEN,"0832-1054, 0832-1055","Upsher-Smith Laboratories, LLC",395d77da-1674-a9a4-e063-6394a90aa3d7,"0832-1054-90, 0832-1054-11, 0832-1054-15, 0832-1054-10, 0832-1055-90, 0832-1055-11, 0832-1055-15, 0832-1055-10","Baclofen, Tablet, 10 mg (NDC 0832-1054-11)",Tablet,,"N0000000196, N0000000116, N0000175759",ANDA074584,,BACLOFEN,gamma-Aminobutyric Acid-ergic Agonist [EPC],,To Be Discontinued,,,,H789N3FKE8,0832-1054-11,716-315-2000,"GABA A Agonists [MoA], GABA B Agonists [MoA]"
Otsuka ICU Medical LLC,"ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, PROLINE, SERINE, TAURINE, THREONINE, TRYPTOPHAN, TYROSINE, VALINE",,12/08/2020,Reverified,INTRAVENOUS,Amino Acid Injection,"800341, 800345",,46e74ce4-cd7e-437f-bf54-ca9b98eb2663,09/17/2025,HUMAN PRESCRIPTION DRUG,,Gastroenterology,AMINOSYN-PF,0990-4179,ICU Medical Inc.,439cfaaa-c9cf-4292-95fe-038bacdb7e38,0990-4179-05,"Aminosyn-PF 10%, Injection, 0.1 (NDC 0990-4179-05)",Injection,Unavailable,"N0000175780, M0000922",NDA019492,Amino Acids [CS],"ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, PROLINE, SERINE, TAURINE, AND TYROSINE",Amino Acid [EPC],,Current,Shortage of an active ingredient,"Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,"OF5P57N2ZX, 94ZLA3W45F, 30KYC7MIAI, 3KX376GY7L, TE7660XO1C, 4QD397987E, 04Y7590D77, GMW67QNF9C, TTL6G7LIWZ, AE28F7PNPL, 47E5O17Y3R, 9DLQ4CIU6V, 452VLY9402, 1EQV5MLY3D, 2ZD004190S, 8DUH1N11BX, 42HK56048U, HG18B9YRS7",0990-4179-05,1-866-829-9025 or ProductAvailability@icumed.com,
Pfizer Inc.,GLIPIZIDE,,07/24/2025,New,ORAL,"Glipizide Tablet, Extended Release","310489, 314006, 315107, 865568, 865571, 865573",,eed99b60-d043-4249-9b2a-f05e46fb588d,07/24/2025,HUMAN PRESCRIPTION DRUG,07/24/2025,Endocrinology/Metabolism,GLUCOTROL XL,"0049-0178, 0049-0170, 0049-0174",Roerig,ce46d6b5-eab4-4630-8480-f13885be938e,"0049-0170-01, 0049-0174-02, 0049-0174-03, 0049-0178-07, 0049-0178-08","Glucatrol XL, Tablet, Extended Release, 10 mg tablets; bottle of 500 (NDC 0049-0178-08)",Tablet,,"N0000175608, M0020795",NDA020329,Sulfonylurea Compounds [CS],GLIPIZIDE,Sulfonylurea [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,X7WDT95N5C,0049-0178-08,800-533-4535,
"Dr. Reddy's Laboratories, Inc.",,,07/26/2023,Reverified,,"Methylphenidate Hydrochloride Tablet, Extended Release",,,,09/16/2025,,,Psychiatry,,,,,,"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 43598-438-01)",Tablet,Unavailable,,,,,,,Current,Other,Estimated availability TBD,,,43598-438-01,866-732-3952,
"Mylan Institutional, a Viatris Company",RIFAMPIN,,02/17/2021,Reverified,INTRAVENOUS,Rifampin Injection,312821,,8be91604-d7cd-4f2b-997d-e3364e4092e5,09/17/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,RIFAMPIN,67457-445,Mylan Institutional LLC,f1107e3c-754b-407d-9d66-23f545c0c692,67457-445-60,"Rifampin, Injection, 600 mg/10 mL (NDC 67457-445-60)",Injection,Available,"N0000175500, M0019113",ANDA065421,Rifamycins [CS],RIFAMPIN,Rifamycin Antibacterial [EPC],,Current,,,,VJT6J7R4TR,67457-445-60,800-796-9526,
Otsuka ICU Medical LLC,DEXTROSE MONOHYDRATE,,03/01/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 10% Injection,"1795477, 1795480, 1795481, 1795607, 1795609, 1795610, 1795612, 1795616, 1795618, 1795621",,8b25b7e0-703e-4b43-a4eb-52863511602d,09/17/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0990-7930, 0990-7923, 0990-7922","ICU Medical, Inc.",09b10612-c937-4d10-becb-9768e10caa2c,"0990-7923-20, 0990-7923-23, 0990-7923-36, 0990-7923-37, 0990-7923-13, 0990-7922-02, 0990-7922-03, 0990-7922-09, 0990-7922-53, 0990-7922-55, 0990-7922-61, 0990-7930-02, 0990-7930-03, 0990-7930-09","Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-03)",Injection,Available,,NDA018080,,DEXTROSE MONOHYDRATE,,,Current,,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,LX22YL083G,0990-7930-03,1-866-829-9025 or ProductAvailability@icumed.com,
Baxter Healthcare,DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795609, 1795616",,7de48bdb-9a05-4f2a-bbff-dcfeb284ca6e,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,0338-0551,Baxter Healthcare Company,e702be26-651e-4d4a-9d79-4df9f53821c9,"0338-0551-11, 0338-0551-18","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-18)",Injection,Available,,NDA020179,,DEXTROSE MONOHYDRATE,,,Current,,,,LX22YL083G,0338-0551-18,888-229-0001,
Norvium Bioscience LLC,IBANDRONATE SODIUM,,03/05/2025,New,INTRAVENOUS,Ibandronate Sodium Injection,904952,,a70566e1-cbe5-472a-85ae-08a14117552a,03/05/2025,HUMAN PRESCRIPTION DRUG,03/05/2025,Endocrinology/Metabolism,IBANDRONATE SODIUM,67457-524,Mylan Institutional LLC,270c89b1-757a-41ef-8067-d9034a4bdc9e,67457-524-33,"Ibandronate Sodium, Injection, 3 mg/3 mL (NDC 67457-524-33)",Injection,,,ANDA202671,,IBANDRONATE SODIUM,,,To Be Discontinued,,,,J12U072QL0,67457-524-33,888-282-0125,
"Mylan Institutional, a Viatris Company",LEUCOVORIN CALCIUM,,01/01/2012,Revised,"INTRAMUSCULAR, INTRAVENOUS",Leucovorin Calcium Injection,"237788, 1803932, 1803937",,1cb701ca-2478-4268-9d69-80293965d59d,07/08/2025,HUMAN PRESCRIPTION DRUG,,"Oncology, Pediatric",LEUCOVORIN CALCIUM,"67457-530, 67457-528, 67457-529",Mylan Institutional LLC,2890b03c-dbef-4db8-8b07-c042d7765677,"67457-528-10, 67457-529-20, 67457-530-35","Leucovorin Calcium Preservative Free, Injection, 350 mg/17.5 mL (NDC 67457-530-35)",Injection,,,ANDA203800,,LEUCOVORIN CALCIUM,,Available,Resolved,,,07/08/2025,RPR1R4C0P4,67457-530-35,800-796-9526,
Sintetica US,LIDOCAINE HYDROCHLORIDE ANHYDROUS,,02/22/2012,Reverified,RETROBULBAR,Lidocaine Hydrochloride Injection,1010844,,a7529e5b-47b1-4148-98dd-65aecc33a8c3,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",NA,83090-007,Sintetica US LLC,eff2e41b-a181-2c76-e053-2995a90aa8b0,"83090-007-01, 83090-007-10","Lidocaine Hydrochloride, Injection, 40 mg/1 mL (NDC 83090-007-10)",Injection,Available,,ANDA214269,,LIDOCAINE HYDROCHLORIDE,,,Current,,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 4% 10X5ML)  is Preservative free.",,EC2CNF7XFP,83090-007-10,"844-425-3131, SinteticaCS@eversana.com",
"Teva Pharmaceuticals USA, Inc.",AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension",,,4c0f348a-a65d-409c-8668-207c82a5e3cb,05/02/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,AMOXICILLIN,"0093-4161, 0093-2263, 0093-2264, 0093-4160, 0093-4155, 0093-2267, 0093-2268, 0093-3107, 0093-3109","Teva Pharmaceuticals USA, Inc.",8988589b-0893-4233-ac9c-9884ceb0c2c4,"0093-2263-01, 0093-2264-01, 0093-4160-76, 0093-4160-78, 0093-4160-73, 0093-4155-79, 0093-4155-73, 0093-4155-80, 0093-4161-76, 0093-4161-78, 0093-4161-73, 0093-2267-01, 0093-2268-01, 0093-3107-01, 0093-3107-05, 0093-3109-53, 0093-3109-06, 0093-3109-01, 0093-3109-05","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0093-4161-73)","Powder, For Suspension",,,ANDA065119,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0093-4161-73,800-545-8800,
"Laboratorios Grifols, S.A.",SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807631, 1807632, 1807633, 1807634, 1807639",,28f79c75-82d2-4912-81fc-a723b5ccf4c1,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,79672-613,Nextgen Pharmaceuticals LLC,3c545b9f-67e4-489d-bb60-c39c990d7dda,"79672-613-01, 79672-613-10, 79672-613-02, 79672-613-20, 79672-613-03, 79672-613-30, 79672-613-04, 79672-613-40, 79672-613-05, 79672-613-50","Sodium Chloride 0.9%, 500 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-04)",Injection,,,ANDA207956,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,79672-613-04,800-848-0462,
"Teva Pharmaceuticals USA, Inc.",CARBAMAZEPINE,Decreased Central Nervous System Disorganized Electrical Activity [PE],06/10/2025,New,ORAL,Carbamazepine Tablet,"308973, 308979",,bfd63965-56e6-4af7-b7ef-45a5105d4d35,06/10/2025,HUMAN PRESCRIPTION DRUG,06/10/2025,Neurology,CARBAMAZEPINE,"0093-0109, 0093-0778","Teva Pharmaceuticals USA, Inc.",042aa2c6-95ff-410a-abcf-a8ee79fa96d8,"0093-0109-01, 0093-0109-10, 0093-0778-01","Epitol, Tablet, 200 mg (NDC 0093-0109-01)",Tablet,,"N0000008486, N0000175751, N0000185506, N0000191266, N0000187064, N0000185507, N0000185607",ANDA070541,,CARBAMAZEPINE,Mood Stabilizer [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,33CM23913M,0093-0109-01,800-545-8800,"Cytochrome P450 3A4 Inducers [MoA], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA]"
GlaxoSmithKline,DAPRODUSTAT,,11/21/2024,New,ORAL,Daprodustat Tablet,"2628215, 2628221, 2628223, 2628225, 2628227, 2628229, 2628231, 2628233, 2628235, 2628237",,d82aa06e-5a33-4844-99b7-4701313455a4,11/21/2024,HUMAN PRESCRIPTION DRUG,11/21/2024,Hematology,JESDUVROQ,"0173-0897, 0173-0903, 0173-0906, 0173-0911, 0173-0914",GlaxoSmithKline LLC,d52a823a-35bd-4c6a-a016-4b4f21a43d7d,"0173-0897-13, 0173-0897-56, 0173-0903-13, 0173-0903-56, 0173-0906-13, 0173-0906-56, 0173-0911-13, 0173-0911-56, 0173-0914-13, 0173-0914-56","Jesduvroq, Tablet, 1 mg (NDC 0173-0897-56)",Tablet,,"N0000194080, N0000194079",NDA216951,,DAPRODUSTAT,Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC],,To Be Discontinued,,Discontinuing for Business Reasons.,,JVR38ZM64B,0173-0897-56,888-825-5249,Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors [MoA]
"Hikma Pharmaceuticals USA, Inc.",DEXAMETHASONE SODIUM PHOSPHATE,,02/08/2019,Reverified,"INTRA-ARTICULAR, INTRALESIONAL, INTRAMUSCULAR, INTRAVENOUS, SOFT TISSUE",Dexamethasone Sodium Phosphate Injection,"309696, 1116927, 1812194",,0277cc0a-2fd4-4605-a310-b613be84ee26,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Other, Pulmonary/Allergy, Rheumatology",DEXAMETHASONE SODIUM PHOSPHATE,"0641-6146, 0641-0367, 0641-6145",Hikma Pharmaceuticals USA Inc.,84665497-7e82-4733-bcfd-3177817ac0b3,"0641-0367-21, 0641-0367-25, 0641-6145-01, 0641-6145-25, 0641-6146-01, 0641-6146-10, 0641-6146-25","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6146-25)",Injection,Unavailable,,ANDA084282,,DEXAMETHASONE SODIUM PHOSPHATE,,,Current,Demand increase for the drug,Additional lots will be available in the April 2025 timeframe.  Product will be made available as it is released.,,AI9376Y64P,0641-6146-25,800-631-2174,
"Mylan Institutional, a Viatris Company",ETOMIDATE,General Anesthesia [PE],10/05/2022,Reverified,INTRAVENOUS,Etomidate Injection,"1654006, 1654008",,461e34d1-b862-4a02-9727-548c907aac48,09/17/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ETOMIDATE,"67457-902, 67457-903",Mylan Institutional LLC,25fc0aef-d4b3-4b33-897c-81cc7cdae470,"67457-902-00, 67457-902-10, 67457-903-00, 67457-903-20","Etomidate, Injection, 2 mg/1 mL (NDC 67457-902-10)",Injection,Available,"N0000175975, N0000175681",ANDA201044,,ETOMIDATE,General Anesthetic [EPC],,Current,,,,Z22628B598,67457-902-10,800-796-9526,
"Hospira, Inc., a Pfizer Company",LIDOCAINE HYDROCHLORIDE,,02/22/2012,Reverified,"INFILTRATION, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010671, 1010900, 1737343, 1737562, 1737566, 1737568, 1737636, 1737757, 1737763",,3b2dd84e-cee8-4e58-d494-395a65a353a0,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE HYDROCHLORIDE,"0409-4276, 0409-4713, 0409-4278, 0409-4279, 0409-4776, 0409-4282, 0409-4277, 0409-4275","Hospira, Inc.",c0b4635b-1473-4c48-89c6-620762cd687f,"0409-4713-12, 0409-4713-26, 0409-4713-02, 0409-4713-72, 0409-4713-62, 0409-4713-75, 0409-4713-65, 0409-4713-42, 0409-4713-25, 0409-4713-32, 0409-4278-16, 0409-4278-01, 0409-4279-16, 0409-4279-02, 0409-4776-10, 0409-4776-01, 0409-4282-11, 0409-4282-25, 0409-4282-01, 0409-4282-12, 0409-4282-02, 0409-4277-16, 0409-4277-01, 0409-4277-17, 0409-4277-02, 0409-4276-16, 0409-4276-01, 0409-4276-17, 0409-4276-02, 0409-4275-16, 0409-4275-01","Lidocaine Hydrochloride In Plastic Container, Injection, 500 mg/50 mL (1%; 10 mg/mL) (NDC 0409-4276-02)",Injection,Available,,ANDA088299,,LIDOCAINE HYDROCHLORIDE,,,Current,,,,V13007Z41A,0409-4276-02,844-646-4398,
"Upsher-Smith Laboratories, LLC",MEMANTINE HYDROCHLORIDE,,04/28/2025,New,ORAL,Memantine Hydrochloride Tablet,"996561, 996571",,6e0ade9e-b721-4701-bcb7-de464e19e707,04/28/2025,HUMAN PRESCRIPTION DRUG,04/28/2025,Neurology,MEMANTINE HYDROCHLORIDE,"0832-1113, 0832-1112","Upsher-Smith Laboratories, LLC",398273bb-cd0b-d984-e063-6394a90a89ab,"0832-1112-60, 0832-1113-60","Memantine Hydrochloride, Tablet, 10 mg (NDC 0832-1113-60)",Tablet,,,ANDA090043,,MEMANTINE HYDROCHLORIDE,,,To Be Discontinued,,,,JY0WD0UA60,0832-1113-60,800-654-2299,
"Avet Pharmaceuticals, Inc.",MIDAZOLAM HYDROCHLORIDE,,04/02/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Midazolam Hydrochloride Injection,311702,,843cc25e-45ea-4372-ae34-843f805fa869,09/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology",MIDAZOLAM HYDROCHLORIDE,23155-601,Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.,e20feff9-3aca-4bc1-a5c3-44fff8a9459c,"23155-601-31, 23155-601-41, 23155-601-32, 23155-601-42","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-42)",Injection,Available,,ANDA090850,,MIDAZOLAM HYDROCHLORIDE,,,Current,,,,W7TTW573JJ,23155-601-42,855-228-9470,
SpecGx LLC,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 1009145",,72ddd1c9-ddbd-4c95-acd9-003189a353a3,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE,"0406-8892, 0406-8891, 0406-8884, 0406-8885, 0406-8893, 0406-8894",SpecGx LLC,b25a2f3f-ee3a-44c0-a475-f371025c767b,"0406-8891-01, 0406-8884-01, 0406-8892-01, 0406-8885-01, 0406-8893-01, 0406-8894-01","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0406-8892-01)",Tablet,Available,,ANDA040440,,DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE,,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",0406-8892-01,800-325-8888,
Pfizer Inc.,,,07/17/2025,New,,Pemetrexed Ditromethamine Injection,,,,07/17/2025,,07/17/2025,Oncology,,,,,,"Pemetrexed Ditromethamine, Injection, 500 mg Single Dose Vial (NDC 0409-1061-01)",Injection,,,,,,,,To Be Discontinued,,Discontinuation of the manufacture of the drug.,,,0409-1061-01,844-646-4398,
B. Braun Medical Inc.,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807551, 1807552, 1807633, 1807634, 1807639",,7f22c06b-6b4d-4b49-a4b2-d2169f2bd653,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0264-7802, 0264-7800",B. Braun Medical Inc.,9fa9f6b4-63b5-4632-8104-37c3dd1ee8fa,"0264-7800-00, 0264-7800-10, 0264-7800-20, 0264-7802-00, 0264-7802-10","Sodium Chloride 0.9%, Injection, .45 g/100 mL (NDC 0264-7802-00)",Injection,,,NDA019635,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0264-7802-00,800-227-2862,
Kindos Pharmaceuticals Co. Ltd.,BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,"INFILTRATION, PERINEURAL",Bupivacaine Hydrochloride Injection,"1012396, 1012404",,fe340f98-a0f3-446e-b281-47fd91c1e537,08/19/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE,"71288-723, 71288-726",Meitheal Pharmaceuticals Inc,0949c302-51ce-4fc9-8b99-1df94e693718,"71288-723-52, 71288-726-52","Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)",Injection,Available,,ANDA216039,,BUPIVACAINE HYDROCHLORIDE,,,Current,,Meitheal Pharmaceuticals is distributor/labeler; product is available,,7TQO7W3VT8,71288-723-52,844-824-8426,
"Hospira, Inc., a Pfizer Company",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Bupivacaine Hydrochloride Injection,"1725078, 1725082, 1012377, 1012384, 1012396, 1012404, 1672917, 1672919, 1724786, 1724787, 1724880, 1724884, 1867594, 1867596",,"bb44c7e1-d911-4788-908f-09b7b271969b, 02a845c3-4521-4926-e397-25ab536e7cf6",08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE,"0409-1159, 0409-1160, 0409-1162, 0409-1163, 0409-1165, 0409-9043, 0409-9046, 0409-9045, 0409-9042","Hospira, Inc.","40bfa804-5f31-4bd2-b1e3-dcf428710dc1, 3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7","0409-1159-09, 0409-1159-10, 0409-1159-18, 0409-1159-01, 0409-1159-19, 0409-1159-02, 0409-1160-18, 0409-1160-01, 0409-1162-18, 0409-1162-01, 0409-1162-19, 0409-1162-02, 0409-1163-18, 0409-1163-01, 0409-1165-18, 0409-1165-01, 0409-1165-19, 0409-1165-02, 0409-9043-11, 0409-9043-01, 0409-9046-11, 0409-9046-01, 0409-9045-11, 0409-9045-01, 0409-9045-16, 0409-9045-17, 0409-9042-11, 0409-9042-01, 0409-9042-16, 0409-9042-17","Bupivacaine Hydrochloride, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1159-01)",Injection,Available,,ANDA070583,,BUPIVACAINE HYDROCHLORIDE,,,Current,,,,"7TQO7W3VT8, 30Q7KI53AK",0409-1159-01,844-646-4398,
"Prinston Pharmaceutical, Inc.",CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,4acbb7a9-4db5-4497-b8db-9f358b3f6fb4,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"43547-407, 43547-406, 43547-408",Solco Healthcare LLC,dc17b9d4-2890-4f6c-8476-daa39d0cbc9c,"43547-406-10, 43547-406-50, 43547-406-11, 43547-407-10, 43547-407-50, 43547-407-11, 43547-408-10, 43547-408-50","Clonazepam, Tablet, 1 mg (NDC 43547-407-11)",Tablet,Available,"N0000175694, M0002356",ANDA077856,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,Marketed by Solco Healthcare,,5PE9FDE8GB,43547-407-11,"For orders, Solco Healthcare 866-931-9829",
Baxter Healthcare,DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795477, 1795480, 1795481, 1795607, 1795609, 1795610, 1795612, 1795616, 1795618",,3bb406a9-f5cb-403a-b1bb-5c4facbea3d5,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0338-0017, 0338-0023",Baxter Healthcare Corporation,31bb4a5f-733e-4354-9fbf-138dede4db0f,"0338-0017-10, 0338-0017-41, 0338-0017-11, 0338-0017-31, 0338-0017-48, 0338-0017-18, 0338-0017-38, 0338-0017-02, 0338-0017-03, 0338-0017-04, 0338-0023-02, 0338-0023-03, 0338-0023-04","Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-02)",Injection,Available,,NDA016673,,DEXTROSE MONOHYDRATE,,,Current,,,,LX22YL083G,0338-0017-02,888-229-0001,
Aurobindo Pharma USA,AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","308189, 313850",,3cacd754-73f4-496e-a529-9ca39fa6692d,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"65862-071, 65862-070",Aurobindo Pharma Limited,3e3ca279-1838-4348-a01c-df10a8bcb8b9,"65862-070-50, 65862-070-75, 65862-070-01, 65862-071-50, 65862-071-75, 65862-071-01","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 65862-071-75)","Powder, For Suspension",,,ANDA065334,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,65862-071-75,866-850-2876,
"Teva Pharmaceuticals USA, Inc.",CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,8069b1a0-7c06-4252-b44e-e2eef065d9b8,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"0093-0832, 0093-3212, 0093-3213","Teva Pharmaceuticals USA, Inc.",d6abe4e3-7699-4ead-95f4-739a961b23ad,"0093-0832-01, 0093-0832-05, 0093-3212-01, 0093-3212-05, 0093-3213-01, 0093-3213-05","Clonazepam, Tablet, .5 mg (NDC 0093-0832-01)",Tablet,Available,"N0000175694, M0002356",ANDA074569,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,,,5PE9FDE8GB,0093-0832-01,800-545-8800,
Sagent Pharmaceuticals,KETOROLAC TROMETHAMINE,,03/26/2018,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Ketorolac Tromethamine Injection,"860092, 1665459, 1665461",,62591551-a644-4b2c-a0de-982e906fabc3,08/26/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,KETOROLAC TROMETHAMINE,"25021-701, 25021-700",Sagent Pharmaceuticals,ff55e1ab-2a8d-4a56-8b72-5e0a8e00d866,"25021-700-01, 25021-701-01, 25021-701-02","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)",Injection,Available,,ANDA204216,,KETOROLAC TROMETHAMINE,,,Current,,,,4EVE5946BQ,25021-701-02,866-625-1618,
"Fresenius Kabi USA, LLC",MORPHINE SULFATE,,10/31/2017,Revised,"INTRAMUSCULAR, INTRAVENOUS",Morphine Sulfate Injection,"1731993, 1732006, 1732011, 1732136, 2003714",,582f42e5-444e-4246-af8c-e7e28097c69a,09/18/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,MORPHINE SULFATE,"63323-452, 63323-454, 63323-455, 63323-458, 63323-451","Fresenius Kabi USA, LLC",dbf870e7-7bfe-48f0-ba6a-9cc476dfe5cc,"63323-452-00, 63323-452-01, 63323-454-00, 63323-454-01, 63323-455-00, 63323-455-01, 63323-458-00, 63323-458-01, 63323-451-00, 63323-451-01","Morphine Sulfate, Injection, 2 mg/1 mL (NDC 63323-452-01)",Injection,Unavailable,,NDA204223,,MORPHINE SULFATE,,,Current,Demand increase for the drug,Backordered. Next release October 2025. Check wholesalers for inventory.,,X3P646A2J0,63323-452-01,888-386-1300,
"Teva Pharmaceuticals USA, Inc.",OXALIPLATIN,,10/11/2024,New,INTRAVENOUS,Oxaliplatin Injection,"1736776, 1736781",,9e51cc79-620c-48d7-b267-78e43c1ef6e4,10/11/2024,HUMAN PRESCRIPTION DRUG,10/11/2024,Oncology,OXALIPLATIN,"0703-3985, 0703-3986","Teva Parenteral Medicines, Inc.",b349bdd1-79de-44e6-ab0b-892a65bda6f6,"0703-3985-01, 0703-3986-01","Injection, 50 mg/10 mL (NDC 0703-3985-01)",Injection,,"N0000175413, N0000175073",NDA022160,,OXALIPLATIN,Platinum-based Drug [EPC],,To Be Discontinued,,A business decision was made to discontinue this product.,,04ZR38536J,0703-3985-01,800-545-8800,
Sun Pharmaceutical Industries Limited,CLINDAMYCIN HYDROCHLORIDE,,12/05/2024,New,ORAL,Clindamycin Hydrochloride Capsule,"197518, 284215",,1dbd8448-c1e5-46df-8060-50ef82380445,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Anti-Infective,CLINDAMYCIN HYDROCHLORIDE,"63304-693, 63304-692","Sun Pharmaceutical Industries, Inc.",339366d4-2060-1c29-e063-6394a90a1cb7,"63304-692-01, 63304-692-05, 63304-692-77, 63304-692-03, 63304-693-16, 63304-693-01, 63304-693-03, 63304-693-05, 63304-693-77, 63304-693-11, 63304-693-62","Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-05)",Capsule,,,ANDA065061,,CLINDAMYCIN HYDROCHLORIDE,,,To Be Discontinued,,Discontinuing for business reasons,,T20OQ1YN1W,63304-693-05,800-818-4555,
"Teva Pharmaceuticals USA, Inc.",GLIPIZIDE,,02/06/2025,New,ORAL,"Glipizide Tablet, Extended Release","310489, 314006, 315107",,a430577c-f233-40a7-bfd8-3d2bc6f98aa2,02/06/2025,HUMAN PRESCRIPTION DRUG,02/06/2025,Endocrinology/Metabolism,GLIPIZIDE ER,"0591-0900, 0591-0844, 0591-0845","Actavis Pharma, Inc.",90e0de65-ed5f-460a-a96f-77d4d76ceedd,"0591-0900-30, 0591-0844-01, 0591-0844-10, 0591-0845-01, 0591-0845-10","Glipizide, Tablet, Extended Release, 2.5 mg (NDC 0591-0900-30)",Tablet,,"N0000175608, M0020795",ANDA076467,Sulfonylurea Compounds [CS],GLIPIZIDE,Sulfonylurea [EPC],,To Be Discontinued,,A business decision was made to discontinue manufacture of the drug.,,X7WDT95N5C,0591-0900-30,800-545-8800,
"Hikma Pharmaceuticals USA, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,6740a621-9bec-4178-a4fc-a3fc89f34e0a,07/23/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0054-0372, 0054-0660, 0054-0370, 0054-0371, 0054-0373, 0054-0374, 0054-0375",Hikma Pharmaceuticals USA Inc.,5d119550-4386-4bfa-a5d0-bb18e66191b7,"0054-0660-25, 0054-0370-25, 0054-0371-25, 0054-0372-25, 0054-0373-25, 0054-0374-25, 0054-0375-25","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0054-0372-25)",Capsule,Limited Availability,,ANDA202827,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,Available on allocation,,SJT761GEGS,0054-0372-25,800-631-2174,
pharmaand GmbH (pharma&),PEGINTERFERON ALFA-2A,,01/24/2025,Revised,SUBCUTANEOUS,Peginterferon alfa-2a Injection,"351270, 352297, 731326, 731328",,d9290e5b-6d40-2318-e053-2995a90a9916,08/19/2025,HUMAN PRESCRIPTION DRUG,,Antiviral,PEGASYS,"82154-0449, 82154-0451",pharmaand GmbH,3c18e4a2-193f-ef4e-e063-6394a90a56b2,"82154-0449-1, 82154-0451-4","Pegasys, Injection, 180 ug/1 mL (NDC 82154-0449-1)",Injection,Limited Availability,"N0000175521, M0025711",BLA103964,Interferon-alpha [CS],PEGINTERFERON ALFA-2A,Interferon alpha [EPC],,Current,Shortage of an active ingredient,"Pegasys availability will become more limited through Q4 2025. Product replenishment is expected sometime in 2026 and before May 31, 2026.",,Q46947FE7K,82154-0449-1,"800-506-8501, email: medinfo.us@pharmaand.com",
"Hospira, Inc., a Pfizer Company",ROCURONIUM BROMIDE,,02/15/2023,Reverified,INTRAVENOUS,Rocuronium Bromide Injection,1234995,,f01f9986-43f9-40e8-9506-11bfe78f9242,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROCURONIUM BROMIDE,"0409-1403, 0409-5160","Hospira, Inc.",f01f9986-43f9-40e8-9506-11bfe78f9242,"0409-1403-05, 0409-1403-10, 0409-5160-01, 0409-5160-10","Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-1403-10)",Injection,Available,,ANDA205656,,ROCURONIUM BROMIDE,,,Current,,,,I65MW4OFHZ,0409-1403-10,844-646-4398,
"Fresenius Kabi USA, LLC",KETOROLAC TROMETHAMINE,,03/23/2018,Reverified,INTRAMUSCULAR,Ketorolac Tromethamine Injection,"860092, 1665459, 1665461",,"ccf905ca-e164-4779-9485-2d139c821bad, 950b7295-3f68-4027-ac2b-2f7d0f5f8ef9, d1920335-8e45-4960-b6e9-e6f1f9e6820c",09/18/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,KETOROLAC TROMETHAMINE,"63323-162, 63323-161","Fresenius Kabi USA, LLC","2b1c6066-d9e0-40a0-ade5-776fc35a3626, 55ed7afb-db66-4b28-939b-db45b55bf058, ab476c4c-2c72-47b1-bf42-7a89703b0dd4","63323-161-41, 63323-161-16, 63323-162-43, 63323-162-16, 63323-162-45, 63323-162-26, 63323-161-21, 63323-161-12, 63323-162-23, 63323-162-12, 63323-162-25, 63323-162-14, 63323-161-00, 63323-161-01, 63323-162-11, 63323-162-51, 63323-162-00, 63323-162-01, 63323-162-03, 63323-162-02","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-02)",Injection,Available,,ANDA075784,,KETOROLAC TROMETHAMINE,,,Current,,Check wholesaler inventory,,4EVE5946BQ,63323-162-02,888-386-1300,
"Fresenius Kabi USA, LLC",REMIFENTANIL HYDROCHLORIDE,,06/28/2022,Reverified,INTRAVENOUS,Remifentanil Hydrochloride Injection,"1729578, 1729584, 1729710",,d2374b84-81c9-44f9-a4a9-1071281b2531,09/18/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,REMIFENTANIL HYDROCHLORIDE,"63323-724, 63323-723, 63323-725","Fresenius Kabi USA, LLC",2f27e51f-2b55-47ee-bd4a-001b71c60622,"63323-723-01, 63323-723-03, 63323-724-01, 63323-724-05, 63323-725-01, 63323-725-10","Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-724-05)",Injection,Available,,ANDA206223,,REMIFENTANIL HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,5V444H5WIC,63323-724-05,888-386-1300,
InfoRLife SA,ROPIVACAINE HYDROCHLORIDE,,03/27/2018,Reverified,"EPIDURAL, INFILTRATION",Ropivacaine Hydrochloride Injection,"1734347, 1734355, 1734479, 1734481",,8c5c762f-d266-4b1a-809e-f11bfc89bc2d,08/26/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROPIVACAINE HYDROCHLORIDE,"25021-652, 25021-671",Sagent Pharmaceuticals,04d1b1c6-1963-4b42-8479-dbf787b6de17,"25021-671-82, 25021-671-87, 25021-652-82, 25021-652-87","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-82)",Injection,Available,,ANDA206166,,ROPIVACAINE HYDROCHLORIDE,,,Current,,Marketed by Sagent Pharmaceuticals,,V910P86109,25021-652-82,Sagent: 866-625-1618,
"Mylan Pharmaceuticals Inc., a Viatris Company",TOLTERODINE TARTRATE,,02/26/2025,New,ORAL,Tolterodine Tartrate Tablet,"855178, 855180, 855194, 855195",,41eb00d2-64e3-4ec9-8732-4bfc81b04180,02/26/2025,HUMAN PRESCRIPTION DRUG,02/26/2025,Urology,DETROL,"58151-099, 58151-098",Viatris Specialty LLC,f27726af-7a9b-45f4-96e0-1e90a5fdcc18,"58151-098-91, 58151-099-91","Detrol, Tablet, 2 mg (NDC 58151-099-91)",Tablet,,,NDA020771,,TOLTERODINE TARTRATE,,,To Be Discontinued,,,,5T619TQR3R,58151-099-91,800-796-9526,
Eugia US LLC,BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Revised,"EPIDURAL, INTRACAUDAL",Bupivacaine Hydrochloride Injection,"1012396, 1012404, 1724786, 1724787, 1724880, 1724884, 1725078, 1725082",,ffecf450-1f01-4721-8e10-251385852612,09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE,"55150-170, 55150-167, 55150-168, 55150-169, 55150-171, 55150-172, 55150-249, 55150-250",Eugia US LLC,39649703-e633-4a20-ba71-0c04dbf8ff2a,"55150-167-10, 55150-168-30, 55150-169-10, 55150-170-30, 55150-171-10, 55150-172-30, 55150-249-50, 55150-250-50","Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-170-30)",Injection,Available,,ANDA203895,,BUPIVACAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,7TQO7W3VT8,55150-170-30,888-238-7880,
Baxter Healthcare,"ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, PROLINE, SERINE, THREONINE, TRYPTOPHAN, TYROSINE, VALINE",,12/08/2020,Reverified,INTRAVENOUS,Amino Acid Injection,"800584, 800588",,65ffc962-7538-41ea-9afb-4af5fbce4c5b,09/23/2025,HUMAN PRESCRIPTION DRUG,,Gastroenterology,CLINISOL,0338-0502,Baxter Healthcare Corporation,7eab93b5-5590-4381-8674-113a05edeff0,"0338-0502-03, 0338-0502-06","Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)",Injection,Available,"N0000175780, M0000922",ANDA020512,Amino Acids [CS],"LYSINE, LEUCINE, PHENYLALANINE, VALINE, HISTIDINE, ISOLEUCINE, METHIONINE, THREONINE, TRYPTOPHAN, ALANINE, ARGININE, GLYCINE, PROLINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID, TYROSINE",Amino Acid [EPC],,Current,,,,"OF5P57N2ZX, 94ZLA3W45F, 30KYC7MIAI, 3KX376GY7L, TE7660XO1C, 4QD397987E, 04Y7590D77, GMW67QNF9C, TTL6G7LIWZ, AE28F7PNPL, 47E5O17Y3R, 9DLQ4CIU6V, 452VLY9402, 2ZD004190S, 8DUH1N11BX, 42HK56048U, HG18B9YRS7",0338-0502-03,888-229-0001,
"Teva Pharmaceuticals USA, Inc.",CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,8069b1a0-7c06-4252-b44e-e2eef065d9b8,09/15/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"0093-3213, 0093-0832, 0093-3212","Teva Pharmaceuticals USA, Inc.",d6abe4e3-7699-4ead-95f4-739a961b23ad,"0093-0832-01, 0093-0832-05, 0093-3212-01, 0093-3212-05, 0093-3213-01, 0093-3213-05","Clonazepam, Tablet, 2 mg (NDC 0093-3213-05)",Tablet,Available,"N0000175694, M0002356",ANDA074569,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,,,5PE9FDE8GB,0093-3213-05,800-545-8800,
"Elite Laboratories, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,0e024b69-567c-4b40-9c3e-a2daec34256c,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"64850-556, 64850-550, 64850-551, 64850-552, 64850-553, 64850-554, 64850-555","Elite Laboratories, Inc.",e414bb2e-d404-44ea-931c-5998b0a4c87e,"64850-550-01, 64850-551-01, 64850-552-01, 64850-553-01, 64850-554-01, 64850-555-01, 64850-556-01","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 64850-556-01)",Capsule,Limited Availability,,ANDA218604,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,,,SJT761GEGS,64850-556-01,888-852-6657,
"Sun Pharmaceutical Industries, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Revised,ORAL,"Lisdexamfetamine Dimesylate Tablet, Chewable","854830, 854834, 854838, 854842, 854846, 854850, 1593856, 1871456, 1871460, 1871462, 1871464, 1871466, 1871468",,da3148af-f9b6-4725-adae-3595b4c7dc4b,09/22/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"57664-088, 57664-047, 57664-046, 57664-048, 57664-049, 57664-050, 57664-051, 57664-052, 57664-083, 57664-084, 57664-085, 57664-086, 57664-087","Sun Pharmaceutical Industries, Inc.",0b77417a-5789-8818-e063-6294a90ad2e3,"57664-047-88, 57664-046-88, 57664-048-88, 57664-049-88, 57664-050-88, 57664-051-88, 57664-052-88, 57664-083-88, 57664-084-88, 57664-085-88, 57664-086-88, 57664-087-88, 57664-088-88","Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 57664-088-88)","Tablet, Chewable",Limited Availability,,ANDA214134,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Other,Available Q3 2025,,SJT761GEGS,57664-088-88,800-818-4555,
"Dr. Reddy's Laboratories, Inc.",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Reverified,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release","1091155, 1091170, 1091185, 1091210",,7124df7e-6273-a68d-6e35-dc06122d8686,09/16/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE HYDROCHLORIDE,"43598-440, 43598-438, 43598-439, 43598-441",Dr.Reddys Laboratories Inc,528a86ce-1037-944a-e934-15846984dd73,"43598-438-01, 43598-439-01, 43598-440-01, 43598-441-01","Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 43598-440-01)",Tablet,Available,,ANDA213473,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,,Available to existing customers,,4B3SC438HI,43598-440-01,866-732-3952,
"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)",RILUZOLE,,01/26/2024,Reverified,ORAL,Riluzole Oral Suspension,"2058147, 2675565",https://www.fda.gov/media/177206/download,125fdd37-02f7-a610-e063-6294a90a009d,09/15/2025,HUMAN PRESCRIPTION DRUG,,Neurology,TEGLUTIK,70726-0305,EDW PHARMA,125fdd67-c898-437b-e063-6394a90a3543,70726-0305-1,"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0305-1)",Oral Suspension,Available,"N0000175740, M0483511",,Benzothiazoles [CS],RILUZOLE,Benzothiazole [EPC],,Current,,,,7LJ087RS6F,70726-0305-1,610-937-6172,
"Fresenius Kabi USA, LLC",ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Reverified,"EPIDURAL, INFILTRATION",Ropivacaine Hydrochloride Injection,"1734203, 1734204, 1734207, 1734208, 1734347, 1734348, 1734355, 1734356, 1734475, 1734476, 1734479, 1734480, 1734481, 1734482, 1734483, 1734484, 905189, 905191, 1734084, 1734086, 1734090, 1734091",,"dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7, 23d2d448-a744-4877-9f2d-7e57c198da89, c6613708-c1f7-4f5c-91a3-ebbc1d7905c6",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,NAROPIN,"63323-285, 63323-286, 63323-287, 63323-288","Fresenius Kabi USA, LLC","324532ac-4e54-4659-a1a2-9ade22a1ed3f, cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9, 73218c89-8925-468c-84bf-9960b4b3dc3c","63323-286-41, 63323-286-27, 63323-286-43, 63323-286-38, 63323-285-41, 63323-285-28, 63323-285-53, 63323-285-68, 63323-285-59, 63323-285-73, 63323-286-01, 63323-286-20, 63323-286-05, 63323-286-23, 63323-286-09, 63323-286-31, 63323-286-11, 63323-286-35, 63323-286-03, 63323-286-00, 63323-286-33, 63323-286-63, 63323-286-30, 63323-287-01, 63323-287-20, 63323-287-03, 63323-287-21, 63323-288-01, 63323-288-10, 63323-288-06, 63323-288-20, 63323-288-03, 63323-288-11, 63323-288-07, 63323-288-21, 63323-285-01, 63323-285-10, 63323-285-06, 63323-285-20, 63323-285-03, 63323-285-13, 63323-285-07, 63323-285-23, 63323-285-57, 63323-285-64, 63323-285-51, 63323-285-65, 63323-285-02, 63323-285-61, 63323-285-04, 63323-285-63, 63323-285-55, 63323-285-67, 63323-288-23, 63323-288-29, 63323-286-93, 63323-286-95","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-20)",Injection,Unavailable,,NDA020533,,ROPIVACAINE HYDROCHLORIDE,,,Current,Delay in shipping of the drug,Next release not available at this time.,,V910P86109,63323-285-20,888-386-1300,
B. Braun Medical Inc.,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807630, 1807631, 1807632",,cc14fafd-3dcd-4fc8-bdbd-6f355c375768,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,0264-1800,B. Braun Medical Inc.,7d4ee37f-5016-422c-9f66-e675ae22c46a,"0264-1800-36, 0264-1800-31, 0264-1800-32","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0264-1800-31)",Injection,,,NDA017464,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0264-1800-31,800-227-2862,
Aurobindo Pharma USA,"AMLODIPINE BESYLATE, BENAZEPRIL HYDROCHLORIDE",,03/04/2025,New,ORAL,Amlodipine Besylate; Benazepril Hydrochloride Capsule,"898342, 898346, 898350, 898353, 898356, 898359",,99ed4927-9a34-4e8d-8eea-60b63c867d46,03/04/2025,HUMAN PRESCRIPTION DRUG,03/04/2025,Cardiovascular,AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE,"65862-586, 65862-582, 65862-583, 65862-584, 65862-585, 65862-587",Aurobindo Pharma Limited,a45ec3e8-1d14-4c27-9685-976323df8cad,"65862-582-01, 65862-582-05, 65862-583-01, 65862-583-05, 65862-584-01, 65862-584-05, 65862-585-01, 65862-585-05, 65862-586-01, 65862-586-05, 65862-587-01, 65862-587-05","Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 10 mg; 20 mg (NDC 65862-586-05)",Capsule,,,ANDA202239,,AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE,,,To Be Discontinued,,,,"864V2Q084H, N1SN99T69T",65862-586-05,866-850-2876,
GlaxoSmithKline,EPOPROSTENOL SODIUM,,01/31/2025,New,INTRAVENOUS,Epoprostenol Sodium Injection,"211199, 211200, 562501, 562502",,8e4b636e-ee9c-4111-779d-28c8369d283b,01/31/2025,HUMAN PRESCRIPTION DRUG,01/31/2025,Cardiovascular,FLOLAN,"0173-0519, 0173-0517, 0173-0857",GlaxoSmithKline LLC,5e54002e-7b03-46ad-ae01-c76c76967201,"0173-0517-00, 0173-0519-00, 0173-0857-02","Flolan, Injection, 1.5 mg (NDC 0173-0519-00)",Injection,,,NDA020444,,EPOPROSTENOL SODIUM,,,To Be Discontinued,,"The anticipated date that GSK will cease distribution of the product is approximately November 30, 2025.",,"059QF0KO0R, 4K04IQ1OF4",0173-0519-00,888-825-5249,
"Hikma Pharmaceuticals USA, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Revised,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,6740a621-9bec-4178-a4fc-a3fc89f34e0a,08/01/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0054-0660, 0054-0370, 0054-0371, 0054-0372, 0054-0373, 0054-0374, 0054-0375",Hikma Pharmaceuticals USA Inc.,5d119550-4386-4bfa-a5d0-bb18e66191b7,"0054-0660-25, 0054-0370-25, 0054-0371-25, 0054-0372-25, 0054-0373-25, 0054-0374-25, 0054-0375-25","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0054-0660-25)",Capsule,Limited Availability,,ANDA202827,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,Available on allocation,,SJT761GEGS,0054-0660-25,800-631-2174,
"Dr. Reddy's Laboratories, Inc.",,,07/26/2023,Reverified,,"Methylphenidate Hydrochloride Tablet, Extended Release",,,,09/16/2025,,,Psychiatry,,,,,,"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 43598-441-01)",Tablet,Unavailable,,,,,,,Current,Other,Estimated availability TBD,,,43598-441-01,866-732-3952,
"Upsher-Smith Laboratories, LLC",POTASSIUM CHLORIDE,,07/23/2025,New,ORAL,"Potassium Chloride Tablet, Extended Release","312529, 628953",,616f0de7-8843-44a1-8fa6-274d889286aa,07/23/2025,HUMAN PRESCRIPTION DRUG,07/23/2025,"Endocrinology/Metabolism, Gastroenterology",POTASSIUM CHLORIDE,"0832-5323, 0832-5322","Upsher-Smith Laboratories, LLC",39e726b1-eab8-fcf4-e063-6394a90a950a,"0832-5322-11, 0832-5322-10, 0832-5323-11, 0832-5323-10","Potassium Chloride, Tablet, Extended Release, 750 mg (NDC 0832-5323-10)",Tablet,,,NDA019123,,POTASSIUM CHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug product,,660YQ98I10,0832-5323-10,763-315-2000,
B. Braun Medical Inc.,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807630, 1807631, 1807632",,cc14fafd-3dcd-4fc8-bdbd-6f355c375768,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,0264-1800,B. Braun Medical Inc.,7d4ee37f-5016-422c-9f66-e675ae22c46a,"0264-1800-36, 0264-1800-31, 0264-1800-32","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0264-1800-36)",Injection,,,NDA017464,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0264-1800-36,800-227-2862,
Pfizer Inc.,,,01/06/2023,Revised,,Somatropin Injection,"241975, 762830, 762833, 762834, 762836, 762837, 762839, 762841, 762843, 762846, 762849, 762850, 762852, 762857, 762859, 762866, 762868, 762873, 762875, 762895, 762897, 763488, 763489, 996558, 996559",,ffebf88b-d257-4542-9808-74d9b7167765,08/28/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,GENOTROPIN,"0013-2649, 0013-2626, 0013-2646, 0013-2650, 0013-2651, 0013-2652, 0013-2653, 0013-2654, 0013-2655, 0013-2656, 0013-2657, 0013-2658",Pfizer Laboratories Div Pfizer Inc,f09acf87-6e30-47ad-9891-8a49bf6dffbc,"0013-2626-81, 0013-2646-81, 0013-2649-02, 0013-2650-02, 0013-2651-02, 0013-2652-02, 0013-2653-02, 0013-2654-02, 0013-2655-02, 0013-2656-02, 0013-2657-02, 0013-2658-02","Genotropin, Injection, 0.2 mg preservative free (NDC 0013-2649-02)",Injection,,,BLA020280,,SOMATROPIN,,Available,Resolved,,,08/28/2025,,0013-2649-02,800-533-4535,
"Upsher-Smith Laboratories, LLC",TOPIRAMATE,Decreased Central Nervous System Disorganized Electrical Activity [PE],04/24/2025,New,ORAL,"Topiramate Capsule, Extended Release","1494766, 1494769, 1494771, 1494775, 1494778, 1494781, 1812419, 1812421, 1812425, 1812427",,46f54677-3a22-4c38-9b92-923020164e15,04/24/2025,HUMAN PRESCRIPTION DRUG,04/24/2025,Neurology,QUDEXY XR,"0245-1073, 0245-1071, 0245-1072, 0245-1074, 0245-1075","Upsher-Smith Laboratories, LLC",374eeb55-b017-48fd-e063-6294a90a6ad7,"0245-1071-30, 0245-1071-90, 0245-1072-30, 0245-1072-90, 0245-1074-30, 0245-1074-90, 0245-1075-30, 0245-1075-90, 0245-1073-30, 0245-1073-90","Qudexy XR, Capsule, Extended Release, 200 mg (NDC 0245-1073-30)","Capsule, Extended Release",,"N0000008486, N0000185506, N0000182140",NDA205122,,TOPIRAMATE,,,To Be Discontinued,,Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.,,0H73WJJ391,0245-1073-30,716-315-2000,"Cytochrome P450 3A4 Inducers [MoA], Cytochrome P450 2C19 Inhibitors [MoA]"
"Hospira, Inc., a Pfizer Company","BUPIVACAINE HYDROCHLORIDE, EPINEPHRINE BITARTRATE",,02/20/2018,Reverified,"EPIDURAL, INTRACAUDAL, PERINEURAL","Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","1012377, 1012381, 1012384, 1012388, 1012396, 1012400, 1012404, 1012406, 1672917, 1672919, 1673242, 1673243, 1724786, 1724787, 1724794, 1724796, 1724880, 1724884, 1725044, 1725046, 1725078, 1725079, 1725082, 1725083, 1867594, 1867596, 1867612, 1867614",,67578b56-7540-487e-1fba-481255620e78,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,MARCAINE WITH EPINEPHRINE,"0409-1749, 0409-1559, 0409-1560, 0409-1582, 0409-1587, 0409-1610, 0409-1746, 0409-1752, 0409-1755, 0409-2510, 0409-7535, 0409-1250, 0409-5010, 0409-1530, 0409-0525, 0409-7510, 0409-2253","Hospira, Inc.",b083f440-bfb7-449a-b601-c2f59a6f9dcf,"0409-1559-18, 0409-1559-10, 0409-1559-19, 0409-1559-30, 0409-1560-18, 0409-1560-10, 0409-1560-19, 0409-1560-29, 0409-1582-18, 0409-1582-10, 0409-1582-19, 0409-1582-29, 0409-1587-50, 0409-1610-50, 0409-1746-70, 0409-1746-10, 0409-1746-71, 0409-1746-30, 0409-1749-70, 0409-1749-10, 0409-1749-71, 0409-1749-29, 0409-1752-50, 0409-1755-50, 0409-2510-01, 0409-2510-25, 0409-7535-01, 0409-7535-25, 0409-1250-01, 0409-1250-25, 0409-5010-01, 0409-5010-25, 0409-1530-01, 0409-1530-25, 0409-0525-01, 0409-0525-25, 0409-7510-01, 0409-7510-25, 0409-2253-01, 0409-2253-25","Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000) (NDC 0409-1749-10)",Injection,Available,,NDA016964,,BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE,,,Current,,,,"30Q7KI53AK, 7TQO7W3VT8",0409-1749-10,844-646-4398,
"Par Pharmaceutical, Inc.",CANDESARTAN CILEXETIL,,10/15/2024,New,ORAL,Candesartan Cilexetil Tablet,"153822, 153823, 577776, 639537",,1c90aa68-cc12-41ef-aebc-2616ae45683a,10/15/2024,HUMAN PRESCRIPTION DRUG,10/15/2024,Cardiovascular,CANDESARTAN CILEXETIL,"49884-660, 49884-658, 49884-659, 49884-661",Par Pharmaceutical Inc.,fc8868a3-89f5-4414-b3c8-edece3b529f4,"49884-658-09, 49884-659-09, 49884-660-09, 49884-661-09","Atacand, Tablet, 16 mg (NDC 49884-660-09)",Tablet,,,NDA020838,,CANDESARTAN CILEXETIL,,,To Be Discontinued,,,,R85M2X0D68,49884-660-09,800-828-9393,
"Teva Pharmaceuticals USA, Inc.",HYDROCORTISONE,,03/24/2025,New,TOPICAL,Hydrocortisone Cream,106258,,aa9dba84-eb38-4ec3-8555-87c948bf2384,03/24/2025,HUMAN PRESCRIPTION DRUG,03/24/2025,Dermatology,HYDROCORTISONE,0472-0321,"Actavis Pharma, Inc.",d74b9b48-0a47-43d1-a89a-f294c4ca1297,0472-0321-26,"Hydrocortisone, Cream, 10 mg/1 g (NDC 0472-0321-26)",Cream,,"N0000175576, N0000175450",ANDA087795,,HYDROCORTISONE,Corticosteroid [EPC],,To Be Discontinued,,A business decision was made to discontinue.,,WI4X0X7BPJ,0472-0321-26,800-545-8800,Corticosteroid Hormone Receptor Agonists [MoA]
"Fresenius Kabi USA, LLC",SODIUM CHLORIDE,,12/08/2021,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Sodium Chloride 0.9% Injection,313002,,e5e325d1-0d58-40c9-9645-3ae402ff9d92,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",BACTERIOSTATIC SODIUM CHLORIDE,63323-924,"Fresenius Kabi USA, LLC",d83b23bf-9f14-4e45-a569-b227cbb08e88,"63323-924-01, 63323-924-10, 63323-924-03, 63323-924-30","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-924-30)",Injection,,,ANDA088911,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,63323-924-30,888-386-1300,
Pfizer Inc.,,,01/06/2023,Revised,,Somatropin Injection,"241975, 762830, 762833, 762834, 762836, 762837, 762839, 762841, 762843, 762846, 762849, 762850, 762852, 762857, 762859, 762866, 762868, 762873, 762875, 762895, 762897, 763488, 763489, 996558, 996559",,ffebf88b-d257-4542-9808-74d9b7167765,08/28/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,GENOTROPIN,"0013-2656, 0013-2626, 0013-2646, 0013-2649, 0013-2650, 0013-2651, 0013-2652, 0013-2653, 0013-2654, 0013-2655, 0013-2657, 0013-2658",Pfizer Laboratories Div Pfizer Inc,f09acf87-6e30-47ad-9891-8a49bf6dffbc,"0013-2626-81, 0013-2646-81, 0013-2649-02, 0013-2650-02, 0013-2651-02, 0013-2652-02, 0013-2653-02, 0013-2654-02, 0013-2655-02, 0013-2656-02, 0013-2657-02, 0013-2658-02","Genotropin, Injection, 1.6 mg preservative free (NDC 0013-2656-02)",Injection,,,BLA020280,,SOMATROPIN,,Available,Resolved,,,08/28/2025,,0013-2656-02,800-533-4535,
"Fresenius Kabi USA, LLC","BUPIVACAINE HYDROCHLORIDE, EPINEPHRINE BITARTRATE",,02/20/2018,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL","Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","1867594, 1867596, 1867618, 1867620, 1012377, 1012384, 1012413, 1012417, 1724786, 1724787, 1724809, 1724810",,"b671015d-f620-4930-a890-5e27a40ae42f, bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,SENSORCAINE MPF,"63323-468, 63323-472, 63323-463, 63323-461","Fresenius Kabi USA, LLC","b671015d-f620-4930-a890-5e27a40ae42f, cc1f6507-eb3e-4398-a1d3-0c56a2099e6b","63323-468-08, 63323-468-38, 63323-472-03, 63323-472-17, 63323-472-01, 63323-472-37, 63323-463-01, 63323-463-57, 63323-461-01, 63323-461-57, 63323-468-02, 63323-468-37, 63323-468-01, 63323-468-17","Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-37)",Injection,Available,,ANDA070966,,BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE,,,Current,,Check wholesalers for inventory,,"7TQO7W3VT8, 30Q7KI53AK",63323-468-37,888-386-1300,
"Teva Pharmaceuticals USA, Inc.",AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension",,,4c0f348a-a65d-409c-8668-207c82a5e3cb,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0093-4161, 0093-2263, 0093-2264, 0093-4160, 0093-4155, 0093-2267, 0093-2268, 0093-3107, 0093-3109","Teva Pharmaceuticals USA, Inc.",8988589b-0893-4233-ac9c-9884ceb0c2c4,"0093-2263-01, 0093-2264-01, 0093-4160-76, 0093-4160-78, 0093-4160-73, 0093-4155-79, 0093-4155-73, 0093-4155-80, 0093-4161-76, 0093-4161-78, 0093-4161-73, 0093-2267-01, 0093-2268-01, 0093-3107-01, 0093-3107-05, 0093-3109-53, 0093-3109-06, 0093-3109-01, 0093-3109-05","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0093-4161-76)","Powder, For Suspension",,,ANDA065119,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0093-4161-76,800-545-8800,
"Hikma Pharmaceuticals USA, Inc.",LORAZEPAM,,09/05/2018,Revised,"INTRAMUSCULAR, INTRAVENOUS",Lorazepam Injection,"206819, 206820, 238100, 238101, 1665188, 1665190, 1665326, 1665327",,5fc0e987-61c9-40c4-b0d5-fcea07c8733e,07/23/2025,HUMAN PRESCRIPTION DRUG,,Neurology,ATIVAN,"0641-6000, 0641-6003, 0641-6002, 0641-6001",Hikma Pharmaceuticals USA Inc.,209b0091-c890-4f69-a693-d0594c2606fe,"0641-6003-01, 0641-6003-25, 0641-6002-01, 0641-6002-10, 0641-6001-01, 0641-6001-25, 0641-6000-01, 0641-6000-10","Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10)",Injection,Unavailable,"N0000175694, M0002356",NDA018140,Benzodiazepines [CS],LORAZEPAM,Benzodiazepine [EPC],,Current,Regulatory delay,Shortage duration unknown,,O26FZP769L,0641-6000-10,800-631-2174,
"Hospira, Inc., a Pfizer Company",SODIUM BICARBONATE,,03/01/2017,Reverified,INTRAVENOUS,Sodium Bicarbonate Injection,1868469,,"0c24b592-4bc8-456f-acac-9c9525844a06, ea9f4498-0d43-4043-8dd1-f22537841c21",08/15/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Pediatric",SODIUM BICARBONATE,0409-5555,"Hospira, Inc.","6493c4d8-9ef7-4ec3-b373-6b3ecf5db9b0, 037c4aeb-4a95-4c37-8214-a30110b1d47f","0409-5555-11, 0409-5555-01, 0409-5555-12, 0409-5555-02","Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-01)",Injection,Available,,ANDA202981,,SODIUM BICARBONATE,,,Current,,,01/03/2025,8MDF5V39QO,0409-5555-01,844-646-4398,
Pfizer Inc.,TALAZOPARIB TOSYLATE,,01/13/2025,New,ORAL,Talazoparib Tosylate Capsule,"2099946, 2099952, 2099954, 2099956, 2591510, 2591512, 2591520, 2591521, 2639960, 2639962, 2639964, 2639966",,f2423edd-6d24-495c-aec1-c2f457f08d9a,01/13/2025,HUMAN PRESCRIPTION DRUG,01/13/2025,Oncology,TALZENNA,"0069-1235, 0069-0296, 0069-1195, 0069-1501, 0069-1751, 0069-1031",Pfizer Laboratories Div Pfizer Inc,2cb65f61-9a14-46d9-85a3-a7eea76160c5,"0069-0296-30, 0069-1195-30, 0069-1501-30, 0069-1751-30, 0069-1031-30, 0069-1235-30","Talzenna, Capsule, .35 mg (NDC 0069-1235-30)",Capsule,,,NDA211651,,TALAZOPARIB,,,To Be Discontinued,,"Supply expected to exhaust late February 2025
Replaced with Soft Gel NDC 0069-0454-30",,02WK9U5NZC,0069-1235-30,800-533-4535,
Accord Healthcare Inc.,ATROPINE SULFATE,,01/01/2012,Revised,INTRAVENOUS,Atropine Sulfate Injection,"1190795, 1666781",,d5e07279-48ca-4f83-9633-299e65a7f821,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology, Pediatric",ATROPINE SULFATE,"16729-525, 16729-526",Accord Healthcare Inc.,2f360fd4-b6b0-7540-e063-6394a90aa720,"16729-525-63, 16729-525-03, 16729-525-08, 16729-526-63, 16729-526-03, 16729-526-08","Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)",Injection,"Unavailable, 75 days",,NDA214652,,ATROPINE SULFATE,,,Current,Requirements related to complying with good manufacturing practices,Manufacturing in process,,03J5ZE7KA5,16729-525-08,"866-941-7875, option 2",
"Hikma Pharmaceuticals USA, Inc.",ETOMIDATE,General Anesthesia [PE],10/05/2022,Revised,INTRAVENOUS,Etomidate Injection,"1654006, 1654008",,98002094-f065-4b5f-963f-2c34b5241316,07/23/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ETOMIDATE,"72572-160, 72572-161","Civica, Inc.",380f0c88-03f8-4cfa-8823-4766c2f7700c,"72572-160-01, 72572-160-10, 72572-161-01, 72572-161-10","Etomidate, Injection, 2 mg/1 mL (NDC 72572-160-10)",Injection,Available,"N0000175975, N0000175681",ANDA202354,,ETOMIDATE,General Anesthetic [EPC],,Current,,Distributed by Civica,,Z22628B598,72572-160-10,800-631-2174,
"Mylan Institutional, a Viatris Company",ETOMIDATE,General Anesthesia [PE],10/05/2022,Reverified,INTRAVENOUS,Etomidate Injection,"1654006, 1654008",,461e34d1-b862-4a02-9727-548c907aac48,09/17/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ETOMIDATE,"67457-903, 67457-902",Mylan Institutional LLC,25fc0aef-d4b3-4b33-897c-81cc7cdae470,"67457-902-00, 67457-902-10, 67457-903-00, 67457-903-20","Etomidate, Injection, 2 mg/1 mL (NDC 67457-903-20)",Injection,Available,"N0000175975, N0000175681",ANDA201044,,ETOMIDATE,General Anesthetic [EPC],,Current,,,,Z22628B598,67457-903-20,800-796-9526,
"Hospira, Inc., a Pfizer Company",FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Revised,"INTRAMUSCULAR, INTRAVENOUS",Furosemide Injection,"1719286, 1719290, 1719291",,"aaced7a8-c3d7-4d66-8c07-aa407b8b3f35, 39fd32f2-6bb7-4a65-d298-e48d26bc80c7",08/15/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,0409-6102,"Hospira, Inc.","c529b0df-a5cb-46ce-8131-38674ee756af, 0d4a39f2-904e-434a-9af1-83bb4febf124","0409-6102-35, 0409-6102-25, 0409-6102-36, 0409-6102-26, 0409-6102-37, 0409-6102-27, 0409-6102-19, 0409-6102-02, 0409-6102-18, 0409-6102-04, 0409-6102-20, 0409-6102-10","Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-27)",Injection,Limited Availability,"N0000175366, N0000175590",NDA018667,,FUROSEMIDE,Loop Diuretic [EPC],,Current,Other,Limited Supply Available. Next Delivery and Estimated Recovery: December 2027,,7LXU5N7ZO5,0409-6102-27,844-646-4398,
"Hospira, Inc., a Pfizer Company",HYDROCORTISONE SODIUM SUCCINATE,,03/24/2023,Revised,"INTRAMUSCULAR, INTRAVENOUS",Hydrocortisone Sodium Succinate Injection,"105398, 238755, 1738586, 1738589, 1738590, 1738592, 1738594, 1738596",https://www.fda.gov/media/187228/download,65eefd58-b166-4d71-ade6-45c8fdf86922,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Pulmonary/Allergy, Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Pediatric, Renal, Rheumatology",SOLU-CORTEF,"0009-0825, 0009-0011, 0009-0013, 0009-0016, 0009-0005",Pharmacia & Upjohn Company LLC,8512044a-4a54-4634-bb97-9e20126adc61,"0009-0825-01, 0009-0011-03, 0009-0011-04, 0009-0013-05, 0009-0013-06, 0009-0016-12, 0009-0005-01","Solu-cortef, Injection, 100 mg/vial (NDC 0009-0825-01)",Injection,Limited Availability,,NDA009866,,HYDROCORTISONE SODIUM SUCCINATE,,,Current,Other,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,50LQB69S1Z,0009-0825-01,844-646-4398,
Sandoz Inc.,AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","239191, 308182, 308189, 308191, 308192, 308194, 313797, 313850",,13bd4214-9b7f-425b-af5f-fc1ddc678230,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0781-6041, 0781-2020, 0781-2613, 0781-5060, 0781-5061, 0781-6039, 0781-6156, 0781-6157",Sandoz Inc,6aa02079-d11c-4d2f-acaf-9548dd9a7ed6,"0781-2020-31, 0781-2020-76, 0781-2020-01, 0781-2020-05, 0781-2613-31, 0781-2613-76, 0781-2613-01, 0781-2613-05, 0781-5060-20, 0781-5060-01, 0781-5061-20, 0781-5061-01, 0781-6039-58, 0781-6039-46, 0781-6039-55, 0781-6156-52, 0781-6156-57, 0781-6156-46, 0781-6041-58, 0781-6041-46, 0781-6041-55, 0781-6157-52, 0781-6157-57, 0781-6157-46","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0781-6041-58)","Powder, For Suspension",,,ANDA065387,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0781-6041-58,800-525-8747,
"Boehringer Ingelheim Pharmaceuticals, Inc.",,,01/06/2025,New,,Adalimumab-adbm Injection,"797544, 2640883, 2640891, 2640893, 2640895, 2640900, 2640902, 2680743, 2680748, 2680756, 2680759",,62f39a7c-00df-4519-a8d4-39bbd0a649ed,01/06/2025,HUMAN PRESCRIPTION DRUG,01/06/2025,Rheumatology,ADALIMUMAB-ADBM,"0597-0545, 0597-0595, 0597-0555, 0597-0585, 0597-0575, 0597-0565","Boehringer Ingelheim Pharmaceuticals, Inc.",79fdef1e-7f86-429d-bc7d-2e99f286204b,"0597-0595-20, 0597-0590-26, 0597-0555-80, 0597-0550-06, 0597-0585-89, 0597-0580-37, 0597-0545-22, 0597-0545-44, 0597-0545-66, 0597-0540-10, 0597-0575-50, 0597-0575-40, 0597-0575-60, 0597-0570-32, 0597-0565-20, 0597-0560-12","Cyltezo, Injection, Kit (NDC 0597-0545-66)",Injection,,,BLA761058,,ADALIMUMAB-ADBM,,,To Be Discontinued,,,,,0597-0545-66,800-243-0127,
"Teva Pharmaceuticals USA, Inc.",MEFLOQUINE HYDROCHLORIDE,,05/14/2024,Revised,ORAL,Mefloquine Hydrochloride Tablet,835913,,09716a24-d7da-42b2-af29-c03a1b6670bd,08/21/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,MEFLOQUINE HYDROCHLORIDE,0555-0171,"Teva Pharmaceuticals USA, Inc.",33a105c5-0e51-4759-857b-6ca8dfae1d13,"0555-0171-88, 0555-0171-78","Mefloquine Hydrochloride, Tablet, 250 mg (NDC 0555-0171-78)",Tablet,,,ANDA076392,,MEFLOQUINE HYDROCHLORIDE,,Available,Resolved,,,08/21/2025,5Y9L3636O3,0555-0171-78,800-545-8800,
"Hikma Pharmaceuticals USA, Inc.",MIDAZOLAM HYDROCHLORIDE,,04/02/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Midazolam Hydrochloride Injection,"311700, 311702",,575d8bf0-7af7-427c-a231-966e2a5e070d,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology",MIDAZOLAM,"0641-6057, 0641-6059, 0641-6056, 0641-6061, 0641-6063, 0641-6060",Hikma Pharmaceuticals USA Inc.,559c03fb-24ea-4b7b-8afd-e33cb3a2340a,"0641-6057-01, 0641-6057-10, 0641-6057-25, 0641-6059-01, 0641-6059-10, 0641-6056-01, 0641-6056-10, 0641-6061-01, 0641-6061-10, 0641-6061-25, 0641-6063-01, 0641-6063-10, 0641-6063-25, 0641-6060-01, 0641-6060-10","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6057-25)",Injection,Available,,ANDA075243,,MIDAZOLAM,,,Current,,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,W7TTW573JJ,0641-6057-25,800-631-2174,
Strides Pharma Inc.,SERTRALINE HYDROCHLORIDE,,01/22/2025,New,ORAL,Sertraline Hydrochloride Tablet,"312938, 312940, 312941",,1f99e897-1b70-40b0-8c19-71d0bba19422,01/22/2025,HUMAN PRESCRIPTION DRUG,01/22/2025,Psychiatry,SERTRALINE HYDROCHLORIDE,"71093-130, 71093-129, 71093-131","ACI Healthcare USA, Inc.",3f41fc19-b54a-46fd-acbf-b411816bccd5,"71093-129-01, 71093-129-03, 71093-129-05, 71093-130-01, 71093-130-03, 71093-130-05, 71093-131-01, 71093-131-03, 71093-131-05","Sertraline Hydrochloride, Tablet, 50 mg (NDC 71093-130-03)",Tablet,,,ANDA076881,,SERTRALINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,UTI8907Y6X,71093-130-03,877-244-9825,
"Hospira, Inc., a Pfizer Company",SODIUM ACETATE ANHYDROUS,,02/03/2016,Reverified,INTRAVENOUS,Sodium Acetate Injection,237371,,"abc41ed1-9512-4bea-9295-1a9ca134b6c2, c3be2468-45e8-4ecc-a30b-e966743a563f",08/15/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Pediatric, Total Parenteral Nutrition",SODIUM ACETATE,0409-3299,"Hospira, Inc.","eadea22b-c475-4596-8c15-e738af5a711d, 99255488-8958-49ab-965c-083119f5ba3c","0409-3299-15, 0409-3299-05, 0409-3299-16, 0409-3299-06, 0409-3299-45, 0409-3299-25, 0409-3299-46, 0409-3299-26","Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-25)",Injection,Available,,NDA018893,,SODIUM ACETATE,,,Current,,,,NVG71ZZ7P0,0409-3299-25,844-646-4398,
Teyro Labs,CARBOPLATIN,,04/28/2023,Reverified,INTRAVENOUS,Carboplatin Injection,597195,https://dps.fda.gov/drugshortages/discontinuations/carboplatin-injection,1c275825-0275-4c73-b650-e4c1519f13b8,09/29/2025,HUMAN PRESCRIPTION DRUG,,Oncology,CARBOPLATIN,60505-6282,Apotex Corp.,0e68e276-b0df-4f03-e063-6394a90a22b9,"60505-6282-1, 60505-6282-3, 60505-6282-6, 60505-6282-7","Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1)",Injection,Unavailable,"N0000175413, N0000175073",ANDA077861,,CARBOPLATIN,Platinum-based Drug [EPC],,Current,Discontinuation of the manufacture of the drug,Discontinuation of the manufacture of the drug.,,BG3F62OND5,60505-6282-1,Apotex Inc.: 800-706-5575,
Baxter Healthcare,CLINDAMYCIN PHOSPHATE,,03/21/2023,Revised,INTRAVENOUS,Clindamycin Phosphate Injection,"309335, 309336, 309339",,78832ac6-04c5-45e0-ae4d-f56d7920dda9,09/23/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,CLINDAMYCIN PHOSPHATE,"0338-3814, 0338-3410, 0338-3612",Baxter Healthcare Company,9373fc85-1d70-4907-842a-ae9e2a3958b3,"0338-3410-50, 0338-3410-24, 0338-3612-50, 0338-3612-24, 0338-3814-50, 0338-3814-24","Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)",Injection,Available,,ANDA208084,,CLINDAMYCIN PHOSPHATE,,,Current,,,,EH6D7113I8,0338-3814-50,888-229-0001,
"Boehringer Ingelheim Pharmaceuticals, Inc.",,,01/06/2025,New,,Adalimumab-adbm Injection,"797544, 2640883, 2640889, 2640891, 2640892, 2640893, 2640894, 2640895, 2640898, 2640900, 2640901, 2640902, 2640903, 2680743, 2680746, 2680748, 2680750, 2680756, 2680757, 2680759, 2680760",,115ea79b-7209-7f19-b35d-36ec0828fbf5,01/06/2025,HUMAN PRESCRIPTION DRUG,01/06/2025,Rheumatology,CYLTEZO,"0597-0495, 0597-0370, 0597-0405, 0597-0400, 0597-0375, 0597-0485","Boehringer Ingelheim Pharmaceuticals, Inc.",48e59974-6012-4a21-9348-552d590632b1,"0597-0370-82, 0597-0370-72, 0597-0370-45, 0597-0405-80, 0597-0405-10, 0597-0400-89, 0597-0375-48, 0597-0375-97, 0597-0375-23, 0597-0375-16, 0597-0375-53, 0597-0485-46, 0597-0485-20, 0597-0480-12, 0597-0495-47, 0597-0495-50, 0597-0495-40, 0597-0495-60, 0597-0490-32","Cyltezo, Injection, Kit (NDC 0597-0495-40)",Injection,,,BLA761058,,ADALIMUMAB-ADBM,,,To Be Discontinued,,,,,0597-0495-40,800-243-0127,
"Upsher-Smith Laboratories, LLC",FLUPHENAZINE HYDROCHLORIDE,,09/18/2025,New,ORAL,Fluphenazine Hydrochloride Tablet,"859841, 860918, 865117, 865123",,f07bb3f1-c68c-441b-9de4-99a219f2500a,09/18/2025,HUMAN PRESCRIPTION DRUG,09/18/2025,"Neurology, Psychiatry",FLUPHENAZINE HYDROCHLORIDE,"0832-6003, 0832-6004, 0832-6005, 0832-6006","Upsher-Smith Laboratories,LLC",3bb74f82-8872-9829-e063-6294a90aeace,"0832-6004-11, 0832-6003-11, 0832-6005-11, 0832-6006-11","Fluphenazine Hydrochloride, Tablet, 1 mg (NDC 0832-6003-11)",Tablet,,,ANDA213784,,FLUPHENAZINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug.,,ZOU145W1XL,0832-6003-11,763-315-2000,
"Solco Healthcare US, LLC",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,68b10d9f-ca3e-493d-a309-45f1d7e08061,08/05/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"43547-604, 43547-602, 43547-603, 43547-605, 43547-606, 43547-607, 43547-608","Solco Healthcare US,LLC",7bb11568-67a4-4221-bb9b-23af37a1791c,"43547-602-10, 43547-603-10, 43547-604-10, 43547-605-10, 43547-606-10, 43547-607-10, 43547-608-10","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 43547-604-10)",Capsule,Limited Availability,,ANDA216266,,LISDEXAMFETAMINE DIMESYLATE CAPSULES,,,Current,Shortage of an active ingredient,On allocation,,SJT761GEGS,43547-604-10,866-931-9829,
Pfizer Inc.,METHYLPREDNISOLONE ACETATE,,12/15/2021,Revised,"INTRALESIONAL, INTRAMUSCULAR, INTRASYNOVIAL, SOFT TISSUE",Methylprednisolone Acetate Injection,"1358510, 1358512, 1358610, 1358612, 1358617, 1358619",,823b0010-2b57-4e76-b5ac-4a8c2963438f,08/15/2025,HUMAN PRESCRIPTION DRUG,,Rheumatology,DEPO-MEDROL,"0009-0306, 0009-0274, 0009-0280",Pharmacia & Upjohn Company LLC,4cf5a255-1360-4511-9b58-b92e3492ef12,"0009-0274-01, 0009-0280-02, 0009-0280-51, 0009-0280-03, 0009-0280-52, 0009-0306-02, 0009-0306-12","Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-12)",Injection,Unavailable,,NDA011757,,METHYLPREDNISOLONE ACETATE,,,Current,Demand increase for the drug,Next Delivery: October 2025; Estimated Recovery: March 2026,,43502P7F0P,0009-0306-12,844-646-4398,
"Upsher-Smith Laboratories, LLC",POTASSIUM CHLORIDE,,07/23/2025,New,ORAL,"Potassium Chloride Tablet, Extended Release","312529, 628953, 628958, 832718",,1ff53330-065c-4213-9c0c-ac498621d09d,07/23/2025,HUMAN PRESCRIPTION DRUG,07/23/2025,"Endocrinology/Metabolism, Gastroenterology",KLOR-CON,"0245-5316, 0245-5315","Upsher-Smith Laboratories, LLC",39e77e07-bdc8-28e9-e063-6394a90a120c,"0245-5315-11, 0245-5315-15, 0245-5315-89, 0245-5315-01, 0245-5316-11, 0245-5316-15, 0245-5316-89, 0245-5316-01","Klor-Con, Tablet, Extended Release, 750 mg (NDC 0245-5316-01)",Tablet,,,NDA019123,,POTASSIUM CHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug product,,660YQ98I10,0245-5316-01,763-315-2000,
InfoRLife SA,ROPIVACAINE HYDROCHLORIDE,,03/27/2018,Reverified,"EPIDURAL, INFILTRATION",Ropivacaine Hydrochloride Injection,"1734347, 1734355, 1734479, 1734481",,"8c5c762f-d266-4b1a-809e-f11bfc89bc2d, 9572b3de-684c-4028-a577-5aa69ba6b02d",08/26/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROPIVACAINE HYDROCHLORIDE,"25021-671, 25021-652",Sagent Pharmaceuticals,"04d1b1c6-1963-4b42-8479-dbf787b6de17, 2eb59cb8-dab8-43f4-ad73-672446e104ca","25021-671-82, 25021-671-87, 25021-652-82, 25021-652-87, 25021-671-66, 25021-671-67","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-87)",Injection,Available,,ANDA206166,,ROPIVACAINE HYDROCHLORIDE,,,Current,,Marketed by Sagent Pharmaceuticals,,V910P86109,25021-671-87,Sagent: 866-625-1618,
"Fresenius Kabi USA, LLC","BUPIVACAINE HYDROCHLORIDE, EPINEPHRINE BITARTRATE",,02/20/2018,Reverified,"INFILTRATION, PERINEURAL","Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","1012377, 1012384, 1012413, 1012417, 1724786, 1724787, 1724809, 1724810, 1867594, 1867596, 1867618, 1867620",,bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb,09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,SENSORCAINE,"63323-461, 63323-472, 63323-463, 63323-468","Fresenius Kabi USA, LLC",cc1f6507-eb3e-4398-a1d3-0c56a2099e6b,"63323-472-03, 63323-472-17, 63323-472-01, 63323-472-37, 63323-463-01, 63323-463-57, 63323-461-01, 63323-461-57, 63323-468-02, 63323-468-37, 63323-468-01, 63323-468-17","Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-461-57)",Injection,Available,,ANDA070967,,BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE,,,Current,,Check wholesaler for inventory,,"30Q7KI53AK, 7TQO7W3VT8",63323-461-57,888-386-1300,
Sagent Pharmaceuticals,CLINDAMYCIN PHOSPHATE,,03/21/2023,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Clindamycin Phosphate Injection,"1737244, 1737578, 1737581",,7a6967b3-5563-4bed-9eee-d400f800e799,08/26/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,CLINDAMYCIN,25021-115,Sagent Pharmaceuticals,4662502b-ce7c-4278-854d-cf8632ac9b83,"25021-115-02, 25021-115-04, 25021-115-06","Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06)",Injection,Available,,ANDA090108,,CLINDAMYCIN PHOSPHATE,,,Current,,,,EH6D7113I8,25021-115-06,866-625-1618,
"Fresenius Kabi USA, LLC",FENTANYL CITRATE,,01/01/2012,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Fentanyl Citrate Injection,"2474267, 2474269",,0c10e465-4117-48ba-a454-23ccb7a3fcc7,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Pediatric",FENTANYL CITRATE,"63323-808, 63323-810","Fresenius Kabi USA, LLC",076a6b49-1197-4c83-a9cd-a353d9c65ebc,"63323-808-01, 63323-808-11, 63323-810-00, 63323-810-20","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 63323-808-11)",Injection,Available,,ANDA212086,,FENTANYL CITRATE,,,Current,,Check wholesalers for inventory,,MUN5LYG46H,63323-808-11,888-386-1300,
Eugia US LLC,LIDOCAINE HYDROCHLORIDE,,06/13/2018,Revised,"INFILTRATION, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010671",,"ccc38d8a-43fd-44c0-985e-32af9ed956ab, ef782e5e-e2d7-465a-99c6-b12611f3158c",09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,LIDOCAINE HYDROCHLORIDE,"55150-251, 55150-252, 55150-254, 55150-255, 55150-253, 55150-256",Eugia US LLC,"ccc38d8a-43fd-44c0-985e-32af9ed956ab, 0b1f03c2-db2f-4f90-acc0-d73abd731bf6","55150-251-24, 55150-252-24, 55150-254-24, 55150-255-24, 55150-251-10, 55150-252-20, 55150-253-50, 55150-254-10, 55150-255-20, 55150-256-50","Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)",Injection,Available,,ANDA207182,,LIDOCAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,V13007Z41A,55150-251-10,888-238-7880,
"Par Pharmaceutical, Inc.",METHYLPREDNISOLONE ACETATE,,06/16/2022,Reverified,"INTRA-ARTERIAL, INTRALESIONAL, INTRAMUSCULAR, SOFT TISSUE",Methylprednisolone Acetate Injection,"1358610, 1358617",,631f7d3e-5620-4be3-b918-2f0d38a97890,09/17/2025,HUMAN PRESCRIPTION DRUG,,Rheumatology,METHYLPREDNISOLONE ACETATE,"42023-240, 42023-239, 42023-238","Endo USA, Inc.",9d6bd79b-4885-454e-b127-c5978e501024,"42023-240-01, 42023-239-01, 42023-238-01","Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 42023-240-01)",Injection,Available,,ANDA214297,,METHYLPREDNISOLONE ACETATE,,,Current,,,,43502P7F0P,42023-240-01,800-828-9393,
"Laboratorios Grifols, S.A.",SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807631, 1807632, 1807633, 1807634, 1807639",,28f79c75-82d2-4912-81fc-a723b5ccf4c1,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,79672-613,Nextgen Pharmaceuticals LLC,3c545b9f-67e4-489d-bb60-c39c990d7dda,"79672-613-01, 79672-613-10, 79672-613-02, 79672-613-20, 79672-613-03, 79672-613-30, 79672-613-04, 79672-613-40, 79672-613-05, 79672-613-50","Sodium Chloride 0.9%, 100 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-02)",Injection,,,ANDA207956,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,79672-613-02,800-848-0462,
"Hospira, Inc., a Pfizer Company",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,"INFILTRATION, PERINEURAL",Bupivacaine Hydrochloride Injection,"1012377, 1012384, 1012396, 1012404, 1672917, 1672919, 1724786, 1724787, 1724880, 1724884, 1725078, 1725082, 1867594, 1867596",,02a845c3-4521-4926-e397-25ab536e7cf6,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE,"0409-1160, 0409-1159, 0409-1162, 0409-1163, 0409-1165, 0409-9043, 0409-9046, 0409-9045, 0409-9042","Hospira, Inc.",3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7,"0409-1159-18, 0409-1159-01, 0409-1159-19, 0409-1159-02, 0409-1160-18, 0409-1160-01, 0409-1162-18, 0409-1162-01, 0409-1162-19, 0409-1162-02, 0409-1163-18, 0409-1163-01, 0409-1165-18, 0409-1165-01, 0409-1165-19, 0409-1165-02, 0409-9043-11, 0409-9043-01, 0409-9046-11, 0409-9046-01, 0409-9045-11, 0409-9045-01, 0409-9045-16, 0409-9045-17, 0409-9042-11, 0409-9042-01, 0409-9042-16, 0409-9042-17","Bupivacaine Hydrochloride, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1160-01)",Injection,Available,,ANDA070590,,BUPIVACAINE HYDROCHLORIDE,,,Current,,,,"30Q7KI53AK, 7TQO7W3VT8",0409-1160-01,844-646-4398,
"Fresenius Kabi USA, LLC",DEXAMETHASONE SODIUM PHOSPHATE,,02/08/2019,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Dexamethasone Sodium Phosphate Injection,1812079,,"cca2c160-9188-48e8-9505-49a52388dcb7, 7cbd9005-7df2-47ee-adb3-7244c1c69bc3",09/18/2025,HUMAN PRESCRIPTION DRUG,,"Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Other, Pulmonary/Allergy, Rheumatology",DEXAMETHASONE SODIUM PHOSPHATE,"63323-506, 63323-516","Fresenius Kabi USA, LLC","5dcedfda-976c-4aa4-a3cf-909c324a09d4, 5284d2ce-44c2-4731-bf19-0cfc760265c8","63323-506-00, 63323-506-01, 63323-506-03, 63323-506-13, 63323-516-01, 63323-516-10, 63323-506-41, 63323-506-16","Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 63323-506-01)",Injection,Available,,ANDA040491,,DEXAMETHASONE SODIUM PHOSPHATE,,,Current,,Check wholesalers for inventory,,AI9376Y64P,63323-506-01,888-386-1300,
Eugia US LLC,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"309710, 1718906, 1718909",,8c162541-986b-4b30-866c-b2631ba2c975,09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE HYDROCHLORIDE,"55150-297, 55150-209, 55150-296",Eugia US LLC,cc0d3661-5f2e-43fb-a2ae-7d3f89c7e58c,"55150-209-02, 55150-296-10, 55150-297-10","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-297-10)",Injection,Available,,ANDA210321,,DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE,,,Current,,Check wholesalers for inventory,,1018WH7F9I,55150-297-10,888-238-7880,
"Hospira, Inc., a Pfizer Company",DOPAMINE HYDROCHLORIDE,,08/27/2025,New,INTRAVENOUS,Dopamine Hydrochloride Injection,"1292887, 1743877, 1743879",,08f23f6e-150d-45ea-098e-f2edf64c21a1,08/27/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,DOPAMINE HYDROCHLORIDE IN DEXTROSE,"0409-7809, 0409-7810","Hospira, Inc.",3b4d4d9d-5e19-420f-a447-1ad8346844d9,"0409-7809-11, 0409-7809-22, 0409-7809-31, 0409-7809-24, 0409-7810-11, 0409-7810-22","Dopamine Hydrochloride in Dextrose 5% in plastic container, Injection, 800 mg/500 mL (1,600 mcg/mL) (NDC 0409-7809-24)",Injection,,,NDA018826,,DOPAMINE HYDROCHLORIDE IN DEXTROSE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,7L3E358N9L,0409-7809-24,844-646-4398,
"Fresenius Kabi USA, LLC",HYDROMORPHONE HYDROCHLORIDE,,10/31/2017,Reverified,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Hydromorphone Hydrochloride Injection,"897756, 897757, 1433251, 1872265, 1872269, 1872752, 2277368, 2277370",,9eebd88a-5632-460f-b7b6-26c8a180540d,09/18/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,DILAUDID,"76045-009, 76045-010, 76045-121","Fresenius Kabi USA, LLC",97bfcafb-2037-47dc-a0ae-f7b8007c47df,"76045-009-96, 76045-009-06, 76045-009-01, 76045-009-11, 76045-010-01, 76045-010-11, 76045-121-01, 76045-121-11","Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)",Injection,Unavailable,,NDA019034,,HYDROMORPHONE HYDROCHLORIDE,,,Current,Other,Backordered. Next release September 2025. Check wholesalers for inventory.,,L960UP2KRW,76045-009-06,888-386-1300,
Takeda Pharmaceuticals USA Inc.,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,"Lisdexamfetamine Dimesylate Tablet, Chewable","854830, 854832, 854834, 854836, 854838, 854840, 854842, 854844, 854846, 854848, 854850, 854852, 1593856, 1593858, 1871456, 1871459, 1871460, 1871461, 1871462, 1871463, 1871464, 1871465, 1871466, 1871467, 1871468, 1871469",,704e4378-ca83-445c-8b45-3cfa51c1ecad,08/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,VYVANSE,"59417-115, 59417-101, 59417-102, 59417-103, 59417-104, 59417-105, 59417-106, 59417-107, 59417-116, 59417-117, 59417-118, 59417-119, 59417-120","Takeda Pharmaceuticals America, Inc.",756b98a0-fada-44b2-a606-f2e71ef8cc84,"59417-101-10, 59417-102-10, 59417-103-10, 59417-104-10, 59417-105-10, 59417-106-10, 59417-107-10, 59417-115-01, 59417-116-01, 59417-117-01, 59417-118-01, 59417-119-01, 59417-120-01","Vyvanse, Tablet, Chewable, 10 mg (NDC 59417-115-01)","Tablet, Chewable",Available,,NDA208510,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,59417-115-01,877-TAKEDA-7 (1-877-825-3327),
Baxter Healthcare,NITROGLYCERIN,Vasodilation [PE],10/06/2023,Revised,INTRAVENOUS,Nitroglycerin Injection,"312004, 1868494, 1868562",,457a026c-ebce-4701-9deb-2d7652759a99,09/23/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,NITROGLYCERIN IN DEXTROSE,"0338-1049, 0338-1047, 0338-1051",Baxter Healthcare Company,71811937-e908-4b65-aff2-4b345fa0954b,"0338-1047-02, 0338-1049-02, 0338-1051-02","Nitroglycerin in Dextrose 5%, Injection, 20 mg/100 mL (NDC 0338-1049-02)",Injection,Unavailable,"N0000175415, M0014874, N0000009909",NDA019970,Nitrates [CS],NITROGLYCERIN,Nitrate Vasodilator [EPC],,Current,Other,Manufacturing delay; Recovery in November 2025,,G59M7S0WS3,0338-1049-02,Baxter Healthcare 888-229-0001,
Aurobindo Pharma USA,BENAZEPRIL HYDROCHLORIDE,,02/07/2025,New,ORAL,Benazepril Hydrochloride Tablet,"898687, 898690, 898719",,09e383a8-e912-4cf7-8fb3-05545af80dd0,02/07/2025,HUMAN PRESCRIPTION DRUG,02/07/2025,Cardiovascular,BENAZEPRIL HYDROCHLORIDE,"65862-118, 65862-116, 65862-117",Aurobindo Pharma Limited,65334c7f-e49f-44d9-a6c1-6c1ce6e88fbe,"65862-116-90, 65862-116-01, 65862-117-90, 65862-117-01, 65862-118-90, 65862-118-01","Benazepril Hydrochloride, Tablet, 40 mg (NDC 65862-118-01)",Tablet,,,ANDA078212,,BENAZEPRIL HYDROCHLORIDE,,,To Be Discontinued,,,,N1SN99T69T,65862-118-01,866-850-2876,
"Fresenius Kabi USA, LLC",BUMETANIDE,Increased Diuresis at Loop of Henle [PE],01/31/2018,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Bumetanide Injection,"282486, 1727569",,a007f3aa-3977-4be3-a9a2-db3d458bca58,09/18/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,BUMETANIDE,"65219-572, 65219-570","Fresenius Kabi USA, LLC",aaff61c4-203b-4905-9138-0f98959ad013,"65219-570-01, 65219-570-04, 65219-572-01, 65219-572-10","Bumetanide, Injection, .25 mg/1 mL (NDC 65219-572-10)",Injection,Available,"N0000175366, N0000175590",ANDA216434,,BUMETANIDE,Loop Diuretic [EPC],,Current,,Check wholesalers for inventory,,0Y2S3XUQ5H,65219-572-10,888-386-1300,
Novartis Pharmaceuticals Corporation,"AMLODIPINE BESYLATE, BENAZEPRIL HYDROCHLORIDE",,06/24/2025,New,ORAL,Amlodipine Besylate; Benazepril Hydrochloride Capsule,"898342, 898344, 898346, 898348, 898353, 898355, 898356, 898358",,94ae6054-b7ae-4212-a567-4f803af8f2c7,06/24/2025,HUMAN PRESCRIPTION DRUG,06/24/2025,Cardiovascular,LOTREL,"0078-0364, 0078-0405, 0078-0406, 0078-0379",Novartis Pharmaceuticals Corporation,b9db75d9-9d1e-4b2d-9876-5f5520feaecc,"0078-0405-05, 0078-0406-05, 0078-0364-05, 0078-0379-05","Lotrel, Capsule, 10 mg; 20 mg (NDC 0078-0364-05)",Capsule,,,NDA020364,,AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE,,,To Be Discontinued,,Permanent discontinuation in the manufacturing of the drug,,"864V2Q084H, N1SN99T69T",0078-0364-05,888-669-6682,
"Hikma Pharmaceuticals USA, Inc.",MIDAZOLAM HYDROCHLORIDE,,04/02/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Midazolam Hydrochloride Injection,"311700, 311702",,575d8bf0-7af7-427c-a231-966e2a5e070d,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology",MIDAZOLAM,"0641-6056, 0641-6057, 0641-6059, 0641-6061, 0641-6063, 0641-6060",Hikma Pharmaceuticals USA Inc.,559c03fb-24ea-4b7b-8afd-e33cb3a2340a,"0641-6057-01, 0641-6057-10, 0641-6057-25, 0641-6059-01, 0641-6059-10, 0641-6056-01, 0641-6056-10, 0641-6061-01, 0641-6061-10, 0641-6061-25, 0641-6063-01, 0641-6063-10, 0641-6063-25, 0641-6060-01, 0641-6060-10","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6056-10)",Injection,Available,,ANDA075243,,MIDAZOLAM,,,Current,,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,W7TTW573JJ,0641-6056-10,800-631-2174,
Gland Pharma Limited,,,04/02/2020,Reverified,,Midazolam Hydrochloride Injection,,,,09/29/2025,,,"Anesthesia, Neurology",,,,,,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 47781-589-17)",Injection,Unavailable,,,,,,,Current,Other,Distributed by Alvogen,,,47781-589-17,Athenex: 855-273-0154; Alvogen: 973-532-7840,
Slate Run Pharmaceuticals,LEUCOVORIN CALCIUM,,01/01/2012,Revised,"INTRAMUSCULAR, INTRAVENOUS",Leucovorin Calcium Injection,"237788, 1803930, 1803932, 1803937, 2055036",,d8bdd60c-9a1c-4ef4-ba6b-b911849128f1,07/08/2025,HUMAN PRESCRIPTION DRUG,,"Oncology, Pediatric",LEUCOVORIN CALCIUM,"70436-118, 70436-116, 70436-117, 70436-120, 70436-119","Slate Run Pharmaceuticals, LLC",2a4aaed3-885e-bc10-e063-6294a90a61af,"70436-116-80, 70436-116-82, 70436-117-80, 70436-118-80, 70436-120-80, 70436-119-80","Leucovorin Calcium, Injection, 200 mg (NDC 70436-118-80)",Injection,,,ANDA217021,,LEUCOVORIN CALCIUM,,Available,Resolved,,,07/08/2025,RPR1R4C0P4,70436-118-80,888-447-0095,
"Hospira, Inc., a Pfizer Company",MEPERIDINE HYDROCHLORIDE,,05/30/2025,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Meperidine Hydrochloride Injection,"860792, 861463, 861473, 861493, 861494, 861522, 861529, 861617, 1242106, 1242503, 2539186, 2539188, 2539191, 2539192",,b31d1308-28c3-43f4-e0a6-2f3ed76b8975,08/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,DEMEROL,"0409-1176, 0409-1181, 0409-1178, 0409-1179, 0409-1180, 0409-1362, 0409-1418","Hospira, Inc.",1271f15f-ccda-4892-8fb0-9bb2d38ded4a,"0409-1181-30, 0409-1176-03, 0409-1176-30, 0409-1178-03, 0409-1178-30, 0409-1179-03, 0409-1179-30, 0409-1180-59, 0409-1180-69, 0409-1362-11, 0409-1362-01, 0409-1418-11, 0409-1418-01","Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)",Injection,Unavailable,,NDA021171,,MEPERIDINE HYDROCHLORIDE,,,Current,Other,Next Delivery: October 2025; Estimated Recovery: December 2025,,N8E7F7Q170,0409-1176-30,844-646-4398,
Eugia US LLC,LIDOCAINE HYDROCHLORIDE,,02/20/2018,Revised,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Lidocaine Hydrochloride Injection,"1737562, 1737566, 1737568, 1737757, 1737761",,"9916b09d-a116-469d-92d5-60e50ea9782b, 89701fac-7536-4f16-87fb-f4cc121e74ee",09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,LIDOCAINE HYDROCHLORIDE,"55150-162, 55150-161, 55150-163, 55150-164, 55150-165",Eugia US LLC,"9916b09d-a116-469d-92d5-60e50ea9782b, 9b60bc92-6093-49f9-a6ba-075104ff7bb5","55150-161-09, 55150-162-09, 55150-163-00, 55150-164-09, 55150-165-09, 55150-161-02, 55150-162-05, 55150-163-30, 55150-164-02, 55150-165-05","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-162-05)",Injection,Available,,ANDA203082,,LIDOCAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,V13007Z41A,55150-162-05,888-238-7880,
"Sun Pharmaceutical Industries, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Revised,ORAL,"Lisdexamfetamine Dimesylate Tablet, Chewable","854830, 854834, 854838, 854842, 854846, 854850, 1593856, 1871456, 1871460, 1871462, 1871464, 1871466, 1871468",,da3148af-f9b6-4725-adae-3595b4c7dc4b,09/22/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"57664-084, 57664-047, 57664-046, 57664-048, 57664-049, 57664-050, 57664-051, 57664-052, 57664-083, 57664-085, 57664-086, 57664-087, 57664-088","Sun Pharmaceutical Industries, Inc.",0b77417a-5789-8818-e063-6294a90ad2e3,"57664-047-88, 57664-046-88, 57664-048-88, 57664-049-88, 57664-050-88, 57664-051-88, 57664-052-88, 57664-083-88, 57664-084-88, 57664-085-88, 57664-086-88, 57664-087-88, 57664-088-88","Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 57664-084-88)","Tablet, Chewable",Limited Availability,,ANDA214134,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Other,Available Q3 2025,,SJT761GEGS,57664-084-88,800-818-4555,
Chartwell Molecular Holdings LLC,"HYDROCHLOROTHIAZIDE, QUINAPRIL HYDROCHLORIDE",Increased Diuresis [PE],01/19/2023,Reverified,ORAL,Quinapril/Hydrochlorothiazide Tablet,"310796, 310797, 310809",,2eae533f-d0af-47e8-a1f2-94bc8cc89b5a,08/19/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,QUINAPRIL AND HYDROCHLOROTHIAZIDE,"62135-669, 62135-667, 62135-668","Chartwell RX, LLC",0c3f4504-d57e-aa79-e063-6294a90ad5b8,"62135-667-90, 62135-668-90, 62135-669-90","Quinapril/Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 62135-669-90)",Tablet,Available,"N0000175359, N0000175419, M0471776",ANDA076374,Thiazides [CS],QUINAPRIL AND HYDROCHLOROTHIAZIDE,Thiazide Diuretic [EPC],,Current,,,,"0J48LPH2TH, 33067B3N2M",62135-669-90,845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com,
Strides Pharma Inc.,MINOCYCLINE HYDROCHLORIDE,,01/22/2025,New,ORAL,Minocycline Hydrochloride Tablet,"207362, 207364, 403840",,d6e136ba-c9b1-4846-ae2a-98a29cb4504d,01/22/2025,HUMAN PRESCRIPTION DRUG,01/22/2025,Antiviral,MINOCYCLINE HYDROCHLORIDE,"64380-155, 64380-154, 64380-156",Strides Pharma Science Limited,73a30dc4-352b-4307-b902-07ffefc99a99,"64380-154-01, 64380-155-01, 64380-156-01","Minocycline Hydrochloride, Tablet, 75 mg (NDC 64380-155-01)",Tablet,,,ANDA065131,,MINOCYCLINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,0020414E5U,64380-155-01,877-244-9825,
Sandoz Inc.,ROCURONIUM BROMIDE,,02/15/2023,Reverified,INTRAVENOUS,Rocuronium Bromide Injection,1234995,,cb28d869-6510-4402-9462-f6bb25fa0fa8,09/24/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROCURONIUM BROMIDE,0781-3220,Sandoz Inc,eaf32464-7950-434a-e053-2a95a90aa2dc,"0781-3220-70, 0781-3220-92, 0781-3220-75, 0781-3220-95","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-92)",Injection,Available,,ANDA079195,,ROCURONIUM BROMIDE,,,Current,,,,I65MW4OFHZ,0781-3220-92,800-525-8747,
"Teva Pharmaceuticals USA, Inc.","FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE",,06/13/2025,New,RESPIRATORY (INHALATION),Fluticasone Propionate; Salmeterol Xinafoate Powder,"1918194, 1918199, 1918203, 1918205, 1918209, 1918211",,9c122b91-a11f-49ca-80bb-3eec5112db87,06/13/2025,HUMAN PRESCRIPTION DRUG,06/13/2025,Pulmonary/Allergy,AIRDUO RESPICLICK,"59310-812, 59310-805, 59310-822","Teva Respiratory, LLC",b597bc2d-bf1e-4f9b-826a-b3e39ed56545,"59310-805-06, 59310-805-08, 59310-812-06, 59310-812-08, 59310-822-06, 59310-822-08","AirDuo RespiClick, Powder, 113 ug; 14 ug (NDC 59310-812-06)",Powder,,,NDA208799,,FLUTICASONE PROPIONATE AND SALMETEROL,,,To Be Discontinued,,,,"O2GMZ0LF5W, 6EW8Q962A5",59310-812-06,800-545-8800,
"Upsher-Smith Laboratories, LLC",BUMETANIDE,Increased Diuresis at Loop of Henle [PE],05/02/2025,New,ORAL,Bumetanide Tablet,"197417, 197418, 197419",,ff5dc8c6-b2f2-41d3-8e56-a953aa721b59,05/02/2025,HUMAN PRESCRIPTION DRUG,05/02/2025,Cardiovascular,BUMETANIDE,"0832-0541, 0832-0540, 0832-0542","Upsher-Smith Laboratories, LLC",d53166d9-64ca-4b76-81a7-b70a60c53b12,"0832-0540-11, 0832-0541-11, 0832-0541-10, 0832-0542-11, 0832-0542-10","Bumetanide, Tablet, 1 mg (NDC 0832-0541-11)",Tablet,,"N0000175366, N0000175590",ANDA209916,,BUMETANIDE,Loop Diuretic [EPC],,To Be Discontinued,,,,0Y2S3XUQ5H,0832-0541-11,800-654-2299,
Leo Pharma Inc.,AZELAIC ACID,"Decreased Protein Synthesis [PE], Decreased Sebaceous Gland Activity [PE]",01/13/2025,New,TOPICAL,Azelaic Acid Gel,"1041518, 1043748",,bea1957c-55ca-48cd-8cbc-ed44d546a857,01/13/2025,HUMAN PRESCRIPTION DRUG,01/13/2025,Dermatology,FINACEA,50222-505,LEO Pharma Inc.,dd017db5-9d51-45eb-bb37-d3daa5949168,50222-505-50,"Finacea, Gel, .15 g/1 g (NDC 50222-505-50)",Gel,,"N0000008841, N0000009982",NDA021470,,AZELAIC ACID,,,To Be Discontinued,,,,F2VW3D43YT,50222-505-50,978-760-9954,
Baxter Healthcare,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718906, 1718909",,aea9a3ad-c244-42be-9cd3-5df83fe2b522,09/23/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE,"43066-557, 43066-555",Baxter Healthcare Company,949ed273-6b79-4f54-8284-a710082edd77,"43066-555-24, 43066-557-12","Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 43066-557-12)",Injection,Available,,ANDA208532,,DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE,,,Current,,,,1018WH7F9I,43066-557-12,888-229-0001,
Aurobindo Pharma USA,QUINAPRIL HYDROCHLORIDE,,01/19/2023,Reverified,ORAL,Quinapril Hydrochloride Tablet,"312748, 312749, 312750, 314203",,93e6e668-5306-4f26-81d8-cbc3a7a5e787,09/17/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,QUINAPRIL,"65862-617, 65862-618, 65862-619, 65862-620",Aurobindo Pharma Limited,5263abd5-ce46-4918-9bb0-9632861bcbc9,"65862-617-30, 65862-617-90, 65862-617-99, 65862-617-55, 65862-617-10, 65862-617-78, 65862-618-30, 65862-618-90, 65862-618-99, 65862-618-55, 65862-618-10, 65862-618-78, 65862-619-30, 65862-619-90, 65862-619-99, 65862-619-19, 65862-619-10, 65862-619-78, 65862-620-30, 65862-620-90, 65862-620-99, 65862-620-39, 65862-620-10, 65862-620-78","Quinapril Hydrochloride, Tablet, 5 mg (NDC 65862-617-90)",Tablet,Discontinued,,ANDA202725,,QUINAPRIL HYDROCHLORIDE,,,Current,Discontinuation of the manufacture of the drug,,,33067B3N2M,65862-617-90,866-850-2876,
"Fresenius Kabi USA, LLC",ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Reverified,"EPIDURAL, INFILTRATION",Ropivacaine Hydrochloride Injection,"1734203, 1734204, 1734207, 1734208, 1734347, 1734348, 1734355, 1734356, 1734475, 1734476, 1734479, 1734480, 1734481, 1734482, 1734483, 1734484, 905189, 905191, 1734084, 1734086, 1734090, 1734091",,"dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7, 23d2d448-a744-4877-9f2d-7e57c198da89, c6613708-c1f7-4f5c-91a3-ebbc1d7905c6",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,NAROPIN,"63323-285, 63323-286, 63323-287, 63323-288","Fresenius Kabi USA, LLC","324532ac-4e54-4659-a1a2-9ade22a1ed3f, cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9, 73218c89-8925-468c-84bf-9960b4b3dc3c","63323-286-41, 63323-286-27, 63323-286-43, 63323-286-38, 63323-285-41, 63323-285-28, 63323-285-53, 63323-285-68, 63323-285-59, 63323-285-73, 63323-286-01, 63323-286-20, 63323-286-05, 63323-286-23, 63323-286-09, 63323-286-31, 63323-286-11, 63323-286-35, 63323-286-03, 63323-286-00, 63323-286-33, 63323-286-63, 63323-286-30, 63323-287-01, 63323-287-20, 63323-287-03, 63323-287-21, 63323-288-01, 63323-288-10, 63323-288-06, 63323-288-20, 63323-288-03, 63323-288-11, 63323-288-07, 63323-288-21, 63323-285-01, 63323-285-10, 63323-285-06, 63323-285-20, 63323-285-03, 63323-285-13, 63323-285-07, 63323-285-23, 63323-285-57, 63323-285-64, 63323-285-51, 63323-285-65, 63323-285-02, 63323-285-61, 63323-285-04, 63323-285-63, 63323-285-55, 63323-285-67, 63323-288-23, 63323-288-29, 63323-286-93, 63323-286-95","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-13)",Injection,Available,,NDA020533,,ROPIVACAINE HYDROCHLORIDE,,,Current,,,,V910P86109,63323-285-13,888-386-1300,
"Elite Laboratories, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,e677690f-790f-4626-ad78-097cdb6ea540,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","64850-501, 64850-500, 64850-502, 64850-503, 64850-504, 64850-505, 64850-506","Elite Laboratories, Inc.",b65e0266-7172-4730-8f93-eb42e08fb7b8,"64850-500-01, 64850-500-05, 64850-500-30, 64850-501-01, 64850-501-05, 64850-501-30, 64850-502-01, 64850-502-05, 64850-502-30, 64850-503-01, 64850-503-05, 64850-503-30, 64850-504-01, 64850-504-05, 64850-504-30, 64850-505-01, 64850-505-05, 64850-505-30, 64850-506-01, 64850-506-05, 64850-506-30","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 64850-501-01)",Tablet,Limited Availability,,ANDA211352,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,Shortage of an active ingredient,3 months,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",64850-501-01,888-852-6657,
Eli Lilly and Co.,,,01/06/2023,Revised,"INTRAMUSCULAR, SUBCUTANEOUS",Somatropin Injection,"582969, 582971, 582974, 582976, 729232, 729234",,a774e1ae-3997-49ee-8b0e-99a2b315d409,08/28/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,HUMATROPE,"0002-8148, 0002-8147, 0002-8149",Eli Lilly and Company,aa99e905-657f-4561-8c02-d7c0409c44e3,"0002-8147-01, 0002-7554-01, 0002-7618-01, 0002-8148-01, 0002-7555-01, 0002-7619-01, 0002-8149-01, 0002-7556-01","Humatrope, Injection, 12 mg/cartridge (NDC 0002-8148-01)",Injection,,,BLA019640,,SOMATROPIN,,Available,Resolved,,,08/28/2025,,0002-8148-01,800-545-5979,
"Teva Pharmaceuticals USA, Inc.",CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,8069b1a0-7c06-4252-b44e-e2eef065d9b8,09/15/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"0093-3212, 0093-0832, 0093-3213","Teva Pharmaceuticals USA, Inc.",d6abe4e3-7699-4ead-95f4-739a961b23ad,"0093-0832-01, 0093-0832-05, 0093-3212-01, 0093-3212-05, 0093-3213-01, 0093-3213-05","Clonazepam, Tablet, 1 mg (NDC 0093-3212-05)",Tablet,Available,"N0000175694, M0002356",ANDA074569,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,,,5PE9FDE8GB,0093-3212-05,800-545-8800,
"Fresenius Kabi USA, LLC","EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE ANHYDROUS",,10/14/2016,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL","Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","1010033, 1010035, 1010671, 1010673, 1010688, 1010692, 1010745, 1010749, 1010751, 1010755, 1010759, 1010763, 1010900, 1010902, 1737343, 1737345, 1737562, 1737563, 1737566, 1737567, 1737568, 1737569, 1737570, 1737571, 1737757, 1737758, 1737761, 1737762, 1867938, 1867940, 1867943, 1867944, 1867992, 1867993, 1867996, 1867997, 1868028, 1868029",,ba082c2f-64f4-419d-9c88-74f203316e17,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",XYLOCAINE MPF,"63323-487, 63323-492, 63323-491, 63323-495, 63323-485, 63323-486, 63323-484, 63323-489, 63323-488, 63323-481, 63323-483, 63323-482","Fresenius Kabi USA, LLC",ea480a68-5927-4278-9deb-2956961da428,"63323-492-04, 63323-492-27, 63323-492-09, 63323-492-57, 63323-492-07, 63323-492-37, 63323-492-03, 63323-492-31, 63323-491-01, 63323-491-57, 63323-495-09, 63323-495-27, 63323-495-04, 63323-495-07, 63323-485-01, 63323-485-27, 63323-485-03, 63323-485-57, 63323-486-01, 63323-486-17, 63323-486-02, 63323-486-27, 63323-486-05, 63323-486-57, 63323-484-57, 63323-489-02, 63323-489-27, 63323-489-03, 63323-489-21, 63323-489-01, 63323-489-17, 63323-488-07, 63323-488-37, 63323-488-03, 63323-488-31, 63323-488-01, 63323-488-17, 63323-481-01, 63323-481-57, 63323-483-03, 63323-483-27, 63323-483-01, 63323-483-57, 63323-482-01, 63323-482-17, 63323-482-03, 63323-482-27, 63323-482-05, 63323-482-57, 63323-487-01, 63323-487-17, 63323-487-07, 63323-487-37, 63323-487-03, 63323-487-31","Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-37)",Injection,Available,,NDA006488,,LIDOCAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,"EC2CNF7XFP, 30Q7KI53AK",63323-487-37,888-386-1300,
"Hikma Pharmaceuticals USA, Inc.",LORAZEPAM,,09/05/2018,Revised,"INTRAMUSCULAR, INTRAVENOUS",Lorazepam Injection,"238100, 238101, 1665188, 1665326",,e9b54e42-04cf-4c62-90e1-36f7b31a4e81,07/23/2025,HUMAN PRESCRIPTION DRUG,,Neurology,LORAZEPAM,"0641-6046, 0641-6044, 0641-6045, 0641-6047",Hikma Pharmaceuticals USA Inc.,7c73dbc6-2623-4443-9b05-97dec7a0be2e,"0641-6044-01, 0641-6044-25, 0641-6046-01, 0641-6046-10, 0641-6045-01, 0641-6045-25, 0641-6047-01, 0641-6047-10","Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10)",Injection,Unavailable,"N0000175694, M0002356",NDA018140,Benzodiazepines [CS],LORAZEPAM,Benzodiazepine [EPC],,Current,Regulatory delay,Shortage duration unknown,,O26FZP769L,0641-6046-10,800-631-2174,
Watson Pharma Private Limited,POTASSIUM CITRATE,,07/17/2025,New,ORAL,"Potassium Citrate Tablet, Extended Release","199376, 199381, 898490",,ac173781-486b-461c-97ae-8b5c69e20792,07/17/2025,HUMAN PRESCRIPTION DRUG,07/17/2025,Renal,POTASSIUM CITRATE,"0591-2742, 0591-2682, 0591-2729","Actavis Pharma, Inc.",b81078a3-490a-4a03-a9a5-9c64acde67bf,"0591-2682-01, 0591-2729-01, 0591-2742-01","Potassium Citrate, Tablet, Extended Release, 15 meq (NDC 0591-2742-01)",Tablet,,,ANDA209758,,POTASSIUM CITRATE,,,To Be Discontinued,,A business decision was made to discontinue.,,EE90ONI6FF,0591-2742-01,800-545-8800,
"Teva Pharmaceuticals USA, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Revised,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,cffbbb15-d776-41ae-a8a6-687f2c07bfa4,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","0555-0972, 0555-0971, 0555-0775, 0555-0776, 0555-0777, 0555-0973, 0555-0974","Teva Pharmaceuticals USA, Inc.",88468f3d-7d03-4cee-aabf-3abc8c9b5e38,"0555-0971-02, 0555-0775-02, 0555-0972-02, 0555-0776-02, 0555-0777-02, 0555-0973-02, 0555-0974-02","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0555-0972-02)",Tablet,Limited Availability,,ANDA040422,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,Other,Estimated recovery: December 2025,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",0555-0972-02,800-545-8800,
Granules Pharmaceuticals Inc.,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,b0b4eccc-34c7-483d-966f-82d588358e1b,09/08/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","70010-114, 70010-111, 70010-112, 70010-113, 70010-115, 70010-116, 70010-117",Granules Pharmaceuticals Inc.,2fab399e-2a43-5134-e063-6294a90ae09a,"70010-111-01, 70010-111-03, 70010-112-01, 70010-112-03, 70010-113-01, 70010-113-03, 70010-114-01, 70010-114-03, 70010-115-01, 70010-115-03, 70010-116-01, 70010-116-03, 70010-117-01, 70010-117-03","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 70010-114-01)",Tablet,Available,,ANDA215771,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",70010-114-01,877-770-3183,
Baxter Healthcare,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807631, 1807632, 1807633, 1807634, 1807639",,958d35f0-6834-43be-a700-fa58f38b4c19,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0338-9543, 0338-9657, 0338-9659, 0338-9661, 0338-9663",Baxter Healthcare Corporation,6680afa2-1474-4bc3-afee-a333a042fd3f,"0338-9543-01, 0338-9543-02, 0338-9543-03, 0338-9543-04, 0338-9543-05, 0338-9543-06, 0338-9543-12, 0338-9657-75, 0338-9659-75, 0338-9661-60, 0338-9663-60","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-06)",Injection,,,NDA016677,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0338-9543-06,888-229-0001,
InfoRLife SA,ROPIVACAINE HYDROCHLORIDE,,03/27/2018,Reverified,"EPIDURAL, INFILTRATION",Ropivacaine Hydrochloride Injection,"1734347, 1734355, 1734479, 1734481",,"8c5c762f-d266-4b1a-809e-f11bfc89bc2d, 9572b3de-684c-4028-a577-5aa69ba6b02d",08/26/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROPIVACAINE HYDROCHLORIDE,"25021-671, 25021-652",Sagent Pharmaceuticals,"04d1b1c6-1963-4b42-8479-dbf787b6de17, 2eb59cb8-dab8-43f4-ad73-672446e104ca","25021-671-82, 25021-671-87, 25021-652-82, 25021-652-87, 25021-671-66, 25021-671-67","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-66)",Injection,Available,,ANDA206166,,ROPIVACAINE HYDROCHLORIDE,,,Current,,Marketed by Sagent Pharmaceuticals,,V910P86109,25021-671-66,Sagent: 866-625-1618,
"Mylan Pharmaceuticals Inc., a Viatris Company",TOLTERODINE TARTRATE,,02/26/2025,New,ORAL,Tolterodine Tartrate Tablet,"855178, 855180, 855194, 855195",,41eb00d2-64e3-4ec9-8732-4bfc81b04180,02/26/2025,HUMAN PRESCRIPTION DRUG,02/26/2025,Urology,DETROL,"58151-098, 58151-099",Viatris Specialty LLC,f27726af-7a9b-45f4-96e0-1e90a5fdcc18,"58151-098-91, 58151-099-91","Detrol, Tablet, 1 mg (NDC 58151-098-91)",Tablet,,,NDA020771,,TOLTERODINE TARTRATE,,,To Be Discontinued,,,,5T619TQR3R,58151-098-91,800-796-9526,
Cheplapharm Arzneimittel GmbH,CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529, 206157, 206159, 206160",,cfa0d79a-843c-4b88-95a1-e9511d649ca1,09/15/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",KLONOPIN,"61269-620, 61269-605, 61269-610","H2-Pharma, LLC",c8a147a4-9ebc-4c69-a5b6-bf7547dc6334,"61269-605-10, 61269-610-10, 61269-620-10","Klonopin, Tablet, 2 mg (NDC 61269-620-10)",Tablet,Available,"N0000175694, M0002356",NDA017533,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,Marketed by H2-Pharma,,5PE9FDE8GB,61269-620-10,orders@h2-pharma.com,
"Teva Pharmaceuticals USA, Inc.",GLYBURIDE,,06/10/2025,New,ORAL,Glyburide Tablet,"310536, 310539, 314000",,e84c0dfc-a4e9-4c89-b6ea-45732eb412f5,06/10/2025,HUMAN PRESCRIPTION DRUG,06/10/2025,Endocrinology/Metabolism,GLYBURIDE,"0093-8035, 0093-8034, 0093-8036","Teva Pharmaceuticals USA, Inc.",00e55b1b-81b5-4df1-8a6d-4d54ac403e76,"0093-8034-01, 0093-8035-01, 0093-8035-05, 0093-8036-01","Glyburide (Micronized), Tablet, 3 mg (NDC 0093-8035-01)",Tablet,,"N0000175608, M0020795",ANDA074686,Sulfonylurea Compounds [CS],GLYBURIDE,Sulfonylurea [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,SX6K58TVWC,0093-8035-01,800-545-8800,
Eugia US LLC,FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Furosemide Injection,"1719286, 1719290, 1719291",,421aa6d5-623b-4dc2-abd5-bb9e7765bf37,09/25/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,"55150-324, 55150-322, 55150-323",Eugia US LLC,26acfb26-d058-453e-8c05-61ec44b25118,"55150-322-01, 55150-322-25, 55150-323-01, 55150-323-25, 55150-324-01, 55150-324-25","Furosemide, Injection, 100 mg/10 mL (NDC 55150-324-25)",Injection,Available,"N0000175366, N0000175590",ANDA212174,,FUROSEMIDE,Loop Diuretic [EPC],,Current,,Check wholesalers for inventory,,7LXU5N7ZO5,55150-324-25,888-238-7880,
"Hospira, Inc., a Pfizer Company",HYDROCORTISONE SODIUM SUCCINATE,,03/24/2023,Revised,"INTRAMUSCULAR, INTRAVENOUS",Hydrocortisone Sodium Succinate Injection,"105398, 238755, 1738586, 1738589, 1738590, 1738592, 1738594, 1738596",,65eefd58-b166-4d71-ade6-45c8fdf86922,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Pulmonary/Allergy, Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Pediatric, Renal, Rheumatology",SOLU-CORTEF,"0009-0013, 0009-0825, 0009-0011, 0009-0016, 0009-0005",Pharmacia & Upjohn Company LLC,8512044a-4a54-4634-bb97-9e20126adc61,"0009-0825-01, 0009-0011-03, 0009-0011-04, 0009-0013-05, 0009-0013-06, 0009-0016-12, 0009-0005-01","Solu-cortef, Injection, 250 mg/vial (NDC 0009-0013-05)",Injection,Limited Availability,,NDA009866,,HYDROCORTISONE SODIUM SUCCINATE,,,Current,Other,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,50LQB69S1Z,0009-0013-05,844-646-4398,
Sun Pharmaceutical Industries Limited,IMATINIB MESYLATE,,12/05/2024,New,ORAL,Imatinib Mesylate Tablet,"403878, 403879",,be5b9047-155b-59ca-e053-2995a90ad3dc,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Hematology,IMATINIB MESYLATE,"68001-490, 68001-491",BluePoint Laboratories,05c9d227-d639-916a-e063-6294a90a66a6,"68001-490-05, 68001-491-04","Imatinib Mesylate, Tablet, 100 mg (NDC 68001-490-05)",Tablet,,,ANDA078340,,IMATINIB MESYLATE,,,To Be Discontinued,,Discontinuing for business reasons,,8A1O1M485B,68001-490-05,800-818-4555,
Novadoz Pharmaceuticals LLC,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Revised,ORAL,"Lisdexamfetamine Dimesylate Tablet, Chewable","1871456, 1871460, 1871462, 1871464, 1871466, 1871468",,a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"72205-133, 72205-132, 72205-134, 72205-135, 72205-136, 72205-137",Novadoz Pharmaceuticals LLC,a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811,"72205-132-91, 72205-133-91, 72205-134-91, 72205-135-91, 72205-136-91, 72205-137-91","Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 72205-133-91)","Tablet, Chewable",Available,,ANDA218306,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,,,SJT761GEGS,72205-133-91,(855) 668-2369; customerservice@novadozpharma.com,
Pfizer Inc.,METHYLPREDNISOLONE ACETATE,,12/15/2021,Revised,"INTRALESIONAL, INTRAMUSCULAR, INTRASYNOVIAL, SOFT TISSUE, INTRA-ARTICULAR",Methylprednisolone Acetate Injection,"1743779, 1743781, 1743855, 1743856",,"bf1b104d-85cb-414d-a366-78068c82c883, 9a7b3837-e038-48bf-97e9-78ad463760dc",08/15/2025,HUMAN PRESCRIPTION DRUG,,Rheumatology,DEPO-MEDROL,"0009-3073, 0009-3475",Pharmacia & Upjohn Company LLC,"d7ccf8b4-deb4-43c1-b67b-1f610d6d8425, befd723e-d1e2-41b9-83f1-17bca0c2a941","0009-3073-22, 0009-3073-23, 0009-3475-22, 0009-3475-23, 0009-3073-01, 0009-3073-03, 0009-3475-01, 0009-3475-03","Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23)",Injection,Available,,NDA011757,,METHYLPREDNISOLONE ACETATE,,,Current,,,,43502P7F0P,0009-3073-23,844-646-4398,
Pfizer Inc.,,,01/06/2023,Revised,,Somatropin Injection,"241975, 762830, 762833, 762834, 762836, 762837, 762839, 762841, 762843, 762846, 762849, 762850, 762852, 762857, 762859, 762866, 762868, 762873, 762875, 762895, 762897, 763488, 763489, 996558, 996559",,ffebf88b-d257-4542-9808-74d9b7167765,08/28/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,GENOTROPIN,"0013-2657, 0013-2626, 0013-2646, 0013-2649, 0013-2650, 0013-2651, 0013-2652, 0013-2653, 0013-2654, 0013-2655, 0013-2656, 0013-2658",Pfizer Laboratories Div Pfizer Inc,f09acf87-6e30-47ad-9891-8a49bf6dffbc,"0013-2626-81, 0013-2646-81, 0013-2649-02, 0013-2650-02, 0013-2651-02, 0013-2652-02, 0013-2653-02, 0013-2654-02, 0013-2655-02, 0013-2656-02, 0013-2657-02, 0013-2658-02","Genotropin, Injection, 1.8 mg preservative free (NDC 0013-2657-02)",Injection,,,BLA020280,,SOMATROPIN,,Available,Resolved,,,08/28/2025,,0013-2657-02,800-533-4535,
Aurobindo Pharma USA,"AMLODIPINE BESYLATE, BENAZEPRIL HYDROCHLORIDE",,03/04/2025,New,ORAL,Amlodipine Besylate; Benazepril Hydrochloride Capsule,"898342, 898346, 898350, 898353, 898356, 898359",,99ed4927-9a34-4e8d-8eea-60b63c867d46,03/04/2025,HUMAN PRESCRIPTION DRUG,03/04/2025,Cardiovascular,AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE,"65862-584, 65862-582, 65862-583, 65862-585, 65862-586, 65862-587",Aurobindo Pharma Limited,a45ec3e8-1d14-4c27-9685-976323df8cad,"65862-582-01, 65862-582-05, 65862-583-01, 65862-583-05, 65862-584-01, 65862-584-05, 65862-585-01, 65862-585-05, 65862-586-01, 65862-586-05, 65862-587-01, 65862-587-05","Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 20 mg (NDC 65862-584-01)",Capsule,,,ANDA202239,,AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE,,,To Be Discontinued,,,,"864V2Q084H, N1SN99T69T",65862-584-01,866-850-2876,
"Hospira, Inc., a Pfizer Company","EPINEPHRINE, LIDOCAINE HYDROCHLORIDE",,02/22/2012,Reverified,"INFILTRATION, PERINEURAL","Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","1010688, 1010745, 1010751, 1010759, 1867996, 1867998",,2f94f711-14c4-48ec-c5a3-c5ec4b8e8729,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE,"0409-3177, 0409-1209, 0409-3178, 0409-3181, 0409-3182, 0409-3183, 0409-0007, 0409-0147","Hospira, Inc.",d16a4711-e663-455e-a1fe-236a41ca4e8f,"0409-1209-10, 0409-1209-01, 0409-1209-05, 0409-1209-70, 0409-1209-65, 0409-3177-16, 0409-3177-01, 0409-3178-16, 0409-3178-01, 0409-3178-17, 0409-3178-02, 0409-3178-18, 0409-3178-03, 0409-3181-11, 0409-3181-01, 0409-3182-11, 0409-3182-01, 0409-3182-21, 0409-3182-02, 0409-3182-31, 0409-3182-03, 0409-3183-11, 0409-3183-01, 0409-0007-01, 0409-0007-10, 0409-0147-01, 0409-0147-10","Lidocaine Hydrochloride And Epinephrine, Injection, 2.5 g/50 mL (0.5%; 1:200,000) (NDC 0409-3177-01)",Injection,Available,"N0000000209, N0000000245, N0000175552, N0000175555, N0000175570, M0003647",ANDA089635,Catecholamines [CS],LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE,"alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC], Catecholamine [EPC]",,Current,,,12/19/2024,"V13007Z41A, YKH834O4BH",0409-3177-01,844-646-4398,"Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA]"
Pfizer Inc.,"ESTROGENS, ESTERIFIED",,07/29/2025,New,ORAL,Esterified Estrogens Tablet,"197666, 197667, 197668, 197669, 212039, 212232, 212373, 212464",,e0141598-0bb2-4cf0-c9b8-6867b34bbb17,07/29/2025,HUMAN PRESCRIPTION DRUG,07/29/2025,Endocrinology/Metabolism,MENEST,"61570-075, 61570-072, 61570-073, 61570-074",Pfizer Laboratories Div Pfizer Inc,78aaf71c-8f0d-47c4-9fcf-f5e7e9b84bfb,"61570-072-01, 61570-073-01, 61570-074-01, 61570-075-50","Menest, Tablet, 2.5 mg (NDC 61570-075-50)",Tablet,,,ANDA084949,,ESTERIFIED ESTROGENS,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,3ASP8Q3768,61570-075-50,800-533-4535,
"Teva Pharmaceuticals USA, Inc.",PRAVASTATIN SODIUM,,06/13/2025,New,ORAL,Pravastatin Sodium Tablet,"904458, 904467, 904475",,99e0e848-f8f3-4b42-b880-8fbc42633948,06/13/2025,HUMAN PRESCRIPTION DRUG,06/13/2025,Cardiovascular,PRAVASTATIN SODIUM,"0093-7201, 0093-0771, 0093-7202","Teva Pharmaceuticals USA, Inc.",72579e23-23ef-4ab7-ad64-24d5ea7997eb,"0093-0771-98, 0093-0771-10, 0093-7201-98, 0093-7201-10, 0093-7202-98, 0093-7202-10","Pravastatin Sodium, Tablet, 20 mg (NDC 0093-7201-10)",Tablet,,,ANDA076056,,PRAVASTATIN SODIUM,,,To Be Discontinued,,,,3M8608UQ61,0093-7201-10,800-545-8800,
Gland Pharma Limited,ETOMIDATE,General Anesthesia [PE],10/05/2022,Reverified,INTRAVENOUS,Etomidate Injection,"1654006, 1654008",,8b6c54d8-3f3f-4290-841c-976bea01086f,09/29/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ETOMIDATE,"72266-147, 72266-146",Fosun Pharma USA Inc,2b365133-b609-3285-e063-6394a90a69a6,"72266-146-01, 72266-146-10, 72266-147-01, 72266-147-10","Etomidate, Injection, 2 mg/1 mL (NDC 72266-147-10)",Injection,Available,"N0000175975, N0000175681",ANDA209058,,ETOMIDATE INJECTION,General Anesthetic [EPC],,Current,,"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.",,Z22628B598,72266-147-10,833-291-9645,
"Hospira, Inc., a Pfizer Company",HYDROMORPHONE HYDROCHLORIDE,,10/31/2017,Reverified,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Hydromorphone Hydrochloride Injection,"1724338, 1724340, 1724341",,3832ede8-d3fc-455d-ecab-3b77be5869f5,08/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,HYDROMORPHONE HYDROCHLORIDE,0409-2634,"Hospira, Inc.",f0c8c83c-fb41-4571-a72e-6542311351dd,"0409-2634-10, 0409-2634-01, 0409-2634-25, 0409-2634-05, 0409-2634-50","Hydromorphone Hydrochloride, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-2634-05)",Injection,Available,,ANDA078591,,HYDROMORPHONE HYDROCHLORIDE,,,Current,,,01/02/2025,L960UP2KRW,0409-2634-05,844-646-4398,
Oryza Pharmaceuticals Inc.,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Revised,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 1009145",,acd27181-a3f3-4c38-85d8-029a4a82e7c2,09/16/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","72516-012, 72516-016, 72516-015, 72516-014, 72516-013, 72516-011",Oryza Pharmaceuticals Inc.,39fb17a2-617d-37dc-e063-6394a90a1be3,"72516-016-01, 72516-015-01, 72516-014-01, 72516-013-01, 72516-012-01, 72516-011-01","Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 72516-012-01)",Tablet,Unavailable,,ANDA210293,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,Shortage of an active ingredient,Estimated availability October 2025,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",72516-012-01,855-257-0292,
Novast Labs,OXALIPLATIN,,04/22/2025,New,INTRAVENOUS,Oxaliplatin Injection,"1736776, 1736781",,9613ae3d-72e2-40f7-8151-b43e915a6f1c,04/22/2025,HUMAN PRESCRIPTION DRUG,04/22/2025,Oncology,OXALIPLATIN,"50742-405, 50742-406","Ingenus Pharmaceuticals, LLC",91b1d13f-6401-496f-a2e5-76e84775efd0,"50742-405-10, 50742-406-20","Oxaliplatin, Injection, 50 mg/10 mL (NDC 50742-405-10)",Injection,,"N0000175413, N0000175073",ANDA207562,,OXALIPLATIN,Platinum-based Drug [EPC],,To Be Discontinued,,This product is distributed by Ingenus Pharmaceuticals. Customer service: customerservice@ingenus.com or 866-321-5031,,04ZR38536J,50742-405-10,866-321-5031 (Ingenus Pharmaceuticals),
"Teva Pharmaceuticals USA, Inc.",AMANTADINE HYDROCHLORIDE,,02/05/2025,New,ORAL,Amantadine Hydrochloride Capsule,849395,,d9c9eaf7-dcc7-49c1-99d4-49f4dac3779f,02/05/2025,HUMAN PRESCRIPTION DRUG,02/05/2025,"Antiviral, Neurology",AMANTADINE HYDROCHLORIDE,0591-4920,"Actavis Pharma, Inc.",67ce5a52-d507-4333-b0a0-b7177f896aec,"0591-4920-01, 0591-4920-05","Amantadine Hydrochloride, Capsule, 100 mg (NDC 0591-4920-01)",Capsule,,,ANDA208096,,AMANTADINE HYDROCHLORIDE,,,To Be Discontinued,,A business decision was made to discontinue manufacture of the drug.,,M6Q1EO9TD0,0591-4920-01,800-545-8800,
"Dr. Reddy's Laboratories, Inc.",AZACITIDINE,,12/18/2020,Reverified,"INTRAVENOUS, SUBCUTANEOUS",Azacitidine Injection,485246,,71d8d758-86c9-b571-aed1-719654fd4b82,09/16/2025,HUMAN PRESCRIPTION DRUG,,Oncology,AZACITIDINE,43598-305,Dr. Reddy's Laboratories Inc.,02505064-3ef0-d191-30cf-4042beb17c79,43598-305-62,"Azacitidine, Injection, 100 mg (NDC 43598-305-62)",Injection,Available,"N0000000233, N0000175595",ANDA201537,,AZACITIDINE,Nucleoside Metabolic Inhibitor [EPC],,Current,,Available to existing customers,,M801H13NRU,43598-305-62,866-732-3952,Nucleic Acid Synthesis Inhibitors [MoA]
Sun Pharmaceutical Industries Limited,IMATINIB MESYLATE,,12/05/2024,New,ORAL,Imatinib Mesylate Tablet,"403878, 403879",,07764bf9-21b4-4e32-9d7e-e348f8e4291f,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Hematology,IMATINIB MESYLATE,"47335-472, 47335-475","Sun Pharmaceutical Industries, Inc.",ad13dbca-474d-4492-9c25-e0e175143d8c,"47335-472-83, 47335-472-88, 47335-472-13, 47335-472-81, 47335-475-83, 47335-475-88, 47335-475-13, 47335-475-64","Imatinib Mesylate, Tablet, 100 mg (NDC 47335-472-83)",Tablet,,,ANDA078340,,IMATINIB MESYLATE,,,To Be Discontinued,,Discontinuing for business reasons,,8A1O1M485B,47335-472-83,800-818-4555,
"EMD Serono, Inc.",LEVOTHYROXINE SODIUM,,07/10/2025,New,ORAL,Levothyroxine Sodium Tablet,"892246, 892251, 966153, 966160, 966166, 966173, 966177, 966182, 966187, 966196, 966202, 966207, 966220, 966221, 966222, 966224, 966225, 966248, 966249, 966253, 966270, 2104866",,bc3c6830-ba68-4ba3-9896-a12d0ad0b275,07/10/2025,HUMAN PRESCRIPTION DRUG,07/10/2025,Endocrinology/Metabolism,EUTHYROX,"72305-137, 72305-025, 72305-050, 72305-075, 72305-088, 72305-100, 72305-112, 72305-125, 72305-150, 72305-175, 72305-200","Provell Pharmaceuticals, LLC",45657074-8874-49f4-a8ef-3ca7e210c16e,"72305-025-30, 72305-025-90, 72305-050-30, 72305-050-90, 72305-075-30, 72305-075-90, 72305-088-30, 72305-088-90, 72305-100-30, 72305-100-90, 72305-112-30, 72305-112-90, 72305-125-30, 72305-125-90, 72305-137-30, 72305-137-90, 72305-150-30, 72305-150-90, 72305-175-30, 72305-175-90, 72305-200-30, 72305-200-90","Euthyrox, Tablet, 137 ug (NDC 72305-137-90)",Tablet,,,NDA021292,,LEVOTHYROXINE SODIUM,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,9J765S329G,72305-137-90,888-899-7041,
"Fresenius Kabi USA, LLC",METHOTREXATE SODIUM,,03/13/2023,Reverified,"INTRA-ARTERIAL, INTRAMUSCULAR, INTRATHECAL, INTRAVENOUS",Methotrexate Sodium Injection,311625,,ec476b11-0b3c-4139-b1eb-a3daa76bc271,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Rheumatology, Oncology",METHOTREXATE,63323-122,"Fresenius Kabi USA, LLC",3d21237a-ef53-4592-bf06-0c739696203d,63323-122-50,"Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50)",Injection,Available,,ANDA040266,,METHOTREXATE SODIUM,,,Current,,Check wholesaler for inventory,,3IG1E710ZN,63323-122-50,888-386-1300,
Baxter Healthcare,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807551, 1807552, 1807627, 1807630, 1807631, 1807632, 1807633, 1807634, 1807639",,f55bd888-5e01-474d-871b-24654c070178,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0338-0049, 0338-0043",Baxter Healthcare Corporation,6ab23768-efd2-4ff1-b336-0dda08dc56e1,"0338-0049-01, 0338-0049-02, 0338-0049-03, 0338-0049-04, 0338-0049-10, 0338-0049-41, 0338-0049-11, 0338-0049-31, 0338-0049-48, 0338-0049-18, 0338-0049-38, 0338-0043-03, 0338-0043-04","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-11)",Injection,,,NDA016677,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0338-0049-11,888-229-0001,
"Teva Pharmaceuticals USA, Inc.",,,07/12/2022,Revised,,"Streptozocin Powder, For Solution",,,,09/15/2025,,,Oncology,,,,,,"Zanosar, Powder, For Solution, 100 mg/1 mL (NDC 0703-4636-01)","Powder, For Solution",Unavailable,,,,,,,Current,Other,Estimated recovery: TBD,,,0703-4636-01,800-545-8800,
"Upsher-Smith Laboratories, LLC",BUMETANIDE,Increased Diuresis at Loop of Henle [PE],05/02/2025,New,ORAL,Bumetanide Tablet,"197417, 197418, 197419",,ff5dc8c6-b2f2-41d3-8e56-a953aa721b59,05/02/2025,HUMAN PRESCRIPTION DRUG,05/02/2025,Cardiovascular,BUMETANIDE,"0832-0541, 0832-0540, 0832-0542","Upsher-Smith Laboratories, LLC",d53166d9-64ca-4b76-81a7-b70a60c53b12,"0832-0540-11, 0832-0541-11, 0832-0541-10, 0832-0542-11, 0832-0542-10","Bumetanide, Tablet, 1 mg (NDC 0832-0541-10)",Tablet,,"N0000175366, N0000175590",ANDA209916,,BUMETANIDE,Loop Diuretic [EPC],,To Be Discontinued,,,,0Y2S3XUQ5H,0832-0541-10,800-654-2299,
"Fresenius Kabi USA, LLC",DEXTROSE MONOHYDRATE,,03/01/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 10% Injection,"1795477, 1795480, 1795481",,3b8f2692-4371-4f1a-95af-b41842131fdd,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,63323-824,"Fresenius Kabi USA, LLC",d4eda8d8-e374-469e-8ac0-9c9fb7a58aaf,"63323-824-24, 63323-824-74, 63323-824-25, 63323-824-75, 63323-824-26, 63323-824-76","Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-74)",Injection,Available,,ANDA209448,,DEXTROSE MONOHYDRATE,,,Current,,Check wholesalers for inventory,,LX22YL083G,63323-824-74,888-386-1300,
Baxter Healthcare,DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795477, 1795480, 1795481, 1795607, 1795609, 1795610, 1795612, 1795616, 1795618",,3bb406a9-f5cb-403a-b1bb-5c4facbea3d5,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0338-0017, 0338-0023",Baxter Healthcare Corporation,31bb4a5f-733e-4354-9fbf-138dede4db0f,"0338-0017-10, 0338-0017-41, 0338-0017-11, 0338-0017-31, 0338-0017-48, 0338-0017-18, 0338-0017-38, 0338-0017-02, 0338-0017-03, 0338-0017-04, 0338-0023-02, 0338-0023-03, 0338-0023-04","Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-38)",Injection,Available,,NDA016673,,DEXTROSE MONOHYDRATE,,,Current,,,,LX22YL083G,0338-0017-38,888-229-0001,
"Fresenius Kabi USA, LLC",LIDOCAINE HYDROCHLORIDE ANHYDROUS,,02/22/2012,Reverified,"INFILTRATION, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010035, 1010671, 1010673, 1010688, 1010692, 1010745, 1010749, 1010751, 1010755, 1010759, 1010763, 1010900, 1010902, 1737343, 1737345, 1737562, 1737563, 1737566, 1737567, 1737568, 1737569, 1737570, 1737571, 1737757, 1737758, 1737761, 1737762, 1867938, 1867940, 1867943, 1867944, 1867992, 1867993, 1867996, 1867997, 1868028, 1868029",,"ba082c2f-64f4-419d-9c88-74f203316e17, 4dd52202-8eef-4136-92dd-ada573b7cf74",09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",XYLOCAINE,"63323-486, 63323-492, 63323-491, 63323-495, 63323-485, 63323-484, 63323-489, 63323-488, 63323-481, 63323-483, 63323-482, 63323-487","Fresenius Kabi USA, LLC","ea480a68-5927-4278-9deb-2956961da428, 0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33","63323-492-04, 63323-492-27, 63323-492-09, 63323-492-57, 63323-492-07, 63323-492-37, 63323-492-03, 63323-492-31, 63323-491-01, 63323-491-57, 63323-495-09, 63323-495-27, 63323-495-04, 63323-495-07, 63323-485-01, 63323-485-27, 63323-485-03, 63323-485-57, 63323-486-01, 63323-486-17, 63323-486-02, 63323-486-27, 63323-486-05, 63323-486-57, 63323-484-57, 63323-489-02, 63323-489-27, 63323-489-03, 63323-489-21, 63323-489-01, 63323-489-17, 63323-488-07, 63323-488-37, 63323-488-03, 63323-488-31, 63323-488-01, 63323-488-17, 63323-481-01, 63323-481-57, 63323-483-03, 63323-483-27, 63323-483-01, 63323-483-57, 63323-482-01, 63323-482-17, 63323-482-03, 63323-482-27, 63323-482-05, 63323-482-57, 63323-487-01, 63323-487-17, 63323-487-07, 63323-487-37, 63323-487-03, 63323-487-31, 63323-492-41, 63323-492-16, 63323-492-43, 63323-492-36, 63323-492-45, 63323-492-26, 63323-485-41, 63323-485-26, 63323-486-41, 63323-486-26, 63323-482-41, 63323-482-26, 63323-495-41, 63323-495-26","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-57)",Injection,Available,,NDA006488,,LIDOCAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,"EC2CNF7XFP, 30Q7KI53AK",63323-486-57,888-386-1300,
"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)",RILUZOLE,,01/26/2024,Reverified,ORAL,Riluzole Oral Suspension,"2058147, 2675565",https://www.fda.gov/media/185611/download?attachment,0f2b5cfc-a23d-699a-e063-6394a90a67d1,09/15/2025,HUMAN PRESCRIPTION DRUG,,Neurology,TEGLUTIK,70726-0304,"EDW PHARMA, INC",10e69e6c-1158-96e0-e063-6294a90ac44d,70726-0304-1,"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0304-1)",Oral Suspension,Available,"N0000175740, M0483511",,Benzothiazoles [CS],RILUZOLE,Benzothiazole [EPC],,Current,,,,7LJ087RS6F,70726-0304-1,610-937-6172,
"Hospira, Inc., a Pfizer Company",SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807547, 1807631, 1807632, 1807633",,a2a964f7-c3ec-4dfb-e3a0-6d8136a80397,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0409-7101, 0409-7132","Hospira, Inc.",9d75502b-257f-4a37-9a85-b98c4278c474,"0409-7101-68, 0409-7101-66, 0409-7101-69, 0409-7101-67, 0409-7101-04, 0409-7101-02, 0409-7132-68, 0409-7132-66, 0409-7132-69, 0409-7132-67, 0409-7132-04, 0409-7132-02","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (9%, 9mg/mL) (NDC 0409-7101-67)",Injection,,,NDA019465,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0409-7101-67,844-646-4398,
"Teva Pharmaceuticals USA, Inc.",CARBAMAZEPINE,Decreased Central Nervous System Disorganized Electrical Activity [PE],06/10/2025,New,ORAL,Carbamazepine Tablet,"211817, 308979",,32bbe864-7374-44da-8c6e-e733f0648243,06/10/2025,HUMAN PRESCRIPTION DRUG,06/10/2025,Neurology,EPITOL,0093-0090,"Teva Pharmaceuticals USA, Inc.",5c31da75-fc21-4ab2-9487-64169767ebd0,0093-0090-01,"Epitol, Tablet, 200 mg (NDC 0093-0090-01)",Tablet,,"N0000008486, N0000175751, N0000185506, N0000191266, N0000187064, N0000185507, N0000185607",ANDA070541,,CARBAMAZEPINE,Mood Stabilizer [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,33CM23913M,0093-0090-01,800-545-8800,"Cytochrome P450 3A4 Inducers [MoA], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA]"
"Hospira, Inc., a Pfizer Company",DOBUTAMINE HYDROCHLORIDE,,11/06/2017,Revised,INTRAVENOUS,Dobutamine Hydrochloride Injection,1812168,,"dc537761-d5f4-488d-24ab-b2bcd2b17b7a, 89becb0c-da60-4f43-0a98-29ff7a9eca58",08/15/2025,HUMAN PRESCRIPTION DRUG,,"Cardiovascular, Pediatric, Renal",DOBUTAMINE,0409-2344,"Hospira, Inc.","e71e9520-871b-479d-9652-1857fceca863, 5d6b1dfe-d679-4aea-97a6-3d074a202afe","0409-2344-01, 0409-2344-62, 0409-2344-02, 0409-2344-68, 0409-2344-88","Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-02)",Injection,Available,,ANDA074086,,DOBUTAMINE,,,Current,,,12/19/2024,0WR771DJXV,0409-2344-02,844-646-4398,
"Teva Pharmaceuticals USA, Inc.",HYDROCORTISONE,,03/24/2025,New,TOPICAL,Hydrocortisone Cream,310891,,a5f16c13-2a51-4541-bf9e-d80bc01a8dbd,03/24/2025,HUMAN PRESCRIPTION DRUG,03/24/2025,Dermatology,HYDROCORTISONE,0472-0337,"Actavis Pharma, Inc.",527a8d09-450b-4b8e-ad19-78fbba9732c5,"0472-0337-20, 0472-0337-30","Hydrocortisone, Cream, 25 mg/1 g (NDC 0472-0337-30)",Cream,,"N0000175576, N0000175450",ANDA089682,,HYDROCORTISONE,Corticosteroid [EPC],,To Be Discontinued,,A business decision was made to discontinue.,,WI4X0X7BPJ,0472-0337-30,800-545-8800,Corticosteroid Hormone Receptor Agonists [MoA]
"Upsher-Smith Laboratories, LLC",POTASSIUM CHLORIDE,,07/23/2025,New,ORAL,"Potassium Chloride Tablet, Extended Release","312529, 628953",,616f0de7-8843-44a1-8fa6-274d889286aa,07/23/2025,HUMAN PRESCRIPTION DRUG,07/23/2025,"Endocrinology/Metabolism, Gastroenterology",POTASSIUM CHLORIDE,"0832-5322, 0832-5323","Upsher-Smith Laboratories, LLC",39e726b1-eab8-fcf4-e063-6394a90a950a,"0832-5322-11, 0832-5322-10, 0832-5323-11, 0832-5323-10","Potassium Chloride, Tablet, Extended Release, 600 mg (NDC 0832-5322-10)",Tablet,,,NDA019123,,POTASSIUM CHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug product,,660YQ98I10,0832-5322-10,763-315-2000,
"Par Pharmaceutical, Inc.",CANDESARTAN CILEXETIL,,10/15/2024,New,ORAL,Candesartan Cilexetil Tablet,"153822, 153823, 577776, 639537",,1c90aa68-cc12-41ef-aebc-2616ae45683a,10/15/2024,HUMAN PRESCRIPTION DRUG,10/15/2024,Cardiovascular,CANDESARTAN CILEXETIL,"49884-658, 49884-659, 49884-660, 49884-661",Par Pharmaceutical Inc.,fc8868a3-89f5-4414-b3c8-edece3b529f4,"49884-658-09, 49884-659-09, 49884-660-09, 49884-661-09","Atacand, Tablet, 4 mg (NDC 49884-658-09)",Tablet,,,NDA020838,,CANDESARTAN CILEXETIL,,,To Be Discontinued,,,,R85M2X0D68,49884-658-09,800-828-9393,
"SteriMax, Inc.",CEFOTAXIME SODIUM,,02/17/2015,Reverified,"INTRAMUSCULAR, INTRAVENOUS","Cefotaxime Sodium Powder, for Solution","1656313, 1656318",https://www.fda.gov/media/152896/download,8efe3bd0-c43a-2bd6-e053-2a95a90a92fa,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",CEFOTAXIME,"21586-011, 21586-012",SteriMax Inc.,425c90b3-5006-427e-95f6-93ee7918fb8b,"21586-011-01, 21586-011-02, 21586-012-01, 21586-012-02","Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 21586-011-02)","Powder, For Solution",Available,,,,CEFOTAXIME INJECTION,,,Current,,,,258J72S7TZ,21586-011-02,800-881-3550,
Eli Lilly and Co.,DULOXETINE HYDROCHLORIDE,,10/18/2024,New,ORAL,"Duloxetine Hydrochloride Capsule, Delayed Release","596926, 596928, 596930, 596932, 596934, 615186",,2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba,10/18/2024,HUMAN PRESCRIPTION DRUG,10/18/2024,Psychiatry,CYMBALTA,"0002-3235, 0002-3240, 0002-3270",Eli Lilly and Company,aa5061b1-f237-425a-9d05-575c333dfd37,"0002-3235-60, 0002-3240-30, 0002-3240-90, 0002-3270-30","Cymbalta, Capsule, Delayed Release, 20 mg (NDC 0002-3235-60)",Capsule,,,NDA021427,,DULOXETINE HYDROCHLORIDE,,,To Be Discontinued,,Business decision to discontinue,,9044SC542W,0002-3235-60,800-545-5979,
"EMD Serono, Inc.",LEVOTHYROXINE SODIUM,,07/10/2025,New,ORAL,Levothyroxine Sodium Tablet,"892246, 892251, 966153, 966160, 966166, 966173, 966177, 966182, 966187, 966196, 966202, 966207, 966220, 966221, 966222, 966224, 966225, 966248, 966249, 966253, 966270, 2104866",,bc3c6830-ba68-4ba3-9896-a12d0ad0b275,07/10/2025,HUMAN PRESCRIPTION DRUG,07/10/2025,Endocrinology/Metabolism,EUTHYROX,"72305-137, 72305-025, 72305-050, 72305-075, 72305-088, 72305-100, 72305-112, 72305-125, 72305-150, 72305-175, 72305-200","Provell Pharmaceuticals, LLC",45657074-8874-49f4-a8ef-3ca7e210c16e,"72305-025-30, 72305-025-90, 72305-050-30, 72305-050-90, 72305-075-30, 72305-075-90, 72305-088-30, 72305-088-90, 72305-100-30, 72305-100-90, 72305-112-30, 72305-112-90, 72305-125-30, 72305-125-90, 72305-137-30, 72305-137-90, 72305-150-30, 72305-150-90, 72305-175-30, 72305-175-90, 72305-200-30, 72305-200-90","Euthyrox, Tablet, 137 ug (NDC 72305-137-30)",Tablet,,,NDA021292,,LEVOTHYROXINE SODIUM,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,9J765S329G,72305-137-30,888-899-7041,
Granules Pharmaceuticals Inc.,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,b0b4eccc-34c7-483d-966f-82d588358e1b,09/08/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","70010-111, 70010-112, 70010-113, 70010-114, 70010-115, 70010-116, 70010-117",Granules Pharmaceuticals Inc.,2fab399e-2a43-5134-e063-6294a90ae09a,"70010-111-01, 70010-111-03, 70010-112-01, 70010-112-03, 70010-113-01, 70010-113-03, 70010-114-01, 70010-114-03, 70010-115-01, 70010-115-03, 70010-116-01, 70010-116-03, 70010-117-01, 70010-117-03","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 70010-111-01)",Tablet,Available,,ANDA215771,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",70010-111-01,877-770-3183,
"Hikma Pharmaceuticals USA, Inc.",LORAZEPAM,,09/05/2018,Revised,"INTRAMUSCULAR, INTRAVENOUS",Lorazepam Injection,"206819, 206820, 238100, 238101, 1665188, 1665190, 1665326, 1665327",,5fc0e987-61c9-40c4-b0d5-fcea07c8733e,07/23/2025,HUMAN PRESCRIPTION DRUG,,Neurology,ATIVAN,"0641-6002, 0641-6003, 0641-6001, 0641-6000",Hikma Pharmaceuticals USA Inc.,209b0091-c890-4f69-a693-d0594c2606fe,"0641-6003-01, 0641-6003-25, 0641-6002-01, 0641-6002-10, 0641-6001-01, 0641-6001-25, 0641-6000-01, 0641-6000-10","Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)",Injection,Unavailable,"N0000175694, M0002356",NDA018140,Benzodiazepines [CS],LORAZEPAM,Benzodiazepine [EPC],,Current,Regulatory delay,Shortage duration unknown,,O26FZP769L,0641-6002-10,800-631-2174,
"Upsher-Smith Laboratories, LLC",NYSTATIN,,04/28/2025,New,TOPICAL,Nystatin Topical Powder,"584414, 646456",,01b44f91-9b68-464a-9693-b5d3e793bf3c,04/28/2025,HUMAN PRESCRIPTION DRUG,04/28/2025,"Anti-Infective, Dermatology",NYAMYC,0832-0465,"Upsher-Smith Laboratories, LLC",3984f88f-d61f-1fa9-e063-6394a90acb11,"0832-0465-15, 0832-0465-30, 0832-0465-60","Nystatin, Topical Powder, 100000 [USP'U]/1 g (NDC 0832-0465-15)",Topical Powder,,"N0000175498, M0017172",ANDA065183,Polyenes [CS],NYSTATIN,Polyene Antifungal [EPC],,To Be Discontinued,,,,BDF1O1C72E,0832-0465-15,800-654-2299,
"Teva Pharmaceuticals USA, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Revised,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,cffbbb15-d776-41ae-a8a6-687f2c07bfa4,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","0555-0777, 0555-0971, 0555-0775, 0555-0972, 0555-0776, 0555-0973, 0555-0974","Teva Pharmaceuticals USA, Inc.",88468f3d-7d03-4cee-aabf-3abc8c9b5e38,"0555-0971-02, 0555-0775-02, 0555-0972-02, 0555-0776-02, 0555-0777-02, 0555-0973-02, 0555-0974-02","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)",Tablet,Available,,ANDA040422,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",0555-0777-02,800-545-8800,
"Fresenius Kabi USA, LLC",WATER,,11/23/2021,Reverified,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Sterile Water Injection,,,e71c6c83-d518-496c-b2ab-efd5987e4783,09/18/2025,HUMAN PRESCRIPTION DRUG,,Other,STERILE WATER,63323-185,"Fresenius Kabi USA, LLC",42c6c812-706a-425b-b8cb-931006e40484,"63323-185-07, 63323-185-10, 63323-185-09, 63323-185-50, 63323-185-08, 63323-185-20, 63323-185-04, 63323-185-05","Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-20)",Injection,Available,,ANDA088400,,WATER,,,Current,,Check wholesalers for inventory,,059QF0KO0R,63323-185-20,888-386-1300,
"Teva Pharmaceuticals USA, Inc.",VERAPAMIL HYDROCHLORIDE,,01/23/2025,New,ORAL,"Verapamil Hydrochloride Capsule, Extended Release",,,0742cf97-601b-4c13-a6c3-1a6a616ed292,01/23/2025,HUMAN PRESCRIPTION DRUG,01/23/2025,Cardiovascular,VERAPAMIL HYDROCHLORIDE,"0591-2880, 0591-2882, 0591-2884, 0591-2886",Teva Pharmaceuticals Inc,319554df-fc0d-428a-9799-a352100f1ce9,"0591-2880-01, 0591-2882-01, 0591-2884-01, 0591-2886-01","Verelan, Capsule, Extended Release, 120 mg (NDC 0591-2880-01)","Capsule, Extended Release",,,NDA019614,,VERAPAMIL HYDROCHLORIDE,,,To Be Discontinued,,,,V3888OEY5R,0591-2880-01,800-545-8800,
Baxter Healthcare,KETOROLAC TROMETHAMINE,,06/06/2018,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Ketorolac Tromethamine Injection,"860092, 1665459, 1665461",,4b58836d-9d58-4539-9691-9e11c505ef2a,09/23/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,KETOROLAC TROMETHAMINE,"0338-0069, 0338-0072, 0338-0076",Baxter Healthcare Corporation,2da4dd8a-1b18-481d-b733-9c031d9ea7e3,"0338-0069-10, 0338-0072-25, 0338-0076-10","Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)",Injection,Available,,ANDA209900,,KETOROLAC TROMETHAMINE,,,Current,,,,4EVE5946BQ,0338-0069-10,888-229-0001,
"Hospira, Inc., a Pfizer Company",KETOROLAC TROMETHAMINE,,03/26/2018,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Ketorolac Tromethamine Injection,"860092, 1665459, 1665461",,8accbb78-fc64-45d5-69b0-35c23a1d2a2e,08/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,KETOROLAC TROMETHAMINE,"0409-3795, 0409-3793, 0409-3796","Hospira, Inc.",60f4ed51-f1c1-45d4-b43a-969678901bdd,"0409-3793-19, 0409-3793-01, 0409-3793-25, 0409-3795-19, 0409-3795-01, 0409-3795-25, 0409-3796-19, 0409-3796-01, 0409-3796-25","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0409-3795-01)",Injection,Available,,ANDA074802,,KETOROLAC TROMETHAMINE,,,Current,,,,4EVE5946BQ,0409-3795-01,844-646-4398,
"Fresenius Kabi USA, LLC",MIDAZOLAM HYDROCHLORIDE,,04/02/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Midazolam Hydrochloride Injection,"311700, 311702",,a91ce254-14a3-4cbf-8ab8-5da252aa3fdc,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology",MIDAZOLAM,"63323-411, 63323-412","Fresenius Kabi USA, LLC",9814447b-a93e-42ad-b57e-5db0a5b7f552,"63323-411-22, 63323-411-27, 63323-411-15, 63323-411-12, 63323-411-18, 63323-411-25, 63323-411-13, 63323-411-10, 63323-412-18, 63323-412-25, 63323-412-03, 63323-412-02, 63323-412-06, 63323-412-05, 63323-412-13, 63323-412-10","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)",Injection,Available,,ANDA075154,,MIDAZOLAM HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,W7TTW573JJ,63323-411-25,888-386-1300,
"Sunrise Pharmaceutical, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,ac102599-3a5b-4154-899e-6ff262be7ff7,09/03/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","11534-194, 11534-190, 11534-191, 11534-192, 11534-193, 11534-195, 11534-196","SUNRISE PHARMACEUTICAL, INC.",86a00bec-51eb-4d73-a945-b1937970b29a,"11534-190-01, 11534-190-03, 11534-191-01, 11534-191-03, 11534-192-01, 11534-192-03, 11534-193-01, 11534-193-03, 11534-194-01, 11534-194-03, 11534-195-01, 11534-195-03, 11534-196-01, 11534-196-03","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 11534-194-01)",Tablet,Available,,ANDA209799,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",11534-194-01,732-382-6085 Monday to Friday 9 am to 3:45 pm,
"Huons Co., Ltd",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,SUBARACHNOID,Bupivacaine Hydrochloride Injection,1724784,,2dc693df-3218-4a90-b3f7-21e80966a851,09/17/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE,73293-0002,"Huons Co., Ltd.",2e641a0d-4d42-e7cd-e063-6394a90a47d4,"73293-0002-1, 73293-0002-2","Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 73293-0002-2)",Injection,Available,,ANDA212822,,BUPIVACAINE HYDROCHLORIDE,,,Current,,,,7TQO7W3VT8,73293-0002-2,+82-2-854-4700 or via email intbiz@huons.com,
"Teva Pharmaceuticals USA, Inc.",CELECOXIB,,08/15/2025,New,ORAL,Celecoxib Capsule,"205322, 205323, 349514, 686379",,05224473-27dc-4f6d-a52a-c40a7af2f2f4,08/15/2025,HUMAN PRESCRIPTION DRUG,08/15/2025,Analgesia/Addiction,CELECOXIB,"0591-3983, 0591-3982, 0591-3984, 0591-3985","Actavis Pharma, Inc.",64c601bc-9b67-400f-9e30-e26de56f2f8b,"0591-3982-60, 0591-3983-01, 0591-3983-05, 0591-3984-01, 0591-3984-05, 0591-3985-60","Celecoxib, Capsule, 100 mg (NDC 0591-3983-05)",Capsule,,"N0000000160, M0001335, N0000175722",ANDA200562,"Anti-Inflammatory Agents, Non-Steroidal [CS]",CELECOXIB,Nonsteroidal Anti-inflammatory Drug [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,JCX84Q7J1L,0591-3983-05,800-545-8800,Cyclooxygenase Inhibitors [MoA]
"Hospira, Inc., a Pfizer Company",LIDOCAINE HYDROCHLORIDE,,02/22/2012,Revised,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010671, 1010900, 1737343, 1737562, 1737566, 1737568, 1737636, 1737757, 1737763",,3b2dd84e-cee8-4e58-d494-395a65a353a0,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE HYDROCHLORIDE,"0409-4282, 0409-4713, 0409-4278, 0409-4279, 0409-4776, 0409-4277, 0409-4276, 0409-4275","Hospira, Inc.",c0b4635b-1473-4c48-89c6-620762cd687f,"0409-4713-12, 0409-4713-26, 0409-4713-02, 0409-4713-72, 0409-4713-62, 0409-4713-75, 0409-4713-65, 0409-4713-42, 0409-4713-25, 0409-4713-32, 0409-4278-16, 0409-4278-01, 0409-4279-16, 0409-4279-02, 0409-4776-10, 0409-4776-01, 0409-4282-11, 0409-4282-25, 0409-4282-01, 0409-4282-12, 0409-4282-02, 0409-4277-16, 0409-4277-01, 0409-4277-17, 0409-4277-02, 0409-4276-16, 0409-4276-01, 0409-4276-17, 0409-4276-02, 0409-4275-16, 0409-4275-01","Lidocaine Hydrochloride, Injection, 40 mg/2 mL (2%; 20 mg/mL) (NDC 0409-4282-01)",Injection,Limited Availability,,ANDA088294,,LIDOCAINE HYDROCHLORIDE,,,Current,Demand increase for the drug,Limited Supply Available. Next Delivery and Estimated Recovery: September 2025,,V13007Z41A,0409-4282-01,844-646-4398,
Pfizer Inc.,LINEZOLID,,10/11/2024,New,INTRAVENOUS,Linezolid Solution,"1662285, 1662286",,122faa9e-c71a-4597-9552-5fb330b7d8b9,10/11/2024,HUMAN PRESCRIPTION DRUG,10/11/2024,Anti-Infective,ZYVOX,0009-4992,Pharmacia & Upjohn Company LLC,ed34e168-103f-4015-bfff-00383e0a5dcd,"0009-4992-01, 0009-4992-02","Zyvox, Solution, 600 mg/300 mL (NDC 0009-4992-02)",Solution,,"N0000175495, M0361132",NDA021131,Oxazolidinones [CS],LINEZOLID,Oxazolidinone Antibacterial [EPC],,To Be Discontinued,,,,ISQ9I6J12J,0009-4992-02,844-646-4398,
"Actavis Pharma, Inc.",MEMANTINE HYDROCHLORIDE,,11/21/2024,New,ORAL,Memantine Hydrochloride Tablet,"996561, 996571, 996572",,72973b46-f307-4a9e-8fb1-ad2cbccfd736,11/21/2024,HUMAN PRESCRIPTION DRUG,11/21/2024,Neurology,MEMANTINE HYDROCHLORIDE,"0591-3870, 0591-3875, 0591-3900","Actavis Pharma, Inc.",985e1190-b8a0-4775-9a20-ad1924b14fb2,"0591-3870-60, 0591-3870-45, 0591-3870-44, 0591-3875-60, 0591-3875-45, 0591-3875-44, 0591-3900-87","Namenda, Tablet, 5 mg (NDC 0591-3870-44)",Tablet,,,NDA021487,,MEMANTINE HYDROCHLORIDE,,,To Be Discontinued,,,,JY0WD0UA60,0591-3870-44,800-545-8800,
"Avet Pharmaceuticals, Inc.",MIDAZOLAM HYDROCHLORIDE,,04/02/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Midazolam Hydrochloride Injection,311702,,843cc25e-45ea-4372-ae34-843f805fa869,09/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology",MIDAZOLAM HYDROCHLORIDE,23155-601,Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.,e20feff9-3aca-4bc1-a5c3-44fff8a9459c,"23155-601-31, 23155-601-41, 23155-601-32, 23155-601-42","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-41)",Injection,Available,,ANDA090850,,MIDAZOLAM HYDROCHLORIDE,,,Current,,,,W7TTW573JJ,23155-601-41,855-228-9470,
Eugia US LLC,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"309710, 1718906, 1718909",,8c162541-986b-4b30-866c-b2631ba2c975,09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE HYDROCHLORIDE,"55150-296, 55150-209, 55150-297",Eugia US LLC,cc0d3661-5f2e-43fb-a2ae-7d3f89c7e58c,"55150-209-02, 55150-296-10, 55150-297-10","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-296-10)",Injection,Available,,ANDA210321,,DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE,,,Current,,Check wholesalers for inventory,,1018WH7F9I,55150-296-10,888-238-7880,
"Fresenius Kabi USA, LLC",HYDROMORPHONE HYDROCHLORIDE,,10/31/2017,Reverified,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Hydromorphone Hydrochloride Injection,"897653, 897753, 1724276, 1724338, 1724340, 1724341",,e034eb96-03e0-46e1-8b92-5e1f94555e7b,09/18/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,HYDROMORPHONE HYDROCHLORIDE,"63323-852, 63323-851, 63323-853, 63323-854","Fresenius Kabi USA, LLC",9e8522c6-595c-46f9-bb25-272aa4683e0f,"63323-851-03, 63323-851-10, 63323-851-07, 63323-851-15, 63323-851-50, 63323-852-03, 63323-852-25, 63323-853-03, 63323-853-25, 63323-854-03, 63323-854-10","Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-852-25)",Injection,Available,,NDA019034,,HYDROMORPHONE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,L960UP2KRW,63323-852-25,888-386-1300,
Sun Pharmaceutical Industries Limited,IMATINIB MESYLATE,,12/05/2024,New,ORAL,Imatinib Mesylate Tablet,"403878, 403879",,07764bf9-21b4-4e32-9d7e-e348f8e4291f,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Hematology,IMATINIB MESYLATE,"47335-472, 47335-475","Sun Pharmaceutical Industries, Inc.",ad13dbca-474d-4492-9c25-e0e175143d8c,"47335-472-83, 47335-472-88, 47335-472-13, 47335-472-81, 47335-475-83, 47335-475-88, 47335-475-13, 47335-475-64","Imatinib Mesylate, Tablet, 100 mg (NDC 47335-472-13)",Tablet,,,ANDA078340,,IMATINIB MESYLATE,,,To Be Discontinued,,Discontinuing for business reasons,,8A1O1M485B,47335-472-13,800-818-4555,
"Hikma Pharmaceuticals USA, Inc.",KETOROLAC TROMETHAMINE,,06/06/2018,Revised,"INTRAMUSCULAR, INTRAVENOUS",Ketorolac Tromethamine Injection,"860092, 1665459, 1665461",,0c2c75c9-ed7b-46a8-9543-429bf2d8f090,07/23/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,KETOROLAC TROMETHAMINE,"0641-6042, 0641-6043, 0641-6041",Hikma Pharmaceuticals USA Inc.,25d6c438-45d2-4162-91c2-b5caa0f86bf3,"0641-6043-01, 0641-6043-25, 0641-6042-01, 0641-6042-25, 0641-6041-01, 0641-6041-25","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6042-25)",Injection,Unavailable,,ANDA075772,,KETOROLAC TROMETHAMINE,,,Current,Other,Shortage recovery: TBD,,4EVE5946BQ,0641-6042-25,800-631-2174,
"Hikma Pharmaceuticals USA, Inc.",MORPHINE SULFATE,,11/03/2017,Reverified,"EPIDURAL, INTRATHECAL, INTRAVENOUS",Morphine Sulfate Injection,"892473, 892489, 1728783, 1728800",,ebb18761-e5c4-4238-bb84-f9549f500210,07/23/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,DURAMORPH,"0641-6020, 0641-6019",Hikma Pharmaceuticals USA Inc.,d8bb0ae2-68bc-40ff-ad67-867bb8b71bc7,"0641-6020-01, 0641-6020-10, 0641-6019-01, 0641-6019-10","Duramorph (Morphine Sulfate Injection, USP), Injection, .5 mg/1 mL (NDC 0641-6020-10)",Injection,Available,,NDA018565,,MORPHINE SULFATE,,,Current,,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,X3P646A2J0,0641-6020-10,800-631-2174,
Alvogen,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,c907301d-e24d-9609-5529-fed14f94549f,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII","47781-178, 47781-174, 47781-175, 47781-176, 47781-177, 47781-179, 47781-180",Alvogen Inc.,0374f0f7-9297-810c-38b3-623a72709a7d,"47781-174-30, 47781-174-05, 47781-174-01, 47781-175-30, 47781-175-05, 47781-175-01, 47781-176-30, 47781-176-05, 47781-176-01, 47781-177-30, 47781-177-05, 47781-177-01, 47781-178-30, 47781-178-05, 47781-178-01, 47781-179-30, 47781-179-05, 47781-179-01, 47781-180-30, 47781-180-05, 47781-180-01","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 47781-178-01)",Tablet,Available,,ANDA207388,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 15 MG,CLL",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",47781-178-01,844-842-8672 and email: CustomerService-US@alvogen.com,
Chartwell Molecular Holdings LLC,QUINAPRIL HYDROCHLORIDE,,01/19/2023,Reverified,ORAL,Quinapril Hydrochloride Tablet,"312748, 312749, 312750, 314203",,dbc43dbd-94aa-40e2-a9ea-766110cc8687,08/19/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,QUINAPRIL,"62135-485, 62135-484, 62135-486, 62135-487","Chartwell RX, LLC",09cd5cb9-4fdf-f133-e063-6294a90af691,"62135-484-60, 62135-485-90, 62135-486-90, 62135-487-90","Quinapril Hydrochloride, Tablet, 10 mg (NDC 62135-485-90)",Tablet,Available,,ANDA076803,,QUINAPRIL,,,Current,,,,33067B3N2M,62135-485-90,845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com,
"Hospira, Inc., a Pfizer Company",SODIUM BICARBONATE,,03/01/2017,Revised,INTRAVENOUS,Sodium Bicarbonate Injection,2198792,,85ac5491-eb50-4bd1-b5ed-c34457632311,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Pediatric",SODIUM BICARBONATE,0409-5534,"Hospira, Inc.",a212b6af-ae47-44c9-a89f-01e0540fddb7,"0409-5534-24, 0409-5534-14","Sodium Bicarbonate, Injection, 5 mEq/10 mL (4.2%, 0.5 mEq/mL) Syringes (NDC 0409-5534-14)",Injection,Unavailable,,ANDA202679,,SODIUM BICARBONATE,,,Current,Other,Next Delivery and Estimated Recovery: December 2025,01/03/2025,8MDF5V39QO,0409-5534-14,844-646-4398,
"Upsher-Smith Laboratories, LLC",AMANTADINE HYDROCHLORIDE,,07/23/2025,New,ORAL,Amantadine Hydrochloride Tablet,849395,,63d9d4aa-5f92-45b0-98d0-d6ec38b727cb,07/23/2025,HUMAN PRESCRIPTION DRUG,07/23/2025,"Antiviral, Neurology",AMANTADINE HYDROCHLORIDE,0832-0111,"Upsher-Smith Laboratories, LLC",395d9ef2-7ea2-c602-e063-6394a90a6ef0,"0832-0111-00, 0832-0111-50, 0832-0111-89, 0832-0111-03","Amantadine Hydrochloride, Tablet, 100 mg (NDC 0832-0111-03)",Tablet,,,ANDA076186,,AMANTADINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug product,,M6Q1EO9TD0,0832-0111-03,763-315-2000,
"Fresenius Kabi USA, LLC",CARBOPLATIN,,04/28/2023,Reverified,INTRAVENOUS,Carboplatin Injection,597195,,b4fa7aac-c9d2-4af4-a281-3e6cfc502ff6,09/18/2025,HUMAN PRESCRIPTION DRUG,,Oncology,CARBOPLATIN,63323-172,"Fresenius Kabi USA, LLC",3a1dd588-13b0-4d58-8d46-3a25a4fc6b40,63323-172-60,"Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60)",Injection,Available,"N0000175413, N0000175073",ANDA077266,,CARBOPLATIN,Platinum-based Drug [EPC],,Current,,Check wholesalers for inventory,,BG3F62OND5,63323-172-60,888-386-1300,
Apotex Corp.,GEFITINIB,,02/05/2025,New,ORAL,Gefitinib Tablet,349472,,257a3e9c-019e-ef38-de25-1ebd7585c3ea,02/05/2025,HUMAN PRESCRIPTION DRUG,02/05/2025,Oncology,GEFITINIB,60505-4512,Apotex Corp.,54a3934f-8705-b2e7-f5c5-a85ac5c546d8,"60505-4512-1, 60505-4512-3","Gefitinib, Tablet, 250 mg (NDC 60505-4512-3)",Tablet,,"N0000175605, N0000175076",ANDA209532,,GEFITINIB,Kinase Inhibitor [EPC],,To Be Discontinued,,,,S65743JHBS,60505-4512-3,800-706-5575,Protein Kinase Inhibitors [MoA]
"Hospira, Inc., a Pfizer Company",OXAPROZIN,,07/17/2025,New,ORAL,Oxaprozin Tablet,"207243, 312132",,ea1de47e-3101-4414-817c-0a098af8988c,07/17/2025,HUMAN PRESCRIPTION DRUG,07/17/2025,Analgesia/Addiction,DAYPRO,0025-1381,Pfizer Laboratories Div Pfizer Inc,b8c736b5-aa87-41f8-a25a-dd3c5654a4be,"0025-1381-31, 0025-1381-34, 0025-1381-51","Daypro, Tablet, 600 mg (NDC 0025-1381-31)",Tablet,,"N0000000160, M0001335, N0000175722",NDA018841,"Anti-Inflammatory Agents, Non-Steroidal [CS]",OXAPROZIN,Nonsteroidal Anti-inflammatory Drug [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug.,,MHJ80W9LRB,0025-1381-31,800-533-4535,Cyclooxygenase Inhibitors [MoA]
"Mylan Institutional, a Viatris Company",DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,309710,,ebdfe2e8-30ca-4f18-935a-41bcbbce4937,09/17/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE,67457-251,Mylan Institutional LLC,7c66a6ac-0548-4555-b9d1-077feb277c37,"67457-251-00, 67457-251-02","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 67457-251-02)",Injection,Available,,ANDA202881,,DEXMEDETOMIDINE,,,Current,,,,1018WH7F9I,67457-251-02,800-796-9526,
Torrent Pharma Inc.,,,06/13/2025,New,,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,,,,06/13/2025,,06/13/2025,Cardiovascular,,,,,,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 25 mg; 40 mg (NDC 13668-382-30)",Tablet,,,,,,,,To Be Discontinued,,A business decision was made to discontinue manufacture of the product.,,,13668-382-30,908-280-3333,
Pfizer Inc.,METHYLPREDNISOLONE ACETATE,,12/15/2021,Revised,"INTRALESIONAL, INTRAMUSCULAR, INTRASYNOVIAL, SOFT TISSUE",Methylprednisolone Acetate Injection,"1358510, 1358512, 1358610, 1358612, 1358617, 1358619",,823b0010-2b57-4e76-b5ac-4a8c2963438f,08/15/2025,HUMAN PRESCRIPTION DRUG,,Rheumatology,DEPO-MEDROL,"0009-0280, 0009-0274, 0009-0306",Pharmacia & Upjohn Company LLC,4cf5a255-1360-4511-9b58-b92e3492ef12,"0009-0274-01, 0009-0280-02, 0009-0280-51, 0009-0280-03, 0009-0280-52, 0009-0306-02, 0009-0306-12","Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-51)",Injection,Unavailable,,NDA011757,,METHYLPREDNISOLONE ACETATE,,,Current,Demand increase for the drug,Next Delivery: August 2025; Estimated Recovery: September 2025,,43502P7F0P,0009-0280-51,844-646-4398,
"Bausch Health Americas, Inc.",PIMECROLIMUS,,02/28/2025,New,TOPICAL,Pimecrolimus Cream,"352085, 562806",,e4027e5a-0f9b-4070-b196-f60172f45c4c,02/28/2025,HUMAN PRESCRIPTION DRUG,02/28/2025,Dermatology,ELIDEL,"0187-5100, 0187-5102, 0187-5101, 0187-5103","Bausch Health US, LLC",2f802a3f-c021-45c1-8693-5689c30c3fc6,"0187-5102-03, 0187-5101-02, 0187-5100-01, 0187-5103-04","Elidel, Cream, 30gm (NDC 0187-5100-01)",Cream,,"N0000175457, N0000175458",NDA021302,,PIMECROLIMUS,Calcineurin Inhibitor Immunosuppressant [EPC],,To Be Discontinued,,Authorized generic is still marketed and available under NDC 68682-110-01,,7KYV510875,0187-5100-01,908-927-1400,Calcineurin Inhibitors [MoA]
"Fresenius Kabi USA, LLC",,,07/24/2017,Revised,,Sodium Bicarbonate Injection,,,,09/18/2025,,,"Endocrinology/Metabolism, Gastroenterology, Pediatric",,,,,,"Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 63323-083-05)",Injection,Unavailable,,,,,,,Current,Other,Backordered. Next release October 2025. Check wholesalers for inventory.,,,63323-083-05,888-386-1300,
"Mylan Pharmaceuticals Inc., a Viatris Company",,,02/14/2025,New,,Erythromycin  Topical Gel,,,,02/14/2025,,02/14/2025,"Anti-Infective, Dermatology",,,,,,"Erygel, Topical Gel, 20 mg/1 g (NDC 0378-8075-60)",Topical Gel,,,,,,,,To Be Discontinued,,,,,0378-8075-60,800-796-9526,
Otsuka ICU Medical LLC,"CALCIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, SODIUM LACTATE",,10/11/2024,Reverified,INTRAVENOUS,Lactated Ringers Injection,"847627, 847630",,d310d170-5eeb-471b-af1a-0e845001d21d,09/17/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other",LACTATED RINGERS,"0990-7953, 0990-7929",ICU Medical Inc.,f0f79123-edc9-43ff-a696-0356b6f03952,"0990-7929-03, 0990-7929-09, 0990-7953-02, 0990-7953-03, 0990-7953-09","Lactated Ringers, Injection, 20 mg/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0990-7953-03)",Injection,Available,,NDA017641,,"SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, AND CALCIUM CHLORIDE",,,Current,,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,"LX22YL083G, 660YQ98I10, TU7HW0W0QT, 451W47IQ8X, M4I0D6VV5M",0990-7953-03,1-866-829-9025 or ProductAvailability@icumed.com,
Sandoz Inc.,TRAVOPROST,,03/18/2025,New,OPHTHALMIC,Travoprost Solution/Drops,284008,,c17aa704-1ec6-4610-a448-4964bdb1cba1,03/18/2025,HUMAN PRESCRIPTION DRUG,03/18/2025,Ophthalmology,TRAVOPROST OPHTHALMIC SOLUTION,0781-6185,Sandoz Inc,ed706e46-4b7c-44ed-9e23-22a39061af45,"0781-6185-56, 0781-6185-75","Travatan Z, Solution/Drops, 2.5 mL (NDC 0781-6185-56)",Solution/Drops,,"N0000175454, M0017805",NDA021994,Prostaglandins [CS],TRAVOPROST,Prostaglandin Analog [EPC],,To Be Discontinued,,Business related decision to discontinue the product,,WJ68R08KX9,0781-6185-56,800-525-8747,
Baxter Healthcare,"ALANINE, ARGININE, GLYCINE, HISTIDINE, ISOLEUCINE, LEUCINE, LYSINE HYDROCHLORIDE, METHIONINE, PHENYLALANINE, PROLINE, SERINE, THREONINE, TRYPTOPHAN, TYROSINE, VALINE",,12/08/2020,Revised,INTRAVENOUS,Amino Acid Injection,"801644, 801648",,8543b5be-0f43-4891-9e56-d7c39fe839b5,09/23/2025,HUMAN PRESCRIPTION DRUG,,Gastroenterology,TRAVASOL,0338-0644,Baxter Healthcare Corporation,e0279078-016d-48fd-8de1-c894422b33ff,"0338-0644-03, 0338-0644-04, 0338-0644-06","Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)",Injection,Unavailable,"N0000175780, M0000922",NDA018931,Amino Acids [CS],"LEUCINE, PHENYLALANINE, LYSINE HYDROCHLORIDE, METHIONINE, ISOLEUCINE, VALINE, HISTIDINE, THREONINE, TRYPTOPHAN, ALANINE, GLYCINE, ARGININE, PROLINE, TYROSINE, SERINE",Amino Acid [EPC],,Current,Other,Recovery in October 2025,,"OF5P57N2ZX, 94ZLA3W45F, TE7660XO1C, 4QD397987E, 04Y7590D77, GMW67QNF9C, JNJ23Q2COM, AE28F7PNPL, 47E5O17Y3R, 9DLQ4CIU6V, 452VLY9402, 2ZD004190S, 8DUH1N11BX, 42HK56048U, HG18B9YRS7",0338-0644-03,888-229-0001,
"Hospira, Inc., a Pfizer Company",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Revised,"EPIDURAL, RETROBULBAR",Bupivacaine Hydrochloride Injection,"1012377, 1012381, 1012384, 1012388, 1012396, 1012400, 1012404, 1012406, 1672917, 1672919, 1673242, 1673243, 1724786, 1724787, 1724794, 1724796, 1724880, 1724884, 1725044, 1725046, 1725078, 1725079, 1725082, 1725083, 1867594, 1867596, 1867612, 1867614",,67578b56-7540-487e-1fba-481255620e78,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,MARCAINE,"0409-1582, 0409-1559, 0409-1560, 0409-1587, 0409-1610, 0409-1746, 0409-1749, 0409-1752, 0409-1755, 0409-2510, 0409-7535, 0409-1250, 0409-5010, 0409-1530, 0409-0525, 0409-7510, 0409-2253","Hospira, Inc.",b083f440-bfb7-449a-b601-c2f59a6f9dcf,"0409-1559-18, 0409-1559-10, 0409-1559-19, 0409-1559-30, 0409-1560-18, 0409-1560-10, 0409-1560-19, 0409-1560-29, 0409-1582-18, 0409-1582-10, 0409-1582-19, 0409-1582-29, 0409-1587-50, 0409-1610-50, 0409-1746-70, 0409-1746-10, 0409-1746-71, 0409-1746-30, 0409-1749-70, 0409-1749-10, 0409-1749-71, 0409-1749-29, 0409-1752-50, 0409-1755-50, 0409-2510-01, 0409-2510-25, 0409-7535-01, 0409-7535-25, 0409-1250-01, 0409-1250-25, 0409-5010-01, 0409-5010-25, 0409-1530-01, 0409-1530-25, 0409-0525-01, 0409-0525-25, 0409-7510-01, 0409-7510-25, 0409-2253-01, 0409-2253-25","Marcaine, Injection, Marcaine 75 mg/10 mL (7.5 mg/mL) (NDC 0409-1582-10)",Injection,Limited Availability,,NDA016964,,BUPIVACAINE HYDROCHLORIDE,,,Current,Other,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: December 2025,,"30Q7KI53AK, 7TQO7W3VT8",0409-1582-10,844-646-4398,
"Assertio Specialty Pharmaceuticals, LLC",METHOTREXATE,,08/29/2025,New,SUBCUTANEOUS,Methotrexate Injection,"1441402, 1441407, 1441411, 1441413, 1441416, 1441418, 1441422, 1441424, 1747179, 1747181, 1747185, 1747187, 1747192, 1747194",,7dcd02d7-1ce0-43fc-8f25-2f0bb0caba2f,08/29/2025,HUMAN PRESCRIPTION DRUG,08/29/2025,Rheumatology,OTREXUP,"82497-015, 82497-010, 82497-012, 82497-017, 82497-020, 82497-022, 82497-025","Otter Pharmaceuticals, LLC",9aaba145-f343-4498-b754-fb7c78181bd7,"82497-010-02, 82497-010-04, 82497-012-02, 82497-012-04, 82497-015-02, 82497-015-04, 82497-017-02, 82497-017-04, 82497-020-02, 82497-020-04, 82497-022-02, 82497-022-04, 82497-025-02, 82497-025-04","Otrexup, Injection, 15 mg/.4 mL (NDC 82497-015-04)",Injection,,"N0000175584, N0000000111",NDA204824,,METHOTREXATE,Folate Analog Metabolic Inhibitor [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,YL5FZ2Y5U1,82497-015-04,224-441-6390,Folic Acid Metabolism Inhibitors [MoA]
"Mylan Pharmaceuticals Inc., a Viatris Company",METHYLPHENIDATE,Central Nervous System Stimulation [PE],02/28/2025,Reverified,TRANSDERMAL,"Methylphenidate Film, Extended Release","753436, 753438, 753440, 753441",,1643b6a5-80da-4d4f-8c5f-feb907875702,09/17/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE,"0378-8260, 0378-8261, 0378-8262, 0378-8263",Mylan Pharmaceuticals Inc.,c17e03ec-3756-4043-ae82-33a0ef18380c,"0378-8260-16, 0378-8260-93, 0378-8261-16, 0378-8261-93, 0378-8262-16, 0378-8262-93, 0378-8263-16, 0378-8263-93","Methylphenidate, Film, Extended Release, 10mg/9hrs (NDC 0378-8260-93)","Film, Extended Release",Available,"N0000175739, N0000175729",ANDA206497,,METHYLPHENIDATE,Central Nervous System Stimulant [EPC],,Current,,,,207ZZ9QZ49,0378-8260-93,800-796-9526,
"Epic Pharma, LLC","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961",,1757e132-061d-4773-89ed-fdc77f69008f,09/18/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","42806-345, 42806-339, 42806-341, 42806-343, 42806-344","Epic Pharma, LLC",f11301e2-3b5d-468d-b44c-45839e7e5dfb,"42806-339-01, 42806-341-01, 42806-343-01, 42806-344-01, 42806-345-01","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)",Tablet,Limited Availability,,ANDA040444,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,Shortage of an active ingredient,Limited availability until end of September 2025,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",42806-345-01,(718) 276-8600 ext. 3,
Aurobindo Pharma USA,"HYDROCHLOROTHIAZIDE, QUINAPRIL HYDROCHLORIDE",Increased Diuresis [PE],01/19/2023,Reverified,ORAL,Quinapril/Hydrochlorothiazide Tablet,"310796, 310797, 310809",,50a58159-9572-4445-9859-b392632597da,09/17/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE,"65862-163, 65862-161, 65862-162",Aurobindo Pharma Limited,5842ecc2-874a-481b-8997-afa9d862dc5d,"65862-161-90, 65862-162-30, 65862-162-90, 65862-163-90","Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 65862-163-90)",Tablet,Discontinued,"N0000175359, N0000175419, M0471776",ANDA078450,Thiazides [CS],QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE,Thiazide Diuretic [EPC],,Current,Discontinuation of the manufacture of the drug,,,"0J48LPH2TH, 33067B3N2M",65862-163-90,866-850-2876,
B. Braun Medical Inc.,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807639, 1807551, 1807552, 1807633, 1807634",,"47a0313f-36df-4fa6-a828-c9e1946ba9b0, 7f22c06b-6b4d-4b49-a4b2-d2169f2bd653",08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0264-7800, 0264-7802",B. Braun Medical Inc.,"318417ff-d599-47b8-8181-89c3bb3b2e8d, 9fa9f6b4-63b5-4632-8104-37c3dd1ee8fa","0264-7800-09, 0264-7800-00, 0264-7800-10, 0264-7800-20, 0264-7802-00, 0264-7802-10","Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-7800-00)",Injection,,,NDA019635,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0264-7800-00,800-227-2862,
"Hikma Pharmaceuticals USA, Inc.",MEPERIDINE HYDROCHLORIDE,,05/30/2025,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Meperidine Hydrochloride Injection,"861476, 1665685, 1665697",,e0e998da-f056-4fce-be8e-ed60cf3b461b,07/23/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,MEPERIDINE HYDROCHLORIDE,"0641-6052, 0641-6053, 0641-6054",Hikma Pharmaceuticals USA Inc.,9566d54d-7343-4695-94ff-8b5f2d384c81,"0641-6053-01, 0641-6053-25, 0641-6054-01, 0641-6054-25, 0641-6052-01, 0641-6052-25","Meperidine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6052-25)",Injection,Unavailable,,ANDA080445,,MEPERIDINE HYDROCHLORIDE,,,Current,Shortage of an active ingredient,Additional Lots scheduled to be available in the October-November 2025 timeframe.,,N8E7F7Q170,0641-6052-25,800-631-2174,
"Vertical Pharmaceuticals, LLC",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Reverified,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release",,,22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d,09/16/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,RELEXXII,"68025-098, 68025-088, 68025-089, 68025-095, 68025-096, 68025-097, 68025-084","Vertical Pharmaceuticals, LLC",86f477e9-07fc-466b-913e-1a4434c91df4,"68025-088-30, 68025-089-30, 68025-095-10, 68025-095-30, 68025-096-10, 68025-096-30, 68025-097-10, 68025-097-30, 68025-084-30, 68025-098-10, 68025-098-30","Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-30)",Tablet,Available,,NDA216117,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,,,,4B3SC438HI,68025-098-30,800-541-4802,
Baxter Healthcare,DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795477, 1795480, 1795481, 1795607, 1795609, 1795610, 1795612, 1795616, 1795618",,3bb406a9-f5cb-403a-b1bb-5c4facbea3d5,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0338-0017, 0338-0023",Baxter Healthcare Corporation,31bb4a5f-733e-4354-9fbf-138dede4db0f,"0338-0017-10, 0338-0017-41, 0338-0017-11, 0338-0017-31, 0338-0017-48, 0338-0017-18, 0338-0017-38, 0338-0017-02, 0338-0017-03, 0338-0017-04, 0338-0023-02, 0338-0023-03, 0338-0023-04","Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-48)",Injection,Available,,NDA016673,,DEXTROSE MONOHYDRATE,,,Current,,,,LX22YL083G,0338-0017-48,888-229-0001,
"Hospira, Inc., a Pfizer Company",KETOROLAC TROMETHAMINE,,03/26/2018,Revised,"INTRAMUSCULAR, INTRAVENOUS",Ketorolac Tromethamine Injection,"860092, 1665459, 1665461",,8accbb78-fc64-45d5-69b0-35c23a1d2a2e,08/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,KETOROLAC TROMETHAMINE,"0409-3793, 0409-3795, 0409-3796","Hospira, Inc.",60f4ed51-f1c1-45d4-b43a-969678901bdd,"0409-3793-19, 0409-3793-01, 0409-3793-25, 0409-3795-19, 0409-3795-01, 0409-3795-25, 0409-3796-19, 0409-3796-01, 0409-3796-25","Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0409-3793-01)",Injection,Limited Availability,,ANDA074802,,KETOROLAC TROMETHAMINE,,,Current,Other,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,4EVE5946BQ,0409-3793-01,844-646-4398,
pharmaand GmbH (pharma&),PEGINTERFERON ALFA-2A,,01/24/2025,Revised,SUBCUTANEOUS,Peginterferon alfa-2a Injection,"351270, 352297, 731326, 731328",,d9290e5b-6d40-2318-e053-2995a90a9916,08/19/2025,HUMAN PRESCRIPTION DRUG,,Antiviral,PEGASYS,"82154-0451, 82154-0449",pharmaand GmbH,3c18e4a2-193f-ef4e-e063-6394a90a56b2,"82154-0449-1, 82154-0451-4","Pegasys, Injection, 180 ug/.5 mL (NDC 82154-0451-4)",Injection,Limited Availability,"N0000175521, M0025711",BLA103964,Interferon-alpha [CS],PEGINTERFERON ALFA-2A,Interferon alpha [EPC],,Current,Shortage of an active ingredient,"Pegasys availability will become more limited through Q4 2025. Product replenishment is expected sometime in 2026 and before May 31, 2026.",,Q46947FE7K,82154-0451-4,"800-506-8501, email: medinfo.us@pharmaand.com",
"Actavis Pharma, Inc.",PILOCARPINE HYDROCHLORIDE,,09/19/2025,New,ORAL,Pilocarpine Hydrochloride Tablet,"1000913, 1001004",,610022b7-7dc9-405a-a580-104657f43bdf,09/19/2025,HUMAN PRESCRIPTION DRUG,09/19/2025,Other,PILOCARPINE HYDROCHLORIDE,"0228-2837, 0228-2801","Actavis Pharma, Inc.",7db72b88-d664-4f26-901c-46c901b20d80,"0228-2801-11, 0228-2837-11","Salagen, Tablet, 7.5 mg (NDC 0228-2837-11)",Tablet,,,NDA020237,,PILOCARPINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug.,,0WW6D218XJ,0228-2837-11,800-545-8800,
"Fresenius Kabi USA, LLC",DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718900, 1718906, 1718909",,4d5d2294-89a0-4b6f-aa00-d39a0393b6a8,09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE HYDROCHLORIDE,63323-671,"Fresenius Kabi USA, LLC",27411591-44a1-44c4-89c3-dd8c2687f0e2,"63323-671-02, 63323-671-20, 63323-671-05, 63323-671-50, 63323-671-01, 63323-671-00","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-00)",Injection,Unavailable,,ANDA208129,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,Delay in shipping of the drug,Not available at this time.,,1018WH7F9I,63323-671-00,888-386-1300,
"Hospira, Inc., a Pfizer Company","EPINEPHRINE, LIDOCAINE HYDROCHLORIDE",,02/22/2012,Reverified,"INFILTRATION, PERINEURAL","Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","1010688, 1010745, 1010751, 1010759, 1867996, 1867998",,2f94f711-14c4-48ec-c5a3-c5ec4b8e8729,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE,"0409-3182, 0409-1209, 0409-3177, 0409-3178, 0409-3181, 0409-3183, 0409-0007, 0409-0147","Hospira, Inc.",d16a4711-e663-455e-a1fe-236a41ca4e8f,"0409-1209-10, 0409-1209-01, 0409-1209-05, 0409-1209-70, 0409-1209-65, 0409-3177-16, 0409-3177-01, 0409-3178-16, 0409-3178-01, 0409-3178-17, 0409-3178-02, 0409-3178-18, 0409-3178-03, 0409-3181-11, 0409-3181-01, 0409-3182-11, 0409-3182-01, 0409-3182-21, 0409-3182-02, 0409-3182-31, 0409-3182-03, 0409-3183-11, 0409-3183-01, 0409-0007-01, 0409-0007-10, 0409-0147-01, 0409-0147-10","Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:100,000) (NDC 0409-3182-01)",Injection,Available,"N0000000209, N0000000245, N0000175552, N0000175555, N0000175570, M0003647",ANDA089646,Catecholamines [CS],LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE,"alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC], Catecholamine [EPC]",,Current,,,,"V13007Z41A, YKH834O4BH",0409-3182-01,844-646-4398,"Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA]"
"Actavis Pharma, Inc.",EZETIMIBE,Decreased Cholesterol Absorption [PE],06/27/2025,New,ORAL,Ezetimibe Tablet,349556,,f26e7a4e-b3d9-4cf8-baf0-7423d46cd8ba,06/27/2025,HUMAN PRESCRIPTION DRUG,06/27/2025,Cardiovascular,EZETIMIBE,0591-3713,"Actavis Pharma, Inc.",24aaf5ca-08e0-4db8-9734-cf2a606f8e57,"0591-3713-30, 0591-3713-19, 0591-3713-05","Ezetimibe, Tablet, 10 mg (NDC 0591-3713-19)",Tablet,,"N0000008553, N0000175911",ANDA200831,,EZETIMIBE,Dietary Cholesterol Absorption Inhibitor [EPC],,To Be Discontinued,,A business decision was made to discontinue manufacture of the product,,EOR26LQQ24,0591-3713-19,800-545-8800,
Sandoz Inc.,AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","239191, 308182, 308189, 308191, 308192, 308194, 313797, 313850",,13bd4214-9b7f-425b-af5f-fc1ddc678230,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0781-6156, 0781-2020, 0781-2613, 0781-5060, 0781-5061, 0781-6039, 0781-6041, 0781-6157",Sandoz Inc,6aa02079-d11c-4d2f-acaf-9548dd9a7ed6,"0781-2020-31, 0781-2020-76, 0781-2020-01, 0781-2020-05, 0781-2613-31, 0781-2613-76, 0781-2613-01, 0781-2613-05, 0781-5060-20, 0781-5060-01, 0781-5061-20, 0781-5061-01, 0781-6039-58, 0781-6039-46, 0781-6039-55, 0781-6156-52, 0781-6156-57, 0781-6156-46, 0781-6041-58, 0781-6041-46, 0781-6041-55, 0781-6157-52, 0781-6157-57, 0781-6157-46","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0781-6156-46)","Powder, For Suspension",,,ANDA065378,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0781-6156-46,800-525-8747,
"Hospira, Inc., a Pfizer Company",MEPERIDINE HYDROCHLORIDE,,05/30/2025,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Meperidine Hydrochloride Injection,"860792, 861463, 861473, 861493, 861494, 861522, 861529, 861617, 1242106, 1242503, 2539186, 2539188, 2539191, 2539192",,b31d1308-28c3-43f4-e0a6-2f3ed76b8975,08/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,DEMEROL,"0409-1362, 0409-1181, 0409-1176, 0409-1178, 0409-1179, 0409-1180, 0409-1418","Hospira, Inc.",1271f15f-ccda-4892-8fb0-9bb2d38ded4a,"0409-1181-30, 0409-1176-03, 0409-1176-30, 0409-1178-03, 0409-1178-30, 0409-1179-03, 0409-1179-30, 0409-1180-59, 0409-1180-69, 0409-1362-11, 0409-1362-01, 0409-1418-11, 0409-1418-01","Demerol, Injection, 25 mg/1 mL (NDC 0409-1362-01)",Injection,Unavailable,,NDA021171,,MEPERIDINE HYDROCHLORIDE,,,Current,Discontinuation of the manufacture of the drug,,,N8E7F7Q170,0409-1362-01,844-646-4398,
"Sunrise Pharmaceutical, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,ac102599-3a5b-4154-899e-6ff262be7ff7,09/03/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","11534-192, 11534-190, 11534-191, 11534-193, 11534-194, 11534-195, 11534-196","SUNRISE PHARMACEUTICAL, INC.",86a00bec-51eb-4d73-a945-b1937970b29a,"11534-190-01, 11534-190-03, 11534-191-01, 11534-191-03, 11534-192-01, 11534-192-03, 11534-193-01, 11534-193-03, 11534-194-01, 11534-194-03, 11534-195-01, 11534-195-03, 11534-196-01, 11534-196-03","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 11534-192-01)",Tablet,Available,,ANDA209799,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",11534-192-01,732-382-6085 Monday to Friday 9 am to 3:45 pm,
"Fresenius Kabi USA, LLC",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Bupivacaine Hydrochloride Injection,"1724880, 1724881, 1725078, 1725175, 1724884, 1724885, 1725082, 1725177, 1672917, 1672919, 1673296, 1673298, 1012391, 1012396, 1012404, 1012421, 1012455, 1012457",,"e700eb7b-8b14-49c9-96b2-331f18776e45, b6bfc04a-1868-4630-9ca1-8c027af97ce3, dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175, eb6d8fee-def4-4c96-9972-695e8cea8ea8",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,SENSORCAINE MPF,"63323-464, 63323-466, 63323-462, 63323-465, 63323-467, 63323-460","Fresenius Kabi USA, LLC","b41b5dbd-7aff-4d97-ac97-f4355393ee4e, d3ba9fb9-63c8-4597-bb0a-cd01d31a24b6, 13a48007-3784-46f2-bd4d-da1004186b81, 2b1a1f80-cb29-4ac1-9e72-20225ed45715","63323-464-01, 63323-464-17, 63323-466-03, 63323-466-17, 63323-464-08, 63323-464-38, 63323-466-08, 63323-466-38, 63323-462-03, 63323-462-38, 63323-464-09, 63323-464-39, 63323-466-09, 63323-466-39, 63323-465-01, 63323-465-57, 63323-467-01, 63323-467-57, 63323-460-01, 63323-460-37, 63323-464-02, 63323-464-37, 63323-464-03, 63323-464-31, 63323-466-01, 63323-466-37, 63323-466-02, 63323-466-31, 63323-462-04, 63323-462-17, 63323-462-01, 63323-462-37, 63323-462-02, 63323-462-31","Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-31)",Injection,Unavailable,,"ANDA070552, NDA018304",,BUPIVACAINE HYDROCHLORIDE,,,Current,Demand increase for the drug,Not available at this time.,,"7TQO7W3VT8, 30Q7KI53AK",63323-464-31,888-386-1300,
"Hospira, Inc., a Pfizer Company","BUPIVACAINE HYDROCHLORIDE, EPINEPHRINE BITARTRATE",,02/20/2018,Reverified,"INFILTRATION, PERINEURAL","Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","1012377, 1012381, 1012384, 1012388, 1012396, 1012400, 1012404, 1012406, 1672917, 1672919, 1673242, 1673243, 1724786, 1724787, 1724794, 1724796, 1724880, 1724884, 1725044, 1725046, 1725078, 1725079, 1725082, 1725083, 1867594, 1867596, 1867612, 1867614",,67578b56-7540-487e-1fba-481255620e78,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,MARCAINE WITH EPINEPHRINE,"0409-1752, 0409-1559, 0409-1560, 0409-1582, 0409-1587, 0409-1610, 0409-1746, 0409-1749, 0409-1755, 0409-2510, 0409-7535, 0409-1250, 0409-5010, 0409-1530, 0409-0525, 0409-7510, 0409-2253","Hospira, Inc.",b083f440-bfb7-449a-b601-c2f59a6f9dcf,"0409-1559-18, 0409-1559-10, 0409-1559-19, 0409-1559-30, 0409-1560-18, 0409-1560-10, 0409-1560-19, 0409-1560-29, 0409-1582-18, 0409-1582-10, 0409-1582-19, 0409-1582-29, 0409-1587-50, 0409-1610-50, 0409-1746-70, 0409-1746-10, 0409-1746-71, 0409-1746-30, 0409-1749-70, 0409-1749-10, 0409-1749-71, 0409-1749-29, 0409-1752-50, 0409-1755-50, 0409-2510-01, 0409-2510-25, 0409-7535-01, 0409-7535-25, 0409-1250-01, 0409-1250-25, 0409-5010-01, 0409-5010-25, 0409-1530-01, 0409-1530-25, 0409-0525-01, 0409-0525-25, 0409-7510-01, 0409-7510-25, 0409-2253-01, 0409-2253-25","Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000) (NDC 0409-1752-50)",Injection,Available,,NDA016964,,BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE,,,Current,,,,"30Q7KI53AK, 7TQO7W3VT8",0409-1752-50,844-646-4398,
Rubicon Research Private Limited,CLONAZEPAM,,03/27/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"72888-153, 72888-152, 72888-154",Advagen Pharma Ltd,36cf156e-5980-a21b-e063-6294a90ab3a0,"72888-152-30, 72888-152-01, 72888-152-05, 72888-152-00, 72888-153-30, 72888-153-01, 72888-153-05, 72888-153-00, 72888-154-30, 72888-154-01, 72888-154-05, 72888-154-00","Clonazepam, Tablet, 1 mg (NDC 72888-153-01)",Tablet,Available,"N0000175694, M0002356",ANDA075468,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,Marketed by Advagen Pharma Ltd.,,5PE9FDE8GB,72888-153-01,sales@advagenpharma.com,
"EMD Serono, Inc.",LEVOTHYROXINE SODIUM,,07/10/2025,New,ORAL,Levothyroxine Sodium Tablet,"892246, 892251, 966153, 966160, 966166, 966173, 966177, 966182, 966187, 966196, 966202, 966207, 966220, 966221, 966222, 966224, 966225, 966248, 966249, 966253, 966270, 2104866",,bc3c6830-ba68-4ba3-9896-a12d0ad0b275,07/10/2025,HUMAN PRESCRIPTION DRUG,07/10/2025,Endocrinology/Metabolism,EUTHYROX,"72305-075, 72305-025, 72305-050, 72305-088, 72305-100, 72305-112, 72305-125, 72305-137, 72305-150, 72305-175, 72305-200","Provell Pharmaceuticals, LLC",45657074-8874-49f4-a8ef-3ca7e210c16e,"72305-025-30, 72305-025-90, 72305-050-30, 72305-050-90, 72305-075-30, 72305-075-90, 72305-088-30, 72305-088-90, 72305-100-30, 72305-100-90, 72305-112-30, 72305-112-90, 72305-125-30, 72305-125-90, 72305-137-30, 72305-137-90, 72305-150-30, 72305-150-90, 72305-175-30, 72305-175-90, 72305-200-30, 72305-200-90","Euthyrox, Tablet, 75 ug (NDC 72305-075-90)",Tablet,,,NDA021292,,LEVOTHYROXINE SODIUM,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,9J765S329G,72305-075-90,888-899-7041,
"Hospira, Inc., a Pfizer Company",LIDOCAINE HYDROCHLORIDE,,02/22/2012,Reverified,"INFILTRATION, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010671, 1010900, 1737343, 1737562, 1737566, 1737568, 1737636, 1737757, 1737763",,3b2dd84e-cee8-4e58-d494-395a65a353a0,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE HYDROCHLORIDE,"0409-4276, 0409-4713, 0409-4278, 0409-4279, 0409-4776, 0409-4282, 0409-4277, 0409-4275","Hospira, Inc.",c0b4635b-1473-4c48-89c6-620762cd687f,"0409-4713-12, 0409-4713-26, 0409-4713-02, 0409-4713-72, 0409-4713-62, 0409-4713-75, 0409-4713-65, 0409-4713-42, 0409-4713-25, 0409-4713-32, 0409-4278-16, 0409-4278-01, 0409-4279-16, 0409-4279-02, 0409-4776-10, 0409-4776-01, 0409-4282-11, 0409-4282-25, 0409-4282-01, 0409-4282-12, 0409-4282-02, 0409-4277-16, 0409-4277-01, 0409-4277-17, 0409-4277-02, 0409-4276-16, 0409-4276-01, 0409-4276-17, 0409-4276-02, 0409-4275-16, 0409-4275-01","Lidocaine Hydrochloride In Plastic Container, Injection, 200 mg/20 mL (1%; 10 mg/mL) (NDC 0409-4276-01)",Injection,Available,,ANDA088299,,LIDOCAINE HYDROCHLORIDE,,,Current,,,,V13007Z41A,0409-4276-01,844-646-4398,
Apotex Corp.,ADEFOVIR DIPIVOXIL,,07/29/2025,New,ORAL,Adefovir Dipivoxil Tablet,881341,,08e07fae-3191-b6a3-c894-d3a8cc53923f,07/29/2025,HUMAN PRESCRIPTION DRUG,07/29/2025,Antiviral,ADEFOVIR DIPIVOXIL,60505-3947,Apotex Corp.,bd0233d0-e141-a321-66a5-4afd09dbabfe,60505-3947-3,"Adefovir Dipivoxil, Tablet, 10 mg (NDC 60505-3947-3)",Tablet,,,ANDA205459,,ADEFOVIR DIPIVOXIL,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,U6Q8Z01514,60505-3947-3,800-706-5575,
"Fresenius Kabi USA, LLC",SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807631, 1807632, 1807633, 1807634, 1807639",,037ac04d-f8f3-4bb8-993a-ac8f7683ff83,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"65219-472, 65219-466, 65219-468, 65219-470, 65219-474","Fresenius Kabi USA, LLC",4110390b-2806-4c92-b283-a90115f89114,"65219-466-05, 65219-466-60, 65219-468-05, 65219-468-50, 65219-470-05, 65219-470-30, 65219-472-05, 65219-472-20, 65219-474-05, 65219-474-10","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 65219-472-20)",Injection,,,ANDA207310,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,65219-472-20,888-386-1300,
Teyro Labs,CARBOPLATIN,,04/28/2023,Reverified,INTRAVENOUS,Carboplatin Injection,597195,https://dps.fda.gov/drugshortages/discontinuations/carboplatin-injection,1c275825-0275-4c73-b650-e4c1519f13b8,09/29/2025,HUMAN PRESCRIPTION DRUG,,Oncology,CARBOPLATIN,60505-6282,Apotex Corp.,0e68e276-b0df-4f03-e063-6394a90a22b9,"60505-6282-1, 60505-6282-3, 60505-6282-6, 60505-6282-7","Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3)",Injection,Limited Availability,"N0000175413, N0000175073",ANDA077861,,CARBOPLATIN,Platinum-based Drug [EPC],,Current,Discontinuation of the manufacture of the drug,Discontinuation of the manufacture of the drug.,,BG3F62OND5,60505-6282-3,Apotex Inc.: 800-706-5575,
"Hospira, Inc., a Pfizer Company",HYDROMORPHONE HYDROCHLORIDE,,11/01/2017,Reverified,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Hydromorphone Hydrochloride Injection,"897756, 897757, 1433251, 1724383, 1724644, 1872271, 2675350",,f9ca2ef5-46d8-475a-a26e-f7c8becd6db7,08/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,HYDROMORPHONE HYDROCHLORIDE,"0409-1805, 0409-1283, 0409-1312, 0409-1380, 0409-4264","Hospira, Inc.",53b6867a-0ae3-48ff-b257-9e58cc76de9c,"0409-1283-17, 0409-1283-37, 0409-1312-16, 0409-1312-36, 0409-1380-11, 0409-1380-01, 0409-4264-11, 0409-4264-01, 0409-1805-10, 0409-1805-01","Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)",Injection,Available,,NDA200403,,HYDROMORPHONE HYDROCHLORIDE,,,Current,,,,L960UP2KRW,0409-1805-01,844-646-4398,
"Fresenius Kabi USA, LLC",LIDOCAINE HYDROCHLORIDE ANHYDROUS,,02/22/2012,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010035, 1010671, 1010673, 1010688, 1010692, 1010745, 1010749, 1010751, 1010755, 1010759, 1010763, 1010900, 1010902, 1737343, 1737345, 1737562, 1737563, 1737566, 1737567, 1737568, 1737569, 1737570, 1737571, 1737757, 1737758, 1737761, 1737762, 1867938, 1867940, 1867943, 1867944, 1867992, 1867993, 1867996, 1867997, 1868028, 1868029",,"ba082c2f-64f4-419d-9c88-74f203316e17, 4dd52202-8eef-4136-92dd-ada573b7cf74",09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",XYLOCAINE MPF,"63323-495, 63323-492, 63323-491, 63323-485, 63323-486, 63323-484, 63323-489, 63323-488, 63323-481, 63323-483, 63323-482, 63323-487","Fresenius Kabi USA, LLC","ea480a68-5927-4278-9deb-2956961da428, 0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33","63323-492-04, 63323-492-27, 63323-492-09, 63323-492-57, 63323-492-07, 63323-492-37, 63323-492-03, 63323-492-31, 63323-491-01, 63323-491-57, 63323-495-09, 63323-495-27, 63323-495-04, 63323-495-07, 63323-485-01, 63323-485-27, 63323-485-03, 63323-485-57, 63323-486-01, 63323-486-17, 63323-486-02, 63323-486-27, 63323-486-05, 63323-486-57, 63323-484-57, 63323-489-02, 63323-489-27, 63323-489-03, 63323-489-21, 63323-489-01, 63323-489-17, 63323-488-07, 63323-488-37, 63323-488-03, 63323-488-31, 63323-488-01, 63323-488-17, 63323-481-01, 63323-481-57, 63323-483-03, 63323-483-27, 63323-483-01, 63323-483-57, 63323-482-01, 63323-482-17, 63323-482-03, 63323-482-27, 63323-482-05, 63323-482-57, 63323-487-01, 63323-487-17, 63323-487-07, 63323-487-37, 63323-487-03, 63323-487-31, 63323-492-41, 63323-492-16, 63323-492-43, 63323-492-36, 63323-492-45, 63323-492-26, 63323-485-41, 63323-485-26, 63323-486-41, 63323-486-26, 63323-482-41, 63323-482-26, 63323-495-41, 63323-495-26","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-27)",Injection,Available,,NDA006488,,LIDOCAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,"EC2CNF7XFP, 30Q7KI53AK",63323-495-27,888-386-1300,
"Teva Pharmaceuticals USA, Inc.",PRAVASTATIN SODIUM,,06/13/2025,New,ORAL,Pravastatin Sodium Tablet,904481,,f66cb1c1-5ff1-4b0b-89d0-8ecaee26b0b8,06/13/2025,HUMAN PRESCRIPTION DRUG,06/13/2025,Cardiovascular,PRAVASTATIN SODIUM,0480-7270,"Teva Pharmaceuticals, Inc.",95e8c960-5096-43a9-8807-89cdf404a214,"0480-7270-98, 0480-7270-10","Pravastatin Sodium, Tablet, 80 mg (NDC 0480-7270-98)",Tablet,,,ANDA077793,,PRAVASTATIN SODIUM,,,To Be Discontinued,,,,3M8608UQ61,0480-7270-98,800-545-8800,
Pfizer Inc.,DOCETAXEL ANHYDROUS,Microtubule Inhibition [PE],06/24/2025,New,INTRAVENOUS,Docetaxel Injection,"1093280, 1860619",,00c61d11-d6b7-4618-b6f6-2592dbcc8af7,06/24/2025,HUMAN PRESCRIPTION DRUG,06/24/2025,Oncology,DOCETAXEL,"0409-0016, 0409-2026","Hospira, Inc.",8156a5f8-7002-479d-a08d-3c68f92c1396,"0409-2026-01, 0409-0016-01","Docetaxel, Injection, 160 mg/16 mL (10 mg/mL) Multiple Dose ONCO-TAIN™ Glass Fliptop Vial Novaplus®  (NDC 0409-0016-01)",Injection,,"N0000175085, N0000175592",NDA022234,,DOCETAXEL ANHYDROUS,Microtubule Inhibitor [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,699121PHCA,0409-0016-01,844-646-4398,
"Fresenius Kabi USA, LLC",FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Furosemide Injection,"1719286, 1719290, 1719291",,"3747bbcd-783d-4baa-bb5b-b6827bf390e3, c794c95a-654e-48fe-9596-201fc122ff75",09/18/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,63323-280,"Fresenius Kabi USA, LLC","9804efac-5457-417a-8de7-a688467759c0, 64b3fb5f-3516-4e39-b74e-e0e402ed9c4d","63323-280-41, 63323-280-16, 63323-280-43, 63323-280-26, 63323-280-45, 63323-280-36, 63323-280-01, 63323-280-02, 63323-280-03, 63323-280-04, 63323-280-05, 63323-280-10","Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-02)",Injection,Available,"N0000175366, N0000175590",NDA018902,,FUROSEMIDE,Loop Diuretic [EPC],,Current,,Check wholesalers for inventory,,7LXU5N7ZO5,63323-280-02,888-386-1300,
"Hospira, Inc., a Pfizer Company",HYDROCORTISONE SODIUM SUCCINATE,,03/24/2023,Revised,"INTRAMUSCULAR, INTRAVENOUS",Hydrocortisone Sodium Succinate Injection,"105398, 238755, 1738586, 1738589, 1738590, 1738592, 1738594, 1738596",,65eefd58-b166-4d71-ade6-45c8fdf86922,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Pulmonary/Allergy, Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Pediatric, Renal, Rheumatology",SOLU-CORTEF,"0009-0005, 0009-0825, 0009-0011, 0009-0013, 0009-0016",Pharmacia & Upjohn Company LLC,8512044a-4a54-4634-bb97-9e20126adc61,"0009-0825-01, 0009-0011-03, 0009-0011-04, 0009-0013-05, 0009-0013-06, 0009-0016-12, 0009-0005-01","Solu-cortef, Injection, 1000 mg/vial (NDC 0009-0005-01)",Injection,Limited Availability,,NDA009866,,HYDROCORTISONE SODIUM SUCCINATE,,,Current,Other,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,50LQB69S1Z,0009-0005-01,844-646-4398,
"Genentech, Inc",OSELTAMIVIR PHOSPHATE,,07/08/2025,New,ORAL,Oseltamivir Phosphate Capsule,"261315, 312122, 728109, 728111, 728113, 728115, 1115698, 1115700",,ee3c9555-60f2-4f82-a760-11983c86e97b,07/08/2025,HUMAN PRESCRIPTION DRUG,07/08/2025,Antiviral,TAMIFLU,"0004-0802, 0004-0801, 0004-0800, 0004-0822","Genentech, Inc.",7ab9f8e7-2dd7-4e79-b837-10582f2249ce,"0004-0802-85, 0004-0801-85, 0004-0800-85, 0004-0800-07, 0004-0800-08, 0004-0822-05","Tamiflu, Capsule, 30 mg (NDC 0004-0802-85)",Capsule,,,NDA021087,,OSELTAMIVIR PHOSPHATE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,4A3O49NGEZ,0004-0802-85,800-551-2231,
"Upsher-Smith Laboratories, LLC",OXYBUTYNIN CHLORIDE,,05/14/2025,New,ORAL,Oxybutynin Chloride Tablet,863664,,3ee6835a-7a7d-49a9-8460-2f1dd270ead3,05/14/2025,HUMAN PRESCRIPTION DRUG,05/14/2025,Renal,OXYBUTYNIN CHLORIDE,0832-0038,"Upsher-Smith Laboratories, LLC",2f3b30f0-e463-2de1-e063-6394a90a1b69,"0832-0038-00, 0832-0038-50, 0832-0038-10, 0832-0038-89, 0832-0038-01","Oxybutynin Chloride, Tablet, 5 mg (NDC 0832-0038-50)",Tablet,,,ANDA074625,,OXYBUTYNIN CHLORIDE,,,To Be Discontinued,,,,L9F3D9RENQ,0832-0038-50,800-654-2299,
Strides Pharma Inc.,DONEPEZIL HYDROCHLORIDE,,01/28/2025,New,ORAL,Donepezil Hydrochloride Tablet,"997223, 997229",,297e86e8-d248-4cc9-9d9c-2ef9efb4414d,01/28/2025,HUMAN PRESCRIPTION DRUG,01/28/2025,Neurology,DONEPEZIL HYDROCHLORIDE,"71093-128, 71093-127","ACI Healthcare USA, Inc.",a4736add-da84-411f-8e6f-9de67bf467f8,"71093-127-01, 71093-127-03, 71093-127-05, 71093-127-06, 71093-128-01, 71093-128-03, 71093-128-05, 71093-128-06","Donepezil Hydrochloride, Tablet, 10 mg (NDC 71093-128-05)",Tablet,,,ANDA078662,,DONEPEZIL HYDROCHLORIDE,,,To Be Discontinued,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,3O2T2PJ89D,71093-128-05,877-244-9825,
Sagent Pharmaceuticals,METHYLPREDNISOLONE ACETATE,,12/15/2021,Reverified,"INTRA-ARTICULAR, INTRALESIONAL, INTRAMUSCULAR, INTRASYNOVIAL, SOFT TISSUE",Methylprednisolone Acetate Injection,"1358610, 1358617",,f98314ea-a4e4-4f78-987b-3e9b45a08bb4,08/26/2025,HUMAN PRESCRIPTION DRUG,,Rheumatology,METHYLPREDNISOLONE ACETATE,"25021-820, 25021-821",Sagent Pharmaceuticals,13e1ca54-4fc4-4e93-a52d-c9320865e3cb,"25021-820-05, 25021-820-10, 25021-821-05","Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-05)",Injection,Available,,ANDA201835,,METHYLPREDNISOLONE ACETATE,,,Current,,,,43502P7F0P,25021-820-05,866-625-1618,
Pfizer Inc.,PENICILLIN G BENZATHINE,,04/26/2023,Revised,INTRAMUSCULAR,Penicillin G Benzathine Injection,"731564, 731566, 731567, 731568, 731570, 731571",https://www.fda.gov/media/188355/download,012d46f1-d0a0-4676-a879-cd320297ab16,08/25/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,BICILLIN L-A,"60793-700, 60793-701, 60793-702",Pfizer Laboratories Div Pfizer Inc,4b3694af-9d77-487f-8838-b75aec6636da,"60793-700-01, 60793-700-10, 60793-701-02, 60793-701-10, 60793-702-04, 60793-702-10","Bicillin L-A, Injection, 600000 [iU]/1 mL (NDC 60793-700-10)",Injection,Unavailable,,NDA050141,,PENICILLIN G BENZATHINE,,,Current,Demand increase for the drug,Next Delivery: October 2025; Estimated Recovery: December 2025,,RIT82F58GK,60793-700-10,844-646-4398,
"Lupin Pharmaceuticals, Inc.",QUINAPRIL HYDROCHLORIDE,,01/19/2023,Reverified,ORAL,Quinapril Hydrochloride Tablet,"312748, 312749, 312750, 314203",,8ded0773-3aec-4e89-9836-d22a5a84abf0,09/18/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,QUINAPRIL,"68180-557, 68180-556, 68180-558, 68180-554, 68180-559","Lupin Pharmaceuticals, Inc.",a9598a21-6f99-4c86-ace6-b5638da2bec8,"68180-556-09, 68180-557-09, 68180-557-03, 68180-558-09, 68180-558-03, 68180-554-09, 68180-554-03, 68180-559-03, 68180-559-09","Quinapril Hydrochloride, Tablet, 10 mg (NDC 68180-557-09)",Tablet,Unavailable,,ANDA077690,,QUINAPRIL,,,Current,Requirements related to complying with good manufacturing practices,,,33067B3N2M,68180-557-09,"Lupin Pharmaceuticals, Inc.",
"XGen Pharmaceuticals DJB, Inc.",ROCURONIUM BROMIDE,,02/15/2023,Reverified,INTRAVENOUS,Rocuronium Bromide Injection,1234995,,b73f192c-2912-4ec3-9b4f-05a58d9b35ba,09/04/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROCURONIUM BROMIDE,39822-4200,"XGen Pharmaceuticals DJB, Inc.",eedcfb07-4e23-3152-e053-2995a90a6e6a,"39822-4200-1, 39822-4200-2, 39822-4200-5, 39822-4200-6","Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 39822-4200-2)",Injection,Available,,ANDA091115,,ROCURONIUM BROMIDE,,,Current,,Tamarang is the application holder and X-Gen is the distributor/labeler,,I65MW4OFHZ,39822-4200-2,866-390-4411,
"Somerset Therapeutics, LLC",ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Reverified,"EPIDURAL, INFILTRATION, PERINEURAL",Ropivacaine Hydrochloride Injection,"905189, 1734084, 1734090, 1734203, 1734207, 1734475, 1734483",,ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64,08/19/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROPIVACAINE HYDROCHLORIDE,"70069-064, 70069-061, 70069-062, 70069-063, 70069-065, 70069-066, 70069-067","Somerset Therapeutics, LLC",5d7b0e44-19ce-4127-b3e8-d7e6e65f1818,"70069-061-01, 70069-061-25, 70069-061-10, 70069-062-01, 70069-062-25, 70069-062-10, 70069-063-01, 70069-063-25, 70069-064-01, 70069-064-10, 70069-064-25, 70069-065-01, 70069-065-25, 70069-066-01, 70069-066-25, 70069-066-10, 70069-067-01, 70069-067-25, 70069-067-10","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-01)",Injection,Available,,ANDA207636,,ROPIVACAINE HYDROCHLORIDE,,,Current,,,,V910P86109,70069-064-01,732-554-1019,
Sun Pharmaceutical Industries Limited,IMATINIB MESYLATE,,12/05/2024,New,ORAL,Imatinib Mesylate Tablet,"403878, 403879",,07764bf9-21b4-4e32-9d7e-e348f8e4291f,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Hematology,IMATINIB MESYLATE,"47335-472, 47335-475","Sun Pharmaceutical Industries, Inc.",ad13dbca-474d-4492-9c25-e0e175143d8c,"47335-472-83, 47335-472-88, 47335-472-13, 47335-472-81, 47335-475-83, 47335-475-88, 47335-475-13, 47335-475-64","Imatinib Mesylate, Tablet, 100 mg (NDC 47335-472-88)",Tablet,,,ANDA078340,,IMATINIB MESYLATE,,,To Be Discontinued,,Discontinuing for business reasons,,8A1O1M485B,47335-472-88,800-818-4555,
Baxter Healthcare,"CALCIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, SODIUM LACTATE",,10/11/2024,Reverified,INTRAVENOUS,Lactated Ringers Injection,847627,,6acc9f96-7088-45a7-b48f-1a861e3467ab,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other",LACTATED RINGERS AND DEXTROSE,0338-0125,Baxter Healthcare Corporation,8fc5f645-fb02-4ecf-9c07-5d515b96d7ca,"0338-0125-03, 0338-0125-04","Lactated Ringers, Injection, 20 mg/100 mL; 5 g/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0338-0125-04)",Injection,Available,,NDA016679,,"SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, CALCIUM CHLORIDE AND DEXTROSE MONOHYDRATE",,,Current,,,,"M4I0D6VV5M, LX22YL083G, 660YQ98I10, 451W47IQ8X, TU7HW0W0QT",0338-0125-04,888-229-0001,
B. Braun Medical Inc.,SODIUM CHLORIDE,,04/28/2023,Revised,IRRIGATION,Sodium Chloride 0.9% Irrigation,486515,,0d59a04a-32e6-485b-b638-a1e6c09e9642,07/02/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,0264-2201,B. Braun Medical Inc.,35e26a6d-60d6-4388-84e9-c481a3b69ee7,"0264-2201-00, 0264-2201-10, 0264-2201-50, 0264-2201-70","Sodium Chloride 0.9%, Irrigation, .9 g/100mL (NDC 0264-2201-00)",Irrigation,,,NDA016733,,SODIUM CHLORIDE,,Available,Resolved,,,07/02/2025,451W47IQ8X,0264-2201-00,800-227-2862,
Baxter Healthcare,"ALANINE, ARGININE, ASPARTIC ACID, CYSTEINE HYDROCHLORIDE, GLUTAMIC ACID, GLYCINE, HISTIDINE, ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, PROLINE, SERINE, TAURINE, THREONINE, TRYPTOPHAN, TYROSINE, VALINE",,12/08/2020,Reverified,INTRAVENOUS,Amino Acid Injection,"801395, 801398, 801403, 801405",,9afdcc3e-0d06-47f4-86ca-40da48b2b02b,09/23/2025,HUMAN PRESCRIPTION DRUG,,Gastroenterology,PREMASOL - SULFITE-FREE (AMINO ACID),"0338-1130, 0338-1131",Baxter Healthcare Company,4083b5c8-ad5f-43f6-ab19-3c87acb2883f,"0338-1130-03, 0338-1130-04, 0338-1130-06, 0338-1131-03","Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-03)",Injection,Available,"N0000175780, M0000922",ANDA075880,Amino Acids [CS],"LEUCINE, LYSINE, ISOLEUCINE, VALINE, HISTIDINE, PHENYLALANINE, THREONINE, METHIONINE, TRYPTOPHAN, TYROSINE, N-ACETYL-TYROSINE, ARGININE, PROLINE, ALANINE, GLUTAMIC ACIDE, SERINE, GLYCINE, ASPARTIC ACID, TAURINE, CYSTEINE HYDROCHLORIDE",Amino Acid [EPC],,Current,,,,"OF5P57N2ZX, 94ZLA3W45F, 30KYC7MIAI, ZT934N0X4W, 3KX376GY7L, TE7660XO1C, 4QD397987E, 04Y7590D77, GMW67QNF9C, TTL6G7LIWZ, AE28F7PNPL, 47E5O17Y3R, 9DLQ4CIU6V, 452VLY9402, 1EQV5MLY3D, 2ZD004190S, 8DUH1N11BX, 42HK56048U, HG18B9YRS7",0338-1130-03,888-229-0001,
"Hikma Pharmaceuticals USA, Inc.",AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","239191, 313797",,077f4a65-3cfb-4cb1-99f2-e27ffc5939c0,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0143-9889, 0143-9888",Hikma Pharmaceuticals USA Inc.,c2fa2c99-c735-4834-a8a5-04a30da8a002,"0143-9888-80, 0143-9888-01, 0143-9888-15, 0143-9889-80, 0143-9889-01, 0143-9889-15","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0143-9889-15)","Powder, For Suspension",,,ANDA065322,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0143-9889-15,800-631-2174,
Strides Pharma Inc.,LIDOCAINE,Local Anesthesia [PE],01/28/2025,New,TOPICAL,Lidocaine Ointment,1543069,,8b1efeaa-31b1-4f34-960f-7a920ac07355,01/28/2025,HUMAN PRESCRIPTION DRUG,01/28/2025,Anesthesia,LIDOCAINE,64380-789,Strides Pharma Science Limited,e6c9429c-13b9-4932-abad-e605c4c7fb68,"64380-789-32, 64380-789-23, 64380-789-33","Lidocaine, Ointment, 5%, 30 gram tubes (NDC 64380-789-23)",Ointment,,"N0000175682, M0000897, N0000175426, N0000175976",ANDA210958,Amides [CS],LIDOCAINE,"Amide Local Anesthetic [EPC], Antiarrhythmic [EPC]",,To Be Discontinued,,,,98PI200987,64380-789-23,877-244-9825,
"Vertical Pharmaceuticals, LLC",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Reverified,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release",,,22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d,09/16/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,RELEXXII,"68025-098, 68025-088, 68025-089, 68025-095, 68025-096, 68025-097, 68025-084","Vertical Pharmaceuticals, LLC",86f477e9-07fc-466b-913e-1a4434c91df4,"68025-088-30, 68025-089-30, 68025-095-10, 68025-095-30, 68025-096-10, 68025-096-30, 68025-097-10, 68025-097-30, 68025-084-30, 68025-098-10, 68025-098-30","Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-10)",Tablet,Unavailable,,NDA216117,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,Other,Estimated recovery: TBD,,4B3SC438HI,68025-098-10,800-541-4802,
"Cephalon, LLC",FILGRASTIM,Increased Myeloid Cell Production [PE],06/13/2025,New,SUBCUTANEOUS,Tbo-filgrastim Injection,"1433768, 1433771, 1442681, 1442683, 2101456, 2101459, 2101464, 2101465",,df918ec2-0907-443f-a52a-b72866959644,06/13/2025,HUMAN PRESCRIPTION DRUG,06/13/2025,Hematology,GRANIX,"63459-920, 63459-910, 63459-912, 63459-918","Cephalon, LLC",3ab24490-b46f-4d38-b525-3d84752bfdf4,"63459-910-01, 63459-910-12, 63459-910-11, 63459-910-15, 63459-910-18, 63459-910-17, 63459-910-36, 63459-912-01, 63459-912-12, 63459-912-11, 63459-912-15, 63459-912-18, 63459-912-17, 63459-912-36, 63459-918-53, 63459-918-59, 63459-920-53, 63459-920-59","Granix, Injection, 480 ug/1.6 mL (NDC 63459-920-59)",Injection,,"M0024696, N0000009451, N0000175666",BLA125294,Granulocyte Colony-Stimulating Factor [CS],TBO-FILGRASTIM,Leukocyte Growth Factor [EPC],,To Be Discontinued,,,,PVI5M0M1GW,63459-920-59,800-545-8800,
"Fresenius Kabi USA, LLC",DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718900, 1718906, 1718909",,4d5d2294-89a0-4b6f-aa00-d39a0393b6a8,09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE HYDROCHLORIDE,63323-671,"Fresenius Kabi USA, LLC",27411591-44a1-44c4-89c3-dd8c2687f0e2,"63323-671-02, 63323-671-20, 63323-671-05, 63323-671-50, 63323-671-01, 63323-671-00","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-50)",Injection,Unavailable,,ANDA208129,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,Delay in shipping of the drug,Not available at this time.,,1018WH7F9I,63323-671-50,888-386-1300,
Baxter Healthcare,FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Reverified,INTRAVENOUS,Furosemide Injection,"1719286, 1719290, 1719291",,c71371a7-75c5-45b8-b762-8d782d4c71bc,09/23/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,"36000-282, 36000-063, 36000-064, 36000-065, 36000-283, 36000-284",Baxter Healthcare Corporation,109082ab-0793-4752-8a02-42d204efe741,"36000-063-05, 36000-064-05, 36000-065-05, 36000-282-25, 36000-283-25, 36000-284-25","Furosemide, Injection, 10 mg/1 mL (NDC 36000-282-25)",Injection,Available,"N0000175366, N0000175590",ANDA202747,,FUROSEMIDE,Loop Diuretic [EPC],,Current,,,,7LXU5N7ZO5,36000-282-25,888-229-0001,
Bausch & Lomb Incorporated,HYDROXYPROPYL CELLULOSE (1600000 WAMW),,05/01/2020,Revised,OPHTHALMIC,Hydroxypropyl Cellulose (1600000 Wamw) Insert,"476707, 754512",,cc7a6a52-0b77-4df7-8403-dd21c1334f6c,09/17/2025,HUMAN PRESCRIPTION DRUG,,Ophthalmology,LACRISERT,24208-800,Bausch & Lomb Incorporated,1e1a2eb7-408a-9cae-e063-6394a90a544b,"24208-800-60, 24208-800-10","Lacrisert, Insert, 5 mg (NDC 24208-800-60)",Insert,Unavailable,,NDA018771,,HYDROXYPROPYL CELLULOSE,,,Current,Discontinuation of the manufacture of the drug,Discontinuation of the manufacture of the drug,,RFW2ET671P,24208-800-60,800-553-5340,
Aurobindo Pharma USA,AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","239191, 313797",,234d0dfc-cb24-413f-b798-129c73eb848e,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"65862-707, 65862-706",Aurobindo Pharma Limited,f4a410c9-3a78-48f9-8195-915896a974ff,"65862-706-80, 65862-706-01, 65862-706-55, 65862-707-80, 65862-707-01, 65862-707-55","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 65862-707-01)","Powder, For Suspension",,,ANDA204030,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,65862-707-01,866-850-2876,
Aurobindo Pharma USA,QUINAPRIL HYDROCHLORIDE,,01/19/2023,Reverified,ORAL,Quinapril Hydrochloride Tablet,"312748, 312749, 312750, 314203",,93e6e668-5306-4f26-81d8-cbc3a7a5e787,09/17/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,QUINAPRIL,"65862-618, 65862-617, 65862-619, 65862-620",Aurobindo Pharma Limited,5263abd5-ce46-4918-9bb0-9632861bcbc9,"65862-617-30, 65862-617-90, 65862-617-99, 65862-617-55, 65862-617-10, 65862-617-78, 65862-618-30, 65862-618-90, 65862-618-99, 65862-618-55, 65862-618-10, 65862-618-78, 65862-619-30, 65862-619-90, 65862-619-99, 65862-619-19, 65862-619-10, 65862-619-78, 65862-620-30, 65862-620-90, 65862-620-99, 65862-620-39, 65862-620-10, 65862-620-78","Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)",Tablet,Discontinued,,ANDA202725,,QUINAPRIL HYDROCHLORIDE,,,Current,Discontinuation of the manufacture of the drug,,,33067B3N2M,65862-618-90,866-850-2876,
Eli Lilly and Co.,,,01/06/2023,Revised,"INTRAMUSCULAR, SUBCUTANEOUS",Somatropin Injection,"582969, 582971, 582974, 582976, 729232, 729234",,a774e1ae-3997-49ee-8b0e-99a2b315d409,08/28/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,HUMATROPE,"0002-8149, 0002-8147, 0002-8148",Eli Lilly and Company,aa99e905-657f-4561-8c02-d7c0409c44e3,"0002-8147-01, 0002-7554-01, 0002-7618-01, 0002-8148-01, 0002-7555-01, 0002-7619-01, 0002-8149-01, 0002-7556-01","Humatrope, Injection, 24 mg/cartridge (NDC 0002-8149-01)",Injection,,,BLA019640,,SOMATROPIN,,Available,Resolved,,,08/28/2025,,0002-8149-01,800-545-5979,
"Upsher-Smith Laboratories, LLC",CHOLESTYRAMINE,,05/14/2025,New,ORAL,Cholestyramine Powder,"848951, 1801279",,dd434ef8-8af3-434c-a0a0-9a0b18459ba0,05/14/2025,HUMAN PRESCRIPTION DRUG,05/14/2025,Cardiovascular,PREVALITE,0245-0036,"Upsher-Smith Laboratories, LLC",39e73fd2-1ad0-aae8-e063-6294a90acd5a,"0245-0036-89, 0245-0036-42, 0245-0036-60, 0245-0036-23","Prevalite, Powder, 4 g/5.5 g (NDC 0245-0036-60)",Powder,,"N0000180292, N0000175365",ANDA073263,,CHOLESTYRAMINE,Bile Acid Sequestrant [EPC],,To Be Discontinued,,A business decision was made to discontinue the product.,,4B33BGI082,0245-0036-60,800-654-2299,Bile-acid Binding Activity [MoA]
"Actavis Pharma, Inc.",DESONIDE,,09/18/2025,New,TOPICAL,Desonide Lotion,"197572, 349351",,ff5d4cd8-ab4d-4a9e-b84b-445c81eeea99,09/18/2025,HUMAN PRESCRIPTION DRUG,09/18/2025,Dermatology,DESONIDE,"0472-0803, 0472-0804","Actavis Pharma, Inc.",f3953b9e-138f-4d86-8eea-0fc03c3c2747,"0472-0804-15, 0472-0804-60, 0472-0803-02, 0472-0803-04","Desowen, Lotion, .5 mg/1 mL (NDC 0472-0803-02)",Lotion,,"N0000175576, N0000175450",ANDA072354,,DESONIDE,Corticosteroid [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug.,,J280872D1O,0472-0803-02,800-545-8800,Corticosteroid Hormone Receptor Agonists [MoA]
Takeda Pharmaceuticals USA Inc.,FEBUXOSTAT,,01/22/2025,New,ORAL,Febuxostat Tablet,"834235, 834239, 834241, 834243",,54de10ef-fe5f-4930-b91d-6bbb04c664bd,01/22/2025,HUMAN PRESCRIPTION DRUG,01/22/2025,Other,ULORIC,"64764-918, 64764-677","Takeda Pharmaceuticals America, Inc.",fecf6101-9a35-4781-bea4-e7b92b4afb81,"64764-918-30, 64764-918-90, 64764-918-18, 64764-918-11, 64764-677-30, 64764-677-13, 64764-677-19, 64764-677-11","Uloric, Tablet, 40 mg (NDC 64764-918-30)",Tablet,,"N0000175698, N0000000206",NDA021856,,FEBUXOSTAT,Xanthine Oxidase Inhibitor [EPC],,To Be Discontinued,,Anticipate continued distribution to wholesalers until March 2026,,101V0R1N2E,64764-918-30,855-268-1825,Xanthine Oxidase Inhibitors [MoA]
"Novo Nordisk, Inc.",INSULIN ASPART,,07/21/2025,New,"INTRAVENOUS, SUBCUTANEOUS",Insulin Aspart Injection,"311040, 1653196, 1653202",,bee5b358-c863-420b-be73-ced2e920c499,07/21/2025,HUMAN PRESCRIPTION DRUG,07/21/2025,Endocrinology/Metabolism,INSULIN ASPART,"73070-103, 73070-100, 73070-102","Novo Nordisk Pharma, Inc.",393af9a3-df9a-40b2-a5e6-bfa5434a2552,"73070-100-11, 73070-102-10, 73070-102-15, 73070-103-10, 73070-103-15","Insulin Aspart, Injection, 3 mL Insulin Aspart FlexPen® (NDC 73070-103-15)",Injection,,"M0011417, N0000175453",BLA020986,Insulin [CS],INSULIN ASPART,Insulin Analog [EPC],,To Be Discontinued,,"Unbranded Insulin Aspart 3 mL FlexPen® will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,D933668QVX,73070-103-15,609-987-5800,
Eugia US LLC,LIDOCAINE HYDROCHLORIDE,,02/20/2018,Revised,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Lidocaine Hydrochloride Injection,"1737562, 1737566, 1737568, 1737757, 1737761",,"9916b09d-a116-469d-92d5-60e50ea9782b, 89701fac-7536-4f16-87fb-f4cc121e74ee",09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,LIDOCAINE HYDROCHLORIDE,"55150-165, 55150-161, 55150-162, 55150-163, 55150-164",Eugia US LLC,"9916b09d-a116-469d-92d5-60e50ea9782b, 9b60bc92-6093-49f9-a6ba-075104ff7bb5","55150-161-09, 55150-162-09, 55150-163-00, 55150-164-09, 55150-165-09, 55150-161-02, 55150-162-05, 55150-163-30, 55150-164-02, 55150-165-05","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)",Injection,Available,,ANDA203082,,LIDOCAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,V13007Z41A,55150-165-05,888-238-7880,
"Fresenius Kabi USA, LLC",LIDOCAINE HYDROCHLORIDE,,02/22/2012,Reverified,INTRAVENOUS,Lidocaine Hydrochloride Injection,1737761,,f1b26274-a55e-4321-b96c-ce0df830f205,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE,63323-208,"Fresenius Kabi USA, LLC",289524c2-d0be-443d-aedf-39d621f217a5,"63323-208-01, 63323-208-05","Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)",Injection,Available,,NDA017584,,LIDOCAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,V13007Z41A,63323-208-05,888-386-1300,
Aurobindo Pharma USA,METOPROLOL TARTRATE,,06/03/2025,New,ORAL,Metoprolol Tartrate Tablet,"866511, 866514, 866924",,2b705cb6-cb75-4c2a-907a-4bd45d18bc2c,06/03/2025,HUMAN PRESCRIPTION DRUG,06/03/2025,Cardiovascular,METOPROLOL TARTRATE,"65862-062, 65862-063, 65862-064",Aurobindo Pharma Limited,d265c99d-8e77-4a78-b542-15e957d9d335,"65862-062-01, 65862-062-99, 65862-063-60, 65862-063-01, 65862-063-99, 65862-064-60, 65862-064-01, 65862-064-99","Metoprolol Tartrate, Tablet, 25 mg (NDC 65862-062-99)",Tablet,,,ANDA077739,,METOPROLOL TARTRATE,,,To Be Discontinued,,Permanent discontinuation in the manufacturing of the drug,,W5S57Y3A5L,65862-062-99,866-850-2876,
Pfizer Inc.,QUINAPRIL HYDROCHLORIDE,,01/19/2023,Reverified,ORAL,Quinapril Hydrochloride Tablet,"207891, 207892, 207893, 207895, 312748, 312749, 312750, 314203",,63cf5651-d52c-4d27-9fd4-ed9cd9724dff,08/15/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,ACCUPRIL,"0071-0535, 0071-0527, 0071-0530, 0071-0532, 0071-1205, 0071-1410, 0071-1620, 0071-1840",Parke-Davis Div of Pfizer Inc,ee20d3b1-a5c8-4510-a931-3872df7b77f4,"0071-0527-23, 0071-0530-23, 0071-0530-40, 0071-0532-23, 0071-0532-40, 0071-0535-23, 0071-1205-23, 0071-1410-23, 0071-1620-23, 0071-1840-23","Accupril, Tablet, 40 mg (NDC 0071-0535-23)",Tablet,Unavailable,,NDA019885,,QUINAPRIL HYDROCHLORIDE,,,Current,Delay in shipping of the drug,Next Delivery and Estimated Recovery: TBD,,33067B3N2M,0071-0535-23,800-533-4535,
"Hikma Pharmaceuticals USA, Inc.",BUMETANIDE,Increased Diuresis at Loop of Henle [PE],01/31/2018,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Bumetanide Injection,"282486, 1727569",,681b5e9d-e2c7-4f29-aaad-e06d4a528c11,07/23/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,BUMETANIDE,"0641-6007, 0641-6008",Hikma Pharmaceuticals USA Inc.,99d2fc38-7e1e-4209-aa57-089794eda8a6,"0641-6007-01, 0641-6007-10, 0641-6008-01, 0641-6008-10","Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6007-10)",Injection,Available,"N0000175366, N0000175590",ANDA079196,,BUMETANIDE,Loop Diuretic [EPC],,Current,,,,0Y2S3XUQ5H,0641-6007-10,800-631-2174,
Janssen Pharmaceuticals,HALOPERIDOL DECANOATE,,04/07/2025,New,INTRAMUSCULAR,Haloperidol Decanoate Injection,"1719803, 1719862",,9f0f42a8-5f7c-4be7-93ef-3ec225502cc6,04/07/2025,HUMAN PRESCRIPTION DRUG,04/07/2025,Psychiatry,HALOPERIDOL DECANOATE,"10147-0921, 10147-0922",Patriot Pharmaceuticals LLC,2e815b50-b5db-72e4-e063-6294a90afd55,"10147-0921-3, 10147-0922-5","Haloperidol Decanoate, Injection, 50 mg/1 mL (NDC 10147-0921-3)",Injection,,,NDA018701,,HALOPERIDOL DECANOATE,,,To Be Discontinued,,Marketed by Patriot Pharmaceuticals LLC; Last batch expiration date 5/31/2025,,AC20PJ4101,10147-0921-3,800-526-7736,
"Fresenius Kabi USA, LLC",BUMETANIDE,Increased Diuresis at Loop of Henle [PE],01/31/2018,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Bumetanide Injection,"282486, 1727569",,a007f3aa-3977-4be3-a9a2-db3d458bca58,09/18/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,BUMETANIDE,"65219-570, 65219-572","Fresenius Kabi USA, LLC",aaff61c4-203b-4905-9138-0f98959ad013,"65219-570-01, 65219-570-04, 65219-572-01, 65219-572-10","Bumetanide, Injection, .25 mg/1 mL (NDC 65219-570-04)",Injection,Available,"N0000175366, N0000175590",ANDA216434,,BUMETANIDE,Loop Diuretic [EPC],,Current,,Check wholesalers for inventory,,0Y2S3XUQ5H,65219-570-04,888-386-1300,
"Avet Pharmaceuticals, Inc.",DESIPRAMINE HYDROCHLORIDE,,08/12/2025,New,ORAL,Desipramine Hydrochloride Tablet,"1099288, 1099292, 1099296, 1099300, 1099304, 1099316",,ee14dd2c-c54b-4cd1-a3a0-f7ad5a5a0ed0,08/12/2025,HUMAN PRESCRIPTION DRUG,08/12/2025,Psychiatry,DESIPRAMINE HYDROCHLORIDE,"23155-580, 23155-578, 23155-579, 23155-581, 23155-582, 23155-583",Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.,49984729-ddde-44ed-927b-8a4ba65cefa0,"23155-578-01, 23155-579-01, 23155-580-01, 23155-581-01, 23155-582-01, 23155-583-25","Desipramine Hydrochloride, Tablet, 50 mg (NDC 23155-580-01)",Tablet,,,ANDA207433,,DESIPRAMINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,1Y58DO4MY1,23155-580-01,855-228-9470,
GlaxoSmithKline,WATER,,01/31/2025,New,INTRAVENOUS,Epoprostenol Sodium Injection,"211199, 211200, 562501, 562502",,8e4b636e-ee9c-4111-779d-28c8369d283b,01/31/2025,HUMAN PRESCRIPTION DRUG,01/31/2025,Cardiovascular,DILUENT,"0173-0857, 0173-0517, 0173-0519",GlaxoSmithKline LLC,5e54002e-7b03-46ad-ae01-c76c76967201,"0173-0517-00, 0173-0519-00, 0173-0857-02","Flolan, Injection, 1 mL/1 mL (NDC 0173-0857-02)",Injection,,,NDA020444,,WATER,,,To Be Discontinued,,"The anticipated date that GSK will cease distribution of the product is approximately November 30, 2025.",,"059QF0KO0R, 4K04IQ1OF4",0173-0857-02,888-825-5249,
"Novo Nordisk, Inc.",INSULIN DEGLUDEC,,07/21/2025,New,SUBCUTANEOUS,Insulin Degludec Injection,"1670011, 1670021, 2107520",,c1be283d-4b1d-4996-b2a7-4488dbff3037,07/21/2025,HUMAN PRESCRIPTION DRUG,07/21/2025,Endocrinology/Metabolism,INSULIN DEGLUDEC,"73070-400, 73070-403, 73070-503","Novo Nordisk Pharma, Inc.",c1be283d-4b1d-4996-b2a7-4488dbff3037,"73070-403-15, 73070-503-15, 73070-400-11","Insulin Degludec, Injection, 10 mL Insulin Degludec vial (NDC 73070-400-11)",Injection,,"M0011417, N0000175453",BLA203314,Insulin [CS],INSULIN DEGLUDEC,Insulin Analog [EPC],,To Be Discontinued,,"Unbranded Insulin Degludec 10 mL vial will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,54Q18076QB,73070-400-11,609-987-5800,
Alembic Pharmaceuticals,KETOROLAC TROMETHAMINE,,03/23/2018,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Ketorolac Tromethamine Injection,"860092, 1665459, 1665461",,419cf756-3c96-4bb8-ae96-6aea5a5f3afd,09/17/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,KETOROLAC TROMETHAMINE,"62332-599, 62332-600, 62332-601",Alembic Pharmaceuticals Inc.,9030f496-5021-4454-ac16-dbb376315608,"62332-599-01, 62332-599-25, 62332-600-01, 62332-600-25, 62332-601-02, 62332-601-25","Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 62332-599-25)",Injection,Available,,ANDA214456,,KETOROLAC TROMETHAMINE,,,Current,,,,4EVE5946BQ,62332-599-25,908-393-9604,
Kindos Pharmaceuticals Co. Ltd.,LEUCOVORIN CALCIUM,,01/01/2012,Revised,"INTRAMUSCULAR, INTRAVENOUS",Leucovorin Calcium Injection,"237788, 1803930, 1803932, 1803937, 2055036",,9df20901-6980-4d4e-89ec-40f3c1f91852,07/08/2025,HUMAN PRESCRIPTION DRUG,,"Oncology, Pediatric",LEUCOVORIN CALCIUM,"71288-164, 71288-160, 71288-161, 71288-162, 71288-163",Meitheal Pharmaceuticals Inc.,077a459b-e884-4452-aed3-0857a38ce26f,"71288-160-10, 71288-161-20, 71288-162-30, 71288-163-30, 71288-164-50","Leucovorin Calcium, Injection, 500 mg/50 mL (NDC 71288-164-50)",Injection,,,ANDA216590,,LEUCOVORIN CALCIUM,,Available,Resolved,,,07/08/2025,RPR1R4C0P4,71288-164-50,"Meitheal Pharmaceuticals, Inc.: 844-824-8426",
Watson Pharma Private Limited,POTASSIUM CITRATE,,07/17/2025,New,ORAL,"Potassium Citrate Tablet, Extended Release","199376, 199381, 898490",,ac173781-486b-461c-97ae-8b5c69e20792,07/17/2025,HUMAN PRESCRIPTION DRUG,07/17/2025,Renal,POTASSIUM CITRATE,"0591-2682, 0591-2729, 0591-2742","Actavis Pharma, Inc.",b81078a3-490a-4a03-a9a5-9c64acde67bf,"0591-2682-01, 0591-2729-01, 0591-2742-01","Potassium Citrate, Tablet, Extended Release, 5 meq (NDC 0591-2682-01)",Tablet,,,ANDA209758,,POTASSIUM CITRATE,,,To Be Discontinued,,A business decision was made to discontinue.,,EE90ONI6FF,0591-2682-01,800-545-8800,
Sandoz Inc.,ADALIMUMAB,,04/14/2025,New,SUBCUTANEOUS,Adalimumab-adaz Injection,"2641644, 2641650, 2641653, 2641654, 2641655, 2641658, 2641660, 2641661, 2641662, 2641663, 2641664, 2641665, 2641666, 2641667, 2641668, 2641669, 2641670, 2641671, 2641672, 2641673",,1ac7d061-3380-468c-b077-c05f8dfbc829,04/14/2025,HUMAN PRESCRIPTION DRUG,04/14/2025,Rheumatology,HYRIMOZ,"61314-509, 61314-454, 61314-473, 61314-476, 61314-517, 61314-531",Sandoz Inc,bd62cde8-792c-4194-949e-ad87a6d5aef0,"61314-454-20, 61314-454-36, 61314-454-68, 61314-473-64, 61314-473-20, 61314-473-92, 61314-476-64, 61314-509-64, 61314-517-36, 61314-531-64","Hyrimoz, Injection, 10 mg/.1 mL (NDC 61314-509-64)",Injection,,"N0000175610, N0000175451, M0001357",BLA761071,"Antibodies, Monoclonal [CS]",ADALIMUMAB-ADAZ,Tumor Necrosis Factor Blocker [EPC],,To Be Discontinued,,,,FYS6T7F842,61314-509-64,800-525-8747,Tumor Necrosis Factor Receptor Blocking Activity [MoA]
Cumberland Pharmaceuticals Inc.,,,03/14/2022,Reverified,,Conivaptan Hydrochloride Injection,,,,09/16/2025,,,Cardiovascular,,,,,,"Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10)",Injection,Unavailable,,,,,,,Current,Delay in shipping of the drug,,,,66220-160-10,615-255-0068,
Eli Lilly and Co.,FLUOXETINE HYDROCHLORIDE,,10/03/2024,New,ORAL,Fluoxetine Hydrochloride Capsule,"104849, 205535, 261287, 310384, 310385, 313989",,c88f33ed-6dfb-4c5e-bc01-d8e36dd97299,10/03/2024,HUMAN PRESCRIPTION DRUG,10/03/2024,Psychiatry,PROZAC,"0777-3105, 0777-3104, 0777-3107",Dista Products Company,d7b3b74e-319e-4360-aa57-af39ccbfb19a,"0777-3104-02, 0777-3105-02, 0777-3105-30, 0777-3107-30","Prozac, Capsule, 20 mg (NDC 0777-3105-02)",Capsule,,,NDA018936,,FLUOXETINE HYDROCHLORIDE,,,To Be Discontinued,,,,I9W7N6B1KJ,0777-3105-02,800-545-5979,
"Fresenius Kabi USA, LLC",LIDOCAINE HYDROCHLORIDE ANHYDROUS,,02/22/2012,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010035, 1010671, 1010673, 1010688, 1010692, 1010745, 1010749, 1010751, 1010755, 1010759, 1010763, 1010900, 1010902, 1737343, 1737345, 1737562, 1737563, 1737566, 1737567, 1737568, 1737569, 1737570, 1737571, 1737757, 1737758, 1737761, 1737762, 1867938, 1867940, 1867943, 1867944, 1867992, 1867993, 1867996, 1867997, 1868028, 1868029",,"ba082c2f-64f4-419d-9c88-74f203316e17, 4dd52202-8eef-4136-92dd-ada573b7cf74",09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",XYLOCAINE MPF,"63323-495, 63323-492, 63323-491, 63323-485, 63323-486, 63323-484, 63323-489, 63323-488, 63323-481, 63323-483, 63323-482, 63323-487","Fresenius Kabi USA, LLC","ea480a68-5927-4278-9deb-2956961da428, 0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33","63323-492-04, 63323-492-27, 63323-492-09, 63323-492-57, 63323-492-07, 63323-492-37, 63323-492-03, 63323-492-31, 63323-491-01, 63323-491-57, 63323-495-09, 63323-495-27, 63323-495-04, 63323-495-07, 63323-485-01, 63323-485-27, 63323-485-03, 63323-485-57, 63323-486-01, 63323-486-17, 63323-486-02, 63323-486-27, 63323-486-05, 63323-486-57, 63323-484-57, 63323-489-02, 63323-489-27, 63323-489-03, 63323-489-21, 63323-489-01, 63323-489-17, 63323-488-07, 63323-488-37, 63323-488-03, 63323-488-31, 63323-488-01, 63323-488-17, 63323-481-01, 63323-481-57, 63323-483-03, 63323-483-27, 63323-483-01, 63323-483-57, 63323-482-01, 63323-482-17, 63323-482-03, 63323-482-27, 63323-482-05, 63323-482-57, 63323-487-01, 63323-487-17, 63323-487-07, 63323-487-37, 63323-487-03, 63323-487-31, 63323-492-41, 63323-492-16, 63323-492-43, 63323-492-36, 63323-492-45, 63323-492-26, 63323-485-41, 63323-485-26, 63323-486-41, 63323-486-26, 63323-482-41, 63323-482-26, 63323-495-41, 63323-495-26","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-07)",Injection,Available,,NDA006488,,LIDOCAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,"EC2CNF7XFP, 30Q7KI53AK",63323-495-07,888-386-1300,
"XGen Pharmaceuticals DJB, Inc.",ROCURONIUM BROMIDE,,02/15/2023,Reverified,INTRAVENOUS,Rocuronium Bromide Injection,1234995,,b73f192c-2912-4ec3-9b4f-05a58d9b35ba,09/04/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROCURONIUM BROMIDE,39822-4200,"XGen Pharmaceuticals DJB, Inc.",eedcfb07-4e23-3152-e053-2995a90a6e6a,"39822-4200-1, 39822-4200-2, 39822-4200-5, 39822-4200-6","Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 39822-4200-6)",Injection,Available,,ANDA091115,,ROCURONIUM BROMIDE,,,Current,,Tamarang is the application holder and X-Gen is the distributor/labeler,,I65MW4OFHZ,39822-4200-6,866-390-4411,
Baxter Healthcare,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807631, 1807632, 1807633, 1807634, 1807639",,958d35f0-6834-43be-a700-fa58f38b4c19,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0338-9543, 0338-9657, 0338-9659, 0338-9661, 0338-9663",Baxter Healthcare Corporation,6680afa2-1474-4bc3-afee-a333a042fd3f,"0338-9543-01, 0338-9543-02, 0338-9543-03, 0338-9543-04, 0338-9543-05, 0338-9543-06, 0338-9543-12, 0338-9657-75, 0338-9659-75, 0338-9661-60, 0338-9663-60","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-06)",Injection,,,NDA016677,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0338-9543-06,888-229-0001,
"Laboratorios Grifols, S.A.",SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807631, 1807632, 1807633, 1807634, 1807639",,28f79c75-82d2-4912-81fc-a723b5ccf4c1,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,79672-613,Nextgen Pharmaceuticals LLC,3c545b9f-67e4-489d-bb60-c39c990d7dda,"79672-613-01, 79672-613-10, 79672-613-02, 79672-613-20, 79672-613-03, 79672-613-30, 79672-613-04, 79672-613-40, 79672-613-05, 79672-613-50","Sodium Chloride 0.9%, 1000 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-05)",Injection,,,ANDA207956,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,79672-613-05,800-848-0462,
"EMD Serono, Inc.",LEVOTHYROXINE SODIUM,,07/10/2025,New,ORAL,Levothyroxine Sodium Tablet,"892246, 892251, 966153, 966160, 966166, 966173, 966177, 966182, 966187, 966196, 966202, 966207, 966220, 966221, 966222, 966224, 966225, 966248, 966249, 966253, 966270, 2104866",,bc3c6830-ba68-4ba3-9896-a12d0ad0b275,07/10/2025,HUMAN PRESCRIPTION DRUG,07/10/2025,Endocrinology/Metabolism,EUTHYROX,"72305-075, 72305-025, 72305-050, 72305-088, 72305-100, 72305-112, 72305-125, 72305-137, 72305-150, 72305-175, 72305-200","Provell Pharmaceuticals, LLC",45657074-8874-49f4-a8ef-3ca7e210c16e,"72305-025-30, 72305-025-90, 72305-050-30, 72305-050-90, 72305-075-30, 72305-075-90, 72305-088-30, 72305-088-90, 72305-100-30, 72305-100-90, 72305-112-30, 72305-112-90, 72305-125-30, 72305-125-90, 72305-137-30, 72305-137-90, 72305-150-30, 72305-150-90, 72305-175-30, 72305-175-90, 72305-200-30, 72305-200-90","Euthyrox, Tablet, 75 ug (NDC 72305-075-30)",Tablet,,,NDA021292,,LEVOTHYROXINE SODIUM,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,9J765S329G,72305-075-30,888-899-7041,
SpecGx LLC,NALTREXONE HYDROCHLORIDE,,02/29/2024,Reverified,ORAL,Naltrexone Hydrochloride Tablet,1483744,,06ff2d5a-e62b-4fa4-bbdb-01938535bc65,09/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,NALTREXONE HYDROCHLORIDE,0406-1170,SpecGx LLC,9ed13551-325e-4b82-a266-72fc89ed27dc,"0406-1170-03, 0406-1170-01","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 0406-1170-01)",Tablet,Limited Availability,,ANDA076264,,NALTREXONE HYDROCHLORIDE,,,Current,Demand increase for the drug,Long term allocations to all customers with intermittent backorder expected through 2025.,,Z6375YW9SF,0406-1170-01,800-325-8888,
"Upsher-Smith Laboratories, LLC",BUMETANIDE,Increased Diuresis at Loop of Henle [PE],05/02/2025,New,ORAL,Bumetanide Tablet,"197417, 197418, 197419",,ff5dc8c6-b2f2-41d3-8e56-a953aa721b59,05/02/2025,HUMAN PRESCRIPTION DRUG,05/02/2025,Cardiovascular,BUMETANIDE,"0832-0542, 0832-0540, 0832-0541","Upsher-Smith Laboratories, LLC",d53166d9-64ca-4b76-81a7-b70a60c53b12,"0832-0540-11, 0832-0541-11, 0832-0541-10, 0832-0542-11, 0832-0542-10","Bumetanide, Tablet, 2 mg (NDC 0832-0542-11)",Tablet,,"N0000175366, N0000175590",ANDA209916,,BUMETANIDE,Loop Diuretic [EPC],,To Be Discontinued,,,,0Y2S3XUQ5H,0832-0542-11,800-654-2299,
"Hospira, Inc., a Pfizer Company",HEPARIN SODIUM,,11/14/2017,Reverified,INTRAVENOUS,Heparin Sodium Injection,"1658690, 1658692",,32e34077-aff1-4ec7-f9b0-b8e240768fb8,08/15/2025,HUMAN PRESCRIPTION DRUG,,Hematology,HEPARIN SODIUM,"0409-7620, 0409-1005, 0409-2222","Hospira, Inc.",c38c96a5-ff8a-43b6-a598-dfd044719d89,"0409-7620-13, 0409-7620-03, 0409-7620-49, 0409-7620-59, 0409-1005-01, 0409-1005-20, 0409-2222-01, 0409-2222-12","Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-7620-03)",Injection,Available,,NDA018916,,HEPARIN SODIUM,,,Current,,,01/02/2025,ZZ45AB24CA,0409-7620-03,844-646-4398,
"Noven Pharmaceuticals, Inc.",METHYLPHENIDATE,Central Nervous System Stimulation [PE],02/28/2025,Revised,TRANSDERMAL,"Methylphenidate Film, Extended Release",,,7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb,08/19/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE TRANSDERMAL SYSTEM,"0574-2410, 0574-2415, 0574-2420, 0574-2430",PADAGIS US LLC,b743ef45-2fc0-4086-8a02-6078e6a09eaa,"0574-2410-65, 0574-2415-65, 0574-2420-65, 0574-2430-65","Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65)","Film, Extended Release",Available,"N0000175739, N0000175729",NDA021514,,METHYLPHENIDATE,Central Nervous System Stimulant [EPC],,Current,,Available. Distributed by Padagis US LLC,,207ZZ9QZ49,0574-2410-65,800-455-8070,
Pfizer Inc.,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718900, 1718902, 1718906, 1718907, 1718909, 1718910, 2396891, 2396892",,4419162d-81d4-49bd-96de-1729440bdb74,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,PRECEDEX,"0409-3301, 0409-1454, 0409-1174, 0409-2815","Hospira, Inc.",8d48de06-361f-418b-bfec-8ef85f94d5bc,"0409-1454-01, 0409-1454-20, 0409-3301-01, 0409-3301-10, 0409-1174-01, 0409-1174-10, 0409-2815-01","Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-3301-10)",Injection,Available,,NDA021038,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,,,,1018WH7F9I,0409-3301-10,844-646-4398,
"Dr. Reddy's Laboratories, Inc.",METHAMPHETAMINE HYDROCHLORIDE,,03/17/2023,Reverified,ORAL,Methamphetamine Hydrochloride Tablet,977860,,f31f580f-1f08-4a0f-b078-0b9e3308f712,09/16/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHAMPHETAMINE HYDROCHLORIDE,68308-115,Mayne Pharma Commercial LLC,ffc2cd39-e42b-5821-e053-6394a90a9974,68308-115-01,"Methamphetamine Hydrochloride, Tablet, 5 mg (NDC 68308-115-01)",Tablet,Available,,ANDA091189,,METHAMPHETAMINE HYDROCHLORIDE,,,Current,,Available to existing customers,,997F43Z9CV,68308-115-01,866-732-3952,
SpecGx LLC,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 1009145",,72ddd1c9-ddbd-4c95-acd9-003189a353a3,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE,"0406-8894, 0406-8891, 0406-8884, 0406-8892, 0406-8885, 0406-8893",SpecGx LLC,b25a2f3f-ee3a-44c0-a475-f371025c767b,"0406-8891-01, 0406-8884-01, 0406-8892-01, 0406-8885-01, 0406-8893-01, 0406-8894-01","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0406-8894-01)",Tablet,Available,,ANDA040440,,DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE,,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",0406-8894-01,800-325-8888,
"Hikma Pharmaceuticals USA, Inc.",PROMETHAZINE HYDROCHLORIDE,,11/21/2023,Revised,"INTRAMUSCULAR, INTRAVENOUS",Promethazine Hydrochloride Injection,"992460, 992462, 992858, 992876",,6f7e47cc-f823-4336-8107-f980e3049617,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Gastroenterology, Pediatric, Pulmonary/Allergy",PHENERGAN,"0641-6082, 0641-6083",Hikma Pharmaceuticals USA Inc.,a64f0625-8d56-4994-8908-13614ca7b09f,"0641-6082-01, 0641-6082-25, 0641-6083-01, 0641-6083-25","Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6082-25)",Injection,Available,,ANDA083312,,PROMETHAZINE HYDROCHLORIDE,,,Current,,Currently available.  Additional product will be made available as it is released.,,R61ZEH7I1I,0641-6082-25,800-631-2174,
"Hikma Pharmaceuticals USA, Inc.",AZACITIDINE,,12/18/2020,Reverified,"INTRAVENOUS, SUBCUTANEOUS",Azacitidine Injection,485246,,ff73515d-bd55-4eb5-992b-d2138c80887e,07/23/2025,HUMAN PRESCRIPTION DRUG,,Oncology,AZACITIDINE,0143-9606,Hikma Pharmaceuticals USA Inc.,592a688f-2e42-4e91-a3ea-34befe2a4e07,0143-9606-01,"Azacitidine, Injection, 100 mg/ Vial (NDC 0143-9606-01)",Injection,Available,"N0000000233, N0000175595",ANDA209337,,AZACITIDINE,Nucleoside Metabolic Inhibitor [EPC],,Current,,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,M801H13NRU,0143-9606-01,1-800-631-2174,Nucleic Acid Synthesis Inhibitors [MoA]
"Fresenius Kabi USA, LLC",LIDOCAINE HYDROCHLORIDE ANHYDROUS,,02/22/2012,Reverified,INFILTRATION,Lidocaine Hydrochloride Injection,"1010033, 1010035, 1010671, 1010673, 1010688, 1010692, 1010745, 1010749, 1010751, 1010755, 1010759, 1010763, 1010900, 1010902, 1737343, 1737345, 1737562, 1737563, 1737566, 1737567, 1737568, 1737569, 1737570, 1737571, 1737757, 1737758, 1737761, 1737762, 1867938, 1867940, 1867943, 1867944, 1867992, 1867993, 1867996, 1867997, 1868028, 1868029",,ba082c2f-64f4-419d-9c88-74f203316e17,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",XYLOCAINE MPF,"63323-491, 63323-492, 63323-495, 63323-485, 63323-486, 63323-484, 63323-489, 63323-488, 63323-481, 63323-483, 63323-482, 63323-487","Fresenius Kabi USA, LLC",ea480a68-5927-4278-9deb-2956961da428,"63323-492-04, 63323-492-27, 63323-492-09, 63323-492-57, 63323-492-07, 63323-492-37, 63323-492-03, 63323-492-31, 63323-491-01, 63323-491-57, 63323-495-09, 63323-495-27, 63323-495-04, 63323-495-07, 63323-485-01, 63323-485-27, 63323-485-03, 63323-485-57, 63323-486-01, 63323-486-17, 63323-486-02, 63323-486-27, 63323-486-05, 63323-486-57, 63323-484-57, 63323-489-02, 63323-489-27, 63323-489-03, 63323-489-21, 63323-489-01, 63323-489-17, 63323-488-07, 63323-488-37, 63323-488-03, 63323-488-31, 63323-488-01, 63323-488-17, 63323-481-01, 63323-481-57, 63323-483-03, 63323-483-27, 63323-483-01, 63323-483-57, 63323-482-01, 63323-482-17, 63323-482-03, 63323-482-27, 63323-482-05, 63323-482-57, 63323-487-01, 63323-487-17, 63323-487-07, 63323-487-37, 63323-487-03, 63323-487-31","Xylocaine, Injection, 5 mg/1 mL (NDC 63323-491-57)",Injection,Available,,NDA006488,,LIDOCAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,"EC2CNF7XFP, 30Q7KI53AK",63323-491-57,888-386-1300,
Takeda Pharmaceuticals USA Inc.,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854832, 854834, 854836, 854838, 854840, 854842, 854844, 854846, 854848, 854850, 854852, 1593856, 1593858, 1871456, 1871459, 1871460, 1871461, 1871462, 1871463, 1871464, 1871465, 1871466, 1871467, 1871468, 1871469",,704e4378-ca83-445c-8b45-3cfa51c1ecad,08/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,VYVANSE,"59417-101, 59417-102, 59417-103, 59417-104, 59417-105, 59417-106, 59417-107, 59417-115, 59417-116, 59417-117, 59417-118, 59417-119, 59417-120","Takeda Pharmaceuticals America, Inc.",756b98a0-fada-44b2-a606-f2e71ef8cc84,"59417-101-10, 59417-102-10, 59417-103-10, 59417-104-10, 59417-105-10, 59417-106-10, 59417-107-10, 59417-115-01, 59417-116-01, 59417-117-01, 59417-118-01, 59417-119-01, 59417-120-01","Vyvanse, Capsule, 10 mg (NDC 59417-101-10)",Capsule,Available,,NDA021977,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,59417-101-10,877-TAKEDA-7 (1-877-825-3327),
Baxter Healthcare,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807631, 1807632",,fbc01464-8885-4075-af41-911ffec5ae92,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,0338-0553,Baxter Healthcare Corporation,aca96e4a-a57b-47ac-bd60-e65c29e19743,"0338-0553-11, 0338-0553-18","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0338-0553-18)",Injection,,,NDA020178,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0338-0553-18,888-229-0001,
"Hospira, Inc., a Pfizer Company","BUPIVACAINE HYDROCHLORIDE, EPINEPHRINE BITARTRATE",,02/20/2018,Reverified,"EPIDURAL, INTRACAUDAL, PERINEURAL","Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","1012377, 1012381, 1012384, 1012388, 1012396, 1012400, 1012404, 1012406, 1672917, 1672919, 1673242, 1673243, 1724786, 1724787, 1724794, 1724796, 1724880, 1724884, 1725044, 1725046, 1725078, 1725079, 1725082, 1725083, 1867594, 1867596, 1867612, 1867614",,67578b56-7540-487e-1fba-481255620e78,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,MARCAINE WITH EPINEPHRINE,"0409-1749, 0409-1559, 0409-1560, 0409-1582, 0409-1587, 0409-1610, 0409-1746, 0409-1752, 0409-1755, 0409-2510, 0409-7535, 0409-1250, 0409-5010, 0409-1530, 0409-0525, 0409-7510, 0409-2253","Hospira, Inc.",b083f440-bfb7-449a-b601-c2f59a6f9dcf,"0409-1559-18, 0409-1559-10, 0409-1559-19, 0409-1559-30, 0409-1560-18, 0409-1560-10, 0409-1560-19, 0409-1560-29, 0409-1582-18, 0409-1582-10, 0409-1582-19, 0409-1582-29, 0409-1587-50, 0409-1610-50, 0409-1746-70, 0409-1746-10, 0409-1746-71, 0409-1746-30, 0409-1749-70, 0409-1749-10, 0409-1749-71, 0409-1749-29, 0409-1752-50, 0409-1755-50, 0409-2510-01, 0409-2510-25, 0409-7535-01, 0409-7535-25, 0409-1250-01, 0409-1250-25, 0409-5010-01, 0409-5010-25, 0409-1530-01, 0409-1530-25, 0409-0525-01, 0409-0525-25, 0409-7510-01, 0409-7510-25, 0409-2253-01, 0409-2253-25","Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000) (NDC 0409-1749-29)",Injection,Available,,NDA016964,,BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE,,,Current,,,,"30Q7KI53AK, 7TQO7W3VT8",0409-1749-29,844-646-4398,
Baxter Healthcare,DEXTROSE MONOHYDRATE,,03/01/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 10% Injection,"1795477, 1795480, 1795481, 1795607, 1795609, 1795610, 1795612, 1795616, 1795618",,3bb406a9-f5cb-403a-b1bb-5c4facbea3d5,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0338-0023, 0338-0017",Baxter Healthcare Corporation,31bb4a5f-733e-4354-9fbf-138dede4db0f,"0338-0017-10, 0338-0017-41, 0338-0017-11, 0338-0017-31, 0338-0017-48, 0338-0017-18, 0338-0017-38, 0338-0017-02, 0338-0017-03, 0338-0017-04, 0338-0023-02, 0338-0023-03, 0338-0023-04","Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)",Injection,Available,,NDA016694,,DEXTROSE MONOHYDRATE,,,Current,,,,LX22YL083G,0338-0023-02,888-229-0001,
Eugia US LLC,LIDOCAINE HYDROCHLORIDE,,02/20/2018,Revised,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Lidocaine Hydrochloride Injection,"1737562, 1737566, 1737568, 1737757, 1737761",,"9916b09d-a116-469d-92d5-60e50ea9782b, 89701fac-7536-4f16-87fb-f4cc121e74ee",09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,LIDOCAINE HYDROCHLORIDE,"55150-161, 55150-162, 55150-163, 55150-164, 55150-165",Eugia US LLC,"9916b09d-a116-469d-92d5-60e50ea9782b, 9b60bc92-6093-49f9-a6ba-075104ff7bb5","55150-161-09, 55150-162-09, 55150-163-00, 55150-164-09, 55150-165-09, 55150-161-02, 55150-162-05, 55150-163-30, 55150-164-02, 55150-165-05","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)",Injection,Available,,ANDA203082,,LIDOCAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,V13007Z41A,55150-161-02,888-238-7880,
"Hospira, Inc., a Pfizer Company",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Revised,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Bupivacaine Hydrochloride Injection,"1012377, 1012381, 1012384, 1012388, 1012396, 1012400, 1012404, 1012406, 1672917, 1672919, 1673242, 1673243, 1724786, 1724787, 1724794, 1724796, 1724880, 1724884, 1725044, 1725046, 1725078, 1725079, 1725082, 1725083, 1867594, 1867596, 1867612, 1867614",,67578b56-7540-487e-1fba-481255620e78,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,MARCAINE,"0409-1559, 0409-1560, 0409-1582, 0409-1587, 0409-1610, 0409-1746, 0409-1749, 0409-1752, 0409-1755, 0409-2510, 0409-7535, 0409-1250, 0409-5010, 0409-1530, 0409-0525, 0409-7510, 0409-2253","Hospira, Inc.",b083f440-bfb7-449a-b601-c2f59a6f9dcf,"0409-1559-18, 0409-1559-10, 0409-1559-19, 0409-1559-30, 0409-1560-18, 0409-1560-10, 0409-1560-19, 0409-1560-29, 0409-1582-18, 0409-1582-10, 0409-1582-19, 0409-1582-29, 0409-1587-50, 0409-1610-50, 0409-1746-70, 0409-1746-10, 0409-1746-71, 0409-1746-30, 0409-1749-70, 0409-1749-10, 0409-1749-71, 0409-1749-29, 0409-1752-50, 0409-1755-50, 0409-2510-01, 0409-2510-25, 0409-7535-01, 0409-7535-25, 0409-1250-01, 0409-1250-25, 0409-5010-01, 0409-5010-25, 0409-1530-01, 0409-1530-25, 0409-0525-01, 0409-0525-25, 0409-7510-01, 0409-7510-25, 0409-2253-01, 0409-2253-25","Marcaine, Injection, Marcaine 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1559-10)",Injection,Limited Availability,,NDA016964,,BUPIVACAINE HYDROCHLORIDE,,,Current,Demand increase for the drug,Limited Supply Available. Next Delivery and Estimated Recovery: December 2025,,"30Q7KI53AK, 7TQO7W3VT8",0409-1559-10,844-646-4398,
"Mylan Pharmaceuticals Inc., a Viatris Company",METHYLPHENIDATE,Central Nervous System Stimulation [PE],02/28/2025,Reverified,TRANSDERMAL,"Methylphenidate Film, Extended Release","753436, 753438, 753440, 753441",,1643b6a5-80da-4d4f-8c5f-feb907875702,09/17/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE,"0378-8261, 0378-8260, 0378-8262, 0378-8263",Mylan Pharmaceuticals Inc.,c17e03ec-3756-4043-ae82-33a0ef18380c,"0378-8260-16, 0378-8260-93, 0378-8261-16, 0378-8261-93, 0378-8262-16, 0378-8262-93, 0378-8263-16, 0378-8263-93","Methylphenidate, Film, Extended Release, 15mg/9hrs (NDC 0378-8261-93)","Film, Extended Release",Available,"N0000175739, N0000175729",ANDA206497,,METHYLPHENIDATE,Central Nervous System Stimulant [EPC],,Current,,,,207ZZ9QZ49,0378-8261-93,800-796-9526,
"Teva Pharmaceuticals USA, Inc.",CARBOPLATIN,,04/28/2023,Revised,INTRAVENOUS,Carboplatin Injection,597195,,"f330f5a2-2cad-402f-bcbb-26245a753276, e176b6ef-2ff6-498b-a9d8-7a634d147f37",09/15/2025,HUMAN PRESCRIPTION DRUG,,Oncology,CARBOPLATIN,"0703-4248, 0703-4244, 0703-4246, 0703-4239","Teva Parenteral Medicines, Inc.","bed4c1cf-f3ef-4faa-b2a4-24ee9a9879df, b943761e-6a46-45a0-bdb4-1fec1e101f8c","0703-4244-01, 0703-4246-01, 0703-4248-01, 0703-4239-01, 0703-4244-81, 0703-4246-81, 0703-4248-81, 0703-4239-81","Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)",Injection,Available,"N0000175413, N0000175073",ANDA077269,,CARBOPLATIN,Platinum-based Drug [EPC],,Current,,,,BG3F62OND5,0703-4248-01,800-545-8800,
Amneal Pharmaceuticals,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850",,c11cb3b6-3dff-477b-a249-b4c3118edc5f,09/17/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"65162-023, 65162-024, 65162-025, 65162-026, 65162-027, 65162-028",Amneal Pharmaceuticals LLC,759471b0-6930-4e65-9417-e1c334a0eb68,"65162-023-09, 65162-024-09, 65162-025-09, 65162-026-09, 65162-027-09, 65162-028-09","Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 65162-023-09)",Capsule,Unavailable,,ANDA202830,,LISDEXAMFETAMINE,,,Current,Shortage of an active ingredient,Shortage of an active ingredient,,SJT761GEGS,65162-023-09,866-525-7270,
"Elite Laboratories, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,0e024b69-567c-4b40-9c3e-a2daec34256c,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"64850-552, 64850-550, 64850-551, 64850-553, 64850-554, 64850-555, 64850-556","Elite Laboratories, Inc.",e414bb2e-d404-44ea-931c-5998b0a4c87e,"64850-550-01, 64850-551-01, 64850-552-01, 64850-553-01, 64850-554-01, 64850-555-01, 64850-556-01","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 64850-552-01)",Capsule,Limited Availability,,ANDA218604,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,,,SJT761GEGS,64850-552-01,888-852-6657,
"Fresenius Kabi USA, LLC",MORPHINE SULFATE,,10/31/2017,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Morphine Sulfate Injection,"1731993, 1732006, 1732011, 1732136, 2003714",,582f42e5-444e-4246-af8c-e7e28097c69a,09/18/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,MORPHINE SULFATE,"63323-451, 63323-452, 63323-454, 63323-455, 63323-458","Fresenius Kabi USA, LLC",dbf870e7-7bfe-48f0-ba6a-9cc476dfe5cc,"63323-452-00, 63323-452-01, 63323-454-00, 63323-454-01, 63323-455-00, 63323-455-01, 63323-458-00, 63323-458-01, 63323-451-00, 63323-451-01","Morphine Sulfate, Injection, 10 mg/1 mL (NDC 63323-451-01)",Injection,Available,,NDA204223,,MORPHINE SULFATE,,,Current,,Check wholesalers for inventory,,X3P646A2J0,63323-451-01,888-386-1300,
Otsuka ICU Medical LLC,DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795477, 1795480, 1795481, 1795607, 1795609, 1795610, 1795612, 1795616, 1795618, 1795621",,8b25b7e0-703e-4b43-a4eb-52863511602d,09/17/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0990-7922, 0990-7923, 0990-7930","ICU Medical, Inc.",09b10612-c937-4d10-becb-9768e10caa2c,"0990-7923-20, 0990-7923-23, 0990-7923-36, 0990-7923-37, 0990-7923-13, 0990-7922-02, 0990-7922-03, 0990-7922-09, 0990-7922-53, 0990-7922-55, 0990-7922-61, 0990-7930-02, 0990-7930-03, 0990-7930-09","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-03)",Injection,Available,,NDA016367,,DEXTROSE MONOHYDRATE,,,Current,,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,LX22YL083G,0990-7922-03,1-866-829-9025 or ProductAvailability@icumed.com,
AstraZeneca AB,EXENATIDE,,10/25/2024,New,SUBCUTANEOUS,Exenatide Synthetic Injection,"847910, 847913, 847915, 847917",,53d03c03-ebf7-418d-88a8-533eabd2ee4f,10/25/2024,HUMAN PRESCRIPTION DRUG,10/25/2024,Endocrinology/Metabolism,BYETTA,"0310-6512, 0310-6524",AstraZeneca Pharmaceuticals LP,7333a7dd-9449-4c61-b36d-c5d8d7cc239b,"0310-6512-01, 0310-6512-85, 0310-6524-01","Byetta, Injection, 300MCG/1.2ML (250MCG/ML) (NDC 0310-6512-01)",Injection,,"N0000178480, M0160181, N0000020058",NDA021773,Glucagon-Like Peptide 1 [CS],EXENATIDE,GLP-1 Receptor Agonist [EPC],,To Be Discontinued,,,,9P1872D4OL,0310-6512-01,800-236-9933,Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
Aurobindo Pharma USA,AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","308189, 313850",,3cacd754-73f4-496e-a529-9ca39fa6692d,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"65862-070, 65862-071",Aurobindo Pharma Limited,3e3ca279-1838-4348-a01c-df10a8bcb8b9,"65862-070-50, 65862-070-75, 65862-070-01, 65862-071-50, 65862-071-75, 65862-071-01","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 65862-070-50)","Powder, For Suspension",,,ANDA065334,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,65862-070-50,866-850-2876,
Sandoz Inc.,SOMATROPIN,,01/06/2023,Revised,SUBCUTANEOUS,Somatropin Injection,"241975, 645884, 854302, 864110, 1736267, 1736337",,58d84ffa-4056-4e36-ad67-7bd4aef444a5,08/28/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,OMNITROPE,"0781-3004, 0781-3001, 0781-4004",Sandoz Inc,4285f380-615e-420b-b756-1e0a775f785b,"0781-3001-26, 0781-3001-07, 0781-3004-26, 0781-3004-07, 0781-4004-36, 0781-4014-71, 0781-4024-72","Omnitrope, Injection, 10 mg/1.5 mL (NDC 0781-3004-07)",Injection,,"N0000175606, M0028842",BLA021426,Human Growth Hormone [CS],SOMATROPIN,Recombinant Human Growth Hormone [EPC],Available,Resolved,,,08/28/2025,NQX9KB6PCL,0781-3004-07,800-525-8747,
Eli Lilly and Co.,DULAGLUTIDE,,12/15/2022,Revised,SUBCUTANEOUS,Dulaglutide Injection,"1551295, 1551300, 1551304, 1551306, 2395777, 2395779, 2395783, 2395785",,463050bd-2b1c-40f5-b3c3-0a04bb433309,06/13/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,TRULICITY,"0002-1434, 0002-1433, 0002-2236, 0002-3182",Eli Lilly and Company,2a046089-7cd3-43d3-9f7f-27e3e4b49f0d,"0002-1433-01, 0002-1433-80, 0002-1433-61, 0002-1434-01, 0002-1434-80, 0002-1434-61, 0002-2236-01, 0002-2236-80, 0002-2236-61, 0002-3182-01, 0002-3182-80, 0002-3182-61","Trulicity, Injection, 1.5 mg/.5 mL (NDC 0002-1434-80)",Injection,,"N0000178480, M0160181, N0000020058",BLA125469,Glucagon-Like Peptide 1 [CS],DULAGLUTIDE,GLP-1 Receptor Agonist [EPC],Available,Resolved,,,06/13/2025,WTT295HSY5,0002-1434-80,800-545-5979,Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
"Teva Pharmaceuticals USA, Inc.",GLYBURIDE,,06/10/2025,New,ORAL,Glyburide Tablet,"310536, 310539, 314000",,e84c0dfc-a4e9-4c89-b6ea-45732eb412f5,06/10/2025,HUMAN PRESCRIPTION DRUG,06/10/2025,Endocrinology/Metabolism,GLYBURIDE,"0093-8034, 0093-8035, 0093-8036","Teva Pharmaceuticals USA, Inc.",00e55b1b-81b5-4df1-8a6d-4d54ac403e76,"0093-8034-01, 0093-8035-01, 0093-8035-05, 0093-8036-01","Glyburide (Micronized), Tablet, 1.5 mg (NDC 0093-8034-01)",Tablet,,"N0000175608, M0020795",ANDA074686,Sulfonylurea Compounds [CS],GLYBURIDE,Sulfonylurea [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,SX6K58TVWC,0093-8034-01,800-545-8800,
"Novo Nordisk, Inc.",INSULIN ASPART,,07/21/2025,New,"INTRAVENOUS, SUBCUTANEOUS",Insulin Aspart Injection,"311040, 1653196, 1653202",,bee5b358-c863-420b-be73-ced2e920c499,07/21/2025,HUMAN PRESCRIPTION DRUG,07/21/2025,Endocrinology/Metabolism,INSULIN ASPART,"73070-100, 73070-102, 73070-103","Novo Nordisk Pharma, Inc.",393af9a3-df9a-40b2-a5e6-bfa5434a2552,"73070-100-11, 73070-102-10, 73070-102-15, 73070-103-10, 73070-103-15","Insulin Aspart, Injection, 10 mL Insulin Aspart vial (NDC 73070-100-11)",Injection,,"M0011417, N0000175453",BLA020986,Insulin [CS],INSULIN ASPART,Insulin Analog [EPC],,To Be Discontinued,,"Unbranded Insulin Aspart 10 mL vial will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,D933668QVX,73070-100-11,609-987-5800,
Granules Pharmaceuticals Inc.,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,b0b4eccc-34c7-483d-966f-82d588358e1b,09/08/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","70010-113, 70010-111, 70010-112, 70010-114, 70010-115, 70010-116, 70010-117",Granules Pharmaceuticals Inc.,2fab399e-2a43-5134-e063-6294a90ae09a,"70010-111-01, 70010-111-03, 70010-112-01, 70010-112-03, 70010-113-01, 70010-113-03, 70010-114-01, 70010-114-03, 70010-115-01, 70010-115-03, 70010-116-01, 70010-116-03, 70010-117-01, 70010-117-03","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 70010-113-01)",Tablet,Available,,ANDA215771,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",70010-113-01,877-770-3183,
Milla Pharmaceuticals,SODIUM ACETATE,,03/23/2016,Revised,INTRAVENOUS,Sodium Acetate Injection,"237371, 312965",,1ea1466d-a492-4056-e063-6394a90a80bf,09/16/2025,HUMAN PRESCRIPTION DRUG,,Total Parenteral Nutrition,SODIUM ACETATE,"71357-007, 71357-008, 71357-009",MILLA PHARMACEUTICALS INC.,2913569b-0f7e-8027-e063-6294a90aaf78,"71357-007-01, 71357-007-10, 71357-008-01, 71357-008-10, 71357-009-01, 71357-009-10","Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 71357-007-10)",Injection,Available,,ANDA214805,,SODIUM ACETATE,,,Current,,,,4550K0SC9B,71357-007-10,833-251-8463,
Aurobindo Pharma USA,CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,b1582eb7-af35-45d5-a52e-0e380d08527d,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"59651-722, 59651-723, 59651-724",Aurobindo Pharma Limited,b1582eb7-af35-45d5-a52e-0e380d08527d,"59651-722-01, 59651-722-99, 59651-723-01, 59651-723-99, 59651-724-01, 59651-724-05","Clonazepam, Tablet, .5 mg (NDC 59651-722-01)",Tablet,Available,"N0000175694, M0002356",ANDA075150,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,,,5PE9FDE8GB,59651-722-01,866-850-2876,
Baxter Healthcare,DOBUTAMINE HYDROCHLORIDE,,11/06/2017,Reverified,INTRAVENOUS,Dobutamine Hydrochloride Injection,"309985, 309986, 309987",,6b17b98b-e06d-42ed-925f-69aa2699dead,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Cardiovascular, Pediatric, Renal",DOBUTAMINE HYDROCHLORIDE IN DEXTROSE,"0338-1075, 0338-1073, 0338-1077",Baxter Healthcare Corporation,2ac85da3-8337-4b3b-8cda-d9399780542f,"0338-1073-02, 0338-1075-02, 0338-1077-02","Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 mg/100 mL (NDC 0338-1075-02)",Injection,Available,,NDA020255,,DOBUTAMINE HYDROCHLORIDE,,,Current,,,,0WR771DJXV,0338-1075-02,888-229-0001,
Novadoz Pharmaceuticals LLC,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Revised,ORAL,"Lisdexamfetamine Dimesylate Tablet, Chewable","1871456, 1871460, 1871462, 1871464, 1871466, 1871468",,a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"72205-137, 72205-132, 72205-133, 72205-134, 72205-135, 72205-136",Novadoz Pharmaceuticals LLC,a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811,"72205-132-91, 72205-133-91, 72205-134-91, 72205-135-91, 72205-136-91, 72205-137-91","Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 72205-137-91)","Tablet, Chewable",Available,,ANDA218306,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,,,SJT761GEGS,72205-137-91,(855) 668-2369; customerservice@novadozpharma.com,
"Teva Pharmaceuticals USA, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Revised,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541365, 541878, 541879, 541892, 541894, 577957, 577960, 577961, 577962, 687043, 687045, 1009145, 1009147",,f22635fe-821d-4cde-aa12-419f8b53db81,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,ADDERALL,"57844-110, 57844-105, 57844-117, 57844-112, 57844-115, 57844-120, 57844-130","Teva Pharmaceuticals USA, Inc.",79af1dc6-c7cf-41b1-a750-e9b47c2187ff,"57844-105-01, 57844-117-01, 57844-110-01, 57844-112-01, 57844-115-01, 57844-120-01, 57844-130-01","Adderall, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 57844-110-01)",Tablet,Available,,ANDA040422,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",57844-110-01,800-545-8800,
"Hospira, Inc., a Pfizer Company",ATROPINE SULFATE,,01/01/2012,Reverified,INTRAVENOUS,Atropine Sulfate Injection,"1190546, 1190551, 1190552",,ad8916e7-206e-409e-2582-30d072845dd4,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology, Pediatric",ATROPINE SULFATE,"0409-1630, 0409-9630, 0409-4910, 0409-4911","Hospira, Inc.",9211a9e9-35d0-457d-ac95-4ad43ea6bf28,"0409-1630-15, 0409-1630-10, 0409-9630-15, 0409-9630-05, 0409-4910-11, 0409-4910-34, 0409-4911-11, 0409-4911-34","Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-1630-10)",Injection,Available,,NDA021146,,ATROPINE SULFATE,,,Current,,,,03J5ZE7KA5,0409-1630-10,844-646-4398,
Eugia US LLC,AZACITIDINE,,12/22/2020,Revised,"INTRAVENOUS, SUBCUTANEOUS",Azacitidine Injection,485246,,ecd108bd-bb5f-4b2e-ad91-210fca452e9b,09/05/2025,HUMAN PRESCRIPTION DRUG,,Oncology,AZACITIDINE,55150-393,Eugia US LLC,e89b9510-86df-4095-b6d3-4eb05b613c4f,55150-393-01,"Azacitidine, Injection, 100 mg/4 mL (NDC 55150-393-01)",Injection,Available,"N0000000233, N0000175595",ANDA215066,,AZACITIDINE,Nucleoside Metabolic Inhibitor [EPC],,Current,,Check wholesalers for inventory,,M801H13NRU,55150-393-01,888-238-7880,Nucleic Acid Synthesis Inhibitors [MoA]
"Novo Nordisk, Inc.",LIRAGLUTIDE,,07/18/2023,Reverified,SUBCUTANEOUS,Liraglutide Injection,897122,,14bf9812-14ee-46ce-93b1-686e4906cbbc,09/16/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,LIRAGLUTIDE,0480-3667,"Teva Pharmaceuticals USA, Inc.",b56c797c-a46a-4dbf-a367-9d7f26c7d29d,"0480-3667-19, 0480-3667-22, 0480-3667-20","Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)",Injection,Available,"N0000178480, M0160181, N0000020058",NDA022341,Glucagon-Like Peptide 1 [CS],LIRAGLUTIDE,GLP-1 Receptor Agonist [EPC],,Current,,Distributed by Teva,,839I73S42A,0480-3667-20,833-493-4689,Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
"Actavis Pharma, Inc.",MEMANTINE HYDROCHLORIDE,,11/21/2024,New,ORAL,Memantine Hydrochloride Tablet,"996561, 996571, 996572",,72973b46-f307-4a9e-8fb1-ad2cbccfd736,11/21/2024,HUMAN PRESCRIPTION DRUG,11/21/2024,Neurology,MEMANTINE HYDROCHLORIDE,"0591-3875, 0591-3870, 0591-3900","Actavis Pharma, Inc.",985e1190-b8a0-4775-9a20-ad1924b14fb2,"0591-3870-60, 0591-3870-45, 0591-3870-44, 0591-3875-60, 0591-3875-45, 0591-3875-44, 0591-3900-87","Namenda, Tablet, 10 mg (NDC 0591-3875-44)",Tablet,,,NDA021487,,MEMANTINE HYDROCHLORIDE,,,To Be Discontinued,,,,JY0WD0UA60,0591-3875-44,800-545-8800,
"Fresenius Kabi USA, LLC",MORPHINE SULFATE,,10/31/2017,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Morphine Sulfate Injection,"894912, 894914, 998212, 998213, 1442790",,"1f53de80-efc8-4930-b3e3-fba0d026af05, b62ee1ef-db55-417a-a02e-b103890f9c4b",09/18/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,MORPHINE SULFATE,"76045-005, 76045-004, 76045-006, 76045-007, 76045-008","Fresenius Kabi, USA LLC, Fresenius Kabi USA, LLC","286bce70-23cd-4d5b-989b-230d6cdd5a91, e064585d-2d2d-41cd-a0f1-43494ce4775b","76045-004-01, 76045-004-11, 76045-005-01, 76045-005-11, 76045-006-01, 76045-006-11, 76045-007-01, 76045-007-11, 76045-008-01, 76045-008-11, 76045-004-02, 76045-004-12, 76045-005-02, 76045-005-12, 76045-006-02, 76045-006-12, 76045-007-00, 76045-007-10, 76045-008-00, 76045-008-10","Morphine Sulfate, Injection, 4 mg/1 mL (NDC 76045-005-11)",Injection,Available,,NDA204223,,MORPHINE SULFATE,,,Current,,Check wholesalers for inventory,,X3P646A2J0,76045-005-11,888-386-1300,
"Teva Pharmaceuticals USA, Inc.",,,01/06/2025,New,,Ezetimibe; Simvastatin Tablet,,,,01/06/2025,,01/06/2025,Cardiovascular,,,,,,"EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 20 mg (NDC 45963-566-30)",Tablet,,,,,,,,To Be Discontinued,,,,,45963-566-30,800-545-8800,
Baxter Healthcare,"CALCIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, SODIUM LACTATE",,10/11/2024,Reverified,INTRAVENOUS,Lactated Ringers Injection,847630,,dad7735c-709b-40ea-ab7a-15577e24a966,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other",LACTATED RINGERS,0338-0117,Baxter Healthcare Company,a3c6770a-d279-4ea9-b8ed-5484be18121e,"0338-0117-02, 0338-0117-03, 0338-0117-04","Lactated Ringers, Injection, 500 mL bag, 24 count (NDC 0338-0117-03)",Injection,Available,,NDA016682,,"SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM LACTATE AND CALCIUM CHLORIDE",,,Current,,,,"M4I0D6VV5M, 660YQ98I10, 451W47IQ8X, TU7HW0W0QT",0338-0117-03,888-229-0001,
Takeda Pharmaceuticals USA Inc.,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854832, 854834, 854836, 854838, 854840, 854842, 854844, 854846, 854848, 854850, 854852, 1593856, 1593858, 1871456, 1871459, 1871460, 1871461, 1871462, 1871463, 1871464, 1871465, 1871466, 1871467, 1871468, 1871469",,704e4378-ca83-445c-8b45-3cfa51c1ecad,08/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,VYVANSE,"59417-107, 59417-101, 59417-102, 59417-103, 59417-104, 59417-105, 59417-106, 59417-115, 59417-116, 59417-117, 59417-118, 59417-119, 59417-120","Takeda Pharmaceuticals America, Inc.",756b98a0-fada-44b2-a606-f2e71ef8cc84,"59417-101-10, 59417-102-10, 59417-103-10, 59417-104-10, 59417-105-10, 59417-106-10, 59417-107-10, 59417-115-01, 59417-116-01, 59417-117-01, 59417-118-01, 59417-119-01, 59417-120-01","Vyvanse, Capsule, 70 mg (NDC 59417-107-10)",Capsule,Available,,NDA021977,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,59417-107-10,877-TAKEDA-7 (1-877-825-3327),
"Mylan Pharmaceuticals Inc., a Viatris Company",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,efbde0f6-b848-4664-b741-c6c630e66108,09/17/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0378-6860, 0378-6854, 0378-6855, 0378-6856, 0378-6857, 0378-6858, 0378-6859",Mylan Pharmaceuticals Inc.,2dfa8600-1b2a-47e8-b58d-c9681b8795cb,"0378-6854-77, 0378-6855-77, 0378-6856-77, 0378-6857-77, 0378-6858-77, 0378-6859-77, 0378-6860-77","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0378-6860-77)",Capsule,Available,,ANDA202835,,LISDEXAMFETAMINE,,,Current,,,,SJT761GEGS,0378-6860-77,800-796-9526,
"Hikma Pharmaceuticals USA, Inc.",MEPERIDINE HYDROCHLORIDE,,05/30/2025,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Meperidine Hydrochloride Injection,"861476, 1665685, 1665697",,e0e998da-f056-4fce-be8e-ed60cf3b461b,07/23/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,MEPERIDINE HYDROCHLORIDE,"0641-6054, 0641-6053, 0641-6052",Hikma Pharmaceuticals USA Inc.,9566d54d-7343-4695-94ff-8b5f2d384c81,"0641-6053-01, 0641-6053-25, 0641-6054-01, 0641-6054-25, 0641-6052-01, 0641-6052-25","Meperidine Hydrochloride, Injection, 100 mg/1 mL (NDC 0641-6054-25)",Injection,Unavailable,,ANDA080445,,MEPERIDINE HYDROCHLORIDE,,,Current,Shortage of an active ingredient,Additional Lots scheduled to be available in the October-November 2025 timeframe.,,N8E7F7Q170,0641-6054-25,800-631-2174,
Aurobindo Pharma USA,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,a582d57f-d191-4ca5-b105-585b2d8a0e3e,09/17/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","13107-072, 13107-068, 13107-069, 13107-070, 13107-071, 13107-073, 13107-074","Aurolife Pharma, LLC",95842af2-8d9d-4eb1-ba39-86cdbd829a79,"13107-068-50, 13107-068-01, 13107-068-25, 13107-068-05, 13107-068-99, 13107-069-50, 13107-069-01, 13107-069-25, 13107-069-05, 13107-069-99, 13107-070-50, 13107-070-01, 13107-070-25, 13107-070-05, 13107-070-99, 13107-071-50, 13107-071-01, 13107-071-25, 13107-071-05, 13107-071-99, 13107-072-50, 13107-072-01, 13107-072-25, 13107-072-05, 13107-072-99, 13107-073-50, 13107-073-01, 13107-073-25, 13107-073-05, 13107-073-99, 13107-074-50, 13107-074-01, 13107-074-25, 13107-074-05, 13107-074-99","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 13107-072-01)",Tablet,Unavailable,,ANDA202424,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,Shortage of an active ingredient,Estimated availability December 2025,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",13107-072-01,(866) 850-2876 OR CustomerService@AurobindoUSA.com,
"Vertical Pharmaceuticals, LLC",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Reverified,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release",,,22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d,09/16/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,RELEXXII,"68025-096, 68025-088, 68025-089, 68025-095, 68025-097, 68025-084, 68025-098","Vertical Pharmaceuticals, LLC",86f477e9-07fc-466b-913e-1a4434c91df4,"68025-088-30, 68025-089-30, 68025-095-10, 68025-095-30, 68025-096-10, 68025-096-30, 68025-097-10, 68025-097-30, 68025-084-30, 68025-098-10, 68025-098-30","Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-10)",Tablet,Unavailable,,NDA216117,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,Other,Estimated recovery: TBD,,4B3SC438HI,68025-096-10,800-541-4802,
"XGen Pharmaceuticals DJB, Inc.",PROMETHAZINE HYDROCHLORIDE,,11/21/2023,Revised,"INTRAMUSCULAR, INTRAVENOUS",Promethazine Hydrochloride Injection,992460,,1d02d52b-84bb-4e81-b352-125029eb39f6,09/04/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Gastroenterology, Other, Pulmonary/Allergy",PROMETHAZINE HYDROCHLORIDE,39822-5525,"XGen Pharmaceuticals DJB, Inc.",0e3526e1-38be-1d89-e063-6294a90a775d,"39822-5525-2, 39822-5525-3","Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 39822-5525-3)",Injection,Limited Availability,,ANDA040737,,PROMETHAZINE HYDROCHLORIDE,,,Current,Demand increase for the drug,,,R61ZEH7I1I,39822-5525-3,866-390-4411,
Chartwell Molecular Holdings LLC,"HYDROCHLOROTHIAZIDE, QUINAPRIL HYDROCHLORIDE",Increased Diuresis [PE],01/19/2023,Reverified,ORAL,Quinapril/Hydrochlorothiazide Tablet,"310796, 310797, 310809",,2eae533f-d0af-47e8-a1f2-94bc8cc89b5a,08/19/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,QUINAPRIL AND HYDROCHLOROTHIAZIDE,"62135-668, 62135-667, 62135-669","Chartwell RX, LLC",0c3f4504-d57e-aa79-e063-6294a90ad5b8,"62135-667-90, 62135-668-90, 62135-669-90","Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 62135-668-90)",Tablet,Available,"N0000175359, N0000175419, M0471776",ANDA076374,Thiazides [CS],QUINAPRIL AND HYDROCHLOROTHIAZIDE,Thiazide Diuretic [EPC],,Current,,,,"0J48LPH2TH, 33067B3N2M",62135-668-90,845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com,
"Fresenius Kabi USA, LLC",WATER,,11/23/2021,Reverified,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Sterile Water Injection,,,e71c6c83-d518-496c-b2ab-efd5987e4783,09/18/2025,HUMAN PRESCRIPTION DRUG,,Other,STERILE WATER,63323-185,"Fresenius Kabi USA, LLC",42c6c812-706a-425b-b8cb-931006e40484,"63323-185-07, 63323-185-10, 63323-185-09, 63323-185-50, 63323-185-08, 63323-185-20, 63323-185-04, 63323-185-05","Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-50)",Injection,Available,,ANDA088400,,WATER,,,Current,,Check wholesalers for inventory,,059QF0KO0R,63323-185-50,888-386-1300,
"Upsher-Smith Laboratories, LLC",AMANTADINE HYDROCHLORIDE,,07/23/2025,New,ORAL,Amantadine Hydrochloride Capsule,849389,,5232b933-1df9-43b4-8ac2-61bfa4855e68,07/23/2025,HUMAN PRESCRIPTION DRUG,07/23/2025,"Antiviral, Neurology",AMANTADINE HYDROCHLORIDE,0832-1015,"Upsher-Smith Laboratories, LLC",398493aa-8a67-10e2-e063-6394a90aef8d,"0832-1015-00, 0832-1015-50","Amantadine Hydrochloride, Capsule, 100 mg (NDC 0832-1015-50)",Capsule,,,ANDA070589,,AMANTADINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug product,,M6Q1EO9TD0,0832-1015-50,763-315-2000,
"Hospira, Inc., a Pfizer Company",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,SUBARACHNOID,Bupivacaine Hydrochloride Injection,1724784,,7a8d2539-4422-4312-0298-207ef1a2948e,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE SPINAL,0409-3613,"Hospira, Inc.",43a8f8dd-af5e-486d-bd36-a7f2956f2bc0,"0409-3613-11, 0409-3613-01","Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)",Injection,Available,,ANDA071810,,BUPIVACAINE HYDROCHLORIDE IN DEXTROSE,,,Current,,,,7TQO7W3VT8,0409-3613-01,844-646-4398,
Cheplapharm Arzneimittel GmbH,CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529, 206157, 206159, 206160",,cfa0d79a-843c-4b88-95a1-e9511d649ca1,09/15/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",KLONOPIN,"61269-610, 61269-605, 61269-620","H2-Pharma, LLC",c8a147a4-9ebc-4c69-a5b6-bf7547dc6334,"61269-605-10, 61269-610-10, 61269-620-10","Klonopin, Tablet, 1 mg (NDC 61269-610-10)",Tablet,Available,"N0000175694, M0002356",NDA017533,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,Marketed by H2-Pharma,,5PE9FDE8GB,61269-610-10,orders@h2-pharma.com,
B. Braun Medical Inc.,DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795609, 1795616, 1795618",,60b6d7c3-0164-46c9-aa38-b5aa1c31a5d5,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,0264-1510,B. Braun Medical Inc.,0a144591-6cfa-4aed-a067-c95aebc29057,"0264-1510-36, 0264-1510-31, 0264-1510-32","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-31)",Injection,Available,,NDA016730,,DEXTROSE,,,Current,,,,LX22YL083G,0264-1510-31,800-227-2862,
Strides Pharma Inc.,DONEPEZIL HYDROCHLORIDE,,01/28/2025,New,ORAL,Donepezil Hydrochloride Tablet,"997223, 997229",,297e86e8-d248-4cc9-9d9c-2ef9efb4414d,01/28/2025,HUMAN PRESCRIPTION DRUG,01/28/2025,Neurology,DONEPEZIL HYDROCHLORIDE,"71093-127, 71093-128","ACI Healthcare USA, Inc.",a4736add-da84-411f-8e6f-9de67bf467f8,"71093-127-01, 71093-127-03, 71093-127-05, 71093-127-06, 71093-128-01, 71093-128-03, 71093-128-05, 71093-128-06","Donepezil Hydrochloride, Tablet, 5 mg (NDC 71093-127-01)",Tablet,,,ANDA078662,,DONEPEZIL HYDROCHLORIDE,,,To Be Discontinued,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,3O2T2PJ89D,71093-127-01,877-244-9825,
"Laboratorios Grifols, S.A.",SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807631, 1807632, 1807633, 1807634, 1807639",,28f79c75-82d2-4912-81fc-a723b5ccf4c1,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,79672-613,Nextgen Pharmaceuticals LLC,3c545b9f-67e4-489d-bb60-c39c990d7dda,"79672-613-01, 79672-613-10, 79672-613-02, 79672-613-20, 79672-613-03, 79672-613-30, 79672-613-04, 79672-613-40, 79672-613-05, 79672-613-50","Sodium Chloride 0.9%, 250 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-03)",Injection,,,ANDA207956,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,79672-613-03,800-848-0462,
Pfizer Inc.,TALAZOPARIB TOSYLATE,,01/13/2025,New,ORAL,Talazoparib Tosylate Capsule,"2099946, 2099952, 2099954, 2099956, 2591510, 2591512, 2591520, 2591521, 2639960, 2639962, 2639964, 2639966",,f2423edd-6d24-495c-aec1-c2f457f08d9a,01/13/2025,HUMAN PRESCRIPTION DRUG,01/13/2025,Oncology,TALZENNA,"0069-1031, 0069-0296, 0069-1195, 0069-1501, 0069-1751, 0069-1235",Pfizer Laboratories Div Pfizer Inc,2cb65f61-9a14-46d9-85a3-a7eea76160c5,"0069-0296-30, 0069-1195-30, 0069-1501-30, 0069-1751-30, 0069-1031-30, 0069-1235-30","Talzenna, Capsule, .1 mg (NDC 0069-1031-30)",Capsule,,,NDA211651,,TALAZOPARIB,,,To Be Discontinued,,"Supply expected to exhaust late February 2025
Replaced with Soft Gel NDC 0069-0252-30",,02WK9U5NZC,0069-1031-30,800-533-4535,
Apotex Corp.,,,01/27/2025,New,,Bendamustine Hydrochloride Injection,,,,01/27/2025,,01/27/2025,Oncology,,,,,,"Bendamustine Hydrochloride, Injection, 25 mg (NDC 60505-6095-0)",Injection,,,,,,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,,60505-6095-0,800-706-5575,
Eugia US LLC,DEXAMETHASONE SODIUM PHOSPHATE,,02/08/2019,Revised,"INTRAMUSCULAR, INTRAVENOUS",Dexamethasone Sodium Phosphate Injection,309696,,224c34c9-cadc-40cb-a9b7-a9772fd0208e,09/05/2025,HUMAN PRESCRIPTION DRUG,,"Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Other, Pulmonary/Allergy, Rheumatology",DEXAMETHASONE SODIUM PHOSPHATE,55150-305,Eugia US LLC,46f657ae-77ec-4eca-a1eb-df540d94eded,"55150-305-01, 55150-305-10","Dexamethasone Sodium Phosphate, Injection, 100 mg/10 mL (NDC 55150-305-10)",Injection,Unavailable,,ANDA210967,,DEXAMETHASONE SODIUM PHOSPHATE,,,Current,Demand increase for the drug,On backorder. Recovery: TBD. Check wholesalers for inventory,,AI9376Y64P,55150-305-10,888-238-7880,
Baxter Healthcare,DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795477, 1795480, 1795481, 1795607, 1795609, 1795610, 1795612, 1795616, 1795618",,3bb406a9-f5cb-403a-b1bb-5c4facbea3d5,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0338-0017, 0338-0023",Baxter Healthcare Corporation,31bb4a5f-733e-4354-9fbf-138dede4db0f,"0338-0017-10, 0338-0017-41, 0338-0017-11, 0338-0017-31, 0338-0017-48, 0338-0017-18, 0338-0017-38, 0338-0017-02, 0338-0017-03, 0338-0017-04, 0338-0023-02, 0338-0023-03, 0338-0023-04","Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-41)",Injection,Available,,NDA016673,,DEXTROSE MONOHYDRATE,,,Current,,,,LX22YL083G,0338-0017-41,888-229-0001,
Torrent Pharma Inc.,,,06/13/2025,New,,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,,,,06/13/2025,,06/13/2025,Cardiovascular,,,,,,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 40 mg (NDC 13668-386-90)",Tablet,,,,,,,,To Be Discontinued,,A business decision was made to discontinue manufacture of the product.,,,13668-386-90,908-280-3333,
"Sun Pharmaceutical Industries, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Revised,ORAL,"Lisdexamfetamine Dimesylate Tablet, Chewable","854830, 854834, 854838, 854842, 854846, 854850, 1593856, 1871456, 1871460, 1871462, 1871464, 1871466, 1871468",,da3148af-f9b6-4725-adae-3595b4c7dc4b,09/22/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"57664-087, 57664-047, 57664-046, 57664-048, 57664-049, 57664-050, 57664-051, 57664-052, 57664-083, 57664-084, 57664-085, 57664-086, 57664-088","Sun Pharmaceutical Industries, Inc.",0b77417a-5789-8818-e063-6294a90ad2e3,"57664-047-88, 57664-046-88, 57664-048-88, 57664-049-88, 57664-050-88, 57664-051-88, 57664-052-88, 57664-083-88, 57664-084-88, 57664-085-88, 57664-086-88, 57664-087-88, 57664-088-88","Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 57664-087-88)","Tablet, Chewable",Limited Availability,,ANDA214134,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Other,Available Q3 2025,,SJT761GEGS,57664-087-88,800-818-4555,
Pfizer Inc.,METHYLPREDNISOLONE ACETATE,,12/15/2021,Reverified,"INTRALESIONAL, INTRAMUSCULAR, INTRASYNOVIAL, SOFT TISSUE",Methylprednisolone Acetate Injection,"1358510, 1358512, 1358610, 1358612, 1358617, 1358619",,823b0010-2b57-4e76-b5ac-4a8c2963438f,08/15/2025,HUMAN PRESCRIPTION DRUG,,Rheumatology,DEPO-MEDROL,"0009-0274, 0009-0280, 0009-0306",Pharmacia & Upjohn Company LLC,4cf5a255-1360-4511-9b58-b92e3492ef12,"0009-0274-01, 0009-0280-02, 0009-0280-51, 0009-0280-03, 0009-0280-52, 0009-0306-02, 0009-0306-12","Depo-medrol, Injection, 20 mg/1 mL (NDC 0009-0274-01)",Injection,Available,,NDA011757,,METHYLPREDNISOLONE ACETATE,,,Current,,,,43502P7F0P,0009-0274-01,844-646-4398,
"Fresenius Kabi USA, LLC",ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Reverified,"EPIDURAL, INFILTRATION",Ropivacaine Hydrochloride Injection,"1734203, 1734204, 1734207, 1734208, 1734347, 1734348, 1734355, 1734356, 1734475, 1734476, 1734479, 1734480, 1734481, 1734482, 1734483, 1734484, 905189, 905191, 1734084, 1734086, 1734090, 1734091",,"dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7, 23d2d448-a744-4877-9f2d-7e57c198da89, c6613708-c1f7-4f5c-91a3-ebbc1d7905c6",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,NAROPIN,"63323-285, 63323-286, 63323-287, 63323-288","Fresenius Kabi USA, LLC","324532ac-4e54-4659-a1a2-9ade22a1ed3f, cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9, 73218c89-8925-468c-84bf-9960b4b3dc3c","63323-286-41, 63323-286-27, 63323-286-43, 63323-286-38, 63323-285-41, 63323-285-28, 63323-285-53, 63323-285-68, 63323-285-59, 63323-285-73, 63323-286-01, 63323-286-20, 63323-286-05, 63323-286-23, 63323-286-09, 63323-286-31, 63323-286-11, 63323-286-35, 63323-286-03, 63323-286-00, 63323-286-33, 63323-286-63, 63323-286-30, 63323-287-01, 63323-287-20, 63323-287-03, 63323-287-21, 63323-288-01, 63323-288-10, 63323-288-06, 63323-288-20, 63323-288-03, 63323-288-11, 63323-288-07, 63323-288-21, 63323-285-01, 63323-285-10, 63323-285-06, 63323-285-20, 63323-285-03, 63323-285-13, 63323-285-07, 63323-285-23, 63323-285-57, 63323-285-64, 63323-285-51, 63323-285-65, 63323-285-02, 63323-285-61, 63323-285-04, 63323-285-63, 63323-285-55, 63323-285-67, 63323-288-23, 63323-288-29, 63323-286-93, 63323-286-95","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-10)",Injection,Unavailable,,NDA020533,,ROPIVACAINE HYDROCHLORIDE,,,Current,Demand increase for the drug,Next release not available at this time.,,V910P86109,63323-285-10,888-386-1300,
Eugia US LLC,BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Revised,"EPIDURAL, RETROBULBAR",Bupivacaine Hydrochloride Injection,"1012396, 1012404, 1724786, 1724787, 1724880, 1724884, 1725078, 1725082",,ffecf450-1f01-4721-8e10-251385852612,09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE,"55150-171, 55150-167, 55150-168, 55150-169, 55150-170, 55150-172, 55150-249, 55150-250",Eugia US LLC,39649703-e633-4a20-ba71-0c04dbf8ff2a,"55150-167-10, 55150-168-30, 55150-169-10, 55150-170-30, 55150-171-10, 55150-172-30, 55150-249-50, 55150-250-50","Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-171-10)",Injection,Available,,ANDA203895,,BUPIVACAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,7TQO7W3VT8,55150-171-10,888-238-7880,
Aurobindo Pharma USA,"AMLODIPINE BESYLATE, BENAZEPRIL HYDROCHLORIDE",,03/04/2025,New,ORAL,Amlodipine Besylate; Benazepril Hydrochloride Capsule,"898342, 898346, 898350, 898353, 898356, 898359",,99ed4927-9a34-4e8d-8eea-60b63c867d46,03/04/2025,HUMAN PRESCRIPTION DRUG,03/04/2025,Cardiovascular,AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE,"65862-586, 65862-582, 65862-583, 65862-584, 65862-585, 65862-587",Aurobindo Pharma Limited,a45ec3e8-1d14-4c27-9685-976323df8cad,"65862-582-01, 65862-582-05, 65862-583-01, 65862-583-05, 65862-584-01, 65862-584-05, 65862-585-01, 65862-585-05, 65862-586-01, 65862-586-05, 65862-587-01, 65862-587-05","Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 10 mg; 20 mg (NDC 65862-586-01)",Capsule,,,ANDA202239,,AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE,,,To Be Discontinued,,,,"864V2Q084H, N1SN99T69T",65862-586-01,866-850-2876,
"Teva Pharmaceuticals USA, Inc.",GLYBURIDE,,06/10/2025,New,ORAL,Glyburide Tablet,"310536, 310539, 314000",,e84c0dfc-a4e9-4c89-b6ea-45732eb412f5,06/10/2025,HUMAN PRESCRIPTION DRUG,06/10/2025,Endocrinology/Metabolism,GLYBURIDE,"0093-8036, 0093-8034, 0093-8035","Teva Pharmaceuticals USA, Inc.",00e55b1b-81b5-4df1-8a6d-4d54ac403e76,"0093-8034-01, 0093-8035-01, 0093-8035-05, 0093-8036-01","Glyburide (Micronized), Tablet, 6 mg (NDC 0093-8036-01)",Tablet,,"N0000175608, M0020795",ANDA074686,Sulfonylurea Compounds [CS],GLYBURIDE,Sulfonylurea [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,SX6K58TVWC,0093-8036-01,800-545-8800,
SpecGx LLC,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,806a1c15-0842-4787-b2ad-09a21fd96b37,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0406-5116, 0406-5111, 0406-5112, 0406-5113, 0406-5114, 0406-5115, 0406-5117",SpecGx LLC,3ffc0695-83f7-4898-9fd7-451c0989cfe0,"0406-5111-01, 0406-5112-01, 0406-5113-01, 0406-5114-01, 0406-5115-01, 0406-5116-01, 0406-5117-01","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0406-5116-01)",Capsule,Limited Availability,,ANDA211840,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,Allocation to all customers.,,SJT761GEGS,0406-5116-01,800-325-8888,
Eugia US LLC,FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Furosemide Injection,"1719286, 1719290, 1719291",,421aa6d5-623b-4dc2-abd5-bb9e7765bf37,09/25/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,"55150-322, 55150-323, 55150-324",Eugia US LLC,26acfb26-d058-453e-8c05-61ec44b25118,"55150-322-01, 55150-322-25, 55150-323-01, 55150-323-25, 55150-324-01, 55150-324-25","Furosemide, Injection, 20 mg/2 mL (NDC 55150-322-25)",Injection,Available,"N0000175366, N0000175590",ANDA212174,,FUROSEMIDE,Loop Diuretic [EPC],,Current,,Check wholesalers for inventory,,7LXU5N7ZO5,55150-322-25,888-238-7880,
B. Braun Medical Inc.,"DEXTROSE MONOHYDRATE, LIDOCAINE HYDROCHLORIDE ANHYDROUS",,10/25/2017,Reverified,INTRAVENOUS,Lidocaine Hydrochloride Injection,"1737723, 1737742, 1737744",,7dff29d9-522d-40eb-a9d9-42377912d640,09/16/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,LIDOCAINE HYDROCHLORIDE AND DEXTROSE,"0264-9594, 0264-9598",B. Braun Medical Inc.,26f23356-9e1f-4c5f-9959-06d53037a715,"0264-9598-20, 0264-9594-20, 0264-9594-10","Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-10)",Injection,Available,,NDA019830,,LIDOCAINE HYDROCHLORIDE ANHYDROUS AND DEXTROSE MONOHYDRATE,,,Current,,,,"LX22YL083G, EC2CNF7XFP",0264-9594-10,800-227-2862,
"Teva Pharmaceuticals USA, Inc.",POTASSIUM CHLORIDE,,05/19/2025,New,ORAL,"Potassium Chloride Capsule, Extended Release","312504, 315183",,ed5baaf6-270b-4dd3-b100-36030c0098fc,05/19/2025,HUMAN PRESCRIPTION DRUG,05/19/2025,"Endocrinology/Metabolism, Gastroenterology",POTASSIUM CHLORIDE,"62037-559, 62037-560","Actavis Pharma, Inc.",b97da107-c56e-48ea-ba34-d3d64a5b9f46,"62037-559-01, 62037-559-05, 62037-560-01, 62037-560-05, 62037-560-10, 62037-560-90","Potassium Chloride, Capsule, Extended Release, 600 mg (NDC 62037-559-01)","Capsule, Extended Release",,,ANDA077419,,POTASSIUM CHLORIDE,,,To Be Discontinued,,,,660YQ98I10,62037-559-01,800-545-8800,
"Fresenius Kabi USA, LLC","EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE ANHYDROUS",,10/14/2016,Revised,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL","Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","1010033, 1010035, 1010671, 1010673, 1010688, 1010692, 1010745, 1010749, 1010751, 1010755, 1010759, 1010763, 1010900, 1010902, 1737343, 1737345, 1737562, 1737563, 1737566, 1737567, 1737568, 1737569, 1737570, 1737571, 1737757, 1737758, 1737761, 1737762, 1867938, 1867940, 1867943, 1867944, 1867992, 1867993, 1867996, 1867997, 1868028, 1868029",,ba082c2f-64f4-419d-9c88-74f203316e17,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",XYLOCAINE MPF,"63323-487, 63323-492, 63323-491, 63323-495, 63323-485, 63323-486, 63323-484, 63323-489, 63323-488, 63323-481, 63323-483, 63323-482","Fresenius Kabi USA, LLC",ea480a68-5927-4278-9deb-2956961da428,"63323-492-04, 63323-492-27, 63323-492-09, 63323-492-57, 63323-492-07, 63323-492-37, 63323-492-03, 63323-492-31, 63323-491-01, 63323-491-57, 63323-495-09, 63323-495-27, 63323-495-04, 63323-495-07, 63323-485-01, 63323-485-27, 63323-485-03, 63323-485-57, 63323-486-01, 63323-486-17, 63323-486-02, 63323-486-27, 63323-486-05, 63323-486-57, 63323-484-57, 63323-489-02, 63323-489-27, 63323-489-03, 63323-489-21, 63323-489-01, 63323-489-17, 63323-488-07, 63323-488-37, 63323-488-03, 63323-488-31, 63323-488-01, 63323-488-17, 63323-481-01, 63323-481-57, 63323-483-03, 63323-483-27, 63323-483-01, 63323-483-57, 63323-482-01, 63323-482-17, 63323-482-03, 63323-482-27, 63323-482-05, 63323-482-57, 63323-487-01, 63323-487-17, 63323-487-07, 63323-487-37, 63323-487-03, 63323-487-31","Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-17)",Injection,Available,,NDA006488,,LIDOCAINE HYDROCHLORIDE,,,Current,Demand increase for the drug,Check wholesalers for inventory,,"EC2CNF7XFP, 30Q7KI53AK",63323-487-17,888-386-1300,
"Fresenius Kabi USA, LLC",HEPARIN SODIUM,,11/14/2017,Revised,INTRAVENOUS,Heparin Sodium Injection,"1658690, 1658692",,25b0ba06-3274-4a3f-8c39-42d13764ecdf,09/18/2025,HUMAN PRESCRIPTION DRUG,,Hematology,HEPARIN SODIUM,63323-519,"Fresenius Kabi USA, LLC",3bbbe74a-1246-41a6-9fc3-ca0230529b40,"63323-519-02, 63323-519-77, 63323-519-01, 63323-519-10","Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-77)",Injection,Unavailable,,ANDA212441,,HEPARIN SODIUM,,,Current,Other,Backordered. Next release October 2025. Check wholesalers for inventory.,,ZZ45AB24CA,63323-519-77,888-386-1300,
Sandoz Inc.,AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","239191, 308182, 308189, 308191, 308192, 308194, 313797, 313850",,13bd4214-9b7f-425b-af5f-fc1ddc678230,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0781-6039, 0781-2020, 0781-2613, 0781-5060, 0781-5061, 0781-6156, 0781-6041, 0781-6157",Sandoz Inc,6aa02079-d11c-4d2f-acaf-9548dd9a7ed6,"0781-2020-31, 0781-2020-76, 0781-2020-01, 0781-2020-05, 0781-2613-31, 0781-2613-76, 0781-2613-01, 0781-2613-05, 0781-5060-20, 0781-5060-01, 0781-5061-20, 0781-5061-01, 0781-6039-58, 0781-6039-46, 0781-6039-55, 0781-6156-52, 0781-6156-57, 0781-6156-46, 0781-6041-58, 0781-6041-46, 0781-6041-55, 0781-6157-52, 0781-6157-57, 0781-6157-46","Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0781-6039-46)","Powder, For Suspension",,,ANDA065387,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0781-6039-46,800-525-8747,
Kindos Pharmaceuticals Co. Ltd.,BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,PERINEURAL,Bupivacaine Hydrochloride Injection,"1012396, 1012404",,fe340f98-a0f3-446e-b281-47fd91c1e537,08/19/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE,"71288-726, 71288-723",Meitheal Pharmaceuticals Inc,0949c302-51ce-4fc9-8b99-1df94e693718,"71288-723-52, 71288-726-52","Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52)",Injection,Available,,ANDA216039,,BUPIVACAINE HYDROCHLORIDE,,,Current,,Meitheal Pharmaceuticals is distributor/labeler; product is available,,7TQO7W3VT8,71288-726-52,844-824-8426,
"Fresenius Kabi USA, LLC",DEXAMETHASONE SODIUM PHOSPHATE,,02/08/2019,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Dexamethasone Sodium Phosphate Injection,"1116927, 1812194",,"2b626a48-c7aa-4443-9164-a08ff069ccd1, 4fedef4f-ec96-4f36-b2f0-01e243e3b89e",09/18/2025,HUMAN PRESCRIPTION DRUG,,"Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Other, Pulmonary/Allergy, Rheumatology",DEXAMETHASONE SODIUM PHOSPHATE,63323-165,"Fresenius Kabi USA, LLC","a832bff9-0bb3-4350-abb5-d57b9417070c, 9dd90418-e564-4bc5-9077-506a1c2c1bce","63323-165-11, 63323-165-51, 63323-165-13, 63323-165-53, 63323-165-02, 63323-165-01, 63323-165-03, 63323-165-05, 63323-165-30, 63323-165-16, 63323-165-26","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-01)",Injection,Available,,ANDA084916,,DEXAMETHASONE SODIUM PHOSPHATE,,,Current,,Check wholesalers for inventory.,,AI9376Y64P,63323-165-01,888-386-1300,
"EMD Serono, Inc.",LEVOTHYROXINE SODIUM,,07/10/2025,New,ORAL,Levothyroxine Sodium Tablet,"892246, 892251, 966153, 966160, 966166, 966173, 966177, 966182, 966187, 966196, 966202, 966207, 966220, 966221, 966222, 966224, 966225, 966248, 966249, 966253, 966270, 2104866",,bc3c6830-ba68-4ba3-9896-a12d0ad0b275,07/10/2025,HUMAN PRESCRIPTION DRUG,07/10/2025,Endocrinology/Metabolism,EUTHYROX,"72305-150, 72305-025, 72305-050, 72305-075, 72305-088, 72305-100, 72305-112, 72305-125, 72305-137, 72305-175, 72305-200","Provell Pharmaceuticals, LLC",45657074-8874-49f4-a8ef-3ca7e210c16e,"72305-025-30, 72305-025-90, 72305-050-30, 72305-050-90, 72305-075-30, 72305-075-90, 72305-088-30, 72305-088-90, 72305-100-30, 72305-100-90, 72305-112-30, 72305-112-90, 72305-125-30, 72305-125-90, 72305-137-30, 72305-137-90, 72305-150-30, 72305-150-90, 72305-175-30, 72305-175-90, 72305-200-30, 72305-200-90","Euthyrox, Tablet, 150 ug (NDC 72305-150-90)",Tablet,,,NDA021292,,LEVOTHYROXINE SODIUM,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,9J765S329G,72305-150-90,888-899-7041,
Apotex Corp.,LISDEXAMFETAMINE DIMESYLATE,,11/01/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,ecad4442-a644-18e3-6ff2-fdbac45eec47,09/29/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"60505-4740, 60505-4739, 60505-4741, 60505-4742, 60505-4743, 60505-4744, 60505-4745",Apotex Corp.,c8e0c70d-2f5b-8d85-fa45-572e8f5f7b4c,"60505-4739-1, 60505-4740-1, 60505-4741-1, 60505-4742-1, 60505-4743-1, 60505-4744-1, 60505-4745-1","Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)",Capsule,Available,,ANDA216944,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,Product currently available,,SJT761GEGS,60505-4740-1,800-706-5575,
Takeda Pharmaceuticals USA Inc.,PARATHYROID HORMONE,,09/11/2019,Reverified,SUBCUTANEOUS,Parathyroid Hormone Injection,"1602023, 1602028, 1602032, 1602034, 1602038, 1602040, 1602044, 1602046",,d11fba31-0a6c-11e3-8ffd-0800200c9a66,08/15/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,NATPARA (PARATHYROID HORMONE),"68875-0202, 68875-0203, 68875-0204, 68875-0205","Takeda Pharmaceuticals America, Inc.",17d2bb82-605c-43be-9918-63aeb7102d8c,"68875-0202-1, 68875-0202-2, 68875-0203-1, 68875-0203-2, 68875-0204-1, 68875-0204-2, 68875-0205-1, 68875-0205-2","Natpara, Injection, 25 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0202-2)",Powder,Limited Availability,"M0015931, N0000180851",BLA125511,Parathyroid Hormone [CS],PARATHYROID HORMONE,Parathyroid Hormone [EPC],,Current,Discontinuation of the manufacture of the drug,Takeda will be ceasing manufacturing of Natpara at the end of 2024 with a priority to maintain treatment continuity for patients enrolled in the U.S. Special Use Program until inventory is depleted or expired.,,N19A0T0E5J,68875-0202-2,866-888-0660,
"Dr. Reddy's Laboratories, Inc.",RAMELTEON,,01/08/2025,New,ORAL,Ramelteon Tablet,577348,,b71cd925-1bae-5a6a-072b-941ad6d3ce65,01/08/2025,HUMAN PRESCRIPTION DRUG,01/08/2025,Other,RAMELTEON,43598-741,Dr.Reddys Laboratories Inc,54220029-c5df-b277-af7e-2786da03bbed,"43598-741-30, 43598-741-01, 43598-741-10","Tablet, 8 mg (NDC 43598-741-01)",Tablet,,"N0000175743, N0000000250",ANDA091693,,RAMELTEON,Melatonin Receptor Agonist [EPC],,To Be Discontinued,,,,901AS54I69,43598-741-01,866-732-3952,Melatonin Receptor Agonists [MoA]
"Hospira, Inc., a Pfizer Company",ROCURONIUM BROMIDE,,02/15/2023,Reverified,INTRAVENOUS,Rocuronium Bromide Injection,1234995,,c96726ef-f1fa-4ebb-ba33-3479c3902a8e,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROCURONIUM BROMIDE,"0409-3189, 0409-7037","Hospira, Inc.",c96726ef-f1fa-4ebb-ba33-3479c3902a8e,"0409-3189-05, 0409-3189-10, 0409-7037-01, 0409-7037-10","Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-3189-10)",Injection,Available,,ANDA205656,,ROCURONIUM BROMIDE,,,Current,,,,I65MW4OFHZ,0409-3189-10,844-646-4398,
Rubicon Research Private Limited,CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"72888-152, 72888-153, 72888-154",Advagen Pharma Ltd,36cf156e-5980-a21b-e063-6294a90ab3a0,"72888-152-30, 72888-152-01, 72888-152-05, 72888-152-00, 72888-153-30, 72888-153-01, 72888-153-05, 72888-153-00, 72888-154-30, 72888-154-01, 72888-154-05, 72888-154-00","Clonazepam, Tablet, .5 mg (NDC 72888-152-30)",Tablet,Available,"N0000175694, M0002356",ANDA075468,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,Marketed by Advagen Pharma Ltd.,,5PE9FDE8GB,72888-152-30,sales@advagenpharma.com,
"Lupin Pharmaceuticals, Inc.",RIFAMPIN,,12/22/2021,Reverified,ORAL,Rifampin Capsule,,,b56004f0-f23d-47f6-80c7-39884fccbccc,09/18/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,RIFAMPIN,"68180-658, 68180-659","Lupin Pharmaceuticals, Inc.",751434c4-f772-4821-899c-3ce2e44be6fe,"68180-658-06, 68180-658-01, 68180-659-06, 68180-659-07, 68180-659-01","Rifampin, Capsule, 150 mg (NDC 68180-658-06)",Capsule,Available,"N0000175500, M0019113",ANDA090034,Rifamycins [CS],RIFAMPIN,Rifamycin Antibacterial [EPC],,Current,,,,VJT6J7R4TR,68180-658-06,866-587-4617,
Sandoz Inc.,ADALIMUMAB,,04/14/2025,New,SUBCUTANEOUS,Adalimumab-adaz Injection,"2641644, 2641650, 2641653, 2641654, 2641655, 2641658, 2641660, 2641661, 2641662, 2641663, 2641664, 2641665, 2641666, 2641667, 2641668, 2641669, 2641670, 2641671, 2641672, 2641673",,1ac7d061-3380-468c-b077-c05f8dfbc829,04/14/2025,HUMAN PRESCRIPTION DRUG,04/14/2025,Rheumatology,HYRIMOZ,"61314-476, 61314-454, 61314-473, 61314-509, 61314-517, 61314-531",Sandoz Inc,bd62cde8-792c-4194-949e-ad87a6d5aef0,"61314-454-20, 61314-454-36, 61314-454-68, 61314-473-64, 61314-473-20, 61314-473-92, 61314-476-64, 61314-509-64, 61314-517-36, 61314-531-64","Hyrimoz, Injection, 20 mg/.2 mL (NDC 61314-476-64)",Injection,,"N0000175610, N0000175451, M0001357",BLA761071,"Antibodies, Monoclonal [CS]",ADALIMUMAB-ADAZ,Tumor Necrosis Factor Blocker [EPC],,To Be Discontinued,,,,FYS6T7F842,61314-476-64,800-525-8747,Tumor Necrosis Factor Receptor Blocking Activity [MoA]
GlaxoSmithKline,DAPRODUSTAT,,11/21/2024,New,ORAL,Daprodustat Tablet,"2628215, 2628221, 2628223, 2628225, 2628227, 2628229, 2628231, 2628233, 2628235, 2628237",,d82aa06e-5a33-4844-99b7-4701313455a4,11/21/2024,HUMAN PRESCRIPTION DRUG,11/21/2024,Hematology,JESDUVROQ,"0173-0906, 0173-0897, 0173-0903, 0173-0911, 0173-0914",GlaxoSmithKline LLC,d52a823a-35bd-4c6a-a016-4b4f21a43d7d,"0173-0897-13, 0173-0897-56, 0173-0903-13, 0173-0903-56, 0173-0906-13, 0173-0906-56, 0173-0911-13, 0173-0911-56, 0173-0914-13, 0173-0914-56","Jesduvroq, Tablet, 4 mg (NDC 0173-0906-13)",Tablet,,"N0000194080, N0000194079",NDA216951,,DAPRODUSTAT,Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC],,To Be Discontinued,,Discontinuing for Business Reasons.,,JVR38ZM64B,0173-0906-13,888-825-5249,Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors [MoA]
Pfizer Inc.,"ESTROGENS, ESTERIFIED",,07/29/2025,New,ORAL,Esterified Estrogens Tablet,"197666, 197667, 197668, 197669, 212039, 212232, 212373, 212464",,e0141598-0bb2-4cf0-c9b8-6867b34bbb17,07/29/2025,HUMAN PRESCRIPTION DRUG,07/29/2025,Endocrinology/Metabolism,MENEST,"61570-073, 61570-072, 61570-074, 61570-075",Pfizer Laboratories Div Pfizer Inc,78aaf71c-8f0d-47c4-9fcf-f5e7e9b84bfb,"61570-072-01, 61570-073-01, 61570-074-01, 61570-075-50","Menest, Tablet, .625 mg (NDC 61570-073-01)",Tablet,,,ANDA084948,,ESTERIFIED ESTROGENS,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,3ASP8Q3768,61570-073-01,800-533-4535,
"Meitheal Pharmaceuticals, Inc.",FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Furosemide Injection,"1719286, 1719290, 1719291",,a2e3c748-28ce-4c50-a182-721912919840,08/19/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,71288-203,Meitheal Pharmaceuticals Inc.,78b32838-f75b-4aba-9b4b-9978f755fced,"71288-203-02, 71288-203-03, 71288-203-04, 71288-203-05, 71288-203-10, 71288-203-11","Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-05)",Injection,Available,"N0000175366, N0000175590",ANDA212803,,FUROSEMIDE,Loop Diuretic [EPC],,Current,,,,7LXU5N7ZO5,71288-203-05,844-824-8426,
"Teva Pharmaceuticals USA, Inc.",,,02/06/2025,New,,"Glipizide Tablet, Extended Release",,,,02/06/2025,,02/06/2025,Endocrinology/Metabolism,,,,,,"Glipizide, Tablet, Extended Release, 10 mg (NDC 0591-0845-10)",Tablet,,,,,,,,To Be Discontinued,,A business decision was made to discontinue manufacture of the drug.,,,0591-0845-10,800-545-8800,
"Fresenius Kabi USA, LLC",HEPARIN SODIUM,,11/14/2017,Revised,INTRAVENOUS,Heparin Sodium Injection,"1658690, 1658692",,25b0ba06-3274-4a3f-8c39-42d13764ecdf,09/18/2025,HUMAN PRESCRIPTION DRUG,,Hematology,HEPARIN SODIUM,63323-519,"Fresenius Kabi USA, LLC",3bbbe74a-1246-41a6-9fc3-ca0230529b40,"63323-519-02, 63323-519-77, 63323-519-01, 63323-519-10","Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-10)",Injection,Unavailable,,ANDA212441,,HEPARIN SODIUM,,,Current,Other,Backordered. Next release October 2025. Check wholesalers for inventory.,,ZZ45AB24CA,63323-519-10,888-386-1300,
Amneal Pharmaceuticals,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850",,c11cb3b6-3dff-477b-a249-b4c3118edc5f,09/17/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"65162-028, 65162-023, 65162-024, 65162-025, 65162-026, 65162-027",Amneal Pharmaceuticals LLC,759471b0-6930-4e65-9417-e1c334a0eb68,"65162-023-09, 65162-024-09, 65162-025-09, 65162-026-09, 65162-027-09, 65162-028-09","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 65162-028-09)",Capsule,Unavailable,,ANDA202830,,LISDEXAMFETAMINE,,,Current,Shortage of an active ingredient,Shortage of an active ingredient,,SJT761GEGS,65162-028-09,866-525-7270,
"Sunrise Pharmaceutical, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,ac102599-3a5b-4154-899e-6ff262be7ff7,09/03/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","11534-190, 11534-191, 11534-192, 11534-193, 11534-194, 11534-195, 11534-196","SUNRISE PHARMACEUTICAL, INC.",86a00bec-51eb-4d73-a945-b1937970b29a,"11534-190-01, 11534-190-03, 11534-191-01, 11534-191-03, 11534-192-01, 11534-192-03, 11534-193-01, 11534-193-03, 11534-194-01, 11534-194-03, 11534-195-01, 11534-195-03, 11534-196-01, 11534-196-03","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 11534-190-01)",Tablet,Available,,ANDA209799,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",11534-190-01,732-382-6085 Monday to Friday 9 am to 3:45 pm,
"Hospira, Inc., a Pfizer Company",SODIUM CHLORIDE,,01/01/2020,Revised,INTRAVENOUS,Sodium Chloride 23.4% Injection,313016,,af6aebad-ef03-4d19-9a40-18e5a278b812,07/02/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Pediatric, Total Parenteral Nutrition",SODIUM CHLORIDE,0409-1141,"Hospira, Inc.",eb5856a5-e97c-4990-9ef1-97c8f221a59a,"0409-1141-12, 0409-1141-02","Sodium Chloride, Injection, 400 mEq/100 mL (4 mEq/mL) (NDC 0409-1141-02)",Injection,,,NDA018897,,SODIUM CHLORIDE,,Available,Resolved,,,07/02/2025,451W47IQ8X,0409-1141-02,844-646-4398,
"Fresenius Kabi USA, LLC",TIGECYCLINE,,12/09/2024,New,INTRAVENOUS,Tigecycline Injection,581531,,acf5dbe5-ca75-4300-816f-b3f4625f6e7d,12/09/2024,HUMAN PRESCRIPTION DRUG,12/09/2024,Anti-Infective,TIGECYCLINE,63323-960,"Fresenius Kabi USA, LLC",0a2a6def-f494-41f8-8125-4296924b1753,"63323-960-01, 63323-960-10","Injection, 50 mg/5 mL (NDC 63323-960-10)",Injection,,"N0000175938, M0021223",NDA205645,Tetracyclines [CS],TIGECYCLINE,Tetracycline-class Antibacterial [EPC],,To Be Discontinued,,Check wholesalers for inventory.,,70JE2N95KR,63323-960-10,888-386-1300,
"Fresenius Kabi USA, LLC",DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Revised,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,309710,,c1b8eb58-596b-481d-beb6-ba9d2237abf4,09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE HYDROCHLORIDE,63323-421,"Fresenius Kabi USA, LLC",19087b96-58fb-400b-b5c6-689e5e33c5c8,"63323-421-01, 63323-421-02","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 63323-421-02)",Injection,Available,,ANDA201072,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,,Short-dated supply (7 months from expiry) available upon request. Check wholesaler for inventory.,,1018WH7F9I,63323-421-02,888-386-1300,
"Hikma Pharmaceuticals USA, Inc.",AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","239191, 313797",,077f4a65-3cfb-4cb1-99f2-e27ffc5939c0,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0143-9888, 0143-9889",Hikma Pharmaceuticals USA Inc.,c2fa2c99-c735-4834-a8a5-04a30da8a002,"0143-9888-80, 0143-9888-01, 0143-9888-15, 0143-9889-80, 0143-9889-01, 0143-9889-15","Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0143-9888-01)","Powder, For Suspension",,,ANDA065322,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0143-9888-01,800-631-2174,
B. Braun Medical Inc.,"DEXTROSE MONOHYDRATE, LIDOCAINE HYDROCHLORIDE ANHYDROUS",,10/25/2017,Reverified,INTRAVENOUS,Lidocaine Hydrochloride Injection,"1737723, 1737742, 1737744",,7dff29d9-522d-40eb-a9d9-42377912d640,09/16/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,LIDOCAINE HYDROCHLORIDE AND DEXTROSE,"0264-9598, 0264-9594",B. Braun Medical Inc.,26f23356-9e1f-4c5f-9959-06d53037a715,"0264-9598-20, 0264-9594-20, 0264-9594-10","Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .8 g/100 mL (NDC 0264-9598-20)",Injection,Available,,NDA019830,,LIDOCAINE HYDROCHLORIDE ANHYDROUS AND DEXTROSE MONOHYDRATE,,,Current,,,,"LX22YL083G, EC2CNF7XFP",0264-9598-20,800-227-2862,
Takeda Pharmaceuticals USA Inc.,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,"Lisdexamfetamine Dimesylate Tablet, Chewable","854830, 854832, 854834, 854836, 854838, 854840, 854842, 854844, 854846, 854848, 854850, 854852, 1593856, 1593858, 1871456, 1871459, 1871460, 1871461, 1871462, 1871463, 1871464, 1871465, 1871466, 1871467, 1871468, 1871469",,704e4378-ca83-445c-8b45-3cfa51c1ecad,08/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,VYVANSE,"59417-117, 59417-101, 59417-102, 59417-103, 59417-104, 59417-105, 59417-106, 59417-107, 59417-115, 59417-116, 59417-118, 59417-119, 59417-120","Takeda Pharmaceuticals America, Inc.",756b98a0-fada-44b2-a606-f2e71ef8cc84,"59417-101-10, 59417-102-10, 59417-103-10, 59417-104-10, 59417-105-10, 59417-106-10, 59417-107-10, 59417-115-01, 59417-116-01, 59417-117-01, 59417-118-01, 59417-119-01, 59417-120-01","Vyvanse, Tablet, Chewable, 30 mg (NDC 59417-117-01)","Tablet, Chewable",Available,,NDA208510,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,59417-117-01,877-TAKEDA-7 (1-877-825-3327),
"Fresenius Kabi USA, LLC",ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Reverified,"EPIDURAL, INFILTRATION, PERINEURAL",Ropivacaine Hydrochloride Injection,"1734203, 1734204, 1734207, 1734208, 1734347, 1734348, 1734355, 1734356, 1734475, 1734476, 1734479, 1734480, 1734481, 1734482, 1734483, 1734484, 905189, 905191, 1734084, 1734086, 1734090, 1734091",,"dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7, 23d2d448-a744-4877-9f2d-7e57c198da89, c6613708-c1f7-4f5c-91a3-ebbc1d7905c6",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,NAROPIN,"63323-286, 63323-285, 63323-287, 63323-288","Fresenius Kabi USA, LLC","324532ac-4e54-4659-a1a2-9ade22a1ed3f, cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9, 73218c89-8925-468c-84bf-9960b4b3dc3c","63323-286-41, 63323-286-27, 63323-286-43, 63323-286-38, 63323-285-41, 63323-285-28, 63323-285-53, 63323-285-68, 63323-285-59, 63323-285-73, 63323-286-01, 63323-286-20, 63323-286-05, 63323-286-23, 63323-286-09, 63323-286-31, 63323-286-11, 63323-286-35, 63323-286-03, 63323-286-00, 63323-286-33, 63323-286-63, 63323-286-30, 63323-287-01, 63323-287-20, 63323-287-03, 63323-287-21, 63323-288-01, 63323-288-10, 63323-288-06, 63323-288-20, 63323-288-03, 63323-288-11, 63323-288-07, 63323-288-21, 63323-285-01, 63323-285-10, 63323-285-06, 63323-285-20, 63323-285-03, 63323-285-13, 63323-285-07, 63323-285-23, 63323-285-57, 63323-285-64, 63323-285-51, 63323-285-65, 63323-285-02, 63323-285-61, 63323-285-04, 63323-285-63, 63323-285-55, 63323-285-67, 63323-288-23, 63323-288-29, 63323-286-93, 63323-286-95","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-31)",Injection,Unavailable,,NDA020533,,ROPIVACAINE HYDROCHLORIDE,,,Current,Delay in shipping of the drug,Not available at this time.,,V910P86109,63323-286-31,888-386-1300,
Amneal Pharmaceuticals,METHYLPREDNISOLONE ACETATE,,12/15/2021,Reverified,"INTRA-ARTICULAR, INTRALESIONAL, INTRAMUSCULAR, INTRASYNOVIAL, SOFT TISSUE",Methylprednisolone Acetate Injection,"1743779, 1743855",,d944240d-2c19-46ba-ad4f-3fbee7b8629c,09/17/2025,HUMAN PRESCRIPTION DRUG,,Rheumatology,METHYLPREDNISOLONE ACETATE,"70121-1573, 70121-1574",Amneal Pharmaceuticals LLC,0bdaa3cf-cf32-4959-b87a-65215ac4648d,"70121-1573-1, 70121-1573-5, 70121-1574-1, 70121-1574-5","Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-1)",Injection,Available,,ANDA210043,,METHYLPREDNISOLONE ACETATE,,,Current,,,,43502P7F0P,70121-1573-1,866-525-7270,
Baxter Healthcare,SODIUM CHLORIDE,,04/28/2023,Revised,IRRIGATION,Sodium Chloride 0.9% Irrigation,486515,,b3b4b176-41f0-4ca8-90d4-3fba5707564a,07/02/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,0338-0048,Baxter Healthcare Corporation,123eac3f-8e50-4689-bf00-cf9407eb70ee,"0338-0048-02, 0338-0048-03, 0338-0048-04, 0338-0048-05","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0338-0048-02)",Irrigation,,,NDA017427,,SODIUM CHLORIDE,,,Resolved,,,07/02/2025,451W47IQ8X,0338-0048-02,888-229-0001,
Sandoz Inc.,SOMATROPIN,,01/06/2023,Revised,SUBCUTANEOUS,Somatropin Injection,"241975, 645884, 854302, 864110, 1736267, 1736337",,58d84ffa-4056-4e36-ad67-7bd4aef444a5,08/28/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,OMNITROPE,"0781-3001, 0781-3004, 0781-4004",Sandoz Inc,4285f380-615e-420b-b756-1e0a775f785b,"0781-3001-26, 0781-3001-07, 0781-3004-26, 0781-3004-07, 0781-4004-36, 0781-4014-71, 0781-4024-72","Omnitrope, Injection, 5 mg/1.5 mL (NDC 0781-3001-07)",Injection,,"N0000175606, M0028842",BLA021426,Human Growth Hormone [CS],SOMATROPIN,Recombinant Human Growth Hormone [EPC],Available,Resolved,,,08/28/2025,NQX9KB6PCL,0781-3001-07,800-525-8747,
"Mylan Pharmaceuticals Inc., a Viatris Company",TOLTERODINE TARTRATE,,02/26/2025,New,ORAL,"Tolterodine Tartrate Capsule, Extended Release","855182, 855184, 855189, 855191",,d7274947-4f88-47ee-a39f-bd5ac46fcf8d,02/26/2025,HUMAN PRESCRIPTION DRUG,02/26/2025,Urology,DETROL LA,"58151-104, 58151-103",Viatris Specialty LLC,a1e49744-9302-47ee-92af-8b19aa0b2fc1,"58151-103-93, 58151-103-77, 58151-103-05, 58151-104-93, 58151-104-77, 58151-104-05","Detrol LA, Capsule, Extended Release, 4 mg (NDC 58151-104-77)","Capsule, Extended Release",,,NDA021228,,TOLTERODINE TARTRATE,,,To Be Discontinued,,,,5T619TQR3R,58151-104-77,800-796-9526,
B. Braun Medical Inc.,"DEXTROSE, UNSPECIFIED FORM",,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795477, 1795480, 1795481, 1795607, 1795610, 1795612",,085614c7-ada4-4e2c-87c0-c9bc2f18365a,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0264-7510, 0264-7520",B. Braun Medical Inc.,c9f87749-8dd5-41fd-b393-f63d45fd00ef,"0264-7510-00, 0264-7510-10, 0264-7510-20, 0264-7520-00, 0264-7520-10, 0264-7520-20","Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-20)",Injection,Available,,NDA019626,,DEXTROSE,,,Current,,,,IY9XDZ35W2,0264-7510-20,800-227-2862,
Pfizer Inc.,GLIPIZIDE,,03/17/2025,New,ORAL,"Glipizide Tablet, Extended Release","310489, 314006, 315107, 865568, 865571, 865573",,eed99b60-d043-4249-9b2a-f05e46fb588d,03/17/2025,HUMAN PRESCRIPTION DRUG,03/17/2025,Endocrinology/Metabolism,GLUCOTROL XL,"0049-0174, 0049-0170, 0049-0178",Roerig,ce46d6b5-eab4-4630-8480-f13885be938e,"0049-0170-01, 0049-0174-02, 0049-0174-03, 0049-0178-07, 0049-0178-08","Glucotrol XL, Tablet, Extended Release, 5 mg (NDC 0049-0174-03)",Tablet,,"N0000175608, M0020795",NDA020329,Sulfonylurea Compounds [CS],GLIPIZIDE,Sulfonylurea [EPC],,To Be Discontinued,,Supply expected to exhaust early April 2025,,X7WDT95N5C,0049-0174-03,800-533-4535,
"Hikma Pharmaceuticals USA, Inc.",LORAZEPAM,,09/05/2018,Revised,"INTRAMUSCULAR, INTRAVENOUS",Lorazepam Injection,"206819, 206820, 238100, 238101, 1665188, 1665190, 1665326, 1665327",,5fc0e987-61c9-40c4-b0d5-fcea07c8733e,07/23/2025,HUMAN PRESCRIPTION DRUG,,Neurology,ATIVAN,"0641-6003, 0641-6002, 0641-6001, 0641-6000",Hikma Pharmaceuticals USA Inc.,209b0091-c890-4f69-a693-d0594c2606fe,"0641-6003-01, 0641-6003-25, 0641-6002-01, 0641-6002-10, 0641-6001-01, 0641-6001-25, 0641-6000-01, 0641-6000-10","Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)",Injection,Unavailable,"N0000175694, M0002356",NDA018140,Benzodiazepines [CS],LORAZEPAM,Benzodiazepine [EPC],,Current,Regulatory delay,Shortage duration unknown,,O26FZP769L,0641-6003-25,800-631-2174,
"Hospira, Inc., a Pfizer Company",MIDAZOLAM HYDROCHLORIDE,,04/02/2020,Revised,"INTRAMUSCULAR, INTRAVENOUS",Midazolam Hydrochloride Injection,"311700, 311702",,affecd4d-1f78-4bbe-5a8d-86849bbdc520,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology",MIDAZOLAM,"0409-2596, 0409-2587","Hospira, Inc.",923cfac2-557d-40b4-9ee0-3e933685a5fc,"0409-2587-04, 0409-2587-05, 0409-2596-13, 0409-2596-03, 0409-2596-15, 0409-2596-05","Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)",Injection,Unavailable,,ANDA075293,,MIDAZOLAM HYDROCHLORIDE,,,Current,Other,Next Delivery: August 2025; Estimated Recovery: September 2025,,W7TTW573JJ,0409-2596-03,844-646-4398,
"Hospira, Inc., a Pfizer Company",SODIUM BICARBONATE,,03/01/2017,Revised,INTRAVENOUS,Sodium Bicarbonate Injection,"727995, 792582",,ea20a5eb-641e-48cd-bcfa-74c04c45dfda,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Pediatric",SODIUM BICARBONATE,"0409-4916, 0409-6637","Hospira, Inc.",56e30ea7-c42d-41cf-a18e-c5eaba620fc0,"0409-4916-24, 0409-4916-14, 0409-6637-24, 0409-6637-14","Sodium Bicarbonate, Injection, 44.6 mEq/50 mL (7.5%, 0.9 mEq/mL) Syringes (NDC 0409-4916-14)",Injection,Unavailable,,ANDA202494,,SODIUM BICARBONATE,,,Current,Other,Shortage per Manufacturer: Manufacturing Delay,01/03/2025,8MDF5V39QO,0409-4916-14,844-646-4398,
Baxter Healthcare,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807551, 1807552, 1807627, 1807630, 1807631, 1807632, 1807633, 1807634, 1807639",,f55bd888-5e01-474d-871b-24654c070178,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0338-0049, 0338-0043",Baxter Healthcare Corporation,6ab23768-efd2-4ff1-b336-0dda08dc56e1,"0338-0049-01, 0338-0049-02, 0338-0049-03, 0338-0049-04, 0338-0049-10, 0338-0049-41, 0338-0049-11, 0338-0049-31, 0338-0049-48, 0338-0049-18, 0338-0049-38, 0338-0043-03, 0338-0043-04","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-04)",Injection,,,NDA016677,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0338-0049-04,888-229-0001,
Strides Pharma Inc.,AMANTADINE HYDROCHLORIDE,,02/12/2025,New,ORAL,Amantadine Hydrochloride Capsule,849389,,e4d8f36f-d668-4728-8dca-b1c22bd9aedb,02/12/2025,HUMAN PRESCRIPTION DRUG,02/12/2025,"Antiviral, Neurology",AMANTADINE HYDROCHLORIDE,42543-493,Strides Pharma Inc.,a3230bf0-95b8-4beb-b1f5-a35614de5afa,"42543-493-01, 42543-493-05","Amantadine Hydrochloride, Capsule, 100 mg (NDC 42543-493-05)",Capsule,,,ANDA209047,,AMANTADINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation of manufacture of drug based on business decision,,M6Q1EO9TD0,42543-493-05,877-244-9825,
Teyro Labs,CARBOPLATIN,,03/28/2025,New,INTRAVENOUS,Carboplatin Injection,597195,,1c275825-0275-4c73-b650-e4c1519f13b8,03/28/2025,HUMAN PRESCRIPTION DRUG,03/28/2025,Oncology,CARBOPLATIN,60505-6282,Apotex Corp.,0e68e276-b0df-4f03-e063-6394a90a22b9,"60505-6282-1, 60505-6282-3, 60505-6282-6, 60505-6282-7","Carboplatin, Injection, 10 mg/1 mL (NDC 60505-6282-3)",Injection,,"N0000175413, N0000175073",ANDA077861,,CARBOPLATIN,Platinum-based Drug [EPC],,To Be Discontinued,,Discontinuation due to low sales volume. Supply currently available with November 2025 expiry dating. Wholesaler & Distributor through Marketing partner (Apotex Inc.),,BG3F62OND5,60505-6282-3,800-706-5575,
Accord Healthcare Inc.,CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,ebc11109-e7bf-452d-b675-4b3236d54164,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"16729-138, 16729-136, 16729-137",Accord Healthcare Inc.,0e1e7f41-f78b-27cf-e063-6394a90a1ae0,"16729-136-00, 16729-136-16, 16729-137-00, 16729-137-16, 16729-138-00, 16729-138-16","Clonazepam, Tablet, 2 mg (NDC 16729-138-16)",Tablet,Available,"N0000175694, M0002356",ANDA077147,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,,,5PE9FDE8GB,16729-138-16,"866-941-7875, option 2",
B. Braun Medical Inc.,"DEXTROSE, UNSPECIFIED FORM",,03/01/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 10% Injection,"1795477, 1795480, 1795481, 1795607, 1795610, 1795612",,085614c7-ada4-4e2c-87c0-c9bc2f18365a,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0264-7520, 0264-7510",B. Braun Medical Inc.,c9f87749-8dd5-41fd-b393-f63d45fd00ef,"0264-7510-00, 0264-7510-10, 0264-7510-20, 0264-7520-00, 0264-7520-10, 0264-7520-20","Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-10)",Injection,Available,,NDA019626,,DEXTROSE,,,Current,,,,IY9XDZ35W2,0264-7520-10,800-227-2862,
Alvogen,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Revised,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,c907301d-e24d-9609-5529-fed14f94549f,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII","47781-180, 47781-174, 47781-175, 47781-176, 47781-177, 47781-178, 47781-179",Alvogen Inc.,0374f0f7-9297-810c-38b3-623a72709a7d,"47781-174-30, 47781-174-05, 47781-174-01, 47781-175-30, 47781-175-05, 47781-175-01, 47781-176-30, 47781-176-05, 47781-176-01, 47781-177-30, 47781-177-05, 47781-177-01, 47781-178-30, 47781-178-05, 47781-178-01, 47781-179-30, 47781-179-05, 47781-179-01, 47781-180-30, 47781-180-05, 47781-180-01","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 47781-180-01)",Tablet,Unavailable,,ANDA207388,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 30 MG,CLL",,,Current,Other,Supporting contracted business only; Resupply Q3 2025,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",47781-180-01,844-842-8672 and email: CustomerService-US@alvogen.com,
"Hospira, Inc., a Pfizer Company",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,"EPIDURAL, INTRACAUDAL, PERINEURAL",Bupivacaine Hydrochloride Injection,"1012377, 1012381, 1012384, 1012388, 1012396, 1012400, 1012404, 1012406, 1672917, 1672919, 1673242, 1673243, 1724786, 1724787, 1724794, 1724796, 1724880, 1724884, 1725044, 1725046, 1725078, 1725079, 1725082, 1725083, 1867594, 1867596, 1867612, 1867614",,67578b56-7540-487e-1fba-481255620e78,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,MARCAINE,"0409-1560, 0409-1559, 0409-1582, 0409-1587, 0409-1610, 0409-1746, 0409-1749, 0409-1752, 0409-1755, 0409-2510, 0409-7535, 0409-1250, 0409-5010, 0409-1530, 0409-0525, 0409-7510, 0409-2253","Hospira, Inc.",b083f440-bfb7-449a-b601-c2f59a6f9dcf,"0409-1559-18, 0409-1559-10, 0409-1559-19, 0409-1559-30, 0409-1560-18, 0409-1560-10, 0409-1560-19, 0409-1560-29, 0409-1582-18, 0409-1582-10, 0409-1582-19, 0409-1582-29, 0409-1587-50, 0409-1610-50, 0409-1746-70, 0409-1746-10, 0409-1746-71, 0409-1746-30, 0409-1749-70, 0409-1749-10, 0409-1749-71, 0409-1749-29, 0409-1752-50, 0409-1755-50, 0409-2510-01, 0409-2510-25, 0409-7535-01, 0409-7535-25, 0409-1250-01, 0409-1250-25, 0409-5010-01, 0409-5010-25, 0409-1530-01, 0409-1530-25, 0409-0525-01, 0409-0525-25, 0409-7510-01, 0409-7510-25, 0409-2253-01, 0409-2253-25","Marcaine, Injection, Marcaine 50 mg/10 mL (5 mg/mL) (NDC 0409-1560-10)",Injection,Available,,NDA016964,,BUPIVACAINE HYDROCHLORIDE,,,Current,,,,"30Q7KI53AK, 7TQO7W3VT8",0409-1560-10,844-646-4398,
"EMD Serono, Inc.",LEVOTHYROXINE SODIUM,,07/10/2025,New,ORAL,Levothyroxine Sodium Tablet,"892246, 892251, 966153, 966160, 966166, 966173, 966177, 966182, 966187, 966196, 966202, 966207, 966220, 966221, 966222, 966224, 966225, 966248, 966249, 966253, 966270, 2104866",,bc3c6830-ba68-4ba3-9896-a12d0ad0b275,07/10/2025,HUMAN PRESCRIPTION DRUG,07/10/2025,Endocrinology/Metabolism,EUTHYROX,"72305-200, 72305-025, 72305-050, 72305-075, 72305-088, 72305-100, 72305-112, 72305-125, 72305-137, 72305-150, 72305-175","Provell Pharmaceuticals, LLC",45657074-8874-49f4-a8ef-3ca7e210c16e,"72305-025-30, 72305-025-90, 72305-050-30, 72305-050-90, 72305-075-30, 72305-075-90, 72305-088-30, 72305-088-90, 72305-100-30, 72305-100-90, 72305-112-30, 72305-112-90, 72305-125-30, 72305-125-90, 72305-137-30, 72305-137-90, 72305-150-30, 72305-150-90, 72305-175-30, 72305-175-90, 72305-200-30, 72305-200-90","Euthyrox, Tablet, 200 ug (NDC 72305-200-90)",Tablet,,,NDA021292,,LEVOTHYROXINE SODIUM,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,9J765S329G,72305-200-90,888-899-7041,
"Solco Healthcare US, LLC",QUINAPRIL HYDROCHLORIDE,,01/19/2023,Reverified,ORAL,Quinapril Hydrochloride Tablet,"312748, 312749, 312750, 314203",,cd46691d-5593-4a9f-a937-999c6803e312,09/17/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,QUINAPRIL,"43547-411, 43547-410, 43547-412, 43547-413","Solco Healthcare US, LLC",b8f1731a-cbac-4f64-a8d4-320b80b335e1,"43547-410-09, 43547-411-09, 43547-412-09, 43547-413-09","Quinapril Hydrochloride, Tablet, 10 mg (NDC 43547-411-09)",Tablet,Unavailable,,ANDA205823,,QUINAPRIL,,,Current,Shortage of an active ingredient,Not available. Long-term backorder for all NDCs. No estimated release date at this time.,,33067B3N2M,43547-411-09,866-931-9829,
"Fresenius Kabi USA, LLC",ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Reverified,EPIDURAL,Ropivacaine Hydrochloride Injection,"905189, 905191, 1734084, 1734086, 1734090, 1734091, 1734203, 1734204, 1734207, 1734208, 1734347, 1734348, 1734355, 1734356, 1734475, 1734476, 1734479, 1734480, 1734481, 1734482, 1734483, 1734484",,"23d2d448-a744-4877-9f2d-7e57c198da89, c6613708-c1f7-4f5c-91a3-ebbc1d7905c6, 56dfabf7-f7a8-4601-b17a-cb16fb995b0f",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,NAROPIN,"63323-288, 63323-286, 63323-287, 63323-285","Fresenius Kabi USA, LLC","cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9, 73218c89-8925-468c-84bf-9960b4b3dc3c, 75465ceb-e894-487d-aa80-671fa0841fce","63323-286-01, 63323-286-20, 63323-286-05, 63323-286-23, 63323-286-09, 63323-286-31, 63323-286-11, 63323-286-35, 63323-286-03, 63323-286-00, 63323-286-33, 63323-286-63, 63323-286-30, 63323-287-01, 63323-287-20, 63323-287-03, 63323-287-21, 63323-288-01, 63323-288-10, 63323-288-06, 63323-288-20, 63323-288-03, 63323-288-11, 63323-288-07, 63323-288-21, 63323-285-01, 63323-285-10, 63323-285-06, 63323-285-20, 63323-285-03, 63323-285-13, 63323-285-07, 63323-285-23, 63323-285-57, 63323-285-64, 63323-285-51, 63323-285-65, 63323-285-02, 63323-285-61, 63323-285-04, 63323-285-63, 63323-285-55, 63323-285-67, 63323-288-23, 63323-288-29, 63323-286-93, 63323-286-95, 63323-288-25, 63323-288-27","Naropin, Injection, 10 mg/1 mL (NDC 63323-288-21)",Injection,Available,,NDA020533,,ROPIVACAINE HYDROCHLORIDE,,,Current,,,,V910P86109,63323-288-21,888-386-1300,
"Hospira, Inc., a Pfizer Company",SODIUM CHLORIDE,,06/21/2018,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Sodium Chloride 0.9% Injection,"1807628, 1807631, 1807637, 1807638",,8eb172da-dcd4-4660-4a8f-ad44a14b4af7,08/08/2025,HUMAN PRESCRIPTION DRUG,,Other,SODIUM CHLORIDE,"0409-4888, 0409-1918","Hospira, Inc.",9ee88abb-024a-4a3b-9776-1777eaf2f760,"0409-4888-02, 0409-4888-10, 0409-4888-03, 0409-4888-20, 0409-4888-06, 0409-4888-50, 0409-4888-01, 0409-4888-12, 0409-4888-90, 0409-1918-42, 0409-1918-32, 0409-1918-43, 0409-1918-33, 0409-1918-45, 0409-1918-35","Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-4888-50)",Injection,,,NDA018803,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0409-4888-50,844-646-4398,
"Hospira, Inc., a Pfizer Company",CARBOPLATIN,,04/28/2023,Reverified,INTRAVENOUS,Carboplatin Injection,597195,,c3ae9880-44bb-4f4e-93d8-8a5e21708a30,08/15/2025,HUMAN PRESCRIPTION DRUG,,Oncology,CARBOPLATIN,61703-339,"Hospira, Inc.",0ddf4411-7138-412a-908a-fadf22bdfb79,"61703-339-18, 61703-339-22, 61703-339-50, 61703-339-56","Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)",Injection,Available,"N0000175413, N0000175073",ANDA076517,,CARBOPLATIN,Platinum-based Drug [EPC],,Current,,,,BG3F62OND5,61703-339-22,844-646-4398,
Fera Pharmaceuticals,,,09/24/2019,Reverified,OPHTHALMIC,Echothiophate Iodide Ophthalmic Solution,"205739, 310049",,8afc8951-db76-4f27-8752-7c0d6aa47244,09/17/2025,HUMAN PRESCRIPTION DRUG,,Ophthalmology,PHOSPHOLINE IODIDE,48102-053,"Fera Pharmaceuticals, LLC",66abcfcf-b16e-4181-b1db-96bfba0ab95e,"48102-053-05, 48102-054-05, 48102-055-05","Phospholine Iodide, Ophthalmic Solution, 0.125% (NDC 48102-053-05)",Ophthalmic Solution,Available,,NDA011963,,ECHOTHIOPHATE IODIDE FOR OPHTHALMIC SOLUTION,,,Current,,Available through limited distribution by Walgreens Specialty Pharmacy.,,,48102-053-05,516-277-1449,
"Fresenius Kabi USA, LLC",FENTANYL CITRATE,,01/01/2012,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Fentanyl Citrate Injection,"1735003, 1735007, 1735008, 1735013, 2168270",,38d0c14a-a0c1-44cc-a939-0304eb8037d6,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Pediatric",FENTANYL CITRATE,63323-806,"Fresenius Kabi USA, LLC",341b092a-1f6f-40f1-98f2-9346bf2e1242,"63323-806-11, 63323-806-01, 63323-806-12, 63323-806-02, 63323-806-13, 63323-806-05, 63323-806-14, 63323-806-20, 63323-806-50","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-05)",Injection,Available,,ANDA210762,,FENTANYL CITRATE,,,Current,,Check wholesalers for inventory,,MUN5LYG46H,63323-806-05,888-386-1300,
Granules Pharmaceuticals Inc.,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,b0b4eccc-34c7-483d-966f-82d588358e1b,09/08/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","70010-116, 70010-111, 70010-112, 70010-113, 70010-114, 70010-115, 70010-117",Granules Pharmaceuticals Inc.,2fab399e-2a43-5134-e063-6294a90ae09a,"70010-111-01, 70010-111-03, 70010-112-01, 70010-112-03, 70010-113-01, 70010-113-03, 70010-114-01, 70010-114-03, 70010-115-01, 70010-115-03, 70010-116-01, 70010-116-03, 70010-117-01, 70010-117-03","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 70010-116-01)",Tablet,Available,,ANDA215771,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",70010-116-01,877-770-3183,
"Teva Pharmaceuticals USA, Inc.",PRAVASTATIN SODIUM,,06/13/2025,New,ORAL,Pravastatin Sodium Tablet,"904458, 904467, 904475",,99e0e848-f8f3-4b42-b880-8fbc42633948,06/13/2025,HUMAN PRESCRIPTION DRUG,06/13/2025,Cardiovascular,PRAVASTATIN SODIUM,"0093-0771, 0093-7201, 0093-7202","Teva Pharmaceuticals USA, Inc.",72579e23-23ef-4ab7-ad64-24d5ea7997eb,"0093-0771-98, 0093-0771-10, 0093-7201-98, 0093-7201-10, 0093-7202-98, 0093-7202-10","Pravastatin Sodium, Tablet, 10 mg (NDC 0093-0771-98)",Tablet,,,ANDA076056,,PRAVASTATIN SODIUM,,,To Be Discontinued,,,,3M8608UQ61,0093-0771-98,800-545-8800,
"Hikma Pharmaceuticals USA, Inc.",PROMETHAZINE HYDROCHLORIDE,,11/21/2023,Revised,"INTRAMUSCULAR, INTRAVENOUS",Promethazine Hydrochloride Injection,"992460, 992858",,13d9e59d-eadb-41d5-9f47-9c11a6efb31c,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Gastroenterology, Pediatric, Pulmonary/Allergy",PROMETHAZINE HYDROCHLORIDE,"0641-1495, 0641-1496",Hikma Pharmaceuticals USA Inc.,80a400d2-d293-4180-bfa7-7a8ce0734bc5,"0641-1495-31, 0641-1495-35, 0641-1496-31, 0641-1496-35","Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)",Injection,Unavailable,,ANDA083312,,PROMETHAZINE HYDROCHLORIDE,,,Current,Demand increase for the drug,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,R61ZEH7I1I,0641-1495-35,800-631-2174,
"Hospira, Inc., a Pfizer Company",SODIUM ACETATE ANHYDROUS,,02/03/2016,Reverified,INTRAVENOUS,Sodium Acetate Injection,237371,,"abc41ed1-9512-4bea-9295-1a9ca134b6c2, c3be2468-45e8-4ecc-a30b-e966743a563f",08/15/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Pediatric, Total Parenteral Nutrition",SODIUM ACETATE,0409-3299,"Hospira, Inc.","eadea22b-c475-4596-8c15-e738af5a711d, 99255488-8958-49ab-965c-083119f5ba3c","0409-3299-15, 0409-3299-05, 0409-3299-16, 0409-3299-06, 0409-3299-45, 0409-3299-25, 0409-3299-46, 0409-3299-26","Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-26)",Injection,Available,,NDA018893,,SODIUM ACETATE,,,Current,,,,NVG71ZZ7P0,0409-3299-26,844-646-4398,
Eli Lilly and Co.,,,10/29/2024,New,"INTRAMUSCULAR, SUBCUTANEOUS",Somatropin Injection,"582969, 582971, 582974, 582976, 729232, 729234",,a774e1ae-3997-49ee-8b0e-99a2b315d409,10/29/2024,HUMAN PRESCRIPTION DRUG,10/29/2024,Endocrinology/Metabolism,HUMATROPE,"0002-8148, 0002-8147, 0002-8149",Eli Lilly and Company,aa99e905-657f-4561-8c02-d7c0409c44e3,"0002-8147-01, 0002-7554-01, 0002-7618-01, 0002-8148-01, 0002-7555-01, 0002-7619-01, 0002-8149-01, 0002-7556-01","Humatrope, Injection, Humatrope Kit 12 mg (0002-8148-01): 1 TRAY in 1 CARTON (0002-8148-01) / 1 KIT in 1 TRAY * 2.88 mL in 1 CARTRIDGE (0002-7555-01) * 2.88 mL in 1 SYRINGE (0002-7619-01) (NDC 0002-8148-01)",Injection,,,BLA019640,,SOMATROPIN,,,To Be Discontinued,,Business decision to discontinue. Discontinuation includes the associated HumatroPen injection device.,,,0002-8148-01,800-545-5979,
Torrent Pharma Inc.,"AMLODIPINE, HYDROCHLOROTHIAZIDE, OLMESARTAN MEDOXOMIL",Increased Diuresis [PE],06/13/2025,New,ORAL,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,"999967, 999986, 999991, 999996, 1000001",,85b8f9c6-aa53-4aa1-85d6-19f823d0d252,06/13/2025,HUMAN PRESCRIPTION DRUG,06/13/2025,Cardiovascular,"OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE 40/5/25 MG","13668-385, 13668-397, 13668-386, 13668-383, 13668-382",Torrent Pharmaceuticals Limited,5bedf6c6-6b23-40e7-8c96-2cedcc682973,"13668-397-30, 13668-397-90, 13668-397-05, 13668-386-30, 13668-386-90, 13668-386-05, 13668-385-30, 13668-385-90, 13668-385-05, 13668-383-30, 13668-383-90, 13668-383-05, 13668-382-30, 13668-382-90, 13668-382-05","Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 25 mg; 40 mg (NDC 13668-385-05)",Tablet,,"N0000175359, N0000175419, M0471776, N0000000069, N0000175421, N0000175566, M0006414, N0000190114",ANDA203580,"Thiazides [CS], Dihydropyridines [CS]","OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE TABLET 40/5/25 MG","Thiazide Diuretic [EPC], Dihydropyridine Calcium Channel Blocker [EPC], Calcium Channel Blocker [EPC]",,To Be Discontinued,,A business decision was made to discontinue manufacture of the product.,,"0J48LPH2TH, 1J444QC288, 6M97XTV3HD",13668-385-05,908-280-3333,"Calcium Channel Antagonists [MoA], Cytochrome P450 3A Inhibitors [MoA]"
Gland Pharma Limited,ETOMIDATE,General Anesthesia [PE],10/05/2022,Reverified,INTRAVENOUS,Etomidate Injection,"1654006, 1654008",,8b6c54d8-3f3f-4290-841c-976bea01086f,09/29/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ETOMIDATE,"72266-146, 72266-147",Fosun Pharma USA Inc,2b365133-b609-3285-e063-6394a90a69a6,"72266-146-01, 72266-146-10, 72266-147-01, 72266-147-10","Etomidate, Injection, 2 mg/1 mL (NDC 72266-146-10)",Injection,Available,"N0000175975, N0000175681",ANDA209058,,ETOMIDATE INJECTION,General Anesthetic [EPC],,Current,,"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.",,Z22628B598,72266-146-10,833-291-9645,
Sagent Pharmaceuticals,,,04/07/2020,Reverified,,Furosemide Injection,,,,08/26/2025,,,Cardiovascular,,,,,,"Furosemide, Injection, 10 mg/1 mL (NDC 70860-302-02)",Injection,"Unavailable, Please use Sagent label",,,,,,,Current,Other,Use Sagent NDC 25021-311-02,,,70860-302-02,866-625-1618,
Takeda Pharmaceuticals USA Inc.,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854832, 854834, 854836, 854838, 854840, 854842, 854844, 854846, 854848, 854850, 854852, 1593856, 1593858, 1871456, 1871459, 1871460, 1871461, 1871462, 1871463, 1871464, 1871465, 1871466, 1871467, 1871468, 1871469",,704e4378-ca83-445c-8b45-3cfa51c1ecad,08/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,VYVANSE,"59417-103, 59417-101, 59417-102, 59417-104, 59417-105, 59417-106, 59417-107, 59417-115, 59417-116, 59417-117, 59417-118, 59417-119, 59417-120","Takeda Pharmaceuticals America, Inc.",756b98a0-fada-44b2-a606-f2e71ef8cc84,"59417-101-10, 59417-102-10, 59417-103-10, 59417-104-10, 59417-105-10, 59417-106-10, 59417-107-10, 59417-115-01, 59417-116-01, 59417-117-01, 59417-118-01, 59417-119-01, 59417-120-01","Vyvanse, Capsule, 30 mg (NDC 59417-103-10)",Capsule,Available,,NDA021977,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,59417-103-10,877-TAKEDA-7 (1-877-825-3327),
SpecGx LLC,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,806a1c15-0842-4787-b2ad-09a21fd96b37,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0406-5113, 0406-5111, 0406-5112, 0406-5114, 0406-5115, 0406-5116, 0406-5117",SpecGx LLC,3ffc0695-83f7-4898-9fd7-451c0989cfe0,"0406-5111-01, 0406-5112-01, 0406-5113-01, 0406-5114-01, 0406-5115-01, 0406-5116-01, 0406-5117-01","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0406-5113-01)",Capsule,Limited Availability,,ANDA211840,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,Allocation to all customers.,,SJT761GEGS,0406-5113-01,800-325-8888,
Aurobindo Pharma USA,METOPROLOL TARTRATE,,06/03/2025,New,ORAL,Metoprolol Tartrate Tablet,"866511, 866514, 866924",,2b705cb6-cb75-4c2a-907a-4bd45d18bc2c,06/03/2025,HUMAN PRESCRIPTION DRUG,06/03/2025,Cardiovascular,METOPROLOL TARTRATE,"65862-064, 65862-062, 65862-063",Aurobindo Pharma Limited,d265c99d-8e77-4a78-b542-15e957d9d335,"65862-062-01, 65862-062-99, 65862-063-60, 65862-063-01, 65862-063-99, 65862-064-60, 65862-064-01, 65862-064-99","Metoprolol Tartrate, Tablet, 100 mg (NDC 65862-064-01)",Tablet,,,ANDA077739,,METOPROLOL TARTRATE,,,To Be Discontinued,,Permanent discontinuation in the manufacturing of the drug,,W5S57Y3A5L,65862-064-01,866-850-2876,
"Hospira, Inc., a Pfizer Company",MIDAZOLAM HYDROCHLORIDE,,04/02/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Midazolam Hydrochloride Injection,"311700, 311702",,affecd4d-1f78-4bbe-5a8d-86849bbdc520,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology",MIDAZOLAM,"0409-2596, 0409-2587","Hospira, Inc.",923cfac2-557d-40b4-9ee0-3e933685a5fc,"0409-2587-04, 0409-2587-05, 0409-2596-13, 0409-2596-03, 0409-2596-15, 0409-2596-05","Midazolam Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-2596-05)",Injection,Available,,ANDA075293,,MIDAZOLAM HYDROCHLORIDE,,,Current,,,,W7TTW573JJ,0409-2596-05,844-646-4398,
"Hospira, Inc., a Pfizer Company",WATER,,11/23/2021,Reverified,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Sterile Water Injection,,,2b9ea23a-f9e9-48a8-25b7-519e3bbd6828,08/15/2025,HUMAN PRESCRIPTION DRUG,,Other,STERILE WATER,0409-4887,"Hospira, Inc.",900859c0-a075-4fb1-98ce-0e329acc009a,"0409-4887-25, 0409-4887-99, 0409-4887-31, 0409-4887-05, 0409-4887-17, 0409-4887-10, 0409-4887-32, 0409-4887-34, 0409-4887-23, 0409-4887-20, 0409-4887-24, 0409-4887-50","Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-50)",Injection,Available,,NDA018801,,WATER,,,Current,,,,059QF0KO0R,0409-4887-50,844-646-4398,
"Mylan Pharmaceuticals Inc., a Viatris Company",VARENICLINE TARTRATE,,02/06/2025,New,ORAL,Varenicline Tartrate Tablet,"636671, 636676, 749289",,4233fb78-ac6c-49f3-aad8-7e4bee18cac6,02/06/2025,HUMAN PRESCRIPTION DRUG,02/06/2025,Analgesia/Addiction,VARENICLINE,"0378-5090, 0378-5089, 0378-5091",Mylan Pharmaceuticals Inc.,5b7b6e3b-f427-4000-b252-968f3adbaa3b,"0378-5089-73, 0378-5090-73, 0378-5091-85, 0378-5089-46, 0378-5090-23","Varenicline Tartrate, Tablet, 1 mg (NDC 0378-5090-73)",Tablet,,,ANDA202019,,VARENICLINE,,,To Be Discontinued,,Permanent discontinuation in the manufacturing of the drug,,82269ASB48,0378-5090-73,800-796-9526,
Accord Healthcare Inc.,CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,ebc11109-e7bf-452d-b675-4b3236d54164,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"16729-137, 16729-136, 16729-138",Accord Healthcare Inc.,0e1e7f41-f78b-27cf-e063-6394a90a1ae0,"16729-136-00, 16729-136-16, 16729-137-00, 16729-137-16, 16729-138-00, 16729-138-16","Clonazepam, Tablet, 1 mg (NDC 16729-137-16)",Tablet,Available,"N0000175694, M0002356",ANDA077147,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,,,5PE9FDE8GB,16729-137-16,"866-941-7875, option 2",
Baxter Healthcare,DEXTROSE MONOHYDRATE,,03/01/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 10% Injection,"1795477, 1795480, 1795481, 1795607, 1795609, 1795610, 1795612, 1795616, 1795618",,3bb406a9-f5cb-403a-b1bb-5c4facbea3d5,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0338-0023, 0338-0017",Baxter Healthcare Corporation,31bb4a5f-733e-4354-9fbf-138dede4db0f,"0338-0017-10, 0338-0017-41, 0338-0017-11, 0338-0017-31, 0338-0017-48, 0338-0017-18, 0338-0017-38, 0338-0017-02, 0338-0017-03, 0338-0017-04, 0338-0023-02, 0338-0023-03, 0338-0023-04","Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-04)",Injection,Available,,NDA016694,,DEXTROSE MONOHYDRATE,,,Current,,,,LX22YL083G,0338-0023-04,888-229-0001,
Baxter Healthcare,DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795477, 1795480, 1795481, 1795607, 1795609, 1795610, 1795612, 1795616, 1795618",,3bb406a9-f5cb-403a-b1bb-5c4facbea3d5,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0338-0017, 0338-0023",Baxter Healthcare Corporation,31bb4a5f-733e-4354-9fbf-138dede4db0f,"0338-0017-10, 0338-0017-41, 0338-0017-11, 0338-0017-31, 0338-0017-48, 0338-0017-18, 0338-0017-38, 0338-0017-02, 0338-0017-03, 0338-0017-04, 0338-0023-02, 0338-0023-03, 0338-0023-04","Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-11)",Injection,Available,,NDA016673,,DEXTROSE MONOHYDRATE,,,Current,,,,LX22YL083G,0338-0017-11,888-229-0001,
Apotex Corp.,LISDEXAMFETAMINE DIMESYLATE,,11/01/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,ecad4442-a644-18e3-6ff2-fdbac45eec47,09/29/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"60505-4744, 60505-4739, 60505-4740, 60505-4741, 60505-4742, 60505-4743, 60505-4745",Apotex Corp.,c8e0c70d-2f5b-8d85-fa45-572e8f5f7b4c,"60505-4739-1, 60505-4740-1, 60505-4741-1, 60505-4742-1, 60505-4743-1, 60505-4744-1, 60505-4745-1","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 60505-4744-1)",Capsule,Available,,ANDA216944,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,Product currently available,,SJT761GEGS,60505-4744-1,800-706-5575,
"Hikma Pharmaceuticals USA, Inc.",PROMETHAZINE HYDROCHLORIDE,,11/21/2023,Revised,"INTRAMUSCULAR, INTRAVENOUS",Promethazine Hydrochloride Injection,"992460, 992462, 992858, 992876",,481866da-a712-48a5-853f-8e84aacaab6d,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Gastroenterology, Pediatric, Pulmonary/Allergy",PHENERGAN,"0641-6084, 0641-6085",Hikma Pharmaceuticals USA Inc.,7d6e64fc-bbf2-4ea9-b866-8115c448e687,"0641-6084-01, 0641-6084-25, 0641-6085-01, 0641-6085-25","Phenergen, Injection, 25 mg/1 mL (NDC 0641-6084-25)",Injection,Unavailable,,ANDA083312,,PROMETHAZINE HYDROCHLORIDE,,,Current,Other,This presentation is temporarily on backorder.  Recovery is TBD at this time.,,R61ZEH7I1I,0641-6084-25,800-631-2174,
Otsuka ICU Medical LLC,WATER,,04/28/2023,Reverified,IRRIGATION,Sterile Water Irrigant,150985,https://www.fda.gov/media/182619/download?attachment,e3484bc6-ed7f-43ef-9d49-c131a8dff2dd,09/17/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",STERILE WATER,"0990-7139, 0990-6139, 0990-7973",ICU Medical Inc.,22b6a1e5-20c1-481b-96d5-329e3fc999f5,"0990-6139-22, 0990-6139-03, 0990-7139-09, 0990-7139-36, 0990-7973-05, 0990-7973-07, 0990-7973-08","Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-09)",Irrigant,Limited Availability,,NDA017513,,WATER,,,Current,Other,"Allocated to Contracted Customers Only. Estimated Recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,059QF0KO0R,0990-7139-09,1-866-829-9025 or ProductAvailability@icumed.com,
Amneal Pharmaceuticals,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718906, 1718909",,eb1ba463-ab42-4f49-9ebe-3ad5af108326,09/17/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE HYDROCHLORIDE,"70121-1389, 70121-1388",Amneal Pharmaceuticals LLC,795f643f-855c-4ba4-9bad-a96334c1a2fb,"70121-1388-1, 70121-1388-8, 70121-1389-1, 70121-1389-7","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1389-7)",Injection,Available,,ANDA207551,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,,,,1018WH7F9I,70121-1389-7,866-525-7270,
"Hospira, Inc., a Pfizer Company",HYDROMORPHONE HYDROCHLORIDE,,10/31/2017,Reverified,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Hydromorphone Hydrochloride Injection,"1724338, 1724340, 1724341",,3832ede8-d3fc-455d-ecab-3b77be5869f5,08/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,HYDROMORPHONE HYDROCHLORIDE,0409-2634,"Hospira, Inc.",f0c8c83c-fb41-4571-a72e-6542311351dd,"0409-2634-10, 0409-2634-01, 0409-2634-25, 0409-2634-05, 0409-2634-50","Hydromorphone Hydrochloride, Injection, 500 mg/50 mL (10 mg/mL) (NDC 0409-2634-50)",Injection,Available,,ANDA078591,,HYDROMORPHONE HYDROCHLORIDE,,,Current,,,01/02/2025,L960UP2KRW,0409-2634-50,844-646-4398,
"EMD Serono, Inc.",LEVOTHYROXINE SODIUM,,07/10/2025,New,ORAL,Levothyroxine Sodium Tablet,"892246, 892251, 966153, 966160, 966166, 966173, 966177, 966182, 966187, 966196, 966202, 966207, 966220, 966221, 966222, 966224, 966225, 966248, 966249, 966253, 966270, 2104866",,bc3c6830-ba68-4ba3-9896-a12d0ad0b275,07/10/2025,HUMAN PRESCRIPTION DRUG,07/10/2025,Endocrinology/Metabolism,EUTHYROX,"72305-112, 72305-025, 72305-050, 72305-075, 72305-088, 72305-100, 72305-125, 72305-137, 72305-150, 72305-175, 72305-200","Provell Pharmaceuticals, LLC",45657074-8874-49f4-a8ef-3ca7e210c16e,"72305-025-30, 72305-025-90, 72305-050-30, 72305-050-90, 72305-075-30, 72305-075-90, 72305-088-30, 72305-088-90, 72305-100-30, 72305-100-90, 72305-112-30, 72305-112-90, 72305-125-30, 72305-125-90, 72305-137-30, 72305-137-90, 72305-150-30, 72305-150-90, 72305-175-30, 72305-175-90, 72305-200-30, 72305-200-90","Euthyrox, Tablet, 112 ug (NDC 72305-112-90)",Tablet,,,NDA021292,,LEVOTHYROXINE SODIUM,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,9J765S329G,72305-112-90,888-899-7041,
"Novo Nordisk, Inc.",LIRAGLUTIDE,,07/18/2023,Reverified,SUBCUTANEOUS,Liraglutide Injection,897122,,14bf9812-14ee-46ce-93b1-686e4906cbbc,09/16/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,LIRAGLUTIDE,0480-3667,"Teva Pharmaceuticals USA, Inc.",b56c797c-a46a-4dbf-a367-9d7f26c7d29d,"0480-3667-19, 0480-3667-22, 0480-3667-20","Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)",Injection,Available,"N0000178480, M0160181, N0000020058",NDA022341,Glucagon-Like Peptide 1 [CS],LIRAGLUTIDE,GLP-1 Receptor Agonist [EPC],,Current,,Distributed by Teva,,839I73S42A,0480-3667-22,833-493-4689,Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
Novadaq Technologies,,,08/23/2024,Revised,,Indocyanine Green Injection,,,,08/26/2025,,,"Medical Imaging, Ophthalmology, Other",,,,,,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-306-23)",Injection,,,,,,,Available,Resolved,,,08/26/2025,,66259-306-23,800-624-4422,
"Solco Healthcare US, LLC",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,68b10d9f-ca3e-493d-a309-45f1d7e08061,08/05/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"43547-607, 43547-602, 43547-603, 43547-604, 43547-605, 43547-606, 43547-608","Solco Healthcare US,LLC",7bb11568-67a4-4221-bb9b-23af37a1791c,"43547-602-10, 43547-603-10, 43547-604-10, 43547-605-10, 43547-606-10, 43547-607-10, 43547-608-10","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 43547-607-10)",Capsule,Limited Availability,,ANDA216266,,LISDEXAMFETAMINE DIMESYLATE CAPSULES,,,Current,Shortage of an active ingredient,On allocation,,SJT761GEGS,43547-607-10,866-931-9829,
Sagent Pharmaceuticals,METHYLPREDNISOLONE ACETATE,,12/15/2021,Reverified,"INTRA-ARTICULAR, INTRALESIONAL, INTRAMUSCULAR, INTRASYNOVIAL, SOFT TISSUE",Methylprednisolone Acetate Injection,"1358610, 1358617",,f98314ea-a4e4-4f78-987b-3e9b45a08bb4,08/26/2025,HUMAN PRESCRIPTION DRUG,,Rheumatology,METHYLPREDNISOLONE ACETATE,"25021-821, 25021-820",Sagent Pharmaceuticals,13e1ca54-4fc4-4e93-a52d-c9320865e3cb,"25021-820-05, 25021-820-10, 25021-821-05","Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 25021-821-05)",Injection,Available,,ANDA201835,,METHYLPREDNISOLONE ACETATE,,,Current,,,,43502P7F0P,25021-821-05,866-625-1618,
Eli Lilly and Co.,ATOMOXETINE HYDROCHLORIDE,,10/22/2024,New,ORAL,Atomoxetine Hydrochloride Capsule,"349591, 349592, 349593, 349594, 349595, 352317, 352318, 352319, 352320, 352321, 608139, 608143, 617945, 617947",,309de576-c318-404a-bc15-660c2b1876fb,10/22/2024,HUMAN PRESCRIPTION DRUG,10/22/2024,Psychiatry,STRATTERA,"0002-3229, 0002-3227, 0002-3238, 0002-3228, 0002-3239, 0002-3250, 0002-3251",Eli Lilly and Company,90fd3143-d5d4-4343-9570-b3863e31b1a0,"0002-3227-30, 0002-3238-30, 0002-3228-30, 0002-3229-30, 0002-3239-30, 0002-3250-30, 0002-3251-30","Strattera, Capsule, 40 mg (NDC 0002-3229-30)",Capsule,,,NDA021411,,ATOMOXETINE HYDROCHLORIDE,,,To Be Discontinued,,Business decision to discontinue,,57WVB6I2W0,0002-3229-30,800-545-5979,
"Teva Pharmaceuticals USA, Inc.",CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,8069b1a0-7c06-4252-b44e-e2eef065d9b8,09/15/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"0093-0832, 0093-3212, 0093-3213","Teva Pharmaceuticals USA, Inc.",d6abe4e3-7699-4ead-95f4-739a961b23ad,"0093-0832-01, 0093-0832-05, 0093-3212-01, 0093-3212-05, 0093-3213-01, 0093-3213-05","Clonazepam, Tablet, .5 mg (NDC 0093-0832-05)",Tablet,Available,"N0000175694, M0002356",ANDA074569,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,,,5PE9FDE8GB,0093-0832-05,800-545-8800,
"Teva Pharmaceuticals USA, Inc.",,,01/06/2025,New,,Ezetimibe; Simvastatin Tablet,,,,01/06/2025,,01/06/2025,Cardiovascular,,,,,,"EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 40 mg (NDC 45963-567-30)",Tablet,,,,,,,,To Be Discontinued,,,,,45963-567-30,800-545-8800,
"Hospira, Inc., a Pfizer Company",FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Revised,"INTRAMUSCULAR, INTRAVENOUS",Furosemide Injection,"1719286, 1719290, 1719291",,"aaced7a8-c3d7-4d66-8c07-aa407b8b3f35, 39fd32f2-6bb7-4a65-d298-e48d26bc80c7",08/15/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,0409-6102,"Hospira, Inc.","c529b0df-a5cb-46ce-8131-38674ee756af, 0d4a39f2-904e-434a-9af1-83bb4febf124","0409-6102-35, 0409-6102-25, 0409-6102-36, 0409-6102-26, 0409-6102-37, 0409-6102-27, 0409-6102-19, 0409-6102-02, 0409-6102-18, 0409-6102-04, 0409-6102-20, 0409-6102-10","Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-25)",Injection,Limited Availability,"N0000175366, N0000175590",NDA018667,,FUROSEMIDE,Loop Diuretic [EPC],,Current,Other,Limited Supply Available. Next Delivery and Estimated Recovery: December 2027,,7LXU5N7ZO5,0409-6102-25,844-646-4398,
"Hospira, Inc., a Pfizer Company",LIDOCAINE HYDROCHLORIDE,,02/22/2012,Revised,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010671, 1010900, 1737343, 1737562, 1737566, 1737568, 1737636, 1737757, 1737763",,3b2dd84e-cee8-4e58-d494-395a65a353a0,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE HYDROCHLORIDE,"0409-4776, 0409-4713, 0409-4278, 0409-4279, 0409-4282, 0409-4277, 0409-4276, 0409-4275","Hospira, Inc.",c0b4635b-1473-4c48-89c6-620762cd687f,"0409-4713-12, 0409-4713-26, 0409-4713-02, 0409-4713-72, 0409-4713-62, 0409-4713-75, 0409-4713-65, 0409-4713-42, 0409-4713-25, 0409-4713-32, 0409-4278-16, 0409-4278-01, 0409-4279-16, 0409-4279-02, 0409-4776-10, 0409-4776-01, 0409-4282-11, 0409-4282-25, 0409-4282-01, 0409-4282-12, 0409-4282-02, 0409-4277-16, 0409-4277-01, 0409-4277-17, 0409-4277-02, 0409-4276-16, 0409-4276-01, 0409-4276-17, 0409-4276-02, 0409-4275-16, 0409-4275-01","Lidocaine Hydrochloride Preservative Free, Injection, 300 mg/20 mL (1.5%; 15 mg/mL) (NDC 0409-4776-01)",Injection,Limited Availability,,ANDA080408,,LIDOCAINE HYDROCHLORIDE,,,Current,Other,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: December 2025,,V13007Z41A,0409-4776-01,844-646-4398,
"Novo Nordisk, Inc.",LIRAGLUTIDE,,07/18/2023,Reverified,SUBCUTANEOUS,Liraglutide Injection,"897122, 1598268",,3946d389-0926-4f77-a708-0acb8153b143,09/16/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,SAXENDA,0169-2800,Novo Nordisk,70ed8ee8-a9dd-4c48-b96c-c0730120ef56,"0169-2800-15, 0169-2800-90, 0169-2800-97","Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)",Injection,Available,"N0000178480, M0160181, N0000020058",NDA206321,Glucagon-Like Peptide 1 [CS],LIRAGLUTIDE,GLP-1 Receptor Agonist [EPC],,Current,,,,839I73S42A,0169-2800-15,833-493-4689,Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
"Actavis Pharma, Inc.",PILOCARPINE HYDROCHLORIDE,,09/19/2025,New,ORAL,Pilocarpine Hydrochloride Tablet,"1000913, 1001004",,610022b7-7dc9-405a-a580-104657f43bdf,09/19/2025,HUMAN PRESCRIPTION DRUG,09/19/2025,Other,PILOCARPINE HYDROCHLORIDE,"0228-2801, 0228-2837","Actavis Pharma, Inc.",7db72b88-d664-4f26-901c-46c901b20d80,"0228-2801-11, 0228-2837-11","Salagen, Tablet, 5 mg (NDC 0228-2801-11)",Tablet,,,NDA020237,,PILOCARPINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug.,,0WW6D218XJ,0228-2801-11,800-545-8800,
Otsuka ICU Medical LLC,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807548, 1807549, 1807550, 1807551, 1807552, 1807627, 1807630, 1807631, 1807632, 1807633, 1807634, 1807639",,5f372b75-d7a4-471e-8ac6-290040fc84b0,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0990-7983, 0990-7730, 0990-7984, 0990-7985",ICU Medical Inc.,87c57bfa-0bf7-41fd-b954-eb753d5d9d7f,"0990-7730-36, 0990-7730-37, 0990-7983-61, 0990-7983-02, 0990-7983-03, 0990-7983-09, 0990-7983-55, 0990-7983-53, 0990-7984-37, 0990-7984-20, 0990-7984-13, 0990-7984-23, 0990-7984-36, 0990-7985-02, 0990-7985-03, 0990-7985-09","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-61)",Injection,,,NDA016366,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0990-7983-61,1-866-829-9025 or ProductAvailability@icumed.com,
"Mylan Institutional, a Viatris Company",DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718906, 1718909",,f140de5a-f13d-46b4-a742-049c63e474f5,09/17/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE HYDROCHLORIDE,"67457-924, 67457-925",Mylan Institutional LLC,b51a1fb0-fcee-4a76-9eaf-91c35813c242,"67457-924-00, 67457-924-50, 67457-925-00, 67457-925-10","Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 67457-924-50)",Injection,Available,,ANDA212571,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,,,,1018WH7F9I,67457-924-50,800-796-9526,
Baxter Healthcare,DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795609, 1795616",,0bfb32b2-d034-4219-a055-3448f0c424f7,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0338-9147, 0338-9143",Baxter Healthcare Company,539f43d0-ac05-4261-a87d-8b34b07e0dd7,"0338-9147-30, 0338-9143-30","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-9147-30)",Injection,Available,,NDA020179,,DEXTROSE MONOHYDRATE,,,Current,,,,LX22YL083G,0338-9147-30,888-229-0001,
Otsuka ICU Medical LLC,DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795477, 1795480, 1795481, 1795607, 1795609, 1795610, 1795612, 1795616, 1795618, 1795621",,8b25b7e0-703e-4b43-a4eb-52863511602d,09/17/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0990-7922, 0990-7923, 0990-7930","ICU Medical, Inc.",09b10612-c937-4d10-becb-9768e10caa2c,"0990-7923-20, 0990-7923-23, 0990-7923-36, 0990-7923-37, 0990-7923-13, 0990-7922-02, 0990-7922-03, 0990-7922-09, 0990-7922-53, 0990-7922-55, 0990-7922-61, 0990-7930-02, 0990-7930-03, 0990-7930-09","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-09)",Injection,Available,,NDA016367,,DEXTROSE MONOHYDRATE,,,Current,,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,LX22YL083G,0990-7922-09,1-866-829-9025 or ProductAvailability@icumed.com,
"Hospira, Inc., a Pfizer Company","EPINEPHRINE, LIDOCAINE HYDROCHLORIDE",,02/22/2012,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL","Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","1010688, 1010745, 1010751, 1010759, 1867996, 1867998",,2f94f711-14c4-48ec-c5a3-c5ec4b8e8729,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE,"0409-3181, 0409-1209, 0409-3177, 0409-3178, 0409-3182, 0409-3183, 0409-0007, 0409-0147","Hospira, Inc.",d16a4711-e663-455e-a1fe-236a41ca4e8f,"0409-1209-10, 0409-1209-01, 0409-1209-05, 0409-1209-70, 0409-1209-65, 0409-3177-16, 0409-3177-01, 0409-3178-16, 0409-3178-01, 0409-3178-17, 0409-3178-02, 0409-3178-18, 0409-3178-03, 0409-3181-11, 0409-3181-01, 0409-3182-11, 0409-3182-01, 0409-3182-21, 0409-3182-02, 0409-3182-31, 0409-3182-03, 0409-3183-11, 0409-3183-01, 0409-0007-01, 0409-0007-10, 0409-0147-01, 0409-0147-10","Lidocaine Hydrochloride And Epinephrine, Injection, 450 mg/30 mL (1.5%; 1:200,000) (NDC 0409-3181-01)",Injection,Available,"N0000000209, N0000000245, N0000175552, N0000175555, N0000175570, M0003647",ANDA089645,Catecholamines [CS],LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE,"alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC], Catecholamine [EPC]",,Current,,,,"V13007Z41A, YKH834O4BH",0409-3181-01,844-646-4398,"Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA]"
Sagent Pharmaceuticals,LEUCOVORIN CALCIUM,,01/01/2012,Revised,"INTRAMUSCULAR, INTRAVENOUS",Leucovorin Calcium Injection,"237788, 1803930, 1803932, 1803937",,9d0e5356-ff39-4a8e-944c-e808a21ef4b2,07/08/2025,HUMAN PRESCRIPTION DRUG,,"Oncology, Pediatric",LEUCOVORIN CALCIUM,"25021-813, 25021-814, 25021-815, 25021-816",Sagent Pharmaceuticals,ff2ba160-e2f9-4ab9-9e67-2409f02c923e,"25021-813-10, 25021-814-30, 25021-815-30, 25021-816-30","Leucovorin Calcium, Injection, 50 mg/5 mL (NDC 25021-813-10)",Injection,,,ANDA200753,,LEUCOVORIN CALCIUM,,Available,Resolved,,,07/08/2025,RPR1R4C0P4,25021-813-10,866-625-1618,
Eugia US LLC,LIDOCAINE HYDROCHLORIDE,,02/20/2018,Revised,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Lidocaine Hydrochloride Injection,"1737562, 1737566, 1737568, 1737757, 1737761",,"9916b09d-a116-469d-92d5-60e50ea9782b, 89701fac-7536-4f16-87fb-f4cc121e74ee",09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,LIDOCAINE HYDROCHLORIDE,"55150-163, 55150-161, 55150-162, 55150-164, 55150-165",Eugia US LLC,"9916b09d-a116-469d-92d5-60e50ea9782b, 9b60bc92-6093-49f9-a6ba-075104ff7bb5","55150-161-09, 55150-162-09, 55150-163-00, 55150-164-09, 55150-165-09, 55150-161-02, 55150-162-05, 55150-163-30, 55150-164-02, 55150-165-05","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-163-30)",Injection,Unavailable,,ANDA203082,,LIDOCAINE HYDROCHLORIDE,,,Current,Demand increase for the drug,On backorder. Recovery: TBD. Check wholesalers for inventory,,V13007Z41A,55150-163-30,888-238-7880,
"Fresenius Kabi USA, LLC",SODIUM CHLORIDE,,06/21/2018,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Sodium Chloride 0.9% Injection,"1807632, 1807636, 1807637, 1807638",,"f2a98378-9678-4738-9670-fc7a215c0606, f62481fd-fcdb-4be6-ac13-29c590e925c3",08/08/2025,HUMAN PRESCRIPTION DRUG,,Other,SODIUM CHLORIDE,63323-186,"Fresenius Kabi USA, LLC","debc17b5-4d24-473c-8396-e409433ce57c, 75c567e3-582b-4fff-9a72-f326f1d13c8f","63323-186-00, 63323-186-04, 63323-186-02, 63323-186-01, 63323-186-10, 63323-186-03, 63323-186-20","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-186-20)",Injection,,,ANDA088912,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,63323-186-20,888-386-1300,
B. Braun Medical Inc.,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807639, 1807551, 1807552, 1807633, 1807634",,"47a0313f-36df-4fa6-a828-c9e1946ba9b0, 7f22c06b-6b4d-4b49-a4b2-d2169f2bd653",08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0264-7800, 0264-7802",B. Braun Medical Inc.,"318417ff-d599-47b8-8181-89c3bb3b2e8d, 9fa9f6b4-63b5-4632-8104-37c3dd1ee8fa","0264-7800-09, 0264-7800-00, 0264-7800-10, 0264-7800-20, 0264-7802-00, 0264-7802-10","Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-7800-09)",Injection,,,NDA019635,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0264-7800-09,800-227-2862,
"Fresenius Kabi USA, LLC","EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE ANHYDROUS",,10/14/2016,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL","Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","1010033, 1010035, 1010671, 1010673, 1010688, 1010692, 1010745, 1010749, 1010751, 1010755, 1010759, 1010763, 1010900, 1010902, 1737343, 1737345, 1737562, 1737563, 1737566, 1737567, 1737568, 1737569, 1737570, 1737571, 1737757, 1737758, 1737761, 1737762, 1867938, 1867940, 1867943, 1867944, 1867992, 1867993, 1867996, 1867997, 1868028, 1868029",,ba082c2f-64f4-419d-9c88-74f203316e17,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",XYLOCAINE MPF,"63323-489, 63323-492, 63323-491, 63323-495, 63323-485, 63323-486, 63323-484, 63323-488, 63323-481, 63323-483, 63323-482, 63323-487","Fresenius Kabi USA, LLC",ea480a68-5927-4278-9deb-2956961da428,"63323-492-04, 63323-492-27, 63323-492-09, 63323-492-57, 63323-492-07, 63323-492-37, 63323-492-03, 63323-492-31, 63323-491-01, 63323-491-57, 63323-495-09, 63323-495-27, 63323-495-04, 63323-495-07, 63323-485-01, 63323-485-27, 63323-485-03, 63323-485-57, 63323-486-01, 63323-486-17, 63323-486-02, 63323-486-27, 63323-486-05, 63323-486-57, 63323-484-57, 63323-489-02, 63323-489-27, 63323-489-03, 63323-489-21, 63323-489-01, 63323-489-17, 63323-488-07, 63323-488-37, 63323-488-03, 63323-488-31, 63323-488-01, 63323-488-17, 63323-481-01, 63323-481-57, 63323-483-03, 63323-483-27, 63323-483-01, 63323-483-57, 63323-482-01, 63323-482-17, 63323-482-03, 63323-482-27, 63323-482-05, 63323-482-57, 63323-487-01, 63323-487-17, 63323-487-07, 63323-487-37, 63323-487-03, 63323-487-31","Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-27)",Injection,Available,,NDA006488,,"LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE",,,Current,,Check wholesalers for inventory,,"EC2CNF7XFP, 30Q7KI53AK",63323-489-27,888-386-1300,
"Fresenius Kabi USA, LLC",ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Reverified,"EPIDURAL, INFILTRATION, PERINEURAL",Ropivacaine Hydrochloride Injection,"1734203, 1734204, 1734207, 1734208, 1734347, 1734348, 1734355, 1734356, 1734475, 1734476, 1734479, 1734480, 1734481, 1734482, 1734483, 1734484, 905189, 905191, 1734084, 1734086, 1734090, 1734091",,"dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7, 23d2d448-a744-4877-9f2d-7e57c198da89, c6613708-c1f7-4f5c-91a3-ebbc1d7905c6",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,NAROPIN,"63323-286, 63323-285, 63323-287, 63323-288","Fresenius Kabi USA, LLC","324532ac-4e54-4659-a1a2-9ade22a1ed3f, cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9, 73218c89-8925-468c-84bf-9960b4b3dc3c","63323-286-41, 63323-286-27, 63323-286-43, 63323-286-38, 63323-285-41, 63323-285-28, 63323-285-53, 63323-285-68, 63323-285-59, 63323-285-73, 63323-286-01, 63323-286-20, 63323-286-05, 63323-286-23, 63323-286-09, 63323-286-31, 63323-286-11, 63323-286-35, 63323-286-03, 63323-286-00, 63323-286-33, 63323-286-63, 63323-286-30, 63323-287-01, 63323-287-20, 63323-287-03, 63323-287-21, 63323-288-01, 63323-288-10, 63323-288-06, 63323-288-20, 63323-288-03, 63323-288-11, 63323-288-07, 63323-288-21, 63323-285-01, 63323-285-10, 63323-285-06, 63323-285-20, 63323-285-03, 63323-285-13, 63323-285-07, 63323-285-23, 63323-285-57, 63323-285-64, 63323-285-51, 63323-285-65, 63323-285-02, 63323-285-61, 63323-285-04, 63323-285-63, 63323-285-55, 63323-285-67, 63323-288-23, 63323-288-29, 63323-286-93, 63323-286-95","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-23)",Injection,Available,,NDA020533,,ROPIVACAINE HYDROCHLORIDE,,,Current,,,,V910P86109,63323-286-23,888-386-1300,
"Teva Pharmaceuticals USA, Inc.","HOMATROPINE METHYLBROMIDE, HYDROCODONE BITARTRATE",,09/11/2025,New,ORAL,Homatropine Methylbromide and Hydrocodone Bitartrate Syrup,"992668, 992675",,a324c912-a3ef-4296-b9a8-b0fec687eb06,09/11/2025,HUMAN PRESCRIPTION DRUG,09/11/2025,Analgesia/Addiction,HYDROMET,0472-1030,"Actavis Pharma, Inc.",6edda2e2-7ff0-4cc2-bd99-5a424bb6fbca,0472-1030-16,"Hydromet, Syrup, 1.5 mg/5 mL; 5 mg/5 mL (NDC 0472-1030-16)",Syrup,,,ANDA088017,,HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE,,,To Be Discontinued,,,,"68JRS2HC1C, NO70W886KK",0472-1030-16,800-545-8800,
"Teva Pharmaceuticals USA, Inc.",ISOSORBIDE MONONITRATE,Vasodilation [PE],11/13/2024,New,ORAL,Isosorbide Mononitrate Tablet,"311192, 311197",,ae8f74f0-e600-4452-8557-958b603e2709,11/13/2024,HUMAN PRESCRIPTION DRUG,11/13/2024,Cardiovascular,ISOSORBIDE MONONITRATE,"0228-2631, 0228-2620","Actavis Pharma, Inc.",1cb05f66-1c19-4300-8745-8c74c1dccb2b,"0228-2631-11, 0228-2620-11","Tablet, 10 mg (NDC 0228-2631-11)",Tablet,,"N0000175415, M0014874, N0000009909",ANDA075037,Nitrates [CS],ISOSORBIDE MONONITRATE,Nitrate Vasodilator [EPC],,To Be Discontinued,,A business decision was made to discontinue manufacture of this product.,,LX1OH63030,0228-2631-11,800-545-8800,
Sagent Pharmaceuticals,LEUCOVORIN CALCIUM,,01/01/2012,Revised,"INTRAMUSCULAR, INTRAVENOUS",Leucovorin Calcium Injection,"237788, 1803930, 1803932, 1803937",,9d0e5356-ff39-4a8e-944c-e808a21ef4b2,07/08/2025,HUMAN PRESCRIPTION DRUG,,"Oncology, Pediatric",LEUCOVORIN CALCIUM,"25021-816, 25021-813, 25021-814, 25021-815",Sagent Pharmaceuticals,ff2ba160-e2f9-4ab9-9e67-2409f02c923e,"25021-813-10, 25021-814-30, 25021-815-30, 25021-816-30","Leucovorin Calcium, Injection, 350 mg/17.5 mL (NDC 25021-816-30)",Injection,,,ANDA200855,,LEUCOVORIN CALCIUM,,Available,Resolved,,,07/08/2025,RPR1R4C0P4,25021-816-30,866-625-1618,
"Elite Laboratories, Inc.",NALTREXONE HYDROCHLORIDE,,02/29/2024,Revised,ORAL,Naltrexone Hydrochloride Tablet,1483744,,5f188bdc-2009-43aa-ad32-f06dbfac2642,09/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,NALTREXONE HYDROCHLORIDE,64850-300,"Elite Laboratories, Inc.",cae1ac14-ab22-42d1-8449-5e36c137b905,"64850-300-30, 64850-300-01","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 64850-300-01)",Tablet,Available,,ANDA075274,,NALTREXONE HYDROCHLORIDE,,,Current,,,,Z6375YW9SF,64850-300-01,888-852-6657,
"Fresenius Kabi USA, LLC",ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Reverified,"EPIDURAL, INFILTRATION, PERINEURAL",Ropivacaine Hydrochloride Injection,"1734203, 1734204, 1734207, 1734208, 1734347, 1734348, 1734355, 1734356, 1734475, 1734476, 1734479, 1734480, 1734481, 1734482, 1734483, 1734484, 905189, 905191, 1734084, 1734086, 1734090, 1734091",,"dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7, 23d2d448-a744-4877-9f2d-7e57c198da89, c6613708-c1f7-4f5c-91a3-ebbc1d7905c6",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,NAROPIN,"63323-286, 63323-285, 63323-287, 63323-288","Fresenius Kabi USA, LLC","324532ac-4e54-4659-a1a2-9ade22a1ed3f, cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9, 73218c89-8925-468c-84bf-9960b4b3dc3c","63323-286-41, 63323-286-27, 63323-286-43, 63323-286-38, 63323-285-41, 63323-285-28, 63323-285-53, 63323-285-68, 63323-285-59, 63323-285-73, 63323-286-01, 63323-286-20, 63323-286-05, 63323-286-23, 63323-286-09, 63323-286-31, 63323-286-11, 63323-286-35, 63323-286-03, 63323-286-00, 63323-286-33, 63323-286-63, 63323-286-30, 63323-287-01, 63323-287-20, 63323-287-03, 63323-287-21, 63323-288-01, 63323-288-10, 63323-288-06, 63323-288-20, 63323-288-03, 63323-288-11, 63323-288-07, 63323-288-21, 63323-285-01, 63323-285-10, 63323-285-06, 63323-285-20, 63323-285-03, 63323-285-13, 63323-285-07, 63323-285-23, 63323-285-57, 63323-285-64, 63323-285-51, 63323-285-65, 63323-285-02, 63323-285-61, 63323-285-04, 63323-285-63, 63323-285-55, 63323-285-67, 63323-288-23, 63323-288-29, 63323-286-93, 63323-286-95","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-20)",Injection,Unavailable,,NDA020533,,ROPIVACAINE HYDROCHLORIDE,,,Current,Delay in shipping of the drug,Not available at this time.,,V910P86109,63323-286-20,888-386-1300,
Baxter Healthcare,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807551, 1807552, 1807627, 1807630, 1807631, 1807632, 1807633, 1807634, 1807639",,f55bd888-5e01-474d-871b-24654c070178,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0338-0049, 0338-0043",Baxter Healthcare Corporation,6ab23768-efd2-4ff1-b336-0dda08dc56e1,"0338-0049-01, 0338-0049-02, 0338-0049-03, 0338-0049-04, 0338-0049-10, 0338-0049-41, 0338-0049-11, 0338-0049-31, 0338-0049-48, 0338-0049-18, 0338-0049-38, 0338-0043-03, 0338-0043-04","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-41)",Injection,,,NDA016677,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0338-0049-41,888-229-0001,
Pfizer Inc.,CLINDAMYCIN PHOSPHATE,,03/21/2023,Revised,"INTRAMUSCULAR, INTRAVENOUS",Clindamycin Phosphate Injection,"205964, 309335, 309336, 309339, 685574, 685576, 685578, 706461, 1737244, 1737245, 1737578, 1737579, 1737581, 1737582",,05a75685-0af5-407c-ac57-e380c882b49d,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,CLEOCIN PHOSPHATE,"0009-0728, 0009-0870, 0009-0775, 0009-0902, 0009-3124, 0009-3447, 0009-3381, 0009-3375, 0009-3382, 0009-6582",Pharmacia & Upjohn Company LLC,ac3ba828-3240-4b06-8741-5d1b58e313da,"0009-0870-21, 0009-0870-26, 0009-0775-20, 0009-0775-26, 0009-0902-11, 0009-0902-18, 0009-0728-05, 0009-0728-09, 0009-3124-01, 0009-3124-03, 0009-3447-01, 0009-3447-03, 0009-3381-01, 0009-3381-02, 0009-3375-01, 0009-3375-02, 0009-3382-01, 0009-3382-02, 0009-6582-02, 0009-6582-01","Cleocin Phosphate, Injection, Cleocin Phosphate 9 g/60 mL (150 mg/mL) (NDC 0009-0728-09)",Injection,Unavailable,,NDA050441,,CLINDAMYCIN PHOSPHATE,,,Current,Demand increase for the drug,Next Delivery: February 2026; Estimated Recovery: March 2026,,EH6D7113I8,0009-0728-09,800-533-4535,
Eugia US LLC,LIDOCAINE HYDROCHLORIDE,,02/20/2018,Revised,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Lidocaine Hydrochloride Injection,"1737566, 1737568, 1737757",,5524cbfd-d6e6-42eb-aaa5-22495e0a86b6,09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,LIDOCAINE HYDROCHLORIDE,"55150-159, 55150-158, 55150-160",Eugia US LLC,e2600451-756c-4986-9e8e-26ce1d865afd,"55150-158-72, 55150-159-74, 55150-160-72","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-159-74)",Injection,Unavailable,,ANDA203040,,LIDOCAINE HYDROCHLORIDE,,,Current,Demand increase for the drug,On backorder. Recovery: TBD. Check wholesalers for inventory,,V13007Z41A,55150-159-74,888-238-7880,
Rhodes Pharmaceuticals L.P.,LISDEXAMFETAMINE DIMESYLATE,,01/11/2024,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,d918b40d-a461-41bc-b6c0-83dc76c28e32,08/05/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"42858-167, 42858-161, 42858-162, 42858-163, 42858-164, 42858-165, 42858-166",Rhodes Pharmaceuticals,4bb64a6b-cce9-4c4a-81c3-06e2e59315c3,"42858-161-01, 42858-162-01, 42858-163-01, 42858-164-01, 42858-165-01, 42858-166-01, 42858-167-01","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 42858-167-01)",Capsule,Available,,ANDA215330,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,42858-167-01,888-827-0616,
"Hospira, Inc., a Pfizer Company",SODIUM ACETATE ANHYDROUS,,02/03/2016,Reverified,INTRAVENOUS,Sodium Acetate Injection,1859490,,"ce9a7469-c4ba-4f60-8f7a-47ef0974316e, c91ede49-c7cc-47b7-0f93-e6841dd5916a",08/15/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Pediatric, Total Parenteral Nutrition",SODIUM ACETATE,0409-7299,"Hospira, Inc.","7ed61ab6-b7ad-45ae-b660-0ed685661bc7, c434d6ad-d2f5-43eb-81d5-b6165b652aa7","0409-7299-45, 0409-7299-25, 0409-7299-83, 0409-7299-73","Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-73)",Injection,Available,,NDA018893,,SODIUM ACETATE,,,Current,,,,NVG71ZZ7P0,0409-7299-73,844-646-4398,
"Harrow Eye, LLC",TRIAMCINOLONE ACETONIDE,,09/27/2021,Reverified,OPHTHALMIC,Triamcinolone Acetonide Injection,"1086259, 1792144",,2267978c-72ad-9229-e063-6394a90a09d0,09/17/2025,HUMAN PRESCRIPTION DRUG,,Ophthalmology,TRIESENCE,82667-800,"Harrow Eye, LLC",2267b3ab-3e4d-fecb-e063-6394a90acd28,82667-800-01,"Triesence, Injection, 40 mg/1 mL (NDC 82667-800-01)",Injection,Limited Availability,"N0000175576, N0000175450",NDA022048,,TRIAMCINOLONE ACETONIDE,Corticosteroid [EPC],,Current,Requirements related to complying with good manufacturing practices,Estimated duration: 12 months,,F446C597KA,82667-800-01,(615) 733-4734,Corticosteroid Hormone Receptor Agonists [MoA]
"Hospira, Inc., a Pfizer Company",LIDOCAINE HYDROCHLORIDE,,02/22/2012,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Lidocaine Hydrochloride Injection,1737761,,9c18eaf1-4a0b-4916-70b2-88a827494711,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE HYDROCHLORIDE,0409-2066,"Hospira, Inc.",7ec189f1-7357-4bc2-b1d3-57cbb695252d,"0409-2066-10, 0409-2066-05","Lidocaine Hydrochloride, Injection, 100 mg/5 mL (2%; 20 mg/mL) (NDC 0409-2066-05)",Injection,Available,,ANDA040078,,LIDOCAINE HYDROCHLORIDE,,,Current,,,12/19/2024,V13007Z41A,0409-2066-05,844-646-4398,
Takeda Pharmaceuticals USA Inc.,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854832, 854834, 854836, 854838, 854840, 854842, 854844, 854846, 854848, 854850, 854852, 1593856, 1593858, 1871456, 1871459, 1871460, 1871461, 1871462, 1871463, 1871464, 1871465, 1871466, 1871467, 1871468, 1871469",,704e4378-ca83-445c-8b45-3cfa51c1ecad,08/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,VYVANSE,"59417-104, 59417-101, 59417-102, 59417-103, 59417-105, 59417-106, 59417-107, 59417-115, 59417-116, 59417-117, 59417-118, 59417-119, 59417-120","Takeda Pharmaceuticals America, Inc.",756b98a0-fada-44b2-a606-f2e71ef8cc84,"59417-101-10, 59417-102-10, 59417-103-10, 59417-104-10, 59417-105-10, 59417-106-10, 59417-107-10, 59417-115-01, 59417-116-01, 59417-117-01, 59417-118-01, 59417-119-01, 59417-120-01","Vyvanse, Capsule, 40 mg (NDC 59417-104-10)",Capsule,Available,,NDA021977,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,59417-104-10,877-TAKEDA-7 (1-877-825-3327),
Sun Pharmaceutical Industries Limited,PANTOPRAZOLE SODIUM,,12/05/2024,New,INTRAVENOUS,Pantoprazole Sodium Injection,283669,,d9fcf6a2-3788-4955-84d9-3c319b13267c,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Gastroenterology,PANTOPRAZOLE SODIUM,62756-129,"Sun Pharmaceutical Industries, Inc.",ef1bb9ed-b534-4698-abf5-836dcce85f45,"62756-129-40, 62756-129-44, 62756-129-45","Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 62756-129-44)",Injection,,,ANDA077674,,PANTOPRAZOLE SODIUM,,,To Be Discontinued,,Discontinuing for business reasons,,6871619Q5X,62756-129-44,800-818-4555,
"Fresenius Kabi USA, LLC",SODIUM ACETATE,,03/23/2016,Reverified,INTRAVENOUS,Sodium Acetate Injection,312965,,d7fabf08-d4e0-4bb5-8416-2e8ffe27c04b,09/18/2025,HUMAN PRESCRIPTION DRUG,,Total Parenteral Nutrition,SODIUM ACETATE,63323-032,"Fresenius Kabi USA, LLC",37c19fc5-c1ce-4ea0-9cba-4cdf32112091,"63323-032-04, 63323-032-00","Sodium Acetate, Injection, 4 meq/100 mL (NDC 63323-032-00)",Injection,Available,,ANDA206687,,SODIUM ACETATE,,,Current,,Check wholesalers for inventory,,4550K0SC9B,63323-032-00,888-386-1300,
MSN Laboratories Private Limited,BUMETANIDE,Increased Diuresis at Loop of Henle [PE],12/13/2017,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Bumetanide Injection,"282486, 1727569",,387edfd4-be85-41cd-8a6d-14e6a022b5a9,09/15/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,BUMETANIDE,"72205-102, 72205-101",Novadoz Pharmaceuticals LLC,387edfd4-be85-41cd-8a6d-14e6a022b5a9,"72205-101-01, 72205-101-07, 72205-102-01, 72205-102-07","Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)",Injection,Available,"N0000175366, N0000175590",ANDA215364,,BUMETANIDE,Loop Diuretic [EPC],,Current,,,,0Y2S3XUQ5H,72205-102-01,Distributed by: Novadoz Pharmaceuticals LLC; Telephone: (855) 668-2369; customerservice@novadozpharma.com,
"Mylan Institutional, a Viatris Company",DEXAMETHASONE SODIUM PHOSPHATE,,02/08/2019,Reverified,"INTRA-ARTICULAR, INTRALESIONAL, INTRAMUSCULAR, INTRAVENOUS, SOFT TISSUE",Dexamethasone Sodium Phosphate Injection,"309696, 1116927, 1812194",,dff598e8-e662-411f-978d-4ba3fb8ef7db,09/17/2025,HUMAN PRESCRIPTION DRUG,,"Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Other, Pulmonary/Allergy, Rheumatology",DEXAMETHASONE SODIUM PHOSPHATE,"67457-422, 67457-423, 67457-421, 67457-420",Mylan Institutional LLC,dd5c82b6-a194-462c-9626-34a9b410cfea,"67457-423-00, 67457-423-12, 67457-422-00, 67457-422-54, 67457-421-00, 67457-421-30, 67457-420-00, 67457-420-10","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-422-54)",Injection,Available,,ANDA040803,,DEXAMETHASONE SODIUM PHOSPHATE,,,Current,,,,AI9376Y64P,67457-422-54,800-796-9526,
Afaxys Pharma,,,03/05/2025,Revised,,Lidocaine Hydrochloride Injection,,,,03/05/2025,,03/05/2025,"Anesthesia, Pediatric",,,,,,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 50102-400-10)",Injection,,,,,,,,To Be Discontinued,,,03/05/2025,,50102-400-10,713-724-0238,
Apotex Corp.,LISDEXAMFETAMINE DIMESYLATE,,11/01/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,ecad4442-a644-18e3-6ff2-fdbac45eec47,09/29/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"60505-4741, 60505-4739, 60505-4740, 60505-4742, 60505-4743, 60505-4744, 60505-4745",Apotex Corp.,c8e0c70d-2f5b-8d85-fa45-572e8f5f7b4c,"60505-4739-1, 60505-4740-1, 60505-4741-1, 60505-4742-1, 60505-4743-1, 60505-4744-1, 60505-4745-1","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 60505-4741-1)",Capsule,Available,,ANDA216944,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,Product currently available,,SJT761GEGS,60505-4741-1,800-706-5575,
"Teva Pharmaceuticals USA, Inc.",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Revised,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release","1091155, 1091170, 1091185, 1091210",,85ef422d-af27-4126-9841-6892af1871d6,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE HYDROCHLORIDE,"62037-727, 62037-725, 62037-734, 62037-726","Actavis Pharma, Inc.",794291a5-d481-4cfe-9dbb-2d1391bb68d5,"62037-725-01, 62037-734-01, 62037-726-01, 62037-727-01","Methylphenidate Hydrochloride Extended-Release Tablets, USP   CII, Tablet, Extended Release, 54 mg (NDC 62037-727-01)",Tablet,Limited Availability,,ANDA076655,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,Demand increase for the drug,Limited Availability,,4B3SC438HI,62037-727-01,800-545-8800,
"Upsher-Smith Laboratories, LLC",OXYBUTYNIN CHLORIDE,,05/14/2025,New,ORAL,Oxybutynin Chloride Tablet,863664,,3ee6835a-7a7d-49a9-8460-2f1dd270ead3,05/14/2025,HUMAN PRESCRIPTION DRUG,05/14/2025,Renal,OXYBUTYNIN CHLORIDE,0832-0038,"Upsher-Smith Laboratories, LLC",2f3b30f0-e463-2de1-e063-6394a90a1b69,"0832-0038-00, 0832-0038-50, 0832-0038-10, 0832-0038-89, 0832-0038-01","Oxybutynin Chloride, Tablet, 5 mg (NDC 0832-0038-00)",Tablet,,,ANDA074625,,OXYBUTYNIN CHLORIDE,,,To Be Discontinued,,,,L9F3D9RENQ,0832-0038-00,800-654-2299,
"Fresenius Kabi USA, LLC",SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807631, 1807632, 1807633, 1807634, 1807639",,037ac04d-f8f3-4bb8-993a-ac8f7683ff83,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"65219-468, 65219-466, 65219-470, 65219-472, 65219-474","Fresenius Kabi USA, LLC",4110390b-2806-4c92-b283-a90115f89114,"65219-466-05, 65219-466-60, 65219-468-05, 65219-468-50, 65219-470-05, 65219-470-30, 65219-472-05, 65219-472-20, 65219-474-05, 65219-474-10","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 65219-468-50)",Injection,,,ANDA207310,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,65219-468-50,888-386-1300,
Aurobindo Pharma USA,CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,b1582eb7-af35-45d5-a52e-0e380d08527d,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"59651-723, 59651-722, 59651-724",Aurobindo Pharma Limited,b1582eb7-af35-45d5-a52e-0e380d08527d,"59651-722-01, 59651-722-99, 59651-723-01, 59651-723-99, 59651-724-01, 59651-724-05","Clonazepam, Tablet, 1 mg (NDC 59651-723-01)",Tablet,Available,"N0000175694, M0002356",ANDA075150,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,,,5PE9FDE8GB,59651-723-01,866-850-2876,
Eugia US LLC,ETOMIDATE,General Anesthesia [PE],10/05/2022,Reverified,INTRAVENOUS,Etomidate Injection,"1654006, 1654008",,0820f15a-046b-4185-a2b3-2e4051ee3d82,09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ETOMIDATE,"55150-222, 55150-221",Eugia US LLC,278b160e-cdc4-451e-9405-cb001f443680,"55150-221-10, 55150-222-20","Etomidate, Injection, 40 mg/20 mL (NDC 55150-222-20)",Injection,Unavailable,"N0000175975, N0000175681",ANDA206126,,ETOMIDATE,General Anesthetic [EPC],,Current,Demand increase for the drug,On backorder. Recovery: TBD. Check wholesalers for inventory,,Z22628B598,55150-222-20,888-238-7880,
"Hospira, Inc., a Pfizer Company",MORPHINE SULFATE,,10/31/2017,Reverified,INTRAVENOUS,Morphine Sulfate Injection,,,be420e8b-bcb0-49b5-bb4d-1df8b9959809,08/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,MORPHINE SULFATE,"0409-1893, 0409-1890, 0409-1891, 0409-1892, 0409-1894","Hospira, Inc.",cced2ec0-6c94-4cf0-87fb-041667ee3214,"0409-1890-03, 0409-1890-01, 0409-1890-13, 0409-1890-23, 0409-1891-03, 0409-1891-01, 0409-1891-13, 0409-1891-23, 0409-1892-03, 0409-1892-01, 0409-1892-13, 0409-1892-23, 0409-1893-03, 0409-1893-01, 0409-1893-13, 0409-1893-23, 0409-1894-03, 0409-1894-01","Morphine Sulfate, Injection, 10 mg/1 mL Syringes (NDC 0409-1893-01)",Injection,Unavailable,,NDA202515,,MORPHINE SULFATE,,,Current,Discontinuation of the manufacture of the drug,Discontinuation of the manufacture of the drug,,X3P646A2J0,0409-1893-01,844-646-4398,
"Genentech, Inc",PIRFENIDONE,,02/05/2025,New,ORAL,Pirfenidone Capsule,"1592279, 1592285, 1868014, 1868016, 1868018, 1868020",,2e8c3537-36d7-4de5-9b5c-7a624b9a9e6e,02/05/2025,HUMAN PRESCRIPTION DRUG,02/05/2025,Pulmonary/Allergy,ESBRIET,"50242-121, 50242-122, 50242-123","Genentech, Inc.",98714ede-f5d3-4338-aa0f-bbadaf339b85,"50242-121-01, 50242-122-86, 50242-122-06, 50242-123-01","Esbriet, Capsule, 267 mg (NDC 50242-121-01)",Capsule,,"N0000191420, M0018236",NDA022535,Pyridones [CS],PIRFENIDONE,Pyridone [EPC],,To Be Discontinued,,,,D7NLD2JX7U,50242-121-01,800-551-2231,
"Epic Pharma, LLC",RIFAMPIN,,12/22/2021,Reverified,ORAL,Rifampin Capsule,"198201, 198202",,0391f1e1-70d4-4b15-8b58-055bb6a385b8,09/18/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,RIFAMPIN,"42806-799, 42806-801","EPIC PHARMA, LLC",a4ac02e8-68ac-4e79-8ca5-0939dd002c87,"42806-801-30, 42806-801-01, 42806-799-30, 42806-799-60, 42806-799-01, 42806-799-05","Rifampin, Capsule, 300 mg (NDC 42806-799-01)",Capsule,Unavailable,"N0000175500, M0019113",ANDA064150,Rifamycins [CS],RIFAMPIN,Rifamycin Antibacterial [EPC],,Current,Discontinuation of the manufacture of the drug,Discontinuation of the manufacture of the drug.,,VJT6J7R4TR,42806-799-01,(718) 276-8600 ext. 3,
"Laboratorios Grifols, S.A.",SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807631, 1807632, 1807633, 1807634, 1807639",,eb811d79-fdb8-1f1a-c2ad-1cc4bfc7eadf,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,76297-001,LABORATORIOS GRIFOLS SA,ff5ef1ef-2a0d-476d-8483-ffd7cd47c635,"76297-001-12, 76297-001-11, 76297-001-22, 76297-001-21, 76297-001-32, 76297-001-31, 76297-001-02, 76297-001-01, 76297-001-42, 76297-001-41, 76297-001-52, 76297-001-51, 76297-001-62, 76297-001-61, 76297-001-72, 76297-001-71, 76297-001-82, 76297-001-81, 76297-001-92, 76297-001-91","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-21)",Injection,,,ANDA207956,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,76297-001-21,800-848-0462,
Sandoz Inc.,TRAVOPROST,,03/18/2025,New,OPHTHALMIC,Travoprost Solution/Drops,284008,,c17aa704-1ec6-4610-a448-4964bdb1cba1,03/18/2025,HUMAN PRESCRIPTION DRUG,03/18/2025,Ophthalmology,TRAVOPROST OPHTHALMIC SOLUTION,0781-6185,Sandoz Inc,ed706e46-4b7c-44ed-9e23-22a39061af45,"0781-6185-56, 0781-6185-75","Travatan Z, Solution/Drops, 5 mL (NDC 0781-6185-75)",Solution/Drops,,"N0000175454, M0017805",NDA021994,Prostaglandins [CS],TRAVOPROST,Prostaglandin Analog [EPC],,To Be Discontinued,,Business related decision to discontinue the product,,WJ68R08KX9,0781-6185-75,800-525-8747,
GlaxoSmithKline,DAPRODUSTAT,,11/21/2024,New,ORAL,Daprodustat Tablet,"2628215, 2628221, 2628223, 2628225, 2628227, 2628229, 2628231, 2628233, 2628235, 2628237",,d82aa06e-5a33-4844-99b7-4701313455a4,11/21/2024,HUMAN PRESCRIPTION DRUG,11/21/2024,Hematology,JESDUVROQ,"0173-0903, 0173-0897, 0173-0906, 0173-0911, 0173-0914",GlaxoSmithKline LLC,d52a823a-35bd-4c6a-a016-4b4f21a43d7d,"0173-0897-13, 0173-0897-56, 0173-0903-13, 0173-0903-56, 0173-0906-13, 0173-0906-56, 0173-0911-13, 0173-0911-56, 0173-0914-13, 0173-0914-56","Jesduvroq, Tablet, 2 mg (NDC 0173-0903-13)",Tablet,,"N0000194080, N0000194079",NDA216951,,DAPRODUSTAT,Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC],,To Be Discontinued,,Discontinuing for Business Reasons.,,JVR38ZM64B,0173-0903-13,888-825-5249,Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors [MoA]
B. Braun Medical Inc.,DEXTROSE,,10/11/2024,Reverified,INTRAVENOUS,Dextrose Monohydrate 70% Injection,237656,,8ccb10fe-75a5-440b-8cd4-b11f4e98f7b0,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,0264-7387,B. Braun Medical Inc.,200c4b9e-283a-4dea-b33a-9bb4936b2b99,0264-7387-50,"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0264-7387-50)",Injection,Available,,NDA019626,,DEXTROSE,,,Current,,,,IY9XDZ35W2,0264-7387-50,800-227-2862,
"Teva Pharmaceuticals USA, Inc.",GLIPIZIDE,,02/06/2025,New,ORAL,"Glipizide Tablet, Extended Release","310489, 314006, 315107",,a430577c-f233-40a7-bfd8-3d2bc6f98aa2,02/06/2025,HUMAN PRESCRIPTION DRUG,02/06/2025,Endocrinology/Metabolism,GLIPIZIDE ER,"0591-0844, 0591-0900, 0591-0845","Actavis Pharma, Inc.",90e0de65-ed5f-460a-a96f-77d4d76ceedd,"0591-0900-30, 0591-0844-01, 0591-0844-10, 0591-0845-01, 0591-0845-10","Glipizide, Tablet, Extended Release, 5 mg (NDC 0591-0844-10)",Tablet,,"N0000175608, M0020795",ANDA076467,Sulfonylurea Compounds [CS],GLIPIZIDE,Sulfonylurea [EPC],,To Be Discontinued,,A business decision was made to discontinue manufacture of the drug.,,X7WDT95N5C,0591-0844-10,800-545-8800,
Novadaq Technologies,,,08/23/2024,Revised,,Indocyanine Green Injection,,,,08/26/2025,,,"Medical Imaging, Ophthalmology, Other",,,,,,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-936-25)",Injection,,,,,,,Available,Resolved,,,08/26/2025,,66259-936-25,800-624-4422,
Sintetica US,LIDOCAINE HYDROCHLORIDE ANHYDROUS,,02/22/2012,Reverified,INFILTRATION,Lidocaine Hydrochloride Injection,"1737566, 1737568, 1737570, 1737757, 1737761, 1737763",,aa3e688a-308c-4a82-a268-28ccf1677c55,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",NA,"83090-005, 83090-001, 83090-002, 83090-003, 83090-004, 83090-006",Sintetica US LLC,0d18f291-3a92-421e-8841-6be743b1f154,"83090-001-01, 83090-001-10, 83090-002-01, 83090-002-10, 83090-003-01, 83090-003-10, 83090-004-01, 83090-004-10, 83090-005-01, 83090-005-10, 83090-006-01, 83090-006-10","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 83090-005-10)",Injection,Available,,ANDA214267,,LIDOCAINE HYDROCHLORIDE,,,Current,,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 2% 10X5ML)  is Preservative free.",,EC2CNF7XFP,83090-005-10,"844-425-3131, SinteticaCS@eversana.com",
"Fresenius Kabi USA, LLC",MORPHINE SULFATE,,10/31/2017,Revised,"INTRAMUSCULAR, INTRAVENOUS",Morphine Sulfate Injection,"894912, 894914, 998212, 998213, 1442790",,"1f53de80-efc8-4930-b3e3-fba0d026af05, b62ee1ef-db55-417a-a02e-b103890f9c4b",09/18/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,MORPHINE SULFATE,"76045-004, 76045-005, 76045-006, 76045-007, 76045-008","Fresenius Kabi, USA LLC, Fresenius Kabi USA, LLC","286bce70-23cd-4d5b-989b-230d6cdd5a91, e064585d-2d2d-41cd-a0f1-43494ce4775b","76045-004-01, 76045-004-11, 76045-005-01, 76045-005-11, 76045-006-01, 76045-006-11, 76045-007-01, 76045-007-11, 76045-008-01, 76045-008-11, 76045-004-02, 76045-004-12, 76045-005-02, 76045-005-12, 76045-006-02, 76045-006-12, 76045-007-00, 76045-007-10, 76045-008-00, 76045-008-10","Morphine Sulfate, Injection, 2 mg/1 mL (NDC 76045-004-11)",Injection,Unavailable,,NDA204223,,MORPHINE SULFATE,,,Current,Other,Backordered. Next release October 2025. Check wholesalers for inventory.,,X3P646A2J0,76045-004-11,888-386-1300,
Sandoz Inc.,OXALIPLATIN,,10/16/2024,New,INTRAVENOUS,Oxaliplatin Injection,"1736776, 1736781",,86f6c19d-30d1-42e3-8d46-5e3f45776e85,10/16/2024,HUMAN PRESCRIPTION DRUG,10/16/2024,Oncology,OXALIPLATIN,"0781-9317, 0781-9315",Sandoz Inc,ac83b4cd-5026-4dd5-b733-125d28ba3c95,"0781-9315-70, 0781-9317-80","Injection, 5 mg/1 mL (NDC 0781-9317-80)",Injection,,"N0000175413, N0000175073",ANDA078817,,OXALIPLATIN,Platinum-based Drug [EPC],,To Be Discontinued,,A business decision was made to discontinue this product.,,04ZR38536J,0781-9317-80,800-525-8747,
Pfizer Inc.,,,01/19/2023,Reverified,,Quinapril/Hydrochlorothiazide Tablet,,,,08/15/2025,,,Cardiovascular,,,,,,"Accuretic, Tablet, 20 mg/12.5 mg (NDC 0071-0220-23)",Tablet,Unavailable,,,,,,,Current,Delay in shipping of the drug,Next Delivery and Estimated Recovery: TBD,,,0071-0220-23,800-533-4535,
Bristol Myers Squibb Co.,ATAZANAVIR SULFATE,,06/04/2025,New,ORAL,Atazanavir Sulfate Oral Powder,"402093, 402094, 402246, 402247, 664741, 664743, 1598985, 1598989",,165cff62-b284-4a27-a65d-9ec8a5bfcdd8,06/04/2025,HUMAN PRESCRIPTION DRUG,06/04/2025,Antiviral,REYATAZ,"0003-3638, 0003-3624, 0003-3631, 0003-3622","E.R. Squibb & Sons, L.L.C.",510c2d51-4943-401c-a008-ea22f61c6938,"0003-3624-12, 0003-3631-12, 0003-3622-12, 0003-3638-10","Reyataz, Oral Powder, 50 mg (NDC 0003-3638-10)",Oral Powder,,,NDA206352,,ATAZANAVIR,,,To Be Discontinued,,Permanent discontinuation,,4MT4VIE29P,0003-3638-10,1-800-332-2056; for Medical Inquiries (1-800-321-1335),
Accord Healthcare Inc.,CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,ebc11109-e7bf-452d-b675-4b3236d54164,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"16729-136, 16729-137, 16729-138",Accord Healthcare Inc.,0e1e7f41-f78b-27cf-e063-6394a90a1ae0,"16729-136-00, 16729-136-16, 16729-137-00, 16729-137-16, 16729-138-00, 16729-138-16","Clonazepam, Tablet, .5 mg (NDC 16729-136-16)",Tablet,Available,"N0000175694, M0002356",ANDA077147,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,,,5PE9FDE8GB,16729-136-16,"866-941-7875, option 2",
Sagent Pharmaceuticals,FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Furosemide Injection,"1719286, 1719290, 1719291",,d63c1277-dd7e-4d21-9e80-68143f55e2dc,08/26/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,25021-311,Sagent Pharmaceuticals,222ce48f-2856-4be2-b16f-6fca38c0dceb,"25021-311-02, 25021-311-04, 25021-311-10","Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)",Injection,Available,"N0000175366, N0000175590",ANDA213902,,FUROSEMIDE,Loop Diuretic [EPC],,Current,,,,7LXU5N7ZO5,25021-311-04,866-625-1618,
"Hikma Pharmaceuticals USA, Inc.",AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","239191, 313797",,077f4a65-3cfb-4cb1-99f2-e27ffc5939c0,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0143-9888, 0143-9889",Hikma Pharmaceuticals USA Inc.,c2fa2c99-c735-4834-a8a5-04a30da8a002,"0143-9888-80, 0143-9888-01, 0143-9888-15, 0143-9889-80, 0143-9889-01, 0143-9889-15","Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0143-9888-80)","Powder, For Suspension",,,ANDA065322,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0143-9888-80,800-631-2174,
"Teva Pharmaceuticals USA, Inc.",PRAVASTATIN SODIUM,,06/13/2025,New,ORAL,Pravastatin Sodium Tablet,"904458, 904467, 904475",,99e0e848-f8f3-4b42-b880-8fbc42633948,06/13/2025,HUMAN PRESCRIPTION DRUG,06/13/2025,Cardiovascular,PRAVASTATIN SODIUM,"0093-7202, 0093-0771, 0093-7201","Teva Pharmaceuticals USA, Inc.",72579e23-23ef-4ab7-ad64-24d5ea7997eb,"0093-0771-98, 0093-0771-10, 0093-7201-98, 0093-7201-10, 0093-7202-98, 0093-7202-10","Pravastatin Sodium, Tablet, 40 mg (NDC 0093-7202-98)",Tablet,,,ANDA076056,,PRAVASTATIN SODIUM,,,To Be Discontinued,,,,3M8608UQ61,0093-7202-98,800-545-8800,
AbbVie Inc.,SILODOSIN,,02/20/2025,New,ORAL,Silodosin Capsule,"809477, 809481, 826612, 826614",,da0314f6-b1d6-44ee-8b1e-f763dbb8613f,02/20/2025,HUMAN PRESCRIPTION DRUG,02/20/2025,Urology,RAPAFLO,"0023-6147, 0023-6142","Allergan, Inc.",34eec0b8-ef99-4d69-bd3f-da1373da2e49,"0023-6142-90, 0023-6142-30, 0023-6147-30","Rapaflo, Capsule, 4 mg (NDC 0023-6147-30)",Capsule,,"N0000000099, N0000175553",NDA022206,,SILODOSIN,alpha-Adrenergic Blocker [EPC],,To Be Discontinued,,Last lot in distribution expires March 2026. Last sale date will be June 2025.,,CUZ39LUY82,0023-6147-30,800-633-9110,Adrenergic alpha-Antagonists [MoA]
Pfizer Inc.,,,01/06/2023,Revised,,Somatropin Injection,"241975, 762830, 762833, 762834, 762836, 762837, 762839, 762841, 762843, 762846, 762849, 762850, 762852, 762857, 762859, 762866, 762868, 762873, 762875, 762895, 762897, 763488, 763489, 996558, 996559",,ffebf88b-d257-4542-9808-74d9b7167765,08/28/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,GENOTROPIN,"0013-2650, 0013-2626, 0013-2646, 0013-2649, 0013-2651, 0013-2652, 0013-2653, 0013-2654, 0013-2655, 0013-2656, 0013-2657, 0013-2658",Pfizer Laboratories Div Pfizer Inc,f09acf87-6e30-47ad-9891-8a49bf6dffbc,"0013-2626-81, 0013-2646-81, 0013-2649-02, 0013-2650-02, 0013-2651-02, 0013-2652-02, 0013-2653-02, 0013-2654-02, 0013-2655-02, 0013-2656-02, 0013-2657-02, 0013-2658-02","Genotropin, Injection, 0.4 mg preservative free (NDC 0013-2650-02)",Injection,,,BLA020280,,SOMATROPIN,,Available,Resolved,,,08/28/2025,,0013-2650-02,800-533-4535,
"Hospira, Inc., a Pfizer Company",WATER,,11/23/2021,Reverified,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Sterile Water Injection,,,2b9ea23a-f9e9-48a8-25b7-519e3bbd6828,08/15/2025,HUMAN PRESCRIPTION DRUG,,Other,STERILE WATER,0409-4887,"Hospira, Inc.",900859c0-a075-4fb1-98ce-0e329acc009a,"0409-4887-25, 0409-4887-99, 0409-4887-31, 0409-4887-05, 0409-4887-17, 0409-4887-10, 0409-4887-32, 0409-4887-34, 0409-4887-23, 0409-4887-20, 0409-4887-24, 0409-4887-50","Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-10)",Injection,Available,,NDA018801,,WATER,,,Current,,,,059QF0KO0R,0409-4887-10,844-646-4398,
Sun Pharmaceutical Industries Limited,CLINDAMYCIN HYDROCHLORIDE,,12/05/2024,New,ORAL,Clindamycin Hydrochloride Capsule,"197518, 284215",,1dbd8448-c1e5-46df-8060-50ef82380445,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Anti-Infective,CLINDAMYCIN HYDROCHLORIDE,"63304-692, 63304-693","Sun Pharmaceutical Industries, Inc.",339366d4-2060-1c29-e063-6394a90a1cb7,"63304-692-01, 63304-692-05, 63304-692-77, 63304-692-03, 63304-693-16, 63304-693-01, 63304-693-03, 63304-693-05, 63304-693-77, 63304-693-11, 63304-693-62","Clindamycin Hydrochloride, Capsule, 150 mg (NDC 63304-692-01)",Capsule,,,ANDA065061,,CLINDAMYCIN HYDROCHLORIDE,,,To Be Discontinued,,Discontinuing for business reasons,,T20OQ1YN1W,63304-692-01,800-818-4555,
AstraZeneca AB,"DAPAGLIFLOZIN, SAXAGLIPTIN HYDROCHLORIDE",,03/03/2025,New,ORAL,Dapagliflozin; Saxaglipitin Hydrochloride Tablet,"1925498, 1925504, 2169274, 2169276",,423c489c-085b-4320-b892-7868ebd6dc6b,03/03/2025,HUMAN PRESCRIPTION DRUG,03/03/2025,Endocrinology/Metabolism,QTERN,"0310-6780, 0310-6770",AstraZeneca Pharmaceuticals LP,d675ddaa-3a40-4323-9edd-b04f13f10a03,"0310-6780-30, 0310-6780-95, 0310-6770-30, 0310-6770-95","Qtern, Tablet, 10 mg; 5 mg (NDC 0310-6780-30)",Tablet,,"N0000187059, N0000187058",NDA209091,,DAPAGLIFLOZIN AND SAXAGLIPTIN,Sodium-Glucose Cotransporter 2 Inhibitor [EPC],,To Be Discontinued,,,,"1ULL0QJ8UC, Z8J84YIX6L",0310-6780-30,800-236-9933,Sodium-Glucose Transporter 2 Inhibitors [MoA]
Accord Healthcare Inc.,FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Revised,"INTRAMUSCULAR, INTRAVENOUS",Furosemide Injection,"1719286, 1719290, 1719291",,f6f64972-714c-4ee9-8a5e-9ffcab41a73b,09/16/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,"16729-500, 16729-501, 16729-502","Accord Healthcare, Inc.",1cfab300-d796-6a68-e063-6394a90a73f9,"16729-500-30, 16729-500-08, 16729-501-64, 16729-501-43, 16729-502-03, 16729-502-43","Furosemide, Injection, 10 mg/1 mL (NDC 16729-500-08)",Injection,Unavailable,"N0000175366, N0000175590",ANDA070017,,FUROSEMIDE,Loop Diuretic [EPC],,Current,Requirements related to complying with good manufacturing practices,Unavailable,,7LXU5N7ZO5,16729-500-08,866-941-7875,
"Teva Pharmaceuticals USA, Inc.",HYDROCORTISONE,,03/24/2025,New,TOPICAL,Hydrocortisone Cream,310891,,a5f16c13-2a51-4541-bf9e-d80bc01a8dbd,03/24/2025,HUMAN PRESCRIPTION DRUG,03/24/2025,Dermatology,HYDROCORTISONE,0472-0337,"Actavis Pharma, Inc.",527a8d09-450b-4b8e-ad19-78fbba9732c5,"0472-0337-20, 0472-0337-30","Hydrocortisone, Cream, 25 mg/1 g (NDC 0472-0337-20)",Cream,,"N0000175576, N0000175450",ANDA089682,,HYDROCORTISONE,Corticosteroid [EPC],,To Be Discontinued,,A business decision was made to discontinue.,,WI4X0X7BPJ,0472-0337-20,800-545-8800,Corticosteroid Hormone Receptor Agonists [MoA]
Aurobindo Pharma USA,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,a582d57f-d191-4ca5-b105-585b2d8a0e3e,09/17/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","13107-073, 13107-068, 13107-069, 13107-070, 13107-071, 13107-072, 13107-074","Aurolife Pharma, LLC",95842af2-8d9d-4eb1-ba39-86cdbd829a79,"13107-068-50, 13107-068-01, 13107-068-25, 13107-068-05, 13107-068-99, 13107-069-50, 13107-069-01, 13107-069-25, 13107-069-05, 13107-069-99, 13107-070-50, 13107-070-01, 13107-070-25, 13107-070-05, 13107-070-99, 13107-071-50, 13107-071-01, 13107-071-25, 13107-071-05, 13107-071-99, 13107-072-50, 13107-072-01, 13107-072-25, 13107-072-05, 13107-072-99, 13107-073-50, 13107-073-01, 13107-073-25, 13107-073-05, 13107-073-99, 13107-074-50, 13107-074-01, 13107-074-25, 13107-074-05, 13107-074-99","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 13107-073-01)",Tablet,Unavailable,,ANDA202424,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,Shortage of an active ingredient,Estimated availability December 2025,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",13107-073-01,(866) 850-2876 or CustomerService@AurobindoUSA.com,
Novadoz Pharmaceuticals LLC,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Revised,ORAL,"Lisdexamfetamine Dimesylate Tablet, Chewable","1871456, 1871460, 1871462, 1871464, 1871466, 1871468",,a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"72205-134, 72205-132, 72205-133, 72205-135, 72205-136, 72205-137",Novadoz Pharmaceuticals LLC,a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811,"72205-132-91, 72205-133-91, 72205-134-91, 72205-135-91, 72205-136-91, 72205-137-91","Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 72205-134-91)","Tablet, Chewable",Available,,ANDA218306,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,,,SJT761GEGS,72205-134-91,(855) 668-2369; customerservice@novadozpharma.com,
Pfizer Inc.,TRIAZOLAM,,09/29/2025,New,ORAL,Triazolam Tablet,"198318, 208681",,a0da0dba-a56d-486b-a45b-e8a7cdfbeac6,09/29/2025,HUMAN PRESCRIPTION DRUG,09/29/2025,Psychiatry,HALCION,0009-0017,Pharmacia & Upjohn Company LLC,923c70f5-d9ac-4be2-8c29-9b4b5b7e124d,"0009-0017-55, 0009-0017-58","Halcion, Tablet, .25 mg (NDC 0009-0017-58)",Tablet,,"N0000175694, M0002356",NDA017892,Benzodiazepines [CS],TRIAZOLAM,Benzodiazepine [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug.,,1HM943223R,0009-0017-58,800-533-4535,
GlaxoSmithKline,DAPRODUSTAT,,11/21/2024,New,ORAL,Daprodustat Tablet,"2628215, 2628221, 2628223, 2628225, 2628227, 2628229, 2628231, 2628233, 2628235, 2628237",,d82aa06e-5a33-4844-99b7-4701313455a4,11/21/2024,HUMAN PRESCRIPTION DRUG,11/21/2024,Hematology,JESDUVROQ,"0173-0911, 0173-0897, 0173-0903, 0173-0906, 0173-0914",GlaxoSmithKline LLC,d52a823a-35bd-4c6a-a016-4b4f21a43d7d,"0173-0897-13, 0173-0897-56, 0173-0903-13, 0173-0903-56, 0173-0906-13, 0173-0906-56, 0173-0911-13, 0173-0911-56, 0173-0914-13, 0173-0914-56","Jesduvroq, Tablet, 6 mg (NDC 0173-0911-56)",Tablet,,"N0000194080, N0000194079",NDA216951,,DAPRODUSTAT,Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC],,To Be Discontinued,,Discontinuing for Business Reasons.,,JVR38ZM64B,0173-0911-56,888-825-5249,Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors [MoA]
Aurobindo Pharma USA,QUINAPRIL HYDROCHLORIDE,,01/19/2023,Reverified,ORAL,Quinapril Hydrochloride Tablet,"312748, 312749, 312750, 314203",,93e6e668-5306-4f26-81d8-cbc3a7a5e787,09/17/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,QUINAPRIL,"65862-618, 65862-617, 65862-619, 65862-620",Aurobindo Pharma Limited,5263abd5-ce46-4918-9bb0-9632861bcbc9,"65862-617-30, 65862-617-90, 65862-617-99, 65862-617-55, 65862-617-10, 65862-617-78, 65862-618-30, 65862-618-90, 65862-618-99, 65862-618-55, 65862-618-10, 65862-618-78, 65862-619-30, 65862-619-90, 65862-619-99, 65862-619-19, 65862-619-10, 65862-619-78, 65862-620-30, 65862-620-90, 65862-620-99, 65862-620-39, 65862-620-10, 65862-620-78","Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)",Tablet,Discontinued,,ANDA202725,,QUINAPRIL HYDROCHLORIDE,,,Current,Discontinuation of the manufacture of the drug,,,33067B3N2M,65862-618-90,866-850-2876,
"Fresenius Kabi USA, LLC",ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Reverified,"EPIDURAL, INFILTRATION, PERINEURAL",Ropivacaine Hydrochloride Injection,"1734203, 1734204, 1734207, 1734208, 1734347, 1734348, 1734355, 1734356, 1734475, 1734476, 1734479, 1734480, 1734481, 1734482, 1734483, 1734484, 905189, 905191, 1734084, 1734086, 1734090, 1734091",,"dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7, 23d2d448-a744-4877-9f2d-7e57c198da89, c6613708-c1f7-4f5c-91a3-ebbc1d7905c6",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,NAROPIN,"63323-286, 63323-285, 63323-287, 63323-288","Fresenius Kabi USA, LLC","324532ac-4e54-4659-a1a2-9ade22a1ed3f, cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9, 73218c89-8925-468c-84bf-9960b4b3dc3c","63323-286-41, 63323-286-27, 63323-286-43, 63323-286-38, 63323-285-41, 63323-285-28, 63323-285-53, 63323-285-68, 63323-285-59, 63323-285-73, 63323-286-01, 63323-286-20, 63323-286-05, 63323-286-23, 63323-286-09, 63323-286-31, 63323-286-11, 63323-286-35, 63323-286-03, 63323-286-00, 63323-286-33, 63323-286-63, 63323-286-30, 63323-287-01, 63323-287-20, 63323-287-03, 63323-287-21, 63323-288-01, 63323-288-10, 63323-288-06, 63323-288-20, 63323-288-03, 63323-288-11, 63323-288-07, 63323-288-21, 63323-285-01, 63323-285-10, 63323-285-06, 63323-285-20, 63323-285-03, 63323-285-13, 63323-285-07, 63323-285-23, 63323-285-57, 63323-285-64, 63323-285-51, 63323-285-65, 63323-285-02, 63323-285-61, 63323-285-04, 63323-285-63, 63323-285-55, 63323-285-67, 63323-288-23, 63323-288-29, 63323-286-93, 63323-286-95","Naropin, Injection, 5 mg/1 mL (NDC 63323-286-63)",Injection,Available,,NDA020533,,ROPIVACAINE HYDROCHLORIDE,,,Current,,,,V910P86109,63323-286-63,888-386-1300,
"Mylan Specialty, a Viatris Company",CROMOLYN SODIUM,,11/03/2023,Reverified,ORAL,Cromolyn Sodium Concentrate,"831261, 831269",,00623958-a8fe-47d1-a0d2-0aa4e2f7966e,09/17/2025,HUMAN PRESCRIPTION DRUG,,Pulmonary/Allergy,GASTROCROM,0037-0678,Viatris Specialty LLC,15aec235-80e7-4d95-b48c-bbca69b4b04d,"0037-0678-08, 0037-0678-96","Gastrocrom, Concentrate, 20 mg/1 mL (NDC 0037-0678-96)",Concentrate,Available,,NDA020479,,CROMOLYN SODIUM,,,Current,,,,Q2WXR1I0PK,0037-0678-96,(800) 796-9526,
"Sun Pharmaceutical Industries, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Revised,ORAL,"Lisdexamfetamine Dimesylate Tablet, Chewable","854830, 854834, 854838, 854842, 854846, 854850, 1593856, 1871456, 1871460, 1871462, 1871464, 1871466, 1871468",,da3148af-f9b6-4725-adae-3595b4c7dc4b,09/22/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"57664-083, 57664-047, 57664-046, 57664-048, 57664-049, 57664-050, 57664-051, 57664-052, 57664-084, 57664-085, 57664-086, 57664-087, 57664-088","Sun Pharmaceutical Industries, Inc.",0b77417a-5789-8818-e063-6294a90ad2e3,"57664-047-88, 57664-046-88, 57664-048-88, 57664-049-88, 57664-050-88, 57664-051-88, 57664-052-88, 57664-083-88, 57664-084-88, 57664-085-88, 57664-086-88, 57664-087-88, 57664-088-88","Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 57664-083-88)","Tablet, Chewable",Limited Availability,,ANDA214134,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Other,Available Q3 2025,,SJT761GEGS,57664-083-88,800-818-4555,
B. Braun Medical Inc.,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807639, 1807551, 1807552, 1807633, 1807634",,"47a0313f-36df-4fa6-a828-c9e1946ba9b0, 7f22c06b-6b4d-4b49-a4b2-d2169f2bd653",08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0264-7800, 0264-7802",B. Braun Medical Inc.,"318417ff-d599-47b8-8181-89c3bb3b2e8d, 9fa9f6b4-63b5-4632-8104-37c3dd1ee8fa","0264-7800-09, 0264-7800-00, 0264-7800-10, 0264-7800-20, 0264-7802-00, 0264-7802-10","Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-7800-10)",Injection,,,NDA019635,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0264-7800-10,800-227-2862,
"Hikma Pharmaceuticals USA, Inc.",LIRAGLUTIDE,,07/18/2023,Reverified,SUBCUTANEOUS,Liraglutide Injection,897122,,2100ec49-57b2-4330-ab5f-057ce9b7e4d0,07/23/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,LIRAGLUTIDE,0143-9144,Hikma Pharmaceuticals USA Inc.,f242c0f8-6d4f-4a78-a1fd-433a0672dbd3,"0143-9144-03, 0143-9144-02","Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)",Injection,Available,"N0000178480, M0160181, N0000020058",ANDA215503,Glucagon-Like Peptide 1 [CS],LIRAGLUTIDE,GLP-1 Receptor Agonist [EPC],,Current,,Product will be made available as it is released.,,839I73S42A,0143-9144-02,800-631-2174,Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
"Mylan Pharmaceuticals Inc., a Viatris Company",METHYLPHENIDATE,Central Nervous System Stimulation [PE],02/28/2025,Reverified,TRANSDERMAL,"Methylphenidate Film, Extended Release","753436, 753438, 753440, 753441",,1643b6a5-80da-4d4f-8c5f-feb907875702,09/17/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE,"0378-8262, 0378-8260, 0378-8261, 0378-8263",Mylan Pharmaceuticals Inc.,c17e03ec-3756-4043-ae82-33a0ef18380c,"0378-8260-16, 0378-8260-93, 0378-8261-16, 0378-8261-93, 0378-8262-16, 0378-8262-93, 0378-8263-16, 0378-8263-93","Methylphenidate, Film, Extended Release, 20mg/9hrs (NDC 0378-8262-93)","Film, Extended Release",Available,"N0000175739, N0000175729",ANDA206497,,METHYLPHENIDATE,Central Nervous System Stimulant [EPC],,Current,,,,207ZZ9QZ49,0378-8262-93,800-796-9526,
"Hikma Pharmaceuticals USA, Inc.",LEUCOVORIN CALCIUM,,01/01/2012,Revised,"INTRAMUSCULAR, INTRAVENOUS",Leucovorin Calcium Injection,"237788, 1803930, 1803932, 1803937",,cc52077f-5663-4f79-a273-0aecf655e038,07/08/2025,HUMAN PRESCRIPTION DRUG,,"Oncology, Pediatric",LEUCOVORIN CALCIUM,"0143-9555, 0143-9554, 0143-9553, 0143-9552",Hikma Pharmaceuticals USA Inc.,e2d1484b-2920-45ab-9207-4caa5285fef4,"0143-9555-01, 0143-9554-01, 0143-9553-01, 0143-9552-01","Leucovorin Calcium, Injection, 50 mg/5 mL (NDC 0143-9555-01)",Injection,,,ANDA089384,,LEUCOVORIN CALCIUM,,Available,Resolved,,,07/08/2025,RPR1R4C0P4,0143-9555-01,800-631-2174,
Takeda Pharmaceuticals USA Inc.,FEBUXOSTAT,,01/22/2025,New,ORAL,Febuxostat Tablet,"834235, 834239, 834241, 834243",,54de10ef-fe5f-4930-b91d-6bbb04c664bd,01/22/2025,HUMAN PRESCRIPTION DRUG,01/22/2025,Other,ULORIC,"64764-677, 64764-918","Takeda Pharmaceuticals America, Inc.",fecf6101-9a35-4781-bea4-e7b92b4afb81,"64764-918-30, 64764-918-90, 64764-918-18, 64764-918-11, 64764-677-30, 64764-677-13, 64764-677-19, 64764-677-11","Uloric, Tablet, 80 mg (NDC 64764-677-30)",Tablet,,"N0000175698, N0000000206",NDA021856,,FEBUXOSTAT,Xanthine Oxidase Inhibitor [EPC],,To Be Discontinued,,Anticipate continued distribution to wholesalers until March 2026,,101V0R1N2E,64764-677-30,855-268-1825,Xanthine Oxidase Inhibitors [MoA]
"Hospira, Inc., a Pfizer Company",LIDOCAINE HYDROCHLORIDE,,02/22/2012,Reverified,INTRAVENOUS,Lidocaine Hydrochloride Injection,"1012066, 1012068",,ad1ef0a8-88db-4648-c098-d009eaeb4e5b,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE HYDROCHLORIDE,"0409-9137, 0409-4903, 0409-4904, 0409-1323","Hospira, Inc.",477abea3-c873-4265-82e8-5508ef54399f,"0409-4903-11, 0409-4903-34, 0409-4904-11, 0409-4904-34, 0409-1323-15, 0409-1323-05, 0409-9137-11, 0409-9137-05","Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 50 mg/5mL (1%, 10 mg/1 mL) Syringes (NDC 0409-9137-05)",Injection,Available,,ANDA040302,,LIDOCAINE HYDROCHLORIDE,,,Current,,,,V13007Z41A,0409-9137-05,844-646-4398,
"Teva Pharmaceuticals USA, Inc.",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Revised,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release","1091155, 1091170, 1091185, 1091210",,85ef422d-af27-4126-9841-6892af1871d6,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE HYDROCHLORIDE,"62037-726, 62037-725, 62037-734, 62037-727","Actavis Pharma, Inc.",794291a5-d481-4cfe-9dbb-2d1391bb68d5,"62037-725-01, 62037-734-01, 62037-726-01, 62037-727-01","Methylphenidate Hydrochloride Extended-Release Tablets, USP   CII, Tablet, Extended Release, 36 mg (NDC 62037-726-01)",Tablet,Available,,ANDA076772,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,,,,4B3SC438HI,62037-726-01,800-545-8800,
"Hospira, Inc., a Pfizer Company",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,"EPIDURAL, RETROBULBAR",Bupivacaine Hydrochloride Injection,"1012377, 1012384, 1012396, 1012404, 1672917, 1672919, 1724786, 1724787, 1724880, 1724884, 1725078, 1725082, 1867594, 1867596",,02a845c3-4521-4926-e397-25ab536e7cf6,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE,"0409-1165, 0409-1159, 0409-1160, 0409-1162, 0409-1163, 0409-9043, 0409-9046, 0409-9045, 0409-9042","Hospira, Inc.",3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7,"0409-1159-18, 0409-1159-01, 0409-1159-19, 0409-1159-02, 0409-1160-18, 0409-1160-01, 0409-1162-18, 0409-1162-01, 0409-1162-19, 0409-1162-02, 0409-1163-18, 0409-1163-01, 0409-1165-18, 0409-1165-01, 0409-1165-19, 0409-1165-02, 0409-9043-11, 0409-9043-01, 0409-9046-11, 0409-9046-01, 0409-9045-11, 0409-9045-01, 0409-9045-16, 0409-9045-17, 0409-9042-11, 0409-9042-01, 0409-9042-16, 0409-9042-17","Bupivacaine Hydrochloride, Injection, 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1165-02)",Injection,Available,,ANDA070585,,BUPIVACAINE HYDROCHLORIDE,,,Current,,,,"30Q7KI53AK, 7TQO7W3VT8",0409-1165-02,844-646-4398,
Eli Lilly and Co.,FLUOXETINE HYDROCHLORIDE,,10/03/2024,New,ORAL,Fluoxetine Hydrochloride Capsule,"104849, 205535, 261287, 310384, 310385, 313989",,c88f33ed-6dfb-4c5e-bc01-d8e36dd97299,10/03/2024,HUMAN PRESCRIPTION DRUG,10/03/2024,Psychiatry,PROZAC,"0777-3107, 0777-3104, 0777-3105",Dista Products Company,d7b3b74e-319e-4360-aa57-af39ccbfb19a,"0777-3104-02, 0777-3105-02, 0777-3105-30, 0777-3107-30","Prozac, Capsule, 40 mg (NDC 0777-3107-30)",Capsule,,,NDA018936,,FLUOXETINE HYDROCHLORIDE,,,To Be Discontinued,,,,I9W7N6B1KJ,0777-3107-30,800-545-5979,
"Boehringer Ingelheim Pharmaceuticals, Inc.",,,01/06/2025,New,,Adalimumab-adbm Injection,"797544, 2640883, 2640891, 2640893, 2640895, 2640900, 2640902, 2680743, 2680748, 2680756, 2680759",,62f39a7c-00df-4519-a8d4-39bbd0a649ed,01/06/2025,HUMAN PRESCRIPTION DRUG,01/06/2025,Rheumatology,ADALIMUMAB-ADBM,"0597-0545, 0597-0595, 0597-0555, 0597-0585, 0597-0575, 0597-0565","Boehringer Ingelheim Pharmaceuticals, Inc.",79fdef1e-7f86-429d-bc7d-2e99f286204b,"0597-0595-20, 0597-0590-26, 0597-0555-80, 0597-0550-06, 0597-0585-89, 0597-0580-37, 0597-0545-22, 0597-0545-44, 0597-0545-66, 0597-0540-10, 0597-0575-50, 0597-0575-40, 0597-0575-60, 0597-0570-32, 0597-0565-20, 0597-0560-12","Cyltezo, Injection, Kit (NDC 0597-0545-44)",Injection,,,BLA761058,,ADALIMUMAB-ADBM,,,To Be Discontinued,,,,,0597-0545-44,800-243-0127,
Eugia US LLC,BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Revised,"EPIDURAL, INTRACAUDAL",Bupivacaine Hydrochloride Injection,"1012396, 1012404, 1724786, 1724787, 1724880, 1724884, 1725078, 1725082",,ffecf450-1f01-4721-8e10-251385852612,09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE,"55150-169, 55150-167, 55150-168, 55150-170, 55150-171, 55150-172, 55150-249, 55150-250",Eugia US LLC,39649703-e633-4a20-ba71-0c04dbf8ff2a,"55150-167-10, 55150-168-30, 55150-169-10, 55150-170-30, 55150-171-10, 55150-172-30, 55150-249-50, 55150-250-50","Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-169-10)",Injection,Available,,ANDA203895,,BUPIVACAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,7TQO7W3VT8,55150-169-10,888-238-7880,
"EMD Serono, Inc.",LEVOTHYROXINE SODIUM,,07/10/2025,New,ORAL,Levothyroxine Sodium Tablet,"892246, 892251, 966153, 966160, 966166, 966173, 966177, 966182, 966187, 966196, 966202, 966207, 966220, 966221, 966222, 966224, 966225, 966248, 966249, 966253, 966270, 2104866",,bc3c6830-ba68-4ba3-9896-a12d0ad0b275,07/10/2025,HUMAN PRESCRIPTION DRUG,07/10/2025,Endocrinology/Metabolism,EUTHYROX,"72305-050, 72305-025, 72305-075, 72305-088, 72305-100, 72305-112, 72305-125, 72305-137, 72305-150, 72305-175, 72305-200","Provell Pharmaceuticals, LLC",45657074-8874-49f4-a8ef-3ca7e210c16e,"72305-025-30, 72305-025-90, 72305-050-30, 72305-050-90, 72305-075-30, 72305-075-90, 72305-088-30, 72305-088-90, 72305-100-30, 72305-100-90, 72305-112-30, 72305-112-90, 72305-125-30, 72305-125-90, 72305-137-30, 72305-137-90, 72305-150-30, 72305-150-90, 72305-175-30, 72305-175-90, 72305-200-30, 72305-200-90","Euthyrox, Tablet, 50 ug (NDC 72305-050-90)",Tablet,,,NDA021292,,LEVOTHYROXINE SODIUM,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,9J765S329G,72305-050-90,888-899-7041,
"Mylan Pharmaceuticals Inc., a Viatris Company",TOLTERODINE TARTRATE,,02/26/2025,New,ORAL,"Tolterodine Tartrate Capsule, Extended Release","855182, 855184, 855189, 855191",,d7274947-4f88-47ee-a39f-bd5ac46fcf8d,02/26/2025,HUMAN PRESCRIPTION DRUG,02/26/2025,Urology,DETROL LA,"58151-104, 58151-103",Viatris Specialty LLC,a1e49744-9302-47ee-92af-8b19aa0b2fc1,"58151-103-93, 58151-103-77, 58151-103-05, 58151-104-93, 58151-104-77, 58151-104-05","Detrol LA, Capsule, Extended Release, 4 mg (NDC 58151-104-93)","Capsule, Extended Release",,,NDA021228,,TOLTERODINE TARTRATE,,,To Be Discontinued,,,,5T619TQR3R,58151-104-93,800-796-9526,
"Meitheal Pharmaceuticals, Inc.",AZACITIDINE,,12/18/2020,Reverified,"INTRAVENOUS, SUBCUTANEOUS",Azacitidine Injection,485246,,97b0917a-03fa-4cc4-91cf-1bed57a988c9,08/19/2025,HUMAN PRESCRIPTION DRUG,,Oncology,AZACITIDINE,71288-115,Meitheal Pharmaceuticals Inc.,bad343f5-0c12-47de-93e7-9b2af3670b7c,71288-115-30,"Azacitidine, Injection, 100 mg/30 mL (NDC 71288-115-30)",Injection,Available,"N0000000233, N0000175595",ANDA212128,,AZACITIDINE,Nucleoside Metabolic Inhibitor [EPC],,Current,,,,M801H13NRU,71288-115-30,844-824-8426,Nucleic Acid Synthesis Inhibitors [MoA]
Pfizer Inc.,,,01/06/2023,Revised,,Somatropin Injection,"241975, 762830, 762833, 762834, 762836, 762837, 762839, 762841, 762843, 762846, 762849, 762850, 762852, 762857, 762859, 762866, 762868, 762873, 762875, 762895, 762897, 763488, 763489, 996558, 996559",,ffebf88b-d257-4542-9808-74d9b7167765,08/28/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,GENOTROPIN,"0013-2658, 0013-2626, 0013-2646, 0013-2649, 0013-2650, 0013-2651, 0013-2652, 0013-2653, 0013-2654, 0013-2655, 0013-2656, 0013-2657",Pfizer Laboratories Div Pfizer Inc,f09acf87-6e30-47ad-9891-8a49bf6dffbc,"0013-2626-81, 0013-2646-81, 0013-2649-02, 0013-2650-02, 0013-2651-02, 0013-2652-02, 0013-2653-02, 0013-2654-02, 0013-2655-02, 0013-2656-02, 0013-2657-02, 0013-2658-02","Genotropin, Injection, 2.0 mg preservative free (NDC 0013-2658-02)",Injection,,,BLA020280,,SOMATROPIN,,Available,Resolved,,,08/28/2025,,0013-2658-02,800-533-4535,
"Hospira, Inc., a Pfizer Company",FENTANYL CITRATE,,01/01/2012,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Fentanyl Citrate Injection,"1735003, 1735004, 1735006, 1735007, 1735008, 1735013",,bfa8018a-4cbc-434b-e09e-782872b0340a,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Pediatric",FENTANYL CITRATE,"0409-9094, 0409-9093","Hospira, Inc.",e4b31fdd-00af-416d-b14e-dbac0c83da97,"0409-9093-37, 0409-9093-32, 0409-9093-45, 0409-9093-35, 0409-9093-41, 0409-9093-36, 0409-9093-31, 0409-9093-38, 0409-9094-12, 0409-9094-22, 0409-9094-18, 0409-9094-25, 0409-9094-17, 0409-9094-28, 0409-9094-16, 0409-9094-31, 0409-9094-41, 0409-9094-61","Fentanyl Citrate, Injection, 2500 mcg/50 mL (50 ug/1 mL) (NDC 0409-9094-61)",Injection,Available,,NDA019115,,FENTANYL CITRATE,,,Current,,,,MUN5LYG46H,0409-9094-61,844-646-4398,
"Hikma Pharmaceuticals USA, Inc.",AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","308189, 313850",,d46f1091-33dc-4f8f-9c34-75dcfedb4b4c,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0143-9887, 0143-9886",Hikma Pharmaceuticals USA Inc.,606474e1-adba-4ffa-83d5-6565fc12c892,"0143-9886-01, 0143-9886-50, 0143-9886-75, 0143-9887-01, 0143-9887-50, 0143-9887-75","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0143-9887-50)","Powder, For Suspension",,,ANDA065325,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0143-9887-50,800-631-2174,
"Hospira, Inc., a Pfizer Company",HYDROMORPHONE HYDROCHLORIDE,,10/31/2017,Reverified,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Hydromorphone Hydrochloride Injection,"897653, 897753, 897756, 897757, 897758, 1433251, 1724276, 1724383, 1724644",,e9c9ef18-7dfc-4322-b2fc-29b934c30f8b,08/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,HYDROMORPHONE HYDROCHLORIDE,"0409-1304, 0409-2552, 0409-3356, 0409-2540, 0409-3365, 0409-1283, 0409-1312","Hospira, Inc.",58ff0e68-b78f-4ebd-a91b-b53bbdefc544,"0409-2552-11, 0409-2552-01, 0409-3356-11, 0409-3356-01, 0409-2540-11, 0409-2540-01, 0409-3365-11, 0409-3365-01, 0409-3365-10, 0409-1283-03, 0409-1283-31, 0409-1283-09, 0409-1283-10, 0409-1283-04, 0409-1283-05, 0409-1312-03, 0409-1312-30, 0409-1312-09, 0409-1312-10, 0409-1304-03, 0409-1304-31","Hydromorphone Hydrochloride, Injection, 4 mg/1 mL Syringes (NDC 0409-1304-31)",Injection,Available,,NDA200403,,HYDROMORPHONE HYDROCHLORIDE,,,Current,,,01/02/2025,L960UP2KRW,0409-1304-31,844-646-4398,
Alvogen,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,7f2dd6ee-3363-c87c-9693-ed838942556c,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"47781-562, 47781-563, 47781-564, 47781-565, 47781-566, 47781-567, 47781-568",Alvogen Inc.,9114d946-92cb-c19d-c6f2-aef77294461f,"47781-562-01, 47781-563-01, 47781-564-01, 47781-565-01, 47781-566-01, 47781-567-01, 47781-568-01","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 47781-562-01)",Capsule,Available,,ANDA214547,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,47781-562-01,844-842-8672 and email: CustomerService-US@alvogen.com,
"Hospira, Inc., a Pfizer Company",METHOTREXATE SODIUM,,03/13/2023,Reverified,"INTRAMUSCULAR, INTRATHECAL, INTRAVENOUS, SUBCUTANEOUS",Methotrexate Sodium Injection,"1655956, 1946772",,"0d63ba29-b692-41b4-87e8-351265c8273f, 0e30eaef-5a09-4104-8a11-c32933eadeab",08/15/2025,HUMAN PRESCRIPTION DRUG,,"Rheumatology, Oncology",METHOTREXATE,"61703-408, 61703-350","Hospira, Inc.","95b8b8da-da4e-4bba-9038-3cf65f3d5c1a, 37b3e76b-ac3d-4f93-adf1-91f52f676b8a","61703-350-37, 61703-350-38, 61703-408-41, 61703-350-09, 61703-350-10, 61703-408-25","Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25)",Injection,Available,,NDA011719,,METHOTREXATE,,,Current,,,,3IG1E710ZN,61703-408-25,844-646-4398,
GlaxoSmithKline,DAPRODUSTAT,,11/21/2024,New,ORAL,Daprodustat Tablet,"2628215, 2628221, 2628223, 2628225, 2628227, 2628229, 2628231, 2628233, 2628235, 2628237",,d82aa06e-5a33-4844-99b7-4701313455a4,11/21/2024,HUMAN PRESCRIPTION DRUG,11/21/2024,Hematology,JESDUVROQ,"0173-0911, 0173-0897, 0173-0903, 0173-0906, 0173-0914",GlaxoSmithKline LLC,d52a823a-35bd-4c6a-a016-4b4f21a43d7d,"0173-0897-13, 0173-0897-56, 0173-0903-13, 0173-0903-56, 0173-0906-13, 0173-0906-56, 0173-0911-13, 0173-0911-56, 0173-0914-13, 0173-0914-56","Jesduvroq, Tablet, 6 mg (NDC 0173-0911-13)",Tablet,,"N0000194080, N0000194079",NDA216951,,DAPRODUSTAT,Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC],,To Be Discontinued,,Discontinuing for Business Reasons.,,JVR38ZM64B,0173-0911-13,888-825-5249,Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors [MoA]
Gland Pharma Limited,KETOROLAC TROMETHAMINE,,06/06/2018,Reverified,INTRAMUSCULAR,Ketorolac Tromethamine Injection,"860092, 1665459, 1665461",,1aae6a4d-0909-4672-aa26-e3f2d8c4d413,09/29/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,KETOROLAC TROMETHAMINE,"72266-119, 72266-234, 72266-118",FOSUN PHARMA USA INC,228ec94a-f777-f61b-e063-6394a90a21a5,"72266-234-01, 72266-234-25, 72266-118-01, 72266-118-25, 72266-119-01, 72266-119-25","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-119-25)",Injection,Available,,ANDA204216,,KETOROLAC TROMETHAMINE,,,Current,,"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.",,4EVE5946BQ,72266-119-25,833-291-9645,
"Ritedose Pharmaceuticals, LLC",ALBUTEROL SULFATE,,10/25/2022,Reverified,RESPIRATORY (INHALATION),Albuterol Sulfate Solution,245314,,fdb4ac5a-bf0d-4896-89f7-1828c081b79e,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Pediatric, Pulmonary/Allergy","ALBUTEROL SULFATE INHALATION SOLUTION, 0.5%",76204-027,"Ritedose Pharmaceuticals, LLC",311a77d8-9e60-23e8-e063-6394a90a9e69,"76204-027-11, 76204-027-01","Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 76204-027-01)",Solution,Available,,ANDA218386,,ALBUTEROL SULFATE,,,Current,,,,021SEF3731,76204-027-01,803-806-3300,
"Hospira, Inc., a Pfizer Company",SODIUM ACETATE ANHYDROUS,,02/03/2016,Reverified,INTRAVENOUS,Sodium Acetate Injection,1859490,,"ce9a7469-c4ba-4f60-8f7a-47ef0974316e, c91ede49-c7cc-47b7-0f93-e6841dd5916a",08/15/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Pediatric, Total Parenteral Nutrition",SODIUM ACETATE,0409-7299,"Hospira, Inc.","7ed61ab6-b7ad-45ae-b660-0ed685661bc7, c434d6ad-d2f5-43eb-81d5-b6165b652aa7","0409-7299-45, 0409-7299-25, 0409-7299-83, 0409-7299-73","Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-25)",Injection,Available,,NDA018893,,SODIUM ACETATE,,,Current,,,,NVG71ZZ7P0,0409-7299-25,844-646-4398,
Eli Lilly and Co.,,,10/29/2024,New,"INTRAMUSCULAR, SUBCUTANEOUS",Somatropin Injection,"582969, 582971, 582974, 582976, 729232, 729234",,a774e1ae-3997-49ee-8b0e-99a2b315d409,10/29/2024,HUMAN PRESCRIPTION DRUG,10/29/2024,Endocrinology/Metabolism,HUMATROPE,"0002-8149, 0002-8147, 0002-8148",Eli Lilly and Company,aa99e905-657f-4561-8c02-d7c0409c44e3,"0002-8147-01, 0002-7554-01, 0002-7618-01, 0002-8148-01, 0002-7555-01, 0002-7619-01, 0002-8149-01, 0002-7556-01","Humatrope, Injection, Humatrope Kit 24 mg (0002-8149-01): 1 TRAY in 1 CARTON (0002-8149-01) / 1 KIT in 1 TRAY * 2.88 mL in 1 CARTRIDGE (0002-7556-01) * 2.88 mL in 1 SYRINGE (0002-7619-01) (NDC 0002-8149-01)",Injection,,,BLA019640,,SOMATROPIN,,,To Be Discontinued,,Business decision to discontinue. Discontinuation includes the associated HumatroPen injection device.,,,0002-8149-01,800-545-5979,
Teyro Labs,CARBOPLATIN,,04/28/2023,Reverified,INTRAVENOUS,Carboplatin Injection,597195,,1c275825-0275-4c73-b650-e4c1519f13b8,09/29/2025,HUMAN PRESCRIPTION DRUG,,Oncology,CARBOPLATIN,60505-6282,Apotex Corp.,0e68e276-b0df-4f03-e063-6394a90a22b9,"60505-6282-1, 60505-6282-3, 60505-6282-6, 60505-6282-7","Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6)",Injection,Available,"N0000175413, N0000175073",ANDA077861,,CARBOPLATIN,Platinum-based Drug [EPC],,Current,,Wholesaler & Distributor through Marketing partner (Apotex Inc.),,BG3F62OND5,60505-6282-6,Apotex Inc.: 800-706-5575,
"Vertical Pharmaceuticals, LLC",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Reverified,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release",,,22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d,09/16/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,RELEXXII,"68025-095, 68025-088, 68025-089, 68025-096, 68025-097, 68025-084, 68025-098","Vertical Pharmaceuticals, LLC",86f477e9-07fc-466b-913e-1a4434c91df4,"68025-088-30, 68025-089-30, 68025-095-10, 68025-095-30, 68025-096-10, 68025-096-30, 68025-097-10, 68025-097-30, 68025-084-30, 68025-098-10, 68025-098-30","Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-30)",Tablet,Available,,NDA216117,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,,,,4B3SC438HI,68025-095-30,800-541-4802,
Sagent Pharmaceuticals,METHYLPREDNISOLONE ACETATE,,12/15/2021,Reverified,"INTRA-ARTICULAR, INTRALESIONAL, INTRAMUSCULAR, INTRASYNOVIAL, SOFT TISSUE",Methylprednisolone Acetate Injection,"1358610, 1358617",,f98314ea-a4e4-4f78-987b-3e9b45a08bb4,08/26/2025,HUMAN PRESCRIPTION DRUG,,Rheumatology,METHYLPREDNISOLONE ACETATE,"25021-820, 25021-821",Sagent Pharmaceuticals,13e1ca54-4fc4-4e93-a52d-c9320865e3cb,"25021-820-05, 25021-820-10, 25021-821-05","Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-10)",Injection,Available,,ANDA201835,,METHYLPREDNISOLONE ACETATE,,,Current,,,,43502P7F0P,25021-820-10,866-625-1618,
"Fresenius Kabi USA, LLC",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,"EPIDURAL, INTRACAUDAL, PERINEURAL, INFILTRATION",Bupivacaine Hydrochloride Injection,"1724880, 1724881, 1725078, 1725175, 1724884, 1724885, 1725082, 1725177, 1672917, 1672919, 1673296, 1673298, 1012391, 1012396, 1012404, 1012421, 1012455, 1012457",,"e700eb7b-8b14-49c9-96b2-331f18776e45, b6bfc04a-1868-4630-9ca1-8c027af97ce3, dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175, eb6d8fee-def4-4c96-9972-695e8cea8ea8",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,SENSORCAINE MPF,"63323-466, 63323-464, 63323-462, 63323-465, 63323-467, 63323-460","Fresenius Kabi USA, LLC","b41b5dbd-7aff-4d97-ac97-f4355393ee4e, d3ba9fb9-63c8-4597-bb0a-cd01d31a24b6, 13a48007-3784-46f2-bd4d-da1004186b81, 2b1a1f80-cb29-4ac1-9e72-20225ed45715","63323-464-01, 63323-464-17, 63323-466-03, 63323-466-17, 63323-464-08, 63323-464-38, 63323-466-08, 63323-466-38, 63323-462-03, 63323-462-38, 63323-464-09, 63323-464-39, 63323-466-09, 63323-466-39, 63323-465-01, 63323-465-57, 63323-467-01, 63323-467-57, 63323-460-01, 63323-460-37, 63323-464-02, 63323-464-37, 63323-464-03, 63323-464-31, 63323-466-01, 63323-466-37, 63323-466-02, 63323-466-31, 63323-462-04, 63323-462-17, 63323-462-01, 63323-462-37, 63323-462-02, 63323-462-31","Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-31)",Injection,Unavailable,,"ANDA070553, NDA018304",,BUPIVACAINE HYDROCHLORIDE,,,Current,Delay in shipping of the drug,Not available at this time.,,"7TQO7W3VT8, 30Q7KI53AK",63323-466-31,888-386-1300,
Sagent Pharmaceuticals,KETOROLAC TROMETHAMINE,,03/26/2018,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Ketorolac Tromethamine Injection,"860092, 1665459, 1665461",,62591551-a644-4b2c-a0de-982e906fabc3,08/26/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,KETOROLAC TROMETHAMINE,"25021-700, 25021-701",Sagent Pharmaceuticals,ff55e1ab-2a8d-4a56-8b72-5e0a8e00d866,"25021-700-01, 25021-701-01, 25021-701-02","Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)",Injection,Available,,ANDA204216,,KETOROLAC TROMETHAMINE,,,Current,,,,4EVE5946BQ,25021-700-01,866-625-1618,
"Hospira, Inc., a Pfizer Company",LIDOCAINE HYDROCHLORIDE,,02/22/2012,Reverified,"RETROBULBAR, TOPICAL",Lidocaine Hydrochloride Injection,1010844,,89a4bd73-89f4-4fd7-2c9f-921e1da8f96b,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE HYDROCHLORIDE,0409-4283,"Hospira, Inc.",499e9cfa-ea8d-487c-a8b3-fd7e1917d25f,"0409-4283-11, 0409-4283-25, 0409-4283-01","Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/5 mL (4%; 40 mg/mL) (NDC 0409-4283-01)",Injection,Available,,ANDA088295,,LIDOCAINE HYDROCHLORIDE,,,Current,,,,V13007Z41A,0409-4283-01,844-646-4398,
SpecGx LLC,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,806a1c15-0842-4787-b2ad-09a21fd96b37,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0406-5117, 0406-5111, 0406-5112, 0406-5113, 0406-5114, 0406-5115, 0406-5116",SpecGx LLC,3ffc0695-83f7-4898-9fd7-451c0989cfe0,"0406-5111-01, 0406-5112-01, 0406-5113-01, 0406-5114-01, 0406-5115-01, 0406-5116-01, 0406-5117-01","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0406-5117-01)",Capsule,Limited Availability,,ANDA211840,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,Allocation to all customers.,,SJT761GEGS,0406-5117-01,800-325-8888,
"Hospira, Inc., a Pfizer Company",SODIUM BICARBONATE,,03/01/2017,Revised,INTRAVENOUS,Sodium Bicarbonate Injection,1868486,,"8664c7ce-707b-4c6c-9ce4-7160b5f877f8, 084f5572-8c1f-4802-b179-ca0cc838fc68",08/15/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Pediatric",SODIUM BICARBONATE,0409-6625,"Hospira, Inc.","4f89e8d5-75cf-49e3-be27-721e95d829d4, fc0c3d8b-0cfb-4d2a-bd9e-4c77266c4ade","0409-6625-30, 0409-6625-35, 0409-6625-22, 0409-6625-14","Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-35)",Injection,Unavailable,,ANDA202432,,SODIUM BICARBONATE,,,Current,Other,Next Delivery and Estimated Recovery: March 2026,01/03/2025,8MDF5V39QO,0409-6625-35,844-646-4398,
"Hospira, Inc., a Pfizer Company",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Revised,SUBARACHNOID,Bupivacaine Hydrochloride Injection,"1724784, 1724792",,9679cc05-2f8a-4e88-53b5-6e9122c8b8c0,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,MARCAINE SPINAL,0409-1761,"Hospira, Inc.",f3862f77-3621-4730-923e-9efbfa18e03f,"0409-1761-19, 0409-1761-02, 0409-1761-18, 0409-1761-62, 0409-1761-05, 0409-1761-10","Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)",Injection,Limited Availability,,NDA018692,,BUPIVACAINE HYDROCHLORIDE IN DEXTROSE,,,Current,Other,Limited Supply Available. Next Delivery: October 2025; Estimated Recovery: December 2025,,7TQO7W3VT8,0409-1761-10,844-646-4398,
"Hospira, Inc., a Pfizer Company","EPINEPHRINE, LIDOCAINE HYDROCHLORIDE",,02/22/2012,Reverified,"INFILTRATION, PERINEURAL","Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","1010688, 1010745, 1010751, 1010759, 1867996, 1867998",,2f94f711-14c4-48ec-c5a3-c5ec4b8e8729,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE,"0409-3178, 0409-1209, 0409-3177, 0409-3181, 0409-3182, 0409-3183, 0409-0007, 0409-0147","Hospira, Inc.",d16a4711-e663-455e-a1fe-236a41ca4e8f,"0409-1209-10, 0409-1209-01, 0409-1209-05, 0409-1209-70, 0409-1209-65, 0409-3177-16, 0409-3177-01, 0409-3178-16, 0409-3178-01, 0409-3178-17, 0409-3178-02, 0409-3178-18, 0409-3178-03, 0409-3181-11, 0409-3181-01, 0409-3182-11, 0409-3182-01, 0409-3182-21, 0409-3182-02, 0409-3182-31, 0409-3182-03, 0409-3183-11, 0409-3183-01, 0409-0007-01, 0409-0007-10, 0409-0147-01, 0409-0147-10","Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)",Injection,Available,"N0000000209, N0000000245, N0000175552, N0000175555, N0000175570, M0003647",ANDA089644,Catecholamines [CS],LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE,"alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC], Catecholamine [EPC]",,Current,,,,"V13007Z41A, YKH834O4BH",0409-3178-02,844-646-4398,"Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA]"
Sun Pharmaceutical Industries Limited,IMATINIB MESYLATE,,12/05/2024,New,ORAL,Imatinib Mesylate Tablet,"403878, 403879",,07764bf9-21b4-4e32-9d7e-e348f8e4291f,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Hematology,IMATINIB MESYLATE,"47335-475, 47335-472","Sun Pharmaceutical Industries, Inc.",ad13dbca-474d-4492-9c25-e0e175143d8c,"47335-472-83, 47335-472-88, 47335-472-13, 47335-472-81, 47335-475-83, 47335-475-88, 47335-475-13, 47335-475-64","Imatinib Mesylate, Tablet, 400 mg (NDC 47335-475-88)",Tablet,,,ANDA078340,,IMATINIB MESYLATE,,,To Be Discontinued,,Discontinuing for business reasons,,8A1O1M485B,47335-475-88,800-818-4555,
"Hospira, Inc., a Pfizer Company",KETOROLAC TROMETHAMINE,,03/26/2018,Revised,INTRAMUSCULAR,Ketorolac Tromethamine Injection,"860092, 1665459, 1665461",,8accbb78-fc64-45d5-69b0-35c23a1d2a2e,08/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,KETOROLAC TROMETHAMINE,"0409-3796, 0409-3793, 0409-3795","Hospira, Inc.",60f4ed51-f1c1-45d4-b43a-969678901bdd,"0409-3793-19, 0409-3793-01, 0409-3793-25, 0409-3795-19, 0409-3795-01, 0409-3795-25, 0409-3796-19, 0409-3796-01, 0409-3796-25","Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)",Injection,Limited Availability,,ANDA074802,,KETOROLAC TROMETHAMINE,,,Current,Other,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,4EVE5946BQ,0409-3796-01,844-646-4398,
Rhodes Pharmaceuticals L.P.,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,d918b40d-a461-41bc-b6c0-83dc76c28e32,08/05/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"42858-162, 42858-161, 42858-163, 42858-164, 42858-165, 42858-166, 42858-167",Rhodes Pharmaceuticals,4bb64a6b-cce9-4c4a-81c3-06e2e59315c3,"42858-161-01, 42858-162-01, 42858-163-01, 42858-164-01, 42858-165-01, 42858-166-01, 42858-167-01","Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 42858-162-01)",Capsule,Available,,ANDA215330,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,42858-162-01,888-827-0616,
Baxter Healthcare,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807631, 1807632, 1807633, 1807634, 1807639",,958d35f0-6834-43be-a700-fa58f38b4c19,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0338-9543, 0338-9657, 0338-9659, 0338-9661, 0338-9663",Baxter Healthcare Corporation,6680afa2-1474-4bc3-afee-a333a042fd3f,"0338-9543-01, 0338-9543-02, 0338-9543-03, 0338-9543-04, 0338-9543-05, 0338-9543-06, 0338-9543-12, 0338-9657-75, 0338-9659-75, 0338-9661-60, 0338-9663-60","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-02)",Injection,,,NDA016677,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0338-9543-02,888-229-0001,
GlaxoSmithKline,DAPRODUSTAT,,11/21/2024,New,ORAL,Daprodustat Tablet,"2628215, 2628221, 2628223, 2628225, 2628227, 2628229, 2628231, 2628233, 2628235, 2628237",,d82aa06e-5a33-4844-99b7-4701313455a4,11/21/2024,HUMAN PRESCRIPTION DRUG,11/21/2024,Hematology,JESDUVROQ,"0173-0897, 0173-0903, 0173-0906, 0173-0911, 0173-0914",GlaxoSmithKline LLC,d52a823a-35bd-4c6a-a016-4b4f21a43d7d,"0173-0897-13, 0173-0897-56, 0173-0903-13, 0173-0903-56, 0173-0906-13, 0173-0906-56, 0173-0911-13, 0173-0911-56, 0173-0914-13, 0173-0914-56","Jesduvroq, Tablet, 1 mg (NDC 0173-0897-13)",Tablet,,"N0000194080, N0000194079",NDA216951,,DAPRODUSTAT,Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC],,To Be Discontinued,,Discontinuing for Business Reasons.,,JVR38ZM64B,0173-0897-13,888-825-5249,Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors [MoA]
"Hikma Pharmaceuticals USA, Inc.",FENTANYL CITRATE,,12/20/2023,Revised,INTRAVENOUS,Fentanyl Citrate Injection,"1735003, 1735007, 1735008, 1735013, 2168270, 2474269, 2629337",,ce5db1c2-feb1-4ad2-847a-d02e865bd47e,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Pediatric",FENTANYL CITRATE,"0641-6030, 0641-6024, 0641-6027, 0641-6025, 0641-6028, 0641-6026, 0641-6029, 0641-6247, 0641-6248, 0641-6249",Hikma Pharmaceuticals USA Inc.,aca9742b-d890-426a-8296-14ca64748238,"0641-6024-01, 0641-6024-10, 0641-6027-01, 0641-6027-25, 0641-6025-01, 0641-6025-10, 0641-6028-01, 0641-6028-10, 0641-6028-25, 0641-6026-01, 0641-6026-05, 0641-6029-01, 0641-6029-25, 0641-6030-01, 0641-6247-01, 0641-6247-25, 0641-6248-01, 0641-6248-10, 0641-6249-01, 0641-6249-10","Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)",Injection,Available,,NDA019101,,FENTANYL CITRATE,,,Current,,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,MUN5LYG46H,0641-6030-01,800-631-2174,
Janssen Pharmaceuticals,HALOPERIDOL DECANOATE,,04/07/2025,New,INTRAMUSCULAR,Haloperidol Decanoate Injection,"1719803, 1719847, 1719862, 1720026",,af0159a8-dff5-449a-aa2b-a0c430081e21,04/07/2025,HUMAN PRESCRIPTION DRUG,04/07/2025,Psychiatry,HALDOL DECANOATE,"50458-254, 50458-253","Janssen Pharmaceuticals, Inc.",2cf0430f-e455-8d17-e063-6394a90a5cd3,"50458-253-01, 50458-253-03, 50458-254-14","Haldol, Injection, 100 mg/1 mL (NDC 50458-254-14)",Injection,,,NDA018701,,HALOPERIDOL DECANOATE,,,To Be Discontinued,,Last batch expiration date 8/31/2025,,AC20PJ4101,50458-254-14,800-526-7736,
"Assertio Specialty Pharmaceuticals, LLC",METHOTREXATE,,08/29/2025,New,SUBCUTANEOUS,Methotrexate Injection,"1441402, 1441407, 1441411, 1441413, 1441416, 1441418, 1441422, 1441424, 1747179, 1747181, 1747185, 1747187, 1747192, 1747194",,7dcd02d7-1ce0-43fc-8f25-2f0bb0caba2f,08/29/2025,HUMAN PRESCRIPTION DRUG,08/29/2025,Rheumatology,OTREXUP,"82497-025, 82497-010, 82497-012, 82497-015, 82497-017, 82497-020, 82497-022","Otter Pharmaceuticals, LLC",9aaba145-f343-4498-b754-fb7c78181bd7,"82497-010-02, 82497-010-04, 82497-012-02, 82497-012-04, 82497-015-02, 82497-015-04, 82497-017-02, 82497-017-04, 82497-020-02, 82497-020-04, 82497-022-02, 82497-022-04, 82497-025-02, 82497-025-04","Otrexup, Injection, 25 mg/.4 mL (NDC 82497-025-04)",Injection,,"N0000175584, N0000000111",NDA204824,,METHOTREXATE,Folate Analog Metabolic Inhibitor [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,YL5FZ2Y5U1,82497-025-04,224-441-6390,Folic Acid Metabolism Inhibitors [MoA]
"Fresenius Kabi USA, LLC",REMIFENTANIL HYDROCHLORIDE,,06/28/2022,Reverified,INTRAVENOUS,Remifentanil Hydrochloride Injection,"1729578, 1729584, 1729710",,d2374b84-81c9-44f9-a4a9-1071281b2531,09/18/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,REMIFENTANIL HYDROCHLORIDE,"63323-725, 63323-723, 63323-724","Fresenius Kabi USA, LLC",2f27e51f-2b55-47ee-bd4a-001b71c60622,"63323-723-01, 63323-723-03, 63323-724-01, 63323-724-05, 63323-725-01, 63323-725-10","Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-725-10)",Injection,Available,,ANDA206223,,REMIFENTANIL HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,5V444H5WIC,63323-725-10,888-386-1300,
Pfizer Inc.,,,04/28/2023,New,,Prazosin Hydrochloride Capsule,,,,04/28/2023,,04/28/2023,Cardiovascular,,,,,,"Minipress, Capsule, 5 mg (NDC 0069-4380-71)",Capsule,,,,,,,,To Be Discontinued,,Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023,04/28/2023,,0069-4380-71,800-533-4535,
"Hospira, Inc., a Pfizer Company",ETOMIDATE,General Anesthesia [PE],10/05/2022,Revised,INTRAVENOUS,Etomidate Injection,"1654006, 1654008, 1654009, 1654011",,b7ed5bf8-ba75-44dc-8f81-96b4ad5766be,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,AMIDATE,0409-6695,"Hospira, Inc.",b59f4852-2843-4a8f-a597-306ebddb259a,"0409-6695-11, 0409-6695-01, 0409-6695-12, 0409-6695-02","Amidate, Injection, 2 mg/mL (NDC 0409-6695-02)",Injection,Unavailable,"N0000175975, N0000175681",NDA018227,,ETOMIDATE,General Anesthetic [EPC],,Current,Other,Next Delivery: February 2026; Estimated Recovery: March 2026,,Z22628B598,0409-6695-02,844-646-4398,
Eugia US LLC,ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Revised,"EPIDURAL, INFILTRATION, PERINEURAL",Ropivacaine Hydrochloride Injection,"905189, 1734084, 1734090, 1734207, 1734347, 1734475, 1734483",,3763b7b6-da49-4658-b93d-28f5da24d09e,09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROPIVACAINE HYDROCHLORIDE,"55150-195, 55150-196, 55150-197, 55150-198, 55150-199, 55150-200, 55150-201",Eugia US LLC,34725b26-d6e9-4d1b-95a0-da03764cc102,"55150-195-20, 55150-196-99, 55150-197-20, 55150-198-30, 55150-199-20, 55150-200-10, 55150-201-20","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-195-20)",Injection,Available,,ANDA205612,,ROPIVACAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,V910P86109,55150-195-20,888-238-7880,
"Lannett Company, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,f92497b5-baea-4760-b615-45a0b6184402,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","0527-0764, 0527-0760, 0527-0761, 0527-0762, 0527-0763, 0527-0765, 0527-0766","Lannett Company, Inc.",e0804f43-4685-4017-b839-3212d1167362,"0527-0760-37, 0527-0761-37, 0527-0762-37, 0527-0763-37, 0527-0764-37, 0527-0765-37, 0527-0766-37","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0527-0764-37)",Tablet,Available,,ANDA215565,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",0527-0764-37,844-834-0530,
"Teva Pharmaceuticals USA, Inc.",TOBRAMYCIN,,06/16/2025,New,RESPIRATORY (INHALATION),Tobramycin Solution,348719,,c5f65e5b-c851-45da-a0e8-215d9a4e6ad3,06/16/2025,HUMAN PRESCRIPTION DRUG,06/16/2025,Pulmonary/Allergy,TOBRAMYCIN,0093-4085,"Teva Pharmaceuticals USA, Inc.",f42ab3e7-da6a-435e-987f-f99b1dc649f0,0093-4085-63,"Tobramycin, Solution, 300 mg/5 mL (NDC 0093-4085-63)",Solution,,"N0000175477, M0000946",ANDA091589,Aminoglycosides [CS],TOBRAMYCIN,Aminoglycoside Antibacterial [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,VZ8RRZ51VK,0093-4085-63,800-545-8800,
"Hospira, Inc., a Pfizer Company",BLEOMYCIN SULFATE,,06/13/2025,New,"INTRAMUSCULAR, INTRAPLEURAL, INTRAVENOUS, SUBCUTANEOUS",Bleomycin Sulfate Injection,"1726673, 1726676",,e629ba5a-4e08-4249-9551-af6dbd98a7e4,06/13/2025,HUMAN PRESCRIPTION DRUG,06/13/2025,"Hematology, Oncology, Pediatric",BLEOMYCIN,"0409-0323, 0409-0332","Hospira, Inc.",d9e9c332-1b3f-469c-83b8-41e15183e635,"0409-0323-20, 0409-0332-20","Bleomycin Sulfate, Injection, 30 [USP'U] (NDC 0409-0323-20)",Injection,,,ANDA065031,,BLEOMYCIN,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,7DP3NTV15T,0409-0323-20,844-646-4398,
GlaxoSmithKline,DAPRODUSTAT,,11/21/2024,New,ORAL,Daprodustat Tablet,"2628215, 2628221, 2628223, 2628225, 2628227, 2628229, 2628231, 2628233, 2628235, 2628237",,d82aa06e-5a33-4844-99b7-4701313455a4,11/21/2024,HUMAN PRESCRIPTION DRUG,11/21/2024,Hematology,JESDUVROQ,"0173-0903, 0173-0897, 0173-0906, 0173-0911, 0173-0914",GlaxoSmithKline LLC,d52a823a-35bd-4c6a-a016-4b4f21a43d7d,"0173-0897-13, 0173-0897-56, 0173-0903-13, 0173-0903-56, 0173-0906-13, 0173-0906-56, 0173-0911-13, 0173-0911-56, 0173-0914-13, 0173-0914-56","Jesduvroq, Tablet, 2 mg (NDC 0173-0903-56)",Tablet,,"N0000194080, N0000194079",NDA216951,,DAPRODUSTAT,Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC],,To Be Discontinued,,Discontinuing for Business Reasons.,,JVR38ZM64B,0173-0903-56,888-825-5249,Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors [MoA]
Novadaq Technologies,,,08/23/2024,Revised,,Indocyanine Green Injection,,,,08/26/2025,,,"Medical Imaging, Ophthalmology, Other",,,,,,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-903-24)",Injection,,,,,,,Available,Resolved,,,08/26/2025,,66259-903-24,800-624-4422,
Eugia US LLC,LIDOCAINE HYDROCHLORIDE,,06/13/2018,Revised,"INFILTRATION, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010671",,ef782e5e-e2d7-465a-99c6-b12611f3158c,09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,LIDOCAINE HYDROCHLORIDE,"55150-256, 55150-251, 55150-252, 55150-253, 55150-254, 55150-255",Eugia US LLC,0b1f03c2-db2f-4f90-acc0-d73abd731bf6,"55150-251-10, 55150-252-20, 55150-253-50, 55150-254-10, 55150-255-20, 55150-256-50","Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-256-50)",Injection,Unavailable,,ANDA207182,,LIDOCAINE HYDROCHLORIDE,,,Current,Demand increase for the drug,On backorder. Recovery: TBD. Check wholesalers for inventory,,V13007Z41A,55150-256-50,888-238-7880,
"Sun Pharmaceutical Industries, Inc.",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Revised,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release","1091155, 1091170, 1091185, 1091210",,d048e52d-7406-4fc1-9a72-c073bafc7439,09/22/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE HYDROCHLORIDE,"57664-608, 57664-606, 57664-607, 57664-609","Sun Pharmaceutical Industries, Inc.",0da4b745-d498-8823-e063-6394a90a4524,"57664-606-88, 57664-607-88, 57664-608-88, 57664-609-88","Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88)",Tablet,Unavailable,,ANDA205135,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,Discontinuation of the manufacture of the drug,Currently not marketed,,4B3SC438HI,57664-608-88,800-818-4555,
"Upsher-Smith Laboratories, LLC",MIDODRINE HYDROCHLORIDE,,04/28/2025,New,ORAL,Midodrine Hydrochloride Tablet,"993462, 993466, 993470",,4c3517f3-1c68-4ade-b5f1-c488a3a335c1,04/28/2025,HUMAN PRESCRIPTION DRUG,04/28/2025,Cardiovascular,MIDODRINE HYDROCHLORIDE,"0245-0211, 0245-0212, 0245-0213","Upsher-Smith laboratories, LLC",18b0b9f5-6026-479e-af12-92b0e71a9d6b,"0245-0211-11, 0245-0211-89, 0245-0211-01, 0245-0212-11, 0245-0212-89, 0245-0212-01, 0245-0213-11, 0245-0213-89, 0245-0213-01","Orvaten, Tablet, 2.5 mg (NDC 0245-0211-11)",Tablet,,,ANDA076725,,MIDODRINE HYDROCHLORIDE,,,To Be Discontinued,,,,59JV96YTXV,0245-0211-11,800-654-2299,
Pfizer Inc.,,,01/19/2023,Reverified,,Quinapril/Hydrochlorothiazide Tablet,,,,08/15/2025,,,Cardiovascular,,,,,,"Accuretic, Tablet, 10 mg/12.5 mg (NDC 0071-0222-23)",Tablet,Unavailable,,,,,,,Current,Delay in shipping of the drug,Next Delivery and Estimated Recovery: TBD,,,0071-0222-23,800-533-4535,
"Amphastar Pharmaceuticals, Inc.",LIDOCAINE HYDROCHLORIDE,,02/22/2012,Reverified,INTRAVENOUS,Lidocaine Hydrochloride Injection,1012068,,5d3e9984-cef9-46f2-a6c9-3be8b26f45b3,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE HYDROCHLORIDE,76329-3390,"International Medication Systems, Limited",3d910bb6-792f-41f3-8b28-b33bcbec5ccb,76329-3390-1,"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 76329-3390-1)",Injection,Available,,ANDA083173,,LIDOCAINE HYDROCHLORIDE,,,Current,,old NDC 0548-3390-00,,V13007Z41A,76329-3390-1,800-423-4136,
"Hikma Pharmaceuticals USA, Inc.",,,12/08/2023,Revised,,Lidocaine Hydrochloride Solution,,,,08/29/2025,,,Anesthesia,,,,,,"Lidocaine Viscous (Lidocaine Hydrochloride), Solution, 20 mg/1 mL (NDC 0054-0548-44)",Solution,,,,,,,Available,Resolved,,,08/29/2025,,0054-0548-44,800-631-2174,
"Hikma Pharmaceuticals USA, Inc.",,,05/03/2022,Reverified,,Sufentanil Citrate Injection,,,,07/23/2025,,,"Analgesia/Addiction, Pediatric",,,,,,"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-01)",Injection,Unavailable,,,,,,,Current,Other,Not currently manufactured,,,17478-050-01,800-631-2174,
"Actavis Pharma, Inc.",DESONIDE,,05/28/2025,New,TOPICAL,Desonide Cream,"197572, 349351",,ff5d4cd8-ab4d-4a9e-b84b-445c81eeea99,05/28/2025,HUMAN PRESCRIPTION DRUG,05/28/2025,Dermatology,DESONIDE,"0472-0804, 0472-0803","Actavis Pharma, Inc.",f3953b9e-138f-4d86-8eea-0fc03c3c2747,"0472-0804-15, 0472-0804-60, 0472-0803-02, 0472-0803-04","Desowen, Cream, .5 mg/1 g (NDC 0472-0804-15)",Cream,,"N0000175576, N0000175450",NDA019048,,DESONIDE,Corticosteroid [EPC],,To Be Discontinued,,,,J280872D1O,0472-0804-15,800-545-8800,Corticosteroid Hormone Receptor Agonists [MoA]
"Fresenius Kabi USA, LLC",KETOROLAC TROMETHAMINE,,03/23/2018,Reverified,INTRAMUSCULAR,Ketorolac Tromethamine Injection,"860092, 1665459, 1665461",,"ccf905ca-e164-4779-9485-2d139c821bad, 950b7295-3f68-4027-ac2b-2f7d0f5f8ef9, d1920335-8e45-4960-b6e9-e6f1f9e6820c",09/18/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,KETOROLAC TROMETHAMINE,"63323-162, 63323-161","Fresenius Kabi USA, LLC","2b1c6066-d9e0-40a0-ade5-776fc35a3626, 55ed7afb-db66-4b28-939b-db45b55bf058, ab476c4c-2c72-47b1-bf42-7a89703b0dd4","63323-161-41, 63323-161-16, 63323-162-43, 63323-162-16, 63323-162-45, 63323-162-26, 63323-161-21, 63323-161-12, 63323-162-23, 63323-162-12, 63323-162-25, 63323-162-14, 63323-161-00, 63323-161-01, 63323-162-11, 63323-162-51, 63323-162-00, 63323-162-01, 63323-162-03, 63323-162-02","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-01)",Injection,Available,,ANDA075784,,KETOROLAC TROMETHAMINE,,,Current,,Check wholesaler inventory,,4EVE5946BQ,63323-162-01,888-386-1300,
"Lannett Company, Inc.",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Revised,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release","2001564, 2001565, 2001566, 2001568",,3d1f5aff-5d39-496c-b5ed-7f3c70ec641c,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE HYDROCHLORIDE,"62175-313, 62175-310, 62175-311, 62175-312","Lannett Company, Inc.",fd0e4ddf-c516-4464-aeca-eb1d3bd24667,"62175-310-37, 62175-311-37, 62175-312-37, 62175-313-37","Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62175-313-37)",Tablet,Available,,ANDA091695,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,Shortage of an active ingredient,Limited Availability,,4B3SC438HI,62175-313-37,844-834-0530,
Pfizer Inc.,,,01/06/2023,Revised,,Somatropin Injection,"241975, 762830, 762833, 762834, 762836, 762837, 762839, 762841, 762843, 762846, 762849, 762850, 762852, 762857, 762859, 762866, 762868, 762873, 762875, 762895, 762897, 763488, 763489, 996558, 996559",,ffebf88b-d257-4542-9808-74d9b7167765,08/28/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,GENOTROPIN,"0013-2655, 0013-2626, 0013-2646, 0013-2649, 0013-2650, 0013-2651, 0013-2652, 0013-2653, 0013-2654, 0013-2656, 0013-2657, 0013-2658",Pfizer Laboratories Div Pfizer Inc,f09acf87-6e30-47ad-9891-8a49bf6dffbc,"0013-2626-81, 0013-2646-81, 0013-2649-02, 0013-2650-02, 0013-2651-02, 0013-2652-02, 0013-2653-02, 0013-2654-02, 0013-2655-02, 0013-2656-02, 0013-2657-02, 0013-2658-02","Genotropin, Injection, 1.4 mg preservative free (NDC 0013-2655-02)",Injection,,,BLA020280,,SOMATROPIN,,Available,Resolved,,,08/28/2025,,0013-2655-02,800-533-4535,
"Hospira, Inc., a Pfizer Company",FENTANYL CITRATE,,01/01/2012,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Fentanyl Citrate Injection,"1735003, 1735004, 1735006, 1735007, 1735008, 1735013",,bfa8018a-4cbc-434b-e09e-782872b0340a,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Pediatric",FENTANYL CITRATE,"0409-9094, 0409-9093","Hospira, Inc.",e4b31fdd-00af-416d-b14e-dbac0c83da97,"0409-9093-37, 0409-9093-32, 0409-9093-45, 0409-9093-35, 0409-9093-41, 0409-9093-36, 0409-9093-31, 0409-9093-38, 0409-9094-12, 0409-9094-22, 0409-9094-18, 0409-9094-25, 0409-9094-17, 0409-9094-28, 0409-9094-16, 0409-9094-31, 0409-9094-41, 0409-9094-61","Fentanyl Citrate, Injection, 250 mcg/5 mL (50 ug/1 mL) (NDC 0409-9094-25)",Injection,Available,,NDA019115,,FENTANYL CITRATE,,,Current,,,,MUN5LYG46H,0409-9094-25,844-646-4398,
Sandoz Inc.,AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","239191, 308182, 308189, 308191, 308192, 308194, 313797, 313850",,13bd4214-9b7f-425b-af5f-fc1ddc678230,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0781-6039, 0781-2020, 0781-2613, 0781-5060, 0781-5061, 0781-6156, 0781-6041, 0781-6157",Sandoz Inc,6aa02079-d11c-4d2f-acaf-9548dd9a7ed6,"0781-2020-31, 0781-2020-76, 0781-2020-01, 0781-2020-05, 0781-2613-31, 0781-2613-76, 0781-2613-01, 0781-2613-05, 0781-5060-20, 0781-5060-01, 0781-5061-20, 0781-5061-01, 0781-6039-58, 0781-6039-46, 0781-6039-55, 0781-6156-52, 0781-6156-57, 0781-6156-46, 0781-6041-58, 0781-6041-46, 0781-6041-55, 0781-6157-52, 0781-6157-57, 0781-6157-46","Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 0781-6039-58)","Powder, For Suspension",,,ANDA065387,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0781-6039-58,800-525-8747,
Baxter Healthcare,LIDOCAINE HYDROCHLORIDE,,10/25/2017,Reverified,INTRAVENOUS,Lidocaine Hydrochloride Injection,"1737723, 1737742, 1737744",,f21512ea-c7c3-4766-b976-b2c0b5616bf0,09/23/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,LIDOCAINE HYDROCHLORIDE AND DEXTROSE,"0338-0409, 0338-0411",Baxter Healthcare Corporation,6bb9f86c-595a-47f7-b6e9-792966edb852,"0338-0409-03, 0338-0409-02, 0338-0411-02","Lidocaine Hydrochloride And Dextrose, Injection, 4 mg/1 mL (NDC 0338-0409-03)",Injection,Available,,NDA018461,,LIDOCAINE HYDROCHLORIDE,,,Current,,,,V13007Z41A,0338-0409-03,888-229-0001,
"Hospira, Inc., a Pfizer Company",MEPERIDINE HYDROCHLORIDE,,05/30/2025,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Meperidine Hydrochloride Injection,"860792, 861463, 861473, 861493, 861494, 861522, 861529, 861617, 1242106, 1242503, 2539186, 2539188, 2539191, 2539192",,b31d1308-28c3-43f4-e0a6-2f3ed76b8975,08/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,DEMEROL,"0409-1180, 0409-1181, 0409-1176, 0409-1178, 0409-1179, 0409-1362, 0409-1418","Hospira, Inc.",1271f15f-ccda-4892-8fb0-9bb2d38ded4a,"0409-1181-30, 0409-1176-03, 0409-1176-30, 0409-1178-03, 0409-1178-30, 0409-1179-03, 0409-1179-30, 0409-1180-59, 0409-1180-69, 0409-1362-11, 0409-1362-01, 0409-1418-11, 0409-1418-01","Demerol, Injection, 100 mg/1 mL (NDC 0409-1180-69)",Injection,Unavailable,,NDA021171,,MEPERIDINE HYDROCHLORIDE,,,Current,Discontinuation of the manufacture of the drug,,,N8E7F7Q170,0409-1180-69,844-646-4398,
SpecGx LLC,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 1009145",,72ddd1c9-ddbd-4c95-acd9-003189a353a3,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE,"0406-8891, 0406-8884, 0406-8892, 0406-8885, 0406-8893, 0406-8894",SpecGx LLC,b25a2f3f-ee3a-44c0-a475-f371025c767b,"0406-8891-01, 0406-8884-01, 0406-8892-01, 0406-8885-01, 0406-8893-01, 0406-8894-01","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0406-8891-01)",Tablet,Available,,ANDA040440,,DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE,,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",0406-8891-01,800-325-8888,
"Hospira, Inc., a Pfizer Company",CARBOPLATIN,,04/28/2023,Reverified,INTRAVENOUS,Carboplatin Injection,597195,,47677091-fd20-49af-933c-c9dd2be21de9,08/15/2025,HUMAN PRESCRIPTION DRUG,,Oncology,CARBOPLATIN,"61703-360, 61703-150, 61703-262, 61703-600","Hospira, Inc.",5aa72c15-8033-4559-b257-373371b18958,"61703-360-18, 61703-150-05, 61703-262-05, 61703-600-05","Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18)",Injection,Available,"N0000175413, N0000175073",ANDA076517,,CARBOPLATIN,Platinum-based Drug [EPC],,Current,,,,BG3F62OND5,61703-360-18,844-646-4398,
"Hospira, Inc., a Pfizer Company",DEXTROSE MONOHYDRATE,,01/13/2022,Revised,INTRAVENOUS,Dextrose Monohydrate 50% Injection,"727517, 1795514",,4ed365da-4e62-4329-c1b9-c197ab4fb6e1,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Pediatric",DEXTROSE,"0409-7517, 0409-4902, 0409-6648, 0409-0505","Hospira, Inc.",0fca7d54-4d75-455b-a1d7-d25e31702264,"0409-7517-66, 0409-7517-16, 0409-4902-64, 0409-4902-34, 0409-6648-16, 0409-6648-02, 0409-0505-15, 0409-0505-25","Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-7517-16)",Injection,Available,,NDA019445,,DEXTROSE MONOHYDRATE,,,Current,,,,LX22YL083G,0409-7517-16,844-646-4398,
"Teva Pharmaceuticals USA, Inc.",METHOTREXATE SODIUM,,03/13/2023,Revised,"INTRA-ARTERIAL, INTRAMUSCULAR, INTRATHECAL, INTRAVENOUS",Methotrexate Sodium Injection,,,346ec9ce-dc98-4a55-b55e-d3af11f2d703,09/15/2025,HUMAN PRESCRIPTION DRUG,,"Rheumatology, Oncology",METHOTREXATE,"0703-3675, 0703-3671, 0703-3678","Teva Parenteral Medicines, Inc.",e81074cc-12b4-4ac9-a5bb-749188989b2c,"0703-3671-01, 0703-3675-01, 0703-3678-01","Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)",Injection,Limited Availability,,ANDA040843,,METHOTREXATE,,,Current,Other,Estimated recovery: October 2025,,3IG1E710ZN,0703-3675-01,800-545-8800,
"Noven Pharmaceuticals, Inc.",METHYLPHENIDATE,Central Nervous System Stimulation [PE],02/28/2025,Reverified,TRANSDERMAL,"Methylphenidate Film, Extended Release",,,2c312c31-3198-4775-91ab-294e0b4b9e7f,08/19/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,DAYTRANA,"68968-5555, 68968-5552, 68968-5553, 68968-5554","Noven Therapeutics, LLC",55f4b5f4-6d3c-4677-a94c-d47ffb59a91a,"68968-5552-3, 68968-5553-3, 68968-5554-3, 68968-5555-3","Daytrana, Film, Extended Release, 30 mg (NDC 68968-5555-3)","Film, Extended Release",Unavailable,"N0000175739, N0000175729",NDA021514,,METHYLPHENIDATE,Central Nervous System Stimulant [EPC],,Current,Shortage of an active ingredient,Estimated availability TBD,,207ZZ9QZ49,68968-5555-3,800-455-8070,
Pfizer Inc.,METHYLPREDNISOLONE ACETATE,,12/15/2021,Reverified,"INTRALESIONAL, INTRAMUSCULAR, INTRASYNOVIAL, SOFT TISSUE",Methylprednisolone Acetate Injection,"1358510, 1358512, 1358610, 1358612, 1358617, 1358619",,823b0010-2b57-4e76-b5ac-4a8c2963438f,08/15/2025,HUMAN PRESCRIPTION DRUG,,Rheumatology,DEPO-MEDROL,"0009-0306, 0009-0274, 0009-0280",Pharmacia & Upjohn Company LLC,4cf5a255-1360-4511-9b58-b92e3492ef12,"0009-0274-01, 0009-0280-02, 0009-0280-51, 0009-0280-03, 0009-0280-52, 0009-0306-02, 0009-0306-12","Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-02)",Injection,Available,,NDA011757,,METHYLPREDNISOLONE ACETATE,,,Current,,,,43502P7F0P,0009-0306-02,844-646-4398,
"Sunrise Pharmaceutical, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,ac102599-3a5b-4154-899e-6ff262be7ff7,09/03/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","11534-191, 11534-190, 11534-192, 11534-193, 11534-194, 11534-195, 11534-196","SUNRISE PHARMACEUTICAL, INC.",86a00bec-51eb-4d73-a945-b1937970b29a,"11534-190-01, 11534-190-03, 11534-191-01, 11534-191-03, 11534-192-01, 11534-192-03, 11534-193-01, 11534-193-03, 11534-194-01, 11534-194-03, 11534-195-01, 11534-195-03, 11534-196-01, 11534-196-03","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 11534-191-01)",Tablet,Available,,ANDA209799,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",11534-191-01,732-382-6085 Monday to Friday 9 am to 3:45 pm,
"Mitsubishi Tanabe Pharma America, Inc.",EDARAVONE,,12/05/2024,New,INTRAVENOUS,Edaravone Injection,"1924316, 1924317, 2602117, 2602122",,0ce2c1c4-2a40-485c-b7cb-96a9b85d9d11,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Neurology,RADICAVA,"70510-2171, 70510-2321, 70510-2322","Mitsubishi Tanabe Pharma America, Inc.",abe2c188-af45-49b9-a914-2d9bc12a726f,"70510-2171-1, 70510-2171-2, 70510-2321-1, 70510-2321-2, 70510-2323-1, 70510-2322-1, 70510-2324-1","Radicava, Injection, 30 mg/100 mL (NDC 70510-2171-2)",Injection,,,NDA209176,,EDARAVONE,,,To Be Discontinued,,"A business decision was made to discontinue manufacture of this product. Distribution will end as early as April 1, 2025. The discontinuation of Radicava (edaravone) injection will not impact the commercial availability of Radicava ORS (edaravone) oral suspension.",,S798V6YJRP,70510-2171-2,855-457-6968,
"Hospira, Inc., a Pfizer Company","EPINEPHRINE, LIDOCAINE HYDROCHLORIDE",,02/22/2012,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL","Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","1010688, 1010745, 1010751, 1010759, 1867996, 1867998",,2f94f711-14c4-48ec-c5a3-c5ec4b8e8729,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE,"0409-3183, 0409-1209, 0409-3177, 0409-3178, 0409-3181, 0409-3182, 0409-0007, 0409-0147","Hospira, Inc.",d16a4711-e663-455e-a1fe-236a41ca4e8f,"0409-1209-10, 0409-1209-01, 0409-1209-05, 0409-1209-70, 0409-1209-65, 0409-3177-16, 0409-3177-01, 0409-3178-16, 0409-3178-01, 0409-3178-17, 0409-3178-02, 0409-3178-18, 0409-3178-03, 0409-3181-11, 0409-3181-01, 0409-3182-11, 0409-3182-01, 0409-3182-21, 0409-3182-02, 0409-3182-31, 0409-3182-03, 0409-3183-11, 0409-3183-01, 0409-0007-01, 0409-0007-10, 0409-0147-01, 0409-0147-10","Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:200,000) (NDC 0409-3183-01)",Injection,Available,"N0000000209, N0000000245, N0000175552, N0000175555, N0000175570, M0003647",ANDA089651,Catecholamines [CS],LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE,"alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC], Catecholamine [EPC]",,Current,,,,"V13007Z41A, YKH834O4BH",0409-3183-01,844-646-4398,"Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA]"
"Hikma Pharmaceuticals USA, Inc.",AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","239191, 313797",,077f4a65-3cfb-4cb1-99f2-e27ffc5939c0,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0143-9889, 0143-9888",Hikma Pharmaceuticals USA Inc.,c2fa2c99-c735-4834-a8a5-04a30da8a002,"0143-9888-80, 0143-9888-01, 0143-9888-15, 0143-9889-80, 0143-9889-01, 0143-9889-15","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0143-9889-01)","Powder, For Suspension",,,ANDA065322,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0143-9889-01,800-631-2174,
"Hikma Pharmaceuticals USA, Inc.",LIDOCAINE HYDROCHLORIDE,,06/13/2018,Revised,"EPIDURAL, INFILTRATION, INTRACAUDAL",Lidocaine Hydrochloride Injection,"1737566, 1737761",,1631e5ca-03d0-4d3b-91e3-2dc14f4eb0e1,07/23/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,LIDOCAINE HYDROCHLORIDE,"0143-9595, 0143-9594",Hikma Pharmaceuticals USA Inc.,94a2c3cf-9d57-4185-884d-e52af6c139c8,"0143-9595-01, 0143-9595-25, 0143-9594-01, 0143-9594-25","Lidocaine Hydrochloride, Preservative Free, Injection, 10 mg/1 mL (NDC 0143-9595-25)",Injection,Available,,ANDA084625,,LIDOCAINE HYDROCHLORIDE,,,Current,,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,V13007Z41A,0143-9595-25,800-631-2174,
"Hikma Pharmaceuticals USA, Inc.",REMIFENTANIL HYDROCHLORIDE,,06/28/2022,Reverified,INTRAVENOUS,Remifentanil Hydrochloride Injection,"1729578, 1729584, 1729710",,9d289052-1eb6-4ba2-a3ca-d2e542a052ae,07/23/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,REMIFENTANIL HYDROCHLORIDE,"0143-9392, 0143-9391, 0143-9393",Hikma Pharmaceuticals USA Inc.,5c5e498b-d829-4f78-bcca-466631014767,"0143-9391-01, 0143-9391-10, 0143-9392-01, 0143-9392-10, 0143-9393-01, 0143-9393-10","Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10)",Injection,Unavailable,,ANDA210594,,REMIFENTANIL HYDROCHLORIDE,,,Current,Demand increase for the drug,,,5V444H5WIC,0143-9392-10,800-631-2174,
Takeda Pharmaceuticals USA Inc.,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854832, 854834, 854836, 854838, 854840, 854842, 854844, 854846, 854848, 854850, 854852, 1593856, 1593858, 1871456, 1871459, 1871460, 1871461, 1871462, 1871463, 1871464, 1871465, 1871466, 1871467, 1871468, 1871469",,704e4378-ca83-445c-8b45-3cfa51c1ecad,08/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,VYVANSE,"59417-105, 59417-101, 59417-102, 59417-103, 59417-104, 59417-106, 59417-107, 59417-115, 59417-116, 59417-117, 59417-118, 59417-119, 59417-120","Takeda Pharmaceuticals America, Inc.",756b98a0-fada-44b2-a606-f2e71ef8cc84,"59417-101-10, 59417-102-10, 59417-103-10, 59417-104-10, 59417-105-10, 59417-106-10, 59417-107-10, 59417-115-01, 59417-116-01, 59417-117-01, 59417-118-01, 59417-119-01, 59417-120-01","Vyvanse, Capsule, 50 mg (NDC 59417-105-10)",Capsule,Available,,NDA021977,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,59417-105-10,877-TAKEDA-7 (1-877-825-3327),
B. Braun Medical Inc.,WATER,,04/28/2023,Reverified,IRRIGATION,Sterile Water Irrigant,150985,,f4284eb6-e553-46d4-90d8-efc80a90a480,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",STERILE WATER,0264-2101,B. Braun Medical Inc.,969bdf41-6565-42fb-8ac1-8661a928cc22,"0264-2101-00, 0264-2101-10, 0264-2101-50, 0264-2101-70","Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-00)",Irrigant,Available,,NDA016734,,WATER,,,Current,,,,059QF0KO0R,0264-2101-00,800-227-2862,
Accord Healthcare Inc.,ATROPINE SULFATE,,01/01/2012,Reverified,"ENDOTRACHEAL, INTRAMEDULLARY, INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Atropine Sulfate Injection,1190776,,f3cb74e9-b4ac-4efe-bd8e-8a71970ee7c7,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology, Pediatric",ATROPINE SULFATE,16729-512,Accord Healthcare Inc.,275def6c-5b2d-918b-e063-6294a90aa71f,"16729-512-05, 16729-512-43","Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-512-43)",Injection,Unavailable,,ANDA213424,,ATROPINE SULFATE,,,Current,Requirements related to complying with good manufacturing practices,Resupply TBD,,03J5ZE7KA5,16729-512-43,"866-941-7875, option 2",
"Hikma Pharmaceuticals USA, Inc.",DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,309710,,de6f01a2-9f2d-4c68-9c02-06643704acb1,07/23/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE HCL,0143-9532,Hikma Pharmaceuticals USA Inc.,27ff2cf4-825d-4e29-bd8d-ffccffa13c74,"0143-9532-01, 0143-9532-25","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 0143-9532-25)",Injection,Unavailable,,ANDA205046,,DEXMEDETOMIDINE HCL,,,Current,Demand increase for the drug,Shortage duration is unknown at this time.,,1018WH7F9I,0143-9532-25,800-631-2174,
"EMD Serono, Inc.",LEVOTHYROXINE SODIUM,,07/10/2025,New,ORAL,Levothyroxine Sodium Tablet,"892246, 892251, 966153, 966160, 966166, 966173, 966177, 966182, 966187, 966196, 966202, 966207, 966220, 966221, 966222, 966224, 966225, 966248, 966249, 966253, 966270, 2104866",,bc3c6830-ba68-4ba3-9896-a12d0ad0b275,07/10/2025,HUMAN PRESCRIPTION DRUG,07/10/2025,Endocrinology/Metabolism,EUTHYROX,"72305-175, 72305-025, 72305-050, 72305-075, 72305-088, 72305-100, 72305-112, 72305-125, 72305-137, 72305-150, 72305-200","Provell Pharmaceuticals, LLC",45657074-8874-49f4-a8ef-3ca7e210c16e,"72305-025-30, 72305-025-90, 72305-050-30, 72305-050-90, 72305-075-30, 72305-075-90, 72305-088-30, 72305-088-90, 72305-100-30, 72305-100-90, 72305-112-30, 72305-112-90, 72305-125-30, 72305-125-90, 72305-137-30, 72305-137-90, 72305-150-30, 72305-150-90, 72305-175-30, 72305-175-90, 72305-200-30, 72305-200-90","Euthyrox, Tablet, 175 ug (NDC 72305-175-90)",Tablet,,,NDA021292,,LEVOTHYROXINE SODIUM,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,9J765S329G,72305-175-90,888-899-7041,
"Teva Pharmaceuticals USA, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Revised,ORAL,Lisdexamfetamine Dimesylate Capsule,,,c32b5dce-2de4-4db0-a4ba-d2ce3b0a32fc,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0480-3565, 0480-3566, 0480-3567, 0480-3568, 0480-3569, 0480-3570, 0480-3564","Teva Pharmaceuticals, Inc.",6cfe6c98-51b1-45a4-831c-33624ab129cb,"0480-3565-01, 0480-3566-01, 0480-3567-01, 0480-3568-01, 0480-3569-01, 0480-3570-01, 0480-3564-01","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0480-3565-01)",Capsule,Available,,ANDA202802,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,0480-3565-01,800-545-8800,
SpecGx LLC,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 1009145",,72ddd1c9-ddbd-4c95-acd9-003189a353a3,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE,"0406-8885, 0406-8891, 0406-8884, 0406-8892, 0406-8893, 0406-8894",SpecGx LLC,b25a2f3f-ee3a-44c0-a475-f371025c767b,"0406-8891-01, 0406-8884-01, 0406-8892-01, 0406-8885-01, 0406-8893-01, 0406-8894-01","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0406-8885-01)",Tablet,Available,,ANDA040440,,DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE,,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",0406-8885-01,800-325-8888,
Baxter Healthcare,DOPAMINE HYDROCHLORIDE,,11/06/2017,Reverified,INTRAVENOUS,Dopamine Hydrochloride Injection,"1292887, 1743869, 1743871, 1743877, 1743879",,cb97d4a0-89ed-407c-a763-209386b6f75c,09/23/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,DOPAMINE HYDROCHLORIDE AND DEXTROSE,"0338-1007, 0338-1005, 0338-1009",Baxter Healthcare Corporation,1b91b75f-c6e4-4425-bea8-023458ecf8f9,"0338-1005-02, 0338-1005-03, 0338-1007-02, 0338-1007-03, 0338-1009-02","Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-02)",Injection,Available,,NDA019615,,DOPAMINE HYDROCHLORIDE,,,Current,,,,7L3E358N9L,0338-1007-02,888-229-0001,
Chartwell Molecular Holdings LLC,FLURAZEPAM HYDROCHLORIDE,,08/03/2022,Reverified,ORAL,Flurazepam Hydrochloride Capsule,"1298088, 1298091",,8f476891-1346-4e8c-ac1b-f8cbdc64f5a1,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Other",FLURAZEPAM HYDROCHLORIDE,"62135-736, 62135-737","Chartwell RX, LLC",25893c92-c8f1-567a-e063-6294a90a00d4,"62135-736-30, 62135-736-90, 62135-737-30, 62135-737-90","Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-30)",Capsule,Available,,ANDA072368,,FLURAZEPAM HYDROCHLORIDE,,,Current,,,,756RDM536M,62135-736-30,845-268-5000 Ext. 510,
"Teva Pharmaceuticals USA, Inc.",METHOTREXATE SODIUM,,03/13/2023,Revised,"INTRA-ARTERIAL, INTRAMUSCULAR, INTRATHECAL, INTRAVENOUS",Methotrexate Sodium Injection,,,346ec9ce-dc98-4a55-b55e-d3af11f2d703,09/15/2025,HUMAN PRESCRIPTION DRUG,,"Rheumatology, Oncology",METHOTREXATE,"0703-3671, 0703-3675, 0703-3678","Teva Parenteral Medicines, Inc.",e81074cc-12b4-4ac9-a5bb-749188989b2c,"0703-3671-01, 0703-3675-01, 0703-3678-01","Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)",Injection,Limited Availability,,ANDA040843,,METHOTREXATE,,,Current,Other,Estimated recovery: October 2025,,3IG1E710ZN,0703-3671-01,800-545-8800,
SpecGx LLC,METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Reverified,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release","2001565, 2001566, 2001568",,b1b0f2ff-d9df-42ab-b471-226ecf97e075,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE,"0406-0154, 0406-0127, 0406-0136",SpecGx LLC,7a3a8731-e545-455e-83c3-888f4923e901,"0406-0127-01, 0406-0136-01, 0406-0154-01","Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 0406-0154-01)",Tablet,Unavailable,,ANDA202608,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,Shortage of an active ingredient,Backorder. Next release expected in October 2025.,,4B3SC438HI,0406-0154-01,800-325-8888,
Baxter Healthcare,"ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, PROLINE, SERINE, THREONINE, TRYPTOPHAN, TYROSINE, VALINE",,12/08/2020,Reverified,INTRAVENOUS,Amino Acid Injection,"801133, 801136",,cc2ace81-5881-43f1-ba94-41b674adc2fc,09/23/2025,HUMAN PRESCRIPTION DRUG,,Gastroenterology,PROSOL,0338-0499,Baxter Healthcare Corporation,ee240b46-c2a9-42e0-8750-a5a554becea3,0338-0499-06,"PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, Injection, 2.76 g/100 mL; 1.96 g/100 mL; 600 mg/100 mL; 1.02 g/100 mL; 2.06 g/100 mL; 1.18 g/100 mL; 1.08 g/100 mL; 1.08 g/100 mL; 1.35 g/100 mL; 760 mg/100 mL; 1 g/100 mL; 1.34 g/100 mL; 1.02 g/100 mL; 980 mg/100 mL; 320 mg/100 mL; 50 mg/100 mL; 1.44 g/100 mL (NDC 0338-0499-06)",Injection,Available,"N0000175780, M0000922",NDA020849,Amino Acids [CS],"VALINE, LYSINE, HISTIDINE, ISOLEUCINE, LEUCINE, PHENYLALANINE, THREONINE, METHIONINE, TRYPTOPHAN, ALANINE, GLYCINE, ARGININE, PROLINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID AND TYROSINE",Amino Acid [EPC],,Current,,,,"OF5P57N2ZX, 94ZLA3W45F, 30KYC7MIAI, 3KX376GY7L, TE7660XO1C, 4QD397987E, 04Y7590D77, GMW67QNF9C, TTL6G7LIWZ, AE28F7PNPL, 47E5O17Y3R, 9DLQ4CIU6V, 452VLY9402, 2ZD004190S, 8DUH1N11BX, 42HK56048U, HG18B9YRS7",0338-0499-06,888-229-0001,
"Upsher-Smith Laboratories, LLC",DIVALPROEX SODIUM,,04/28/2025,New,ORAL,"Divalproex Sodium Tablet, Delayed Release","1099625, 1099678, 1099870",,02304a23-4a5f-47bc-9687-4044b43f7a20,04/28/2025,HUMAN PRESCRIPTION DRUG,04/28/2025,Neurology,DIVALPROEX SODIUM,"0832-7123, 0832-7122, 0832-7124","Upsher-Smith Laboratories, LLC",38e51a59-5802-77a6-e063-6394a90af6c6,"0832-7122-11, 0832-7122-15, 0832-7123-11, 0832-7123-15, 0832-7123-89, 0832-7123-01, 0832-7124-11, 0832-7124-15, 0832-7124-89, 0832-7124-01","Divalproex Sodium, Tablet, Delayed Release, 250 mg (NDC 0832-7123-15)",Tablet,,,ANDA078182,,DIVALPROEX SODIUM,,,To Be Discontinued,,Discontinuation of manufacture of drug based on business decision.,,644VL95AO6,0832-7123-15,800-654-2299,
"Novo Nordisk, Inc.",INSULIN DEGLUDEC,,07/21/2025,New,SUBCUTANEOUS,Insulin Degludec Injection,"1670011, 1670021, 2107520",,c1be283d-4b1d-4996-b2a7-4488dbff3037,07/21/2025,HUMAN PRESCRIPTION DRUG,07/21/2025,Endocrinology/Metabolism,INSULIN DEGLUDEC,"73070-503, 73070-403, 73070-400","Novo Nordisk Pharma, Inc.",c1be283d-4b1d-4996-b2a7-4488dbff3037,"73070-403-15, 73070-503-15, 73070-400-11","Insulin Degludec, Injection, 3 mL Insulin Degludec 200 units/mL (U-200) FlexTouch® (NDC 73070-503-15)",Injection,,"M0011417, N0000175453",BLA203314,Insulin [CS],INSULIN DEGLUDEC,Insulin Analog [EPC],,To Be Discontinued,,"Unbranded Insulin Degludec 3 mL U-200 FlexTouch® will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,54Q18076QB,73070-503-15,609-987-5800,
SpecGx LLC,NALTREXONE HYDROCHLORIDE,,02/29/2024,Reverified,ORAL,Naltrexone Hydrochloride Tablet,1483744,,06ff2d5a-e62b-4fa4-bbdb-01938535bc65,09/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,NALTREXONE HYDROCHLORIDE,0406-1170,SpecGx LLC,9ed13551-325e-4b82-a266-72fc89ed27dc,"0406-1170-03, 0406-1170-01","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 0406-1170-03)",Tablet,Available,,ANDA076264,,NALTREXONE HYDROCHLORIDE,,,Current,Demand increase for the drug,Long term allocations to all customers with intermittent backorder expected through 2025.,,Z6375YW9SF,0406-1170-03,800-325-8888,
"Actavis Pharma, Inc.",ONDANSETRON HYDROCHLORIDE,,11/04/2024,New,ORAL,Ondansetron Hydrochloride Tablet,"198052, 312086",,90d19fd2-6de4-4e55-9469-53b8957c8326,11/04/2024,HUMAN PRESCRIPTION DRUG,11/04/2024,Gastroenterology,ONDANSETRON,"45963-538, 45963-539","ACTAVIS PHARMA, INC.",362baa9c-5ad9-402b-b4cb-7c4f2e051686,"45963-538-30, 45963-539-30","Tablet, 4 mg (NDC 45963-538-30)",Tablet,,,ANDA077851,,ONDANSETRON,,,To Be Discontinued,,,,NMH84OZK2B,45963-538-30,800-545-8800,
"Upsher-Smith Laboratories, LLC",OXYBUTYNIN CHLORIDE,,05/14/2025,New,ORAL,Oxybutynin Chloride Tablet,863664,,3ee6835a-7a7d-49a9-8460-2f1dd270ead3,05/14/2025,HUMAN PRESCRIPTION DRUG,05/14/2025,Renal,OXYBUTYNIN CHLORIDE,0832-0038,"Upsher-Smith Laboratories, LLC",2f3b30f0-e463-2de1-e063-6394a90a1b69,"0832-0038-00, 0832-0038-50, 0832-0038-10, 0832-0038-89, 0832-0038-01","Oxybutynin Chloride, Tablet, 5 mg (NDC 0832-0038-01)",Tablet,,,ANDA074625,,OXYBUTYNIN CHLORIDE,,,To Be Discontinued,,,,L9F3D9RENQ,0832-0038-01,800-654-2299,
Sandoz Inc.,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577961",,288dafc4-fe6e-4891-832f-511022c87445,09/24/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","0185-2098, 0185-0831, 0185-0842, 0185-0853, 0185-0864, 0185-2099",Sandoz Inc,d68cd1d1-3bb4-4afa-9786-687cf1766ae1,"0185-0831-01, 0185-0842-01, 0185-0853-01, 0185-0864-01, 0185-2099-01, 0185-2098-01","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0185-2098-01)",Tablet,Available,,ANDA040439,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",0185-2098-01,800-525-8747,
"Teva Pharmaceuticals USA, Inc.",URSODIOL,,03/28/2025,New,ORAL,Ursodiol Tablet,"858733, 858751",,0a7c1ae6-4878-43e7-9026-073f74af64c0,03/28/2025,HUMAN PRESCRIPTION DRUG,03/28/2025,Other,URSODIOL,"0591-3005, 0591-2998","Actavis Pharma, Inc.",3ca902a9-d8c3-4c4b-a49f-efc62cf2028a,"0591-2998-01, 0591-3005-01","Ursodiol, Tablet, 500 mg (NDC 0591-3005-01)",Tablet,,"N0000175802, M0002475",NDA020675,Bile Acids and Salts [CS],URSODIOL,Bile Acid [EPC],,To Be Discontinued,,A business decision was made to discontinue manufacture of the drug.,,724L30Y2QR,0591-3005-01,800-545-8800,
"Fresenius Kabi USA, LLC",KETOROLAC TROMETHAMINE,,03/23/2018,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Ketorolac Tromethamine Injection,"860113, 860114, 860115",,3d88cbe6-5230-47aa-80af-0c41283d1f00,09/18/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,KETOROLAC TROMETHAMINE,"76045-104, 76045-105, 76045-107, 76045-209","Fresenius Kabi USA, LLC",0dab642d-7fcf-4301-8ac9-10e64a040c6b,"76045-104-10, 76045-105-20, 76045-107-10, 76045-209-00, 76045-209-10","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 76045-104-10)",Injection,Unavailable,,ANDA203242,,KETOROLAC TROMETHAMINE,,,Current,Other,Not available at this time.,,4EVE5946BQ,76045-104-10,888-386-1300,
"Upsher-Smith Laboratories, LLC",MIDODRINE HYDROCHLORIDE,,04/28/2025,New,ORAL,Midodrine Hydrochloride Tablet,"993462, 993466, 993470",,4c3517f3-1c68-4ade-b5f1-c488a3a335c1,04/28/2025,HUMAN PRESCRIPTION DRUG,04/28/2025,Cardiovascular,MIDODRINE HYDROCHLORIDE,"0245-0213, 0245-0211, 0245-0212","Upsher-Smith laboratories, LLC",18b0b9f5-6026-479e-af12-92b0e71a9d6b,"0245-0211-11, 0245-0211-89, 0245-0211-01, 0245-0212-11, 0245-0212-89, 0245-0212-01, 0245-0213-11, 0245-0213-89, 0245-0213-01","Orvaten, Tablet, 10 mg (NDC 0245-0213-01)",Tablet,,,ANDA076725,,MIDODRINE HYDROCHLORIDE,,,To Be Discontinued,,,,59JV96YTXV,0245-0213-01,800-654-2299,
"Fresenius Kabi USA, LLC",ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Reverified,EPIDURAL,Ropivacaine Hydrochloride Injection,"905189, 905191, 1734084, 1734086, 1734090, 1734091, 1734203, 1734204, 1734207, 1734208, 1734347, 1734348, 1734355, 1734356, 1734475, 1734476, 1734479, 1734480, 1734481, 1734482, 1734483, 1734484",,"23d2d448-a744-4877-9f2d-7e57c198da89, c6613708-c1f7-4f5c-91a3-ebbc1d7905c6, 56dfabf7-f7a8-4601-b17a-cb16fb995b0f",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,NAROPIN,"63323-288, 63323-286, 63323-287, 63323-285","Fresenius Kabi USA, LLC","cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9, 73218c89-8925-468c-84bf-9960b4b3dc3c, 75465ceb-e894-487d-aa80-671fa0841fce","63323-286-01, 63323-286-20, 63323-286-05, 63323-286-23, 63323-286-09, 63323-286-31, 63323-286-11, 63323-286-35, 63323-286-03, 63323-286-00, 63323-286-33, 63323-286-63, 63323-286-30, 63323-287-01, 63323-287-20, 63323-287-03, 63323-287-21, 63323-288-01, 63323-288-10, 63323-288-06, 63323-288-20, 63323-288-03, 63323-288-11, 63323-288-07, 63323-288-21, 63323-285-01, 63323-285-10, 63323-285-06, 63323-285-20, 63323-285-03, 63323-285-13, 63323-285-07, 63323-285-23, 63323-285-57, 63323-285-64, 63323-285-51, 63323-285-65, 63323-285-02, 63323-285-61, 63323-285-04, 63323-285-63, 63323-285-55, 63323-285-67, 63323-288-23, 63323-288-29, 63323-286-93, 63323-286-95, 63323-288-25, 63323-288-27","Naropin, Injection, 10 mg/1 mL (NDC 63323-288-20)",Injection,Unavailable,,NDA020533,,ROPIVACAINE HYDROCHLORIDE,,,Current,Delay in shipping of the drug,Next release not available at this time.,,V910P86109,63323-288-20,888-386-1300,
Baxter Healthcare,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807631, 1807632, 1807633, 1807634, 1807639",,958d35f0-6834-43be-a700-fa58f38b4c19,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0338-9543, 0338-9657, 0338-9659, 0338-9661, 0338-9663",Baxter Healthcare Corporation,6680afa2-1474-4bc3-afee-a333a042fd3f,"0338-9543-01, 0338-9543-02, 0338-9543-03, 0338-9543-04, 0338-9543-05, 0338-9543-06, 0338-9543-12, 0338-9657-75, 0338-9659-75, 0338-9661-60, 0338-9663-60","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-9543-04)",Injection,,,NDA016677,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0338-9543-04,888-229-0001,
Torrent Pharma Inc.,"AMLODIPINE, HYDROCHLOROTHIAZIDE, OLMESARTAN MEDOXOMIL",Increased Diuresis [PE],06/13/2025,New,ORAL,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,"999967, 999986, 999991, 999996, 1000001",,85b8f9c6-aa53-4aa1-85d6-19f823d0d252,06/13/2025,HUMAN PRESCRIPTION DRUG,06/13/2025,Cardiovascular,"OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE 20/5/12.5 MG","13668-397, 13668-386, 13668-385, 13668-383, 13668-382",Torrent Pharmaceuticals Limited,5bedf6c6-6b23-40e7-8c96-2cedcc682973,"13668-397-30, 13668-397-90, 13668-397-05, 13668-386-30, 13668-386-90, 13668-386-05, 13668-385-30, 13668-385-90, 13668-385-05, 13668-383-30, 13668-383-90, 13668-383-05, 13668-382-30, 13668-382-90, 13668-382-05","Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 20 mg (NDC 13668-397-05)",Tablet,,"N0000175359, N0000175419, M0471776, N0000000069, N0000175421, N0000175566, M0006414, N0000190114",ANDA203580,"Thiazides [CS], Dihydropyridines [CS]","OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE TABLET 20/5/12.5 MG","Thiazide Diuretic [EPC], Dihydropyridine Calcium Channel Blocker [EPC], Calcium Channel Blocker [EPC]",,To Be Discontinued,,A business decision was made to discontinue manufacture of the product.,,"0J48LPH2TH, 1J444QC288, 6M97XTV3HD",13668-397-05,908-280-3333,"Calcium Channel Antagonists [MoA], Cytochrome P450 3A Inhibitors [MoA]"
"EMD Serono, Inc.",LEVOTHYROXINE SODIUM,,07/10/2025,New,ORAL,Levothyroxine Sodium Tablet,"892246, 892251, 966153, 966160, 966166, 966173, 966177, 966182, 966187, 966196, 966202, 966207, 966220, 966221, 966222, 966224, 966225, 966248, 966249, 966253, 966270, 2104866",,bc3c6830-ba68-4ba3-9896-a12d0ad0b275,07/10/2025,HUMAN PRESCRIPTION DRUG,07/10/2025,Endocrinology/Metabolism,EUTHYROX,"72305-088, 72305-025, 72305-050, 72305-075, 72305-100, 72305-112, 72305-125, 72305-137, 72305-150, 72305-175, 72305-200","Provell Pharmaceuticals, LLC",45657074-8874-49f4-a8ef-3ca7e210c16e,"72305-025-30, 72305-025-90, 72305-050-30, 72305-050-90, 72305-075-30, 72305-075-90, 72305-088-30, 72305-088-90, 72305-100-30, 72305-100-90, 72305-112-30, 72305-112-90, 72305-125-30, 72305-125-90, 72305-137-30, 72305-137-90, 72305-150-30, 72305-150-90, 72305-175-30, 72305-175-90, 72305-200-30, 72305-200-90","Euthyrox, Tablet, 88 ug (NDC 72305-088-90)",Tablet,,,NDA021292,,LEVOTHYROXINE SODIUM,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,9J765S329G,72305-088-90,888-899-7041,
"Teva Pharmaceuticals USA, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Revised,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541365, 541878, 541879, 541892, 541894, 577957, 577960, 577961, 577962, 687043, 687045, 1009145, 1009147",,f22635fe-821d-4cde-aa12-419f8b53db81,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,ADDERALL,"57844-112, 57844-105, 57844-117, 57844-110, 57844-115, 57844-120, 57844-130","Teva Pharmaceuticals USA, Inc.",79af1dc6-c7cf-41b1-a750-e9b47c2187ff,"57844-105-01, 57844-117-01, 57844-110-01, 57844-112-01, 57844-115-01, 57844-120-01, 57844-130-01","Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)",Tablet,Available,,ANDA040422,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",57844-112-01,800-545-8800,
Bristol Myers Squibb Co.,ATAZANAVIR SULFATE,,06/04/2025,New,ORAL,Atazanavir Sulfate Capsule,"402093, 402094, 402246, 402247, 664741, 664743, 1598985, 1598989",,165cff62-b284-4a27-a65d-9ec8a5bfcdd8,06/04/2025,HUMAN PRESCRIPTION DRUG,06/04/2025,Antiviral,REYATAZ,"0003-3622, 0003-3624, 0003-3631, 0003-3638","E.R. Squibb & Sons, L.L.C.",510c2d51-4943-401c-a008-ea22f61c6938,"0003-3624-12, 0003-3631-12, 0003-3622-12, 0003-3638-10","Reyataz, Capsule, 300 mg (NDC 0003-3622-12)",Capsule,,,NDA021567,,ATAZANAVIR,,,To Be Discontinued,,Permanent discontinuation,,4MT4VIE29P,0003-3622-12,1-800-332-2056; for Medical Inquiries (1-800-321-1335),
Torrent Pharma Inc.,"AMLODIPINE, HYDROCHLOROTHIAZIDE, OLMESARTAN MEDOXOMIL",Increased Diuresis [PE],06/13/2025,New,ORAL,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,"999967, 999986, 999991, 999996, 1000001",,85b8f9c6-aa53-4aa1-85d6-19f823d0d252,06/13/2025,HUMAN PRESCRIPTION DRUG,06/13/2025,Cardiovascular,"OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE 40/5/25 MG","13668-385, 13668-397, 13668-386, 13668-383, 13668-382",Torrent Pharmaceuticals Limited,5bedf6c6-6b23-40e7-8c96-2cedcc682973,"13668-397-30, 13668-397-90, 13668-397-05, 13668-386-30, 13668-386-90, 13668-386-05, 13668-385-30, 13668-385-90, 13668-385-05, 13668-383-30, 13668-383-90, 13668-383-05, 13668-382-30, 13668-382-90, 13668-382-05","Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 25 mg; 40 mg (NDC 13668-385-90)",Tablet,,"N0000175359, N0000175419, M0471776, N0000000069, N0000175421, N0000175566, M0006414, N0000190114",ANDA203580,"Thiazides [CS], Dihydropyridines [CS]","OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE TABLET 40/5/25 MG","Thiazide Diuretic [EPC], Dihydropyridine Calcium Channel Blocker [EPC], Calcium Channel Blocker [EPC]",,To Be Discontinued,,A business decision was made to discontinue manufacture of the product.,,"0J48LPH2TH, 1J444QC288, 6M97XTV3HD",13668-385-90,908-280-3333,"Calcium Channel Antagonists [MoA], Cytochrome P450 3A Inhibitors [MoA]"
Armas Pharmaceuticals Inc,AZACITIDINE,,12/18/2020,Reverified,"INTRAVENOUS, SUBCUTANEOUS",Azacitidine Injection,485246,,5c0a2d5f-8c34-4c04-8425-7543965cedd4,09/16/2025,HUMAN PRESCRIPTION DRUG,,Oncology,AZACITIDINE,72485-201,Armas Pharmaceuticals Inc.,ca345575-17a6-43a3-aa02-3d4bb9d136c5,72485-201-01,"Azacitidine, Injection, 100 mg (NDC 72485-201-01)",Injection,Available,"N0000000233, N0000175595",ANDA207518,,AZACITIDINE,Nucleoside Metabolic Inhibitor [EPC],,Current,,,,M801H13NRU,72485-201-01,1-732-637-1971,Nucleic Acid Synthesis Inhibitors [MoA]
"Hospira, Inc., a Pfizer Company",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Revised,"EPIDURAL, INTRACAUDAL, PERINEURAL",Bupivacaine Hydrochloride Injection,"1012377, 1012384, 1012396, 1012404, 1672917, 1672919, 1724786, 1724787, 1724880, 1724884, 1725078, 1725082, 1867594, 1867596",,02a845c3-4521-4926-e397-25ab536e7cf6,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE,"0409-1162, 0409-1159, 0409-1160, 0409-1163, 0409-1165, 0409-9043, 0409-9046, 0409-9045, 0409-9042","Hospira, Inc.",3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7,"0409-1159-18, 0409-1159-01, 0409-1159-19, 0409-1159-02, 0409-1160-18, 0409-1160-01, 0409-1162-18, 0409-1162-01, 0409-1162-19, 0409-1162-02, 0409-1163-18, 0409-1163-01, 0409-1165-18, 0409-1165-01, 0409-1165-19, 0409-1165-02, 0409-9043-11, 0409-9043-01, 0409-9046-11, 0409-9046-01, 0409-9045-11, 0409-9045-01, 0409-9045-16, 0409-9045-17, 0409-9042-11, 0409-9042-01, 0409-9042-16, 0409-9042-17","Bupivacaine Hydrochloride, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1162-02)",Injection,Limited Available,,ANDA070584,,BUPIVACAINE HYDROCHLORIDE,,,Current,Other,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,"30Q7KI53AK, 7TQO7W3VT8",0409-1162-02,844-646-4398,
"Hospira, Inc., a Pfizer Company",CARBOPLATIN,,04/28/2023,Reverified,INTRAVENOUS,Carboplatin Injection,597195,,c3ae9880-44bb-4f4e-93d8-8a5e21708a30,08/15/2025,HUMAN PRESCRIPTION DRUG,,Oncology,CARBOPLATIN,61703-339,"Hospira, Inc.",0ddf4411-7138-412a-908a-fadf22bdfb79,"61703-339-18, 61703-339-22, 61703-339-50, 61703-339-56","Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56)",Injection,Available,"N0000175413, N0000175073",ANDA076517,,CARBOPLATIN,Platinum-based Drug [EPC],,Current,,,,BG3F62OND5,61703-339-56,844-646-4398,
Slate Run Pharmaceuticals,LEUCOVORIN CALCIUM,,01/01/2012,Revised,"INTRAMUSCULAR, INTRAVENOUS",Leucovorin Calcium Injection,"237788, 1803930, 1803932, 1803937, 2055036",,d8bdd60c-9a1c-4ef4-ba6b-b911849128f1,07/08/2025,HUMAN PRESCRIPTION DRUG,,"Oncology, Pediatric",LEUCOVORIN CALCIUM,"70436-116, 70436-117, 70436-118, 70436-120, 70436-119","Slate Run Pharmaceuticals, LLC",2a4aaed3-885e-bc10-e063-6294a90a61af,"70436-116-80, 70436-116-82, 70436-117-80, 70436-118-80, 70436-120-80, 70436-119-80","Leucovorin Calcium, Injection, 50 mg (NDC 70436-116-82)",Injection,,,ANDA217021,,LEUCOVORIN CALCIUM,,Available,Resolved,,,07/08/2025,RPR1R4C0P4,70436-116-82,888-447-0095,
Eugia US LLC,LIDOCAINE HYDROCHLORIDE,,06/13/2018,Revised,"INFILTRATION, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010671",,"ccc38d8a-43fd-44c0-985e-32af9ed956ab, ef782e5e-e2d7-465a-99c6-b12611f3158c",09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,LIDOCAINE HYDROCHLORIDE,"55150-255, 55150-251, 55150-252, 55150-254, 55150-253, 55150-256",Eugia US LLC,"ccc38d8a-43fd-44c0-985e-32af9ed956ab, 0b1f03c2-db2f-4f90-acc0-d73abd731bf6","55150-251-24, 55150-252-24, 55150-254-24, 55150-255-24, 55150-251-10, 55150-252-20, 55150-253-50, 55150-254-10, 55150-255-20, 55150-256-50","Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)",Injection,Available,,ANDA207182,,LIDOCAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,V13007Z41A,55150-255-20,888-238-7880,
"Lannett Company, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,2cedb4c2-1e40-4bc4-b9f4-127150c4afbd,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0527-4665, 0527-4661, 0527-4662, 0527-4663, 0527-4664, 0527-4666, 0527-4667","Lannett Company, Inc.",981ca74f-737d-45e5-a3b2-b25256263768,"0527-4661-37, 0527-4662-37, 0527-4663-37, 0527-4664-37, 0527-4665-37, 0527-4666-37, 0527-4667-37","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0527-4665-37)",Capsule,Limited Availability,,ANDA215802,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,Limited Availability,,SJT761GEGS,0527-4665-37,844-834-0530,
Fresenius Medical Care North America,SODIUM CHLORIDE,,06/10/2025,New,INTRAVENOUS,Sodium Chloride 0.9% Injection,1807639,,9a1220fb-6853-45ae-838c-10d8596e1af7,06/10/2025,HUMAN PRESCRIPTION DRUG,06/10/2025,"Gastroenterology, Renal",SODIUM CHLORIDE,46163-300,"Fresenius Medical Care de Mexico, S.A. de C.V.",2658bf7c-78a1-7a7a-e063-6394a90aac0c,46163-300-10,"Sodium Chloride 0.9% in Plastic Container, Injection, 900 mg/100 mL (NDC 46163-300-10)",Injection,,,ANDA078177,,SODIUM CHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,451W47IQ8X,46163-300-10,800-323-5188,
B. Braun Medical Inc.,WATER,,04/28/2023,Reverified,IRRIGATION,Sterile Water Irrigant,150985,,f4284eb6-e553-46d4-90d8-efc80a90a480,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",STERILE WATER,0264-2101,B. Braun Medical Inc.,969bdf41-6565-42fb-8ac1-8661a928cc22,"0264-2101-00, 0264-2101-10, 0264-2101-50, 0264-2101-70","Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-10)",Irrigant,Available,,NDA016734,,WATER,,,Current,,,,059QF0KO0R,0264-2101-10,800-227-2862,
Apotex Corp.,,,01/28/2025,New,,Teriflunomide Tablet,,,,01/28/2025,,01/28/2025,Neurology,,,,,,"Teriflunomide, Tablet, 14 mg (NDC 60505-4478-3)",Tablet,,,,,,,,To Be Discontinued,,,,,60505-4478-3,800-706-5575,
Eugia US LLC,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"309710, 1718906, 1718909",,8c162541-986b-4b30-866c-b2631ba2c975,09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE,"55150-209, 55150-296, 55150-297",Eugia US LLC,cc0d3661-5f2e-43fb-a2ae-7d3f89c7e58c,"55150-209-02, 55150-296-10, 55150-297-10","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 55150-209-02)",Injection,Available,,ANDA205867,,DEXMEDETOMIDINE,,,Current,,Check wholesalers for inventory,,1018WH7F9I,55150-209-02,888-238-7880,
Amneal Pharmaceuticals,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850",,c11cb3b6-3dff-477b-a249-b4c3118edc5f,09/17/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"65162-026, 65162-023, 65162-024, 65162-025, 65162-027, 65162-028",Amneal Pharmaceuticals LLC,759471b0-6930-4e65-9417-e1c334a0eb68,"65162-023-09, 65162-024-09, 65162-025-09, 65162-026-09, 65162-027-09, 65162-028-09","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 65162-026-09)",Capsule,Unavailable,,ANDA202830,,LISDEXAMFETAMINE,,,Current,Shortage of an active ingredient,Shortage of an active ingredient,,SJT761GEGS,65162-026-09,866-525-7270,
"Hospira, Inc., a Pfizer Company",MEPERIDINE HYDROCHLORIDE,,05/30/2025,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Meperidine Hydrochloride Injection,"860792, 861463, 861473, 861493, 861494, 861522, 861529, 861617, 1242106, 1242503, 2539186, 2539188, 2539191, 2539192",,b31d1308-28c3-43f4-e0a6-2f3ed76b8975,08/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,DEMEROL,"0409-1181, 0409-1176, 0409-1178, 0409-1179, 0409-1180, 0409-1362, 0409-1418","Hospira, Inc.",1271f15f-ccda-4892-8fb0-9bb2d38ded4a,"0409-1181-30, 0409-1176-03, 0409-1176-30, 0409-1178-03, 0409-1178-30, 0409-1179-03, 0409-1179-30, 0409-1180-59, 0409-1180-69, 0409-1362-11, 0409-1362-01, 0409-1418-11, 0409-1418-01","Demerol, Injection, 50 mg/1 mL (NDC 0409-1181-30)",Injection,Unavailable,,NDA021171,,MEPERIDINE HYDROCHLORIDE,,,Current,Demand increase for the drug,Next Delivery and Estimated Recovery: September 2025,,N8E7F7Q170,0409-1181-30,844-646-4398,
"Fresenius Kabi USA, LLC",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,PERINEURAL,Bupivacaine Hydrochloride Injection,"1012391, 1012396, 1012404, 1012421, 1012455, 1012457, 1672917, 1672919, 1673296, 1673298, 1724880, 1724881, 1724884, 1724885, 1725078, 1725082, 1725175, 1725177",,eb6d8fee-def4-4c96-9972-695e8cea8ea8,09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,SENSORCAINE,"63323-467, 63323-465, 63323-460, 63323-464, 63323-466, 63323-462","Fresenius Kabi USA, LLC",2b1a1f80-cb29-4ac1-9e72-20225ed45715,"63323-465-01, 63323-465-57, 63323-467-01, 63323-467-57, 63323-460-01, 63323-460-37, 63323-464-02, 63323-464-37, 63323-464-03, 63323-464-31, 63323-466-01, 63323-466-37, 63323-466-02, 63323-466-31, 63323-462-04, 63323-462-17, 63323-462-01, 63323-462-37, 63323-462-02, 63323-462-31","Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-467-57)",Injection,Available,,NDA018304,,BUPIVACAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,"30Q7KI53AK, 7TQO7W3VT8",63323-467-57,888-386-1300,
Baxter Healthcare,DOPAMINE HYDROCHLORIDE,,11/06/2017,Reverified,INTRAVENOUS,Dopamine Hydrochloride Injection,"1292887, 1743869, 1743871, 1743877, 1743879",,cb97d4a0-89ed-407c-a763-209386b6f75c,09/23/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,DOPAMINE HYDROCHLORIDE AND DEXTROSE,"0338-1005, 0338-1007, 0338-1009",Baxter Healthcare Corporation,1b91b75f-c6e4-4425-bea8-023458ecf8f9,"0338-1005-02, 0338-1005-03, 0338-1007-02, 0338-1007-03, 0338-1009-02","Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-03)",Injection,Available,,NDA019615,,DOPAMINE HYDROCHLORIDE,,,Current,,,,7L3E358N9L,0338-1005-03,888-229-0001,
"Meitheal Pharmaceuticals, Inc.",LIRAGLUTIDE,,07/18/2023,Reverified,SUBCUTANEOUS,Liraglutide Injection,897122,,0efc3a89-211a-4496-baab-e8265e07de2b,08/19/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,LIRAGLUTIDE,71288-563,Meitheal Pharmaceuticals Inc.,31f901b4-0477-38aa-e063-6294a90ac708,"71288-563-84, 71288-563-85","Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)",Injection,Available,"N0000178480, M0160181, N0000020058",ANDA218115,Glucagon-Like Peptide 1 [CS],LIRAGLUTIDE,GLP-1 Receptor Agonist [EPC],,Current,,,,839I73S42A,71288-563-84,844-824-8426,Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
"Mylan Pharmaceuticals Inc., a Viatris Company",METHYLPHENIDATE,Central Nervous System Stimulation [PE],02/28/2025,Reverified,TRANSDERMAL,"Methylphenidate Film, Extended Release","753436, 753438, 753440, 753441",,1643b6a5-80da-4d4f-8c5f-feb907875702,09/17/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE,"0378-8263, 0378-8260, 0378-8261, 0378-8262",Mylan Pharmaceuticals Inc.,c17e03ec-3756-4043-ae82-33a0ef18380c,"0378-8260-16, 0378-8260-93, 0378-8261-16, 0378-8261-93, 0378-8262-16, 0378-8262-93, 0378-8263-16, 0378-8263-93","Methylphenidate, Film, Extended Release, 30mg/9hrs (NDC 0378-8263-93)","Film, Extended Release",Available,"N0000175739, N0000175729",ANDA206497,,METHYLPHENIDATE,Central Nervous System Stimulant [EPC],,Current,,,,207ZZ9QZ49,0378-8263-93,800-796-9526,
"Hospira, Inc., a Pfizer Company","BUPIVACAINE HYDROCHLORIDE, EPINEPHRINE BITARTRATE",,02/20/2018,Revised,PERINEURAL,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","1012377, 1012384, 1012396, 1012404, 1672917, 1672919, 1724786, 1724787, 1724880, 1724884, 1725078, 1725082, 1867594, 1867596",,02a845c3-4521-4926-e397-25ab536e7cf6,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE,"0409-9046, 0409-1159, 0409-1160, 0409-1162, 0409-1163, 0409-1165, 0409-9043, 0409-9045, 0409-9042","Hospira, Inc.",3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7,"0409-1159-18, 0409-1159-01, 0409-1159-19, 0409-1159-02, 0409-1160-18, 0409-1160-01, 0409-1162-18, 0409-1162-01, 0409-1162-19, 0409-1162-02, 0409-1163-18, 0409-1163-01, 0409-1165-18, 0409-1165-01, 0409-1165-19, 0409-1165-02, 0409-9043-11, 0409-9043-01, 0409-9046-11, 0409-9046-01, 0409-9045-11, 0409-9045-01, 0409-9045-16, 0409-9045-17, 0409-9042-11, 0409-9042-01, 0409-9042-16, 0409-9042-17","Bupivacaine Hydrochloride And Epinephrine, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-9046-01)",Injection,Unavailable,,ANDA071170,,BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE,,,Current,Other,Shortage per Manufacturer: Manufacturing Delay,,"30Q7KI53AK, 7TQO7W3VT8",0409-9046-01,844-646-4398,
"SteriMax, Inc.",CEFOTAXIME SODIUM,,02/17/2015,Reverified,"INTRAMUSCULAR, INTRAVENOUS","Cefotaxime Sodium Powder, for Solution","1656313, 1656318",https://www.fda.gov/media/152896/download,8efe3bd0-c43a-2bd6-e053-2a95a90a92fa,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",CEFOTAXIME,"21586-012, 21586-011",SteriMax Inc.,425c90b3-5006-427e-95f6-93ee7918fb8b,"21586-011-01, 21586-011-02, 21586-012-01, 21586-012-02","Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 21586-012-02)","Powder, For Solution",Available,,,,CEFOTAXIME INJECTION,,,Current,,,,258J72S7TZ,21586-012-02,800-881-3550,
Sandoz Inc.,CLINDAMYCIN,"Decreased Sebaceous Gland Activity [PE], Neuromuscular Blockade [PE]",03/21/2023,Reverified,INTRAVENOUS,Clindamycin Phosphate Injection,"309335, 309336, 309339",,231d95a6-5e5f-4a45-a92b-d3d16ef0a7ca,09/24/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,CLINDAMYCIN IN 5 PERCENT DEXTROSE,"0781-3288, 0781-3289, 0781-3290",Sandoz Inc,e9ea55df-4c10-43a8-97f1-02e6fce12f2b,"0781-3288-91, 0781-3288-09, 0781-3289-91, 0781-3289-09, 0781-3290-91, 0781-3290-09","Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 6 mg/1 mL (NDC 0781-3288-09)",Injection,Available,"N0000009982, N0000175443, M0515779, N0000175731",ANDA201692,Lincosamides [CS],CLINDAMYCIN IN 5 PERCENT DEXTROSE,Lincosamide Antibacterial [EPC],,Current,,,,3U02EL437C,0781-3288-09,800-525-8747,
Novartis Pharmaceuticals Corporation,,,12/09/2024,New,,Lodoxamide Tromethamine Solution,,,,12/09/2024,,12/09/2024,Ophthalmology,,,,,,"Alomide, Solution, 1 mg/1 mL (NDC 0078-0736-10)",Solution,,,,,,,,To Be Discontinued,,"Novartis has made a business decision to permanently discontinue ALOMIDE® (lodoxamide tromethamine) ophthalmic solution, 0.1%
Discontinuation of the product is due in part to manufacturing concerns.
Short-dated material is available until January 2025.",,,0078-0736-10,888-669-6682,
Eugia US LLC,BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Revised,"EPIDURAL, RETROBULBAR",Bupivacaine Hydrochloride Injection,"1012396, 1012404, 1724786, 1724787, 1724880, 1724884, 1725078, 1725082",,ffecf450-1f01-4721-8e10-251385852612,09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE,"55150-172, 55150-167, 55150-168, 55150-169, 55150-170, 55150-171, 55150-249, 55150-250",Eugia US LLC,39649703-e633-4a20-ba71-0c04dbf8ff2a,"55150-167-10, 55150-168-30, 55150-169-10, 55150-170-30, 55150-171-10, 55150-172-30, 55150-249-50, 55150-250-50","Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-172-30)",Injection,Available,,ANDA203895,,BUPIVACAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,7TQO7W3VT8,55150-172-30,888-238-7880,
Sandoz Inc.,CLINDAMYCIN,"Decreased Sebaceous Gland Activity [PE], Neuromuscular Blockade [PE]",03/21/2023,Reverified,INTRAVENOUS,Clindamycin Phosphate Injection,"309335, 309336, 309339",,231d95a6-5e5f-4a45-a92b-d3d16ef0a7ca,09/24/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,CLINDAMYCIN IN 5 PERCENT DEXTROSE,"0781-3290, 0781-3288, 0781-3289",Sandoz Inc,e9ea55df-4c10-43a8-97f1-02e6fce12f2b,"0781-3288-91, 0781-3288-09, 0781-3289-91, 0781-3289-09, 0781-3290-91, 0781-3290-09","Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 0781-3290-09)",Injection,Available,"N0000009982, N0000175443, M0515779, N0000175731",ANDA201692,Lincosamides [CS],CLINDAMYCIN IN 5 PERCENT DEXTROSE,Lincosamide Antibacterial [EPC],,Current,,,,3U02EL437C,0781-3290-09,800-525-8747,
"Upsher-Smith Laboratories, LLC",DIVALPROEX SODIUM,,04/28/2025,New,ORAL,"Divalproex Sodium Tablet, Delayed Release","1099625, 1099678, 1099870",,02304a23-4a5f-47bc-9687-4044b43f7a20,04/28/2025,HUMAN PRESCRIPTION DRUG,04/28/2025,Neurology,DIVALPROEX SODIUM,"0832-7122, 0832-7123, 0832-7124","Upsher-Smith Laboratories, LLC",38e51a59-5802-77a6-e063-6394a90af6c6,"0832-7122-11, 0832-7122-15, 0832-7123-11, 0832-7123-15, 0832-7123-89, 0832-7123-01, 0832-7124-11, 0832-7124-15, 0832-7124-89, 0832-7124-01","Divalproex Sodium, Tablet, Delayed Release, 125 mg (NDC 0832-7122-15)",Tablet,,,ANDA078182,,DIVALPROEX SODIUM,,,To Be Discontinued,,Discontinuation of manufacture of drug based on business decision.,,644VL95AO6,0832-7122-15,800-654-2299,
"Hikma Pharmaceuticals USA, Inc.",FENTANYL CITRATE,,12/20/2023,Revised,"INTRAMUSCULAR, INTRAVENOUS",Fentanyl Citrate Injection,"1735003, 1735007, 1735008, 1735013, 2168270, 2474269, 2629337",,ce5db1c2-feb1-4ad2-847a-d02e865bd47e,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Pediatric",FENTANYL CITRATE,"0641-6027, 0641-6024, 0641-6025, 0641-6028, 0641-6026, 0641-6029, 0641-6030, 0641-6247, 0641-6248, 0641-6249",Hikma Pharmaceuticals USA Inc.,aca9742b-d890-426a-8296-14ca64748238,"0641-6024-01, 0641-6024-10, 0641-6027-01, 0641-6027-25, 0641-6025-01, 0641-6025-10, 0641-6028-01, 0641-6028-10, 0641-6028-25, 0641-6026-01, 0641-6026-05, 0641-6029-01, 0641-6029-25, 0641-6030-01, 0641-6247-01, 0641-6247-25, 0641-6248-01, 0641-6248-10, 0641-6249-01, 0641-6249-10","Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)",Injection,Available,,NDA019101,,FENTANYL CITRATE,,,Current,,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,MUN5LYG46H,0641-6027-25,800-631-2174,
"Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)",FONDAPARINUX SODIUM,,09/29/2025,New,SUBCUTANEOUS,Fondaparinux Sodium Injection,"861356, 861360, 861363, 861365",,baa50757-a927-4d56-a933-5d7798fe6ab0,09/29/2025,HUMAN PRESCRIPTION DRUG,09/29/2025,Hematology,FONDAPARINUX SODIUM,"0781-3454, 0781-3443, 0781-3465, 0781-3476",Sandoz Inc.,3d5a4b69-462b-7e51-e063-6294a90a0721,"0781-3443-94, 0781-3443-12, 0781-3443-95, 0781-3454-94, 0781-3454-12, 0781-3454-95, 0781-3465-94, 0781-3465-12, 0781-3465-95, 0781-3476-94, 0781-3476-12, 0781-3476-95","Fondaparinux Sodium, Injection, 5 mg/.4 mL (NDC 0781-3454-95)",Injection,,,ANDA206812,,FONDAPARINUX SODIUM,,,To Be Discontinued,,Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc.,,X0Q6N9USOZ,0781-3454-95,"609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)",
Strides Pharma Inc.,SERTRALINE HYDROCHLORIDE,,01/22/2025,New,ORAL,Sertraline Hydrochloride Tablet,"312938, 312940, 312941",,1f99e897-1b70-40b0-8c19-71d0bba19422,01/22/2025,HUMAN PRESCRIPTION DRUG,01/22/2025,Psychiatry,SERTRALINE HYDROCHLORIDE,"71093-131, 71093-129, 71093-130","ACI Healthcare USA, Inc.",3f41fc19-b54a-46fd-acbf-b411816bccd5,"71093-129-01, 71093-129-03, 71093-129-05, 71093-130-01, 71093-130-03, 71093-130-05, 71093-131-01, 71093-131-03, 71093-131-05","Sertraline Hydrochloride, Tablet, 100 mg (NDC 71093-131-05)",Tablet,,,ANDA076881,,SERTRALINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,UTI8907Y6X,71093-131-05,877-244-9825,
Sandoz Inc.,CLINDAMYCIN,"Decreased Sebaceous Gland Activity [PE], Neuromuscular Blockade [PE]",03/21/2023,Reverified,INTRAVENOUS,Clindamycin Phosphate Injection,"309335, 309336",,80217bd6-2bc4-401c-9345-22532b36a24f,09/24/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,CLINDAMYCIN IN 5 PERCENT DEXTROSE,"72572-074, 72572-076","Civica, Inc.",e40b6e7f-1d37-4d0a-ace3-e5accc461e02,"72572-074-01, 72572-074-24, 72572-076-01, 72572-076-24","Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 72572-074-24)",Injection,Available,"N0000009982, N0000175443, M0515779, N0000175731",ANDA201692,Lincosamides [CS],CLINDAMYCIN IN 5 PERCENT DEXTROSE,Lincosamide Antibacterial [EPC],,Current,,Civica Label,,3U02EL437C,72572-074-24,800-525-8747,
AstraZeneca AB,"DAPAGLIFLOZIN, SAXAGLIPTIN HYDROCHLORIDE",,03/03/2025,New,ORAL,Dapagliflozin; Saxaglipitin Hydrochloride Tablet,"1925498, 1925504, 2169274, 2169276",,423c489c-085b-4320-b892-7868ebd6dc6b,03/03/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,QTERN,"0310-6770, 0310-6780",AstraZeneca Pharmaceuticals LP,d675ddaa-3a40-4323-9edd-b04f13f10a03,"0310-6780-30, 0310-6780-95, 0310-6770-30, 0310-6770-95","Qtern, Tablet, 5 mg; 5 mg (NDC 0310-6770-30)",Tablet,,"N0000187059, N0000187058",NDA209091,,DAPAGLIFLOZIN AND SAXAGLIPTIN,Sodium-Glucose Cotransporter 2 Inhibitor [EPC],,To Be Discontinued,,,,"1ULL0QJ8UC, Z8J84YIX6L",0310-6770-30,800-236-9933,Sodium-Glucose Transporter 2 Inhibitors [MoA]
"Jiangsu Hengrui Pharmaceuticals Co., Ltd.",DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718900, 1718906, 1718909",,809e8f77-390f-4cc8-8c8a-4f67a249c9df,09/02/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE,"0781-3493, 0781-3494, 0781-3495",Sandoz Inc.,fdf227d9-008e-60f8-e053-6294a90af5c4,"0781-3493-95, 0781-3494-95, 0781-3495-95","Dexmedetomidine Hydrochloride, Injection, 80 mcg/20 mL  (NDC 0781-3493-95)",Injection,Available,,ANDA209065,,DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE,,,Current,,Marketed by Sandoz Inc.; Customer service: 800-525-8747,,1018WH7F9I,0781-3493-95,See Related Information section below for customer service information,
"Jiangsu Hengrui Pharmaceuticals Co., Ltd.",DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,309710,,eee6145b-d83f-4596-92d3-733934d8a3a4,09/02/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE,83634-600,Avenacy Inc.,3e30e931-4d42-465c-9e4b-cd3137ba5fe2,"83634-600-41, 83634-600-02","Dexmedetomidine Hydrochloride, Injection, 200 mcg/2 mL (NDC 83634-600-02)",Injection,Unavailable,,ANDA209065,,DEXMEDETOMIDINE,,,Current,Demand increase for the drug,Distributed by Avenacy; Contact information: 877-283-6229,,1018WH7F9I,83634-600-02,See Related Information section below for customer service information,
"Elite Laboratories, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,0e024b69-567c-4b40-9c3e-a2daec34256c,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"64850-550, 64850-551, 64850-552, 64850-553, 64850-554, 64850-555, 64850-556","Elite Laboratories, Inc.",e414bb2e-d404-44ea-931c-5998b0a4c87e,"64850-550-01, 64850-551-01, 64850-552-01, 64850-553-01, 64850-554-01, 64850-555-01, 64850-556-01","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 64850-550-01)",Capsule,Limited Availability,,ANDA218604,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,,,SJT761GEGS,64850-550-01,888-852-6657,
Eugia US LLC,DEXAMETHASONE SODIUM PHOSPHATE,,02/08/2019,Revised,"INTRA-ARTICULAR, INTRALESIONAL, INTRAMUSCULAR, INTRAVENOUS, SOFT TISSUE",Dexamethasone Sodium Phosphate Injection,"1116927, 1812194",,ce7ad5a4-a9c5-42d6-87cc-ca16556208d2,09/05/2025,HUMAN PRESCRIPTION DRUG,,"Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Other, Pulmonary/Allergy, Rheumatology",DEXAMETHASONE SODIUM PHOSPHATE,"55150-237, 55150-238, 55150-239",Eugia US LLC,34b1362a-f970-485f-bdac-3a02217157c9,"55150-237-01, 55150-238-05, 55150-239-30","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 55150-237-01)",Injection,Unavailable,,ANDA206781,,DEXAMETHASONE SODIUM PHOSPHATE,,,Current,Demand increase for the drug,On backorder. Recovery: TBD. Check wholesalers for inventory,,AI9376Y64P,55150-237-01,888-238-7880,
"Fresenius Kabi USA, LLC","EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE ANHYDROUS",,10/14/2016,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL","Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","1010033, 1010035, 1010671, 1010673, 1010688, 1010692, 1010745, 1010749, 1010751, 1010755, 1010759, 1010763, 1010900, 1010902, 1737343, 1737345, 1737562, 1737563, 1737566, 1737567, 1737568, 1737569, 1737570, 1737571, 1737757, 1737758, 1737761, 1737762, 1867938, 1867940, 1867943, 1867944, 1867992, 1867993, 1867996, 1867997, 1868028, 1868029",,ba082c2f-64f4-419d-9c88-74f203316e17,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",XYLOCAINE MPF,"63323-489, 63323-492, 63323-491, 63323-495, 63323-485, 63323-486, 63323-484, 63323-488, 63323-481, 63323-483, 63323-482, 63323-487","Fresenius Kabi USA, LLC",ea480a68-5927-4278-9deb-2956961da428,"63323-492-04, 63323-492-27, 63323-492-09, 63323-492-57, 63323-492-07, 63323-492-37, 63323-492-03, 63323-492-31, 63323-491-01, 63323-491-57, 63323-495-09, 63323-495-27, 63323-495-04, 63323-495-07, 63323-485-01, 63323-485-27, 63323-485-03, 63323-485-57, 63323-486-01, 63323-486-17, 63323-486-02, 63323-486-27, 63323-486-05, 63323-486-57, 63323-484-57, 63323-489-02, 63323-489-27, 63323-489-03, 63323-489-21, 63323-489-01, 63323-489-17, 63323-488-07, 63323-488-37, 63323-488-03, 63323-488-31, 63323-488-01, 63323-488-17, 63323-481-01, 63323-481-57, 63323-483-03, 63323-483-27, 63323-483-01, 63323-483-57, 63323-482-01, 63323-482-17, 63323-482-03, 63323-482-27, 63323-482-05, 63323-482-57, 63323-487-01, 63323-487-17, 63323-487-07, 63323-487-37, 63323-487-03, 63323-487-31","Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-17)",Injection,Available,,NDA006488,,"LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE",,,Current,,Check wholesalers for inventory,,"EC2CNF7XFP, 30Q7KI53AK",63323-489-17,888-386-1300,
"Mylan Pharmaceuticals Inc., a Viatris Company",,,02/06/2025,New,,Varenicline Tartrate Tablet,"636671, 636676, 749289",,4233fb78-ac6c-49f3-aad8-7e4bee18cac6,02/06/2025,HUMAN PRESCRIPTION DRUG,02/06/2025,Analgesia/Addiction,VARENICLINE,"0378-5091, 0378-5089, 0378-5090",Mylan Pharmaceuticals Inc.,5b7b6e3b-f427-4000-b252-968f3adbaa3b,"0378-5089-73, 0378-5090-73, 0378-5091-85, 0378-5089-46, 0378-5090-23","Varenicline Tartrate, Tablet, 0.5mg/1mg  (NDC 0378-5091-85)",Tablet,,,ANDA202019,,VARENICLINE,,,To Be Discontinued,,Permanent discontinuation in the manufacturing of the drug,,82269ASB48,0378-5091-85,800-796-9526,
"Teva Pharmaceuticals USA, Inc.",CARBAMAZEPINE,Decreased Central Nervous System Disorganized Electrical Activity [PE],06/10/2025,New,ORAL,Carbamazepine Tablet,"308973, 308979",,bfd63965-56e6-4af7-b7ef-45a5105d4d35,06/10/2025,HUMAN PRESCRIPTION DRUG,06/10/2025,Neurology,CARBAMAZEPINE,"0093-0109, 0093-0778","Teva Pharmaceuticals USA, Inc.",042aa2c6-95ff-410a-abcf-a8ee79fa96d8,"0093-0109-01, 0093-0109-10, 0093-0778-01","Epitol, Tablet, 200 mg (NDC 0093-0109-10)",Tablet,,"N0000008486, N0000175751, N0000185506, N0000191266, N0000187064, N0000185507, N0000185607",ANDA070541,,CARBAMAZEPINE,Mood Stabilizer [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,33CM23913M,0093-0109-10,800-545-8800,"Cytochrome P450 3A4 Inducers [MoA], Cytochrome P450 1A2 Inducers [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA]"
Baxter Healthcare,DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795477, 1795480, 1795481, 1795607, 1795609, 1795610, 1795612, 1795616, 1795618",,3bb406a9-f5cb-403a-b1bb-5c4facbea3d5,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0338-0017, 0338-0023",Baxter Healthcare Corporation,31bb4a5f-733e-4354-9fbf-138dede4db0f,"0338-0017-10, 0338-0017-41, 0338-0017-11, 0338-0017-31, 0338-0017-48, 0338-0017-18, 0338-0017-38, 0338-0017-02, 0338-0017-03, 0338-0017-04, 0338-0023-02, 0338-0023-03, 0338-0023-04","Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-31)",Injection,Available,,NDA016673,,DEXTROSE MONOHYDRATE,,,Current,,,,LX22YL083G,0338-0017-31,888-229-0001,
"Fresenius Kabi USA, LLC","BUPIVACAINE HYDROCHLORIDE, EPINEPHRINE BITARTRATE",,02/20/2018,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL","Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","1672917, 1672919, 1673296, 1673298, 1724880, 1724881, 1724884, 1724885, 1725078, 1725082, 1725175, 1725177, 1012391, 1012396, 1012404, 1012421, 1012455, 1012457",,"dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175, eb6d8fee-def4-4c96-9972-695e8cea8ea8",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,SENSORCAINE MPF,"63323-462, 63323-464, 63323-466, 63323-465, 63323-467, 63323-460","Fresenius Kabi USA, LLC","13a48007-3784-46f2-bd4d-da1004186b81, 2b1a1f80-cb29-4ac1-9e72-20225ed45715","63323-462-03, 63323-462-38, 63323-464-09, 63323-464-39, 63323-466-09, 63323-466-39, 63323-465-01, 63323-465-57, 63323-467-01, 63323-467-57, 63323-460-01, 63323-460-37, 63323-464-02, 63323-464-37, 63323-464-03, 63323-464-31, 63323-466-01, 63323-466-37, 63323-466-02, 63323-466-31, 63323-462-04, 63323-462-17, 63323-462-01, 63323-462-37, 63323-462-02, 63323-462-31","Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31)",Injection,Unavailable,,NDA018304,,BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE,,,Current,Delay in shipping of the drug,Not available at this time.,,"30Q7KI53AK, 7TQO7W3VT8",63323-462-31,888-386-1300,
GlaxoSmithKline,DAPRODUSTAT,,11/21/2024,New,ORAL,Daprodustat Tablet,"2628215, 2628221, 2628223, 2628225, 2628227, 2628229, 2628231, 2628233, 2628235, 2628237",,d82aa06e-5a33-4844-99b7-4701313455a4,11/21/2024,HUMAN PRESCRIPTION DRUG,11/21/2024,Hematology,JESDUVROQ,"0173-0914, 0173-0897, 0173-0903, 0173-0906, 0173-0911",GlaxoSmithKline LLC,d52a823a-35bd-4c6a-a016-4b4f21a43d7d,"0173-0897-13, 0173-0897-56, 0173-0903-13, 0173-0903-56, 0173-0906-13, 0173-0906-56, 0173-0911-13, 0173-0911-56, 0173-0914-13, 0173-0914-56","Jesduvroq, Tablet, 8 mg (NDC 0173-0914-13)",Tablet,,"N0000194080, N0000194079",NDA216951,,DAPRODUSTAT,Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC],,To Be Discontinued,,Discontinuing for Business Reasons.,,JVR38ZM64B,0173-0914-13,888-825-5249,Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors [MoA]
"Teva Pharmaceuticals USA, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Revised,ORAL,Lisdexamfetamine Dimesylate Capsule,,,c32b5dce-2de4-4db0-a4ba-d2ce3b0a32fc,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0480-3569, 0480-3565, 0480-3566, 0480-3567, 0480-3568, 0480-3570, 0480-3564","Teva Pharmaceuticals, Inc.",6cfe6c98-51b1-45a4-831c-33624ab129cb,"0480-3565-01, 0480-3566-01, 0480-3567-01, 0480-3568-01, 0480-3569-01, 0480-3570-01, 0480-3564-01","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0480-3569-01)",Capsule,Limited Availability,,ANDA202802,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Other,Limited Availability,,SJT761GEGS,0480-3569-01,800-545-8800,
Oryza Pharmaceuticals Inc.,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 1009145",,acd27181-a3f3-4c38-85d8-029a4a82e7c2,09/16/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","72516-013, 72516-016, 72516-015, 72516-014, 72516-012, 72516-011",Oryza Pharmaceuticals Inc.,39fb17a2-617d-37dc-e063-6394a90a1be3,"72516-016-01, 72516-015-01, 72516-014-01, 72516-013-01, 72516-012-01, 72516-011-01","Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 72516-013-01)",Tablet,Unavailable,,ANDA210293,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,Shortage of an active ingredient,Estimated availability October 2025,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",72516-013-01,855-257-0292,
"Upsher-Smith Laboratories, LLC",MIDODRINE HYDROCHLORIDE,,04/28/2025,New,ORAL,Midodrine Hydrochloride Tablet,"993462, 993466, 993470",,4c3517f3-1c68-4ade-b5f1-c488a3a335c1,04/28/2025,HUMAN PRESCRIPTION DRUG,04/28/2025,Cardiovascular,MIDODRINE HYDROCHLORIDE,"0245-0212, 0245-0211, 0245-0213","Upsher-Smith laboratories, LLC",18b0b9f5-6026-479e-af12-92b0e71a9d6b,"0245-0211-11, 0245-0211-89, 0245-0211-01, 0245-0212-11, 0245-0212-89, 0245-0212-01, 0245-0213-11, 0245-0213-89, 0245-0213-01","Orvaten, Tablet, 5 mg (NDC 0245-0212-01)",Tablet,,,ANDA076725,,MIDODRINE HYDROCHLORIDE,,,To Be Discontinued,,,,59JV96YTXV,0245-0212-01,800-654-2299,
Swedish Orphan Biovitrum AB,PALIVIZUMAB,,08/13/2025,New,INTRAMUSCULAR,Palivizumab Injection,"1657341, 1657343, 1657361, 1657362",,3a0096c7-8139-44cd-bba4-520ab05c2cb2,08/13/2025,HUMAN PRESCRIPTION DRUG,08/13/2025,Antiviral,SYNAGIS,"66658-230, 66658-231",Swedish Orphan Biovitrum AB (publ),825a4b3c-e419-457c-8862-fd7b74a171ed,"66658-231-01, 66658-230-01","Synagis, Injection, 50 mg/.5 mL (NDC 66658-230-01)",Injection,,"M0001357, N0000175615, N0000175623",BLA103770,"Antibodies, Monoclonal [CS]",PALIVIZUMAB,Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,DQ448MW7KS,66658-230-01,866-773-5274,Fusion Protein Inhibitors [MoA]
"Solco Healthcare US, LLC",QUINAPRIL HYDROCHLORIDE,,01/19/2023,Reverified,ORAL,Quinapril Hydrochloride Tablet,"312748, 312749, 312750, 314203",,cd46691d-5593-4a9f-a937-999c6803e312,09/17/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,QUINAPRIL,"43547-413, 43547-410, 43547-411, 43547-412","Solco Healthcare US, LLC",b8f1731a-cbac-4f64-a8d4-320b80b335e1,"43547-410-09, 43547-411-09, 43547-412-09, 43547-413-09","Quinapril Hydrochloride, Tablet, 40 mg (NDC 43547-413-09)",Tablet,Unavailable,,ANDA205823,,QUINAPRIL,,,Current,Shortage of an active ingredient,Not available. Long-term backorder for all NDCs. No estimated release date at this time.,,33067B3N2M,43547-413-09,866-931-9829,
"Fresenius Kabi USA, LLC",ROCURONIUM BROMIDE,,02/15/2023,Reverified,INTRAVENOUS,Rocuronium Bromide Injection,1234995,,"f1933332-1ae0-4dc1-be4c-694849e6c9f9, fb9524b2-c353-4747-8954-7ca2529eabb2",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROCURONIUM,63323-426,"Fresenius Kabi USA, LLC","d6e2ff8d-838d-4c27-8e73-230548b09d63, 3f4d5e11-2c14-4406-8954-04dba2fc65ff","63323-426-02, 63323-426-05, 63323-426-01, 63323-426-10, 63323-426-12, 63323-426-15","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)",Injection,Available,,ANDA078651,,ROCURONIUM BROMIDE,,,Current,,Check wholesalers for inventory,,I65MW4OFHZ,63323-426-05,888-386-1300,
"Teva Pharmaceuticals USA, Inc.",DOXYCYCLINE HYCLATE,,05/02/2025,New,ORAL,Doxycycline Hyclate Tablet,1650143,,a569ba80-ffea-40b2-9fbe-a42810b1fccb,05/02/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,DOXYCYCLINE HYCLATE,0591-5553,"Actavis Pharma, Inc.",0fb9a3f8-9ebb-4c21-8a73-9f082b39039c,"0591-5553-50, 0591-5553-05","Doxycycline Hyclate, Tablet, 100 mg (NDC 0591-5553-05)",Tablet,,,ANDA062421,,DOXYCYCLINE HYCLATE,,,To Be Discontinued,,,,19XTS3T51U,0591-5553-05,800-545-8800,
"Mylan Institutional, a Viatris Company",LEUCOVORIN CALCIUM,,01/01/2012,Revised,"INTRAMUSCULAR, INTRAVENOUS",Leucovorin Calcium Injection,"237788, 1803932, 1803937",,1cb701ca-2478-4268-9d69-80293965d59d,07/08/2025,HUMAN PRESCRIPTION DRUG,,"Oncology, Pediatric",LEUCOVORIN CALCIUM,"67457-528, 67457-529, 67457-530",Mylan Institutional LLC,2890b03c-dbef-4db8-8b07-c042d7765677,"67457-528-10, 67457-529-20, 67457-530-35","Leucovorin Calcium Preservative Free, Injection, 100 mg/10 mL (NDC 67457-528-10)",Injection,,,ANDA203800,,LEUCOVORIN CALCIUM,,Available,Resolved,,,07/08/2025,RPR1R4C0P4,67457-528-10,800-796-9526,
"Hospira, Inc., a Pfizer Company",MIDAZOLAM HYDROCHLORIDE,,04/02/2020,Revised,"INTRAMUSCULAR, INTRAVENOUS",Midazolam Hydrochloride Injection,"1666800, 1666814, 1666823, 1666798",,"b95415fa-17c2-42ab-a6b0-e628d01c94ed, 1abda8b8-48a8-4995-af86-39220d1aa240",08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology",MIDAZOLAM,"0409-2305, 0409-2308, 0409-0001","Hospira, Inc.","b303a281-6633-47d5-bf29-5e9055e26da6, 8c3cf34b-901d-407a-946d-a1556bb24551","0409-2305-55, 0409-2305-50, 0409-2308-69, 0409-2308-49, 0409-2308-70, 0409-2308-50, 0409-2305-16, 0409-2305-17, 0409-2305-04, 0409-2305-05, 0409-2308-21, 0409-2308-01, 0409-2308-22, 0409-2308-02, 0409-0001-01, 0409-0001-25","Midazolam Hydrochloride Preservative Free, Injection, 5 mg/5 mL (1 mg/mL) (NDC 0409-2305-05)",Injection,Limited Availability,,ANDA075857,,MIDAZOLAM HYDROCHLORIDE,,,Current,Demand increase for the drug,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,W7TTW573JJ,0409-2305-05,844-646-4398,
"Upsher-Smith Laboratories, LLC",POTASSIUM CHLORIDE,,07/23/2025,New,ORAL,"Potassium Chloride Tablet, Extended Release","312529, 628953, 628958, 832718",,1ff53330-065c-4213-9c0c-ac498621d09d,07/23/2025,HUMAN PRESCRIPTION DRUG,07/23/2025,"Endocrinology/Metabolism, Gastroenterology",KLOR-CON,"0245-5315, 0245-5316","Upsher-Smith Laboratories, LLC",39e77e07-bdc8-28e9-e063-6394a90a120c,"0245-5315-11, 0245-5315-15, 0245-5315-89, 0245-5315-01, 0245-5316-11, 0245-5316-15, 0245-5316-89, 0245-5316-01","Klor-Con, Tablet, Extended Release, 600 mg (NDC 0245-5315-01)",Tablet,,,NDA019123,,POTASSIUM CHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug product,,660YQ98I10,0245-5315-01,763-315-2000,
"Par Pharmaceutical, Inc.",,,10/15/2024,New,,Candesartan Cilexetil Tablet,,,,10/15/2024,,10/15/2024,Cardiovascular,,,,,,"Atacand, Tablet, 32 mg (NDC 49884-661-09)",Tablet,,,,,,,,To Be Discontinued,,,,,49884-661-09,800-828-9393,
"Avet Pharmaceuticals, Inc.",DESIPRAMINE HYDROCHLORIDE,,08/12/2025,New,ORAL,Desipramine Hydrochloride Tablet,"1099288, 1099292, 1099296, 1099300, 1099304, 1099316",,ee14dd2c-c54b-4cd1-a3a0-f7ad5a5a0ed0,08/12/2025,HUMAN PRESCRIPTION DRUG,08/12/2025,Psychiatry,DESIPRAMINE HYDROCHLORIDE,"23155-581, 23155-578, 23155-579, 23155-580, 23155-582, 23155-583",Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.,49984729-ddde-44ed-927b-8a4ba65cefa0,"23155-578-01, 23155-579-01, 23155-580-01, 23155-581-01, 23155-582-01, 23155-583-25","Desipramine Hydrochloride, Tablet, 75 mg (NDC 23155-581-01)",Tablet,,,ANDA207433,,DESIPRAMINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,1Y58DO4MY1,23155-581-01,855-228-9470,
Pfizer Inc.,ETHIONAMIDE,,07/16/2025,New,ORAL,Ethionamide Tablet,"197681, 835721",,04a413fe-95f4-47a7-42ac-283a9e78297d,07/16/2025,HUMAN PRESCRIPTION DRUG,07/16/2025,Anti-Infective,TRECATOR,0008-4117,"Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.",24a0b78d-6cf2-4539-a3de-b3b077383da0,0008-4117-01,"Trecator, Tablet, 250 mg (NDC 0008-4117-01)",Tablet,,N0000175483,NDA013026,,ETHIONAMIDE,Antimycobacterial [EPC],,To Be Discontinued,,"Discontinuation of the manufacture of the drug.
Supply expected to exhaust September 2025",,OAY8ORS3CQ,0008-4117-01,844-646-4398,
"Fresenius Kabi USA, LLC",HYDROMORPHONE HYDROCHLORIDE,,10/31/2017,Reverified,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Hydromorphone Hydrochloride Injection,"897653, 897753, 1724276, 1724338, 1724340, 1724341",,e034eb96-03e0-46e1-8b92-5e1f94555e7b,09/18/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,HYDROMORPHONE HYDROCHLORIDE,"63323-853, 63323-851, 63323-852, 63323-854","Fresenius Kabi USA, LLC",9e8522c6-595c-46f9-bb25-272aa4683e0f,"63323-851-03, 63323-851-10, 63323-851-07, 63323-851-15, 63323-851-50, 63323-852-03, 63323-852-25, 63323-853-03, 63323-853-25, 63323-854-03, 63323-854-10","Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)",Injection,Unavailable,,NDA019034,,HYDROMORPHONE HYDROCHLORIDE,,,Current,Other,Backordered. Next release not available at this time. Check wholesalers for inventory.,,L960UP2KRW,63323-853-25,888-386-1300,
"Fresenius Kabi USA, LLC",MORPHINE SULFATE,,10/31/2017,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Morphine Sulfate Injection,"1731993, 1732006, 1732011, 1732136, 2003714",,582f42e5-444e-4246-af8c-e7e28097c69a,09/18/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,MORPHINE SULFATE,"63323-455, 63323-452, 63323-454, 63323-458, 63323-451","Fresenius Kabi USA, LLC",dbf870e7-7bfe-48f0-ba6a-9cc476dfe5cc,"63323-452-00, 63323-452-01, 63323-454-00, 63323-454-01, 63323-455-00, 63323-455-01, 63323-458-00, 63323-458-01, 63323-451-00, 63323-451-01","Morphine Sulfate, Injection, 5 mg/1 mL (NDC 63323-455-01)",Injection,Unavailable,,NDA204223,,MORPHINE SULFATE,,,Current,Demand increase for the drug,Not available at this time.,,X3P646A2J0,63323-455-01,888-386-1300,
"Hikma Pharmaceuticals USA, Inc.",MORPHINE SULFATE,,11/03/2017,Reverified,INTRAVENOUS,Morphine Sulfate Injection,"1731993, 1732006, 1732011",,6023606c-150c-40c5-9175-598efe2a56c3,07/23/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,MORPHINE SULFATE,"0641-6125, 0641-6126, 0641-6127",Hikma Pharmaceuticals USA Inc.,fa18221d-2353-4cf6-a210-fb33ee79d3d9,"0641-6126-01, 0641-6126-25, 0641-6127-01, 0641-6127-25, 0641-6125-01, 0641-6125-25","Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0641-6125-25)",Injection,Available,,ANDA205758,,MORPHINE SULFATE,,,Current,,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,X3P646A2J0,0641-6125-25,800-631-2174,
Accord Healthcare Inc.,CARBOPLATIN,,04/28/2023,Revised,INTRAVENOUS,Carboplatin Injection,597195,,48aa7ef3-9f44-2a08-e054-00144ff88e88,09/16/2025,HUMAN PRESCRIPTION DRUG,,Oncology,CARBOPLATIN,16729-295,"Accord Healthcare, Inc.",35cf6068-f31a-211b-e063-6294a90a6b53,"16729-295-31, 16729-295-33, 16729-295-34, 16729-295-12, 16729-295-38","Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12)",Injection,Available,"N0000175413, N0000175073",ANDA206775,,CARBOPLATIN,Platinum-based Drug [EPC],,Current,,,,BG3F62OND5,16729-295-12,"866-941-7875, option 2",
B. Braun Medical Inc.,"ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, PROLINE, SERINE, THREONINE, TRYPTOPHAN, TYROSINE, VALINE",,12/08/2020,Revised,INTRAVENOUS,Amino Acid Injection,"800584, 1601982",,a3244d1a-45b0-4e4c-bd96-f0632d761a1f,09/16/2025,HUMAN PRESCRIPTION DRUG,,Gastroenterology,PLENAMINE,0264-4500,B. Braun Medical Inc.,e55957d3-67af-4b6d-9232-55b654e0076f,"0264-4500-00, 0264-4500-05","Plenamine, Injection, 0.15 (NDC 0264-4500-05)",Injection,Available,"N0000175780, M0000922",ANDA091112,Amino Acids [CS],"LYSINE ACETATE, LEUCINE, PHENYLALANINE, VALINE, ISOLEUCINE, METHIONINE, THREONINE, TRYPTOPHAN, ALANINE, ARGININE, GLYCINE, HISTIDINE, PROLINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID, AND TYROSINE",Amino Acid [EPC],,Current,,,,"OF5P57N2ZX, 94ZLA3W45F, 30KYC7MIAI, 3KX376GY7L, TE7660XO1C, 4QD397987E, 04Y7590D77, GMW67QNF9C, TTL6G7LIWZ, AE28F7PNPL, 47E5O17Y3R, 9DLQ4CIU6V, 452VLY9402, 2ZD004190S, 8DUH1N11BX, 42HK56048U, HG18B9YRS7",0264-4500-05,800-227-2862,
Otsuka ICU Medical LLC,DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795477, 1795480, 1795481, 1795607, 1795609, 1795610, 1795612, 1795616, 1795618, 1795621",,8b25b7e0-703e-4b43-a4eb-52863511602d,09/17/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0990-7922, 0990-7923, 0990-7930","ICU Medical, Inc.",09b10612-c937-4d10-becb-9768e10caa2c,"0990-7923-20, 0990-7923-23, 0990-7923-36, 0990-7923-37, 0990-7923-13, 0990-7922-02, 0990-7922-03, 0990-7922-09, 0990-7922-53, 0990-7922-55, 0990-7922-61, 0990-7930-02, 0990-7930-03, 0990-7930-09","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-02)",Injection,Available,,NDA016367,,DEXTROSE MONOHYDRATE,,,Current,,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,LX22YL083G,0990-7922-02,1-866-829-9025 or ProductAvailability@icumed.com,
Gland Pharma Limited,FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Furosemide Injection,"1719286, 1719290, 1719291",,d63c1277-dd7e-4d21-9e80-68143f55e2dc,09/29/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,25021-311,Sagent Pharmaceuticals,222ce48f-2856-4be2-b16f-6fca38c0dceb,"25021-311-02, 25021-311-04, 25021-311-10","Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)",Injection,Available,"N0000175366, N0000175590",ANDA213902,,FUROSEMIDE,Loop Diuretic [EPC],,Current,Other,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,7LXU5N7ZO5,25021-311-10,866-625-1918,
Strides Pharma Inc.,DONEPEZIL HYDROCHLORIDE,,01/28/2025,New,ORAL,Donepezil Hydrochloride Tablet,"997223, 997229",,297e86e8-d248-4cc9-9d9c-2ef9efb4414d,01/28/2025,HUMAN PRESCRIPTION DRUG,01/28/2025,Neurology,DONEPEZIL HYDROCHLORIDE,"71093-127, 71093-128","ACI Healthcare USA, Inc.",a4736add-da84-411f-8e6f-9de67bf467f8,"71093-127-01, 71093-127-03, 71093-127-05, 71093-127-06, 71093-128-01, 71093-128-03, 71093-128-05, 71093-128-06","Donepezil Hydrochloride, Tablet, 5 mg (NDC 71093-127-05)",Tablet,,,ANDA078662,,DONEPEZIL HYDROCHLORIDE,,,To Be Discontinued,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,3O2T2PJ89D,71093-127-05,877-244-9825,
"Vertical Pharmaceuticals, LLC",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Reverified,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release",,,22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d,09/16/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,RELEXXII,"68025-097, 68025-088, 68025-089, 68025-095, 68025-096, 68025-084, 68025-098","Vertical Pharmaceuticals, LLC",86f477e9-07fc-466b-913e-1a4434c91df4,"68025-088-30, 68025-089-30, 68025-095-10, 68025-095-30, 68025-096-10, 68025-096-30, 68025-097-10, 68025-097-30, 68025-084-30, 68025-098-10, 68025-098-30","Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-10)",Tablet,Unavailable,,NDA216117,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,Other,Estimated recovery: TBD,,4B3SC438HI,68025-097-10,800-541-4802,
Pfizer Inc.,METHYLPREDNISOLONE ACETATE,,12/15/2021,Revised,"INTRA-ARTICULAR, INTRALESIONAL, INTRAMUSCULAR, SOFT TISSUE",Methylprednisolone Acetate Injection,"1743779, 1743781, 1743855, 1743856",,9a7b3837-e038-48bf-97e9-78ad463760dc,08/15/2025,HUMAN PRESCRIPTION DRUG,,Rheumatology,DEPO-MEDROL,"0009-3475, 0009-3073",Pharmacia & Upjohn Company LLC,befd723e-d1e2-41b9-83f1-17bca0c2a941,"0009-3073-01, 0009-3073-03, 0009-3475-01, 0009-3475-03","Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-03)",Injection,Unavailable,,NDA011757,,METHYLPREDNISOLONE ACETATE,,,Current,Demand increase for the drug,Next Delivery: September 2025; Estimated Recovery: June 2026,,43502P7F0P,0009-3475-03,844-646-4398,
"Fresenius Kabi USA, LLC",SODIUM CHLORIDE,,06/21/2018,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Sodium Chloride 0.9% Injection,"1807632, 1807636, 1807637, 1807638",,"f2a98378-9678-4738-9670-fc7a215c0606, f62481fd-fcdb-4be6-ac13-29c590e925c3",08/08/2025,HUMAN PRESCRIPTION DRUG,,Other,SODIUM CHLORIDE,63323-186,"Fresenius Kabi USA, LLC","debc17b5-4d24-473c-8396-e409433ce57c, 75c567e3-582b-4fff-9a72-f326f1d13c8f","63323-186-00, 63323-186-04, 63323-186-02, 63323-186-01, 63323-186-10, 63323-186-03, 63323-186-20","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-186-02)",Injection,,,ANDA088912,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,63323-186-02,888-386-1300,
B. Braun Medical Inc.,METRONIDAZOLE,,01/13/2022,Reverified,INTRAVENOUS,Metronidazole Injection,311683,,fd191c06-9d3b-4e46-9f79-90f6af614947,09/16/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,METRONIDAZOLE,0264-5535,B. Braun Medical Inc.,ff10d27d-6a3a-45db-ae74-72ba2f442dd6,0264-5535-32,"Metro I.v. In Plastic Container, Injection, 500 mg/100 mL (NDC 0264-5535-32)",Injection,Limited Availability,"N0000175435, M0014907",NDA018900,Nitroimidazoles [CS],METRONIDAZOLE,Nitroimidazole Antimicrobial [EPC],,Current,Discontinuation of the manufacture of the drug,Temporary discontinuation of the manufacture of the drug. Some lots are available through exhaustion of inventory,,140QMO216E,0264-5535-32,800-227-2862,
B. Braun Medical Inc.,"CALCIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, SODIUM LACTATE",,10/11/2024,Reverified,INTRAVENOUS,Lactated Ringers Injection,847630,,"d3d29c8f-c326-4097-814a-7f4e08c67068, f6d82772-638c-4584-b9d3-8833669f5963",09/16/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other",LACTATED RINGERS,0264-7750,B. Braun Medical Inc.,"f67c6808-1eeb-4299-a0b7-694863bcad5a, ed789cd7-83ae-4ec1-a696-e87c1569da49","0264-7750-00, 0264-7750-10, 0264-7750-20, 0264-7750-07","Lactated Ringers, Injection, .02 g/100 mL; .03 g/100 mL; .6 g/100 mL; .31 g/100 mL (NDC 0264-7750-00)",Injection,Available,,NDA019632,,"SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, AND CALCIUM CHLORIDE",,,Current,,,,"M4I0D6VV5M, 660YQ98I10, 451W47IQ8X, TU7HW0W0QT",0264-7750-00,800-227-2862,
"Hospira, Inc., a Pfizer Company",ATROPINE SULFATE,,02/19/2025,New,INTRAVENOUS,Atropine Sulfate Injection,"1190546, 1190551, 1190552",,ad8916e7-206e-409e-2582-30d072845dd4,02/19/2025,HUMAN PRESCRIPTION DRUG,02/19/2025,"Anesthesia, Neurology, Pediatric",ATROPINE SULFATE,"0409-4910, 0409-1630, 0409-9630, 0409-4911","Hospira, Inc.",9211a9e9-35d0-457d-ac95-4ad43ea6bf28,"0409-1630-15, 0409-1630-10, 0409-9630-15, 0409-9630-05, 0409-4910-11, 0409-4910-34, 0409-4911-11, 0409-4911-34","Atropine Sulfate, Injection, .1 mg/1 mL (NDC 0409-4910-34)",Injection,,,NDA021146,,ATROPINE SULFATE,,,To Be Discontinued,,,,03J5ZE7KA5,0409-4910-34,844-646-4398,
Torrent Pharma Inc.,,,06/13/2025,New,,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,,,,06/13/2025,,06/13/2025,Cardiovascular,,,,,,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 12.5 mg; 40 mg (NDC 13668-383-30)",Tablet,,,,,,,,To Be Discontinued,,A business decision was made to discontinue manufacture of the product.,,,13668-383-30,908-280-3333,
"Fresenius Kabi USA, LLC",HYDROMORPHONE HYDROCHLORIDE,,11/01/2017,Reverified,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Hydromorphone Hydrochloride Injection,"897756, 897757, 1433251, 1872265, 1872269, 1872752, 2277368, 2277370",,9eebd88a-5632-460f-b7b6-26c8a180540d,09/18/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,DILAUDID,"76045-010, 76045-009, 76045-121","Fresenius Kabi USA, LLC",97bfcafb-2037-47dc-a0ae-f7b8007c47df,"76045-009-96, 76045-009-06, 76045-009-01, 76045-009-11, 76045-010-01, 76045-010-11, 76045-121-01, 76045-121-11","Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11)",Injection,Available,,NDA019034,,HYDROMORPHONE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,L960UP2KRW,76045-010-11,888-386-1300,
"Hospira, Inc., a Pfizer Company",HYDROCORTISONE SODIUM SUCCINATE,,03/24/2023,Revised,"INTRAMUSCULAR, INTRAVENOUS",Hydrocortisone Sodium Succinate Injection,"105398, 238755, 1738586, 1738589, 1738590, 1738592, 1738594, 1738596",,65eefd58-b166-4d71-ade6-45c8fdf86922,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Pulmonary/Allergy, Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Pediatric, Renal, Rheumatology",SOLU-CORTEF,"0009-0016, 0009-0825, 0009-0011, 0009-0013, 0009-0005",Pharmacia & Upjohn Company LLC,8512044a-4a54-4634-bb97-9e20126adc61,"0009-0825-01, 0009-0011-03, 0009-0011-04, 0009-0013-05, 0009-0013-06, 0009-0016-12, 0009-0005-01","Solu-cortef, Injection, 500 mg/vial (NDC 0009-0016-12)",Injection,Limited Availability,,NDA009866,,HYDROCORTISONE SODIUM SUCCINATE,,,Current,Other,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,50LQB69S1Z,0009-0016-12,844-646-4398,
Slate Run Pharmaceuticals,LEUCOVORIN CALCIUM,,01/01/2012,Revised,"INTRAMUSCULAR, INTRAVENOUS",Leucovorin Calcium Injection,"237788, 1803930, 1803932, 1803937, 2055036",,d8bdd60c-9a1c-4ef4-ba6b-b911849128f1,07/08/2025,HUMAN PRESCRIPTION DRUG,,"Oncology, Pediatric",LEUCOVORIN CALCIUM,"70436-120, 70436-116, 70436-117, 70436-118, 70436-119","Slate Run Pharmaceuticals, LLC",2a4aaed3-885e-bc10-e063-6294a90a61af,"70436-116-80, 70436-116-82, 70436-117-80, 70436-118-80, 70436-120-80, 70436-119-80","Leucovorin Calcium, Injection, 500 mg (NDC 70436-120-80)",Injection,,,ANDA217021,,LEUCOVORIN CALCIUM,,Available,Resolved,,,07/08/2025,RPR1R4C0P4,70436-120-80,888-447-0095,
Otsuka ICU Medical LLC,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807548, 1807549, 1807550, 1807551, 1807552, 1807627, 1807630, 1807631, 1807632, 1807633, 1807634, 1807639",,5f372b75-d7a4-471e-8ac6-290040fc84b0,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0990-7984, 0990-7730, 0990-7983, 0990-7985",ICU Medical Inc.,87c57bfa-0bf7-41fd-b954-eb753d5d9d7f,"0990-7730-36, 0990-7730-37, 0990-7983-61, 0990-7983-02, 0990-7983-03, 0990-7983-09, 0990-7983-55, 0990-7983-53, 0990-7984-37, 0990-7984-20, 0990-7984-13, 0990-7984-23, 0990-7984-36, 0990-7985-02, 0990-7985-03, 0990-7985-09","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-23)",Injection,,,NDA016366,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0990-7984-23,1-866-829-9025 or ProductAvailability@icumed.com,
Alvogen,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,c907301d-e24d-9609-5529-fed14f94549f,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII","47781-174, 47781-175, 47781-176, 47781-177, 47781-178, 47781-179, 47781-180",Alvogen Inc.,0374f0f7-9297-810c-38b3-623a72709a7d,"47781-174-30, 47781-174-05, 47781-174-01, 47781-175-30, 47781-175-05, 47781-175-01, 47781-176-30, 47781-176-05, 47781-176-01, 47781-177-30, 47781-177-05, 47781-177-01, 47781-178-30, 47781-178-05, 47781-178-01, 47781-179-30, 47781-179-05, 47781-179-01, 47781-180-30, 47781-180-05, 47781-180-01","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 47781-174-01)",Tablet,Available,,ANDA207388,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 5 MG,CLL",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",47781-174-01,844-842-8672 and email: CustomerService-US@alvogen.com,
"Hospira, Inc., a Pfizer Company",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,SUBARACHNOID,Bupivacaine Hydrochloride Injection,"1724784, 1724792",,9679cc05-2f8a-4e88-53b5-6e9122c8b8c0,08/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,MARCAINE SPINAL,0409-1761,"Hospira, Inc.",f3862f77-3621-4730-923e-9efbfa18e03f,"0409-1761-19, 0409-1761-02, 0409-1761-18, 0409-1761-62, 0409-1761-05, 0409-1761-10","Marcaine, Injection, 0.75% 15 mg/2 mL (NDC 0409-1761-62)",Injection,Available,,NDA018692,,BUPIVACAINE HYDROCHLORIDE IN DEXTROSE,,,Current,,,,7TQO7W3VT8,0409-1761-62,844-646-4398,
"Sun Pharmaceutical Industries, Inc.",NALTREXONE HYDROCHLORIDE,,02/29/2024,Revised,ORAL,Naltrexone Hydrochloride Tablet,1483744,,0f30f885-d0cd-4fa6-a8e0-142f08a56792,09/22/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,NALTREXONE HYDROCHLORIDE,47335-326,"Sun Pharmaceutical Industries, Inc.",b0c2b60a-dc96-483b-933e-2fed58b64372,"47335-326-83, 47335-326-88, 47335-326-08, 47335-326-18","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 47335-326-18)",Tablet,Unavailable,,ANDA090356,,NALTREXONE HYDROCHLORIDE,,,Current,Other,Currently not marketed,,Z6375YW9SF,47335-326-18,800-818-4555,
Alvogen,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,7f2dd6ee-3363-c87c-9693-ed838942556c,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"47781-563, 47781-562, 47781-564, 47781-565, 47781-566, 47781-567, 47781-568",Alvogen Inc.,9114d946-92cb-c19d-c6f2-aef77294461f,"47781-562-01, 47781-563-01, 47781-564-01, 47781-565-01, 47781-566-01, 47781-567-01, 47781-568-01","Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 47781-563-01)",Capsule,Available,,ANDA214547,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,47781-563-01,844-842-8672 and email: CustomerService-US@alvogen.com,
Sun Pharmaceutical Industries Limited,TIAGABINE HYDROCHLORIDE,,12/09/2024,New,ORAL,Tiagabine Hydrochloride Tablet,"1299911, 1299917",,7eeb2d81-c5d7-46a0-aa5c-149b55df71bd,12/09/2024,HUMAN PRESCRIPTION DRUG,12/09/2024,Neurology,TIAGABINE HYDROCHLORIDE,"62756-224, 62756-200","Sun Pharmaceutical Industries, Inc.",57975e74-e45b-4fd9-9718-bfc9690acae5,"62756-200-83, 62756-200-18, 62756-224-83, 62756-224-88, 62756-224-08, 62756-224-18","Tiagabine Hydrochloride, Tablet, 4 mg (NDC 62756-224-83)",Tablet,,,ANDA077555,,TIAGABINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuing for business reasons,,DQH6T6D8OY,62756-224-83,800-818-4555,
Baxter Healthcare,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718906, 1718909",,8ccb45a7-8290-469c-9644-a4dca967d88f,09/23/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE HYDROCHLORIDE,"0338-9557, 0338-9555",Baxter Healthcare Company,34598b0d-5824-4586-b19c-5189a626c27a,"0338-9555-24, 0338-9557-12","Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 0338-9557-12)",Injection,Limited Availability,,ANDA208532,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,Demand increase for the drug,Recovery in November 2025,,1018WH7F9I,0338-9557-12,888-229-0001,
"Elite Laboratories, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,e677690f-790f-4626-ad78-097cdb6ea540,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","64850-502, 64850-500, 64850-501, 64850-503, 64850-504, 64850-505, 64850-506","Elite Laboratories, Inc.",b65e0266-7172-4730-8f93-eb42e08fb7b8,"64850-500-01, 64850-500-05, 64850-500-30, 64850-501-01, 64850-501-05, 64850-501-30, 64850-502-01, 64850-502-05, 64850-502-30, 64850-503-01, 64850-503-05, 64850-503-30, 64850-504-01, 64850-504-05, 64850-504-30, 64850-505-01, 64850-505-05, 64850-505-30, 64850-506-01, 64850-506-05, 64850-506-30","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 64850-502-01)",Tablet,Limited Availability,,ANDA211352,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,Shortage of an active ingredient,3 months,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",64850-502-01,888-852-6657,
Eugia US LLC,ROCURONIUM BROMIDE,,02/15/2023,Revised,INTRAVENOUS,Rocuronium Bromide Injection,1234995,,116385ea-69fc-4f44-b463-6210291032df,09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROCURONIUM BROMIDE,"55150-225, 55150-226",Eugia US LLC,256e0877-720b-40a2-be71-d503e8b860ab,"55150-225-05, 55150-226-10","Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 55150-225-05)",Injection,Available,,ANDA206206,,ROCURONIUM BROMIDE,,,Current,,Check wholesalers for inventory,,I65MW4OFHZ,55150-225-05,888-238-7880,
Ferring,,,03/12/2021,Reverified,,Desmopressin Acetate Spray,,,,09/17/2025,,,Hematology,,,,,,"Stimate, Spray, 1.5 mg/1 mL (NDC 0053-6871-00)",Spray,Unavailable,,,,,,,Current,Requirements related to complying with good manufacturing practices,,,,0053-6871-00,888-337-7464,
"Fresenius Kabi USA, LLC",SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807631, 1807632, 1807633, 1807634, 1807639",,037ac04d-f8f3-4bb8-993a-ac8f7683ff83,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"65219-466, 65219-468, 65219-470, 65219-472, 65219-474","Fresenius Kabi USA, LLC",4110390b-2806-4c92-b283-a90115f89114,"65219-466-05, 65219-466-60, 65219-468-05, 65219-468-50, 65219-470-05, 65219-470-30, 65219-472-05, 65219-472-20, 65219-474-05, 65219-474-10","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 65219-466-60)",Injection,,,ANDA207310,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,65219-466-60,888-386-1300,
"Upsher-Smith Laboratories, LLC",CHOLESTYRAMINE,,05/14/2025,New,ORAL,Cholestyramine Powder,"848951, 1801279",,dd434ef8-8af3-434c-a0a0-9a0b18459ba0,05/14/2025,HUMAN PRESCRIPTION DRUG,05/14/2025,Cardiovascular,PREVALITE,0245-0036,"Upsher-Smith Laboratories, LLC",39e73fd2-1ad0-aae8-e063-6294a90acd5a,"0245-0036-89, 0245-0036-42, 0245-0036-60, 0245-0036-23","Prevalite, Powder, 4 g/5.5 g (NDC 0245-0036-42)",Powder,,"N0000180292, N0000175365",ANDA073263,,CHOLESTYRAMINE,Bile Acid Sequestrant [EPC],,To Be Discontinued,,A business decision was made to discontinue the product.,,4B33BGI082,0245-0036-42,800-654-2299,Bile-acid Binding Activity [MoA]
Baxter Healthcare,DOBUTAMINE HYDROCHLORIDE,,11/06/2017,Reverified,INTRAVENOUS,Dobutamine Hydrochloride Injection,"309985, 309986, 309987",,6b17b98b-e06d-42ed-925f-69aa2699dead,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Cardiovascular, Pediatric, Renal",DOBUTAMINE HYDROCHLORIDE IN DEXTROSE,"0338-1077, 0338-1073, 0338-1075",Baxter Healthcare Corporation,2ac85da3-8337-4b3b-8cda-d9399780542f,"0338-1073-02, 0338-1075-02, 0338-1077-02","Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/100 mL (NDC 0338-1077-02)",Injection,Available,,NDA020255,,DOBUTAMINE HYDROCHLORIDE,,,Current,,,,0WR771DJXV,0338-1077-02,888-229-0001,
Sun Pharmaceutical Industries Limited,CLINDAMYCIN HYDROCHLORIDE,,12/05/2024,New,ORAL,Clindamycin Hydrochloride Capsule,"197518, 284215",,1dbd8448-c1e5-46df-8060-50ef82380445,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Anti-Infective,CLINDAMYCIN HYDROCHLORIDE,"63304-693, 63304-692","Sun Pharmaceutical Industries, Inc.",339366d4-2060-1c29-e063-6394a90a1cb7,"63304-692-01, 63304-692-05, 63304-692-77, 63304-692-03, 63304-693-16, 63304-693-01, 63304-693-03, 63304-693-05, 63304-693-77, 63304-693-11, 63304-693-62","Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-62)",Capsule,,,ANDA065061,,CLINDAMYCIN HYDROCHLORIDE,,,To Be Discontinued,,Discontinuing for business reasons,,T20OQ1YN1W,63304-693-62,800-818-4555,
Eli Lilly and Co.,DULAGLUTIDE,,12/15/2022,Revised,SUBCUTANEOUS,Dulaglutide Injection,"1551295, 1551300, 1551304, 1551306, 2395777, 2395779, 2395783, 2395785",,463050bd-2b1c-40f5-b3c3-0a04bb433309,06/13/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,TRULICITY,"0002-2236, 0002-1433, 0002-1434, 0002-3182",Eli Lilly and Company,2a046089-7cd3-43d3-9f7f-27e3e4b49f0d,"0002-1433-01, 0002-1433-80, 0002-1433-61, 0002-1434-01, 0002-1434-80, 0002-1434-61, 0002-2236-01, 0002-2236-80, 0002-2236-61, 0002-3182-01, 0002-3182-80, 0002-3182-61","Trulicity, Injection, 3 mg/.5 mL (NDC 0002-2236-80)",Injection,,"N0000178480, M0160181, N0000020058",BLA125469,Glucagon-Like Peptide 1 [CS],DULAGLUTIDE,GLP-1 Receptor Agonist [EPC],Available,Resolved,,,06/13/2025,WTT295HSY5,0002-2236-80,800-545-5979,Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
"Fresenius Kabi USA, LLC","EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE ANHYDROUS",,10/14/2016,Revised,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL","Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","1010033, 1010035, 1010671, 1010673, 1010688, 1010692, 1010745, 1010749, 1010751, 1010755, 1010759, 1010763, 1010900, 1010902, 1737343, 1737345, 1737562, 1737563, 1737566, 1737567, 1737568, 1737569, 1737570, 1737571, 1737757, 1737758, 1737761, 1737762, 1867938, 1867940, 1867943, 1867944, 1867992, 1867993, 1867996, 1867997, 1868028, 1868029",,ba082c2f-64f4-419d-9c88-74f203316e17,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",XYLOCAINE MPF,"63323-488, 63323-492, 63323-491, 63323-495, 63323-485, 63323-486, 63323-484, 63323-489, 63323-481, 63323-483, 63323-482, 63323-487","Fresenius Kabi USA, LLC",ea480a68-5927-4278-9deb-2956961da428,"63323-492-04, 63323-492-27, 63323-492-09, 63323-492-57, 63323-492-07, 63323-492-37, 63323-492-03, 63323-492-31, 63323-491-01, 63323-491-57, 63323-495-09, 63323-495-27, 63323-495-04, 63323-495-07, 63323-485-01, 63323-485-27, 63323-485-03, 63323-485-57, 63323-486-01, 63323-486-17, 63323-486-02, 63323-486-27, 63323-486-05, 63323-486-57, 63323-484-57, 63323-489-02, 63323-489-27, 63323-489-03, 63323-489-21, 63323-489-01, 63323-489-17, 63323-488-07, 63323-488-37, 63323-488-03, 63323-488-31, 63323-488-01, 63323-488-17, 63323-481-01, 63323-481-57, 63323-483-03, 63323-483-27, 63323-483-01, 63323-483-57, 63323-482-01, 63323-482-17, 63323-482-03, 63323-482-27, 63323-482-05, 63323-482-57, 63323-487-01, 63323-487-17, 63323-487-07, 63323-487-37, 63323-487-03, 63323-487-31","Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-37)",Injection,Available,,NDA006488,,"LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE",,,Current,,7 mos expiry available upon request. Check wholesaler for inventory.,,"EC2CNF7XFP, 30Q7KI53AK",63323-488-37,888-386-1300,
"Hikma Pharmaceuticals USA, Inc.",AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","308189, 313850",,d46f1091-33dc-4f8f-9c34-75dcfedb4b4c,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0143-9887, 0143-9886",Hikma Pharmaceuticals USA Inc.,606474e1-adba-4ffa-83d5-6565fc12c892,"0143-9886-01, 0143-9886-50, 0143-9886-75, 0143-9887-01, 0143-9887-50, 0143-9887-75","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0143-9887-75)","Powder, For Suspension",,,ANDA065325,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0143-9887-75,800-631-2174,
"Novo Nordisk, Inc.",INSULIN ASPART,,07/21/2025,New,"INTRAVENOUS, SUBCUTANEOUS",Insulin Aspart Injection,"311040, 1653196, 1653202",,bee5b358-c863-420b-be73-ced2e920c499,07/21/2025,HUMAN PRESCRIPTION DRUG,07/21/2025,Endocrinology/Metabolism,INSULIN ASPART,"73070-102, 73070-100, 73070-103","Novo Nordisk Pharma, Inc.",393af9a3-df9a-40b2-a5e6-bfa5434a2552,"73070-100-11, 73070-102-10, 73070-102-15, 73070-103-10, 73070-103-15","Insulin Aspart, Injection, 3 mL Insulin Aspart PenFill® cartridge (NDC 73070-102-15)",Injection,,"M0011417, N0000175453",BLA020986,Insulin [CS],INSULIN ASPART,Insulin Analog [EPC],,To Be Discontinued,,"Unbranded Insulin Aspart 3 mL PenFill® cartridge will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,D933668QVX,73070-102-15,609-987-5800,
Eugia US LLC,LIDOCAINE HYDROCHLORIDE,,02/20/2018,Revised,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Lidocaine Hydrochloride Injection,"1737566, 1737568, 1737757",,5524cbfd-d6e6-42eb-aaa5-22495e0a86b6,09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,LIDOCAINE HYDROCHLORIDE,"55150-160, 55150-158, 55150-159",Eugia US LLC,e2600451-756c-4986-9e8e-26ce1d865afd,"55150-158-72, 55150-159-74, 55150-160-72","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-160-72)",Injection,Unavailable,,ANDA203040,,LIDOCAINE HYDROCHLORIDE,,,Current,Demand increase for the drug,On backorder. Recovery: TBD. Check wholesalers for inventory,,V13007Z41A,55150-160-72,888-238-7880,
Sandoz Inc.,AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","239191, 308182, 308189, 308191, 308192, 308194, 313797, 313850",,13bd4214-9b7f-425b-af5f-fc1ddc678230,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0781-6041, 0781-2020, 0781-2613, 0781-5060, 0781-5061, 0781-6039, 0781-6156, 0781-6157",Sandoz Inc,6aa02079-d11c-4d2f-acaf-9548dd9a7ed6,"0781-2020-31, 0781-2020-76, 0781-2020-01, 0781-2020-05, 0781-2613-31, 0781-2613-76, 0781-2613-01, 0781-2613-05, 0781-5060-20, 0781-5060-01, 0781-5061-20, 0781-5061-01, 0781-6039-58, 0781-6039-46, 0781-6039-55, 0781-6156-52, 0781-6156-57, 0781-6156-46, 0781-6041-58, 0781-6041-46, 0781-6041-55, 0781-6157-52, 0781-6157-57, 0781-6157-46","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0781-6041-46)","Powder, For Suspension",,,ANDA065387,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0781-6041-46,800-525-8747,
"Lupin Pharmaceuticals, Inc.",RIFAMPIN,,12/22/2021,Reverified,ORAL,Rifampin Capsule,,,b56004f0-f23d-47f6-80c7-39884fccbccc,09/18/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,RIFAMPIN,"68180-659, 68180-658","Lupin Pharmaceuticals, Inc.",751434c4-f772-4821-899c-3ce2e44be6fe,"68180-658-06, 68180-658-01, 68180-659-06, 68180-659-07, 68180-659-01","Rifampin, Capsule, 300 mg (NDC 68180-659-07)",Capsule,Available,"N0000175500, M0019113",ANDA090034,Rifamycins [CS],RIFAMPIN,Rifamycin Antibacterial [EPC],,Current,,,,VJT6J7R4TR,68180-659-07,866-587-4617,
"Laboratorios Grifols, S.A.",SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807631, 1807632, 1807633, 1807634, 1807639",,eb811d79-fdb8-1f1a-c2ad-1cc4bfc7eadf,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,76297-001,LABORATORIOS GRIFOLS SA,ff5ef1ef-2a0d-476d-8483-ffd7cd47c635,"76297-001-12, 76297-001-11, 76297-001-22, 76297-001-21, 76297-001-32, 76297-001-31, 76297-001-02, 76297-001-01, 76297-001-42, 76297-001-41, 76297-001-52, 76297-001-51, 76297-001-62, 76297-001-61, 76297-001-72, 76297-001-71, 76297-001-82, 76297-001-81, 76297-001-92, 76297-001-91","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-11)",Injection,,,ANDA207956,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,76297-001-11,800-848-0462,
Accord Healthcare Inc.,CARBOPLATIN,,04/28/2023,Reverified,INTRAVENOUS,Carboplatin Injection,597195,,48aa7ef3-9f44-2a08-e054-00144ff88e88,09/16/2025,HUMAN PRESCRIPTION DRUG,,Oncology,CARBOPLATIN,16729-295,"Accord Healthcare, Inc.",35cf6068-f31a-211b-e063-6294a90a6b53,"16729-295-31, 16729-295-33, 16729-295-34, 16729-295-12, 16729-295-38","Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33)",Injection,Unavailable,"N0000175413, N0000175073",ANDA206775,,CARBOPLATIN,Platinum-based Drug [EPC],,Current,Requirements related to complying with good manufacturing practices,SKU status from FDA is non-Exempt,,BG3F62OND5,16729-295-33,"866-941-7875, option 2",
Torrent Pharma Inc.,,,06/13/2025,New,,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,,,,06/13/2025,,06/13/2025,Cardiovascular,,,,,,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 12.5 mg; 40 mg (NDC 13668-383-05)",Tablet,,,,,,,,To Be Discontinued,,A business decision was made to discontinue manufacture of the product.,,,13668-383-05,908-280-3333,
Strides Pharma Inc.,DONEPEZIL HYDROCHLORIDE,,01/28/2025,New,ORAL,Donepezil Hydrochloride Tablet,"997223, 997229",,297e86e8-d248-4cc9-9d9c-2ef9efb4414d,01/28/2025,HUMAN PRESCRIPTION DRUG,01/28/2025,Neurology,DONEPEZIL HYDROCHLORIDE,"71093-127, 71093-128","ACI Healthcare USA, Inc.",a4736add-da84-411f-8e6f-9de67bf467f8,"71093-127-01, 71093-127-03, 71093-127-05, 71093-127-06, 71093-128-01, 71093-128-03, 71093-128-05, 71093-128-06","Donepezil Hydrochloride, Tablet, 5 mg (NDC 71093-127-03)",Tablet,,,ANDA078662,,DONEPEZIL HYDROCHLORIDE,,,To Be Discontinued,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,3O2T2PJ89D,71093-127-03,877-244-9825,
Gland Pharma Limited,,,04/02/2020,Reverified,,Midazolam Hydrochloride Injection,,,,09/29/2025,,,"Anesthesia, Neurology",,,,,,"Midazolam Hydrochloride, Injection, 2 mg/2 mL (NDC 47781-588-68)",Injection,Available,,,,,,,Current,Other,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,,47781-588-68,Athenex: 855-273-0154; Alvogen: 973-532-7840,
Otsuka ICU Medical LLC,WATER,,04/28/2023,Reverified,IRRIGATION,Sterile Water Irrigant,150985,https://www.fda.gov/media/182619/download?attachment,e3484bc6-ed7f-43ef-9d49-c131a8dff2dd,09/17/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",STERILE WATER,"0990-6139, 0990-7139, 0990-7973",ICU Medical Inc.,22b6a1e5-20c1-481b-96d5-329e3fc999f5,"0990-6139-22, 0990-6139-03, 0990-7139-09, 0990-7139-36, 0990-7973-05, 0990-7973-07, 0990-7973-08","Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-03)",Irrigant,Limited Availability,,NDA017513,,WATER,,,Current,Other,"Allocated to Contracted Customers Only. Estimated Recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,059QF0KO0R,0990-6139-03,1-866-829-9025 or ProductAvailability@icumed.com,
Norvium Bioscience LLC,IBUTILIDE FUMARATE,,03/05/2025,New,INTRAVENOUS,Ibutilide Fumarate Injection,979120,,c25d21e7-6136-4a7a-b139-12f53116fc3d,03/05/2025,HUMAN PRESCRIPTION DRUG,03/05/2025,Cardiovascular,IBUTILIDE FUMARATE,67457-366,Mylan Institutional LLC,88628540-e907-4411-8aa3-bc2a368e460d,67457-366-10,"Ibutilide Fumarate, Injection, .1 mg/1 mL (NDC 67457-366-10)",Injection,,,ANDA090643,,IBUTILIDE FUMARATE,,,To Be Discontinued,,,,9L5X4M5L6I,67457-366-10,888-282-0125,
"Fresenius Kabi USA, LLC",KETOROLAC TROMETHAMINE,,03/23/2018,Reverified,INTRAMUSCULAR,Ketorolac Tromethamine Injection,"860113, 860114, 860115",,3d88cbe6-5230-47aa-80af-0c41283d1f00,09/18/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,KETOROLAC TROMETHAMINE,"76045-105, 76045-104, 76045-107, 76045-209","Fresenius Kabi USA, LLC",0dab642d-7fcf-4301-8ac9-10e64a040c6b,"76045-104-10, 76045-105-20, 76045-107-10, 76045-209-00, 76045-209-10","Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 76045-105-20)",Injection,Unavailable,,ANDA203242,,KETOROLAC TROMETHAMINE,,,Current,Other,Not available at this time.,,4EVE5946BQ,76045-105-20,888-386-1300,
"Prinston Pharmaceutical, Inc.",CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,4acbb7a9-4db5-4497-b8db-9f358b3f6fb4,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"43547-408, 43547-406, 43547-407",Solco Healthcare LLC,dc17b9d4-2890-4f6c-8476-daa39d0cbc9c,"43547-406-10, 43547-406-50, 43547-406-11, 43547-407-10, 43547-407-50, 43547-407-11, 43547-408-10, 43547-408-50","Clonazepam, Tablet, 2 mg (NDC 43547-408-50)",Tablet,Available,"N0000175694, M0002356",ANDA077856,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,Marketed by Solco Healthcare,,5PE9FDE8GB,43547-408-50,"For orders, Solco Healthcare 866-931-9829",
Baxter Healthcare,DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795607, 1795609, 1795610, 1795612, 1795616",,36e9478c-5df0-4b47-b97d-de3626d7cb29,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0338-0066, 0338-9651, 0338-9649, 0338-9655, 0338-9653, 0338-0078, 0338-0062, 0338-0074, 0338-0070, 0338-0082",Baxter Healthcare Corporation,66eb82f8-6755-42aa-b20c-192a640e8068,"0338-9651-75, 0338-9649-75, 0338-9655-60, 0338-9653-60, 0338-0078-20, 0338-0062-30, 0338-0074-30, 0338-0066-20, 0338-0070-10, 0338-0070-12, 0338-0082-10","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0066-20)",Injection,Available,,NDA016673,,DEXTROSE MONOHYDRATE,,,Current,,,,LX22YL083G,0338-0066-20,888-229-0001,
"Hospira, Inc., a Pfizer Company",DOPAMINE HYDROCHLORIDE,,11/06/2017,Revised,INTRAVENOUS,Dopamine Hydrochloride Injection,"1292887, 1743877, 1743879",,08f23f6e-150d-45ea-098e-f2edf64c21a1,08/15/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,DOPAMINE HYDROCHLORIDE IN DEXTROSE,"0409-7809, 0409-7810","Hospira, Inc.",3b4d4d9d-5e19-420f-a447-1ad8346844d9,"0409-7809-11, 0409-7809-22, 0409-7809-31, 0409-7809-24, 0409-7810-11, 0409-7810-22","Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-7809-22)",Injection,Unavailable,,NDA018826,,DOPAMINE HYDROCHLORIDE IN DEXTROSE,,,Current,Demand increase for the drug,Next Delivery: October 2025; Estimated Recovery: December 2025,,7L3E358N9L,0409-7809-22,844-646-4398,
"Hikma Pharmaceuticals USA, Inc.",AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","308189, 313850",,d46f1091-33dc-4f8f-9c34-75dcfedb4b4c,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0143-9886, 0143-9887",Hikma Pharmaceuticals USA Inc.,606474e1-adba-4ffa-83d5-6565fc12c892,"0143-9886-01, 0143-9886-50, 0143-9886-75, 0143-9887-01, 0143-9887-50, 0143-9887-75","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0143-9886-50)","Powder, For Suspension",,,ANDA065325,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0143-9886-50,800-631-2174,
Chartwell Molecular Holdings LLC,LIDOCAINE HYDROCHLORIDE ANHYDROUS,,12/08/2023,Revised,OROPHARYNGEAL,Lidocaine Hydrochloride Solution,1010739,,c05f49a2-7512-48e7-9730-f8ee05519b9d,08/29/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,LIDOCAINE HYDROCHLORIDE,"62135-712, 62135-871","Chartwell RX, LLC",1a8a5120-d592-7d82-e063-6394a90af7c1,"62135-712-42, 62135-871-51, 62135-871-24","Lidocaine Hydrochloride Viscous, Solution, 20 mg/1 mL (NDC 62135-712-42)",Solution,,,ANDA040708,,LIDOCAINE HYDROCHLORIDE,,Available,Resolved,,,08/29/2025,EC2CNF7XFP,62135-712-42,845-268-5000 Ext. 510,
"Hikma Pharmaceuticals USA, Inc.",PROPRANOLOL HYDROCHLORIDE,,10/31/2023,Reverified,INTRAVENOUS,Propranolol Hydrochloride Injection,856443,,91f2ff1d-68d8-4e83-a2db-618f0410ead7,07/23/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,PROPRANOLOL HYDROCHLORIDE,0143-9872,Hikma Pharmaceuticals USA Inc.,e8fc99d6-98e1-4c9f-80e7-327fb2817f08,"0143-9872-01, 0143-9872-10","Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 0143-9872-10)",Injection,Unavailable,,ANDA077760,,PROPRANOLOL HYDROCHLORIDE,,,Current,Shortage of an active ingredient,,,F8A3652H1V,0143-9872-10,800-631-2174,
Sun Pharmaceutical Industries Limited,TIAGABINE HYDROCHLORIDE,,12/09/2024,New,ORAL,Tiagabine Hydrochloride Tablet,"1299911, 1299917",,7eeb2d81-c5d7-46a0-aa5c-149b55df71bd,12/09/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Neurology,TIAGABINE HYDROCHLORIDE,"62756-200, 62756-224","Sun Pharmaceutical Industries, Inc.",57975e74-e45b-4fd9-9718-bfc9690acae5,"62756-200-83, 62756-200-18, 62756-224-83, 62756-224-88, 62756-224-08, 62756-224-18","Tiagabine Hydrochloride, Tablet, 2 mg (NDC 62756-200-18)",Tablet,,,ANDA077555,,TIAGABINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuing for business reasons,,DQH6T6D8OY,62756-200-18,800-818-4555,
"Teva Pharmaceuticals USA, Inc.",VERAPAMIL HYDROCHLORIDE,,01/23/2025,New,ORAL,"Verapamil Hydrochloride Capsule, Extended Release",,,0742cf97-601b-4c13-a6c3-1a6a616ed292,01/23/2025,HUMAN PRESCRIPTION DRUG,01/23/2025,Cardiovascular,VERAPAMIL HYDROCHLORIDE,"0591-2882, 0591-2880, 0591-2884, 0591-2886",Teva Pharmaceuticals Inc,319554df-fc0d-428a-9799-a352100f1ce9,"0591-2880-01, 0591-2882-01, 0591-2884-01, 0591-2886-01","Verelan, Capsule, Extended Release, 180 mg (NDC 0591-2882-01)","Capsule, Extended Release",,,NDA019614,,VERAPAMIL HYDROCHLORIDE,,,To Be Discontinued,,,,V3888OEY5R,0591-2882-01,800-545-8800,
AbbVie Inc.,SILODOSIN,,02/20/2025,New,ORAL,Silodosin Capsule,"809477, 809481, 826612, 826614",,da0314f6-b1d6-44ee-8b1e-f763dbb8613f,02/20/2025,HUMAN PRESCRIPTION DRUG,02/20/2025,Urology,RAPAFLO,"0023-6142, 0023-6147","Allergan, Inc.",34eec0b8-ef99-4d69-bd3f-da1373da2e49,"0023-6142-90, 0023-6142-30, 0023-6147-30","Rapaflo, Capsule, 8 mg (NDC 0023-6142-30)",Capsule,,"N0000000099, N0000175553",NDA022206,,SILODOSIN,alpha-Adrenergic Blocker [EPC],,To Be Discontinued,,Last lot in distribution expires March 2026. Last sale date will be June 2025.,,CUZ39LUY82,0023-6142-30,800-633-9110,Adrenergic alpha-Antagonists [MoA]
Sun Pharmaceutical Industries Limited,CLINDAMYCIN HYDROCHLORIDE,,12/05/2024,New,ORAL,Clindamycin Hydrochloride Capsule,"197518, 284215",,1dbd8448-c1e5-46df-8060-50ef82380445,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Anti-Infective,CLINDAMYCIN HYDROCHLORIDE,"63304-692, 63304-693","Sun Pharmaceutical Industries, Inc.",339366d4-2060-1c29-e063-6394a90a1cb7,"63304-692-01, 63304-692-05, 63304-692-77, 63304-692-03, 63304-693-16, 63304-693-01, 63304-693-03, 63304-693-05, 63304-693-77, 63304-693-11, 63304-693-62","Clindamycin Hydrochloride, Capsule, 150 mg (NDC 63304-692-03)",Capsule,,,ANDA065061,,CLINDAMYCIN HYDROCHLORIDE,,,To Be Discontinued,,Discontinuing for business reasons,,T20OQ1YN1W,63304-692-03,800-818-4555,
Slayback Pharma,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718900, 1718906, 1718909",,e5d28ed8-e427-4850-81aa-98702d3b6a5d,09/17/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE HYDROCHLORIDE,71225-126,Slayback Pharma LLC,027725dc-e468-446c-b702-ab0f8a9e3be5,"71225-126-02, 71225-126-05, 71225-126-03, 71225-126-06, 71225-126-01, 71225-126-04","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 71225-126-05)",Injection,Available,,ANDA212791,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,,,,1018WH7F9I,71225-126-05,844-566-2505,
"Upsher-Smith Laboratories, LLC",DIVALPROEX SODIUM,,04/28/2025,New,ORAL,"Divalproex Sodium Tablet, Delayed Release","1099625, 1099678, 1099870",,02304a23-4a5f-47bc-9687-4044b43f7a20,04/28/2025,HUMAN PRESCRIPTION DRUG,04/28/2025,Neurology,DIVALPROEX SODIUM,"0832-7122, 0832-7123, 0832-7124","Upsher-Smith Laboratories, LLC",38e51a59-5802-77a6-e063-6394a90af6c6,"0832-7122-11, 0832-7122-15, 0832-7123-11, 0832-7123-15, 0832-7123-89, 0832-7123-01, 0832-7124-11, 0832-7124-15, 0832-7124-89, 0832-7124-01","Divalproex Sodium, Tablet, Delayed Release, 125 mg (NDC 0832-7122-11)",Tablet,,,ANDA078182,,DIVALPROEX SODIUM,,,To Be Discontinued,,Discontinuation of manufacture of drug based on business decision.,,644VL95AO6,0832-7122-11,800-654-2299,
Takeda Pharmaceuticals USA Inc.,PARATHYROID HORMONE,,09/11/2019,Reverified,SUBCUTANEOUS,Parathyroid Hormone Injection,"1602023, 1602028, 1602032, 1602034, 1602038, 1602040, 1602044, 1602046",,d11fba31-0a6c-11e3-8ffd-0800200c9a66,08/15/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,NATPARA (PARATHYROID HORMONE),"68875-0203, 68875-0202, 68875-0204, 68875-0205","Takeda Pharmaceuticals America, Inc.",17d2bb82-605c-43be-9918-63aeb7102d8c,"68875-0202-1, 68875-0202-2, 68875-0203-1, 68875-0203-2, 68875-0204-1, 68875-0204-2, 68875-0205-1, 68875-0205-2","Natpara, Injection, 50 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0203-2)",Powder,Limited Availability,"M0015931, N0000180851",BLA125511,Parathyroid Hormone [CS],PARATHYROID HORMONE,Parathyroid Hormone [EPC],,Current,Discontinuation of the manufacture of the drug,Takeda will be ceasing manufacturing of Natpara at the end of 2024 with a priority to maintain treatment continuity for patients enrolled in the U.S. Special Use Program until inventory is depleted or expired.,,N19A0T0E5J,68875-0203-2,866-888-0660,
Baxter Healthcare,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807551, 1807552, 1807627, 1807630, 1807631, 1807632, 1807633, 1807634, 1807639",,f55bd888-5e01-474d-871b-24654c070178,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0338-0049, 0338-0043",Baxter Healthcare Corporation,6ab23768-efd2-4ff1-b336-0dda08dc56e1,"0338-0049-01, 0338-0049-02, 0338-0049-03, 0338-0049-04, 0338-0049-10, 0338-0049-41, 0338-0049-11, 0338-0049-31, 0338-0049-48, 0338-0049-18, 0338-0049-38, 0338-0043-03, 0338-0043-04","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-10)",Injection,,,NDA016677,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0338-0049-10,888-229-0001,
"ESTEVE PHARMACEUTICALS, S.A.",STREPTOZOCIN,,07/12/2022,Revised,INTRAVENOUS,"Streptozocin Powder, For Solution","207948, 239180",https://www.fda.gov/media/187353/download?attachment,f31d3bff-6fc6-c35f-e053-2995a90a596b,09/17/2025,HUMAN PRESCRIPTION DRUG,,Oncology,ZANOSAR,68118-100,"ESTEVE PHARMACEUTICALS, S.A.",34f45d46-dc6b-eb56-e063-6394a90ae407,68118-100-01,"Zanosar, Powder, For Solution, 1 g/10 mL (NDC 68118-100-01)","Powder, For Solution",Available,"N0000000236, N0000175558",,,STREPTOZOCIN,Alkylating Drug [EPC],,Current,,,,5W494URQ81,68118-100-01,USSZTOrders@esteve.com,Alkylating Activity [MoA]
Pfizer Inc.,TALAZOPARIB TOSYLATE,,01/13/2025,New,ORAL,Talazoparib Tosylate Capsule,"2099946, 2099952, 2099954, 2099956, 2591510, 2591512, 2591520, 2591521, 2639960, 2639962, 2639964, 2639966",,f2423edd-6d24-495c-aec1-c2f457f08d9a,01/13/2025,HUMAN PRESCRIPTION DRUG,01/13/2025,Oncology,TALZENNA,"0069-1751, 0069-0296, 0069-1195, 0069-1501, 0069-1031, 0069-1235",Pfizer Laboratories Div Pfizer Inc,2cb65f61-9a14-46d9-85a3-a7eea76160c5,"0069-0296-30, 0069-1195-30, 0069-1501-30, 0069-1751-30, 0069-1031-30, 0069-1235-30","Talzenna, Capsule, .75 mg (NDC 0069-1751-30)",Capsule,,,NDA211651,,TALAZOPARIB,,,To Be Discontinued,,"Supply expected to exhaust late February 2025
Replaced with Soft Gel NDC 0069-0655-30",,02WK9U5NZC,0069-1751-30,800-533-4535,
Accord Healthcare Inc.,ATROPINE SULFATE,,01/01/2012,Revised,INTRAVENOUS,Atropine Sulfate Injection,"1190795, 1666781",,d5e07279-48ca-4f83-9633-299e65a7f821,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology, Pediatric",ATROPINE SULFATE,"16729-526, 16729-525",Accord Healthcare Inc.,2f360fd4-b6b0-7540-e063-6394a90aa720,"16729-525-63, 16729-525-03, 16729-525-08, 16729-526-63, 16729-526-03, 16729-526-08","Atropine Sulfate, Injection, 1 mg/1 mL (NDC 16729-526-08)",Injection,"Unavailable, 75 days",,NDA214652,,ATROPINE SULFATE,,,Current,Requirements related to complying with good manufacturing practices,Manufacturing in process,,03J5ZE7KA5,16729-526-08,"866-941-7875, option 2",
Eugia US LLC,CARBOPLATIN,,04/28/2023,Revised,INTRAVENOUS,Carboplatin Injection,597195,,"f5fe9a20-47a5-45b9-ab06-c6158d9b6aca, 5abfcb87-bb02-4384-9c9d-7d0e3e809311",09/05/2025,HUMAN PRESCRIPTION DRUG,,Oncology,CARBOPLATIN,"55150-386, 55150-333, 55150-334, 55150-335",Eugia US LLC,"6029d051-ee8d-44cc-8dae-b91c3385d4c3, 5abfcb87-bb02-4384-9c9d-7d0e3e809311","55150-333-01, 55150-334-01, 55150-335-01, 55150-386-01, 55150-335-00, 55150-386-00","Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01)",Injection,Available,"N0000175413, N0000175073",ANDA205487,,CARBOPLATIN,Platinum-based Drug [EPC],,Current,,Check wholesalers for inventory,,BG3F62OND5,55150-386-01,888-238-7880,
"Hospira, Inc., a Pfizer Company","EPINEPHRINE, LIDOCAINE HYDROCHLORIDE",,02/22/2012,Reverified,"INFILTRATION, PERINEURAL","Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","1010688, 1010745, 1010751, 1010759, 1867996, 1867998",,2f94f711-14c4-48ec-c5a3-c5ec4b8e8729,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE,"0409-3178, 0409-1209, 0409-3177, 0409-3181, 0409-3182, 0409-3183, 0409-0007, 0409-0147","Hospira, Inc.",d16a4711-e663-455e-a1fe-236a41ca4e8f,"0409-1209-10, 0409-1209-01, 0409-1209-05, 0409-1209-70, 0409-1209-65, 0409-3177-16, 0409-3177-01, 0409-3178-16, 0409-3178-01, 0409-3178-17, 0409-3178-02, 0409-3178-18, 0409-3178-03, 0409-3181-11, 0409-3181-01, 0409-3182-11, 0409-3182-01, 0409-3182-21, 0409-3182-02, 0409-3182-31, 0409-3182-03, 0409-3183-11, 0409-3183-01, 0409-0007-01, 0409-0007-10, 0409-0147-01, 0409-0147-10","Lidocaine Hydrochloride And Epinephrine, Injection, 200 mg/20 mL (1%; 1:100,000) (NDC 0409-3178-01)",Injection,Available,"N0000000209, N0000000245, N0000175552, N0000175555, N0000175570, M0003647",ANDA089644,Catecholamines [CS],LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE,"alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC], Catecholamine [EPC]",,Current,,,,"V13007Z41A, YKH834O4BH",0409-3178-01,844-646-4398,"Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA]"
"Solco Healthcare US, LLC",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,68b10d9f-ca3e-493d-a309-45f1d7e08061,08/05/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"43547-605, 43547-602, 43547-603, 43547-604, 43547-606, 43547-607, 43547-608","Solco Healthcare US,LLC",7bb11568-67a4-4221-bb9b-23af37a1791c,"43547-602-10, 43547-603-10, 43547-604-10, 43547-605-10, 43547-606-10, 43547-607-10, 43547-608-10","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 43547-605-10)",Capsule,Limited Availability,,ANDA216266,,LISDEXAMFETAMINE DIMESYLATE CAPSULES,,,Current,Shortage of an active ingredient,On allocation,,SJT761GEGS,43547-605-10,866-931-9829,
"Lannett Company, Inc.",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Revised,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release","2001564, 2001565, 2001566, 2001568",,3d1f5aff-5d39-496c-b5ed-7f3c70ec641c,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE HYDROCHLORIDE,"62175-312, 62175-310, 62175-311, 62175-313","Lannett Company, Inc.",fd0e4ddf-c516-4464-aeca-eb1d3bd24667,"62175-310-37, 62175-311-37, 62175-312-37, 62175-313-37","Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62175-312-37)",Tablet,Unavailable,,ANDA091695,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,Shortage of an active ingredient,Unavailable,,4B3SC438HI,62175-312-37,844-834-0530,
"Epic Pharma, LLC",RIFAMPIN,,12/22/2021,Reverified,ORAL,Rifampin Capsule,"198201, 198202",,0391f1e1-70d4-4b15-8b58-055bb6a385b8,09/18/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,RIFAMPIN,"42806-799, 42806-801","EPIC PHARMA, LLC",a4ac02e8-68ac-4e79-8ca5-0939dd002c87,"42806-801-30, 42806-801-01, 42806-799-30, 42806-799-60, 42806-799-01, 42806-799-05","Rifampin, Capsule, 300 mg (NDC 42806-799-05)",Capsule,Unavailable,"N0000175500, M0019113",ANDA064150,Rifamycins [CS],RIFAMPIN,Rifamycin Antibacterial [EPC],,Current,Discontinuation of the manufacture of the drug,Discontinuation of the manufacture of the drug.,,VJT6J7R4TR,42806-799-05,(718) 276-8600 ext. 3,
"Rising Pharma Holdings, Inc.",,,08/03/2022,Reverified,,Flurazepam Hydrochloride Capsule,,,,08/19/2025,,,"Neurology, Other",,,,,,"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 0378-4430-01)",Capsule,Unavailable,,,,,,,Current,Regulatory delay,Anticipated availability: Q3 2025; Delay is due to manufacturing delays at the contract manufacturing facility.,,,0378-4430-01,1-844-874-7464,
"Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)",IRINOTECAN HYDROCHLORIDE,,09/26/2025,New,INTRAVENOUS,Irinotecan Hydrochloride Injection,"1726319, 1726324",,caab50e6-0dad-4ddd-9a6c-96cc2b87aee7,09/26/2025,HUMAN PRESCRIPTION DRUG,09/26/2025,Oncology,IRINOTECAN HYDROCHLORIDE,25021-230,Sagent Pharmaceuticals,6c1863de-2414-4e41-a2fa-7f2f7135af0e,"25021-230-02, 25021-230-05","Irinotecan Hydrochloride, Injection, 40 mg/2 mL (NDC 25021-230-02)",Injection,,,ANDA090675,,IRINOTECAN HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug; Distributed by Sagent Pharmaceuticals,,042LAQ1IIS,25021-230-02,"Company Contact: 609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)",
Oryza Pharmaceuticals Inc.,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Revised,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 1009145",,acd27181-a3f3-4c38-85d8-029a4a82e7c2,09/16/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","72516-014, 72516-016, 72516-015, 72516-013, 72516-012, 72516-011",Oryza Pharmaceuticals Inc.,39fb17a2-617d-37dc-e063-6394a90a1be3,"72516-016-01, 72516-015-01, 72516-014-01, 72516-013-01, 72516-012-01, 72516-011-01","Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 72516-014-01)",Tablet,Unavailable,,ANDA210293,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,Shortage of an active ingredient,Estimated availability October 2025,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",72516-014-01,855-257-0292,
"Hikma Pharmaceuticals USA, Inc.",ROCURONIUM BROMIDE,,02/15/2023,Reverified,INTRAVENOUS,Rocuronium Bromide Injection,1234995,,d3a172a5-01ab-47d8-92ac-a8539b1d4dc4,07/23/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROCURONIUM BROMIDE,"0143-9251, 0143-9250",Hikma Pharmaceuticals USA Inc.,1b6667a4-f267-483a-ae9f-2a514db8a21d,"0143-9250-01, 0143-9250-10, 0143-9251-01, 0143-9251-10","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9251-10)",Injection,Available,,ANDA204679,,ROCURONIUM BROMIDE,,,Current,,,,I65MW4OFHZ,0143-9251-10,800-631-2174,
Milla Pharmaceuticals,,,02/03/2016,Revised,,Sodium Acetate Injection,,,,09/16/2025,,,"Endocrinology/Metabolism, Gastroenterology, Pediatric, Total Parenteral Nutrition",,,,,,"Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 69784-229-10)",Injection,Available,,,,,,,Current,,,,,69784-229-10,833-251-8463,
Gland Pharma Limited,CARBOPLATIN,,04/28/2023,Reverified,INTRAVENOUS,Carboplatin Injection,597195,,5484d2f0-0cc2-4bba-8f26-c7f6539a9606,09/29/2025,HUMAN PRESCRIPTION DRUG,,Oncology,CARBOPLATIN,"54288-164, 54288-165, 54288-166, 54288-167",BPI Labs LLC,5eb7631e-0b41-4aba-ba7a-f544ac9627fd,"54288-165-01, 54288-166-01, 54288-167-01, 54288-164-01","Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01)",Injection,Unavailable,"N0000175413, N0000175073",ANDA207324,,CARBOPLATIN,Platinum-based Drug [EPC],,Current,Discontinuation of the manufacture of the drug,"Discontinued; Distributed by BPI Labs, LLC",,BG3F62OND5,54288-164-01,"Distributed by BPI Labs, LLC;  Customer service number:  (727) 471-0850 Ext 270",
Amneal Pharmaceuticals,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850",,c11cb3b6-3dff-477b-a249-b4c3118edc5f,09/17/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"65162-025, 65162-023, 65162-024, 65162-026, 65162-027, 65162-028",Amneal Pharmaceuticals LLC,759471b0-6930-4e65-9417-e1c334a0eb68,"65162-023-09, 65162-024-09, 65162-025-09, 65162-026-09, 65162-027-09, 65162-028-09","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 65162-025-09)",Capsule,Unavailable,,ANDA202830,,LISDEXAMFETAMINE,,,Current,Shortage of an active ingredient,Shortage of an active ingredient,,SJT761GEGS,65162-025-09,866-525-7270,
Sandoz Inc.,TAMSULOSIN HYDROCHLORIDE,,04/10/2025,New,ORAL,Tamsulosin Hydrochloride Capsule,863669,,fb120098-b007-4a33-80b8-b7279c7668ee,04/10/2025,HUMAN PRESCRIPTION DRUG,04/10/2025,Urology,TAMSULOSIN HYDROCHLORIDE,0781-2076,Sandoz Inc,98c2abd9-1998-48cd-83f9-f5f94ff39345,"0781-2076-01, 0781-2076-10, 0781-2076-92","Tamsulosin Hydrochloride, Capsule, .4 mg (NDC 0781-2076-92)",Capsule,,,ANDA078015,,TAMSULOSIN HYDROCHLORIDE,,,To Be Discontinued,,,,11SV1951MR,0781-2076-92,800-525-8747,
Baxter Healthcare,FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Reverified,INTRAVENOUS,Furosemide Injection,"1719286, 1719290, 1719291",,c71371a7-75c5-45b8-b762-8d782d4c71bc,09/23/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,"36000-284, 36000-063, 36000-064, 36000-065, 36000-282, 36000-283",Baxter Healthcare Corporation,109082ab-0793-4752-8a02-42d204efe741,"36000-063-05, 36000-064-05, 36000-065-05, 36000-282-25, 36000-283-25, 36000-284-25","Furosemide, Injection, 10 mg/1 mL (NDC 36000-284-25)",Injection,Unavailable,"N0000175366, N0000175590",ANDA202747,,FUROSEMIDE,Loop Diuretic [EPC],,Current,Other,Estimated recovery: end of 2025,,7LXU5N7ZO5,36000-284-25,888-229-0001,
Sun Pharmaceutical Industries Limited,IMATINIB MESYLATE,,12/05/2024,New,ORAL,Imatinib Mesylate Tablet,"403878, 403879",,be5b9047-155b-59ca-e053-2995a90ad3dc,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Hematology,IMATINIB MESYLATE,"68001-491, 68001-490",BluePoint Laboratories,05c9d227-d639-916a-e063-6294a90a66a6,"68001-490-05, 68001-491-04","Imatinib Mesylate, Tablet, 400 mg (NDC 68001-491-04)",Tablet,,,ANDA078340,,IMATINIB MESYLATE,,,To Be Discontinued,,Discontinuing for business reasons,,8A1O1M485B,68001-491-04,800-818-4555,
Eugia US LLC,ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Revised,"EPIDURAL, INFILTRATION, PERINEURAL",Ropivacaine Hydrochloride Injection,"905189, 1734084, 1734090, 1734207, 1734347, 1734475, 1734483",,3763b7b6-da49-4658-b93d-28f5da24d09e,09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROPIVACAINE HYDROCHLORIDE,"55150-196, 55150-195, 55150-197, 55150-198, 55150-199, 55150-200, 55150-201",Eugia US LLC,34725b26-d6e9-4d1b-95a0-da03764cc102,"55150-195-20, 55150-196-99, 55150-197-20, 55150-198-30, 55150-199-20, 55150-200-10, 55150-201-20","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-196-99)",Injection,Unavailable,,ANDA205612,,ROPIVACAINE HYDROCHLORIDE,,,Current,Demand increase for the drug,On backorder. Recovery: TBD. Check wholesalers for inventory,,V910P86109,55150-196-99,888-238-7880,
"Laboratorios Grifols, S.A.",SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807631, 1807632, 1807633, 1807634, 1807639",,eb811d79-fdb8-1f1a-c2ad-1cc4bfc7eadf,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,76297-001,LABORATORIOS GRIFOLS SA,ff5ef1ef-2a0d-476d-8483-ffd7cd47c635,"76297-001-12, 76297-001-11, 76297-001-22, 76297-001-21, 76297-001-32, 76297-001-31, 76297-001-02, 76297-001-01, 76297-001-42, 76297-001-41, 76297-001-52, 76297-001-51, 76297-001-62, 76297-001-61, 76297-001-72, 76297-001-71, 76297-001-82, 76297-001-81, 76297-001-92, 76297-001-91","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-01)",Injection,,,ANDA207956,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,76297-001-01,800-848-0462,
Guerbet LLC,SODIUM CHLORIDE,,06/21/2018,Revised,INTRAVASCULAR,Sodium Chloride 0.9% Injection,,,e4540d03-06b4-4b4d-b859-75c13e5c20dd,08/08/2025,HUMAN PRESCRIPTION DRUG,,Other,SODIUM CHLORIDE,0019-1188,Liebel-Flarsheim Company LLC,cdff7813-7b00-4f61-a017-18ab8910d49d,"0019-1188-81, 0019-1188-27","Sodium Chloride 0.9% In Plastic Container, Injection, .9 mg/1 mL (NDC 0019-1188-27)",Injection,,,NDA021569,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0019-1188-27,877-729-6679,
Eli Lilly and Co.,ATOMOXETINE HYDROCHLORIDE,,10/22/2024,New,ORAL,Atomoxetine Hydrochloride Capsule,"349591, 349592, 349593, 349594, 349595, 352317, 352318, 352319, 352320, 352321, 608139, 608143, 617945, 617947",,309de576-c318-404a-bc15-660c2b1876fb,10/22/2024,HUMAN PRESCRIPTION DRUG,10/22/2024,Psychiatry,STRATTERA,"0002-3239, 0002-3227, 0002-3238, 0002-3228, 0002-3229, 0002-3250, 0002-3251",Eli Lilly and Company,90fd3143-d5d4-4343-9570-b3863e31b1a0,"0002-3227-30, 0002-3238-30, 0002-3228-30, 0002-3229-30, 0002-3239-30, 0002-3250-30, 0002-3251-30","Strattera, Capsule, 60 mg (NDC 0002-3239-30)",Capsule,,,NDA021411,,ATOMOXETINE HYDROCHLORIDE,,,To Be Discontinued,,Business decision to discontinue,,57WVB6I2W0,0002-3239-30,800-545-5979,
Baxter Healthcare,CLINDAMYCIN PHOSPHATE,,03/21/2023,Reverified,INTRAVENOUS,Clindamycin Phosphate Injection,"309335, 309336, 309339",,44fa506b-90ac-42de-831b-5f3f1a500fc0,09/23/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,CLINDAMYCIN PHOSPHATE,"0338-9549, 0338-9545, 0338-9553",Baxter Healthcare Company,12bdbbc9-fbb0-4a0a-9147-37df8ac5dc5e,"0338-9545-50, 0338-9545-24, 0338-9549-50, 0338-9549-24, 0338-9553-50, 0338-9553-24","Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9549-50)",Injection,Unavailable,,NDA208083,,CLINDAMYCIN PHOSPHATE,,,Current,Other,Estimated recovery: October 2025,,EH6D7113I8,0338-9549-50,888-229-0001,
"Solco Healthcare US, LLC",QUINAPRIL HYDROCHLORIDE,,01/19/2023,Reverified,ORAL,Quinapril Hydrochloride Tablet,"312748, 312749, 312750, 314203",,cd46691d-5593-4a9f-a937-999c6803e312,09/17/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,QUINAPRIL,"43547-410, 43547-411, 43547-412, 43547-413","Solco Healthcare US, LLC",b8f1731a-cbac-4f64-a8d4-320b80b335e1,"43547-410-09, 43547-411-09, 43547-412-09, 43547-413-09","Quinapril Hydrochloride, Tablet, 5 mg (NDC 43547-410-09)",Tablet,Unavailable,,ANDA205823,,QUINAPRIL,,,Current,Shortage of an active ingredient,Not available. Long-term backorder for all NDCs. No estimated release date at this time.,,33067B3N2M,43547-410-09,866-931-9829,
Pfizer Inc.,CLINDAMYCIN PHOSPHATE,,03/21/2023,Revised,"INTRAMUSCULAR, INTRAVENOUS",Clindamycin Phosphate Injection,"205964, 309335, 309336, 309339, 685574, 685576, 685578, 706461, 1737244, 1737245, 1737578, 1737579, 1737581, 1737582",,05a75685-0af5-407c-ac57-e380c882b49d,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,CLEOCIN PHOSPHATE,"0009-0902, 0009-0870, 0009-0775, 0009-0728, 0009-3124, 0009-3447, 0009-3381, 0009-3375, 0009-3382, 0009-6582",Pharmacia & Upjohn Company LLC,ac3ba828-3240-4b06-8741-5d1b58e313da,"0009-0870-21, 0009-0870-26, 0009-0775-20, 0009-0775-26, 0009-0902-11, 0009-0902-18, 0009-0728-05, 0009-0728-09, 0009-3124-01, 0009-3124-03, 0009-3447-01, 0009-3447-03, 0009-3381-01, 0009-3381-02, 0009-3375-01, 0009-3375-02, 0009-3382-01, 0009-3382-02, 0009-6582-02, 0009-6582-01","Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)",Injection,Limited Availability,,NDA050441,,CLINDAMYCIN PHOSPHATE,,,Current,Other,Limited Supply Available. Next Delivery and Estimated Recovery: December 2025,,EH6D7113I8,0009-0902-18,800-533-4535,
Baxter Healthcare,DOPAMINE HYDROCHLORIDE,,11/06/2017,Reverified,INTRAVENOUS,Dopamine Hydrochloride Injection,"1292887, 1743869, 1743871, 1743877, 1743879",,cb97d4a0-89ed-407c-a763-209386b6f75c,09/23/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,DOPAMINE HYDROCHLORIDE AND DEXTROSE,"0338-1007, 0338-1005, 0338-1009",Baxter Healthcare Corporation,1b91b75f-c6e4-4425-bea8-023458ecf8f9,"0338-1005-02, 0338-1005-03, 0338-1007-02, 0338-1007-03, 0338-1009-02","Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-03)",Injection,Available,,NDA019615,,DOPAMINE HYDROCHLORIDE,,,Current,,,,7L3E358N9L,0338-1007-03,888-229-0001,
Eli Lilly and Co.,DULOXETINE HYDROCHLORIDE,,10/18/2024,New,ORAL,"Duloxetine Hydrochloride Capsule, Delayed Release","596926, 596928, 596930, 596932, 596934, 615186",,2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba,10/18/2024,HUMAN PRESCRIPTION DRUG,10/18/2024,Psychiatry,CYMBALTA,"0002-3270, 0002-3235, 0002-3240",Eli Lilly and Company,aa5061b1-f237-425a-9d05-575c333dfd37,"0002-3235-60, 0002-3240-30, 0002-3240-90, 0002-3270-30","Cymbalta, Capsule, Delayed Release, 60 mg (NDC 0002-3270-30)",Capsule,,,NDA021427,,DULOXETINE HYDROCHLORIDE,,,To Be Discontinued,,Business decision to discontinue,,9044SC542W,0002-3270-30,800-545-5979,
"Hospira, Inc., a Pfizer Company",GEMCITABINE HYDROCHLORIDE,,09/11/2025,New,INTRAVENOUS,Gemcitabine Hydrochloride Injection,"1720960, 1720975, 1720977",,"dc02a23b-3ff9-4441-aa91-8e9e629a7315, e18ed1cb-7dd0-4001-bfda-17d1f4587fb8",09/11/2025,HUMAN PRESCRIPTION DRUG,09/11/2025,Oncology,GEMCITABINE,"0409-0183, 0409-0181, 0409-0182","Hospira, Inc.","cc0f68d1-df16-441c-b4d7-da06b4baf1e5, 15f70b30-31dc-4c45-902b-69cad93f7308","0409-0181-01, 0409-0183-01, 0409-0182-01, 0409-0181-25, 0409-0182-25, 0409-0183-25","Gemcitabine Hydrochloride, Injection, 200 mg/5.26 mL (38 mg/mL), sterile solution in a single-dose glass vial NovaPlus (NDC 0409-0183-25)",Injection,,,NDA200795,,GEMCITABINE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,U347PV74IL,0409-0183-25,844-646-4398,
"Sun Pharmaceutical Industries, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Revised,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856, 1871456, 1871460, 1871462, 1871464, 1871466, 1871468",,da3148af-f9b6-4725-adae-3595b4c7dc4b,09/22/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"57664-052, 57664-047, 57664-046, 57664-048, 57664-049, 57664-050, 57664-051, 57664-083, 57664-084, 57664-085, 57664-086, 57664-087, 57664-088","Sun Pharmaceutical Industries, Inc.",0b77417a-5789-8818-e063-6294a90ad2e3,"57664-047-88, 57664-046-88, 57664-048-88, 57664-049-88, 57664-050-88, 57664-051-88, 57664-052-88, 57664-083-88, 57664-084-88, 57664-085-88, 57664-086-88, 57664-087-88, 57664-088-88","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 57664-052-88)",Capsule,Limited Availability,,ANDA214484,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,Additional supply anticipated early 2026,,SJT761GEGS,57664-052-88,800-818-4555,
"Fresenius Kabi USA, LLC",SODIUM CHLORIDE,,09/18/2023,Revised,INTRAVENOUS,Sodium Chloride 23.4% Injection,1807571,,4a655cde-283f-4ec8-a3d9-5f539c55c204,07/02/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Endocrinology/Metabolism, Total Parenteral Nutrition, Pediatric",SODIUM CHLORIDE,63323-093,"Fresenius Kabi USA, LLC",570d0b0e-2f05-4b8b-af0f-ad8e7588aad9,"63323-093-01, 63323-093-30","Sodium Chloride 23.4%, Injection, 4 meq/1 mL (NDC 63323-093-30)",Injection,,,ANDA212248,,SODIUM CHLORIDE,,Available,Resolved,,,07/02/2025,451W47IQ8X,63323-093-30,888-386-1300,
Otsuka ICU Medical LLC,DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795477, 1795480, 1795481, 1795607, 1795609, 1795610, 1795612, 1795616, 1795618, 1795621",,8b25b7e0-703e-4b43-a4eb-52863511602d,09/17/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0990-7923, 0990-7922, 0990-7930","ICU Medical, Inc.",09b10612-c937-4d10-becb-9768e10caa2c,"0990-7923-20, 0990-7923-23, 0990-7923-36, 0990-7923-37, 0990-7923-13, 0990-7922-02, 0990-7922-03, 0990-7922-09, 0990-7922-53, 0990-7922-55, 0990-7922-61, 0990-7930-02, 0990-7930-03, 0990-7930-09","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-37)",Injection,Available,,NDA016367,,DEXTROSE MONOHYDRATE,,,Current,,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,LX22YL083G,0990-7923-37,1-866-829-9025 or ProductAvailability@icumed.com,
"Hospira, Inc., a Pfizer Company",DEXTROSE MONOHYDRATE,,01/13/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 50% Injection,"727517, 1795514",,4ed365da-4e62-4329-c1b9-c197ab4fb6e1,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Pediatric",DEXTROSE,"0409-6648, 0409-7517, 0409-4902, 0409-0505","Hospira, Inc.",0fca7d54-4d75-455b-a1d7-d25e31702264,"0409-7517-66, 0409-7517-16, 0409-4902-64, 0409-4902-34, 0409-6648-16, 0409-6648-02, 0409-0505-15, 0409-0505-25","Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02)",Injection,Available,,NDA019445,,DEXTROSE MONOHYDRATE,,,Current,,,,LX22YL083G,0409-6648-02,844-646-4398,
"Lannett Company, Inc.",LISDEXAMFETAMINE DIMESYLATE,,09/20/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,2cedb4c2-1e40-4bc4-b9f4-127150c4afbd,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0527-4666, 0527-4661, 0527-4662, 0527-4663, 0527-4664, 0527-4665, 0527-4667","Lannett Company, Inc.",981ca74f-737d-45e5-a3b2-b25256263768,"0527-4661-37, 0527-4662-37, 0527-4663-37, 0527-4664-37, 0527-4665-37, 0527-4666-37, 0527-4667-37","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0527-4666-37)",Capsule,Limited Availability,,ANDA215802,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,Limited Availability,,SJT761GEGS,0527-4666-37,844-834-0530,
"Teva Pharmaceuticals USA, Inc.",CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,8069b1a0-7c06-4252-b44e-e2eef065d9b8,09/15/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"0093-3212, 0093-0832, 0093-3213","Teva Pharmaceuticals USA, Inc.",d6abe4e3-7699-4ead-95f4-739a961b23ad,"0093-0832-01, 0093-0832-05, 0093-3212-01, 0093-3212-05, 0093-3213-01, 0093-3213-05","Clonazepam, Tablet, 1 mg (NDC 0093-3212-01)",Tablet,Available,"N0000175694, M0002356",ANDA074569,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,,,5PE9FDE8GB,0093-3212-01,800-545-8800,
Eli Lilly and Co.,DULAGLUTIDE,,12/15/2022,Revised,SUBCUTANEOUS,Dulaglutide Injection,"1551295, 1551300, 1551304, 1551306, 2395777, 2395779, 2395783, 2395785",,463050bd-2b1c-40f5-b3c3-0a04bb433309,06/13/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,TRULICITY,"0002-1433, 0002-1434, 0002-2236, 0002-3182",Eli Lilly and Company,2a046089-7cd3-43d3-9f7f-27e3e4b49f0d,"0002-1433-01, 0002-1433-80, 0002-1433-61, 0002-1434-01, 0002-1434-80, 0002-1434-61, 0002-2236-01, 0002-2236-80, 0002-2236-61, 0002-3182-01, 0002-3182-80, 0002-3182-61","Trulicity, Injection, .75 mg/.5 mL (NDC 0002-1433-80)",Injection,,"N0000178480, M0160181, N0000020058",BLA125469,Glucagon-Like Peptide 1 [CS],DULAGLUTIDE,GLP-1 Receptor Agonist [EPC],Available,Resolved,,,06/13/2025,WTT295HSY5,0002-1433-80,800-545-5979,Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
"Fresenius Kabi USA, LLC","EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE ANHYDROUS",,10/14/2016,Reverified,"INFILTRATION, PERINEURAL","Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","1010033, 1010035, 1010671, 1010673, 1010688, 1010692, 1010745, 1010749, 1010751, 1010755, 1010759, 1010763, 1010900, 1010902, 1737343, 1737345, 1737562, 1737563, 1737566, 1737567, 1737568, 1737569, 1737570, 1737571, 1737757, 1737758, 1737761, 1737762, 1867938, 1867940, 1867943, 1867944, 1867992, 1867993, 1867996, 1867997, 1868028, 1868029",,ba082c2f-64f4-419d-9c88-74f203316e17,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",XYLOCAINE,"63323-483, 63323-492, 63323-491, 63323-495, 63323-485, 63323-486, 63323-484, 63323-489, 63323-488, 63323-481, 63323-482, 63323-487","Fresenius Kabi USA, LLC",ea480a68-5927-4278-9deb-2956961da428,"63323-492-04, 63323-492-27, 63323-492-09, 63323-492-57, 63323-492-07, 63323-492-37, 63323-492-03, 63323-492-31, 63323-491-01, 63323-491-57, 63323-495-09, 63323-495-27, 63323-495-04, 63323-495-07, 63323-485-01, 63323-485-27, 63323-485-03, 63323-485-57, 63323-486-01, 63323-486-17, 63323-486-02, 63323-486-27, 63323-486-05, 63323-486-57, 63323-484-57, 63323-489-02, 63323-489-27, 63323-489-03, 63323-489-21, 63323-489-01, 63323-489-17, 63323-488-07, 63323-488-37, 63323-488-03, 63323-488-31, 63323-488-01, 63323-488-17, 63323-481-01, 63323-481-57, 63323-483-03, 63323-483-27, 63323-483-01, 63323-483-57, 63323-482-01, 63323-482-17, 63323-482-03, 63323-482-27, 63323-482-05, 63323-482-57, 63323-487-01, 63323-487-17, 63323-487-07, 63323-487-37, 63323-487-03, 63323-487-31","Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-57)",Injection,Available,,NDA006488,,"LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE",,,Current,,Check wholesalers for inventory,,"EC2CNF7XFP, 30Q7KI53AK",63323-483-57,888-386-1300,
"EMD Serono, Inc.",LEVOTHYROXINE SODIUM,,07/10/2025,New,ORAL,Levothyroxine Sodium Tablet,"892246, 892251, 966153, 966160, 966166, 966173, 966177, 966182, 966187, 966196, 966202, 966207, 966220, 966221, 966222, 966224, 966225, 966248, 966249, 966253, 966270, 2104866",,bc3c6830-ba68-4ba3-9896-a12d0ad0b275,07/10/2025,HUMAN PRESCRIPTION DRUG,07/10/2025,Endocrinology/Metabolism,EUTHYROX,"72305-125, 72305-025, 72305-050, 72305-075, 72305-088, 72305-100, 72305-112, 72305-137, 72305-150, 72305-175, 72305-200","Provell Pharmaceuticals, LLC",45657074-8874-49f4-a8ef-3ca7e210c16e,"72305-025-30, 72305-025-90, 72305-050-30, 72305-050-90, 72305-075-30, 72305-075-90, 72305-088-30, 72305-088-90, 72305-100-30, 72305-100-90, 72305-112-30, 72305-112-90, 72305-125-30, 72305-125-90, 72305-137-30, 72305-137-90, 72305-150-30, 72305-150-90, 72305-175-30, 72305-175-90, 72305-200-30, 72305-200-90","Euthyrox, Tablet, 125 ug (NDC 72305-125-90)",Tablet,,,NDA021292,,LEVOTHYROXINE SODIUM,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,9J765S329G,72305-125-90,888-899-7041,
"Teva Pharmaceuticals USA, Inc.",AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension",,,4c0f348a-a65d-409c-8668-207c82a5e3cb,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0093-4161, 0093-2263, 0093-2264, 0093-4160, 0093-4155, 0093-2267, 0093-2268, 0093-3107, 0093-3109","Teva Pharmaceuticals USA, Inc.",8988589b-0893-4233-ac9c-9884ceb0c2c4,"0093-2263-01, 0093-2264-01, 0093-4160-76, 0093-4160-78, 0093-4160-73, 0093-4155-79, 0093-4155-73, 0093-4155-80, 0093-4161-76, 0093-4161-78, 0093-4161-73, 0093-2267-01, 0093-2268-01, 0093-3107-01, 0093-3107-05, 0093-3109-53, 0093-3109-06, 0093-3109-01, 0093-3109-05","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0093-4161-78)","Powder, For Suspension",,,ANDA065119,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0093-4161-78,800-545-8800,
SpecGx LLC,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,806a1c15-0842-4787-b2ad-09a21fd96b37,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0406-5115, 0406-5111, 0406-5112, 0406-5113, 0406-5114, 0406-5116, 0406-5117",SpecGx LLC,3ffc0695-83f7-4898-9fd7-451c0989cfe0,"0406-5111-01, 0406-5112-01, 0406-5113-01, 0406-5114-01, 0406-5115-01, 0406-5116-01, 0406-5117-01","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0406-5115-01)",Capsule,Limited Availability,,ANDA211840,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,Allocation to all customers.,,SJT761GEGS,0406-5115-01,800-325-8888,
"Upsher-Smith Laboratories, LLC",,,04/28/2025,New,,Midodrine Hydrochloride Tablet,,,,04/28/2025,,04/28/2025,Cardiovascular,,,,,,"Orvaten, Tablet, 5 mg (NDC 55154-5623-0)",Tablet,,,,,,,,To Be Discontinued,,,,,55154-5623-0,800-654-2299,
"Teva Pharmaceuticals USA, Inc.",NORTRIPTYLINE HYDROCHLORIDE,,05/23/2025,New,ORAL,Nortriptyline Hydrochloride Capsule,"198045, 198046, 198047, 317136",,b58d473a-b19f-4d2a-b1ae-dd398d7a29e1,05/23/2025,HUMAN PRESCRIPTION DRUG,05/23/2025,Psychiatry,NORTRIPTYLINE HYDROCHLORIDE,"0093-0813, 0093-0810, 0093-0811, 0093-0812","Teva Pharmaceuticals USA, Inc.",2af44b27-b029-4cec-b74d-2b705888f52e,"0093-0810-01, 0093-0810-05, 0093-0811-01, 0093-0811-05, 0093-0812-01, 0093-0812-05, 0093-0813-01, 0093-0813-05","Nortriptyline Hydrochloride, Capsule, 75 mg (NDC 0093-0813-05)",Capsule,,,ANDA074132,,NORTRIPTYLINE HYDROCHLORIDE,,,To Be Discontinued,,Permanent discontinuation of specific package size/ SKU for business reasons.,,00FN6IH15D,0093-0813-05,800-545-8800,
Pfizer Inc.,,,04/28/2023,New,,Prazosin Hydrochloride Capsule,,,,04/28/2023,,04/28/2023,Cardiovascular,,,,,,"Minipress, Capsule, 2 mg (NDC 0069-4370-71)",Capsule,,,,,,,,To Be Discontinued,,Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023,04/28/2023,,0069-4370-71,800-533-4535,
"Teva Pharmaceuticals USA, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Revised,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,cffbbb15-d776-41ae-a8a6-687f2c07bfa4,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","0555-0776, 0555-0971, 0555-0775, 0555-0972, 0555-0777, 0555-0973, 0555-0974","Teva Pharmaceuticals USA, Inc.",88468f3d-7d03-4cee-aabf-3abc8c9b5e38,"0555-0971-02, 0555-0775-02, 0555-0972-02, 0555-0776-02, 0555-0777-02, 0555-0973-02, 0555-0974-02","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0555-0776-02)",Tablet,Limited Availability,,ANDA040422,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,Other,Estimated recovery: November 2025,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",0555-0776-02,800-545-8800,
Sun Pharmaceutical Industries Limited,VECURONIUM BROMIDE,,09/08/2025,New,INTRAVENOUS,Vecuronium Bromide Injection,859437,,a14da3ee-a731-4282-be9d-407473517470,09/08/2025,HUMAN PRESCRIPTION DRUG,09/08/2025,Anesthesia,VECURONIUM BROMIDE,"47335-932, 47335-931","Sun Pharmaceutical Industries, Inc.",82d6bc45-04a5-409a-9223-da1884b2468f,"47335-931-40, 47335-931-44, 47335-932-40, 47335-932-44","Vecuronium Bromide, Injection, 20 mg (NDC 47335-932-44)",Injection,,,ANDA079001,,VECURONIUM BROMIDE,,,To Be Discontinued,,The 10 mg presentation remains available.,,7E4PHP5N1D,47335-932-44,800-818-4555,
Eugia US LLC,CARBOPLATIN,,04/28/2023,Revised,INTRAVENOUS,Carboplatin Injection,597195,,"f5fe9a20-47a5-45b9-ab06-c6158d9b6aca, 5abfcb87-bb02-4384-9c9d-7d0e3e809311",09/05/2025,HUMAN PRESCRIPTION DRUG,,Oncology,CARBOPLATIN,"55150-335, 55150-333, 55150-334, 55150-386",Eugia US LLC,"6029d051-ee8d-44cc-8dae-b91c3385d4c3, 5abfcb87-bb02-4384-9c9d-7d0e3e809311","55150-333-01, 55150-334-01, 55150-335-01, 55150-386-01, 55150-335-00, 55150-386-00","Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)",Injection,Unavailable,"N0000175413, N0000175073",ANDA205487,,CARBOPLATIN,Platinum-based Drug [EPC],,Current,Demand increase for the drug,On backorder. Recovery: TBD. Check wholesalers for inventory,,BG3F62OND5,55150-335-01,888-238-7880,
"Teva Pharmaceuticals USA, Inc.","BENZOYL PEROXIDE, CLINDAMYCIN PHOSPHATE",,08/01/2025,New,TOPICAL,Clindamycin Phosphate; Benzoyl Peroxide Gel,885131,,87622142-000b-460b-977e-92d6735f5337,08/01/2025,HUMAN PRESCRIPTION DRUG,08/01/2025,Dermatology,CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE,0591-3916,"Actavis Pharma, Inc.",c2dcadb5-8ef3-4c6a-af4f-bf201184a6d0,0591-3916-68,"Clindamycin Phosphate; Benzoyl Peroxide, Gel, 25 mg/1 g; 10 mg/1 g (NDC 0591-3916-68)",Gel,,,ANDA205128,,CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE,,,To Be Discontinued,,A business decision was made to discontinue manufacture of the product.,,"W9WZN9A0GM, EH6D7113I8",0591-3916-68,800-545-8800,
Ferring,,,03/12/2021,Reverified,,Desmopressin Acetate Spray,,,,09/17/2025,,,Hematology,,,,,,"Desmopressin Acetate, Spray, 10 ug/.1 mL (NDC 69918-501-05)",Spray,Unavailable,,,,,,,Current,Requirements related to complying with good manufacturing practices,,,,69918-501-05,888-337-7464,
"Hospira, Inc., a Pfizer Company",HYDROCORTISONE SODIUM SUCCINATE,,03/24/2023,Revised,"INTRAMUSCULAR, INTRAVENOUS",Hydrocortisone Sodium Succinate Injection,"105398, 238755, 1738586, 1738589, 1738590, 1738592, 1738594, 1738596",https://www.fda.gov/media/187228/download,65eefd58-b166-4d71-ade6-45c8fdf86922,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Pulmonary/Allergy, Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Pediatric, Renal, Rheumatology",SOLU-CORTEF,"0009-0011, 0009-0825, 0009-0013, 0009-0016, 0009-0005",Pharmacia & Upjohn Company LLC,8512044a-4a54-4634-bb97-9e20126adc61,"0009-0825-01, 0009-0011-03, 0009-0011-04, 0009-0013-05, 0009-0013-06, 0009-0016-12, 0009-0005-01","Solu-cortef, Injection, 100 mg/vial (NDC 0009-0011-04)",Injection,Limited Availability,,NDA009866,,HYDROCORTISONE SODIUM SUCCINATE,,,Current,Demand increase for the drug,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,12/19/2024,50LQB69S1Z,0009-0011-04,844-646-4398,
Pfizer Inc.,METHYLPREDNISOLONE ACETATE,,12/15/2021,Revised,"INTRALESIONAL, INTRAMUSCULAR, INTRASYNOVIAL, SOFT TISSUE",Methylprednisolone Acetate Injection,"1358510, 1358512, 1358610, 1358612, 1358617, 1358619",,823b0010-2b57-4e76-b5ac-4a8c2963438f,08/15/2025,HUMAN PRESCRIPTION DRUG,,Rheumatology,DEPO-MEDROL,"0009-0280, 0009-0274, 0009-0306",Pharmacia & Upjohn Company LLC,4cf5a255-1360-4511-9b58-b92e3492ef12,"0009-0274-01, 0009-0280-02, 0009-0280-51, 0009-0280-03, 0009-0280-52, 0009-0306-02, 0009-0306-12","Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)",Injection,Available,,NDA011757,,METHYLPREDNISOLONE ACETATE,,,Current,,,,43502P7F0P,0009-0280-03,844-646-4398,
"Caplin Steriles, Ltd.",ROPIVACAINE HYDROCHLORIDE,,12/22/2020,Reverified,"EPIDURAL, INFILTRATION, PERINEURAL",Ropivacaine Hydrochloride Injection,"1734084, 1734207, 1734475, 1734483",,781d4b7f-7556-4695-8d48-7772d7a0d8e9,09/16/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROPIVACAINE HYDROCHLORIDE,"43066-019, 43066-015, 43066-023, 43066-027",Baxter Healthcare Corporation,ef624077-2197-426c-9521-8f966f49240b,"43066-015-01, 43066-015-10, 43066-019-01, 43066-019-10, 43066-023-01, 43066-023-10, 43066-027-01, 43066-027-10","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-019-10)",Injection,Available,,ANDA212808,,ROPIVACAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory; Marketed by Baxter,,V910P86109,43066-019-10,888-229-0001,
"Hospira, Inc., a Pfizer Company",SODIUM CHLORIDE,,06/21/2018,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Sodium Chloride 0.9% Injection,"1807628, 1807631, 1807637, 1807638",,8eb172da-dcd4-4660-4a8f-ad44a14b4af7,08/08/2025,HUMAN PRESCRIPTION DRUG,,Other,SODIUM CHLORIDE,"0409-4888, 0409-1918","Hospira, Inc.",9ee88abb-024a-4a3b-9776-1777eaf2f760,"0409-4888-02, 0409-4888-10, 0409-4888-03, 0409-4888-20, 0409-4888-06, 0409-4888-50, 0409-4888-01, 0409-4888-12, 0409-4888-90, 0409-1918-42, 0409-1918-32, 0409-1918-43, 0409-1918-33, 0409-1918-45, 0409-1918-35","Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-4888-12)",Injection,,,NDA018803,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0409-4888-12,844-646-4398,
Rubicon Research Private Limited,CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"72888-152, 72888-153, 72888-154",Advagen Pharma Ltd,36cf156e-5980-a21b-e063-6294a90ab3a0,"72888-152-30, 72888-152-01, 72888-152-05, 72888-152-00, 72888-153-30, 72888-153-01, 72888-153-05, 72888-153-00, 72888-154-30, 72888-154-01, 72888-154-05, 72888-154-00","Clonazepam, Tablet, .5 mg (NDC 72888-152-05)",Tablet,Available,"N0000175694, M0002356",ANDA075468,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,Marketed by Advagen Pharma Ltd.,,5PE9FDE8GB,72888-152-05,sales@advagenpharma.com,
"Mylan Institutional, a Viatris Company",DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718906, 1718909",,f140de5a-f13d-46b4-a742-049c63e474f5,09/17/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE HYDROCHLORIDE,"67457-925, 67457-924",Mylan Institutional LLC,b51a1fb0-fcee-4a76-9eaf-91c35813c242,"67457-924-00, 67457-924-50, 67457-925-00, 67457-925-10","Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 67457-925-10)",Injection,Available,,ANDA212571,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,,,,1018WH7F9I,67457-925-10,800-796-9526,
Otsuka ICU Medical LLC,DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795477, 1795480, 1795481, 1795607, 1795609, 1795610, 1795612, 1795616, 1795618, 1795621",,8b25b7e0-703e-4b43-a4eb-52863511602d,09/17/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0990-7923, 0990-7922, 0990-7930","ICU Medical, Inc.",09b10612-c937-4d10-becb-9768e10caa2c,"0990-7923-20, 0990-7923-23, 0990-7923-36, 0990-7923-37, 0990-7923-13, 0990-7922-02, 0990-7922-03, 0990-7922-09, 0990-7922-53, 0990-7922-55, 0990-7922-61, 0990-7930-02, 0990-7930-03, 0990-7930-09","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-20)",Injection,Available,,NDA016367,,DEXTROSE MONOHYDRATE,,,Current,,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,LX22YL083G,0990-7923-20,1-866-829-9025 or ProductAvailability@icumed.com,
"Noven Pharmaceuticals, Inc.",METHYLPHENIDATE,Central Nervous System Stimulation [PE],02/28/2025,Reverified,TRANSDERMAL,"Methylphenidate Film, Extended Release",,,2c312c31-3198-4775-91ab-294e0b4b9e7f,08/19/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,DAYTRANA,"68968-5554, 68968-5552, 68968-5553, 68968-5555","Noven Therapeutics, LLC",55f4b5f4-6d3c-4677-a94c-d47ffb59a91a,"68968-5552-3, 68968-5553-3, 68968-5554-3, 68968-5555-3","Daytrana, Film, Extended Release, 20 mg (NDC 68968-5554-3)","Film, Extended Release",Unavailable,"N0000175739, N0000175729",NDA021514,,METHYLPHENIDATE,Central Nervous System Stimulant [EPC],,Current,Shortage of an active ingredient,Estimated availability TBD,,207ZZ9QZ49,68968-5554-3,800-455-8070,
"Fresenius Kabi USA, LLC",MIDAZOLAM HYDROCHLORIDE,,04/02/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Midazolam Hydrochloride Injection,"311700, 311702",,a91ce254-14a3-4cbf-8ab8-5da252aa3fdc,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology",MIDAZOLAM,"63323-411, 63323-412","Fresenius Kabi USA, LLC",9814447b-a93e-42ad-b57e-5db0a5b7f552,"63323-411-22, 63323-411-27, 63323-411-15, 63323-411-12, 63323-411-18, 63323-411-25, 63323-411-13, 63323-411-10, 63323-412-18, 63323-412-25, 63323-412-03, 63323-412-02, 63323-412-06, 63323-412-05, 63323-412-13, 63323-412-10","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-10)",Injection,Unavailable,,ANDA075154,,MIDAZOLAM HYDROCHLORIDE,,,Current,Delay in shipping of the drug,Not available at this time.,,W7TTW573JJ,63323-411-10,888-386-1300,
"Somerset Therapeutics, LLC",ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Reverified,"EPIDURAL, INFILTRATION, PERINEURAL",Ropivacaine Hydrochloride Injection,"905189, 1734084, 1734090, 1734203, 1734207, 1734475, 1734483",,ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64,08/19/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROPIVACAINE HYDROCHLORIDE,"70069-061, 70069-062, 70069-063, 70069-064, 70069-065, 70069-066, 70069-067","Somerset Therapeutics, LLC",5d7b0e44-19ce-4127-b3e8-d7e6e65f1818,"70069-061-01, 70069-061-25, 70069-061-10, 70069-062-01, 70069-062-25, 70069-062-10, 70069-063-01, 70069-063-25, 70069-064-01, 70069-064-10, 70069-064-25, 70069-065-01, 70069-065-25, 70069-066-01, 70069-066-25, 70069-066-10, 70069-067-01, 70069-067-25, 70069-067-10","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-10)",Injection,Available,,ANDA207636,,ROPIVACAINE HYDROCHLORIDE,,,Current,,,,V910P86109,70069-061-10,732-554-1019,
"Caplin Steriles, Ltd.",ROPIVACAINE HYDROCHLORIDE,,12/22/2020,Reverified,"EPIDURAL, INFILTRATION, PERINEURAL",Ropivacaine Hydrochloride Injection,"1734084, 1734207, 1734475, 1734483",,781d4b7f-7556-4695-8d48-7772d7a0d8e9,09/16/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROPIVACAINE HYDROCHLORIDE,"43066-027, 43066-015, 43066-019, 43066-023",Baxter Healthcare Corporation,ef624077-2197-426c-9521-8f966f49240b,"43066-015-01, 43066-015-10, 43066-019-01, 43066-019-10, 43066-023-01, 43066-023-10, 43066-027-01, 43066-027-10","Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 43066-027-10)",Injection,Available,,ANDA212808,,ROPIVACAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory; Marketed by Baxter,,V910P86109,43066-027-10,888-229-0001,
"Fresenius Kabi USA, LLC",SODIUM CHLORIDE,,01/01/2020,Revised,INTRAVENOUS,Sodium Chloride 23.4% Injection,313016,,b6e33138-841a-471f-a934-c4086cbc23f6,07/02/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Endocrinology/Metabolism, Total Parenteral Nutrition, Pediatric",SODIUM CHLORIDE,63323-099,"Fresenius Kabi USA, LLC",f5197532-af45-42c9-919b-30d00276650e,"63323-099-03, 63323-099-63","Sodium Chloride 23.4%, Injection, 4 meq/1 mL (NDC 63323-099-63)",Injection,,,ANDA217796,,SODIUM CHLORIDE,,Available,Resolved,,,07/02/2025,451W47IQ8X,63323-099-63,888-386-1300,
"Upsher-Smith Laboratories, LLC",TOPIRAMATE,Decreased Central Nervous System Disorganized Electrical Activity [PE],04/24/2025,New,ORAL,"Topiramate Capsule, Extended Release","1494766, 1494769, 1494771, 1494775, 1494778, 1494781, 1812419, 1812421, 1812425, 1812427",,46f54677-3a22-4c38-9b92-923020164e15,04/24/2025,HUMAN PRESCRIPTION DRUG,04/24/2025,Neurology,QUDEXY XR,"0245-1075, 0245-1071, 0245-1072, 0245-1074, 0245-1073","Upsher-Smith Laboratories, LLC",374eeb55-b017-48fd-e063-6294a90a6ad7,"0245-1071-30, 0245-1071-90, 0245-1072-30, 0245-1072-90, 0245-1074-30, 0245-1074-90, 0245-1075-30, 0245-1075-90, 0245-1073-30, 0245-1073-90","Qudexy XR, Capsule, Extended Release, 150 mg (NDC 0245-1075-30)","Capsule, Extended Release",,"N0000008486, N0000185506, N0000182140",NDA205122,,TOPIRAMATE,,,To Be Discontinued,,Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.,,0H73WJJ391,0245-1075-30,716-315-2000,"Cytochrome P450 3A4 Inducers [MoA], Cytochrome P450 2C19 Inhibitors [MoA]"
"Hikma Pharmaceuticals USA, Inc.",CEFOTAXIME SODIUM,,02/17/2015,Reverified,INTRAVENOUS,"Cefotaxime Sodium Powder, for Solution",309065,,ef1a6dc6-bc3d-4f09-8f92-7ff328f56561,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",CEFOTAXIME,0143-9935,Hikma Pharmaceuticals USA Inc.,e25af43f-54cb-4526-a8a5-6bef0a7939c7,0143-9935-01,"Cefotaxime Sodium, Powder, for Solution, 10 g (NDC 0143-9935-01)","Powder, For Solution",Unavailable,,ANDA065071,,CEFOTAXIME,,,Current,Demand increase for the drug,Shortage duration is unknown at this time.,,258J72S7TZ,0143-9935-01,800-631-2174,
"Hospira, Inc., a Pfizer Company","EPINEPHRINE, LIDOCAINE HYDROCHLORIDE",,02/22/2012,Reverified,"INFILTRATION, PERINEURAL","Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","1010688, 1010745, 1010751, 1010759, 1867996, 1867998",,2f94f711-14c4-48ec-c5a3-c5ec4b8e8729,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE,"0409-3182, 0409-1209, 0409-3177, 0409-3178, 0409-3181, 0409-3183, 0409-0007, 0409-0147","Hospira, Inc.",d16a4711-e663-455e-a1fe-236a41ca4e8f,"0409-1209-10, 0409-1209-01, 0409-1209-05, 0409-1209-70, 0409-1209-65, 0409-3177-16, 0409-3177-01, 0409-3178-16, 0409-3178-01, 0409-3178-17, 0409-3178-02, 0409-3178-18, 0409-3178-03, 0409-3181-11, 0409-3181-01, 0409-3182-11, 0409-3182-01, 0409-3182-21, 0409-3182-02, 0409-3182-31, 0409-3182-03, 0409-3183-11, 0409-3183-01, 0409-0007-01, 0409-0007-10, 0409-0147-01, 0409-0147-10","Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)",Injection,Available,"N0000000209, N0000000245, N0000175552, N0000175555, N0000175570, M0003647",ANDA089646,Catecholamines [CS],LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE,"alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC], Catecholamine [EPC]",,Current,,,,"V13007Z41A, YKH834O4BH",0409-3182-03,844-646-4398,"Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA]"
Janssen Pharmaceuticals,METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Reverified,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release","1091155, 1091157, 1091170, 1091172, 1091185, 1091187, 1091210, 1091212",,1a88218c-5b18-4220-8f56-526de1a276cd,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,CONCERTA,"50458-587, 50458-585, 50458-588, 50458-586","Janssen Pharmaceuticals, Inc.",23987e85-013d-3aaa-e063-6394a90a1f2d,"50458-585-01, 50458-588-01, 50458-586-01, 50458-587-01","Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01)",Tablet,Available,,NDA021121,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,,,,4B3SC438HI,50458-587-01,800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET,
WG Critical Care,MIDAZOLAM,,04/02/2020,Reverified,INTRAVENOUS,Midazolam Hydrochloride Injection,"2541170, 2541171",,f051776f-94c5-4e34-80ed-f45b9c36881e,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology",MIDAZOLAM IN SODIUM CHLORIDE,"44567-610, 44567-611","WG Critical Care, LLC.",8b577103-b84e-4344-a3ff-b18b77f856cc,"44567-610-01, 44567-610-10, 44567-611-01, 44567-611-10","Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-610-10)",Injection,Available,"N0000175694, M0002356",NDA211844,Benzodiazepines [CS],MIDAZOLAM,Benzodiazepine [EPC],,Current,,Please check wholesalers and distributors for inventory.,,R60L0SM5BC,44567-610-10,888-493-0861,
"Hospira, Inc., a Pfizer Company",BUPIVACAINE HYDROCHLORIDE,,01/10/2025,New,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Bupivacaine Hydrochloride Injection,"1725078, 1725082, 1012377, 1012384, 1012396, 1012404, 1672917, 1672919, 1724786, 1724787, 1724880, 1724884, 1867594, 1867596",,"bb44c7e1-d911-4788-908f-09b7b271969b, 02a845c3-4521-4926-e397-25ab536e7cf6",01/10/2025,HUMAN PRESCRIPTION DRUG,01/10/2025,Anesthesia,BUPIVACAINE HYDROCHLORIDE,"0409-1159, 0409-1160, 0409-1162, 0409-1163, 0409-1165, 0409-9043, 0409-9046, 0409-9045, 0409-9042","Hospira, Inc.","40bfa804-5f31-4bd2-b1e3-dcf428710dc1, 3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7","0409-1159-09, 0409-1159-10, 0409-1159-18, 0409-1159-01, 0409-1159-19, 0409-1159-02, 0409-1160-18, 0409-1160-01, 0409-1162-18, 0409-1162-01, 0409-1162-19, 0409-1162-02, 0409-1163-18, 0409-1163-01, 0409-1165-18, 0409-1165-01, 0409-1165-19, 0409-1165-02, 0409-9043-11, 0409-9043-01, 0409-9046-11, 0409-9046-01, 0409-9045-11, 0409-9045-01, 0409-9045-16, 0409-9045-17, 0409-9042-11, 0409-9042-01, 0409-9042-16, 0409-9042-17","Bupivacaine Hydrochloride, Injection, 0.25%; 75 mg/30 mL (2.5 mg/mL); 30 mL Single Dose Glass Teartop Vial NOVAPLUS (NDC 0409-1159-10)",Injection,,,ANDA070583,,BUPIVACAINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,"7TQO7W3VT8, 30Q7KI53AK",0409-1159-10,844-646-4398,
"Fresenius Kabi USA, LLC","BUPIVACAINE HYDROCHLORIDE, EPINEPHRINE BITARTRATE",,02/20/2018,Revised,"EPIDURAL, RETROBULBAR","Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","1012391, 1012396, 1012404, 1012421, 1012455, 1012457, 1672917, 1672919, 1673296, 1673298, 1724880, 1724881, 1724884, 1724885, 1725078, 1725082, 1725175, 1725177",,eb6d8fee-def4-4c96-9972-695e8cea8ea8,09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,SENSORCAINE MPF,"63323-460, 63323-465, 63323-467, 63323-464, 63323-466, 63323-462","Fresenius Kabi USA, LLC",2b1a1f80-cb29-4ac1-9e72-20225ed45715,"63323-465-01, 63323-465-57, 63323-467-01, 63323-467-57, 63323-460-01, 63323-460-37, 63323-464-02, 63323-464-37, 63323-464-03, 63323-464-31, 63323-466-01, 63323-466-37, 63323-466-02, 63323-466-31, 63323-462-04, 63323-462-17, 63323-462-01, 63323-462-37, 63323-462-02, 63323-462-31","Sensorcaine, Injection, 7.5 mg/1 mL; .005 mg/1 mL (NDC 63323-460-37)",Injection,Available,,NDA018304,,BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE,,,Current,,7 mos expiry available upon request. Check wholesaler for inventory.,,"30Q7KI53AK, 7TQO7W3VT8",63323-460-37,888-386-1300,
Baxter Healthcare,DOBUTAMINE HYDROCHLORIDE,,11/06/2017,Reverified,INTRAVENOUS,Dobutamine Hydrochloride Injection,"309985, 309986, 309987",,6b17b98b-e06d-42ed-925f-69aa2699dead,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Cardiovascular, Pediatric, Renal",DOBUTAMINE HYDROCHLORIDE IN DEXTROSE,"0338-1073, 0338-1075, 0338-1077",Baxter Healthcare Corporation,2ac85da3-8337-4b3b-8cda-d9399780542f,"0338-1073-02, 0338-1075-02, 0338-1077-02","Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 mg/100 mL (NDC 0338-1073-02)",Injection,Available,,NDA020255,,DOBUTAMINE HYDROCHLORIDE,,,Current,,,,0WR771DJXV,0338-1073-02,888-229-0001,
Rhodes Pharmaceuticals L.P.,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,d918b40d-a461-41bc-b6c0-83dc76c28e32,08/05/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"42858-163, 42858-161, 42858-162, 42858-164, 42858-165, 42858-166, 42858-167",Rhodes Pharmaceuticals,4bb64a6b-cce9-4c4a-81c3-06e2e59315c3,"42858-161-01, 42858-162-01, 42858-163-01, 42858-164-01, 42858-165-01, 42858-166-01, 42858-167-01","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 42858-163-01)",Capsule,Available,,ANDA215330,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,42858-163-01,888-827-0616,
"Elite Laboratories, Inc.",NALTREXONE HYDROCHLORIDE,,02/29/2024,Revised,ORAL,Naltrexone Hydrochloride Tablet,1483744,,60276f5c-657a-4b60-bcd0-44234903d7e0,09/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,NALTREXONE HYDROCHLORIDE,51224-206,TAGI Pharma Inc.,c82a0ed4-3236-4166-90a8-f5e43e6dd883,"51224-206-30, 51224-206-50","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 51224-206-30)",Tablet,Available,,ANDA075274,,NALTREXONE HYDROCHLORIDE,,,Current,,Marketed by Tagi Pharma; Customer service: 800-397-9228,,Z6375YW9SF,51224-206-30,888-852-6657,
"Teva Pharmaceuticals USA, Inc.",SILVER NITRATE,,10/15/2024,New,TOPICAL,Silver Nitrate Solution,312952,,6956c883-fc1b-49be-97bc-e642e0aa907d,10/15/2024,HUMAN PRESCRIPTION DRUG,10/15/2024,Dermatology,SILVER NITRATE,0093-9614,"Teva Pharmaceuticals USA, Inc.",868ab0ba-c1bb-41a4-96cc-e9ec8ddb64a1,0093-9614-13,"Solution, .005 g/1 mL (NDC 0093-9614-13)",Solution,,,,,SILVER NITRATE,,,To Be Discontinued,,,,95IT3W8JZE,0093-9614-13,800-545-8800,
"Hospira, Inc., a Pfizer Company",SODIUM BICARBONATE,,03/01/2017,Revised,INTRAVENOUS,Sodium Bicarbonate Injection,1868469,,"0c24b592-4bc8-456f-acac-9c9525844a06, ea9f4498-0d43-4043-8dd1-f22537841c21",08/15/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Pediatric",SODIUM BICARBONATE,0409-5555,"Hospira, Inc.","6493c4d8-9ef7-4ec3-b373-6b3ecf5db9b0, 037c4aeb-4a95-4c37-8214-a30110b1d47f","0409-5555-11, 0409-5555-01, 0409-5555-12, 0409-5555-02","Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-02)",Injection,Limited Availability,,ANDA202981,,SODIUM BICARBONATE,,,Current,Other,Limited Supply Available. Next Delivery and Estimated Recovery: September 2025,01/03/2025,8MDF5V39QO,0409-5555-02,844-646-4398,
Pfizer Inc.,TALAZOPARIB TOSYLATE,,01/13/2025,New,ORAL,Talazoparib Tosylate Capsule,"2099946, 2099952, 2099954, 2099956, 2591510, 2591512, 2591520, 2591521, 2639960, 2639962, 2639964, 2639966",,f2423edd-6d24-495c-aec1-c2f457f08d9a,01/13/2025,HUMAN PRESCRIPTION DRUG,01/13/2025,Oncology,TALZENNA,"0069-1195, 0069-0296, 0069-1501, 0069-1751, 0069-1031, 0069-1235",Pfizer Laboratories Div Pfizer Inc,2cb65f61-9a14-46d9-85a3-a7eea76160c5,"0069-0296-30, 0069-1195-30, 0069-1501-30, 0069-1751-30, 0069-1031-30, 0069-1235-30","Talzenna, Capsule, 1 mg (NDC 0069-1195-30)",Capsule,,,NDA211651,,TALAZOPARIB,,,To Be Discontinued,,"Supply expected to exhaust late February 2025
Replaced with Soft Gel NDC 0069-0757-30",,02WK9U5NZC,0069-1195-30,800-533-4535,
"Teva Pharmaceuticals USA, Inc.",FINASTERIDE,,08/19/2025,New,ORAL,Finasteride Tablet,310346,,77589cc3-c440-4695-800c-82a0e5128a6c,08/19/2025,HUMAN PRESCRIPTION DRUG,08/19/2025,Urology,FINASTERIDE,0093-7355,"Teva Pharmaceuticals USA, Inc.",ea83e229-c434-4097-81dd-e3b48814d5dc,"0093-7355-56, 0093-7355-98, 0093-7355-05","Finasteride, Tablet, 5 mg (NDC 0093-7355-05)",Tablet,,"N0000175836, N0000000126",ANDA076511,,FINASTERIDE,5-alpha Reductase Inhibitor [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug product,,57GNO57U7G,0093-7355-05,800-545-8800,5-alpha Reductase Inhibitors [MoA]
"Fresenius Kabi USA, LLC",HYDROMORPHONE HYDROCHLORIDE,,10/31/2017,Reverified,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Hydromorphone Hydrochloride Injection,"897653, 897753, 1724276, 1724338, 1724340, 1724341",,e034eb96-03e0-46e1-8b92-5e1f94555e7b,09/18/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,HYDROMORPHONE HYDROCHLORIDE,"63323-851, 63323-852, 63323-853, 63323-854","Fresenius Kabi USA, LLC",9e8522c6-595c-46f9-bb25-272aa4683e0f,"63323-851-03, 63323-851-10, 63323-851-07, 63323-851-15, 63323-851-50, 63323-852-03, 63323-852-25, 63323-853-03, 63323-853-25, 63323-854-03, 63323-854-10","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-10)",Injection,Unavailable,,NDA019034,,HYDROMORPHONE HYDROCHLORIDE,,,Current,Demand increase for the drug,Backordered. Next release not available at this time. Check wholesaler for inventory.,,L960UP2KRW,63323-851-10,888-386-1300,
"Elite Laboratories, Inc.",NALTREXONE HYDROCHLORIDE,,02/29/2024,Revised,ORAL,Naltrexone Hydrochloride Tablet,1483744,,5f188bdc-2009-43aa-ad32-f06dbfac2642,09/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,NALTREXONE HYDROCHLORIDE,64850-300,"Elite Laboratories, Inc.",cae1ac14-ab22-42d1-8449-5e36c137b905,"64850-300-30, 64850-300-01","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 64850-300-30)",Tablet,Available,,ANDA075274,,NALTREXONE HYDROCHLORIDE,,,Current,,,,Z6375YW9SF,64850-300-30,888-852-6657,
"Hikma Pharmaceuticals USA, Inc.",ROCURONIUM BROMIDE,,02/15/2023,Reverified,INTRAVENOUS,Rocuronium Bromide Injection,1234995,,d3a172a5-01ab-47d8-92ac-a8539b1d4dc4,07/23/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROCURONIUM BROMIDE,"0143-9250, 0143-9251",Hikma Pharmaceuticals USA Inc.,1b6667a4-f267-483a-ae9f-2a514db8a21d,"0143-9250-01, 0143-9250-10, 0143-9251-01, 0143-9251-10","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9250-10)",Injection,Available,,ANDA204679,,ROCURONIUM BROMIDE,,,Current,,Additional lots will be available.  Product will be made available as it is released.,,I65MW4OFHZ,0143-9250-10,800-631-2174,
Bristol Myers Squibb Co.,AZACITIDINE,,12/18/2020,Reverified,"INTRAVENOUS, SUBCUTANEOUS",Azacitidine Injection,"485246, 545206",,3495a71a-cc04-4776-851f-f185956f32af,09/17/2025,HUMAN PRESCRIPTION DRUG,,Oncology,VIDAZA,59572-102,Celgene Corporation,8cba79e2-11fa-4eb9-87e7-827ca781fbf3,59572-102-01,"Vidaza, Injection, 100 mg (NDC 59572-102-01)",Injection,Available,"N0000000233, N0000175595",NDA050794,,AZACITIDINE,Nucleoside Metabolic Inhibitor [EPC],,Current,,,,M801H13NRU,59572-102-01,1-888-423-5436,Nucleic Acid Synthesis Inhibitors [MoA]
"Actavis Pharma, Inc.",MEMANTINE HYDROCHLORIDE,,11/21/2024,New,ORAL,Memantine Hydrochloride Tablet,"996561, 996571, 996572",,72973b46-f307-4a9e-8fb1-ad2cbccfd736,11/21/2024,HUMAN PRESCRIPTION DRUG,11/21/2024,Neurology,MEMANTINE HYDROCHLORIDE,"0591-3875, 0591-3870, 0591-3900","Actavis Pharma, Inc.",985e1190-b8a0-4775-9a20-ad1924b14fb2,"0591-3870-60, 0591-3870-45, 0591-3870-44, 0591-3875-60, 0591-3875-45, 0591-3875-44, 0591-3900-87","Namenda, Tablet, 10 mg (NDC 0591-3875-60)",Tablet,,,NDA021487,,MEMANTINE HYDROCHLORIDE,,,To Be Discontinued,,,,JY0WD0UA60,0591-3875-60,800-545-8800,
"Amphastar Pharmaceuticals, Inc.",MORPHINE SULFATE,,12/06/2018,Reverified,INTRAVENOUS,Morphine Sulfate Injection,,,1034467f-d436-4b87-a902-c7e8885daa8a,09/16/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,MORPHINE SULFATE,76329-1912,"International Medication Systems, Limited",99799101-d92b-485b-93ec-f2b5a2e5ca26,"76329-1912-0, 76329-1912-1","Morphine Sulfate, Injection, 1 mg/1 mL (NDC 76329-1912-1)",Injection,Available,,ANDA202861,,MORPHINE SULFATE,,,Current,,,,X3P646A2J0,76329-1912-1,800-423-4136,
Novast Labs,OXALIPLATIN,,04/22/2025,New,INTRAVENOUS,Oxaliplatin Injection,"1736776, 1736781",,9613ae3d-72e2-40f7-8151-b43e915a6f1c,04/22/2025,HUMAN PRESCRIPTION DRUG,04/22/2025,Oncology,OXALIPLATIN,"50742-406, 50742-405","Ingenus Pharmaceuticals, LLC",91b1d13f-6401-496f-a2e5-76e84775efd0,"50742-405-10, 50742-406-20","Oxaliplatin, Injection, 100 mg/20 mL (NDC 50742-406-20)",Injection,,"N0000175413, N0000175073",ANDA207562,,OXALIPLATIN,Platinum-based Drug [EPC],,To Be Discontinued,,This product is distributed by Ingenus Pharmaceuticals. Customer service: customerservice@ingenus.com or 866-321-5031,,04ZR38536J,50742-406-20,866-321-5031 (Ingenus Pharmaceuticals),
"Teva Pharmaceuticals USA, Inc.",AMANTADINE HYDROCHLORIDE,,02/05/2025,New,ORAL,Amantadine Hydrochloride Capsule,849395,,d9c9eaf7-dcc7-49c1-99d4-49f4dac3779f,02/05/2025,HUMAN PRESCRIPTION DRUG,02/05/2025,"Antiviral, Neurology",AMANTADINE HYDROCHLORIDE,0591-4920,"Actavis Pharma, Inc.",67ce5a52-d507-4333-b0a0-b7177f896aec,"0591-4920-01, 0591-4920-05","Amantadine Hydrochloride, Capsule, 100 mg (NDC 0591-4920-05)",Capsule,,,ANDA208096,,AMANTADINE HYDROCHLORIDE,,,To Be Discontinued,,A business decision was made to discontinue manufacture of the drug.,,M6Q1EO9TD0,0591-4920-05,800-545-8800,
"Mylan Pharmaceuticals Inc., a Viatris Company",TOLTERODINE TARTRATE,,02/26/2025,New,ORAL,"Tolterodine Tartrate Capsule, Extended Release","855182, 855184, 855189, 855191",,d7274947-4f88-47ee-a39f-bd5ac46fcf8d,02/26/2025,HUMAN PRESCRIPTION DRUG,02/26/2025,Urology,DETROL LA,"58151-103, 58151-104",Viatris Specialty LLC,a1e49744-9302-47ee-92af-8b19aa0b2fc1,"58151-103-93, 58151-103-77, 58151-103-05, 58151-104-93, 58151-104-77, 58151-104-05","Detrol LA, Capsule, Extended Release, 2 mg (NDC 58151-103-77)","Capsule, Extended Release",,,NDA021228,,TOLTERODINE TARTRATE,,,To Be Discontinued,,,,5T619TQR3R,58151-103-77,800-796-9526,
"Hospira, Inc., a Pfizer Company","BUPIVACAINE HYDROCHLORIDE, EPINEPHRINE BITARTRATE",,02/20/2018,Revised,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL","Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","1012377, 1012384, 1012396, 1012404, 1672917, 1672919, 1724786, 1724787, 1724880, 1724884, 1725078, 1725082, 1867594, 1867596",,02a845c3-4521-4926-e397-25ab536e7cf6,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE,"0409-9042, 0409-1159, 0409-1160, 0409-1162, 0409-1163, 0409-1165, 0409-9043, 0409-9046, 0409-9045","Hospira, Inc.",3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7,"0409-1159-18, 0409-1159-01, 0409-1159-19, 0409-1159-02, 0409-1160-18, 0409-1160-01, 0409-1162-18, 0409-1162-01, 0409-1162-19, 0409-1162-02, 0409-1163-18, 0409-1163-01, 0409-1165-18, 0409-1165-01, 0409-1165-19, 0409-1165-02, 0409-9043-11, 0409-9043-01, 0409-9046-11, 0409-9046-01, 0409-9045-11, 0409-9045-01, 0409-9045-16, 0409-9045-17, 0409-9042-11, 0409-9042-01, 0409-9042-16, 0409-9042-17","Bupivacaine Hydrochloride And Epinephrine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-9042-01)",Injection,Unavailable,,ANDA071165,,BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE,,,Current,Other,Shortage per Manufacturer: Manufacturing Delay,,"30Q7KI53AK, 7TQO7W3VT8",0409-9042-01,844-646-4398,
Sun Pharmaceutical Industries Limited,CLINDAMYCIN HYDROCHLORIDE,,12/05/2024,New,ORAL,Clindamycin Hydrochloride Capsule,"197518, 284215",,1dbd8448-c1e5-46df-8060-50ef82380445,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Anti-Infective,CLINDAMYCIN HYDROCHLORIDE,"63304-693, 63304-692","Sun Pharmaceutical Industries, Inc.",339366d4-2060-1c29-e063-6394a90a1cb7,"63304-692-01, 63304-692-05, 63304-692-77, 63304-692-03, 63304-693-16, 63304-693-01, 63304-693-03, 63304-693-05, 63304-693-77, 63304-693-11, 63304-693-62","Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-03)",Capsule,,,ANDA065061,,CLINDAMYCIN HYDROCHLORIDE,,,To Be Discontinued,,Discontinuing for business reasons,,T20OQ1YN1W,63304-693-03,800-818-4555,
"Hospira, Inc., a Pfizer Company",DOPAMINE HYDROCHLORIDE,,11/06/2017,Revised,INTRAVENOUS,Dopamine Hydrochloride Injection,"1292887, 1743877, 1743879",,08f23f6e-150d-45ea-098e-f2edf64c21a1,08/15/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,DOPAMINE HYDROCHLORIDE IN DEXTROSE,"0409-7809, 0409-7810","Hospira, Inc.",3b4d4d9d-5e19-420f-a447-1ad8346844d9,"0409-7809-11, 0409-7809-22, 0409-7809-31, 0409-7809-24, 0409-7810-11, 0409-7810-22","Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/500 mL (1.6 mg/1 mL) (NDC 0409-7809-24)",Injection,Unavailable,,NDA018826,,DOPAMINE HYDROCHLORIDE IN DEXTROSE,,,Current,Other,Shortage per Manufacturer: Manufacturing Delay,,7L3E358N9L,0409-7809-24,844-646-4398,
"Noven Pharmaceuticals, Inc.",METHYLPHENIDATE,Central Nervous System Stimulation [PE],02/28/2025,Revised,TRANSDERMAL,"Methylphenidate Film, Extended Release",,,7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb,08/19/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE TRANSDERMAL SYSTEM,"0574-2430, 0574-2410, 0574-2415, 0574-2420",PADAGIS US LLC,b743ef45-2fc0-4086-8a02-6078e6a09eaa,"0574-2410-65, 0574-2415-65, 0574-2420-65, 0574-2430-65","Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65)","Film, Extended Release",Unavailable,"N0000175739, N0000175729",NDA021514,,METHYLPHENIDATE,Central Nervous System Stimulant [EPC],,Current,Shortage of an active ingredient,Estimated availability: early September 2025. Distributed by Padagis US LLC,,207ZZ9QZ49,0574-2430-65,800-455-8070,
B. Braun Medical Inc.,"DEXTROSE, UNSPECIFIED FORM",,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795477, 1795480, 1795481, 1795607, 1795610, 1795612",,085614c7-ada4-4e2c-87c0-c9bc2f18365a,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0264-7510, 0264-7520",B. Braun Medical Inc.,c9f87749-8dd5-41fd-b393-f63d45fd00ef,"0264-7510-00, 0264-7510-10, 0264-7510-20, 0264-7520-00, 0264-7520-10, 0264-7520-20","Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-00)",Injection,Available,,NDA019626,,DEXTROSE,,,Current,,,,IY9XDZ35W2,0264-7510-00,800-227-2862,
"EMD Serono, Inc.",LEVOTHYROXINE SODIUM,,07/10/2025,New,ORAL,Levothyroxine Sodium Tablet,"892246, 892251, 966153, 966160, 966166, 966173, 966177, 966182, 966187, 966196, 966202, 966207, 966220, 966221, 966222, 966224, 966225, 966248, 966249, 966253, 966270, 2104866",,bc3c6830-ba68-4ba3-9896-a12d0ad0b275,07/10/2025,HUMAN PRESCRIPTION DRUG,07/10/2025,Endocrinology/Metabolism,EUTHYROX,"72305-175, 72305-025, 72305-050, 72305-075, 72305-088, 72305-100, 72305-112, 72305-125, 72305-137, 72305-150, 72305-200","Provell Pharmaceuticals, LLC",45657074-8874-49f4-a8ef-3ca7e210c16e,"72305-025-30, 72305-025-90, 72305-050-30, 72305-050-90, 72305-075-30, 72305-075-90, 72305-088-30, 72305-088-90, 72305-100-30, 72305-100-90, 72305-112-30, 72305-112-90, 72305-125-30, 72305-125-90, 72305-137-30, 72305-137-90, 72305-150-30, 72305-150-90, 72305-175-30, 72305-175-90, 72305-200-30, 72305-200-90","Euthyrox, Tablet, 175 ug (NDC 72305-175-30)",Tablet,,,NDA021292,,LEVOTHYROXINE SODIUM,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,9J765S329G,72305-175-30,888-899-7041,
Accord Healthcare Inc.,METHOTREXATE,,03/13/2023,Reverified,"INTRA-ARTERIAL, INTRAMUSCULAR, INTRATHECAL, INTRAVENOUS",Methotrexate Sodium Injection,"1655956, 1655959, 1655960",,dd035a9f-cd40-4314-b9d8-2294b8a924e2,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Rheumatology, Oncology",METHOTREXATE,16729-277,"Accord Healthcare, Inc.",2bae3cfe-7aa0-c14c-e063-6294a90a19f4,"16729-277-30, 16729-277-03, 16729-277-35","Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)",Injection,Unavailable,"N0000175584, N0000000111",ANDA040716,,METHOTREXATE,Folate Analog Metabolic Inhibitor [EPC],,Current,Shortage of an active ingredient,Resupply: estimated 21 days,,YL5FZ2Y5U1,16729-277-35,"866-941-7875, option 2",Folic Acid Metabolism Inhibitors [MoA]
SpecGx LLC,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 1009145",,72ddd1c9-ddbd-4c95-acd9-003189a353a3,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE,"0406-8884, 0406-8891, 0406-8892, 0406-8885, 0406-8893, 0406-8894",SpecGx LLC,b25a2f3f-ee3a-44c0-a475-f371025c767b,"0406-8891-01, 0406-8884-01, 0406-8892-01, 0406-8885-01, 0406-8893-01, 0406-8894-01","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0406-8884-01)",Tablet,Available,,ANDA040440,,DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE,,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",0406-8884-01,800-325-8888,
Pfizer Inc.,METHYLPREDNISOLONE ACETATE,,12/15/2021,Revised,"INTRALESIONAL, INTRAMUSCULAR, INTRASYNOVIAL, SOFT TISSUE",Methylprednisolone Acetate Injection,"1358510, 1358512, 1358610, 1358612, 1358617, 1358619",,823b0010-2b57-4e76-b5ac-4a8c2963438f,08/15/2025,HUMAN PRESCRIPTION DRUG,,Rheumatology,DEPO-MEDROL,"0009-0280, 0009-0274, 0009-0306",Pharmacia & Upjohn Company LLC,4cf5a255-1360-4511-9b58-b92e3492ef12,"0009-0274-01, 0009-0280-02, 0009-0280-51, 0009-0280-03, 0009-0280-52, 0009-0306-02, 0009-0306-12","Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-02)",Injection,Limited Availability,,NDA011757,,METHYLPREDNISOLONE ACETATE,,,Current,Other,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,43502P7F0P,0009-0280-02,844-646-4398,
Sun Pharmaceutical Industries Limited,TIAGABINE HYDROCHLORIDE,,12/09/2024,New,ORAL,Tiagabine Hydrochloride Tablet,"1299911, 1299917",,7eeb2d81-c5d7-46a0-aa5c-149b55df71bd,12/09/2024,HUMAN PRESCRIPTION DRUG,12/09/2024,Neurology,TIAGABINE HYDROCHLORIDE,"62756-224, 62756-200","Sun Pharmaceutical Industries, Inc.",57975e74-e45b-4fd9-9718-bfc9690acae5,"62756-200-83, 62756-200-18, 62756-224-83, 62756-224-88, 62756-224-08, 62756-224-18","Tiagabine Hydrochloride, Tablet, 4 mg (NDC 62756-224-08)",Tablet,,,ANDA077555,,TIAGABINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuing for business reasons,,DQH6T6D8OY,62756-224-08,800-818-4555,
"Actavis Pharma, Inc.",EZETIMIBE,Decreased Cholesterol Absorption [PE],06/27/2025,New,ORAL,Ezetimibe Tablet,349556,,f26e7a4e-b3d9-4cf8-baf0-7423d46cd8ba,06/27/2025,HUMAN PRESCRIPTION DRUG,06/27/2025,Cardiovascular,EZETIMIBE,0591-3713,"Actavis Pharma, Inc.",24aaf5ca-08e0-4db8-9734-cf2a606f8e57,"0591-3713-30, 0591-3713-19, 0591-3713-05","Ezetimibe, Tablet, 10 mg (NDC 0591-3713-05)",Tablet,,"N0000008553, N0000175911",ANDA200831,,EZETIMIBE,Dietary Cholesterol Absorption Inhibitor [EPC],,To Be Discontinued,,A business decision was made to discontinue manufacture of the product,,EOR26LQQ24,0591-3713-05,800-545-8800,
"Fresenius Kabi USA, LLC",FENTANYL CITRATE,,01/01/2012,Revised,"INTRAMUSCULAR, INTRAVENOUS",Fentanyl Citrate Injection,"1735003, 1735007, 1735008, 1735013, 2168270",,38d0c14a-a0c1-44cc-a939-0304eb8037d6,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Pediatric",FENTANYL CITRATE,63323-806,"Fresenius Kabi USA, LLC",341b092a-1f6f-40f1-98f2-9346bf2e1242,"63323-806-11, 63323-806-01, 63323-806-12, 63323-806-02, 63323-806-13, 63323-806-05, 63323-806-14, 63323-806-20, 63323-806-50","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)",Injection,Unavailable,,ANDA210762,,FENTANYL CITRATE,,,Current,Other,Backordered. Next release October 2025. Check wholesalers for inventory.,,MUN5LYG46H,63323-806-50,888-386-1300,
"Hospira, Inc., a Pfizer Company",GEMCITABINE HYDROCHLORIDE,,09/11/2025,New,INTRAVENOUS,Gemcitabine Hydrochloride Injection,"1720960, 1720975, 1720977",,"dc02a23b-3ff9-4441-aa91-8e9e629a7315, e18ed1cb-7dd0-4001-bfda-17d1f4587fb8",09/11/2025,HUMAN PRESCRIPTION DRUG,09/11/2025,Oncology,GEMCITABINE,"0409-0181, 0409-0183, 0409-0182","Hospira, Inc.","cc0f68d1-df16-441c-b4d7-da06b4baf1e5, 15f70b30-31dc-4c45-902b-69cad93f7308","0409-0181-01, 0409-0183-01, 0409-0182-01, 0409-0181-25, 0409-0182-25, 0409-0183-25","Gemcitabine Hydrochloride, Injection, 1 g/26.3 mL (38 mg/mL), sterile solution in a single-dose glass vial  NovaPlus (NDC 0409-0181-25)",Injection,,,NDA200795,,GEMCITABINE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,U347PV74IL,0409-0181-25,844-646-4398,
"Hikma Pharmaceuticals USA, Inc.",LIDOCAINE HYDROCHLORIDE,,06/13/2018,Revised,"INFILTRATION, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010671",,5523fdfe-69fd-49a5-b51f-73e2223d49a9,07/23/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,LIDOCAINE,"0143-9575, 0143-9579, 0143-9578, 0143-9577, 0143-9576, 0143-9172, 0143-9173",Hikma Pharmaceuticals USA Inc.,3e5c0afe-9377-4040-ab89-55a6dbb5693c,"0143-9579-01, 0143-9579-25, 0143-9578-01, 0143-9578-10, 0143-9577-01, 0143-9577-10, 0143-9576-01, 0143-9576-25, 0143-9575-01, 0143-9575-10, 0143-9172-01, 0143-9172-10, 0143-9173-01, 0143-9173-10","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0143-9575-10)",Injection,Available,,ANDA080407,,LIDOCAINE HYDROCHLORIDE,,,Current,,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,V13007Z41A,0143-9575-10,800-631-2174,
"Elite Laboratories, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,0e024b69-567c-4b40-9c3e-a2daec34256c,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"64850-554, 64850-550, 64850-551, 64850-552, 64850-553, 64850-555, 64850-556","Elite Laboratories, Inc.",e414bb2e-d404-44ea-931c-5998b0a4c87e,"64850-550-01, 64850-551-01, 64850-552-01, 64850-553-01, 64850-554-01, 64850-555-01, 64850-556-01","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 64850-554-01)",Capsule,Limited Availability,,ANDA218604,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,,,SJT761GEGS,64850-554-01,888-852-6657,
"Hikma Pharmaceuticals USA, Inc.",MIDAZOLAM HYDROCHLORIDE,,04/02/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Midazolam Hydrochloride Injection,"311700, 311702",,575d8bf0-7af7-427c-a231-966e2a5e070d,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology",MIDAZOLAM,"0641-6059, 0641-6057, 0641-6056, 0641-6061, 0641-6063, 0641-6060",Hikma Pharmaceuticals USA Inc.,559c03fb-24ea-4b7b-8afd-e33cb3a2340a,"0641-6057-01, 0641-6057-10, 0641-6057-25, 0641-6059-01, 0641-6059-10, 0641-6056-01, 0641-6056-10, 0641-6061-01, 0641-6061-10, 0641-6061-25, 0641-6063-01, 0641-6063-10, 0641-6063-25, 0641-6060-01, 0641-6060-10","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)",Injection,Available,,ANDA075243,,MIDAZOLAM,,,Current,,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,W7TTW573JJ,0641-6059-01,800-631-2174,
"Elite Laboratories, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,e677690f-790f-4626-ad78-097cdb6ea540,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","64850-503, 64850-500, 64850-501, 64850-502, 64850-504, 64850-505, 64850-506","Elite Laboratories, Inc.",b65e0266-7172-4730-8f93-eb42e08fb7b8,"64850-500-01, 64850-500-05, 64850-500-30, 64850-501-01, 64850-501-05, 64850-501-30, 64850-502-01, 64850-502-05, 64850-502-30, 64850-503-01, 64850-503-05, 64850-503-30, 64850-504-01, 64850-504-05, 64850-504-30, 64850-505-01, 64850-505-05, 64850-505-30, 64850-506-01, 64850-506-05, 64850-506-30","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 64850-503-01)",Tablet,Limited Availability,,ANDA211352,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,Shortage of an active ingredient,3 months,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",64850-503-01,888-852-6657,
"Fresenius Kabi USA, LLC",ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Reverified,"EPIDURAL, INFILTRATION",Ropivacaine Hydrochloride Injection,"1734203, 1734204, 1734207, 1734208, 1734347, 1734348, 1734355, 1734356, 1734475, 1734476, 1734479, 1734480, 1734481, 1734482, 1734483, 1734484, 905189, 905191, 1734084, 1734086, 1734090, 1734091",,"dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7, 23d2d448-a744-4877-9f2d-7e57c198da89, c6613708-c1f7-4f5c-91a3-ebbc1d7905c6",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,NAROPIN,"63323-285, 63323-286, 63323-287, 63323-288","Fresenius Kabi USA, LLC","324532ac-4e54-4659-a1a2-9ade22a1ed3f, cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9, 73218c89-8925-468c-84bf-9960b4b3dc3c","63323-286-41, 63323-286-27, 63323-286-43, 63323-286-38, 63323-285-41, 63323-285-28, 63323-285-53, 63323-285-68, 63323-285-59, 63323-285-73, 63323-286-01, 63323-286-20, 63323-286-05, 63323-286-23, 63323-286-09, 63323-286-31, 63323-286-11, 63323-286-35, 63323-286-03, 63323-286-00, 63323-286-33, 63323-286-63, 63323-286-30, 63323-287-01, 63323-287-20, 63323-287-03, 63323-287-21, 63323-288-01, 63323-288-10, 63323-288-06, 63323-288-20, 63323-288-03, 63323-288-11, 63323-288-07, 63323-288-21, 63323-285-01, 63323-285-10, 63323-285-06, 63323-285-20, 63323-285-03, 63323-285-13, 63323-285-07, 63323-285-23, 63323-285-57, 63323-285-64, 63323-285-51, 63323-285-65, 63323-285-02, 63323-285-61, 63323-285-04, 63323-285-63, 63323-285-55, 63323-285-67, 63323-288-23, 63323-288-29, 63323-286-93, 63323-286-95","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-23)",Injection,Available,,NDA020533,,ROPIVACAINE HYDROCHLORIDE,,,Current,,,,V910P86109,63323-285-23,888-386-1300,
Strides Pharma Inc.,SERTRALINE HYDROCHLORIDE,,01/22/2025,New,ORAL,Sertraline Hydrochloride Tablet,"312938, 312940, 312941",,1f99e897-1b70-40b0-8c19-71d0bba19422,01/22/2025,HUMAN PRESCRIPTION DRUG,01/22/2025,Psychiatry,SERTRALINE HYDROCHLORIDE,"71093-130, 71093-129, 71093-131","ACI Healthcare USA, Inc.",3f41fc19-b54a-46fd-acbf-b411816bccd5,"71093-129-01, 71093-129-03, 71093-129-05, 71093-130-01, 71093-130-03, 71093-130-05, 71093-131-01, 71093-131-03, 71093-131-05","Sertraline Hydrochloride, Tablet, 50 mg (NDC 71093-130-05)",Tablet,,,ANDA076881,,SERTRALINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,UTI8907Y6X,71093-130-05,877-244-9825,
Ailex Pharmaceuticals,CROMOLYN SODIUM,,11/03/2023,Revised,ORAL,Cromolyn Sodium Concentrate,831261,,a742664b-265e-49f9-9744-d04e1fb620ae,08/15/2025,HUMAN PRESCRIPTION DRUG,,Pulmonary/Allergy,CROMOLYN SODIUM,81665-104,Omnivium Pharmaceuticals LLC,3df4d7be-4e96-4e6d-ba6e-b9c93acd76e2,81665-104-96,"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 81665-104-96)",Concentrate,Available,,ANDA209264,,CROMOLYN SODIUM,,,Current,,Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195,,Q2WXR1I0PK,81665-104-96,Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195 or customerservice@omniviumpharma.com,
"Hikma Pharmaceuticals USA, Inc.",FENTANYL CITRATE,,12/20/2023,Revised,"INTRAMUSCULAR, INTRAVENOUS",Fentanyl Citrate Injection,"1735003, 1735007, 1735008, 1735013, 2168270, 2474269, 2629337",,ce5db1c2-feb1-4ad2-847a-d02e865bd47e,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Pediatric",FENTANYL CITRATE,"0641-6025, 0641-6024, 0641-6027, 0641-6028, 0641-6026, 0641-6029, 0641-6030, 0641-6247, 0641-6248, 0641-6249",Hikma Pharmaceuticals USA Inc.,aca9742b-d890-426a-8296-14ca64748238,"0641-6024-01, 0641-6024-10, 0641-6027-01, 0641-6027-25, 0641-6025-01, 0641-6025-10, 0641-6028-01, 0641-6028-10, 0641-6028-25, 0641-6026-01, 0641-6026-05, 0641-6029-01, 0641-6029-25, 0641-6030-01, 0641-6247-01, 0641-6247-25, 0641-6248-01, 0641-6248-10, 0641-6249-01, 0641-6249-10","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6025-10)",Injection,Unavailable,,NDA019101,,FENTANYL CITRATE,,,Current,Other,Inventory available in vial presentations.,,MUN5LYG46H,0641-6025-10,800-631-2174,
"Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)",FONDAPARINUX SODIUM,,09/29/2025,New,SUBCUTANEOUS,Fondaparinux Sodium Injection,"861356, 861360, 861363, 861365",,baa50757-a927-4d56-a933-5d7798fe6ab0,09/29/2025,HUMAN PRESCRIPTION DRUG,09/29/2025,Hematology,FONDAPARINUX SODIUM,"0781-3476, 0781-3443, 0781-3454, 0781-3465",Sandoz Inc.,3d5a4b69-462b-7e51-e063-6294a90a0721,"0781-3443-94, 0781-3443-12, 0781-3443-95, 0781-3454-94, 0781-3454-12, 0781-3454-95, 0781-3465-94, 0781-3465-12, 0781-3465-95, 0781-3476-94, 0781-3476-12, 0781-3476-95","Fondaparinux Sodium, Injection, 10 mg/.8 mL (NDC 0781-3476-95)",Injection,,,ANDA206812,,FONDAPARINUX SODIUM,,,To Be Discontinued,,Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc.,,X0Q6N9USOZ,0781-3476-95,"609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)",
"Mylan Institutional, a Viatris Company",REMIFENTANIL HYDROCHLORIDE,,06/28/2022,Reverified,INTRAVENOUS,Remifentanil Hydrochloride Injection,"1729578, 1729581, 1729584, 1729586, 1729710, 1729712",,8b4c8696-e23e-4c51-a4d2-babab5bd945a,09/17/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,ULTIVA,"72078-034, 72078-035, 72078-036",Mylan Institutional LLC,c10cf43f-066a-43ff-9166-242cbb7754af,"72078-034-00, 72078-034-01, 72078-035-00, 72078-035-02, 72078-036-00, 72078-036-05","Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01)",Injection,Available,,NDA020630,,REMIFENTANIL HYDROCHLORIDE,,,Current,,,,5V444H5WIC,72078-034-01,800-796-9526,
"Elite Laboratories, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,e677690f-790f-4626-ad78-097cdb6ea540,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","64850-505, 64850-500, 64850-501, 64850-502, 64850-503, 64850-504, 64850-506","Elite Laboratories, Inc.",b65e0266-7172-4730-8f93-eb42e08fb7b8,"64850-500-01, 64850-500-05, 64850-500-30, 64850-501-01, 64850-501-05, 64850-501-30, 64850-502-01, 64850-502-05, 64850-502-30, 64850-503-01, 64850-503-05, 64850-503-30, 64850-504-01, 64850-504-05, 64850-504-30, 64850-505-01, 64850-505-05, 64850-505-30, 64850-506-01, 64850-506-05, 64850-506-30","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 64850-505-01)",Tablet,Limited Availability,,ANDA211352,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,Shortage of an active ingredient,3 months,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",64850-505-01,888-852-6657,
Strides Pharma Inc.,SERTRALINE HYDROCHLORIDE,,01/22/2025,New,ORAL,Sertraline Hydrochloride Tablet,"312938, 312940, 312941",,1f99e897-1b70-40b0-8c19-71d0bba19422,01/22/2025,HUMAN PRESCRIPTION DRUG,01/22/2025,Psychiatry,SERTRALINE HYDROCHLORIDE,"71093-131, 71093-129, 71093-130","ACI Healthcare USA, Inc.",3f41fc19-b54a-46fd-acbf-b411816bccd5,"71093-129-01, 71093-129-03, 71093-129-05, 71093-130-01, 71093-130-03, 71093-130-05, 71093-131-01, 71093-131-03, 71093-131-05","Sertraline Hydrochloride, Tablet, 100 mg (NDC 71093-131-03)",Tablet,,,ANDA076881,,SERTRALINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,UTI8907Y6X,71093-131-03,877-244-9825,
Slayback Pharma,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718900, 1718906, 1718909",,e5d28ed8-e427-4850-81aa-98702d3b6a5d,09/17/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE HYDROCHLORIDE,71225-126,Slayback Pharma LLC,027725dc-e468-446c-b702-ab0f8a9e3be5,"71225-126-02, 71225-126-05, 71225-126-03, 71225-126-06, 71225-126-01, 71225-126-04","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 71225-126-06)",Injection,Available,,ANDA212791,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,,,,1018WH7F9I,71225-126-06,844-566-2505,
Amneal Pharmaceuticals,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718906, 1718909",,eb1ba463-ab42-4f49-9ebe-3ad5af108326,09/17/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE HYDROCHLORIDE,"70121-1389, 70121-1388",Amneal Pharmaceuticals LLC,795f643f-855c-4ba4-9bad-a96334c1a2fb,"70121-1388-1, 70121-1388-8, 70121-1389-1, 70121-1389-7","Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 100 mL (NDC 70121-1389-1)",Injection,Available,,ANDA207551,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,,,,1018WH7F9I,70121-1389-1,866-525-7270,
"Hikma Pharmaceuticals USA, Inc.",LORAZEPAM,,05/03/2018,Revised,"INTRAMUSCULAR, INTRAVENOUS",Lorazepam Injection,"238100, 238101, 1665188, 1665326",,e9b54e42-04cf-4c62-90e1-36f7b31a4e81,07/23/2025,HUMAN PRESCRIPTION DRUG,,Neurology,LORAZEPAM,"0641-6047, 0641-6044, 0641-6046, 0641-6045",Hikma Pharmaceuticals USA Inc.,7c73dbc6-2623-4443-9b05-97dec7a0be2e,"0641-6044-01, 0641-6044-25, 0641-6046-01, 0641-6046-10, 0641-6045-01, 0641-6045-25, 0641-6047-01, 0641-6047-10","Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10)",Injection,Unavailable,"N0000175694, M0002356",NDA018140,Benzodiazepines [CS],LORAZEPAM,Benzodiazepine [EPC],,Current,Regulatory delay,Shortage duration unknown,,O26FZP769L,0641-6047-10,800-631-2174,
Aurobindo Pharma USA,METOPROLOL TARTRATE,,06/03/2025,New,ORAL,Metoprolol Tartrate Tablet,"866511, 866514, 866924",,2b705cb6-cb75-4c2a-907a-4bd45d18bc2c,06/03/2025,HUMAN PRESCRIPTION DRUG,06/03/2025,Cardiovascular,METOPROLOL TARTRATE,"65862-063, 65862-062, 65862-064",Aurobindo Pharma Limited,d265c99d-8e77-4a78-b542-15e957d9d335,"65862-062-01, 65862-062-99, 65862-063-60, 65862-063-01, 65862-063-99, 65862-064-60, 65862-064-01, 65862-064-99","Metoprolol Tartrate, Tablet, 50 mg (NDC 65862-063-01)",Tablet,,,ANDA077739,,METOPROLOL TARTRATE,,,To Be Discontinued,,Permanent discontinuation in the manufacturing of the drug,,W5S57Y3A5L,65862-063-01,866-850-2876,
"Teva Pharmaceuticals USA, Inc.",PRAVASTATIN SODIUM,,06/13/2025,New,ORAL,Pravastatin Sodium Tablet,"904458, 904467, 904475",,99e0e848-f8f3-4b42-b880-8fbc42633948,06/13/2025,HUMAN PRESCRIPTION DRUG,06/13/2025,Cardiovascular,PRAVASTATIN SODIUM,"0093-7202, 0093-0771, 0093-7201","Teva Pharmaceuticals USA, Inc.",72579e23-23ef-4ab7-ad64-24d5ea7997eb,"0093-0771-98, 0093-0771-10, 0093-7201-98, 0093-7201-10, 0093-7202-98, 0093-7202-10","Pravastatin Sodium, Tablet, 40 mg (NDC 0093-7202-10)",Tablet,,,ANDA076056,,PRAVASTATIN SODIUM,,,To Be Discontinued,,,,3M8608UQ61,0093-7202-10,800-545-8800,
"Fresenius Kabi USA, LLC",DEXAMETHASONE SODIUM PHOSPHATE,,02/08/2019,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Dexamethasone Sodium Phosphate Injection,2099700,,4dd55929-fe0a-4884-ae0d-6f9435920eb7,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Other, Pulmonary/Allergy, Rheumatology",DEXAMETHASONE SODIUM PHOSPHATE,"76045-109, 76045-212","Fresenius Kabi USA, LLC",9f09143c-220b-46f8-b3ef-44bc348f7eec,"76045-109-01, 76045-109-10, 76045-212-00, 76045-212-10","Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-109-10)",Injection,Available,,ANDA209192,,DEXAMETHASONE SODIUM PHOSPHATE,,,Current,,Check wholesalers for inventory,,AI9376Y64P,76045-109-10,888-386-1300,
Sandoz Inc.,AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","239191, 308182, 308189, 308191, 308192, 308194, 313797, 313850",,13bd4214-9b7f-425b-af5f-fc1ddc678230,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0781-6157, 0781-2020, 0781-2613, 0781-5060, 0781-5061, 0781-6039, 0781-6156, 0781-6041",Sandoz Inc,6aa02079-d11c-4d2f-acaf-9548dd9a7ed6,"0781-2020-31, 0781-2020-76, 0781-2020-01, 0781-2020-05, 0781-2613-31, 0781-2613-76, 0781-2613-01, 0781-2613-05, 0781-5060-20, 0781-5060-01, 0781-5061-20, 0781-5061-01, 0781-6039-58, 0781-6039-46, 0781-6039-55, 0781-6156-52, 0781-6156-57, 0781-6156-46, 0781-6041-58, 0781-6041-46, 0781-6041-55, 0781-6157-52, 0781-6157-57, 0781-6157-46","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0781-6157-57)","Powder, For Suspension",,,ANDA065378,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0781-6157-57,800-545-8747,
"Fresenius Kabi USA, LLC",MIDAZOLAM HYDROCHLORIDE,,04/02/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Midazolam Hydrochloride Injection,"311700, 311702",,"a91ce254-14a3-4cbf-8ab8-5da252aa3fdc, 09daf48f-1d44-4b7b-bb53-bd5635b93ca6",09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology",MIDAZOLAM,"63323-412, 63323-411","Fresenius Kabi USA, LLC","9814447b-a93e-42ad-b57e-5db0a5b7f552, c2aaa2df-aa73-4ea7-96be-528010260e25","63323-411-22, 63323-411-27, 63323-411-15, 63323-411-12, 63323-411-18, 63323-411-25, 63323-411-13, 63323-411-10, 63323-412-18, 63323-412-25, 63323-412-03, 63323-412-02, 63323-412-06, 63323-412-05, 63323-412-13, 63323-412-10, 63323-412-00","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-10)",Injection,Unavailable,,"ANDA075154, ANDA208878",,MIDAZOLAM HYDROCHLORIDE,,,Current,Demand increase for the drug,Not available at this time.,,W7TTW573JJ,63323-412-10,888-386-1300,
Strides Pharma Inc.,SERTRALINE HYDROCHLORIDE,,01/22/2025,New,ORAL,Sertraline Hydrochloride Tablet,"312938, 312940, 312941",,1f99e897-1b70-40b0-8c19-71d0bba19422,01/22/2025,HUMAN PRESCRIPTION DRUG,01/22/2025,Psychiatry,SERTRALINE HYDROCHLORIDE,"71093-129, 71093-130, 71093-131","ACI Healthcare USA, Inc.",3f41fc19-b54a-46fd-acbf-b411816bccd5,"71093-129-01, 71093-129-03, 71093-129-05, 71093-130-01, 71093-130-03, 71093-130-05, 71093-131-01, 71093-131-03, 71093-131-05","Sertraline Hydrochloride, Tablet, 25 mg (NDC 71093-129-03)",Tablet,,,ANDA076881,,SERTRALINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,UTI8907Y6X,71093-129-03,877-244-9825,
"Lannett Company, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,f92497b5-baea-4760-b615-45a0b6184402,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","0527-0766, 0527-0760, 0527-0761, 0527-0762, 0527-0763, 0527-0764, 0527-0765","Lannett Company, Inc.",e0804f43-4685-4017-b839-3212d1167362,"0527-0760-37, 0527-0761-37, 0527-0762-37, 0527-0763-37, 0527-0764-37, 0527-0765-37, 0527-0766-37","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0527-0766-37)",Tablet,Available,,ANDA215565,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",0527-0766-37,844-834-0530,
"Teva Pharmaceuticals USA, Inc.",CELECOXIB,,08/15/2025,New,ORAL,Celecoxib Capsule,"205322, 205323, 349514, 686379",,05224473-27dc-4f6d-a52a-c40a7af2f2f4,08/15/2025,HUMAN PRESCRIPTION DRUG,08/15/2025,Analgesia/Addiction,CELECOXIB,"0591-3984, 0591-3982, 0591-3983, 0591-3985","Actavis Pharma, Inc.",64c601bc-9b67-400f-9e30-e26de56f2f8b,"0591-3982-60, 0591-3983-01, 0591-3983-05, 0591-3984-01, 0591-3984-05, 0591-3985-60","Celecoxib, Capsule, 200 mg (NDC 0591-3984-05)",Capsule,,"N0000000160, M0001335, N0000175722",ANDA200562,"Anti-Inflammatory Agents, Non-Steroidal [CS]",CELECOXIB,Nonsteroidal Anti-inflammatory Drug [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,JCX84Q7J1L,0591-3984-05,800-545-8800,Cyclooxygenase Inhibitors [MoA]
Baxter Healthcare,CLINDAMYCIN PHOSPHATE,,03/21/2023,Revised,INTRAVENOUS,Clindamycin Phosphate Injection,"309335, 309336, 309339",,44fa506b-90ac-42de-831b-5f3f1a500fc0,09/23/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,CLINDAMYCIN PHOSPHATE,"0338-9553, 0338-9545, 0338-9549",Baxter Healthcare Company,12bdbbc9-fbb0-4a0a-9147-37df8ac5dc5e,"0338-9545-50, 0338-9545-24, 0338-9549-50, 0338-9549-24, 0338-9553-50, 0338-9553-24","Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-9553-50)",Injection,Limited Availability,,NDA208083,,CLINDAMYCIN PHOSPHATE,,,Current,Demand increase for the drug,Estimated recovery: October 2025,,EH6D7113I8,0338-9553-50,888-229-0001,
Aurobindo Pharma USA,"AMLODIPINE BESYLATE, BENAZEPRIL HYDROCHLORIDE",,03/04/2025,New,ORAL,Amlodipine Besylate; Benazepril Hydrochloride Capsule,"898342, 898346, 898350, 898353, 898356, 898359",,99ed4927-9a34-4e8d-8eea-60b63c867d46,03/04/2025,HUMAN PRESCRIPTION DRUG,03/04/2025,Cardiovascular,AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE,"65862-583, 65862-582, 65862-584, 65862-585, 65862-586, 65862-587",Aurobindo Pharma Limited,a45ec3e8-1d14-4c27-9685-976323df8cad,"65862-582-01, 65862-582-05, 65862-583-01, 65862-583-05, 65862-584-01, 65862-584-05, 65862-585-01, 65862-585-05, 65862-586-01, 65862-586-05, 65862-587-01, 65862-587-05","Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 10 mg (NDC 65862-583-05)",Capsule,,,ANDA202239,,AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE,,,To Be Discontinued,,,,"864V2Q084H, N1SN99T69T",65862-583-05,866-850-2876,
"Hospira, Inc., a Pfizer Company",FENTANYL CITRATE,,01/01/2012,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Fentanyl Citrate Injection,"1735003, 1735004, 1735006, 1735007, 1735008, 1735013",,bfa8018a-4cbc-434b-e09e-782872b0340a,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Pediatric",FENTANYL CITRATE,"0409-9094, 0409-9093","Hospira, Inc.",e4b31fdd-00af-416d-b14e-dbac0c83da97,"0409-9093-37, 0409-9093-32, 0409-9093-45, 0409-9093-35, 0409-9093-41, 0409-9093-36, 0409-9093-31, 0409-9093-38, 0409-9094-12, 0409-9094-22, 0409-9094-18, 0409-9094-25, 0409-9094-17, 0409-9094-28, 0409-9094-16, 0409-9094-31, 0409-9094-41, 0409-9094-61","Fentanyl Citrate, Injection, 500 mcg/10 mL (50 ug/1 mL) (NDC 0409-9094-28)",Injection,Available,,NDA019115,,FENTANYL CITRATE,,,Current,,,01/02/2025,MUN5LYG46H,0409-9094-28,844-646-4398,
Rubicon Research Private Limited,LIDOCAINE HYDROCHLORIDE,,12/08/2023,Revised,"ORAL, TOPICAL",Lidocaine Hydrochloride Solution,1010739,,ae40021b-8df8-4b16-aac0-dcec88f76c7d,08/29/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,LIDOCAINE HYDROCHLORIDE,72888-125,Advagen Pharma Ltd,314135bb-9f25-3673-e063-6294a90ae8c2,72888-125-26,"Lidocaine Hydrochloride, Solution, 20 mg/1 mL (NDC 72888-125-26)",Solution,,,ANDA216780,,LIDOCAINE HYDROCHLORIDE,,Available,Resolved,,,08/29/2025,V13007Z41A,72888-125-26,Daliya.Bharati@advagenpharma.com,
"Hospira, Inc., a Pfizer Company",MIDAZOLAM HYDROCHLORIDE,,04/02/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Midazolam Hydrochloride Injection,"1666800, 1666814, 1666823, 1666798",,"b95415fa-17c2-42ab-a6b0-e628d01c94ed, 1abda8b8-48a8-4995-af86-39220d1aa240",08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology",MIDAZOLAM,"0409-2308, 0409-2305, 0409-0001","Hospira, Inc.","b303a281-6633-47d5-bf29-5e9055e26da6, 8c3cf34b-901d-407a-946d-a1556bb24551","0409-2305-55, 0409-2305-50, 0409-2308-69, 0409-2308-49, 0409-2308-70, 0409-2308-50, 0409-2305-16, 0409-2305-17, 0409-2305-04, 0409-2305-05, 0409-2308-21, 0409-2308-01, 0409-2308-22, 0409-2308-02, 0409-0001-01, 0409-0001-25","Midazolam Hydrochloride Preservative Free, Injection, 10 mg/2 mL (5 mg/mL) (NDC 0409-2308-02)",Injection,Available,,ANDA075857,,MIDAZOLAM HYDROCHLORIDE,,,Current,,,,W7TTW573JJ,0409-2308-02,844-646-4398,
"Upsher-Smith Laboratories, LLC",MIDODRINE HYDROCHLORIDE,,04/28/2025,New,ORAL,Midodrine Hydrochloride Tablet,"993462, 993466, 993470",,4c3517f3-1c68-4ade-b5f1-c488a3a335c1,04/28/2025,HUMAN PRESCRIPTION DRUG,04/28/2025,Cardiovascular,MIDODRINE HYDROCHLORIDE,"0245-0213, 0245-0211, 0245-0212","Upsher-Smith laboratories, LLC",18b0b9f5-6026-479e-af12-92b0e71a9d6b,"0245-0211-11, 0245-0211-89, 0245-0211-01, 0245-0212-11, 0245-0212-89, 0245-0212-01, 0245-0213-11, 0245-0213-89, 0245-0213-01","Orvaten, Tablet, 10 mg (NDC 0245-0213-11)",Tablet,,,ANDA076725,,MIDODRINE HYDROCHLORIDE,,,To Be Discontinued,,,,59JV96YTXV,0245-0213-11,800-654-2299,
Pfizer Inc.,,,04/28/2023,New,,Prazosin Hydrochloride Capsule,,,,04/28/2023,,04/28/2023,Cardiovascular,,,,,,"Minipress, Capsule, 1 mg (NDC 0069-4310-71)",Capsule,,,,,,,,To Be Discontinued,,Discontinuation of the manufacture of the drug. Supply expected to exhaust in August 2023,04/28/2023,,0069-4310-71,800-533-4535,
Ingenus Pharmaceuticals LLC,CARBOPLATIN,,04/28/2023,Reverified,INTRAVENOUS,Carboplatin Injection,597195,,475caee0-15a6-4f0d-bca7-f3e472b323f7,09/15/2025,HUMAN PRESCRIPTION DRUG,,Oncology,CARBOPLATIN,"50742-448, 50742-447","Ingenus Pharmaceuticals, LLC",69fafb3c-1c18-4d34-83b2-3ab9ddaa6769,"50742-447-45, 50742-448-60","Carboplatin, Injection, 600 mg/60 mL (NDC 50742-448-60)",Injection,Unavailable,"N0000175413, N0000175073",ANDA208487,,CARBOPLATIN,Platinum-based Drug [EPC],,Current,Other,"For any other information, please contact the Ingenus Customer Service team at 866-321-5031.",,BG3F62OND5,50742-448-60,866-321-5031,
Granules Pharmaceuticals Inc.,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,b0b4eccc-34c7-483d-966f-82d588358e1b,09/08/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","70010-115, 70010-111, 70010-112, 70010-113, 70010-114, 70010-116, 70010-117",Granules Pharmaceuticals Inc.,2fab399e-2a43-5134-e063-6294a90ae09a,"70010-111-01, 70010-111-03, 70010-112-01, 70010-112-03, 70010-113-01, 70010-113-03, 70010-114-01, 70010-114-03, 70010-115-01, 70010-115-03, 70010-116-01, 70010-116-03, 70010-117-01, 70010-117-03","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 70010-115-01)",Tablet,Available,,ANDA215771,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",70010-115-01,877-770-3183,
Baxter Healthcare,METRONIDAZOLE,,01/13/2022,Reverified,INTRAVENOUS,Metronidazole Injection,311683,,d2112f37-5080-4a19-bcc3-6386b49abe1d,09/23/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,METRONIDAZOLE,0338-1055,Baxter Healthcare Corporation,3e7d4d73-778e-4e49-bd5b-2c70c5c92488,0338-1055-48,"Flagyl I.v. Rtu In Plastic Container, Injection, 500 mg/100 mL (NDC 0338-1055-48)",Injection,Available,"N0000175435, M0014907",NDA018657,Nitroimidazoles [CS],METRONIDAZOLE,Nitroimidazole Antimicrobial [EPC],,Current,,,,140QMO216E,0338-1055-48,888-229-0001,
Gland Pharma Limited,,,04/02/2020,Reverified,,Midazolam Hydrochloride Injection,,,,09/29/2025,,,"Anesthesia, Neurology",,,,,,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 47781-589-91)",Injection,Available,,,,,,,Current,Other,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,,47781-589-91,Athenex: 855-273-0154; Alvogen: 973-532-7840,
"Teva Pharmaceuticals USA, Inc.",PRAVASTATIN SODIUM,,06/13/2025,New,ORAL,Pravastatin Sodium Tablet,"904458, 904467, 904475",,99e0e848-f8f3-4b42-b880-8fbc42633948,06/13/2025,HUMAN PRESCRIPTION DRUG,06/13/2025,Cardiovascular,PRAVASTATIN SODIUM,"0093-0771, 0093-7201, 0093-7202","Teva Pharmaceuticals USA, Inc.",72579e23-23ef-4ab7-ad64-24d5ea7997eb,"0093-0771-98, 0093-0771-10, 0093-7201-98, 0093-7201-10, 0093-7202-98, 0093-7202-10","Pravastatin Sodium, Tablet, 10 mg (NDC 0093-0771-10)",Tablet,,,ANDA076056,,PRAVASTATIN SODIUM,,,To Be Discontinued,,,,3M8608UQ61,0093-0771-10,800-545-8800,
Otsuka ICU Medical LLC,DEXTROSE MONOHYDRATE,,03/01/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 10% Injection,"1795477, 1795480, 1795481, 1795607, 1795609, 1795610, 1795612, 1795616, 1795618, 1795621",,8b25b7e0-703e-4b43-a4eb-52863511602d,09/17/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0990-7930, 0990-7923, 0990-7922","ICU Medical, Inc.",09b10612-c937-4d10-becb-9768e10caa2c,"0990-7923-20, 0990-7923-23, 0990-7923-36, 0990-7923-37, 0990-7923-13, 0990-7922-02, 0990-7922-03, 0990-7922-09, 0990-7922-53, 0990-7922-55, 0990-7922-61, 0990-7930-02, 0990-7930-03, 0990-7930-09","Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-02)",Injection,Available,,NDA018080,,DEXTROSE MONOHYDRATE,,,Current,,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,LX22YL083G,0990-7930-02,1-866-829-9025 or ProductAvailability@icumed.com,
"Teva Pharmaceuticals USA, Inc.",ISONIAZID,,11/21/2024,New,ORAL,Isoniazid Tablet,"197832, 311166",,9499f1cf-2f46-4047-8b71-90aee7dee854,11/21/2024,HUMAN PRESCRIPTION DRUG,11/21/2024,Anti-Infective,ISONIAZID,"0555-0071, 0555-0066","Teva Pharmaceuticals USA, Inc.",ead93989-8a7e-4483-917e-388152515e1d,"0555-0066-02, 0555-0071-01, 0555-0071-02","Tablet, 300 mg (NDC 0555-0071-01)",Tablet,,N0000175483,ANDA080937,,ISONIAZID,Antimycobacterial [EPC],,To Be Discontinued,,Product available through 12/03/2024,,V83O1VOZ8L,0555-0071-01,800-545-8800,
"Actavis Pharma, Inc.",ACYCLOVIR,,03/03/2025,New,TOPICAL,Acyclovir Ointment,197312,,b360a808-a24d-4f3c-89a7-9941422d17d6,03/03/2025,HUMAN PRESCRIPTION DRUG,03/03/2025,Dermatology,ACYCLOVIR,0591-1159,"ACTAVIS PHARMA, INC.",9a0c599a-742a-48f5-ae69-cd9e8cbaa604,0591-1159-30,"Zovirax, Ointment, 50 mg/1 g (NDC 0591-1159-30)",Ointment,,"N0000020060, N0000180187, N0000180188, N0000175468, N0000175459",NDA018604,,ACYCLOVIR,"Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC], Herpes Zoster Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC], Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]",,To Be Discontinued,,,,X4HES1O11F,0591-1159-30,800-545-8800,DNA Polymerase Inhibitors [MoA]
Rhodes Pharmaceuticals L.P.,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,d918b40d-a461-41bc-b6c0-83dc76c28e32,08/05/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"42858-164, 42858-161, 42858-162, 42858-163, 42858-165, 42858-166, 42858-167",Rhodes Pharmaceuticals,4bb64a6b-cce9-4c4a-81c3-06e2e59315c3,"42858-161-01, 42858-162-01, 42858-163-01, 42858-164-01, 42858-165-01, 42858-166-01, 42858-167-01","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 42858-164-01)",Capsule,Available,,ANDA215330,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,42858-164-01,888-827-0616,
Takeda Pharmaceuticals USA Inc.,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,"Lisdexamfetamine Dimesylate Tablet, Chewable","854830, 854832, 854834, 854836, 854838, 854840, 854842, 854844, 854846, 854848, 854850, 854852, 1593856, 1593858, 1871456, 1871459, 1871460, 1871461, 1871462, 1871463, 1871464, 1871465, 1871466, 1871467, 1871468, 1871469",,704e4378-ca83-445c-8b45-3cfa51c1ecad,08/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,VYVANSE,"59417-118, 59417-101, 59417-102, 59417-103, 59417-104, 59417-105, 59417-106, 59417-107, 59417-115, 59417-116, 59417-117, 59417-119, 59417-120","Takeda Pharmaceuticals America, Inc.",756b98a0-fada-44b2-a606-f2e71ef8cc84,"59417-101-10, 59417-102-10, 59417-103-10, 59417-104-10, 59417-105-10, 59417-106-10, 59417-107-10, 59417-115-01, 59417-116-01, 59417-117-01, 59417-118-01, 59417-119-01, 59417-120-01","Vyvanse, Tablet, Chewable, 40 mg (NDC 59417-118-01)","Tablet, Chewable",Available,,NDA208510,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,59417-118-01,877-TAKEDA-7 (1-877-825-3327),
"Novo Nordisk, Inc.",SOMATROPIN,,01/06/2023,Revised,SUBCUTANEOUS,Somatropin Injection,"847243, 847245, 847247, 847348, 849850, 849851, 1736262, 1736329",,1058e17c-9261-459c-a3e6-fae38d196c14,08/28/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,NORDITROPIN,"0169-7704, 0169-7705, 0169-7708, 0169-7703",Novo Nordisk,b67c2419-4feb-4ce1-b97e-88760a8e1aee,"0169-7704-21, 0169-7704-92, 0169-7705-21, 0169-7705-92, 0169-7708-21, 0169-7708-92, 0169-7703-11, 0169-7703-91, 0169-7703-21, 0169-7703-92","Norditropin, Injection, 5 mg/1.5 mL (NDC 0169-7704-21)",Injection,,"N0000175606, M0028842",BLA021148,Human Growth Hormone [CS],SOMATROPIN,Recombinant Human Growth Hormone [EPC],Available,Resolved,,,08/28/2025,NQX9KB6PCL,0169-7704-21,609-987-5800,
Pfizer Inc.,,,01/06/2023,Revised,,Somatropin Injection,"241975, 762830, 762833, 762834, 762836, 762837, 762839, 762841, 762843, 762846, 762849, 762850, 762852, 762857, 762859, 762866, 762868, 762873, 762875, 762895, 762897, 763488, 763489, 996558, 996559",,ffebf88b-d257-4542-9808-74d9b7167765,08/28/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,GENOTROPIN,"0013-2653, 0013-2626, 0013-2646, 0013-2649, 0013-2650, 0013-2651, 0013-2652, 0013-2654, 0013-2655, 0013-2656, 0013-2657, 0013-2658",Pfizer Laboratories Div Pfizer Inc,f09acf87-6e30-47ad-9891-8a49bf6dffbc,"0013-2626-81, 0013-2646-81, 0013-2649-02, 0013-2650-02, 0013-2651-02, 0013-2652-02, 0013-2653-02, 0013-2654-02, 0013-2655-02, 0013-2656-02, 0013-2657-02, 0013-2658-02","Genotropin, Injection, 1.0 mg preservative free (NDC 0013-2653-02)",Injection,,,BLA020280,,SOMATROPIN,,Available,Resolved,,,08/28/2025,,0013-2653-02,800-533-4535,
"Upsher-Smith Laboratories, LLC",BACLOFEN,,04/23/2025,New,ORAL,Baclofen Tablet,"197391, 197392",,b2747a9d-5fca-4657-9e4b-4112607f30d8,04/23/2025,HUMAN PRESCRIPTION DRUG,04/23/2025,Neurology,BACLOFEN,"0832-1054, 0832-1055","Upsher-Smith Laboratories, LLC",395d77da-1674-a9a4-e063-6394a90aa3d7,"0832-1054-90, 0832-1054-11, 0832-1054-15, 0832-1054-10, 0832-1055-90, 0832-1055-11, 0832-1055-15, 0832-1055-10","Baclofen, Tablet, 10 mg (NDC 0832-1054-90)",Tablet,,"N0000000196, N0000000116, N0000175759",ANDA074584,,BACLOFEN,gamma-Aminobutyric Acid-ergic Agonist [EPC],,To Be Discontinued,,,,H789N3FKE8,0832-1054-90,716-315-2000,"GABA A Agonists [MoA], GABA B Agonists [MoA]"
Pfizer Inc.,LINEZOLID,,10/11/2024,New,INTRAVENOUS,Linezolid Solution,"262091, 311345, 311347, 581614, 1662278, 1662280, 1662285, 1662286",,6e70e63b-bfd5-478d-a8ee-8ba22c9efabd,10/11/2024,HUMAN PRESCRIPTION DRUG,10/11/2024,Anti-Infective,ZYVOX,"0009-5137, 0009-5140, 0009-5136, 0009-5138",Pharmacia & Upjohn Company LLC,b4924d28-18e3-4c36-9d23-881d29c20560,"0009-5137-01, 0009-5137-04, 0009-5140-01, 0009-5140-04, 0009-5136-01, 0009-5136-04, 0009-5138-02, 0009-5138-03","Zyvox, Solution, 200 mg/100 mL (NDC 0009-5137-04)",Solution,,"N0000175495, M0361132",NDA021131,Oxazolidinones [CS],LINEZOLID,Oxazolidinone Antibacterial [EPC],,To Be Discontinued,,,,ISQ9I6J12J,0009-5137-04,844-646-4398,
"Lannett Company, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,2cedb4c2-1e40-4bc4-b9f4-127150c4afbd,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0527-4662, 0527-4661, 0527-4663, 0527-4664, 0527-4665, 0527-4666, 0527-4667","Lannett Company, Inc.",981ca74f-737d-45e5-a3b2-b25256263768,"0527-4661-37, 0527-4662-37, 0527-4663-37, 0527-4664-37, 0527-4665-37, 0527-4666-37, 0527-4667-37","Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0527-4662-37)",Capsule,Limited Availability,,ANDA215802,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,Limited Availability,,SJT761GEGS,0527-4662-37,844-834-0530,
"Exela Pharma Sciences, LLC",SODIUM BICARBONATE,,07/24/2017,Revised,INTRAVENOUS,Sodium Bicarbonate Injection,"807284, 1868486, 1923484, 2198792",,e9698a4f-1a95-4f28-a945-e8009d1d6dd4,09/15/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Pediatric",SODIUM BICARBONATE,"51754-5011, 51754-5001, 51754-5002, 51754-5012","Exela Pharma Sciences, LLC",4da0ba66-756d-4b4d-8018-81ca16578ef1,"51754-5001-5, 51754-5001-4, 51754-5011-4, 51754-5002-5, 51754-5012-4","Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5011-4)",Injection,Limited Availability,,ANDA211091,,SODIUM BICARBONATE,,,Current,Demand increase for the drug,Next batch release expected in 2 weeks.,,8MDF5V39QO,51754-5011-4,828-758-5474 ext. 154,
"Hospira, Inc., a Pfizer Company",DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795609, 1795610, 1795616",,10e98cb0-31a5-4ad1-3eaa-aa4af387a42d,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,0409-7100,"Hospira, Inc.",477c216c-7446-473a-892d-918faf1dc877,"0409-7100-68, 0409-7100-66, 0409-7100-69, 0409-7100-67, 0409-7100-04, 0409-7100-02","Dextrose 5% In Plastic Container, Injection, 5 g/100mL (5%) Plastic (NDC 0409-7100-67)",Injection,Available,,NDA019466,,DEXTROSE MONOHYDRATE,,,Current,,,,LX22YL083G,0409-7100-67,844-646-4398,
"Hospira, Inc., a Pfizer Company",FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Revised,"INTRAMUSCULAR, INTRAVENOUS",Furosemide Injection,"1719286, 1719290, 1719291",,"aaced7a8-c3d7-4d66-8c07-aa407b8b3f35, 39fd32f2-6bb7-4a65-d298-e48d26bc80c7",08/15/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,0409-6102,"Hospira, Inc.","c529b0df-a5cb-46ce-8131-38674ee756af, 0d4a39f2-904e-434a-9af1-83bb4febf124","0409-6102-35, 0409-6102-25, 0409-6102-36, 0409-6102-26, 0409-6102-37, 0409-6102-27, 0409-6102-19, 0409-6102-02, 0409-6102-18, 0409-6102-04, 0409-6102-20, 0409-6102-10","Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-02)",Injection,Limited Availability,"N0000175366, N0000175590",NDA018667,,FUROSEMIDE,Loop Diuretic [EPC],,Current,Other,Limited Supply Available. Next Delivery and Estimated Recovery: September 2025,,7LXU5N7ZO5,0409-6102-02,844-646-4398,
Rhodes Pharmaceuticals L.P.,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,d918b40d-a461-41bc-b6c0-83dc76c28e32,08/05/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"42858-161, 42858-162, 42858-163, 42858-164, 42858-165, 42858-166, 42858-167",Rhodes Pharmaceuticals,4bb64a6b-cce9-4c4a-81c3-06e2e59315c3,"42858-161-01, 42858-162-01, 42858-163-01, 42858-164-01, 42858-165-01, 42858-166-01, 42858-167-01","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 42858-161-01)",Capsule,Available,,ANDA215330,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,42858-161-01,888-827-0616,
Pfizer Inc.,TALAZOPARIB TOSYLATE,,01/13/2025,New,ORAL,Talazoparib Tosylate Capsule,"2099946, 2099952, 2099954, 2099956, 2591510, 2591512, 2591520, 2591521, 2639960, 2639962, 2639964, 2639966",,f2423edd-6d24-495c-aec1-c2f457f08d9a,01/13/2025,HUMAN PRESCRIPTION DRUG,01/13/2025,Oncology,TALZENNA,"0069-0296, 0069-1195, 0069-1501, 0069-1751, 0069-1031, 0069-1235",Pfizer Laboratories Div Pfizer Inc,2cb65f61-9a14-46d9-85a3-a7eea76160c5,"0069-0296-30, 0069-1195-30, 0069-1501-30, 0069-1751-30, 0069-1031-30, 0069-1235-30","Talzenna, Capsule, .25 mg (NDC 0069-0296-30)",Capsule,,,NDA211651,,TALAZOPARIB,,,To Be Discontinued,,"Supply expected to exhaust late February 2025
Replaced with Soft Gel NDC 0069-0353-30",,02WK9U5NZC,0069-0296-30,800-533-4535,
"Hospira, Inc., a Pfizer Company",DOBUTAMINE HYDROCHLORIDE,,11/06/2017,Revised,INTRAVENOUS,Dobutamine Hydrochloride Injection,1812168,,"dc537761-d5f4-488d-24ab-b2bcd2b17b7a, 89becb0c-da60-4f43-0a98-29ff7a9eca58",08/15/2025,HUMAN PRESCRIPTION DRUG,,"Cardiovascular, Pediatric, Renal",DOBUTAMINE,0409-2344,"Hospira, Inc.","e71e9520-871b-479d-9652-1857fceca863, 5d6b1dfe-d679-4aea-97a6-3d074a202afe","0409-2344-01, 0409-2344-62, 0409-2344-02, 0409-2344-68, 0409-2344-88","Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-01)",Injection,Available,,ANDA074086,,DOBUTAMINE,,,Current,,,12/19/2024,0WR771DJXV,0409-2344-01,844-646-4398,
"Elite Laboratories, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,0e024b69-567c-4b40-9c3e-a2daec34256c,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"64850-553, 64850-550, 64850-551, 64850-552, 64850-554, 64850-555, 64850-556","Elite Laboratories, Inc.",e414bb2e-d404-44ea-931c-5998b0a4c87e,"64850-550-01, 64850-551-01, 64850-552-01, 64850-553-01, 64850-554-01, 64850-555-01, 64850-556-01","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 64850-553-01)",Capsule,Limited Availability,,ANDA218604,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,,,SJT761GEGS,64850-553-01,888-852-6657,
"Hikma Pharmaceuticals USA, Inc.",MORPHINE SULFATE,,11/03/2017,Reverified,INTRAVENOUS,Morphine Sulfate Injection,"1731993, 1732006, 1732011",,6023606c-150c-40c5-9175-598efe2a56c3,07/23/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,MORPHINE SULFATE,"0641-6126, 0641-6127, 0641-6125",Hikma Pharmaceuticals USA Inc.,fa18221d-2353-4cf6-a210-fb33ee79d3d9,"0641-6126-01, 0641-6126-25, 0641-6127-01, 0641-6127-25, 0641-6125-01, 0641-6125-25","Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0641-6126-25)",Injection,Unavailable,,ANDA205758,,MORPHINE SULFATE,,,Current,Demand increase for the drug,Additional lots will be available in the May 2025 timeframe.  Product will be made available as it is released.,,X3P646A2J0,0641-6126-25,800-631-2174,
"Fresenius Kabi USA, LLC",REMIFENTANIL HYDROCHLORIDE,,06/28/2022,Reverified,INTRAVENOUS,Remifentanil Hydrochloride Injection,"1729578, 1729584, 1729710",,"5b8025d2-3424-477b-9cff-3990a98c2a65, d2374b84-81c9-44f9-a4a9-1071281b2531",09/18/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,REMIFENTANIL HYDROCHLORIDE,"63323-723, 63323-724, 63323-725","Fresenius Kabi USA, LLC","406a07e3-a3f8-4fef-901e-021d00743c40, 2f27e51f-2b55-47ee-bd4a-001b71c60622","63323-723-04, 63323-723-06, 63323-723-01, 63323-723-03, 63323-724-01, 63323-724-05, 63323-725-01, 63323-725-10","Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03)",Injection,Available,,ANDA206223,,REMIFENTANIL HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,5V444H5WIC,63323-723-03,888-386-1300,
B. Braun Medical Inc.,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807639, 1807551, 1807552, 1807633, 1807634",,"47a0313f-36df-4fa6-a828-c9e1946ba9b0, 7f22c06b-6b4d-4b49-a4b2-d2169f2bd653",08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0264-7800, 0264-7802",B. Braun Medical Inc.,"318417ff-d599-47b8-8181-89c3bb3b2e8d, 9fa9f6b4-63b5-4632-8104-37c3dd1ee8fa","0264-7800-09, 0264-7800-00, 0264-7800-10, 0264-7800-20, 0264-7802-00, 0264-7802-10","Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-7800-20)",Injection,,,NDA019635,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0264-7800-20,800-227-2862,
"Hikma Pharmaceuticals USA, Inc.",FENTANYL CITRATE,,12/20/2023,Revised,"INTRAMUSCULAR, INTRAVENOUS",Fentanyl Citrate Injection,"1735003, 1735007, 1735008, 1735013, 2168270, 2474269, 2629337",,ce5db1c2-feb1-4ad2-847a-d02e865bd47e,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Pediatric",FENTANYL CITRATE,"0641-6024, 0641-6027, 0641-6025, 0641-6028, 0641-6026, 0641-6029, 0641-6030, 0641-6247, 0641-6248, 0641-6249",Hikma Pharmaceuticals USA Inc.,aca9742b-d890-426a-8296-14ca64748238,"0641-6024-01, 0641-6024-10, 0641-6027-01, 0641-6027-25, 0641-6025-01, 0641-6025-10, 0641-6028-01, 0641-6028-10, 0641-6028-25, 0641-6026-01, 0641-6026-05, 0641-6029-01, 0641-6029-25, 0641-6030-01, 0641-6247-01, 0641-6247-25, 0641-6248-01, 0641-6248-10, 0641-6249-01, 0641-6249-10","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6024-10)",Injection,Unavailable,,NDA019101,,FENTANYL CITRATE,,,Current,Other,Inventory available in vial presentations.,,MUN5LYG46H,0641-6024-10,800-631-2174,
Gland Pharma Limited,,,04/02/2020,Reverified,,Midazolam Hydrochloride Injection,,,,09/29/2025,,,"Anesthesia, Neurology",,,,,,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 70860-601-05)",Injection,Available,,,,,,,Current,Other,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,,70860-601-05,Athenex: 855-273-0154; Alvogen: 973-532-7840,
"Sun Pharmaceutical Industries, Inc.",NALTREXONE HYDROCHLORIDE,,02/29/2024,Revised,ORAL,Naltrexone Hydrochloride Tablet,1483744,,0f30f885-d0cd-4fa6-a8e0-142f08a56792,09/22/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,NALTREXONE HYDROCHLORIDE,47335-326,"Sun Pharmaceutical Industries, Inc.",b0c2b60a-dc96-483b-933e-2fed58b64372,"47335-326-83, 47335-326-88, 47335-326-08, 47335-326-18","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 47335-326-08)",Tablet,Unavailable,,ANDA090356,,NALTREXONE HYDROCHLORIDE,,,Current,Other,Currently not marketed,,Z6375YW9SF,47335-326-08,800-818-4555,
Eugia US LLC,ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Revised,"EPIDURAL, INFILTRATION, PERINEURAL",Ropivacaine Hydrochloride Injection,"905189, 1734084, 1734090, 1734207, 1734347, 1734475, 1734483",,3763b7b6-da49-4658-b93d-28f5da24d09e,09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROPIVACAINE HYDROCHLORIDE,"55150-198, 55150-195, 55150-196, 55150-197, 55150-199, 55150-200, 55150-201",Eugia US LLC,34725b26-d6e9-4d1b-95a0-da03764cc102,"55150-195-20, 55150-196-99, 55150-197-20, 55150-198-30, 55150-199-20, 55150-200-10, 55150-201-20","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-198-30)",Injection,Available,,ANDA205612,,ROPIVACAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,V910P86109,55150-198-30,888-238-7880,
Eli Lilly and Co.,ATOMOXETINE HYDROCHLORIDE,,10/22/2024,New,ORAL,Atomoxetine Hydrochloride Capsule,"349591, 349592, 349593, 349594, 349595, 352317, 352318, 352319, 352320, 352321, 608139, 608143, 617945, 617947",,309de576-c318-404a-bc15-660c2b1876fb,10/22/2024,HUMAN PRESCRIPTION DRUG,10/22/2024,Psychiatry,STRATTERA,"0002-3251, 0002-3227, 0002-3238, 0002-3228, 0002-3229, 0002-3239, 0002-3250",Eli Lilly and Company,90fd3143-d5d4-4343-9570-b3863e31b1a0,"0002-3227-30, 0002-3238-30, 0002-3228-30, 0002-3229-30, 0002-3239-30, 0002-3250-30, 0002-3251-30","Strattera, Capsule, 100 mg (NDC 0002-3251-30)",Capsule,,,NDA021411,,ATOMOXETINE HYDROCHLORIDE,,,To Be Discontinued,,Business decision to discontinue,,57WVB6I2W0,0002-3251-30,800-545-5979,
"Teva Pharmaceuticals USA, Inc.",CELECOXIB,,08/15/2025,New,ORAL,Celecoxib Capsule,"205322, 205323, 349514, 686379",,05224473-27dc-4f6d-a52a-c40a7af2f2f4,08/15/2025,HUMAN PRESCRIPTION DRUG,08/15/2025,Analgesia/Addiction,CELECOXIB,"0591-3985, 0591-3982, 0591-3983, 0591-3984","Actavis Pharma, Inc.",64c601bc-9b67-400f-9e30-e26de56f2f8b,"0591-3982-60, 0591-3983-01, 0591-3983-05, 0591-3984-01, 0591-3984-05, 0591-3985-60","Celecoxib, Capsule, 400 mg (NDC 0591-3985-60)",Capsule,,"N0000000160, M0001335, N0000175722",ANDA200562,"Anti-Inflammatory Agents, Non-Steroidal [CS]",CELECOXIB,Nonsteroidal Anti-inflammatory Drug [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,JCX84Q7J1L,0591-3985-60,800-545-8800,Cyclooxygenase Inhibitors [MoA]
Apotex Corp.,LISDEXAMFETAMINE DIMESYLATE,,11/01/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,ecad4442-a644-18e3-6ff2-fdbac45eec47,09/29/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"60505-4743, 60505-4739, 60505-4740, 60505-4741, 60505-4742, 60505-4744, 60505-4745",Apotex Corp.,c8e0c70d-2f5b-8d85-fa45-572e8f5f7b4c,"60505-4739-1, 60505-4740-1, 60505-4741-1, 60505-4742-1, 60505-4743-1, 60505-4744-1, 60505-4745-1","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)",Capsule,Available,,ANDA216944,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,Product currently available,,SJT761GEGS,60505-4743-1,800-706-5575,
"Hikma Pharmaceuticals USA, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,6740a621-9bec-4178-a4fc-a3fc89f34e0a,07/23/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0054-0374, 0054-0660, 0054-0370, 0054-0371, 0054-0372, 0054-0373, 0054-0375",Hikma Pharmaceuticals USA Inc.,5d119550-4386-4bfa-a5d0-bb18e66191b7,"0054-0660-25, 0054-0370-25, 0054-0371-25, 0054-0372-25, 0054-0373-25, 0054-0374-25, 0054-0375-25","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0054-0374-25)",Capsule,Limited Availability,,ANDA202827,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,Available on allocation,,SJT761GEGS,0054-0374-25,800-631-2174,
Chartwell Molecular Holdings LLC,NALTREXONE HYDROCHLORIDE,,02/29/2024,Reverified,ORAL,Naltrexone Hydrochloride Tablet,1483744,,adb7c4dc-221a-4d91-9687-0d78913a92ad,08/19/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,NALTREXONE HYDROCHLORIDE,62135-242,"Chartwell RX, LLC",1adc57cf-70f9-75b9-e063-6294a90a0de0,"62135-242-30, 62135-242-60, 62135-242-90","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 62135-242-60)",Tablet,Available,,ANDA207905,,NALTREXONE HYDROCHLORIDE,,,Current,,,,Z6375YW9SF,62135-242-60,845-268-5000 Ext. 510,
"Fresenius Kabi USA, LLC",SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807631, 1807632, 1807633, 1807634, 1807639",,037ac04d-f8f3-4bb8-993a-ac8f7683ff83,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"65219-474, 65219-466, 65219-468, 65219-470, 65219-472","Fresenius Kabi USA, LLC",4110390b-2806-4c92-b283-a90115f89114,"65219-466-05, 65219-466-60, 65219-468-05, 65219-468-50, 65219-470-05, 65219-470-30, 65219-472-05, 65219-472-20, 65219-474-05, 65219-474-10","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 65219-474-10)",Injection,,,ANDA207310,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,65219-474-10,888-386-1300,
Otsuka ICU Medical LLC,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807548, 1807549, 1807550, 1807551, 1807552, 1807627, 1807630, 1807631, 1807632, 1807633, 1807634, 1807639",,5f372b75-d7a4-471e-8ac6-290040fc84b0,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0990-7983, 0990-7730, 0990-7984, 0990-7985",ICU Medical Inc.,87c57bfa-0bf7-41fd-b954-eb753d5d9d7f,"0990-7730-36, 0990-7730-37, 0990-7983-61, 0990-7983-02, 0990-7983-03, 0990-7983-09, 0990-7983-55, 0990-7983-53, 0990-7984-37, 0990-7984-20, 0990-7984-13, 0990-7984-23, 0990-7984-36, 0990-7985-02, 0990-7985-03, 0990-7985-09","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-03)",Injection,,,NDA016366,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0990-7983-03,1-866-829-9025 or ProductAvailability@icumed.com,
Otsuka ICU Medical LLC,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807548, 1807549, 1807550, 1807551, 1807552, 1807627, 1807630, 1807631, 1807632, 1807633, 1807634, 1807639",,5f372b75-d7a4-471e-8ac6-290040fc84b0,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0990-7983, 0990-7730, 0990-7984, 0990-7985",ICU Medical Inc.,87c57bfa-0bf7-41fd-b954-eb753d5d9d7f,"0990-7730-36, 0990-7730-37, 0990-7983-61, 0990-7983-02, 0990-7983-03, 0990-7983-09, 0990-7983-55, 0990-7983-53, 0990-7984-37, 0990-7984-20, 0990-7984-13, 0990-7984-23, 0990-7984-36, 0990-7985-02, 0990-7985-03, 0990-7985-09","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-55)",Injection,,,NDA016366,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0990-7983-55,1-866-829-9025 or ProductAvailability@icumed.com,
Strides Pharma Inc.,DONEPEZIL HYDROCHLORIDE,,01/28/2025,New,ORAL,Donepezil Hydrochloride Tablet,"997223, 997229",,297e86e8-d248-4cc9-9d9c-2ef9efb4414d,01/28/2025,HUMAN PRESCRIPTION DRUG,01/28/2025,Neurology,DONEPEZIL HYDROCHLORIDE,"71093-128, 71093-127","ACI Healthcare USA, Inc.",a4736add-da84-411f-8e6f-9de67bf467f8,"71093-127-01, 71093-127-03, 71093-127-05, 71093-127-06, 71093-128-01, 71093-128-03, 71093-128-05, 71093-128-06","Donepezil Hydrochloride, Tablet, 10 mg (NDC 71093-128-03)",Tablet,,,ANDA078662,,DONEPEZIL HYDROCHLORIDE,,,To Be Discontinued,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,3O2T2PJ89D,71093-128-03,877-244-9825,
"EMD Serono, Inc.",LEVOTHYROXINE SODIUM,,07/10/2025,New,ORAL,Levothyroxine Sodium Tablet,"892246, 892251, 966153, 966160, 966166, 966173, 966177, 966182, 966187, 966196, 966202, 966207, 966220, 966221, 966222, 966224, 966225, 966248, 966249, 966253, 966270, 2104866",,bc3c6830-ba68-4ba3-9896-a12d0ad0b275,07/10/2025,HUMAN PRESCRIPTION DRUG,07/10/2025,Endocrinology/Metabolism,EUTHYROX,"72305-112, 72305-025, 72305-050, 72305-075, 72305-088, 72305-100, 72305-125, 72305-137, 72305-150, 72305-175, 72305-200","Provell Pharmaceuticals, LLC",45657074-8874-49f4-a8ef-3ca7e210c16e,"72305-025-30, 72305-025-90, 72305-050-30, 72305-050-90, 72305-075-30, 72305-075-90, 72305-088-30, 72305-088-90, 72305-100-30, 72305-100-90, 72305-112-30, 72305-112-90, 72305-125-30, 72305-125-90, 72305-137-30, 72305-137-90, 72305-150-30, 72305-150-90, 72305-175-30, 72305-175-90, 72305-200-30, 72305-200-90","Euthyrox, Tablet, 112 ug (NDC 72305-112-30)",Tablet,,,NDA021292,,LEVOTHYROXINE SODIUM,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,9J765S329G,72305-112-30,888-899-7041,
Amneal Pharmaceuticals,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850",,c11cb3b6-3dff-477b-a249-b4c3118edc5f,09/17/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"65162-024, 65162-023, 65162-025, 65162-026, 65162-027, 65162-028",Amneal Pharmaceuticals LLC,759471b0-6930-4e65-9417-e1c334a0eb68,"65162-023-09, 65162-024-09, 65162-025-09, 65162-026-09, 65162-027-09, 65162-028-09","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 65162-024-09)",Capsule,Unavailable,,ANDA202830,,LISDEXAMFETAMINE,,,Current,Shortage of an active ingredient,Shortage of an active ingredient,,SJT761GEGS,65162-024-09,866-525-7270,
"ICU Medical, Inc.",SODIUM CHLORIDE,,04/28/2023,Revised,IRRIGATION,Sodium Chloride 0.9% Irrigation,486515,,3cfdeee0-ff14-4341-8396-b11c2a037c60,07/02/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0990-6138, 0990-7138, 0990-7972",ICU Medical Inc.,9ceb78f6-0be4-4dbb-9fd0-9728b5ad5c7b,"0990-7138-09, 0990-7138-36, 0990-6138-22, 0990-6138-03, 0990-7972-05, 0990-7972-07","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0990-6138-22)",Irrigation,,,NDA017514,,SODIUM CHLORIDE,,Available,Resolved,,,07/02/2025,451W47IQ8X,0990-6138-22,1-866-829-9025 or ProductAvailability@icumed.com,
"Hikma Pharmaceuticals USA, Inc.",LIRAGLUTIDE,,07/18/2023,Reverified,SUBCUTANEOUS,Liraglutide Injection,897122,,2100ec49-57b2-4330-ab5f-057ce9b7e4d0,07/23/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,LIRAGLUTIDE,0143-9144,Hikma Pharmaceuticals USA Inc.,f242c0f8-6d4f-4a78-a1fd-433a0672dbd3,"0143-9144-03, 0143-9144-02","Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)",Injection,Available,"N0000178480, M0160181, N0000020058",ANDA215503,Glucagon-Like Peptide 1 [CS],LIRAGLUTIDE,GLP-1 Receptor Agonist [EPC],,Current,,Product will be made available as it is released.,,839I73S42A,0143-9144-03,800-631-2174,Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
Baxter Healthcare,HEPARIN SODIUM,,11/14/2017,Revised,INTRAVENOUS,Heparin Sodium Injection,"1658690, 1658692",,0d929726-76c3-48fc-b4e7-fd06409f9fb3,09/23/2025,HUMAN PRESCRIPTION DRUG,,Hematology,HEPARIN SODIUM IN SODIUM CHLORIDE,"0338-0431, 0338-0433, 0338-0424, 0338-0428",Baxter Healthcare Corporation,68b37381-6db4-4ac0-ba6b-3204add02665,"0338-0431-03, 0338-0433-04, 0338-0424-18, 0338-0428-12","Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0431-03)",Injection,Limited Availability,,NDA018609,,HEPARIN SODIUM,,,Current,Demand increase for the drug,Recovery November 2025,,ZZ45AB24CA,0338-0431-03,888-229-0001,
"Teva Pharmaceuticals USA, Inc.",POTASSIUM CHLORIDE,,05/19/2025,New,ORAL,"Potassium Chloride Capsule, Extended Release","312504, 315183",,ed5baaf6-270b-4dd3-b100-36030c0098fc,05/19/2025,HUMAN PRESCRIPTION DRUG,05/19/2025,"Endocrinology/Metabolism, Gastroenterology",POTASSIUM CHLORIDE,"62037-560, 62037-559","Actavis Pharma, Inc.",b97da107-c56e-48ea-ba34-d3d64a5b9f46,"62037-559-01, 62037-559-05, 62037-560-01, 62037-560-05, 62037-560-10, 62037-560-90","Potassium Chloride, Capsule, Extended Release, 750 mg (NDC 62037-560-10)","Capsule, Extended Release",,,ANDA077419,,POTASSIUM CHLORIDE,,,To Be Discontinued,,,,660YQ98I10,62037-560-10,800-545-8800,
Micro Labs LTD,CROMOLYN SODIUM,,11/03/2023,Reverified,ORAL,Cromolyn Sodium Concentrate,831261,,93f80edb-3b38-423e-8cd6-5b5cb4393ec2,09/15/2025,HUMAN PRESCRIPTION DRUG,,Pulmonary/Allergy,CROMOLYN SODIUM,42571-132,Micro Labs Limited,22ffea9c-cd39-22dd-e063-6394a90aae4b,"42571-132-21, 42571-132-52","Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 42571-132-52)",Concentrate,Available,,ANDA202745,,CROMOLYN SODIUM,,,Current,,,,Q2WXR1I0PK,42571-132-52,(908) 484-7410,
Sun Pharmaceutical Industries Limited,IMATINIB MESYLATE,,12/05/2024,New,ORAL,Imatinib Mesylate Tablet,"403878, 403879",,07764bf9-21b4-4e32-9d7e-e348f8e4291f,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Hematology,IMATINIB MESYLATE,"47335-475, 47335-472","Sun Pharmaceutical Industries, Inc.",ad13dbca-474d-4492-9c25-e0e175143d8c,"47335-472-83, 47335-472-88, 47335-472-13, 47335-472-81, 47335-475-83, 47335-475-88, 47335-475-13, 47335-475-64","Imatinib Mesylate, Tablet, 400 mg (NDC 47335-475-83)",Tablet,,,ANDA078340,,IMATINIB MESYLATE,,,To Be Discontinued,,Discontinuing for business reasons,,8A1O1M485B,47335-475-83,800-818-4555,
Aurobindo Pharma USA,AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","308189, 313850",,3cacd754-73f4-496e-a529-9ca39fa6692d,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"65862-071, 65862-070",Aurobindo Pharma Limited,3e3ca279-1838-4348-a01c-df10a8bcb8b9,"65862-070-50, 65862-070-75, 65862-070-01, 65862-071-50, 65862-071-75, 65862-071-01","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 65862-071-50)","Powder, For Suspension",,,ANDA065334,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,65862-071-50,866-850-2876,
Sintetica US,LIDOCAINE HYDROCHLORIDE ANHYDROUS,,02/22/2012,Reverified,INFILTRATION,Lidocaine Hydrochloride Injection,"1737566, 1737568, 1737570, 1737757, 1737761, 1737763",,aa3e688a-308c-4a82-a268-28ccf1677c55,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",NA,"83090-006, 83090-001, 83090-002, 83090-003, 83090-004, 83090-005",Sintetica US LLC,0d18f291-3a92-421e-8841-6be743b1f154,"83090-001-01, 83090-001-10, 83090-002-01, 83090-002-10, 83090-003-01, 83090-003-10, 83090-004-01, 83090-004-10, 83090-005-01, 83090-005-10, 83090-006-01, 83090-006-10","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 83090-006-10)",Injection,Available,,ANDA214267,,LIDOCAINE HYDROCHLORIDE,,,Current,,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 2% 10X10ML) is Preservative free.",,EC2CNF7XFP,83090-006-10,"844-425-3131, SinteticaCS@eversana.com",
"Mylan Pharmaceuticals Inc., a Viatris Company",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,efbde0f6-b848-4664-b741-c6c630e66108,09/17/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0378-6855, 0378-6854, 0378-6856, 0378-6857, 0378-6858, 0378-6859, 0378-6860",Mylan Pharmaceuticals Inc.,2dfa8600-1b2a-47e8-b58d-c9681b8795cb,"0378-6854-77, 0378-6855-77, 0378-6856-77, 0378-6857-77, 0378-6858-77, 0378-6859-77, 0378-6860-77","Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0378-6855-77)",Capsule,Available,,ANDA202835,,LISDEXAMFETAMINE,,,Current,,,,SJT761GEGS,0378-6855-77,800-796-9526,
"Hikma Pharmaceuticals USA, Inc.",METHAMPHETAMINE HYDROCHLORIDE,,03/17/2023,Revised,ORAL,Methamphetamine Hydrochloride Tablet,977860,,90c02ac6-e5e2-4c97-8c68-81e4e389a195,08/01/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHAMPHETAMINE HYDROCHLORIDE,0054-0389,Hikma Pharmaceuticals USA Inc.,9f3c9287-0615-4d2e-823d-673b33586e06,0054-0389-25,"Methamphetamine Hydrochloride, Tablet, 5 mg (NDC 0054-0389-25)",Tablet,Available,,ANDA203846,,METHAMPHETAMINE HYDROCHLORIDE,,,Current,,,,997F43Z9CV,0054-0389-25,800-631-2174,
"Epic Pharma, LLC","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961",,1757e132-061d-4773-89ed-fdc77f69008f,09/18/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","42806-344, 42806-339, 42806-341, 42806-343, 42806-345","Epic Pharma, LLC",f11301e2-3b5d-468d-b44c-45839e7e5dfb,"42806-339-01, 42806-341-01, 42806-343-01, 42806-344-01, 42806-345-01","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 42806-344-01)",Tablet,Limited Availability,,ANDA040444,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,Shortage of an active ingredient,Limited availability until end of September 2025,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",42806-344-01,(718) 276-8600 ext. 3,
Laboratoires Delbert,,,04/26/2023,Reverified,,Penicillin G Benzathine Injection,"2671687, 2671693, 2671695, 2671697",https://www.fda.gov/media/180283/download?attachment,5a026d0c-6f91-4ee3-b193-b2186a37e7ca,09/17/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,EXTENCILLINE,"81284-522, 81284-521, 81284-523, 81284-524",Provepharm Inc.,5eb42da3-7f4f-4071-9a35-14565343b49c,"81284-521-01, 81284-523-00, 81284-735-00, 81284-522-01, 81284-524-00","Extencilline, Injection, 2,400,000 units (NDC 81284-522-01)",Injection,Available,,,,BENZATHINE BENZYLPENICILLIN,,,Current,,,,RIT82F58GK,81284-522-01,Provepharm: rahul.poria@provepharm.com,
"Exela Pharma Sciences, LLC",SODIUM BICARBONATE,,07/24/2017,Revised,INTRAVENOUS,Sodium Bicarbonate Injection,"807284, 1868486, 1923484, 2198792",,e9698a4f-1a95-4f28-a945-e8009d1d6dd4,09/15/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Pediatric",SODIUM BICARBONATE,"51754-5012, 51754-5001, 51754-5011, 51754-5002","Exela Pharma Sciences, LLC",4da0ba66-756d-4b4d-8018-81ca16578ef1,"51754-5001-5, 51754-5001-4, 51754-5011-4, 51754-5002-5, 51754-5012-4","Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 51754-5012-4)",Injection,Limited Availability,,ANDA211091,,SODIUM BICARBONATE,,,Current,Demand increase for the drug,Next batch release expected in 2 weeks.,,8MDF5V39QO,51754-5012-4,828-758-5474 ext. 154,
Accord Healthcare Inc.,CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,ebc11109-e7bf-452d-b675-4b3236d54164,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"16729-137, 16729-136, 16729-138",Accord Healthcare Inc.,0e1e7f41-f78b-27cf-e063-6394a90a1ae0,"16729-136-00, 16729-136-16, 16729-137-00, 16729-137-16, 16729-138-00, 16729-138-16","Clonazepam, Tablet, 1 mg (NDC 16729-137-00)",Tablet,Available,"N0000175694, M0002356",ANDA077147,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,,,5PE9FDE8GB,16729-137-00,"866-941-7875, option 2",
"Trigen Laboratories, LLC",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Reverified,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release","1091155, 1091170, 1091185, 1091210, 1995461",,c45dc1de-adfa-4b3c-a7dc-cffbc8eac74f,09/04/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE HYDROCHLORIDE,"13811-710, 13811-709, 13811-706, 13811-707, 13811-708","Trigen Laboratories, LLC",354443b1-a623-43b0-b984-f8de2f6c60b2,"13811-709-10, 13811-706-10, 13811-707-10, 13811-708-10, 13811-710-10, 13811-710-30","Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30)",Tablet,Limited Availability,,ANDA205327,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,Demand increase for the drug,Allocation to current contracted customers,,4B3SC438HI,13811-710-30,800-541-4802,
Sandoz Inc.,ROCURONIUM BROMIDE,,02/15/2023,Reverified,INTRAVENOUS,Rocuronium Bromide Injection,1234995,,cb28d869-6510-4402-9462-f6bb25fa0fa8,09/24/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROCURONIUM BROMIDE,0781-3220,Sandoz Inc,eaf32464-7950-434a-e053-2a95a90aa2dc,"0781-3220-70, 0781-3220-92, 0781-3220-75, 0781-3220-95","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-95)",Injection,Available,,ANDA079195,,ROCURONIUM BROMIDE,,,Current,,,,I65MW4OFHZ,0781-3220-95,800-525-8747,
Accord Healthcare Inc.,CARBOPLATIN,,04/28/2023,Revised,INTRAVENOUS,Carboplatin Injection,597195,,48aa7ef3-9f44-2a08-e054-00144ff88e88,09/16/2025,HUMAN PRESCRIPTION DRUG,,Oncology,CARBOPLATIN,16729-295,"Accord Healthcare, Inc.",35cf6068-f31a-211b-e063-6294a90a6b53,"16729-295-31, 16729-295-33, 16729-295-34, 16729-295-12, 16729-295-38","Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34)",Injection,Limited Availability,"N0000175413, N0000175073",ANDA206775,,CARBOPLATIN,Platinum-based Drug [EPC],,Current,Requirements related to complying with good manufacturing practices,Limited Availability,,BG3F62OND5,16729-295-34,"866-941-7875, option 2",
Baxter Healthcare,DOPAMINE HYDROCHLORIDE,,11/06/2017,Reverified,INTRAVENOUS,Dopamine Hydrochloride Injection,"1292887, 1743869, 1743871, 1743877, 1743879",,cb97d4a0-89ed-407c-a763-209386b6f75c,09/23/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,DOPAMINE HYDROCHLORIDE AND DEXTROSE,"0338-1005, 0338-1007, 0338-1009",Baxter Healthcare Corporation,1b91b75f-c6e4-4425-bea8-023458ecf8f9,"0338-1005-02, 0338-1005-03, 0338-1007-02, 0338-1007-03, 0338-1009-02","Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-02)",Injection,Available,,NDA019615,,DOPAMINE HYDROCHLORIDE,,,Current,,,,7L3E358N9L,0338-1005-02,888-229-0001,
"Fresenius Kabi USA, LLC",HYDROMORPHONE HYDROCHLORIDE,,11/01/2017,Reverified,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Hydromorphone Hydrochloride Injection,"897756, 897757, 1433251, 1872265, 1872269, 1872752, 2277368, 2277370",,9eebd88a-5632-460f-b7b6-26c8a180540d,09/18/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,DILAUDID,"76045-121, 76045-009, 76045-010","Fresenius Kabi USA, LLC",97bfcafb-2037-47dc-a0ae-f7b8007c47df,"76045-009-96, 76045-009-06, 76045-009-01, 76045-009-11, 76045-010-01, 76045-010-11, 76045-121-01, 76045-121-11","Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)",Injection,Available,,NDA019034,,HYDROMORPHONE HYDROCHLORIDE,,,Current,Other,Check wholesalers for inventory,,L960UP2KRW,76045-121-11,888-386-1300,
"Trigen Laboratories, LLC",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Reverified,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release","1091155, 1091170, 1091185, 1091210, 1995461",,c45dc1de-adfa-4b3c-a7dc-cffbc8eac74f,09/04/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE HYDROCHLORIDE,"13811-707, 13811-709, 13811-706, 13811-708, 13811-710","Trigen Laboratories, LLC",354443b1-a623-43b0-b984-f8de2f6c60b2,"13811-709-10, 13811-706-10, 13811-707-10, 13811-708-10, 13811-710-10, 13811-710-30","Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10)",Tablet,Limited Availability,,ANDA205327,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,Demand increase for the drug,Allocation to current contracted customers,,4B3SC438HI,13811-707-10,800-541-4802,
"Hospira, Inc., a Pfizer Company",MIDAZOLAM HYDROCHLORIDE,,04/02/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Midazolam Hydrochloride Injection,"1666800, 1666814, 1666823, 1666798",,"b95415fa-17c2-42ab-a6b0-e628d01c94ed, 1abda8b8-48a8-4995-af86-39220d1aa240",08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology",MIDAZOLAM,"0409-2308, 0409-2305, 0409-0001","Hospira, Inc.","b303a281-6633-47d5-bf29-5e9055e26da6, 8c3cf34b-901d-407a-946d-a1556bb24551","0409-2305-55, 0409-2305-50, 0409-2308-69, 0409-2308-49, 0409-2308-70, 0409-2308-50, 0409-2305-16, 0409-2305-17, 0409-2305-04, 0409-2305-05, 0409-2308-21, 0409-2308-01, 0409-2308-22, 0409-2308-02, 0409-0001-01, 0409-0001-25","Midazolam Hydrochloride Preservative Free, Injection, 5 mg/mL (5 mg/mL) (NDC 0409-2308-01)",Injection,Available,,ANDA075857,,MIDAZOLAM HYDROCHLORIDE,,,Current,,,,W7TTW573JJ,0409-2308-01,844-646-4398,
"Avet Pharmaceuticals, Inc.",DESIPRAMINE HYDROCHLORIDE,,08/12/2025,New,ORAL,Desipramine Hydrochloride Tablet,"1099288, 1099292, 1099296, 1099300, 1099304, 1099316",,ee14dd2c-c54b-4cd1-a3a0-f7ad5a5a0ed0,08/12/2025,HUMAN PRESCRIPTION DRUG,08/12/2025,Psychiatry,DESIPRAMINE HYDROCHLORIDE,"23155-582, 23155-578, 23155-579, 23155-580, 23155-581, 23155-583",Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.,49984729-ddde-44ed-927b-8a4ba65cefa0,"23155-578-01, 23155-579-01, 23155-580-01, 23155-581-01, 23155-582-01, 23155-583-25","Desipramine Hydrochloride, Tablet, 100 mg (NDC 23155-582-01)",Tablet,,,ANDA207433,,DESIPRAMINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,1Y58DO4MY1,23155-582-01,855-228-9470,
Sagent Pharmaceuticals,LEUCOVORIN CALCIUM,,01/01/2012,Revised,"INTRAMUSCULAR, INTRAVENOUS",Leucovorin Calcium Injection,"237788, 1803930, 1803932, 1803937",,9d0e5356-ff39-4a8e-944c-e808a21ef4b2,07/08/2025,HUMAN PRESCRIPTION DRUG,,"Oncology, Pediatric",LEUCOVORIN CALCIUM,"25021-814, 25021-813, 25021-815, 25021-816",Sagent Pharmaceuticals,ff2ba160-e2f9-4ab9-9e67-2409f02c923e,"25021-813-10, 25021-814-30, 25021-815-30, 25021-816-30","Leucovorin Calcium, Injection, 100 mg/10 mL (NDC 25021-814-30)",Injection,,,ANDA200753,,LEUCOVORIN CALCIUM,,Available,Resolved,,,07/08/2025,RPR1R4C0P4,25021-814-30,866-625-1618,
"Dr. Reddy's Laboratories, Inc.",,,07/26/2023,Reverified,,"Methylphenidate Hydrochloride Tablet, Extended Release",,,,09/16/2025,,,Psychiatry,,,,,,"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 43598-439-01)",Tablet,Unavailable,,,,,,,Current,Other,Estimated availability TBD,,,43598-439-01,866-732-3952,
Aurobindo Pharma USA,METOPROLOL TARTRATE,,06/03/2025,New,ORAL,Metoprolol Tartrate Tablet,"866511, 866514, 866924",,2b705cb6-cb75-4c2a-907a-4bd45d18bc2c,06/03/2025,HUMAN PRESCRIPTION DRUG,06/03/2025,Cardiovascular,METOPROLOL TARTRATE,"65862-062, 65862-063, 65862-064",Aurobindo Pharma Limited,d265c99d-8e77-4a78-b542-15e957d9d335,"65862-062-01, 65862-062-99, 65862-063-60, 65862-063-01, 65862-063-99, 65862-064-60, 65862-064-01, 65862-064-99","Metoprolol Tartrate, Tablet, 25 mg (NDC 65862-062-01)",Tablet,,,ANDA077739,,METOPROLOL TARTRATE,,,To Be Discontinued,,Permanent discontinuation in the manufacturing of the drug,,W5S57Y3A5L,65862-062-01,866-850-2876,
InfoRLife SA,ROPIVACAINE HYDROCHLORIDE,,03/27/2018,Reverified,"EPIDURAL, INFILTRATION",Ropivacaine Hydrochloride Injection,"1734347, 1734355, 1734479, 1734481",,8c5c762f-d266-4b1a-809e-f11bfc89bc2d,08/26/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROPIVACAINE HYDROCHLORIDE,"25021-652, 25021-671",Sagent Pharmaceuticals,04d1b1c6-1963-4b42-8479-dbf787b6de17,"25021-671-82, 25021-671-87, 25021-652-82, 25021-652-87","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-87)",Injection,Available,,ANDA206166,,ROPIVACAINE HYDROCHLORIDE,,,Current,,Marketed by Sagent Pharmaceuticals,,V910P86109,25021-652-87,Sagent: 866-625-1618,
B. Braun Medical Inc.,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807630, 1807631, 1807632",,cc14fafd-3dcd-4fc8-bdbd-6f355c375768,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,0264-1800,B. Braun Medical Inc.,7d4ee37f-5016-422c-9f66-e675ae22c46a,"0264-1800-36, 0264-1800-31, 0264-1800-32","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 0264-1800-32)",Injection,,,NDA017464,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0264-1800-32,800-227-2862,
B. Braun Medical Inc.,"ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, PROLINE, SERINE, THREONINE, TRYPTOPHAN, TYROSINE, VALINE",,12/08/2020,Revised,INTRAVENOUS,Amino Acid Injection,"800584, 1601982",,a3244d1a-45b0-4e4c-bd96-f0632d761a1f,09/16/2025,HUMAN PRESCRIPTION DRUG,,Gastroenterology,PLENAMINE,0264-4500,B. Braun Medical Inc.,e55957d3-67af-4b6d-9232-55b654e0076f,"0264-4500-00, 0264-4500-05","Plenamine, Injection, 0.15 (NDC 0264-4500-00)",Injection,Available,"N0000175780, M0000922",ANDA091112,Amino Acids [CS],"LYSINE ACETATE, LEUCINE, PHENYLALANINE, VALINE, ISOLEUCINE, METHIONINE, THREONINE, TRYPTOPHAN, ALANINE, ARGININE, GLYCINE, HISTIDINE, PROLINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID, AND TYROSINE",Amino Acid [EPC],,Current,,,,"OF5P57N2ZX, 94ZLA3W45F, 30KYC7MIAI, 3KX376GY7L, TE7660XO1C, 4QD397987E, 04Y7590D77, GMW67QNF9C, TTL6G7LIWZ, AE28F7PNPL, 47E5O17Y3R, 9DLQ4CIU6V, 452VLY9402, 2ZD004190S, 8DUH1N11BX, 42HK56048U, HG18B9YRS7",0264-4500-00,800-227-2862,
Pfizer Inc.,CLINDAMYCIN PHOSPHATE,,03/21/2023,Revised,"INTRAMUSCULAR, INTRAVENOUS",Clindamycin Phosphate Injection,"205964, 309335, 309336, 309339, 685574, 685576, 685578, 706461, 1737244, 1737245, 1737578, 1737579, 1737581, 1737582",,05a75685-0af5-407c-ac57-e380c882b49d,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,CLEOCIN PHOSPHATE,"0009-0870, 0009-0775, 0009-0902, 0009-0728, 0009-3124, 0009-3447, 0009-3381, 0009-3375, 0009-3382, 0009-6582",Pharmacia & Upjohn Company LLC,ac3ba828-3240-4b06-8741-5d1b58e313da,"0009-0870-21, 0009-0870-26, 0009-0775-20, 0009-0775-26, 0009-0902-11, 0009-0902-18, 0009-0728-05, 0009-0728-09, 0009-3124-01, 0009-3124-03, 0009-3447-01, 0009-3447-03, 0009-3381-01, 0009-3381-02, 0009-3375-01, 0009-3375-02, 0009-3382-01, 0009-3382-02, 0009-6582-02, 0009-6582-01","Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26)",Injection,Available,,NDA050441,,CLINDAMYCIN PHOSPHATE,,,Current,,,,EH6D7113I8,0009-0870-26,800-533-4535,
Sandoz Inc.,CLINDAMYCIN,"Decreased Sebaceous Gland Activity [PE], Neuromuscular Blockade [PE]",03/21/2023,Reverified,INTRAVENOUS,Clindamycin Phosphate Injection,"309335, 309336, 309339",,231d95a6-5e5f-4a45-a92b-d3d16ef0a7ca,09/24/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,CLINDAMYCIN IN 5 PERCENT DEXTROSE,"0781-3289, 0781-3288, 0781-3290",Sandoz Inc,e9ea55df-4c10-43a8-97f1-02e6fce12f2b,"0781-3288-91, 0781-3288-09, 0781-3289-91, 0781-3289-09, 0781-3290-91, 0781-3290-09","Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 0781-3289-09)",Injection,Available,"N0000009982, N0000175443, M0515779, N0000175731",ANDA201692,Lincosamides [CS],CLINDAMYCIN IN 5 PERCENT DEXTROSE,Lincosamide Antibacterial [EPC],,Current,,,,3U02EL437C,0781-3289-09,800-525-8747,
"Actavis Pharma, Inc.",DESONIDE,,09/18/2025,New,TOPICAL,Desonide Lotion,"197572, 349351",,ff5d4cd8-ab4d-4a9e-b84b-445c81eeea99,09/18/2025,HUMAN PRESCRIPTION DRUG,09/18/2025,Dermatology,DESONIDE,"0472-0803, 0472-0804","Actavis Pharma, Inc.",f3953b9e-138f-4d86-8eea-0fc03c3c2747,"0472-0804-15, 0472-0804-60, 0472-0803-02, 0472-0803-04","Desowen, Lotion, .5 mg/1 mL (NDC 0472-0803-04)",Lotion,,"N0000175576, N0000175450",ANDA072354,,DESONIDE,Corticosteroid [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug.,,J280872D1O,0472-0803-04,800-545-8800,Corticosteroid Hormone Receptor Agonists [MoA]
"Hikma Pharmaceuticals USA, Inc.",FENTANYL CITRATE,,12/20/2023,Revised,INTRAVENOUS,Fentanyl Citrate Injection,"1735003, 1735007, 1735008, 1735013, 2168270, 2474269, 2629337",,ce5db1c2-feb1-4ad2-847a-d02e865bd47e,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Pediatric",FENTANYL CITRATE,"0641-6026, 0641-6024, 0641-6027, 0641-6025, 0641-6028, 0641-6029, 0641-6030, 0641-6247, 0641-6248, 0641-6249",Hikma Pharmaceuticals USA Inc.,aca9742b-d890-426a-8296-14ca64748238,"0641-6024-01, 0641-6024-10, 0641-6027-01, 0641-6027-25, 0641-6025-01, 0641-6025-10, 0641-6028-01, 0641-6028-10, 0641-6028-25, 0641-6026-01, 0641-6026-05, 0641-6029-01, 0641-6029-25, 0641-6030-01, 0641-6247-01, 0641-6247-25, 0641-6248-01, 0641-6248-10, 0641-6249-01, 0641-6249-10","Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6026-05)",Injection,Unavailable,,NDA019101,,FENTANYL CITRATE,,,Current,Other,Inventory available in vial presentations.,,MUN5LYG46H,0641-6026-05,800-631-2174,
"Hospira, Inc., a Pfizer Company",LIDOCAINE HYDROCHLORIDE,,02/22/2012,Revised,"INFILTRATION, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010671, 1010900, 1737343, 1737562, 1737566, 1737568, 1737636, 1737757, 1737763",,3b2dd84e-cee8-4e58-d494-395a65a353a0,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE HYDROCHLORIDE,"0409-4277, 0409-4713, 0409-4278, 0409-4279, 0409-4776, 0409-4282, 0409-4276, 0409-4275","Hospira, Inc.",c0b4635b-1473-4c48-89c6-620762cd687f,"0409-4713-12, 0409-4713-26, 0409-4713-02, 0409-4713-72, 0409-4713-62, 0409-4713-75, 0409-4713-65, 0409-4713-42, 0409-4713-25, 0409-4713-32, 0409-4278-16, 0409-4278-01, 0409-4279-16, 0409-4279-02, 0409-4776-10, 0409-4776-01, 0409-4282-11, 0409-4282-25, 0409-4282-01, 0409-4282-12, 0409-4282-02, 0409-4277-16, 0409-4277-01, 0409-4277-17, 0409-4277-02, 0409-4276-16, 0409-4276-01, 0409-4276-17, 0409-4276-02, 0409-4275-16, 0409-4275-01","Lidocaine Hydrochloride In Plastic Container, Injection, 1,000 mg/50 mL (2%; 20 mg/mL) (NDC 0409-4277-02)",Injection,Limited Availability,,ANDA088327,,LIDOCAINE HYDROCHLORIDE,,,Current,Other,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: December 2025,,V13007Z41A,0409-4277-02,844-646-4398,
"Hospira, Inc., a Pfizer Company",LIDOCAINE HYDROCHLORIDE,,02/22/2012,Revised,"INFILTRATION, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010671, 1010900, 1737343, 1737562, 1737566, 1737568, 1737636, 1737757, 1737763",,3b2dd84e-cee8-4e58-d494-395a65a353a0,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE HYDROCHLORIDE,"0409-4275, 0409-4713, 0409-4278, 0409-4279, 0409-4776, 0409-4282, 0409-4277, 0409-4276","Hospira, Inc.",c0b4635b-1473-4c48-89c6-620762cd687f,"0409-4713-12, 0409-4713-26, 0409-4713-02, 0409-4713-72, 0409-4713-62, 0409-4713-75, 0409-4713-65, 0409-4713-42, 0409-4713-25, 0409-4713-32, 0409-4278-16, 0409-4278-01, 0409-4279-16, 0409-4279-02, 0409-4776-10, 0409-4776-01, 0409-4282-11, 0409-4282-25, 0409-4282-01, 0409-4282-12, 0409-4282-02, 0409-4277-16, 0409-4277-01, 0409-4277-17, 0409-4277-02, 0409-4276-16, 0409-4276-01, 0409-4276-17, 0409-4276-02, 0409-4275-16, 0409-4275-01","Lidocaine Hydrochloride In Plastic Container, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4275-01)",Injection,Unavailable,,ANDA088325,,LIDOCAINE HYDROCHLORIDE,,,Current,Other,Next Delivery: August 2025; Estimated Recovery: December 2025,12/19/2024,V13007Z41A,0409-4275-01,844-646-4398,
Aurobindo Pharma USA,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,a582d57f-d191-4ca5-b105-585b2d8a0e3e,09/17/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","13107-070, 13107-068, 13107-069, 13107-071, 13107-072, 13107-073, 13107-074","Aurolife Pharma, LLC",95842af2-8d9d-4eb1-ba39-86cdbd829a79,"13107-068-50, 13107-068-01, 13107-068-25, 13107-068-05, 13107-068-99, 13107-069-50, 13107-069-01, 13107-069-25, 13107-069-05, 13107-069-99, 13107-070-50, 13107-070-01, 13107-070-25, 13107-070-05, 13107-070-99, 13107-071-50, 13107-071-01, 13107-071-25, 13107-071-05, 13107-071-99, 13107-072-50, 13107-072-01, 13107-072-25, 13107-072-05, 13107-072-99, 13107-073-50, 13107-073-01, 13107-073-25, 13107-073-05, 13107-073-99, 13107-074-50, 13107-074-01, 13107-074-25, 13107-074-05, 13107-074-99","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 13107-070-01)",Tablet,Unavailable,,ANDA202424,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,Shortage of an active ingredient,Estimated availability December 2025,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",13107-070-01,(866) 850-2876 or CustomerService@AurobindoUSA.com,
"Teva Pharmaceuticals USA, Inc.",MINOCYCLINE HYDROCHLORIDE,,05/23/2025,New,ORAL,Minocycline Hydrochloride Capsule,"197984, 197985, 314108",,a5fc4d50-50b2-46e0-b722-4c6b2ec47d06,05/23/2025,HUMAN PRESCRIPTION DRUG,05/23/2025,Anti-Infective,MINOCYCLINE HYDROCHLORIDE,"0591-3153, 0591-5694, 0591-5695","Actavis Pharma, Inc.",2d74faa2-99c4-4f01-adc6-60110d2b24da,"0591-5694-60, 0591-5694-01, 0591-3153-01, 0591-5695-50","Minocycline Hydrochloride, Capsule, 75 mg (NDC 0591-3153-01)",Capsule,,,ANDA063065,,MINOCYCLINE HYDROCHLORIDE,,,To Be Discontinued,,Permanent discontinuation of manufacture due to business decision.,,0020414E5U,0591-3153-01,800-545-8800,
"Hospira, Inc., a Pfizer Company",SODIUM BICARBONATE,,03/01/2017,Reverified,INTRAVENOUS,Sodium Bicarbonate Injection,1868486,,"8664c7ce-707b-4c6c-9ce4-7160b5f877f8, 084f5572-8c1f-4802-b179-ca0cc838fc68",08/15/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Pediatric",SODIUM BICARBONATE,0409-6625,"Hospira, Inc.","4f89e8d5-75cf-49e3-be27-721e95d829d4, fc0c3d8b-0cfb-4d2a-bd9e-4c77266c4ade","0409-6625-30, 0409-6625-35, 0409-6625-22, 0409-6625-14","Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-14)",Injection,Available,,ANDA202432,,SODIUM BICARBONATE,,,Current,,,,8MDF5V39QO,0409-6625-14,844-646-4398,
Cheplapharm Arzneimittel GmbH,CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529, 206157, 206159, 206160",,cfa0d79a-843c-4b88-95a1-e9511d649ca1,09/15/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",KLONOPIN,"61269-605, 61269-610, 61269-620","H2-Pharma, LLC",c8a147a4-9ebc-4c69-a5b6-bf7547dc6334,"61269-605-10, 61269-610-10, 61269-620-10","Klonopin, Tablet, .5 mg (NDC 61269-605-10)",Tablet,Available,"N0000175694, M0002356",NDA017533,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,Marketed by H2-Pharma,,5PE9FDE8GB,61269-605-10,orders@h2-pharma.com,
Gland Pharma Limited,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718906, 1718909",,d174c19d-56f1-4ef4-087c-23c26db8e40b,09/29/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE HYDROCHLORIDE,"43598-976, 43598-975",Dr.Reddy's Laboratories Inc,5785a11f-7784-4ae0-8029-f50b782eaf4a,"43598-976-11, 43598-976-58, 43598-975-11, 43598-975-58","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-976-58)",Injection,Available,,ANDA209307,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,,Distributed by DRL,,1018WH7F9I,43598-976-58,Distributed by DRL,
Takeda Pharmaceuticals USA Inc.,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,"Lisdexamfetamine Dimesylate Tablet, Chewable","854830, 854832, 854834, 854836, 854838, 854840, 854842, 854844, 854846, 854848, 854850, 854852, 1593856, 1593858, 1871456, 1871459, 1871460, 1871461, 1871462, 1871463, 1871464, 1871465, 1871466, 1871467, 1871468, 1871469",,704e4378-ca83-445c-8b45-3cfa51c1ecad,08/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,VYVANSE,"59417-119, 59417-101, 59417-102, 59417-103, 59417-104, 59417-105, 59417-106, 59417-107, 59417-115, 59417-116, 59417-117, 59417-118, 59417-120","Takeda Pharmaceuticals America, Inc.",756b98a0-fada-44b2-a606-f2e71ef8cc84,"59417-101-10, 59417-102-10, 59417-103-10, 59417-104-10, 59417-105-10, 59417-106-10, 59417-107-10, 59417-115-01, 59417-116-01, 59417-117-01, 59417-118-01, 59417-119-01, 59417-120-01","Vyvanse, Tablet, Chewable, 50 mg (NDC 59417-119-01)","Tablet, Chewable",Available,,NDA208510,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,59417-119-01,877-TAKEDA-7 (1-877-825-3327),
"Fresenius Kabi USA, LLC",SODIUM CHLORIDE,,09/18/2023,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,313016,,8b44bfd3-70a4-4b47-bc7b-590f63b8cc75,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Endocrinology/Metabolism, Total Parenteral Nutrition, Pediatric",SODIUM CHLORIDE,63323-095,"Fresenius Kabi USA, LLC",5db02ff9-4936-46b0-8fb5-3fc491895ae1,"63323-095-02, 63323-095-61","Sodium Chloride 0.9%, Injection, 4 meq/1 mL (NDC 63323-095-61)",Injection,,,ANDA212070,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,63323-095-61,888-386-1300,
"Mylan Pharmaceuticals Inc., a Viatris Company",TRETINOIN,,02/04/2025,New,TOPICAL,Tretinoin Cream,106302,,b5e385a2-f6f9-41cb-8a33-eedba397043f,02/04/2025,HUMAN PRESCRIPTION DRUG,02/04/2025,Dermatology,TRETINOIN,0472-0117,"Actavis Pharma, Inc.",b99bedbe-3d36-47dd-b84c-05f8bb394b83,"0472-0117-20, 0472-0117-45","Avita, Cream, .25 mg/1 g (NDC 0472-0117-20)",Cream,,"N0000175607, M0018962",NDA020404,Retinoids [CS],TRETINOIN,Retinoid [EPC],,To Be Discontinued,,,,5688UTC01R,0472-0117-20,800-796-9526,
HQ Specialty Pharma,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718906, 1718909, 1788947",,0d2710f2-ee47-4114-ab5c-8dca74cdcb8d,09/17/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE IN DEXTROSE,"44567-603, 44567-600, 44567-601, 44567-602","WG Critical Care, LLC",e6fa3e27-b374-49b6-a678-a5954f5beae8,"44567-600-04, 44567-601-04, 44567-602-24, 44567-603-24","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-603-24)",Injection,Available,,NDA206628,,DEXMEDETOMIDINE,,,Current,,Marketed by WG Critical Care,,1018WH7F9I,44567-603-24,WG Critical Care 888-493-0861,
Otsuka ICU Medical LLC,DEXTROSE MONOHYDRATE,,10/11/2024,Reverified,INTRAVENOUS,Dextrose Monohydrate 70% Injection,"237649, 237650, 237656, 242694, 1795518",,b5cb7a5a-bbe8-4217-a82e-da818f7771c9,09/17/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0990-7918, 0990-7935, 0990-7936, 0990-7937, 0990-8004",ICU Medical Inc.,8b5e0f3a-7f61-4ea2-a454-bf57d41e03ae,"0990-7918-19, 0990-7935-19, 0990-7936-19, 0990-7937-19, 0990-8004-15","DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7918-19)",Injection,Available,,NDA018561,,DEXTROSE,,,Current,,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,LX22YL083G,0990-7918-19,1-866-829-9025 or ProductAvailability@icumed.com,
"Upsher-Smith Laboratories, LLC",DIVALPROEX SODIUM,,04/28/2025,New,ORAL,"Divalproex Sodium Tablet, Delayed Release","1099625, 1099678, 1099870",,02304a23-4a5f-47bc-9687-4044b43f7a20,04/28/2025,HUMAN PRESCRIPTION DRUG,04/28/2025,Neurology,DIVALPROEX SODIUM,"0832-7124, 0832-7122, 0832-7123","Upsher-Smith Laboratories, LLC",38e51a59-5802-77a6-e063-6394a90af6c6,"0832-7122-11, 0832-7122-15, 0832-7123-11, 0832-7123-15, 0832-7123-89, 0832-7123-01, 0832-7124-11, 0832-7124-15, 0832-7124-89, 0832-7124-01","Divalproex Sodium, Tablet, Delayed Release, 500 mg (NDC 0832-7124-15)",Tablet,,,ANDA078182,,DIVALPROEX SODIUM,,,To Be Discontinued,,Discontinuation of manufacture of drug based on business decision.,,644VL95AO6,0832-7124-15,800-654-2299,
Pfizer Inc.,"ESTROGENS, ESTERIFIED",,07/29/2025,New,ORAL,Esterified Estrogens Tablet,"197666, 197667, 197668, 197669, 212039, 212232, 212373, 212464",,e0141598-0bb2-4cf0-c9b8-6867b34bbb17,07/29/2025,HUMAN PRESCRIPTION DRUG,07/29/2025,Endocrinology/Metabolism,MENEST,"61570-072, 61570-073, 61570-074, 61570-075",Pfizer Laboratories Div Pfizer Inc,78aaf71c-8f0d-47c4-9fcf-f5e7e9b84bfb,"61570-072-01, 61570-073-01, 61570-074-01, 61570-075-50","Menest, Tablet, .3 mg (NDC 61570-072-01)",Tablet,,,ANDA084951,,ESTERIFIED ESTROGENS,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,3ASP8Q3768,61570-072-01,800-533-4535,
"Somerset Therapeutics, LLC",ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Reverified,"EPIDURAL, INFILTRATION, PERINEURAL",Ropivacaine Hydrochloride Injection,"905189, 1734084, 1734090, 1734203, 1734207, 1734475, 1734483",,ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64,08/19/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROPIVACAINE HYDROCHLORIDE,"70069-061, 70069-062, 70069-063, 70069-064, 70069-065, 70069-066, 70069-067","Somerset Therapeutics, LLC",5d7b0e44-19ce-4127-b3e8-d7e6e65f1818,"70069-061-01, 70069-061-25, 70069-061-10, 70069-062-01, 70069-062-25, 70069-062-10, 70069-063-01, 70069-063-25, 70069-064-01, 70069-064-10, 70069-064-25, 70069-065-01, 70069-065-25, 70069-066-01, 70069-066-25, 70069-066-10, 70069-067-01, 70069-067-25, 70069-067-10","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-25)",Injection,Available,,ANDA207636,,ROPIVACAINE HYDROCHLORIDE,,,Current,,,,V910P86109,70069-061-25,732-554-1019,
"Laboratorios Grifols, S.A.",SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807631, 1807632, 1807633, 1807634, 1807639",,28f79c75-82d2-4912-81fc-a723b5ccf4c1,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,79672-613,Nextgen Pharmaceuticals LLC,3c545b9f-67e4-489d-bb60-c39c990d7dda,"79672-613-01, 79672-613-10, 79672-613-02, 79672-613-20, 79672-613-03, 79672-613-30, 79672-613-04, 79672-613-40, 79672-613-05, 79672-613-50","Sodium Chloride 0.9%, 50 mL Fleboflex Plastic Container, Injection, 0.9% (NDC 79672-613-01)",Injection,,,ANDA207956,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,79672-613-01,800-848-0462,
"Hospira, Inc., a Pfizer Company",ATROPINE SULFATE,,01/01/2012,Revised,INTRAVENOUS,Atropine Sulfate Injection,"1190546, 1190551, 1190552",https://dps.fda.gov/drugshortages/discontinuations/atropine-sulfate-injection,ad8916e7-206e-409e-2582-30d072845dd4,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology, Pediatric",ATROPINE SULFATE,"0409-4910, 0409-1630, 0409-9630, 0409-4911","Hospira, Inc.",9211a9e9-35d0-457d-ac95-4ad43ea6bf28,"0409-1630-15, 0409-1630-10, 0409-9630-15, 0409-9630-05, 0409-4910-11, 0409-4910-34, 0409-4911-11, 0409-4911-34","Atropine Sulfate, Injection, 0.5 mg/5 mL (0.1 mg/mL) Syringes (NDC 0409-4910-34)",Injection,Unavailable,,NDA021146,,ATROPINE SULFATE,,,Current,Other,Next Delivery and Estimated Recovery: December 2028,,03J5ZE7KA5,0409-4910-34,844-646-4398,
"Hospira, Inc., a Pfizer Company",HYDROMORPHONE HYDROCHLORIDE,,10/31/2017,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Hydromorphone Hydrochloride Injection,"897756, 897757, 1433251, 1724383, 1724644, 1872271, 2675350, 897653, 897753, 897758, 1724276",,"f9ca2ef5-46d8-475a-a26e-f7c8becd6db7, e9c9ef18-7dfc-4322-b2fc-29b934c30f8b",08/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,HYDROMORPHONE HYDROCHLORIDE,"0409-1312, 0409-1283, 0409-1380, 0409-4264, 0409-1805, 0409-2552, 0409-3356, 0409-2540, 0409-3365, 0409-1304","Hospira, Inc.","53b6867a-0ae3-48ff-b257-9e58cc76de9c, 58ff0e68-b78f-4ebd-a91b-b53bbdefc544","0409-1283-17, 0409-1283-37, 0409-1312-16, 0409-1312-36, 0409-1380-11, 0409-1380-01, 0409-4264-11, 0409-4264-01, 0409-1805-10, 0409-1805-01, 0409-2552-11, 0409-2552-01, 0409-3356-11, 0409-3356-01, 0409-2540-11, 0409-2540-01, 0409-3365-11, 0409-3365-01, 0409-3365-10, 0409-1283-03, 0409-1283-31, 0409-1283-09, 0409-1283-10, 0409-1283-04, 0409-1283-05, 0409-1312-03, 0409-1312-30, 0409-1312-09, 0409-1312-10, 0409-1304-03, 0409-1304-31","Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-36)",Injection,Limited Availability,,NDA200403,,HYDROMORPHONE HYDROCHLORIDE,,,Current,Other,Limited Supply Available. Next Delivery: January 2026; Estimated Recovery: March 2026,,L960UP2KRW,0409-1312-36,844-646-4398,
Intercept Pharmaceuticals,OBETICHOLIC ACID,,09/19/2025,New,ORAL,Obeticholic Acid Tablet,"1798364, 1798370, 1798373, 1798375",,cdfbe0cd-eb15-45a1-ac17-531bcda21aec,09/19/2025,HUMAN PRESCRIPTION DRUG,09/19/2025,Gastroenterology,OCALIVA,"69516-005, 69516-010",Intercept Pharmaceuticals Inc,44a7331c-fc85-4906-948e-01bbba5e7e61,"69516-005-30, 69516-010-30","Ocaliva, Tablet, 5 mg (NDC 69516-005-30)",Tablet,,"N0000192561, N0000192560",NDA207999,,OBETICHOLIC ACID,Farnesoid X Receptor Agonist [EPC],,To Be Discontinued,,"Business decision. Products will not be available after November 14, 2025.",,0462Z4S4OZ,69516-005-30,1-844-782-4278,Farnesoid X Receptor Agonists [MoA]
Pfizer Inc.,,,10/15/2024,New,,Azithromycin for Suspension,,,,10/15/2024,,10/15/2024,Anti-Infective,,,,,,"Zithromax, for Suspension, 100 mg/5 mL (NDC 59762-3110-1)",,,,,,,,,To Be Discontinued,,,,,59762-3110-1,Viatris Customer Service: 1-800-796-9523,
AstraZeneca AB,EXENATIDE,,10/25/2024,New,SUBCUTANEOUS,Exenatide Synthetic Injection,"847910, 847913, 847915, 847917",,53d03c03-ebf7-418d-88a8-533eabd2ee4f,10/25/2024,HUMAN PRESCRIPTION DRUG,10/25/2024,Endocrinology/Metabolism,BYETTA,"0310-6524, 0310-6512",AstraZeneca Pharmaceuticals LP,7333a7dd-9449-4c61-b36d-c5d8d7cc239b,"0310-6512-01, 0310-6512-85, 0310-6524-01","Byetta, Injection, 600MCG/2.4ML (250MCG/ML) (NDC 0310-6524-01)",Injection,,"N0000178480, M0160181, N0000020058",NDA021773,Glucagon-Like Peptide 1 [CS],EXENATIDE,GLP-1 Receptor Agonist [EPC],,To Be Discontinued,,,,9P1872D4OL,0310-6524-01,800-236-9933,Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
Rhodes Pharmaceuticals L.P.,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,d918b40d-a461-41bc-b6c0-83dc76c28e32,08/05/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"42858-165, 42858-161, 42858-162, 42858-163, 42858-164, 42858-166, 42858-167",Rhodes Pharmaceuticals,4bb64a6b-cce9-4c4a-81c3-06e2e59315c3,"42858-161-01, 42858-162-01, 42858-163-01, 42858-164-01, 42858-165-01, 42858-166-01, 42858-167-01","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 42858-165-01)",Capsule,Available,,ANDA215330,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,42858-165-01,888-827-0616,
Takeda Pharmaceuticals USA Inc.,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,"Lisdexamfetamine Dimesylate Tablet, Chewable","854830, 854832, 854834, 854836, 854838, 854840, 854842, 854844, 854846, 854848, 854850, 854852, 1593856, 1593858, 1871456, 1871459, 1871460, 1871461, 1871462, 1871463, 1871464, 1871465, 1871466, 1871467, 1871468, 1871469",,704e4378-ca83-445c-8b45-3cfa51c1ecad,08/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,VYVANSE,"59417-120, 59417-101, 59417-102, 59417-103, 59417-104, 59417-105, 59417-106, 59417-107, 59417-115, 59417-116, 59417-117, 59417-118, 59417-119","Takeda Pharmaceuticals America, Inc.",756b98a0-fada-44b2-a606-f2e71ef8cc84,"59417-101-10, 59417-102-10, 59417-103-10, 59417-104-10, 59417-105-10, 59417-106-10, 59417-107-10, 59417-115-01, 59417-116-01, 59417-117-01, 59417-118-01, 59417-119-01, 59417-120-01","Vyvanse, Tablet, Chewable, 60 mg (NDC 59417-120-01)","Tablet, Chewable",Available,,NDA208510,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,59417-120-01,877-TAKEDA-7 (1-877-825-3327),
"Mylan Pharmaceuticals Inc., a Viatris Company",TRETINOIN,,02/04/2025,New,TOPICAL,Tretinoin Cream,106302,,b5e385a2-f6f9-41cb-8a33-eedba397043f,02/04/2025,HUMAN PRESCRIPTION DRUG,02/04/2025,Dermatology,TRETINOIN,0472-0117,"Actavis Pharma, Inc.",b99bedbe-3d36-47dd-b84c-05f8bb394b83,"0472-0117-20, 0472-0117-45","Avita, Cream, .25 mg/1 g (NDC 0472-0117-45)",Cream,,"N0000175607, M0018962",NDA020404,Retinoids [CS],TRETINOIN,Retinoid [EPC],,To Be Discontinued,,,,5688UTC01R,0472-0117-45,800-796-9526,
"Fresenius Kabi USA, LLC","EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE ANHYDROUS",,10/14/2016,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL","Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","1010033, 1010035, 1010671, 1010673, 1010688, 1010692, 1010745, 1010749, 1010751, 1010755, 1010759, 1010763, 1010900, 1010902, 1737343, 1737345, 1737562, 1737563, 1737566, 1737567, 1737568, 1737569, 1737570, 1737571, 1737757, 1737758, 1737761, 1737762, 1867938, 1867940, 1867943, 1867944, 1867992, 1867993, 1867996, 1867997, 1868028, 1868029",,ba082c2f-64f4-419d-9c88-74f203316e17,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",XYLOCAINE MPF,"63323-488, 63323-492, 63323-491, 63323-495, 63323-485, 63323-486, 63323-484, 63323-489, 63323-481, 63323-483, 63323-482, 63323-487","Fresenius Kabi USA, LLC",ea480a68-5927-4278-9deb-2956961da428,"63323-492-04, 63323-492-27, 63323-492-09, 63323-492-57, 63323-492-07, 63323-492-37, 63323-492-03, 63323-492-31, 63323-491-01, 63323-491-57, 63323-495-09, 63323-495-27, 63323-495-04, 63323-495-07, 63323-485-01, 63323-485-27, 63323-485-03, 63323-485-57, 63323-486-01, 63323-486-17, 63323-486-02, 63323-486-27, 63323-486-05, 63323-486-57, 63323-484-57, 63323-489-02, 63323-489-27, 63323-489-03, 63323-489-21, 63323-489-01, 63323-489-17, 63323-488-07, 63323-488-37, 63323-488-03, 63323-488-31, 63323-488-01, 63323-488-17, 63323-481-01, 63323-481-57, 63323-483-03, 63323-483-27, 63323-483-01, 63323-483-57, 63323-482-01, 63323-482-17, 63323-482-03, 63323-482-27, 63323-482-05, 63323-482-57, 63323-487-01, 63323-487-17, 63323-487-07, 63323-487-37, 63323-487-03, 63323-487-31","Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-17)",Injection,Available,,NDA006488,,"LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE",,,Current,,Check wholesalers for inventory,,"EC2CNF7XFP, 30Q7KI53AK",63323-488-17,888-386-1300,
Strides Pharma Inc.,LIDOCAINE,Local Anesthesia [PE],01/28/2025,New,TOPICAL,Lidocaine Ointment,1543069,,8b1efeaa-31b1-4f34-960f-7a920ac07355,01/28/2025,HUMAN PRESCRIPTION DRUG,01/28/2025,Anesthesia,LIDOCAINE,64380-789,Strides Pharma Science Limited,e6c9429c-13b9-4932-abad-e605c4c7fb68,"64380-789-32, 64380-789-23, 64380-789-33","Lidocaine, Ointment, 5%, 50 gram jar (NDC 64380-789-33)",Ointment,,"N0000175682, M0000897, N0000175426, N0000175976",ANDA210958,Amides [CS],LIDOCAINE,"Amide Local Anesthetic [EPC], Antiarrhythmic [EPC]",,To Be Discontinued,,,,98PI200987,64380-789-33,877-244-9825,
"Vertical Pharmaceuticals, LLC",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Reverified,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release",,,22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d,09/16/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,RELEXXII,"68025-084, 68025-088, 68025-089, 68025-095, 68025-096, 68025-097, 68025-098","Vertical Pharmaceuticals, LLC",86f477e9-07fc-466b-913e-1a4434c91df4,"68025-088-30, 68025-089-30, 68025-095-10, 68025-095-30, 68025-096-10, 68025-096-30, 68025-097-10, 68025-097-30, 68025-084-30, 68025-098-10, 68025-098-30","Relexxii, Tablet, Extended Release, 72 mg (NDC 68025-084-30)",Tablet,Available,,NDA216117,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,,,,4B3SC438HI,68025-084-30,800-541-4802,
"Hospira, Inc., a Pfizer Company","EPINEPHRINE, LIDOCAINE HYDROCHLORIDE",,02/22/2012,Reverified,"INFILTRATION, PERINEURAL","Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","1010688, 1010745, 1010751, 1010759, 1867996, 1867998",,2f94f711-14c4-48ec-c5a3-c5ec4b8e8729,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE,"0409-3182, 0409-1209, 0409-3177, 0409-3178, 0409-3181, 0409-3183, 0409-0007, 0409-0147","Hospira, Inc.",d16a4711-e663-455e-a1fe-236a41ca4e8f,"0409-1209-10, 0409-1209-01, 0409-1209-05, 0409-1209-70, 0409-1209-65, 0409-3177-16, 0409-3177-01, 0409-3178-16, 0409-3178-01, 0409-3178-17, 0409-3178-02, 0409-3178-18, 0409-3178-03, 0409-3181-11, 0409-3181-01, 0409-3182-11, 0409-3182-01, 0409-3182-21, 0409-3182-02, 0409-3182-31, 0409-3182-03, 0409-3183-11, 0409-3183-01, 0409-0007-01, 0409-0007-10, 0409-0147-01, 0409-0147-10","Lidocaine Hydrochloride and Epinephrine, Injection, 600 mg/30 mL (2%; 1:100,000) (NDC 0409-3182-02)",Injection,Available,"N0000000209, N0000000245, N0000175552, N0000175555, N0000175570, M0003647",ANDA089646,Catecholamines [CS],LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE,"alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC], Catecholamine [EPC]",,Current,,,12/19/2024,"V13007Z41A, YKH834O4BH",0409-3182-02,844-646-4398,"Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA]"
Novadaq Technologies,,,08/23/2024,Revised,,Indocyanine Green Injection,,,,08/26/2025,,,"Medical Imaging, Ophthalmology, Other",,,,,,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-936-15)",Injection,,,,,,,Available,Resolved,,,08/26/2025,,66259-936-15,800-624-4422,
"Hospira, Inc., a Pfizer Company",MEPERIDINE HYDROCHLORIDE,,05/30/2025,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Meperidine Hydrochloride Injection,"860792, 861463, 861473, 861493, 861494, 861522, 861529, 861617, 1242106, 1242503, 2539186, 2539188, 2539191, 2539192",,b31d1308-28c3-43f4-e0a6-2f3ed76b8975,08/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,DEMEROL,"0409-1418, 0409-1181, 0409-1176, 0409-1178, 0409-1179, 0409-1180, 0409-1362","Hospira, Inc.",1271f15f-ccda-4892-8fb0-9bb2d38ded4a,"0409-1181-30, 0409-1176-03, 0409-1176-30, 0409-1178-03, 0409-1178-30, 0409-1179-03, 0409-1179-30, 0409-1180-59, 0409-1180-69, 0409-1362-11, 0409-1362-01, 0409-1418-11, 0409-1418-01","Demerol, Injection, 50 mg/1 mL (NDC 0409-1418-01)",Injection,Unavailable,,NDA021171,,MEPERIDINE HYDROCHLORIDE,,,Current,Discontinuation of the manufacture of the drug,,,N8E7F7Q170,0409-1418-01,844-646-4398,
"Epic Pharma, LLC",RIFAMPIN,,12/22/2021,Reverified,ORAL,Rifampin Capsule,"198201, 198202",,0391f1e1-70d4-4b15-8b58-055bb6a385b8,09/18/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,RIFAMPIN,"42806-799, 42806-801","EPIC PHARMA, LLC",a4ac02e8-68ac-4e79-8ca5-0939dd002c87,"42806-801-30, 42806-801-01, 42806-799-30, 42806-799-60, 42806-799-01, 42806-799-05","Rifampin, Capsule, 300 mg (NDC 42806-799-60)",Capsule,Available,"N0000175500, M0019113",ANDA064150,Rifamycins [CS],RIFAMPIN,Rifamycin Antibacterial [EPC],,Current,,,,VJT6J7R4TR,42806-799-60,(718) 276-8600 ext. 3,
"Hospira, Inc., a Pfizer Company","BUPIVACAINE HYDROCHLORIDE, EPINEPHRINE BITARTRATE",,02/20/2018,Reverified,PERINEURAL,"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","1012377, 1012381, 1012384, 1012388, 1012396, 1012400, 1012404, 1012406, 1672917, 1672919, 1673242, 1673243, 1724786, 1724787, 1724794, 1724796, 1724880, 1724884, 1725044, 1725046, 1725078, 1725079, 1725082, 1725083, 1867594, 1867596, 1867612, 1867614",,67578b56-7540-487e-1fba-481255620e78,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,MARCAINE WITH EPINEPHRINE,"0409-1755, 0409-1559, 0409-1560, 0409-1582, 0409-1587, 0409-1610, 0409-1746, 0409-1749, 0409-1752, 0409-2510, 0409-7535, 0409-1250, 0409-5010, 0409-1530, 0409-0525, 0409-7510, 0409-2253","Hospira, Inc.",b083f440-bfb7-449a-b601-c2f59a6f9dcf,"0409-1559-18, 0409-1559-10, 0409-1559-19, 0409-1559-30, 0409-1560-18, 0409-1560-10, 0409-1560-19, 0409-1560-29, 0409-1582-18, 0409-1582-10, 0409-1582-19, 0409-1582-29, 0409-1587-50, 0409-1610-50, 0409-1746-70, 0409-1746-10, 0409-1746-71, 0409-1746-30, 0409-1749-70, 0409-1749-10, 0409-1749-71, 0409-1749-29, 0409-1752-50, 0409-1755-50, 0409-2510-01, 0409-2510-25, 0409-7535-01, 0409-7535-25, 0409-1250-01, 0409-1250-25, 0409-5010-01, 0409-5010-25, 0409-1530-01, 0409-1530-25, 0409-0525-01, 0409-0525-25, 0409-7510-01, 0409-7510-25, 0409-2253-01, 0409-2253-25","Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000) (NDC 0409-1755-50)",Injection,Available,,NDA016964,,BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE,,,Current,,,,"30Q7KI53AK, 7TQO7W3VT8",0409-1755-50,844-646-4398,
Sagent Pharmaceuticals,CLINDAMYCIN PHOSPHATE,,03/21/2023,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Clindamycin Phosphate Injection,"1737244, 1737578, 1737581",,7a6967b3-5563-4bed-9eee-d400f800e799,08/26/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,CLINDAMYCIN,25021-115,Sagent Pharmaceuticals,4662502b-ce7c-4278-854d-cf8632ac9b83,"25021-115-02, 25021-115-04, 25021-115-06","Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04)",Injection,Available,,ANDA090108,,CLINDAMYCIN PHOSPHATE,,,Current,,,,EH6D7113I8,25021-115-04,866-625-1618,
Gland Pharma Limited,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,,,b93a71ed-0f9e-1ff9-e053-2995a90a789d,09/29/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE,66794-230,Piramal Critical Care Inc,3f76a806-297b-184b-e063-6394a90a7404,"66794-230-02, 66794-230-42","Dexmedetomidine Hydrochloride, Injection, 200 ug/2 mL (NDC 66794-230-42)",Injection,Available,,ANDA202126,,DEXMEDETOMIDINE,,,Current,,Marketed by Piramal Critical Care Inc.: 800-414-1901,,1018WH7F9I,66794-230-42,855-273-0154,
"Teva Pharmaceuticals USA, Inc.",GLIPIZIDE,,02/06/2025,New,ORAL,"Glipizide Tablet, Extended Release","310489, 314006, 315107",,a430577c-f233-40a7-bfd8-3d2bc6f98aa2,02/06/2025,HUMAN PRESCRIPTION DRUG,02/06/2025,Endocrinology/Metabolism,GLIPIZIDE ER,"0591-0844, 0591-0900, 0591-0845","Actavis Pharma, Inc.",90e0de65-ed5f-460a-a96f-77d4d76ceedd,"0591-0900-30, 0591-0844-01, 0591-0844-10, 0591-0845-01, 0591-0845-10","Glipizide, Tablet, Extended Release, 5 mg (NDC 0591-0844-01)",Tablet,,"N0000175608, M0020795",ANDA076467,Sulfonylurea Compounds [CS],GLIPIZIDE,Sulfonylurea [EPC],,To Be Discontinued,,A business decision was made to discontinue manufacture of the drug.,,X7WDT95N5C,0591-0844-01,800-545-8800,
"Mylan Pharmaceuticals Inc., a Viatris Company",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,efbde0f6-b848-4664-b741-c6c630e66108,09/17/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0378-6858, 0378-6854, 0378-6855, 0378-6856, 0378-6857, 0378-6859, 0378-6860",Mylan Pharmaceuticals Inc.,2dfa8600-1b2a-47e8-b58d-c9681b8795cb,"0378-6854-77, 0378-6855-77, 0378-6856-77, 0378-6857-77, 0378-6858-77, 0378-6859-77, 0378-6860-77","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0378-6858-77)",Capsule,Available,,ANDA202835,,LISDEXAMFETAMINE,,,Current,,,,SJT761GEGS,0378-6858-77,800-796-9526,
"Solco Healthcare US, LLC",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,68b10d9f-ca3e-493d-a309-45f1d7e08061,08/05/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"43547-608, 43547-602, 43547-603, 43547-604, 43547-605, 43547-606, 43547-607","Solco Healthcare US,LLC",7bb11568-67a4-4221-bb9b-23af37a1791c,"43547-602-10, 43547-603-10, 43547-604-10, 43547-605-10, 43547-606-10, 43547-607-10, 43547-608-10","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 43547-608-10)",Capsule,Limited Availability,,ANDA216266,,LISDEXAMFETAMINE DIMESYLATE CAPSULES,,,Current,Shortage of an active ingredient,On allocation,,SJT761GEGS,43547-608-10,866-931-9829,
"Fresenius Kabi USA, LLC",MORPHINE SULFATE,,10/31/2017,Revised,"INTRAMUSCULAR, INTRAVENOUS",Morphine Sulfate Injection,"1731993, 1732006, 1732011, 1732136, 2003714",,582f42e5-444e-4246-af8c-e7e28097c69a,09/18/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,MORPHINE SULFATE,"63323-454, 63323-452, 63323-455, 63323-458, 63323-451","Fresenius Kabi USA, LLC",dbf870e7-7bfe-48f0-ba6a-9cc476dfe5cc,"63323-452-00, 63323-452-01, 63323-454-00, 63323-454-01, 63323-455-00, 63323-455-01, 63323-458-00, 63323-458-01, 63323-451-00, 63323-451-01","Morphine Sulfate, Injection, 4 mg/1 mL (NDC 63323-454-01)",Injection,Unavailable,,NDA204223,,MORPHINE SULFATE,,,Current,Other,Backordered. Next release not available at this time. Check wholesalers for inventory.,,X3P646A2J0,63323-454-01,888-386-1300,
"Teva Pharmaceuticals USA, Inc.",OXALIPLATIN,,10/11/2024,New,INTRAVENOUS,Oxaliplatin Injection,"1736776, 1736781",,9e51cc79-620c-48d7-b267-78e43c1ef6e4,10/11/2024,HUMAN PRESCRIPTION DRUG,10/11/2024,Oncology,OXALIPLATIN,"0703-3986, 0703-3985","Teva Parenteral Medicines, Inc.",b349bdd1-79de-44e6-ab0b-892a65bda6f6,"0703-3985-01, 0703-3986-01","Injection, 100 mg/20 mL (NDC 0703-3986-01)",Injection,,"N0000175413, N0000175073",NDA022160,,OXALIPLATIN,Platinum-based Drug [EPC],,To Be Discontinued,,A business decision was made to discontinue this product.,,04ZR38536J,0703-3986-01,800-545-8800,
"Lupin Pharmaceuticals, Inc.",QUINAPRIL HYDROCHLORIDE,,01/19/2023,Reverified,ORAL,Quinapril Hydrochloride Tablet,"312748, 312749, 312750, 314203",,8ded0773-3aec-4e89-9836-d22a5a84abf0,09/18/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,QUINAPRIL,"68180-554, 68180-556, 68180-557, 68180-558, 68180-559","Lupin Pharmaceuticals, Inc.",a9598a21-6f99-4c86-ace6-b5638da2bec8,"68180-556-09, 68180-557-09, 68180-557-03, 68180-558-09, 68180-558-03, 68180-554-09, 68180-554-03, 68180-559-03, 68180-559-09","Quinapril Hydrochloride, Tablet, 40 mg (NDC 68180-554-09)",Tablet,Unavailable,,ANDA077690,,QUINAPRIL,,,Current,Requirements related to complying with good manufacturing practices,,,33067B3N2M,68180-554-09,866-587-4617,
"Hospira, Inc., a Pfizer Company",FENTANYL CITRATE,,01/01/2012,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Fentanyl Citrate Injection,"1735003, 1735004, 1735006, 1735007, 1735008, 1735013",,bfa8018a-4cbc-434b-e09e-782872b0340a,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Pediatric",FENTANYL CITRATE,"0409-9094, 0409-9093","Hospira, Inc.",e4b31fdd-00af-416d-b14e-dbac0c83da97,"0409-9093-37, 0409-9093-32, 0409-9093-45, 0409-9093-35, 0409-9093-41, 0409-9093-36, 0409-9093-31, 0409-9093-38, 0409-9094-12, 0409-9094-22, 0409-9094-18, 0409-9094-25, 0409-9094-17, 0409-9094-28, 0409-9094-16, 0409-9094-31, 0409-9094-41, 0409-9094-61","Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)",Injection,Available,,NDA019115,,FENTANYL CITRATE,,,Current,,,,MUN5LYG46H,0409-9094-31,844-646-4398,
Novadaq Technologies,,,08/23/2024,Revised,,Indocyanine Green Injection,,,,08/26/2025,,,"Medical Imaging, Ophthalmology, Other",,,,,,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-937-26)",Injection,,,,,,,Available,Resolved,,,08/26/2025,,66259-937-26,800-624-4422,
B. Braun Medical Inc.,"CALCIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, SODIUM LACTATE",,10/11/2024,Reverified,INTRAVENOUS,Lactated Ringers Injection,847630,,aad6e18f-04f8-4799-b366-873ec5a50317,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other",LACTATED RINGERS,0264-7500,B. Braun Medical Inc.,39ca9e18-9a9f-4dce-8176-558a8f1e6c17,"0264-7500-00, 0264-7500-10","Lactated Ringers, Injection, .02 g/100 mL; .03 g/100 mL; .6 g/100 mL; .31 g/100 mL (NDC 0264-7500-00)",Injection,Unavailable,,NDA019632,,"SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, AND CALCIUM CHLORIDE",,,Current,Other,Product not yet launched,,"M4I0D6VV5M, 660YQ98I10, 451W47IQ8X, TU7HW0W0QT",0264-7500-00,800-227-2862,
Otsuka ICU Medical LLC,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807548, 1807549, 1807550, 1807551, 1807552, 1807627, 1807630, 1807631, 1807632, 1807633, 1807634, 1807639",,5f372b75-d7a4-471e-8ac6-290040fc84b0,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0990-7984, 0990-7730, 0990-7983, 0990-7985",ICU Medical Inc.,87c57bfa-0bf7-41fd-b954-eb753d5d9d7f,"0990-7730-36, 0990-7730-37, 0990-7983-61, 0990-7983-02, 0990-7983-03, 0990-7983-09, 0990-7983-55, 0990-7983-53, 0990-7984-37, 0990-7984-20, 0990-7984-13, 0990-7984-23, 0990-7984-36, 0990-7985-02, 0990-7985-03, 0990-7985-09","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-13)",Injection,,,NDA016366,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0990-7984-13,1-866-829-9025 or ProductAvailability@icumed.com,
"Sun Pharmaceutical Industries, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Revised,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856, 1871456, 1871460, 1871462, 1871464, 1871466, 1871468",,da3148af-f9b6-4725-adae-3595b4c7dc4b,09/22/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"57664-049, 57664-047, 57664-046, 57664-048, 57664-050, 57664-051, 57664-052, 57664-083, 57664-084, 57664-085, 57664-086, 57664-087, 57664-088","Sun Pharmaceutical Industries, Inc.",0b77417a-5789-8818-e063-6294a90ad2e3,"57664-047-88, 57664-046-88, 57664-048-88, 57664-049-88, 57664-050-88, 57664-051-88, 57664-052-88, 57664-083-88, 57664-084-88, 57664-085-88, 57664-086-88, 57664-087-88, 57664-088-88","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 57664-049-88)",Capsule,Limited Availability,,ANDA214484,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,Additional supply anticipated early 2026,,SJT761GEGS,57664-049-88,800-818-4555,
"Hospira, Inc., a Pfizer Company",ROCURONIUM BROMIDE,,02/15/2023,Reverified,INTRAVENOUS,Rocuronium Bromide Injection,1234995,,c96726ef-f1fa-4ebb-ba33-3479c3902a8e,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROCURONIUM BROMIDE,"0409-7037, 0409-3189","Hospira, Inc.",c96726ef-f1fa-4ebb-ba33-3479c3902a8e,"0409-3189-05, 0409-3189-10, 0409-7037-01, 0409-7037-10","Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-7037-10)",Injection,Available,,ANDA205656,,ROCURONIUM BROMIDE,,,Current,,,,I65MW4OFHZ,0409-7037-10,844-646-4398,
"ICU Medical, Inc.",SODIUM CHLORIDE,,04/28/2023,Revised,IRRIGATION,Sodium Chloride 0.9% Irrigation,486515,,3cfdeee0-ff14-4341-8396-b11c2a037c60,07/02/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0990-7138, 0990-6138, 0990-7972",ICU Medical Inc.,9ceb78f6-0be4-4dbb-9fd0-9728b5ad5c7b,"0990-7138-09, 0990-7138-36, 0990-6138-22, 0990-6138-03, 0990-7972-05, 0990-7972-07","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0990-7138-36)",Irrigation,,,NDA017514,,SODIUM CHLORIDE,,Available,Resolved,,,07/02/2025,451W47IQ8X,0990-7138-36,1-866-829-9025 or ProductAvailability@icumed.com,
Padagis US LLC,BACITRACIN,Decreased Cell Wall Synthesis & Repair [PE],03/03/2025,Reverified,OPHTHALMIC,Bacitracin Ophthalmic Ointment,308508,,6ed2f2bd-9d2f-46af-a44c-95a02ca034de,09/17/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Ophthalmology",BACITRACIN,0574-4022,Padagis US LLC,cad3576e-8534-4132-ac3b-13919e15dc01,"0574-4022-11, 0574-4022-01, 0574-4022-13, 0574-4022-35","Bacitracin, Ophthalmic Ointment, 3.5 g (NDC 0574-4022-35)",Ophthalmic Ointment,Unavailable,N0000008479,ANDA061212,,BACITRACIN,,,Current,Discontinuation of the manufacture of the drug,Shortage is estimated for 18 months,,58H6RWO52I,0574-4022-35,866-634-9120,
"Fresenius Kabi USA, LLC",LEUCOVORIN CALCIUM,,01/01/2012,Revised,"INTRAMUSCULAR, INTRAVENOUS",Leucovorin Calcium Injection,"1803937, 2055036",,e3b957dc-a542-4f69-b8a0-7df401ee706f,07/08/2025,HUMAN PRESCRIPTION DRUG,,"Oncology, Pediatric",LEUCOVORIN CALCIUM,"63323-711, 63323-710","Fresenius Kabi USA, LLC",2497bd71-0f85-48ec-9353-d591e1c728f8,"63323-710-50, 63323-711-00","Leucovorin Calcium Preservative Free, Injection, 500 mg/50 mL (NDC 63323-711-00)",Injection,,,ANDA040286,,LEUCOVORIN CALCIUM,,Available,Resolved,,,07/08/2025,RPR1R4C0P4,63323-711-00,888-386-1300,
Baxter Healthcare,LIDOCAINE HYDROCHLORIDE,,10/25/2017,Reverified,INTRAVENOUS,Lidocaine Hydrochloride Injection,"1737723, 1737742, 1737744",,f21512ea-c7c3-4766-b976-b2c0b5616bf0,09/23/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,LIDOCAINE HYDROCHLORIDE AND DEXTROSE,"0338-0411, 0338-0409",Baxter Healthcare Corporation,6bb9f86c-595a-47f7-b6e9-792966edb852,"0338-0409-03, 0338-0409-02, 0338-0411-02","Lidocaine Hydrochloride And Dextrose, Injection, 8 mg/1 mL (NDC 0338-0411-02)",Injection,Available,,NDA018461,,LIDOCAINE HYDROCHLORIDE,,,Current,,,,V13007Z41A,0338-0411-02,888-229-0001,
"Solco Healthcare US, LLC",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,68b10d9f-ca3e-493d-a309-45f1d7e08061,08/05/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"43547-602, 43547-603, 43547-604, 43547-605, 43547-606, 43547-607, 43547-608","Solco Healthcare US,LLC",7bb11568-67a4-4221-bb9b-23af37a1791c,"43547-602-10, 43547-603-10, 43547-604-10, 43547-605-10, 43547-606-10, 43547-607-10, 43547-608-10","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 43547-602-10)",Capsule,Limited Availability,,ANDA216266,,LISDEXAMFETAMINE DIMESYLATE CAPSULES,,,Current,Shortage of an active ingredient,On allocation,,SJT761GEGS,43547-602-10,866-931-9829,
"Dr. Reddy's Laboratories, Inc.",,,01/08/2025,New,,Ramelteon Tablet,,,,01/08/2025,,01/08/2025,Other,,,,,,"Tablet, 8 mg (NDC 72162-2169-3)",Tablet,,,,,,,,To Be Discontinued,,,,,72162-2169-3,866-732-3952,
Prasco Laboratories,SUMATRIPTAN,,09/08/2025,New,NASAL,Sumatriptan Nasal Spray,"313159, 314227",,f63e616b-ae0c-432b-badc-8c45023aa725,09/08/2025,HUMAN PRESCRIPTION DRUG,09/08/2025,Neurology,SUMATRIPTAN,"66993-082, 66993-081",Prasco Laboratories,b15509b9-4a5b-46ed-be80-b5f6e6e79444,"66993-081-69, 66993-082-69","Imitrex, Nasal Spray, 20 mg/100 uL (NDC 66993-082-69)",Nasal Spray,,"N0000175763, N0000175764, N0000175765",NDA020626,,SUMATRIPTAN,Serotonin-1b and Serotonin-1d Receptor Agonist [EPC],,To Be Discontinued,,"This product discontinuation is a business-related decision. The anticipated date that Prasco will cease distribution of the product is approximately March 16, 2026.",,8R78F6L9VO,66993-082-69,866-525-0688,"Serotonin 1b Receptor Agonists [MoA], Serotonin 1d Receptor Agonists [MoA]"
"Hikma Pharmaceuticals USA, Inc.",LEUCOVORIN CALCIUM,,01/01/2012,Revised,"INTRAMUSCULAR, INTRAVENOUS",Leucovorin Calcium Injection,"237788, 1803930, 1803932, 1803937",,cc52077f-5663-4f79-a273-0aecf655e038,07/08/2025,HUMAN PRESCRIPTION DRUG,,"Oncology, Pediatric",LEUCOVORIN CALCIUM,"0143-9553, 0143-9555, 0143-9554, 0143-9552",Hikma Pharmaceuticals USA Inc.,e2d1484b-2920-45ab-9207-4caa5285fef4,"0143-9555-01, 0143-9554-01, 0143-9553-01, 0143-9552-01","Leucovorin Calcium, Injection, 200 mg/20 mL (NDC 0143-9553-01)",Injection,,,ANDA040056,,LEUCOVORIN CALCIUM,,Available,Resolved,,,07/08/2025,RPR1R4C0P4,0143-9553-01,800-631-2174,
Apotex Corp.,LISDEXAMFETAMINE DIMESYLATE,,11/01/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,ecad4442-a644-18e3-6ff2-fdbac45eec47,09/29/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"60505-4742, 60505-4739, 60505-4740, 60505-4741, 60505-4743, 60505-4744, 60505-4745",Apotex Corp.,c8e0c70d-2f5b-8d85-fa45-572e8f5f7b4c,"60505-4739-1, 60505-4740-1, 60505-4741-1, 60505-4742-1, 60505-4743-1, 60505-4744-1, 60505-4745-1","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 60505-4742-1)",Capsule,Available,,ANDA216944,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,Product currently available,,SJT761GEGS,60505-4742-1,800-706-5575,
Otsuka ICU Medical LLC,WATER,,04/28/2023,Reverified,IRRIGATION,Sterile Water Irrigant,150985,https://www.fda.gov/media/182619/download?attachment,e3484bc6-ed7f-43ef-9d49-c131a8dff2dd,09/17/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",STERILE WATER,"0990-6139, 0990-7139, 0990-7973",ICU Medical Inc.,22b6a1e5-20c1-481b-96d5-329e3fc999f5,"0990-6139-22, 0990-6139-03, 0990-7139-09, 0990-7139-36, 0990-7973-05, 0990-7973-07, 0990-7973-08","Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-22)",Irrigant,Unavailable,,NDA017513,,WATER,,,Current,Other,"Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,059QF0KO0R,0990-6139-22,1-866-829-9025 or ProductAvailability@icumed.com,
"Hospira, Inc., a Pfizer Company",HEPARIN SODIUM,,11/14/2017,Reverified,INTRAVENOUS,Heparin Sodium Injection,"1658690, 1658692",,32e34077-aff1-4ec7-f9b0-b8e240768fb8,08/15/2025,HUMAN PRESCRIPTION DRUG,,Hematology,HEPARIN SODIUM,"0409-7620, 0409-1005, 0409-2222","Hospira, Inc.",c38c96a5-ff8a-43b6-a598-dfd044719d89,"0409-7620-13, 0409-7620-03, 0409-7620-49, 0409-7620-59, 0409-1005-01, 0409-1005-20, 0409-2222-01, 0409-2222-12","Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-7620-59)",Injection,Available,,NDA018916,,HEPARIN SODIUM,,,Current,,,01/02/2025,ZZ45AB24CA,0409-7620-59,844-646-4398,
"Hospira, Inc., a Pfizer Company",HYDROMORPHONE HYDROCHLORIDE,,10/31/2017,Reverified,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Hydromorphone Hydrochloride Injection,"1724338, 1724340, 1724341",,3832ede8-d3fc-455d-ecab-3b77be5869f5,08/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,HYDROMORPHONE HYDROCHLORIDE,0409-2634,"Hospira, Inc.",f0c8c83c-fb41-4571-a72e-6542311351dd,"0409-2634-10, 0409-2634-01, 0409-2634-25, 0409-2634-05, 0409-2634-50","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-01)",Injection,Available,,ANDA078591,,HYDROMORPHONE HYDROCHLORIDE,,,Current,,,01/02/2025,L960UP2KRW,0409-2634-01,844-646-4398,
Baxter Healthcare,NITROGLYCERIN,Vasodilation [PE],10/06/2023,Reverified,INTRAVENOUS,Nitroglycerin Injection,"312004, 1868494, 1868562",,457a026c-ebce-4701-9deb-2d7652759a99,09/23/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,NITROGLYCERIN IN DEXTROSE,"0338-1047, 0338-1049, 0338-1051",Baxter Healthcare Company,71811937-e908-4b65-aff2-4b345fa0954b,"0338-1047-02, 0338-1049-02, 0338-1051-02","Nitroglycerin in Dextrose 5%, Injection, 10 mg/100 mL (NDC 0338-1047-02)",Injection,Unavailable,"N0000175415, M0014874, N0000009909",NDA019970,Nitrates [CS],NITROGLYCERIN,Nitrate Vasodilator [EPC],,Current,Other,Manufacturing delay; Recovery in October 2025,,G59M7S0WS3,0338-1047-02,Baxter Healthcare 888-229-0001,
Sun Pharmaceutical Industries Limited,PANTOPRAZOLE SODIUM,,12/05/2024,New,INTRAVENOUS,Pantoprazole Sodium Injection,283669,,d9fcf6a2-3788-4955-84d9-3c319b13267c,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Gastroenterology,PANTOPRAZOLE SODIUM,62756-129,"Sun Pharmaceutical Industries, Inc.",ef1bb9ed-b534-4698-abf5-836dcce85f45,"62756-129-40, 62756-129-44, 62756-129-45","Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 62756-129-40)",Injection,,,ANDA077674,,PANTOPRAZOLE SODIUM,,,To Be Discontinued,,Discontinuing for business reasons,,6871619Q5X,62756-129-40,800-818-4555,
Baxter Healthcare,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807551, 1807552, 1807627, 1807630, 1807631, 1807632, 1807633, 1807634, 1807639",,f55bd888-5e01-474d-871b-24654c070178,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0338-0049, 0338-0043",Baxter Healthcare Corporation,6ab23768-efd2-4ff1-b336-0dda08dc56e1,"0338-0049-01, 0338-0049-02, 0338-0049-03, 0338-0049-04, 0338-0049-10, 0338-0049-41, 0338-0049-11, 0338-0049-31, 0338-0049-48, 0338-0049-18, 0338-0049-38, 0338-0043-03, 0338-0043-04","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-02)",Injection,,,NDA016677,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0338-0049-02,888-229-0001,
"Sun Pharmaceutical Industries, Inc.",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Revised,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release","1091155, 1091170, 1091185, 1091210",,d048e52d-7406-4fc1-9a72-c073bafc7439,09/22/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE HYDROCHLORIDE,"57664-607, 57664-606, 57664-608, 57664-609","Sun Pharmaceutical Industries, Inc.",0da4b745-d498-8823-e063-6394a90a4524,"57664-606-88, 57664-607-88, 57664-608-88, 57664-609-88","Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88)",Tablet,Unavailable,,ANDA205135,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,Discontinuation of the manufacture of the drug,Currently not marketed,,4B3SC438HI,57664-607-88,800-818-4555,
Pfizer Inc.,QUINAPRIL HYDROCHLORIDE,,01/19/2023,Reverified,ORAL,Quinapril Hydrochloride Tablet,"207891, 207892, 207893, 207895, 312748, 312749, 312750, 314203",,63cf5651-d52c-4d27-9fd4-ed9cd9724dff,08/15/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,ACCUPRIL,"0071-0527, 0071-0530, 0071-0532, 0071-0535, 0071-1205, 0071-1410, 0071-1620, 0071-1840",Parke-Davis Div of Pfizer Inc,ee20d3b1-a5c8-4510-a931-3872df7b77f4,"0071-0527-23, 0071-0530-23, 0071-0530-40, 0071-0532-23, 0071-0532-40, 0071-0535-23, 0071-1205-23, 0071-1410-23, 0071-1620-23, 0071-1840-23","Accupril, Tablet, 5 mg (NDC 0071-0527-23)",Tablet,Unavailable,,NDA019885,,QUINAPRIL HYDROCHLORIDE,,,Current,Delay in shipping of the drug,Next Delivery and Estimated Recovery: TBD,,33067B3N2M,0071-0527-23,800-533-4535,
"Fresenius Kabi USA, LLC",,,07/24/2017,Reverified,,Sodium Bicarbonate Injection,,,,09/18/2025,,,"Endocrinology/Metabolism, Gastroenterology, Pediatric",,,,,,"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 63323-089-50)",Injection,Unavailable,,,,,,,Current,Other,Backordered. Next release October 2025. Check wholesalers for inventory.,,,63323-089-50,888-386-1300,
"Hospira, Inc., a Pfizer Company",ATROPINE SULFATE,,01/01/2012,Reverified,INTRAVENOUS,Atropine Sulfate Injection,"1190546, 1190551, 1190552",,ad8916e7-206e-409e-2582-30d072845dd4,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology, Pediatric",ATROPINE SULFATE,"0409-9630, 0409-1630, 0409-4910, 0409-4911","Hospira, Inc.",9211a9e9-35d0-457d-ac95-4ad43ea6bf28,"0409-1630-15, 0409-1630-10, 0409-9630-15, 0409-9630-05, 0409-4910-11, 0409-4910-34, 0409-4911-11, 0409-4911-34","Atropine Sulfate, Injection, 0.25 mg/5 mL (0.05 mg/mL) Syringes (NDC 0409-9630-05)",Injection,Available,,NDA021146,,ATROPINE SULFATE,,,Current,,,,03J5ZE7KA5,0409-9630-05,844-646-4398,
Aurobindo Pharma USA,CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,b1582eb7-af35-45d5-a52e-0e380d08527d,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"59651-724, 59651-722, 59651-723",Aurobindo Pharma Limited,b1582eb7-af35-45d5-a52e-0e380d08527d,"59651-722-01, 59651-722-99, 59651-723-01, 59651-723-99, 59651-724-01, 59651-724-05","Clonazepam, Tablet, 2 mg (NDC 59651-724-05)",Tablet,Available,"N0000175694, M0002356",ANDA075150,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,,,5PE9FDE8GB,59651-724-05,866-850-2876,
Sagent Pharmaceuticals,,,04/07/2020,Reverified,,Furosemide Injection,,,,08/26/2025,,,Cardiovascular,,,,,,"Furosemide, Injection, 10 mg/1 mL (NDC 70860-302-10)",Injection,"Unavailable, Please use Sagent label",,,,,,,Current,Other,Use Sagent NDC 25021-311-10,,,70860-302-10,866-625-1618,
"Assertio Specialty Pharmaceuticals, LLC",METHOTREXATE,,08/29/2025,New,SUBCUTANEOUS,Methotrexate Injection,"1441402, 1441407, 1441411, 1441413, 1441416, 1441418, 1441422, 1441424, 1747179, 1747181, 1747185, 1747187, 1747192, 1747194",,7dcd02d7-1ce0-43fc-8f25-2f0bb0caba2f,08/29/2025,HUMAN PRESCRIPTION DRUG,08/29/2025,Rheumatology,OTREXUP,"82497-010, 82497-012, 82497-015, 82497-017, 82497-020, 82497-022, 82497-025","Otter Pharmaceuticals, LLC",9aaba145-f343-4498-b754-fb7c78181bd7,"82497-010-02, 82497-010-04, 82497-012-02, 82497-012-04, 82497-015-02, 82497-015-04, 82497-017-02, 82497-017-04, 82497-020-02, 82497-020-04, 82497-022-02, 82497-022-04, 82497-025-02, 82497-025-04","Otrexup, Injection, 10 mg/.4 mL (NDC 82497-010-04)",Injection,,"N0000175584, N0000000111",NDA204824,,METHOTREXATE,Folate Analog Metabolic Inhibitor [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,YL5FZ2Y5U1,82497-010-04,224-441-6390,Folic Acid Metabolism Inhibitors [MoA]
"Vertical Pharmaceuticals, LLC",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Reverified,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release",,,22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d,09/16/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,RELEXXII,"68025-096, 68025-088, 68025-089, 68025-095, 68025-097, 68025-084, 68025-098","Vertical Pharmaceuticals, LLC",86f477e9-07fc-466b-913e-1a4434c91df4,"68025-088-30, 68025-089-30, 68025-095-10, 68025-095-30, 68025-096-10, 68025-096-30, 68025-097-10, 68025-097-30, 68025-084-30, 68025-098-10, 68025-098-30","Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-30)",Tablet,Available,,NDA216117,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,,,,4B3SC438HI,68025-096-30,800-541-4802,
"Epic Pharma, LLC","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961",,1757e132-061d-4773-89ed-fdc77f69008f,09/18/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","42806-341, 42806-339, 42806-343, 42806-344, 42806-345","Epic Pharma, LLC",f11301e2-3b5d-468d-b44c-45839e7e5dfb,"42806-339-01, 42806-341-01, 42806-343-01, 42806-344-01, 42806-345-01","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)",Tablet,Limited Availability,,ANDA040444,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,Shortage of an active ingredient,Limited availability until end of September 2025,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",42806-341-01,(718) 276-8600 ext. 3,
"Fresenius Kabi USA, LLC",ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Reverified,"EPIDURAL, INFILTRATION",Ropivacaine Hydrochloride Injection,"1734203, 1734204, 1734207, 1734208, 1734347, 1734348, 1734355, 1734356, 1734475, 1734476, 1734479, 1734480, 1734481, 1734482, 1734483, 1734484, 905189, 905191, 1734084, 1734086, 1734090, 1734091",,"dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7, 23d2d448-a744-4877-9f2d-7e57c198da89, c6613708-c1f7-4f5c-91a3-ebbc1d7905c6",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,NAROPIN,"63323-285, 63323-286, 63323-287, 63323-288","Fresenius Kabi USA, LLC","324532ac-4e54-4659-a1a2-9ade22a1ed3f, cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9, 73218c89-8925-468c-84bf-9960b4b3dc3c","63323-286-41, 63323-286-27, 63323-286-43, 63323-286-38, 63323-285-41, 63323-285-28, 63323-285-53, 63323-285-68, 63323-285-59, 63323-285-73, 63323-286-01, 63323-286-20, 63323-286-05, 63323-286-23, 63323-286-09, 63323-286-31, 63323-286-11, 63323-286-35, 63323-286-03, 63323-286-00, 63323-286-33, 63323-286-63, 63323-286-30, 63323-287-01, 63323-287-20, 63323-287-03, 63323-287-21, 63323-288-01, 63323-288-10, 63323-288-06, 63323-288-20, 63323-288-03, 63323-288-11, 63323-288-07, 63323-288-21, 63323-285-01, 63323-285-10, 63323-285-06, 63323-285-20, 63323-285-03, 63323-285-13, 63323-285-07, 63323-285-23, 63323-285-57, 63323-285-64, 63323-285-51, 63323-285-65, 63323-285-02, 63323-285-61, 63323-285-04, 63323-285-63, 63323-285-55, 63323-285-67, 63323-288-23, 63323-288-29, 63323-286-93, 63323-286-95","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-65)",Injection,Available,,NDA020533,,ROPIVACAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,V910P86109,63323-285-65,888-386-1300,
Gland Pharma Limited,CARBOPLATIN,,04/28/2023,Reverified,INTRAVENOUS,Carboplatin Injection,597195,,5484d2f0-0cc2-4bba-8f26-c7f6539a9606,09/29/2025,HUMAN PRESCRIPTION DRUG,,Oncology,CARBOPLATIN,"54288-167, 54288-165, 54288-166, 54288-164",BPI Labs LLC,5eb7631e-0b41-4aba-ba7a-f544ac9627fd,"54288-165-01, 54288-166-01, 54288-167-01, 54288-164-01","Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)",Injection,Limited Availability,"N0000175413, N0000175073",ANDA207324,,CARBOPLATIN,Platinum-based Drug [EPC],,Current,Demand increase for the drug,"Estimated recovery: Q4 2025; Distributed by BPI Labs, LLC",,BG3F62OND5,54288-167-01,"Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270",
"Actavis Pharma, Inc.",,,11/21/2024,New,ORAL,Memantine Hydrochloride Tablet,"996561, 996571, 996572",,72973b46-f307-4a9e-8fb1-ad2cbccfd736,11/21/2024,HUMAN PRESCRIPTION DRUG,11/21/2024,Neurology,MEMANTINE HYDROCHLORIDE,"0591-3900, 0591-3870, 0591-3875","Actavis Pharma, Inc.",985e1190-b8a0-4775-9a20-ad1924b14fb2,"0591-3870-60, 0591-3870-45, 0591-3870-44, 0591-3875-60, 0591-3875-45, 0591-3875-44, 0591-3900-87","Namenda, Tablet, Kit (NDC 0591-3900-87)",Tablet,,,NDA021487,,MEMANTINE HYDROCHLORIDE,,,To Be Discontinued,,,,JY0WD0UA60,0591-3900-87,800-545-8800,
"Epic Pharma, LLC","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961",,1757e132-061d-4773-89ed-fdc77f69008f,09/18/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","42806-343, 42806-339, 42806-341, 42806-344, 42806-345","Epic Pharma, LLC",f11301e2-3b5d-468d-b44c-45839e7e5dfb,"42806-339-01, 42806-341-01, 42806-343-01, 42806-344-01, 42806-345-01","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)",Tablet,Limited Availability,,ANDA040444,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,Shortage of an active ingredient,Limited availability until end of September 2025,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",42806-343-01,(718) 276-8600 ext. 3,
"Teva Pharmaceuticals USA, Inc.",POTASSIUM CHLORIDE,,05/19/2025,New,ORAL,"Potassium Chloride Capsule, Extended Release","312504, 315183",,ed5baaf6-270b-4dd3-b100-36030c0098fc,05/19/2025,HUMAN PRESCRIPTION DRUG,05/19/2025,"Endocrinology/Metabolism, Gastroenterology",POTASSIUM CHLORIDE,"62037-560, 62037-559","Actavis Pharma, Inc.",b97da107-c56e-48ea-ba34-d3d64a5b9f46,"62037-559-01, 62037-559-05, 62037-560-01, 62037-560-05, 62037-560-10, 62037-560-90","Potassium Chloride, Capsule, Extended Release, 750 mg (NDC 62037-560-01)","Capsule, Extended Release",,,ANDA077419,,POTASSIUM CHLORIDE,,,To Be Discontinued,,,,660YQ98I10,62037-560-01,800-545-8800,
"Upsher-Smith Laboratories, LLC",PROPAFENONE HYDROCHLORIDE,,05/14/2025,New,ORAL,"Propafenone Hydrochloride Capsule, Extended Release","861156, 861164, 861171",,8aa6f58a-2980-4caa-9c54-d55d69d5d132,05/14/2025,HUMAN PRESCRIPTION DRUG,05/14/2025,Cardiovascular,PROPAFENONE HYDROCHLORIDE,"0832-0741, 0832-0740, 0832-0742","Upsher-Smith Laboratories, LLC",398513af-dd95-49eb-e063-6394a90a73f4,"0832-0740-60, 0832-0741-60, 0832-0742-60","Propafenone Hydrochloride, Capsule, Extended Release, 325 mg (NDC 0832-0741-60)","Capsule, Extended Release",,,ANDA212744,,PROPAFENONE HYDROCHLORIDE,,,To Be Discontinued,,A business decision was made to discontinue the product.,,33XCH0HOCD,0832-0741-60,800-654-2299,
"Fresenius Kabi USA, LLC",ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Reverified,"EPIDURAL, INFILTRATION",Ropivacaine Hydrochloride Injection,"1734203, 1734204, 1734207, 1734208, 1734347, 1734348, 1734355, 1734356, 1734475, 1734476, 1734479, 1734480, 1734481, 1734482, 1734483, 1734484, 905189, 905191, 1734084, 1734086, 1734090, 1734091",,"dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7, 23d2d448-a744-4877-9f2d-7e57c198da89, c6613708-c1f7-4f5c-91a3-ebbc1d7905c6",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,NAROPIN,"63323-285, 63323-286, 63323-287, 63323-288","Fresenius Kabi USA, LLC","324532ac-4e54-4659-a1a2-9ade22a1ed3f, cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9, 73218c89-8925-468c-84bf-9960b4b3dc3c","63323-286-41, 63323-286-27, 63323-286-43, 63323-286-38, 63323-285-41, 63323-285-28, 63323-285-53, 63323-285-68, 63323-285-59, 63323-285-73, 63323-286-01, 63323-286-20, 63323-286-05, 63323-286-23, 63323-286-09, 63323-286-31, 63323-286-11, 63323-286-35, 63323-286-03, 63323-286-00, 63323-286-33, 63323-286-63, 63323-286-30, 63323-287-01, 63323-287-20, 63323-287-03, 63323-287-21, 63323-288-01, 63323-288-10, 63323-288-06, 63323-288-20, 63323-288-03, 63323-288-11, 63323-288-07, 63323-288-21, 63323-285-01, 63323-285-10, 63323-285-06, 63323-285-20, 63323-285-03, 63323-285-13, 63323-285-07, 63323-285-23, 63323-285-57, 63323-285-64, 63323-285-51, 63323-285-65, 63323-285-02, 63323-285-61, 63323-285-04, 63323-285-63, 63323-285-55, 63323-285-67, 63323-288-23, 63323-288-29, 63323-286-93, 63323-286-95","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-64)",Injection,Available,,NDA020533,,ROPIVACAINE HYDROCHLORIDE,,,Current,,,,V910P86109,63323-285-64,888-386-1300,
"Fresenius Kabi USA, LLC",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,"EPIDURAL, RETROBULBAR",Bupivacaine Hydrochloride Injection,"1012377, 1012384, 1012413, 1012417, 1724786, 1724787, 1724809, 1724810, 1867594, 1867596, 1867618, 1867620",,bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb,09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,SENSORCAINE MPF,"63323-472, 63323-463, 63323-461, 63323-468","Fresenius Kabi USA, LLC",cc1f6507-eb3e-4398-a1d3-0c56a2099e6b,"63323-472-03, 63323-472-17, 63323-472-01, 63323-472-37, 63323-463-01, 63323-463-57, 63323-461-01, 63323-461-57, 63323-468-02, 63323-468-37, 63323-468-01, 63323-468-17","Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-37)",Injection,Available,,ANDA070554,,BUPIVACAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,"30Q7KI53AK, 7TQO7W3VT8",63323-472-37,888-386-1300,
"Sun Pharmaceutical Industries, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Revised,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856, 1871456, 1871460, 1871462, 1871464, 1871466, 1871468",,da3148af-f9b6-4725-adae-3595b4c7dc4b,09/22/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"57664-048, 57664-047, 57664-046, 57664-049, 57664-050, 57664-051, 57664-052, 57664-083, 57664-084, 57664-085, 57664-086, 57664-087, 57664-088","Sun Pharmaceutical Industries, Inc.",0b77417a-5789-8818-e063-6294a90ad2e3,"57664-047-88, 57664-046-88, 57664-048-88, 57664-049-88, 57664-050-88, 57664-051-88, 57664-052-88, 57664-083-88, 57664-084-88, 57664-085-88, 57664-086-88, 57664-087-88, 57664-088-88","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 57664-048-88)",Capsule,Limited Availability,,ANDA214484,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,Additional supply anticipated early 2026,,SJT761GEGS,57664-048-88,800-818-4555,
Aurobindo Pharma USA,AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","239191, 313797",,234d0dfc-cb24-413f-b798-129c73eb848e,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"65862-707, 65862-706",Aurobindo Pharma Limited,f4a410c9-3a78-48f9-8195-915896a974ff,"65862-706-80, 65862-706-01, 65862-706-55, 65862-707-80, 65862-707-01, 65862-707-55","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 65862-707-55)","Powder, For Suspension",,,ANDA204030,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,65862-707-55,866-850-2876,
Renew Pharmaceuticals Limited,,,08/23/2024,Revised,,Indocyanine Green Injection,,,ccd92843-1f0a-4ece-9978-4b300d158886,08/26/2025,HUMAN PRESCRIPTION DRUG,,"Medical Imaging, Ophthalmology, Other",IC-GREEN,70100-825,Renew Pharmaceuticals Limited,2ecb091b-3588-4985-8223-a84825c0886a,"70100-825-02, 70100-725-01, 0409-4887-17","IC-GREEN, Injection, 25 mg (NDC 70100-825-02)",Injection,,,NDA011525,,INDOCYANINE GREEN,,Available,Resolved,,,08/26/2025,,70100-825-02,888-393-3767,
"Teva Pharmaceuticals USA, Inc.",AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension",,,4c0f348a-a65d-409c-8668-207c82a5e3cb,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0093-4155, 0093-2263, 0093-2264, 0093-4160, 0093-4161, 0093-2267, 0093-2268, 0093-3107, 0093-3109","Teva Pharmaceuticals USA, Inc.",8988589b-0893-4233-ac9c-9884ceb0c2c4,"0093-2263-01, 0093-2264-01, 0093-4160-76, 0093-4160-78, 0093-4160-73, 0093-4155-79, 0093-4155-73, 0093-4155-80, 0093-4161-76, 0093-4161-78, 0093-4161-73, 0093-2267-01, 0093-2268-01, 0093-3107-01, 0093-3107-05, 0093-3109-53, 0093-3109-06, 0093-3109-01, 0093-3109-05","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0093-4155-73)","Powder, For Suspension",,,ANDA061931,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0093-4155-73,800-545-8800,
"Upsher-Smith Laboratories, LLC",POTASSIUM CHLORIDE,,07/23/2025,New,ORAL,"Potassium Chloride Tablet, Extended Release","312529, 628953",,616f0de7-8843-44a1-8fa6-274d889286aa,07/23/2025,HUMAN PRESCRIPTION DRUG,07/23/2025,"Endocrinology/Metabolism, Gastroenterology",POTASSIUM CHLORIDE,"0832-5322, 0832-5323","Upsher-Smith Laboratories, LLC",39e726b1-eab8-fcf4-e063-6394a90a950a,"0832-5322-11, 0832-5322-10, 0832-5323-11, 0832-5323-10","Potassium Chloride, Tablet, Extended Release, 600 mg (NDC 0832-5322-11)",Tablet,,,NDA019123,,POTASSIUM CHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug product,,660YQ98I10,0832-5322-11,763-315-2000,
Eugia US LLC,ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Revised,EPIDURAL,Ropivacaine Hydrochloride Injection,"905189, 1734084, 1734090, 1734207, 1734347, 1734475, 1734483",,3763b7b6-da49-4658-b93d-28f5da24d09e,09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROPIVACAINE HYDROCHLORIDE,"55150-201, 55150-195, 55150-196, 55150-197, 55150-198, 55150-199, 55150-200",Eugia US LLC,34725b26-d6e9-4d1b-95a0-da03764cc102,"55150-195-20, 55150-196-99, 55150-197-20, 55150-198-30, 55150-199-20, 55150-200-10, 55150-201-20","Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-201-20)",Injection,Available,,ANDA205612,,ROPIVACAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,V910P86109,55150-201-20,888-238-7880,
Pfizer Inc.,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"284397, 309710, 1718900, 1718902, 1718906, 1718907, 1718909, 1718910, 2396891, 2396892",,548a88c0-afda-427e-75ac-5af0cfa2224c,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,PRECEDEX,"0409-1638, 0409-1660, 0409-1434, 0409-1596, 0409-7838, 0409-7853, 0409-7875","Hospira, Inc.",231f50fe-2c91-44b9-946e-33b836c07b94,"0409-1660-55, 0409-1660-50, 0409-1660-35, 0409-1660-10, 0409-1660-22, 0409-1660-20, 0409-1638-32, 0409-1638-02, 0409-1434-01, 0409-1596-01, 0409-1596-10, 0409-7838-01, 0409-7838-24, 0409-7853-01, 0409-7853-24, 0409-7875-01, 0409-7875-12","Precedex, Injection, 200 mcg/2 mL (100 mcg/mL) (NDC 0409-1638-02)",Injection,Available,,NDA021038,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,,,,1018WH7F9I,0409-1638-02,844-646-4398,
"Teva Pharmaceuticals USA, Inc.",GLYBURIDE,,06/10/2025,New,ORAL,Glyburide Tablet,"310536, 310539, 314000",,e84c0dfc-a4e9-4c89-b6ea-45732eb412f5,06/10/2025,HUMAN PRESCRIPTION DRUG,06/10/2025,Endocrinology/Metabolism,GLYBURIDE,"0093-8035, 0093-8034, 0093-8036","Teva Pharmaceuticals USA, Inc.",00e55b1b-81b5-4df1-8a6d-4d54ac403e76,"0093-8034-01, 0093-8035-01, 0093-8035-05, 0093-8036-01","Glyburide (Micronized), Tablet, 3 mg (NDC 0093-8035-05)",Tablet,,"N0000175608, M0020795",ANDA074686,Sulfonylurea Compounds [CS],GLYBURIDE,Sulfonylurea [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,SX6K58TVWC,0093-8035-05,800-545-8800,
"Upsher-Smith Laboratories, LLC",TOPIRAMATE,Decreased Central Nervous System Disorganized Electrical Activity [PE],04/24/2025,New,ORAL,"Topiramate Capsule, Extended Release","1494766, 1494769, 1494771, 1494775, 1494778, 1494781, 1812419, 1812421, 1812425, 1812427",,46f54677-3a22-4c38-9b92-923020164e15,04/24/2025,HUMAN PRESCRIPTION DRUG,04/24/2025,Neurology,QUDEXY XR,"0245-1072, 0245-1071, 0245-1074, 0245-1075, 0245-1073","Upsher-Smith Laboratories, LLC",374eeb55-b017-48fd-e063-6294a90a6ad7,"0245-1071-30, 0245-1071-90, 0245-1072-30, 0245-1072-90, 0245-1074-30, 0245-1074-90, 0245-1075-30, 0245-1075-90, 0245-1073-30, 0245-1073-90","Qudexy XR, Capsule, Extended Release, 50 mg (NDC 0245-1072-30)","Capsule, Extended Release",,"N0000008486, N0000185506, N0000182140",NDA205122,,TOPIRAMATE,,,To Be Discontinued,,Upsher-Smith will continue to provide their generic Topiramate Extended-release Capsules.,,0H73WJJ391,0245-1072-30,716-315-2000,"Cytochrome P450 3A4 Inducers [MoA], Cytochrome P450 2C19 Inhibitors [MoA]"
Aurobindo Pharma USA,BENAZEPRIL HYDROCHLORIDE,,02/07/2025,New,ORAL,Benazepril Hydrochloride Tablet,"898687, 898690, 898719",,09e383a8-e912-4cf7-8fb3-05545af80dd0,02/07/2025,HUMAN PRESCRIPTION DRUG,02/07/2025,Cardiovascular,BENAZEPRIL HYDROCHLORIDE,"65862-116, 65862-117, 65862-118",Aurobindo Pharma Limited,65334c7f-e49f-44d9-a6c1-6c1ce6e88fbe,"65862-116-90, 65862-116-01, 65862-117-90, 65862-117-01, 65862-118-90, 65862-118-01","Benazepril Hydrochloride, Tablet, 10 mg (NDC 65862-116-01)",Tablet,,,ANDA078212,,BENAZEPRIL HYDROCHLORIDE,,,To Be Discontinued,,,,N1SN99T69T,65862-116-01,866-850-2876,
Otsuka ICU Medical LLC,"ACETYL L-TYROSINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, PROLINE, SERINE, THREONINE, TRYPTOPHAN, VALINE",,12/08/2020,Reverified,INTRAVENOUS,Amino Acid Injection,"800188, 800192, 800237, 800241",,5b426208-f090-4650-86c3-89040ba45c2d,09/17/2025,HUMAN PRESCRIPTION DRUG,,Gastroenterology,AMINOSYN II,"0990-7171, 0990-7172",ICU Medical Inc.,8e4121e2-89a0-4f4e-98b9-1530dec5972b,"0990-7172-17, 0990-7171-17","Aminosyn II 15% In Plastic Container, Injection, 0.15 (NDC 0990-7171-17)",Injection,Available,"N0000175780, M0000922",NDA020041,Amino Acids [CS],"ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, HISTIDINE, PROLINE, SERINE, N-ACETYLTYROSINE, AND GLYCINE",Amino Acid [EPC],,Current,,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,"9DLQ4CIU6V, 452VLY9402, 3KX376GY7L, 2ZD004190S, DA8G610ZO5, 30KYC7MIAI, AE28F7PNPL, GMW67QNF9C, 94ZLA3W45F, OF5P57N2ZX, TE7660XO1C, 4QD397987E, TTL6G7LIWZ, 47E5O17Y3R, 8DUH1N11BX, 04Y7590D77, HG18B9YRS7",0990-7171-17,1-866-829-9025 or ProductAvailability@icumed.com,
AbbVie Inc.,CYCLOSPORINE,,12/05/2024,New,ORAL,Cyclosporine Oral Solution,,,29891f95-9079-4880-7abc-194e49767dd5,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Transplant,GENGRAF,0074-7269,AbbVie Inc.,e7317e31-31d8-4af8-b92d-cd58d8a44a1f,0074-7269-50,"Gengraf, Oral Solution, 100 mg/ml (NDC 0074-7269-50)",Oral Solution,,"N0000175457, N0000175458, N0000182141, N0000185503",ANDA065025,,CYCLOSPORINE,Calcineurin Inhibitor Immunosuppressant [EPC],,To Be Discontinued,,"Abbvie has made a business decision to permanently discontinue GENGRAF Oral Solution (cyclosporine oral solution, USP) 100 mg/mL .",,83HN0GTJ6D,0074-7269-50,800-633-9110,"Calcineurin Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]"
"Fresenius Kabi USA, LLC",LIDOCAINE HYDROCHLORIDE ANHYDROUS,,02/22/2012,Reverified,"INFILTRATION, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010035, 1010671, 1010673, 1010688, 1010692, 1010745, 1010749, 1010751, 1010755, 1010759, 1010763, 1010900, 1010902, 1737343, 1737345, 1737562, 1737563, 1737566, 1737567, 1737568, 1737569, 1737570, 1737571, 1737757, 1737758, 1737761, 1737762, 1867938, 1867940, 1867943, 1867944, 1867992, 1867993, 1867996, 1867997, 1868028, 1868029",,ba082c2f-64f4-419d-9c88-74f203316e17,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",XYLOCAINE,"63323-484, 63323-492, 63323-491, 63323-495, 63323-485, 63323-486, 63323-489, 63323-488, 63323-481, 63323-483, 63323-482, 63323-487","Fresenius Kabi USA, LLC",ea480a68-5927-4278-9deb-2956961da428,"63323-492-04, 63323-492-27, 63323-492-09, 63323-492-57, 63323-492-07, 63323-492-37, 63323-492-03, 63323-492-31, 63323-491-01, 63323-491-57, 63323-495-09, 63323-495-27, 63323-495-04, 63323-495-07, 63323-485-01, 63323-485-27, 63323-485-03, 63323-485-57, 63323-486-01, 63323-486-17, 63323-486-02, 63323-486-27, 63323-486-05, 63323-486-57, 63323-484-57, 63323-489-02, 63323-489-27, 63323-489-03, 63323-489-21, 63323-489-01, 63323-489-17, 63323-488-07, 63323-488-37, 63323-488-03, 63323-488-31, 63323-488-01, 63323-488-17, 63323-481-01, 63323-481-57, 63323-483-03, 63323-483-27, 63323-483-01, 63323-483-57, 63323-482-01, 63323-482-17, 63323-482-03, 63323-482-27, 63323-482-05, 63323-482-57, 63323-487-01, 63323-487-17, 63323-487-07, 63323-487-37, 63323-487-03, 63323-487-31","Xylocaine, Injection, 5 mg/1 mL (NDC 63323-484-57)",Injection,Unavailable,,NDA006488,,LIDOCAINE HYDROCHLORIDE,,,Current,Demand increase for the drug,Next release not available at this time.,,"EC2CNF7XFP, 30Q7KI53AK",63323-484-57,888-386-1300,
"Fresenius Kabi USA, LLC",LIDOCAINE HYDROCHLORIDE ANHYDROUS,,02/22/2012,Reverified,"INFILTRATION, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010035, 1010671, 1010673, 1010688, 1010692, 1010745, 1010749, 1010751, 1010755, 1010759, 1010763, 1010900, 1010902, 1737343, 1737345, 1737562, 1737563, 1737566, 1737567, 1737568, 1737569, 1737570, 1737571, 1737757, 1737758, 1737761, 1737762, 1867938, 1867940, 1867943, 1867944, 1867992, 1867993, 1867996, 1867997, 1868028, 1868029",,"ba082c2f-64f4-419d-9c88-74f203316e17, 4dd52202-8eef-4136-92dd-ada573b7cf74",09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",XYLOCAINE,"63323-486, 63323-492, 63323-491, 63323-495, 63323-485, 63323-484, 63323-489, 63323-488, 63323-481, 63323-483, 63323-482, 63323-487","Fresenius Kabi USA, LLC","ea480a68-5927-4278-9deb-2956961da428, 0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33","63323-492-04, 63323-492-27, 63323-492-09, 63323-492-57, 63323-492-07, 63323-492-37, 63323-492-03, 63323-492-31, 63323-491-01, 63323-491-57, 63323-495-09, 63323-495-27, 63323-495-04, 63323-495-07, 63323-485-01, 63323-485-27, 63323-485-03, 63323-485-57, 63323-486-01, 63323-486-17, 63323-486-02, 63323-486-27, 63323-486-05, 63323-486-57, 63323-484-57, 63323-489-02, 63323-489-27, 63323-489-03, 63323-489-21, 63323-489-01, 63323-489-17, 63323-488-07, 63323-488-37, 63323-488-03, 63323-488-31, 63323-488-01, 63323-488-17, 63323-481-01, 63323-481-57, 63323-483-03, 63323-483-27, 63323-483-01, 63323-483-57, 63323-482-01, 63323-482-17, 63323-482-03, 63323-482-27, 63323-482-05, 63323-482-57, 63323-487-01, 63323-487-17, 63323-487-07, 63323-487-37, 63323-487-03, 63323-487-31, 63323-492-41, 63323-492-16, 63323-492-43, 63323-492-36, 63323-492-45, 63323-492-26, 63323-485-41, 63323-485-26, 63323-486-41, 63323-486-26, 63323-482-41, 63323-482-26, 63323-495-41, 63323-495-26","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-17)",Injection,Available,,NDA006488,,LIDOCAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,"EC2CNF7XFP, 30Q7KI53AK",63323-486-17,888-386-1300,
"Teva Pharmaceuticals USA, Inc.",AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension",,,4c0f348a-a65d-409c-8668-207c82a5e3cb,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0093-4160, 0093-2263, 0093-2264, 0093-4155, 0093-4161, 0093-2267, 0093-2268, 0093-3107, 0093-3109","Teva Pharmaceuticals USA, Inc.",8988589b-0893-4233-ac9c-9884ceb0c2c4,"0093-2263-01, 0093-2264-01, 0093-4160-76, 0093-4160-78, 0093-4160-73, 0093-4155-79, 0093-4155-73, 0093-4155-80, 0093-4161-76, 0093-4161-78, 0093-4161-73, 0093-2267-01, 0093-2268-01, 0093-3107-01, 0093-3107-05, 0093-3109-53, 0093-3109-06, 0093-3109-01, 0093-3109-05","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0093-4160-73)","Powder, For Suspension",,,ANDA065119,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0093-4160-73,800-545-8800,
"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)",RILUZOLE,,01/26/2024,Reverified,ORAL,Riluzole Oral Suspension,"2058147, 2675565",https://www.fda.gov/media/185612/download?attachment,1a3aeb59-d589-8d12-e063-6394a90a0a3a,09/15/2025,HUMAN PRESCRIPTION DRUG,,Neurology,TEGLUTIK,70726-0306,EDW PHARMA,1ae0e94b-14fa-9671-e063-6394a90a3d6f,70726-0306-1,"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0306-1)",Oral Suspension,Available,"N0000175740, M0483511",,Benzothiazoles [CS],RILUZOLE,Benzothiazole [EPC],,Current,,,,7LJ087RS6F,70726-0306-1,610-937-6172,
"Teva Pharmaceuticals USA, Inc.",,,01/10/2025,New,ORAL,"Ethinyl Estradiol; Norethindrone Tablet, Chewable","1095223, 1099638, 1607990, 1650201",,c0db84ca-b8d4-4ed2-b2f6-19347283146e,01/10/2025,HUMAN PRESCRIPTION DRUG,01/10/2025,Reproductive,LAYOLIS FE,52544-064,"Actavis Pharma, Inc.",82960ca4-6fe9-40c5-8688-8b3d2b65327a,52544-064-31,"Tablet, Chewable, Kit (NDC 52544-064-31)","Tablet, Chewable",,,NDA022573,,"NORETHINDRONE, ETHINYL ESTRADIOL, AND FERROUS FUMARATE",,,To Be Discontinued,,,,,52544-064-31,800-545-8800,
"Hikma Pharmaceuticals USA, Inc.",FENTANYL CITRATE,,12/20/2023,Revised,"INTRAMUSCULAR, INTRAVENOUS",Fentanyl Citrate Injection,"1735003, 1735007, 1735008, 1735013, 2168270, 2474269, 2629337",,ce5db1c2-feb1-4ad2-847a-d02e865bd47e,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Pediatric",FENTANYL CITRATE,"0641-6028, 0641-6024, 0641-6027, 0641-6025, 0641-6026, 0641-6029, 0641-6030, 0641-6247, 0641-6248, 0641-6249",Hikma Pharmaceuticals USA Inc.,aca9742b-d890-426a-8296-14ca64748238,"0641-6024-01, 0641-6024-10, 0641-6027-01, 0641-6027-25, 0641-6025-01, 0641-6025-10, 0641-6028-01, 0641-6028-10, 0641-6028-25, 0641-6026-01, 0641-6026-05, 0641-6029-01, 0641-6029-25, 0641-6030-01, 0641-6247-01, 0641-6247-25, 0641-6248-01, 0641-6248-10, 0641-6249-01, 0641-6249-10","Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6028-25)",Injection,Available,,NDA019101,,FENTANYL CITRATE,,,Current,,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,MUN5LYG46H,0641-6028-25,800-631-2174,
Eli Lilly and Co.,ATOMOXETINE HYDROCHLORIDE,,10/22/2024,New,ORAL,Atomoxetine Hydrochloride Capsule,"349591, 349592, 349593, 349594, 349595, 352317, 352318, 352319, 352320, 352321, 608139, 608143, 617945, 617947",,309de576-c318-404a-bc15-660c2b1876fb,10/22/2024,HUMAN PRESCRIPTION DRUG,10/22/2024,Psychiatry,STRATTERA,"0002-3250, 0002-3227, 0002-3238, 0002-3228, 0002-3229, 0002-3239, 0002-3251",Eli Lilly and Company,90fd3143-d5d4-4343-9570-b3863e31b1a0,"0002-3227-30, 0002-3238-30, 0002-3228-30, 0002-3229-30, 0002-3239-30, 0002-3250-30, 0002-3251-30","Strattera, Capsule, 80 mg (NDC 0002-3250-30)",Capsule,,,NDA021411,,ATOMOXETINE HYDROCHLORIDE,,,To Be Discontinued,,Business decision to discontinue,,57WVB6I2W0,0002-3250-30,800-545-5979,
"Hainan Poly Pharm. Co., Ltd.",DOBUTAMINE HYDROCHLORIDE,,11/06/2017,Reverified,INTRAVENOUS,Dobutamine Hydrochloride Injection,1812168,,ee09a55f-9992-48bb-b8d6-1184bd548536,09/15/2025,HUMAN PRESCRIPTION DRUG,,"Cardiovascular, Pediatric, Renal",DOBUTAMINE,70436-203,Slate Run Pharmaceuticals,f5cd978c-4e1d-2447-e053-2a95a90add3f,"70436-203-80, 70436-203-82","Dobutamine Hydrochloride, Injection, 250 mg/20 mL (NDC 70436-203-80)",Injection,Available,,ANDA216131,,DOBUTAMINE,,,Current,,"Distributed by Slate Run Pharmaceuticals, LLC, 1-844-529-8988",,0WR771DJXV,70436-203-80,"Slate Run Pharmaceuticals, LLC: 844-529-8988",
"Fresenius Kabi USA, LLC",LIDOCAINE HYDROCHLORIDE ANHYDROUS,,02/22/2012,Reverified,"INFILTRATION, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010035, 1010671, 1010673, 1010688, 1010692, 1010745, 1010749, 1010751, 1010755, 1010759, 1010763, 1010900, 1010902, 1737343, 1737345, 1737562, 1737563, 1737566, 1737567, 1737568, 1737569, 1737570, 1737571, 1737757, 1737758, 1737761, 1737762, 1867938, 1867940, 1867943, 1867944, 1867992, 1867993, 1867996, 1867997, 1868028, 1868029",,"ba082c2f-64f4-419d-9c88-74f203316e17, 4dd52202-8eef-4136-92dd-ada573b7cf74",09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",XYLOCAINE,"63323-485, 63323-492, 63323-491, 63323-495, 63323-486, 63323-484, 63323-489, 63323-488, 63323-481, 63323-483, 63323-482, 63323-487","Fresenius Kabi USA, LLC","ea480a68-5927-4278-9deb-2956961da428, 0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33","63323-492-04, 63323-492-27, 63323-492-09, 63323-492-57, 63323-492-07, 63323-492-37, 63323-492-03, 63323-492-31, 63323-491-01, 63323-491-57, 63323-495-09, 63323-495-27, 63323-495-04, 63323-495-07, 63323-485-01, 63323-485-27, 63323-485-03, 63323-485-57, 63323-486-01, 63323-486-17, 63323-486-02, 63323-486-27, 63323-486-05, 63323-486-57, 63323-484-57, 63323-489-02, 63323-489-27, 63323-489-03, 63323-489-21, 63323-489-01, 63323-489-17, 63323-488-07, 63323-488-37, 63323-488-03, 63323-488-31, 63323-488-01, 63323-488-17, 63323-481-01, 63323-481-57, 63323-483-03, 63323-483-27, 63323-483-01, 63323-483-57, 63323-482-01, 63323-482-17, 63323-482-03, 63323-482-27, 63323-482-05, 63323-482-57, 63323-487-01, 63323-487-17, 63323-487-07, 63323-487-37, 63323-487-03, 63323-487-31, 63323-492-41, 63323-492-16, 63323-492-43, 63323-492-36, 63323-492-45, 63323-492-26, 63323-485-41, 63323-485-26, 63323-486-41, 63323-486-26, 63323-482-41, 63323-482-26, 63323-495-41, 63323-495-26","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-27)",Injection,Available,,NDA006488,,LIDOCAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,"EC2CNF7XFP, 30Q7KI53AK",63323-485-27,888-386-1300,
"Vertical Pharmaceuticals, LLC",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Reverified,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release",,,22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d,09/16/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,RELEXXII,"68025-097, 68025-088, 68025-089, 68025-095, 68025-096, 68025-084, 68025-098","Vertical Pharmaceuticals, LLC",86f477e9-07fc-466b-913e-1a4434c91df4,"68025-088-30, 68025-089-30, 68025-095-10, 68025-095-30, 68025-096-10, 68025-096-30, 68025-097-10, 68025-097-30, 68025-084-30, 68025-098-10, 68025-098-30","Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-30)",Tablet,Available,,NDA216117,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,,,,4B3SC438HI,68025-097-30,800-541-4802,
"Fresenius Kabi USA, LLC",ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Reverified,"EPIDURAL, INFILTRATION",Ropivacaine Hydrochloride Injection,"1734203, 1734204, 1734207, 1734208, 1734347, 1734348, 1734355, 1734356, 1734475, 1734476, 1734479, 1734480, 1734481, 1734482, 1734483, 1734484, 905189, 905191, 1734084, 1734086, 1734090, 1734091",,"dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7, 23d2d448-a744-4877-9f2d-7e57c198da89, c6613708-c1f7-4f5c-91a3-ebbc1d7905c6",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,NAROPIN,"63323-285, 63323-286, 63323-287, 63323-288","Fresenius Kabi USA, LLC","324532ac-4e54-4659-a1a2-9ade22a1ed3f, cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9, 73218c89-8925-468c-84bf-9960b4b3dc3c","63323-286-41, 63323-286-27, 63323-286-43, 63323-286-38, 63323-285-41, 63323-285-28, 63323-285-53, 63323-285-68, 63323-285-59, 63323-285-73, 63323-286-01, 63323-286-20, 63323-286-05, 63323-286-23, 63323-286-09, 63323-286-31, 63323-286-11, 63323-286-35, 63323-286-03, 63323-286-00, 63323-286-33, 63323-286-63, 63323-286-30, 63323-287-01, 63323-287-20, 63323-287-03, 63323-287-21, 63323-288-01, 63323-288-10, 63323-288-06, 63323-288-20, 63323-288-03, 63323-288-11, 63323-288-07, 63323-288-21, 63323-285-01, 63323-285-10, 63323-285-06, 63323-285-20, 63323-285-03, 63323-285-13, 63323-285-07, 63323-285-23, 63323-285-57, 63323-285-64, 63323-285-51, 63323-285-65, 63323-285-02, 63323-285-61, 63323-285-04, 63323-285-63, 63323-285-55, 63323-285-67, 63323-288-23, 63323-288-29, 63323-286-93, 63323-286-95","Naropin, Injection, 2 mg/1 mL (NDC 63323-285-61)",Injection,Unavailable,,NDA020533,,ROPIVACAINE HYDROCHLORIDE,,,Current,Delay in shipping of the drug,Next release not available at this time.,,V910P86109,63323-285-61,888-386-1300,
Torrent Pharma Inc.,"AMLODIPINE, HYDROCHLOROTHIAZIDE, OLMESARTAN MEDOXOMIL",Increased Diuresis [PE],06/13/2025,New,ORAL,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,"999967, 999986, 999991, 999996, 1000001",,85b8f9c6-aa53-4aa1-85d6-19f823d0d252,06/13/2025,HUMAN PRESCRIPTION DRUG,06/13/2025,Cardiovascular,"OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE 20/5/12.5 MG","13668-397, 13668-386, 13668-385, 13668-383, 13668-382",Torrent Pharmaceuticals Limited,5bedf6c6-6b23-40e7-8c96-2cedcc682973,"13668-397-30, 13668-397-90, 13668-397-05, 13668-386-30, 13668-386-90, 13668-386-05, 13668-385-30, 13668-385-90, 13668-385-05, 13668-383-30, 13668-383-90, 13668-383-05, 13668-382-30, 13668-382-90, 13668-382-05","Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 20 mg (NDC 13668-397-30)",Tablet,,"N0000175359, N0000175419, M0471776, N0000000069, N0000175421, N0000175566, M0006414, N0000190114",ANDA203580,"Thiazides [CS], Dihydropyridines [CS]","OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE TABLET 20/5/12.5 MG","Thiazide Diuretic [EPC], Dihydropyridine Calcium Channel Blocker [EPC], Calcium Channel Blocker [EPC]",,To Be Discontinued,,A business decision was made to discontinue manufacture of the product.,,"0J48LPH2TH, 1J444QC288, 6M97XTV3HD",13668-397-30,908-280-3333,"Calcium Channel Antagonists [MoA], Cytochrome P450 3A Inhibitors [MoA]"
Gland Pharma Limited,,,03/23/2018,Reverified,,Ketorolac Tromethamine Injection,,,,09/29/2025,,,Analgesia/Addiction,,,,,,"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 70860-700-02)",Injection,Available,,,,,,,Current,Other,"Athenex is not active, supplying through Sagent NDC  25021-700-01",,,70860-700-02,833-291-9645,
Sanofi-Aventis U.S. LLC,RIFAMPIN,,02/17/2021,Reverified,INTRAVENOUS,Rifampin Injection,"207436, 312821",,036ab68e-5085-4edc-bd83-784b43d64eab,09/17/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,RIFADIN IV,0068-0597,Sanofi-Aventis U.S. LLC,73a70d16-e9be-48b7-99d1-57ea074ddb9b,0068-0597-01,"Rifadin, Injection, 600 mg/10 mL (NDC 0068-0597-01)",Injection,Available,"N0000175500, M0019113",NDA050627,Rifamycins [CS],RIFAMPIN,Rifamycin Antibacterial [EPC],,Current,,,,VJT6J7R4TR,0068-0597-01,800-633-1610,
"Fresenius Kabi USA, LLC",WATER,,11/23/2021,Reverified,INTRAVENOUS,Sterile Water Injection,,,b45e9f1d-9c48-4b46-8541-d846b89540df,09/18/2025,HUMAN PRESCRIPTION DRUG,,Other,STERILE WATER,63323-178,"Fresenius Kabi USA, LLC",d40f0ff2-4abf-4030-b4e1-2b85ad7448a0,63323-178-76,"Sterile Water, Injection, 1000 mL/1000 mL (NDC 63323-178-76)",Injection,Available,,ANDA209689,,WATER,,,Current,,Check wholesalers for inventory,,059QF0KO0R,63323-178-76,888-386-1300,
Torrent Pharma Inc.,,,06/13/2025,New,,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,,,,06/13/2025,,06/13/2025,Cardiovascular,,,,,,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 12.5 mg; 40 mg (NDC 13668-383-90)",Tablet,,,,,,,,To Be Discontinued,,A business decision was made to discontinue manufacture of the product.,,,13668-383-90,908-280-3333,
"Hospira, Inc., a Pfizer Company",HEPARIN SODIUM,,04/29/2025,New,"INTRAVENOUS, SUBCUTANEOUS",Heparin Sodium Injection,"1361853, 1659260",,c8c4edd2-ee9e-4558-6b8c-b83adc242a0a,04/29/2025,HUMAN PRESCRIPTION DRUG,04/29/2025,Hematology,HEPARIN SODIUM,"0409-1402, 0409-1316","Hospira, Inc.",d77ce65b-d238-4187-aef4-593bc074d335,"0409-1402-27, 0409-1402-12, 0409-1316-11, 0409-1316-32","Heparin Sodium, Injection, 5000 [USP'U]/1 mL (NDC 0409-1402-12)",Injection,,,ANDA088100,,HEPARIN SODIUM,,,To Be Discontinued,,Discontinuation of the manufacture of the drug.,,ZZ45AB24CA,0409-1402-12,844-646-4398,
"Teva Pharmaceuticals USA, Inc.",IRINOTECAN HYDROCHLORIDE,,08/04/2025,New,INTRAVENOUS,Irinotecan Hydrochloride Injection,"1726319, 1726324",,5e1fdcaa-918f-4cd8-9c7a-4c538d866198,08/04/2025,HUMAN PRESCRIPTION DRUG,08/04/2025,Oncology,IRINOTECAN HYDROCHLORIDE,45963-614,"Actavis Pharma, Inc.",8f2da07f-1d3e-4d8b-8083-805da8a780db,"45963-614-51, 45963-614-55","Irinotecan Hydrochloride, Injection, 20 mg/1 mL (NDC 45963-614-55)",Injection,,,ANDA078589,,IRINOTECAN HYDROCHLORIDE,,,To Be Discontinued,,Product not anticipated to be available beyond mid-late September 2025,,042LAQ1IIS,45963-614-55,800-545-8800,
"Hikma Pharmaceuticals USA, Inc.",AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","308189, 313850",,d46f1091-33dc-4f8f-9c34-75dcfedb4b4c,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0143-9887, 0143-9886",Hikma Pharmaceuticals USA Inc.,606474e1-adba-4ffa-83d5-6565fc12c892,"0143-9886-01, 0143-9886-50, 0143-9886-75, 0143-9887-01, 0143-9887-50, 0143-9887-75","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0143-9887-01)","Powder, For Suspension",,,ANDA065325,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0143-9887-01,800-631-2174,
"Actavis Pharma, Inc.",,,11/04/2024,New,,Albuterol Sulfate Syrup,,,,11/04/2024,,11/04/2024,Pulmonary/Allergy,,,,,,"Syrup, 2 mg/5 mL (NDC 0472-0825-16)",Syrup,,,,,,,,To Be Discontinued,,,,,0472-0825-16,800-545-8800,
"Prinston Pharmaceutical, Inc.",CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,4acbb7a9-4db5-4497-b8db-9f358b3f6fb4,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"43547-408, 43547-406, 43547-407",Solco Healthcare LLC,dc17b9d4-2890-4f6c-8476-daa39d0cbc9c,"43547-406-10, 43547-406-50, 43547-406-11, 43547-407-10, 43547-407-50, 43547-407-11, 43547-408-10, 43547-408-50","Clonazepam, Tablet, 2 mg (NDC 43547-408-10)",Tablet,Available,"N0000175694, M0002356",ANDA077856,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,Marketed by Solco Healthcare,,5PE9FDE8GB,43547-408-10,"For orders, Solco Healthcare 866-931-9829",
"Hikma Pharmaceuticals USA, Inc.",ETOMIDATE,General Anesthesia [PE],10/05/2022,Revised,INTRAVENOUS,Etomidate Injection,"1654006, 1654008",,4312e3c3-34de-4cb3-8abd-c24d24a4bea1,07/23/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ETOMIDATE,"0143-9310, 0143-9311",Hikma Pharmaceuticals USA Inc.,c15bd8c1-34e3-40f2-b31a-634136fe197c,"0143-9310-01, 0143-9310-10, 0143-9311-01, 0143-9311-10","Etomidate, Injection, 2 mg/1 mL (NDC 0143-9310-10)",Injection,Available,"N0000175975, N0000175681",ANDA202354,,ETOMIDATE,General Anesthetic [EPC],,Current,,Novaplus,,Z22628B598,0143-9310-10,800-631-2174,
"Fresenius Kabi USA, LLC",LIDOCAINE HYDROCHLORIDE ANHYDROUS,,02/22/2012,Reverified,"INFILTRATION, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010035, 1010671, 1010673, 1010688, 1010692, 1010745, 1010749, 1010751, 1010755, 1010759, 1010763, 1010900, 1010902, 1737343, 1737345, 1737562, 1737563, 1737566, 1737567, 1737568, 1737569, 1737570, 1737571, 1737757, 1737758, 1737761, 1737762, 1867938, 1867940, 1867943, 1867944, 1867992, 1867993, 1867996, 1867997, 1868028, 1868029",,"ba082c2f-64f4-419d-9c88-74f203316e17, 4dd52202-8eef-4136-92dd-ada573b7cf74",09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",XYLOCAINE,"63323-486, 63323-492, 63323-491, 63323-495, 63323-485, 63323-484, 63323-489, 63323-488, 63323-481, 63323-483, 63323-482, 63323-487","Fresenius Kabi USA, LLC","ea480a68-5927-4278-9deb-2956961da428, 0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33","63323-492-04, 63323-492-27, 63323-492-09, 63323-492-57, 63323-492-07, 63323-492-37, 63323-492-03, 63323-492-31, 63323-491-01, 63323-491-57, 63323-495-09, 63323-495-27, 63323-495-04, 63323-495-07, 63323-485-01, 63323-485-27, 63323-485-03, 63323-485-57, 63323-486-01, 63323-486-17, 63323-486-02, 63323-486-27, 63323-486-05, 63323-486-57, 63323-484-57, 63323-489-02, 63323-489-27, 63323-489-03, 63323-489-21, 63323-489-01, 63323-489-17, 63323-488-07, 63323-488-37, 63323-488-03, 63323-488-31, 63323-488-01, 63323-488-17, 63323-481-01, 63323-481-57, 63323-483-03, 63323-483-27, 63323-483-01, 63323-483-57, 63323-482-01, 63323-482-17, 63323-482-03, 63323-482-27, 63323-482-05, 63323-482-57, 63323-487-01, 63323-487-17, 63323-487-07, 63323-487-37, 63323-487-03, 63323-487-31, 63323-492-41, 63323-492-16, 63323-492-43, 63323-492-36, 63323-492-45, 63323-492-26, 63323-485-41, 63323-485-26, 63323-486-41, 63323-486-26, 63323-482-41, 63323-482-26, 63323-495-41, 63323-495-26","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-27)",Injection,Available,,NDA006488,,LIDOCAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,"EC2CNF7XFP, 30Q7KI53AK",63323-486-27,888-386-1300,
SpecGx LLC,METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Reverified,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release","2001565, 2001566, 2001568",,b1b0f2ff-d9df-42ab-b471-226ecf97e075,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE,"0406-0136, 0406-0127, 0406-0154",SpecGx LLC,7a3a8731-e545-455e-83c3-888f4923e901,"0406-0127-01, 0406-0136-01, 0406-0154-01","Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 0406-0136-01)",Tablet,Limited Availability,,ANDA202608,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,Shortage of an active ingredient,Allocation to all customers. Short term backorder expected in September with recovery in October 2025.,,4B3SC438HI,0406-0136-01,800-325-8888,
Accord Healthcare Inc.,NALTREXONE HYDROCHLORIDE,,02/29/2024,Reverified,ORAL,Naltrexone Hydrochloride Tablet,1483744,,49aa3d6d-2270-4615-aafa-b440859ab870,09/16/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,NALTREXONE HYDROCHLORIDE,16729-081,"Accord Healthcare, Inc.",116829bb-2104-3117-e063-6294a90afdb8,"16729-081-10, 16729-081-01, 16729-081-16, 16729-081-17","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 16729-081-10)",Tablet,Available,,ANDA091205,,NALTREXONE HYDROCHLORIDE,,,Current,,,,Z6375YW9SF,16729-081-10,"866-941-7857, option 2",
"Novo Nordisk, Inc.",INSULIN DEGLUDEC,,07/21/2025,New,SUBCUTANEOUS,Insulin Degludec Injection,"1670011, 1670021, 2107520",,c1be283d-4b1d-4996-b2a7-4488dbff3037,07/21/2025,HUMAN PRESCRIPTION DRUG,07/21/2025,Endocrinology/Metabolism,INSULIN DEGLUDEC,"73070-403, 73070-503, 73070-400","Novo Nordisk Pharma, Inc.",c1be283d-4b1d-4996-b2a7-4488dbff3037,"73070-403-15, 73070-503-15, 73070-400-11","Insulin Degludec, Injection, 3 mL Insulin Degludec 100 units/mL (U-100) FlexTouch® (NDC 73070-403-15)",Injection,,"M0011417, N0000175453",BLA203314,Insulin [CS],INSULIN DEGLUDEC,Insulin Analog [EPC],,To Be Discontinued,,"Unbranded Insulin Degludec 3 mL U-100 FlexTouch® will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,54Q18076QB,73070-403-15,609-987-5800,
Sandoz Inc.,AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","239191, 308182, 308189, 308191, 308192, 308194, 313797, 313850",,13bd4214-9b7f-425b-af5f-fc1ddc678230,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0781-6041, 0781-2020, 0781-2613, 0781-5060, 0781-5061, 0781-6039, 0781-6156, 0781-6157",Sandoz Inc,6aa02079-d11c-4d2f-acaf-9548dd9a7ed6,"0781-2020-31, 0781-2020-76, 0781-2020-01, 0781-2020-05, 0781-2613-31, 0781-2613-76, 0781-2613-01, 0781-2613-05, 0781-5060-20, 0781-5060-01, 0781-5061-20, 0781-5061-01, 0781-6039-58, 0781-6039-46, 0781-6039-55, 0781-6156-52, 0781-6156-57, 0781-6156-46, 0781-6041-58, 0781-6041-46, 0781-6041-55, 0781-6157-52, 0781-6157-57, 0781-6157-46","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0781-6041-55)","Powder, For Suspension",,,ANDA065387,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0781-6041-55,800-525-8747,
"Huons Co., Ltd. (South Korea)",LIDOCAINE HYDROCHLORIDE,,07/14/2018,Reverified,INTRAVENOUS,Lidocaine Hydrochloride Injection,"1737566, 1737761",,8ec2d256-fc4f-44f6-bee2-eef2bf3bf580,09/17/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,LIDOCAINE HYDROCHLORIDE,"73293-0001, 73293-0003","Huons Co., Ltd.",14a172be-a2db-c9da-e063-6294a90ad411,"73293-0001-1, 73293-0001-2, 73293-0003-1, 73293-0003-2","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 73293-0001-2)",Injection,Available,,ANDA212821,,LIDOCAINE HYDROCHLORIDE,,,Current,,,,V13007Z41A,73293-0001-2,intbiz@huons.com,
"Hospira, Inc., a Pfizer Company",METHOTREXATE SODIUM,,03/13/2023,Reverified,"INTRAMUSCULAR, INTRATHECAL, INTRAVENOUS, SUBCUTANEOUS",Methotrexate Sodium Injection,"1655956, 1946772",,bd287e89-32f9-4396-95fa-4b562869f476,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Rheumatology, Oncology",METHOTREXATE,"61703-124, 61703-161","Hospira, Inc.",6bb8643f-6ab4-4e1c-bcf9-b82e8cf18910,"61703-124-40, 61703-161-02, 61703-161-05","Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40)",Injection,Available,,NDA011719,,METHOTREXATE,,,Current,,,,3IG1E710ZN,61703-124-40,844-646-4398,
"Teva Pharmaceuticals USA, Inc.",VERAPAMIL HYDROCHLORIDE,,01/23/2025,New,ORAL,"Verapamil Hydrochloride Capsule, Extended Release",,,0742cf97-601b-4c13-a6c3-1a6a616ed292,01/23/2025,HUMAN PRESCRIPTION DRUG,01/23/2025,Cardiovascular,VERAPAMIL HYDROCHLORIDE,"0591-2886, 0591-2880, 0591-2882, 0591-2884",Teva Pharmaceuticals Inc,319554df-fc0d-428a-9799-a352100f1ce9,"0591-2880-01, 0591-2882-01, 0591-2884-01, 0591-2886-01","Verelan, Capsule, Extended Release, 360 mg (NDC 0591-2886-01)","Capsule, Extended Release",,,NDA019614,,VERAPAMIL HYDROCHLORIDE,,,To Be Discontinued,,,,V3888OEY5R,0591-2886-01,800-545-8800,
"Upsher-Smith Laboratories, LLC",BUMETANIDE,Increased Diuresis at Loop of Henle [PE],05/02/2025,New,ORAL,Bumetanide Tablet,"197417, 197418, 197419",,ff5dc8c6-b2f2-41d3-8e56-a953aa721b59,05/02/2025,HUMAN PRESCRIPTION DRUG,05/02/2025,Cardiovascular,BUMETANIDE,"0832-0542, 0832-0540, 0832-0541","Upsher-Smith Laboratories, LLC",d53166d9-64ca-4b76-81a7-b70a60c53b12,"0832-0540-11, 0832-0541-11, 0832-0541-10, 0832-0542-11, 0832-0542-10","Bumetanide, Tablet, 2 mg (NDC 0832-0542-10)",Tablet,,"N0000175366, N0000175590",ANDA209916,,BUMETANIDE,Loop Diuretic [EPC],,To Be Discontinued,,,,0Y2S3XUQ5H,0832-0542-10,800-654-2299,
"Avet Pharmaceuticals, Inc.",FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Furosemide Injection,"1719286, 1719290, 1719291",,7d0db0f7-bf4f-4b0b-9359-2a838626e04b,09/15/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,83634-302,Avenacy Inc.,1b3f2803-b618-4447-b5ac-cd2bdc7de3e8,"83634-302-42, 83634-302-02, 83634-302-43, 83634-302-04, 83634-302-41, 83634-302-10","Furosemide, Injection, 10 mg/1 mL; 2mL vial (NDC 83634-302-02)",Injection,Available,"N0000175366, N0000175590",ANDA203428,,FUROSEMIDE,Loop Diuretic [EPC],,Current,,Distributed by Avenacy; Contact information: 877-283-6229,,7LXU5N7ZO5,83634-302-02,855-228-9470,
"Lannett Company, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,2cedb4c2-1e40-4bc4-b9f4-127150c4afbd,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0527-4667, 0527-4661, 0527-4662, 0527-4663, 0527-4664, 0527-4665, 0527-4666","Lannett Company, Inc.",981ca74f-737d-45e5-a3b2-b25256263768,"0527-4661-37, 0527-4662-37, 0527-4663-37, 0527-4664-37, 0527-4665-37, 0527-4666-37, 0527-4667-37","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0527-4667-37)",Capsule,Unavailable,,ANDA215802,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,Unavailable,,SJT761GEGS,0527-4667-37,844-834-0530,
"Teva Pharmaceuticals USA, Inc.",ISONIAZID,,11/21/2024,New,ORAL,Isoniazid Tablet,"197832, 311166",,9499f1cf-2f46-4047-8b71-90aee7dee854,11/21/2024,HUMAN PRESCRIPTION DRUG,11/21/2024,Anti-Infective,ISONIAZID,"0555-0066, 0555-0071","Teva Pharmaceuticals USA, Inc.",ead93989-8a7e-4483-917e-388152515e1d,"0555-0066-02, 0555-0071-01, 0555-0071-02","Tablet, 100 mg (NDC 0555-0066-02)",Tablet,,N0000175483,ANDA080936,,ISONIAZID,Antimycobacterial [EPC],,To Be Discontinued,,Product available through 12/03/2024,,V83O1VOZ8L,0555-0066-02,800-545-8800,
"Hikma Pharmaceuticals USA, Inc.",PROMETHAZINE HYDROCHLORIDE,,11/21/2023,Revised,"INTRAMUSCULAR, INTRAVENOUS",Promethazine Hydrochloride Injection,"992460, 992858",,4bf3912c-8339-401e-9711-dad6acf15f11,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Gastroenterology, Pediatric, Pulmonary/Allergy",PROMETHAZINE HYDROCHLORIDE,"0641-0928, 0641-0929",Hikma Pharmaceuticals USA Inc.,9f14d3f5-ad01-44b5-a2b7-16ed5f501f87,"0641-0928-21, 0641-0928-25, 0641-0929-21, 0641-0929-25","Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-0928-25)",Injection,Unavailable,,ANDA083312,,PROMETHAZINE HYDROCHLORIDE,,,Current,Other,This presentation is temporarily on backorder.  Recovery is TBD at this time.,,R61ZEH7I1I,0641-0928-25,800-631-2174,
Sun Pharmaceutical Industries Limited,CLINDAMYCIN HYDROCHLORIDE,,12/05/2024,New,ORAL,Clindamycin Hydrochloride Capsule,"197518, 284215",,1dbd8448-c1e5-46df-8060-50ef82380445,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Anti-Infective,CLINDAMYCIN HYDROCHLORIDE,"63304-693, 63304-692","Sun Pharmaceutical Industries, Inc.",339366d4-2060-1c29-e063-6394a90a1cb7,"63304-692-01, 63304-692-05, 63304-692-77, 63304-692-03, 63304-693-16, 63304-693-01, 63304-693-03, 63304-693-05, 63304-693-77, 63304-693-11, 63304-693-62","Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-16)",Capsule,,,ANDA065061,,CLINDAMYCIN HYDROCHLORIDE,,,To Be Discontinued,,Discontinuing for business reasons,,T20OQ1YN1W,63304-693-16,800-818-4555,
Pfizer Inc.,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"284397, 309710, 1718900, 1718902, 1718906, 1718907, 1718909, 1718910, 2396891, 2396892",,548a88c0-afda-427e-75ac-5af0cfa2224c,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,PRECEDEX,"0409-1660, 0409-1638, 0409-1434, 0409-1596, 0409-7838, 0409-7853, 0409-7875","Hospira, Inc.",231f50fe-2c91-44b9-946e-33b836c07b94,"0409-1660-55, 0409-1660-50, 0409-1660-35, 0409-1660-10, 0409-1660-22, 0409-1660-20, 0409-1638-32, 0409-1638-02, 0409-1434-01, 0409-1596-01, 0409-1596-10, 0409-7838-01, 0409-7838-24, 0409-7853-01, 0409-7853-24, 0409-7875-01, 0409-7875-12","Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1660-50)",Injection,Available,,NDA021038,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,,,,1018WH7F9I,0409-1660-50,844-646-4398,
"Teva Pharmaceuticals USA, Inc.",ESZOPICLONE,,06/26/2025,New,ORAL,Eszopiclone Tablet,"485440, 485442, 485465",,2435e2f1-bc52-488f-80e9-f1758e354aae,06/26/2025,HUMAN PRESCRIPTION DRUG,06/26/2025,Neurology,ESZOPICLONE,"0093-5537, 0093-5538, 0093-5539","Teva Pharmaceuticals USA, Inc.",b7cc855f-8510-4cb2-a941-18d3c4472236,"0093-5537-56, 0093-5538-01, 0093-5539-01","Eszopiclone, Tablet, 1 mg (NDC 0093-5537-56)",Tablet,,,ANDA091169,,ESZOPICLONE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,UZX80K71OE,0093-5537-56,800-545-8800,
"Hikma Pharmaceuticals USA, Inc.",LIDOCAINE HYDROCHLORIDE,,06/13/2018,Revised,"INFILTRATION, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010671",,5523fdfe-69fd-49a5-b51f-73e2223d49a9,07/23/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,LIDOCAINE,"0143-9577, 0143-9579, 0143-9578, 0143-9576, 0143-9575, 0143-9172, 0143-9173",Hikma Pharmaceuticals USA Inc.,3e5c0afe-9377-4040-ab89-55a6dbb5693c,"0143-9579-01, 0143-9579-25, 0143-9578-01, 0143-9578-10, 0143-9577-01, 0143-9577-10, 0143-9576-01, 0143-9576-25, 0143-9575-01, 0143-9575-10, 0143-9172-01, 0143-9172-10, 0143-9173-01, 0143-9173-10","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 0143-9577-10)",Injection,Available,,ANDA080407,,LIDOCAINE HYDROCHLORIDE,,,Current,,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,V13007Z41A,0143-9577-10,800-631-2174,
"Par Pharmaceutical, Inc.",DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"309710, 1718906, 1718909",,1ee59985-4c1d-48f7-b8f9-5584c2d55e08,09/17/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE HYDROCHLORIDE,"42023-186, 42023-146, 42023-187","ENDO USA, Inc.",d518b2d2-b39c-47ac-b45f-8c6a045a8dae,"42023-146-25, 42023-186-20, 42023-187-10","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-186-20)",Injection,Available,,ANDA208266,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,,Please check wholesalers for inventory,,1018WH7F9I,42023-186-20,800-828-9393,
"Upsher-Smith Laboratories, LLC",,,04/23/2025,New,,Baclofen Tablet,,,,04/23/2025,,04/23/2025,Neurology,,,,,,"Baclofen, Tablet, 10 mg (NDC 50090-6868-1)",Tablet,,,,,,,,To Be Discontinued,,,,,50090-6868-1,716-315-2000,
"Actavis Pharma, Inc.",DESONIDE,,05/28/2025,New,TOPICAL,Desonide Cream,"197572, 349351",,ff5d4cd8-ab4d-4a9e-b84b-445c81eeea99,05/28/2025,HUMAN PRESCRIPTION DRUG,05/28/2025,Dermatology,DESONIDE,"0472-0804, 0472-0803","Actavis Pharma, Inc.",f3953b9e-138f-4d86-8eea-0fc03c3c2747,"0472-0804-15, 0472-0804-60, 0472-0803-02, 0472-0803-04","Desowen, Cream, .5 mg/1 g (NDC 0472-0804-60)",Cream,,"N0000175576, N0000175450",NDA019048,,DESONIDE,Corticosteroid [EPC],,To Be Discontinued,,,,J280872D1O,0472-0804-60,800-545-8800,Corticosteroid Hormone Receptor Agonists [MoA]
"EMD Serono, Inc.",LEVOTHYROXINE SODIUM,,07/10/2025,New,ORAL,Levothyroxine Sodium Tablet,"892246, 892251, 966153, 966160, 966166, 966173, 966177, 966182, 966187, 966196, 966202, 966207, 966220, 966221, 966222, 966224, 966225, 966248, 966249, 966253, 966270, 2104866",,bc3c6830-ba68-4ba3-9896-a12d0ad0b275,07/10/2025,HUMAN PRESCRIPTION DRUG,07/10/2025,Endocrinology/Metabolism,EUTHYROX,"72305-150, 72305-025, 72305-050, 72305-075, 72305-088, 72305-100, 72305-112, 72305-125, 72305-137, 72305-175, 72305-200","Provell Pharmaceuticals, LLC",45657074-8874-49f4-a8ef-3ca7e210c16e,"72305-025-30, 72305-025-90, 72305-050-30, 72305-050-90, 72305-075-30, 72305-075-90, 72305-088-30, 72305-088-90, 72305-100-30, 72305-100-90, 72305-112-30, 72305-112-90, 72305-125-30, 72305-125-90, 72305-137-30, 72305-137-90, 72305-150-30, 72305-150-90, 72305-175-30, 72305-175-90, 72305-200-30, 72305-200-90","Euthyrox, Tablet, 150 ug (NDC 72305-150-30)",Tablet,,,NDA021292,,LEVOTHYROXINE SODIUM,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,9J765S329G,72305-150-30,888-899-7041,
Sandoz Inc.,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577961",,288dafc4-fe6e-4891-832f-511022c87445,09/24/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","0185-0853, 0185-0831, 0185-0842, 0185-0864, 0185-2099, 0185-2098",Sandoz Inc,d68cd1d1-3bb4-4afa-9786-687cf1766ae1,"0185-0831-01, 0185-0842-01, 0185-0853-01, 0185-0864-01, 0185-2099-01, 0185-2098-01","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0185-0853-01)",Tablet,Available,,ANDA040439,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",0185-0853-01,800-525-8747,
"Upsher-Smith Laboratories, LLC",NYSTATIN,,04/28/2025,New,TOPICAL,Nystatin Topical Powder,"584414, 646456",,01b44f91-9b68-464a-9693-b5d3e793bf3c,04/28/2025,HUMAN PRESCRIPTION DRUG,04/28/2025,"Anti-Infective, Dermatology",NYAMYC,0832-0465,"Upsher-Smith Laboratories, LLC",3984f88f-d61f-1fa9-e063-6394a90acb11,"0832-0465-15, 0832-0465-30, 0832-0465-60","Nystatin, Topical Powder, 100000 [USP'U]/1 g (NDC 0832-0465-60)",Topical Powder,,"N0000175498, M0017172",ANDA065183,Polyenes [CS],NYSTATIN,Polyene Antifungal [EPC],,To Be Discontinued,,,,BDF1O1C72E,0832-0465-60,800-654-2299,
"Sage Therapeutics, Inc.",,,10/29/2024,New,,Brexanolone Solution,,,,10/29/2024,,10/29/2024,Psychiatry,,,,,,"Zulresso, Solution, 5 mg/1 mL (NDC 72152-547-20)",Solution,,,,,,,,To Be Discontinued,,,,,72152-547-20,844-472-4379,
Chartwell Molecular Holdings LLC,QUINAPRIL HYDROCHLORIDE,,01/19/2023,Reverified,ORAL,Quinapril Hydrochloride Tablet,"312748, 312749, 312750, 314203",,dbc43dbd-94aa-40e2-a9ea-766110cc8687,08/19/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,QUINAPRIL,"62135-484, 62135-485, 62135-486, 62135-487","Chartwell RX, LLC",09cd5cb9-4fdf-f133-e063-6294a90af691,"62135-484-60, 62135-485-90, 62135-486-90, 62135-487-90","Quinapril Hydrochloride, Tablet, 5 mg (NDC 62135-484-60)",Tablet,Available,,ANDA076803,,QUINAPRIL,,,Current,,,,33067B3N2M,62135-484-60,845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com,
Eugia US LLC,ETOMIDATE,General Anesthesia [PE],10/05/2022,Reverified,INTRAVENOUS,Etomidate Injection,"1654006, 1654008",,0820f15a-046b-4185-a2b3-2e4051ee3d82,09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ETOMIDATE,"55150-221, 55150-222",Eugia US LLC,278b160e-cdc4-451e-9405-cb001f443680,"55150-221-10, 55150-222-20","Etomidate, Injection, 20 mg/10 mL (NDC 55150-221-10)",Injection,Available,"N0000175975, N0000175681",ANDA206126,,ETOMIDATE,General Anesthetic [EPC],,Current,,Check wholesalers for inventory,,Z22628B598,55150-221-10,888-238-7880,
Baxter Healthcare,SODIUM CHLORIDE,,04/28/2023,Revised,IRRIGATION,Sodium Chloride 0.9% Irrigation,486515,,b3b4b176-41f0-4ca8-90d4-3fba5707564a,07/02/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,0338-0048,Baxter Healthcare Corporation,123eac3f-8e50-4689-bf00-cf9407eb70ee,"0338-0048-02, 0338-0048-03, 0338-0048-04, 0338-0048-05","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0338-0048-04)",Irrigation,,,NDA017427,,SODIUM CHLORIDE,,,Resolved,,,07/02/2025,451W47IQ8X,0338-0048-04,888-229-0001,
"Hikma Pharmaceuticals USA, Inc.",DOPAMINE HYDROCHLORIDE,,11/06/2017,Revised,INTRAVENOUS,Dopamine Hydrochloride Injection,"1743938, 1743941, 1743950, 1743953",,0e499952-46c7-4172-8c70-186312e240a3,07/23/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,DOPAMINE HYDROCHLORIDE,"0143-9252, 0143-9253, 0143-9254, 0143-9255",Hikma Pharmaceuticals USA Inc.,67349236-e8e3-45ec-a76d-2a0a150d8d59,"0143-9252-01, 0143-9252-25, 0143-9253-01, 0143-9253-25, 0143-9254-01, 0143-9254-25, 0143-9255-01, 0143-9255-25","Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9252-25)",Injection,Unavailable,,ANDA207707,,DOPAMINE HYDROCHLORIDE,,,Current,Demand increase for the drug,Additional lots will be available in the October 2025 timeframe.  Product will be made available as it is released.,,7L3E358N9L,0143-9252-25,800-631-2174,
Aurobindo Pharma USA,AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","239191, 313797",,234d0dfc-cb24-413f-b798-129c73eb848e,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"65862-706, 65862-707",Aurobindo Pharma Limited,f4a410c9-3a78-48f9-8195-915896a974ff,"65862-706-80, 65862-706-01, 65862-706-55, 65862-707-80, 65862-707-01, 65862-707-55","Amoxicillin, Powder, For Suspension, 125 mg/5 mL (NDC 65862-706-01)","Powder, For Suspension",,,ANDA204030,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,65862-706-01,866-850-2876,
Pfizer Inc.,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"284397, 309710, 1718900, 1718902, 1718906, 1718907, 1718909, 1718910, 2396891, 2396892",,548a88c0-afda-427e-75ac-5af0cfa2224c,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,PRECEDEX,"0409-1596, 0409-1660, 0409-1638, 0409-1434, 0409-7838, 0409-7853, 0409-7875","Hospira, Inc.",231f50fe-2c91-44b9-946e-33b836c07b94,"0409-1660-55, 0409-1660-50, 0409-1660-35, 0409-1660-10, 0409-1660-22, 0409-1660-20, 0409-1638-32, 0409-1638-02, 0409-1434-01, 0409-1596-01, 0409-1596-10, 0409-7838-01, 0409-7838-24, 0409-7853-01, 0409-7853-24, 0409-7875-01, 0409-7875-12","Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1596-10)",Injection,Available,,NDA021038,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,,,,1018WH7F9I,0409-1596-10,844-646-4398,
B. Braun Medical Inc.,"CALCIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, SODIUM LACTATE",,10/11/2024,Reverified,INTRAVENOUS,Lactated Ringers Injection,847630,,"d3d29c8f-c326-4097-814a-7f4e08c67068, f6d82772-638c-4584-b9d3-8833669f5963",09/16/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other",LACTATED RINGERS,0264-7750,B. Braun Medical Inc.,"f67c6808-1eeb-4299-a0b7-694863bcad5a, ed789cd7-83ae-4ec1-a696-e87c1569da49","0264-7750-00, 0264-7750-10, 0264-7750-20, 0264-7750-07","Lactated Ringers, Injection, .02 g/100 mL; .03 g/100 mL; .6 g/100 mL; .31 g/100 mL (NDC 0264-7750-10)",Injection,Available,,NDA019632,,"SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, AND CALCIUM CHLORIDE",,,Current,,,,"M4I0D6VV5M, 660YQ98I10, 451W47IQ8X, TU7HW0W0QT",0264-7750-10,800-227-2862,
Gland Pharma Limited,METRONIDAZOLE,,01/13/2022,Revised,INTRAVENOUS,Metronidazole Injection,311683,,7187779a-1f4c-4607-af53-4119e324aad5,09/29/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,METRONIDAZOLE,47335-993,"Sun Pharmaceutical Industries, Inc.",9549fa19-5d89-4ad8-82ac-5d023072b126,47335-993-01,"Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 47335-993-01)",Injection,Unavailable,"N0000175435, M0014907",ANDA212435,Nitroimidazoles [CS],METRONIDAZOLE,Nitroimidazole Antimicrobial [EPC],,Current,Shortage of an active ingredient,Unavailable,,140QMO216E,47335-993-01,Distributed by Sun Pharma,
"Teva Pharmaceuticals USA, Inc.",VERAPAMIL HYDROCHLORIDE,,01/23/2025,New,ORAL,"Verapamil Hydrochloride Capsule, Extended Release",,,0742cf97-601b-4c13-a6c3-1a6a616ed292,01/23/2025,HUMAN PRESCRIPTION DRUG,01/23/2025,Cardiovascular,VERAPAMIL HYDROCHLORIDE,"0591-2884, 0591-2880, 0591-2882, 0591-2886",Teva Pharmaceuticals Inc,319554df-fc0d-428a-9799-a352100f1ce9,"0591-2880-01, 0591-2882-01, 0591-2884-01, 0591-2886-01","Verelan, Capsule, Extended Release, 240 mg (NDC 0591-2884-01)","Capsule, Extended Release",,,NDA019614,,VERAPAMIL HYDROCHLORIDE,,,To Be Discontinued,,,,V3888OEY5R,0591-2884-01,800-545-8800,
"Boehringer Ingelheim Pharmaceuticals, Inc.",,,03/03/2025,New,,Adalimumab-adbm Injection,"797544, 2640883, 2640889, 2640891, 2640892, 2640893, 2640894, 2640895, 2640898, 2640900, 2640901, 2640902, 2640903, 2680743, 2680746, 2680748, 2680750, 2680756, 2680757, 2680759, 2680760",,115ea79b-7209-7f19-b35d-36ec0828fbf5,03/03/2025,HUMAN PRESCRIPTION DRUG,03/03/2025,Rheumatology,CYLTEZO,"0597-0375, 0597-0370, 0597-0405, 0597-0400, 0597-0485, 0597-0495","Boehringer Ingelheim Pharmaceuticals, Inc.",48e59974-6012-4a21-9348-552d590632b1,"0597-0370-82, 0597-0370-72, 0597-0370-45, 0597-0405-80, 0597-0405-10, 0597-0400-89, 0597-0375-48, 0597-0375-97, 0597-0375-23, 0597-0375-16, 0597-0375-53, 0597-0485-46, 0597-0485-20, 0597-0480-12, 0597-0495-47, 0597-0495-50, 0597-0495-40, 0597-0495-60, 0597-0490-32","Cyltezo, Injection, Kit (NDC 0597-0375-16)",Injection,,,BLA761058,,ADALIMUMAB-ADBM,,,To Be Discontinued,,,,,0597-0375-16,800-243-0127,
"Avet Pharmaceuticals, Inc.",FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Furosemide Injection,"1719286, 1719290, 1719291",,7d0db0f7-bf4f-4b0b-9359-2a838626e04b,09/15/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,83634-302,Avenacy Inc.,1b3f2803-b618-4447-b5ac-cd2bdc7de3e8,"83634-302-42, 83634-302-02, 83634-302-43, 83634-302-04, 83634-302-41, 83634-302-10","Furosemide, Injection, 10 mg/1 mL (NDC 83634-302-10)",Injection,Available,"N0000175366, N0000175590",ANDA203428,,FUROSEMIDE,Loop Diuretic [EPC],,Current,,Distributed by Avenacy; Contact information: 877-283-6229,,7LXU5N7ZO5,83634-302-10,855-228-9470,
"Hospira, Inc., a Pfizer Company",HYDROMORPHONE HYDROCHLORIDE,,10/31/2017,Reverified,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Hydromorphone Hydrochloride Injection,"897756, 897757, 1433251, 1724383, 1724644, 1872271, 2675350, 897653, 897753, 897758, 1724276",,"f9ca2ef5-46d8-475a-a26e-f7c8becd6db7, e9c9ef18-7dfc-4322-b2fc-29b934c30f8b",08/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,HYDROMORPHONE HYDROCHLORIDE,"0409-1312, 0409-1283, 0409-1380, 0409-4264, 0409-1805, 0409-2552, 0409-3356, 0409-2540, 0409-3365, 0409-1304","Hospira, Inc.","53b6867a-0ae3-48ff-b257-9e58cc76de9c, 58ff0e68-b78f-4ebd-a91b-b53bbdefc544","0409-1283-17, 0409-1283-37, 0409-1312-16, 0409-1312-36, 0409-1380-11, 0409-1380-01, 0409-4264-11, 0409-4264-01, 0409-1805-10, 0409-1805-01, 0409-2552-11, 0409-2552-01, 0409-3356-11, 0409-3356-01, 0409-2540-11, 0409-2540-01, 0409-3365-11, 0409-3365-01, 0409-3365-10, 0409-1283-03, 0409-1283-31, 0409-1283-09, 0409-1283-10, 0409-1283-04, 0409-1283-05, 0409-1312-03, 0409-1312-30, 0409-1312-09, 0409-1312-10, 0409-1304-03, 0409-1304-31","Hydromorphone Hydrochloride, Injection, 2 mg/1 mL Syringes (NDC 0409-1312-30)",Injection,Available,,NDA200403,,HYDROMORPHONE HYDROCHLORIDE,,,Current,,,01/02/2025,L960UP2KRW,0409-1312-30,844-646-4398,
"Upsher-Smith Laboratories, LLC",MEMANTINE HYDROCHLORIDE,,04/28/2025,New,ORAL,Memantine Hydrochloride Tablet,"996561, 996571",,6e0ade9e-b721-4701-bcb7-de464e19e707,04/28/2025,HUMAN PRESCRIPTION DRUG,04/28/2025,Neurology,MEMANTINE HYDROCHLORIDE,"0832-1112, 0832-1113","Upsher-Smith Laboratories, LLC",398273bb-cd0b-d984-e063-6394a90a89ab,"0832-1112-60, 0832-1113-60","Memantine Hydrochloride, Tablet, 5 mg (NDC 0832-1112-60)",Tablet,,,ANDA090043,,MEMANTINE HYDROCHLORIDE,,,To Be Discontinued,,,,JY0WD0UA60,0832-1112-60,800-654-2299,
"Upsher-Smith Laboratories, LLC",OXYBUTYNIN CHLORIDE,,05/14/2025,New,ORAL,Oxybutynin Chloride Tablet,863664,,3ee6835a-7a7d-49a9-8460-2f1dd270ead3,05/14/2025,HUMAN PRESCRIPTION DRUG,05/14/2025,Renal,OXYBUTYNIN CHLORIDE,0832-0038,"Upsher-Smith Laboratories, LLC",2f3b30f0-e463-2de1-e063-6394a90a1b69,"0832-0038-00, 0832-0038-50, 0832-0038-10, 0832-0038-89, 0832-0038-01","Oxybutynin Chloride, Tablet, 5 mg (NDC 0832-0038-10)",Tablet,,,ANDA074625,,OXYBUTYNIN CHLORIDE,,,To Be Discontinued,,,,L9F3D9RENQ,0832-0038-10,800-654-2299,
"Fresenius Kabi USA, LLC",DEXAMETHASONE SODIUM PHOSPHATE,,02/08/2019,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Dexamethasone Sodium Phosphate Injection,,,cca2c160-9188-48e8-9505-49a52388dcb7,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Other, Pulmonary/Allergy, Rheumatology",DEXAMETHASONE SODIUM PHOSPHATE,"63323-516, 63323-506","Fresenius Kabi USA, LLC",5dcedfda-976c-4aa4-a3cf-909c324a09d4,"63323-506-00, 63323-506-01, 63323-506-03, 63323-506-13, 63323-516-01, 63323-516-10","Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 63323-516-10)",Injection,Available,,ANDA040572,,DEXAMETHASONE SODIUM PHOSPHATE,,,Current,,Check wholesalers for inventory,,AI9376Y64P,63323-516-10,888-386-1300,
"Upsher-Smith Laboratories, LLC",FLUPHENAZINE HYDROCHLORIDE,,09/18/2025,New,ORAL,Fluphenazine Hydrochloride Tablet,"859841, 860918, 865117, 865123",,f07bb3f1-c68c-441b-9de4-99a219f2500a,09/18/2025,HUMAN PRESCRIPTION DRUG,09/18/2025,"Neurology, Psychiatry",FLUPHENAZINE HYDROCHLORIDE,"0832-6005, 0832-6004, 0832-6003, 0832-6006","Upsher-Smith Laboratories,LLC",3bb74f82-8872-9829-e063-6294a90aeace,"0832-6004-11, 0832-6003-11, 0832-6005-11, 0832-6006-11","Fluphenazine Hydrochloride, Tablet, 5 mg (NDC 0832-6005-11)",Tablet,,,ANDA213784,,FLUPHENAZINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug.,,ZOU145W1XL,0832-6005-11,763-315-2000,
"Lannett Company, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Revised,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,2cedb4c2-1e40-4bc4-b9f4-127150c4afbd,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0527-4663, 0527-4661, 0527-4662, 0527-4664, 0527-4665, 0527-4666, 0527-4667","Lannett Company, Inc.",981ca74f-737d-45e5-a3b2-b25256263768,"0527-4661-37, 0527-4662-37, 0527-4663-37, 0527-4664-37, 0527-4665-37, 0527-4666-37, 0527-4667-37","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0527-4663-37)",Capsule,Unavailable,,ANDA215802,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,Unavailable,,SJT761GEGS,0527-4663-37,844-834-0530,
Pfizer Inc.,,,01/19/2023,Reverified,,Quinapril/Hydrochlorothiazide Tablet,,,,08/15/2025,,,Cardiovascular,,,,,,"Accuretic, Tablet, 25 mg/20 mg (NDC 0071-0223-23)",Tablet,Unavailable,,,,,,,Current,Delay in shipping of the drug,Next Delivery and Estimated Recovery: TBD,,,0071-0223-23,800-533-4535,
B. Braun Medical Inc.,SODIUM CHLORIDE,,04/28/2023,Revised,IRRIGATION,Sodium Chloride 0.9% Irrigation,486515,,5bd9b176-0402-4a3f-a6b4-c3f393fc092a,07/02/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE FOR IRRIGATION,0264-7388,B. Braun Medical Inc.,69f7d8f6-65cd-45bd-83f7-7249905a2e72,"0264-7388-50, 0264-7388-60","Sodium Chloride 0.9%, Irrigation, .9 g/100mL (NDC 0264-7388-50)",Irrigation,,,NDA016733,,SODIUM CHLORIDE FOR IRRIGATION,,Available,Resolved,,,07/02/2025,451W47IQ8X,0264-7388-50,800-227-2862,
Eli Lilly and Co.,ATOMOXETINE HYDROCHLORIDE,,10/22/2024,New,ORAL,Atomoxetine Hydrochloride Capsule,"349591, 349592, 349593, 349594, 349595, 352317, 352318, 352319, 352320, 352321, 608139, 608143, 617945, 617947",,309de576-c318-404a-bc15-660c2b1876fb,10/22/2024,HUMAN PRESCRIPTION DRUG,10/22/2024,Psychiatry,STRATTERA,"0002-3227, 0002-3238, 0002-3228, 0002-3229, 0002-3239, 0002-3250, 0002-3251",Eli Lilly and Company,90fd3143-d5d4-4343-9570-b3863e31b1a0,"0002-3227-30, 0002-3238-30, 0002-3228-30, 0002-3229-30, 0002-3239-30, 0002-3250-30, 0002-3251-30","Strattera, Capsule, 10 mg (NDC 0002-3227-30)",Capsule,,,NDA021411,,ATOMOXETINE HYDROCHLORIDE,,,To Be Discontinued,,Business decision to discontinue,,57WVB6I2W0,0002-3227-30,800-545-5979,
Kindos Pharmaceuticals Co. Ltd.,BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,"EPIDURAL, INTRACAUDAL, PERINEURAL",Bupivacaine Hydrochloride Injection,"1724786, 1724787, 1724880, 1724884, 1725078, 1725082",,daec9ee4-b666-485e-a153-4b5e5acc48a1,08/19/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE,"71288-725, 71288-721, 71288-722, 71288-724, 71288-727, 71288-728",Meitheal Pharmaceuticals Inc,b085b86e-d32f-494e-8a4a-3080ff240109,"71288-721-11, 71288-722-32, 71288-724-11, 71288-725-32, 71288-727-11, 71288-728-32","Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32)",Injection,Available,,ANDA216040,,BUPIVACAINE HYDROCHLORIDE,,,Current,,Meitheal Pharmaceuticals is distributor/labeler; product is available,,7TQO7W3VT8,71288-725-32,844-824-8426,
"Hospira, Inc., a Pfizer Company",DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795609, 1795610, 1795616",,10e98cb0-31a5-4ad1-3eaa-aa4af387a42d,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,0409-7100,"Hospira, Inc.",477c216c-7446-473a-892d-918faf1dc877,"0409-7100-68, 0409-7100-66, 0409-7100-69, 0409-7100-67, 0409-7100-04, 0409-7100-02","Dextrose 5% In Plastic Container, Injection, 12.5 g/250mL (5%) (NDC 0409-7100-02)",Injection,Available,,NDA019466,,DEXTROSE MONOHYDRATE,,,Current,,,,LX22YL083G,0409-7100-02,844-646-4398,
Accord Healthcare Inc.,ATROPINE SULFATE,,01/01/2020,Reverified,INTRAVENOUS,Atropine Sulfate Injection,"1190546, 1190551, 1190552",,c82cb295-ffce-47d6-97ad-a8aa723f4e4f,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology, Pediatric",ATROPINE SULFATE,"16729-483, 16729-484","Accord Healthcare, Inc.,",275da8b0-80b1-6c78-e063-6394a90a97a3,"16729-483-03, 16729-483-31, 16729-484-90, 16729-484-31, 16729-484-45, 16729-484-03","Atropine Sulfate, Injection, .05 mg/1 mL (NDC 16729-483-03)",Injection,Unavailable,,ANDA212868,,ATROPINE SULFATE,,,Current,Discontinuation of the manufacture of the drug,Discontinuation of the manufacture of the drug,,03J5ZE7KA5,16729-483-03,"866-941-7875, option 2",
Gland Pharma Limited,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718906, 1718909",,d174c19d-56f1-4ef4-087c-23c26db8e40b,09/29/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE HYDROCHLORIDE,"43598-975, 43598-976",Dr.Reddy's Laboratories Inc,5785a11f-7784-4ae0-8029-f50b782eaf4a,"43598-976-11, 43598-976-58, 43598-975-11, 43598-975-58","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-975-58)",Injection,Available,,ANDA209307,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,,Distributed by DRL,,1018WH7F9I,43598-975-58,Distributed by DRL,
Gland Pharma Limited,KETOROLAC TROMETHAMINE,,06/06/2018,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Ketorolac Tromethamine Injection,"860092, 1665459, 1665461",,1aae6a4d-0909-4672-aa26-e3f2d8c4d413,09/29/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,KETOROLAC TROMETHAMINE,"72266-118, 72266-234, 72266-119",FOSUN PHARMA USA INC,228ec94a-f777-f61b-e063-6394a90a21a5,"72266-234-01, 72266-234-25, 72266-118-01, 72266-118-25, 72266-119-01, 72266-119-25","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-118-25)",Injection,Available,,ANDA204216,,KETOROLAC TROMETHAMINE,,,Current,,"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.",,4EVE5946BQ,72266-118-25,833-291-9645,
"Fresenius Kabi USA, LLC",LIDOCAINE HYDROCHLORIDE,,02/22/2012,Reverified,"INFILTRATION, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1737757",,cddb2b22-fce3-8967-6e54-dca3df5ac4b3,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE,"63323-201, 63323-202","Fresenius Kabi USA, LLC",d19c26f4-1214-40f7-9680-43c885613306,"63323-201-01, 63323-201-02, 63323-201-03, 63323-201-10, 63323-202-01, 63323-202-02","Lidocaine Hydrochloride In Plastic Container, Injection, 10 mg/1 mL (NDC 63323-201-02)",Injection,Available,,ANDA088586,,LIDOCAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,V13007Z41A,63323-201-02,888-386-1300,
"Teva Pharmaceuticals USA, Inc.",AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension",,,4c0f348a-a65d-409c-8668-207c82a5e3cb,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0093-4160, 0093-2263, 0093-2264, 0093-4155, 0093-4161, 0093-2267, 0093-2268, 0093-3107, 0093-3109","Teva Pharmaceuticals USA, Inc.",8988589b-0893-4233-ac9c-9884ceb0c2c4,"0093-2263-01, 0093-2264-01, 0093-4160-76, 0093-4160-78, 0093-4160-73, 0093-4155-79, 0093-4155-73, 0093-4155-80, 0093-4161-76, 0093-4161-78, 0093-4161-73, 0093-2267-01, 0093-2268-01, 0093-3107-01, 0093-3107-05, 0093-3109-53, 0093-3109-06, 0093-3109-01, 0093-3109-05","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0093-4160-78)","Powder, For Suspension",,,ANDA065119,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0093-4160-78,800-545-8800,
Takeda Pharmaceuticals USA Inc.,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854832, 854834, 854836, 854838, 854840, 854842, 854844, 854846, 854848, 854850, 854852, 1593856, 1593858, 1871456, 1871459, 1871460, 1871461, 1871462, 1871463, 1871464, 1871465, 1871466, 1871467, 1871468, 1871469",,704e4378-ca83-445c-8b45-3cfa51c1ecad,08/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,VYVANSE,"59417-102, 59417-101, 59417-103, 59417-104, 59417-105, 59417-106, 59417-107, 59417-115, 59417-116, 59417-117, 59417-118, 59417-119, 59417-120","Takeda Pharmaceuticals America, Inc.",756b98a0-fada-44b2-a606-f2e71ef8cc84,"59417-101-10, 59417-102-10, 59417-103-10, 59417-104-10, 59417-105-10, 59417-106-10, 59417-107-10, 59417-115-01, 59417-116-01, 59417-117-01, 59417-118-01, 59417-119-01, 59417-120-01","Vyvanse, Capsule, 20 mg (NDC 59417-102-10)",Capsule,Available,,NDA021977,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,59417-102-10,877-TAKEDA-7 (1-877-825-3327),
Aurobindo Pharma USA,METOPROLOL TARTRATE,,06/03/2025,New,ORAL,Metoprolol Tartrate Tablet,"866511, 866514, 866924",,2b705cb6-cb75-4c2a-907a-4bd45d18bc2c,06/03/2025,HUMAN PRESCRIPTION DRUG,06/03/2025,Cardiovascular,METOPROLOL TARTRATE,"65862-063, 65862-062, 65862-064",Aurobindo Pharma Limited,d265c99d-8e77-4a78-b542-15e957d9d335,"65862-062-01, 65862-062-99, 65862-063-60, 65862-063-01, 65862-063-99, 65862-064-60, 65862-064-01, 65862-064-99","Metoprolol Tartrate, Tablet, 50 mg (NDC 65862-063-99)",Tablet,,,ANDA077739,,METOPROLOL TARTRATE,,,To Be Discontinued,,Permanent discontinuation in the manufacturing of the drug,,W5S57Y3A5L,65862-063-99,866-850-2876,
"Lannett Company, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,f92497b5-baea-4760-b615-45a0b6184402,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","0527-0761, 0527-0760, 0527-0762, 0527-0763, 0527-0764, 0527-0765, 0527-0766","Lannett Company, Inc.",e0804f43-4685-4017-b839-3212d1167362,"0527-0760-37, 0527-0761-37, 0527-0762-37, 0527-0763-37, 0527-0764-37, 0527-0765-37, 0527-0766-37","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0527-0761-37)",Tablet,Available,,ANDA215565,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",0527-0761-37,844-834-0530,
"Hospira, Inc., a Pfizer Company",WATER,,11/23/2021,Reverified,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Sterile Water Injection,,,2b9ea23a-f9e9-48a8-25b7-519e3bbd6828,08/15/2025,HUMAN PRESCRIPTION DRUG,,Other,STERILE WATER,0409-4887,"Hospira, Inc.",900859c0-a075-4fb1-98ce-0e329acc009a,"0409-4887-25, 0409-4887-99, 0409-4887-31, 0409-4887-05, 0409-4887-17, 0409-4887-10, 0409-4887-32, 0409-4887-34, 0409-4887-23, 0409-4887-20, 0409-4887-24, 0409-4887-50","Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-20)",Injection,Available,,NDA018801,,WATER,,,Current,,,,059QF0KO0R,0409-4887-20,844-646-4398,
"Elite Laboratories, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,0e024b69-567c-4b40-9c3e-a2daec34256c,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"64850-555, 64850-550, 64850-551, 64850-552, 64850-553, 64850-554, 64850-556","Elite Laboratories, Inc.",e414bb2e-d404-44ea-931c-5998b0a4c87e,"64850-550-01, 64850-551-01, 64850-552-01, 64850-553-01, 64850-554-01, 64850-555-01, 64850-556-01","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 64850-555-01)",Capsule,Limited Availability,,ANDA218604,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,,,SJT761GEGS,64850-555-01,888-852-6657,
"Hikma Pharmaceuticals USA, Inc.",MIDAZOLAM HYDROCHLORIDE,,04/02/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Midazolam Hydrochloride Injection,"311700, 311702",,575d8bf0-7af7-427c-a231-966e2a5e070d,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology",MIDAZOLAM,"0641-6061, 0641-6057, 0641-6059, 0641-6056, 0641-6063, 0641-6060",Hikma Pharmaceuticals USA Inc.,559c03fb-24ea-4b7b-8afd-e33cb3a2340a,"0641-6057-01, 0641-6057-10, 0641-6057-25, 0641-6059-01, 0641-6059-10, 0641-6056-01, 0641-6056-10, 0641-6061-01, 0641-6061-10, 0641-6061-25, 0641-6063-01, 0641-6063-10, 0641-6063-25, 0641-6060-01, 0641-6060-10","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6061-25)",Injection,Available,,ANDA075243,,MIDAZOLAM,,,Current,,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,W7TTW573JJ,0641-6061-25,800-631-2174,
GlaxoSmithKline,EPOPROSTENOL SODIUM,,01/31/2025,New,INTRAVENOUS,Epoprostenol Sodium Injection,"211199, 211200, 562501, 562502",,8e4b636e-ee9c-4111-779d-28c8369d283b,01/31/2025,HUMAN PRESCRIPTION DRUG,01/31/2025,Cardiovascular,FLOLAN,"0173-0517, 0173-0519, 0173-0857",GlaxoSmithKline LLC,5e54002e-7b03-46ad-ae01-c76c76967201,"0173-0517-00, 0173-0519-00, 0173-0857-02","Flolan, Injection, .5 mg (NDC 0173-0517-00)",Injection,,,NDA020444,,EPOPROSTENOL SODIUM,,,To Be Discontinued,,"The anticipated date that GSK will cease distribution of the product is approximately November 30, 2025.",,"059QF0KO0R, 4K04IQ1OF4",0173-0517-00,888-825-5249,
"EMD Serono, Inc.",LEVOTHYROXINE SODIUM,,07/10/2025,New,ORAL,Levothyroxine Sodium Tablet,"892246, 892251, 966153, 966160, 966166, 966173, 966177, 966182, 966187, 966196, 966202, 966207, 966220, 966221, 966222, 966224, 966225, 966248, 966249, 966253, 966270, 2104866",,bc3c6830-ba68-4ba3-9896-a12d0ad0b275,07/10/2025,HUMAN PRESCRIPTION DRUG,07/10/2025,Endocrinology/Metabolism,EUTHYROX,"72305-025, 72305-050, 72305-075, 72305-088, 72305-100, 72305-112, 72305-125, 72305-137, 72305-150, 72305-175, 72305-200","Provell Pharmaceuticals, LLC",45657074-8874-49f4-a8ef-3ca7e210c16e,"72305-025-30, 72305-025-90, 72305-050-30, 72305-050-90, 72305-075-30, 72305-075-90, 72305-088-30, 72305-088-90, 72305-100-30, 72305-100-90, 72305-112-30, 72305-112-90, 72305-125-30, 72305-125-90, 72305-137-30, 72305-137-90, 72305-150-30, 72305-150-90, 72305-175-30, 72305-175-90, 72305-200-30, 72305-200-90","Euthyrox, Tablet, 25 ug (NDC 72305-025-30)",Tablet,,,NDA021292,,LEVOTHYROXINE SODIUM,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,9J765S329G,72305-025-30,888-899-7041,
PAI Pharma,LIDOCAINE HYDROCHLORIDE,,05/18/2023,Revised,ORAL,Lidocaine Hydrochloride Solution,1010739,,d5e23ede-957c-4a32-b1c6-268acb773c31,08/29/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,LIDOCAINE HYDROCHLORIDE,"0121-4950, 0121-0950","PAI Holdings, LLC dba PAI Pharma",8bd8bb07-066a-4c8c-ac5b-76f746318a49,"0121-0950-03, 0121-4950-15, 0121-4950-40","Lidocaine Hydrochloride Viscous, Solution, 20 mg/1 mL (NDC 0121-4950-40)",Solution,,,ANDA218138,,LIDOCAINE HYDROCHLORIDE,,Available,Resolved,,,08/29/2025,V13007Z41A,0121-4950-40,800-845-8210,
Takeda Pharmaceuticals USA Inc.,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854832, 854834, 854836, 854838, 854840, 854842, 854844, 854846, 854848, 854850, 854852, 1593856, 1593858, 1871456, 1871459, 1871460, 1871461, 1871462, 1871463, 1871464, 1871465, 1871466, 1871467, 1871468, 1871469",,704e4378-ca83-445c-8b45-3cfa51c1ecad,08/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,VYVANSE,"59417-106, 59417-101, 59417-102, 59417-103, 59417-104, 59417-105, 59417-107, 59417-115, 59417-116, 59417-117, 59417-118, 59417-119, 59417-120","Takeda Pharmaceuticals America, Inc.",756b98a0-fada-44b2-a606-f2e71ef8cc84,"59417-101-10, 59417-102-10, 59417-103-10, 59417-104-10, 59417-105-10, 59417-106-10, 59417-107-10, 59417-115-01, 59417-116-01, 59417-117-01, 59417-118-01, 59417-119-01, 59417-120-01","Vyvanse, Capsule, 60 mg (NDC 59417-106-10)",Capsule,Available,,NDA021977,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,59417-106-10,877-TAKEDA-7 (1-877-825-3327),
"Trigen Laboratories, LLC",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Reverified,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release",,,dd8d7b6e-c23d-4e16-bb53-959e9127ebc6,09/04/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE HYDROCHLORIDE,"13811-700, 13811-711","Trigen Laboratories, LLC",ba649db4-df0d-4587-8370-3f866e66e54b,"13811-711-30, 13811-700-30","Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30)",Tablet,Limited Availability,,NDA216117,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,Demand increase for the drug,Allocation to current contracted customers,,4B3SC438HI,13811-700-30,800-541-4802,
Otsuka ICU Medical LLC,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807548, 1807549, 1807550, 1807551, 1807552, 1807627, 1807630, 1807631, 1807632, 1807633, 1807634, 1807639",,5f372b75-d7a4-471e-8ac6-290040fc84b0,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0990-7984, 0990-7730, 0990-7983, 0990-7985",ICU Medical Inc.,87c57bfa-0bf7-41fd-b954-eb753d5d9d7f,"0990-7730-36, 0990-7730-37, 0990-7983-61, 0990-7983-02, 0990-7983-03, 0990-7983-09, 0990-7983-55, 0990-7983-53, 0990-7984-37, 0990-7984-20, 0990-7984-13, 0990-7984-23, 0990-7984-36, 0990-7985-02, 0990-7985-03, 0990-7985-09","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7984-36)",Injection,,,NDA016366,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0990-7984-36,1-866-829-9025 or ProductAvailability@icumed.com,
"Upsher-Smith Laboratories, LLC",AMANTADINE HYDROCHLORIDE,,07/23/2025,New,ORAL,Amantadine Hydrochloride Capsule,849389,,5232b933-1df9-43b4-8ac2-61bfa4855e68,07/23/2025,HUMAN PRESCRIPTION DRUG,07/23/2025,"Antiviral, Neurology",AMANTADINE HYDROCHLORIDE,0832-1015,"Upsher-Smith Laboratories, LLC",398493aa-8a67-10e2-e063-6394a90aef8d,"0832-1015-00, 0832-1015-50","Amantadine Hydrochloride, Capsule, 100 mg (NDC 0832-1015-00)",Capsule,,,ANDA070589,,AMANTADINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug product,,M6Q1EO9TD0,0832-1015-00,763-315-2000,
Teyro Labs,CARBOPLATIN,,03/28/2025,New,INTRAVENOUS,Carboplatin Injection,597195,,1c275825-0275-4c73-b650-e4c1519f13b8,03/28/2025,HUMAN PRESCRIPTION DRUG,03/28/2025,Oncology,CARBOPLATIN,60505-6282,Apotex Corp.,0e68e276-b0df-4f03-e063-6394a90a22b9,"60505-6282-1, 60505-6282-3, 60505-6282-6, 60505-6282-7","Carboplatin, Injection, 10 mg/1 mL (NDC 60505-6282-1)",Injection,,"N0000175413, N0000175073",ANDA077861,,CARBOPLATIN,Platinum-based Drug [EPC],,To Be Discontinued,,Discontinuation due to low sales volume. Supply currently available with June 2025 expiry dating. Wholesaler & Distributor through Marketing partner (Apotex Inc.),,BG3F62OND5,60505-6282-1,800-706-5575,
Rubicon Research Private Limited,CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"72888-152, 72888-153, 72888-154",Advagen Pharma Ltd,36cf156e-5980-a21b-e063-6294a90ab3a0,"72888-152-30, 72888-152-01, 72888-152-05, 72888-152-00, 72888-153-30, 72888-153-01, 72888-153-05, 72888-153-00, 72888-154-30, 72888-154-01, 72888-154-05, 72888-154-00","Clonazepam, Tablet, .5 mg (NDC 72888-152-00)",Tablet,Information pending,"N0000175694, M0002356",ANDA075468,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,Marketed by Advagen Pharma Ltd.,,5PE9FDE8GB,72888-152-00,sales@advagenpharma.com,
"Fresenius Kabi USA, LLC",DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795607, 1795609, 1795610, 1795612, 1795616",,576a22d8-5f2f-497e-80ad-1842ca74bb53,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"65219-462, 65219-456, 65219-464, 65219-458, 65219-460","FRESENIUS KABI USA, LLC",efc3b0c9-518a-47db-bb3e-ebdfd4646e9b,"65219-456-05, 65219-456-60, 65219-464-05, 65219-464-50, 65219-458-05, 65219-458-30, 65219-460-05, 65219-460-20, 65219-462-05, 65219-462-10","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-462-10)",Injection,Available,,ANDA207449,,DEXTROSE MONOHYDRATE,,,Current,,Check wholesalers for inventory,,LX22YL083G,65219-462-10,888-386-1300,
Sandoz Inc.,ADALIMUMAB,,04/14/2025,New,SUBCUTANEOUS,Adalimumab-adaz Injection,"2641644, 2641650, 2641653, 2641654, 2641655, 2641658, 2641660, 2641661, 2641662, 2641663, 2641664, 2641665, 2641666, 2641667, 2641668, 2641669, 2641670, 2641671, 2641672, 2641673",,1ac7d061-3380-468c-b077-c05f8dfbc829,04/14/2025,HUMAN PRESCRIPTION DRUG,04/14/2025,Rheumatology,HYRIMOZ,"61314-454, 61314-473, 61314-476, 61314-509, 61314-517, 61314-531",Sandoz Inc,bd62cde8-792c-4194-949e-ad87a6d5aef0,"61314-454-20, 61314-454-36, 61314-454-68, 61314-473-64, 61314-473-20, 61314-473-92, 61314-476-64, 61314-509-64, 61314-517-36, 61314-531-64","Hyrimoz, Injection, 80 mg/.8 mL (NDC 61314-454-20)",Injection,,"N0000175610, N0000175451, M0001357",BLA761071,"Antibodies, Monoclonal [CS]",ADALIMUMAB-ADAZ,Tumor Necrosis Factor Blocker [EPC],,To Be Discontinued,,,,FYS6T7F842,61314-454-20,800-525-8747,Tumor Necrosis Factor Receptor Blocking Activity [MoA]
Sandoz Inc.,AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","239191, 308182, 308189, 308191, 308192, 308194, 313797, 313850",,13bd4214-9b7f-425b-af5f-fc1ddc678230,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0781-6157, 0781-2020, 0781-2613, 0781-5060, 0781-5061, 0781-6039, 0781-6156, 0781-6041",Sandoz Inc,6aa02079-d11c-4d2f-acaf-9548dd9a7ed6,"0781-2020-31, 0781-2020-76, 0781-2020-01, 0781-2020-05, 0781-2613-31, 0781-2613-76, 0781-2613-01, 0781-2613-05, 0781-5060-20, 0781-5060-01, 0781-5061-20, 0781-5061-01, 0781-6039-58, 0781-6039-46, 0781-6039-55, 0781-6156-52, 0781-6156-57, 0781-6156-46, 0781-6041-58, 0781-6041-46, 0781-6041-55, 0781-6157-52, 0781-6157-57, 0781-6157-46","Amoxicillin, Powder, For Suspension, 400 mg/5 mL (NDC 0781-6157-46)","Powder, For Suspension",,,ANDA065378,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0781-6157-46,800-525-8747,
"Noven Pharmaceuticals, Inc.",METHYLPHENIDATE,Central Nervous System Stimulation [PE],02/28/2025,Revised,TRANSDERMAL,"Methylphenidate Film, Extended Release",,,7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb,08/19/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE TRANSDERMAL SYSTEM,"0574-2415, 0574-2410, 0574-2420, 0574-2430",PADAGIS US LLC,b743ef45-2fc0-4086-8a02-6078e6a09eaa,"0574-2410-65, 0574-2415-65, 0574-2420-65, 0574-2430-65","Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65)","Film, Extended Release",Unavailable,"N0000175739, N0000175729",NDA021514,,METHYLPHENIDATE,Central Nervous System Stimulant [EPC],,Current,Shortage of an active ingredient,Estimated availability: end October 2025. Distributed by Padagis US LLC,,207ZZ9QZ49,0574-2415-65,800-455-8070,
Pfizer Inc.,,,01/06/2023,Revised,,Somatropin Injection,"241975, 762830, 762833, 762834, 762836, 762837, 762839, 762841, 762843, 762846, 762849, 762850, 762852, 762857, 762859, 762866, 762868, 762873, 762875, 762895, 762897, 763488, 763489, 996558, 996559",,ffebf88b-d257-4542-9808-74d9b7167765,08/28/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,GENOTROPIN,"0013-2654, 0013-2626, 0013-2646, 0013-2649, 0013-2650, 0013-2651, 0013-2652, 0013-2653, 0013-2655, 0013-2656, 0013-2657, 0013-2658",Pfizer Laboratories Div Pfizer Inc,f09acf87-6e30-47ad-9891-8a49bf6dffbc,"0013-2626-81, 0013-2646-81, 0013-2649-02, 0013-2650-02, 0013-2651-02, 0013-2652-02, 0013-2653-02, 0013-2654-02, 0013-2655-02, 0013-2656-02, 0013-2657-02, 0013-2658-02","Genotropin, Injection, 1.2 mg preservative free (NDC 0013-2654-02)",Injection,,,BLA020280,,SOMATROPIN,,Available,Resolved,,,08/28/2025,,0013-2654-02,800-533-4535,
Rubicon Research Private Limited,CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"72888-154, 72888-152, 72888-153",Advagen Pharma Ltd,36cf156e-5980-a21b-e063-6294a90ab3a0,"72888-152-30, 72888-152-01, 72888-152-05, 72888-152-00, 72888-153-30, 72888-153-01, 72888-153-05, 72888-153-00, 72888-154-30, 72888-154-01, 72888-154-05, 72888-154-00","Clonazepam, Tablet, 2 mg (NDC 72888-154-01)",Tablet,Available,"N0000175694, M0002356",ANDA075468,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,Marketed by Advagen Pharma Ltd.,,5PE9FDE8GB,72888-154-01,sales@advagenpharma.com,
"Hospira, Inc., a Pfizer Company",FENTANYL CITRATE,,01/01/2012,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Fentanyl Citrate Injection,"1735003, 1735004, 1735006, 1735007, 1735008, 1735013",,bfa8018a-4cbc-434b-e09e-782872b0340a,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Pediatric",FENTANYL CITRATE,"0409-9094, 0409-9093","Hospira, Inc.",e4b31fdd-00af-416d-b14e-dbac0c83da97,"0409-9093-37, 0409-9093-32, 0409-9093-45, 0409-9093-35, 0409-9093-41, 0409-9093-36, 0409-9093-31, 0409-9093-38, 0409-9094-12, 0409-9094-22, 0409-9094-18, 0409-9094-25, 0409-9094-17, 0409-9094-28, 0409-9094-16, 0409-9094-31, 0409-9094-41, 0409-9094-61","Fentanyl Citrate, Injection, 100 mcg/2 mL (50 ug/1 mL) (NDC 0409-9094-22)",Injection,Available,,NDA019115,,FENTANYL CITRATE,,,Current,,,,MUN5LYG46H,0409-9094-22,844-646-4398,
"Teva Pharmaceuticals USA, Inc.",,,02/06/2025,New,,"Glipizide Tablet, Extended Release",,,,02/06/2025,,02/06/2025,Endocrinology/Metabolism,,,,,,"Glipizide, Tablet, Extended Release, 10 mg (NDC 0591-0845-01)",Tablet,,,,,,,,To Be Discontinued,,A business decision was made to discontinue manufacture of the drug.,,,0591-0845-01,800-545-8800,
Apotex Corp.,LISDEXAMFETAMINE DIMESYLATE,,11/01/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,ecad4442-a644-18e3-6ff2-fdbac45eec47,09/29/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"60505-4745, 60505-4739, 60505-4740, 60505-4741, 60505-4742, 60505-4743, 60505-4744",Apotex Corp.,c8e0c70d-2f5b-8d85-fa45-572e8f5f7b4c,"60505-4739-1, 60505-4740-1, 60505-4741-1, 60505-4742-1, 60505-4743-1, 60505-4744-1, 60505-4745-1","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 60505-4745-1)",Capsule,Available,,ANDA216944,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,Product currently available,,SJT761GEGS,60505-4745-1,800-706-5575,
"Hospira, Inc., a Pfizer Company",MORPHINE SULFATE,,07/08/2025,New,INTRAVENOUS,Morphine Sulfate Injection,,,be420e8b-bcb0-49b5-bb4d-1df8b9959809,07/08/2025,HUMAN PRESCRIPTION DRUG,07/08/2025,Analgesia/Addiction,MORPHINE SULFATE,"0409-1893, 0409-1890, 0409-1891, 0409-1892, 0409-1894","Hospira, Inc.",cced2ec0-6c94-4cf0-87fb-041667ee3214,"0409-1890-03, 0409-1890-01, 0409-1890-13, 0409-1890-23, 0409-1891-03, 0409-1891-01, 0409-1891-13, 0409-1891-23, 0409-1892-03, 0409-1892-01, 0409-1892-13, 0409-1892-23, 0409-1893-03, 0409-1893-01, 0409-1893-13, 0409-1893-23, 0409-1894-03, 0409-1894-01","Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0409-1893-01)",Injection,,,NDA202515,,MORPHINE SULFATE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,X3P646A2J0,0409-1893-01,844-646-4398,
"Hikma Pharmaceuticals USA, Inc.",PROMETHAZINE HYDROCHLORIDE,,11/21/2023,Revised,INTRAMUSCULAR,Promethazine Hydrochloride Injection,"992460, 992462, 992858, 992876",,481866da-a712-48a5-853f-8e84aacaab6d,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Gastroenterology, Pediatric, Pulmonary/Allergy",PHENERGAN,"0641-6085, 0641-6084",Hikma Pharmaceuticals USA Inc.,7d6e64fc-bbf2-4ea9-b866-8115c448e687,"0641-6084-01, 0641-6084-25, 0641-6085-01, 0641-6085-25","Phenergen, Injection, 50 mg/1 mL (NDC 0641-6085-25)",Injection,Unavailable,,ANDA083312,,PROMETHAZINE HYDROCHLORIDE,,,Current,Other,This presentation is temporarily on backorder.  Recovery is TBD at this time.,,R61ZEH7I1I,0641-6085-25,800-631-2174,
"Fresenius Kabi USA, LLC",AZACITIDINE,,12/18/2020,Reverified,"INTRAVENOUS, SUBCUTANEOUS",Azacitidine Injection,485246,,3b594aba-e798-4105-b801-0b0d970747c1,09/18/2025,HUMAN PRESCRIPTION DRUG,,Oncology,AZACITIDINE,63323-771,"Fresenius Kabi USA, LLC",4becda8d-8042-4cf1-bef3-c0ec3c23eebe,63323-771-39,"Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)",Injection,Available,"N0000000233, N0000175595",ANDA207518,,AZACITIDINE,Nucleoside Metabolic Inhibitor [EPC],,Current,,Check wholesaler inventory,,M801H13NRU,63323-771-39,1-888-386-1300,Nucleic Acid Synthesis Inhibitors [MoA]
Accord Healthcare Inc.,CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,ebc11109-e7bf-452d-b675-4b3236d54164,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"16729-136, 16729-137, 16729-138",Accord Healthcare Inc.,0e1e7f41-f78b-27cf-e063-6394a90a1ae0,"16729-136-00, 16729-136-16, 16729-137-00, 16729-137-16, 16729-138-00, 16729-138-16","Clonazepam, Tablet, .5 mg (NDC 16729-136-00)",Tablet,Available,"N0000175694, M0002356",ANDA077147,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,,,5PE9FDE8GB,16729-136-00,"866-941-7875, option 2",
"Hospira, Inc., a Pfizer Company",DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795609, 1795610, 1795616",,10e98cb0-31a5-4ad1-3eaa-aa4af387a42d,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,0409-7100,"Hospira, Inc.",477c216c-7446-473a-892d-918faf1dc877,"0409-7100-68, 0409-7100-66, 0409-7100-69, 0409-7100-67, 0409-7100-04, 0409-7100-02","Dextrose 5% In Plastic Container, Injection, 2.5 g/50mL (5%, 50mg/mL) (NDC 0409-7100-66)",Injection,Available,,NDA019466,,DEXTROSE MONOHYDRATE,,,Current,,,,LX22YL083G,0409-7100-66,844-646-4398,
Baxter Healthcare,DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795607, 1795609, 1795610, 1795612, 1795616",,36e9478c-5df0-4b47-b97d-de3626d7cb29,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0338-0062, 0338-9651, 0338-9649, 0338-9655, 0338-9653, 0338-0078, 0338-0074, 0338-0066, 0338-0070, 0338-0082",Baxter Healthcare Corporation,66eb82f8-6755-42aa-b20c-192a640e8068,"0338-9651-75, 0338-9649-75, 0338-9655-60, 0338-9653-60, 0338-0078-20, 0338-0062-30, 0338-0074-30, 0338-0066-20, 0338-0070-10, 0338-0070-12, 0338-0082-10","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0062-30)",Injection,Available,,NDA016673,,DEXTROSE MONOHYDRATE,,,Current,,,,LX22YL083G,0338-0062-30,888-229-0001,
Strides Pharma Inc.,DONEPEZIL HYDROCHLORIDE,,01/28/2025,New,ORAL,Donepezil Hydrochloride Tablet,"997223, 997229",,297e86e8-d248-4cc9-9d9c-2ef9efb4414d,01/28/2025,HUMAN PRESCRIPTION DRUG,01/28/2025,Neurology,DONEPEZIL HYDROCHLORIDE,"71093-128, 71093-127","ACI Healthcare USA, Inc.",a4736add-da84-411f-8e6f-9de67bf467f8,"71093-127-01, 71093-127-03, 71093-127-05, 71093-127-06, 71093-128-01, 71093-128-03, 71093-128-05, 71093-128-06","Donepezil Hydrochloride, Tablet, 10 mg (NDC 71093-128-06)",Tablet,,,ANDA078662,,DONEPEZIL HYDROCHLORIDE,,,To Be Discontinued,,Current product distributor: ACI Healthcare USA Inc. Supply expected to exhaust in September 2026; Discontinuation of manufacture of drug,,3O2T2PJ89D,71093-128-06,877-244-9825,
"Avet Pharmaceuticals, Inc.",FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Reverified,INTRAVENOUS,Furosemide Injection,"1719286, 1719290, 1719291",,1b9117d5-0dd9-4577-a1fd-bb0aaf7e68ec,09/15/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,23155-473,Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.,936eaafa-5088-4ebc-85bc-685ffb85c81f,"23155-473-31, 23155-473-41, 23155-473-32, 23155-473-42, 23155-473-43, 23155-473-33, 23155-473-44, 23155-473-45","Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)",Injection,Available,"N0000175366, N0000175590",ANDA203428,,FUROSEMIDE,Loop Diuretic [EPC],,Current,,,,7LXU5N7ZO5,23155-473-44,855-228-9470,
"Hospira, Inc., a Pfizer Company",MEPERIDINE HYDROCHLORIDE,,05/30/2025,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Meperidine Hydrochloride Injection,"860792, 861463, 861473, 861493, 861494, 861522, 861529, 861617, 1242106, 1242503, 2539186, 2539188, 2539191, 2539192",,b31d1308-28c3-43f4-e0a6-2f3ed76b8975,08/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,DEMEROL,"0409-1178, 0409-1181, 0409-1176, 0409-1179, 0409-1180, 0409-1362, 0409-1418","Hospira, Inc.",1271f15f-ccda-4892-8fb0-9bb2d38ded4a,"0409-1181-30, 0409-1176-03, 0409-1176-30, 0409-1178-03, 0409-1178-30, 0409-1179-03, 0409-1179-30, 0409-1180-59, 0409-1180-69, 0409-1362-11, 0409-1362-01, 0409-1418-11, 0409-1418-01","Demerol, Injection, 50 mg/1 mL (NDC 0409-1178-30)",Injection,Unavailable,,NDA021171,,MEPERIDINE HYDROCHLORIDE,,,Current,Other,Next Delivery: October 2025; Estimated Recovery: December 2025,,N8E7F7Q170,0409-1178-30,844-646-4398,
"Vertical Pharmaceuticals, LLC",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Reverified,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release",,,22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d,09/16/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,RELEXXII,"68025-088, 68025-089, 68025-095, 68025-096, 68025-097, 68025-084, 68025-098","Vertical Pharmaceuticals, LLC",86f477e9-07fc-466b-913e-1a4434c91df4,"68025-088-30, 68025-089-30, 68025-095-10, 68025-095-30, 68025-096-10, 68025-096-30, 68025-097-10, 68025-097-30, 68025-084-30, 68025-098-10, 68025-098-30","Relexxii, Tablet, Extended Release, 45 mg (NDC 68025-088-30)",Tablet,Available,,NDA216117,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,,,,4B3SC438HI,68025-088-30,800-541-4802,
"ICU Medical, Inc.",SODIUM CHLORIDE,,04/28/2023,Revised,IRRIGATION,Sodium Chloride 0.9% Irrigation,486515,,3cfdeee0-ff14-4341-8396-b11c2a037c60,07/02/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0990-6138, 0990-7138, 0990-7972",ICU Medical Inc.,9ceb78f6-0be4-4dbb-9fd0-9728b5ad5c7b,"0990-7138-09, 0990-7138-36, 0990-6138-22, 0990-6138-03, 0990-7972-05, 0990-7972-07","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0990-6138-03)",Irrigation,,,NDA017514,,SODIUM CHLORIDE,,Available,Resolved,,,07/02/2025,451W47IQ8X,0990-6138-03,1-866-829-9025 or ProductAvailability@icumed.com,
"Hospira, Inc., a Pfizer Company",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Bupivacaine Hydrochloride Injection,"1012377, 1012381, 1012384, 1012388, 1012396, 1012400, 1012404, 1012406, 1672917, 1672919, 1673242, 1673243, 1724786, 1724787, 1724794, 1724796, 1724880, 1724884, 1725044, 1725046, 1725078, 1725079, 1725082, 1725083, 1867594, 1867596, 1867612, 1867614",,67578b56-7540-487e-1fba-481255620e78,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,MARCAINE,"0409-1559, 0409-1560, 0409-1582, 0409-1587, 0409-1610, 0409-1746, 0409-1749, 0409-1752, 0409-1755, 0409-2510, 0409-7535, 0409-1250, 0409-5010, 0409-1530, 0409-0525, 0409-7510, 0409-2253","Hospira, Inc.",b083f440-bfb7-449a-b601-c2f59a6f9dcf,"0409-1559-18, 0409-1559-10, 0409-1559-19, 0409-1559-30, 0409-1560-18, 0409-1560-10, 0409-1560-19, 0409-1560-29, 0409-1582-18, 0409-1582-10, 0409-1582-19, 0409-1582-29, 0409-1587-50, 0409-1610-50, 0409-1746-70, 0409-1746-10, 0409-1746-71, 0409-1746-30, 0409-1749-70, 0409-1749-10, 0409-1749-71, 0409-1749-29, 0409-1752-50, 0409-1755-50, 0409-2510-01, 0409-2510-25, 0409-7535-01, 0409-7535-25, 0409-1250-01, 0409-1250-25, 0409-5010-01, 0409-5010-25, 0409-1530-01, 0409-1530-25, 0409-0525-01, 0409-0525-25, 0409-7510-01, 0409-7510-25, 0409-2253-01, 0409-2253-25","Marcaine, Injection, Marcaine 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1559-30)",Injection,Available,,NDA016964,,BUPIVACAINE HYDROCHLORIDE,,,Current,,,,"30Q7KI53AK, 7TQO7W3VT8",0409-1559-30,844-646-4398,
"Prinston Pharmaceutical, Inc.",CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,4acbb7a9-4db5-4497-b8db-9f358b3f6fb4,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"43547-406, 43547-407, 43547-408",Solco Healthcare LLC,dc17b9d4-2890-4f6c-8476-daa39d0cbc9c,"43547-406-10, 43547-406-50, 43547-406-11, 43547-407-10, 43547-407-50, 43547-407-11, 43547-408-10, 43547-408-50","Clonazepam, Tablet, .5 mg (NDC 43547-406-10)",Tablet,Available,"N0000175694, M0002356",ANDA077856,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,Marketed by Solco Healthcare,,5PE9FDE8GB,43547-406-10,"For orders, Solco Healthcare 866-931-9829",
"Par Pharmaceutical, Inc.",DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"309710, 1718906, 1718909",,1ee59985-4c1d-48f7-b8f9-5584c2d55e08,09/17/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE HYDROCHLORIDE,"42023-187, 42023-146, 42023-186","ENDO USA, Inc.",d518b2d2-b39c-47ac-b45f-8c6a045a8dae,"42023-146-25, 42023-186-20, 42023-187-10","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-187-10)",Injection,Available,,ANDA208266,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,,Please check wholesalers for inventory,,1018WH7F9I,42023-187-10,800-828-9393,
"Fresenius Kabi USA, LLC",FENTANYL CITRATE,,01/01/2012,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Fentanyl Citrate Injection,"1735003, 1735007, 1735008, 1735013, 2168270",,38d0c14a-a0c1-44cc-a939-0304eb8037d6,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Pediatric",FENTANYL CITRATE,63323-806,"Fresenius Kabi USA, LLC",341b092a-1f6f-40f1-98f2-9346bf2e1242,"63323-806-11, 63323-806-01, 63323-806-12, 63323-806-02, 63323-806-13, 63323-806-05, 63323-806-14, 63323-806-20, 63323-806-50","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-20)",Injection,Unavailable,,ANDA210762,,FENTANYL CITRATE,,,Current,Other,Backordered. Next release not available at this time. Check wholesalers for inventory.,,MUN5LYG46H,63323-806-20,888-386-1300,
"Fresenius Kabi USA, LLC",MIDAZOLAM HYDROCHLORIDE,,04/02/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Midazolam Hydrochloride Injection,"311700, 311702",,"a91ce254-14a3-4cbf-8ab8-5da252aa3fdc, 09daf48f-1d44-4b7b-bb53-bd5635b93ca6",09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology",MIDAZOLAM,"63323-412, 63323-411","Fresenius Kabi USA, LLC","9814447b-a93e-42ad-b57e-5db0a5b7f552, c2aaa2df-aa73-4ea7-96be-528010260e25","63323-411-22, 63323-411-27, 63323-411-15, 63323-411-12, 63323-411-18, 63323-411-25, 63323-411-13, 63323-411-10, 63323-412-18, 63323-412-25, 63323-412-03, 63323-412-02, 63323-412-06, 63323-412-05, 63323-412-13, 63323-412-10, 63323-412-00","Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-25)",Injection,Available,,"ANDA075154, ANDA208878",,MIDAZOLAM HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,W7TTW573JJ,63323-412-25,888-386-1300,
"Hospira, Inc., a Pfizer Company",MORPHINE SULFATE,,10/31/2017,Reverified,"EPIDURAL, INTRATHECAL, INTRAVENOUS",Morphine Sulfate Injection,"1728783, 1728800",,1d181906-f3ec-4222-1883-e61577a3122e,08/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,MORPHINE SULFATE,"0409-3815, 0409-3814","Hospira, Inc.",ed66921f-64ef-4109-8b78-575b3d0434f0,"0409-3814-11, 0409-3814-12, 0409-3815-11, 0409-3815-12","Morphine Sulfate, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-3815-12)",Injection,Available,,ANDA073510,,MORPHINE SULFATE,,,Current,,,01/03/2025,X3P646A2J0,0409-3815-12,844-646-4398,
Aurobindo Pharma USA,"AMLODIPINE BESYLATE, BENAZEPRIL HYDROCHLORIDE",,03/04/2025,New,ORAL,Amlodipine Besylate; Benazepril Hydrochloride Capsule,"898342, 898346, 898350, 898353, 898356, 898359",,99ed4927-9a34-4e8d-8eea-60b63c867d46,03/04/2025,HUMAN PRESCRIPTION DRUG,03/04/2025,Cardiovascular,AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE,"65862-583, 65862-582, 65862-584, 65862-585, 65862-586, 65862-587",Aurobindo Pharma Limited,a45ec3e8-1d14-4c27-9685-976323df8cad,"65862-582-01, 65862-582-05, 65862-583-01, 65862-583-05, 65862-584-01, 65862-584-05, 65862-585-01, 65862-585-05, 65862-586-01, 65862-586-05, 65862-587-01, 65862-587-05","Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 10 mg (NDC 65862-583-01)",Capsule,,,ANDA202239,,AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE,,,To Be Discontinued,,,,"864V2Q084H, N1SN99T69T",65862-583-01,866-850-2876,
"Hikma Pharmaceuticals USA, Inc.",HYDROMORPHONE HYDROCHLORIDE,,11/01/2017,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Hydromorphone Hydrochloride Injection,897745,,c729424e-e483-4bf8-b86c-ce56636dcffa,07/23/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,HYDROMORPHONE HYDROCHLORIDE,0641-6254,Hikma Pharmaceuticals USA Inc.,ba25ec4f-3b81-4960-bf74-6a1e4c6be45c,0641-6254-01,"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)",Injection,Available,,NDA217812,,HYDROMORPHONE HYDROCHLORIDE,,,Current,,Additional lots are scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,L960UP2KRW,0641-6254-01,800-631-2174,
"Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)",IRINOTECAN HYDROCHLORIDE,,09/26/2025,New,INTRAVENOUS,Irinotecan Hydrochloride Injection,"1726319, 1726324",,caab50e6-0dad-4ddd-9a6c-96cc2b87aee7,09/26/2025,HUMAN PRESCRIPTION DRUG,09/26/2025,Oncology,IRINOTECAN HYDROCHLORIDE,25021-230,Sagent Pharmaceuticals,6c1863de-2414-4e41-a2fa-7f2f7135af0e,"25021-230-02, 25021-230-05","Irinotecan Hydrochloride, Injection, 100 mg/5 mL (NDC 25021-230-05)",Injection,,,ANDA090675,,IRINOTECAN HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug; Distributed by Sagent Pharmaceuticals,,042LAQ1IIS,25021-230-05,"Company Contact: 609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)",
"EMD Serono, Inc.",LEVOTHYROXINE SODIUM,,07/10/2025,New,ORAL,Levothyroxine Sodium Tablet,"892246, 892251, 966153, 966160, 966166, 966173, 966177, 966182, 966187, 966196, 966202, 966207, 966220, 966221, 966222, 966224, 966225, 966248, 966249, 966253, 966270, 2104866",,bc3c6830-ba68-4ba3-9896-a12d0ad0b275,07/10/2025,HUMAN PRESCRIPTION DRUG,07/10/2025,Endocrinology/Metabolism,EUTHYROX,"72305-200, 72305-025, 72305-050, 72305-075, 72305-088, 72305-100, 72305-112, 72305-125, 72305-137, 72305-150, 72305-175","Provell Pharmaceuticals, LLC",45657074-8874-49f4-a8ef-3ca7e210c16e,"72305-025-30, 72305-025-90, 72305-050-30, 72305-050-90, 72305-075-30, 72305-075-90, 72305-088-30, 72305-088-90, 72305-100-30, 72305-100-90, 72305-112-30, 72305-112-90, 72305-125-30, 72305-125-90, 72305-137-30, 72305-137-90, 72305-150-30, 72305-150-90, 72305-175-30, 72305-175-90, 72305-200-30, 72305-200-90","Euthyrox, Tablet, 200 ug (NDC 72305-200-30)",Tablet,,,NDA021292,,LEVOTHYROXINE SODIUM,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,9J765S329G,72305-200-30,888-899-7041,
"Sun Pharmaceutical Industries, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Revised,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856, 1871456, 1871460, 1871462, 1871464, 1871466, 1871468",,da3148af-f9b6-4725-adae-3595b4c7dc4b,09/22/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"57664-050, 57664-047, 57664-046, 57664-048, 57664-049, 57664-051, 57664-052, 57664-083, 57664-084, 57664-085, 57664-086, 57664-087, 57664-088","Sun Pharmaceutical Industries, Inc.",0b77417a-5789-8818-e063-6294a90ad2e3,"57664-047-88, 57664-046-88, 57664-048-88, 57664-049-88, 57664-050-88, 57664-051-88, 57664-052-88, 57664-083-88, 57664-084-88, 57664-085-88, 57664-086-88, 57664-087-88, 57664-088-88","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 57664-050-88)",Capsule,Limited Availability,,ANDA214484,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,Additional supply anticipated early 2026,,SJT761GEGS,57664-050-88,800-818-4555,
"Avet Pharmaceuticals, Inc.",MIDAZOLAM HYDROCHLORIDE,,04/02/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Midazolam Hydrochloride Injection,1666798,,8b690f5c-2923-4c34-a8f7-11af5f546b62,09/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology",MIDAZOLAM HYDROCHLORIDE,23155-600,Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.,c4800842-cb3b-4907-9abe-20bac2726c0c,"23155-600-31, 23155-600-41","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)",Injection,Available,,ANDA090696,,MIDAZOLAM HYDROCHLORIDE,,,Current,,,,W7TTW573JJ,23155-600-41,855-228-9470,
Apotex Corp.,AMBRISENTAN,,01/14/2025,New,ORAL,Ambrisentan Tablet,,,291a782a-77e1-8a8e-e1c8-2626f305c2b7,01/14/2025,HUMAN PRESCRIPTION DRUG,01/14/2025,Cardiovascular,AMBRISENTAN,"60505-4553, 60505-4552",Apotex Corp.,9525d4e3-a712-40cf-a52f-9d16bc156220,"60505-4552-1, 60505-4552-0, 60505-4552-3, 60505-4553-1, 60505-4553-0, 60505-4553-3","Ambrisentan, Tablet, 10 mg (NDC 60505-4553-3)",Tablet,,"N0000175581, N0000175364",ANDA210701,,AMBRISENTAN,Endothelin Receptor Antagonist [EPC],,To Be Discontinued,,,,HW6NV07QEC,60505-4553-3,Tablet,Endothelin Receptor Antagonists [MoA]
"Fresenius Kabi USA, LLC",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Bupivacaine Hydrochloride Injection,"1724880, 1724881, 1725078, 1725175, 1724884, 1724885, 1725082, 1725177, 1672917, 1672919, 1673296, 1673298, 1012391, 1012396, 1012404, 1012421, 1012455, 1012457",,"e700eb7b-8b14-49c9-96b2-331f18776e45, b6bfc04a-1868-4630-9ca1-8c027af97ce3, dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175, eb6d8fee-def4-4c96-9972-695e8cea8ea8",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,SENSORCAINE MPF,"63323-464, 63323-466, 63323-462, 63323-465, 63323-467, 63323-460","Fresenius Kabi USA, LLC","b41b5dbd-7aff-4d97-ac97-f4355393ee4e, d3ba9fb9-63c8-4597-bb0a-cd01d31a24b6, 13a48007-3784-46f2-bd4d-da1004186b81, 2b1a1f80-cb29-4ac1-9e72-20225ed45715","63323-464-01, 63323-464-17, 63323-466-03, 63323-466-17, 63323-464-08, 63323-464-38, 63323-466-08, 63323-466-38, 63323-462-03, 63323-462-38, 63323-464-09, 63323-464-39, 63323-466-09, 63323-466-39, 63323-465-01, 63323-465-57, 63323-467-01, 63323-467-57, 63323-460-01, 63323-460-37, 63323-464-02, 63323-464-37, 63323-464-03, 63323-464-31, 63323-466-01, 63323-466-37, 63323-466-02, 63323-466-31, 63323-462-04, 63323-462-17, 63323-462-01, 63323-462-37, 63323-462-02, 63323-462-31","Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-37)",Injection,Available,,"ANDA070552, NDA018304",,BUPIVACAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,"7TQO7W3VT8, 30Q7KI53AK",63323-464-37,888-386-1300,
"Hikma Pharmaceuticals USA, Inc.",CEFOTAXIME SODIUM,,02/17/2015,Reverified,"INTRAMUSCULAR, INTRAVENOUS","Cefotaxime Sodium Powder, for Solution","309068, 1656313, 1656318",,ed23b6bc-32c7-4c50-a53d-313ae78e5623,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",CEFOTAXIME,"0143-9933, 0143-9931, 0143-9930",Hikma Pharmaceuticals USA Inc.,7e0897ec-2275-4438-9cc5-4c951e52ad97,"0143-9931-01, 0143-9931-25, 0143-9933-01, 0143-9933-25, 0143-9930-01, 0143-9930-10","Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 0143-9933-25)","Powder, For Solution",Unavailable,,ANDA065072,,CEFOTAXIME,,,Current,Demand increase for the drug,Shortage duration is unknown at this time.,,258J72S7TZ,0143-9933-25,800-631-2174,
Rubicon Research Private Limited,CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"72888-153, 72888-152, 72888-154",Advagen Pharma Ltd,36cf156e-5980-a21b-e063-6294a90ab3a0,"72888-152-30, 72888-152-01, 72888-152-05, 72888-152-00, 72888-153-30, 72888-153-01, 72888-153-05, 72888-153-00, 72888-154-30, 72888-154-01, 72888-154-05, 72888-154-00","Clonazepam, Tablet, 1 mg (NDC 72888-153-30)",Tablet,Available,"N0000175694, M0002356",ANDA075468,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,Marketed by Advagen Pharma Ltd.,,5PE9FDE8GB,72888-153-30,sales@advagenpharma.com,
"Lannett Company, Inc.",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Revised,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release","2001564, 2001565, 2001566, 2001568",,3d1f5aff-5d39-496c-b5ed-7f3c70ec641c,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE HYDROCHLORIDE,"62175-310, 62175-311, 62175-312, 62175-313","Lannett Company, Inc.",fd0e4ddf-c516-4464-aeca-eb1d3bd24667,"62175-310-37, 62175-311-37, 62175-312-37, 62175-313-37","Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62175-310-37)",Tablet,Available,,ANDA091695,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,Shortage of an active ingredient,Limited Availability,,4B3SC438HI,62175-310-37,844-834-0530,
"Bausch Health Americas, Inc.",PIMECROLIMUS,,02/28/2025,New,TOPICAL,Pimecrolimus Cream,"352085, 562806",,e4027e5a-0f9b-4070-b196-f60172f45c4c,02/28/2025,HUMAN PRESCRIPTION DRUG,02/28/2025,Dermatology,ELIDEL,"0187-5102, 0187-5101, 0187-5100, 0187-5103","Bausch Health US, LLC",2f802a3f-c021-45c1-8693-5689c30c3fc6,"0187-5102-03, 0187-5101-02, 0187-5100-01, 0187-5103-04","Elidel, Cream, 100gm (NDC 0187-5102-03)",Cream,,"N0000175457, N0000175458",NDA021302,,PIMECROLIMUS,Calcineurin Inhibitor Immunosuppressant [EPC],,To Be Discontinued,,Authorized generics is still marketed and available under NDC 68682-112-03,,7KYV510875,0187-5102-03,908-927-1400,Calcineurin Inhibitors [MoA]
"Hikma Pharmaceuticals USA, Inc.",FENTANYL CITRATE,,12/20/2023,Revised,"INTRAMUSCULAR, INTRAVENOUS",Fentanyl Citrate Injection,"1735003, 1735007, 1735008, 1735013, 2168270, 2474269, 2629337",,ce5db1c2-feb1-4ad2-847a-d02e865bd47e,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Pediatric",FENTANYL CITRATE,"0641-6247, 0641-6024, 0641-6027, 0641-6025, 0641-6028, 0641-6026, 0641-6029, 0641-6030, 0641-6248, 0641-6249",Hikma Pharmaceuticals USA Inc.,aca9742b-d890-426a-8296-14ca64748238,"0641-6024-01, 0641-6024-10, 0641-6027-01, 0641-6027-25, 0641-6025-01, 0641-6025-10, 0641-6028-01, 0641-6028-10, 0641-6028-25, 0641-6026-01, 0641-6026-05, 0641-6029-01, 0641-6029-25, 0641-6030-01, 0641-6247-01, 0641-6247-25, 0641-6248-01, 0641-6248-10, 0641-6249-01, 0641-6249-10","Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6247-25)",Injection,Available,,NDA019101,,FENTANYL CITRATE,,,Current,,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,MUN5LYG46H,0641-6247-25,800-631-2174,
"Elite Laboratories, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,0e024b69-567c-4b40-9c3e-a2daec34256c,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"64850-551, 64850-550, 64850-552, 64850-553, 64850-554, 64850-555, 64850-556","Elite Laboratories, Inc.",e414bb2e-d404-44ea-931c-5998b0a4c87e,"64850-550-01, 64850-551-01, 64850-552-01, 64850-553-01, 64850-554-01, 64850-555-01, 64850-556-01","Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 64850-551-01)",Capsule,Limited Availability,,ANDA218604,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,,,SJT761GEGS,64850-551-01,888-852-6657,
Pfizer Inc.,PENICILLIN G BENZATHINE,,04/26/2023,Revised,INTRAMUSCULAR,Penicillin G Benzathine Injection,"731564, 731566, 731567, 731568, 731570, 731571",https://www.fda.gov/media/188355/download,012d46f1-d0a0-4676-a879-cd320297ab16,08/25/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,BICILLIN L-A,"60793-702, 60793-700, 60793-701",Pfizer Laboratories Div Pfizer Inc,4b3694af-9d77-487f-8838-b75aec6636da,"60793-700-01, 60793-700-10, 60793-701-02, 60793-701-10, 60793-702-04, 60793-702-10","Bicillin L-A, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10)",Injection,Unavailable,,NDA050141,,PENICILLIN G BENZATHINE,,,Current,Other,Shortage per Manufacturer: Manufacturing Delay,,RIT82F58GK,60793-702-10,844-646-4398,
Eugia US LLC,BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Revised,"EPIDURAL, INFILTRATION, INTRACAUDAL",Bupivacaine Hydrochloride Injection,"1012396, 1012404, 1724786, 1724787, 1724880, 1724884, 1725078, 1725082",,ffecf450-1f01-4721-8e10-251385852612,09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE,"55150-167, 55150-168, 55150-169, 55150-170, 55150-171, 55150-172, 55150-249, 55150-250",Eugia US LLC,39649703-e633-4a20-ba71-0c04dbf8ff2a,"55150-167-10, 55150-168-30, 55150-169-10, 55150-170-30, 55150-171-10, 55150-172-30, 55150-249-50, 55150-250-50","Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-167-10)",Injection,Available,,ANDA203895,,BUPIVACAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,7TQO7W3VT8,55150-167-10,888-238-7880,
"Hospira, Inc., a Pfizer Company",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,"EPIDURAL, RETROBULBAR",Bupivacaine Hydrochloride Injection,"1012377, 1012384, 1012396, 1012404, 1672917, 1672919, 1724786, 1724787, 1724880, 1724884, 1725078, 1725082, 1867594, 1867596",,02a845c3-4521-4926-e397-25ab536e7cf6,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE,"0409-1165, 0409-1159, 0409-1160, 0409-1162, 0409-1163, 0409-9043, 0409-9046, 0409-9045, 0409-9042","Hospira, Inc.",3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7,"0409-1159-18, 0409-1159-01, 0409-1159-19, 0409-1159-02, 0409-1160-18, 0409-1160-01, 0409-1162-18, 0409-1162-01, 0409-1162-19, 0409-1162-02, 0409-1163-18, 0409-1163-01, 0409-1165-18, 0409-1165-01, 0409-1165-19, 0409-1165-02, 0409-9043-11, 0409-9043-01, 0409-9046-11, 0409-9046-01, 0409-9045-11, 0409-9045-01, 0409-9045-16, 0409-9045-17, 0409-9042-11, 0409-9042-01, 0409-9042-16, 0409-9042-17","Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 0409-1165-01)",Injection,Available,,ANDA070585,,BUPIVACAINE HYDROCHLORIDE,,,Current,,,,"30Q7KI53AK, 7TQO7W3VT8",0409-1165-01,844-646-4398,
"Teva Pharmaceuticals USA, Inc.","EZETIMIBE, SIMVASTATIN",Decreased Cholesterol Absorption [PE],01/06/2025,New,ORAL,Ezetimibe; Simvastatin Tablet,"476345, 476349, 476350, 476351",,00680bea-d2fb-4362-ba67-e866b732e9ed,01/06/2025,HUMAN PRESCRIPTION DRUG,01/06/2025,Cardiovascular,EZETIMIBE AND SIMVASTATIN,"45963-568, 45963-565, 45963-566, 45963-567","Actavis Pharma, Inc.",bd64aee1-c95f-4767-8d31-af93dd0ab692,"45963-565-30, 45963-565-08, 45963-566-30, 45963-566-08, 45963-567-30, 45963-567-08, 45963-568-30, 45963-568-08","EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 80 mg (NDC 45963-568-08)",Tablet,,"N0000175589, N0000000121, N0000008553, N0000175911",ANDA202968,,EZETIMIBE AND SIMVASTATIN,"HMG-CoA Reductase Inhibitor [EPC], Dietary Cholesterol Absorption Inhibitor [EPC]",,To Be Discontinued,,,,"AGG2FN16EV, EOR26LQQ24",45963-568-08,800-545-8800,Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]
"Hospira, Inc., a Pfizer Company",FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Revised,"INTRAMUSCULAR, INTRAVENOUS",Furosemide Injection,"1719286, 1719290, 1719291",,"aaced7a8-c3d7-4d66-8c07-aa407b8b3f35, 39fd32f2-6bb7-4a65-d298-e48d26bc80c7",08/15/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,0409-6102,"Hospira, Inc.","c529b0df-a5cb-46ce-8131-38674ee756af, 0d4a39f2-904e-434a-9af1-83bb4febf124","0409-6102-35, 0409-6102-25, 0409-6102-36, 0409-6102-26, 0409-6102-37, 0409-6102-27, 0409-6102-19, 0409-6102-02, 0409-6102-18, 0409-6102-04, 0409-6102-20, 0409-6102-10","Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-26)",Injection,Limited Availability,"N0000175366, N0000175590",NDA018667,,FUROSEMIDE,Loop Diuretic [EPC],,Current,Other,Limited Supply Available. Next Delivery and Estimated Recovery: December 2027,,7LXU5N7ZO5,0409-6102-26,844-646-4398,
Aurobindo Pharma USA,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,a582d57f-d191-4ca5-b105-585b2d8a0e3e,09/17/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","13107-069, 13107-068, 13107-070, 13107-071, 13107-072, 13107-073, 13107-074","Aurolife Pharma, LLC",95842af2-8d9d-4eb1-ba39-86cdbd829a79,"13107-068-50, 13107-068-01, 13107-068-25, 13107-068-05, 13107-068-99, 13107-069-50, 13107-069-01, 13107-069-25, 13107-069-05, 13107-069-99, 13107-070-50, 13107-070-01, 13107-070-25, 13107-070-05, 13107-070-99, 13107-071-50, 13107-071-01, 13107-071-25, 13107-071-05, 13107-071-99, 13107-072-50, 13107-072-01, 13107-072-25, 13107-072-05, 13107-072-99, 13107-073-50, 13107-073-01, 13107-073-25, 13107-073-05, 13107-073-99, 13107-074-50, 13107-074-01, 13107-074-25, 13107-074-05, 13107-074-99","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 13107-069-01)",Tablet,Unavailable,,ANDA202424,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,Shortage of an active ingredient,Estimated availability December 2025,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",13107-069-01,(866) 850-2876 or CustomerService@AurobindoUSA.com,
"Fresenius Kabi USA, LLC",WATER,,11/23/2021,Reverified,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Sterile Water Injection,,,e71c6c83-d518-496c-b2ab-efd5987e4783,09/18/2025,HUMAN PRESCRIPTION DRUG,,Other,STERILE WATER,63323-185,"Fresenius Kabi USA, LLC",42c6c812-706a-425b-b8cb-931006e40484,"63323-185-07, 63323-185-10, 63323-185-09, 63323-185-50, 63323-185-08, 63323-185-20, 63323-185-04, 63323-185-05","Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-10)",Injection,Available,,ANDA088400,,WATER,,,Current,,Check wholesalers for inventory,,059QF0KO0R,63323-185-10,888-386-1300,
Pfizer Inc.,TALAZOPARIB TOSYLATE,,01/13/2025,New,ORAL,Talazoparib Tosylate Capsule,"2099946, 2099952, 2099954, 2099956, 2591510, 2591512, 2591520, 2591521, 2639960, 2639962, 2639964, 2639966",,f2423edd-6d24-495c-aec1-c2f457f08d9a,01/13/2025,HUMAN PRESCRIPTION DRUG,01/13/2025,Oncology,TALZENNA,"0069-1501, 0069-0296, 0069-1195, 0069-1751, 0069-1031, 0069-1235",Pfizer Laboratories Div Pfizer Inc,2cb65f61-9a14-46d9-85a3-a7eea76160c5,"0069-0296-30, 0069-1195-30, 0069-1501-30, 0069-1751-30, 0069-1031-30, 0069-1235-30","Talzenna, Capsule, .5 mg (NDC 0069-1501-30)",Capsule,,,NDA211651,,TALAZOPARIB,,,To Be Discontinued,,"Supply expected to exhaust late February 2025
Replaced with Soft Gel NDC 0069-0546-30",,02WK9U5NZC,0069-1501-30,800-533-4535,
Strides Pharma Inc.,LIDOCAINE,Local Anesthesia [PE],01/28/2025,New,TOPICAL,Lidocaine Ointment,1543069,,8b1efeaa-31b1-4f34-960f-7a920ac07355,01/28/2025,HUMAN PRESCRIPTION DRUG,01/28/2025,Anesthesia,LIDOCAINE,64380-789,Strides Pharma Science Limited,e6c9429c-13b9-4932-abad-e605c4c7fb68,"64380-789-32, 64380-789-23, 64380-789-33","Lidocaine, Ointment, 5%, 35.44 gram tubes (NDC 64380-789-32)",Ointment,,"N0000175682, M0000897, N0000175426, N0000175976",ANDA210958,Amides [CS],LIDOCAINE,"Amide Local Anesthetic [EPC], Antiarrhythmic [EPC]",,To Be Discontinued,,,,98PI200987,64380-789-32,877-244-9825,
"Dr. Reddy's Laboratories, Inc.",RAMELTEON,,01/08/2025,New,ORAL,Ramelteon Tablet,577348,,b71cd925-1bae-5a6a-072b-941ad6d3ce65,01/08/2025,HUMAN PRESCRIPTION DRUG,01/08/2025,Other,RAMELTEON,43598-741,Dr.Reddys Laboratories Inc,54220029-c5df-b277-af7e-2786da03bbed,"43598-741-30, 43598-741-01, 43598-741-10","Tablet, 8 mg (NDC 43598-741-30)",Tablet,,"N0000175743, N0000000250",ANDA091693,,RAMELTEON,Melatonin Receptor Agonist [EPC],,To Be Discontinued,,,,901AS54I69,43598-741-30,866-732-3952,Melatonin Receptor Agonists [MoA]
"Amphastar Pharmaceuticals, Inc.",DEXTROSE MONOHYDRATE,,01/13/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 50% Injection,727517,,fcc7ac79-cd70-4f03-a4de-f051f9ca1f7d,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Pediatric",DEXTROSE MONOHYDRATE,76329-3302,"International Medication Systems, Limited",45b366a9-6c0c-4643-9951-4ff880b29c83,76329-3302-1,"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 76329-3302-1)",Injection,Available,,ANDA203451,,DEXTROSE MONOHYDRATE,,,Current,,,,LX22YL083G,76329-3302-1,800-423-4136,
"Bausch Health Americas, Inc.",PIMECROLIMUS,,02/28/2025,New,TOPICAL,Pimecrolimus Cream,"352085, 562806",,e4027e5a-0f9b-4070-b196-f60172f45c4c,02/28/2025,HUMAN PRESCRIPTION DRUG,02/28/2025,Dermatology,ELIDEL,"0187-5101, 0187-5102, 0187-5100, 0187-5103","Bausch Health US, LLC",2f802a3f-c021-45c1-8693-5689c30c3fc6,"0187-5102-03, 0187-5101-02, 0187-5100-01, 0187-5103-04","Elidel, Cream, 60gm (NDC 0187-5101-02)",Cream,,"N0000175457, N0000175458",NDA021302,,PIMECROLIMUS,Calcineurin Inhibitor Immunosuppressant [EPC],,To Be Discontinued,,Authorized generics is still marketed and available under NDC 68682-111-02,,7KYV510875,0187-5101-02,908-927-1400,Calcineurin Inhibitors [MoA]
Otsuka ICU Medical LLC,DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795477, 1795480, 1795481, 1795607, 1795609, 1795610, 1795612, 1795616, 1795618, 1795621",,8b25b7e0-703e-4b43-a4eb-52863511602d,09/17/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0990-7923, 0990-7922, 0990-7930","ICU Medical, Inc.",09b10612-c937-4d10-becb-9768e10caa2c,"0990-7923-20, 0990-7923-23, 0990-7923-36, 0990-7923-37, 0990-7923-13, 0990-7922-02, 0990-7922-03, 0990-7922-09, 0990-7922-53, 0990-7922-55, 0990-7922-61, 0990-7930-02, 0990-7930-03, 0990-7930-09","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-36)",Injection,Available,,NDA016367,,DEXTROSE MONOHYDRATE,,,Current,,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,LX22YL083G,0990-7923-36,1-866-829-9025 or ProductAvailability@icumed.com,
"Hospira, Inc., a Pfizer Company",DEXTROSE MONOHYDRATE,,01/13/2022,Revised,INTRAVENOUS,Dextrose Monohydrate 50% Injection,"727517, 1795514",,4ed365da-4e62-4329-c1b9-c197ab4fb6e1,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Pediatric",DEXTROSE,"0409-4902, 0409-7517, 0409-6648, 0409-0505","Hospira, Inc.",0fca7d54-4d75-455b-a1d7-d25e31702264,"0409-7517-66, 0409-7517-16, 0409-4902-64, 0409-4902-34, 0409-6648-16, 0409-6648-02, 0409-0505-15, 0409-0505-25","Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-4902-34)",Injection,Unavailable,,,,DEXTROSE MONOHYDRATE,,,Current,Other,Shortage per Manufacturer: Manufacturing Delay,,LX22YL083G,0409-4902-34,844-646-4398,
"Teva Pharmaceuticals USA, Inc.",DOXYCYCLINE HYCLATE,,06/13/2025,New,ORAL,Doxycycline Hyclate Tablet,1650143,,a569ba80-ffea-40b2-9fbe-a42810b1fccb,06/13/2025,HUMAN PRESCRIPTION DRUG,06/13/2025,Anti-Infective,DOXYCYCLINE HYCLATE,0591-5553,"Actavis Pharma, Inc.",0fb9a3f8-9ebb-4c21-8a73-9f082b39039c,"0591-5553-50, 0591-5553-05","Doxycycline Hyclate, Tablet, 100 mg (NDC 0591-5553-05)",Tablet,,,ANDA062421,,DOXYCYCLINE HYCLATE,,,To Be Discontinued,,,,19XTS3T51U,0591-5553-05,800-545-8800,
"Mylan Pharmaceuticals Inc., a Viatris Company",,,02/14/2025,New,,Erythromycin  Topical Gel,,,,02/14/2025,,02/14/2025,"Anti-Infective, Dermatology",,,,,,"Erygel, Topical Gel, 20 mg/1 g (NDC 0378-8075-93)",Topical Gel,,,,,,,,To Be Discontinued,,,,,0378-8075-93,800-796-9526,
Novadaq Technologies,,,08/23/2024,Revised,,Indocyanine Green Injection,,,,08/26/2025,,,"Medical Imaging, Ophthalmology, Other",,,,,,"Spy Agent Green Kit, Injection, 25 mg (NDC 66259-903-14)",Injection,,,,,,,Available,Resolved,,,08/26/2025,,66259-903-14,800-624-4422,
Otsuka ICU Medical LLC,"CALCIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, SODIUM LACTATE",,10/11/2024,Reverified,INTRAVENOUS,Lactated Ringers Injection,"847627, 847630",,d310d170-5eeb-471b-af1a-0e845001d21d,09/17/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other",LACTATED RINGERS,"0990-7953, 0990-7929",ICU Medical Inc.,f0f79123-edc9-43ff-a696-0356b6f03952,"0990-7929-03, 0990-7929-09, 0990-7953-02, 0990-7953-03, 0990-7953-09","Lactated Ringers, Injection, 20 mg/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0990-7953-09)",Injection,Available,,NDA017641,,"SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, AND CALCIUM CHLORIDE",,,Current,,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,"LX22YL083G, 660YQ98I10, TU7HW0W0QT, 451W47IQ8X, M4I0D6VV5M",0990-7953-09,1-866-829-9025 or ProductAvailability@icumed.com,
Chartwell Molecular Holdings LLC,MEFLOQUINE HYDROCHLORIDE,,05/14/2024,Revised,ORAL,Mefloquine Hydrochloride Tablet,835913,,b884d22b-aae7-4f14-9a04-ae4029a229f0,08/21/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,MEFLOQUINE HYDROCHLORIDE,62135-973,"Chartwell RX, LLC",2732839a-191a-570f-e063-6294a90a40a4,"62135-973-25, 62135-973-11","Mefloquine Hydrochloride, Tablet, 250 mg (NDC 62135-973-25)",Tablet,,,ANDA076175,,MEFLOQUINE HYDROCHLORIDE,,Available,Resolved,,,08/21/2025,5Y9L3636O3,62135-973-25,845-268-5000,
Baxter Healthcare,ROCURONIUM BROMIDE,,02/15/2023,Reverified,INTRAVENOUS,Rocuronium Bromide Injection,1234995,,31e15c3f-aefa-4379-b684-7707744fe40d,09/23/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROCURONIUM BROMIDE,"43066-007, 43066-013",Baxter Healthcare Corporation,9e0317de-2d78-4fd8-8926-4c7b476f3ed4,"43066-007-10, 43066-013-10","Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 43066-007-10)",Injection,Available,,ANDA091115,,ROCURONIUM BROMIDE,,,Current,,,,I65MW4OFHZ,43066-007-10,888-229-0001,
Curium US LLC,"SODIUM PYROPHOSPHATE, STANNOUS CHLORIDE",,12/27/2023,Reverified,INTRAVENOUS,Technetium TC-99M Pyrophosphate Kit Injection,,,304b63f4-a32e-4700-805d-5bc9f27e7d6a,09/15/2025,HUMAN PRESCRIPTION DRUG,,Medical Imaging,TECHNESCAN PYP,69945-094,Curium US LLC,3635fabe-0b23-171b-e063-6394a90ae8c1,69945-094-20,"Technescan PYP, Injection, 11.9 mg/10 mL; 3.2 mg/10 mL (NDC 69945-094-20)",Injection,Unavailable,,NDA017538,,TECHNETIUM TC 99M PYROPHOSPHATE,,,Current,Shortage of an active ingredient,Unavailable,,"O352864B8Z, 1BQV3749L5",69945-094-20,888-744-1414,
"Chiesi USA, Inc.",,,04/01/2025,New,,Zileuton Tablet,,,,04/01/2025,,04/01/2025,Pulmonary/Allergy,,,,,,"Zyflo, Tablet, 600 mg (NDC 10122-901-12)",Tablet,,,,,,,,To Be Discontinued,,,,,10122-901-12,888-466-6505,
"Amphastar Pharmaceuticals, Inc.",ATROPINE SULFATE,,01/01/2020,Reverified,INTRAVENOUS,Atropine Sulfate Injection,1190546,,b72d0a82-6163-460f-965a-12f6da47370a,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology, Pediatric",ATROPINE SULFATE,76329-3340,"International Medication Systems, Limited",697aa53c-f31f-463a-a752-d2faaad354db,76329-3340-1,"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 76329-3340-1)",Injection,Available,,ANDA212461,,ATROPINE SULFATE,,,Current,,,,03J5ZE7KA5,76329-3340-1,800-423-4136,
Aurobindo Pharma USA,CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,b1582eb7-af35-45d5-a52e-0e380d08527d,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"59651-723, 59651-722, 59651-724",Aurobindo Pharma Limited,b1582eb7-af35-45d5-a52e-0e380d08527d,"59651-722-01, 59651-722-99, 59651-723-01, 59651-723-99, 59651-724-01, 59651-724-05","Clonazepam, Tablet, 1 mg (NDC 59651-723-99)",Tablet,Available,"N0000175694, M0002356",ANDA075150,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,,,5PE9FDE8GB,59651-723-99,866-850-2876,
GlaxoSmithKline,DAPRODUSTAT,,11/21/2024,New,ORAL,Daprodustat Tablet,"2628215, 2628221, 2628223, 2628225, 2628227, 2628229, 2628231, 2628233, 2628235, 2628237",,d82aa06e-5a33-4844-99b7-4701313455a4,11/21/2024,HUMAN PRESCRIPTION DRUG,11/21/2024,Hematology,JESDUVROQ,"0173-0914, 0173-0897, 0173-0903, 0173-0906, 0173-0911",GlaxoSmithKline LLC,d52a823a-35bd-4c6a-a016-4b4f21a43d7d,"0173-0897-13, 0173-0897-56, 0173-0903-13, 0173-0903-56, 0173-0906-13, 0173-0906-56, 0173-0911-13, 0173-0911-56, 0173-0914-13, 0173-0914-56","Jesduvroq, Tablet, 8 mg (NDC 0173-0914-56)",Tablet,,"N0000194080, N0000194079",NDA216951,,DAPRODUSTAT,Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC],,To Be Discontinued,,Discontinuing for Business Reasons.,,JVR38ZM64B,0173-0914-56,888-825-5249,Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors [MoA]
"Meitheal Pharmaceuticals, Inc.",DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2021,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,309710,,8fa36783-b94d-4084-8c41-40ee64192074,08/19/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE,71288-505,Meitheal Pharmaceuticals Inc.,74e25a75-2d63-4f39-b6d0-a73392bd1040,"71288-505-02, 71288-505-03","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 71288-505-03)",Injection,Available,,ANDA204843,,DEXMEDETOMIDINE,,,Current,,,,1018WH7F9I,71288-505-03,844-824-8426,
"Teva Pharmaceuticals USA, Inc.",ISONIAZID,,11/21/2024,New,ORAL,Isoniazid Tablet,"197832, 311166",,9499f1cf-2f46-4047-8b71-90aee7dee854,11/21/2024,HUMAN PRESCRIPTION DRUG,11/21/2024,Anti-Infective,ISONIAZID,"0555-0071, 0555-0066","Teva Pharmaceuticals USA, Inc.",ead93989-8a7e-4483-917e-388152515e1d,"0555-0066-02, 0555-0071-01, 0555-0071-02","Tablet, 300 mg (NDC 0555-0071-02)",Tablet,,N0000175483,ANDA080937,,ISONIAZID,Antimycobacterial [EPC],,To Be Discontinued,,Product available through 12/03/2024,,V83O1VOZ8L,0555-0071-02,800-545-8800,
Piramal Critical Care Inc.,ROCURONIUM BROMIDE,,02/15/2023,Reverified,INTRAVENOUS,Rocuronium Bromide Injection,,,98255b70-51f9-8d16-e053-2995a90a8f97,09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROCURONIUM,"66794-228, 66794-229",Piramal Critical Care Inc,3f9e12e4-d3c5-fba6-e063-6294a90a7fd6,"66794-229-02, 66794-229-41, 66794-228-02, 66794-228-41","Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 66794-228-41)",Injection,Limited Availability,,ANDA210437,,ROCURONIUM,,,Current,Demand increase for the drug,On allocation,,I65MW4OFHZ,66794-228-41,800-414-1901,
"Teva Pharmaceuticals USA, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Revised,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541365, 541878, 541879, 541892, 541894, 577957, 577960, 577961, 577962, 687043, 687045, 1009145, 1009147",,f22635fe-821d-4cde-aa12-419f8b53db81,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,ADDERALL,"57844-105, 57844-117, 57844-110, 57844-112, 57844-115, 57844-120, 57844-130","Teva Pharmaceuticals USA, Inc.",79af1dc6-c7cf-41b1-a750-e9b47c2187ff,"57844-105-01, 57844-117-01, 57844-110-01, 57844-112-01, 57844-115-01, 57844-120-01, 57844-130-01","Adderall, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 57844-105-01)",Tablet,Available,,ANDA040422,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",57844-105-01,800-545-8800,
Pfizer Inc.,CLINDAMYCIN PHOSPHATE,,03/21/2023,Revised,"INTRAMUSCULAR, INTRAVENOUS",Clindamycin Phosphate Injection,"1737244, 1737245, 1737578, 1737579, 1737581, 1737582",,a0a2eff7-b7de-42fe-8e5a-0cfbed38bb4b,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,CLEOCIN PHOSPHATE,"0009-5095, 0009-3051, 0009-4073",Pharmacia & Upjohn Company LLC,9c0a7367-763b-48c3-95b1-173b74c50f4b,"0009-3051-01, 0009-3051-02, 0009-4073-03, 0009-4073-04, 0009-5095-05, 0009-5095-06","Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL) (NDC 0009-5095-06)",Injection,Limited Availability,,NDA050441,,CLINDAMYCIN PHOSPHATE,,,Current,Other,Limited Supply Available. Next Delivery: April 2026; Estimated Recovery: June 2026,,EH6D7113I8,0009-5095-06,800-533-4535,
"Avet Pharmaceuticals, Inc.",DESIPRAMINE HYDROCHLORIDE,,08/12/2025,New,ORAL,Desipramine Hydrochloride Tablet,"1099288, 1099292, 1099296, 1099300, 1099304, 1099316",,ee14dd2c-c54b-4cd1-a3a0-f7ad5a5a0ed0,08/12/2025,HUMAN PRESCRIPTION DRUG,08/12/2025,Psychiatry,DESIPRAMINE HYDROCHLORIDE,"23155-583, 23155-578, 23155-579, 23155-580, 23155-581, 23155-582",Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.,49984729-ddde-44ed-927b-8a4ba65cefa0,"23155-578-01, 23155-579-01, 23155-580-01, 23155-581-01, 23155-582-01, 23155-583-25","Desipramine Hydrochloride, Tablet, 150 mg (NDC 23155-583-25)",Tablet,,,ANDA207433,,DESIPRAMINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,1Y58DO4MY1,23155-583-25,855-228-9470,
Novartis Pharmaceuticals Corporation,"AMLODIPINE BESYLATE, BENAZEPRIL HYDROCHLORIDE",,06/24/2025,New,ORAL,Amlodipine Besylate; Benazepril Hydrochloride Capsule,"898342, 898344, 898346, 898348, 898353, 898355, 898356, 898358",,94ae6054-b7ae-4212-a567-4f803af8f2c7,06/24/2025,HUMAN PRESCRIPTION DRUG,06/24/2025,Cardiovascular,LOTREL,"0078-0405, 0078-0406, 0078-0364, 0078-0379",Novartis Pharmaceuticals Corporation,b9db75d9-9d1e-4b2d-9876-5f5520feaecc,"0078-0405-05, 0078-0406-05, 0078-0364-05, 0078-0379-05","Lotrel, Capsule, 5 mg; 10 mg (NDC 0078-0405-05)",Capsule,,,NDA020364,,AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE,,,To Be Discontinued,,Permanent discontinuation in the manufacturing of the drug,,"864V2Q084H, N1SN99T69T",0078-0405-05,888-669-6682,
"Hikma Pharmaceuticals USA, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,6740a621-9bec-4178-a4fc-a3fc89f34e0a,07/23/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0054-0375, 0054-0660, 0054-0370, 0054-0371, 0054-0372, 0054-0373, 0054-0374",Hikma Pharmaceuticals USA Inc.,5d119550-4386-4bfa-a5d0-bb18e66191b7,"0054-0660-25, 0054-0370-25, 0054-0371-25, 0054-0372-25, 0054-0373-25, 0054-0374-25, 0054-0375-25","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0054-0375-25)",Capsule,Limited Availability,,ANDA202827,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,Available on allocation,,SJT761GEGS,0054-0375-25,800-631-2174,
Oryza Pharmaceuticals Inc.,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 1009145",,acd27181-a3f3-4c38-85d8-029a4a82e7c2,09/16/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","72516-016, 72516-015, 72516-014, 72516-013, 72516-012, 72516-011",Oryza Pharmaceuticals Inc.,39fb17a2-617d-37dc-e063-6394a90a1be3,"72516-016-01, 72516-015-01, 72516-014-01, 72516-013-01, 72516-012-01, 72516-011-01","Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 72516-016-01)",Tablet,Available,,ANDA210293,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",72516-016-01,855-257-0292,
Baxter Healthcare,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807551, 1807552, 1807627, 1807630, 1807631, 1807632, 1807633, 1807634, 1807639",,f55bd888-5e01-474d-871b-24654c070178,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0338-0049, 0338-0043",Baxter Healthcare Corporation,6ab23768-efd2-4ff1-b336-0dda08dc56e1,"0338-0049-01, 0338-0049-02, 0338-0049-03, 0338-0049-04, 0338-0049-10, 0338-0049-41, 0338-0049-11, 0338-0049-31, 0338-0049-48, 0338-0049-18, 0338-0049-38, 0338-0043-03, 0338-0043-04","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-18)",Injection,,,NDA016677,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0338-0049-18,888-229-0001,
Otsuka ICU Medical LLC,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807548, 1807549, 1807550, 1807551, 1807552, 1807627, 1807630, 1807631, 1807632, 1807633, 1807634, 1807639",,5f372b75-d7a4-471e-8ac6-290040fc84b0,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0990-7983, 0990-7730, 0990-7984, 0990-7985",ICU Medical Inc.,87c57bfa-0bf7-41fd-b954-eb753d5d9d7f,"0990-7730-36, 0990-7730-37, 0990-7983-61, 0990-7983-02, 0990-7983-03, 0990-7983-09, 0990-7983-55, 0990-7983-53, 0990-7984-37, 0990-7984-20, 0990-7984-13, 0990-7984-23, 0990-7984-36, 0990-7985-02, 0990-7985-03, 0990-7985-09","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-09)",Injection,,,NDA016366,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0990-7983-09,1-866-829-9025 or ProductAvailability@icumed.com,
"Avet Pharmaceuticals, Inc.",DESIPRAMINE HYDROCHLORIDE,,08/12/2025,New,ORAL,Desipramine Hydrochloride Tablet,"1099288, 1099292, 1099296, 1099300, 1099304, 1099316",,ee14dd2c-c54b-4cd1-a3a0-f7ad5a5a0ed0,08/12/2025,HUMAN PRESCRIPTION DRUG,08/12/2025,Psychiatry,DESIPRAMINE HYDROCHLORIDE,"23155-579, 23155-578, 23155-580, 23155-581, 23155-582, 23155-583",Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.,49984729-ddde-44ed-927b-8a4ba65cefa0,"23155-578-01, 23155-579-01, 23155-580-01, 23155-581-01, 23155-582-01, 23155-583-25","Desipramine Hydrochloride, Tablet, 25 mg (NDC 23155-579-01)",Tablet,,,ANDA207433,,DESIPRAMINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,1Y58DO4MY1,23155-579-01,855-228-9470,
Otsuka ICU Medical LLC,DEXTROSE MONOHYDRATE,,03/01/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 10% Injection,1795477,,cb578dba-094c-4787-951d-763d12fd06e1,09/17/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,0990-7938,ICU Medical Inc.,68b6e64a-44fb-42d5-8273-297f23b8eefb,0990-7938-19,"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7938-19)",Injection,Available,,NDA018080,,DEXTROSE MONOHYDRATE,,,Current,,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,LX22YL083G,0990-7938-19,1-866-829-9025 or ProductAvailability@icumed.com,
"Teva Pharmaceuticals USA, Inc.","EZETIMIBE, SIMVASTATIN",Decreased Cholesterol Absorption [PE],01/06/2025,New,ORAL,Ezetimibe; Simvastatin Tablet,"476345, 476349, 476350, 476351",,00680bea-d2fb-4362-ba67-e866b732e9ed,01/06/2025,HUMAN PRESCRIPTION DRUG,01/06/2025,Cardiovascular,EZETIMIBE AND SIMVASTATIN,"45963-565, 45963-566, 45963-567, 45963-568","Actavis Pharma, Inc.",bd64aee1-c95f-4767-8d31-af93dd0ab692,"45963-565-30, 45963-565-08, 45963-566-30, 45963-566-08, 45963-567-30, 45963-567-08, 45963-568-30, 45963-568-08","EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 10 mg (NDC 45963-565-08)",Tablet,,"N0000175589, N0000000121, N0000008553, N0000175911",ANDA202968,,EZETIMIBE AND SIMVASTATIN,"HMG-CoA Reductase Inhibitor [EPC], Dietary Cholesterol Absorption Inhibitor [EPC]",,To Be Discontinued,,,,"AGG2FN16EV, EOR26LQQ24",45963-565-08,800-545-8800,Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]
"Hikma Pharmaceuticals USA, Inc.",KETOROLAC TROMETHAMINE,,06/06/2018,Revised,"INTRAMUSCULAR, INTRAVENOUS",Ketorolac Tromethamine Injection,"860092, 1665459, 1665461",,0c2c75c9-ed7b-46a8-9543-429bf2d8f090,07/23/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,KETOROLAC TROMETHAMINE,"0641-6041, 0641-6043, 0641-6042",Hikma Pharmaceuticals USA Inc.,25d6c438-45d2-4162-91c2-b5caa0f86bf3,"0641-6043-01, 0641-6043-25, 0641-6042-01, 0641-6042-25, 0641-6041-01, 0641-6041-25","Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0641-6041-25)",Injection,Unavailable,,ANDA075772,,KETOROLAC TROMETHAMINE,,,Current,Other,Shortage recovery: TBD,,4EVE5946BQ,0641-6041-25,800-631-2174,
Kindos Pharmaceuticals Co. Ltd.,BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,"EPIDURAL, RETROBULBAR",Bupivacaine Hydrochloride Injection,"1724786, 1724787, 1724880, 1724884, 1725078, 1725082",,daec9ee4-b666-485e-a153-4b5e5acc48a1,08/19/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE,"71288-728, 71288-721, 71288-722, 71288-724, 71288-725, 71288-727",Meitheal Pharmaceuticals Inc,b085b86e-d32f-494e-8a4a-3080ff240109,"71288-721-11, 71288-722-32, 71288-724-11, 71288-725-32, 71288-727-11, 71288-728-32","Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32)",Injection,Available,,ANDA216040,,BUPIVACAINE HYDROCHLORIDE,,,Current,,Meitheal Pharmaceuticals is distributor/labeler; product is available,,7TQO7W3VT8,71288-728-32,844-824-8426,
"Fresenius Kabi USA, LLC",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,"EPIDURAL, RETROBULBAR",Bupivacaine Hydrochloride Injection,"1012377, 1012384, 1012413, 1012417, 1724786, 1724787, 1724809, 1724810, 1867594, 1867596, 1867618, 1867620",,bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb,09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,SENSORCAINE MPF,"63323-472, 63323-463, 63323-461, 63323-468","Fresenius Kabi USA, LLC",cc1f6507-eb3e-4398-a1d3-0c56a2099e6b,"63323-472-03, 63323-472-17, 63323-472-01, 63323-472-37, 63323-463-01, 63323-463-57, 63323-461-01, 63323-461-57, 63323-468-02, 63323-468-37, 63323-468-01, 63323-468-17","Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-17)",Injection,Available,,ANDA070554,,BUPIVACAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,"30Q7KI53AK, 7TQO7W3VT8",63323-472-17,888-386-1300,
"Fresenius Kabi USA, LLC",DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795607, 1795609, 1795610, 1795612, 1795616",,576a22d8-5f2f-497e-80ad-1842ca74bb53,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"65219-464, 65219-456, 65219-458, 65219-460, 65219-462","FRESENIUS KABI USA, LLC",efc3b0c9-518a-47db-bb3e-ebdfd4646e9b,"65219-456-05, 65219-456-60, 65219-464-05, 65219-464-50, 65219-458-05, 65219-458-30, 65219-460-05, 65219-460-20, 65219-462-05, 65219-462-10","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-464-50)",Injection,Available,,ANDA207449,,DEXTROSE MONOHYDRATE,,,Current,,Check wholesalers for inventory,,LX22YL083G,65219-464-50,888-386-1300,
"Teva Pharmaceuticals USA, Inc.",HYDROMORPHONE HYDROCHLORIDE,,11/01/2017,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Hydromorphone Hydrochloride Injection,"1724338, 1724340, 1724341",,f0b78db9-a38c-41bb-8233-5e93f7f18c5c,09/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,HYDROMORPHONE HYDROCHLORIDE,"0703-0113, 0703-0110, 0703-0018","Teva Parenteral Medicines, Inc.",c32108cc-7b73-4921-9f9e-54b3d60c1c6e,"0703-0110-01, 0703-0110-03, 0703-0113-01, 0703-0113-03, 0703-0018-01","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0113-03)",Injection,Available,,ANDA078591,,HYDROMORPHONE HYDROCHLORIDE,,,Current,Shortage of an active ingredient,Estimated recovery: December  2025,,L960UP2KRW,0703-0113-03,800-545-8800,
"Assertio Specialty Pharmaceuticals, LLC",METHOTREXATE,,08/29/2025,New,SUBCUTANEOUS,Methotrexate Injection,"1441402, 1441407, 1441411, 1441413, 1441416, 1441418, 1441422, 1441424, 1747179, 1747181, 1747185, 1747187, 1747192, 1747194",,7dcd02d7-1ce0-43fc-8f25-2f0bb0caba2f,08/29/2025,HUMAN PRESCRIPTION DRUG,08/29/2025,Rheumatology,OTREXUP,"82497-012, 82497-010, 82497-015, 82497-017, 82497-020, 82497-022, 82497-025","Otter Pharmaceuticals, LLC",9aaba145-f343-4498-b754-fb7c78181bd7,"82497-010-02, 82497-010-04, 82497-012-02, 82497-012-04, 82497-015-02, 82497-015-04, 82497-017-02, 82497-017-04, 82497-020-02, 82497-020-04, 82497-022-02, 82497-022-04, 82497-025-02, 82497-025-04","Otrexup, Injection, 12.5 mg/.4 mL (NDC 82497-012-04)",Injection,,"N0000175584, N0000000111",NDA204824,,METHOTREXATE,Folate Analog Metabolic Inhibitor [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,YL5FZ2Y5U1,82497-012-04,224-441-6390,Folic Acid Metabolism Inhibitors [MoA]
"Lupin Pharmaceuticals, Inc.",QUINAPRIL HYDROCHLORIDE,,01/19/2023,Reverified,ORAL,Quinapril Hydrochloride Tablet,"312748, 312749, 312750, 314203",,8ded0773-3aec-4e89-9836-d22a5a84abf0,09/18/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,QUINAPRIL,"68180-558, 68180-556, 68180-557, 68180-554, 68180-559","Lupin Pharmaceuticals, Inc.",a9598a21-6f99-4c86-ace6-b5638da2bec8,"68180-556-09, 68180-557-09, 68180-557-03, 68180-558-09, 68180-558-03, 68180-554-09, 68180-554-03, 68180-559-03, 68180-559-09","Quinapril Hydrochloride, Tablet, 20 mg (NDC 68180-558-09)",Tablet,Unavailable,,ANDA077690,,QUINAPRIL,,,Current,Requirements related to complying with good manufacturing practices,,,33067B3N2M,68180-558-09,866-587-4617,
Baxter Healthcare,"CALCIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, SODIUM LACTATE",,10/11/2024,Reverified,INTRAVENOUS,Lactated Ringers Injection,847627,,6acc9f96-7088-45a7-b48f-1a861e3467ab,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other",LACTATED RINGERS AND DEXTROSE,0338-0125,Baxter Healthcare Corporation,8fc5f645-fb02-4ecf-9c07-5d515b96d7ca,"0338-0125-03, 0338-0125-04","Lactated Ringers, Injection, 20 mg/100 mL; 5 g/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0338-0125-03)",Injection,Unavailable,,NDA016679,,"SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, CALCIUM CHLORIDE AND DEXTROSE MONOHYDRATE",,,Current,Discontinuation of the manufacture of the drug,Product Discontinued,,"M4I0D6VV5M, LX22YL083G, 660YQ98I10, 451W47IQ8X, TU7HW0W0QT",0338-0125-03,888-229-0001,
"Fresenius Kabi USA, LLC",LIDOCAINE HYDROCHLORIDE ANHYDROUS,,02/22/2012,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Lidocaine Hydrochloride Injection,"1737562, 1737563, 1737566, 1737567, 1737568, 1737569, 1737570, 1737571, 1737636, 1737637, 1737640, 1737641, 1737763, 1737764",,d5e0d06f-ba1e-44d4-aa89-39d6c146dc23,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",XYLOCAINE MPF,"63323-493, 63323-492, 63323-496","Fresenius Kabi USA, LLC",fa12a8e8-09fd-496f-8cc6-ffe0eb02e2df,"63323-492-08, 63323-492-97, 63323-493-03, 63323-493-97, 63323-493-01, 63323-493-91, 63323-496-03, 63323-496-97","Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-97)",Injection,Unavailable,,NDA006488,,LIDOCAINE HYDROCHLORIDE,,,Current,Demand increase for the drug,Next release not available at this time.,,EC2CNF7XFP,63323-493-97,888-386-1300,
"Hospira, Inc., a Pfizer Company",AZITHROMYCIN MONOHYDRATE,,09/09/2025,New,INTRAVENOUS,Azithromycin Injection,1668238,,d2f4907f-b952-403b-229e-cc5b8327a773,09/09/2025,HUMAN PRESCRIPTION DRUG,09/09/2025,Anti-Infective,AZITHROMYCIN,0409-0144,"Hospira, Inc.",0daee3b8-efec-4ff2-aedf-87035563373f,"0409-0144-21, 0409-0144-11","Azithromycin, Injection, 500 mg Single Dose ADD-Vantage® Glass Vial (NDC 0409-0144-11)",Injection,,,ANDA065500,,AZITHROMYCIN,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,JTE4MNN1MD,0409-0144-11,844-646-4398,
"Hospira, Inc., a Pfizer Company",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Revised,"INFILTRATION, PERINEURAL",Bupivacaine Hydrochloride Injection,"1012377, 1012381, 1012384, 1012388, 1012396, 1012400, 1012404, 1012406, 1672917, 1672919, 1673242, 1673243, 1724786, 1724787, 1724794, 1724796, 1724880, 1724884, 1725044, 1725046, 1725078, 1725079, 1725082, 1725083, 1867594, 1867596, 1867612, 1867614",,67578b56-7540-487e-1fba-481255620e78,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,MARCAINE,"0409-1587, 0409-1559, 0409-1560, 0409-1582, 0409-1610, 0409-1746, 0409-1749, 0409-1752, 0409-1755, 0409-2510, 0409-7535, 0409-1250, 0409-5010, 0409-1530, 0409-0525, 0409-7510, 0409-2253","Hospira, Inc.",b083f440-bfb7-449a-b601-c2f59a6f9dcf,"0409-1559-18, 0409-1559-10, 0409-1559-19, 0409-1559-30, 0409-1560-18, 0409-1560-10, 0409-1560-19, 0409-1560-29, 0409-1582-18, 0409-1582-10, 0409-1582-19, 0409-1582-29, 0409-1587-50, 0409-1610-50, 0409-1746-70, 0409-1746-10, 0409-1746-71, 0409-1746-30, 0409-1749-70, 0409-1749-10, 0409-1749-71, 0409-1749-29, 0409-1752-50, 0409-1755-50, 0409-2510-01, 0409-2510-25, 0409-7535-01, 0409-7535-25, 0409-1250-01, 0409-1250-25, 0409-5010-01, 0409-5010-25, 0409-1530-01, 0409-1530-25, 0409-0525-01, 0409-0525-25, 0409-7510-01, 0409-7510-25, 0409-2253-01, 0409-2253-25","Marcaine, Injection, Marcaine 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1587-50)",Injection,Unavailable,,NDA016964,,BUPIVACAINE HYDROCHLORIDE,,,Current,Other,Next Delivery: August 2025; Estimated Recovery: December 2025,,"30Q7KI53AK, 7TQO7W3VT8",0409-1587-50,844-646-4398,
"Hikma Pharmaceuticals USA, Inc.",CEFOTAXIME SODIUM,,02/17/2015,Reverified,"INTRAMUSCULAR, INTRAVENOUS","Cefotaxime Sodium Powder, for Solution","309068, 1656313, 1656318",,ed23b6bc-32c7-4c50-a53d-313ae78e5623,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",CEFOTAXIME,"0143-9930, 0143-9931, 0143-9933",Hikma Pharmaceuticals USA Inc.,7e0897ec-2275-4438-9cc5-4c951e52ad97,"0143-9931-01, 0143-9931-25, 0143-9933-01, 0143-9933-25, 0143-9930-01, 0143-9930-10","Cefotaxime Sodium, Powder, for Solution, 500 mg (NDC 0143-9930-10)","Powder, For Solution",Unavailable,,ANDA065072,,CEFOTAXIME,,,Current,Demand increase for the drug,Shortage duration is unknown at this time.,,258J72S7TZ,0143-9930-10,800-631-2174,
Rubicon Research Private Limited,CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"72888-152, 72888-153, 72888-154",Advagen Pharma Ltd,36cf156e-5980-a21b-e063-6294a90ab3a0,"72888-152-30, 72888-152-01, 72888-152-05, 72888-152-00, 72888-153-30, 72888-153-01, 72888-153-05, 72888-153-00, 72888-154-30, 72888-154-01, 72888-154-05, 72888-154-00","Clonazepam, Tablet, .5 mg (NDC 72888-152-01)",Tablet,Available,"N0000175694, M0002356",ANDA075468,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,Marketed by Advagen Pharma Ltd.,,5PE9FDE8GB,72888-152-01,sales@advagenpharma.com,
"Hikma Pharmaceuticals USA, Inc.",MORPHINE SULFATE,,11/03/2017,Reverified,"EPIDURAL, INTRATHECAL, INTRAVENOUS",Morphine Sulfate Injection,"892473, 892489, 1728783, 1728800",,ebb18761-e5c4-4238-bb84-f9549f500210,07/23/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,DURAMORPH,"0641-6019, 0641-6020",Hikma Pharmaceuticals USA Inc.,d8bb0ae2-68bc-40ff-ad67-867bb8b71bc7,"0641-6020-01, 0641-6020-10, 0641-6019-01, 0641-6019-10","Duramorph (Morphine Sulfate Injection, USP), Injection, 1 mg/1 mL (NDC 0641-6019-10)",Injection,Available,,NDA018565,,MORPHINE SULFATE,,,Current,,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,X3P646A2J0,0641-6019-10,800-631-2174,
Sun Pharmaceutical Industries Limited,CLINDAMYCIN HYDROCHLORIDE,,12/05/2024,New,ORAL,Clindamycin Hydrochloride Capsule,"197518, 284215",,1dbd8448-c1e5-46df-8060-50ef82380445,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Anti-Infective,CLINDAMYCIN HYDROCHLORIDE,"63304-693, 63304-692","Sun Pharmaceutical Industries, Inc.",339366d4-2060-1c29-e063-6394a90a1cb7,"63304-692-01, 63304-692-05, 63304-692-77, 63304-692-03, 63304-693-16, 63304-693-01, 63304-693-03, 63304-693-05, 63304-693-77, 63304-693-11, 63304-693-62","Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-77)",Capsule,,,ANDA065061,,CLINDAMYCIN HYDROCHLORIDE,,,To Be Discontinued,,Discontinuing for business reasons,,T20OQ1YN1W,63304-693-77,800-818-4555,
Sagent Pharmaceuticals,LEUCOVORIN CALCIUM,,01/01/2012,Revised,"INTRAMUSCULAR, INTRAVENOUS",Leucovorin Calcium Injection,"237788, 1803930, 1803932, 1803937",,9d0e5356-ff39-4a8e-944c-e808a21ef4b2,07/08/2025,HUMAN PRESCRIPTION DRUG,,"Oncology, Pediatric",LEUCOVORIN CALCIUM,"25021-815, 25021-813, 25021-814, 25021-816",Sagent Pharmaceuticals,ff2ba160-e2f9-4ab9-9e67-2409f02c923e,"25021-813-10, 25021-814-30, 25021-815-30, 25021-816-30","Leucovorin Calcium, Injection, 200 mg/20 mL (NDC 25021-815-30)",Injection,,,ANDA200753,,LEUCOVORIN CALCIUM,,Available,Resolved,,,07/08/2025,RPR1R4C0P4,25021-815-30,866-625-1618,
"Fresenius Kabi USA, LLC",LEUCOVORIN CALCIUM,,03/23/2018,Revised,"INTRAMUSCULAR, INTRAVENOUS",Leucovorin Calcium Injection,"2099993, 2104714",,"d5d4f0fd-7520-43a9-9acc-f7e117e1f6ee, 4b72d1fd-f389-45d9-b43b-510b45c92263",07/08/2025,HUMAN PRESCRIPTION DRUG,,"Oncology, Pediatric",LEUCOVORIN CALCIUM,63323-631,"Fresenius Kabi USA, LLC","d1c72e5d-c25e-4b9c-b3dc-a8d0b746db3f, a0d41f71-6197-4c9a-8cd2-217945cb722b","63323-631-10, 63323-631-50","Leucovorin Calcium, Injection, 10 mg/1 mL (NDC 63323-631-10)",Injection,,,"ANDA207241, ANDA207226",,LEUCOVORIN CALCIUM,,Available,Resolved,,,07/08/2025,RPR1R4C0P4,63323-631-10,888-386-1300,
"Teva Pharmaceuticals USA, Inc.",PRAVASTATIN SODIUM,,06/13/2025,New,ORAL,Pravastatin Sodium Tablet,"904458, 904467, 904475",,99e0e848-f8f3-4b42-b880-8fbc42633948,06/13/2025,HUMAN PRESCRIPTION DRUG,06/13/2025,Cardiovascular,PRAVASTATIN SODIUM,"0093-7201, 0093-0771, 0093-7202","Teva Pharmaceuticals USA, Inc.",72579e23-23ef-4ab7-ad64-24d5ea7997eb,"0093-0771-98, 0093-0771-10, 0093-7201-98, 0093-7201-10, 0093-7202-98, 0093-7202-10","Pravastatin Sodium, Tablet, 20 mg (NDC 0093-7201-98)",Tablet,,,ANDA076056,,PRAVASTATIN SODIUM,,,To Be Discontinued,,,,3M8608UQ61,0093-7201-98,800-545-8800,
"Fresenius Kabi USA, LLC",DEXAMETHASONE SODIUM PHOSPHATE,,02/08/2019,Reverified,"INTRA-ARTICULAR, INTRALESIONAL, INTRAMUSCULAR, INTRAVENOUS, SOFT TISSUE",Dexamethasone Sodium Phosphate Injection,1812095,,88d25d19-acff-477b-86c8-9797782045b8,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Other, Pulmonary/Allergy, Rheumatology",DEXAMETHASONE SODIUM PHOSPHATE,76045-106,"Fresenius Kabi USA, LLC",916ef348-1e5b-40b4-9d12-508fc2ce567c,76045-106-10,"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-106-10)",Injection,Unavailable,,ANDA203129,,DEXAMETHASONE SODIUM PHOSPHATE,,,Current,Demand increase for the drug,Not available at this time.,,AI9376Y64P,76045-106-10,888-386-1300,
"Sun Pharmaceutical Industries, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Revised,ORAL,"Lisdexamfetamine Dimesylate Tablet, Chewable","854830, 854834, 854838, 854842, 854846, 854850, 1593856, 1871456, 1871460, 1871462, 1871464, 1871466, 1871468",,da3148af-f9b6-4725-adae-3595b4c7dc4b,09/22/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"57664-086, 57664-047, 57664-046, 57664-048, 57664-049, 57664-050, 57664-051, 57664-052, 57664-083, 57664-084, 57664-085, 57664-087, 57664-088","Sun Pharmaceutical Industries, Inc.",0b77417a-5789-8818-e063-6294a90ad2e3,"57664-047-88, 57664-046-88, 57664-048-88, 57664-049-88, 57664-050-88, 57664-051-88, 57664-052-88, 57664-083-88, 57664-084-88, 57664-085-88, 57664-086-88, 57664-087-88, 57664-088-88","Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 57664-086-88)","Tablet, Chewable",Limited Availability,,ANDA214134,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Other,Available Q3 2025,,SJT761GEGS,57664-086-88,800-818-4555,
Accord Healthcare Inc.,NALTREXONE HYDROCHLORIDE,,02/29/2024,Reverified,ORAL,Naltrexone Hydrochloride Tablet,1483744,,49aa3d6d-2270-4615-aafa-b440859ab870,09/16/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,NALTREXONE HYDROCHLORIDE,16729-081,"Accord Healthcare, Inc.",116829bb-2104-3117-e063-6294a90afdb8,"16729-081-10, 16729-081-01, 16729-081-16, 16729-081-17","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 16729-081-01)",Tablet,Available,,ANDA091205,,NALTREXONE HYDROCHLORIDE,,,Current,,,,Z6375YW9SF,16729-081-01,"866-941-7875, option 2",
"Epic Pharma, LLC",RIFAMPIN,,12/22/2021,Reverified,ORAL,Rifampin Capsule,"198201, 198202",,0391f1e1-70d4-4b15-8b58-055bb6a385b8,09/18/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,RIFAMPIN,"42806-801, 42806-799","EPIC PHARMA, LLC",a4ac02e8-68ac-4e79-8ca5-0939dd002c87,"42806-801-30, 42806-801-01, 42806-799-30, 42806-799-60, 42806-799-01, 42806-799-05","Rifampin, Capsule, 150 mg (NDC 42806-801-30)",Capsule,Available,"N0000175500, M0019113",ANDA064150,Rifamycins [CS],RIFAMPIN,Rifamycin Antibacterial [EPC],,Current,,,,VJT6J7R4TR,42806-801-30,(718) 276-8600 ext. 3,
"Upsher-Smith Laboratories, LLC",DIVALPROEX SODIUM,,04/28/2025,New,ORAL,"Divalproex Sodium Tablet, Delayed Release","1099625, 1099678, 1099870",,02304a23-4a5f-47bc-9687-4044b43f7a20,04/28/2025,HUMAN PRESCRIPTION DRUG,04/28/2025,Neurology,DIVALPROEX SODIUM,"0832-7123, 0832-7122, 0832-7124","Upsher-Smith Laboratories, LLC",38e51a59-5802-77a6-e063-6394a90af6c6,"0832-7122-11, 0832-7122-15, 0832-7123-11, 0832-7123-15, 0832-7123-89, 0832-7123-01, 0832-7124-11, 0832-7124-15, 0832-7124-89, 0832-7124-01","Divalproex Sodium, Tablet, Delayed Release, 250 mg (NDC 0832-7123-01)",Tablet,,,ANDA078182,,DIVALPROEX SODIUM,,,To Be Discontinued,,Discontinuation of manufacture of drug based on business decision.,,644VL95AO6,0832-7123-01,800-654-2299,
Gland Pharma Limited,,,04/02/2020,Reverified,,Midazolam Hydrochloride Injection,,,,09/29/2025,,,"Anesthesia, Neurology",,,,,,"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 70860-601-10)",Injection,Available,,,,,,,Current,Other,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,,70860-601-10,Athenex: 855-273-0154; Alvogen: 973-532-7840,
"Hospira, Inc., a Pfizer Company",MORPHINE SULFATE,,10/31/2017,Reverified,INTRAVENOUS,Morphine Sulfate Injection,,,ee8057d1-ed12-4e18-9efa-d83504abf612,08/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,MORPHINE SULFATE,"0409-1896, 0409-2022","Hospira, Inc.",47aaa2d4-32ee-4ba8-bb5e-b48ffae6c72e,"0409-1896-20, 0409-2022-01","Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)",Injection,Available,,NDA202515,,MORPHINE SULFATE,,,Current,,,01/03/2025,X3P646A2J0,0409-1896-20,844-646-4398,
"Lupin Pharmaceuticals, Inc.",RIFAMPIN,,12/22/2021,Reverified,ORAL,Rifampin Capsule,,,b56004f0-f23d-47f6-80c7-39884fccbccc,09/18/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,RIFAMPIN,"68180-659, 68180-658","Lupin Pharmaceuticals, Inc.",751434c4-f772-4821-899c-3ce2e44be6fe,"68180-658-06, 68180-658-01, 68180-659-06, 68180-659-07, 68180-659-01","Rifampin, Capsule, 300 mg (NDC 68180-659-06)",Capsule,Available,"N0000175500, M0019113",ANDA090034,Rifamycins [CS],RIFAMPIN,Rifamycin Antibacterial [EPC],,Current,,,,VJT6J7R4TR,68180-659-06,866-587-4617,
Eugia US LLC,ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Revised,"EPIDURAL, INFILTRATION, PERINEURAL",Ropivacaine Hydrochloride Injection,"905189, 1734084, 1734090, 1734207, 1734347, 1734475, 1734483",,3763b7b6-da49-4658-b93d-28f5da24d09e,09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROPIVACAINE HYDROCHLORIDE,"55150-197, 55150-195, 55150-196, 55150-198, 55150-199, 55150-200, 55150-201",Eugia US LLC,34725b26-d6e9-4d1b-95a0-da03764cc102,"55150-195-20, 55150-196-99, 55150-197-20, 55150-198-30, 55150-199-20, 55150-200-10, 55150-201-20","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-197-20)",Injection,Available,,ANDA205612,,ROPIVACAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,V910P86109,55150-197-20,888-238-7880,
"Laboratorios Grifols, S.A.",SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807631, 1807632, 1807633, 1807634, 1807639",,eb811d79-fdb8-1f1a-c2ad-1cc4bfc7eadf,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,76297-001,LABORATORIOS GRIFOLS SA,ff5ef1ef-2a0d-476d-8483-ffd7cd47c635,"76297-001-12, 76297-001-11, 76297-001-22, 76297-001-21, 76297-001-32, 76297-001-31, 76297-001-02, 76297-001-01, 76297-001-42, 76297-001-41, 76297-001-52, 76297-001-51, 76297-001-62, 76297-001-61, 76297-001-72, 76297-001-71, 76297-001-82, 76297-001-81, 76297-001-92, 76297-001-91","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 76297-001-41)",Injection,,,ANDA207956,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,76297-001-41,800-848-0462,
Torrent Pharma Inc.,,,06/13/2025,New,,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,,,,06/13/2025,,06/13/2025,Cardiovascular,,,,,,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 25 mg; 40 mg (NDC 13668-382-90)",Tablet,,,,,,,,To Be Discontinued,,A business decision was made to discontinue manufacture of the product.,,,13668-382-90,908-280-3333,
Genus Lifesciences,ISONIAZID,,07/01/2025,New,ORAL,Isoniazid Tablet,"197832, 311166",,f0b46d1d-2300-457d-a7bd-a88a3f8d2235,07/01/2025,HUMAN PRESCRIPTION DRUG,07/01/2025,Anti-Infective,ISONIAZID,"64950-217, 64950-216",Genus Lifesciences,6ea58bc8-a5a8-47a1-81e1-f769924e1502,"64950-216-10, 64950-217-03, 64950-217-10","Isoniazid, Tablet, 300 mg (NDC 64950-217-03)",Tablet,,N0000175483,ANDA080937,,ISONIAZID,Antimycobacterial [EPC],,To Be Discontinued,,Product expected to be available until August 2025.,,V83O1VOZ8L,64950-217-03,610-782-9780,
SpecGx LLC,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,806a1c15-0842-4787-b2ad-09a21fd96b37,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0406-5114, 0406-5111, 0406-5112, 0406-5113, 0406-5115, 0406-5116, 0406-5117",SpecGx LLC,3ffc0695-83f7-4898-9fd7-451c0989cfe0,"0406-5111-01, 0406-5112-01, 0406-5113-01, 0406-5114-01, 0406-5115-01, 0406-5116-01, 0406-5117-01","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0406-5114-01)",Capsule,Limited Availability,,ANDA211840,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,Allocation to all customers.,,SJT761GEGS,0406-5114-01,800-325-8888,
Baxter Healthcare,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807551, 1807552, 1807627, 1807630, 1807631, 1807632, 1807633, 1807634, 1807639",,f55bd888-5e01-474d-871b-24654c070178,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0338-0049, 0338-0043",Baxter Healthcare Corporation,6ab23768-efd2-4ff1-b336-0dda08dc56e1,"0338-0049-01, 0338-0049-02, 0338-0049-03, 0338-0049-04, 0338-0049-10, 0338-0049-41, 0338-0049-11, 0338-0049-31, 0338-0049-48, 0338-0049-18, 0338-0049-38, 0338-0043-03, 0338-0043-04","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-03)",Injection,,,NDA016677,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0338-0049-03,888-229-0001,
"Hikma Pharmaceuticals USA, Inc.",DEXAMETHASONE SODIUM PHOSPHATE,,02/08/2019,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Dexamethasone Sodium Phosphate Injection,"309696, 1116927, 1812194",,0277cc0a-2fd4-4605-a310-b613be84ee26,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Other, Pulmonary/Allergy, Rheumatology",DEXAMETHASONE SODIUM PHOSPHATE,"0641-0367, 0641-6145, 0641-6146",Hikma Pharmaceuticals USA Inc.,84665497-7e82-4733-bcfd-3177817ac0b3,"0641-0367-21, 0641-0367-25, 0641-6145-01, 0641-6145-25, 0641-6146-01, 0641-6146-10, 0641-6146-25","Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 0641-0367-25)",Injection,Available,,ANDA087702,,DEXAMETHASONE SODIUM PHOSPHATE,,,Current,,Currently available.  Additional product will be made available as it is released.,,AI9376Y64P,0641-0367-25,800-631-2174,
"Hospira, Inc., a Pfizer Company",DOPAMINE HYDROCHLORIDE,,11/06/2017,Revised,INTRAVENOUS,Dopamine Hydrochloride Injection,"1292887, 1743877, 1743879",,08f23f6e-150d-45ea-098e-f2edf64c21a1,08/15/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,DOPAMINE HYDROCHLORIDE IN DEXTROSE,"0409-7810, 0409-7809","Hospira, Inc.",3b4d4d9d-5e19-420f-a447-1ad8346844d9,"0409-7809-11, 0409-7809-22, 0409-7809-31, 0409-7809-24, 0409-7810-11, 0409-7810-22","Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-7810-22)",Injection,Unavailable,,NDA018826,,DOPAMINE HYDROCHLORIDE IN DEXTROSE,,,Current,Other,Next Delivery: October 2025; Estimated Recovery: December 2025,,7L3E358N9L,0409-7810-22,844-646-4398,
"Fresenius Kabi USA, LLC",HYDROMORPHONE HYDROCHLORIDE,,10/31/2017,Reverified,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Hydromorphone Hydrochloride Injection,"897653, 897753, 1724276, 1724338, 1724340, 1724341",,e034eb96-03e0-46e1-8b92-5e1f94555e7b,09/18/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,HYDROMORPHONE HYDROCHLORIDE,"63323-851, 63323-852, 63323-853, 63323-854","Fresenius Kabi USA, LLC",9e8522c6-595c-46f9-bb25-272aa4683e0f,"63323-851-03, 63323-851-10, 63323-851-07, 63323-851-15, 63323-851-50, 63323-852-03, 63323-852-25, 63323-853-03, 63323-853-25, 63323-854-03, 63323-854-10","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-15)",Injection,Unavailable,,NDA019034,,HYDROMORPHONE HYDROCHLORIDE,,,Current,Other,Backordered. Next release not available at this time. Check wholesaler for inventory.,,L960UP2KRW,63323-851-15,888-386-1300,
Alvogen,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,7f2dd6ee-3363-c87c-9693-ed838942556c,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"47781-564, 47781-562, 47781-563, 47781-565, 47781-566, 47781-567, 47781-568",Alvogen Inc.,9114d946-92cb-c19d-c6f2-aef77294461f,"47781-562-01, 47781-563-01, 47781-564-01, 47781-565-01, 47781-566-01, 47781-567-01, 47781-568-01","Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 47781-564-01)",Capsule,Available,,ANDA214547,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,47781-564-01,844-842-8672 and email: CustomerService-US@alvogen.com,
Novadoz Pharmaceuticals LLC,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Revised,ORAL,"Lisdexamfetamine Dimesylate Tablet, Chewable","1871456, 1871460, 1871462, 1871464, 1871466, 1871468",,a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"72205-135, 72205-132, 72205-133, 72205-134, 72205-136, 72205-137",Novadoz Pharmaceuticals LLC,a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811,"72205-132-91, 72205-133-91, 72205-134-91, 72205-135-91, 72205-136-91, 72205-137-91","Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 72205-135-91)","Tablet, Chewable",Available,,ANDA218306,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,,,SJT761GEGS,72205-135-91,(855) 668-2369; customerservice@novadozpharma.com,
Janssen Pharmaceuticals,METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Reverified,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release","1091155, 1091157, 1091170, 1091172, 1091185, 1091187, 1091210, 1091212",,1a88218c-5b18-4220-8f56-526de1a276cd,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,CONCERTA,"50458-586, 50458-585, 50458-588, 50458-587","Janssen Pharmaceuticals, Inc.",23987e85-013d-3aaa-e063-6394a90a1f2d,"50458-585-01, 50458-588-01, 50458-586-01, 50458-587-01","Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01)",Tablet,Available,,NDA021121,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,,,,4B3SC438HI,50458-586-01,800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET,
"Somerset Therapeutics, LLC",DEXAMETHASONE SODIUM PHOSPHATE,,02/08/2019,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Dexamethasone Sodium Phosphate Injection,1812079,,799028e2-c0e4-494f-89ff-1b786babc34a,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Other, Pulmonary/Allergy, Rheumatology",DEXAMETHASONE SODIUM PHOSPHATE,70069-021,"Somerset Therapeutics, LLC",73618326-ff56-4a30-9d6d-6b019b61c2cd,"70069-021-01, 70069-021-25","Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 70069-021-25)",Injection,Available,,ANDA207442,,DEXAMETHASONE SODIUM PHOSPHATE,,,Current,,,,AI9376Y64P,70069-021-25,732-554-1019,
"Lannett Company, Inc.",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Revised,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release","2001564, 2001565, 2001566, 2001568",,3d1f5aff-5d39-496c-b5ed-7f3c70ec641c,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE HYDROCHLORIDE,"62175-311, 62175-310, 62175-312, 62175-313","Lannett Company, Inc.",fd0e4ddf-c516-4464-aeca-eb1d3bd24667,"62175-310-37, 62175-311-37, 62175-312-37, 62175-313-37","Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37)",Tablet,Unavailable,,ANDA091695,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,Shortage of an active ingredient,Unavailable,,4B3SC438HI,62175-311-37,844-834-0530,
"Fresenius Kabi USA, LLC",MIDAZOLAM HYDROCHLORIDE,,04/02/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Midazolam Hydrochloride Injection,"311700, 311702",,a91ce254-14a3-4cbf-8ab8-5da252aa3fdc,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology",MIDAZOLAM,"63323-411, 63323-412","Fresenius Kabi USA, LLC",9814447b-a93e-42ad-b57e-5db0a5b7f552,"63323-411-22, 63323-411-27, 63323-411-15, 63323-411-12, 63323-411-18, 63323-411-25, 63323-411-13, 63323-411-10, 63323-412-18, 63323-412-25, 63323-412-03, 63323-412-02, 63323-412-06, 63323-412-05, 63323-412-13, 63323-412-10","Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-12)",Injection,Available,,ANDA075154,,MIDAZOLAM HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,W7TTW573JJ,63323-411-12,888-386-1300,
"Hikma Pharmaceuticals USA, Inc.",SODIUM CHLORIDE,,06/21/2018,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Sodium Chloride 0.9% Injection,"1807636, 1807637",,e5ee8caa-b6ca-45ba-98fb-8305e6282141,08/08/2025,HUMAN PRESCRIPTION DRUG,,Other,SODIUM CHLORIDE,"0641-0497, 0641-6144",Hikma Pharmaceuticals USA Inc.,0950e98d-bfec-40e8-9f56-ba90e0d6e8c8,"0641-0497-17, 0641-0497-25, 0641-6144-01, 0641-6144-25","Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 0641-0497-25)",Injection,,,ANDA201833,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0641-0497-25,800-631-2174,
"Hospira, Inc., a Pfizer Company",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,"EPIDURAL, RETROBULBAR",Bupivacaine Hydrochloride Injection,"1012377, 1012381, 1012384, 1012388, 1012396, 1012400, 1012404, 1012406, 1672917, 1672919, 1673242, 1673243, 1724786, 1724787, 1724794, 1724796, 1724880, 1724884, 1725044, 1725046, 1725078, 1725079, 1725082, 1725083, 1867594, 1867596, 1867612, 1867614",,67578b56-7540-487e-1fba-481255620e78,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,MARCAINE,"0409-1582, 0409-1559, 0409-1560, 0409-1587, 0409-1610, 0409-1746, 0409-1749, 0409-1752, 0409-1755, 0409-2510, 0409-7535, 0409-1250, 0409-5010, 0409-1530, 0409-0525, 0409-7510, 0409-2253","Hospira, Inc.",b083f440-bfb7-449a-b601-c2f59a6f9dcf,"0409-1559-18, 0409-1559-10, 0409-1559-19, 0409-1559-30, 0409-1560-18, 0409-1560-10, 0409-1560-19, 0409-1560-29, 0409-1582-18, 0409-1582-10, 0409-1582-19, 0409-1582-29, 0409-1587-50, 0409-1610-50, 0409-1746-70, 0409-1746-10, 0409-1746-71, 0409-1746-30, 0409-1749-70, 0409-1749-10, 0409-1749-71, 0409-1749-29, 0409-1752-50, 0409-1755-50, 0409-2510-01, 0409-2510-25, 0409-7535-01, 0409-7535-25, 0409-1250-01, 0409-1250-25, 0409-5010-01, 0409-5010-25, 0409-1530-01, 0409-1530-25, 0409-0525-01, 0409-0525-25, 0409-7510-01, 0409-7510-25, 0409-2253-01, 0409-2253-25","Marcaine, Injection, Marcaine 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1582-29)",Injection,Available,,NDA016964,,BUPIVACAINE HYDROCHLORIDE,,,Current,,,,"30Q7KI53AK, 7TQO7W3VT8",0409-1582-29,844-646-4398,
"Fresenius Kabi USA, LLC","EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE ANHYDROUS",,10/14/2016,Reverified,"INFILTRATION, PERINEURAL","Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","1010033, 1010035, 1010671, 1010673, 1010688, 1010692, 1010745, 1010749, 1010751, 1010755, 1010759, 1010763, 1010900, 1010902, 1737343, 1737345, 1737562, 1737563, 1737566, 1737567, 1737568, 1737569, 1737570, 1737571, 1737757, 1737758, 1737761, 1737762, 1867938, 1867940, 1867943, 1867944, 1867992, 1867993, 1867996, 1867997, 1868028, 1868029",,"ba082c2f-64f4-419d-9c88-74f203316e17, 4dd52202-8eef-4136-92dd-ada573b7cf74",09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",XYLOCAINE,"63323-482, 63323-492, 63323-491, 63323-495, 63323-485, 63323-486, 63323-484, 63323-489, 63323-488, 63323-481, 63323-483, 63323-487","Fresenius Kabi USA, LLC","ea480a68-5927-4278-9deb-2956961da428, 0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33","63323-492-04, 63323-492-27, 63323-492-09, 63323-492-57, 63323-492-07, 63323-492-37, 63323-492-03, 63323-492-31, 63323-491-01, 63323-491-57, 63323-495-09, 63323-495-27, 63323-495-04, 63323-495-07, 63323-485-01, 63323-485-27, 63323-485-03, 63323-485-57, 63323-486-01, 63323-486-17, 63323-486-02, 63323-486-27, 63323-486-05, 63323-486-57, 63323-484-57, 63323-489-02, 63323-489-27, 63323-489-03, 63323-489-21, 63323-489-01, 63323-489-17, 63323-488-07, 63323-488-37, 63323-488-03, 63323-488-31, 63323-488-01, 63323-488-17, 63323-481-01, 63323-481-57, 63323-483-03, 63323-483-27, 63323-483-01, 63323-483-57, 63323-482-01, 63323-482-17, 63323-482-03, 63323-482-27, 63323-482-05, 63323-482-57, 63323-487-01, 63323-487-17, 63323-487-07, 63323-487-37, 63323-487-03, 63323-487-31, 63323-492-41, 63323-492-16, 63323-492-43, 63323-492-36, 63323-492-45, 63323-492-26, 63323-485-41, 63323-485-26, 63323-486-41, 63323-486-26, 63323-482-41, 63323-482-26, 63323-495-41, 63323-495-26","Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-17)",Injection,Available,,NDA006488,,"LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE",,,Current,,Check wholesalers for inventory,,"EC2CNF7XFP, 30Q7KI53AK",63323-482-17,888-386-1300,
"Fresenius Kabi USA, LLC","EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE ANHYDROUS",,10/14/2016,Reverified,"INFILTRATION, PERINEURAL","Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","1010033, 1010035, 1010671, 1010673, 1010688, 1010692, 1010745, 1010749, 1010751, 1010755, 1010759, 1010763, 1010900, 1010902, 1737343, 1737345, 1737562, 1737563, 1737566, 1737567, 1737568, 1737569, 1737570, 1737571, 1737757, 1737758, 1737761, 1737762, 1867938, 1867940, 1867943, 1867944, 1867992, 1867993, 1867996, 1867997, 1868028, 1868029",,ba082c2f-64f4-419d-9c88-74f203316e17,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",XYLOCAINE,"63323-481, 63323-492, 63323-491, 63323-495, 63323-485, 63323-486, 63323-484, 63323-489, 63323-488, 63323-483, 63323-482, 63323-487","Fresenius Kabi USA, LLC",ea480a68-5927-4278-9deb-2956961da428,"63323-492-04, 63323-492-27, 63323-492-09, 63323-492-57, 63323-492-07, 63323-492-37, 63323-492-03, 63323-492-31, 63323-491-01, 63323-491-57, 63323-495-09, 63323-495-27, 63323-495-04, 63323-495-07, 63323-485-01, 63323-485-27, 63323-485-03, 63323-485-57, 63323-486-01, 63323-486-17, 63323-486-02, 63323-486-27, 63323-486-05, 63323-486-57, 63323-484-57, 63323-489-02, 63323-489-27, 63323-489-03, 63323-489-21, 63323-489-01, 63323-489-17, 63323-488-07, 63323-488-37, 63323-488-03, 63323-488-31, 63323-488-01, 63323-488-17, 63323-481-01, 63323-481-57, 63323-483-03, 63323-483-27, 63323-483-01, 63323-483-57, 63323-482-01, 63323-482-17, 63323-482-03, 63323-482-27, 63323-482-05, 63323-482-57, 63323-487-01, 63323-487-17, 63323-487-07, 63323-487-37, 63323-487-03, 63323-487-31","Xylocaine, Injection, .005 mg/1 mL; 5 mg/1 mL (NDC 63323-481-57)",Injection,Available,,NDA006488,,"LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE",,,Current,,Check wholesalers for inventory,,"EC2CNF7XFP, 30Q7KI53AK",63323-481-57,888-386-1300,
"Mylan Pharmaceuticals Inc., a Viatris Company",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,efbde0f6-b848-4664-b741-c6c630e66108,09/17/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0378-6854, 0378-6855, 0378-6856, 0378-6857, 0378-6858, 0378-6859, 0378-6860",Mylan Pharmaceuticals Inc.,2dfa8600-1b2a-47e8-b58d-c9681b8795cb,"0378-6854-77, 0378-6855-77, 0378-6856-77, 0378-6857-77, 0378-6858-77, 0378-6859-77, 0378-6860-77","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0378-6854-77)",Capsule,Available,,ANDA202835,,LISDEXAMFETAMINE,,,Current,,,,SJT761GEGS,0378-6854-77,800-796-9526,
"Hospira, Inc., a Pfizer Company",ATROPINE SULFATE,,01/01/2012,Revised,INTRAVENOUS,Atropine Sulfate Injection,"1190546, 1190551, 1190552",,ad8916e7-206e-409e-2582-30d072845dd4,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology, Pediatric",ATROPINE SULFATE,"0409-4911, 0409-1630, 0409-9630, 0409-4910","Hospira, Inc.",9211a9e9-35d0-457d-ac95-4ad43ea6bf28,"0409-1630-15, 0409-1630-10, 0409-9630-15, 0409-9630-05, 0409-4910-11, 0409-4910-34, 0409-4911-11, 0409-4911-34","Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-4911-34)",Injection,Unavailable.,,NDA021146,,ATROPINE SULFATE,,,Current,Other,Next Delivery: January 2026; Estimated Recovery: March 2026,,03J5ZE7KA5,0409-4911-34,844-646-4398,
Baxter Healthcare,"ALANINE, ARGININE, GLYCINE, HISTIDINE, ISOLEUCINE, LEUCINE, LYSINE HYDROCHLORIDE, METHIONINE, PHENYLALANINE, PROLINE, SERINE, THREONINE, TRYPTOPHAN, TYROSINE, VALINE",,12/08/2020,Revised,INTRAVENOUS,Amino Acid Injection,"801644, 801648",,8543b5be-0f43-4891-9e56-d7c39fe839b5,09/23/2025,HUMAN PRESCRIPTION DRUG,,Gastroenterology,TRAVASOL,0338-0644,Baxter Healthcare Corporation,e0279078-016d-48fd-8de1-c894422b33ff,"0338-0644-03, 0338-0644-04, 0338-0644-06","Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-04)",Injection,Available,"N0000175780, M0000922",NDA018931,Amino Acids [CS],"LEUCINE, PHENYLALANINE, LYSINE HYDROCHLORIDE, METHIONINE, ISOLEUCINE, VALINE, HISTIDINE, THREONINE, TRYPTOPHAN, ALANINE, GLYCINE, ARGININE, PROLINE, TYROSINE, SERINE",Amino Acid [EPC],,Current,,,,"OF5P57N2ZX, 94ZLA3W45F, TE7660XO1C, 4QD397987E, 04Y7590D77, GMW67QNF9C, JNJ23Q2COM, AE28F7PNPL, 47E5O17Y3R, 9DLQ4CIU6V, 452VLY9402, 2ZD004190S, 8DUH1N11BX, 42HK56048U, HG18B9YRS7",0338-0644-04,888-229-0001,
"Teva Pharmaceuticals USA, Inc.",,,01/06/2025,New,,Ezetimibe; Simvastatin Tablet,,,,01/06/2025,,01/06/2025,Cardiovascular,,,,,,"EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 20 mg (NDC 45963-566-08)",Tablet,,,,,,,,To Be Discontinued,,,,,45963-566-08,800-545-8800,
"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)",RILUZOLE,,01/26/2024,Reverified,ORAL,Riluzole Oral Suspension,"2058147, 2059266",,75d68f19-4208-109e-e053-2991aa0ac857,09/15/2025,HUMAN PRESCRIPTION DRUG,,Neurology,TIGLUTIK,70726-0303,"EDW PHARMA, INC",2012817c-c76a-40d4-a2c8-cdb211737f3d,"70726-0303-2, 70726-0303-1","Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-2)",Oral Suspension,Unavailable,"N0000175740, M0483511",NDA209080,Benzothiazoles [CS],RILUZOLE,Benzothiazole [EPC],,Current,Requirements related to complying with good manufacturing practices,Next release not available at this time; Shortage per Manufacturer: Product manufacturing interrupted due to viscosity testing,,7LJ087RS6F,70726-0303-2,610-937-6172,
Baxter Healthcare,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807551, 1807552, 1807627, 1807630, 1807631, 1807632, 1807633, 1807634, 1807639",,f55bd888-5e01-474d-871b-24654c070178,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0338-0049, 0338-0043",Baxter Healthcare Corporation,6ab23768-efd2-4ff1-b336-0dda08dc56e1,"0338-0049-01, 0338-0049-02, 0338-0049-03, 0338-0049-04, 0338-0049-10, 0338-0049-41, 0338-0049-11, 0338-0049-31, 0338-0049-48, 0338-0049-18, 0338-0049-38, 0338-0043-03, 0338-0043-04","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-48)",Injection,,,NDA016677,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0338-0049-48,888-229-0001,
"Teva Pharmaceuticals USA, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Revised,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541365, 541878, 541879, 541892, 541894, 577957, 577960, 577961, 577962, 687043, 687045, 1009145, 1009147",,f22635fe-821d-4cde-aa12-419f8b53db81,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,ADDERALL,"57844-120, 57844-105, 57844-117, 57844-110, 57844-112, 57844-115, 57844-130","Teva Pharmaceuticals USA, Inc.",79af1dc6-c7cf-41b1-a750-e9b47c2187ff,"57844-105-01, 57844-117-01, 57844-110-01, 57844-112-01, 57844-115-01, 57844-120-01, 57844-130-01","Adderall, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 57844-120-01)",Tablet,Available,,ANDA040422,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",57844-120-01,800-545-8800,
"Hospira, Inc., a Pfizer Company",VANCOMYCIN HYDROCHLORIDE,,09/09/2025,New,INTRAVENOUS,Vancomycin Hydrochloride Injection,"1807513, 1807516, 1807518",,2fd9de3f-a95f-451c-a687-d2e1306e53bf,09/09/2025,HUMAN PRESCRIPTION DRUG,09/09/2025,Anti-Infective,VANCOMYCIN HYDROCHLORIDE,"0409-6535, 0409-6531, 0409-6534","Hospira, Inc.",771a44e0-5858-449c-be36-438a9ff52e67,"0409-6531-11, 0409-6531-01, 0409-6535-11, 0409-6535-01, 0409-6534-11, 0409-6534-01","Vancomycin Hydrochloride, Injection, 1 g Single Dose ADD-Vantage® Glass Vial (NDC 0409-6535-01)",Injection,,,ANDA062933,,VANCOMYCIN HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,71WO621TJD,0409-6535-01,844-646-4398,
"Jiangsu Hengrui Pharmaceuticals Co., Ltd.",DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718900, 1718906, 1718909",,809e8f77-390f-4cc8-8c8a-4f67a249c9df,09/02/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE,"0781-3494, 0781-3493, 0781-3495",Sandoz Inc.,fdf227d9-008e-60f8-e053-6294a90af5c4,"0781-3493-95, 0781-3494-95, 0781-3495-95","Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL  (NDC 0781-3494-95)",Injection,Available,,ANDA209065,,DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE,,,Current,,Marketed by Sandoz Inc.; Customer service: 800-525-8747,,1018WH7F9I,0781-3494-95,See Related Information section below for customer service information,
"Hikma Pharmaceuticals USA, Inc.",FENTANYL CITRATE,,12/20/2023,Revised,INTRAVENOUS,Fentanyl Citrate Injection,"1735003, 1735007, 1735008, 1735013, 2168270, 2474269, 2629337",,ce5db1c2-feb1-4ad2-847a-d02e865bd47e,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Pediatric",FENTANYL CITRATE,"0641-6029, 0641-6024, 0641-6027, 0641-6025, 0641-6028, 0641-6026, 0641-6030, 0641-6247, 0641-6248, 0641-6249",Hikma Pharmaceuticals USA Inc.,aca9742b-d890-426a-8296-14ca64748238,"0641-6024-01, 0641-6024-10, 0641-6027-01, 0641-6027-25, 0641-6025-01, 0641-6025-10, 0641-6028-01, 0641-6028-10, 0641-6028-25, 0641-6026-01, 0641-6026-05, 0641-6029-01, 0641-6029-25, 0641-6030-01, 0641-6247-01, 0641-6247-25, 0641-6248-01, 0641-6248-10, 0641-6249-01, 0641-6249-10","Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6029-25)",Injection,Available,,NDA019101,,FENTANYL CITRATE,,,Current,,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,MUN5LYG46H,0641-6029-25,800-631-2174,
Pfizer Inc.,METHYLPREDNISOLONE ACETATE,,12/15/2021,Revised,"INTRA-ARTICULAR, INTRALESIONAL, INTRAMUSCULAR, SOFT TISSUE",Methylprednisolone Acetate Injection,"1743779, 1743781, 1743855, 1743856",,9a7b3837-e038-48bf-97e9-78ad463760dc,08/15/2025,HUMAN PRESCRIPTION DRUG,,Rheumatology,DEPO-MEDROL,"0009-3475, 0009-3073",Pharmacia & Upjohn Company LLC,befd723e-d1e2-41b9-83f1-17bca0c2a941,"0009-3073-01, 0009-3073-03, 0009-3475-01, 0009-3475-03","Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)",Injection,Available,,NDA011757,,METHYLPREDNISOLONE ACETATE,,,Current,,,,43502P7F0P,0009-3475-01,844-646-4398,
"Upsher-Smith Laboratories, LLC",CHOLESTYRAMINE,,05/14/2025,New,ORAL,Cholestyramine Powder,"848951, 1801279",,dd434ef8-8af3-434c-a0a0-9a0b18459ba0,05/14/2025,HUMAN PRESCRIPTION DRUG,05/14/2025,Cardiovascular,PREVALITE,0245-0036,"Upsher-Smith Laboratories, LLC",39e73fd2-1ad0-aae8-e063-6294a90acd5a,"0245-0036-89, 0245-0036-42, 0245-0036-60, 0245-0036-23","Prevalite, Powder, 4 g/5.5 g (NDC 0245-0036-23)",Powder,,"N0000180292, N0000175365",ANDA073263,,CHOLESTYRAMINE,Bile Acid Sequestrant [EPC],,To Be Discontinued,,A business decision was made to discontinue the product.,,4B33BGI082,0245-0036-23,800-654-2299,Bile-acid Binding Activity [MoA]
"Hikma Pharmaceuticals USA, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,6740a621-9bec-4178-a4fc-a3fc89f34e0a,07/23/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0054-0370, 0054-0660, 0054-0371, 0054-0372, 0054-0373, 0054-0374, 0054-0375",Hikma Pharmaceuticals USA Inc.,5d119550-4386-4bfa-a5d0-bb18e66191b7,"0054-0660-25, 0054-0370-25, 0054-0371-25, 0054-0372-25, 0054-0373-25, 0054-0374-25, 0054-0375-25","Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0054-0370-25)",Capsule,Limited Availability,,ANDA202827,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,Available on allocation,,SJT761GEGS,0054-0370-25,800-631-2174,
"Hospira, Inc., a Pfizer Company",WATER,,12/03/2021,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Sterile Water Injection,,,87d6e9dc-fe3b-4593-ac9a-d7493d1959c7,08/15/2025,HUMAN PRESCRIPTION DRUG,,Other,BACTERIOSTATIC WATER,"0409-3977, 0409-1093","Hospira, Inc.",e421caa9-6011-4cdf-a16c-6fe96d8b958a,"0409-3977-01, 0409-3977-03, 0409-1093-14, 0409-1093-04","Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)",Injection,Limited Availability,,NDA018802,,BACTERIOSTATIC WATER,,,Current,Other,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: December 2025,,059QF0KO0R,0409-3977-03,844-646-4398,
"Teva Pharmaceuticals USA, Inc.","EZETIMIBE, SIMVASTATIN",Decreased Cholesterol Absorption [PE],01/06/2025,New,ORAL,Ezetimibe; Simvastatin Tablet,"476345, 476349, 476350, 476351",,00680bea-d2fb-4362-ba67-e866b732e9ed,01/06/2025,HUMAN PRESCRIPTION DRUG,01/06/2025,Cardiovascular,EZETIMIBE AND SIMVASTATIN,"45963-568, 45963-565, 45963-566, 45963-567","Actavis Pharma, Inc.",bd64aee1-c95f-4767-8d31-af93dd0ab692,"45963-565-30, 45963-565-08, 45963-566-30, 45963-566-08, 45963-567-30, 45963-567-08, 45963-568-30, 45963-568-08","EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 80 mg (NDC 45963-568-30)",Tablet,,"N0000175589, N0000000121, N0000008553, N0000175911",ANDA202968,,EZETIMIBE AND SIMVASTATIN,"HMG-CoA Reductase Inhibitor [EPC], Dietary Cholesterol Absorption Inhibitor [EPC]",,To Be Discontinued,,,,"AGG2FN16EV, EOR26LQQ24",45963-568-30,800-545-8800,Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]
"Hospira, Inc., a Pfizer Company",SUFENTANIL CITRATE,,05/03/2022,Revised,"EPIDURAL, INTRAVENOUS",Sufentanil Citrate Injection,"1809097, 1809102, 1809104",,20293943-46ff-4345-1aa4-929b4e017a25,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Pediatric",SUFENTANIL CITRATE,0409-3382,"Hospira, Inc.",589d789c-2fbd-40ee-bbe4-8906afa2062d,"0409-3382-11, 0409-3382-21, 0409-3382-12, 0409-3382-22, 0409-3382-15, 0409-3382-25","Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)",Injection,Available,,ANDA074534,,SUFENTANIL CITRATE,,,Current,,,,S9ZFX8403R,0409-3382-21,844-646-4398,
"Teva Pharmaceuticals USA, Inc.",OXAZEPAM,,12/04/2024,Revised,ORAL,Oxazepam Capsule,"198057, 198059, 312134",,a0d5a4c1-ec79-42e6-8e8f-ae4d144edb43,07/03/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Psychiatry",OXAZEPAM,"0228-2073, 0228-2067, 0228-2069","Actavis Pharma, Inc.",3473450d-0e2d-43ed-9cc9-d8c63a201085,"0228-2067-10, 0228-2069-10, 0228-2073-10","Oxazepam, Capsule, 30 mg (NDC 0228-2073-10)",Capsule,,"N0000175694, M0002356",ANDA072253,Benzodiazepines [CS],OXAZEPAM,Benzodiazepine [EPC],Available,Resolved,,,07/03/2025,6GOW6DWN2A,0228-2073-10,800-545-8800,
InfoRLife SA,ROPIVACAINE HYDROCHLORIDE,,03/27/2018,Reverified,"EPIDURAL, INFILTRATION",Ropivacaine Hydrochloride Injection,"1734347, 1734355, 1734479, 1734481",,"8c5c762f-d266-4b1a-809e-f11bfc89bc2d, 9572b3de-684c-4028-a577-5aa69ba6b02d",08/26/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROPIVACAINE HYDROCHLORIDE,"25021-671, 25021-652",Sagent Pharmaceuticals,"04d1b1c6-1963-4b42-8479-dbf787b6de17, 2eb59cb8-dab8-43f4-ad73-672446e104ca","25021-671-82, 25021-671-87, 25021-652-82, 25021-652-87, 25021-671-66, 25021-671-67","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-67)",Injection,Available,,ANDA206166,,ROPIVACAINE HYDROCHLORIDE,,,Current,,Marketed by Sagent Pharmaceuticals,,V910P86109,25021-671-67,Sagent: 866-625-1618,
Baxter Healthcare,SODIUM CHLORIDE,,04/28/2023,Revised,IRRIGATION,Sodium Chloride 0.9% Irrigation,486515,,b3b4b176-41f0-4ca8-90d4-3fba5707564a,07/02/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,0338-0048,Baxter Healthcare Corporation,123eac3f-8e50-4689-bf00-cf9407eb70ee,"0338-0048-02, 0338-0048-03, 0338-0048-04, 0338-0048-05","Sodium Chloride 0.9% In Plastic Container, Irrigation, 900 mg/100 mL (NDC 0338-0048-03)",Irrigation,,,NDA017427,,SODIUM CHLORIDE,,,Resolved,,,07/02/2025,451W47IQ8X,0338-0048-03,888-229-0001,
"Hospira, Inc., a Pfizer Company",SODIUM CHLORIDE,,12/08/2021,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Sodium Chloride 0.9% Injection,313002,,376093e7-e09e-4a57-3199-195e45251866,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",BACTERIOSTATIC SODIUM CHLORIDE,0409-1966,"Hospira, Inc.",2d3125e0-c89b-46d5-a350-07d1e7936ebd,"0409-1966-02, 0409-1966-07, 0409-1966-06, 0409-1966-12, 0409-1966-01, 0409-1966-05","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-1966-12)",Injection,,,NDA018800,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0409-1966-12,844-646-4398,
Pfizer Inc.,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Revised,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718900, 1718902, 1718906, 1718907, 1718909, 1718910, 2396891, 2396892",,4419162d-81d4-49bd-96de-1729440bdb74,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,PRECEDEX,"0409-2815, 0409-1454, 0409-3301, 0409-1174","Hospira, Inc.",8d48de06-361f-418b-bfec-8ef85f94d5bc,"0409-1454-01, 0409-1454-20, 0409-3301-01, 0409-3301-10, 0409-1174-01, 0409-1174-10, 0409-2815-01","Precedex, Injection, 1000 mcg/250 mL Glass Bottle NovaPlus (NDC 0409-2815-01)",Injection,Limited Availability,,NDA021038,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,Other,Limited Supply Available. Next Delivery: November 2025; Estimated Recovery: December 2025,,1018WH7F9I,0409-2815-01,844-646-4398,
"Teva Pharmaceuticals USA, Inc.","FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE",,06/13/2025,New,RESPIRATORY (INHALATION),Fluticasone Propionate; Salmeterol Xinafoate Powder,"1918194, 1918199, 1918203, 1918205, 1918209, 1918211",,9c122b91-a11f-49ca-80bb-3eec5112db87,06/13/2025,HUMAN PRESCRIPTION DRUG,06/13/2025,Pulmonary/Allergy,AIRDUO RESPICLICK,"59310-822, 59310-805, 59310-812","Teva Respiratory, LLC",b597bc2d-bf1e-4f9b-826a-b3e39ed56545,"59310-805-06, 59310-805-08, 59310-812-06, 59310-812-08, 59310-822-06, 59310-822-08","AirDuo RespiClick, Powder, 232 ug; 14 ug (NDC 59310-822-06)",Powder,,,NDA208799,,FLUTICASONE PROPIONATE AND SALMETEROL,,,To Be Discontinued,,,,"O2GMZ0LF5W, 6EW8Q962A5",59310-822-06,800-545-8800,
Chartwell Molecular Holdings LLC,"HYDROCHLOROTHIAZIDE, QUINAPRIL HYDROCHLORIDE",Increased Diuresis [PE],01/19/2023,Reverified,ORAL,Quinapril/Hydrochlorothiazide Tablet,"310796, 310797, 310809",,2eae533f-d0af-47e8-a1f2-94bc8cc89b5a,08/19/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,QUINAPRIL AND HYDROCHLOROTHIAZIDE,"62135-667, 62135-668, 62135-669","Chartwell RX, LLC",0c3f4504-d57e-aa79-e063-6294a90ad5b8,"62135-667-90, 62135-668-90, 62135-669-90","Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 62135-667-90)",Tablet,Available,"N0000175359, N0000175419, M0471776",ANDA076374,Thiazides [CS],QUINAPRIL AND HYDROCHLOROTHIAZIDE,Thiazide Diuretic [EPC],,Current,,,,"0J48LPH2TH, 33067B3N2M",62135-667-90,845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com,
"Hospira, Inc., a Pfizer Company",SODIUM BICARBONATE,,03/01/2017,Revised,INTRAVENOUS,Sodium Bicarbonate Injection,792577,,e4ef2cb3-3d80-4d71-b50f-15571caac73a,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Pediatric",SODIUM BICARBONATE,0409-4900,"Hospira, Inc.",0c5d5b91-676a-469d-aeb9-58162696f73c,"0409-4900-24, 0409-4900-14","Sodium Bicarbonate, Injection, 10 mEq/10 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-4900-14)",Injection,Unavailable,,ANDA202495,,SODIUM BICARBONATE,,,Current,Other,Next Delivery: January 2026; Estimated Recovery: March 2026,01/03/2025,8MDF5V39QO,0409-4900-14,844-646-4398,
"Medefil, Inc.",WATER,,11/23/2021,Reverified,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Sterile Water Injection,,,99e99a50-82d5-aff6-e053-2a95a90a8c56,08/15/2025,HUMAN PRESCRIPTION DRUG,,Other,STERILE WATER,64253-020,"Medefil, Inc.",2b39b41d-419a-dab8-e063-6394a90a319a,"64253-020-21, 64253-020-23, 64253-020-30, 64253-020-35, 64253-020-52, 64253-020-25, 64253-020-91","Sterile Water, Injection, 10 mL/10 mL (NDC 64253-020-30)",Injection,Available,,ANDA211188,,STERILE WATER FOR INJECTION,,,Current,,,,059QF0KO0R,64253-020-30,630-682-4600,
"Mylan Pharmaceuticals Inc., a Viatris Company","AZELASTINE HYDROCHLORIDE, FLUTICASONE PROPIONATE",,09/04/2025,New,NASAL,Azelastine Hydrochloride; Fluticasone Propionate Nasal Spray,1797847,,7b5cc5a0-0d47-46b5-b5fb-eb9cc248ae9e,09/04/2025,HUMAN PRESCRIPTION DRUG,09/04/2025,Pulmonary/Allergy,AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE,0378-3458,Mylan Pharmaceuticals Inc.,cd436445-1d30-448a-b838-e86cf2f104bf,0378-3458-23,"Azelastine Hydrochloride; Fluticasone Propionate, Nasal Spray, 137 ug; 50 ug (NDC 0378-3458-23)",Nasal Spray,,,NDA202236,,AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,"0L591QR10I, O2GMZ0LF5W",0378-3458-23,800-796-9526,
Baxter Healthcare,DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795609, 1795616",,7de48bdb-9a05-4f2a-bbff-dcfeb284ca6e,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,0338-0551,Baxter Healthcare Company,e702be26-651e-4d4a-9d79-4df9f53821c9,"0338-0551-11, 0338-0551-18","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-11)",Injection,Available,,NDA020179,,DEXTROSE MONOHYDRATE,,,Current,,,,LX22YL083G,0338-0551-11,888-229-0001,
"Hospira, Inc., a Pfizer Company","EPINEPHRINE, LIDOCAINE HYDROCHLORIDE",,02/22/2012,Reverified,"INFILTRATION, PERINEURAL","Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","1010688, 1010745, 1010751, 1010759, 1867996, 1867998",,2f94f711-14c4-48ec-c5a3-c5ec4b8e8729,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE,"0409-3178, 0409-1209, 0409-3177, 0409-3181, 0409-3182, 0409-3183, 0409-0007, 0409-0147","Hospira, Inc.",d16a4711-e663-455e-a1fe-236a41ca4e8f,"0409-1209-10, 0409-1209-01, 0409-1209-05, 0409-1209-70, 0409-1209-65, 0409-3177-16, 0409-3177-01, 0409-3178-16, 0409-3178-01, 0409-3178-17, 0409-3178-02, 0409-3178-18, 0409-3178-03, 0409-3181-11, 0409-3181-01, 0409-3182-11, 0409-3182-01, 0409-3182-21, 0409-3182-02, 0409-3182-31, 0409-3182-03, 0409-3183-11, 0409-3183-01, 0409-0007-01, 0409-0007-10, 0409-0147-01, 0409-0147-10","Lidocaine Hydrochloride And Epinephrine, Injection, 500 mg/50 mL (1%; 1:100,000) (NDC 0409-3178-03)",Injection,Available,"N0000000209, N0000000245, N0000175552, N0000175555, N0000175570, M0003647",ANDA089644,Catecholamines [CS],LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE,"alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC], Catecholamine [EPC]",,Current,,,12/19/2024,"V13007Z41A, YKH834O4BH",0409-3178-03,844-646-4398,"Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA]"
Baxter Healthcare,HEPARIN SODIUM,,11/14/2017,Reverified,INTRAVENOUS,Heparin Sodium Injection,"1658690, 1658692",,0d929726-76c3-48fc-b4e7-fd06409f9fb3,09/23/2025,HUMAN PRESCRIPTION DRUG,,Hematology,HEPARIN SODIUM IN SODIUM CHLORIDE,"0338-0433, 0338-0431, 0338-0424, 0338-0428",Baxter Healthcare Corporation,68b37381-6db4-4ac0-ba6b-3204add02665,"0338-0431-03, 0338-0433-04, 0338-0424-18, 0338-0428-12","Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0433-04)",Injection,Available,,NDA018609,,HEPARIN SODIUM,,,Current,,,,ZZ45AB24CA,0338-0433-04,888-229-0001,
"Hospira, Inc., a Pfizer Company",LIDOCAINE HYDROCHLORIDE,,02/22/2012,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010671, 1010900, 1737343, 1737562, 1737566, 1737568, 1737636, 1737757, 1737763",,3b2dd84e-cee8-4e58-d494-395a65a353a0,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE HYDROCHLORIDE,"0409-4279, 0409-4713, 0409-4278, 0409-4776, 0409-4282, 0409-4277, 0409-4276, 0409-4275","Hospira, Inc.",c0b4635b-1473-4c48-89c6-620762cd687f,"0409-4713-12, 0409-4713-26, 0409-4713-02, 0409-4713-72, 0409-4713-62, 0409-4713-75, 0409-4713-65, 0409-4713-42, 0409-4713-25, 0409-4713-32, 0409-4278-16, 0409-4278-01, 0409-4279-16, 0409-4279-02, 0409-4776-10, 0409-4776-01, 0409-4282-11, 0409-4282-25, 0409-4282-01, 0409-4282-12, 0409-4282-02, 0409-4277-16, 0409-4277-01, 0409-4277-17, 0409-4277-02, 0409-4276-16, 0409-4276-01, 0409-4276-17, 0409-4276-02, 0409-4275-16, 0409-4275-01","Lidocaine Hydrochloride, Injection, 300 mg/30 mL (1%; 10 mg/mL) (NDC 0409-4279-02)",Injection,Available,,ANDA088329,,LIDOCAINE HYDROCHLORIDE,,,Current,,,,V13007Z41A,0409-4279-02,844-646-4398,
"Sun Pharmaceutical Industries, Inc.",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Revised,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release","1091155, 1091170, 1091185, 1091210",,d048e52d-7406-4fc1-9a72-c073bafc7439,09/22/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE HYDROCHLORIDE,"57664-606, 57664-607, 57664-608, 57664-609","Sun Pharmaceutical Industries, Inc.",0da4b745-d498-8823-e063-6394a90a4524,"57664-606-88, 57664-607-88, 57664-608-88, 57664-609-88","Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88)",Tablet,Unavailable,,ANDA205135,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,Discontinuation of the manufacture of the drug,Currently not marketed,,4B3SC438HI,57664-606-88,800-818-4555,
WG Critical Care,MIDAZOLAM,,04/02/2020,Reverified,INTRAVENOUS,Midazolam Hydrochloride Injection,"2541170, 2541171",,f051776f-94c5-4e34-80ed-f45b9c36881e,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology",MIDAZOLAM IN SODIUM CHLORIDE,"44567-611, 44567-610","WG Critical Care, LLC.",8b577103-b84e-4344-a3ff-b18b77f856cc,"44567-610-01, 44567-610-10, 44567-611-01, 44567-611-10","Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-611-10)",Injection,Available,"N0000175694, M0002356",NDA211844,Benzodiazepines [CS],MIDAZOLAM,Benzodiazepine [EPC],,Current,,Please check wholesalers and distributors for inventory.,,R60L0SM5BC,44567-611-10,888-493-0861,
Pfizer Inc.,QUINAPRIL HYDROCHLORIDE,,01/19/2023,Reverified,ORAL,Quinapril Hydrochloride Tablet,"207891, 207892, 207893, 207895, 312748, 312749, 312750, 314203",,63cf5651-d52c-4d27-9fd4-ed9cd9724dff,08/15/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,ACCUPRIL,"0071-0532, 0071-0527, 0071-0530, 0071-0535, 0071-1205, 0071-1410, 0071-1620, 0071-1840",Parke-Davis Div of Pfizer Inc,ee20d3b1-a5c8-4510-a931-3872df7b77f4,"0071-0527-23, 0071-0530-23, 0071-0530-40, 0071-0532-23, 0071-0532-40, 0071-0535-23, 0071-1205-23, 0071-1410-23, 0071-1620-23, 0071-1840-23","Accupril, Tablet, 20 mg (NDC 0071-0532-23)",Tablet,Unavailable,,NDA019885,,QUINAPRIL HYDROCHLORIDE,,,Current,Delay in shipping of the drug,Next Delivery and Estimated Recovery: TBD,,33067B3N2M,0071-0532-23,800-533-4535,
"Hikma Pharmaceuticals USA, Inc.",PROMETHAZINE HYDROCHLORIDE,,11/21/2023,Revised,INTRAMUSCULAR,Promethazine Hydrochloride Injection,"992460, 992462, 992858, 992876",,6f7e47cc-f823-4336-8107-f980e3049617,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Gastroenterology, Pediatric, Pulmonary/Allergy",PHENERGAN,"0641-6083, 0641-6082",Hikma Pharmaceuticals USA Inc.,a64f0625-8d56-4994-8908-13614ca7b09f,"0641-6082-01, 0641-6082-25, 0641-6083-01, 0641-6083-25","Phenergen, Injection, 50 mg/1 mL (NDC 0641-6083-25)",Injection,Available,,ANDA083312,,PROMETHAZINE HYDROCHLORIDE,,,Current,,Additional lots will be scheduled for manufacturing to meet demand.  Product will be made available as it is released.,,R61ZEH7I1I,0641-6083-25,800-631-2174,
"Boehringer Ingelheim Pharmaceuticals, Inc.",TELMISARTAN,,10/22/2024,New,ORAL,Telmisartan Tablet,"205304, 205305, 213431, 213432, 282755, 284531",,cfb9309f-e0df-4a55-9542-0e869fce05fb,10/22/2024,HUMAN PRESCRIPTION DRUG,10/22/2024,Cardiovascular,MICARDIS,"0597-0041, 0597-0039, 0597-0040","Boehringer Ingelheim Pharmaceuticals, Inc.",333f0ca9-928d-45af-92b9-9ea8a4d02f7d,"0597-0039-37, 0597-0040-37, 0597-0041-37","Micardis, Tablet, 80 mg (NDC 0597-0041-37)",Tablet,,"N0000000070, N0000175561",NDA020850,,TELMISARTAN,Angiotensin 2 Receptor Blocker [EPC],,To Be Discontinued,,Discontinued for business reasons,,U5SYW473RQ,0597-0041-37,800-243-0127,Angiotensin 2 Receptor Antagonists [MoA]
Aurobindo Pharma USA,CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,b1582eb7-af35-45d5-a52e-0e380d08527d,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"59651-724, 59651-722, 59651-723",Aurobindo Pharma Limited,b1582eb7-af35-45d5-a52e-0e380d08527d,"59651-722-01, 59651-722-99, 59651-723-01, 59651-723-99, 59651-724-01, 59651-724-05","Clonazepam, Tablet, 2 mg (NDC 59651-724-01)",Tablet,Available,"N0000175694, M0002356",ANDA075150,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,,,5PE9FDE8GB,59651-724-01,866-850-2876,
"Teva Pharmaceuticals USA, Inc.",DOXYCYCLINE HYCLATE,,05/02/2025,New,ORAL,Doxycycline Hyclate Tablet,1650143,,a569ba80-ffea-40b2-9fbe-a42810b1fccb,05/02/2025,HUMAN PRESCRIPTION DRUG,05/02/2025,Anti-Infective,DOXYCYCLINE HYCLATE,0591-5553,"Actavis Pharma, Inc.",0fb9a3f8-9ebb-4c21-8a73-9f082b39039c,"0591-5553-50, 0591-5553-05","Doxycycline Hyclate, Tablet, 100 mg (NDC 0591-5553-50)",Tablet,,,ANDA062421,,DOXYCYCLINE HYCLATE,,,To Be Discontinued,,,,19XTS3T51U,0591-5553-50,800-545-8800,
Amneal Pharmaceuticals,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718906, 1718909",,eb1ba463-ab42-4f49-9ebe-3ad5af108326,09/17/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE HYDROCHLORIDE,"70121-1388, 70121-1389",Amneal Pharmaceuticals LLC,795f643f-855c-4ba4-9bad-a96334c1a2fb,"70121-1388-1, 70121-1388-8, 70121-1389-1, 70121-1389-7","Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 50 mL (NDC 70121-1388-1)",Injection,Available,,ANDA207551,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,,,,1018WH7F9I,70121-1388-1,877-835-5472,
"Hikma Pharmaceuticals USA, Inc.",LIDOCAINE HYDROCHLORIDE,,12/08/2023,Revised,"ORAL, TOPICAL",Lidocaine Hydrochloride Solution,1010739,,79b42076-359d-4258-b1d8-f40e67ac5424,08/29/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,LIDOCAINE VISCOUS,"0054-3500, 0054-0548",Hikma Pharmaceuticals USA Inc.,182f3e6b-1622-4eef-80e5-d08ffbbbd30e,"0054-3500-49, 0054-0548-44","Lidocaine Viscous (Lidocaine Hydrochloride), Solution, 20 mg/1 mL (NDC 0054-3500-49)",Solution,,,ANDA088802,,LIDOCAINE HYDROCHLORIDE,,Available,Resolved,,,08/29/2025,V13007Z41A,0054-3500-49,800-631-2174,
"Sun Pharmaceutical Industries, Inc.",TECHNETIUM TC-99M PYROPHOSPHATE,,12/27/2023,Revised,INTRAVENOUS,Technetium TC-99M Pyrophosphate Kit Injection,,,1f0cbd23-2fb3-43b7-b8af-7de246151149,09/22/2025,HUMAN PRESCRIPTION DRUG,,Medical Imaging,KIT FOR THE PREPARATION OF TECHNETIUM TC99M PYROPHOSPHATE,45567-0060,"Sun Pharmaceutical Industries, Inc.",3010b45e-eed1-a5d0-e063-6294a90a40cf,"45567-0060-1, 45567-0060-2","CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-1)",Injection,Limited Availability,"N0000177914, N0000000205",NDA019039,,TECHNETIUM TC99M PYROPHOSPHATE,Radioactive Diagnostic Agent [EPC],,Current,Shortage of an active ingredient,Additional supply anticipated early 2026,,5L76I61H2B,45567-0060-1,800-818-4555,Radiopharmaceutical Activity [MoA]
Sun Pharmaceutical Industries Limited,CLINDAMYCIN HYDROCHLORIDE,,12/05/2024,New,ORAL,Clindamycin Hydrochloride Capsule,"197518, 284215",,1dbd8448-c1e5-46df-8060-50ef82380445,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Anti-Infective,CLINDAMYCIN HYDROCHLORIDE,"63304-693, 63304-692","Sun Pharmaceutical Industries, Inc.",339366d4-2060-1c29-e063-6394a90a1cb7,"63304-692-01, 63304-692-05, 63304-692-77, 63304-692-03, 63304-693-16, 63304-693-01, 63304-693-03, 63304-693-05, 63304-693-77, 63304-693-11, 63304-693-62","Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-01)",Capsule,,,ANDA065061,,CLINDAMYCIN HYDROCHLORIDE,,,To Be Discontinued,,Discontinuing for business reasons,,T20OQ1YN1W,63304-693-01,800-818-4555,
"Avet Pharmaceuticals, Inc.",DESIPRAMINE HYDROCHLORIDE,,08/12/2025,New,ORAL,Desipramine Hydrochloride Tablet,"1099288, 1099292, 1099296, 1099300, 1099304, 1099316",,ee14dd2c-c54b-4cd1-a3a0-f7ad5a5a0ed0,08/12/2025,HUMAN PRESCRIPTION DRUG,08/12/2025,Psychiatry,DESIPRAMINE HYDROCHLORIDE,"23155-578, 23155-579, 23155-580, 23155-581, 23155-582, 23155-583",Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.,49984729-ddde-44ed-927b-8a4ba65cefa0,"23155-578-01, 23155-579-01, 23155-580-01, 23155-581-01, 23155-582-01, 23155-583-25","Desipramine Hydrochloride, Tablet, 10 mg (NDC 23155-578-01)",Tablet,,,ANDA207433,,DESIPRAMINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,1Y58DO4MY1,23155-578-01,855-228-9470,
"Fresenius Kabi USA, LLC","EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE ANHYDROUS",,10/14/2016,Reverified,"INFILTRATION, PERINEURAL","Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","1010033, 1010035, 1010671, 1010673, 1010688, 1010692, 1010745, 1010749, 1010751, 1010755, 1010759, 1010763, 1010900, 1010902, 1737343, 1737345, 1737562, 1737563, 1737566, 1737567, 1737568, 1737569, 1737570, 1737571, 1737757, 1737758, 1737761, 1737762, 1867938, 1867940, 1867943, 1867944, 1867992, 1867993, 1867996, 1867997, 1868028, 1868029",,"ba082c2f-64f4-419d-9c88-74f203316e17, 4dd52202-8eef-4136-92dd-ada573b7cf74",09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",XYLOCAINE,"63323-482, 63323-492, 63323-491, 63323-495, 63323-485, 63323-486, 63323-484, 63323-489, 63323-488, 63323-481, 63323-483, 63323-487","Fresenius Kabi USA, LLC","ea480a68-5927-4278-9deb-2956961da428, 0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33","63323-492-04, 63323-492-27, 63323-492-09, 63323-492-57, 63323-492-07, 63323-492-37, 63323-492-03, 63323-492-31, 63323-491-01, 63323-491-57, 63323-495-09, 63323-495-27, 63323-495-04, 63323-495-07, 63323-485-01, 63323-485-27, 63323-485-03, 63323-485-57, 63323-486-01, 63323-486-17, 63323-486-02, 63323-486-27, 63323-486-05, 63323-486-57, 63323-484-57, 63323-489-02, 63323-489-27, 63323-489-03, 63323-489-21, 63323-489-01, 63323-489-17, 63323-488-07, 63323-488-37, 63323-488-03, 63323-488-31, 63323-488-01, 63323-488-17, 63323-481-01, 63323-481-57, 63323-483-03, 63323-483-27, 63323-483-01, 63323-483-57, 63323-482-01, 63323-482-17, 63323-482-03, 63323-482-27, 63323-482-05, 63323-482-57, 63323-487-01, 63323-487-17, 63323-487-07, 63323-487-37, 63323-487-03, 63323-487-31, 63323-492-41, 63323-492-16, 63323-492-43, 63323-492-36, 63323-492-45, 63323-492-26, 63323-485-41, 63323-485-26, 63323-486-41, 63323-486-26, 63323-482-41, 63323-482-26, 63323-495-41, 63323-495-26","Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-27)",Injection,Available,,NDA006488,,"LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE",,,Current,,Check wholesalers for inventory,,"EC2CNF7XFP, 30Q7KI53AK",63323-482-27,888-386-1300,
Baxter Healthcare,DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795607, 1795609, 1795610, 1795612, 1795616",,36e9478c-5df0-4b47-b97d-de3626d7cb29,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0338-0070, 0338-9651, 0338-9649, 0338-9655, 0338-9653, 0338-0078, 0338-0062, 0338-0074, 0338-0066, 0338-0082",Baxter Healthcare Corporation,66eb82f8-6755-42aa-b20c-192a640e8068,"0338-9651-75, 0338-9649-75, 0338-9655-60, 0338-9653-60, 0338-0078-20, 0338-0062-30, 0338-0074-30, 0338-0066-20, 0338-0070-10, 0338-0070-12, 0338-0082-10","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0070-10)",Injection,Available,,NDA016673,,DEXTROSE MONOHYDRATE,,,Current,,,,LX22YL083G,0338-0070-10,888-229-0001,
"EMD Serono, Inc.",LEVOTHYROXINE SODIUM,,07/10/2025,New,ORAL,Levothyroxine Sodium Tablet,"892246, 892251, 966153, 966160, 966166, 966173, 966177, 966182, 966187, 966196, 966202, 966207, 966220, 966221, 966222, 966224, 966225, 966248, 966249, 966253, 966270, 2104866",,bc3c6830-ba68-4ba3-9896-a12d0ad0b275,07/10/2025,HUMAN PRESCRIPTION DRUG,07/10/2025,Endocrinology/Metabolism,EUTHYROX,"72305-025, 72305-050, 72305-075, 72305-088, 72305-100, 72305-112, 72305-125, 72305-137, 72305-150, 72305-175, 72305-200","Provell Pharmaceuticals, LLC",45657074-8874-49f4-a8ef-3ca7e210c16e,"72305-025-30, 72305-025-90, 72305-050-30, 72305-050-90, 72305-075-30, 72305-075-90, 72305-088-30, 72305-088-90, 72305-100-30, 72305-100-90, 72305-112-30, 72305-112-90, 72305-125-30, 72305-125-90, 72305-137-30, 72305-137-90, 72305-150-30, 72305-150-90, 72305-175-30, 72305-175-90, 72305-200-30, 72305-200-90","Euthyrox, Tablet, 25 ug (NDC 72305-025-90)",Tablet,,,NDA021292,,LEVOTHYROXINE SODIUM,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,9J765S329G,72305-025-90,888-899-7041,
Takeda Pharmaceuticals USA Inc.,PARATHYROID HORMONE,,09/11/2019,Reverified,SUBCUTANEOUS,Parathyroid Hormone Injection,"1602023, 1602028, 1602032, 1602034, 1602038, 1602040, 1602044, 1602046",,d11fba31-0a6c-11e3-8ffd-0800200c9a66,08/15/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,NATPARA (PARATHYROID HORMONE),"68875-0204, 68875-0202, 68875-0203, 68875-0205","Takeda Pharmaceuticals America, Inc.",17d2bb82-605c-43be-9918-63aeb7102d8c,"68875-0202-1, 68875-0202-2, 68875-0203-1, 68875-0203-2, 68875-0204-1, 68875-0204-2, 68875-0205-1, 68875-0205-2","Natpara, Injection, 75 ug/.08 mL, Injection, Powder, Lyophilized, For Solution (NDC 68875-0204-2)",Powder,Limited Availability,"M0015931, N0000180851",BLA125511,Parathyroid Hormone [CS],PARATHYROID HORMONE,Parathyroid Hormone [EPC],,Current,Discontinuation of the manufacture of the drug,Takeda will be ceasing manufacturing of Natpara at the end of 2024 with a priority to maintain treatment continuity for patients enrolled in the U.S. Special Use Program until inventory is depleted or expired.,,N19A0T0E5J,68875-0204-2,866-888-0660,
Sandoz Inc.,TAMSULOSIN HYDROCHLORIDE,,04/10/2025,New,ORAL,Tamsulosin Hydrochloride Capsule,863669,,fb120098-b007-4a33-80b8-b7279c7668ee,04/10/2025,HUMAN PRESCRIPTION DRUG,04/10/2025,Urology,TAMSULOSIN HYDROCHLORIDE,0781-2076,Sandoz Inc,98c2abd9-1998-48cd-83f9-f5f94ff39345,"0781-2076-01, 0781-2076-10, 0781-2076-92","Tamsulosin Hydrochloride, Capsule, .4 mg (NDC 0781-2076-01)",Capsule,,,ANDA078015,,TAMSULOSIN HYDROCHLORIDE,,,To Be Discontinued,,,,11SV1951MR,0781-2076-01,800-525-8747,
"Mylan Institutional, a Viatris Company",LEUCOVORIN CALCIUM,,01/01/2012,Revised,"INTRAMUSCULAR, INTRAVENOUS",Leucovorin Calcium Injection,"237788, 1803932, 1803937",,1cb701ca-2478-4268-9d69-80293965d59d,07/08/2025,HUMAN PRESCRIPTION DRUG,,"Oncology, Pediatric",LEUCOVORIN CALCIUM,"67457-529, 67457-528, 67457-530",Mylan Institutional LLC,2890b03c-dbef-4db8-8b07-c042d7765677,"67457-528-10, 67457-529-20, 67457-530-35","Leucovorin Calcium Preservative Free, Injection, 200 mg/20 mL (NDC 67457-529-20)",Injection,,,ANDA203800,,LEUCOVORIN CALCIUM,,Available,Resolved,,,07/08/2025,RPR1R4C0P4,67457-529-20,800-796-9526,
Swedish Orphan Biovitrum AB,PALIVIZUMAB,,08/13/2025,New,INTRAMUSCULAR,Palivizumab Injection,"1657341, 1657343, 1657361, 1657362",,3a0096c7-8139-44cd-bba4-520ab05c2cb2,08/13/2025,HUMAN PRESCRIPTION DRUG,08/13/2025,Antiviral,SYNAGIS,"66658-231, 66658-230",Swedish Orphan Biovitrum AB (publ),825a4b3c-e419-457c-8862-fd7b74a171ed,"66658-231-01, 66658-230-01","Synagis, Injection, 100 mg/1 mL (NDC 66658-231-01)",Injection,,"M0001357, N0000175615, N0000175623",BLA103770,"Antibodies, Monoclonal [CS]",PALIVIZUMAB,Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,DQ448MW7KS,66658-231-01,866-773-5274,Fusion Protein Inhibitors [MoA]
Accord Healthcare Inc.,FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Revised,"INTRAMUSCULAR, INTRAVENOUS",Furosemide Injection,"1719286, 1719290, 1719291",,f6f64972-714c-4ee9-8a5e-9ffcab41a73b,09/16/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,"16729-501, 16729-500, 16729-502","Accord Healthcare, Inc.",1cfab300-d796-6a68-e063-6394a90a73f9,"16729-500-30, 16729-500-08, 16729-501-64, 16729-501-43, 16729-502-03, 16729-502-43","Furosemide, Injection, 10 mg/1 mL (NDC 16729-501-43)",Injection,Unavailable,"N0000175366, N0000175590",ANDA070017,,FUROSEMIDE,Loop Diuretic [EPC],,Current,Requirements related to complying with good manufacturing practices,Unavailable,,7LXU5N7ZO5,16729-501-43,866-941-7875,
"Fresenius Kabi USA, LLC",HYDROMORPHONE HYDROCHLORIDE,,11/01/2017,Reverified,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Hydromorphone Hydrochloride Injection,"897653, 897753, 1724276, 1724338, 1724340, 1724341",,e034eb96-03e0-46e1-8b92-5e1f94555e7b,09/18/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,HYDROMORPHONE HYDROCHLORIDE,"63323-854, 63323-851, 63323-852, 63323-853","Fresenius Kabi USA, LLC",9e8522c6-595c-46f9-bb25-272aa4683e0f,"63323-851-03, 63323-851-10, 63323-851-07, 63323-851-15, 63323-851-50, 63323-852-03, 63323-852-25, 63323-853-03, 63323-853-25, 63323-854-03, 63323-854-10","Hydromorphone Hydrochloride, Injection, 4 mg/1 mL (NDC 63323-854-10)",Injection,Unavailable,,NDA019034,,HYDROMORPHONE HYDROCHLORIDE,,,Current,Other,Backordered. Next release not available at this time. Check wholesaler for inventory.,,L960UP2KRW,63323-854-10,888-386-1300,
Eugia US LLC,LIDOCAINE HYDROCHLORIDE,,02/20/2018,Revised,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Lidocaine Hydrochloride Injection,"1737562, 1737566, 1737568, 1737757, 1737761",,"9916b09d-a116-469d-92d5-60e50ea9782b, 89701fac-7536-4f16-87fb-f4cc121e74ee",09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,LIDOCAINE HYDROCHLORIDE,"55150-164, 55150-161, 55150-162, 55150-163, 55150-165",Eugia US LLC,"9916b09d-a116-469d-92d5-60e50ea9782b, 9b60bc92-6093-49f9-a6ba-075104ff7bb5","55150-161-09, 55150-162-09, 55150-163-00, 55150-164-09, 55150-165-09, 55150-161-02, 55150-162-05, 55150-163-30, 55150-164-02, 55150-165-05","Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-164-02)",Injection,Available,,ANDA203082,,LIDOCAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,V13007Z41A,55150-164-02,888-238-7880,
"Fresenius Kabi USA, LLC",LIDOCAINE HYDROCHLORIDE,,02/22/2012,Reverified,"INFILTRATION, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1737757",,cddb2b22-fce3-8967-6e54-dca3df5ac4b3,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE,"63323-202, 63323-201","Fresenius Kabi USA, LLC",d19c26f4-1214-40f7-9680-43c885613306,"63323-201-01, 63323-201-02, 63323-201-03, 63323-201-10, 63323-202-01, 63323-202-02","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 63323-202-02)",Injection,Available,,ANDA088586,,LIDOCAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,V13007Z41A,63323-202-02,888-386-1300,
SpecGx LLC,METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Reverified,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release","1091145, 1091225",,ed004cf0-eb23-43d2-96dc-20c4ad63824f,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE HYDROCHLORIDE,"0406-1445, 0406-1473",SpecGx LLC,a14563fd-7a73-4e7d-8f13-f449cfaad1a5,"0406-1445-01, 0406-1473-01","Methylin Er, Tablet, Extended Release, 10 mg (NDC 0406-1445-01)",Tablet,Limited Availability,,ANDA075629,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,Shortage of an active ingredient,Allocation to all customers.,,4B3SC438HI,0406-1445-01,800-325-8888,
"Hikma Pharmaceuticals USA, Inc.",VALPROATE SODIUM,,12/30/2020,Revised,INTRAVENOUS,Valproate Sodium Injection,1099648,,bcf57b31-4811-4104-82b3-46fb91a53ee0,07/23/2025,HUMAN PRESCRIPTION DRUG,,Neurology,VALPROATE SODIUM,0143-9785,Hikma Pharmaceuticals USA Inc.,0610e50d-6447-4a0e-bc36-dc0bffa95c7d,"0143-9785-01, 0143-9785-10","Valproate Sodium, Injection, 500 mg/5 mL (NDC 0143-9785-10)",Injection,Unavailable,,ANDA078523,,VALPROATE SODIUM,,,Current,Demand increase for the drug,Additional Lots scheduled to be available in the October 2025 timeframe.,,5VOM6GYJ0D,0143-9785-10,800-631-2174,
"Hospira, Inc., a Pfizer Company","BUPIVACAINE HYDROCHLORIDE, EPINEPHRINE BITARTRATE",,02/20/2018,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL","Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","1012377, 1012381, 1012384, 1012388, 1012396, 1012400, 1012404, 1012406, 1672917, 1672919, 1673242, 1673243, 1724786, 1724787, 1724794, 1724796, 1724880, 1724884, 1725044, 1725046, 1725078, 1725079, 1725082, 1725083, 1867594, 1867596, 1867612, 1867614",,67578b56-7540-487e-1fba-481255620e78,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,MARCAINE WITH EPINEPHRINE,"0409-1746, 0409-1559, 0409-1560, 0409-1582, 0409-1587, 0409-1610, 0409-1749, 0409-1752, 0409-1755, 0409-2510, 0409-7535, 0409-1250, 0409-5010, 0409-1530, 0409-0525, 0409-7510, 0409-2253","Hospira, Inc.",b083f440-bfb7-449a-b601-c2f59a6f9dcf,"0409-1559-18, 0409-1559-10, 0409-1559-19, 0409-1559-30, 0409-1560-18, 0409-1560-10, 0409-1560-19, 0409-1560-29, 0409-1582-18, 0409-1582-10, 0409-1582-19, 0409-1582-29, 0409-1587-50, 0409-1610-50, 0409-1746-70, 0409-1746-10, 0409-1746-71, 0409-1746-30, 0409-1749-70, 0409-1749-10, 0409-1749-71, 0409-1749-29, 0409-1752-50, 0409-1755-50, 0409-2510-01, 0409-2510-25, 0409-7535-01, 0409-7535-25, 0409-1250-01, 0409-1250-25, 0409-5010-01, 0409-5010-25, 0409-1530-01, 0409-1530-25, 0409-0525-01, 0409-0525-25, 0409-7510-01, 0409-7510-25, 0409-2253-01, 0409-2253-25","Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-10)",Injection,Available,,NDA016964,,BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE,,,Current,,,,"30Q7KI53AK, 7TQO7W3VT8",0409-1746-10,844-646-4398,
"Teva Pharmaceuticals USA, Inc.",,,01/06/2025,New,,Cisatracurium Besylate Injection,,,,01/06/2025,,01/06/2025,Anesthesia,,,,,,"CISATRACURIUM BESYLATE PRESERVATIVE FREE, Injection, 10 mg/5 mL (NDC 0703-2033-03)",Injection,,,,,,,,To Be Discontinued,,,,,0703-2033-03,800-545-8800,
"Teva Pharmaceuticals USA, Inc.",,,06/13/2025,New,,Ethinyl Estradiol; Ethinyl Diacetate Tablet,"315096, 748797, 748806, 2000695",,ed075d59-4b6f-467c-bcb1-4dda272d27aa,06/13/2025,HUMAN PRESCRIPTION DRUG,06/13/2025,Reproductive,KELNOR 1/50,0093-8073,"Teva Pharmaceuticals USA, Inc.",ba56e2eb-7101-48d4-9a87-95e4340079b5,"0093-8073-28, 0093-8073-16","Zovia 1/50E-28, Tablet, Kit (NDC 0093-8073-16)",Tablet,,,ANDA072723,,ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL,,,To Be Discontinued,,,,,0093-8073-16,800-545-8800,
"Mylan Pharmaceuticals Inc., a Viatris Company",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,efbde0f6-b848-4664-b741-c6c630e66108,09/17/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0378-6859, 0378-6854, 0378-6855, 0378-6856, 0378-6857, 0378-6858, 0378-6860",Mylan Pharmaceuticals Inc.,2dfa8600-1b2a-47e8-b58d-c9681b8795cb,"0378-6854-77, 0378-6855-77, 0378-6856-77, 0378-6857-77, 0378-6858-77, 0378-6859-77, 0378-6860-77","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0378-6859-77)",Capsule,Available,,ANDA202835,,LISDEXAMFETAMINE,,,Current,,,,SJT761GEGS,0378-6859-77,800-796-9526,
"Hospira, Inc., a Pfizer Company",DOPAMINE HYDROCHLORIDE,,11/06/2017,Revised,INTRAVENOUS,Dopamine Hydrochloride Injection,"1743938, 1743941",,1f306ad2-3606-4525-5a8a-ce78f426c1a2,08/15/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,DOPAMINE HYDROCHLORIDE,"0409-9104, 0409-5820","Hospira, Inc.",a3fac375-0709-4cc0-84db-b0e5a60b7200,"0409-5820-11, 0409-5820-01, 0409-9104-21, 0409-9104-20","Dopamine Hydrochloride, Injection, 400 mg/10mL (40 mg/1 mL) (NDC 0409-9104-20)",Injection,Available,,NDA018132,,DOPAMINE HYDROCHLORIDE,,,Current,,,,7L3E358N9L,0409-9104-20,844-646-4398,
"Caplin Steriles, Ltd.",ETOMIDATE,General Anesthesia [PE],10/05/2022,Reverified,INTRAVENOUS,Etomidate Injection,"1654006, 1654008",,d07efb9e-5264-461d-96d8-e11fa71c5751,09/16/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ETOMIDATE,"65219-447, 65219-445","Fresenius Kabi USA, LLC",30488a7e-ea9e-4a27-95a9-a07149c50282,"65219-445-01, 65219-445-10, 65219-447-02, 65219-447-20","Etomidate, Injection, 2 mg/mL (NDC 65219-447-20)",Injection,Available,"N0000175975, N0000175681",ANDA215028,,ETOMIDATE,General Anesthetic [EPC],,Current,,Check wholesalers for inventory; Marketed by Fresenius Kabi 800-551-7176,,Z22628B598,65219-447-20,800-551-7176,
Rhodes Pharmaceuticals L.P.,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,d918b40d-a461-41bc-b6c0-83dc76c28e32,08/05/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"42858-166, 42858-161, 42858-162, 42858-163, 42858-164, 42858-165, 42858-167",Rhodes Pharmaceuticals,4bb64a6b-cce9-4c4a-81c3-06e2e59315c3,"42858-161-01, 42858-162-01, 42858-163-01, 42858-164-01, 42858-165-01, 42858-166-01, 42858-167-01","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 42858-166-01)",Capsule,Available,,ANDA215330,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,42858-166-01,888-827-0616,
"Upsher-Smith Laboratories, LLC",BACLOFEN,,04/23/2025,New,ORAL,Baclofen Tablet,"197391, 197392",,b2747a9d-5fca-4657-9e4b-4112607f30d8,04/23/2025,HUMAN PRESCRIPTION DRUG,04/23/2025,Neurology,BACLOFEN,"0832-1055, 0832-1054","Upsher-Smith Laboratories, LLC",395d77da-1674-a9a4-e063-6394a90aa3d7,"0832-1054-90, 0832-1054-11, 0832-1054-15, 0832-1054-10, 0832-1055-90, 0832-1055-11, 0832-1055-15, 0832-1055-10","Baclofen, Tablet, 20 mg (NDC 0832-1055-10)",Tablet,,"N0000000196, N0000000116, N0000175759",ANDA074584,,BACLOFEN,gamma-Aminobutyric Acid-ergic Agonist [EPC],,To Be Discontinued,,,,H789N3FKE8,0832-1055-10,716-315-2000,"GABA A Agonists [MoA], GABA B Agonists [MoA]"
Aurobindo Pharma USA,"AMLODIPINE BESYLATE, BENAZEPRIL HYDROCHLORIDE",,03/04/2025,New,ORAL,Amlodipine Besylate; Benazepril Hydrochloride Capsule,"898342, 898346, 898350, 898353, 898356, 898359",,99ed4927-9a34-4e8d-8eea-60b63c867d46,03/04/2025,HUMAN PRESCRIPTION DRUG,03/04/2025,Cardiovascular,AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE,"65862-582, 65862-583, 65862-584, 65862-585, 65862-586, 65862-587",Aurobindo Pharma Limited,a45ec3e8-1d14-4c27-9685-976323df8cad,"65862-582-01, 65862-582-05, 65862-583-01, 65862-583-05, 65862-584-01, 65862-584-05, 65862-585-01, 65862-585-05, 65862-586-01, 65862-586-05, 65862-587-01, 65862-587-05","Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 2.5 mg; 10 mg (NDC 65862-582-01)",Capsule,,,ANDA202239,,AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE,,,To Be Discontinued,,,,"864V2Q084H, N1SN99T69T",65862-582-01,866-850-2876,
"Lannett Company, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,2cedb4c2-1e40-4bc4-b9f4-127150c4afbd,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0527-4661, 0527-4662, 0527-4663, 0527-4664, 0527-4665, 0527-4666, 0527-4667","Lannett Company, Inc.",981ca74f-737d-45e5-a3b2-b25256263768,"0527-4661-37, 0527-4662-37, 0527-4663-37, 0527-4664-37, 0527-4665-37, 0527-4666-37, 0527-4667-37","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0527-4661-37)",Capsule,Limited Availability,,ANDA215802,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,Limited Availability,,SJT761GEGS,0527-4661-37,844-834-0530,
"Boehringer Ingelheim Pharmaceuticals, Inc.",,,10/22/2024,New,,Telmisartan Tablet,,,,10/22/2024,,10/22/2024,Cardiovascular,,,,,,"Micardis, Tablet, 20 mg (NDC 0597-0039-37)",Tablet,,,,,,,,To Be Discontinued,,Discontinued for business reasons,,,0597-0039-37,800-243-0127,
Bristol Myers Squibb Co.,ATAZANAVIR SULFATE,,06/04/2025,New,ORAL,Atazanavir Sulfate Capsule,"402093, 402094, 402246, 402247, 664741, 664743, 1598985, 1598989",,165cff62-b284-4a27-a65d-9ec8a5bfcdd8,06/04/2025,HUMAN PRESCRIPTION DRUG,06/04/2025,Antiviral,REYATAZ,"0003-3631, 0003-3624, 0003-3622, 0003-3638","E.R. Squibb & Sons, L.L.C.",510c2d51-4943-401c-a008-ea22f61c6938,"0003-3624-12, 0003-3631-12, 0003-3622-12, 0003-3638-10","Reyataz, Capsule, 200 mg (NDC 0003-3631-12)",Capsule,,,NDA021567,,ATAZANAVIR,,,To Be Discontinued,,Permanent discontinuation,,4MT4VIE29P,0003-3631-12,1-800-332-2056; for Medical Inquiries (1-800-321-1335),
"Hospira, Inc., a Pfizer Company",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Bupivacaine Hydrochloride Injection,"1725078, 1725082, 1012377, 1012384, 1012396, 1012404, 1672917, 1672919, 1724786, 1724787, 1724880, 1724884, 1867594, 1867596",,"bb44c7e1-d911-4788-908f-09b7b271969b, 02a845c3-4521-4926-e397-25ab536e7cf6",08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE,"0409-1159, 0409-1160, 0409-1162, 0409-1163, 0409-1165, 0409-9043, 0409-9046, 0409-9045, 0409-9042","Hospira, Inc.","40bfa804-5f31-4bd2-b1e3-dcf428710dc1, 3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7","0409-1159-09, 0409-1159-10, 0409-1159-18, 0409-1159-01, 0409-1159-19, 0409-1159-02, 0409-1160-18, 0409-1160-01, 0409-1162-18, 0409-1162-01, 0409-1162-19, 0409-1162-02, 0409-1163-18, 0409-1163-01, 0409-1165-18, 0409-1165-01, 0409-1165-19, 0409-1165-02, 0409-9043-11, 0409-9043-01, 0409-9046-11, 0409-9046-01, 0409-9045-11, 0409-9045-01, 0409-9045-16, 0409-9045-17, 0409-9042-11, 0409-9042-01, 0409-9042-16, 0409-9042-17","Bupivacaine Hydrochloride, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-02)",Injection,Available,,ANDA070583,,BUPIVACAINE HYDROCHLORIDE,,,Current,,,,"7TQO7W3VT8, 30Q7KI53AK",0409-1159-02,844-646-4398,
"Prinston Pharmaceutical, Inc.",CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,4acbb7a9-4db5-4497-b8db-9f358b3f6fb4,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"43547-407, 43547-406, 43547-408",Solco Healthcare LLC,dc17b9d4-2890-4f6c-8476-daa39d0cbc9c,"43547-406-10, 43547-406-50, 43547-406-11, 43547-407-10, 43547-407-50, 43547-407-11, 43547-408-10, 43547-408-50","Clonazepam, Tablet, 1 mg (NDC 43547-407-50)",Tablet,Available,"N0000175694, M0002356",ANDA077856,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,Marketed by Solco Healthcare,,5PE9FDE8GB,43547-407-50,"For orders, Solco Healthcare 866-931-9829",
Torrent Pharma Inc.,,,06/13/2025,New,,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,,,,06/13/2025,,06/13/2025,Cardiovascular,,,,,,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 5 mg; 12.5 mg; 40 mg (NDC 13668-386-05)",Tablet,,,,,,,,To Be Discontinued,,A business decision was made to discontinue manufacture of the product.,,,13668-386-05,908-280-3333,
"Teva Pharmaceuticals USA, Inc.",DOXYCYCLINE HYCLATE,,06/13/2025,New,ORAL,Doxycycline Hyclate Tablet,1650143,,a569ba80-ffea-40b2-9fbe-a42810b1fccb,06/13/2025,HUMAN PRESCRIPTION DRUG,06/13/2025,Anti-Infective,DOXYCYCLINE HYCLATE,0591-5553,"Actavis Pharma, Inc.",0fb9a3f8-9ebb-4c21-8a73-9f082b39039c,"0591-5553-50, 0591-5553-05","Doxycycline Hyclate, Tablet, 100 mg (NDC 0591-5553-50)",Tablet,,,ANDA062421,,DOXYCYCLINE HYCLATE,,,To Be Discontinued,,,,19XTS3T51U,0591-5553-50,800-545-8800,
Accord Healthcare Inc.,METHOTREXATE,,03/13/2023,Reverified,"INTRA-ARTERIAL, INTRAMUSCULAR, INTRATHECAL, INTRAVENOUS",Methotrexate Sodium Injection,"1655956, 1655959, 1655960",,dd035a9f-cd40-4314-b9d8-2294b8a924e2,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Rheumatology, Oncology",METHOTREXATE,16729-277,"Accord Healthcare, Inc.",2bae3cfe-7aa0-c14c-e063-6294a90a19f4,"16729-277-30, 16729-277-03, 16729-277-35","Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)",Injection,Unavailable,"N0000175584, N0000000111",ANDA040716,,METHOTREXATE,Folate Analog Metabolic Inhibitor [EPC],,Current,Shortage of an active ingredient,Resupply: estimated 21 days,,YL5FZ2Y5U1,16729-277-30,"866-941-7875, option 2",Folic Acid Metabolism Inhibitors [MoA]
"Teva Pharmaceuticals USA, Inc.",PHENTERMINE HYDROCHLORIDE,,06/13/2025,New,ORAL,Phentermine Hydrochloride Tablet,"803353, 803354",,f5b2f9d8-2226-476e-9caf-9d41e6891c46,06/13/2025,HUMAN PRESCRIPTION DRUG,06/13/2025,Other,ADIPEX-P,57844-140,"Teva Pharmaceuticals USA, Inc.",0b8644f4-40ad-4c0b-bacb-97dcd2fc2dcd,"57844-140-56, 57844-140-01","Adipex-P, Tablet, 37.5 mg (NDC 57844-140-56)",Tablet,,,ANDA085128,,PHENTERMINE HYDROCHLORIDE,,,To Be Discontinued,,,,0K2I505OTV,57844-140-56,800-545-8800,
Sun Pharmaceutical Industries Limited,TIAGABINE HYDROCHLORIDE,,12/09/2024,New,ORAL,Tiagabine Hydrochloride Tablet,"1299911, 1299917",,7eeb2d81-c5d7-46a0-aa5c-149b55df71bd,12/09/2024,HUMAN PRESCRIPTION DRUG,12/09/2024,Neurology,TIAGABINE HYDROCHLORIDE,"62756-224, 62756-200","Sun Pharmaceutical Industries, Inc.",57975e74-e45b-4fd9-9718-bfc9690acae5,"62756-200-83, 62756-200-18, 62756-224-83, 62756-224-88, 62756-224-08, 62756-224-18","Tiagabine Hydrochloride, Tablet, 4 mg (NDC 62756-224-88)",Tablet,,,ANDA077555,,TIAGABINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuing for business reasons,,DQH6T6D8OY,62756-224-88,800-818-4555,
Accord Healthcare Inc.,ATROPINE SULFATE,,01/01/2020,Reverified,INTRAVENOUS,Atropine Sulfate Injection,"1190546, 1190551, 1190552",,c82cb295-ffce-47d6-97ad-a8aa723f4e4f,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology, Pediatric",ATROPINE SULFATE,"16729-484, 16729-483","Accord Healthcare, Inc.,",275da8b0-80b1-6c78-e063-6394a90a97a3,"16729-483-03, 16729-483-31, 16729-484-90, 16729-484-31, 16729-484-45, 16729-484-03","Atropine Sulfate, Injection, .1 mg/1 mL (NDC 16729-484-90)",Injection,Unavailable,,ANDA212868,,ATROPINE SULFATE,,,Current,Discontinuation of the manufacture of the drug,Discontinuation of the manufacture of the drug,,03J5ZE7KA5,16729-484-90,"866-941-7875, option 2",
"Fresenius Kabi USA, LLC",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,"INFILTRATION, PERINEURAL",Bupivacaine Hydrochloride Injection,"1012391, 1012396, 1012404, 1012421, 1012455, 1012457, 1672917, 1672919, 1673296, 1673298, 1724880, 1724881, 1724884, 1724885, 1725078, 1725082, 1725175, 1725177",,eb6d8fee-def4-4c96-9972-695e8cea8ea8,09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,SENSORCAINE,"63323-465, 63323-467, 63323-460, 63323-464, 63323-466, 63323-462","Fresenius Kabi USA, LLC",2b1a1f80-cb29-4ac1-9e72-20225ed45715,"63323-465-01, 63323-465-57, 63323-467-01, 63323-467-57, 63323-460-01, 63323-460-37, 63323-464-02, 63323-464-37, 63323-464-03, 63323-464-31, 63323-466-01, 63323-466-37, 63323-466-02, 63323-466-31, 63323-462-04, 63323-462-17, 63323-462-01, 63323-462-37, 63323-462-02, 63323-462-31","Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-465-57)",Injection,Available,,NDA018304,,BUPIVACAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,"30Q7KI53AK, 7TQO7W3VT8",63323-465-57,888-386-1300,
"Hospira, Inc., a Pfizer Company","EPINEPHRINE, LIDOCAINE HYDROCHLORIDE",,02/22/2012,Reverified,EPIDURAL,"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","1010688, 1010745, 1010751, 1010759, 1867996, 1867998",,2f94f711-14c4-48ec-c5a3-c5ec4b8e8729,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE,"0409-1209, 0409-3177, 0409-3178, 0409-3181, 0409-3182, 0409-3183, 0409-0007, 0409-0147","Hospira, Inc.",d16a4711-e663-455e-a1fe-236a41ca4e8f,"0409-1209-10, 0409-1209-01, 0409-1209-05, 0409-1209-70, 0409-1209-65, 0409-3177-16, 0409-3177-01, 0409-3178-16, 0409-3178-01, 0409-3178-17, 0409-3178-02, 0409-3178-18, 0409-3178-03, 0409-3181-11, 0409-3181-01, 0409-3182-11, 0409-3182-01, 0409-3182-21, 0409-3182-02, 0409-3182-31, 0409-3182-03, 0409-3183-11, 0409-3183-01, 0409-0007-01, 0409-0007-10, 0409-0147-01, 0409-0147-10","Lidocaine Hydrochloride And Epinephrine, Injection, 75 mg/5 mL (1.5%; 1:200,000) (NDC 0409-1209-01)",Injection,Available,"N0000000209, N0000000245, N0000175552, N0000175555, N0000175570, M0003647",ANDA088571,Catecholamines [CS],LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE,"alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC], Catecholamine [EPC]",,Current,,,,"V13007Z41A, YKH834O4BH",0409-1209-01,844-646-4398,"Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA]"
"Fresenius Kabi USA, LLC",LIDOCAINE HYDROCHLORIDE ANHYDROUS,,02/22/2012,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010035, 1010671, 1010673, 1010688, 1010692, 1010745, 1010749, 1010751, 1010755, 1010759, 1010763, 1010900, 1010902, 1737343, 1737345, 1737562, 1737563, 1737566, 1737567, 1737568, 1737569, 1737570, 1737571, 1737757, 1737758, 1737761, 1737762, 1867938, 1867940, 1867943, 1867944, 1867992, 1867993, 1867996, 1867997, 1868028, 1868029, 1737636, 1737637, 1737640, 1737641, 1737763, 1737764",,"ba082c2f-64f4-419d-9c88-74f203316e17, 4dd52202-8eef-4136-92dd-ada573b7cf74, d5e0d06f-ba1e-44d4-aa89-39d6c146dc23",09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",XYLOCAINE MPF,"63323-492, 63323-491, 63323-495, 63323-485, 63323-486, 63323-484, 63323-489, 63323-488, 63323-481, 63323-483, 63323-482, 63323-487, 63323-493, 63323-496","Fresenius Kabi USA, LLC","ea480a68-5927-4278-9deb-2956961da428, 0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33, fa12a8e8-09fd-496f-8cc6-ffe0eb02e2df","63323-492-04, 63323-492-27, 63323-492-09, 63323-492-57, 63323-492-07, 63323-492-37, 63323-492-03, 63323-492-31, 63323-491-01, 63323-491-57, 63323-495-09, 63323-495-27, 63323-495-04, 63323-495-07, 63323-485-01, 63323-485-27, 63323-485-03, 63323-485-57, 63323-486-01, 63323-486-17, 63323-486-02, 63323-486-27, 63323-486-05, 63323-486-57, 63323-484-57, 63323-489-02, 63323-489-27, 63323-489-03, 63323-489-21, 63323-489-01, 63323-489-17, 63323-488-07, 63323-488-37, 63323-488-03, 63323-488-31, 63323-488-01, 63323-488-17, 63323-481-01, 63323-481-57, 63323-483-03, 63323-483-27, 63323-483-01, 63323-483-57, 63323-482-01, 63323-482-17, 63323-482-03, 63323-482-27, 63323-482-05, 63323-482-57, 63323-487-01, 63323-487-17, 63323-487-07, 63323-487-37, 63323-487-03, 63323-487-31, 63323-492-41, 63323-492-16, 63323-492-43, 63323-492-36, 63323-492-45, 63323-492-26, 63323-485-41, 63323-485-26, 63323-486-41, 63323-486-26, 63323-482-41, 63323-482-26, 63323-495-41, 63323-495-26, 63323-492-08, 63323-492-97, 63323-493-03, 63323-493-97, 63323-493-01, 63323-493-91, 63323-496-03, 63323-496-97","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-27)",Injection,Available,,NDA006488,,LIDOCAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,"EC2CNF7XFP, 30Q7KI53AK",63323-492-27,888-386-1300,
InfoRLife SA,METRONIDAZOLE,,01/13/2022,Reverified,INTRAVENOUS,Metronidazole Injection,311683,,49360d6f-c8b3-420e-af75-154cf7b05255,09/22/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,METRONIDAZOLE,0409-0152,"Hospira, Inc.",016415af-48d9-4058-a80e-f5dd1704e6fc,"0409-0152-01, 0409-0152-24","Metronidazole in Flexible Container, Injection, 500 mg/100 mL (NDC 0409-0152-24)",Injection,Limited Availability,"N0000175435, M0014907",ANDA206191,Nitroimidazoles [CS],METRONIDAZOLE,Nitroimidazole Antimicrobial [EPC],,Current,Other,Labeler: Hospira Inc.,,140QMO216E,0409-0152-24,866-625-1618,
"Sun Pharmaceutical Industries, Inc.",NALTREXONE HYDROCHLORIDE,,02/29/2024,Revised,ORAL,Naltrexone Hydrochloride Tablet,1483744,,0f30f885-d0cd-4fa6-a8e0-142f08a56792,09/22/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,NALTREXONE HYDROCHLORIDE,47335-326,"Sun Pharmaceutical Industries, Inc.",b0c2b60a-dc96-483b-933e-2fed58b64372,"47335-326-83, 47335-326-88, 47335-326-08, 47335-326-18","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 47335-326-88)",Tablet,Limited Availability,,ANDA090356,,NALTREXONE HYDROCHLORIDE,,,Current,Other,Additional supply anticipated early 2026,,Z6375YW9SF,47335-326-88,800-818-4555,
"Teva Pharmaceuticals USA, Inc.",POTASSIUM CHLORIDE,,05/19/2025,New,ORAL,"Potassium Chloride Capsule, Extended Release","312504, 315183",,ed5baaf6-270b-4dd3-b100-36030c0098fc,05/19/2025,HUMAN PRESCRIPTION DRUG,05/19/2025,"Endocrinology/Metabolism, Gastroenterology",POTASSIUM CHLORIDE,"62037-559, 62037-560","Actavis Pharma, Inc.",b97da107-c56e-48ea-ba34-d3d64a5b9f46,"62037-559-01, 62037-559-05, 62037-560-01, 62037-560-05, 62037-560-10, 62037-560-90","Potassium Chloride, Capsule, Extended Release, 600 mg (NDC 62037-559-05)","Capsule, Extended Release",,,ANDA077419,,POTASSIUM CHLORIDE,,,To Be Discontinued,,,,660YQ98I10,62037-559-05,800-545-8800,
"Spectra Medical Devices, LLC",SODIUM CHLORIDE,,06/21/2018,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Sodium Chloride 0.9% Injection,"1807637, 1807646",,7e316d21-d6ad-4976-bd90-268fd7e51361,08/08/2025,HUMAN PRESCRIPTION DRUG,,Other,SODIUM CHLORIDE,"65282-1510, 65282-1505","Spectra Medical Deviecs, LLC",0e649488-3951-382e-e063-6294a90a55c1,"65282-1510-1, 65282-1505-1","Sodium Chloride 0.9%, Injection, 9 mg/1 mL (NDC 65282-1510-1)",Injection,,,ANDA206171,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,65282-1510-1,978-657-0889,
"Hospira, Inc., a Pfizer Company",BLEOMYCIN SULFATE,,06/13/2025,New,"INTRAMUSCULAR, INTRAPLEURAL, INTRAVENOUS, SUBCUTANEOUS",Bleomycin Sulfate Injection,"1726673, 1726676",,e629ba5a-4e08-4249-9551-af6dbd98a7e4,06/13/2025,HUMAN PRESCRIPTION DRUG,06/13/2025,"Hematology, Oncology, Pediatric",BLEOMYCIN,"0409-0332, 0409-0323","Hospira, Inc.",d9e9c332-1b3f-469c-83b8-41e15183e635,"0409-0323-20, 0409-0332-20","Bleomycin Sulfate, Injection, 15 [USP'U] (NDC 0409-0332-20)",Injection,,,ANDA065031,,BLEOMYCIN,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,7DP3NTV15T,0409-0332-20,844-646-4398,
"Mylan Institutional, a Viatris Company",DEXAMETHASONE SODIUM PHOSPHATE,,02/08/2019,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Dexamethasone Sodium Phosphate Injection,"309696, 1116927, 1812194",,dff598e8-e662-411f-978d-4ba3fb8ef7db,09/17/2025,HUMAN PRESCRIPTION DRUG,,"Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Other, Pulmonary/Allergy, Rheumatology",DEXAMETHASONE SODIUM PHOSPHATE,"67457-420, 67457-423, 67457-422, 67457-421",Mylan Institutional LLC,dd5c82b6-a194-462c-9626-34a9b410cfea,"67457-423-00, 67457-423-12, 67457-422-00, 67457-422-54, 67457-421-00, 67457-421-30, 67457-420-00, 67457-420-10","Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 67457-420-10)",Injection,Available,,ANDA040802,,DEXAMETHASONE SODIUM PHOSPHATE,,,Current,,,,AI9376Y64P,67457-420-10,800-796-9526,
"Teva Pharmaceuticals USA, Inc.",FLURBIPROFEN,,11/13/2024,New,ORAL,Flurbiprofen Tablet,197724,,4e5c06f1-f279-4f2f-b10d-0f70005a27e6,11/13/2024,HUMAN PRESCRIPTION DRUG,11/13/2024,Analgesia/Addiction,FLURBIPROFEN,0093-0711,"Teva Pharmaceuticals USA, Inc.",38a133bd-a325-4de2-bcf2-d6e144cc456b,"0093-0711-01, 0093-0711-05","Tablet, 100 mg (NDC 0093-0711-01)",Tablet,,"N0000000160, M0001335, N0000175722",ANDA074431,"Anti-Inflammatory Agents, Non-Steroidal [CS]",FLURBIPROFEN,Nonsteroidal Anti-inflammatory Drug [EPC],,To Be Discontinued,,A business decision was made to discontinue manufacture of the product.,,5GRO578KLP,0093-0711-01,800-545-8800,Cyclooxygenase Inhibitors [MoA]
"Hikma Pharmaceuticals USA, Inc.",METHOTREXATE,,03/13/2023,Reverified,"INTRA-ARTERIAL, INTRAMUSCULAR, INTRATHECAL, INTRAVENOUS",Methotrexate Sodium Injection,"1655959, 1655960, 1655967, 1655968",,3989d30d-56e5-4e8d-9379-c30fecc894f2,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Rheumatology, Oncology",METHOTREXATE,"0143-9519, 0143-9518, 0143-9517, 0143-9516",Hikma Pharmaceuticals USA Inc.,3046ff78-3565-46d1-a88b-283e5ff6e7c3,"0143-9519-10, 0143-9518-01, 0143-9517-01, 0143-9516-01","Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)",Injection,Available,"N0000175584, N0000000111",ANDA089340,,METHOTREXATE,Folate Analog Metabolic Inhibitor [EPC],,Current,,Additional lots are scheduled to be manufactured.  Product will be made available as it is released.,,YL5FZ2Y5U1,0143-9519-10,800-631-2174,Folic Acid Metabolism Inhibitors [MoA]
"Dr. Reddy's Laboratories, Inc.",,,01/08/2025,New,,Ramelteon Tablet,,,,01/08/2025,,01/08/2025,Other,,,,,,"Tablet, 8 mg (NDC 50268-708-15)",Tablet,,,,,,,,To Be Discontinued,,,,,50268-708-15,866-732-3952,
"Actavis Pharma, Inc.",EZETIMIBE,Decreased Cholesterol Absorption [PE],06/27/2025,New,ORAL,Ezetimibe Tablet,349556,,f26e7a4e-b3d9-4cf8-baf0-7423d46cd8ba,06/27/2025,HUMAN PRESCRIPTION DRUG,06/27/2025,Cardiovascular,EZETIMIBE,0591-3713,"Actavis Pharma, Inc.",24aaf5ca-08e0-4db8-9734-cf2a606f8e57,"0591-3713-30, 0591-3713-19, 0591-3713-05","Ezetimibe, Tablet, 10 mg (NDC 0591-3713-30)",Tablet,,"N0000008553, N0000175911",ANDA200831,,EZETIMIBE,Dietary Cholesterol Absorption Inhibitor [EPC],,To Be Discontinued,,A business decision was made to discontinue manufacture of the product,,EOR26LQQ24,0591-3713-30,800-545-8800,
Sandoz Inc.,AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","239191, 308182, 308189, 308191, 308192, 308194, 313797, 313850",,13bd4214-9b7f-425b-af5f-fc1ddc678230,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0781-6156, 0781-2020, 0781-2613, 0781-5060, 0781-5061, 0781-6039, 0781-6041, 0781-6157",Sandoz Inc,6aa02079-d11c-4d2f-acaf-9548dd9a7ed6,"0781-2020-31, 0781-2020-76, 0781-2020-01, 0781-2020-05, 0781-2613-31, 0781-2613-76, 0781-2613-01, 0781-2613-05, 0781-5060-20, 0781-5060-01, 0781-5061-20, 0781-5061-01, 0781-6039-58, 0781-6039-46, 0781-6039-55, 0781-6156-52, 0781-6156-57, 0781-6156-46, 0781-6041-58, 0781-6041-46, 0781-6041-55, 0781-6157-52, 0781-6157-57, 0781-6157-46","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0781-6156-52)","Powder, For Suspension",,,ANDA065378,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0781-6156-52,800-525-8747,
"Solco Healthcare US, LLC",QUINAPRIL HYDROCHLORIDE,,01/19/2023,Reverified,ORAL,Quinapril Hydrochloride Tablet,"312748, 312749, 312750, 314203",,cd46691d-5593-4a9f-a937-999c6803e312,09/17/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,QUINAPRIL,"43547-412, 43547-410, 43547-411, 43547-413","Solco Healthcare US, LLC",b8f1731a-cbac-4f64-a8d4-320b80b335e1,"43547-410-09, 43547-411-09, 43547-412-09, 43547-413-09","Quinapril Hydrochloride, Tablet, 20 mg (NDC 43547-412-09)",Tablet,Unavailable,,ANDA205823,,QUINAPRIL,,,Current,Shortage of an active ingredient,Not available. Long-term backorder for all NDCs. No estimated release date at this time.,,33067B3N2M,43547-412-09,866-931-9829,
"Mylan Pharmaceuticals Inc., a Viatris Company",,,02/14/2025,New,,Erythromycin  Topical Gel,,,,02/14/2025,,02/14/2025,"Anti-Infective, Dermatology",,,,,,"Erygel, Topical Gel, 20 mg/1 g (NDC 0378-8212-60)",Topical Gel,,,,,,,,To Be Discontinued,,,,,0378-8212-60,800-796-9526,
Slate Run Pharmaceuticals,LEUCOVORIN CALCIUM,,01/01/2012,Revised,"INTRAMUSCULAR, INTRAVENOUS",Leucovorin Calcium Injection,"237788, 1803930, 1803932, 1803937, 2055036",,d8bdd60c-9a1c-4ef4-ba6b-b911849128f1,07/08/2025,HUMAN PRESCRIPTION DRUG,,"Oncology, Pediatric",LEUCOVORIN CALCIUM,"70436-117, 70436-116, 70436-118, 70436-120, 70436-119","Slate Run Pharmaceuticals, LLC",2a4aaed3-885e-bc10-e063-6294a90a61af,"70436-116-80, 70436-116-82, 70436-117-80, 70436-118-80, 70436-120-80, 70436-119-80","Leucovorin Calcium, Injection, 100 mg (NDC 70436-117-80)",Injection,,,ANDA217021,,LEUCOVORIN CALCIUM,,Available,Resolved,,,07/08/2025,RPR1R4C0P4,70436-117-80,888-447-0095,
"Teva Pharmaceuticals USA, Inc.",POTASSIUM CHLORIDE,,05/19/2025,New,ORAL,"Potassium Chloride Capsule, Extended Release","312504, 315183",,ed5baaf6-270b-4dd3-b100-36030c0098fc,05/19/2025,HUMAN PRESCRIPTION DRUG,05/19/2025,"Endocrinology/Metabolism, Gastroenterology",POTASSIUM CHLORIDE,"62037-560, 62037-559","Actavis Pharma, Inc.",b97da107-c56e-48ea-ba34-d3d64a5b9f46,"62037-559-01, 62037-559-05, 62037-560-01, 62037-560-05, 62037-560-10, 62037-560-90","Potassium Chloride, Capsule, Extended Release, 750 mg (NDC 62037-560-05)","Capsule, Extended Release",,,ANDA077419,,POTASSIUM CHLORIDE,,,To Be Discontinued,,,,660YQ98I10,62037-560-05,800-545-8800,
"Elite Laboratories, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,e677690f-790f-4626-ad78-097cdb6ea540,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","64850-500, 64850-501, 64850-502, 64850-503, 64850-504, 64850-505, 64850-506","Elite Laboratories, Inc.",b65e0266-7172-4730-8f93-eb42e08fb7b8,"64850-500-01, 64850-500-05, 64850-500-30, 64850-501-01, 64850-501-05, 64850-501-30, 64850-502-01, 64850-502-05, 64850-502-30, 64850-503-01, 64850-503-05, 64850-503-30, 64850-504-01, 64850-504-05, 64850-504-30, 64850-505-01, 64850-505-05, 64850-505-30, 64850-506-01, 64850-506-05, 64850-506-30","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 64850-500-01)",Tablet,Limited Availability,,ANDA211352,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,Shortage of an active ingredient,3 months,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",64850-500-01,888-852-6657,
Eli Lilly and Co.,ATOMOXETINE HYDROCHLORIDE,,10/22/2024,New,ORAL,Atomoxetine Hydrochloride Capsule,"349591, 349592, 349593, 349594, 349595, 352317, 352318, 352319, 352320, 352321, 608139, 608143, 617945, 617947",,309de576-c318-404a-bc15-660c2b1876fb,10/22/2024,HUMAN PRESCRIPTION DRUG,10/22/2024,Psychiatry,STRATTERA,"0002-3238, 0002-3227, 0002-3228, 0002-3229, 0002-3239, 0002-3250, 0002-3251",Eli Lilly and Company,90fd3143-d5d4-4343-9570-b3863e31b1a0,"0002-3227-30, 0002-3238-30, 0002-3228-30, 0002-3229-30, 0002-3239-30, 0002-3250-30, 0002-3251-30","Strattera, Capsule, 18 mg (NDC 0002-3238-30)",Capsule,,,NDA021411,,ATOMOXETINE HYDROCHLORIDE,,,To Be Discontinued,,Business decision to discontinue,,57WVB6I2W0,0002-3238-30,800-545-5979,
"Teva Pharmaceuticals USA, Inc.",AZACITIDINE,,12/22/2020,Revised,"INTRAVENOUS, SUBCUTANEOUS",Azacitidine Injection,485246,,5f0f9ee3-a5b1-4a25-a34c-7f38c8433f4a,09/15/2025,HUMAN PRESCRIPTION DRUG,,Oncology,AZACITIDINE,68001-313,BluePoint Laboratories,36080e4e-a0fe-ba15-e063-6394a90aed5c,68001-313-56,"Azacitidine, Injection, 100 mg (NDC 68001-313-56)",Injection,Unavailable,"N0000000233, N0000175595",NDA208216,,AZACITIDINE,Nucleoside Metabolic Inhibitor [EPC],,Current,Other,Estimated recovery: TBD,,M801H13NRU,68001-313-56,800-545-8800,Nucleic Acid Synthesis Inhibitors [MoA]
"Upsher-Smith Laboratories, LLC",BACLOFEN,,04/23/2025,New,ORAL,Baclofen Tablet,"197391, 197392",,b2747a9d-5fca-4657-9e4b-4112607f30d8,04/23/2025,HUMAN PRESCRIPTION DRUG,04/23/2025,Neurology,BACLOFEN,"0832-1055, 0832-1054","Upsher-Smith Laboratories, LLC",395d77da-1674-a9a4-e063-6394a90aa3d7,"0832-1054-90, 0832-1054-11, 0832-1054-15, 0832-1054-10, 0832-1055-90, 0832-1055-11, 0832-1055-15, 0832-1055-10","Baclofen, Tablet, 20 mg (NDC 0832-1055-90)",Tablet,,"N0000000196, N0000000116, N0000175759",ANDA074584,,BACLOFEN,gamma-Aminobutyric Acid-ergic Agonist [EPC],,To Be Discontinued,,,,H789N3FKE8,0832-1055-90,716-315-2000,"GABA A Agonists [MoA], GABA B Agonists [MoA]"
"Hikma Pharmaceuticals USA, Inc.",AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","239191, 313797",,077f4a65-3cfb-4cb1-99f2-e27ffc5939c0,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0143-9889, 0143-9888",Hikma Pharmaceuticals USA Inc.,c2fa2c99-c735-4834-a8a5-04a30da8a002,"0143-9888-80, 0143-9888-01, 0143-9888-15, 0143-9889-80, 0143-9889-01, 0143-9889-15","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0143-9889-80)","Powder, For Suspension",,,ANDA065322,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0143-9889-80,800-631-2174,
Sun Pharmaceutical Industries Limited,IMATINIB MESYLATE,,12/05/2024,New,ORAL,Imatinib Mesylate Tablet,"403878, 403879",,07764bf9-21b4-4e32-9d7e-e348f8e4291f,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Hematology,IMATINIB MESYLATE,"47335-475, 47335-472","Sun Pharmaceutical Industries, Inc.",ad13dbca-474d-4492-9c25-e0e175143d8c,"47335-472-83, 47335-472-88, 47335-472-13, 47335-472-81, 47335-475-83, 47335-475-88, 47335-475-13, 47335-475-64","Imatinib Mesylate, Tablet, 400 mg (NDC 47335-475-64)",Tablet,,,ANDA078340,,IMATINIB MESYLATE,,,To Be Discontinued,,Discontinuing for business reasons,,8A1O1M485B,47335-475-64,800-818-4555,
"Hospira, Inc., a Pfizer Company",LIDOCAINE HYDROCHLORIDE,,02/22/2012,Reverified,"INFILTRATION, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010671, 1010900, 1737343, 1737562, 1737566, 1737568, 1737636, 1737757, 1737763",,3b2dd84e-cee8-4e58-d494-395a65a353a0,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE HYDROCHLORIDE,"0409-4277, 0409-4713, 0409-4278, 0409-4279, 0409-4776, 0409-4282, 0409-4276, 0409-4275","Hospira, Inc.",c0b4635b-1473-4c48-89c6-620762cd687f,"0409-4713-12, 0409-4713-26, 0409-4713-02, 0409-4713-72, 0409-4713-62, 0409-4713-75, 0409-4713-65, 0409-4713-42, 0409-4713-25, 0409-4713-32, 0409-4278-16, 0409-4278-01, 0409-4279-16, 0409-4279-02, 0409-4776-10, 0409-4776-01, 0409-4282-11, 0409-4282-25, 0409-4282-01, 0409-4282-12, 0409-4282-02, 0409-4277-16, 0409-4277-01, 0409-4277-17, 0409-4277-02, 0409-4276-16, 0409-4276-01, 0409-4276-17, 0409-4276-02, 0409-4275-16, 0409-4275-01","Lidocaine Hydrochloride In Plastic Container, Injection, 400 mg/20 mL (2%; 20 mg/mL) (NDC 0409-4277-01)",Injection,Available,,ANDA088327,,LIDOCAINE HYDROCHLORIDE,,,Current,,,,V13007Z41A,0409-4277-01,844-646-4398,
"Fresenius Kabi USA, LLC",LIDOCAINE HYDROCHLORIDE ANHYDROUS,,02/22/2012,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Lidocaine Hydrochloride Injection,"1737562, 1737563, 1737566, 1737567, 1737568, 1737569, 1737570, 1737571, 1737636, 1737637, 1737640, 1737641, 1737763, 1737764",,d5e0d06f-ba1e-44d4-aa89-39d6c146dc23,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",XYLOCAINE MPF,"63323-496, 63323-492, 63323-493","Fresenius Kabi USA, LLC",fa12a8e8-09fd-496f-8cc6-ffe0eb02e2df,"63323-492-08, 63323-492-97, 63323-493-03, 63323-493-97, 63323-493-01, 63323-493-91, 63323-496-03, 63323-496-97","Xylocaine, Injection, 20 mg/1 mL (NDC 63323-496-97)",Injection,Unavailable,,NDA006488,,LIDOCAINE HYDROCHLORIDE,,,Current,Demand increase for the drug,Next release date not available at this time.,,EC2CNF7XFP,63323-496-97,888-386-1300,
Sun Pharmaceutical Industries Limited,PANTOPRAZOLE SODIUM,,12/05/2024,New,INTRAVENOUS,Pantoprazole Sodium Injection,283669,,d9fcf6a2-3788-4955-84d9-3c319b13267c,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Gastroenterology,PANTOPRAZOLE SODIUM,62756-129,"Sun Pharmaceutical Industries, Inc.",ef1bb9ed-b534-4698-abf5-836dcce85f45,"62756-129-40, 62756-129-44, 62756-129-45","Pantoprazole Sodium, Injection, 40 mg/10 mL (NDC 62756-129-45)",Injection,,,ANDA077674,,PANTOPRAZOLE SODIUM,,,To Be Discontinued,,Discontinuing for business reasons,,6871619Q5X,62756-129-45,800-818-4555,
"Hospira, Inc., a Pfizer Company",SODIUM ACETATE ANHYDROUS,,02/03/2016,Reverified,INTRAVENOUS,Sodium Acetate Injection,237371,,"abc41ed1-9512-4bea-9295-1a9ca134b6c2, c3be2468-45e8-4ecc-a30b-e966743a563f",08/15/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Pediatric, Total Parenteral Nutrition",SODIUM ACETATE,0409-3299,"Hospira, Inc.","eadea22b-c475-4596-8c15-e738af5a711d, 99255488-8958-49ab-965c-083119f5ba3c","0409-3299-15, 0409-3299-05, 0409-3299-16, 0409-3299-06, 0409-3299-45, 0409-3299-25, 0409-3299-46, 0409-3299-26","Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-05)",Injection,Available,,NDA018893,,SODIUM ACETATE,,,Current,,,,NVG71ZZ7P0,0409-3299-05,844-646-4398,
"Mylan Institutional, a Viatris Company",DEXAMETHASONE SODIUM PHOSPHATE,,02/08/2019,Reverified,"INTRA-ARTICULAR, INTRALESIONAL, INTRAMUSCULAR, INTRAVENOUS, SOFT TISSUE",Dexamethasone Sodium Phosphate Injection,"309696, 1116927, 1812194",,dff598e8-e662-411f-978d-4ba3fb8ef7db,09/17/2025,HUMAN PRESCRIPTION DRUG,,"Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Other, Pulmonary/Allergy, Rheumatology",DEXAMETHASONE SODIUM PHOSPHATE,"67457-421, 67457-423, 67457-422, 67457-420",Mylan Institutional LLC,dd5c82b6-a194-462c-9626-34a9b410cfea,"67457-423-00, 67457-423-12, 67457-422-00, 67457-422-54, 67457-421-00, 67457-421-30, 67457-420-00, 67457-420-10","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-421-30)",Injection,Available,,ANDA040803,,DEXAMETHASONE SODIUM PHOSPHATE,,,Current,,,,AI9376Y64P,67457-421-30,800-796-9526,
"Hospira, Inc., a Pfizer Company",DOPAMINE HYDROCHLORIDE,,11/06/2017,Revised,INTRAVENOUS,Dopamine Hydrochloride Injection,"1743938, 1743941",,1f306ad2-3606-4525-5a8a-ce78f426c1a2,08/15/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,DOPAMINE HYDROCHLORIDE,"0409-5820, 0409-9104","Hospira, Inc.",a3fac375-0709-4cc0-84db-b0e5a60b7200,"0409-5820-11, 0409-5820-01, 0409-9104-21, 0409-9104-20","Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)",Injection,Available,,NDA018132,,DOPAMINE HYDROCHLORIDE,,,Current,,,,7L3E358N9L,0409-5820-01,844-646-4398,
"Fresenius Kabi USA, LLC",HYDROMORPHONE HYDROCHLORIDE,,10/31/2017,Reverified,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Hydromorphone Hydrochloride Injection,"897653, 897753, 1724276, 1724338, 1724340, 1724341",,e034eb96-03e0-46e1-8b92-5e1f94555e7b,09/18/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,HYDROMORPHONE HYDROCHLORIDE,"63323-851, 63323-852, 63323-853, 63323-854","Fresenius Kabi USA, LLC",9e8522c6-595c-46f9-bb25-272aa4683e0f,"63323-851-03, 63323-851-10, 63323-851-07, 63323-851-15, 63323-851-50, 63323-852-03, 63323-852-25, 63323-853-03, 63323-853-25, 63323-854-03, 63323-854-10","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-50)",Injection,Unavailable,,NDA019034,,HYDROMORPHONE HYDROCHLORIDE,,,Current,Other,Backordered. Next release not available at this time. Check wholesalers for inventory.,,L960UP2KRW,63323-851-50,888-386-1300,
"Hikma Pharmaceuticals USA, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,6740a621-9bec-4178-a4fc-a3fc89f34e0a,07/23/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0054-0373, 0054-0660, 0054-0370, 0054-0371, 0054-0372, 0054-0374, 0054-0375",Hikma Pharmaceuticals USA Inc.,5d119550-4386-4bfa-a5d0-bb18e66191b7,"0054-0660-25, 0054-0370-25, 0054-0371-25, 0054-0372-25, 0054-0373-25, 0054-0374-25, 0054-0375-25","Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0054-0373-25)",Capsule,Limited Availability,,ANDA202827,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,Available on allocation,,SJT761GEGS,0054-0373-25,800-631-2174,
Chartwell Molecular Holdings LLC,QUINAPRIL HYDROCHLORIDE,,01/19/2023,Reverified,ORAL,Quinapril Hydrochloride Tablet,"312748, 312749, 312750, 314203",,dbc43dbd-94aa-40e2-a9ea-766110cc8687,08/19/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,QUINAPRIL,"62135-487, 62135-484, 62135-485, 62135-486","Chartwell RX, LLC",09cd5cb9-4fdf-f133-e063-6294a90af691,"62135-484-60, 62135-485-90, 62135-486-90, 62135-487-90","Quinapril Hydrochloride, Tablet, 40 mg (NDC 62135-487-90)",Tablet,Available,,ANDA076803,,QUINAPRIL,,,Current,,,,33067B3N2M,62135-487-90,845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com,
"Amphastar Pharmaceuticals, Inc.",SODIUM BICARBONATE,,03/01/2017,Reverified,INTRAVENOUS,Sodium Bicarbonate Injection,792582,,77698221-a01d-4568-a7bc-d3d4e982875d,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Pediatric",SODIUM BICARBONATE,76329-3352,"International Medication Systems, Limited",74a86dc7-0929-40d0-9661-9f9063a8fd7d,76329-3352-1,"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 76329-3352-1)",Injection,Available,,ANDA203449,,SODIUM BICARBONATE,,,Current,,,,8MDF5V39QO,76329-3352-1,800-423-4136,
Sun Pharmaceutical Industries Limited,TIAGABINE HYDROCHLORIDE,,12/09/2024,New,ORAL,Tiagabine Hydrochloride Tablet,"1299911, 1299917",,7eeb2d81-c5d7-46a0-aa5c-149b55df71bd,12/09/2024,HUMAN PRESCRIPTION DRUG,12/09/2024,Neurology,TIAGABINE HYDROCHLORIDE,"62756-224, 62756-200","Sun Pharmaceutical Industries, Inc.",57975e74-e45b-4fd9-9718-bfc9690acae5,"62756-200-83, 62756-200-18, 62756-224-83, 62756-224-88, 62756-224-08, 62756-224-18","Tiagabine Hydrochloride, Tablet, 4 mg (NDC 62756-224-18)",Tablet,,,ANDA077555,,TIAGABINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuing for business reasons,,DQH6T6D8OY,62756-224-18,800-818-4555,
"Fresenius Kabi USA, LLC",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Bupivacaine Hydrochloride Injection,"1724880, 1724881, 1725078, 1725175, 1724884, 1724885, 1725082, 1725177, 1672917, 1672919, 1673296, 1673298, 1012391, 1012396, 1012404, 1012421, 1012455, 1012457",,"e700eb7b-8b14-49c9-96b2-331f18776e45, b6bfc04a-1868-4630-9ca1-8c027af97ce3, dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175, eb6d8fee-def4-4c96-9972-695e8cea8ea8",09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,SENSORCAINE MPF,"63323-464, 63323-466, 63323-462, 63323-465, 63323-467, 63323-460","Fresenius Kabi USA, LLC","b41b5dbd-7aff-4d97-ac97-f4355393ee4e, d3ba9fb9-63c8-4597-bb0a-cd01d31a24b6, 13a48007-3784-46f2-bd4d-da1004186b81, 2b1a1f80-cb29-4ac1-9e72-20225ed45715","63323-464-01, 63323-464-17, 63323-466-03, 63323-466-17, 63323-464-08, 63323-464-38, 63323-466-08, 63323-466-38, 63323-462-03, 63323-462-38, 63323-464-09, 63323-464-39, 63323-466-09, 63323-466-39, 63323-465-01, 63323-465-57, 63323-467-01, 63323-467-57, 63323-460-01, 63323-460-37, 63323-464-02, 63323-464-37, 63323-464-03, 63323-464-31, 63323-466-01, 63323-466-37, 63323-466-02, 63323-466-31, 63323-462-04, 63323-462-17, 63323-462-01, 63323-462-37, 63323-462-02, 63323-462-31","Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-17)",Injection,Available,,"ANDA070552, NDA018304",,BUPIVACAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,"7TQO7W3VT8, 30Q7KI53AK",63323-464-17,888-386-1300,
"Hikma Pharmaceuticals USA, Inc.",CEFOTAXIME SODIUM,,02/17/2015,Reverified,"INTRAMUSCULAR, INTRAVENOUS","Cefotaxime Sodium Powder, for Solution","309068, 1656313, 1656318",,ed23b6bc-32c7-4c50-a53d-313ae78e5623,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",CEFOTAXIME,"0143-9931, 0143-9933, 0143-9930",Hikma Pharmaceuticals USA Inc.,7e0897ec-2275-4438-9cc5-4c951e52ad97,"0143-9931-01, 0143-9931-25, 0143-9933-01, 0143-9933-25, 0143-9930-01, 0143-9930-10","Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 0143-9931-25)","Powder, For Solution",Unavailable,,ANDA065072,,CEFOTAXIME,,,Current,Demand increase for the drug,Shortage duration is unknown at this time.,,258J72S7TZ,0143-9931-25,800-631-2174,
Aurobindo Pharma USA,AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","239191, 313797",,234d0dfc-cb24-413f-b798-129c73eb848e,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"65862-707, 65862-706",Aurobindo Pharma Limited,f4a410c9-3a78-48f9-8195-915896a974ff,"65862-706-80, 65862-706-01, 65862-706-55, 65862-707-80, 65862-707-01, 65862-707-55","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 65862-707-80)","Powder, For Suspension",,,ANDA204030,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,65862-707-80,866-850-2876,
"Hospira, Inc., a Pfizer Company",GEMCITABINE HYDROCHLORIDE,,09/11/2025,New,INTRAVENOUS,Gemcitabine Hydrochloride Injection,"1720960, 1720975, 1720977",,"dc02a23b-3ff9-4441-aa91-8e9e629a7315, e18ed1cb-7dd0-4001-bfda-17d1f4587fb8",09/11/2025,HUMAN PRESCRIPTION DRUG,09/11/2025,Oncology,GEMCITABINE,"0409-0182, 0409-0181, 0409-0183","Hospira, Inc.","cc0f68d1-df16-441c-b4d7-da06b4baf1e5, 15f70b30-31dc-4c45-902b-69cad93f7308","0409-0181-01, 0409-0183-01, 0409-0182-01, 0409-0181-25, 0409-0182-25, 0409-0183-25","Gemcitabine Hydrochloride, Injection, 2 g/52.6 mL (38 mg/mL), sterile solution in a single-dose glass vial NovaPlus (NDC 0409-0182-25)",Injection,,,NDA200795,,GEMCITABINE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,U347PV74IL,0409-0182-25,844-646-4398,
Otsuka ICU Medical LLC,"CALCIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, SODIUM LACTATE",,10/11/2024,Reverified,INTRAVENOUS,Lactated Ringers Injection,"847627, 847630",,d310d170-5eeb-471b-af1a-0e845001d21d,09/17/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other",LACTATED RINGERS,"0990-7953, 0990-7929",ICU Medical Inc.,f0f79123-edc9-43ff-a696-0356b6f03952,"0990-7929-03, 0990-7929-09, 0990-7953-02, 0990-7953-03, 0990-7953-09","Lactated Ringers, Injection, 20 mg/100 mL; 30 mg/100 mL; 600 mg/100 mL; 310 mg/100 mL (NDC 0990-7953-02)",Injection,Available,,NDA017641,,"SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, AND CALCIUM CHLORIDE",,,Current,,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,"LX22YL083G, 660YQ98I10, TU7HW0W0QT, 451W47IQ8X, M4I0D6VV5M",0990-7953-02,1-866-829-9025 or ProductAvailability@icumed.com,
"Sun Pharmaceutical Industries, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Revised,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856, 1871456, 1871460, 1871462, 1871464, 1871466, 1871468",,da3148af-f9b6-4725-adae-3595b4c7dc4b,09/22/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"57664-051, 57664-047, 57664-046, 57664-048, 57664-049, 57664-050, 57664-052, 57664-083, 57664-084, 57664-085, 57664-086, 57664-087, 57664-088","Sun Pharmaceutical Industries, Inc.",0b77417a-5789-8818-e063-6294a90ad2e3,"57664-047-88, 57664-046-88, 57664-048-88, 57664-049-88, 57664-050-88, 57664-051-88, 57664-052-88, 57664-083-88, 57664-084-88, 57664-085-88, 57664-086-88, 57664-087-88, 57664-088-88","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 57664-051-88)",Capsule,Limited Availability,,ANDA214484,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,Additional supply anticipated early 2026,,SJT761GEGS,57664-051-88,800-818-4555,
"Hospira, Inc., a Pfizer Company",MORPHINE SULFATE,,10/31/2017,Revised,INTRAVENOUS,Morphine Sulfate Injection,,,be420e8b-bcb0-49b5-bb4d-1df8b9959809,08/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,MORPHINE SULFATE,"0409-1891, 0409-1890, 0409-1892, 0409-1893, 0409-1894","Hospira, Inc.",cced2ec0-6c94-4cf0-87fb-041667ee3214,"0409-1890-03, 0409-1890-01, 0409-1890-13, 0409-1890-23, 0409-1891-03, 0409-1891-01, 0409-1891-13, 0409-1891-23, 0409-1892-03, 0409-1892-01, 0409-1892-13, 0409-1892-23, 0409-1893-03, 0409-1893-01, 0409-1893-13, 0409-1893-23, 0409-1894-03, 0409-1894-01","Morphine Sulfate, Injection, 4 mg/1 mL Syringes (NDC 0409-1891-01)",Injection,Unavailable,,NDA202515,,MORPHINE SULFATE,,,Current,Other,Next Delivery: October 2025; Estimated Recovery: December 2025,,X3P646A2J0,0409-1891-01,844-646-4398,
Sandoz Inc.,TIGECYCLINE,,01/17/2025,New,"INTRAVENOUS, PARENTERAL",Tigecycline Injection,581531,,50605463-2dc2-4b27-bc51-4d87bb9a8539,01/17/2025,HUMAN PRESCRIPTION DRUG,01/17/2025,Anti-Infective,TIGECYCLINE,0781-3481,Sandoz Inc,7eeef6bf-1bb2-42d7-9ee2-1a3865b9b11c,"0781-3481-70, 0781-3481-92","Tigecycline, Injection, 50 mg/10 mL (NDC 0781-3481-92)",Injection,,"N0000175938, M0021223",ANDA091620,Tetracyclines [CS],TIGECYCLINE,Tetracycline-class Antibacterial [EPC],,To Be Discontinued,,,,70JE2N95KR,0781-3481-92,800-525-8747,
Sintetica US,LIDOCAINE HYDROCHLORIDE ANHYDROUS,,02/22/2012,Reverified,INFILTRATION,Lidocaine Hydrochloride Injection,"1737566, 1737568, 1737570, 1737757, 1737761, 1737763",,aa3e688a-308c-4a82-a268-28ccf1677c55,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",NA,"83090-001, 83090-002, 83090-003, 83090-004, 83090-005, 83090-006",Sintetica US LLC,0d18f291-3a92-421e-8841-6be743b1f154,"83090-001-01, 83090-001-10, 83090-002-01, 83090-002-10, 83090-003-01, 83090-003-10, 83090-004-01, 83090-004-10, 83090-005-01, 83090-005-10, 83090-006-01, 83090-006-10","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 83090-001-10)",Injection,Available,,ANDA214267,,LIDOCAINE HYDROCHLORIDE,,,Current,,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 1% 10X2ML) is Preservative free.",,EC2CNF7XFP,83090-001-10,"844-425-3131, SinteticaCS@eversana.com",
Alvogen,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,7f2dd6ee-3363-c87c-9693-ed838942556c,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"47781-565, 47781-562, 47781-563, 47781-564, 47781-566, 47781-567, 47781-568",Alvogen Inc.,9114d946-92cb-c19d-c6f2-aef77294461f,"47781-562-01, 47781-563-01, 47781-564-01, 47781-565-01, 47781-566-01, 47781-567-01, 47781-568-01","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 47781-565-01)",Capsule,Available,,ANDA214547,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,47781-565-01,844-842-8672 and email: CustomerService-US@alvogen.com,
Novadoz Pharmaceuticals LLC,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Revised,ORAL,"Lisdexamfetamine Dimesylate Tablet, Chewable","1871456, 1871460, 1871462, 1871464, 1871466, 1871468",,a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"72205-136, 72205-132, 72205-133, 72205-134, 72205-135, 72205-137",Novadoz Pharmaceuticals LLC,a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811,"72205-132-91, 72205-133-91, 72205-134-91, 72205-135-91, 72205-136-91, 72205-137-91","Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 72205-136-91)","Tablet, Chewable",Available,,ANDA218306,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,,,SJT761GEGS,72205-136-91,(855) 668-2369; customerservice@novadozpharma.com,
Eugia US LLC,BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Revised,"INFILTRATION, PERINEURAL",Bupivacaine Hydrochloride Injection,"1012396, 1012404, 1724786, 1724787, 1724880, 1724884, 1725078, 1725082",,ffecf450-1f01-4721-8e10-251385852612,09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE,"55150-249, 55150-167, 55150-168, 55150-169, 55150-170, 55150-171, 55150-172, 55150-250",Eugia US LLC,39649703-e633-4a20-ba71-0c04dbf8ff2a,"55150-167-10, 55150-168-30, 55150-169-10, 55150-170-30, 55150-171-10, 55150-172-30, 55150-249-50, 55150-250-50","Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-249-50)",Injection,Available,,ANDA207183,,BUPIVACAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,7TQO7W3VT8,55150-249-50,888-238-7880,
"Hospira, Inc., a Pfizer Company",LIDOCAINE HYDROCHLORIDE,,02/22/2012,Revised,INTRAVENOUS,Lidocaine Hydrochloride Injection,"1012066, 1012068",,ad1ef0a8-88db-4648-c098-d009eaeb4e5b,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE HYDROCHLORIDE,"0409-4903, 0409-4904, 0409-1323, 0409-9137","Hospira, Inc.",477abea3-c873-4265-82e8-5508ef54399f,"0409-4903-11, 0409-4903-34, 0409-4904-11, 0409-4904-34, 0409-1323-15, 0409-1323-05, 0409-9137-11, 0409-9137-05","Lidocaine Hydrochloride, Injection, 100 mg/5mL (2%, 20 mg/1 mL) Syringes (NDC 0409-4903-34)",Injection,Unavailable,,ANDA083158,,LIDOCAINE HYDROCHLORIDE,,,Current,Other,Next Delivery: January 2026; Estimated Recovery: March 2026,12/19/2024,V13007Z41A,0409-4903-34,844-646-4398,
"Lannett Company, Inc.",,,10/12/2022,Reverified,,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",,,,09/15/2025,,,Psychiatry,,,,,,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0527-1502-37)",Tablet,Available,,,,,,,Current,,,,,0527-1502-37,844-834-0530,
"Hospira, Inc., a Pfizer Company",SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807547, 1807631, 1807632, 1807633",,a2a964f7-c3ec-4dfb-e3a0-6d8136a80397,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0409-7101, 0409-7132","Hospira, Inc.",9d75502b-257f-4a37-9a85-b98c4278c474,"0409-7101-68, 0409-7101-66, 0409-7101-69, 0409-7101-67, 0409-7101-04, 0409-7101-02, 0409-7132-68, 0409-7132-66, 0409-7132-69, 0409-7132-67, 0409-7132-04, 0409-7132-02","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (9%, 9mg/mL) (NDC 0409-7101-02)",Injection,,,NDA019465,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0409-7101-02,844-646-4398,
"Mylan Institutional, a Viatris Company",DEXAMETHASONE SODIUM PHOSPHATE,,02/08/2019,Reverified,"INTRA-ARTICULAR, INTRALESIONAL, INTRAMUSCULAR, INTRAVENOUS, SOFT TISSUE",Dexamethasone Sodium Phosphate Injection,"309696, 1116927, 1812194",,dff598e8-e662-411f-978d-4ba3fb8ef7db,09/17/2025,HUMAN PRESCRIPTION DRUG,,"Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Other, Pulmonary/Allergy, Rheumatology",DEXAMETHASONE SODIUM PHOSPHATE,"67457-423, 67457-422, 67457-421, 67457-420",Mylan Institutional LLC,dd5c82b6-a194-462c-9626-34a9b410cfea,"67457-423-00, 67457-423-12, 67457-422-00, 67457-422-54, 67457-421-00, 67457-421-30, 67457-420-00, 67457-420-10","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-423-12)",Injection,Available,,ANDA040803,,DEXAMETHASONE SODIUM PHOSPHATE,,,Current,,,,AI9376Y64P,67457-423-12,800-796-9526,
"Rising Pharma Holdings, Inc.",ALBUTEROL SULFATE,,10/25/2022,Reverified,RESPIRATORY (INHALATION),Albuterol Sulfate Solution,245314,,3236f82c-14e9-dfd4-e063-6294a90ac43d,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Pediatric, Pulmonary/Allergy",ALBUTEROL SULFATE,64980-642,"Rising Pharma Holdings, Inc.",33015e7c-a4d2-ecac-e063-6394a90aae00,64980-642-03,"Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 64980-642-03)",Solution,Available,,ANDA075664,,ALBUTEROL SULFATE,,,Current,,,,021SEF3731,64980-642-03,201-961-9000,
"Hospira, Inc., a Pfizer Company",,,07/08/2025,New,,Morphine Sulfate Injection,,,,07/08/2025,,07/08/2025,Analgesia/Addiction,,,,,,"Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0409-1892-01)",Injection,,,,,,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,,0409-1892-01,844-646-4398,
"Sun Pharmaceutical Industries, Inc.",TECHNETIUM TC-99M PYROPHOSPHATE,,12/27/2023,Revised,INTRAVENOUS,Technetium TC-99M Pyrophosphate Kit Injection,,,1f0cbd23-2fb3-43b7-b8af-7de246151149,09/22/2025,HUMAN PRESCRIPTION DRUG,,Medical Imaging,KIT FOR THE PREPARATION OF TECHNETIUM TC99M PYROPHOSPHATE,45567-0060,"Sun Pharmaceutical Industries, Inc.",3010b45e-eed1-a5d0-e063-6294a90a40cf,"45567-0060-1, 45567-0060-2","CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-2)",Injection,Limited Availability,"N0000177914, N0000000205",NDA019039,,TECHNETIUM TC99M PYROPHOSPHATE,Radioactive Diagnostic Agent [EPC],,Current,Shortage of an active ingredient,Additional supply anticipated early 2026,,5L76I61H2B,45567-0060-2,800-818-4555,Radiopharmaceutical Activity [MoA]
"Upsher-Smith Laboratories, LLC",FLUPHENAZINE HYDROCHLORIDE,,09/18/2025,New,ORAL,Fluphenazine Hydrochloride Tablet,"859841, 860918, 865117, 865123",,f07bb3f1-c68c-441b-9de4-99a219f2500a,09/18/2025,HUMAN PRESCRIPTION DRUG,09/18/2025,"Neurology, Psychiatry",FLUPHENAZINE HYDROCHLORIDE,"0832-6006, 0832-6004, 0832-6003, 0832-6005","Upsher-Smith Laboratories,LLC",3bb74f82-8872-9829-e063-6294a90aeace,"0832-6004-11, 0832-6003-11, 0832-6005-11, 0832-6006-11","Fluphenazine Hydrochloride, Tablet, 10 mg (NDC 0832-6006-11)",Tablet,,,ANDA213784,,FLUPHENAZINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug.,,ZOU145W1XL,0832-6006-11,763-315-2000,
Pfizer Inc.,IDARUBICIN HYDROCHLORIDE,,02/06/2025,New,INTRAVENOUS,Idarubicin Hydrochloride Injection,"1791493, 1791495, 1791498, 1791499, 1791500, 1791501",,0a5a6d93-cc1e-4d7f-8da1-446c134503b3,02/06/2025,HUMAN PRESCRIPTION DRUG,02/06/2025,Oncology,IDAMYCIN PFS,"0013-2576, 0013-2586, 0013-2596",Pfizer Laboratories Div Pfizer Inc,04db6b10-1bb9-4797-99a2-38e33669c56e,"0013-2576-91, 0013-2576-05, 0013-2586-91, 0013-2586-10, 0013-2596-91, 0013-2596-20","Idamycin, Injection, 1 mg/1 mL (NDC 0013-2576-91)",Injection,,,NDA050734,,IDARUBICIN HYDROCHLORIDE,,,To Be Discontinued,,Replaced with NDC 0013-2576-05,,5VV3MDU5IE,0013-2576-91,844-646-4398,
Eli Lilly and Co.,ATOMOXETINE HYDROCHLORIDE,,10/22/2024,New,ORAL,Atomoxetine Hydrochloride Capsule,"349591, 349592, 349593, 349594, 349595, 352317, 352318, 352319, 352320, 352321, 608139, 608143, 617945, 617947",,309de576-c318-404a-bc15-660c2b1876fb,10/22/2024,HUMAN PRESCRIPTION DRUG,10/22/2024,Psychiatry,STRATTERA,"0002-3228, 0002-3227, 0002-3238, 0002-3229, 0002-3239, 0002-3250, 0002-3251",Eli Lilly and Company,90fd3143-d5d4-4343-9570-b3863e31b1a0,"0002-3227-30, 0002-3238-30, 0002-3228-30, 0002-3229-30, 0002-3239-30, 0002-3250-30, 0002-3251-30","Strattera, Capsule, 25 mg (NDC 0002-3228-30)",Capsule,,,NDA021411,,ATOMOXETINE HYDROCHLORIDE,,,To Be Discontinued,,Business decision to discontinue,,57WVB6I2W0,0002-3228-30,800-545-5979,
B. Braun Medical Inc.,"ACETYL L-TYROSINE, ALANINE, ARGININE, ASPARTIC ACID, CYSTEINE HYDROCHLORIDE, GLUTAMIC ACID, GLYCINE, HISTIDINE, ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, PROLINE, SERINE, TAURINE, THREONINE, TRYPTOPHAN, TYROSINE, VALINE",,12/08/2020,Revised,INTRAVENOUS,Amino Acid Injection,"800611, 1189640",,cb6d23ff-3ec5-445a-acbe-f88fd57949bf,09/16/2025,HUMAN PRESCRIPTION DRUG,,Gastroenterology,TROPHAMINE,0264-1933,B. Braun Medical Inc.,07f53291-419d-4d14-ad81-26f00dc0c474,0264-1933-10,"TrophAmine 10%, Injection, 0.1 (NDC 0264-1933-10)",Injection,Available,"N0000175780, M0000922",NDA019018,Amino Acids [CS],"ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, CYSTEINE HYDROCHLORIDE, HISTIDINE, TYROSINE, N-ACETYL-TYROSINE, ALANINE, ARGININE, PROLINE, SERINE, GLYCINE, ASPARTIC ACID, GLUTAMIC ACID, AND TAURINE",Amino Acid [EPC],,Current,,,,"DA8G610ZO5, OF5P57N2ZX, 94ZLA3W45F, 30KYC7MIAI, ZT934N0X4W, 3KX376GY7L, TE7660XO1C, 4QD397987E, 04Y7590D77, GMW67QNF9C, TTL6G7LIWZ, AE28F7PNPL, 47E5O17Y3R, 9DLQ4CIU6V, 452VLY9402, 1EQV5MLY3D, 2ZD004190S, 8DUH1N11BX, 42HK56048U, HG18B9YRS7",0264-1933-10,800-227-2862,
Accord Healthcare Inc.,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,309710,,aa450b4b-4969-465d-b7f2-8da380bbdbed,09/16/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE,16729-432,Accord Healthcare Inc.,ad2504de-4b7e-16ff-e053-2a95a90a60b1,"16729-432-30, 16729-432-93","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-432-93)",Injection,Unavailable,,ANDA204023,,DEXMEDETOMIDINE,,,Current,Discontinuation of the manufacture of the drug,Discontinuation of the manufacture of the drug.,,1018WH7F9I,16729-432-93,"866-941-7875, option 2",
B. Braun Medical Inc.,"DEXTROSE, UNSPECIFIED FORM",,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795477, 1795480, 1795481, 1795607, 1795610, 1795612",,085614c7-ada4-4e2c-87c0-c9bc2f18365a,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0264-7510, 0264-7520",B. Braun Medical Inc.,c9f87749-8dd5-41fd-b393-f63d45fd00ef,"0264-7510-00, 0264-7510-10, 0264-7510-20, 0264-7520-00, 0264-7520-10, 0264-7520-20","Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-10)",Injection,Available,,NDA019626,,DEXTROSE,,,Current,,,,IY9XDZ35W2,0264-7510-10,800-227-2862,
"Teva Pharmaceuticals USA, Inc.",,,05/02/2025,New,,Drospirenone; Ethinyl Estradiol Tablet,"284207, 748797, 748800, 801185",,0d729f4d-2fa3-47f6-8a1f-d8cfea4cff37,05/02/2025,HUMAN PRESCRIPTION DRUG,05/02/2025,Reproductive,OCELLA,0555-9131,"TEVA PHARMACEUTICALS USA, INC.",16f205ad-cc9e-4879-9f7c-9cc3577d48fb,"0555-9131-79, 0555-9131-67","Ocella, Tablet, Kit (NDC 0555-9131-67)",Tablet,,,NDA021098,,DROSPIRENONE AND ETHINYL ESTRADIOL,,,To Be Discontinued,,,,,0555-9131-67,800-545-8800,
"Fresenius Kabi USA, LLC","EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE ANHYDROUS",,10/14/2016,Reverified,"INFILTRATION, PERINEURAL","Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","1010033, 1010035, 1010671, 1010673, 1010688, 1010692, 1010745, 1010749, 1010751, 1010755, 1010759, 1010763, 1010900, 1010902, 1737343, 1737345, 1737562, 1737563, 1737566, 1737567, 1737568, 1737569, 1737570, 1737571, 1737757, 1737758, 1737761, 1737762, 1867938, 1867940, 1867943, 1867944, 1867992, 1867993, 1867996, 1867997, 1868028, 1868029",,"ba082c2f-64f4-419d-9c88-74f203316e17, 4dd52202-8eef-4136-92dd-ada573b7cf74",09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",XYLOCAINE,"63323-482, 63323-492, 63323-491, 63323-495, 63323-485, 63323-486, 63323-484, 63323-489, 63323-488, 63323-481, 63323-483, 63323-487","Fresenius Kabi USA, LLC","ea480a68-5927-4278-9deb-2956961da428, 0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33","63323-492-04, 63323-492-27, 63323-492-09, 63323-492-57, 63323-492-07, 63323-492-37, 63323-492-03, 63323-492-31, 63323-491-01, 63323-491-57, 63323-495-09, 63323-495-27, 63323-495-04, 63323-495-07, 63323-485-01, 63323-485-27, 63323-485-03, 63323-485-57, 63323-486-01, 63323-486-17, 63323-486-02, 63323-486-27, 63323-486-05, 63323-486-57, 63323-484-57, 63323-489-02, 63323-489-27, 63323-489-03, 63323-489-21, 63323-489-01, 63323-489-17, 63323-488-07, 63323-488-37, 63323-488-03, 63323-488-31, 63323-488-01, 63323-488-17, 63323-481-01, 63323-481-57, 63323-483-03, 63323-483-27, 63323-483-01, 63323-483-57, 63323-482-01, 63323-482-17, 63323-482-03, 63323-482-27, 63323-482-05, 63323-482-57, 63323-487-01, 63323-487-17, 63323-487-07, 63323-487-37, 63323-487-03, 63323-487-31, 63323-492-41, 63323-492-16, 63323-492-43, 63323-492-36, 63323-492-45, 63323-492-26, 63323-485-41, 63323-485-26, 63323-486-41, 63323-486-26, 63323-482-41, 63323-482-26, 63323-495-41, 63323-495-26","Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)",Injection,Available,,NDA006488,,"LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE",,,Current,,Check wholesalers for inventory,,"EC2CNF7XFP, 30Q7KI53AK",63323-482-57,888-386-1300,
Strides Pharma Inc.,AMANTADINE HYDROCHLORIDE,,02/12/2025,New,ORAL,Amantadine Hydrochloride Capsule,849389,,e4d8f36f-d668-4728-8dca-b1c22bd9aedb,02/12/2025,HUMAN PRESCRIPTION DRUG,02/12/2025,"Antiviral, Neurology",AMANTADINE HYDROCHLORIDE,42543-493,Strides Pharma Inc.,a3230bf0-95b8-4beb-b1f5-a35614de5afa,"42543-493-01, 42543-493-05","Amantadine Hydrochloride, Capsule, 100 mg (NDC 42543-493-01)",Capsule,,,ANDA209047,,AMANTADINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation of manufacture of drug based on business decision,,M6Q1EO9TD0,42543-493-01,877-244-9825,
"Mylan Pharmaceuticals Inc., a Viatris Company",TOLTERODINE TARTRATE,,02/26/2025,New,ORAL,"Tolterodine Tartrate Capsule, Extended Release","855182, 855184, 855189, 855191",,d7274947-4f88-47ee-a39f-bd5ac46fcf8d,02/26/2025,HUMAN PRESCRIPTION DRUG,02/26/2025,Urology,DETROL LA,"58151-103, 58151-104",Viatris Specialty LLC,a1e49744-9302-47ee-92af-8b19aa0b2fc1,"58151-103-93, 58151-103-77, 58151-103-05, 58151-104-93, 58151-104-77, 58151-104-05","Detrol LA, Capsule, Extended Release, 2 mg (NDC 58151-103-93)","Capsule, Extended Release",,,NDA021228,,TOLTERODINE TARTRATE,,,To Be Discontinued,,,,5T619TQR3R,58151-103-93,800-796-9526,
"Hospira, Inc., a Pfizer Company",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,PERINEURAL,Bupivacaine Hydrochloride Injection,"1012377, 1012384, 1012396, 1012404, 1672917, 1672919, 1724786, 1724787, 1724880, 1724884, 1725078, 1725082, 1867594, 1867596",,02a845c3-4521-4926-e397-25ab536e7cf6,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE,"0409-1163, 0409-1159, 0409-1160, 0409-1162, 0409-1165, 0409-9043, 0409-9046, 0409-9045, 0409-9042","Hospira, Inc.",3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7,"0409-1159-18, 0409-1159-01, 0409-1159-19, 0409-1159-02, 0409-1160-18, 0409-1160-01, 0409-1162-18, 0409-1162-01, 0409-1162-19, 0409-1162-02, 0409-1163-18, 0409-1163-01, 0409-1165-18, 0409-1165-01, 0409-1165-19, 0409-1165-02, 0409-9043-11, 0409-9043-01, 0409-9046-11, 0409-9046-01, 0409-9045-11, 0409-9045-01, 0409-9045-16, 0409-9045-17, 0409-9042-11, 0409-9042-01, 0409-9042-16, 0409-9042-17","Bupivacaine Hydrochloride, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-1163-01)",Injection,Available,,ANDA070597,,BUPIVACAINE HYDROCHLORIDE,,,Current,,,,"30Q7KI53AK, 7TQO7W3VT8",0409-1163-01,844-646-4398,
"Hospira, Inc., a Pfizer Company","BUPIVACAINE HYDROCHLORIDE, EPINEPHRINE BITARTRATE",,02/20/2018,Revised,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL","Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","1012377, 1012384, 1012396, 1012404, 1672917, 1672919, 1724786, 1724787, 1724880, 1724884, 1725078, 1725082, 1867594, 1867596",,02a845c3-4521-4926-e397-25ab536e7cf6,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE,"0409-9042, 0409-1159, 0409-1160, 0409-1162, 0409-1163, 0409-1165, 0409-9043, 0409-9046, 0409-9045","Hospira, Inc.",3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7,"0409-1159-18, 0409-1159-01, 0409-1159-19, 0409-1159-02, 0409-1160-18, 0409-1160-01, 0409-1162-18, 0409-1162-01, 0409-1162-19, 0409-1162-02, 0409-1163-18, 0409-1163-01, 0409-1165-18, 0409-1165-01, 0409-1165-19, 0409-1165-02, 0409-9043-11, 0409-9043-01, 0409-9046-11, 0409-9046-01, 0409-9045-11, 0409-9045-01, 0409-9045-16, 0409-9045-17, 0409-9042-11, 0409-9042-01, 0409-9042-16, 0409-9042-17","Bupivacaine Hydrochloride And Epinephrine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-9042-17)",Injection,Unavailable,,ANDA071165,,BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE,,,Current,Other,Shortage per Manufacturer: Manufacturing Delay,,"30Q7KI53AK, 7TQO7W3VT8",0409-9042-17,844-646-4398,
"Teva Pharmaceuticals USA, Inc.",,,06/13/2025,New,,Drospirenone; Ethinyl Estradiol Tablet,"284207, 748797, 748800, 801185",,0d729f4d-2fa3-47f6-8a1f-d8cfea4cff37,06/13/2025,HUMAN PRESCRIPTION DRUG,06/13/2025,Reproductive,OCELLA,0555-9131,"TEVA PHARMACEUTICALS USA, INC.",16f205ad-cc9e-4879-9f7c-9cc3577d48fb,"0555-9131-79, 0555-9131-67","Yasmin, Tablet, Kit (NDC 0555-9131-67)",Tablet,,,NDA021098,,DROSPIRENONE AND ETHINYL ESTRADIOL,,,To Be Discontinued,,,,,0555-9131-67,800-545-8800,
"Teva Pharmaceuticals USA, Inc.",HYDROMORPHONE HYDROCHLORIDE,,11/01/2017,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Hydromorphone Hydrochloride Injection,"1724338, 1724340, 1724341",,f0b78db9-a38c-41bb-8233-5e93f7f18c5c,09/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,HYDROMORPHONE HYDROCHLORIDE,"0703-0018, 0703-0110, 0703-0113","Teva Parenteral Medicines, Inc.",c32108cc-7b73-4921-9f9e-54b3d60c1c6e,"0703-0110-01, 0703-0110-03, 0703-0113-01, 0703-0113-03, 0703-0018-01","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0018-01)",Injection,Available,,ANDA078591,,HYDROMORPHONE HYDROCHLORIDE,,,Current,Shortage of an active ingredient,Estimated recovery: November 2025,,L960UP2KRW,0703-0018-01,800-545-8800,
Chartwell Molecular Holdings LLC,QUINAPRIL HYDROCHLORIDE,,01/19/2023,Reverified,ORAL,Quinapril Hydrochloride Tablet,"312748, 312749, 312750, 314203",,dbc43dbd-94aa-40e2-a9ea-766110cc8687,08/19/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,QUINAPRIL,"62135-486, 62135-484, 62135-485, 62135-487","Chartwell RX, LLC",09cd5cb9-4fdf-f133-e063-6294a90af691,"62135-484-60, 62135-485-90, 62135-486-90, 62135-487-90","Quinapril Hydrochloride, Tablet, 20 mg (NDC 62135-486-90)",Tablet,Available,,ANDA076803,,QUINAPRIL,,,Current,,,,33067B3N2M,62135-486-90,845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com,
"Dr. Reddy's Laboratories, Inc.",RAMELTEON,,01/08/2025,New,ORAL,Ramelteon Tablet,577348,,b71cd925-1bae-5a6a-072b-941ad6d3ce65,01/08/2025,HUMAN PRESCRIPTION DRUG,01/08/2025,Other,RAMELTEON,43598-741,Dr.Reddys Laboratories Inc,54220029-c5df-b277-af7e-2786da03bbed,"43598-741-30, 43598-741-01, 43598-741-10","Tablet, 8 mg (NDC 43598-741-10)",Tablet,,"N0000175743, N0000000250",ANDA091693,,RAMELTEON,Melatonin Receptor Agonist [EPC],,To Be Discontinued,,,,901AS54I69,43598-741-10,866-732-3952,Melatonin Receptor Agonists [MoA]
"Caplin Steriles, Ltd.",ROPIVACAINE HYDROCHLORIDE,,12/22/2020,Reverified,"EPIDURAL, INFILTRATION, PERINEURAL",Ropivacaine Hydrochloride Injection,"1734084, 1734207, 1734475, 1734483",,781d4b7f-7556-4695-8d48-7772d7a0d8e9,09/16/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROPIVACAINE HYDROCHLORIDE,"43066-015, 43066-019, 43066-023, 43066-027",Baxter Healthcare Corporation,ef624077-2197-426c-9521-8f966f49240b,"43066-015-01, 43066-015-10, 43066-019-01, 43066-019-10, 43066-023-01, 43066-023-10, 43066-027-01, 43066-027-10","Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 43066-015-10)",Injection,Limited Availability,,ANDA212808,,ROPIVACAINE HYDROCHLORIDE,,,Current,Other,Check wholesalers for inventory; Marketed by Baxter,,V910P86109,43066-015-10,888-229-0001,
"Hikma Pharmaceuticals USA, Inc.",,,05/03/2022,Revised,,Sufentanil Citrate Injection,,,,07/23/2025,,,"Analgesia/Addiction, Pediatric",,,,,,"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-02)",Injection,Unavailable,,,,,,,Current,Other,Not currently manufactured,,,17478-050-02,800-631-2174,
Otsuka ICU Medical LLC,DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795477, 1795480, 1795481, 1795607, 1795609, 1795610, 1795612, 1795616, 1795618, 1795621",,8b25b7e0-703e-4b43-a4eb-52863511602d,09/17/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0990-7923, 0990-7922, 0990-7930","ICU Medical, Inc.",09b10612-c937-4d10-becb-9768e10caa2c,"0990-7923-20, 0990-7923-23, 0990-7923-36, 0990-7923-37, 0990-7923-13, 0990-7922-02, 0990-7922-03, 0990-7922-09, 0990-7922-53, 0990-7922-55, 0990-7922-61, 0990-7930-02, 0990-7930-03, 0990-7930-09","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-13)",Injection,Available,,NDA016367,,DEXTROSE MONOHYDRATE,,,Current,,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,LX22YL083G,0990-7923-13,1-866-829-9025 or ProductAvailability@icumed.com,
"Assertio Specialty Pharmaceuticals, LLC",METHOTREXATE,,08/29/2025,New,SUBCUTANEOUS,Methotrexate Injection,"1441402, 1441407, 1441411, 1441413, 1441416, 1441418, 1441422, 1441424, 1747179, 1747181, 1747185, 1747187, 1747192, 1747194",,7dcd02d7-1ce0-43fc-8f25-2f0bb0caba2f,08/29/2025,HUMAN PRESCRIPTION DRUG,08/29/2025,Rheumatology,OTREXUP,"82497-022, 82497-010, 82497-012, 82497-015, 82497-017, 82497-020, 82497-025","Otter Pharmaceuticals, LLC",9aaba145-f343-4498-b754-fb7c78181bd7,"82497-010-02, 82497-010-04, 82497-012-02, 82497-012-04, 82497-015-02, 82497-015-04, 82497-017-02, 82497-017-04, 82497-020-02, 82497-020-04, 82497-022-02, 82497-022-04, 82497-025-02, 82497-025-04","Otrexup, Injection, 22.5 mg/.4 mL (NDC 82497-022-04)",Injection,,"N0000175584, N0000000111",NDA204824,,METHOTREXATE,Folate Analog Metabolic Inhibitor [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,YL5FZ2Y5U1,82497-022-04,224-441-6390,Folic Acid Metabolism Inhibitors [MoA]
"Upsher-Smith Laboratories, LLC",,,04/23/2025,New,,Baclofen Tablet,,,,04/23/2025,,04/23/2025,Neurology,,,,,,"Baclofen, Tablet, 10 mg (NDC 50090-6868-3)",Tablet,,,,,,,,To Be Discontinued,,,,,50090-6868-3,716-315-2000,
Eli Lilly and Co.,DULAGLUTIDE,,12/15/2022,Revised,SUBCUTANEOUS,Dulaglutide Injection,"1551295, 1551300, 1551304, 1551306, 2395777, 2395779, 2395783, 2395785",,463050bd-2b1c-40f5-b3c3-0a04bb433309,06/13/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,TRULICITY,"0002-3182, 0002-1433, 0002-1434, 0002-2236",Eli Lilly and Company,2a046089-7cd3-43d3-9f7f-27e3e4b49f0d,"0002-1433-01, 0002-1433-80, 0002-1433-61, 0002-1434-01, 0002-1434-80, 0002-1434-61, 0002-2236-01, 0002-2236-80, 0002-2236-61, 0002-3182-01, 0002-3182-80, 0002-3182-61","Trulicity, Injection, 4.5 mg/.5 mL (NDC 0002-3182-80)",Injection,,"N0000178480, M0160181, N0000020058",BLA125469,Glucagon-Like Peptide 1 [CS],DULAGLUTIDE,GLP-1 Receptor Agonist [EPC],Available,Resolved,,,06/13/2025,WTT295HSY5,0002-3182-80,800-545-5979,Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
B. Braun Medical Inc.,"CALCIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, SODIUM LACTATE",,10/11/2024,Reverified,INTRAVENOUS,Lactated Ringers Injection,847630,,"d3d29c8f-c326-4097-814a-7f4e08c67068, f6d82772-638c-4584-b9d3-8833669f5963",09/16/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other",LACTATED RINGERS,0264-7750,B. Braun Medical Inc.,"f67c6808-1eeb-4299-a0b7-694863bcad5a, ed789cd7-83ae-4ec1-a696-e87c1569da49","0264-7750-00, 0264-7750-10, 0264-7750-20, 0264-7750-07","Lactated Ringers, Injection, .02 g/100 mL; .03 g/100 mL; .6 g/100 mL; .31 g/100 mL (NDC 0264-7750-20)",Injection,Available,,NDA019632,,"SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, AND CALCIUM CHLORIDE",,,Current,,,,"M4I0D6VV5M, 660YQ98I10, 451W47IQ8X, TU7HW0W0QT",0264-7750-20,800-227-2862,
"Teva Pharmaceuticals USA, Inc.",AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension",,,4c0f348a-a65d-409c-8668-207c82a5e3cb,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0093-4155, 0093-2263, 0093-2264, 0093-4160, 0093-4161, 0093-2267, 0093-2268, 0093-3107, 0093-3109","Teva Pharmaceuticals USA, Inc.",8988589b-0893-4233-ac9c-9884ceb0c2c4,"0093-2263-01, 0093-2264-01, 0093-4160-76, 0093-4160-78, 0093-4160-73, 0093-4155-79, 0093-4155-73, 0093-4155-80, 0093-4161-76, 0093-4161-78, 0093-4161-73, 0093-2267-01, 0093-2268-01, 0093-3107-01, 0093-3107-05, 0093-3109-53, 0093-3109-06, 0093-3109-01, 0093-3109-05","Amoxicillin, Powder, For Suspension, 250 mg/5 mL (NDC 0093-4155-79)","Powder, For Suspension",,,ANDA061931,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0093-4155-79,800-545-8800,
SpecGx LLC,METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Reverified,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release","1091145, 1091225",,ed004cf0-eb23-43d2-96dc-20c4ad63824f,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE HYDROCHLORIDE,"0406-1473, 0406-1445",SpecGx LLC,a14563fd-7a73-4e7d-8f13-f449cfaad1a5,"0406-1445-01, 0406-1473-01","Methylin Er, Tablet, Extended Release, 20 mg (NDC 0406-1473-01)",Tablet,Limited Availability,,ANDA075629,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,Shortage of an active ingredient,Allocation to all customers. Short term backorder expected in September with recovery in October 2025.,,4B3SC438HI,0406-1473-01,800-325-8888,
Piramal Critical Care Inc.,MORPHINE SULFATE,,10/31/2017,Revised,"EPIDURAL, INTRATHECAL",Morphine Sulfate Injection,,,728f3d83-9a63-0c1f-e053-2a91aa0ac7db,09/18/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,MITIGO,"66794-162, 66794-160","Piramal Critical Care, Inc.",3f72fcc3-7855-bdf8-e063-6294a90a20b2,"66794-160-02, 66794-162-02","Mitigo (Morphine Sulfate Injection, USP), Injection, 500 mg/20 mL (NDC 66794-162-02)",Injection,Unavailable,,ANDA204393,,MORPHINE SULFATE,,,Current,Other,Estimated recovery: October 2025; Manufacturing Delay,,X3P646A2J0,66794-162-02,800-414-1901,
"Upsher-Smith Laboratories, LLC",POTASSIUM CHLORIDE,,07/23/2025,New,ORAL,"Potassium Chloride Tablet, Extended Release","312529, 628953",,616f0de7-8843-44a1-8fa6-274d889286aa,07/23/2025,HUMAN PRESCRIPTION DRUG,07/23/2025,"Endocrinology/Metabolism, Gastroenterology",POTASSIUM CHLORIDE,"0832-5323, 0832-5322","Upsher-Smith Laboratories, LLC",39e726b1-eab8-fcf4-e063-6394a90a950a,"0832-5322-11, 0832-5322-10, 0832-5323-11, 0832-5323-10","Potassium Chloride, Tablet, Extended Release, 750 mg (NDC 0832-5323-11)",Tablet,,,NDA019123,,POTASSIUM CHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug product,,660YQ98I10,0832-5323-11,763-315-2000,
Baxter Healthcare,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807631, 1807632",,aeaed9cb-b629-4019-88d2-a916179427de,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0338-9151, 0338-9159",Baxter Healthcare Corporation,39f15dfb-4e73-4959-ad9b-4ee502278b4b,"0338-9159-30, 0338-9151-30","Sodium Chloride 0.9% In Plastic Container, Injection, 450 mg/100 mL (NDC 0338-9151-30)",Injection,,,NDA020178,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0338-9151-30,888-229-0001,
Pfizer Inc.,,,01/06/2023,Revised,,Somatropin Injection,"241975, 762830, 762833, 762834, 762836, 762837, 762839, 762841, 762843, 762846, 762849, 762850, 762852, 762857, 762859, 762866, 762868, 762873, 762875, 762895, 762897, 763488, 763489, 996558, 996559",,ffebf88b-d257-4542-9808-74d9b7167765,08/28/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,GENOTROPIN,"0013-2646, 0013-2626, 0013-2649, 0013-2650, 0013-2651, 0013-2652, 0013-2653, 0013-2654, 0013-2655, 0013-2656, 0013-2657, 0013-2658",Pfizer Laboratories Div Pfizer Inc,f09acf87-6e30-47ad-9891-8a49bf6dffbc,"0013-2626-81, 0013-2646-81, 0013-2649-02, 0013-2650-02, 0013-2651-02, 0013-2652-02, 0013-2653-02, 0013-2654-02, 0013-2655-02, 0013-2656-02, 0013-2657-02, 0013-2658-02","Genotropin, Injection, 12 mg/mL, w/ preservative (NDC 0013-2646-81)",Injection,,,BLA020280,,SOMATROPIN,,Available,Resolved,,,08/28/2025,,0013-2646-81,800-533-4535,
"Fresenius Kabi USA, LLC",VALPROATE SODIUM,,12/30/2020,Reverified,INTRAVENOUS,Valproate Sodium Injection,1099648,,"3dfb6da1-f66a-4618-9f74-d2d6c16c0b58, c572ece7-03d3-4c2a-aeb5-61f2023b28ea",09/18/2025,HUMAN PRESCRIPTION DRUG,,Neurology,VALPROATE SODIUM,63323-494,"Fresenius Kabi USA, LLC","f09a2148-edd9-4918-8359-7554ed263d3a, fff889dc-6006-43c2-be57-01b2a5724b26","63323-494-41, 63323-494-16, 63323-494-01, 63323-494-05","Valproate Sodium, Injection, 100 mg/1 mL (NDC 63323-494-05)",Injection,Available,,ANDA076539,,VALPROATE SODIUM,,,Current,,Checkwholesalers for inventory,,5VOM6GYJ0D,63323-494-05,888-386-1300,
"Par Pharmaceutical, Inc.",CANDESARTAN CILEXETIL,,10/15/2024,New,ORAL,Candesartan Cilexetil Tablet,"153822, 153823, 577776, 639537",,1c90aa68-cc12-41ef-aebc-2616ae45683a,10/15/2024,HUMAN PRESCRIPTION DRUG,10/15/2024,Cardiovascular,CANDESARTAN CILEXETIL,"49884-659, 49884-658, 49884-660, 49884-661",Par Pharmaceutical Inc.,fc8868a3-89f5-4414-b3c8-edece3b529f4,"49884-658-09, 49884-659-09, 49884-660-09, 49884-661-09","Atacand, Tablet, 8 mg (NDC 49884-659-09)",Tablet,,,NDA020838,,CANDESARTAN CILEXETIL,,,To Be Discontinued,,,,R85M2X0D68,49884-659-09,800-828-9393,
"Novo Nordisk, Inc.",INSULIN ASPART,,07/21/2025,New,SUBCUTANEOUS,Insulin Aspart Protamine and Insulin Aspart Mix 70/30 Injectable Suspension,"351297, 847191",,fc94baa4-3606-48bc-a781-9617ab6960ef,07/21/2025,HUMAN PRESCRIPTION DRUG,07/21/2025,Endocrinology/Metabolism,INSULIN ASPART PROTAMINE AND INSULIN ASPART MIX 70/30,"73070-203, 73070-200","Novo Nordisk Pharma, Inc.",ec67820c-4008-4894-b933-34b28704221d,"73070-200-11, 73070-203-10, 73070-203-15","Insulin Aspart Protamine and Insulin Aspart Mix 70/30, Injectable Suspension, 3 mL vial Insulin aspart protamine and insulin aspart Mix 70/30 FlexPen® (NDC 73070-203-15)",Injectable Suspension,,"M0011417, N0000175453",BLA021172,Insulin [CS],INSULIN ASPART,Insulin Analog [EPC],,To Be Discontinued,,"Unbranded Insulin aspart protamine and insulin aspart FlexPen® will continue to be shipped to wholesalers while supplies last, up until the discontinuation dates. Full discontinuation will occur on December 31, 2025.",,D933668QVX,73070-203-15,609-987-5800,
Alvogen,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,7f2dd6ee-3363-c87c-9693-ed838942556c,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"47781-568, 47781-562, 47781-563, 47781-564, 47781-565, 47781-566, 47781-567",Alvogen Inc.,9114d946-92cb-c19d-c6f2-aef77294461f,"47781-562-01, 47781-563-01, 47781-564-01, 47781-565-01, 47781-566-01, 47781-567-01, 47781-568-01","Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 47781-568-01)",Capsule,Available,,ANDA214547,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,47781-568-01,844-842-8672 and email: CustomerService-US@alvogen.com,
"Elite Laboratories, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,08/15/2023,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,e677690f-790f-4626-ad78-097cdb6ea540,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","64850-506, 64850-500, 64850-501, 64850-502, 64850-503, 64850-504, 64850-505","Elite Laboratories, Inc.",b65e0266-7172-4730-8f93-eb42e08fb7b8,"64850-500-01, 64850-500-05, 64850-500-30, 64850-501-01, 64850-501-05, 64850-501-30, 64850-502-01, 64850-502-05, 64850-502-30, 64850-503-01, 64850-503-05, 64850-503-30, 64850-504-01, 64850-504-05, 64850-504-30, 64850-505-01, 64850-505-05, 64850-505-30, 64850-506-01, 64850-506-05, 64850-506-30","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 64850-506-01)",Tablet,Limited Availability,,ANDA211352,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,Shortage of an active ingredient,3 months,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",64850-506-01,888-852-6657,
"Teva Pharmaceuticals USA, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Revised,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541365, 541878, 541879, 541892, 541894, 577957, 577960, 577961, 577962, 687043, 687045, 1009145, 1009147",,f22635fe-821d-4cde-aa12-419f8b53db81,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,ADDERALL,"57844-115, 57844-105, 57844-117, 57844-110, 57844-112, 57844-120, 57844-130","Teva Pharmaceuticals USA, Inc.",79af1dc6-c7cf-41b1-a750-e9b47c2187ff,"57844-105-01, 57844-117-01, 57844-110-01, 57844-112-01, 57844-115-01, 57844-120-01, 57844-130-01","Adderall, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 57844-115-01)",Tablet,Available,,ANDA040422,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",57844-115-01,800-545-8800,
Aurobindo Pharma USA,BENAZEPRIL HYDROCHLORIDE,,02/07/2025,New,ORAL,Benazepril Hydrochloride Tablet,"898687, 898690, 898719",,09e383a8-e912-4cf7-8fb3-05545af80dd0,02/07/2025,HUMAN PRESCRIPTION DRUG,02/07/2025,Cardiovascular,BENAZEPRIL HYDROCHLORIDE,"65862-117, 65862-116, 65862-118",Aurobindo Pharma Limited,65334c7f-e49f-44d9-a6c1-6c1ce6e88fbe,"65862-116-90, 65862-116-01, 65862-117-90, 65862-117-01, 65862-118-90, 65862-118-01","Benazepril Hydrochloride, Tablet, 20 mg (NDC 65862-117-01)",Tablet,,,ANDA078212,,BENAZEPRIL HYDROCHLORIDE,,,To Be Discontinued,,,,N1SN99T69T,65862-117-01,866-850-2876,
"Fresenius Kabi USA, LLC",LIDOCAINE HYDROCHLORIDE ANHYDROUS,,02/22/2012,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010035, 1010671, 1010673, 1010688, 1010692, 1010745, 1010749, 1010751, 1010755, 1010759, 1010763, 1010900, 1010902, 1737343, 1737345, 1737562, 1737563, 1737566, 1737567, 1737568, 1737569, 1737570, 1737571, 1737757, 1737758, 1737761, 1737762, 1867938, 1867940, 1867943, 1867944, 1867992, 1867993, 1867996, 1867997, 1868028, 1868029, 1737636, 1737637, 1737640, 1737641, 1737763, 1737764",,"ba082c2f-64f4-419d-9c88-74f203316e17, 4dd52202-8eef-4136-92dd-ada573b7cf74, d5e0d06f-ba1e-44d4-aa89-39d6c146dc23",09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",XYLOCAINE MPF,"63323-492, 63323-491, 63323-495, 63323-485, 63323-486, 63323-484, 63323-489, 63323-488, 63323-481, 63323-483, 63323-482, 63323-487, 63323-493, 63323-496","Fresenius Kabi USA, LLC","ea480a68-5927-4278-9deb-2956961da428, 0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33, fa12a8e8-09fd-496f-8cc6-ffe0eb02e2df","63323-492-04, 63323-492-27, 63323-492-09, 63323-492-57, 63323-492-07, 63323-492-37, 63323-492-03, 63323-492-31, 63323-491-01, 63323-491-57, 63323-495-09, 63323-495-27, 63323-495-04, 63323-495-07, 63323-485-01, 63323-485-27, 63323-485-03, 63323-485-57, 63323-486-01, 63323-486-17, 63323-486-02, 63323-486-27, 63323-486-05, 63323-486-57, 63323-484-57, 63323-489-02, 63323-489-27, 63323-489-03, 63323-489-21, 63323-489-01, 63323-489-17, 63323-488-07, 63323-488-37, 63323-488-03, 63323-488-31, 63323-488-01, 63323-488-17, 63323-481-01, 63323-481-57, 63323-483-03, 63323-483-27, 63323-483-01, 63323-483-57, 63323-482-01, 63323-482-17, 63323-482-03, 63323-482-27, 63323-482-05, 63323-482-57, 63323-487-01, 63323-487-17, 63323-487-07, 63323-487-37, 63323-487-03, 63323-487-31, 63323-492-41, 63323-492-16, 63323-492-43, 63323-492-36, 63323-492-45, 63323-492-26, 63323-485-41, 63323-485-26, 63323-486-41, 63323-486-26, 63323-482-41, 63323-482-26, 63323-495-41, 63323-495-26, 63323-492-08, 63323-492-97, 63323-493-03, 63323-493-97, 63323-493-01, 63323-493-91, 63323-496-03, 63323-496-97","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-57)",Injection,Available,,NDA006488,,LIDOCAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,"EC2CNF7XFP, 30Q7KI53AK",63323-492-57,888-386-1300,
Novadoz Pharmaceuticals LLC,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Revised,ORAL,"Lisdexamfetamine Dimesylate Tablet, Chewable","1871456, 1871460, 1871462, 1871464, 1871466, 1871468",,a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"72205-132, 72205-133, 72205-134, 72205-135, 72205-136, 72205-137",Novadoz Pharmaceuticals LLC,a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811,"72205-132-91, 72205-133-91, 72205-134-91, 72205-135-91, 72205-136-91, 72205-137-91","Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 72205-132-91)","Tablet, Chewable",Available,,ANDA218306,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,,,SJT761GEGS,72205-132-91,(855) 668-2369; customerservice@novadozpharma.com,
"Hospira, Inc., a Pfizer Company",METHOTREXATE SODIUM,,03/13/2023,Reverified,"INTRAMUSCULAR, INTRATHECAL, INTRAVENOUS, SUBCUTANEOUS",Methotrexate Sodium Injection,"1655956, 1946772",,"0d63ba29-b692-41b4-87e8-351265c8273f, 0e30eaef-5a09-4104-8a11-c32933eadeab",08/15/2025,HUMAN PRESCRIPTION DRUG,,"Rheumatology, Oncology",METHOTREXATE,"61703-408, 61703-350","Hospira, Inc.","95b8b8da-da4e-4bba-9038-3cf65f3d5c1a, 37b3e76b-ac3d-4f93-adf1-91f52f676b8a","61703-350-37, 61703-350-38, 61703-408-41, 61703-350-09, 61703-350-10, 61703-408-25","Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41)",Injection,Available,,NDA011719,,METHOTREXATE,,,Current,,,,3IG1E710ZN,61703-408-41,844-646-4398,
"Teva Pharmaceuticals USA, Inc.",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Revised,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release","1091155, 1091170, 1091185, 1091210",,85ef422d-af27-4126-9841-6892af1871d6,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE HYDROCHLORIDE,"62037-725, 62037-734, 62037-726, 62037-727","Actavis Pharma, Inc.",794291a5-d481-4cfe-9dbb-2d1391bb68d5,"62037-725-01, 62037-734-01, 62037-726-01, 62037-727-01","Methylphenidate Hydrochloride Extended-Release Tablets, USP   CII, Tablet, Extended Release, 18 mg (NDC 62037-725-01)",Tablet,Available,,ANDA076772,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,,,,4B3SC438HI,62037-725-01,800-545-8800,
InfoRLife SA,METRONIDAZOLE,,01/13/2022,Reverified,INTRAVENOUS,Metronidazole Injection,311683,,d46870f5-e2b1-46bd-8413-4a0a8bcf3175,09/22/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,METRONIDAZOLE,25021-131,Sagent Pharmaceuticals,cad111bb-2009-422a-b16e-87d75ade4e4c,25021-131-82,"Metronidazole, Injection, 500 mg/100 mL (NDC 25021-131-82)",Injection,Available,"N0000175435, M0014907",ANDA206191,Nitroimidazoles [CS],METRONIDAZOLE,Nitroimidazole Antimicrobial [EPC],,Current,,Labeler: Sagent Pharmaceuticals,,140QMO216E,25021-131-82,866-625-1618,
"Teva Pharmaceuticals USA, Inc.",OXAZEPAM,,12/04/2024,Revised,ORAL,Oxazepam Capsule,"198057, 198059, 312134",,a0d5a4c1-ec79-42e6-8e8f-ae4d144edb43,07/03/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Psychiatry",OXAZEPAM,"0228-2067, 0228-2069, 0228-2073","Actavis Pharma, Inc.",3473450d-0e2d-43ed-9cc9-d8c63a201085,"0228-2067-10, 0228-2069-10, 0228-2073-10","Oxazepam, Capsule, 10 mg (NDC 0228-2067-10)",Capsule,,"N0000175694, M0002356",ANDA072253,Benzodiazepines [CS],OXAZEPAM,Benzodiazepine [EPC],Available,Resolved,,,07/03/2025,6GOW6DWN2A,0228-2067-10,800-545-8800,
"Sunrise Pharmaceutical, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,ac102599-3a5b-4154-899e-6ff262be7ff7,09/03/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","11534-196, 11534-190, 11534-191, 11534-192, 11534-193, 11534-194, 11534-195","SUNRISE PHARMACEUTICAL, INC.",86a00bec-51eb-4d73-a945-b1937970b29a,"11534-190-01, 11534-190-03, 11534-191-01, 11534-191-03, 11534-192-01, 11534-192-03, 11534-193-01, 11534-193-03, 11534-194-01, 11534-194-03, 11534-195-01, 11534-195-03, 11534-196-01, 11534-196-03","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 11534-196-01)",Tablet,Available,,ANDA209799,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",11534-196-01,732-382-6085 Monday to Friday 9 am to 3:45 pm,
Pfizer Inc.,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718900, 1718902, 1718906, 1718907, 1718909, 1718910, 2396891, 2396892",,4419162d-81d4-49bd-96de-1729440bdb74,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,PRECEDEX,"0409-1174, 0409-1454, 0409-3301, 0409-2815","Hospira, Inc.",8d48de06-361f-418b-bfec-8ef85f94d5bc,"0409-1454-01, 0409-1454-20, 0409-3301-01, 0409-3301-10, 0409-1174-01, 0409-1174-10, 0409-2815-01","Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1174-10)",Injection,Available,,NDA021038,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,,,,1018WH7F9I,0409-1174-10,844-646-4398,
"Teva Pharmaceuticals USA, Inc.",FLURBIPROFEN,,11/13/2024,New,ORAL,Flurbiprofen Tablet,197724,,4e5c06f1-f279-4f2f-b10d-0f70005a27e6,11/13/2024,HUMAN PRESCRIPTION DRUG,11/13/2024,Analgesia/Addiction,FLURBIPROFEN,0093-0711,"Teva Pharmaceuticals USA, Inc.",38a133bd-a325-4de2-bcf2-d6e144cc456b,"0093-0711-01, 0093-0711-05","Tablet, 100 mg (NDC 0093-0711-05)",Tablet,,"N0000000160, M0001335, N0000175722",ANDA074431,"Anti-Inflammatory Agents, Non-Steroidal [CS]",FLURBIPROFEN,Nonsteroidal Anti-inflammatory Drug [EPC],,To Be Discontinued,,A business decision was made to discontinue manufacture of the product.,,5GRO578KLP,0093-0711-05,800-545-8800,Cyclooxygenase Inhibitors [MoA]
Baxter Healthcare,HEPARIN SODIUM,,11/14/2017,Reverified,INTRAVENOUS,Heparin Sodium Injection,"1658690, 1658692",,0d929726-76c3-48fc-b4e7-fd06409f9fb3,09/23/2025,HUMAN PRESCRIPTION DRUG,,Hematology,HEPARIN SODIUM IN SODIUM CHLORIDE,"0338-0424, 0338-0431, 0338-0433, 0338-0428",Baxter Healthcare Corporation,68b37381-6db4-4ac0-ba6b-3204add02665,"0338-0431-03, 0338-0433-04, 0338-0424-18, 0338-0428-12","Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0424-18)",Injection,Unavailable,,NDA018609,,HEPARIN SODIUM,,,Current,Discontinuation of the manufacture of the drug,Product Discontinued - Product code AHB0953U replaced by Product Code 2B0953,,ZZ45AB24CA,0338-0424-18,888-229-0001,
Slate Run Pharmaceuticals,LEUCOVORIN CALCIUM,,01/01/2012,Revised,"INTRAMUSCULAR, INTRAVENOUS",Leucovorin Calcium Injection,"237788, 1803930, 1803932, 1803937, 2055036",,d8bdd60c-9a1c-4ef4-ba6b-b911849128f1,07/08/2025,HUMAN PRESCRIPTION DRUG,,"Oncology, Pediatric",LEUCOVORIN CALCIUM,"70436-119, 70436-116, 70436-117, 70436-118, 70436-120","Slate Run Pharmaceuticals, LLC",2a4aaed3-885e-bc10-e063-6294a90a61af,"70436-116-80, 70436-116-82, 70436-117-80, 70436-118-80, 70436-120-80, 70436-119-80","Leucovorin Calcium, Injection, 350 mg (NDC 70436-119-80)",Injection,,,ANDA217021,,LEUCOVORIN CALCIUM,,Available,Resolved,,,07/08/2025,RPR1R4C0P4,70436-119-80,888-447-0095,
"American Regent, Inc.",NITROGLYCERIN,Vasodilation [PE],10/06/2023,Reverified,INTRAVENOUS,Nitroglycerin Injection,237205,,8c52cdf6-87be-4719-b105-f08be096d462,08/19/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,NITROGLYCERIN,0517-4810,"American Regent, Inc.",ee83c8b9-c31a-4f32-9e9d-0370545204cb,"0517-4810-01, 0517-4810-25","Nitroglycerin, Injection, 5 mg/1 mL (NDC 0517-4810-25)",Injection,Available,"N0000175415, M0014874, N0000009909",ANDA072034,Nitrates [CS],NITROGLYCERIN,Nitrate Vasodilator [EPC],,Current,,,,G59M7S0WS3,0517-4810-25,800-645-1706,
Sun Pharmaceutical Industries Limited,CLINDAMYCIN HYDROCHLORIDE,,12/05/2024,New,ORAL,Clindamycin Hydrochloride Capsule,"197518, 284215",,1dbd8448-c1e5-46df-8060-50ef82380445,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Anti-Infective,CLINDAMYCIN HYDROCHLORIDE,"63304-692, 63304-693","Sun Pharmaceutical Industries, Inc.",339366d4-2060-1c29-e063-6394a90a1cb7,"63304-692-01, 63304-692-05, 63304-692-77, 63304-692-03, 63304-693-16, 63304-693-01, 63304-693-03, 63304-693-05, 63304-693-77, 63304-693-11, 63304-693-62","Clindamycin Hydrochloride, Capsule, 150 mg (NDC 63304-692-77)",Capsule,,,ANDA065061,,CLINDAMYCIN HYDROCHLORIDE,,,To Be Discontinued,,Discontinuing for business reasons,,T20OQ1YN1W,63304-692-77,800-818-4555,
Accord Healthcare Inc.,CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,ebc11109-e7bf-452d-b675-4b3236d54164,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"16729-138, 16729-136, 16729-137",Accord Healthcare Inc.,0e1e7f41-f78b-27cf-e063-6394a90a1ae0,"16729-136-00, 16729-136-16, 16729-137-00, 16729-137-16, 16729-138-00, 16729-138-16","Clonazepam, Tablet, 2 mg (NDC 16729-138-00)",Tablet,Available,"N0000175694, M0002356",ANDA077147,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,,,5PE9FDE8GB,16729-138-00,"866-941-7875, option 2",
B. Braun Medical Inc.,"DEXTROSE, UNSPECIFIED FORM",,03/01/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 10% Injection,"1795477, 1795480, 1795481, 1795607, 1795610, 1795612",,085614c7-ada4-4e2c-87c0-c9bc2f18365a,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0264-7520, 0264-7510",B. Braun Medical Inc.,c9f87749-8dd5-41fd-b393-f63d45fd00ef,"0264-7510-00, 0264-7510-10, 0264-7510-20, 0264-7520-00, 0264-7520-10, 0264-7520-20","Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-00)",Injection,Available,,NDA019626,,DEXTROSE,,,Current,,,,IY9XDZ35W2,0264-7520-00,800-227-2862,
Novartis Pharmaceuticals Corporation,"AMLODIPINE BESYLATE, BENAZEPRIL HYDROCHLORIDE",,06/24/2025,New,ORAL,Amlodipine Besylate; Benazepril Hydrochloride Capsule,"898342, 898344, 898346, 898348, 898353, 898355, 898356, 898358",,94ae6054-b7ae-4212-a567-4f803af8f2c7,06/24/2025,HUMAN PRESCRIPTION DRUG,06/24/2025,Cardiovascular,LOTREL,"0078-0406, 0078-0405, 0078-0364, 0078-0379",Novartis Pharmaceuticals Corporation,b9db75d9-9d1e-4b2d-9876-5f5520feaecc,"0078-0405-05, 0078-0406-05, 0078-0364-05, 0078-0379-05","Lotrel, Capsule, 5 mg; 20 mg (NDC 0078-0406-05)",Capsule,,,NDA020364,,AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE,,,To Be Discontinued,,Permanent discontinuation in the manufacturing of the drug,,"864V2Q084H, N1SN99T69T",0078-0406-05,888-669-6682,
Sagent Pharmaceuticals,KETOROLAC TROMETHAMINE,,03/26/2018,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Ketorolac Tromethamine Injection,"860092, 1665459, 1665461",,62591551-a644-4b2c-a0de-982e906fabc3,08/26/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,KETOROLAC TROMETHAMINE,"25021-701, 25021-700",Sagent Pharmaceuticals,ff55e1ab-2a8d-4a56-8b72-5e0a8e00d866,"25021-700-01, 25021-701-01, 25021-701-02","Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)",Injection,Available,,ANDA204216,,KETOROLAC TROMETHAMINE,,,Current,,,,4EVE5946BQ,25021-701-01,866-625-1618,
"Hikma Pharmaceuticals USA, Inc.",PROMETHAZINE HYDROCHLORIDE,,11/21/2023,Revised,INTRAMUSCULAR,Promethazine Hydrochloride Injection,"992460, 992858",,4bf3912c-8339-401e-9711-dad6acf15f11,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Gastroenterology, Pediatric, Pulmonary/Allergy",PROMETHAZINE HYDROCHLORIDE,"0641-0929, 0641-0928",Hikma Pharmaceuticals USA Inc.,9f14d3f5-ad01-44b5-a2b7-16ed5f501f87,"0641-0928-21, 0641-0928-25, 0641-0929-21, 0641-0929-25","Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)",Injection,Unavailable,,ANDA083312,,PROMETHAZINE HYDROCHLORIDE,,,Current,Other,This presentation is temporarily on backorder.  Recovery is TBD at this time.,,R61ZEH7I1I,0641-0929-25,800-631-2174,
"Fresenius Kabi USA, LLC",ATROPINE SULFATE,,01/01/2012,Reverified,"ENDOTRACHEAL, INTRAMEDULLARY, INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Atropine Sulfate Injection,1190776,,310c8a74-ea24-4357-8099-81e394b1634e,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology, Pediatric",ATROPINE SULFATE,63323-580,"Fresenius Kabi USA, LLC",8039a2a4-4c0a-4062-9ca5-78137ba74082,63323-580-20,"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 63323-580-20)",Injection,Available,,NDA209260,,ATROPINE SULFATE,,,Current,,Check wholesalers for inventory,,03J5ZE7KA5,63323-580-20,888-386-1300,
"Teva Pharmaceuticals USA, Inc.",ESZOPICLONE,,06/26/2025,New,ORAL,Eszopiclone Tablet,"485440, 485442, 485465",,2435e2f1-bc52-488f-80e9-f1758e354aae,06/26/2025,HUMAN PRESCRIPTION DRUG,06/26/2025,Neurology,ESZOPICLONE,"0093-5538, 0093-5537, 0093-5539","Teva Pharmaceuticals USA, Inc.",b7cc855f-8510-4cb2-a941-18d3c4472236,"0093-5537-56, 0093-5538-01, 0093-5539-01","Eszopiclone, Tablet, 2 mg (NDC 0093-5538-01)",Tablet,,,ANDA091169,,ESZOPICLONE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,UZX80K71OE,0093-5538-01,800-545-8800,
ANI Pharmaceuticals,,,11/07/2024,New,,Aminocaproic Acid Tablet,,,,11/07/2024,,11/07/2024,"Cardiovascular, Hematology, Other",,,,,,"Tablet, 500 mg (NDC 62559-225-30)",Tablet,,,,,,,,To Be Discontinued,,"ANI anticipates ceasing distribution on November 30, 2024.",,,62559-225-30,800-434-1121,
"Mylan Pharmaceuticals Inc., a Viatris Company",,,02/14/2025,New,,Erythromycin  Topical Gel,,,,02/14/2025,,02/14/2025,"Anti-Infective, Dermatology",,,,,,"Erygel, Topical Gel, 20 mg/1 g (NDC 0378-8212-93)",Topical Gel,,,,,,,,To Be Discontinued,,,,,0378-8212-93,800-796-9526,
"Teva Pharmaceuticals USA, Inc.",FINASTERIDE,,08/19/2025,New,ORAL,Finasteride Tablet,310346,,77589cc3-c440-4695-800c-82a0e5128a6c,08/19/2025,HUMAN PRESCRIPTION DRUG,08/19/2025,Urology,FINASTERIDE,0093-7355,"Teva Pharmaceuticals USA, Inc.",ea83e229-c434-4097-81dd-e3b48814d5dc,"0093-7355-56, 0093-7355-98, 0093-7355-05","Finasteride, Tablet, 5 mg (NDC 0093-7355-56)",Tablet,,"N0000175836, N0000000126",ANDA076511,,FINASTERIDE,5-alpha Reductase Inhibitor [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug product,,57GNO57U7G,0093-7355-56,800-545-8800,5-alpha Reductase Inhibitors [MoA]
"Rising Pharma Holdings, Inc.",,,08/03/2022,Reverified,,Flurazepam Hydrochloride Capsule,,,,08/19/2025,,,"Neurology, Other",,,,,,"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 0378-4415-01)",Capsule,Unavailable,,,,,,,Current,Regulatory delay,Anticipated availability: Q3 2025; Delay is due to manufacturing delays at the contract manufacturing facility.,,,0378-4415-01,1-844-874-7464,
"Sun Pharmaceutical Industries, Inc.",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Revised,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release","1091155, 1091170, 1091185, 1091210",,d048e52d-7406-4fc1-9a72-c073bafc7439,09/22/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE HYDROCHLORIDE,"57664-609, 57664-606, 57664-607, 57664-608","Sun Pharmaceutical Industries, Inc.",0da4b745-d498-8823-e063-6394a90a4524,"57664-606-88, 57664-607-88, 57664-608-88, 57664-609-88","Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88)",Tablet,Unavailable,,ANDA205135,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,Discontinuation of the manufacture of the drug,Currently not marketed,,4B3SC438HI,57664-609-88,800-818-4555,
"Boehringer Ingelheim Pharmaceuticals, Inc.",TELMISARTAN,,10/22/2024,New,ORAL,Telmisartan Tablet,"205304, 205305, 213431, 213432, 282755, 284531",,cfb9309f-e0df-4a55-9542-0e869fce05fb,10/22/2024,HUMAN PRESCRIPTION DRUG,10/22/2024,Cardiovascular,MICARDIS,"0597-0040, 0597-0039, 0597-0041","Boehringer Ingelheim Pharmaceuticals, Inc.",333f0ca9-928d-45af-92b9-9ea8a4d02f7d,"0597-0039-37, 0597-0040-37, 0597-0041-37","Micardis, Tablet, 40 mg (NDC 0597-0040-37)",Tablet,,"N0000000070, N0000175561",NDA020850,,TELMISARTAN,Angiotensin 2 Receptor Blocker [EPC],,To Be Discontinued,,Discontinued for business reasons,,U5SYW473RQ,0597-0040-37,800-243-0127,Angiotensin 2 Receptor Antagonists [MoA]
Sun Pharmaceutical Industries Limited,IMATINIB MESYLATE,,12/05/2024,New,ORAL,Imatinib Mesylate Tablet,"403878, 403879",,07764bf9-21b4-4e32-9d7e-e348f8e4291f,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Hematology,IMATINIB MESYLATE,"47335-472, 47335-475","Sun Pharmaceutical Industries, Inc.",ad13dbca-474d-4492-9c25-e0e175143d8c,"47335-472-83, 47335-472-88, 47335-472-13, 47335-472-81, 47335-475-83, 47335-475-88, 47335-475-13, 47335-475-64","Imatinib Mesylate, Tablet, 100 mg (NDC 47335-472-81)",Tablet,,,ANDA078340,,IMATINIB MESYLATE,,,To Be Discontinued,,Discontinuing for business reasons,,8A1O1M485B,47335-472-81,800-818-4555,
"Fresenius Kabi USA, LLC",LEUCOVORIN CALCIUM,,01/01/2012,Revised,"INTRAMUSCULAR, INTRAVENOUS",Leucovorin Calcium Injection,"1803937, 2055036",,"ab691d4e-e0d1-4ba1-9c7a-1cdcfcc3c17c, e3b957dc-a542-4f69-b8a0-7df401ee706f",07/08/2025,HUMAN PRESCRIPTION DRUG,,"Oncology, Pediatric",LEUCOVORIN CALCIUM,"63323-710, 63323-711","Fresenius Kabi USA, LLC","b70ccebd-b847-41ff-8c30-9779461465e0, 2497bd71-0f85-48ec-9353-d591e1c728f8","63323-710-59, 63323-710-50, 63323-711-00","Leucovorin Calcium, Injection, 200 mg/20 mL (NDC 63323-710-50)",Injection,,,ANDA040258,,LEUCOVORIN CALCIUM,,Available,Resolved,,,07/08/2025,RPR1R4C0P4,63323-710-50,888-386-1300,
"Teva Pharmaceuticals USA, Inc.",AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension",,,4c0f348a-a65d-409c-8668-207c82a5e3cb,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0093-4160, 0093-2263, 0093-2264, 0093-4155, 0093-4161, 0093-2267, 0093-2268, 0093-3107, 0093-3109","Teva Pharmaceuticals USA, Inc.",8988589b-0893-4233-ac9c-9884ceb0c2c4,"0093-2263-01, 0093-2264-01, 0093-4160-76, 0093-4160-78, 0093-4160-73, 0093-4155-79, 0093-4155-73, 0093-4155-80, 0093-4161-76, 0093-4161-78, 0093-4161-73, 0093-2267-01, 0093-2268-01, 0093-3107-01, 0093-3107-05, 0093-3109-53, 0093-3109-06, 0093-3109-01, 0093-3109-05","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0093-4160-76)","Powder, For Suspension",,,ANDA065119,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0093-4160-76,800-545-8800,
Aurobindo Pharma USA,METOPROLOL TARTRATE,,06/03/2025,New,ORAL,Metoprolol Tartrate Tablet,"866511, 866514, 866924",,2b705cb6-cb75-4c2a-907a-4bd45d18bc2c,06/03/2025,HUMAN PRESCRIPTION DRUG,06/03/2025,Cardiovascular,METOPROLOL TARTRATE,"65862-063, 65862-062, 65862-064",Aurobindo Pharma Limited,d265c99d-8e77-4a78-b542-15e957d9d335,"65862-062-01, 65862-062-99, 65862-063-60, 65862-063-01, 65862-063-99, 65862-064-60, 65862-064-01, 65862-064-99","Metoprolol Tartrate, Tablet, 50 mg (NDC 65862-063-59)",Tablet,,,ANDA077739,,METOPROLOL TARTRATE,,,To Be Discontinued,,Permanent discontinuation in the manufacturing of the drug,,W5S57Y3A5L,65862-063-59,866-850-2876,
"Epic Pharma, LLC",RIFAMPIN,,12/22/2021,Reverified,ORAL,Rifampin Capsule,"198201, 198202",,0391f1e1-70d4-4b15-8b58-055bb6a385b8,09/18/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,RIFAMPIN,"42806-801, 42806-799","EPIC PHARMA, LLC",a4ac02e8-68ac-4e79-8ca5-0939dd002c87,"42806-801-30, 42806-801-01, 42806-799-30, 42806-799-60, 42806-799-01, 42806-799-05","Rifampin, Capsule, 150 mg (NDC 42806-801-01)",Capsule,Unavailable,"N0000175500, M0019113",ANDA064150,Rifamycins [CS],RIFAMPIN,Rifamycin Antibacterial [EPC],,Current,Discontinuation of the manufacture of the drug,Discontinuation of the manufacture of the drug.,,VJT6J7R4TR,42806-801-01,(718) 276-8600 ext. 3,
"Fresenius Kabi USA, LLC",ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Reverified,"EPIDURAL, PERINEURAL",Ropivacaine Hydrochloride Injection,"905189, 905191, 1734084, 1734086, 1734090, 1734091, 1734203, 1734204, 1734207, 1734208, 1734347, 1734348, 1734355, 1734356, 1734475, 1734476, 1734479, 1734480, 1734481, 1734482, 1734483, 1734484",,23d2d448-a744-4877-9f2d-7e57c198da89,09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,NAROPIN,"63323-287, 63323-286, 63323-288, 63323-285","Fresenius Kabi USA, LLC",cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9,"63323-286-01, 63323-286-20, 63323-286-05, 63323-286-23, 63323-286-09, 63323-286-31, 63323-286-11, 63323-286-35, 63323-286-03, 63323-286-00, 63323-286-33, 63323-286-63, 63323-286-30, 63323-287-01, 63323-287-20, 63323-287-03, 63323-287-21, 63323-288-01, 63323-288-10, 63323-288-06, 63323-288-20, 63323-288-03, 63323-288-11, 63323-288-07, 63323-288-21, 63323-285-01, 63323-285-10, 63323-285-06, 63323-285-20, 63323-285-03, 63323-285-13, 63323-285-07, 63323-285-23, 63323-285-57, 63323-285-64, 63323-285-51, 63323-285-65, 63323-285-02, 63323-285-61, 63323-285-04, 63323-285-63","Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-20)",Injection,Unavailable,,NDA020533,,ROPIVACAINE HYDROCHLORIDE,,,Current,Demand increase for the drug,Not available at this time.,,V910P86109,63323-287-20,888-386-1300,
"Upsher-Smith Laboratories, LLC",DIVALPROEX SODIUM,,04/28/2025,New,ORAL,"Divalproex Sodium Tablet, Delayed Release","1099625, 1099678, 1099870",,02304a23-4a5f-47bc-9687-4044b43f7a20,04/28/2025,HUMAN PRESCRIPTION DRUG,04/28/2025,Neurology,DIVALPROEX SODIUM,"0832-7123, 0832-7122, 0832-7124","Upsher-Smith Laboratories, LLC",38e51a59-5802-77a6-e063-6394a90af6c6,"0832-7122-11, 0832-7122-15, 0832-7123-11, 0832-7123-15, 0832-7123-89, 0832-7123-01, 0832-7124-11, 0832-7124-15, 0832-7124-89, 0832-7124-01","Divalproex Sodium, Tablet, Delayed Release, 250 mg (NDC 0832-7123-11)",Tablet,,,ANDA078182,,DIVALPROEX SODIUM,,,To Be Discontinued,,Discontinuation of manufacture of drug based on business decision.,,644VL95AO6,0832-7123-11,800-654-2299,
Fresenius Medical Care North America,"CALCIUM CHLORIDE, DEXTROSE MONOHYDRATE, MAGNESIUM CHLORIDE, SODIUM CHLORIDE, SODIUM LACTATE",,10/11/2024,Revised,INTRAPERITONEAL,Peritoneal Dialysis Solution,,,a98facd6-9daa-4d37-8209-63a0599dbfaa,07/07/2025,HUMAN PRESCRIPTION DRUG,,Renal,DELFLEX,"46163-206, 46163-209, 46163-212","Fresenius Medical Care de Mexico, S.A. de C.V.",38fb0473-107c-1b7a-e063-6294a90aafb8,"46163-209-92, 46163-209-94, 46163-209-95, 46163-212-95, 46163-212-92, 46163-212-94, 46163-206-92, 46163-206-94, 46163-206-95","Peritoneal Dialysis, Solution, Various NDCs (NDC 46163-206-94)",Solution,,,NDA020171,,"DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE",,Available,Resolved,,,07/07/2025,"02F3473H9O, LX22YL083G, TU7HW0W0QT, 451W47IQ8X, M4I0D6VV5M",46163-206-94,800-323-5188,
"Fresenius Kabi USA, LLC",RIFAMPIN,,02/17/2021,Reverified,INTRAVENOUS,Rifampin Injection,312821,,a1f9f1e2-dfc0-4d31-a13b-b656d897b791,09/18/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,RIFAMPIN,63323-351,"Fresenius Kabi USA, LLC",60eb9c46-3c34-455b-a740-c03884565072,63323-351-20,"Rifampin, Injection, 600 mg (NDC 63323-351-20)",Injection,Available,"N0000175500, M0019113",ANDA091181,Rifamycins [CS],RIFAMPIN,Rifamycin Antibacterial [EPC],,Current,,Check wholesalers for inventory,,VJT6J7R4TR,63323-351-20,888-386-1300,
"Fresenius Kabi USA, LLC",SODIUM CHLORIDE,,06/21/2018,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Sodium Chloride 0.9% Injection,"1807632, 1807636, 1807637, 1807638",,"f2a98378-9678-4738-9670-fc7a215c0606, f62481fd-fcdb-4be6-ac13-29c590e925c3",08/08/2025,HUMAN PRESCRIPTION DRUG,,Other,SODIUM CHLORIDE,63323-186,"Fresenius Kabi USA, LLC","debc17b5-4d24-473c-8396-e409433ce57c, 75c567e3-582b-4fff-9a72-f326f1d13c8f","63323-186-00, 63323-186-04, 63323-186-02, 63323-186-01, 63323-186-10, 63323-186-03, 63323-186-20","Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-186-10)",Injection,,,ANDA088912,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,63323-186-10,888-386-1300,
"Assertio Specialty Pharmaceuticals, LLC",METHOTREXATE,,08/29/2025,New,SUBCUTANEOUS,Methotrexate Injection,"1441402, 1441407, 1441411, 1441413, 1441416, 1441418, 1441422, 1441424, 1747179, 1747181, 1747185, 1747187, 1747192, 1747194",,7dcd02d7-1ce0-43fc-8f25-2f0bb0caba2f,08/29/2025,HUMAN PRESCRIPTION DRUG,08/29/2025,Rheumatology,OTREXUP,"82497-017, 82497-010, 82497-012, 82497-015, 82497-020, 82497-022, 82497-025","Otter Pharmaceuticals, LLC",9aaba145-f343-4498-b754-fb7c78181bd7,"82497-010-02, 82497-010-04, 82497-012-02, 82497-012-04, 82497-015-02, 82497-015-04, 82497-017-02, 82497-017-04, 82497-020-02, 82497-020-04, 82497-022-02, 82497-022-04, 82497-025-02, 82497-025-04","Otrexup, Injection, 17.5 mg/.4 mL (NDC 82497-017-04)",Injection,,"N0000175584, N0000000111",NDA204824,,METHOTREXATE,Folate Analog Metabolic Inhibitor [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,YL5FZ2Y5U1,82497-017-04,224-441-6390,Folic Acid Metabolism Inhibitors [MoA]
Amneal Pharmaceuticals,METHYLPREDNISOLONE ACETATE,,12/15/2021,Reverified,"INTRA-ARTICULAR, INTRALESIONAL, INTRAMUSCULAR, INTRASYNOVIAL, SOFT TISSUE",Methylprednisolone Acetate Injection,"1743779, 1743855",,d944240d-2c19-46ba-ad4f-3fbee7b8629c,09/17/2025,HUMAN PRESCRIPTION DRUG,,Rheumatology,METHYLPREDNISOLONE ACETATE,"70121-1573, 70121-1574",Amneal Pharmaceuticals LLC,0bdaa3cf-cf32-4959-b87a-65215ac4648d,"70121-1573-1, 70121-1573-5, 70121-1574-1, 70121-1574-5","Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-5)",Injection,Available,,ANDA210043,,METHYLPREDNISOLONE ACETATE,,,Current,,,,43502P7F0P,70121-1573-5,866-525-7270,
Eugia US LLC,ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Revised,EPIDURAL,Ropivacaine Hydrochloride Injection,"905189, 1734084, 1734090, 1734207, 1734347, 1734475, 1734483",,3763b7b6-da49-4658-b93d-28f5da24d09e,09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROPIVACAINE HYDROCHLORIDE,"55150-200, 55150-195, 55150-196, 55150-197, 55150-198, 55150-199, 55150-201",Eugia US LLC,34725b26-d6e9-4d1b-95a0-da03764cc102,"55150-195-20, 55150-196-99, 55150-197-20, 55150-198-30, 55150-199-20, 55150-200-10, 55150-201-20","Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)",Injection,Unavailable,,ANDA205612,,ROPIVACAINE HYDROCHLORIDE,,,Current,Demand increase for the drug,On backorder. Recovery: TBD. Check wholesalers for inventory,,V910P86109,55150-200-10,888-238-7880,
Sun Pharmaceutical Industries Limited,TIAGABINE HYDROCHLORIDE,,12/09/2024,New,ORAL,Tiagabine Hydrochloride Tablet,"1299911, 1299917",,7eeb2d81-c5d7-46a0-aa5c-149b55df71bd,12/09/2024,HUMAN PRESCRIPTION DRUG,12/09/2024,Neurology,TIAGABINE HYDROCHLORIDE,"62756-200, 62756-224","Sun Pharmaceutical Industries, Inc.",57975e74-e45b-4fd9-9718-bfc9690acae5,"62756-200-83, 62756-200-18, 62756-224-83, 62756-224-88, 62756-224-08, 62756-224-18","Tiagabine Hydrochloride, Tablet, 2 mg (NDC 62756-200-83)",Tablet,,,ANDA077555,,TIAGABINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuing for business reasons,,DQH6T6D8OY,62756-200-83,800-818-4555,
Eugia US LLC,BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Revised,"EPIDURAL, INFILTRATION, INTRACAUDAL",Bupivacaine Hydrochloride Injection,"1012396, 1012404, 1724786, 1724787, 1724880, 1724884, 1725078, 1725082",,ffecf450-1f01-4721-8e10-251385852612,09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE,"55150-168, 55150-167, 55150-169, 55150-170, 55150-171, 55150-172, 55150-249, 55150-250",Eugia US LLC,39649703-e633-4a20-ba71-0c04dbf8ff2a,"55150-167-10, 55150-168-30, 55150-169-10, 55150-170-30, 55150-171-10, 55150-172-30, 55150-249-50, 55150-250-50","Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-168-30)",Injection,Available,,ANDA203895,,BUPIVACAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,7TQO7W3VT8,55150-168-30,888-238-7880,
"Teva Pharmaceuticals USA, Inc.",CARBOPLATIN,,04/28/2023,Revised,INTRAVENOUS,Carboplatin Injection,597195,,"f330f5a2-2cad-402f-bcbb-26245a753276, e176b6ef-2ff6-498b-a9d8-7a634d147f37",09/15/2025,HUMAN PRESCRIPTION DRUG,,Oncology,CARBOPLATIN,"0703-4246, 0703-4244, 0703-4248, 0703-4239","Teva Parenteral Medicines, Inc.","bed4c1cf-f3ef-4faa-b2a4-24ee9a9879df, b943761e-6a46-45a0-bdb4-1fec1e101f8c","0703-4244-01, 0703-4246-01, 0703-4248-01, 0703-4239-01, 0703-4244-81, 0703-4246-81, 0703-4248-81, 0703-4239-81","Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)",Injection,Available,"N0000175413, N0000175073",ANDA077269,,CARBOPLATIN,Platinum-based Drug [EPC],,Current,,,,BG3F62OND5,0703-4246-01,800-545-8800,
Strides Pharma Inc.,SERTRALINE HYDROCHLORIDE,,01/22/2025,New,ORAL,Sertraline Hydrochloride Tablet,"312938, 312940, 312941",,1f99e897-1b70-40b0-8c19-71d0bba19422,01/22/2025,HUMAN PRESCRIPTION DRUG,01/22/2025,Psychiatry,SERTRALINE HYDROCHLORIDE,"71093-130, 71093-129, 71093-131","ACI Healthcare USA, Inc.",3f41fc19-b54a-46fd-acbf-b411816bccd5,"71093-129-01, 71093-129-03, 71093-129-05, 71093-130-01, 71093-130-03, 71093-130-05, 71093-131-01, 71093-131-03, 71093-131-05","Sertraline Hydrochloride, Tablet, 50 mg (NDC 71093-130-01)",Tablet,,,ANDA076881,,SERTRALINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,UTI8907Y6X,71093-130-01,877-244-9825,
Milla Pharmaceuticals,SODIUM ACETATE,,03/23/2016,Revised,INTRAVENOUS,Sodium Acetate Injection,"237371, 312965",,1ea1466d-a492-4056-e063-6394a90a80bf,09/16/2025,HUMAN PRESCRIPTION DRUG,,Total Parenteral Nutrition,SODIUM ACETATE,"71357-008, 71357-007, 71357-009",MILLA PHARMACEUTICALS INC.,2913569b-0f7e-8027-e063-6294a90aaf78,"71357-007-01, 71357-007-10, 71357-008-01, 71357-008-10, 71357-009-01, 71357-009-10","Sodium Acetate, Injection, 200 mEq/100mL (2 mEq/mL) (NDC 71357-008-10)",Injection,Available,,ANDA214805,,"SODIUM ACETATE INJECTION, USP, 200 MEQ/100 ML",,,Current,,,,4550K0SC9B,71357-008-10,833-251-8463,
Gland Pharma Limited,FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Furosemide Injection,"1719286, 1719290, 1719291",,d63c1277-dd7e-4d21-9e80-68143f55e2dc,09/29/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,25021-311,Sagent Pharmaceuticals,222ce48f-2856-4be2-b16f-6fca38c0dceb,"25021-311-02, 25021-311-04, 25021-311-10","Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)",Injection,Available,"N0000175366, N0000175590",ANDA213902,,FUROSEMIDE,Loop Diuretic [EPC],,Current,Other,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,7LXU5N7ZO5,25021-311-04,866-625-1618,
"Hospira, Inc., a Pfizer Company",LIDOCAINE HYDROCHLORIDE,,02/22/2012,Reverified,INTRAVENOUS,Lidocaine Hydrochloride Injection,"1012066, 1012068",,ad1ef0a8-88db-4648-c098-d009eaeb4e5b,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE HYDROCHLORIDE,"0409-1323, 0409-4903, 0409-4904, 0409-9137","Hospira, Inc.",477abea3-c873-4265-82e8-5508ef54399f,"0409-4903-11, 0409-4903-34, 0409-4904-11, 0409-4904-34, 0409-1323-15, 0409-1323-05, 0409-9137-11, 0409-9137-05","Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 100 mg/5mL (2%,20 mg/1 mL) Syringes (NDC 0409-1323-05)",Injection,Available,,ANDA040302,,LIDOCAINE HYDROCHLORIDE,,,Current,,,,V13007Z41A,0409-1323-05,844-646-4398,
"Fresenius Kabi USA, LLC",METHOTREXATE SODIUM,,03/13/2023,Reverified,"INTRA-ARTERIAL, INTRAMUSCULAR, INTRAVENOUS",Methotrexate Sodium Injection,1946772,,b585f621-f6c9-4735-ab61-bd1b401f3df0,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Rheumatology, Oncology",METHOTREXATE,63323-123,"Fresenius Kabi USA, LLC",880c2caa-1b11-45ce-a54e-a3733da367f0,63323-123-10,"Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10)",Injection,Available,,ANDA040263,,METHOTREXATE SODIUM,,,Current,,Check whlolesaler for inventory,,3IG1E710ZN,63323-123-10,888-386-1300,
"XGen Pharmaceuticals DJB, Inc.",PROMETHAZINE HYDROCHLORIDE,,11/21/2023,Revised,"INTRAMUSCULAR, INTRAVENOUS",Promethazine Hydrochloride Injection,992858,,b6f6698f-f23c-452a-9b38-bbb96ab88ae4,09/04/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Gastroenterology, Other, Pulmonary/Allergy",PROMETHAZINE HYDROCHLORIDE,39822-5550,"XGen Pharmaceuticals DJB, Inc.",0e860109-725f-1c28-e063-6394a90a50ef,"39822-5550-5, 39822-5550-6","Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 39822-5550-6)",Injection,Unavailable,,ANDA040737,,PROMETHAZINE HYDROCHLORIDE,,,Current,Demand increase for the drug,Next lots scheduled for release February 2026.,,R61ZEH7I1I,39822-5550-6,866-390-4411,
Baxter Healthcare,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807551, 1807552, 1807627, 1807630, 1807631, 1807632, 1807633, 1807634, 1807639",,f55bd888-5e01-474d-871b-24654c070178,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0338-0049, 0338-0043",Baxter Healthcare Corporation,6ab23768-efd2-4ff1-b336-0dda08dc56e1,"0338-0049-01, 0338-0049-02, 0338-0049-03, 0338-0049-04, 0338-0049-10, 0338-0049-41, 0338-0049-11, 0338-0049-31, 0338-0049-48, 0338-0049-18, 0338-0049-38, 0338-0043-03, 0338-0043-04","Sodium Chloride 0.9% In Plastic Container, Injection, 9 g/1000 mL (NDC 0338-0049-38)",Injection,,,NDA016677,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0338-0049-38,888-229-0001,
Sandoz Inc.,TAMSULOSIN HYDROCHLORIDE,,04/10/2025,New,ORAL,Tamsulosin Hydrochloride Capsule,863669,,fb120098-b007-4a33-80b8-b7279c7668ee,04/10/2025,HUMAN PRESCRIPTION DRUG,04/10/2025,Urology,TAMSULOSIN HYDROCHLORIDE,0781-2076,Sandoz Inc,98c2abd9-1998-48cd-83f9-f5f94ff39345,"0781-2076-01, 0781-2076-10, 0781-2076-92","Tamsulosin Hydrochloride, Capsule, .4 mg (NDC 0781-2076-10)",Capsule,,,ANDA078015,,TAMSULOSIN HYDROCHLORIDE,,,To Be Discontinued,,,,11SV1951MR,0781-2076-10,800-525-8747,
"Upsher-Smith Laboratories, LLC",AMANTADINE HYDROCHLORIDE,,07/23/2025,New,ORAL,Amantadine Hydrochloride Tablet,849395,,63d9d4aa-5f92-45b0-98d0-d6ec38b727cb,07/23/2025,HUMAN PRESCRIPTION DRUG,07/23/2025,"Antiviral, Neurology",AMANTADINE HYDROCHLORIDE,0832-0111,"Upsher-Smith Laboratories, LLC",395d9ef2-7ea2-c602-e063-6394a90a6ef0,"0832-0111-00, 0832-0111-50, 0832-0111-89, 0832-0111-03","Amantadine Hydrochloride, Tablet, 100 mg (NDC 0832-0111-00)",Tablet,,,ANDA076186,,AMANTADINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug product,,M6Q1EO9TD0,0832-0111-00,763-315-2000,
"Fresenius Kabi USA, LLC",KETOROLAC TROMETHAMINE,,03/23/2018,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Ketorolac Tromethamine Injection,"860092, 1665459, 1665461",,"ccf905ca-e164-4779-9485-2d139c821bad, 950b7295-3f68-4027-ac2b-2f7d0f5f8ef9, d1920335-8e45-4960-b6e9-e6f1f9e6820c",09/18/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,KETOROLAC TROMETHAMINE,"63323-161, 63323-162","Fresenius Kabi USA, LLC","2b1c6066-d9e0-40a0-ade5-776fc35a3626, 55ed7afb-db66-4b28-939b-db45b55bf058, ab476c4c-2c72-47b1-bf42-7a89703b0dd4","63323-161-41, 63323-161-16, 63323-162-43, 63323-162-16, 63323-162-45, 63323-162-26, 63323-161-21, 63323-161-12, 63323-162-23, 63323-162-12, 63323-162-25, 63323-162-14, 63323-161-00, 63323-161-01, 63323-162-11, 63323-162-51, 63323-162-00, 63323-162-01, 63323-162-03, 63323-162-02","Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 63323-161-01)",Injection,Available,,ANDA075784,,KETOROLAC TROMETHAMINE,,,Current,,Check wholesaler inventory,,4EVE5946BQ,63323-161-01,888-386-1300,
"EMD Serono, Inc.",LEVOTHYROXINE SODIUM,,07/10/2025,New,ORAL,Levothyroxine Sodium Tablet,"892246, 892251, 966153, 966160, 966166, 966173, 966177, 966182, 966187, 966196, 966202, 966207, 966220, 966221, 966222, 966224, 966225, 966248, 966249, 966253, 966270, 2104866",,bc3c6830-ba68-4ba3-9896-a12d0ad0b275,07/10/2025,HUMAN PRESCRIPTION DRUG,07/10/2025,Endocrinology/Metabolism,EUTHYROX,"72305-050, 72305-025, 72305-075, 72305-088, 72305-100, 72305-112, 72305-125, 72305-137, 72305-150, 72305-175, 72305-200","Provell Pharmaceuticals, LLC",45657074-8874-49f4-a8ef-3ca7e210c16e,"72305-025-30, 72305-025-90, 72305-050-30, 72305-050-90, 72305-075-30, 72305-075-90, 72305-088-30, 72305-088-90, 72305-100-30, 72305-100-90, 72305-112-30, 72305-112-90, 72305-125-30, 72305-125-90, 72305-137-30, 72305-137-90, 72305-150-30, 72305-150-90, 72305-175-30, 72305-175-90, 72305-200-30, 72305-200-90","Euthyrox, Tablet, 50 ug (NDC 72305-050-30)",Tablet,,,NDA021292,,LEVOTHYROXINE SODIUM,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,9J765S329G,72305-050-30,888-899-7041,
"Fresenius Kabi USA, LLC",LIDOCAINE HYDROCHLORIDE ANHYDROUS,,02/22/2012,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010035, 1010671, 1010673, 1010688, 1010692, 1010745, 1010749, 1010751, 1010755, 1010759, 1010763, 1010900, 1010902, 1737343, 1737345, 1737562, 1737563, 1737566, 1737567, 1737568, 1737569, 1737570, 1737571, 1737757, 1737758, 1737761, 1737762, 1867938, 1867940, 1867943, 1867944, 1867992, 1867993, 1867996, 1867997, 1868028, 1868029, 1737636, 1737637, 1737640, 1737641, 1737763, 1737764",,"ba082c2f-64f4-419d-9c88-74f203316e17, 4dd52202-8eef-4136-92dd-ada573b7cf74, d5e0d06f-ba1e-44d4-aa89-39d6c146dc23",09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",XYLOCAINE MPF,"63323-492, 63323-491, 63323-495, 63323-485, 63323-486, 63323-484, 63323-489, 63323-488, 63323-481, 63323-483, 63323-482, 63323-487, 63323-493, 63323-496","Fresenius Kabi USA, LLC","ea480a68-5927-4278-9deb-2956961da428, 0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33, fa12a8e8-09fd-496f-8cc6-ffe0eb02e2df","63323-492-04, 63323-492-27, 63323-492-09, 63323-492-57, 63323-492-07, 63323-492-37, 63323-492-03, 63323-492-31, 63323-491-01, 63323-491-57, 63323-495-09, 63323-495-27, 63323-495-04, 63323-495-07, 63323-485-01, 63323-485-27, 63323-485-03, 63323-485-57, 63323-486-01, 63323-486-17, 63323-486-02, 63323-486-27, 63323-486-05, 63323-486-57, 63323-484-57, 63323-489-02, 63323-489-27, 63323-489-03, 63323-489-21, 63323-489-01, 63323-489-17, 63323-488-07, 63323-488-37, 63323-488-03, 63323-488-31, 63323-488-01, 63323-488-17, 63323-481-01, 63323-481-57, 63323-483-03, 63323-483-27, 63323-483-01, 63323-483-57, 63323-482-01, 63323-482-17, 63323-482-03, 63323-482-27, 63323-482-05, 63323-482-57, 63323-487-01, 63323-487-17, 63323-487-07, 63323-487-37, 63323-487-03, 63323-487-31, 63323-492-41, 63323-492-16, 63323-492-43, 63323-492-36, 63323-492-45, 63323-492-26, 63323-485-41, 63323-485-26, 63323-486-41, 63323-486-26, 63323-482-41, 63323-482-26, 63323-495-41, 63323-495-26, 63323-492-08, 63323-492-97, 63323-493-03, 63323-493-97, 63323-493-01, 63323-493-91, 63323-496-03, 63323-496-97","Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-37)",Injection,Available,,NDA006488,,LIDOCAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,"EC2CNF7XFP, 30Q7KI53AK",63323-492-37,888-386-1300,
"Hospira, Inc., a Pfizer Company",LIDOCAINE HYDROCHLORIDE,,02/22/2012,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010671, 1010900, 1737343, 1737562, 1737566, 1737568, 1737636, 1737757, 1737763",,3b2dd84e-cee8-4e58-d494-395a65a353a0,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE HYDROCHLORIDE,"0409-4713, 0409-4278, 0409-4279, 0409-4776, 0409-4282, 0409-4277, 0409-4276, 0409-4275","Hospira, Inc.",c0b4635b-1473-4c48-89c6-620762cd687f,"0409-4713-12, 0409-4713-26, 0409-4713-02, 0409-4713-72, 0409-4713-62, 0409-4713-75, 0409-4713-65, 0409-4713-42, 0409-4713-25, 0409-4713-32, 0409-4278-16, 0409-4278-01, 0409-4279-16, 0409-4279-02, 0409-4776-10, 0409-4776-01, 0409-4282-11, 0409-4282-25, 0409-4282-01, 0409-4282-12, 0409-4282-02, 0409-4277-16, 0409-4277-01, 0409-4277-17, 0409-4277-02, 0409-4276-16, 0409-4276-01, 0409-4276-17, 0409-4276-02, 0409-4275-16, 0409-4275-01","Lidocaine Hydrochloride Preservative Free, Injection, 50 mg/5 mL (1%; 10 mg/mL) (NDC 0409-4713-02)",Injection,Available,,ANDA080408,,LIDOCAINE HYDROCHLORIDE,,,Current,,,,V13007Z41A,0409-4713-02,844-646-4398,
"Teva Pharmaceuticals USA, Inc.",OXAZEPAM,,12/04/2024,Revised,ORAL,Oxazepam Capsule,"198057, 198059, 312134",,a0d5a4c1-ec79-42e6-8e8f-ae4d144edb43,07/03/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Psychiatry",OXAZEPAM,"0228-2069, 0228-2067, 0228-2073","Actavis Pharma, Inc.",3473450d-0e2d-43ed-9cc9-d8c63a201085,"0228-2067-10, 0228-2069-10, 0228-2073-10","Oxazepam, Capsule, 15 mg (NDC 0228-2069-10)",Capsule,,"N0000175694, M0002356",ANDA072253,Benzodiazepines [CS],OXAZEPAM,Benzodiazepine [EPC],Available,Resolved,,,07/03/2025,6GOW6DWN2A,0228-2069-10,800-545-8800,
Eugia US LLC,ROCURONIUM BROMIDE,,02/15/2023,Revised,INTRAVENOUS,Rocuronium Bromide Injection,1234995,,116385ea-69fc-4f44-b463-6210291032df,09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROCURONIUM BROMIDE,"55150-226, 55150-225",Eugia US LLC,256e0877-720b-40a2-be71-d503e8b860ab,"55150-225-05, 55150-226-10","Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 55150-226-10)",Injection,Unavailable,,ANDA206206,,ROCURONIUM BROMIDE,,,Current,Demand increase for the drug,On backorder. Recovery: TBD. Check wholesalers for inventory,,I65MW4OFHZ,55150-226-10,888-238-7880,
"Fresenius Kabi USA, LLC",SODIUM CHLORIDE,,12/08/2021,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Sodium Chloride 0.9% Injection,313002,,e5e325d1-0d58-40c9-9645-3ae402ff9d92,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",BACTERIOSTATIC SODIUM CHLORIDE,63323-924,"Fresenius Kabi USA, LLC",d83b23bf-9f14-4e45-a569-b227cbb08e88,"63323-924-01, 63323-924-10, 63323-924-03, 63323-924-30","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9 mg/1 mL (NDC 63323-924-10)",Injection,,,ANDA088911,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,63323-924-10,888-386-1300,
Actelion Pharmaceuticals,BOSENTAN,,06/09/2025,New,ORAL,Bosentan Tablet,"349253, 352066, 656659, 656660, 1989081, 1989085",,749e42fb-2fe0-45dd-9268-b43bb3f4081c,06/09/2025,HUMAN PRESCRIPTION DRUG,06/09/2025,Cardiovascular,TRACLEER,"66215-102, 66215-101, 66215-103, 66215-232","Actelion Pharmaceuticals US, Inc.",3bb9bd6a-b0d2-0723-e063-6394a90afc46,"66215-101-06, 66215-101-03, 66215-102-06, 66215-102-03, 66215-103-14, 66215-103-56, 66215-232-14, 66215-232-56","Tracleer, Tablet, 125 mg (NDC 66215-102-03)",Tablet,,,NDA021290,,BOSENTAN,,,To Be Discontinued,,,,Q326023R30,66215-102-03,800-526-7736,
Eli Lilly and Co.,FLUOXETINE HYDROCHLORIDE,,10/03/2024,New,ORAL,Fluoxetine Hydrochloride Capsule,"104849, 205535, 261287, 310384, 310385, 313989",,c88f33ed-6dfb-4c5e-bc01-d8e36dd97299,10/03/2024,HUMAN PRESCRIPTION DRUG,10/03/2024,Psychiatry,PROZAC,"0777-3105, 0777-3104, 0777-3107",Dista Products Company,d7b3b74e-319e-4360-aa57-af39ccbfb19a,"0777-3104-02, 0777-3105-02, 0777-3105-30, 0777-3107-30","Prozac, Capsule, 20 mg (NDC 0777-3105-30)",Capsule,,,NDA018936,,FLUOXETINE HYDROCHLORIDE,,,To Be Discontinued,,,,I9W7N6B1KJ,0777-3105-30,800-545-5979,
Genus Lifesciences,ISONIAZID,,07/01/2025,New,ORAL,Isoniazid Tablet,"197832, 311166",,f0b46d1d-2300-457d-a7bd-a88a3f8d2235,07/01/2025,HUMAN PRESCRIPTION DRUG,07/01/2025,Anti-Infective,ISONIAZID,"64950-217, 64950-216",Genus Lifesciences,6ea58bc8-a5a8-47a1-81e1-f769924e1502,"64950-216-10, 64950-217-03, 64950-217-10","Isoniazid, Tablet, 300 mg (NDC 64950-217-10)",Tablet,,N0000175483,ANDA080937,,ISONIAZID,Antimycobacterial [EPC],,To Be Discontinued,,Product expected to be available until August 2025.,,V83O1VOZ8L,64950-217-10,610-782-9780,
"EMD Serono, Inc.",LEVOTHYROXINE SODIUM,,07/10/2025,New,ORAL,Levothyroxine Sodium Tablet,"892246, 892251, 966153, 966160, 966166, 966173, 966177, 966182, 966187, 966196, 966202, 966207, 966220, 966221, 966222, 966224, 966225, 966248, 966249, 966253, 966270, 2104866",,bc3c6830-ba68-4ba3-9896-a12d0ad0b275,07/10/2025,HUMAN PRESCRIPTION DRUG,07/10/2025,Endocrinology/Metabolism,EUTHYROX,"72305-088, 72305-025, 72305-050, 72305-075, 72305-100, 72305-112, 72305-125, 72305-137, 72305-150, 72305-175, 72305-200","Provell Pharmaceuticals, LLC",45657074-8874-49f4-a8ef-3ca7e210c16e,"72305-025-30, 72305-025-90, 72305-050-30, 72305-050-90, 72305-075-30, 72305-075-90, 72305-088-30, 72305-088-90, 72305-100-30, 72305-100-90, 72305-112-30, 72305-112-90, 72305-125-30, 72305-125-90, 72305-137-30, 72305-137-90, 72305-150-30, 72305-150-90, 72305-175-30, 72305-175-90, 72305-200-30, 72305-200-90","Euthyrox, Tablet, 88 ug (NDC 72305-088-30)",Tablet,,,NDA021292,,LEVOTHYROXINE SODIUM,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,9J765S329G,72305-088-30,888-899-7041,
Granules Pharmaceuticals Inc.,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,b0b4eccc-34c7-483d-966f-82d588358e1b,09/08/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","70010-117, 70010-111, 70010-112, 70010-113, 70010-114, 70010-115, 70010-116",Granules Pharmaceuticals Inc.,2fab399e-2a43-5134-e063-6294a90ae09a,"70010-111-01, 70010-111-03, 70010-112-01, 70010-112-03, 70010-113-01, 70010-113-03, 70010-114-01, 70010-114-03, 70010-115-01, 70010-115-03, 70010-116-01, 70010-116-03, 70010-117-01, 70010-117-03","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 70010-117-01)",Tablet,Available,,ANDA215771,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",70010-117-01,877-770-3183,
"Hikma Pharmaceuticals USA, Inc.",PROMETHAZINE HYDROCHLORIDE,,11/21/2023,Revised,INTRAMUSCULAR,Promethazine Hydrochloride Injection,"992460, 992858",,13d9e59d-eadb-41d5-9f47-9c11a6efb31c,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Gastroenterology, Pediatric, Pulmonary/Allergy",PROMETHAZINE HYDROCHLORIDE,"0641-1496, 0641-1495",Hikma Pharmaceuticals USA Inc.,80a400d2-d293-4180-bfa7-7a8ce0734bc5,"0641-1495-31, 0641-1495-35, 0641-1496-31, 0641-1496-35","Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)",Injection,Available,,ANDA083312,,PROMETHAZINE HYDROCHLORIDE,,,Current,,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,R61ZEH7I1I,0641-1496-35,800-631-2174,
Eugia US LLC,BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Revised,PERINEURAL,Bupivacaine Hydrochloride Injection,"1012396, 1012404, 1724786, 1724787, 1724880, 1724884, 1725078, 1725082",,ffecf450-1f01-4721-8e10-251385852612,09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE,"55150-250, 55150-167, 55150-168, 55150-169, 55150-170, 55150-171, 55150-172, 55150-249",Eugia US LLC,39649703-e633-4a20-ba71-0c04dbf8ff2a,"55150-167-10, 55150-168-30, 55150-169-10, 55150-170-30, 55150-171-10, 55150-172-30, 55150-249-50, 55150-250-50","Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-250-50)",Injection,Available,,ANDA207183,,BUPIVACAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,7TQO7W3VT8,55150-250-50,888-238-7880,
"Lupin Pharmaceuticals, Inc.",,,01/19/2023,Reverified,,Quinapril Hydrochloride Tablet,,,,09/18/2025,,,Cardiovascular,,,,,,"Quinapril Hydrochloride, Tablet, 5 mg (NDC 68180-556-09)",Tablet,Unavailable,,,,,,,Current,Requirements related to complying with good manufacturing practices,,,,68180-556-09,866-587-4617,
Baxter Healthcare,"ALANINE, ARGININE, GLYCINE, HISTIDINE, ISOLEUCINE, LEUCINE, LYSINE HYDROCHLORIDE, METHIONINE, PHENYLALANINE, PROLINE, SERINE, THREONINE, TRYPTOPHAN, TYROSINE, VALINE",,12/08/2020,Reverified,INTRAVENOUS,Amino Acid Injection,"801644, 801648",,8543b5be-0f43-4891-9e56-d7c39fe839b5,09/23/2025,HUMAN PRESCRIPTION DRUG,,Gastroenterology,TRAVASOL,0338-0644,Baxter Healthcare Corporation,e0279078-016d-48fd-8de1-c894422b33ff,"0338-0644-03, 0338-0644-04, 0338-0644-06","Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-06)",Injection,Available,"N0000175780, M0000922",NDA018931,Amino Acids [CS],"LEUCINE, PHENYLALANINE, LYSINE HYDROCHLORIDE, METHIONINE, ISOLEUCINE, VALINE, HISTIDINE, THREONINE, TRYPTOPHAN, ALANINE, GLYCINE, ARGININE, PROLINE, TYROSINE, SERINE",Amino Acid [EPC],,Current,,,,"OF5P57N2ZX, 94ZLA3W45F, TE7660XO1C, 4QD397987E, 04Y7590D77, GMW67QNF9C, JNJ23Q2COM, AE28F7PNPL, 47E5O17Y3R, 9DLQ4CIU6V, 452VLY9402, 2ZD004190S, 8DUH1N11BX, 42HK56048U, HG18B9YRS7",0338-0644-06,888-229-0001,
Gland Pharma Limited,CARBOPLATIN,,04/28/2023,Reverified,INTRAVENOUS,Carboplatin Injection,597195,,5484d2f0-0cc2-4bba-8f26-c7f6539a9606,09/29/2025,HUMAN PRESCRIPTION DRUG,,Oncology,CARBOPLATIN,"54288-166, 54288-165, 54288-167, 54288-164",BPI Labs LLC,5eb7631e-0b41-4aba-ba7a-f544ac9627fd,"54288-165-01, 54288-166-01, 54288-167-01, 54288-164-01","Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)",Injection,Limited Availability,"N0000175413, N0000175073",ANDA207324,,CARBOPLATIN,Platinum-based Drug [EPC],,Current,Demand increase for the drug,"Estimated recovery: Q4 2025; Distributed by BPI Labs, LLC",,BG3F62OND5,54288-166-01,"Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270",
Accord Healthcare Inc.,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,309710,,2b9881f0-4a66-660f-e054-00144ff88e88,09/16/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE,16729-239,Accord Healthcare Inc.,2de0daf8-b7a3-1dca-e063-6394a90a4d0a,"16729-239-30, 16729-239-93","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93)",Injection,Unavailable,,ANDA204023,,DEXMEDETOMIDINE,,,Current,Requirements related to complying with good manufacturing practices,Unavailable,,1018WH7F9I,16729-239-93,"866-941-7875, option 2",
"Hikma Pharmaceuticals USA, Inc.",ETOMIDATE,General Anesthesia [PE],10/05/2022,Revised,INTRAVENOUS,Etomidate Injection,"1654006, 1654008",,4312e3c3-34de-4cb3-8abd-c24d24a4bea1,07/23/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ETOMIDATE,"0143-9311, 0143-9310",Hikma Pharmaceuticals USA Inc.,c15bd8c1-34e3-40f2-b31a-634136fe197c,"0143-9310-01, 0143-9310-10, 0143-9311-01, 0143-9311-10","Etomidate, Injection, 2 mg/1 mL (NDC 0143-9311-10)",Injection,Available,"N0000175975, N0000175681",ANDA202354,,ETOMIDATE,General Anesthetic [EPC],,Current,,Novaplus,,Z22628B598,0143-9311-10,800-631-2174,
"Teva Pharmaceuticals USA, Inc.",HYDROMORPHONE HYDROCHLORIDE,,11/01/2017,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Hydromorphone Hydrochloride Injection,"1724338, 1724340, 1724341",,f0b78db9-a38c-41bb-8233-5e93f7f18c5c,09/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,HYDROMORPHONE HYDROCHLORIDE,"0703-0110, 0703-0113, 0703-0018","Teva Parenteral Medicines, Inc.",c32108cc-7b73-4921-9f9e-54b3d60c1c6e,"0703-0110-01, 0703-0110-03, 0703-0113-01, 0703-0113-03, 0703-0018-01","Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0110-03)",Injection,Available,,ANDA078591,,HYDROMORPHONE HYDROCHLORIDE,,,Current,Shortage of an active ingredient,Estimated recovery: November 2025,,L960UP2KRW,0703-0110-03,800-545-8800,
"Hikma Pharmaceuticals USA, Inc.",LORAZEPAM,,09/05/2018,Revised,"INTRAMUSCULAR, INTRAVENOUS",Lorazepam Injection,"238100, 238101, 1665188, 1665326",,e9b54e42-04cf-4c62-90e1-36f7b31a4e81,07/23/2025,HUMAN PRESCRIPTION DRUG,,Neurology,LORAZEPAM,"0641-6044, 0641-6046, 0641-6045, 0641-6047",Hikma Pharmaceuticals USA Inc.,7c73dbc6-2623-4443-9b05-97dec7a0be2e,"0641-6044-01, 0641-6044-25, 0641-6046-01, 0641-6046-10, 0641-6045-01, 0641-6045-25, 0641-6047-01, 0641-6047-10","Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)",Injection,Unavailable,"N0000175694, M0002356",NDA018140,Benzodiazepines [CS],LORAZEPAM,Benzodiazepine [EPC],,Current,Regulatory delay,Shortage duration unknown,,O26FZP769L,0641-6044-25,800-631-2174,
Strides Pharma Inc.,MINOCYCLINE HYDROCHLORIDE,,01/22/2025,New,ORAL,Minocycline Hydrochloride Tablet,"207362, 207364, 403840",,d6e136ba-c9b1-4846-ae2a-98a29cb4504d,01/22/2025,HUMAN PRESCRIPTION DRUG,01/22/2025,Antiviral,MINOCYCLINE HYDROCHLORIDE,"64380-154, 64380-155, 64380-156",Strides Pharma Science Limited,73a30dc4-352b-4307-b902-07ffefc99a99,"64380-154-01, 64380-155-01, 64380-156-01","Minocycline Hydrochloride, Tablet, 50 mg (NDC 64380-154-01)",Tablet,,,ANDA065131,,MINOCYCLINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,0020414E5U,64380-154-01,877-244-9825,
Teyro Labs,CARBOPLATIN,,04/28/2023,Reverified,INTRAVENOUS,Carboplatin Injection,597195,,1c275825-0275-4c73-b650-e4c1519f13b8,09/29/2025,HUMAN PRESCRIPTION DRUG,,Oncology,CARBOPLATIN,60505-6282,Apotex Corp.,0e68e276-b0df-4f03-e063-6394a90a22b9,"60505-6282-1, 60505-6282-3, 60505-6282-6, 60505-6282-7","Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7)",Injection,Available,"N0000175413, N0000175073",ANDA077861,,CARBOPLATIN,Platinum-based Drug [EPC],,Current,,Wholesaler & Distributor through Marketing partner (Apotex Inc.),,BG3F62OND5,60505-6282-7,Apotex Inc.: 800-706-5575,
Apotex Corp.,DESMOPRESSIN ACETATE,,03/12/2021,Revised,NASAL,Desmopressin Acetate Spray,849506,,1ac423b8-27a6-4cef-4a82-c50bf81b4f49,09/29/2025,HUMAN PRESCRIPTION DRUG,,Hematology,DESMOPRESSIN ACETATE,60505-0815,Apotex Corp.,f90935bd-bb23-2f9c-3271-8508e92d45c4,60505-0815-0,"Desmopressin Acetate (needs No Refrigeration), Spray, 10 ug (NDC 60505-0815-0)",Spray,Available,,ANDA076703,,DESMOPRESSIN ACETATE,,,Current,,,,XB13HYU18U,60505-0815-0,800-706-5575,
"Fresenius Kabi USA, LLC",DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795607, 1795609, 1795610, 1795612, 1795616",,576a22d8-5f2f-497e-80ad-1842ca74bb53,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"65219-456, 65219-464, 65219-458, 65219-460, 65219-462","FRESENIUS KABI USA, LLC",efc3b0c9-518a-47db-bb3e-ebdfd4646e9b,"65219-456-05, 65219-456-60, 65219-464-05, 65219-464-50, 65219-458-05, 65219-458-30, 65219-460-05, 65219-460-20, 65219-462-05, 65219-462-10","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-456-60)",Injection,Available,,ANDA207449,,DEXTROSE MONOHYDRATE,,,Current,,Check wholealers for inventory,,LX22YL083G,65219-456-60,888-386-1300,
"Hospira, Inc., a Pfizer Company",HYDROCORTISONE SODIUM SUCCINATE,,03/24/2023,Revised,"INTRAMUSCULAR, INTRAVENOUS",Hydrocortisone Sodium Succinate Injection,"105398, 238755, 1738586, 1738589, 1738590, 1738592, 1738594, 1738596",,65eefd58-b166-4d71-ade6-45c8fdf86922,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Pulmonary/Allergy, Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Pediatric, Renal, Rheumatology",SOLU-CORTEF,"0009-0013, 0009-0825, 0009-0011, 0009-0016, 0009-0005",Pharmacia & Upjohn Company LLC,8512044a-4a54-4634-bb97-9e20126adc61,"0009-0825-01, 0009-0011-03, 0009-0011-04, 0009-0013-05, 0009-0013-06, 0009-0016-12, 0009-0005-01","Solu-cortef, Injection, 250 mg/vial (NDC 0009-0013-06)",Injection,Limited Availability,,NDA009866,,HYDROCORTISONE SODIUM SUCCINATE,,,Current,Other,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,50LQB69S1Z,0009-0013-06,844-646-4398,
"Elite Laboratories, Inc.",NALTREXONE HYDROCHLORIDE,,02/29/2024,Revised,ORAL,Naltrexone Hydrochloride Tablet,1483744,,60276f5c-657a-4b60-bcd0-44234903d7e0,09/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,NALTREXONE HYDROCHLORIDE,51224-206,TAGI Pharma Inc.,c82a0ed4-3236-4166-90a8-f5e43e6dd883,"51224-206-30, 51224-206-50","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 51224-206-50)",Tablet,Available,,ANDA075274,,NALTREXONE HYDROCHLORIDE,,,Current,,Marketed by Tagi Pharma; Customer service: 800-397-9228,,Z6375YW9SF,51224-206-50,888-852-6657,
Baxter Healthcare,NITROGLYCERIN,Vasodilation [PE],10/06/2023,Revised,INTRAVENOUS,Nitroglycerin Injection,"312004, 1868494, 1868562",,457a026c-ebce-4701-9deb-2d7652759a99,09/23/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,NITROGLYCERIN IN DEXTROSE,"0338-1051, 0338-1047, 0338-1049",Baxter Healthcare Company,71811937-e908-4b65-aff2-4b345fa0954b,"0338-1047-02, 0338-1049-02, 0338-1051-02","Nitroglycerin in Dextrose 5%, Injection, 40 mg/100 mL (NDC 0338-1051-02)",Injection,Unavailable,"N0000175415, M0014874, N0000009909",NDA019970,Nitrates [CS],NITROGLYCERIN,Nitrate Vasodilator [EPC],,Current,Other,Manufacturing delay; Recovery in November 2025,,G59M7S0WS3,0338-1051-02,Baxter Healthcare 888-229-0001,
"Teva Pharmaceuticals USA, Inc.",PRAVASTATIN SODIUM,,06/13/2025,New,ORAL,Pravastatin Sodium Tablet,904481,,f66cb1c1-5ff1-4b0b-89d0-8ecaee26b0b8,06/13/2025,HUMAN PRESCRIPTION DRUG,06/13/2025,Cardiovascular,PRAVASTATIN SODIUM,0480-7270,"Teva Pharmaceuticals, Inc.",95e8c960-5096-43a9-8807-89cdf404a214,"0480-7270-98, 0480-7270-10","Pravastatin Sodium, Tablet, 80 mg (NDC 0480-7270-10)",Tablet,,,ANDA077793,,PRAVASTATIN SODIUM,,,To Be Discontinued,,,,3M8608UQ61,0480-7270-10,800-545-8800,
MSN Laboratories Private Limited,BUMETANIDE,Increased Diuresis at Loop of Henle [PE],12/13/2017,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Bumetanide Injection,"282486, 1727569",,387edfd4-be85-41cd-8a6d-14e6a022b5a9,09/15/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,BUMETANIDE,"72205-101, 72205-102",Novadoz Pharmaceuticals LLC,387edfd4-be85-41cd-8a6d-14e6a022b5a9,"72205-101-01, 72205-101-07, 72205-102-01, 72205-102-07","Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)",Injection,Available,"N0000175366, N0000175590",ANDA215364,,BUMETANIDE,Loop Diuretic [EPC],,Current,,,,0Y2S3XUQ5H,72205-101-01,Distributed by: Novadoz Pharmaceuticals LLC; Telephone: (855) 668-2369; customerservice@novadozpharma.com,
Pfizer Inc.,CLINDAMYCIN PHOSPHATE,,03/21/2023,Revised,"INTRAMUSCULAR, INTRAVENOUS",Clindamycin Phosphate Injection,"1737244, 1737245, 1737578, 1737579, 1737581, 1737582",,a0a2eff7-b7de-42fe-8e5a-0cfbed38bb4b,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,CLEOCIN PHOSPHATE,"0009-3051, 0009-4073, 0009-5095",Pharmacia & Upjohn Company LLC,9c0a7367-763b-48c3-95b1-173b74c50f4b,"0009-3051-01, 0009-3051-02, 0009-4073-03, 0009-4073-04, 0009-5095-05, 0009-5095-06","Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL) (NDC 0009-3051-02)",Injection,Unavailable,,NDA050441,,CLINDAMYCIN PHOSPHATE,,,Current,Other,Next Delivery and Estimated Recovery: December 2025,,EH6D7113I8,0009-3051-02,800-533-4535,
"Jiangsu Hengrui Pharmaceuticals Co., Ltd.",DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718900, 1718906, 1718909",,809e8f77-390f-4cc8-8c8a-4f67a249c9df,09/02/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE,"0781-3495, 0781-3493, 0781-3494",Sandoz Inc.,fdf227d9-008e-60f8-e053-6294a90af5c4,"0781-3493-95, 0781-3494-95, 0781-3495-95","Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (NDC 0781-3495-95)",Injection,Available,,ANDA209065,,DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE,,,Current,,Marketed by Sandoz Inc.; Customer service: 800-525-8747,,1018WH7F9I,0781-3495-95,See Related Information section below for customer service information,
Novartis Pharmaceuticals Corporation,"AMLODIPINE BESYLATE, BENAZEPRIL HYDROCHLORIDE",,06/24/2025,New,ORAL,Amlodipine Besylate; Benazepril Hydrochloride Capsule,"898342, 898344, 898346, 898348, 898353, 898355, 898356, 898358",,94ae6054-b7ae-4212-a567-4f803af8f2c7,06/24/2025,HUMAN PRESCRIPTION DRUG,06/24/2025,Cardiovascular,LOTREL,"0078-0379, 0078-0405, 0078-0406, 0078-0364",Novartis Pharmaceuticals Corporation,b9db75d9-9d1e-4b2d-9876-5f5520feaecc,"0078-0405-05, 0078-0406-05, 0078-0364-05, 0078-0379-05","Lotrel, Capsule, 10 mg; 40 mg (NDC 0078-0379-05)",Capsule,,,NDA020364,,AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE,,,To Be Discontinued,,Permanent discontinuation in the manufacturing of the drug,,"864V2Q084H, N1SN99T69T",0078-0379-05,888-669-6682,
Baxter Healthcare,DEXTROSE MONOHYDRATE,,03/01/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 10% Injection,"1795477, 1795480, 1795481, 1795607, 1795609, 1795610, 1795612, 1795616, 1795618",,3bb406a9-f5cb-403a-b1bb-5c4facbea3d5,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0338-0023, 0338-0017",Baxter Healthcare Corporation,31bb4a5f-733e-4354-9fbf-138dede4db0f,"0338-0017-10, 0338-0017-41, 0338-0017-11, 0338-0017-31, 0338-0017-48, 0338-0017-18, 0338-0017-38, 0338-0017-02, 0338-0017-03, 0338-0017-04, 0338-0023-02, 0338-0023-03, 0338-0023-04","Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-03)",Injection,Available,,NDA016694,,DEXTROSE MONOHYDRATE,,,Current,,,,LX22YL083G,0338-0023-03,888-229-0001,
Sagent Pharmaceuticals,FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Furosemide Injection,"1719286, 1719290, 1719291",,d63c1277-dd7e-4d21-9e80-68143f55e2dc,08/26/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,25021-311,Sagent Pharmaceuticals,222ce48f-2856-4be2-b16f-6fca38c0dceb,"25021-311-02, 25021-311-04, 25021-311-10","Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)",Injection,Available,"N0000175366, N0000175590",ANDA213902,,FUROSEMIDE,Loop Diuretic [EPC],,Current,,,,7LXU5N7ZO5,25021-311-10,866-625-1618,
"Spectra Medical Devices, LLC",LIDOCAINE HYDROCHLORIDE ANHYDROUS,,06/14/2018,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Lidocaine Hydrochloride Injection,1737566,,e8ba012a-08a9-4f67-9f88-3284377e80be,08/19/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,LIDOCAINE HYDROCHLORIDE,65282-1605,"Spectra Medical Devices, LLC",0e8f7cf3-12eb-12f6-e063-6294a90a5da6,65282-1605-1,"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 65282-1605-1)",Injection,Available,,ANDA208017,,LIDOCAINE HYDROCHLORIDE ANHYDROUS,,,Current,,,,EC2CNF7XFP,65282-1605-1,978-657-0889 ext. 5231,
Aurobindo Pharma USA,QUINAPRIL HYDROCHLORIDE,,01/19/2023,Reverified,ORAL,Quinapril Hydrochloride Tablet,"312748, 312749, 312750, 314203",,93e6e668-5306-4f26-81d8-cbc3a7a5e787,09/17/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,QUINAPRIL,"65862-620, 65862-617, 65862-618, 65862-619",Aurobindo Pharma Limited,5263abd5-ce46-4918-9bb0-9632861bcbc9,"65862-617-30, 65862-617-90, 65862-617-99, 65862-617-55, 65862-617-10, 65862-617-78, 65862-618-30, 65862-618-90, 65862-618-99, 65862-618-55, 65862-618-10, 65862-618-78, 65862-619-30, 65862-619-90, 65862-619-99, 65862-619-19, 65862-619-10, 65862-619-78, 65862-620-30, 65862-620-90, 65862-620-99, 65862-620-39, 65862-620-10, 65862-620-78","Quinapril Hydrochloride, Tablet, 40 mg (NDC 65862-620-90)",Tablet,Discontinued,,ANDA202725,,QUINAPRIL HYDROCHLORIDE,,,Current,Discontinuation of the manufacture of the drug,,,33067B3N2M,65862-620-90,866-850-2876,
"Elite Laboratories, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,e677690f-790f-4626-ad78-097cdb6ea540,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","64850-504, 64850-500, 64850-501, 64850-502, 64850-503, 64850-505, 64850-506","Elite Laboratories, Inc.",b65e0266-7172-4730-8f93-eb42e08fb7b8,"64850-500-01, 64850-500-05, 64850-500-30, 64850-501-01, 64850-501-05, 64850-501-30, 64850-502-01, 64850-502-05, 64850-502-30, 64850-503-01, 64850-503-05, 64850-503-30, 64850-504-01, 64850-504-05, 64850-504-30, 64850-505-01, 64850-505-05, 64850-505-30, 64850-506-01, 64850-506-05, 64850-506-30","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 64850-504-01)",Tablet,Limited Availability,,ANDA211352,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,Shortage of an active ingredient,3 months,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",64850-504-01,888-852-6657,
Strides Pharma Inc.,SERTRALINE HYDROCHLORIDE,,01/22/2025,New,ORAL,Sertraline Hydrochloride Tablet,"312938, 312940, 312941",,1f99e897-1b70-40b0-8c19-71d0bba19422,01/22/2025,HUMAN PRESCRIPTION DRUG,01/22/2025,Psychiatry,SERTRALINE HYDROCHLORIDE,"71093-131, 71093-129, 71093-130","ACI Healthcare USA, Inc.",3f41fc19-b54a-46fd-acbf-b411816bccd5,"71093-129-01, 71093-129-03, 71093-129-05, 71093-130-01, 71093-130-03, 71093-130-05, 71093-131-01, 71093-131-03, 71093-131-05","Sertraline Hydrochloride, Tablet, 100 mg (NDC 71093-131-01)",Tablet,,,ANDA076881,,SERTRALINE HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation is a commercial decision based on the current business and not for reasons of safety or effectiveness.,,UTI8907Y6X,71093-131-01,877-244-9825,
"Upsher-Smith Laboratories, LLC",,,04/23/2025,New,,Baclofen Tablet,,,,04/23/2025,,04/23/2025,Neurology,,,,,,"Baclofen, Tablet, 10 mg (NDC 50090-6869-0)",Tablet,,,,,,,,To Be Discontinued,,,,,50090-6869-0,716-315-2000,
Accord Healthcare Inc.,,,01/17/2025,New,,Cyanocobalamin Injection,,,,01/17/2025,,01/17/2025,Hematology,,,,,,"Dodex, Injection, 1000 ug/1 mL (NDC 16729-533-08)",Injection,,,,,,,,To Be Discontinued,,Permanent discontinuation in the manufacturing of the drug.,,,16729-533-08,866-941-7875,
"Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)",FONDAPARINUX SODIUM,,09/29/2025,New,SUBCUTANEOUS,Fondaparinux Sodium Injection,"861356, 861360, 861363, 861365",,baa50757-a927-4d56-a933-5d7798fe6ab0,09/29/2025,HUMAN PRESCRIPTION DRUG,09/29/2025,Hematology,FONDAPARINUX SODIUM,"0781-3465, 0781-3443, 0781-3454, 0781-3476",Sandoz Inc.,3d5a4b69-462b-7e51-e063-6294a90a0721,"0781-3443-94, 0781-3443-12, 0781-3443-95, 0781-3454-94, 0781-3454-12, 0781-3454-95, 0781-3465-94, 0781-3465-12, 0781-3465-95, 0781-3476-94, 0781-3476-12, 0781-3476-95","Fondaparinux Sodium, Injection, 7.5 mg/.6 mL (NDC 0781-3465-95)",Injection,,,ANDA206812,,FONDAPARINUX SODIUM,,,To Be Discontinued,,Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc.,,X0Q6N9USOZ,0781-3465-95,"609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)",
"Hikma Pharmaceuticals USA, Inc.",MEPERIDINE HYDROCHLORIDE,,05/30/2025,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Meperidine Hydrochloride Injection,"861476, 1665685, 1665697",,e0e998da-f056-4fce-be8e-ed60cf3b461b,07/23/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,MEPERIDINE HYDROCHLORIDE,"0641-6053, 0641-6054, 0641-6052",Hikma Pharmaceuticals USA Inc.,9566d54d-7343-4695-94ff-8b5f2d384c81,"0641-6053-01, 0641-6053-25, 0641-6054-01, 0641-6054-25, 0641-6052-01, 0641-6052-25","Meperidine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-6053-25)",Injection,Unavailable,,ANDA080445,,MEPERIDINE HYDROCHLORIDE,,,Current,Shortage of an active ingredient,Additional Lots scheduled to be available in the October-November 2025 timeframe.,,N8E7F7Q170,0641-6053-25,800-631-2174,
"Fresenius Kabi USA, LLC",PROPRANOLOL HYDROCHLORIDE,,10/31/2023,Reverified,INTRAVENOUS,Propranolol Hydrochloride Injection,856443,,f14ea537-dd5c-4c78-9037-9a85e9e610ef,09/18/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,PROPRANOLOL,63323-604,"Fresenius Kabi USA, LLC",505851c4-b18c-4cd7-805c-4e923cc1fa7e,63323-604-01,"Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-604-01)",Injection,Available,,ANDA075826,,PROPRANOLOL HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,F8A3652H1V,63323-604-01,888-386-1300,
"Upsher-Smith Laboratories, LLC",BUMETANIDE,Increased Diuresis at Loop of Henle [PE],05/02/2025,New,ORAL,Bumetanide Tablet,"197417, 197418, 197419",,ff5dc8c6-b2f2-41d3-8e56-a953aa721b59,05/02/2025,HUMAN PRESCRIPTION DRUG,05/02/2025,Cardiovascular,BUMETANIDE,"0832-0540, 0832-0541, 0832-0542","Upsher-Smith Laboratories, LLC",d53166d9-64ca-4b76-81a7-b70a60c53b12,"0832-0540-11, 0832-0541-11, 0832-0541-10, 0832-0542-11, 0832-0542-10","Bumetanide, Tablet, .5 mg (NDC 0832-0540-11)",Tablet,,"N0000175366, N0000175590",ANDA209916,,BUMETANIDE,Loop Diuretic [EPC],,To Be Discontinued,,,,0Y2S3XUQ5H,0832-0540-11,800-654-2299,
Baxter Healthcare,DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795477, 1795480, 1795481, 1795607, 1795609, 1795610, 1795612, 1795616, 1795618",,3bb406a9-f5cb-403a-b1bb-5c4facbea3d5,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0338-0017, 0338-0023",Baxter Healthcare Corporation,31bb4a5f-733e-4354-9fbf-138dede4db0f,"0338-0017-10, 0338-0017-41, 0338-0017-11, 0338-0017-31, 0338-0017-48, 0338-0017-18, 0338-0017-38, 0338-0017-02, 0338-0017-03, 0338-0017-04, 0338-0023-02, 0338-0023-03, 0338-0023-04","Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-18)",Injection,Available,,NDA016673,,DEXTROSE MONOHYDRATE,,,Current,,,,LX22YL083G,0338-0017-18,888-229-0001,
Kindos Pharmaceuticals Co. Ltd.,LEUCOVORIN CALCIUM,,01/01/2012,Revised,"INTRAMUSCULAR, INTRAVENOUS",Leucovorin Calcium Injection,"237788, 1803930, 1803932, 1803937, 2055036",,9df20901-6980-4d4e-89ec-40f3c1f91852,07/08/2025,HUMAN PRESCRIPTION DRUG,,"Oncology, Pediatric",LEUCOVORIN CALCIUM,"71288-162, 71288-160, 71288-161, 71288-163, 71288-164",Meitheal Pharmaceuticals Inc.,077a459b-e884-4452-aed3-0857a38ce26f,"71288-160-10, 71288-161-20, 71288-162-30, 71288-163-30, 71288-164-50","Leucovorin Calcium, Injection, 200 mg/20 mL (NDC 71288-162-30)",Injection,,,ANDA216590,,LEUCOVORIN CALCIUM,,Available,Resolved,,,07/08/2025,RPR1R4C0P4,71288-162-30,"Meitheal Pharmaceuticals, Inc.: 844-824-8426",
"Hospira, Inc., a Pfizer Company",MORPHINE SULFATE,,10/31/2017,Reverified,"EPIDURAL, INTRATHECAL, INTRAVENOUS",Morphine Sulfate Injection,"1728783, 1728800",,1d181906-f3ec-4222-1883-e61577a3122e,08/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,MORPHINE SULFATE,"0409-3814, 0409-3815","Hospira, Inc.",ed66921f-64ef-4109-8b78-575b3d0434f0,"0409-3814-11, 0409-3814-12, 0409-3815-11, 0409-3815-12","Morphine Sulfate, Injection, 5 mg/10 mL (0.5 mg/mL) (NDC 0409-3814-12)",Injection,Available,,ANDA073509,,MORPHINE SULFATE,,,Current,,,,X3P646A2J0,0409-3814-12,844-646-4398,
Baxter Healthcare,CLINDAMYCIN PHOSPHATE,,03/21/2023,Reverified,INTRAVENOUS,Clindamycin Phosphate Injection,"309335, 309336, 309339",,44fa506b-90ac-42de-831b-5f3f1a500fc0,09/23/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,CLINDAMYCIN PHOSPHATE,"0338-9545, 0338-9549, 0338-9553",Baxter Healthcare Company,12bdbbc9-fbb0-4a0a-9147-37df8ac5dc5e,"0338-9545-50, 0338-9545-24, 0338-9549-50, 0338-9549-24, 0338-9553-50, 0338-9553-24","Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9545-50)",Injection,Unavailable,,NDA208083,,CLINDAMYCIN PHOSPHATE,,,Current,Demand increase for the drug,Estimated recovery: November 2025,,EH6D7113I8,0338-9545-50,888-229-0001,
Sintetica US,LIDOCAINE HYDROCHLORIDE ANHYDROUS,,02/22/2012,Reverified,INFILTRATION,Lidocaine Hydrochloride Injection,"1737566, 1737568, 1737570, 1737757, 1737761, 1737763",,aa3e688a-308c-4a82-a268-28ccf1677c55,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",NA,"83090-004, 83090-001, 83090-002, 83090-003, 83090-005, 83090-006",Sintetica US LLC,0d18f291-3a92-421e-8841-6be743b1f154,"83090-001-01, 83090-001-10, 83090-002-01, 83090-002-10, 83090-003-01, 83090-003-10, 83090-004-01, 83090-004-10, 83090-005-01, 83090-005-10, 83090-006-01, 83090-006-10","Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 83090-004-10)",Injection,Available,,ANDA214267,,LIDOCAINE HYDROCHLORIDE,,,Current,,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 2% 10X2ML)  is Preservative free.",,EC2CNF7XFP,83090-004-10,"844-425-3131, SinteticaCS@eversana.com",
Sandoz Inc.,OXALIPLATIN,,10/16/2024,New,INTRAVENOUS,Oxaliplatin Injection,"1736776, 1736781",,86f6c19d-30d1-42e3-8d46-5e3f45776e85,10/16/2024,HUMAN PRESCRIPTION DRUG,10/16/2024,Oncology,OXALIPLATIN,"0781-9315, 0781-9317",Sandoz Inc,ac83b4cd-5026-4dd5-b733-125d28ba3c95,"0781-9315-70, 0781-9317-80","Injection, 5 mg/1 mL (NDC 0781-9315-70)",Injection,,"N0000175413, N0000175073",ANDA078817,,OXALIPLATIN,Platinum-based Drug [EPC],,To Be Discontinued,,A business decision was made to discontinue this product.,,04ZR38536J,0781-9315-70,800-525-8747,
"Hospira, Inc., a Pfizer Company",CARBOPLATIN,,04/28/2023,Reverified,INTRAVENOUS,Carboplatin Injection,597195,,47677091-fd20-49af-933c-c9dd2be21de9,08/15/2025,HUMAN PRESCRIPTION DRUG,,Oncology,CARBOPLATIN,"61703-150, 61703-360, 61703-262, 61703-600","Hospira, Inc.",5aa72c15-8033-4559-b257-373371b18958,"61703-360-18, 61703-150-05, 61703-262-05, 61703-600-05","Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05)",Injection,Available,"N0000175413, N0000175073",ANDA076517,,CARBOPLATIN,Platinum-based Drug [EPC],,Current,,,,BG3F62OND5,61703-150-05,844-646-4398,
Aurobindo Pharma USA,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,a582d57f-d191-4ca5-b105-585b2d8a0e3e,09/17/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","13107-074, 13107-068, 13107-069, 13107-070, 13107-071, 13107-072, 13107-073","Aurolife Pharma, LLC",95842af2-8d9d-4eb1-ba39-86cdbd829a79,"13107-068-50, 13107-068-01, 13107-068-25, 13107-068-05, 13107-068-99, 13107-069-50, 13107-069-01, 13107-069-25, 13107-069-05, 13107-069-99, 13107-070-50, 13107-070-01, 13107-070-25, 13107-070-05, 13107-070-99, 13107-071-50, 13107-071-01, 13107-071-25, 13107-071-05, 13107-071-99, 13107-072-50, 13107-072-01, 13107-072-25, 13107-072-05, 13107-072-99, 13107-073-50, 13107-073-01, 13107-073-25, 13107-073-05, 13107-073-99, 13107-074-50, 13107-074-01, 13107-074-25, 13107-074-05, 13107-074-99","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 13107-074-01)",Tablet,Unavailable,,ANDA202424,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,Shortage of an active ingredient,Estimated availability December 2025,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",13107-074-01,(866) 850-2876 OR CustomerService@AurobindoUSA.com,
"Fresenius Kabi USA, LLC",DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718900, 1718906, 1718909",,4d5d2294-89a0-4b6f-aa00-d39a0393b6a8,09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE HYDROCHLORIDE,63323-671,"Fresenius Kabi USA, LLC",27411591-44a1-44c4-89c3-dd8c2687f0e2,"63323-671-02, 63323-671-20, 63323-671-05, 63323-671-50, 63323-671-01, 63323-671-00","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-20)",Injection,Unavailable,,ANDA208129,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,Other,Not available at this time.,,1018WH7F9I,63323-671-20,888-386-1300,
Aurobindo Pharma USA,AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","308189, 313850",,3cacd754-73f4-496e-a529-9ca39fa6692d,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"65862-070, 65862-071",Aurobindo Pharma Limited,3e3ca279-1838-4348-a01c-df10a8bcb8b9,"65862-070-50, 65862-070-75, 65862-070-01, 65862-071-50, 65862-071-75, 65862-071-01","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 65862-070-01)","Powder, For Suspension",,,ANDA065334,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,65862-070-01,866-850-2876,
"Sunrise Pharmaceutical, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,ac102599-3a5b-4154-899e-6ff262be7ff7,09/03/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","11534-195, 11534-190, 11534-191, 11534-192, 11534-193, 11534-194, 11534-196","SUNRISE PHARMACEUTICAL, INC.",86a00bec-51eb-4d73-a945-b1937970b29a,"11534-190-01, 11534-190-03, 11534-191-01, 11534-191-03, 11534-192-01, 11534-192-03, 11534-193-01, 11534-193-03, 11534-194-01, 11534-194-03, 11534-195-01, 11534-195-03, 11534-196-01, 11534-196-03","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 11534-195-01)",Tablet,Available,,ANDA209799,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",11534-195-01,732-382-6085 Monday to Friday 9 am to 3:45 pm,
"Lannett Company, Inc.",,,10/12/2022,Reverified,,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet",,,,09/15/2025,,,Psychiatry,,,,,,"Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0527-1505-37)",Tablet,Available,,,,,,,Current,,,,,0527-1505-37,844-834-0530,
Rubicon Research Private Limited,CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"72888-154, 72888-152, 72888-153",Advagen Pharma Ltd,36cf156e-5980-a21b-e063-6294a90ab3a0,"72888-152-30, 72888-152-01, 72888-152-05, 72888-152-00, 72888-153-30, 72888-153-01, 72888-153-05, 72888-153-00, 72888-154-30, 72888-154-01, 72888-154-05, 72888-154-00","Clonazepam, Tablet, 2 mg (NDC 72888-154-05)",Tablet,Available,"N0000175694, M0002356",ANDA075468,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,Marketed by Advagen Pharma Ltd.,,5PE9FDE8GB,72888-154-05,sales@advagenpharma.com,
Pfizer Inc.,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718906, 1718907, 1718909, 1718910",,92b7ddaa-e45a-4b64-a802-bb5df8771dd6,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,PRECEDEX,"0409-0155, 0409-4596","Hospira, Inc.",1fdb4815-2990-4926-ba76-25241810489e,"0409-4596-01, 0409-4596-20, 0409-0155-01, 0409-0155-02","Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-0155-02)",Injection,Available,,NDA021038,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,,,,1018WH7F9I,0409-0155-02,844-646-4398,
"Teva Pharmaceuticals USA, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Revised,ORAL,Lisdexamfetamine Dimesylate Capsule,,,c32b5dce-2de4-4db0-a4ba-d2ce3b0a32fc,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0480-3566, 0480-3565, 0480-3567, 0480-3568, 0480-3569, 0480-3570, 0480-3564","Teva Pharmaceuticals, Inc.",6cfe6c98-51b1-45a4-831c-33624ab129cb,"0480-3565-01, 0480-3566-01, 0480-3567-01, 0480-3568-01, 0480-3569-01, 0480-3570-01, 0480-3564-01","Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0480-3566-01)",Capsule,Available,,ANDA202802,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,0480-3566-01,800-545-8800,
"Hospira, Inc., a Pfizer Company",MORPHINE SULFATE,,10/31/2017,Revised,INTRAVENOUS,Morphine Sulfate Injection,,,be420e8b-bcb0-49b5-bb4d-1df8b9959809,08/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,MORPHINE SULFATE,"0409-1890, 0409-1891, 0409-1892, 0409-1893, 0409-1894","Hospira, Inc.",cced2ec0-6c94-4cf0-87fb-041667ee3214,"0409-1890-03, 0409-1890-01, 0409-1890-13, 0409-1890-23, 0409-1891-03, 0409-1891-01, 0409-1891-13, 0409-1891-23, 0409-1892-03, 0409-1892-01, 0409-1892-13, 0409-1892-23, 0409-1893-03, 0409-1893-01, 0409-1893-13, 0409-1893-23, 0409-1894-03, 0409-1894-01","Morphine Sulfate, Injection, 2 mg/1 mL Syringes (NDC 0409-1890-01)",Injection,Unavailable,,NDA202515,,MORPHINE SULFATE,,,Current,Other,Next Delivery: September 2025; Estimated Recovery: December 2025,,X3P646A2J0,0409-1890-01,844-646-4398,
"Hospira, Inc., a Pfizer Company",ROCURONIUM BROMIDE,,02/15/2023,Reverified,INTRAVENOUS,Rocuronium Bromide Injection,1234995,,f01f9986-43f9-40e8-9506-11bfe78f9242,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROCURONIUM BROMIDE,"0409-5160, 0409-1403","Hospira, Inc.",f01f9986-43f9-40e8-9506-11bfe78f9242,"0409-1403-05, 0409-1403-10, 0409-5160-01, 0409-5160-10","Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-5160-10)",Injection,Available,,ANDA205656,,ROCURONIUM BROMIDE,,,Current,,,,I65MW4OFHZ,0409-5160-10,844-646-4398,
"Caplin Steriles, Ltd.",ROPIVACAINE HYDROCHLORIDE,,12/22/2020,Reverified,"EPIDURAL, INFILTRATION, PERINEURAL",Ropivacaine Hydrochloride Injection,"1734084, 1734207, 1734475, 1734483",,781d4b7f-7556-4695-8d48-7772d7a0d8e9,09/16/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROPIVACAINE HYDROCHLORIDE,"43066-023, 43066-015, 43066-019, 43066-027",Baxter Healthcare Corporation,ef624077-2197-426c-9521-8f966f49240b,"43066-015-01, 43066-015-10, 43066-019-01, 43066-019-10, 43066-023-01, 43066-023-10, 43066-027-01, 43066-027-10","Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-023-10)",Injection,Limited Availability,,ANDA212808,,ROPIVACAINE HYDROCHLORIDE,,,Current,Other,Limited supply; Check wholesalers for inventory; Marketed by Baxter,,V910P86109,43066-023-10,888-229-0001,
"Hospira, Inc., a Pfizer Company",SODIUM CHLORIDE,,06/21/2018,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Sodium Chloride 0.9% Injection,"1807628, 1807631, 1807637, 1807638",,8eb172da-dcd4-4660-4a8f-ad44a14b4af7,08/08/2025,HUMAN PRESCRIPTION DRUG,,Other,SODIUM CHLORIDE,"0409-4888, 0409-1918","Hospira, Inc.",9ee88abb-024a-4a3b-9776-1777eaf2f760,"0409-4888-02, 0409-4888-10, 0409-4888-03, 0409-4888-20, 0409-4888-06, 0409-4888-50, 0409-4888-01, 0409-4888-12, 0409-4888-90, 0409-1918-42, 0409-1918-32, 0409-1918-43, 0409-1918-33, 0409-1918-45, 0409-1918-35","Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-4888-20)",Injection,,,NDA018803,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0409-4888-20,844-646-4398,
"Upsher-Smith Laboratories, LLC",BACLOFEN,,04/23/2025,New,ORAL,Baclofen Tablet,"197391, 197392",,b2747a9d-5fca-4657-9e4b-4112607f30d8,04/23/2025,HUMAN PRESCRIPTION DRUG,04/23/2025,Neurology,BACLOFEN,"0832-1054, 0832-1055","Upsher-Smith Laboratories, LLC",395d77da-1674-a9a4-e063-6394a90aa3d7,"0832-1054-90, 0832-1054-11, 0832-1054-15, 0832-1054-10, 0832-1055-90, 0832-1055-11, 0832-1055-15, 0832-1055-10","Baclofen, Tablet, 10 mg (NDC 0832-1054-10)",Tablet,,"N0000000196, N0000000116, N0000175759",ANDA074584,,BACLOFEN,gamma-Aminobutyric Acid-ergic Agonist [EPC],,To Be Discontinued,,,,H789N3FKE8,0832-1054-10,716-315-2000,"GABA A Agonists [MoA], GABA B Agonists [MoA]"
Otsuka ICU Medical LLC,"ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, PROLINE, SERINE, TAURINE, THREONINE, TRYPTOPHAN, TYROSINE, VALINE",,12/08/2020,Reverified,INTRAVENOUS,Amino Acid Injection,"831426, 831430",,2d212e10-7e08-4aeb-b63f-dcc927897769,09/17/2025,HUMAN PRESCRIPTION DRUG,,Gastroenterology,AMINOSYN-PF,0990-4178,ICU Medical Inc.,66a78f44-6cba-437f-bd01-d650bf913401,0990-4178-03,"Aminosyn-PF 7%, Injection, 0.07 (NDC 0990-4178-03)",Injection,Unavailable,"N0000175780, M0000922",NDA019398,Amino Acids [CS],"ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, PROLINE, SERINE, TAURINE, AND TYROSINE",Amino Acid [EPC],,Current,Shortage of an active ingredient,"Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,"OF5P57N2ZX, 94ZLA3W45F, 30KYC7MIAI, 3KX376GY7L, TE7660XO1C, 4QD397987E, 04Y7590D77, GMW67QNF9C, TTL6G7LIWZ, AE28F7PNPL, 47E5O17Y3R, 9DLQ4CIU6V, 452VLY9402, 1EQV5MLY3D, 2ZD004190S, 8DUH1N11BX, 42HK56048U, HG18B9YRS7",0990-4178-03,1-866-829-9025 or ProductAvailability@icumed.com,
Otsuka ICU Medical LLC,DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795477, 1795480, 1795481, 1795607, 1795609, 1795610, 1795612, 1795616, 1795618, 1795621",,8b25b7e0-703e-4b43-a4eb-52863511602d,09/17/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0990-7923, 0990-7922, 0990-7930","ICU Medical, Inc.",09b10612-c937-4d10-becb-9768e10caa2c,"0990-7923-20, 0990-7923-23, 0990-7923-36, 0990-7923-37, 0990-7923-13, 0990-7922-02, 0990-7922-03, 0990-7922-09, 0990-7922-53, 0990-7922-55, 0990-7922-61, 0990-7930-02, 0990-7930-03, 0990-7930-09","Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-23)",Injection,Available,,NDA016367,,DEXTROSE MONOHYDRATE,,,Current,,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,LX22YL083G,0990-7923-23,1-866-829-9025 or ProductAvailability@icumed.com,
"Fresenius Kabi USA, LLC",FENTANYL CITRATE,,01/01/2012,Revised,"INTRAMUSCULAR, INTRAVENOUS",Fentanyl Citrate Injection,"1735003, 1735007, 1735008, 1735013, 2168270",,38d0c14a-a0c1-44cc-a939-0304eb8037d6,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Pediatric",FENTANYL CITRATE,63323-806,"Fresenius Kabi USA, LLC",341b092a-1f6f-40f1-98f2-9346bf2e1242,"63323-806-11, 63323-806-01, 63323-806-12, 63323-806-02, 63323-806-13, 63323-806-05, 63323-806-14, 63323-806-20, 63323-806-50","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-02)",Injection,Unavailable,,ANDA210762,,FENTANYL CITRATE,,,Current,Other,Backordered. Next release October 2025. Check wholesalers for inventory.,,MUN5LYG46H,63323-806-02,888-386-1300,
"Teva Pharmaceuticals USA, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Revised,ORAL,Lisdexamfetamine Dimesylate Capsule,,,c32b5dce-2de4-4db0-a4ba-d2ce3b0a32fc,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0480-3568, 0480-3565, 0480-3566, 0480-3567, 0480-3569, 0480-3570, 0480-3564","Teva Pharmaceuticals, Inc.",6cfe6c98-51b1-45a4-831c-33624ab129cb,"0480-3565-01, 0480-3566-01, 0480-3567-01, 0480-3568-01, 0480-3569-01, 0480-3570-01, 0480-3564-01","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0480-3568-01)",Capsule,Available,,ANDA202802,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,0480-3568-01,800-545-8800,
"Solco Healthcare US, LLC",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,68b10d9f-ca3e-493d-a309-45f1d7e08061,08/05/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"43547-603, 43547-602, 43547-604, 43547-605, 43547-606, 43547-607, 43547-608","Solco Healthcare US,LLC",7bb11568-67a4-4221-bb9b-23af37a1791c,"43547-602-10, 43547-603-10, 43547-604-10, 43547-605-10, 43547-606-10, 43547-607-10, 43547-608-10","Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 43547-603-10)",Capsule,Limited Availability,,ANDA216266,,LISDEXAMFETAMINE DIMESYLATE CAPSULES,,,Current,Shortage of an active ingredient,On allocation,,SJT761GEGS,43547-603-10,866-931-9829,
"Fresenius Kabi USA, LLC",MIDAZOLAM HYDROCHLORIDE,,04/02/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Midazolam Hydrochloride Injection,"998211, 1551393, 1551395",,1cc9ba6e-fa1b-405e-9de8-720c567b2a73,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology",MIDAZOLAM,"76045-211, 76045-001, 76045-002, 76045-003","Fresenius Kabi USA, LLC",ec9c9aee-b95f-4645-bf17-df7f1e3967d3,"76045-211-00, 76045-211-20, 76045-001-00, 76045-001-20, 76045-002-00, 76045-002-10, 76045-003-00, 76045-003-20","Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2 mL (NDC 76045-211-20)",Injection,Available,,ANDA203460,,MIDAZOLAM HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,W7TTW573JJ,76045-211-20,888-386-1300,
Pfizer Inc.,,,01/06/2023,Revised,,Somatropin Injection,"241975, 762830, 762833, 762834, 762836, 762837, 762839, 762841, 762843, 762846, 762849, 762850, 762852, 762857, 762859, 762866, 762868, 762873, 762875, 762895, 762897, 763488, 763489, 996558, 996559",,ffebf88b-d257-4542-9808-74d9b7167765,08/28/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,GENOTROPIN,"0013-2652, 0013-2626, 0013-2646, 0013-2649, 0013-2650, 0013-2651, 0013-2653, 0013-2654, 0013-2655, 0013-2656, 0013-2657, 0013-2658",Pfizer Laboratories Div Pfizer Inc,f09acf87-6e30-47ad-9891-8a49bf6dffbc,"0013-2626-81, 0013-2646-81, 0013-2649-02, 0013-2650-02, 0013-2651-02, 0013-2652-02, 0013-2653-02, 0013-2654-02, 0013-2655-02, 0013-2656-02, 0013-2657-02, 0013-2658-02","Genotropin, Injection, 0.8 mg preservative free (NDC 0013-2652-02)",Injection,,,BLA020280,,SOMATROPIN,,Available,Resolved,,,08/28/2025,,0013-2652-02,800-533-4535,
"Teva Pharmaceuticals USA, Inc.",TOBRAMYCIN,,06/16/2025,New,RESPIRATORY (INHALATION),Tobramycin Solution,1314763,,d03079d2-5617-4628-92b9-3caa757b22c0,06/16/2025,HUMAN PRESCRIPTION DRUG,06/16/2025,Pulmonary/Allergy,TOBRAMYCIN,0093-3750,"Teva Pharmaceuticals USA, Inc.",8aa98982-a156-4bc8-8d31-9a39b88808ed,"0093-3750-28, 0093-3750-63","Tobramycin, Solution, 300 mg/4 mL (NDC 0093-3750-28)",Solution,,"N0000175477, M0000946",ANDA210915,Aminoglycosides [CS],TOBRAMYCIN,Aminoglycoside Antibacterial [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,VZ8RRZ51VK,0093-3750-28,800-545-8800,
"Upsher-Smith Laboratories, LLC",BACLOFEN,,04/23/2025,New,ORAL,Baclofen Tablet,"197391, 197392",,b2747a9d-5fca-4657-9e4b-4112607f30d8,04/23/2025,HUMAN PRESCRIPTION DRUG,04/23/2025,Neurology,BACLOFEN,"0832-1054, 0832-1055","Upsher-Smith Laboratories, LLC",395d77da-1674-a9a4-e063-6394a90aa3d7,"0832-1054-90, 0832-1054-11, 0832-1054-15, 0832-1054-10, 0832-1055-90, 0832-1055-11, 0832-1055-15, 0832-1055-10","Baclofen, Tablet, 10 mg (NDC 0832-1054-15)",Tablet,,"N0000000196, N0000000116, N0000175759",ANDA074584,,BACLOFEN,gamma-Aminobutyric Acid-ergic Agonist [EPC],,To Be Discontinued,,,,H789N3FKE8,0832-1054-15,716-315-2000,"GABA A Agonists [MoA], GABA B Agonists [MoA]"
Apotex Corp.,,,01/27/2025,New,,Bendamustine Hydrochloride Injection,,,,01/27/2025,,01/27/2025,Oncology,,,,,,"Bendamustine Hydrochloride, Injection, 100 mg (NDC 60505-6096-0)",Injection,,,,,,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,,60505-6096-0,800-706-5575,
"Teva Pharmaceuticals USA, Inc.",CELECOXIB,,08/15/2025,New,ORAL,Celecoxib Capsule,"205322, 205323, 349514, 686379",,05224473-27dc-4f6d-a52a-c40a7af2f2f4,08/15/2025,HUMAN PRESCRIPTION DRUG,08/15/2025,Analgesia/Addiction,CELECOXIB,"0591-3982, 0591-3983, 0591-3984, 0591-3985","Actavis Pharma, Inc.",64c601bc-9b67-400f-9e30-e26de56f2f8b,"0591-3982-60, 0591-3983-01, 0591-3983-05, 0591-3984-01, 0591-3984-05, 0591-3985-60","Celecoxib, Capsule, 50 mg (NDC 0591-3982-60)",Capsule,,"N0000000160, M0001335, N0000175722",ANDA200562,"Anti-Inflammatory Agents, Non-Steroidal [CS]",CELECOXIB,Nonsteroidal Anti-inflammatory Drug [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,JCX84Q7J1L,0591-3982-60,800-545-8800,Cyclooxygenase Inhibitors [MoA]
Rubicon Research Private Limited,CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"72888-153, 72888-152, 72888-154",Advagen Pharma Ltd,36cf156e-5980-a21b-e063-6294a90ab3a0,"72888-152-30, 72888-152-01, 72888-152-05, 72888-152-00, 72888-153-30, 72888-153-01, 72888-153-05, 72888-153-00, 72888-154-30, 72888-154-01, 72888-154-05, 72888-154-00","Clonazepam, Tablet, 1 mg (NDC 72888-153-05)",Tablet,Available,"N0000175694, M0002356",ANDA075468,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,Marketed by Advagen Pharma Ltd.,,5PE9FDE8GB,72888-153-05,sales@advagenpharma.com,
"Actavis Pharma, Inc.",,,06/16/2025,New,,"Testosterone Gel; Gel, Metered",,,,06/16/2025,,06/16/2025,Urology,,,,,,"Testosterone, Gel; Gel, Metered, 16.2 mg/1 g (NDC 0591-2925-30)","Gel; Gel, Metered",,,,,,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,,0591-2925-30,800-545-8800,
"Hospira, Inc., a Pfizer Company","BUPIVACAINE HYDROCHLORIDE, EPINEPHRINE BITARTRATE",,02/20/2018,Revised,"INFILTRATION, PERINEURAL","Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","1012377, 1012384, 1012396, 1012404, 1672917, 1672919, 1724786, 1724787, 1724880, 1724884, 1725078, 1725082, 1867594, 1867596",,02a845c3-4521-4926-e397-25ab536e7cf6,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE,"0409-9043, 0409-1159, 0409-1160, 0409-1162, 0409-1163, 0409-1165, 0409-9046, 0409-9045, 0409-9042","Hospira, Inc.",3c6a5b9f-4ea0-4ccd-a384-a90e4ad379e7,"0409-1159-18, 0409-1159-01, 0409-1159-19, 0409-1159-02, 0409-1160-18, 0409-1160-01, 0409-1162-18, 0409-1162-01, 0409-1162-19, 0409-1162-02, 0409-1163-18, 0409-1163-01, 0409-1165-18, 0409-1165-01, 0409-1165-19, 0409-1165-02, 0409-9043-11, 0409-9043-01, 0409-9046-11, 0409-9046-01, 0409-9045-11, 0409-9045-01, 0409-9045-16, 0409-9045-17, 0409-9042-11, 0409-9042-01, 0409-9042-16, 0409-9042-17","Bupivacaine Hydrochloride and Epinephrine, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-9043-01)",Injection,Unavailable,,ANDA071167,,BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE,,,Current,Other,Shortage per Manufacturer: Manufacturing Delay,12/19/2024,"30Q7KI53AK, 7TQO7W3VT8",0409-9043-01,844-646-4398,
Baxter Healthcare,"ALANINE, ARGININE, ASPARTIC ACID, CYSTEINE HYDROCHLORIDE, GLUTAMIC ACID, GLYCINE, HISTIDINE, ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, PROLINE, SERINE, TAURINE, THREONINE, TRYPTOPHAN, TYROSINE, VALINE",,12/08/2020,Reverified,INTRAVENOUS,Amino Acid Injection,"801395, 801398, 801403, 801405",,9afdcc3e-0d06-47f4-86ca-40da48b2b02b,09/23/2025,HUMAN PRESCRIPTION DRUG,,Gastroenterology,PREMASOL - SULFITE-FREE (AMINO ACID),"0338-1130, 0338-1131",Baxter Healthcare Company,4083b5c8-ad5f-43f6-ab19-3c87acb2883f,"0338-1130-03, 0338-1130-04, 0338-1130-06, 0338-1131-03","Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-04)",Injection,Available,"N0000175780, M0000922",ANDA075880,Amino Acids [CS],"LEUCINE, LYSINE, ISOLEUCINE, VALINE, HISTIDINE, PHENYLALANINE, THREONINE, METHIONINE, TRYPTOPHAN, TYROSINE, N-ACETYL-TYROSINE, ARGININE, PROLINE, ALANINE, GLUTAMIC ACIDE, SERINE, GLYCINE, ASPARTIC ACID, TAURINE, CYSTEINE HYDROCHLORIDE",Amino Acid [EPC],,Current,,,,"OF5P57N2ZX, 94ZLA3W45F, 30KYC7MIAI, ZT934N0X4W, 3KX376GY7L, TE7660XO1C, 4QD397987E, 04Y7590D77, GMW67QNF9C, TTL6G7LIWZ, AE28F7PNPL, 47E5O17Y3R, 9DLQ4CIU6V, 452VLY9402, 1EQV5MLY3D, 2ZD004190S, 8DUH1N11BX, 42HK56048U, HG18B9YRS7",0338-1130-04,888-229-0001,
"Teva Pharmaceuticals USA, Inc.",CARBOPLATIN,,04/28/2023,Revised,INTRAVENOUS,Carboplatin Injection,597195,,"f330f5a2-2cad-402f-bcbb-26245a753276, e176b6ef-2ff6-498b-a9d8-7a634d147f37",09/15/2025,HUMAN PRESCRIPTION DRUG,,Oncology,CARBOPLATIN,"0703-4244, 0703-4246, 0703-4248, 0703-4239","Teva Parenteral Medicines, Inc.","bed4c1cf-f3ef-4faa-b2a4-24ee9a9879df, b943761e-6a46-45a0-bdb4-1fec1e101f8c","0703-4244-01, 0703-4246-01, 0703-4248-01, 0703-4239-01, 0703-4244-81, 0703-4246-81, 0703-4248-81, 0703-4239-81","Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)",Injection,Available,"N0000175413, N0000175073",ANDA077269,,CARBOPLATIN,Platinum-based Drug [EPC],,Current,,,,BG3F62OND5,0703-4244-01,800-545-8800,
Sun Pharmaceutical Industries Limited,CLINDAMYCIN HYDROCHLORIDE,,12/05/2024,New,ORAL,Clindamycin Hydrochloride Capsule,"197518, 284215",,1dbd8448-c1e5-46df-8060-50ef82380445,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Anti-Infective,CLINDAMYCIN HYDROCHLORIDE,"63304-693, 63304-692","Sun Pharmaceutical Industries, Inc.",339366d4-2060-1c29-e063-6394a90a1cb7,"63304-692-01, 63304-692-05, 63304-692-77, 63304-692-03, 63304-693-16, 63304-693-01, 63304-693-03, 63304-693-05, 63304-693-77, 63304-693-11, 63304-693-62","Clindamycin Hydrochloride, Capsule, 300 mg (NDC 63304-693-11)",Capsule,,,ANDA065061,,CLINDAMYCIN HYDROCHLORIDE,,,To Be Discontinued,,Discontinuing for business reasons,,T20OQ1YN1W,63304-693-11,800-818-4555,
"Teva Pharmaceuticals USA, Inc.",,,10/15/2024,New,,Levalbuterol Hydrochloride Solution,,,,10/15/2024,,10/15/2024,Pulmonary/Allergy,,,,,,"Solution, 1.25 mg/.5 mL (NDC 0093-4147-56)",Solution,,,,,,,,To Be Discontinued,,,,,0093-4147-56,800-545-8800,
PAI Pharma,LIDOCAINE HYDROCHLORIDE,,12/08/2023,Revised,ORAL,Lidocaine Hydrochloride Solution,1010739,,d5e23ede-957c-4a32-b1c6-268acb773c31,08/29/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,LIDOCAINE HYDROCHLORIDE,"0121-0950, 0121-4950","PAI Holdings, LLC dba PAI Pharma",8bd8bb07-066a-4c8c-ac5b-76f746318a49,"0121-0950-03, 0121-4950-15, 0121-4950-40","Lidocaine Hydrochloride Viscous, Solution, 20 mg/1 mL (NDC 0121-0950-03)",Solution,,,ANDA218138,,LIDOCAINE HYDROCHLORIDE,,Available,Resolved,,,08/29/2025,V13007Z41A,0121-0950-03,800-845-8210,
"Upsher-Smith Laboratories, LLC",PROPAFENONE HYDROCHLORIDE,,05/14/2025,New,ORAL,"Propafenone Hydrochloride Capsule, Extended Release","861156, 861164, 861171",,8aa6f58a-2980-4caa-9c54-d55d69d5d132,05/14/2025,HUMAN PRESCRIPTION DRUG,05/14/2025,Cardiovascular,PROPAFENONE HYDROCHLORIDE,"0832-0742, 0832-0740, 0832-0741","Upsher-Smith Laboratories, LLC",398513af-dd95-49eb-e063-6394a90a73f4,"0832-0740-60, 0832-0741-60, 0832-0742-60","Propafenone Hydrochloride, Capsule, Extended Release, 425 mg (NDC 0832-0742-60)","Capsule, Extended Release",,,ANDA212744,,PROPAFENONE HYDROCHLORIDE,,,To Be Discontinued,,A business decision was made to discontinue the product.,,33XCH0HOCD,0832-0742-60,800-654-2299,
"Meitheal Pharmaceuticals, Inc.",ROCURONIUM BROMIDE,,02/15/2023,Reverified,INTRAVENOUS,Rocuronium Bromide Injection,1234995,,b9abaf64-760d-43e0-8669-a9ca70feab11,08/19/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROCURONIUM BROMIDE,"71288-700, 71288-718",Meitheal Pharmaceuticals Inc.,37295b13-65a4-40fa-8d6c-53aeb45e2939,"71288-700-05, 71288-700-06, 71288-718-10, 71288-718-11","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-700-06)",Injection,Available,,ANDA213453,,ROCURONIUM BROMIDE,,,Current,,,,I65MW4OFHZ,71288-700-06,844-824-8426,
MSN Laboratories Private Limited,BUMETANIDE,Increased Diuresis at Loop of Henle [PE],12/13/2017,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Bumetanide Injection,"282486, 1727569",,387edfd4-be85-41cd-8a6d-14e6a022b5a9,09/15/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,BUMETANIDE,"72205-102, 72205-101",Novadoz Pharmaceuticals LLC,387edfd4-be85-41cd-8a6d-14e6a022b5a9,"72205-101-01, 72205-101-07, 72205-102-01, 72205-102-07","Bumetanide, Injection, .25 mg/1 mL (NDC 72205-102-07)",Injection,Available,"N0000175366, N0000175590",ANDA215364,,BUMETANIDE,Loop Diuretic [EPC],,Current,,,,0Y2S3XUQ5H,72205-102-07,Distributed by: Novadoz Pharmaceuticals LLC; Telephone: (855) 668-2369; customerservice@novadozpharma.com,
Torrent Pharma Inc.,,,06/13/2025,New,,Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil Tablet,,,,06/13/2025,,06/13/2025,Cardiovascular,,,,,,"Amlodipine Besylate; Hydrochlorothiazide; Olmesartan Medoxomil, Tablet, 10 mg; 25 mg; 40 mg (NDC 13668-382-05)",Tablet,,,,,,,,To Be Discontinued,,A business decision was made to discontinue manufacture of the product.,,,13668-382-05,908-280-3333,
"Hikma Pharmaceuticals USA, Inc.",ETOMIDATE,General Anesthesia [PE],10/05/2022,Revised,INTRAVENOUS,Etomidate Injection,"1654006, 1654008",,98002094-f065-4b5f-963f-2c34b5241316,07/23/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ETOMIDATE,"72572-161, 72572-160","Civica, Inc.",380f0c88-03f8-4cfa-8823-4766c2f7700c,"72572-160-01, 72572-160-10, 72572-161-01, 72572-161-10","Etomidate, Injection, 2 mg/1 mL (NDC 72572-161-10)",Injection,Available,"N0000175975, N0000175681",ANDA202354,,ETOMIDATE,General Anesthetic [EPC],,Current,,Distributed by Civica,,Z22628B598,72572-161-10,800-631-2174,
Amneal Pharmaceuticals,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850",,c11cb3b6-3dff-477b-a249-b4c3118edc5f,09/17/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"65162-027, 65162-023, 65162-024, 65162-025, 65162-026, 65162-028",Amneal Pharmaceuticals LLC,759471b0-6930-4e65-9417-e1c334a0eb68,"65162-023-09, 65162-024-09, 65162-025-09, 65162-026-09, 65162-027-09, 65162-028-09","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 65162-027-09)",Capsule,Unavailable,,ANDA202830,,LISDEXAMFETAMINE,,,Current,Shortage of an active ingredient,Shortage of an active ingredient,,SJT761GEGS,65162-027-09,866-525-7270,
"Hikma Pharmaceuticals USA, Inc.",METHOTREXATE,,03/13/2023,Reverified,"INTRA-ARTERIAL, INTRAMUSCULAR, INTRATHECAL, INTRAVENOUS",Methotrexate Sodium Injection,311625,,b080eb92-fc72-4ce6-a7ab-3f9ce2415526,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Rheumatology, Oncology",METHOTREXATE,0143-9830,Hikma Pharmaceuticals USA Inc.,d295fa12-63ca-4760-b291-44ba56ce1b59,0143-9830-01,"Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01)",Injection,Available,"N0000175584, N0000000111",ANDA040632,,METHOTREXATE,Folate Analog Metabolic Inhibitor [EPC],,Current,,Currently available.  Additional product will be made available as it is released.,,YL5FZ2Y5U1,0143-9830-01,800-631-2174,Folic Acid Metabolism Inhibitors [MoA]
Otsuka ICU Medical LLC,SODIUM CHLORIDE,,12/10/2021,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807548, 1807549, 1807550, 1807551, 1807552, 1807627, 1807630, 1807631, 1807632, 1807633, 1807634, 1807639",,5f372b75-d7a4-471e-8ac6-290040fc84b0,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE,"0990-7983, 0990-7730, 0990-7984, 0990-7985",ICU Medical Inc.,87c57bfa-0bf7-41fd-b954-eb753d5d9d7f,"0990-7730-36, 0990-7730-37, 0990-7983-61, 0990-7983-02, 0990-7983-03, 0990-7983-09, 0990-7983-55, 0990-7983-53, 0990-7984-37, 0990-7984-20, 0990-7984-13, 0990-7984-23, 0990-7984-36, 0990-7985-02, 0990-7985-03, 0990-7985-09","Sodium Chloride 0.9% In Plastic Container, Injection, 900 mg/100 mL (NDC 0990-7983-02)",Injection,,,NDA016366,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0990-7983-02,1-866-829-9025 or ProductAvailability@icumed.com,
"Medefil, Inc.",ATROPINE SULFATE,,01/01/2012,Reverified,INTRAVENOUS,Atropine Sulfate Injection,1190546,,fbfdf718-befe-ad22-e053-6294a90a3715,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology, Pediatric",ATROPINE SULFATE,64253-400,"Medefil, Inc.",fbfdf718-beff-ad22-e053-6294a90a3715,"64253-400-30, 64253-400-91","Atropine Sulfate, Injection, .1 mg/1 mL (NDC 64253-400-91)",Injection,Available,,ANDA214970,,ATROPINE SULFATE INJECTION,,,Current,,,,03J5ZE7KA5,64253-400-91,630-682-4600,
Apotex Corp.,AMBRISENTAN,,01/14/2025,New,ORAL,Ambrisentan Tablet,,,291a782a-77e1-8a8e-e1c8-2626f305c2b7,01/14/2025,HUMAN PRESCRIPTION DRUG,01/14/2025,Cardiovascular,AMBRISENTAN,"60505-4552, 60505-4553",Apotex Corp.,9525d4e3-a712-40cf-a52f-9d16bc156220,"60505-4552-1, 60505-4552-0, 60505-4552-3, 60505-4553-1, 60505-4553-0, 60505-4553-3","Ambrisentan, Tablet, 5 mg (NDC 60505-4552-3)",Tablet,,"N0000175581, N0000175364",ANDA210701,,AMBRISENTAN,Endothelin Receptor Antagonist [EPC],,To Be Discontinued,,,,HW6NV07QEC,60505-4552-3,800-706-5575,Endothelin Receptor Antagonists [MoA]
Eli Lilly and Co.,DULOXETINE HYDROCHLORIDE,,10/18/2024,New,ORAL,"Duloxetine Hydrochloride Capsule, Delayed Release","596926, 596928, 596930, 596932, 596934, 615186",,2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba,10/18/2024,HUMAN PRESCRIPTION DRUG,10/18/2024,Psychiatry,CYMBALTA,"0002-3240, 0002-3235, 0002-3270",Eli Lilly and Company,aa5061b1-f237-425a-9d05-575c333dfd37,"0002-3235-60, 0002-3240-30, 0002-3240-90, 0002-3270-30","Cymbalta, Capsule, Delayed Release, 30 mg (NDC 0002-3240-90)",Capsule,,,NDA021427,,DULOXETINE HYDROCHLORIDE,,,To Be Discontinued,,Business decision to discontinue,,9044SC542W,0002-3240-90,800-545-5979,
"Fresenius Kabi USA, LLC",FENTANYL CITRATE,,01/01/2012,Revised,"INTRAMUSCULAR, INTRAVENOUS",Fentanyl Citrate Injection,"1735003, 1735007, 1735008, 1735013, 2168270",,38d0c14a-a0c1-44cc-a939-0304eb8037d6,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Analgesia/Addiction, Pediatric",FENTANYL CITRATE,63323-806,"Fresenius Kabi USA, LLC",341b092a-1f6f-40f1-98f2-9346bf2e1242,"63323-806-11, 63323-806-01, 63323-806-12, 63323-806-02, 63323-806-13, 63323-806-05, 63323-806-14, 63323-806-20, 63323-806-50","Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-01)",Injection,Unavailable,,ANDA210762,,FENTANYL CITRATE,,,Current,Other,Backordered. Next release October 2025. Check wholesalers for inventory.,,MUN5LYG46H,63323-806-01,888-386-1300,
Baxter Healthcare,FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Revised,INTRAVENOUS,Furosemide Injection,"1719286, 1719290, 1719291",,c71371a7-75c5-45b8-b762-8d782d4c71bc,09/23/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,"36000-283, 36000-063, 36000-064, 36000-065, 36000-282, 36000-284",Baxter Healthcare Corporation,109082ab-0793-4752-8a02-42d204efe741,"36000-063-05, 36000-064-05, 36000-065-05, 36000-282-25, 36000-283-25, 36000-284-25","Furosemide, Injection, 10 mg/1 mL (NDC 36000-283-25)",Injection,Available,"N0000175366, N0000175590",ANDA202747,,FUROSEMIDE,Loop Diuretic [EPC],,Current,,,,7LXU5N7ZO5,36000-283-25,888-229-0001,
Renew Pharmaceuticals Limited,,,08/23/2024,Revised,,Indocyanine Green Injection,,,a6f24787-c243-445a-9c55-7c7479b292d9,08/26/2025,HUMAN PRESCRIPTION DRUG,,"Medical Imaging, Ophthalmology, Other",INDOCYANINE GREEN,70100-424,Renew Pharmaceuticals Limited,3abdfd10-c4e6-472e-b4eb-d4953f029132,"70100-424-02, 0409-4887-17","Indocyanine Green, Injection, 25 mg (NDC 70100-424-02)",Injection,,,ANDA040811,,INDOCYANINE GREEN AND WATER,,Available,Resolved,,,08/26/2025,,70100-424-02,888-393-3767,
Eugia US LLC,METHYLPREDNISOLONE ACETATE,,12/15/2021,Revised,"INTRA-ARTICULAR, INTRALESIONAL, INTRAMUSCULAR, SOFT TISSUE",Methylprednisolone Acetate Injection,"1358610, 1358617",,a0cbcdb5-f657-49f7-8f86-cc5959d69db0,09/05/2025,HUMAN PRESCRIPTION DRUG,,Rheumatology,METHYLPREDNISOLONE ACETATE,"55150-313, 55150-314",Eugia US LLC,a0cbcdb5-f657-49f7-8f86-cc5959d69db0,"55150-313-25, 55150-313-01, 55150-314-25, 55150-314-01","Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 55150-313-01)",Injection,Unavailable,,ANDA211930,,METHYLPREDNISOLONE ACETATE,,,Current,Demand increase for the drug,On backorder. Recovery: TBD. Check wholesalers for inventory,,43502P7F0P,55150-313-01,888-238-7880,
"Hospira, Inc., a Pfizer Company",BUPIVACAINE HYDROCHLORIDE,,02/20/2018,Reverified,PERINEURAL,Bupivacaine Hydrochloride Injection,"1012377, 1012381, 1012384, 1012388, 1012396, 1012400, 1012404, 1012406, 1672917, 1672919, 1673242, 1673243, 1724786, 1724787, 1724794, 1724796, 1724880, 1724884, 1725044, 1725046, 1725078, 1725079, 1725082, 1725083, 1867594, 1867596, 1867612, 1867614",,67578b56-7540-487e-1fba-481255620e78,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,MARCAINE,"0409-1610, 0409-1559, 0409-1560, 0409-1582, 0409-1587, 0409-1746, 0409-1749, 0409-1752, 0409-1755, 0409-2510, 0409-7535, 0409-1250, 0409-5010, 0409-1530, 0409-0525, 0409-7510, 0409-2253","Hospira, Inc.",b083f440-bfb7-449a-b601-c2f59a6f9dcf,"0409-1559-18, 0409-1559-10, 0409-1559-19, 0409-1559-30, 0409-1560-18, 0409-1560-10, 0409-1560-19, 0409-1560-29, 0409-1582-18, 0409-1582-10, 0409-1582-19, 0409-1582-29, 0409-1587-50, 0409-1610-50, 0409-1746-70, 0409-1746-10, 0409-1746-71, 0409-1746-30, 0409-1749-70, 0409-1749-10, 0409-1749-71, 0409-1749-29, 0409-1752-50, 0409-1755-50, 0409-2510-01, 0409-2510-25, 0409-7535-01, 0409-7535-25, 0409-1250-01, 0409-1250-25, 0409-5010-01, 0409-5010-25, 0409-1530-01, 0409-1530-25, 0409-0525-01, 0409-0525-25, 0409-7510-01, 0409-7510-25, 0409-2253-01, 0409-2253-25","Marcaine, Injection, Marcaine 250 mg/50 mL (5 mg/mL) (NDC 0409-1610-50)",Injection,Available,,NDA016964,,BUPIVACAINE HYDROCHLORIDE,,,Current,,,,"30Q7KI53AK, 7TQO7W3VT8",0409-1610-50,844-646-4398,
Sagent Pharmaceuticals,CLINDAMYCIN PHOSPHATE,,03/21/2023,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Clindamycin Phosphate Injection,"1737244, 1737578, 1737581",,7a6967b3-5563-4bed-9eee-d400f800e799,08/26/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,CLINDAMYCIN,25021-115,Sagent Pharmaceuticals,4662502b-ce7c-4278-854d-cf8632ac9b83,"25021-115-02, 25021-115-04, 25021-115-06","Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02)",Injection,Available,,ANDA090108,,CLINDAMYCIN PHOSPHATE,,,Current,,,,EH6D7113I8,25021-115-02,866-625-1618,
HQ Specialty Pharma,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718906, 1718909, 1788947",,0d2710f2-ee47-4114-ab5c-8dca74cdcb8d,09/17/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE,"44567-600, 44567-601, 44567-602, 44567-603","WG Critical Care, LLC",e6fa3e27-b374-49b6-a678-a5954f5beae8,"44567-600-04, 44567-601-04, 44567-602-24, 44567-603-24","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-600-04)",Injection,Available,,NDA206628,,DEXMEDETOMIDINE,,,Current,,Marketed by WG Critical Care,,1018WH7F9I,44567-600-04,WG Critical Care 888-493-0861,
Chartwell Molecular Holdings LLC,FLURAZEPAM HYDROCHLORIDE,,08/03/2022,Reverified,ORAL,Flurazepam Hydrochloride Capsule,"1298088, 1298091",,8f476891-1346-4e8c-ac1b-f8cbdc64f5a1,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Oncology, Other",FLURAZEPAM HYDROCHLORIDE,"62135-736, 62135-737","Chartwell RX, LLC",25893c92-c8f1-567a-e063-6294a90a00d4,"62135-736-30, 62135-736-90, 62135-737-30, 62135-737-90","Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-90)",Capsule,Available,,ANDA072368,,FLURAZEPAM HYDROCHLORIDE,,,Current,,,,756RDM536M,62135-736-90,845-268-5000 Ext. 510,
Gland Pharma Limited,MIDAZOLAM HYDROCHLORIDE,,04/02/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Midazolam Hydrochloride Injection,1666798,,401a66d1-9374-40af-acd2-73e573584da2,09/29/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology",MIDAZOLAM,70860-600,"Athenex Pharmaceutical Division, LLC.",12dd97c1-4ccf-a310-e063-6294a90a4316,"70860-600-41, 70860-600-02","Midazolam Hydrochloride, Injection, 2 mg/2 mL (NDC 70860-600-02)",Injection,Available,,ANDA090696,,MIDAZOLAM HYDROCHLORIDE,,,Current,Other,Distributed by Sagent Pharmaceuticals: 1-866-625-1618,,W7TTW573JJ,70860-600-02,Athenex: 855-273-0154; Alvogen: 973-532-7840,
Pfizer Inc.,QUINAPRIL HYDROCHLORIDE,,01/19/2023,Reverified,ORAL,Quinapril Hydrochloride Tablet,"207891, 207892, 207893, 207895, 312748, 312749, 312750, 314203",,63cf5651-d52c-4d27-9fd4-ed9cd9724dff,08/15/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,ACCUPRIL,"0071-0530, 0071-0527, 0071-0532, 0071-0535, 0071-1205, 0071-1410, 0071-1620, 0071-1840",Parke-Davis Div of Pfizer Inc,ee20d3b1-a5c8-4510-a931-3872df7b77f4,"0071-0527-23, 0071-0530-23, 0071-0530-40, 0071-0532-23, 0071-0532-40, 0071-0535-23, 0071-1205-23, 0071-1410-23, 0071-1620-23, 0071-1840-23","Accupril, Tablet, 10 mg (NDC 0071-0530-23)",Tablet,Unavailable,,NDA019885,,QUINAPRIL HYDROCHLORIDE,,,Current,Delay in shipping of the drug,Next Delivery and Estimated Recovery: TBD,,33067B3N2M,0071-0530-23,800-533-4535,
"Boehringer Ingelheim Pharmaceuticals, Inc.",,,01/06/2025,New,,Adalimumab-adbm Injection,"797544, 2640883, 2640889, 2640891, 2640892, 2640893, 2640894, 2640895, 2640898, 2640900, 2640901, 2640902, 2640903, 2680743, 2680746, 2680748, 2680750, 2680756, 2680757, 2680759, 2680760",,115ea79b-7209-7f19-b35d-36ec0828fbf5,01/06/2025,HUMAN PRESCRIPTION DRUG,01/06/2025,Rheumatology,CYLTEZO,"0597-0495, 0597-0370, 0597-0405, 0597-0400, 0597-0375, 0597-0485","Boehringer Ingelheim Pharmaceuticals, Inc.",48e59974-6012-4a21-9348-552d590632b1,"0597-0370-82, 0597-0370-72, 0597-0370-45, 0597-0405-80, 0597-0405-10, 0597-0400-89, 0597-0375-48, 0597-0375-97, 0597-0375-23, 0597-0375-16, 0597-0375-53, 0597-0485-46, 0597-0485-20, 0597-0480-12, 0597-0495-47, 0597-0495-50, 0597-0495-40, 0597-0495-60, 0597-0490-32","Cyltezo, Injection, Kit (NDC 0597-0495-60)",Injection,,,BLA761058,,ADALIMUMAB-ADBM,,,To Be Discontinued,,,,,0597-0495-60,800-243-0127,
"Hikma Pharmaceuticals USA, Inc.",LORAZEPAM,,09/05/2018,Revised,"INTRAMUSCULAR, INTRAVENOUS",Lorazepam Injection,"206819, 206820, 238100, 238101, 1665188, 1665190, 1665326, 1665327",,5fc0e987-61c9-40c4-b0d5-fcea07c8733e,07/23/2025,HUMAN PRESCRIPTION DRUG,,Neurology,ATIVAN,"0641-6001, 0641-6003, 0641-6002, 0641-6000",Hikma Pharmaceuticals USA Inc.,209b0091-c890-4f69-a693-d0594c2606fe,"0641-6003-01, 0641-6003-25, 0641-6002-01, 0641-6002-10, 0641-6001-01, 0641-6001-25, 0641-6000-01, 0641-6000-10","Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)",Injection,Unavailable,"N0000175694, M0002356",NDA018140,Benzodiazepines [CS],LORAZEPAM,Benzodiazepine [EPC],,Current,Regulatory delay,Shortage duration unknown,,O26FZP769L,0641-6001-25,800-631-2174,
"Trigen Laboratories, LLC",METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Reverified,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release","1091155, 1091170, 1091185, 1091210, 1995461",,c45dc1de-adfa-4b3c-a7dc-cffbc8eac74f,09/04/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE HYDROCHLORIDE,"13811-708, 13811-709, 13811-706, 13811-707, 13811-710","Trigen Laboratories, LLC",354443b1-a623-43b0-b984-f8de2f6c60b2,"13811-709-10, 13811-706-10, 13811-707-10, 13811-708-10, 13811-710-10, 13811-710-30","Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10)",Tablet,Limited Availability,,ANDA205327,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,Demand increase for the drug,Allocation to current contracted customers,,4B3SC438HI,13811-708-10,800-541-4802,
"Hikma Pharmaceuticals USA, Inc.",ATROPINE SULFATE,,12/20/2023,Reverified,"ENDOTRACHEAL, INTRAMEDULLARY, INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Atropine Sulfate Injection,1190776,,4c15d3cc-7888-4c82-b3f8-a5d93c5523df,07/23/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology, Pediatric",ATROPINE SULFATE,0641-6251,Hikma Pharmaceuticals USA Inc.,f5ca4281-8c89-4efc-80b1-2fbcf61c7c55,0641-6251-10,"Atropine Sulfate, Injection, 0.4 mg/1 mL (NDC 0641-6251-10)",Injection,Available,,ANDA213561,,ATROPINE SULFATE,,,Current,,,,03J5ZE7KA5,0641-6251-10,800-631-2174,
MSN Laboratories Private Limited,BUMETANIDE,Increased Diuresis at Loop of Henle [PE],12/13/2017,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Bumetanide Injection,"282486, 1727569",,387edfd4-be85-41cd-8a6d-14e6a022b5a9,09/15/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,BUMETANIDE,"72205-101, 72205-102",Novadoz Pharmaceuticals LLC,387edfd4-be85-41cd-8a6d-14e6a022b5a9,"72205-101-01, 72205-101-07, 72205-102-01, 72205-102-07","Bumetanide, Injection, .25 mg/1 mL (NDC 72205-101-07)",Injection,Available,"N0000175366, N0000175590",ANDA215364,,BUMETANIDE,Loop Diuretic [EPC],,Current,,,,0Y2S3XUQ5H,72205-101-07,Distributed by: Novadoz Pharmaceuticals LLC; Telephone: (855) 668-2369; customerservice@novadozpharma.com,
Sun Pharmaceutical Industries Limited,CLINDAMYCIN HYDROCHLORIDE,,12/05/2024,New,ORAL,Clindamycin Hydrochloride Capsule,"197518, 284215",,1dbd8448-c1e5-46df-8060-50ef82380445,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Anti-Infective,CLINDAMYCIN HYDROCHLORIDE,"63304-692, 63304-693","Sun Pharmaceutical Industries, Inc.",339366d4-2060-1c29-e063-6394a90a1cb7,"63304-692-01, 63304-692-05, 63304-692-77, 63304-692-03, 63304-693-16, 63304-693-01, 63304-693-03, 63304-693-05, 63304-693-77, 63304-693-11, 63304-693-62","Clindamycin Hydrochloride, Capsule, 150 mg (NDC 63304-692-05)",Capsule,,,ANDA065061,,CLINDAMYCIN HYDROCHLORIDE,,,To Be Discontinued,,Discontinuing for business reasons,,T20OQ1YN1W,63304-692-05,800-818-4555,
"Caplin Steriles, Ltd.",ETOMIDATE,General Anesthesia [PE],10/05/2022,Reverified,INTRAVENOUS,Etomidate Injection,"1654006, 1654008",,"f38fad46-f2dd-4692-a2a9-a13d0a717bf8, d07efb9e-5264-461d-96d8-e11fa71c5751",09/16/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ETOMIDATE,"65219-445, 65219-447","Fresenius Kabi USA, LLC","446487f1-002e-41d3-846a-67570e797171, 30488a7e-ea9e-4a27-95a9-a07149c50282","65219-445-12, 65219-445-22, 65219-445-01, 65219-445-10, 65219-447-02, 65219-447-20","Etomidate, Injection, 40 mg/20 mL (NDC 65219-445-20)",Injection,Available,"N0000175975, N0000175681",ANDA215028,,ETOMIDATE,General Anesthetic [EPC],,Current,,Check wholesalers for inventory; Marketed by Fresenius Kabi,,Z22628B598,65219-445-20,800-551-7176,
Sintetica US,LIDOCAINE HYDROCHLORIDE ANHYDROUS,,02/22/2012,Reverified,INFILTRATION,Lidocaine Hydrochloride Injection,"1737566, 1737568, 1737570, 1737757, 1737761, 1737763",,aa3e688a-308c-4a82-a268-28ccf1677c55,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",NA,"83090-003, 83090-001, 83090-002, 83090-004, 83090-005, 83090-006",Sintetica US LLC,0d18f291-3a92-421e-8841-6be743b1f154,"83090-001-01, 83090-001-10, 83090-002-01, 83090-002-10, 83090-003-01, 83090-003-10, 83090-004-01, 83090-004-10, 83090-005-01, 83090-005-10, 83090-006-01, 83090-006-10","Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 83090-003-10)",Injection,Available,,ANDA214267,,LIDOCAINE HYDROCHLORIDE,,,Current,,"Inventory available at Cardinal Health, McKesson, Cencora (FKA Amerisource Bergen). Product (LIDOCAINE HCL 1% 10X10ML) is Preservative free.",,EC2CNF7XFP,83090-003-10,"844-425-3131, SinteticaCS@eversana.com",
"Actavis Pharma, Inc.",LIDOCAINE,Local Anesthesia [PE],07/17/2025,New,TOPICAL,Lidocaine Patch,1745091,,c18799cd-9e11-4196-9ab1-0a2a84585e56,07/17/2025,HUMAN PRESCRIPTION DRUG,07/17/2025,Analgesia/Addiction,LIDOCAINE,0591-2679,"Actavis Pharma, Inc.",e0683309-89ba-4804-887f-12fcaf59a2ca,"0591-2679-11, 0591-2679-30","Lidocaine, Patch, 5% (NDC 0591-2679-30)",Patch,,"N0000175682, M0000897, N0000175426, N0000175976",ANDA200675,Amides [CS],LIDOCAINE,"Amide Local Anesthetic [EPC], Antiarrhythmic [EPC]",,To Be Discontinued,,Discontinuation is for the “NovaPlus” label product only.,,98PI200987,0591-2679-30,800-545-8800,
Alvogen,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,7f2dd6ee-3363-c87c-9693-ed838942556c,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"47781-567, 47781-562, 47781-563, 47781-564, 47781-565, 47781-566, 47781-568",Alvogen Inc.,9114d946-92cb-c19d-c6f2-aef77294461f,"47781-562-01, 47781-563-01, 47781-564-01, 47781-565-01, 47781-566-01, 47781-567-01, 47781-568-01","Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 47781-567-01)",Capsule,Available,,ANDA214547,,LISDEXAMFETAMINE DIMESYLATE,,,Current,,,,SJT761GEGS,47781-567-01,844-842-8672 and email: CustomerService-US@alvogen.com,
"Upsher-Smith Laboratories, LLC",MIDODRINE HYDROCHLORIDE,,04/28/2025,New,ORAL,Midodrine Hydrochloride Tablet,"993462, 993466, 993470",,4c3517f3-1c68-4ade-b5f1-c488a3a335c1,04/28/2025,HUMAN PRESCRIPTION DRUG,04/28/2025,Cardiovascular,MIDODRINE HYDROCHLORIDE,"0245-0211, 0245-0212, 0245-0213","Upsher-Smith laboratories, LLC",18b0b9f5-6026-479e-af12-92b0e71a9d6b,"0245-0211-11, 0245-0211-89, 0245-0211-01, 0245-0212-11, 0245-0212-89, 0245-0212-01, 0245-0213-11, 0245-0213-89, 0245-0213-01","Orvaten, Tablet, 2.5 mg (NDC 0245-0211-01)",Tablet,,,ANDA076725,,MIDODRINE HYDROCHLORIDE,,,To Be Discontinued,,,,59JV96YTXV,0245-0211-01,800-654-2299,
Ingenus Pharmaceuticals LLC,CARBOPLATIN,,04/28/2023,Reverified,INTRAVENOUS,Carboplatin Injection,597195,,475caee0-15a6-4f0d-bca7-f3e472b323f7,09/15/2025,HUMAN PRESCRIPTION DRUG,,Oncology,CARBOPLATIN,"50742-447, 50742-448","Ingenus Pharmaceuticals, LLC",69fafb3c-1c18-4d34-83b2-3ab9ddaa6769,"50742-447-45, 50742-448-60","Carboplatin, Injection, 450 mg/45 mL (NDC 50742-447-45)",Injection,Unavailable,"N0000175413, N0000175073",ANDA208487,,CARBOPLATIN,Platinum-based Drug [EPC],,Current,Other,"For any other information, please contact the Ingenus Customer Service team at 866-321-5031.",,BG3F62OND5,50742-447-45,866-321-5031,
"Fresenius Kabi USA, LLC",DEXAMETHASONE SODIUM PHOSPHATE,,02/08/2019,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Dexamethasone Sodium Phosphate Injection,"1116927, 1812194",,"2b626a48-c7aa-4443-9164-a08ff069ccd1, 4fedef4f-ec96-4f36-b2f0-01e243e3b89e",09/18/2025,HUMAN PRESCRIPTION DRUG,,"Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Other, Pulmonary/Allergy, Rheumatology",DEXAMETHASONE SODIUM PHOSPHATE,63323-165,"Fresenius Kabi USA, LLC","a832bff9-0bb3-4350-abb5-d57b9417070c, 9dd90418-e564-4bc5-9077-506a1c2c1bce","63323-165-11, 63323-165-51, 63323-165-13, 63323-165-53, 63323-165-02, 63323-165-01, 63323-165-03, 63323-165-05, 63323-165-30, 63323-165-16, 63323-165-26","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-30)",Injection,Available,,ANDA084916,,DEXAMETHASONE SODIUM PHOSPHATE,,,Current,,Check wholesalers for inventory,,AI9376Y64P,63323-165-30,888-386-1300,
"Avet Pharmaceuticals, Inc.",FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Reverified,INTRAVENOUS,Furosemide Injection,"1719286, 1719290, 1719291",,1b9117d5-0dd9-4577-a1fd-bb0aaf7e68ec,09/15/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,23155-473,Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.,936eaafa-5088-4ebc-85bc-685ffb85c81f,"23155-473-31, 23155-473-41, 23155-473-32, 23155-473-42, 23155-473-43, 23155-473-33, 23155-473-44, 23155-473-45","Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)",Injection,Available,"N0000175366, N0000175590",ANDA203428,,FUROSEMIDE,Loop Diuretic [EPC],,Current,,,,7LXU5N7ZO5,23155-473-42,855-228-9470,
"Hospira, Inc., a Pfizer Company",HYDROMORPHONE HYDROCHLORIDE,,10/31/2017,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Hydromorphone Hydrochloride Injection,"897756, 897757, 1433251, 1724383, 1724644, 1872271, 2675350, 897653, 897753, 897758, 1724276",,"f9ca2ef5-46d8-475a-a26e-f7c8becd6db7, e9c9ef18-7dfc-4322-b2fc-29b934c30f8b",08/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,HYDROMORPHONE HYDROCHLORIDE,"0409-1283, 0409-1312, 0409-1380, 0409-4264, 0409-1805, 0409-2552, 0409-3356, 0409-2540, 0409-3365, 0409-1304","Hospira, Inc.","53b6867a-0ae3-48ff-b257-9e58cc76de9c, 58ff0e68-b78f-4ebd-a91b-b53bbdefc544","0409-1283-17, 0409-1283-37, 0409-1312-16, 0409-1312-36, 0409-1380-11, 0409-1380-01, 0409-4264-11, 0409-4264-01, 0409-1805-10, 0409-1805-01, 0409-2552-11, 0409-2552-01, 0409-3356-11, 0409-3356-01, 0409-2540-11, 0409-2540-01, 0409-3365-11, 0409-3365-01, 0409-3365-10, 0409-1283-03, 0409-1283-31, 0409-1283-09, 0409-1283-10, 0409-1283-04, 0409-1283-05, 0409-1312-03, 0409-1312-30, 0409-1312-09, 0409-1312-10, 0409-1304-03, 0409-1304-31","Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)",Injection,Unavailable,,NDA200403,,HYDROMORPHONE HYDROCHLORIDE,,,Current,Other,Next Delivery: February 2026; Estimated Recovery: March 2026,,L960UP2KRW,0409-1283-37,844-646-4398,
"Boehringer Ingelheim Pharmaceuticals, Inc.",,,01/06/2025,New,,Adalimumab-adbm Injection,"797544, 2640883, 2640891, 2640893, 2640895, 2640900, 2640902, 2680743, 2680748, 2680756, 2680759",,62f39a7c-00df-4519-a8d4-39bbd0a649ed,01/06/2025,HUMAN PRESCRIPTION DRUG,01/06/2025,Rheumatology,ADALIMUMAB-ADBM,"0597-0575, 0597-0595, 0597-0555, 0597-0585, 0597-0545, 0597-0565","Boehringer Ingelheim Pharmaceuticals, Inc.",79fdef1e-7f86-429d-bc7d-2e99f286204b,"0597-0595-20, 0597-0590-26, 0597-0555-80, 0597-0550-06, 0597-0585-89, 0597-0580-37, 0597-0545-22, 0597-0545-44, 0597-0545-66, 0597-0540-10, 0597-0575-50, 0597-0575-40, 0597-0575-60, 0597-0570-32, 0597-0565-20, 0597-0560-12","Cyltezo, Injection, Kit (NDC 0597-0575-60)",Injection,,,BLA761058,,ADALIMUMAB-ADBM,,,To Be Discontinued,,,,,0597-0575-60,800-243-0127,
B. Braun Medical Inc.,"CALCIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, SODIUM LACTATE",,10/11/2024,Reverified,INTRAVENOUS,Lactated Ringers Injection,847627,,190da07e-a616-46e6-b4e5-1c0ba39306e5,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other",DEXTROSE IN LACTATED RINGERS,0264-7751,B. Braun Medical Inc.,63aa1cd2-fda4-4386-8d11-5d1617634ef7,"0264-7751-00, 0264-7751-10","Lactated Ringers, Injection, .02 g/100 mL; 5 g/100 mL; .03 g/100 mL; .6 g/100 mL; .31 g/100 mL (NDC 0264-7751-10)",Injection,Available,,NDA019634,,"DEXTROSE, SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, AND CALCIUM CHLORIDE",,,Current,,,,"M4I0D6VV5M, LX22YL083G, 660YQ98I10, 451W47IQ8X, TU7HW0W0QT",0264-7751-10,800-227-2862,
Eugia US LLC,LIDOCAINE HYDROCHLORIDE,,06/13/2018,Revised,"INFILTRATION, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010671",,"ccc38d8a-43fd-44c0-985e-32af9ed956ab, ef782e5e-e2d7-465a-99c6-b12611f3158c",09/05/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,LIDOCAINE HYDROCHLORIDE,"55150-254, 55150-251, 55150-252, 55150-255, 55150-253, 55150-256",Eugia US LLC,"ccc38d8a-43fd-44c0-985e-32af9ed956ab, 0b1f03c2-db2f-4f90-acc0-d73abd731bf6","55150-251-24, 55150-252-24, 55150-254-24, 55150-255-24, 55150-251-10, 55150-252-20, 55150-253-50, 55150-254-10, 55150-255-20, 55150-256-50","Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-254-10)",Injection,Available,,ANDA207182,,LIDOCAINE HYDROCHLORIDE,,,Current,,Check wholesalers for inventory,,V13007Z41A,55150-254-10,888-238-7880,
"Lannett Company, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,2cedb4c2-1e40-4bc4-b9f4-127150c4afbd,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0527-4664, 0527-4661, 0527-4662, 0527-4663, 0527-4665, 0527-4666, 0527-4667","Lannett Company, Inc.",981ca74f-737d-45e5-a3b2-b25256263768,"0527-4661-37, 0527-4662-37, 0527-4663-37, 0527-4664-37, 0527-4665-37, 0527-4666-37, 0527-4667-37","Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0527-4664-37)",Capsule,Unavailable,,ANDA215802,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,Limited Availability,,SJT761GEGS,0527-4664-37,844-834-0530,
"Noven Pharmaceuticals, Inc.",METHYLPHENIDATE,Central Nervous System Stimulation [PE],02/28/2025,Revised,TRANSDERMAL,"Methylphenidate Film, Extended Release",,,7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb,08/19/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE TRANSDERMAL SYSTEM,"0574-2420, 0574-2410, 0574-2415, 0574-2430",PADAGIS US LLC,b743ef45-2fc0-4086-8a02-6078e6a09eaa,"0574-2410-65, 0574-2415-65, 0574-2420-65, 0574-2430-65","Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65)","Film, Extended Release",Unavailable,"N0000175739, N0000175729",NDA021514,,METHYLPHENIDATE,Central Nervous System Stimulant [EPC],,Current,Shortage of an active ingredient,Estimated availability: early September 2025. Distributed by Padagis US LLC,,207ZZ9QZ49,0574-2420-65,800-455-8070,
Aurobindo Pharma USA,"HYDROCHLOROTHIAZIDE, QUINAPRIL HYDROCHLORIDE",Increased Diuresis [PE],01/19/2023,Reverified,ORAL,Quinapril/Hydrochlorothiazide Tablet,"310796, 310797, 310809",,50a58159-9572-4445-9859-b392632597da,09/17/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE,"65862-161, 65862-162, 65862-163",Aurobindo Pharma Limited,5842ecc2-874a-481b-8997-afa9d862dc5d,"65862-161-90, 65862-162-30, 65862-162-90, 65862-163-90","Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 65862-161-90)",Tablet,Discontinued,"N0000175359, N0000175419, M0471776",ANDA078450,Thiazides [CS],QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE,Thiazide Diuretic [EPC],,Current,Discontinuation of the manufacture of the drug,,,"0J48LPH2TH, 33067B3N2M",65862-161-90,866-850-2876,
B. Braun Medical Inc.,SODIUM CHLORIDE,,06/21/2018,Revised,INTRAVENOUS,Sodium Chloride 0.9% Injection,"1807552, 1807634, 1807639",,e44c41ae-c9c8-4dd8-ba6c-cebb585378aa,08/08/2025,HUMAN PRESCRIPTION DRUG,,Other,SODIUM CHLORIDE,"0264-5802, 0264-5804",B. Braun Medical Inc.,d34ea9bc-a1f9-402a-97cf-894505cee75d,"0264-5802-00, 0264-5802-10, 0264-5804-00","Sodium Chloride 0.9%, Injection, .9 g/100 mL (NDC 0264-5802-10)",Injection,,,NDA019635,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0264-5802-10,800-227-2862,
Baxter Healthcare,WATER,,04/28/2023,Reverified,IRRIGATION,Sterile Water Irrigant,150985,,ef3e79c5-3f58-4b36-a296-64b7d9a651c1,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",STERILE WATER,"0338-0004, 0338-0003",Baxter Healthcare Corporation,43dc7530-ed0a-4976-af2a-0d39a2532fb7,"0338-0003-44, 0338-0003-46, 0338-0003-47, 0338-0004-02, 0338-0004-03, 0338-0004-04, 0338-0004-05","Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-04)",Irrigant,Available,,NDA017428,,WATER,,,Current,,,,059QF0KO0R,0338-0004-04,888-229-0001,
"Teva Pharmaceuticals USA, Inc.",,,01/06/2025,New,,Ezetimibe; Simvastatin Tablet,,,,01/06/2025,,01/06/2025,Cardiovascular,,,,,,"EZETIMIBE AND SIMVASTATIN, Tablet, 10 mg; 40 mg (NDC 45963-567-08)",Tablet,,,,,,,,To Be Discontinued,,,,,45963-567-08,800-545-8800,
"Hospira, Inc., a Pfizer Company",FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Furosemide Injection,"1719286, 1719290, 1719291",,"aaced7a8-c3d7-4d66-8c07-aa407b8b3f35, 39fd32f2-6bb7-4a65-d298-e48d26bc80c7",08/15/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,0409-6102,"Hospira, Inc.","c529b0df-a5cb-46ce-8131-38674ee756af, 0d4a39f2-904e-434a-9af1-83bb4febf124","0409-6102-35, 0409-6102-25, 0409-6102-36, 0409-6102-26, 0409-6102-37, 0409-6102-27, 0409-6102-19, 0409-6102-02, 0409-6102-18, 0409-6102-04, 0409-6102-20, 0409-6102-10","Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-10)",Injection,Available,"N0000175366, N0000175590",NDA018667,,FUROSEMIDE,Loop Diuretic [EPC],,Current,,,,7LXU5N7ZO5,0409-6102-10,844-646-4398,
"Hikma Pharmaceuticals USA, Inc.",AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","308189, 313850",,d46f1091-33dc-4f8f-9c34-75dcfedb4b4c,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0143-9886, 0143-9887",Hikma Pharmaceuticals USA Inc.,606474e1-adba-4ffa-83d5-6565fc12c892,"0143-9886-01, 0143-9886-50, 0143-9886-75, 0143-9887-01, 0143-9887-50, 0143-9887-75","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0143-9886-75)","Powder, For Suspension",,,ANDA065325,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0143-9886-75,800-631-2174,
Pfizer Inc.,PENICILLIN G BENZATHINE,,04/26/2023,Revised,INTRAMUSCULAR,Penicillin G Benzathine Injection,"731564, 731566, 731567, 731568, 731570, 731571",https://www.fda.gov/media/188355/download,012d46f1-d0a0-4676-a879-cd320297ab16,08/25/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,BICILLIN L-A,"60793-701, 60793-700, 60793-702",Pfizer Laboratories Div Pfizer Inc,4b3694af-9d77-487f-8838-b75aec6636da,"60793-700-01, 60793-700-10, 60793-701-02, 60793-701-10, 60793-702-04, 60793-702-10","Bicillin L-A, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10)",Injection,Limited Availability,,NDA050141,,PENICILLIN G BENZATHINE,,,Current,Other,Shortage per Manufacturer: Manufacturing Delay,,RIT82F58GK,60793-701-10,844-646-4398,
"Hikma Pharmaceuticals USA, Inc.",REMIFENTANIL HYDROCHLORIDE,,06/28/2022,Reverified,INTRAVENOUS,Remifentanil Hydrochloride Injection,"1729578, 1729584, 1729710",,9d289052-1eb6-4ba2-a3ca-d2e542a052ae,07/23/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,REMIFENTANIL HYDROCHLORIDE,"0143-9391, 0143-9392, 0143-9393",Hikma Pharmaceuticals USA Inc.,5c5e498b-d829-4f78-bcca-466631014767,"0143-9391-01, 0143-9391-10, 0143-9392-01, 0143-9392-10, 0143-9393-01, 0143-9393-10","Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10)",Injection,Unavailable,,ANDA210594,,REMIFENTANIL HYDROCHLORIDE,,,Current,Demand increase for the drug,,,5V444H5WIC,0143-9391-10,800-631-2174,
"Novo Nordisk, Inc.",SOMATROPIN,,01/06/2023,Revised,SUBCUTANEOUS,Somatropin Injection,"847243, 847245, 847247, 847348, 849850, 849851, 1736262, 1736329",,1058e17c-9261-459c-a3e6-fae38d196c14,08/28/2025,HUMAN PRESCRIPTION DRUG,,Endocrinology/Metabolism,NORDITROPIN,"0169-7703, 0169-7704, 0169-7705, 0169-7708",Novo Nordisk,b67c2419-4feb-4ce1-b97e-88760a8e1aee,"0169-7704-21, 0169-7704-92, 0169-7705-21, 0169-7705-92, 0169-7708-21, 0169-7708-92, 0169-7703-11, 0169-7703-91, 0169-7703-21, 0169-7703-92","Norditropin, Injection, 30 mg/3 mL (NDC 0169-7703-21)",Injection,,"N0000175606, M0028842",BLA021148,Human Growth Hormone [CS],SOMATROPIN,Recombinant Human Growth Hormone [EPC],Available,Resolved,,,08/28/2025,NQX9KB6PCL,0169-7703-21,609-987-5800,
Accord Healthcare Inc.,AZACITIDINE,,12/21/2020,Revised,"INTRAVENOUS, SUBCUTANEOUS",Azacitidine Injection,485246,,70140e11-33f1-2240-e053-2991aa0a0480,09/16/2025,HUMAN PRESCRIPTION DRUG,,Oncology,AZACITIDINE,16729-306,Accord Healthcare Inc.,28604daf-46a3-ef6c-e063-6394a90a4b27,16729-306-10,"Azacitidine, Injection, 100 mg (NDC 16729-306-10)",Injection,Limited Availability,"N0000000233, N0000175595",ANDA207475,,AZACITIDINE,Nucleoside Metabolic Inhibitor [EPC],,Current,Regulatory delay,30 days,,M801H13NRU,16729-306-10,"866-941-7875, option 2",Nucleic Acid Synthesis Inhibitors [MoA]
"Hospira, Inc., a Pfizer Company",CARBOPLATIN,,04/28/2023,Reverified,INTRAVENOUS,Carboplatin Injection,597195,,47677091-fd20-49af-933c-c9dd2be21de9,08/15/2025,HUMAN PRESCRIPTION DRUG,,Oncology,CARBOPLATIN,"61703-600, 61703-360, 61703-150, 61703-262","Hospira, Inc.",5aa72c15-8033-4559-b257-373371b18958,"61703-360-18, 61703-150-05, 61703-262-05, 61703-600-05","Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05)",Injection,Available,"N0000175413, N0000175073",ANDA077059,,CARBOPLATIN,Platinum-based Drug [EPC],,Current,,,,BG3F62OND5,61703-600-05,844-646-4398,
"Par Pharmaceutical, Inc.",DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"309710, 1718906, 1718909",,1ee59985-4c1d-48f7-b8f9-5584c2d55e08,09/17/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE HYDROCHLORIDE,"42023-146, 42023-186, 42023-187","ENDO USA, Inc.",d518b2d2-b39c-47ac-b45f-8c6a045a8dae,"42023-146-25, 42023-186-20, 42023-187-10","Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 42023-146-25)",Injection,Available,,ANDA203972,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,,Please check wholesalers for inventory,,1018WH7F9I,42023-146-25,800-828-9393,
"Fresenius Kabi USA, LLC",DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795607, 1795609, 1795610, 1795612, 1795616",,576a22d8-5f2f-497e-80ad-1842ca74bb53,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"65219-458, 65219-456, 65219-464, 65219-460, 65219-462","FRESENIUS KABI USA, LLC",efc3b0c9-518a-47db-bb3e-ebdfd4646e9b,"65219-456-05, 65219-456-60, 65219-464-05, 65219-464-50, 65219-458-05, 65219-458-30, 65219-460-05, 65219-460-20, 65219-462-05, 65219-462-10","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-458-30)",Injection,Available,,ANDA207449,,DEXTROSE MONOHYDRATE,,,Current,,Check wholesalers for inventory,,LX22YL083G,65219-458-30,888-386-1300,
Otsuka ICU Medical LLC,DEXTROSE MONOHYDRATE,,10/11/2024,Reverified,INTRAVENOUS,Dextrose Monohydrate 70% Injection,237656,,cdf35d11-fbc8-4f8e-85a8-33220312c0b4,09/17/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,0990-7120,ICU Medical Inc.,48864a1e-7a7d-487b-8d74-969a50b6d032,0990-7120-07,"DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7120-07)",Injection,Available,,NDA019893,,DEXTROSE MONOHYDRATE,,,Current,,"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.",,LX22YL083G,0990-7120-07,1-866-829-9025 or ProductAvailability@icumed.com,
"Fresenius Kabi USA, LLC","EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE ANHYDROUS",,10/14/2016,Revised,"INFILTRATION, PERINEURAL","Epinephrine Bitartrate, Lidocaine Hydrochloride Injection","1010033, 1010035, 1010671, 1010673, 1010688, 1010692, 1010745, 1010749, 1010751, 1010755, 1010759, 1010763, 1010900, 1010902, 1737343, 1737345, 1737562, 1737563, 1737566, 1737567, 1737568, 1737569, 1737570, 1737571, 1737757, 1737758, 1737761, 1737762, 1867938, 1867940, 1867943, 1867944, 1867992, 1867993, 1867996, 1867997, 1868028, 1868029",,ba082c2f-64f4-419d-9c88-74f203316e17,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",XYLOCAINE,"63323-483, 63323-492, 63323-491, 63323-495, 63323-485, 63323-486, 63323-484, 63323-489, 63323-488, 63323-481, 63323-482, 63323-487","Fresenius Kabi USA, LLC",ea480a68-5927-4278-9deb-2956961da428,"63323-492-04, 63323-492-27, 63323-492-09, 63323-492-57, 63323-492-07, 63323-492-37, 63323-492-03, 63323-492-31, 63323-491-01, 63323-491-57, 63323-495-09, 63323-495-27, 63323-495-04, 63323-495-07, 63323-485-01, 63323-485-27, 63323-485-03, 63323-485-57, 63323-486-01, 63323-486-17, 63323-486-02, 63323-486-27, 63323-486-05, 63323-486-57, 63323-484-57, 63323-489-02, 63323-489-27, 63323-489-03, 63323-489-21, 63323-489-01, 63323-489-17, 63323-488-07, 63323-488-37, 63323-488-03, 63323-488-31, 63323-488-01, 63323-488-17, 63323-481-01, 63323-481-57, 63323-483-03, 63323-483-27, 63323-483-01, 63323-483-57, 63323-482-01, 63323-482-17, 63323-482-03, 63323-482-27, 63323-482-05, 63323-482-57, 63323-487-01, 63323-487-17, 63323-487-07, 63323-487-37, 63323-487-03, 63323-487-31","Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-27)",Injection,Available,,NDA006488,,"LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE",,,Current,,Check wholesalers for inventory,,"EC2CNF7XFP, 30Q7KI53AK",63323-483-27,888-386-1300,
"Hikma Pharmaceuticals USA, Inc.",MORPHINE SULFATE,,11/03/2017,Reverified,"EPIDURAL, INTRATHECAL",Morphine Sulfate Injection,"892652, 1731522, 1731998, 1731999",,db9ac9e3-d761-4a99-9f34-4946ebe8f255,07/23/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,INFUMORPH 200,"0641-6039, 0641-6040",Hikma Pharmaceuticals USA Inc.,cd3674c8-d894-4dcf-8044-7a1198ed8ed9,"0641-6039-01, 0641-6040-01","Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 mg/1 mL (NDC 0641-6039-01)",Injection,Available,,NDA018565,,MORPHINE SULFATE,,,Current,,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,X3P646A2J0,0641-6039-01,800-631-2174,
Alvogen,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Revised,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,c907301d-e24d-9609-5529-fed14f94549f,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII","47781-179, 47781-174, 47781-175, 47781-176, 47781-177, 47781-178, 47781-180",Alvogen Inc.,0374f0f7-9297-810c-38b3-623a72709a7d,"47781-174-30, 47781-174-05, 47781-174-01, 47781-175-30, 47781-175-05, 47781-175-01, 47781-176-30, 47781-176-05, 47781-176-01, 47781-177-30, 47781-177-05, 47781-177-01, 47781-178-30, 47781-178-05, 47781-178-01, 47781-179-30, 47781-179-05, 47781-179-01, 47781-180-30, 47781-180-05, 47781-180-01","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 47781-179-01)",Tablet,Available,,ANDA207388,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 20 MG,CLL",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",47781-179-01,844-842-8672 and email: CustomerService-US@alvogen.com,
"Hospira, Inc., a Pfizer Company",SODIUM BICARBONATE,,03/01/2017,Revised,INTRAVENOUS,Sodium Bicarbonate Injection,"727995, 792582",,ea20a5eb-641e-48cd-bcfa-74c04c45dfda,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Pediatric",SODIUM BICARBONATE,"0409-6637, 0409-4916","Hospira, Inc.",56e30ea7-c42d-41cf-a18e-c5eaba620fc0,"0409-4916-24, 0409-4916-14, 0409-6637-24, 0409-6637-14","Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-6637-14)",Injection,Unavailable,,ANDA202494,,SODIUM BICARBONATE,,,Current,Other,Shortage per Manufacturer: Manufacturing Delay,01/03/2025,8MDF5V39QO,0409-6637-14,844-646-4398,
"Teva Pharmaceuticals USA, Inc.",CARBOPLATIN,,04/28/2023,Revised,INTRAVENOUS,Carboplatin Injection,597195,,"f330f5a2-2cad-402f-bcbb-26245a753276, e176b6ef-2ff6-498b-a9d8-7a634d147f37",09/15/2025,HUMAN PRESCRIPTION DRUG,,Oncology,CARBOPLATIN,"0703-4239, 0703-4244, 0703-4246, 0703-4248","Teva Parenteral Medicines, Inc.","bed4c1cf-f3ef-4faa-b2a4-24ee9a9879df, b943761e-6a46-45a0-bdb4-1fec1e101f8c","0703-4244-01, 0703-4246-01, 0703-4248-01, 0703-4239-01, 0703-4244-81, 0703-4246-81, 0703-4248-81, 0703-4239-81","Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01)",Injection,Available,"N0000175413, N0000175073",ANDA077269,,CARBOPLATIN,Platinum-based Drug [EPC],,Current,,,,BG3F62OND5,0703-4239-01,800-545-8800,
Eli Lilly and Co.,DULOXETINE HYDROCHLORIDE,,10/18/2024,New,ORAL,"Duloxetine Hydrochloride Capsule, Delayed Release","596926, 596928, 596930, 596932, 596934, 615186",,2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba,10/18/2024,HUMAN PRESCRIPTION DRUG,10/18/2024,Psychiatry,CYMBALTA,"0002-3240, 0002-3235, 0002-3270",Eli Lilly and Company,aa5061b1-f237-425a-9d05-575c333dfd37,"0002-3235-60, 0002-3240-30, 0002-3240-90, 0002-3270-30","Cymbalta, Capsule, Delayed Release, 30 mg (NDC 0002-3240-30)",Capsule,,,NDA021427,,DULOXETINE HYDROCHLORIDE,,,To Be Discontinued,,Business decision to discontinue,,9044SC542W,0002-3240-30,800-545-5979,
"Sun Pharmaceutical Industries, Inc.",LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Revised,ORAL,"Lisdexamfetamine Dimesylate Tablet, Chewable","854830, 854834, 854838, 854842, 854846, 854850, 1593856, 1871456, 1871460, 1871462, 1871464, 1871466, 1871468",,da3148af-f9b6-4725-adae-3595b4c7dc4b,09/22/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"57664-085, 57664-047, 57664-046, 57664-048, 57664-049, 57664-050, 57664-051, 57664-052, 57664-083, 57664-084, 57664-086, 57664-087, 57664-088","Sun Pharmaceutical Industries, Inc.",0b77417a-5789-8818-e063-6294a90ad2e3,"57664-047-88, 57664-046-88, 57664-048-88, 57664-049-88, 57664-050-88, 57664-051-88, 57664-052-88, 57664-083-88, 57664-084-88, 57664-085-88, 57664-086-88, 57664-087-88, 57664-088-88","Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 57664-085-88)","Tablet, Chewable",Limited Availability,,ANDA214134,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Other,Available Q3 2025,,SJT761GEGS,57664-085-88,800-818-4555,
"Hikma Pharmaceuticals USA, Inc.",MORPHINE SULFATE,,11/03/2017,Reverified,INTRAVENOUS,Morphine Sulfate Injection,"1731993, 1732006, 1732011",,6023606c-150c-40c5-9175-598efe2a56c3,07/23/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,MORPHINE SULFATE,"0641-6127, 0641-6126, 0641-6125",Hikma Pharmaceuticals USA Inc.,fa18221d-2353-4cf6-a210-fb33ee79d3d9,"0641-6126-01, 0641-6126-25, 0641-6127-01, 0641-6127-25, 0641-6125-01, 0641-6125-25","Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)",Injection,Available,,ANDA205758,,MORPHINE SULFATE,,,Current,,Additional lots are scheduled to be manufactured. Product will be made available as it is released.,,X3P646A2J0,0641-6127-25,800-631-2174,
Alvogen,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,c907301d-e24d-9609-5529-fed14f94549f,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII","47781-176, 47781-174, 47781-175, 47781-177, 47781-178, 47781-179, 47781-180",Alvogen Inc.,0374f0f7-9297-810c-38b3-623a72709a7d,"47781-174-30, 47781-174-05, 47781-174-01, 47781-175-30, 47781-175-05, 47781-175-01, 47781-176-30, 47781-176-05, 47781-176-01, 47781-177-30, 47781-177-05, 47781-177-01, 47781-178-30, 47781-178-05, 47781-178-01, 47781-179-30, 47781-179-05, 47781-179-01, 47781-180-30, 47781-180-05, 47781-180-01","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 47781-176-01)",Tablet,Available,,ANDA207388,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 10 MG,CLL",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",47781-176-01,844-842-8672 and email: CustomerService-US@alvogen.com,
Sun Pharmaceutical Industries Limited,DIGOXIN,,12/05/2024,New,ORAL,Digoxin Tablet,"197604, 197606",,62795623-a2bc-4dd2-8989-3b9782bfd80e,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Cardiovascular,DIGOXIN,"57664-441, 57664-437","Sun Pharmaceutical Industries, Inc.",1a3e469c-1452-3d1e-e063-6394a90ae73a,"57664-437-88, 57664-437-18, 57664-441-88, 57664-441-18","Digoxin, Tablet, 250 ug (NDC 57664-441-88)",Tablet,,"N0000175568, M0003451",ANDA076363,Cardiac Glycosides [CS],DIGOXIN,Cardiac Glycoside [EPC],,To Be Discontinued,,Discontinuing for business reasons,,73K4184T59,57664-441-88,800-818-4555,
"Teva Pharmaceuticals USA, Inc.",ESZOPICLONE,,06/26/2025,New,ORAL,Eszopiclone Tablet,"485440, 485442, 485465",,2435e2f1-bc52-488f-80e9-f1758e354aae,06/26/2025,HUMAN PRESCRIPTION DRUG,06/26/2025,Neurology,ESZOPICLONE,"0093-5539, 0093-5537, 0093-5538","Teva Pharmaceuticals USA, Inc.",b7cc855f-8510-4cb2-a941-18d3c4472236,"0093-5537-56, 0093-5538-01, 0093-5539-01","Eszopiclone, Tablet, 3 mg (NDC 0093-5539-01)",Tablet,,,ANDA091169,,ESZOPICLONE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,UZX80K71OE,0093-5539-01,800-545-8800,
Nephron Pharmaceuticals Corporation,WATER,,11/23/2021,Reverified,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Sterile Water Injection,,,bc04a883-babc-87a6-e053-2995a90a3dfd,09/15/2025,HUMAN PRESCRIPTION DRUG,,Other,STERILE WATER,0487-6105,Nephron Pharmaceuticals Corporation,39ada97d-53b0-5144-e063-6294a90a91ba,0487-6105-01,"Sterile Water, Injection, 1 mL/1 mL (NDC 0487-6105-01)",Injection,Unavailable,,ANDA211222,,STERILE WATER,,,Current,Other,Product can be manufactured as requested,,059QF0KO0R,0487-6105-01,800-443-4313,
"Hospira, Inc., a Pfizer Company","BUPIVACAINE HYDROCHLORIDE, EPINEPHRINE BITARTRATE",,02/20/2018,Revised,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL","Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection","1012377, 1012381, 1012384, 1012388, 1012396, 1012400, 1012404, 1012406, 1672917, 1672919, 1673242, 1673243, 1724786, 1724787, 1724794, 1724796, 1724880, 1724884, 1725044, 1725046, 1725078, 1725079, 1725082, 1725083, 1867594, 1867596, 1867612, 1867614",,67578b56-7540-487e-1fba-481255620e78,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,MARCAINE WITH EPINEPHRINE,"0409-1746, 0409-1559, 0409-1560, 0409-1582, 0409-1587, 0409-1610, 0409-1749, 0409-1752, 0409-1755, 0409-2510, 0409-7535, 0409-1250, 0409-5010, 0409-1530, 0409-0525, 0409-7510, 0409-2253","Hospira, Inc.",b083f440-bfb7-449a-b601-c2f59a6f9dcf,"0409-1559-18, 0409-1559-10, 0409-1559-19, 0409-1559-30, 0409-1560-18, 0409-1560-10, 0409-1560-19, 0409-1560-29, 0409-1582-18, 0409-1582-10, 0409-1582-19, 0409-1582-29, 0409-1587-50, 0409-1610-50, 0409-1746-70, 0409-1746-10, 0409-1746-71, 0409-1746-30, 0409-1749-70, 0409-1749-10, 0409-1749-71, 0409-1749-29, 0409-1752-50, 0409-1755-50, 0409-2510-01, 0409-2510-25, 0409-7535-01, 0409-7535-25, 0409-1250-01, 0409-1250-25, 0409-5010-01, 0409-5010-25, 0409-1530-01, 0409-1530-25, 0409-0525-01, 0409-0525-25, 0409-7510-01, 0409-7510-25, 0409-2253-01, 0409-2253-25","Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-30)",Injection,Limited Availability,,NDA016964,,BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE,,,Current,Other,Limited Supply Available. Next Delivery: August 2025; Estimated Recovery: September 2025,,"30Q7KI53AK, 7TQO7W3VT8",0409-1746-30,844-646-4398,
SpecGx LLC,METHYLPHENIDATE HYDROCHLORIDE,,07/26/2023,Reverified,ORAL,"Methylphenidate Hydrochloride Tablet, Extended Release","2001565, 2001566, 2001568",,b1b0f2ff-d9df-42ab-b471-226ecf97e075,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE,"0406-0127, 0406-0136, 0406-0154",SpecGx LLC,7a3a8731-e545-455e-83c3-888f4923e901,"0406-0127-01, 0406-0136-01, 0406-0154-01","Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 0406-0127-01)",Tablet,Unavailable,,ANDA202608,,METHYLPHENIDATE HYDROCHLORIDE,,,Current,Shortage of an active ingredient,Backorder expected with next release expected in October 2025.,,4B3SC438HI,0406-0127-01,800-325-8888,
"Hospira, Inc., a Pfizer Company",MIDAZOLAM HYDROCHLORIDE,,04/02/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Midazolam Hydrochloride Injection,"1666800, 1666814, 1666823, 1666798",,"b95415fa-17c2-42ab-a6b0-e628d01c94ed, 1abda8b8-48a8-4995-af86-39220d1aa240",08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Neurology",MIDAZOLAM,"0409-2305, 0409-2308, 0409-0001","Hospira, Inc.","b303a281-6633-47d5-bf29-5e9055e26da6, 8c3cf34b-901d-407a-946d-a1556bb24551","0409-2305-55, 0409-2305-50, 0409-2308-69, 0409-2308-49, 0409-2308-70, 0409-2308-50, 0409-2305-16, 0409-2305-17, 0409-2305-04, 0409-2305-05, 0409-2308-21, 0409-2308-01, 0409-2308-22, 0409-2308-02, 0409-0001-01, 0409-0001-25","Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)",Injection,Available,,ANDA075857,,MIDAZOLAM HYDROCHLORIDE,,,Current,,,,W7TTW573JJ,0409-2305-17,844-646-4398,
"Fresenius Kabi USA, LLC",ROPIVACAINE HYDROCHLORIDE,,03/23/2018,Reverified,"EPIDURAL, PERINEURAL",Ropivacaine Hydrochloride Injection,"905189, 905191, 1734084, 1734086, 1734090, 1734091, 1734203, 1734204, 1734207, 1734208, 1734347, 1734348, 1734355, 1734356, 1734475, 1734476, 1734479, 1734480, 1734481, 1734482, 1734483, 1734484",,23d2d448-a744-4877-9f2d-7e57c198da89,09/18/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,NAROPIN,"63323-287, 63323-286, 63323-288, 63323-285","Fresenius Kabi USA, LLC",cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9,"63323-286-01, 63323-286-20, 63323-286-05, 63323-286-23, 63323-286-09, 63323-286-31, 63323-286-11, 63323-286-35, 63323-286-03, 63323-286-00, 63323-286-33, 63323-286-63, 63323-286-30, 63323-287-01, 63323-287-20, 63323-287-03, 63323-287-21, 63323-288-01, 63323-288-10, 63323-288-06, 63323-288-20, 63323-288-03, 63323-288-11, 63323-288-07, 63323-288-21, 63323-285-01, 63323-285-10, 63323-285-06, 63323-285-20, 63323-285-03, 63323-285-13, 63323-285-07, 63323-285-23, 63323-285-57, 63323-285-64, 63323-285-51, 63323-285-65, 63323-285-02, 63323-285-61, 63323-285-04, 63323-285-63","Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-21)",Injection,Available,,NDA020533,,ROPIVACAINE HYDROCHLORIDE,,,Current,,,,V910P86109,63323-287-21,888-386-1300,
"Hikma Pharmaceuticals USA, Inc.",WATER,,11/23/2021,Reverified,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Sterile Water Injection,,,78ef7ad3-451d-43d0-a9b6-5cf0aadca003,07/23/2025,HUMAN PRESCRIPTION DRUG,,Other,STERILE WATER,0641-6147,Hikma Pharmaceuticals USA Inc.,081540ac-58cf-437f-ba1b-86d5264ec3dc,"0641-6147-01, 0641-6147-10, 0641-6147-25","Sterile Water, Injection, 1 mL/1 mL (NDC 0641-6147-10)",Injection,Available,,ANDA206369,,WATER,,,Current,,Additional lots will be scheduled for manufacturing. Product will be made available as it is released.,,059QF0KO0R,0641-6147-10,800-631-2174,
"Hospira, Inc., a Pfizer Company",VANCOMYCIN HYDROCHLORIDE,,09/09/2025,New,INTRAVENOUS,Vancomycin Hydrochloride Injection,"1807513, 1807516, 1807518, 2049890",,"2fd9de3f-a95f-451c-a687-d2e1306e53bf, f2901045-904f-47bd-74a1-c561facd7f25",09/09/2025,HUMAN PRESCRIPTION DRUG,09/09/2025,Anti-Infective,VANCOMYCIN HYDROCHLORIDE,"0409-6531, 0409-6535, 0409-6534, 0409-6533, 0409-4332, 0409-3515","Hospira, Inc.","771a44e0-5858-449c-be36-438a9ff52e67, 6b13ef5a-c456-4bcf-a9ec-ddc91bbd809a","0409-6531-11, 0409-6531-01, 0409-6535-11, 0409-6535-01, 0409-6534-11, 0409-6534-01, 0409-6531-12, 0409-6531-02, 0409-6533-11, 0409-6533-01, 0409-6533-21, 0409-4332-11, 0409-4332-01, 0409-3515-11, 0409-3515-01","Vancomycin Hydrochloride, Injection, 750 mg Single Dose ADD-Vantage® Glass Vial (NDC 0409-6531-01)",Injection,,,"ANDA062933, ANDA062912",,VANCOMYCIN HYDROCHLORIDE,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,71WO621TJD,0409-6531-01,844-646-4398,
"Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)",FONDAPARINUX SODIUM,,09/29/2025,New,SUBCUTANEOUS,Fondaparinux Sodium Injection,"861356, 861360, 861363, 861365",,baa50757-a927-4d56-a933-5d7798fe6ab0,09/29/2025,HUMAN PRESCRIPTION DRUG,09/29/2025,Hematology,FONDAPARINUX SODIUM,"0781-3443, 0781-3454, 0781-3465, 0781-3476",Sandoz Inc.,3d5a4b69-462b-7e51-e063-6294a90a0721,"0781-3443-94, 0781-3443-12, 0781-3443-95, 0781-3454-94, 0781-3454-12, 0781-3454-95, 0781-3465-94, 0781-3465-12, 0781-3465-95, 0781-3476-94, 0781-3476-12, 0781-3476-95","Fondaparinux Sodium, Injection, 2.5 mg/.5 mL (NDC 0781-3443-95)",Injection,,,ANDA206812,,FONDAPARINUX SODIUM,,,To Be Discontinued,,Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc.,,X0Q6N9USOZ,0781-3443-95,"609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)",
Janssen Pharmaceuticals,HALOPERIDOL DECANOATE,,04/07/2025,New,INTRAMUSCULAR,Haloperidol Decanoate Injection,"1719803, 1719862",,9f0f42a8-5f7c-4be7-93ef-3ec225502cc6,04/07/2025,HUMAN PRESCRIPTION DRUG,04/07/2025,Psychiatry,HALOPERIDOL DECANOATE,"10147-0922, 10147-0921",Patriot Pharmaceuticals LLC,2e815b50-b5db-72e4-e063-6294a90afd55,"10147-0921-3, 10147-0922-5","Haloperidol Decanoate, Injection, 100 mg/1 mL (NDC 10147-0922-5)",Injection,,,NDA018701,,HALOPERIDOL DECANOATE,,,To Be Discontinued,,Marketed by Patriot Pharmaceuticals LLC; Last batch expiration date 10/31/2025,,AC20PJ4101,10147-0922-5,800-526-7736,
Pfizer Inc.,METHYLPREDNISOLONE ACETATE,,12/15/2021,Reverified,"INTRALESIONAL, INTRAMUSCULAR, INTRASYNOVIAL, SOFT TISSUE, INTRA-ARTICULAR",Methylprednisolone Acetate Injection,"1743779, 1743781, 1743855, 1743856",,"bf1b104d-85cb-414d-a366-78068c82c883, 9a7b3837-e038-48bf-97e9-78ad463760dc",08/15/2025,HUMAN PRESCRIPTION DRUG,,Rheumatology,DEPO-MEDROL,"0009-3073, 0009-3475",Pharmacia & Upjohn Company LLC,"d7ccf8b4-deb4-43c1-b67b-1f610d6d8425, befd723e-d1e2-41b9-83f1-17bca0c2a941","0009-3073-22, 0009-3073-23, 0009-3475-22, 0009-3475-23, 0009-3073-01, 0009-3073-03, 0009-3475-01, 0009-3475-03","Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)",Injection,Available,,NDA011757,,METHYLPREDNISOLONE ACETATE,,,Current,,,,43502P7F0P,0009-3073-22,844-646-4398,
Actelion Pharmaceuticals,BOSENTAN,,06/09/2025,New,ORAL,Bosentan Tablet,"349253, 352066, 656659, 656660, 1989081, 1989085",,749e42fb-2fe0-45dd-9268-b43bb3f4081c,06/09/2025,HUMAN PRESCRIPTION DRUG,06/09/2025,Cardiovascular,TRACLEER,"66215-101, 66215-102, 66215-103, 66215-232","Actelion Pharmaceuticals US, Inc.",3bb9bd6a-b0d2-0723-e063-6394a90afc46,"66215-101-06, 66215-101-03, 66215-102-06, 66215-102-03, 66215-103-14, 66215-103-56, 66215-232-14, 66215-232-56","Tracleer, Tablet, 62.5 mg (NDC 66215-101-03)",Tablet,,,NDA021290,,BOSENTAN,,,To Be Discontinued,,,,Q326023R30,66215-101-03,800-526-7736,
Rubicon Research Private Limited,CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"72888-153, 72888-152, 72888-154",Advagen Pharma Ltd,36cf156e-5980-a21b-e063-6294a90ab3a0,"72888-152-30, 72888-152-01, 72888-152-05, 72888-152-00, 72888-153-30, 72888-153-01, 72888-153-05, 72888-153-00, 72888-154-30, 72888-154-01, 72888-154-05, 72888-154-00","Clonazepam, Tablet, 1 mg (NDC 72888-153-00)",Tablet,Information pending,"N0000175694, M0002356",ANDA075468,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,Marketed by Advagen Pharma Ltd.,,5PE9FDE8GB,72888-153-00,sales@advagenpharma.com,
Pfizer Inc.,"ESTROGENS, ESTERIFIED",,07/29/2025,New,ORAL,Esterified Estrogens Tablet,"197666, 197667, 197668, 197669, 212039, 212232, 212373, 212464",,e0141598-0bb2-4cf0-c9b8-6867b34bbb17,07/29/2025,HUMAN PRESCRIPTION DRUG,07/29/2025,Endocrinology/Metabolism,MENEST,"61570-074, 61570-072, 61570-073, 61570-075",Pfizer Laboratories Div Pfizer Inc,78aaf71c-8f0d-47c4-9fcf-f5e7e9b84bfb,"61570-072-01, 61570-073-01, 61570-074-01, 61570-075-50","Menest, Tablet, 1.25 mg (NDC 61570-074-01)",Tablet,,,ANDA084950,,ESTERIFIED ESTROGENS,,,To Be Discontinued,,Discontinuation of the manufacture of the drug,,3ASP8Q3768,61570-074-01,800-533-4535,
"Caplin Steriles, Ltd.",ETOMIDATE,General Anesthesia [PE],10/05/2022,Reverified,INTRAVENOUS,Etomidate Injection,"1654006, 1654008",,75467058-da52-48fa-8d4e-e1025ec7d461,09/16/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ETOMIDATE,"72485-508, 72485-509",Armas Pharmaceuticals Inc.,7444860b-36c1-459d-94ba-d7301d9dc2ca,"72485-508-01, 72485-508-10, 72485-509-01, 72485-509-10","Etomidate, Injection, 2 mg/mL (NDC 72485-508-10)",Injection,Available,"N0000175975, N0000175681",ANDA215028,,ETOMIDATE,General Anesthetic [EPC],,Current,,"Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586",,Z22628B598,72485-508-10,908-803-2586,
"Hospira, Inc., a Pfizer Company",HYDROMORPHONE HYDROCHLORIDE,,10/31/2017,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Hydromorphone Hydrochloride Injection,"897756, 897757, 1433251, 1724383, 1724644, 1872271, 2675350, 897653, 897753, 897758, 1724276",,"f9ca2ef5-46d8-475a-a26e-f7c8becd6db7, e9c9ef18-7dfc-4322-b2fc-29b934c30f8b",08/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,HYDROMORPHONE HYDROCHLORIDE,"0409-1283, 0409-1312, 0409-1380, 0409-4264, 0409-1805, 0409-2552, 0409-3356, 0409-2540, 0409-3365, 0409-1304","Hospira, Inc.","53b6867a-0ae3-48ff-b257-9e58cc76de9c, 58ff0e68-b78f-4ebd-a91b-b53bbdefc544","0409-1283-17, 0409-1283-37, 0409-1312-16, 0409-1312-36, 0409-1380-11, 0409-1380-01, 0409-4264-11, 0409-4264-01, 0409-1805-10, 0409-1805-01, 0409-2552-11, 0409-2552-01, 0409-3356-11, 0409-3356-01, 0409-2540-11, 0409-2540-01, 0409-3365-11, 0409-3365-01, 0409-3365-10, 0409-1283-03, 0409-1283-31, 0409-1283-09, 0409-1283-10, 0409-1283-04, 0409-1283-05, 0409-1312-03, 0409-1312-30, 0409-1312-09, 0409-1312-10, 0409-1304-03, 0409-1304-31","Hydromorphone Hydrochloride, Injection, 1 mg/1 mL Syringes (NDC 0409-1283-31)",Injection,Limited Availability,,NDA200403,,HYDROMORPHONE HYDROCHLORIDE,,,Current,Other,Limited Supply Available. Next Delivery: September 2025; Estimated Recovery: December 2025,01/02/2025,L960UP2KRW,0409-1283-31,844-646-4398,
Aurobindo Pharma USA,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,a582d57f-d191-4ca5-b105-585b2d8a0e3e,09/17/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","13107-068, 13107-069, 13107-070, 13107-071, 13107-072, 13107-073, 13107-074","Aurolife Pharma, LLC",95842af2-8d9d-4eb1-ba39-86cdbd829a79,"13107-068-50, 13107-068-01, 13107-068-25, 13107-068-05, 13107-068-99, 13107-069-50, 13107-069-01, 13107-069-25, 13107-069-05, 13107-069-99, 13107-070-50, 13107-070-01, 13107-070-25, 13107-070-05, 13107-070-99, 13107-071-50, 13107-071-01, 13107-071-25, 13107-071-05, 13107-071-99, 13107-072-50, 13107-072-01, 13107-072-25, 13107-072-05, 13107-072-99, 13107-073-50, 13107-073-01, 13107-073-25, 13107-073-05, 13107-073-99, 13107-074-50, 13107-074-01, 13107-074-25, 13107-074-05, 13107-074-99","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 13107-068-01)",Tablet,Unavailable,,ANDA202424,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,Shortage of an active ingredient,Estimated availability December 2025,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",13107-068-01,(866) 850-2876 or CustomerService@AurobindoUSA.com,
"Teva Pharmaceuticals USA, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Revised,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541365, 541878, 541879, 541892, 541894, 577957, 577960, 577961, 577962, 687043, 687045, 1009145, 1009147",,f22635fe-821d-4cde-aa12-419f8b53db81,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,ADDERALL,"57844-117, 57844-105, 57844-110, 57844-112, 57844-115, 57844-120, 57844-130","Teva Pharmaceuticals USA, Inc.",79af1dc6-c7cf-41b1-a750-e9b47c2187ff,"57844-105-01, 57844-117-01, 57844-110-01, 57844-112-01, 57844-115-01, 57844-120-01, 57844-130-01","Adderall, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 57844-117-01)",Tablet,Available,,ANDA040422,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",57844-117-01,800-545-8800,
"Hospira, Inc., a Pfizer Company",WATER,,11/23/2021,Reverified,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Sterile Water Injection,,,2b9ea23a-f9e9-48a8-25b7-519e3bbd6828,08/15/2025,HUMAN PRESCRIPTION DRUG,,Other,STERILE WATER,0409-4887,"Hospira, Inc.",900859c0-a075-4fb1-98ce-0e329acc009a,"0409-4887-25, 0409-4887-99, 0409-4887-31, 0409-4887-05, 0409-4887-17, 0409-4887-10, 0409-4887-32, 0409-4887-34, 0409-4887-23, 0409-4887-20, 0409-4887-24, 0409-4887-50","Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-99)",Injection,Available,,NDA018801,,WATER,,,Current,,,,059QF0KO0R,0409-4887-99,844-646-4398,
Pfizer Inc.,CLINDAMYCIN PHOSPHATE,,03/21/2023,Revised,"INTRAMUSCULAR, INTRAVENOUS",Clindamycin Phosphate Injection,"1737244, 1737245, 1737578, 1737579, 1737581, 1737582",,a0a2eff7-b7de-42fe-8e5a-0cfbed38bb4b,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,CLEOCIN PHOSPHATE,"0009-4073, 0009-3051, 0009-5095",Pharmacia & Upjohn Company LLC,9c0a7367-763b-48c3-95b1-173b74c50f4b,"0009-3051-01, 0009-3051-02, 0009-4073-03, 0009-4073-04, 0009-5095-05, 0009-5095-06","Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL) (NDC 0009-4073-04)",Injection,Available,,NDA050441,,CLINDAMYCIN PHOSPHATE,,,Current,,,,EH6D7113I8,0009-4073-04,800-533-4535,
Sun Pharmaceutical Industries Limited,DESMOPRESSIN ACETATE,,12/05/2024,New,"INTRAVENOUS, SUBCUTANEOUS",Desmopressin Acetate Injection,849501,,"9fd48eec-aa24-4888-b99f-d409ada958a7, 2dc2cec8-6953-4a33-9356-11534fba1fb8",12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Endocrinology/Metabolism,DESMOPRESSIN ACETATE,62756-529,"Sun Pharmaceutical Industries, Inc.","ec29b269-1ce9-4199-ab07-a51d3e55d604, 129770b0-b59a-4ee3-bc07-2168544c1424","62756-529-40, 62756-529-26","Desmopressin Acetate, Injection, 4 ug/1 mL (NDC 62756-529-40)",Injection,,,ANDA091280,,DESMOPRESSIN ACETATE,,,To Be Discontinued,,Discontinuing for business reasons,,XB13HYU18U,62756-529-40,800-818-4555,
"Fresenius Kabi USA, LLC",FUROSEMIDE,Increased Diuresis at Loop of Henle [PE],04/07/2020,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Furosemide Injection,"1719286, 1719290, 1719291",,"3747bbcd-783d-4baa-bb5b-b6827bf390e3, c794c95a-654e-48fe-9596-201fc122ff75",09/18/2025,HUMAN PRESCRIPTION DRUG,,Cardiovascular,FUROSEMIDE,63323-280,"Fresenius Kabi USA, LLC","9804efac-5457-417a-8de7-a688467759c0, 64b3fb5f-3516-4e39-b74e-e0e402ed9c4d","63323-280-41, 63323-280-16, 63323-280-43, 63323-280-26, 63323-280-45, 63323-280-36, 63323-280-01, 63323-280-02, 63323-280-03, 63323-280-04, 63323-280-05, 63323-280-10","Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-04)",Injection,Available,"N0000175366, N0000175590",NDA018902,,FUROSEMIDE,Loop Diuretic [EPC],,Current,,Check wholesalers for inventory,,7LXU5N7ZO5,63323-280-04,888-386-1300,
"Hikma Pharmaceuticals USA, Inc.",LEUCOVORIN CALCIUM,,01/01/2012,Revised,"INTRAMUSCULAR, INTRAVENOUS",Leucovorin Calcium Injection,"237788, 1803930, 1803932, 1803937",,cc52077f-5663-4f79-a273-0aecf655e038,07/08/2025,HUMAN PRESCRIPTION DRUG,,"Oncology, Pediatric",LEUCOVORIN CALCIUM,"0143-9554, 0143-9555, 0143-9553, 0143-9552",Hikma Pharmaceuticals USA Inc.,e2d1484b-2920-45ab-9207-4caa5285fef4,"0143-9555-01, 0143-9554-01, 0143-9553-01, 0143-9552-01","Leucovorin Calcium, Injection, 100 mg/10 mL (NDC 0143-9554-01)",Injection,,,ANDA089717,,LEUCOVORIN CALCIUM,,Available,Resolved,,,07/08/2025,RPR1R4C0P4,0143-9554-01,800-631-2174,
"Hospira, Inc., a Pfizer Company",LIDOCAINE HYDROCHLORIDE,,02/22/2012,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010671, 1010900, 1737343, 1737562, 1737566, 1737568, 1737636, 1737757, 1737763",,3b2dd84e-cee8-4e58-d494-395a65a353a0,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE HYDROCHLORIDE,"0409-4713, 0409-4278, 0409-4279, 0409-4776, 0409-4282, 0409-4277, 0409-4276, 0409-4275","Hospira, Inc.",c0b4635b-1473-4c48-89c6-620762cd687f,"0409-4713-12, 0409-4713-26, 0409-4713-02, 0409-4713-72, 0409-4713-62, 0409-4713-75, 0409-4713-65, 0409-4713-42, 0409-4713-25, 0409-4713-32, 0409-4278-16, 0409-4278-01, 0409-4279-16, 0409-4279-02, 0409-4776-10, 0409-4776-01, 0409-4282-11, 0409-4282-25, 0409-4282-01, 0409-4282-12, 0409-4282-02, 0409-4277-16, 0409-4277-01, 0409-4277-17, 0409-4277-02, 0409-4276-16, 0409-4276-01, 0409-4276-17, 0409-4276-02, 0409-4275-16, 0409-4275-01","Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/2 mL (1%; 10 mg/mL) (NDC 0409-4713-32)",Injection,Available,,ANDA080408,,LIDOCAINE HYDROCHLORIDE,,,Current,,,,V13007Z41A,0409-4713-32,844-646-4398,
"Mylan Institutional, a Viatris Company",ROCURONIUM BROMIDE,,02/15/2023,Reverified,INTRAVENOUS,Rocuronium Bromide Injection,,,f58803b0-f173-4997-b2f8-0f415b94dacf,09/17/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,ROCURONIUM BROMIDE,67457-228,Mylan Institutional LLC,3316cfdc-67e7-437d-9c90-1c383b53b272,"67457-228-00, 67457-228-05, 67457-228-99, 67457-228-10","Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-10)",Injection,Available,,ANDA079199,,ROCURONIUM BROMIDE,,,Current,,,,I65MW4OFHZ,67457-228-10,800-796-9526,
Sandoz Inc.,"AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577961",,288dafc4-fe6e-4891-832f-511022c87445,09/24/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","0185-0842, 0185-0831, 0185-0853, 0185-0864, 0185-2099, 0185-2098",Sandoz Inc,d68cd1d1-3bb4-4afa-9786-687cf1766ae1,"0185-0831-01, 0185-0842-01, 0185-0853-01, 0185-0864-01, 0185-2099-01, 0185-2098-01","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0185-0842-01)",Tablet,Available,,ANDA040439,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",0185-0842-01,800-525-8747,
"Hospira, Inc., a Pfizer Company",SODIUM CHLORIDE,,12/08/2021,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Sodium Chloride 0.9% Injection,313002,,376093e7-e09e-4a57-3199-195e45251866,08/08/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",BACTERIOSTATIC SODIUM CHLORIDE,0409-1966,"Hospira, Inc.",2d3125e0-c89b-46d5-a350-07d1e7936ebd,"0409-1966-02, 0409-1966-07, 0409-1966-06, 0409-1966-12, 0409-1966-01, 0409-1966-05","Bacteriostatic Sodium Chloride 0.9% In Plastic Container, Injection, 9% (9 mg/1 mL) (NDC 0409-1966-05)",Injection,,,NDA018800,,SODIUM CHLORIDE,,Available,Resolved,,,08/08/2025,451W47IQ8X,0409-1966-05,844-646-4398,
"Teva Pharmaceuticals USA, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Revised,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,cffbbb15-d776-41ae-a8a6-687f2c07bfa4,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","0555-0974, 0555-0971, 0555-0775, 0555-0972, 0555-0776, 0555-0777, 0555-0973","Teva Pharmaceuticals USA, Inc.",88468f3d-7d03-4cee-aabf-3abc8c9b5e38,"0555-0971-02, 0555-0775-02, 0555-0972-02, 0555-0776-02, 0555-0777-02, 0555-0973-02, 0555-0974-02","Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0555-0974-02)",Tablet,Limited Availability,,ANDA040422,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,Other,Limited Availability,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",0555-0974-02,800-545-8800,
Pfizer Inc.,VORICONAZOLE,,07/28/2025,New,ORAL,Voriconazole Tablet,"349434, 349435, 351209, 352218, 352219, 352220, 465355, 546624",,ce3ef5cf-3087-4d92-9d94-9eb8287228db,07/28/2025,HUMAN PRESCRIPTION DRUG,07/28/2025,Anti-Infective,VFEND,"0049-3170, 0049-3180, 0049-3190, 0049-3160",Roerig,c73f8708-e113-451e-a49b-ed5da19e60db,"0049-3170-30, 0049-3180-30, 0049-3190-28, 0049-3160-44","Vfend, Tablet, 50 mg (NDC 0049-3170-30)",Tablet,,"N0000175487, M0002083, N0000182141, N0000182140, N0000185504",NDA021266,Azoles [CS],VORICONAZOLE,Azole Antifungal [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,JFU09I87TR,0049-3170-30,800-533-4535,"Cytochrome P450 3A4 Inhibitors [MoA], Cytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 2C9 Inhibitors [MoA]"
Pfizer Inc.,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718900, 1718902, 1718906, 1718907, 1718909, 1718910, 2396891, 2396892",,4419162d-81d4-49bd-96de-1729440bdb74,08/15/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,PRECEDEX,"0409-1454, 0409-3301, 0409-1174, 0409-2815","Hospira, Inc.",8d48de06-361f-418b-bfec-8ef85f94d5bc,"0409-1454-01, 0409-1454-20, 0409-3301-01, 0409-3301-10, 0409-1174-01, 0409-1174-10, 0409-2815-01","Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1454-20)",Injection,Available,,NDA021038,,DEXMEDETOMIDINE HYDROCHLORIDE,,,Current,,,,1018WH7F9I,0409-1454-20,844-646-4398,
"Hospira, Inc., a Pfizer Company",DOBUTAMINE HYDROCHLORIDE,,11/06/2017,Revised,INTRAVENOUS,Dobutamine Hydrochloride Injection,1812168,,"dc537761-d5f4-488d-24ab-b2bcd2b17b7a, 89becb0c-da60-4f43-0a98-29ff7a9eca58",08/15/2025,HUMAN PRESCRIPTION DRUG,,"Cardiovascular, Pediatric, Renal",DOBUTAMINE,0409-2344,"Hospira, Inc.","e71e9520-871b-479d-9652-1857fceca863, 5d6b1dfe-d679-4aea-97a6-3d074a202afe","0409-2344-01, 0409-2344-62, 0409-2344-02, 0409-2344-68, 0409-2344-88","Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-88)",Injection,Unavailable,,ANDA074086,,DOBUTAMINE,,,Current,Other,Shortage per Manufacturer: Manufacturing Delay,,0WR771DJXV,0409-2344-88,844-646-4398,
"Hospira, Inc., a Pfizer Company",HYDROMORPHONE HYDROCHLORIDE,,11/01/2017,Revised,"INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS",Hydromorphone Hydrochloride Injection,"897756, 897757, 1433251, 1724383, 1724644, 1872271, 2675350",,f9ca2ef5-46d8-475a-a26e-f7c8becd6db7,08/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,HYDROMORPHONE HYDROCHLORIDE,"0409-4264, 0409-1283, 0409-1312, 0409-1380, 0409-1805","Hospira, Inc.",53b6867a-0ae3-48ff-b257-9e58cc76de9c,"0409-1283-17, 0409-1283-37, 0409-1312-16, 0409-1312-36, 0409-1380-11, 0409-1380-01, 0409-4264-11, 0409-4264-01, 0409-1805-10, 0409-1805-01","Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)",Injection,Unavailable,,NDA200403,,HYDROMORPHONE HYDROCHLORIDE,,,Current,Demand increase for the drug,Next Delivery: August 2025; Estimated Recovery: December 2025,,L960UP2KRW,0409-4264-01,844-646-4398,
"Hospira, Inc., a Pfizer Company",,,11/01/2017,Revised,,Hydromorphone Hydrochloride Injection,,,,01/13/2025,,01/13/2025,Analgesia/Addiction,,,,,,"Injection, 1 mg/1 mL (NDC 0409-2552-01)",Injection,,,,,,,,To Be Discontinued,,Discontinuation of the manufacture of the drug.,01/13/2025,,0409-2552-01,844-646-4398,
"Fresenius Kabi USA, LLC",KETOROLAC TROMETHAMINE,,03/23/2018,Reverified,"INTRAMUSCULAR, INTRAVENOUS",Ketorolac Tromethamine Injection,"860113, 860114, 860115",,3d88cbe6-5230-47aa-80af-0c41283d1f00,09/18/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,KETOROLAC TROMETHAMINE,"76045-107, 76045-104, 76045-105, 76045-209","Fresenius Kabi USA, LLC",0dab642d-7fcf-4301-8ac9-10e64a040c6b,"76045-104-10, 76045-105-20, 76045-107-10, 76045-209-00, 76045-209-10","Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 76045-107-10)",Injection,Unavailable,,ANDA203242,,KETOROLAC TROMETHAMINE,,,Current,Other,Not available at this time.,,4EVE5946BQ,76045-107-10,888-386-1300,
Kindos Pharmaceuticals Co. Ltd.,LEUCOVORIN CALCIUM,,01/01/2012,Revised,"INTRAMUSCULAR, INTRAVENOUS",Leucovorin Calcium Injection,"237788, 1803930, 1803932, 1803937, 2055036",,9df20901-6980-4d4e-89ec-40f3c1f91852,07/08/2025,HUMAN PRESCRIPTION DRUG,,"Oncology, Pediatric",LEUCOVORIN CALCIUM,"71288-161, 71288-160, 71288-162, 71288-163, 71288-164",Meitheal Pharmaceuticals Inc.,077a459b-e884-4452-aed3-0857a38ce26f,"71288-160-10, 71288-161-20, 71288-162-30, 71288-163-30, 71288-164-50","Leucovorin Calcium, Injection, 100 mg/10 mL (NDC 71288-161-20)",Injection,,,ANDA216590,,LEUCOVORIN CALCIUM,,Available,Resolved,,,07/08/2025,RPR1R4C0P4,71288-161-20,"Meitheal Pharmaceuticals, Inc.: 844-824-8426",
Sandoz Inc.,AMOXICILLIN,,10/28/2022,Revised,ORAL,"Amoxicillin Powder, For Suspension","239191, 308182, 308189, 308191, 308192, 308194, 313797, 313850",,13bd4214-9b7f-425b-af5f-fc1ddc678230,05/02/2025,HUMAN PRESCRIPTION DRUG,,"Anti-Infective, Pediatric",AMOXICILLIN,"0781-6156, 0781-2020, 0781-2613, 0781-5060, 0781-5061, 0781-6039, 0781-6041, 0781-6157",Sandoz Inc,6aa02079-d11c-4d2f-acaf-9548dd9a7ed6,"0781-2020-31, 0781-2020-76, 0781-2020-01, 0781-2020-05, 0781-2613-31, 0781-2613-76, 0781-2613-01, 0781-2613-05, 0781-5060-20, 0781-5060-01, 0781-5061-20, 0781-5061-01, 0781-6039-58, 0781-6039-46, 0781-6039-55, 0781-6156-52, 0781-6156-57, 0781-6156-46, 0781-6041-58, 0781-6041-46, 0781-6041-55, 0781-6157-52, 0781-6157-57, 0781-6157-46","Amoxicillin, Powder, For Suspension, 200 mg/5 mL (NDC 0781-6156-57)","Powder, For Suspension",,,ANDA065378,,AMOXICILLIN,,Available,Resolved,,,05/02/2025,804826J2HU,0781-6156-57,800-525-8747,
SpecGx LLC,LISDEXAMFETAMINE DIMESYLATE,,07/14/2023,Reverified,ORAL,Lisdexamfetamine Dimesylate Capsule,"854830, 854834, 854838, 854842, 854846, 854850, 1593856",,806a1c15-0842-4787-b2ad-09a21fd96b37,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,LISDEXAMFETAMINE DIMESYLATE,"0406-5111, 0406-5112, 0406-5113, 0406-5114, 0406-5115, 0406-5116, 0406-5117",SpecGx LLC,3ffc0695-83f7-4898-9fd7-451c0989cfe0,"0406-5111-01, 0406-5112-01, 0406-5113-01, 0406-5114-01, 0406-5115-01, 0406-5116-01, 0406-5117-01","Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0406-5111-01)",Capsule,Limited Availability,,ANDA211840,,LISDEXAMFETAMINE DIMESYLATE,,,Current,Shortage of an active ingredient,Allocation to all customers.,,SJT761GEGS,0406-5111-01,800-325-8888,
"Teva Pharmaceuticals USA, Inc.",METHOTREXATE SODIUM,,03/13/2023,Revised,"INTRA-ARTERIAL, INTRAMUSCULAR, INTRATHECAL, INTRAVENOUS",Methotrexate Sodium Injection,,,346ec9ce-dc98-4a55-b55e-d3af11f2d703,09/15/2025,HUMAN PRESCRIPTION DRUG,,"Rheumatology, Oncology",METHOTREXATE,"0703-3678, 0703-3671, 0703-3675","Teva Parenteral Medicines, Inc.",e81074cc-12b4-4ac9-a5bb-749188989b2c,"0703-3671-01, 0703-3675-01, 0703-3678-01","Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)",Injection,Unavailable,,ANDA040843,,METHOTREXATE,,,Current,Other,Estimated recovery: January 2026,,3IG1E710ZN,0703-3678-01,800-545-8800,
"Elite Laboratories, Inc.",NALTREXONE HYDROCHLORIDE,,02/29/2024,Revised,ORAL,Naltrexone Hydrochloride Tablet,1483744,,b09b4b5e-795a-48e7-b7cc-2e29f41c5660,09/15/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,NALTREXONE HYDROCHLORIDE,68094-909,Precision Dose Inc.,48b82306-b0ba-4cb8-817d-896ccde0367b,"68094-909-30, 68094-909-50","Naltrexone Hydrochloride, Tablet, 50 mg (NDC 68094-909-50)",Tablet,Available,,ANDA075274,,NALTREXONE HYDROCHLORIDE,,,Current,,Marketed by Precision Dose; Customer service: 800-397-9228,,Z6375YW9SF,68094-909-50,888-852-6657,
"Sunrise Pharmaceutical, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,ac102599-3a5b-4154-899e-6ff262be7ff7,09/03/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","11534-193, 11534-190, 11534-191, 11534-192, 11534-194, 11534-195, 11534-196","SUNRISE PHARMACEUTICAL, INC.",86a00bec-51eb-4d73-a945-b1937970b29a,"11534-190-01, 11534-190-03, 11534-191-01, 11534-191-03, 11534-192-01, 11534-192-03, 11534-193-01, 11534-193-03, 11534-194-01, 11534-194-03, 11534-195-01, 11534-195-03, 11534-196-01, 11534-196-03","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 11534-193-01)",Tablet,Available,,ANDA209799,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",11534-193-01,732-382-6085 Monday to Friday 9 am to 3:45 pm,
"Lannett Company, Inc.","AMPHETAMINE ASPARTATE MONOHYDRATE, AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, DEXTROAMPHETAMINE SULFATE",,10/12/2022,Reverified,ORAL,"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet","541363, 541878, 541892, 577957, 577961, 687043, 1009145",,f92497b5-baea-4760-b615-45a0b6184402,09/15/2025,HUMAN PRESCRIPTION DRUG,,Psychiatry,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE","0527-0763, 0527-0760, 0527-0761, 0527-0762, 0527-0764, 0527-0765, 0527-0766","Lannett Company, Inc.",e0804f43-4685-4017-b839-3212d1167362,"0527-0760-37, 0527-0761-37, 0527-0762-37, 0527-0763-37, 0527-0764-37, 0527-0765-37, 0527-0766-37","Dextroamp Saccharate, Amp Aspartate, Dextroamp Sulfate And Amp Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0527-0763-37)",Tablet,Available,,ANDA215565,,"DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE",,,Current,,,,"O1ZPV620O4, 6DPV8NK46S, JJ768O327N, G83415V073",0527-0763-37,844-834-0530,
"Fresenius Kabi USA, LLC",,,03/23/2018,Reverified,,Ropivacaine Hydrochloride Injection,,,,09/18/2025,,,Anesthesia,,,,,,"Naropin, Injection, 2 mg/1 mL (NDC 65219-632-10)",Injection,Available,,,,,,,Current,,,,,65219-632-10,888-386-1300,
"Teva Pharmaceuticals USA, Inc.",TOBRAMYCIN,,06/16/2025,New,RESPIRATORY (INHALATION),Tobramycin Solution,1314763,,d03079d2-5617-4628-92b9-3caa757b22c0,06/16/2025,HUMAN PRESCRIPTION DRUG,06/16/2025,Pulmonary/Allergy,TOBRAMYCIN,0093-3750,"Teva Pharmaceuticals USA, Inc.",8aa98982-a156-4bc8-8d31-9a39b88808ed,"0093-3750-28, 0093-3750-63","Tobramycin, Solution, 300 mg/4 mL (NDC 0093-3750-63)",Solution,,"N0000175477, M0000946",ANDA210915,Aminoglycosides [CS],TOBRAMYCIN,Aminoglycoside Antibacterial [EPC],,To Be Discontinued,,Discontinuation of the manufacture of the drug,,VZ8RRZ51VK,0093-3750-63,800-545-8800,
Rubicon Research Private Limited,CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"72888-154, 72888-152, 72888-153",Advagen Pharma Ltd,36cf156e-5980-a21b-e063-6294a90ab3a0,"72888-152-30, 72888-152-01, 72888-152-05, 72888-152-00, 72888-153-30, 72888-153-01, 72888-153-05, 72888-153-00, 72888-154-30, 72888-154-01, 72888-154-05, 72888-154-00","Clonazepam, Tablet, 2 mg (NDC 72888-154-30)",Tablet,Available,"N0000175694, M0002356",ANDA075468,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,Marketed by Advagen Pharma Ltd.,,5PE9FDE8GB,72888-154-30,sales@advagenpharma.com,
HQ Specialty Pharma,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718906, 1718909, 1788947",,0d2710f2-ee47-4114-ab5c-8dca74cdcb8d,09/17/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE IN DEXTROSE,"44567-602, 44567-600, 44567-601, 44567-603","WG Critical Care, LLC",e6fa3e27-b374-49b6-a678-a5954f5beae8,"44567-600-04, 44567-601-04, 44567-602-24, 44567-603-24","Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-602-24)",Injection,Available,,NDA206628,,DEXMEDETOMIDINE,,,Current,,Marketed by WG Critical Care,,1018WH7F9I,44567-602-24,WG Critical Care 888-493-0861,
"Upsher-Smith Laboratories, LLC",DIVALPROEX SODIUM,,04/28/2025,New,ORAL,"Divalproex Sodium Tablet, Delayed Release","1099625, 1099678, 1099870",,02304a23-4a5f-47bc-9687-4044b43f7a20,04/28/2025,HUMAN PRESCRIPTION DRUG,04/28/2025,Neurology,DIVALPROEX SODIUM,"0832-7124, 0832-7122, 0832-7123","Upsher-Smith Laboratories, LLC",38e51a59-5802-77a6-e063-6394a90af6c6,"0832-7122-11, 0832-7122-15, 0832-7123-11, 0832-7123-15, 0832-7123-89, 0832-7123-01, 0832-7124-11, 0832-7124-15, 0832-7124-89, 0832-7124-01","Divalproex Sodium, Tablet, Delayed Release, 500 mg (NDC 0832-7124-11)",Tablet,,,ANDA078182,,DIVALPROEX SODIUM,,,To Be Discontinued,,Discontinuation of manufacture of drug based on business decision.,,644VL95AO6,0832-7124-11,800-654-2299,
"Actavis Pharma, Inc.",MEMANTINE HYDROCHLORIDE,,11/21/2024,New,ORAL,Memantine Hydrochloride Tablet,"996561, 996571, 996572",,72973b46-f307-4a9e-8fb1-ad2cbccfd736,11/21/2024,HUMAN PRESCRIPTION DRUG,11/21/2024,Neurology,MEMANTINE HYDROCHLORIDE,"0591-3870, 0591-3875, 0591-3900","Actavis Pharma, Inc.",985e1190-b8a0-4775-9a20-ad1924b14fb2,"0591-3870-60, 0591-3870-45, 0591-3870-44, 0591-3875-60, 0591-3875-45, 0591-3875-44, 0591-3900-87","Namenda, Tablet, 5 mg (NDC 0591-3870-60)",Tablet,,,NDA021487,,MEMANTINE HYDROCHLORIDE,,,To Be Discontinued,,,,JY0WD0UA60,0591-3870-60,800-545-8800,
Laboratoires Delbert,,,04/26/2023,Reverified,,Penicillin G Benzathine Injection,"2671687, 2671693, 2671695, 2671697",https://www.fda.gov/media/180283/download?attachment,5a026d0c-6f91-4ee3-b193-b2186a37e7ca,09/17/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,EXTENCILLINE,"81284-521, 81284-522, 81284-523, 81284-524",Provepharm Inc.,5eb42da3-7f4f-4071-9a35-14565343b49c,"81284-521-01, 81284-523-00, 81284-735-00, 81284-522-01, 81284-524-00","Extencilline, Injection, 1,200,000 units (NDC 81284-521-01)",Injection,Available,,,,BENZATHINE BENZYLPENICILLIN,,,Current,,,,RIT82F58GK,81284-521-01,Provepharm: rahul.poria@provepharm.com,
Long Grove Pharmaceuticals LLC,SODIUM BICARBONATE,,03/01/2017,Reverified,INTRAVENOUS,Sodium Bicarbonate Injection,1868486,,a26d709b-b294-4b02-9a88-7e840f099a33,09/17/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Pediatric",SODIUM BICARBONATE,81298-7620,"Long Grove Pharmaceuticals, LLC",1a255946-a137-4e13-8203-65dd80b34872,"81298-7620-1, 81298-7620-3","Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 81298-7620-3)",Injection,Available,,ANDA216042,,"SODIUM BICARBONATE INJECTION,",,,Current,,,,8MDF5V39QO,81298-7620-3,833-268-5559,
B. Braun Medical Inc.,SODIUM CHLORIDE,,04/28/2023,Revised,IRRIGATION,Sodium Chloride 0.9% Irrigation,486515,,5bd9b176-0402-4a3f-a6b4-c3f393fc092a,07/02/2025,HUMAN PRESCRIPTION DRUG,,"Gastroenterology, Other, Pediatric",SODIUM CHLORIDE FOR IRRIGATION,0264-7388,B. Braun Medical Inc.,69f7d8f6-65cd-45bd-83f7-7249905a2e72,"0264-7388-50, 0264-7388-60","Sodium Chloride 0.9%, Irrigation, .9 g/100mL (NDC 0264-7388-60)",Irrigation,,,NDA016733,,SODIUM CHLORIDE FOR IRRIGATION,,Available,Resolved,,,07/02/2025,451W47IQ8X,0264-7388-60,800-227-2862,
Gland Pharma Limited,CARBOPLATIN,,04/28/2023,Reverified,INTRAVENOUS,Carboplatin Injection,597195,,5484d2f0-0cc2-4bba-8f26-c7f6539a9606,09/29/2025,HUMAN PRESCRIPTION DRUG,,Oncology,CARBOPLATIN,"54288-165, 54288-166, 54288-167, 54288-164",BPI Labs LLC,5eb7631e-0b41-4aba-ba7a-f544ac9627fd,"54288-165-01, 54288-166-01, 54288-167-01, 54288-164-01","Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)",Injection,Limited Availability,"N0000175413, N0000175073",ANDA207324,,CARBOPLATIN,Platinum-based Drug [EPC],,Current,Demand increase for the drug,"Estimated recovery: Q4 2025; Distributed by BPI Labs, LLC",,BG3F62OND5,54288-165-01,"Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270",
"Hospira, Inc., a Pfizer Company",CARBOPLATIN,,04/28/2023,Reverified,INTRAVENOUS,Carboplatin Injection,597195,,c3ae9880-44bb-4f4e-93d8-8a5e21708a30,08/15/2025,HUMAN PRESCRIPTION DRUG,,Oncology,CARBOPLATIN,61703-339,"Hospira, Inc.",0ddf4411-7138-412a-908a-fadf22bdfb79,"61703-339-18, 61703-339-22, 61703-339-50, 61703-339-56","Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50)",Injection,Available,"N0000175413, N0000175073",ANDA076517,,CARBOPLATIN,Platinum-based Drug [EPC],,Current,,,,BG3F62OND5,61703-339-50,844-646-4398,
Baxter Healthcare,DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795477, 1795480, 1795481, 1795607, 1795609, 1795610, 1795612, 1795616, 1795618",,3bb406a9-f5cb-403a-b1bb-5c4facbea3d5,09/23/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,"0338-0017, 0338-0023",Baxter Healthcare Corporation,31bb4a5f-733e-4354-9fbf-138dede4db0f,"0338-0017-10, 0338-0017-41, 0338-0017-11, 0338-0017-31, 0338-0017-48, 0338-0017-18, 0338-0017-38, 0338-0017-02, 0338-0017-03, 0338-0017-04, 0338-0023-02, 0338-0023-03, 0338-0023-04","Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-03)",Injection,Available,,NDA016673,,DEXTROSE MONOHYDRATE,,,Current,,,,LX22YL083G,0338-0017-03,888-229-0001,
"Hospira, Inc., a Pfizer Company",LIDOCAINE HYDROCHLORIDE,,02/22/2012,Reverified,"EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL",Lidocaine Hydrochloride Injection,"1010033, 1010671, 1010900, 1737343, 1737562, 1737566, 1737568, 1737636, 1737757, 1737763",,3b2dd84e-cee8-4e58-d494-395a65a353a0,08/15/2025,HUMAN PRESCRIPTION DRUG,,"Anesthesia, Pediatric",LIDOCAINE HYDROCHLORIDE,"0409-4282, 0409-4713, 0409-4278, 0409-4279, 0409-4776, 0409-4277, 0409-4276, 0409-4275","Hospira, Inc.",c0b4635b-1473-4c48-89c6-620762cd687f,"0409-4713-12, 0409-4713-26, 0409-4713-02, 0409-4713-72, 0409-4713-62, 0409-4713-75, 0409-4713-65, 0409-4713-42, 0409-4713-25, 0409-4713-32, 0409-4278-16, 0409-4278-01, 0409-4279-16, 0409-4279-02, 0409-4776-10, 0409-4776-01, 0409-4282-11, 0409-4282-25, 0409-4282-01, 0409-4282-12, 0409-4282-02, 0409-4277-16, 0409-4277-01, 0409-4277-17, 0409-4277-02, 0409-4276-16, 0409-4276-01, 0409-4276-17, 0409-4276-02, 0409-4275-16, 0409-4275-01","Lidocaine Hydrochloride, Injection, 200 mg/10 mL (2%; 20 mg/mL) (NDC 0409-4282-02)",Injection,Available,,ANDA088294,,LIDOCAINE HYDROCHLORIDE,,,Current,,,,V13007Z41A,0409-4282-02,844-646-4398,
"Hospira, Inc., a Pfizer Company",LORAZEPAM,,05/03/2018,Revised,"INTRAMUSCULAR, INTRAVENOUS",Lorazepam Injection,"763028, 763029",,20140b19-846b-425f-b191-670e17809945,08/15/2025,HUMAN PRESCRIPTION DRUG,,Neurology,LORAZEPAM,"0409-1985, 0409-1539","Hospira, Inc.",e90a536c-421f-4774-8f88-013e18a8163e,"0409-1539-03, 0409-1539-31, 0409-1985-03, 0409-1985-30","Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)",Injection,Unavailable,"N0000175694, M0002356",ANDA074243,Benzodiazepines [CS],LORAZEPAM,Benzodiazepine [EPC],,Current,Other,Next Delivery: August 2025; Estimated Recovery: December 2025,,O26FZP769L,0409-1985-30,844-646-4398,
Eugia US LLC,DEXAMETHASONE SODIUM PHOSPHATE,,02/08/2019,Revised,"INTRAMUSCULAR, INTRAVENOUS",Dexamethasone Sodium Phosphate Injection,1812079,,29947f67-7868-40af-8ad2-a61f7149b44c,09/05/2025,HUMAN PRESCRIPTION DRUG,,"Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Other, Pulmonary/Allergy, Rheumatology",DEXAMETHASONE SODIUM PHOSPHATE,55150-304,Eugia US LLC,3f5e3c7f-f1d1-431c-877f-4b9ee2cd0dff,"55150-304-01, 55150-304-25","Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 55150-304-25)",Injection,Available,,ANDA210966,,DEXAMETHASONE SODIUM PHOSPHATE,,,Current,,Check wholesalers for inventory,,AI9376Y64P,55150-304-25,888-238-7880,
Baxter Healthcare,DEXMEDETOMIDINE HYDROCHLORIDE,,04/10/2020,Reverified,INTRAVENOUS,Dexmedetomidine Hydrochloride Injection,"1718906, 1718909",,aea9a3ad-c244-42be-9cd3-5df83fe2b522,09/23/2025,HUMAN PRESCRIPTION DRUG,,Anesthesia,DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE,"43066-555, 43066-557",Baxter Healthcare Company,949ed273-6b79-4f54-8284-a710082edd77,"43066-555-24, 43066-557-12","Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 43066-555-24)",Injection,Available,,ANDA208532,,DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE,,,Current,,,,1018WH7F9I,43066-555-24,888-229-0001,
Sun Pharmaceutical Industries Limited,DIGOXIN,,12/05/2024,New,ORAL,Digoxin Tablet,"197604, 197606",,62795623-a2bc-4dd2-8989-3b9782bfd80e,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Cardiovascular,DIGOXIN,"57664-441, 57664-437","Sun Pharmaceutical Industries, Inc.",1a3e469c-1452-3d1e-e063-6394a90ae73a,"57664-437-88, 57664-437-18, 57664-441-88, 57664-441-18","Digoxin, Tablet, 250 ug (NDC 57664-441-18)",Tablet,,"N0000175568, M0003451",ANDA076363,Cardiac Glycosides [CS],DIGOXIN,Cardiac Glycoside [EPC],,To Be Discontinued,,Discontinuing for business reasons,,73K4184T59,57664-441-18,800-818-4555,
Accord Healthcare Inc.,CARBOPLATIN,,04/28/2023,Revised,INTRAVENOUS,Carboplatin Injection,597195,,48aa7ef3-9f44-2a08-e054-00144ff88e88,09/16/2025,HUMAN PRESCRIPTION DRUG,,Oncology,CARBOPLATIN,16729-295,"Accord Healthcare, Inc.",35cf6068-f31a-211b-e063-6294a90a6b53,"16729-295-31, 16729-295-33, 16729-295-34, 16729-295-12, 16729-295-38","Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)",Injection,Unavailable,"N0000175413, N0000175073",ANDA206775,,CARBOPLATIN,Platinum-based Drug [EPC],,Current,Requirements related to complying with good manufacturing practices,Unavailable,,BG3F62OND5,16729-295-31,"866-941-7875, option 2",
B. Braun Medical Inc.,DEXTROSE MONOHYDRATE,,02/14/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 5% Injection,"1795609, 1795616, 1795618",,60b6d7c3-0164-46c9-aa38-b5aa1c31a5d5,09/16/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,0264-1510,B. Braun Medical Inc.,0a144591-6cfa-4aed-a067-c95aebc29057,"0264-1510-36, 0264-1510-31, 0264-1510-32","Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-32)",Injection,Available,,NDA016730,,DEXTROSE,,,Current,,,,LX22YL083G,0264-1510-32,800-227-2862,
Aurobindo Pharma USA,CLONAZEPAM,,03/10/2023,Reverified,ORAL,Clonazepam Tablet,"197527, 197528, 197529",,b1582eb7-af35-45d5-a52e-0e380d08527d,08/19/2025,HUMAN PRESCRIPTION DRUG,,"Neurology, Pediatric, Psychiatry",CLONAZEPAM,"59651-722, 59651-723, 59651-724",Aurobindo Pharma Limited,b1582eb7-af35-45d5-a52e-0e380d08527d,"59651-722-01, 59651-722-99, 59651-723-01, 59651-723-99, 59651-724-01, 59651-724-05","Clonazepam, Tablet, .5 mg (NDC 59651-722-99)",Tablet,Available,"N0000175694, M0002356",ANDA075150,Benzodiazepines [CS],CLONAZEPAM,Benzodiazepine [EPC],,Current,,,,5PE9FDE8GB,59651-722-99,866-850-2876,
"Hikma Pharmaceuticals USA, Inc.",REMIFENTANIL HYDROCHLORIDE,,06/28/2022,Reverified,INTRAVENOUS,Remifentanil Hydrochloride Injection,"1729578, 1729584, 1729710",,9d289052-1eb6-4ba2-a3ca-d2e542a052ae,07/23/2025,HUMAN PRESCRIPTION DRUG,,Analgesia/Addiction,REMIFENTANIL HYDROCHLORIDE,"0143-9393, 0143-9391, 0143-9392",Hikma Pharmaceuticals USA Inc.,5c5e498b-d829-4f78-bcca-466631014767,"0143-9391-01, 0143-9391-10, 0143-9392-01, 0143-9392-10, 0143-9393-01, 0143-9393-10","Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10)",Injection,Unavailable,,ANDA210594,,REMIFENTANIL HYDROCHLORIDE,,,Current,Demand increase for the drug,,,5V444H5WIC,0143-9393-10,800-631-2174,
"Upsher-Smith Laboratories, LLC",,,04/23/2025,New,,Baclofen Tablet,,,,04/23/2025,,04/23/2025,Neurology,,,,,,"Baclofen, Tablet, 10 mg (NDC 50090-6868-0)",Tablet,,,,,,,,To Be Discontinued,,,,,50090-6868-0,716-315-2000,
Baxter Healthcare,"ALANINE, ARGININE, ASPARTIC ACID, CYSTEINE HYDROCHLORIDE, GLUTAMIC ACID, GLYCINE, HISTIDINE, ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, PROLINE, SERINE, TAURINE, THREONINE, TRYPTOPHAN, TYROSINE, VALINE",,12/08/2020,Reverified,INTRAVENOUS,Amino Acid Injection,"801395, 801398, 801403, 801405",,9afdcc3e-0d06-47f4-86ca-40da48b2b02b,09/23/2025,HUMAN PRESCRIPTION DRUG,,Gastroenterology,PREMASOL - SULFITE-FREE (AMINO ACID),"0338-1130, 0338-1131",Baxter Healthcare Company,4083b5c8-ad5f-43f6-ab19-3c87acb2883f,"0338-1130-03, 0338-1130-04, 0338-1130-06, 0338-1131-03","Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-06)",Injection,Available,"N0000175780, M0000922",ANDA075880,Amino Acids [CS],"LEUCINE, LYSINE, ISOLEUCINE, VALINE, HISTIDINE, PHENYLALANINE, THREONINE, METHIONINE, TRYPTOPHAN, TYROSINE, N-ACETYL-TYROSINE, ARGININE, PROLINE, ALANINE, GLUTAMIC ACIDE, SERINE, GLYCINE, ASPARTIC ACID, TAURINE, CYSTEINE HYDROCHLORIDE",Amino Acid [EPC],,Current,,,,"OF5P57N2ZX, 94ZLA3W45F, 30KYC7MIAI, ZT934N0X4W, 3KX376GY7L, TE7660XO1C, 4QD397987E, 04Y7590D77, GMW67QNF9C, TTL6G7LIWZ, AE28F7PNPL, 47E5O17Y3R, 9DLQ4CIU6V, 452VLY9402, 1EQV5MLY3D, 2ZD004190S, 8DUH1N11BX, 42HK56048U, HG18B9YRS7",0338-1130-06,888-229-0001,
Baxter Healthcare,CLINDAMYCIN PHOSPHATE,,03/21/2023,Reverified,INTRAVENOUS,Clindamycin Phosphate Injection,"309335, 309336, 309339",,78832ac6-04c5-45e0-ae4d-f56d7920dda9,09/23/2025,HUMAN PRESCRIPTION DRUG,,Anti-Infective,CLINDAMYCIN PHOSPHATE,"0338-3612, 0338-3410, 0338-3814",Baxter Healthcare Company,9373fc85-1d70-4907-842a-ae9e2a3958b3,"0338-3410-50, 0338-3410-24, 0338-3612-50, 0338-3612-24, 0338-3814-50, 0338-3814-24","Clindamycin Phosphate, Injection, 600 mg/50 mL (NDC 0338-3612-50)",Injection,Available,,ANDA208084,,CLINDAMYCIN PHOSPHATE,,,Current,,,,EH6D7113I8,0338-3612-50,888-229-0001,
Sun Pharmaceutical Industries Limited,DIGOXIN,,12/05/2024,New,ORAL,Digoxin Tablet,"197604, 197606",,62795623-a2bc-4dd2-8989-3b9782bfd80e,12/05/2024,HUMAN PRESCRIPTION DRUG,12/05/2024,Cardiovascular,DIGOXIN,"57664-437, 57664-441","Sun Pharmaceutical Industries, Inc.",1a3e469c-1452-3d1e-e063-6394a90ae73a,"57664-437-88, 57664-437-18, 57664-441-88, 57664-441-18","Digoxin, Tablet, 125 ug (NDC 57664-437-18)",Tablet,,"N0000175568, M0003451",ANDA076363,Cardiac Glycosides [CS],DIGOXIN,Cardiac Glycoside [EPC],,To Be Discontinued,,Discontinuing for business reasons,,73K4184T59,57664-437-18,800-818-4555,
Aurobindo Pharma USA,"AMLODIPINE BESYLATE, BENAZEPRIL HYDROCHLORIDE",,03/04/2025,New,ORAL,Amlodipine Besylate; Benazepril Hydrochloride Capsule,"898342, 898346, 898350, 898353, 898356, 898359",,99ed4927-9a34-4e8d-8eea-60b63c867d46,03/04/2025,HUMAN PRESCRIPTION DRUG,03/04/2025,Cardiovascular,AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE,"65862-584, 65862-582, 65862-583, 65862-585, 65862-586, 65862-587",Aurobindo Pharma Limited,a45ec3e8-1d14-4c27-9685-976323df8cad,"65862-582-01, 65862-582-05, 65862-583-01, 65862-583-05, 65862-584-01, 65862-584-05, 65862-585-01, 65862-585-05, 65862-586-01, 65862-586-05, 65862-587-01, 65862-587-05","Amlodipine Besylate; Benazepril Hydrochloride, Capsule, 5 mg; 20 mg (NDC 65862-584-05)",Capsule,,,ANDA202239,,AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE,,,To Be Discontinued,,,,"864V2Q084H, N1SN99T69T",65862-584-05,866-850-2876,
"Boehringer Ingelheim Pharmaceuticals, Inc.",,,03/03/2025,New,,Adalimumab-adbm Injection,"797544, 2640883, 2640889, 2640891, 2640892, 2640893, 2640894, 2640895, 2640898, 2640900, 2640901, 2640902, 2640903, 2680743, 2680746, 2680748, 2680750, 2680756, 2680757, 2680759, 2680760",,115ea79b-7209-7f19-b35d-36ec0828fbf5,03/03/2025,HUMAN PRESCRIPTION DRUG,03/03/2025,Rheumatology,CYLTEZO,"0597-0375, 0597-0370, 0597-0405, 0597-0400, 0597-0485, 0597-0495","Boehringer Ingelheim Pharmaceuticals, Inc.",48e59974-6012-4a21-9348-552d590632b1,"0597-0370-82, 0597-0370-72, 0597-0370-45, 0597-0405-80, 0597-0405-10, 0597-0400-89, 0597-0375-48, 0597-0375-97, 0597-0375-23, 0597-0375-16, 0597-0375-53, 0597-0485-46, 0597-0485-20, 0597-0480-12, 0597-0495-47, 0597-0495-50, 0597-0495-40, 0597-0495-60, 0597-0490-32","Cyltezo, Injection, Kit (NDC 0597-0375-23)",Injection,,,BLA761058,,ADALIMUMAB-ADBM,,,To Be Discontinued,,,,,0597-0375-23,800-243-0127,
Eugia US LLC,DEXAMETHASONE SODIUM PHOSPHATE,,02/08/2019,Revised,"INTRA-ARTICULAR, INTRALESIONAL, INTRAMUSCULAR, INTRAVENOUS, SOFT TISSUE",Dexamethasone Sodium Phosphate Injection,"1116927, 1812194",,ce7ad5a4-a9c5-42d6-87cc-ca16556208d2,09/05/2025,HUMAN PRESCRIPTION DRUG,,"Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Other, Pulmonary/Allergy, Rheumatology",DEXAMETHASONE SODIUM PHOSPHATE,"55150-239, 55150-237, 55150-238",Eugia US LLC,34b1362a-f970-485f-bdac-3a02217157c9,"55150-237-01, 55150-238-05, 55150-239-30","Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 55150-239-30)",Injection,Unavailable,,ANDA206781,,DEXAMETHASONE SODIUM PHOSPHATE,,,Current,Demand increase for the drug,On backorder. Recovery: TBD. Check wholesalers for inventory,,AI9376Y64P,55150-239-30,888-238-7880,
"Fresenius Kabi USA, LLC",DEXTROSE MONOHYDRATE,,03/01/2022,Reverified,INTRAVENOUS,Dextrose Monohydrate 10% Injection,"1795477, 1795480, 1795481",,3b8f2692-4371-4f1a-95af-b41842131fdd,09/18/2025,HUMAN PRESCRIPTION DRUG,,"Endocrinology/Metabolism, Gastroenterology, Other, Pediatric",DEXTROSE,63323-824,"Fresenius Kabi USA, LLC",d4eda8d8-e374-469e-8ac0-9c9fb7a58aaf,"63323-824-24, 63323-824-74, 63323-824-25, 63323-824-75, 63323-824-26, 63323-824-76","Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-76)",Injection,Available,,ANDA209448,,DEXTROSE MONOHYDRATE,,,Current,,Check wholesalers for inventory,,LX22YL083G,63323-824-76,888-386-1300,
